--
-- PostgreSQL database dump
--

SET statement_timeout = 0;
SET lock_timeout = 0;
SET client_encoding = 'UTF8';
SET standard_conforming_strings = on;
SET check_function_bodies = false;
SET client_min_messages = warning;

--
-- Name: clean; Type: SCHEMA; Schema: -; Owner: postgres
--

CREATE SCHEMA clean;


ALTER SCHEMA clean OWNER TO postgres;

SET search_path = clean, pg_catalog;

--
-- Name: sex_type; Type: TYPE; Schema: clean; Owner: postgres
--

CREATE TYPE sex_type AS ENUM (
    'male',
    'female'
);


ALTER TYPE sex_type OWNER TO postgres;

SET default_tablespace = '';

SET default_with_oids = false;

--
-- Name: condition; Type: TABLE; Schema: clean; Owner: postgres; Tablespace: 
--

CREATE TABLE condition (
    id integer NOT NULL,
    meddra text,
    who_icd_10 text,
    description text
);


ALTER TABLE condition OWNER TO postgres;

--
-- Name: condition_id_seq; Type: SEQUENCE; Schema: clean; Owner: postgres
--

CREATE SEQUENCE condition_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE condition_id_seq OWNER TO postgres;

--
-- Name: condition_id_seq; Type: SEQUENCE OWNED BY; Schema: clean; Owner: postgres
--

ALTER SEQUENCE condition_id_seq OWNED BY condition.id;


--
-- Name: document; Type: TABLE; Schema: clean; Owner: postgres; Tablespace: 
--

CREATE TABLE document (
    id integer NOT NULL,
    label text,
    type text
);


ALTER TABLE document OWNER TO postgres;

--
-- Name: document_id_seq; Type: SEQUENCE; Schema: clean; Owner: postgres
--

CREATE SEQUENCE document_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE document_id_seq OWNER TO postgres;

--
-- Name: document_id_seq; Type: SEQUENCE OWNED BY; Schema: clean; Owner: postgres
--

ALTER SEQUENCE document_id_seq OWNED BY document.id;


--
-- Name: drug; Type: TABLE; Schema: clean; Owner: postgres; Tablespace: 
--

CREATE TABLE drug (
    id integer NOT NULL,
    technical_name text,
    trade_name text,
    who_dde text,
    category text,
    description text
);


ALTER TABLE drug OWNER TO postgres;

--
-- Name: drug_id_seq; Type: SEQUENCE; Schema: clean; Owner: postgres
--

CREATE SEQUENCE drug_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE drug_id_seq OWNER TO postgres;

--
-- Name: drug_id_seq; Type: SEQUENCE OWNED BY; Schema: clean; Owner: postgres
--

ALTER SEQUENCE drug_id_seq OWNED BY drug.id;


--
-- Name: method; Type: TABLE; Schema: clean; Owner: postgres; Tablespace: 
--

CREATE TABLE method (
    id integer NOT NULL,
    description text
);


ALTER TABLE method OWNER TO postgres;

--
-- Name: method_id_seq; Type: SEQUENCE; Schema: clean; Owner: postgres
--

CREATE SEQUENCE method_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE method_id_seq OWNER TO postgres;

--
-- Name: method_id_seq; Type: SEQUENCE OWNED BY; Schema: clean; Owner: postgres
--

ALTER SEQUENCE method_id_seq OWNED BY method.id;


--
-- Name: provenance; Type: TABLE; Schema: clean; Owner: postgres; Tablespace: 
--

CREATE TABLE provenance (
    id integer NOT NULL,
    "timestamp" timestamp without time zone
);


ALTER TABLE provenance OWNER TO postgres;

--
-- Name: provenance_id_seq; Type: SEQUENCE; Schema: clean; Owner: postgres
--

CREATE SEQUENCE provenance_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE provenance_id_seq OWNER TO postgres;

--
-- Name: provenance_id_seq; Type: SEQUENCE OWNED BY; Schema: clean; Owner: postgres
--

ALTER SEQUENCE provenance_id_seq OWNED BY provenance.id;


--
-- Name: register_entry; Type: TABLE; Schema: clean; Owner: postgres; Tablespace: 
--

CREATE TABLE register_entry (
    id integer NOT NULL,
    source_id integer,
    register_info jsonb
);


ALTER TABLE register_entry OWNER TO postgres;

--
-- Name: register_entry_id_seq; Type: SEQUENCE; Schema: clean; Owner: postgres
--

CREATE SEQUENCE register_entry_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE register_entry_id_seq OWNER TO postgres;

--
-- Name: register_entry_id_seq; Type: SEQUENCE OWNED BY; Schema: clean; Owner: postgres
--

ALTER SEQUENCE register_entry_id_seq OWNED BY register_entry.id;


--
-- Name: results_doc; Type: TABLE; Schema: clean; Owner: postgres; Tablespace: 
--

CREATE TABLE results_doc (
    id integer NOT NULL,
    title text,
    type text,
    structured_data text,
    document_id text,
    link text,
    free_text text,
    authors text,
    source text
);


ALTER TABLE results_doc OWNER TO postgres;

--
-- Name: results_doc_id_seq; Type: SEQUENCE; Schema: clean; Owner: postgres
--

CREATE SEQUENCE results_doc_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE results_doc_id_seq OWNER TO postgres;

--
-- Name: results_doc_id_seq; Type: SEQUENCE OWNED BY; Schema: clean; Owner: postgres
--

ALTER SEQUENCE results_doc_id_seq OWNED BY results_doc.id;


--
-- Name: source; Type: TABLE; Schema: clean; Owner: postgres; Tablespace: 
--

CREATE TABLE source (
    id integer NOT NULL,
    title text,
    descrition text,
    category text,
    cochrane boolean
);


ALTER TABLE source OWNER TO postgres;

--
-- Name: source_id_seq; Type: SEQUENCE; Schema: clean; Owner: postgres
--

CREATE SEQUENCE source_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE source_id_seq OWNER TO postgres;

--
-- Name: source_id_seq; Type: SEQUENCE OWNED BY; Schema: clean; Owner: postgres
--

ALTER SEQUENCE source_id_seq OWNED BY source.id;


--
-- Name: trial; Type: TABLE; Schema: clean; Owner: postgres; Tablespace: 
--

CREATE TABLE trial (
    id integer NOT NULL,
    public_title text,
    scientific_title text,
    condition_or_problem text,
    source_of_funding text,
    countries text,
    contacts text,
    date_from date,
    date_to date,
    notes text,
    exclusion_criteria text,
    sample_size text,
    age_from smallint,
    age_to smallint,
    sex sex_type,
    interventions text[],
    outcomes text[]
);


ALTER TABLE trial OWNER TO postgres;

--
-- Name: trial2condition; Type: TABLE; Schema: clean; Owner: postgres; Tablespace: 
--

CREATE TABLE trial2condition (
    trial_id integer NOT NULL,
    condition_id integer NOT NULL
);


ALTER TABLE trial2condition OWNER TO postgres;

--
-- Name: trial2drug; Type: TABLE; Schema: clean; Owner: postgres; Tablespace: 
--

CREATE TABLE trial2drug (
    trial_id integer NOT NULL,
    drug_id integer NOT NULL
);


ALTER TABLE trial2drug OWNER TO postgres;

--
-- Name: trial2method; Type: TABLE; Schema: clean; Owner: postgres; Tablespace: 
--

CREATE TABLE trial2method (
    trial_id integer NOT NULL,
    method_id integer NOT NULL
);


ALTER TABLE trial2method OWNER TO postgres;

--
-- Name: trial_id_seq; Type: SEQUENCE; Schema: clean; Owner: postgres
--

CREATE SEQUENCE trial_id_seq
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE trial_id_seq OWNER TO postgres;

--
-- Name: trial_id_seq; Type: SEQUENCE OWNED BY; Schema: clean; Owner: postgres
--

ALTER SEQUENCE trial_id_seq OWNED BY trial.id;


--
-- Name: id; Type: DEFAULT; Schema: clean; Owner: postgres
--

ALTER TABLE ONLY condition ALTER COLUMN id SET DEFAULT nextval('condition_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: clean; Owner: postgres
--

ALTER TABLE ONLY document ALTER COLUMN id SET DEFAULT nextval('document_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: clean; Owner: postgres
--

ALTER TABLE ONLY drug ALTER COLUMN id SET DEFAULT nextval('drug_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: clean; Owner: postgres
--

ALTER TABLE ONLY method ALTER COLUMN id SET DEFAULT nextval('method_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: clean; Owner: postgres
--

ALTER TABLE ONLY provenance ALTER COLUMN id SET DEFAULT nextval('provenance_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: clean; Owner: postgres
--

ALTER TABLE ONLY register_entry ALTER COLUMN id SET DEFAULT nextval('register_entry_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: clean; Owner: postgres
--

ALTER TABLE ONLY results_doc ALTER COLUMN id SET DEFAULT nextval('results_doc_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: clean; Owner: postgres
--

ALTER TABLE ONLY source ALTER COLUMN id SET DEFAULT nextval('source_id_seq'::regclass);


--
-- Name: id; Type: DEFAULT; Schema: clean; Owner: postgres
--

ALTER TABLE ONLY trial ALTER COLUMN id SET DEFAULT nextval('trial_id_seq'::regclass);


--
-- Data for Name: condition; Type: TABLE DATA; Schema: clean; Owner: postgres
--

COPY condition (id, meddra, who_icd_10, description) FROM stdin;
1177	\N	\N	A - Delusional Disorder
1178	\N	\N	A - Health Care Professionals
1179	\N	\N	A - Healthy volunteers
1180	\N	\N	A - Lay carers/family
1182	\N	\N	A - Schizoaffective disorders
1183	\N	\N	A - Schizophrenia
1188	\N	\N	B - No Minority
1189	\N	\N	B - Delusional disorder
1190	\N	\N	B - Health care professionals
1191	\N	\N	B - Healthy volunteers
1192	\N	\N	B - Lay carers/family
1193	\N	\N	B - Psychotic
1194	\N	\N	B - Schizoaffective disorders
1195	\N	\N	B - Schizophrenia
1196	\N	\N	B - Serious mental illness
1197	\N	\N	C - Not applicable
1198	\N	\N	C - Acute
1199	\N	\N	C - Early post-acute
1200	\N	\N	C - Remission
1201	\N	\N	D - Not applicable
1203	\N	\N	D - Prodromal illness
1204	\N	\N	D - First Episode
1205	\N	\N	D - Early illness
1206	\N	\N	D - Persistent / chronic
1207	\N	\N	D - Late onset
1209	\N	\N	E - Aggression (RE Aggression)
1210	\N	\N	E - Agitation (RE Aggression)
1211	\N	\N	E - Akathisia
1213	\N	\N	E - Depression
1216	\N	\N	E - Movement disorders
1217	\N	\N	E - Negative symptoms
1218	\N	\N	E - Not Applicable
1219	\N	\N	E - Parkinsonism
1220	\N	\N	E - Tardive Dyskinesia
1221	\N	\N	E - Treatment Resistant
1222	\N	\N	E - Weight Gain
1229	\N	\N	C - Partial remission
1231	\N	\N	E - Adherence
1232	\N	\N	C - State Not Described
1233	\N	\N	D - Stage not described
1237	\N	\N	A - Schizotypal
1238	\N	\N	C - Suspected
1239	\N	\N	B - Schizophreniform
1243	\N	\N	E - Relapse
1244	\N	\N	E - Neurocognition
1246	\N	\N	E - Substance Abuse (Substance Abuse)
1247	\N	\N	E - Anxiety (RE Aggression)
1249	\N	\N	B - Schizotypal
1255	\N	\N	E - Mood disorder
1257	\N	\N	E - Alcohol (Substance Abuse)
1258	\N	\N	E - Withdrawal
1261	\N	\N	E - Obsessive compulsive symptoms
1262	\N	\N	E - Positive symptoms
1263	\N	\N	E - Amenorrhea
1264	\N	\N	E - Sialorrhea (Hypersalivation)
1271	\N	\N	E - Hypersalivation
1276	\N	\N	E - Delusions
1277	\N	\N	E - Adverse effects
44936	\N	\N	A - Schizophreniform
44965	\N	\N	E - Mammogen level
44968	\N	\N	E - Social function
44970	\N	\N	E - Prolactin level
44971	\N	\N	E - Cognitive function
44974	\N	\N	E - Compliance
44977	\N	\N	E - Excitement (RE Aggression)
44979	\N	\N	E - Abnormal ECG
44983	\N	\N	E - Memory
44984	\N	\N	E - Electrocardiogram
44985	\N	\N	E - Glucose metabolism
44986	\N	\N	E - Self-esteem
44989	\N	\N	E - Erythrocyte sedimentation rate
44992	\N	\N	E - Constipation
44993	\N	\N	E - Paralytic ileus
44994	\N	\N	E - Enuresis
44995	\N	\N	E - Urinary retention
44998	\N	\N	E - Liver function
45001	\N	\N	E - Sinus tachycardia
45002	\N	\N	E - Xerostomia
45014	\N	\N	E - Behaviour
45017	\N	\N	E - Glucose and lipid metabolism
45019	\N	\N	E - Extrapyramidal symptoms
45021	\N	\N	E - Glucose level
45023	\N	\N	E - Immunity
45025	\N	\N	E - Tremor
45026	\N	\N	E - Leukopenia
45027	\N	\N	E - Potassium level
45029	\N	\N	E - Blood pressure
45037	\N	\N	E - Blood glucose
45039	\N	\N	E - Electroencephalogram
45040	\N	\N	E - Emotion and social function
45045	\N	\N	E - Negative emotions
45047	\N	\N	E - Growth Hormone Level
45048	\N	\N	E - Blood lipid
45060	\N	\N	E - Blood concentration
45062	\N	\N	E - Salivation
45069	\N	\N	E - Expressed emotion and relapse
45081	\N	\N	E - Glutamate level
45096	\N	\N	E - Adverse events
45104	\N	\N	E - Negative behaviour
45112	\N	\N	E - Executive function
45114	\N	\N	E - Blood Drug Level
45118	\N	\N	E - Menstruation
45119	\N	\N	E - Hepatic dysfunction
45121	\N	\N	E - Spinal fracture
45128	\N	\N	E - Negative + Positive symptoms
45134	\N	\N	E - Metabolic syndrome
45138	\N	\N	E - Dystonia
45140	\N	\N	E - Polysialia adverse effects
45145	\N	\N	E - Serum prolactin level
45148	\N	\N	E - Serum lipid
45151	\N	\N	E - Emotional disorder
45153	\N	\N	E - Decubitus
45155	\N	\N	E - Health education
45159	\N	\N	E - Low self-esteem
45161	\N	\N	E - Lipid metabolic
45162	\N	\N	E - Dysphrenia
45168	\N	\N	E - Function improvement
45181	\N	\N	E - Hallucinations
45183	\N	\N	E - Diabetes mellitus
45187	\N	\N	E - Leucocyte
45194	\N	\N	E - Metabolism
45204	\N	\N	E - Sex hormone level
45214	\N	\N	E - Glycometabolism
45236	\N	\N	A - Psychotic
45238	\N	\N	A - Serious Mental Illness
45308	\N	\N	E - Polydipsia-hyponatremia
45314	\N	\N	E - Cardiovascular autonomic reactivity
45317	\N	\N	E - Learning disability
45318	\N	\N	E - Hypnotic action
45321	\N	\N	E - Heart disease
45337	\N	\N	E - Homelessness
45338	\N	\N	E - Cardiovascular disease
45339	\N	\N	E - Sexual functioning
45350	\N	\N	E - Decomposition
45356	\N	\N	E - Post-psychotic depression
45365	\N	\N	E - Hyperlipidemia
45372	\N	\N	E - Visual hypersensitivity attack
45373	\N	\N	E - Influence of comorbid personality disorder and serious mental illness on police contacts
45377	\N	\N	E - Erectile dysfunction
45380	\N	\N	E - Suicide
45398	\N	\N	E - Dementia
45399	\N	\N	E - Hyperprolactinemia
45404	\N	\N	E - Breast Cancer
45421	\N	\N	E - Jail Recidivism
45424	\N	\N	E - Early response to treatment
45425	\N	\N	E - Cholesterol
45429	\N	\N	E - Endogenous depression
45430	\N	\N	E - Sleep
45434	\N	\N	E - Sweat odour
45435	\N	\N	E - Eye abnormalities
45436	\N	\N	E - Metabolic disorder
45438	\N	\N	E - Hyperhomocysteinemia
45448	\N	\N	E - Attention
45450	\N	\N	E - EEG
45461	\N	\N	E - C-reactive protein levels
45533	\N	\N	E - interleukin level
45536	\N	\N	E - Anhedonia
45538	\N	\N	E - Oral hygiene
45539	\N	\N	E - Cardiac outcomes
45543	\N	\N	E - Smoking (Substance Abuse)
45545	\N	\N	E - HIV
45546	\N	\N	E - Stigma
45548	\N	\N	E - Exacerbation (RE Aggression)
45549	\N	\N	E - Economic
45554	\N	\N	E - Hypertension
45555	\N	\N	E - Hypotonic disorders
45556	\N	\N	E - Mental retardation
45559	\N	\N	E - Digestion
45560	\N	\N	E - Defective cerebral circulation
45561	\N	\N	E - Cannabis Use (Substance Abuse)
45562	\N	\N	E - Disturbed
45563	\N	\N	E - Neuroleptic resistant
45564	\N	\N	E - Polydipsia
45565	\N	\N	E - Psychopathology
45566	\N	\N	E - Neurocognitive Deficits
45567	\N	\N	E - Early onset
45568	\N	\N	E - Engagement
45569	\N	\N	E - Employment
45570	\N	\N	E - Dual diagnosis
45571	\N	\N	E - Insulin
45572	\N	\N	E - Self-perception
45573	\N	\N	e - Dystonia-parkinsonism
45574	\N	\N	E - Herpes
45575	\N	\N	E - Rehabilitation
45577	\N	\N	E - Voices
45578	\N	\N	E - PTSD
45579	\N	\N	E - Exercise
45581	\N	\N	E - Independent living
45582	\N	\N	E - Mental disability
45583	\N	\N	E - Paranoia
45584	\N	\N	E - Offenders
45585	\N	\N	E - Postmenopausal
45586	\N	\N	E - Cognition
45587	\N	\N	E - Social cognition
45588	\N	\N	E - Eye movements
45589	\N	\N	E - Amphetamine (Substance Abuse)
45590	\N	\N	E - Diet (Weight)
45591	\N	\N	E - Comorbid
45592	\N	\N	E - HSVI
45593	\N	\N	E - Insomnia
45594	\N	\N	E - Sensory gating
45595	\N	\N	E - Quality of life
45596	\N	\N	E - Stress
45598	\N	\N	E - Obesity (Weight)
45599	\N	\N	E - Excitement and Agitation (RE Aggression)
45600	\N	\N	A - At Risk of Psychosis
45601	\N	\N	A - Family History of Psychosis
45602	\N	\N	A - Mental Illness
45603	\N	\N	A - Not Described
45604	\N	\N	D - Chronic
45605	\N	\N	E - Cardiovascular Risk Factor
45606	\N	\N	E - Childhood Learning Disabilities
45607	\N	\N	E - Drug Dependence (Substance Abuse)
45608	\N	\N	E - Nicotine Dependence (Substance Abuse)
45609	\N	\N	E - Cocaine Dependence (Substance Abuse)
45610	\N	\N	E - Cognitive Impairment
45611	\N	\N	E - Comorbidity
45612	\N	\N	E - Diabetes
45613	\N	\N	E - Dually Diagnosed
45614	\N	\N	E - Diminished P50 Sensory Gating
45615	\N	\N	E - Discrimination
45616	\N	\N	E - Drug and Alcohol Use (Substance Abuse)
45617	\N	\N	E - ECT-Induced Cognitive Impairment
45618	\N	\N	E - Epilepsy
45619	\N	\N	E - Gliadin-Positive
45620	\N	\N	E - Hepatitis
45621	\N	\N	E - Herpes Simplex
45622	\N	\N	E - Methamphetamine Dependence (Substance Abuse)
45623	\N	\N	E - Hyperglycemia
45624	\N	\N	E - Muteness
45625	\N	\N	E - Non-Adherence
45626	\N	\N	E - Hyperprolinemia
45627	\N	\N	E - Impulsivity
45628	\N	\N	E - Marked Social Withdrawal
45629	\N	\N	E - Opioid Dependence (Substance Abuse)
45630	\N	\N	E - Overweight
45631	\N	\N	E - Pathological Gambling
45632	\N	\N	E - Postmenopause
45633	\N	\N	E - Prolactinemia
45634	\N	\N	E - Restless Legs Syndrome
45635	\N	\N	E - Substance Use (Substance Abuse)
45636	\N	\N	E - Unemployment
45637	\N	\N	E - Violence (RE Aggression)
45638	\N	\N	A - Tardive Dyskinesia
45639	\N	\N	E - Asthma
45640	\N	\N	E - COPD
45641	\N	\N	E - Compulsory Admission (RE Aggression)
45642	\N	\N	E - Pregnancy
45643	\N	\N	E - At Risk of Psychosis
45644	\N	\N	E - Acutely Disturbed (RE Aggression)
45645	\N	\N	A - Delirium
45646	\N	\N	A - Illness
45647	\N	\N	E - Chronic HCV Infection
45648	\N	\N	E - Galactorrhea-Amenorrhea Syndrome
45649	\N	\N	E - Psychiatric Illness
45650	\N	\N	E - Suicidal Ideation
\.


--
-- Name: condition_id_seq; Type: SEQUENCE SET; Schema: clean; Owner: postgres
--

SELECT pg_catalog.setval('condition_id_seq', 1, false);


--
-- Data for Name: document; Type: TABLE DATA; Schema: clean; Owner: postgres
--

COPY document (id, label, type) FROM stdin;
\.


--
-- Name: document_id_seq; Type: SEQUENCE SET; Schema: clean; Owner: postgres
--

SELECT pg_catalog.setval('document_id_seq', 1, false);


--
-- Data for Name: drug; Type: TABLE DATA; Schema: clean; Owner: postgres
--

COPY drug (id, technical_name, trade_name, who_dde, category, description) FROM stdin;
\.


--
-- Name: drug_id_seq; Type: SEQUENCE SET; Schema: clean; Owner: postgres
--

SELECT pg_catalog.setval('drug_id_seq', 1, false);


--
-- Data for Name: method; Type: TABLE DATA; Schema: clean; Owner: postgres
--

COPY method (id, description) FROM stdin;
1	Cluster randomisation (events)
2	Cluster randomisation (wards)
3	Cluster randomisation (families)
4	Cluster randomisation (homes)
6	Crossover
7	Blinding - open-label
9	Blinding - unclear
10	Blinding - double
11	Blinding - single
13	Cluster randomisation (mental health workers)
14	Blinding - triple
15	Blinding - multi-blind
16	Cluster randomisation (general practices)
17	Cluster randomisation (mental health centres)
18	Factorial
21	Unclear
22	Unclear - requires translation
24	Non blinded
25	Randomised- no further info
26	Block randomisation
27	Randomised - admission order
28	Randomised- tossing a coin
29	Randomised- drawing straws
30	Randomised - date of admission, odd or even
31	Randomised - consultation order
32	Randomised - random number generation
33	Randomised - number of admission, odd or even
34	Randomised - computer random number generation
35	Randomised - admission  and consultation order
36	Randomised - discharge order
37	Randomised - admission order, even or odd
38	Randomised - admission order and tossing a coin
39	Randomised - admission number, odd or even
40	Randomised - selection order
41	Randomised - random number generation + admission order
42	Randomised - random number generation table
43	Randomised - random number, odd or even
44	Randomised - admission order and random number generation
45	Randomised - case note numbers
46	Randomised - admission order + stratified
47	Randomised - block randomisation
48	Randomised - card
49	Quasi randomization
101	RCT
102	CCT
\.


--
-- Name: method_id_seq; Type: SEQUENCE SET; Schema: clean; Owner: postgres
--

SELECT pg_catalog.setval('method_id_seq', 1, false);


--
-- Data for Name: provenance; Type: TABLE DATA; Schema: clean; Owner: postgres
--

COPY provenance (id, "timestamp") FROM stdin;
\.


--
-- Name: provenance_id_seq; Type: SEQUENCE SET; Schema: clean; Owner: postgres
--

SELECT pg_catalog.setval('provenance_id_seq', 1, false);


--
-- Data for Name: register_entry; Type: TABLE DATA; Schema: clean; Owner: postgres
--

COPY register_entry (id, source_id, register_info) FROM stdin;
\.


--
-- Name: register_entry_id_seq; Type: SEQUENCE SET; Schema: clean; Owner: postgres
--

SELECT pg_catalog.setval('register_entry_id_seq', 1, false);


--
-- Data for Name: results_doc; Type: TABLE DATA; Schema: clean; Owner: postgres
--

COPY results_doc (id, title, type, structured_data, document_id, link, free_text, authors, source) FROM stdin;
\.


--
-- Name: results_doc_id_seq; Type: SEQUENCE SET; Schema: clean; Owner: postgres
--

SELECT pg_catalog.setval('results_doc_id_seq', 1, false);


--
-- Data for Name: source; Type: TABLE DATA; Schema: clean; Owner: postgres
--

COPY source (id, title, descrition, category, cochrane) FROM stdin;
\.


--
-- Name: source_id_seq; Type: SEQUENCE SET; Schema: clean; Owner: postgres
--

SELECT pg_catalog.setval('source_id_seq', 1, false);


--
-- Data for Name: trial; Type: TABLE DATA; Schema: clean; Owner: postgres
--

COPY trial (id, public_title, scientific_title, condition_or_problem, source_of_funding, countries, contacts, date_from, date_to, notes, exclusion_criteria, sample_size, age_from, age_to, sex, interventions, outcomes) FROM stdin;
138	Link 1994	\N	seroquel versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	201	\N	\N	\N	\N	\N
139	Arvanitis 1994	\N	seroquel (Quetiapine furmate) versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	286	\N	\N	\N	\N	\N
140	Aaes-Jorgensen 1981a	\N	cis(Z) + trans(E)-clopenthixol versus cis(Z)-clopenthixol	\N	Denmark	Other Europe	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
142	Aaes-Jorgensen 1981	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
143	Abenson 1964	\N	Methedrine + sodium amytal; Trifluoperazine + methadrine versus Methedrine; sodium amytal; Trifluoperazine versus Placebo//	\N	United Kingdom	\N	\N	\N	Note by Claire: Not Comparing Trifluoperazine	\N	Unclear	\N	\N	\N	\N	\N
144	Aberg 1995	\N	intensive case management versus standard care	\N	Sweden	Department of Psychiatry, Karolinska Institute, St. Goran's Hospital, Stockholm, Sweden.	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
145	Abraham 1987	\N	trifluoperazine + electoconvulsive therapy versus trifluoperazine + Placebo Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	India	Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
146	Abrams 1958	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
147	Abrams 1967	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus control group	\N	United States of America	NY Medical College, Flower and Fifth Avenue Hospitals, NY 10029, USA.	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
149	Abuzzahab 1982	\N	Haloperidol versus thiothixene	\N	United States of America	Clinical Psychopharmacology Consultants, Minneapolis, MN ORIGIN USA	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
150	Abuzzahab 1980	\N	pimozide versus fluphenazine	\N	United States of America	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
151	Acker 1965	\N	phenothiazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
152	Adamson 1970	\N	Mandrax: methaqualone + diphenhydramine versus chloral hydrate	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
153	Adamson 1973	\N	fluphenazine decanoate versus Chlorpromazine	\N	United Kingdom	UK	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
154	Addington 1996	\N	Risperidone versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
155	Adler 1992b	\N	nicotine versus Placebo	\N	United States of America	U Colorado Health Sciences Ctr, Dept of Psychiatry, Denver, US ORIGIN USA	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
156	Adler 1985	\N	propranolol versus lorazepam	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
157	Adler 1988	\N	ICI (B2 antagonist) versus Placebo	\N	Canada//United States of America	Veterans Administration Medical Ctr, Psychiatry Service, New York, NY, US ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
158	Adler 1990	\N	metoprolol versus propranolol	\N	United States of America	Psychiatry Service Medical Center, New York, NY 10010. ORIGIN USA	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
160	Adler 1993	\N	propranolol versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
162	Affleck 1969	\N	penicillamine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
163	Agarwal 1985	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus Chlorpromazine	\N	India	K. G. Medical Coll, Lucknow, India	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
164	Agelink 1997a	\N	Clozapine versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
165	Agrup 1974	\N	flupenthixol decanoate versus Placebo	\N	Sweden	ORIGIN Other Europe	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
166	Aguilar 1994	\N	Biperiden versus Placebo	\N	Spain	Seccion de Psiquiatria, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain. ORIGIN Other Europe	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
168	Ahlfors 1971	\N	fluphenazine enanthate versus pipothiazine undecylenate	\N	Finland	Hesperia Hosp., Helsinki, Finland ORIGIN Other Europe	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
169	Ahlfors 1973	\N	pipotiazine undecylenate versus fluphenazine enanthate	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
170	Ahlfors 1980	\N	clopenthizol decanoate versus perphenazine enanthate	\N	Finland	ORIGIN Other Europe	\N	\N	\N	\N	172	\N	\N	\N	\N	\N
171	Ahlfors 1990	\N	remoxipride versus Haloperidol	\N	Finland	Hesperia Hosp, Helsinki, Finland ORIGIN Other Europe	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
172	Ahmed 1997	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
173	Abraham 1997	\N	Clozapine versus Placebo	\N	United States of America	Allegheny U/Norristown State Hosp Clinical Research Ctr, PA, USA.	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
174	Abse 1960	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
176	Akhtar 1993	\N	vitamin E versus Placebo	\N	India	Central Institute of Psychiatry, Ranchi, Bihar. ORIGIN Mid E./Asia	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
177	Akimoto 1966	\N	Chlorpromazine versus Placebo // Prochlorperazine versus Placebo // Perphenazine versus Placebo // Levomepromazine versus Placebo	\N	Japan	ORIGIN Mid E./Asia	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
178	Akiyama 1983	\N	oxypertine versus Placebo	\N	Japan	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
179	Albert 1980	\N	pipotiazine palmitate versus fluphenazine enanthate	\N	Canada	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
180	Alexander 1993	\N	remoxipride versus once or twice daily	\N	United Kingdom	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
181	Alexander 1979 a	\N	pimozide versus drug-free control group	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
182	Alexander 1991	\N	demeclocycline versus Placebo	\N	United States of America	Thomas Jefferson University Hosp, Philadelphia, PA, US ORIGIN USA	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
185	Allen 1974	\N	interpersonal censure versus neutral	\N	United States of America	U. Delaware ORIGIN USA	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
186	Alpert 1990	\N	nadolol versus Placebo	\N	United States of America	Department of Psychiatry, New York University Medical Center, NY 10016. ORIGIN USA\r\n\r\nORIGIN USA	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
187	Alpert 1978	\N	Chlorpromazine versus l-dopa	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
188	Alpert 1966	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
189	Altamura 1985	\N	fluphenazine enanthate + intramuscular injections versus fluphenazine decanoate + intramuscular injections	\N	Italy	ORIGIN Other Europe	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
190	Altamura 1987	\N	clonazepam versus Haloperidol	\N	Italy	Policlinico-Guardia II, Milan, Italy ORIGIN Other Europe	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
191	Altman 1973 a	\N	 CSG No: 0540 	\N	United States of America	U. Missouri, Medical School, St. Louis ORIGIN USA	\N	\N	\N	\N	151	\N	\N	\N	\N	\N
192	Altman 1973 b	\N	 CSG No: 0632 	\N	United States of America	U. Missouri, Medical School, St. Louis ORIGIN USA	\N	\N	\N	\N	151	\N	\N	\N	\N	\N
196	Amin 1977 a	\N	benzquinamide versus Chlorpromazine	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
197	Ananth 1987	\N	baclofen versus Placebo	\N	United States of America	U California Los Angeles Medical Ctr-Harbor Campus, Torrance, US ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
198	Ananth 1977 a	\N	propericiazine versus Chlorpromazine	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
199	Ananth 1973	\N	nicotinic acid + pyridoxine versus pyridoxine + Placebo	\N	Canada	McGill U., Montreal, Quebec, Canada ORIGIN Canada	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
200	Ananth 1972 a	\N	nicotine acid versus Placebo	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
201	Andersen 1990	\N	remoxipride versus Haloperidol	\N	Denmark	County Hosp, Vordingborg, Denmark ORIGIN Other Europe	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
202	Andersen 1974	\N	pimozide versus trifluoperazine	\N	Sweden	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
203	Ackner 1957	\N	insulin versus barbiturate	\N	United Kingdom	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
204	Adler 1986	\N	propranolol versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
205	Albus 1984	\N	Chlorpromazine versus Placebo	\N	Germany	ORIGIN Other Europe	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
207	Andreoli 1996	\N	Clozapine versus control group	\N	Switzerland	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
208	Andrews 1976	\N	Chlorpromazine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
209	Angus 1969	\N	trifluoperazine versus SK&F	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
210	Angus 1997	\N	Amantadine versus Placebo	\N	Canada	Dr. J. Sugars, Raymond Care Centre, Box 260, Prov. Mental Health Advisory Board, Raymond, Alta. T0K 2S0 ORIGIN Canada	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
211	Anonymous 1996 c	\N	 CSG No: 1075 	\N	United Kingdom	\N	\N	\N	\N	\N	191	\N	\N	\N	\N	\N
212	Anonymous 1996 a	\N	Amisulpride versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	319	\N	\N	\N	\N	\N
215	Anumonye 1976	\N	pimozide versus Chlorpromazine	\N	Nigeria	Lagos University Teaching Hospital, P.M.B. 12003 Lagos, Nigeria ORIGIN Africa	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
216	Aoba 1995	\N	carteolol versus Placebo	\N	Japan	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
218	Allen 1997	\N	Haloperidol versus drug free	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
219	Alvarez 1997	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
220	Amakusa 1973	\N	 CSG No: 2298 	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
224	Apfeldorf 1960	\N	methoxypromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
225	Appleby 1963	\N	therapy treatment program versus control group	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
226	Apter 1978	\N	individual movement therapy versus control group	\N	United States of America	Children's Hosp National Medical Ctr, Washington, DC ORIGIN Mid E./Asia	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
227	Arato 1997	\N	Ziprasidone versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	294	\N	\N	\N	\N	\N
228	Arato 1980	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus simulated Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	Hungary	ORIGIN Other Europe	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
229	Armstrong 1991	\N	psychoeducation group versus psychotherapeutic group	\N	United States of America	U Washington, US ORIGIN USA	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
231	Ashby 1960	\N	nicotinic acid versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
232	Ashcroft 1961	\N	tetrabenazine versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
234	Athanassenas 1983	\N	pimozide versus loxapine	\N	Greece	ORIGIN Other Europe	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
235	Atkinson 1996	\N	education group versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	146	\N	\N	\N	\N	\N
236	Augustin 1996	\N	Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
237	Awad 1990	\N	remoxipride versus Haloperidol	\N	Canada	Wellesley Hosp, Dept of Psychiatry, Toronto, ON, Canada ORIGIN Canada	\N	\N	\N	\N	148	\N	\N	\N	\N	\N
238	Axelson 1996	\N	Risperidone + psychotropic drugs versus Risperidone	\N	Sweden	\N	\N	\N	\N	\N	147	\N	\N	\N	\N	\N
239	Ayd 1956	\N	Reserpine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
240	Azima 1961 a	\N	amphenidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
241	Azima 1959	\N	Reserpine versus Phenobarbital	\N	Canada	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
242	Azima 1962	\N	G-33040 versus Placebo	\N	Canada	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
243	d'Elia 1974	\N	pimozide versus trifluoperazine	\N	Sweden	ORIGIN Other Europe	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
244	Azima 1961 b	\N	monase versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
245	Azima 1960	\N	Haloperidol versus Placebo	\N	Canada	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
246	Azima 1958	\N	object relations therapy versus control group	\N	Canada	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
247	Azorin 1990	\N	Des-enkephalin-gamma-endorphin versus Placebo	\N	France	Ctr Hospitalier Universitaire Timone, Clinique de Psychiatrie, Marseilles, France ORIGIN Other Europe	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
249	Badgett 1996	\N	Haloperidol versus unchanged dose	\N	United States of America	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
252	Bagadia 1981	\N	Chlorpromazine + simulated Electroconvulsive Therapy versus Electroconvulsive Therapy + Placebo//Chlorpromazine versus Placebo	\N	India	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
253	Bailey 1978	\N	sensory-stimulating activities versus control group	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
254	Baker 1960 a	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) (slow treatment) versus Electro Convulsive Therapy (Electroconvulsive Therapy) (fast treatment)	\N	United Kingdom	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
255	Baker 1958 a	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus largactil	\N	United Kingdom	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
256	Baker 1960 b	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) (slow treatment) versus insulin comas	\N	United Kingdom	\N	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
257	Baker 1958 b	\N	7044 RP versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
258	Baker 1959	\N	Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
259	Baker 1983	\N	Antipsychotic agent versus Placebo	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
261	Bakke 1973	\N	fluphenazine versus perphenazine enathate	\N	Norway	ORIGIN Other Europe	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
262	Barker 1969	\N	pericyazine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
263	Barker 1960	\N	modified electro convulsive therapy (Electroconvulsive Therapy) versus unmodified electro convulsive therapy (Electroconvulsive Therapy)	\N	United Kingdom	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
264	Baker 1961	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
265	Balon 1982	\N	fluphenazine decanoate versus hydroxyprotepine decanoate	\N	Russian Federation	ORIGIN Other Europe	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
268	Ban 1975 b	\N	nicotinic acid versus Placebo	\N	Canada	McGill U, Montreal, Canada ORIGIN Canada	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
269	Ban 1977	\N	Chlorpromazine + megavitamins versus Chlorpromazine + Placebo//Chlorpromazine versus megavitamins//megavitamins versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	Vanderbilt U ORIGIN USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
270	Ban 1975 c	\N	thiothixene versus various dosages	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
271	Ban 1975 a	\N	thiothixene versus various dosages	\N	Unclear	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
273	Bandelow 1992	\N	intermittent neruoleptic treatment + early intervention versus continuous neruoleptic treatment	\N	Germany	Germany	\N	\N	\N	\N	364	\N	\N	\N	\N	\N
274	Bankier 1973	\N	fluspirilene versus Placebo//Trifluoperazine versus Placebo//Trifluoperazine versus fluspirilene	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
275	Bao 1988	\N	Clozapine versus Chlorpromazine	\N	China	ORIGIN Mid E./Asia	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
276	Barch 1997	\N	D-amphetamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
278	Barnes 1983	\N	pimozide versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
279	Baro 1970	\N	R 16 341 versus Placebo	\N	Belgium	ORIGIN Other Europe	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
280	Barron 1962	\N	mds 92 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21016	李晶 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
281	Barron 1961	\N	taractan versus Placebo//Trifluoperazine versus Placebo//Trifluoperazine versus taractan	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
282	Barsa 1964	\N	chlorprothixene versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
283	Bartko 1988	\N	Chlorpromazine versus Placebo	\N	Hungary	National Inst for Nervous & Mental Diseases, Budapest, Hungary ORIGIN Other Europe	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
284	Barbee 1992	\N	alprazolam + Haloperidol versus Haloperidol + Placebo//Alprazolam versus Haloperidol//Haloperidol versus Placebo//Alprazolam versus Placebo	\N	United States of America	Department of Psychiatry, School of Medicine, Louisiana State University, New Orleans 70112. ORIGIN USA	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
285	Barron 1964	\N	nortriptyline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
286	Barron 1963	\N	carphenazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
287	Bastecky 1979	\N	clorotepin versus Placebo	\N	Czech Republic	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
288	Bateman 1979	\N	metoclopramide versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
289	Bechelli 1986	\N	Haloperidol versus Pipothiazine Palmitate	\N	Brazil	Psychiatric Hosp of Ribeirao Preto, BrazilORIGIN South/Central America	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
290	Bechelli 1983	\N	pipotiazine versus Placebo	\N	Brazil	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
291	Becker 1969	\N	rehabilitation program (high-staff-patient condition) versus rehabilitation program (low-staff-patient condition)	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
293	Bedell 1989	\N	intensive community-based treatment versus state hospitalization	\N	United States of America	Yeshiva U, Albert Einstein Coll of Medicine, NY, US ORIGIN USA	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
294	Beech 1990	\N	Chlorpromazine versus Placebo	\N	United Kingdom	U Oxford, England ORIGIN UK	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
297	Benkert 1996 b	\N	Amisulpride + Haloperidol versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
298	Bennett 1956	\N	Chlorpromazine versus Reserpine	\N	United States of America	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
299	Bennett 1961	\N	Chlorpromazine versus mepazine versus perphenazine versus prochlorperazine versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
300	Bennie 1982	\N	 CSG No: 0020 	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
301	Berger 1982	\N	naloxone versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
302	Berger 1980	\N	B-endorphin versus saline	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
303	de Beaurepaire 1993	\N	Bromocriptine versus control group	\N	France	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
304	Berger 1983	\N	 CSG No: 0600 	\N	United States of America	Stanford U School of Medicine, VA Mental Health Clinical Research Ctr ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
306	Berger 1981	\N	naloxone versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
307	Bergling 1975	\N	thiothixine versus thioridazine	\N	Sweden	U Umea, Umea & Umedal Psychiatric Hosp, Sweden ORIGIN Other Europe	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
308	Berman 1995 a	\N	clomipramine versus Placebo	\N	United States of America	Commonwealth Research Center, Massachusetts Mental Health Center, Harvard Medical School, Department of Psychiatry, Boston, USA. ORIGIN USA	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
309	Bernstein 1985	\N	press group versus non press groups	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	127	\N	\N	\N	\N	\N
310	Bersani 1990	\N	ritanserin versus Placebo	\N	Italy	U Rome, Italy ORIGIN Other Europe	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
311	Biederman 1979	\N	lithium carbonate + Haloperidol versus Placebo + Haloperidol	\N	Israel	ORIGIN Mid E./Asia	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
312	Bigelow 1991	\N	case management training versus control group	\N	Canada	Ministry of Health Policy, Planning and Legislating Division, Victoria, B.C., Canada. ORIGIN Canada	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
313	Bigelow 1974	\N	aqueous pineal extract versus Placebo	\N	United States of America	St Elizabeths Hosp., Lab. of Clinical Psychopharmacology, Washington, D.C. ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
314	Bigelow 1975	\N	thyrotropin-releasing hormone versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	3	\N	\N	\N	\N	\N
316	Binder 1981	\N	molindone versus Haloperidol	\N	United States of America	U California, San Francisco ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
317	Birchwood 1992	\N	receiving education in a group versus receiving education in a video	\N	United Kingdom	Psychology Department, All Saints Hospital, Winson Green, Birmingham. ORIGIN UK	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
318	Bishop 1963 b	\N	skf-7261 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
319	Bishop 1966 a	\N	thiothixene versus trifluoperazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
320	Bishop 1963 c	\N	benzquinamide versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
322	Bitter 1989	\N	Haloperidol plasma dose	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
12314	Kabes 1984 a	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
323	Leon 1996	\N	treatment adherence group versus control group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
324	Bilder 1992	\N	methylphenidate versus Placebo	\N	United States of America	Long Island Jewish Medical Ctr-Hillside Hosp, Glen Oaks, NY, US ORIGIN USA	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
325	Bjerkenstedt 1989	\N	melperone versus thiothixene	\N	Sweden	Department of Psychiatry, Danderyds Hospital, Sweden. ORIGIN Other Europe	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
326	Bjorndal 1980 a	\N	Haloperidol dose	\N	Denmark	Sct Hans Mental Hosp, Roskilde, Denmark ORIGIN Other Europe	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
327	Blaha 1980	\N	 CSG No: 1952 	\N	Germany	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
329	Boardman 1959	\N	orphenadrine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
330	Bobruff 1981	\N	clonazepam versus phenobarbital	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
331	Bockenheimer 1976	\N	 CSG No: 1963 	\N	Germany	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
332	Bogoch 1957	\N	supplemented diet versus deficient diet	\N	Canada	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
333	Boling 1957	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
334	Bond 1991 b	\N	assertive community treatment versus control group for serious mental illness whose current state is partial remission and whose stage of illness is persistent // chronic	\N	United States of America	Indiana U-Purdue U, Doctoral Program in Rehabilitation Psychology, Indianapolis, US ORIGIN USA	\N	\N	\N	\N	146	\N	\N	\N	\N	\N
336	Bond 1990	\N	assertive community treatment versus drop-in center	\N	United States of America	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
337	Bond 1989	\N	assertive case management versus control group	\N	United States of America	Department of Psychology, Indiana University, Purdue University, Indianapolis. ORIGIN USA\r\n\r\nDepartment of Psychology, IUPUI 46223. ORIGIN USA	\N	\N	\N	\N	212	\N	\N	\N	\N	\N
338	Borison 1989	\N	tiospirone versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
339	Bordeleau 1964	\N	Butaperazine versus prochlorperazine	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
340	Borger 1978	\N	fluspirilene versus Placebo	\N	Netherlands	Psychiatric Ctr Bloemendaal, Hague, Netherlands ORIGIN Other Europe	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
342	Borison 1987	\N	molindone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
343	Borovicka 1997	\N	Clozapine + phenylpropanolamine versus Clozapine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
344	Bosio 1990	\N	 CSG No: 570 	\N	Italy	ORIGIN Other Europe	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
345	Bourgeois 1980	\N	 CSG No: 658 	\N	France	Ctr Carreire, Bordeaux, France ORIGIN Other Europe	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
346	Bowes 1956	\N	Chlorpromazine versus Reserpine	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
348	Boyer 1995	\N	Amisulpride versus Placebo // Amisulpride Dosage // Amisulpride versus Fluphenazine // Amisulpride versus Haloperidol	\N	France	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
352	Braden 1982	\N	lithium versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
353	Brambilla 1992	\N	nimodipine versus Placebo	\N	Italy	Ospedale Psichiatrico Pini, Ctr di Psiconeuroendocrinologia, Milan, Italy ORIGIN Other Europe	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
355	Brandrup 1961	\N	Haloperidol versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
356	Brannen 1969	\N	phenothiazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
357	Braus 1996 a	\N	sertindole versus standard care	\N	United States of America	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
358	Brauzer 1970	\N	Chlorpromazine versus mesoridazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
359	Becker 1983	\N	Chlorpromazine + imipramine versus thiothixene + Placebo//Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
360	Brambilla 1987	\N	Chlorpromazine + Haloperidol versus Haloperidol	\N	Italy	Ospedale Psichiatrico Pini, Milano, Italia. ORIGIN Other Europe	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
361	Brambilla 1976	\N	gonadotropin hormone + Chlorpromazine versus various dosages	\N	Italy	ORIGIN Other Europe	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
362	Bratfos 1979	\N	sulpiride versus Chlorpromazine	\N	Norway	ORIGIN Other Europe	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
363	Breier 1993 a	\N	2-deoxy-D-Glucose versus Placebo	\N	United States of America	Department of Psychiatry, University of Maryland School of Medicine, Baltimore. ORIGIN USA	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
364	Breier 1993 b	\N	neuroleptic treatment versus Placebo	\N	United States of America	Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore. ORIGIN USA	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
365	Breier 1987	\N	neuroleptic treatment versus Placebo	\N	United States of America	Section on Clinical Studies, NIMH, Bethesda, Md. ORIGIN USA	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
366	Breier 1988 c	\N	2-deoxy-D-Glucose versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
367	Brems 1989	\N	stress management program versus control group	\N	United States of America	U Alaska, Anchorage, US ORIGIN USA	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
369	Brengelmann 1959	\N	5-hydroxytryptophan versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
370	Bressler 1971	\N	Chlorpromazine versus thiothixene	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
371	Brewer 1972	\N	ketamine versus thiopentone	\N	United Kingdom	South/Central America	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
372	Brewerton 1983	\N	lithium carbonate + L-tryptophan versus lithium + Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
373	Brill 1959	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus sham Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	United States of America	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
374	British 1992	\N	raclopride versus Haloperidol	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
375	Brizer 1985	\N	methadone + neuroleptic treatment versus Placebo	\N	United States of America	Manhattan Psychiatric Ctr, Dunlap 14-A Research Dept, Ward's Island, NY ORIGIN USA	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
377	Brockington 1978 a	\N	lithium versus Chlorpromazine	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
378	Brooker 1992	\N	psychosocial training versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
379	Broadhurst 1958 a	\N	sodium amytal versus dexedrine	\N	United Kingdom	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
380	Brooker 1968	\N	penicillamine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
382	Browne 1988	\N	Haloperidol versus Placebo	\N	United Kingdom	Purdysburn Hosp, Belfast, Northern Ireland ORIGIN UK	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
383	Bruck 1968	\N	Chlorpromazine versus thioridazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
384	Brugmans 1968	\N	pimozide versus Placebo	\N	Belgium	ORIGIN Other Europe	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
385	Bruno 1965	\N	L- dopa versus Haloperidol	\N	Italy	ORIGIN Other Europe	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
386	Bucci 1971	\N	Chlorpromazine + procyclidine versus Chlorpromazine + isocarboxide	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
387	Buchanan 1975	\N	L- dopa versus Placebo	\N	Australia	John Edis Hosp, New Town, Australia ORIGIN Australia/NZ	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
388	Buchanan 1996	\N	Clozapine + fluoxetine versus Clozapine + Placebo	\N	United States of America	Department of Psychiatry, University of Maryland School of Medicine, Baltimore 21228, USA. ORIGIN USA	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
390	Buchsbaum 1992 a	\N	Haloperidol versus Placebo	\N	United States of America	Department of Psychiatry, University of California, Irvine. ORIGIN USA	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
391	Buffa 1974	\N	glaziovine versus diazepam	\N	Italy	Provincial Neuropsychiatric Hosp., Vercelli, Italy ORIGIN Other Europe	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
392	Buffaloe 1961	\N	stelazine + parnate versus stelazine	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
393	Burgoyne 1996	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
394	Burner 1989	\N	progabide versus Placebo	\N	France	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
395	Burnett 1975	\N	thiothixene versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
396	Burns 1996	\N	GP care versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
399	Bush 1990	\N	intensive outreach program versus control group	\N	United States of America	Division of Mental Health and Gerontology, Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA 30322. ORIGIN USA	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
401	Cabrera 1994	\N	IFN alpha-2b versus Placebo	\N	Cuba	Hosp. Provincial "Dr. Gustavo Aldereguia", Avenida 5 de Septiembre. Cienfuegos, Cuba.ORIGIN South/Central America	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
404	Cahan 1960	\N	trifluoperazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
405	Cai 1988	\N	l-stepholidine versus Placebo	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
406	Caine 1979	\N	Clozapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
407	Callahan 1975	\N	phenothiazine (multiple dosage) versus phenothiazine (single dosage)	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
408	Callen 1982	\N	dialyses versus sham	\N	United States of America	U Oregon Health Sciences Ctr, School of Medicine, Portland ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
409	Calwell 1964	\N	oxypertine versus trifluoperazine	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
410	Campbell 1983	\N	occupational therapy versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
411	Campbell 1972 b	\N	lithium versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
412	Campbell 1972 a	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5571	Itoh 1969 b	\N	\N	\N	Japan	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
414	Caradoc 1986	\N	benztropine mesylate versus Placebo	\N	New Zealand	U Otago Medical School, Dunedin, New Zealand ORIGIN Australia/NZ	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
415	Cardone 1969	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
416	Carey 1956	\N	ritalin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
417	Carman 1981	\N	lithium + neuroleptics versus Placebo + lithium	\N	United States of America	U Alabama Hosp, Birmingham ORIGIN USA	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
418	Carpenter 1992 a	\N	methylphenidate versus Placebo	\N	United States of America	Nathan S. Kline Inst for Psychiatric Research, Orangeburg, NY, US ORIGIN USA	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
419	Carpenter 1983 a	\N	hemodialysis versus sham	\N	United States of America	Maryland Psychiatric Research Ctr, Baltimore ORIGIN USA	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
420	Carpenter 1983 b	\N	psychosocial intervention versus medical model	\N	United States of America	Maryland Psychiatric Research Ctr, Baltimore ORIGIN USA	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
421	Carpenter 1990 a	\N	continuous medication versus targeted medication	\N	United States of America	Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore 21228. ORIGIN USA	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
422	Carpenter 1991 a	\N	carbamazepine versus Placebo	\N	United States of America	Maryland Psychiatric Research Center, Baltimore 21228. ORIGIN USA	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
423	Case 1971	\N	clomacran versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	491	\N	\N	\N	\N	\N
424	Casey 1981	\N	des-tyrosine-endorphin versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
425	Casey 1960 a	\N	promazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	805	\N	\N	\N	\N	\N
426	Casey 1961	\N	Chlorpromazine + imipramine//isocarboxazid//trifluoperazine versus Chlorpromazine + Placebo versus Chlorpromazine + dextro-amphetamine//Chlorpromazine versus dextro-amphetamine//Chlorpromazine versus imipramine//Chlorpromazine versus isocarboxazid//Chlorpromazine versus trifluoperazine//Chlorpromazine versus Placebo//imipramine versus Placebo//isocarboxazid versus Placebo//trifluoperazine versus Placebo//	\N	United States of America	\N	\N	\N	\N	\N	520	\N	\N	\N	\N	\N
427	Casey 1960 b	\N	phenothiazine derivatives versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	640	\N	\N	\N	\N	\N
428	Casley 1986	\N	benzo-pyrone versus Placebo	\N	Australia	U Adelaide, Henry Thomas Lab Microcirculation Research Unit, Australia ORIGIN Australia/NZ	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
429	Casper 1980	\N	Butaperazine Dosage	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
430	Cassady 1992	\N	muscimol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
431	Cassano 1975	\N	sulpiride versus Haloperidol	\N	Italy	ORIGIN Other Europe	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
433	Catapano 1992	\N	Levosulpiride versus Placebo // Levosulpiride Dosage	\N	Italy	ORIGIN Other Europe	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
434	Catapano 1991	\N	 CSG No: 1072 	\N	Italy	U degli Studi, Istituto di Psichiatria, Naples, Italy ORIGIN Other Europe	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
435	Cesarec 1974	\N	fluphenazine versus amphetamine	\N	Sweden	ORIGIN  Sweden	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
436	Ceskova 1993	\N	Risperidone versus Haloperidol	\N	Czech Republic	Psychiatric Department, Masaryk University, Brno, Czech Republic. ORIGIN Other Europe	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
438	Chakos 1995	\N	typical Antipsychotics versus Clozapine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
439	Chang 1989	\N	Haloperidol (10 mg) versus reduced Haloperidol	\N	China	Taipei City Psychiatric Center, Republic of China. ORIGIN Mid E./Asia	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
440	Charalampous 1974	\N	loxapine succinate versus Placebo	\N	United States of America	Baylor Coll of Medicine, Houston, TX ORIGIN USA	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
441	Chaudhry 1997	\N	cyproheptadine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
442	Cheung 1981	\N	 CSG No: 0042 	\N	Hong Kong	ORIGIN China	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
443	Chien 1973	\N	 CSG No: 1276 	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
444	Chien 1978	\N	 CSG No: 1960 	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
445	Chien 1976	\N	 CSG No: 1254 	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
446	Chien 1970	\N	 CSG No: 1779 	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
447	Childers 1962	\N	 CSG No: 1456 	\N	United States of America	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
449	Adler 1994b	\N	vitamin E versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
450	Agnoli 1978	\N	S-Adenosyl-L-Methionine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
452	Andersson 1983	\N	hemodialysis versus sham	\N	Sweden	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
453	Angus 1970	\N	thiothixene versus control group	\N	Denmark	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
454	Aronoff 1970	\N	lithium carbonate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
455	Arvanitis 1995	\N	seroquel (Quetiapine furmate) versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	395	\N	\N	\N	\N	\N
457	Askar 1970	\N	thioridazine versus Placebo	\N	Egypt	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
458	Audini 1994	\N	home based care versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	189	\N	\N	\N	\N	\N
459	Babigian 1991	\N	capitation system versus control group	\N	United States of America	Department of Psychiatry, University of Rochester Medical Center, New York 14642.	\N	\N	\N	\N	1587	\N	\N	\N	\N	\N
460	Bagne 1992	\N	thioridazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
462	Barber 1988	\N	schizophrenic family workshop versus control group	\N	United States of America	\N	\N	\N	\N	\N	637	\N	\N	\N	\N	\N
463	Bartoszyk 1995	\N	EMD 57445 versus Placebo	\N	Germany	Germany	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
464	Blankertz 1996	\N	Omega-3 Fatty Acid versus Placebo	\N	United States of America	Matrix Research Inst, Philadelphia, PA, USA	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
465	Becker 1970	\N	amitryiptyline + perphenazine versus Placebo + perphenazine	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
466	Bender 1997	\N	trimipramine versus phenothiazine	\N	Germany	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
467	Bergheim 1971	\N	thiothixine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
471	Boardman 1956	\N	insulin versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
473	Bondolfi 1995	\N	Risperidone versus Clozapine	\N	Switzerland//France	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
475	Brauzer 1968	\N	thiothixene versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
478	Brown 1983	\N	life skills training versus conventional rehabilitation program	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
479	Bucci 1995	\N	Clozapine versus Placebo	\N	Italy	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
480	Buchanan 1998	\N	Clozapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
481	Buchsbaum 1996	\N	sertindole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
482	Bourdouxhe 1987	\N	zuclopenthixol versus Haloperidol	\N	Belgium	Hopital Sainte-Therese, Montignies-sur-Sambre, Belgium ORIGIN Other Europe	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
483	Chouinard 1986	\N	fluspirliene versus Chlorpromazine	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1723	Malek 1980	\N	hemodialysis versus sham	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
486	Chouinard 1979 a	\N	tryptophan-benserazide versus Chlorpromazine	\N	Canada	McGill U, Allan Memorial Inst, Montreal, Canada ORIGIN Canada	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
487	Chouinard 1994	\N	Risperidone versus Clozapine	\N	Canada	Psychiatric Research Centre, Louis-H. Lafontaine Hospital, University of Montreal, Canada. ORIGIN Canada	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
488	Chouinard 1982 b	\N	pimozide versus Chlorpromazine	\N	Canada	McGill U, Allan Memorial Inst Pharmacology Research Unit, Montreal, Canada ORIGIN Canada	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
489	Chow 1996 a	\N	Clozapine versus Placebo	\N	Canada	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
490	Chow 1996 b	\N	amineptine + treatment as usual versus Placebo + treatment as usual	\N	Hong Kong	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
491	Chowdhury 1980	\N	fluphenazine versus flupenthixol	\N	United Kingdom	New Cross Hosp, Psychiatric Unit, Wolverhampton, England ORIGIN UK	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
492	Citkowitz 1980	\N	paraphrasing versus cues	\N	United States of America	Bronx Psychiatric Ctr, NY ORIGIN USA	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
957	Hitri 1987	\N	Amantadine versus Benztropine // Amantadine versus Trihexyphenidyl // Trihexyphenidyl versus Benztropine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
958	Hoffer 1957	\N	nicotinic acid versus Placebo	\N	Canada	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
959	Hogan 1992	\N	Chlorpromazine versus Haloperidol	\N	Canada	Queen Street Mental Health Centre, Psychology and Biometrics Section, Toronto, Canada. ORIGIN Canada	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
960	Hogarty 1995 a	\N	benztropine mesylate versus glycopyrolate	\N	United States of America	Western Psychiatric Institute and Clinic, University of Pittsburgh, School of Medicine, PA. ORIGIN USA	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
964	Hogarty 1979 a	\N	social therapy + fluphenazine decanoate versus fluphenazine decanoate	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
966	Alexander 1978	\N	pimozide versus drug-free control group	\N	United Kingdom	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
967	Alfredsson 1989	\N	Sulpiride Dosage	\N	Sweden	Department of Psychiatry and Psychology, Karolinska Hospital, Stockholm, Sweden.	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
968	Alpert 1995	\N	remoxipride versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
969	Ananth 1970	\N	 CSG No: 2818 	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
970	Ananth 1972 b	\N	propericiazine versus Chlorpromazine	\N	Canada	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
971	Ananth 1979	\N	 CSG No: 2665 	\N	Canada	McGill U Faculty of Medicine, Montreal, Canada	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
972	Anderson 1976	\N	Haloperidol dose	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
973	Arnold 1956	\N	Reserpine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
974	Bagadia 1980	\N	loxapine versus trifluoperazine	\N	India	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
975	Bankier 1972	\N	mesoridazine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
21017	李明德 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
977	Berman 1995 b	\N	Risperidone + standard care versus Haloperidol + standard care	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
978	Bond 1979	\N	hemodialysis versus sham	\N	Germany	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
979	Borison 1994 a	\N	Risperidone capsule versus Risperidone tablet	\N	United States of America	Department of Psychiatry Medical College of Georgia, Augusta 30912-3800.	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
981	Branchey 1981	\N	neuroleptic decrease versus neuroleptics	\N	United States of America	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
982	Brannen 1981	\N	Bromperidol versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
983	Brauzer 1971	\N	molindone hydrochloride versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
984	Brotman 1969	\N	Butaperazine versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
1626	Liberman 1981	\N	social skills training versus control group // social skills training versus holistic health treatment // holistic program versus social skills training program CSG No: 485	\N	United States of America	ORIGIN USA\r\n\r\nU California, Los Angeles ORIGIN USA	\N	\N	\r\nUser defined field 10\r\n	\N	28	\N	\N	\N	\N	\N
1627	Lichtenberg 1992	\N	fenfluramine versus Placebo	\N	Israel	Department of Research, Ezrath Nashim Hospital, Jerusalem, Israel. ORIGIN Mid E./Asia	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1628	Lieberman 1978	\N	 active learning conditions versus passive learning conditions	\N	Canada	U Montreal, Canada	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
1630	Lieberman 1989	\N	Bromocriptine + Neuroleptic versus Placebo + neuroleptic	\N	United States of America	Hillside Hospital, Division of Long Island Jewish Medical Center, Glen Oaks, NY. ORIGIN USA	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
1631	Lieberman 1984	\N	methylphenidate versus Placebo	\N	United States of America	ORIGIN USA\r\n\r\nHillside Hospital, Long Island Jewish Medical Center, Albert Einstein College of Medicine, Glen Oaks, NY 11004. ORIGIN USA	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
1634	Liebowitz 1976	\N	lithium versus Placebo	\N	United States of America	Yeshiva U, Albert Einstein Coll of Medicine ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1635	Lifschutz 1954	\N	insulin coma therapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	138	\N	\N	\N	\N	\N
1636	Lifshitz 1968	\N	transcranial polarization versus control group	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1637	Ligthart 1956	\N	Ego State Therapy + coramine versus Ego State Therapy + Placebo	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
1638	Lindberg 1981 a	\N	psychotherapy + depot neuroleptics versus depot neruoleptics	\N	Sweden	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
1639	Lindholm 1967	\N	esucos versus Placebo	\N	Sweden	ORIGIN Other Europe	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
1640	Lindstrom 1980	\N	propranolol versus Placebo	\N	Sweden	ORIGIN Other Europe	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1641	Lingjaerde 1982	\N	estazolam versus Placebo	\N	Norway	ORIGIN Other Europe	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
1642	Lingjaerde 1963	\N	nitoman versus Placebo	\N	Germany	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
1643	Linkowski 1979	\N	hemodialysis versus sham	\N	Belgium	ORIGIN Other Europe	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1644	Linn 1979	\N	day care + drugs versus drugs	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	162	\N	\N	\N	\N	\N
1649	Lindstrom 1977	\N	thyrotropin-releasing hormone versus Placebo	\N	Sweden	ORIGIN Other Europe	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1650	Lindstrom 1990	\N	remoxipride versus Haloperidol	\N	Sweden	Psychiatric Research Centre, University of Uppsala, Sweden. ORIGIN Other Europe	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
1651	Lingjaerde 1979	\N	diazepam + neroleptics versus Placebo + neroleptics	\N	Norway	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
1652	Lingl 1964	\N	tranylcypromine + trifluoperazine versus EST	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1653	Linn 1977 a	\N	foster care versus inpatient care	\N	United States of America	VA Hosp, Social Science Research, Miami, FL ORIGIN USA	\N	\N	\N	\N	572	\N	\N	\N	\N	\N
1654	Linn 1977 b	\N	foster care versus inpatient care	\N	United States of America	\N	\N	\N	\N	\N	420	\N	\N	\N	\N	\N
1655	Linn 1985	\N	community nursing homes versus inpatient care	\N	United States of America	\N	\N	\N	\N	\N	403	\N	\N	\N	\N	\N
1656	Linszen 1994	\N	early individual and family intervention versus control group//family intervention	\N	Netherlands	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
1657	Lipinski 1979	\N	naloxone versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
2355	Rogers 1967	\N	therapy versus no therapy	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
1658	Lipton 1988	\N	residential treatment versus standard postischarge care	\N	United States of America	Human Resources Administration, Office of Psychiatry, New York, NY, US ORIGIN USA	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
1659	Litman 1989	\N	caffeine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1661	Litman 1993	\N	idazoxan + fluphenazine versus Placebo + fluphenazine	\N	United States of America	NIMH Experimental Therapeutics Branch, Section on Clinical Studies, Bethesda, MD, US ORIGIN USA	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
1663	Livingston 1968	\N	Antipsychotics versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
21018	李文秀 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
1664	Llorca 1993	\N	Bromocriptine versus cyproheptadine	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1665	Lochner 1963	\N	L-triiodothyironine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1666	Loga 1975	\N	orphenadrine + Chlorpromazine versus phenobarbitone + Chlorpromazine	\N	Yugoslavia	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1667	Lohr 1987	\N	vitamin E versus Placebo	\N	United States of America	San Diego Veterans Administration Medical Ctr, Dept of Psychiatry, La Jolla, CA, US ORIGIN USA	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
1669	Lohr 1996	\N	vitamin E versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
1670	Lomas 1957	\N	pacatal versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1671	Lonowski 1979	\N	deanol versus Placebo	\N	United States of America	Central Louisiana State Hosp, Pineville ORIGIN USA	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
1672	Lonowski 1978	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
1674	Loonen 1992	\N	diltiazem versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
1675	Loprete 1967	\N	etrafon forte versus standard care	\N	United States of America	\N	\N	\N	\N	\N	500	\N	\N	\N	\N	\N
1676	Loranger 1968	\N	neurosterone versus placenbo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1677	Losonczy 1986	\N	apomorphine versus drug free	\N	United States of America	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
1678	Lotstra 1985	\N	check of CCK in CSF by lumbar puncture versus control group	\N	Belgium	Free U of Brussels, Lab of Neuropathology & Neuropeptide Research, Belgium ORIGIN Other Europe	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
1679	Lotstra 1984	\N	caerulein versus Placebo	\N	Belgium	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
1680	Louwerens 1997	\N	Amisulpride versus Haloperidol	\N	Netherlands	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
1681	Louza 1988	\N	Haloperidol dose	\N	Germany	Psychiatric Hospital, University of Munich, Munchen, FRG.	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1682	Lovett 1987	\N	Haloperidol versus Trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
1683	Lowinger 1963	\N	mephenoxalone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
1685	Lucas 1990	\N	caffeine versus Placebo	\N	United States of America	Section of Clinical Studies, National Institute of Mental Health, Bethesda, Maryland 20892. ORIGIN USA	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
1687	Lund 1984	\N	Haloperidol dose	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1688	Lundin 1990	\N	flupenthixol versus fluphenazine decanoate	\N	Sweden	Lanssjukhuset Ryhov, Jonkoping, Sweden\r\n\r\nLillhagens Sjukhus Centrum, Hisings Backa, Sweden	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
1690	Lurie 1992	\N	capitated health care versus traditional fee for service medicaid	\N	United States of America	Division of Health Services Research and Policy, School of Public Health, University of Minnesota, Minneapolis 55455-0392.	\N	\N	\N	\N	739	\N	\N	\N	\N	\N
1691	Lyager 1957 a	\N	Reserpine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
1692	Lyager 1957 b	\N	Reserpine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
1693	Maar 1983	\N	dipotassium clorazepate versus bromazepame	\N	Germany	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
1694	Maas 1993	\N	debrisoquin versus Placebo	\N	United States of America	Department of Psychiatry, University of Texas Health Science Center, San Antonio 78284-7792. ORIGIN USA	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
1695	Martinot 1996 b	\N	benzamide for D2 receptors versus Placebo	\N	France	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1696	Perault 1996	\N	Amisulpride versus Placebo	\N	France	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
1697	Maas 1985	\N	debrisoquin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1698	Maas 1995	\N	clonidine + Haloperidol versus Haloperidol + Placebo	\N	United States of America	Department of Psychiatry, University of Texas Health Science Center at San Antonio 78284-7792, USA.	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1699	MacCarthy 1989	\N	interactive education session versus control group	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	30	\N	\N	\N	\N	\N
1700	MacCrimmon 1978	\N	fluphenazine decanoate versus fluphenazine enanthate	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
1701	Machover 1960	\N	LSD versus no drug	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
1702	Macias 1994	\N	case management + psychosocial rehabilitation versus psychosocial rehabilitation	\N	United States of America	Social Research Inst, Graduate School Social Work Univ Utah, Salt Lake City UT 84112 ORIGIN USA	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
1703	MacKay 1980	\N	lithium versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
1704	MacLeod 1963	\N	thioproperazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
1705	MacPherson 1996	\N	drug educational program versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
1706	Maculans 1964	\N	diazepam versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1707	Madew 1967	\N	therapeutic community program versus control group	\N	Australia//New Zealand	ORIGIN Australia/NZ	\N	\N	\N	\N	111	\N	\N	\N	\N	\N
1708	Madgwick 1958	\N	trifluoperazine versus various dosages	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1709	Maes 1996	\N	m-chlorophenylpiperazine versus Placebo	\N	Belgium	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1710	Magelund 1979 a	\N	a-methyl-p-tyrosine versus Placebo	\N	Denmark	ORIGIN Other Europe	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1711	Magelund 1979 b	\N	metyrosine versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1712	Magnus 1979	\N	fluspirilene versus fluphenazine decanoate	\N	United Kingdom	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
1713	Magnus 1980 a	\N	biperiden hydrochloride versus benzhexol	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1714	Magnusson 1983	\N	hemodialysis versus sham	\N	Sweden	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
1715	Maire 1967	\N	methysergide maleate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
1716	Majewski 1968	\N	 CSG No: 305 	\N	Poland	ORIGIN Other Europe	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1717	Mak 1996 a	\N	family therapy and psychoeducation versus standard care	\N	Hong Kong	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1718	Mak 1996 b	\N	aftercare worker versus control group	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
1719	Makanjuola 1988	\N	Chlorpromazine versus Chlorpromazine sulphoxide	\N	Nigeria	Department of Mental Health, University of Ife, Nigeria. ORIGIN Africa	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
1720	Malamud 1957	\N	rauwolfia derivatives versus Placebos	\N	United States of America	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
1721	Malas 1981	\N	D-L-propranolol versus drug free	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
1722	Malaspina 1994	\N	catecholamine versus Placebo	\N	United States of America	Department of Clinical Psychobiology, New York State Psychiatric Institute, NY 10032. ORIGIN USA	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
2356	Rogers 1993	\N	coached conditions versus uncoached condition	\N	United States of America	Department of Psychology, University of North Texas, Denton 76203-3587. ORIGIN USA	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
2358	Rompel 1978	\N	serenace versus Chlorpromazine	\N	South Africa	ORIGIN Africa	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
2359	Ropert 1988	\N	 CSG No: 3054 	\N	France	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
2360	Ropert 1989	\N	sultopride versus Haloperidol	\N	France	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
2361	Rossi 1992	\N	Bromperidol versus Haloperidol	\N	Italy	ORIGIN Other Europe	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2363	Rosen 1972	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	149	\N	\N	\N	\N	\N
2364	Rosenbaum 1959	\N	sernyl versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
2365	Rosenheck 1997	\N	Clozapine versus Haloperidol	\N	United States of America	Veterans Affairs Connecticut Healthcare System, West Haven 06516, USA.	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
2368	Rosenthal 1997	\N	integrated treatment versus control group	\N	United States of America	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
2369	Rosini 1989	\N	 CSG No: 3039 	\N	Italy	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2370	Rosner 1957	\N	Azacyclonol versus meratran	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
2371	Rosner 1955	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	115	\N	\N	\N	\N	\N
2372	Ross 1970	\N	hydroxyzine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
2373	Rosse 1996	\N	D-cycloserine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
2375	Roubicek 1977	\N	Clozapine versus various dosages	\N	Switzerland	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
2376	Roxburgh 1970	\N	thipropazate dihydrochloride versus Placebo	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	2	\N	\N	\N	\N	\N
2377	Royer 1973	\N	stimulus sets versus information processing models	\N	United States of America	Veterans Administration Hosp., Brecksville, O. ORIGIN USA	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
2379	Ruiz 1976	\N	thiothixene versus Chlorpromazine	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2380	Ruiz 1974	\N	cozapine versus Chlorpromazine	\N	Spain	Escuela Profesional de Psiquiatria de la Facultad de Medicina, Barcelona, Spain. ORIGIN Other Europe	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2381	Ruiz 1975	\N	pimocide versus Placebo	\N	Spain	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2382	Rund 1998	\N	cognitive training program versus control group	\N	Norway	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2383	Ruphan 1991	\N	day care versus control group	\N	Netherlands	Rijksuniversiteit te Groningen, Netherlands	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
2384	Ruskin 1979	\N	Benzodiazepine versus Placebo	\N	Israel	ORIGIN Mid E./Asia	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
2385	Ruskin 1991	\N	Haloperidol versus Placebo	\N	United States of America	Veterans Administration Medical Ctr, Dept of Psychiatry, Baltimore, MD, US ORIGIN USA	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
21019	李忠英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	151	\N	\N	\N	\N	\N
2386	Russell 1982	\N	fluspirilene versus fluphenazine decanoate	\N	Canada	U Western Ontario, London Psychiatric Hosp, Canada ORIGIN Canada	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
2387	Rust 1984	\N	tiapride versus Placebo	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
2388	Rysanek 1986	\N	clorotepin versus ozyprotepin	\N	Czech Republic	Purkyne U Psychiatric Clinic, Brno, Czechoslovakia ORIGIN Other Europe	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
2389	Rzewuska 1995	\N	diltiazem versus Placebo	\N	Poland	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
2390	Sachdev 1993 a	\N	benztropine versus Placebo	\N	Australia	Neuropsychiatric Inst, Matraville, NSW, Australia ORIGIN Australia/NZ	\N	\N	\N	\N	5 6	\N	\N	\N	\N	\N
2391	Sachdev 1993 b	\N	apomorphine versus Placebo	\N	Australia	Prince Henry Hosp, Neuropsychiatric Inst, Sydney, NSW, Australia ORIGIN Australia/NZ	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
2393	Sackler 1951	\N	sex steroid therapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2394	Sacks 1988	\N	acetazolamide + thiamine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2395	Sacks 1989	\N	acetazolamide + thiamine versus Placebo	\N	United States of America	Nathan S. Kline Inst for Psychiatric Research, Cerebral Metabolism Lab, Orangeburg, NY, US ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2396	Sajadi 1984	\N	thioridazine versus Haloperidol	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2398	Saletu 1987	\N	zotepine versus Placebo	\N	Austria	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
2399	Saletu 1994	\N	Amisulpride versus fluphenazine	\N	Austria	Department of Psychiatry, School of Medicine, University of Vienna, Austria. ORIGIN Other Europe	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2400	Saletu 1972	\N	chlordiazepoxide versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2401	Salokangas 1996 a	\N	citalopram versus Placebo	\N	Finland	Department of Psychiatry, Turku University Central Hospital, Finland.\r\n\r\nDepartment of Pharmacology and Clinical Pharmacology, University of Turku, Finland.	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
2402	Saletu 1986	\N	Fluperlapine versus Haloperidol	\N	Austria	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2403	Salisbury 1957	\N	ritalin versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
2404	Salokangas 1996 b	\N	neuroleptics versus Placebo	\N	Finland	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
493	Claghorn 1970 a	\N	oxypertine versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
494	Clark 1968 a	\N	trifluperidol versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
495	Clark 1977 a	\N	butaclamol versus Placebo	\N	United States of America	Central State Griffin Memorial Hosp, Norman, OK ORIGIN USA	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
496	Clark 1972	\N	loxapine succinate versus Placebo	\N	United States of America	U. Oklahoma, Health Sciences Center ORIGIN USA	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
497	Classen 1989 a	\N	remoxipride versus Haloperidol	\N	Germany	Department of Psychiatry, University of Wurzburg, FRG. ORIGIN Other Europe	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
498	Claveria 1975	\N	pimozide versus Antipsychotics	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
499	de Cangas 1994	\N	 CSG No: 1504 	\N	Canada	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
500	Harper 1976	\N	Chlorpromazine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
501	Markowe 1967	\N	insulin versus Chlorpromazine	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
503	Claffey 1962	\N	carphenazine versus piperacetazine	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
504	Claghorn 1983	\N	Clozapine versus Haloperidol	\N	United States of America	University of Texas Health Science Center, Houston. ORIGIN USA	\N	\N	\N	\N	151	\N	\N	\N	\N	\N
505	Claghorn 1972	\N	thioridazine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
507	Claghorn 1974 a	\N	pimozide versus trifluoperazine	\N	United States of America	Texas Research Inst of Mental Sciences, Houston ORIGIN USA	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
508	Claghorn 1974 b	\N	group therapy + thiothixene versus "thiothixene, Chlorpromazine"	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
509	Claghorn 1979	\N	penfluridol versus Chlorpromazine	\N	United States of America	Texas Research Inst of Mental Sciences, Houston ORIGIN USA	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
510	Claghorn 1967 a	\N	 CSG No: 1675 	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
511	Claghorn 1967 c	\N	imipramine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
512	Clark 1973 a	\N	pineal extract versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
513	Clark 1975 a	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
514	Clark 1975 b	\N	synthetic thyroid versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
515	Clark 1975 c	\N	loxapine succinate versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
1182	Chouinard 1970	\N	pimozide versus fluphenazine	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
517	Clausen 1973	\N	amphetamine versus Placebo	\N	United States of America	State U. New York, Upstate Medical Center, Syracuse ORIGIN USA	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
518	Cocito 1970	\N	deydrobenzperidol versus Haloperidol	\N	Italy	ORIGIN Other Europe	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
519	Coffman 1987	\N	rapid parenteral injections of fluphenazine versus Placebo	\N	United States of America	Ohio State U, Columbus, US ORIGIN USA	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
520	Cohen 1980	\N	Haloperidol versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
521	Cohen 1987 c	\N	piquindone versus Placebo	\N	United States of America	Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, California. ORIGIN USA	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
522	Cohen 1985 a	\N	ceruletide versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
523	Cohen 1985 b	\N	depot fluphenazine versus fluphenazine enanthate	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
525	Cohen 1987 a	\N	hydergine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
526	Cohler 1966	\N	atropin sulfate + phenobarbital versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
527	Cole 1994	\N	capitated funding program versus control group	\N	United States of America	\N	\N	\N	\N	\N	422	\N	\N	\N	\N	\N
528	Collard 1958	\N	acepromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
529	Collins 1967	\N	amitriptyline + perphenazine versus perphenazine + Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
530	Collins 1996	\N	Cognitive Behavioral Intervention (Sex, Games, and Videotapes) versus Control Group	\N	United States of America	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
531	Collins 1991	\N	lithium carbonate + neuroleptics versus neuroleptics	\N	United Kingdom	Prestwich Hospital, Manchester, Notts, United Kingdom. ORIGIN UK	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
535	Condray 1997	\N	Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
536	Condray 1995	\N	Haloperidol versus Placebo	\N	United States of America	Highland Drive VA Medical Center, University of Pittsburgh School of Medicine, PA 15206, USA. ORIGIN USA	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
537	Conley 1994 a	\N	remoxipride versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
538	Conley 1994 b	\N	remoxipride versus Haloperidol	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
539	Conte 1997	\N	clonidine versus paroxetine	\N	Italy	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
540	Contreras 1988	\N	apomorphine versus Placebo	\N	United States of America	Audie L. Murphy Memorial Veterans Hosp, Psychiatry Service, San Antonio, TX, US ORIGIN USA	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
543	Cookson 1983	\N	fluphenthixol decanoate dose	\N	United Kingdom	Royal Liverpool Hosp, England ORIGIN UK	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
544	Cooper 1997	\N	zotepine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	121	\N	\N	\N	\N	\N
545	Copas 1977	\N	hostel ward versus general ward	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
547	Coryell 1990	\N	Haloperidol versus medium plasma level group	\N	United States of America	U Iowa Coll of Medicine, Psychiatric Hosp, Iowa City, US ORIGIN USA	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
548	Cotes 1978	\N	flupenthixol versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
549	Cowden 1956 a	\N	Chlorpromazine + group therapy versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
551	Craig 1971	\N	competitive groups (alone and paired ) versus noncompetitive groups (alone and paired )	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
552	Crane 1970	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	175	\N	\N	\N	\N	\N
553	Little 1958	\N	Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	142	\N	\N	\N	\N	\N
554	Crawford 1974	\N	depot fluphenazine versus stelazine	\N	Australia	ORIGIN Australia/NZ	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
557	Creed 1990	\N	day hospital care versus inpatient care	\N	United Kingdom	\N	\N	\N	\N	\N	172	\N	\N	\N	\N	\N
559	Cronholm 1961	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus control group	\N	Sweden	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
560	Crowley 1981	\N	thiothixene versus thioridazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
561	Csernansky 1994	\N	reclopride versus Haloperidol	\N	United States of America	Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110. ORIGIN USA	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
563	Csernansky 1988	\N	alprazolam versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
564	Curry 1972	\N	Chlorpromazine versus fluphenazine decanoate	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
565	Curson 1985	\N	fluphenazine decanoate versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
566	Curson 1986	\N	fluphenazine decanoate versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
12315	Ax 1983	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
567	Curtis 1992	\N	case management versus standard aftercare	\N	United States of America	\N	\N	\N	\N	\N	435	\N	\N	\N	\N	\N
568	Cutler 1997	\N	MDL versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
569	Cutler 1984	\N	Bromocriptine versus control group	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
571	Martin 1996	\N	Risperidone versus various doses	\N	United States of America	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
572	Chouinard 1991	\N	zuclopernthixol acetate versus Haloperidol	\N	Canada	Psychiatric Research Centre, Louis-H. Lafontaine Hospital, University of Montreal, Quebec, Canada. ORIGIN Canada	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
574	Burgoyne 1983	\N	telephone prompting versus control group	\N	United States of America	\N	\N	\N	\N	\N	690	\N	\N	\N	\N	\N
575	Busatto 1995	\N	Risperidone versus Antipsychotics	\N	United Kingdom	Department of Psychological Medicine, Institute of Psychiatry, Denmark Hill, London, UK.	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
576	Caffey 1971	\N	antiparkinson medication versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	500	\N	\N	\N	\N	\N
577	Carman 1979	\N	DHT versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
578	Carpenter 1983 c	\N	dialyses versus sham	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
579	Carranza 1971	\N	sulpiride versus Chlorpromazine	\N	Mexico	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
582	Chatterjee 1980	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus sham Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	India	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
585	Carpenter 1986	\N	psychosocial intervention versus medical model	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
586	Arvanitis 1996a	\N	seroquel 75,150,300,600,750 mgs versus Placebo	\N	United States of America // Austria // Canada // New Zealand // United Kingdom	\N	\N	\N	\N	\N	361	\N	\N	\N	\N	\N
587	Chouinard 1975	\N	amitriptyline hydrochloride versus Placebo	\N	Canada	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
589	Clark 1970 b	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
1012	Hu Teh 1991	\N	 CSG No: 1526 	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
590	Clark 1961	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
591	Claus 1992	\N	Risperidone versus Haloperidol	\N	United States of America//France	Department of Radiology, University Hospital Gasthuisberg, Leuven, Belgium. ORIGIN Other Europe	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
593	Conley 1997 a	\N	Olanzapine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
594	Conte 1995	\N	clonidine versus paroxetine	\N	Italy	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
595	Cookson 1987	\N	fluphenthixol decanoate dose	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
596	Cookson 1991	\N	fluphenazine decanoate versus Haloperidol decanoate	\N	United Kingdom	\N	\N	\N	\N	\N	181	\N	\N	\N	\N	\N
597	Cookson 1986	\N	fluphenazine decanoate versus Haloperidol decanoate	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
598	Cooper 1996	\N	zotepine versus Placebo//Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	159	\N	\N	\N	\N	\N
599	Crow 1986	\N	Chlorpromazine versus Placebo // Flupenthixol versus Placebo // Haloperidol versus Placebo // Pimozide versus Placebo // Trifluoperazine versus Placebo	\N	United Kingdom	\N	\N	\N	Note by Claire: Not for in trifluoperazine versus placebo, can’t separate out individual neuroleptics	\N	120	\N	\N	\N	\N	\N
601	Daniel 1989	\N	apomorphine versus Placebo	\N	United States of America	NIMH Neuroscience Ctr, St Elizabeths Hosp, Washington, DC, US ORIGIN USA	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
602	Davidoff 1996	\N	experimental video group versus control group	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
604	d'Elia 1970	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus bilateral stimulation	\N	Sweden	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
605	d'Elia 1977	\N	penfluridol versus thiothixene	\N	Sweden	ORIGIN Other Europe	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
607	Dabiri 1994	\N	vitamin E versus Placebo	\N	United States of America	Department of Psychiatry, San Mateo County Mental Health Services, Calif. ORIGIN USA	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
608	Dalack 1997 c	\N	smoking ad libitum versus no smoking	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
609	Dalack 1996	\N	smoking ad libitum versus no smoking	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
611	Daston 1959	\N	Chlorpromazine versus promazine	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
612	Davies 1973	\N	Chlorpromazine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
613	Davis 1985 a	\N	apomorphine hydrochloride versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
614	de Buck 1973 b	\N	 CSG No: 637 	\N	Belgium	U Brussels Hosp, Inst of Psychiatry, Research Unit of Clinical Psychopharmacology, Belgium ORIGIN Other Europe	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
615	de Cuyper 1985	\N	milenperone versus Placebo	\N	Belgium	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
617	DeCarlo 1985	\N	verbal therapy versus control group	\N	United States of America	State U New York, Buffalo ORIGIN USA	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
618	de Cuyper 1979	\N	clopimozide versus neuroleptics	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
619	Dehing 1968	\N	tegretol versus Placebo	\N	Belgium	ORIGIN Other Europe	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
620	Del Guidice 1975	\N	fluphenazine enanthate versus Placebo	\N	United States of America	U California, Ctr for Health Sciences, Los Angeles ORIGIN USA	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
621	de Montigny 1979	\N	deanol versus Placebo	\N	Canada	Louis-H. Lafontaine Hosp, Inst National de la Recherche Scientifique-Sante, Montreal, Canada ORIGIN Canada	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
623	Delcker 1990	\N	Amisulpride versus Haloperidol	\N	Germany	Germany	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
624	Den Boer 1990 c	\N	remoxipride versus Haloperidol	\N	Canada	University Hospital, Department of Biological Psychiatry, Utrecht, The Netherlands. ORIGIN Other Europe	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
625	Denber 1972	\N	thiothixene versus trifluoperazine	\N	United States of America	Manhattan State Hosp., Ward's Island, N.Y. ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
626	Denber 1957	\N	Chlorpromazine + diethazine versus various dosage combinations	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
628	Dencker 1994	\N	perphenazine decanoate versus Haloperidol decanoate	\N	Sweden	Department of Clinical Neuroscience, University of Goteborg, Sweden. ORIGIN Other Europe	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
629	Dencker 1978	\N	fluphenazine enanthate dose	\N	Sweden	ORIGIN Other Europe	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
630	Dencker 1980	\N	clopenthixol versus flupenthixol	\N	Sweden	ORIGIN Other Europe	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
632	Denijs 1980	\N	Bromperidol versus Haloperidol	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
633	Deo 1990 a	\N	remoxipride versus Haloperidol	\N	United Kingdom	Oldham & District General Hosp, Manchester, England ORIGIN UK	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
634	Deo 1990 b	\N	remoxipride versus Haloperidol	\N	United Kingdom	Oldham and District General Hospital, Lancashire, United Kingdom. ORIGIN UK	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
635	Deutsch 1971	\N	propericiazine versus thioridazine	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
636	Deutsch 1977 a	\N	trazodone versus Chlorpromazine	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
637	Deutsch 1994	\N	L-tyrosine versus Placebo	\N	United States of America	Department of Veterans Affairs Medical Center, Psychiatry Service, Washington, DC 20422. ORIGIN USA	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
638	DeWolfe 1971	\N	prolixin enanthate versus thiorazine-stelazine	\N	United States of America	Veterans Administration Hospital, Downey, Illinois, U.S.A. ORIGIN USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
639	Diamond 1983	\N	phenytoin versus Placebo	\N	United States of America	U Wisconsin Clinical Science Ctr, Madison ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
640	Nicholas 1996 a	\N	bifrontal Electroconvulsive Therapy versus right unilateral Electroconvulsive Therapy	\N	Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
641	Dillenkoffer 1974	\N	thiothixene versus thioridazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
642	DiMascio 1972	\N	thiothixene versus treatment as usual	\N	United States of America	Commonwealth of Massachusetts, Dept. of Mental Health, Boston ORIGIN USA	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
643	Dimond 1979	\N	piracetam versus Placebo	\N	United Kingdom	U Wales, University Coll, Cardiff ORIGIN UK	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
644	Dittrich 1975	\N	trans-tetrahydrocannabinol versus Placebo	\N	Switzerland	ORIGIN Other Europe	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
646	Dobson 1995	\N	social skills training versus social milieu treatment	\N	Canada	University of Calgary, Calgary, Alberta ORIGIN Canada	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
648	Dohan 1963	\N	neomycin therapy versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
649	Dohan 1973	\N	milk and cereal diet versus cereal free diet	\N	United States of America	U. Pennsylvania Hosp., William Pepper Lab. of Clinical Medicine ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
650	Dohan 1969	\N	milk and cereal diet versus cereal free diet	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
652	Dom 1978	\N	oral clopenthixol versus clopenthixol decanoate	\N	Belgium	ORIGIN Other Europe	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
653	Dom 1973	\N	 CSG No: 355 	\N	Belgium	ORIGIN Other Europe	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
656	Dom 1971	\N	dexetimide versus ethybenztropine dexetimide versus Haloperidol	\N	Belgium	ORIGIN Other Europe	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
790	Gallant 1971 a	\N	metiapine versus trifluoperazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
657	Donlon 1973	\N	group theraputic aftercare setting versus individual theraputic aftercare setting	\N	United States of America	Sacramento County Mental Health Services, Calif. ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
658	Donlon 1977	\N	pimozide versus fluphenazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
660	Dixon 1996	\N	assertive community treatment versus standard care	\N	United States of America	\N	\N	\N	\N	\N	123	\N	\N	\N	\N	\N
661	D'Souza 1996 a	\N	D-cycloserine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
662	D'Souza 1997	\N	glycine ketamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
1184	Conti 1984	\N	Biperiden versus Placebo	\N	Italy	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
663	Donlon 1976 a	\N	fluphenazine enanthate versus fluphenazine decanoate	\N	United States of America	U California Medical School, Davis ORIGIN USA	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
664	Donlon 1980	\N	Haloperidol dose	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
665	Donlon 1978 a	\N	fluphenazine dose	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
666	Donlon 1978 b	\N	penfluridol versus Placebo//Trifluoperazine versus Placebo//penfluridol versus Trifluoperazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
667	Doongaji 1973	\N	unilateral Electro Convulsive Therapy (Electroconvulsive Therapy)versus bilateral Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	India	ORIGIN Mid E./Asia	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
668	Doongaji 1989	\N	centbutindole versus trifluoperazine	\N	India	ORIGIN Mid E./Asia	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
669	Doongaji 1988	\N	penfluridol versus fluphenazine decanoate	\N	India	King Edward Memorial Hosp, Dept of Psychiatry, Bombay, India ORIGIN Mid E./Asia	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
670	Dose 1987	\N	carbamazepine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
671	Double 1993	\N	anticholinergic medication versus Placebo	\N	United Kingdom // Canada	\N	\N	\N	\N	\N	yes	\N	\N	\N	\N	\N
672	Dozier 1993	\N	case management versus standard care	\N	United States of America	\N	\N	\N	\N	\N	417	\N	\N	\N	\N	\N
673	Dransfield 1958	\N	prochlorpherazine versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
674	Dransfield 1959	\N	Deserpidine versus Reserpine	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
676	Drummond 1996	\N	ICI 204,636 versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	380	\N	\N	\N	\N	\N
677	Dube 1976	\N	loxapine succinate versus Chlorpromazine	\N	India	ORIGIN Mid E./Asia	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
678	Dube 1981	\N	lithium versus Placebo	\N	India	U Lucknow, King George's Medical Coll, India ORIGIN Mid E./Asia	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
679	Dubin 1985	\N	thiothixene versus Haloperidol	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	159	\N	\N	\N	\N	\N
680	Dubin 1986	\N	thiothixene versus loxapine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
681	Dufresne 1993	\N	thioridazine versus Haloperidol	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
682	Duinkerke 1993	\N	ritanserin + neuroleptic treatment versus Placebo + neuroleptic treatment	\N	Netherlands	St Jans Hospital, Weert, The Netherlands. ORIGIN Other Europe	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
683	Dumon 1992	\N	propranolol versus Placebo	\N	France	ORIGIN Other Europe	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
685	Dye 1996	\N	Clozapine versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
686	Dysken 1979	\N	sodium amobarbital interviewing versus control group	\N	United States of America	Illinois State Psychiatric Inst, Chicago ORIGIN USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
687	Eberhard 1986	\N	flupenthixol decanoate versus Haloperidol	\N	Sweden	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
688	Eccleston 1985	\N	propranolol versus thioridazine	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
689	Edwards 1980	\N	sulpiride versus trifluoperazine	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
690	Efron 1959	\N	group-centered activity program versus individual-centered activity program	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
691	Egan 1992	\N	vitamin E	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
694	Eitan 1992	\N	Chlorpromazine versus Placebo//Thioridazine versus Placebo//Thioridazine versus Chlorpromazine// trifluoperazine versus Placebo//Chlorpromazine versus trifluoperazine//Haloperidol versus Placebo//Haloperidol versus Chlorpromazine	\N	Israel	Shalvatah Mental Health Center, Hod-Hasharon, Israel. ORIGIN Mid E./Asia	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
696	Ekdawi 1966	\N	methixene hydrochloride versus orphenadrine	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
697	Eklund 1991	\N	Haloperidol decanoate versus Placebo	\N	Sweden	Department of Psychiatry, Sater Hospital, Sweden. ORIGIN Other Europe	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
698	El Islam 1970	\N	unilateral Electro Convulsive Therapy (Electroconvulsive Therapy) + trifluoperazine versus trifluoperazine	\N	Egypt	ORIGIN Mid E./Asia	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
699	Elkashef 1990	\N	vitamin E versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
700	Valencia 1996	\N	critical time intervention (CTI) versus standard care// Intensive case management//Life skills//Supported housing	\N	United States of America	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
702	El Yousef 1974	\N	Butaperazine versus conjugated estrogens	\N	United States of America	Vanderbilt U ORIGIN USA	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
703	Elkes 1954	\N	Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
704	Elliott 1979	\N	earning and spending tokens- token economy ward versus no tokens	\N	United Kingdom	St Crispin Hosp Area Dept of Clinical Psychology, Duston, England ORIGIN UK	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
705	Elman 1997	\N	Clozapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
706	Emrich 1982	\N	DTyE versus Placebo	\N	Germany	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
707	Emrich 1980 a	\N	DTyE versus Placebo	\N	Germany	ORIGIN Other Europe	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
708	Endicott 1963	\N	psychotherapy group versus control group	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
709	Engelhardt 1973	\N	fluphenazine versus Haloperidol	\N	United States of America	State U. New York, Downstate Medical Center, Brooklyn ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
710	Enoch 1960	\N	prochlorperazine versus Placebo//Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
712	Escobar 1983	\N	fluphenazine hydrochloride versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
713	Escobar 1985	\N	molindone versus Haloperidol	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
714	Essock 1995	\N	assertive community treatment versus control group	\N	United States of America	Connecticut Department of Mental Health, Hartford 06106, USA. ORIGIN USA	\N	\N	\N	\N	262	\N	\N	\N	\N	\N
715	Estrella 1996	\N	Risperidone versus Clozapine	\N	Mexico	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
716	Evans 1972	\N	penothiazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
717	Fabre 1995	\N	ICI 204,636 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
718	Fagan 1991	\N	remoxipride versus Placebo	\N	United Kingdom	Astra Clinical Research Unit, Edinburgh, UK. ORIGIN UK	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
719	Faltus 1974	\N	fluphenazine versus neuroleptic treatment	\N	Czech Republic	ORIGIN Other Europe	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
720	Wehnert 1997 a	\N	 CSG No: 2002 	\N	Austria	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
721	Fan 1994	\N	locked-ward treatment versus open-ward treatment	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
722	Faraone 1989	\N	neuroleptic decrease versus neuroleptics	\N	United States of America	Veterans Administration Medical Ctr, Psychiatry Service, Brockton, MA, US ORIGIN USA	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
723	Farde 1989	\N	raclopride versus 1-16 mgs	\N	Sweden	Department of Psychiatry and Psychology, Karolinska Hospital, Stockholm, Sweden. ORIGIN Other Europe	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
725	Fay 1997 a	\N	nifedipine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
726	Fay 1997 b	\N	nifedipine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
727	Fayen 1988	\N	Amantadine versus Trihexyphenidyl	\N	United States of America	Department of Psychiatry, Pritzker School of Medicine, University of Chicago, IL 60637. ORIGIN USA	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
728	Feldman 1956	\N	thorazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
729	Fennig 1987	\N	artane versus Placebo	\N	Israel	ORIGIN Mid E./Asia	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
730	Fensbo 1990	\N	zuclopenthixol acetate + oil solution versus Haloperidol	\N	Denmark	Alborg Psykiatriske Sygehus, Denmark ORIGIN Other Europe\r\n\r\nKAS Nordvang, Glostrup, Denmark. ORIGIN Other Europe	\N	\N	\N	\N	169	\N	\N	\N	\N	\N
731	Fenton 1979	\N	hospital care versus residential care	\N	Canada	\N	\N	\N	\N	\N	162	\N	\N	\N	\N	\N
732	Ferebee 1964	\N	isoniazid versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	25210	\N	\N	\N	\N	\N
733	Ferrari 1997	\N	Risperidone versus conventional neuroleptics	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
734	Ferrero 1987	\N	tryptophan + sodium slicylate versus tryptophan	\N	Switzerland	Institutions Universitaires de Psychiatrie, Service de Psychiatrie II, Geneva, Switzerland ORIGIN Other Europe	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
735	Fink 1958	\N	Chlorpromazine versus insulin coma therapy	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
736	King 1998	\N	seroquel versus various dosages	\N	United Kingdom // Italy // Northern Ireland // Germany	\N	\N	\N	\N	\N	622	\N	\N	\N	\N	\N
737	Fleming 1958 b	\N	cyclizine hydrochloride versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
738	Fleming 1958 a	\N	BW203 versus Placebo//Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
739	Fleming 1959	\N	promazine versus Placebo//Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
740	Fleming 1970	\N	levodopa + fluphenazine + orphenadrine versus fluphenazine + orphenadrine + Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
741	Falloon 1977	\N	social skills training versus control group	\N	United Kingdom	St John's Hosp, Aylesbury, England ORIGIN UK	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
742	Faltus 1976	\N	depot neuroleptics versus peroral neuroleptics	\N	Czech Republic	ORIGIN Mid E./Asia	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
744	Floru 1979	\N	Biperiden versus Placebo // Bupranolol versus Placebo	\N	Germany	ORIGIN Other Europe	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
746	Flynn 1997	\N	Clozapine versus Risperidone	\N	Canada	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
747	Fonagy 1982	\N	punishment versus control group	\N	United Kingdom	U London, University Coll, England ORIGIN UK	\N	\N	\N	\N	3	\N	\N	\N	\N	\N
748	Foote 1958	\N	Chlorpromazine + Reserpine versus Placebo // Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
1956	Merello 1996	\N	L-dopa versus apomorphine	\N	Argentina	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
749	Ford 1994	\N	Antipsychotics versus Placebo	\N	United States of America	Department of Veterans Affairs Medical Center, Palo Alto, CA 94304. ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
750	Ford 1995	\N	case management versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
751	Forrest 1967	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	168	\N	\N	\N	\N	\N
752	Foxx 1985	\N	social skills intervention versus control group	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
753	Frangos 1978	\N	fluspirilene versus fluphenazine decanoate	\N	Greece	ORIGIN Other Europe	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
755	Franklin 1987	\N	case management versus control group	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	417	\N	\N	\N	\N	\N
758	Freeman 1979	\N	treatment monitoring versus control group	\N	United Kingdom	Salford Area Health Authority, Hope Hosp, Manchester, England ORIGIN UK	\N	\N	\N	\N	190	\N	\N	\N	\N	\N
759	Freeman 1962	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
762	Freedman 1958	\N	harmonyl versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
763	Freedman 1961	\N	compazine versus mellaril	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
765	Freedman 1982	\N	clonidine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
766	Freeman 1981	\N	naloxone versus saline	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
767	Freeman 1968	\N	SKF 14336 versus trifluoperazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
768	Freeman 1980 a	\N	ozypertine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
769	Freeman 1973	\N	mesoridazine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
770	Frey 1989	\N	Haloperidol versus Placebo	\N	Germany	Department of Psychology, University of Duisburg, FRG. ORIGIN Other Europe	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
771	Freyan 1959	\N	phenothiazine compounds	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
772	Friedman 1964	\N	psychiatric home treamtent service versus control group	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
773	Friis 1983	\N	Biperiden versus Placebo // Sodium Valproate versus Placebo	\N	Denmark	ORIGIN Other Europe	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
774	Frith 1979	\N	flupenthixol versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
775	Fritze 1988	\N	cognitive training + pharmacotherapy versus pharmacotherapy	\N	Germany	ORIGIN Other Europe	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
776	Fromm 1956	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
777	Fruensgaard 1977	\N	loxapine versus Haloperidol	\N	Denmark	ORIGIN Other Europe	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
778	Fruensgaard 1978 a	\N	loxapine versus perphenazine	\N	Denmark	ORIGIN Other Europe	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
779	Fuentenebro 1989	\N	molindone versus Haloperidol	\N	Spain	U Complutense de Madrid, Spain ORIGIN Other Europe	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
780	Fux 1991	\N	chlorprothixene versus Haloperidol	\N	Israel	Ben Gurion U of the Negev School of Medicine, Beersheva Mental Health Center Div of Psychiatry, Beersheba, Israel ORIGIN Mid E./Asia	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
782	Galbrecht 1968	\N	Chlorpromazine versus thioridazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	310	\N	\N	\N	\N	\N
783	Galderisi 1994	\N	clopenthixol versus Haloperidol	\N	Italy	ORIGIN Other Europe	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
784	Galdi 1988	\N	fluphenazine versus Chlorpromazine	\N	United States of America	Biometric Laboratory, George Washington University, Kensington, Maryland. ORIGIN USA	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
785	Gallant 1968 a	\N	molindone versus trifluoperazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
786	Gallant 1970 a	\N	piperacetazine versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
788	Gallant 1967 a	\N	U-22,394A versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
789	Gallant 1972 b	\N	GP-45795 versus trifluoperazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
791	Gallant 1967 b	\N	BL-KR140 + Chlorpromazine versus Chlorpromazine + Placebo//Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
792	Gallant 1963 c	\N	methysergide versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
793	Gallant 1966	\N	thiothixene versus thioridazine	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
796	Gallant 1964 a	\N	Butaperazine versus Placebo//Trifluoperazine versus Placebo//Trifluoperazine versus butaperazine	\N	United States of America	\N	\N	\N	Note by Claire: Not versus placebo - a withdrawal trial	\N	60	\N	\N	\N	\N	\N
884	Gulmann 1976	\N	penfluridol versus Placebo	\N	Denmark	ORIGIN Other Europe	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
797	Gallant 1964 b	\N	Butaperazine versus Placebo//Trifluoperazine versus Placebo//Trifluoperazine versus butaperazine	\N	United States of America	\N	\N	\N	Note by Claire: Not versus placebo - a withdrawal trial	\N	42	\N	\N	\N	\N	\N
798	Gallant 1973	\N	molindone versus Placebo	\N	United States of America	Tulane U., Medical School ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
799	Gallant 1974	\N	penfluridol versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
800	Gander 1967	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) (indodlon convulsive therapy) versus sham	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
801	Gardner 1955	\N	Chlorpromazine versus Reserpine	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
802	Gardos 1974 a	\N	Chlorpromazine versus continued doctor's choice medication group	\N	United States of America	Boston State Hosp, MA ORIGIN USA	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
804	Gardos 1984	\N	benztropine mesylate IV versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
805	Gardos 1968	\N	trifluoperazine versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
807	Garry 1962 a	\N	SKF 7261 versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
808	Garry 1962 b	\N	Haloperidol versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
809	Garver 1984 a	\N	Haloperidol dose	\N	United States of America	ORIGIN USA\r\n\r\nDepartment of Psychiatry, University of Cincinnati College of Medicine, OH 45267-0559.	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
810	Garza 1989	\N	Haloperidol + phenobarbital sodium versus thiothixene + lorazepam	\N	United States of America	Harris County Psychiatric Center, Houston, TX 77225. ORIGIN USA	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
811	Gattaz 1989	\N	Bromocriptine + Haloperidol versus Haloperidol + Placebo	\N	Germany	Germany	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
812	Gelders 1989	\N	pipamperone versus ritanserin	\N	Netherlands	Clinical R & D Department Psychiatry, Janssen Research Foundation, Beerse. ORIGIN Other Europe	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
813	Gelenberg 1979	\N	Chlorpromazine versus Clozapine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
814	Gendron 1973	\N	AL-1021 versus Chlorpromazine	\N	United States of America	U. Minnesota, Medical School ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
815	George 1981	\N	deanol versus Placebo	\N	Australia	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
816	Georgotas 1981	\N	trebenzomine versus thioridazine	\N	United States of America	New York U Medical Ctr ORIGIN USA	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
818	Gerlach 1974	\N	Clozapine versus Haloperidol	\N	Denmark	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
819	Gerlach 1975 a	\N	penfluridol versus fluphenthixol	\N	Denmark	ORIGIN Other Europe	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
820	Gerlach 1975 b	\N	madopar versus Placebo	\N	Denmark	ORIGIN Other Europe	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
822	Gerlach 1975 c	\N	Clozapine versus Haloperidol	\N	Denmark	Sct Hans Hosp, Roskilde, Denmark ORIGIN Other Europe	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
824	Gerner 1980	\N	B-endorphin versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
825	Gershon 1970 a	\N	Butaperazine versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
827	Gerstenzang 1977	\N	Chlorpromazine versus Haloperidol	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
829	Gibbs 1956	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
830	Gibby 1961	\N	tape + sensory deprivation versus no tape, no deprivation	\N	United States of America	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
831	Gilgash 1957	\N	thorazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
833	Gitlin 1981	\N	naltrexone versus Placebo	\N	United States of America	U California, Los Angeles ORIGIN USA	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
834	Gitlin 1988	\N	fluphenazine decanoate versus Placebo	\N	United States of America	U California Ctr for Health Sciences, Neuropsychiatric Inst, Los Angeles, US ORIGIN USA	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
836	Glazer 1992	\N	fluphenazine decanoate versus Placebo	\N	United States of America	Yale University School of Medicine, New Haven, CT. ORIGIN USA	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
837	Glick 1986	\N	transitional care intervention versus control group	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
838	Glynn 1992	\N	behavioural family management + standard care versus standard care	\N	United States of America	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
839	Godfrey 1990	\N	methylfolate versus Placebo	\N	United Kingdom	Department of Psychiatry, King's College Hospital and Institute of Psychiatry, London, UK. ORIGIN UK	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
840	Godwin 1971	\N	tetrabenazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
841	Goff 1994	\N	trihexyphenidyl versus Placebo	\N	United States of America	Erich Lindemann Mental Health Center, Boston, MA. ORIGIN USA	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
842	Goff 1991	\N	benztropine + Haloperidol versus Placebo + Haloperidol	\N	United States of America	Erich Lindemann Mental Health Center, Boston, Massachusetts 02114. ORIGIN USA	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
20230	朱薇薇 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
843	Goff 1995	\N	fluoxetine versus Haloperidol	\N	United States of America	Freedom Trail Clinic, Boston, MA 02114, USA. ORIGIN USA	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
844	Goff 1996	\N	D-cycloserine + Clozapine versus D-cycloserine + Placebo	\N	United States of America	Psychotic Disorders Program, Massachusetts General Hospital, Boston, USA. goff@psych.mgh.harvard.edu ORIGIN USA	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
845	Goldberg 1972	\N	Acetophenazine versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
846	Goldberg 1967	\N	Acetophenazine versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
847	Goldberg 1987	\N	incremental card sorting groups versus control group	\N	United States of America	Clinical Brain Disorders Branch, National Institute of Mental Health, St. Elizabeths Hospital, Washington, DC 20032. ORIGIN USA	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
848	Goldstein 1978	\N	fluphenazine enanthate + crisis-oriented family therapy versus fluphenazine control	\N	United States of America	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
849	Goller 1960	\N	Reserpine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
850	Guimon 1993	\N	group meetings versus control group	\N	Spain	U Bilbao Medical School, Spain ORIGIN Other Europe	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
851	Gold 1990	\N	Haloperidol dose	\N	United States of America	New York Hospital, Cornell Medical Center, Westchester Division. ORIGIN USA	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
852	Goldberg 1970 a	\N	oxypertine versus Chlorpromazine	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
854	Goldstein 1966 a	\N	trifluoperazine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
855	Gonier 1970	\N	thioridazine versus Haloperidol	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
856	Goodall 1988	\N	fluphenazine decanoate versus Placebo	\N	United Kingdom	Academic Unit of Human Psychopharmacology, Medical College, St Bartholomew's Hospital. ORIGIN UK	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
857	Goode 1983	\N	Bupropion + Haloperidol versus Bupropion	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
858	Gore 1957	\N	Reserpine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
859	Gottfries 1970	\N	flupenthixol versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
860	Goulet 1993	\N	 CSG No: 2251 	\N	Canada	Universite de Montreal, Quebec. ORIGIN Canada	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
861	Govorin 1990	\N	thymaline versus psychotropic drugs	\N	Russian Federation	ORIGIN Other Europe	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
862	Gowardman 1973	\N	pimozide versus Haloperidol	\N	Australia//New Zealand	ORIGIN Australia/NZ	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
863	Gram 1972	\N	lithium versus Placebo	\N	Denmark	ORIGIN Other Europe	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
864	Granacher 1982	\N	thioridazine versus thiothixene	\N	United States of America	U Kentucky Coll of Medicine, Lexington ORIGIN USA	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
865	Grasby 1993	\N	apomorphine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
866	Gravem 1981 a	\N	cis(Z)-clopenthixol versus clopenthixol	\N	Norway	ORIGIN Other Europe	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
867	Gravem 1978	\N	cis(Z)-clopenthixol versus clopenthixol	\N	Norway	ORIGIN Other Europe	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
869	Green 1987	\N	group art therapy versus control group	\N	United States of America	U Cincinnati, Central Psychiatric Clinic, OH, US ORIGIN USA	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
870	Greil 1984	\N	Biperiden versus Placebo	\N	Germany	ORIGIN Other Europe	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
871	Green 1990	\N	subvocal activity versus control group	\N	United States of America	UCLA Research Center, Camarillo 93011. ORIGIN USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
873	Greenberg 1966	\N	abrupt Chlorpromazine withdrawl versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
874	Greenblatt 1977	\N	Amantadine versus Benztropine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
875	Greenblatt 1962	\N	isocarboxazid versus imipramine	\N	United States of America	\N	\N	\N	\N	\N	151	\N	\N	\N	\N	\N
876	Gross 1960 a	\N	ataractic drug dicontinuation versus control group	\N	United States of America	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
877	Gross 1960 b	\N	ataractic drug dicontinuation versus control group	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
878	Grosser 1970	\N	fluphenazine decanoate versus fluphenazine enanthate	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
879	Grove 1972	\N	benzhexol + fluphenazine enanthate versus fluphenazine enanthate + Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
881	Grygier 1958	\N	Chlorpromazine + intensive occulpational therapy versus intensive occulpational therapy	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
882	Guazzelli 1996	\N	L-sulpiride versus Haloperidol	\N	Italy	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
883	Guirguis 1977	\N	Clozapine versus Chlorpromazine	\N	Canada	Canadian Ministry of Health, Queen Street Mental Health Ctr, Toronto, Canada ORIGIN Canada	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
2853	Verhoeven 1984 a	\N	 CSG No: 2195 	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
885	Gunby 1968	\N	fluphenazine versus Chlorpromazine	\N	Norway	ORIGIN Other Europe	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
886	Gunn 1996	\N	Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
887	Gupta 1995 a	\N	alosetron versus Placebo	\N	United States of America	Department of Clinical Pharmacology, Glaxo Research Institute, Research Triangle Park, North Carolina 27709, USA. ORIGIN USA	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
888	Guz 1972	\N	 CSG No: 562 CSG No: 546	\N	Brazil	U. Sao Paulo, Clinical Hosp., BrazilORIGIN South/Central America\r\n\r\nU Sao Paulo, Faculdade de Medicina, BrazilORIGIN South/Central America	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
890	Rolando 1996	\N	oral Risperidone versus tablets of Risperidone	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
891	Haas 1982 a	\N	diazepam versus naloxone	\N	Germany	Germany	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
892	Haastrup 1973	\N	lithium versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
893	Haddock 1997	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + neuroleptics versus neuroleptics	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
894	Haffmans 1996	\N	Risperidone versus Haloperidol	\N	Netherlands	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
895	Hagger 1997	\N	Ziprasidone versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
896	Haider 1968	\N	fluphenazine versus fluphenazine enanthate	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
898	Hall 1977	\N	token economy program versus control group	\N	United Kingdom	Whitchurch Hosp, Cardiff, Wales ORIGIN UK\r\n\r\nORIGIN UK	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
899	Hall 1968	\N	fluphenazine versus Haloperidol	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
900	Hamann 1982	\N	pimozide versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
901	Hamid 1973	\N	mesoridazine versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
902	Hamill 1975	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
903	Hamilton 1979	\N	fluphenthixol decanoate versus fluphenazine decanoate	\N	United Kingdom	Leeds U, England ORIGIN UK	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
904	Hamilton 1963	\N	prochlorperazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
905	Hamilton 1960	\N	thiopropazate dihydrochloride + occupational therapy versus Placebo + occupational therapy//Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
906	Hamilton 1964	\N	occupational therapy versus industrial workshop therapy	\N	United Kingdom	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
907	Hamilton 1962	\N	occupational therapy versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
908	Hamner 1994	\N	seroquel versus Placebo	\N	United States of America	Ralph H Johnson VA Medical Center, Charleston, USA. ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
909	Hankoff 1960	\N	promazine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	169	\N	\N	\N	\N	\N
911	Hanlon 1975	\N	Flupenazine + chlordiazepoxide versus Flupenazine + imipramine versus Flupenazine + Placebo//Flupenazine versus Placebo//Flupenazine versus chlordiazepoxide// Flupenazine versus imipramine//chlordiazepoxide versus imipramine//chlordiazepoxide versus Placebo//imipramine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	211	\N	\N	\N	\N	\N
912	Hanlon 1965	\N	phenothiazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	327	\N	\N	\N	\N	\N
913	Hannes 1974	\N	recreational therapy versus control group	\N	United States of America	Herbert H. Lehman Coll, City U New York ORIGIN USA	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
914	Hanssen 1978	\N	propranolol versus drug free	\N	Sweden	ORIGIN Other Europe	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
915	Hardwick 1957	\N	steroid versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
916	Hargreaves 1959	\N	Azacyclonol versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
917	Hargreaves 1961	\N	promazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
1011	Hsu 1967	\N	fluphenazine enanthate versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
918	Hargreaves 1972	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) delayed onset versus Electro Convulsive Therapy (Electroconvulsive Therapy) same day onset	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
919	Harnryd 1989	\N	melperone versus Placebo	\N	Sweden	Department of Psychiatry and Psychology, Karolinska Institute, Sweden. ORIGIN Other Europe	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
920	Harrington 1994	\N	non experimental site analysis versus experimental design site analysis	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
921	Harrington 1988	\N	structured respondent interview versus semi-structured investigator interview	\N	United Kingdom	Department of Child and Adolescent Psychiatry, Institute of Psychiatry, London. ORIGIN UK	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
922	Harrison 1984	\N	novel word pairs versus familiar word pairs	\N	United States of America	Boston U ORIGIN USA	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
923	Hartelius 1978	\N	flunitrazepam versus Placebo	\N	Sweden	ORIGIN Other Europe	\N	\N	\N	\N	143	\N	\N	\N	\N	\N
924	Hartley 1978	\N	Chlorpromazine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
925	Hartley 1988	\N	Chlorpromazine versus Placebo	\N	Australia	Murdoch U, WAus, Australia ORIGIN Australia/NZ	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
926	Hartmann 1973 a	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
927	Hartmann 1973 b	\N	amitriptyline versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
928	Hartmann 1973 c	\N	Reserpine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
929	Hartmann 1977	\N	fusaric acid + levodopa versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
930	Harvey 1996	\N	intensive case management versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
931	Hartman 1983	\N	cognitive Behavioural treatment versus psychopharmacological treatment	\N	Canada	Clarke Inst of Psychiatry, Behavior Therapy Unit, Toronto, Canada ORIGIN Canada	\N	\N	\N	\N	3	\N	\N	\N	\N	\N
932	Haslam 1975	\N	flupenthixol decanoate versus fluphenazine decanoate	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
933	Haydu 1965	\N	methonine group versus hydroxychloroquine group	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
934	Haydu 1963	\N	Chlorpromazine versus imipramine	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
935	Hayes 1991	\N	activity therapy versus social skills training	\N	Australia	U Queensland, Brisbane, Australia ORIGIN Australia/NZ	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
936	Hays 1960	\N	hypothermia	\N	United Kingdom	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
937	Heath 1964	\N	Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	United Kingdom	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
938	Hebenstreit 1991	\N	controlled release remoxipride	\N	Austria	NO Landesnervenklinik, Mauer/Amstetten, Austria ORIGIN Other Europe	\N	\N	\N	\N	148	\N	\N	\N	\N	\N
939	Hedberg 1971	\N	trifluoperazine + tranylcypromine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
940	Hegarty 1959	\N	trifluopromazine hydrochloride	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
941	Hegarty 1961	\N	nialamide	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
943	Heikkila 1992 a	\N	zuclopenthixol	\N	Denmark	ORIGIN Other Europe	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
944	Heikkila 1981 a	\N	cis(z)-clopenthixol	\N	Finland	ORIGIN Other Europe	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
946	Heikkila 1981 b	\N	cis(z)-clopenthixol	\N	United Kingdom	ORIGIN Other Europe	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
947	Heikkinen 1993	\N	molindone	\N	Finland	ORIGIN Other Europe	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
948	Hekimian 1967	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
949	Heresco 1996 a	\N	glycine	\N	Israel	ORIGIN Mid E./Asia	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
950	Herrera 1990	\N	thioridazine versus Placebo	\N	United States of America	City U New York, Mt Sinai School of Medicine, US ORIGIN USA	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
951	Hershon 1972	\N	trifluoperazine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
952	Herz 1989 a	\N	intermittent medication protocol versus maintenance medication	\N	United States of America	Department of Psychiatry, State University of New York. ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
953	Herz 1991	\N	intermittent medication protocol versus maintenance medication	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
954	Hine 1958	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
955	Hirsch 1996	\N	neuroleptic treatment versus Placebo	\N	United Kingdom	Department of Psychiatry, Charing Cross & Westminster Medical School, London. ORIGIN UK	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
956	Hirsch 1989 a	\N	depot-Antipsychotic injections versus Placebo	\N	United Kingdom	Charing Cross and Westminster Medical School, London, U.K. ORIGIN UK	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
985	Cabrera 1990	\N	 CSG No: 2774 	\N	Cuba	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
987	Holden 1970 a	\N	fluphenazine versus Haloperidol	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
988	Hollister 1987	\N	thiothixene versus high//low dosages	\N	United States of America	Harris County Psychiatric Centre, Houston, Texas 77225. ORIGIN USA	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
989	Hollister 1974	\N	aliphatic versus piperazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	320	\N	\N	\N	\N	\N
991	Hollister 1956 a	\N	Chlorpromazine versus Reserpine	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
992	Hollister 1956 b	\N	Reserpine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
993	Hollister 1956 c	\N	Reserpine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
994	Hollister 1956 d	\N	Clozapine + Reserpine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
995	Holloway 1996	\N	intensive case management versus standard care	\N	United States of America	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
1137	Jones 1968	\N	Chlorpromazine + Haloperidol versus Haloperidol	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
996	Holman 1983	\N	Omega-3 Fatty Acid versus Placebo	\N	Australia	Hobson Park Hosp, Traralgon, Australia ORIGIN Australia/NZ	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
997	Holmberg 1956	\N	Chlorpromazine versus Reserpine	\N	Sweden	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
998	Holt 1960	\N	isocarboxazid versus imipramine	\N	United States of America	\N	\N	\N	\N	\N	134	\N	\N	\N	\N	\N
999	Holt 1984	\N	Chlorpromazine versus no drug control	\N	Puerto Rico	ORIGIN South/Central America	\N	\N	\N	\N	577	\N	\N	\N	\N	\N
1000	Hommer 1985	\N	ceruletide versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
1001	Hommer 1984	\N	prazosin versus Placebo	\N	United States of America	NIMH Clinical Neuroscience Branch, Section on Clinical Studies, Bethesda, MD ORIGIN USA	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
1004	Honigfeld 1984 a	\N	Clozapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
1006	Houston 1956	\N	meratran versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1007	Howanitz 1996	\N	Clozapine versus Chlorpromazine	\N	United States of America	Department of Psychiatry, VA New Jersey Health Care System, Lyons 07939, USA.\r\n\r\nVeterans Affairs New Jersey Health Care System, Lyons Veterans Affairs Medical Ctr, Dept of Psychiatry, Lyons, NJ, USA	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
1008	Howard 1974	\N	Haloperidol versus Placebo	\N	United States of America	Eastern State Hosp, Williamsburg, VA ORIGIN USA	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
1010	Hrebicek 1965	\N	combined convulive therapy versus classical methods	\N	Czech Republic	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
1013	Huang 1987	\N	 CSG No: 1029 	\N	United States of America	Medical Coll of Wisconsin, US ORIGIN USA	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
1014	Huegel 1997	\N	benztropine + Haloperidol versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
1015	Hunt 1967	\N	oxypertine versus trifluoperazine	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1016	Hurst 1960	\N	Chlorpromazine versus pecazine	\N	United Kingdom	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
1017	Hutt 1964	\N	occupation groups- handicrafts shop versus industrial workshop	\N	United Kingdom	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
1019	Huygens 1973 a	\N	penfluridol versus Placebo	\N	Netherlands	Sancta Maria Psychiatric Hosp., Noordwijkerhout, Netherlands ORIGIN Other Europe	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
1021	Inanaga 1978	\N	protirelin versus Placebo	\N	Japan	ORIGIN Mid E./Asia	\N	\N	\N	\N	143	\N	\N	\N	\N	\N
1022	Inderbitzin 1994	\N	fluphenazine decanoate versus control group	\N	United States of America	Department of Psychiatry, Grady Memorial Hospital, Atlanta, GA 30335. ORIGIN USA	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
1023	Innis 1986	\N	cholecystokinin versus Placebo	\N	United States of America	Yale U, Connecticut Mental Health Ctr, Clinical Neuroscience Research Unit ORIGIN USA	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
1024	Iqbal 1991 a	\N	m-chlorophenylpiperazine versus Placebo	\N	United States of America	Department of Psychiatry, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY 10467. ORIGIN USA	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
1025	Iqbal 1991 b	\N	m-chlorophenylpiperazine versus Placebo	\N	United States of America	Yeshiva U, Albert Einstein Coll of Medicine/Montefiore Medical Ctr, Bronx, NY, US ORIGIN USA	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
1026	Irwin 1986	\N	L-5-hydroxytryptophan versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
1027	Irwin 1988	\N	propranolol versus Placebo	\N	United States of America	Veterans Administration Hosp, Dept of Psychiatry, San Diego, CA, US ORIGIN USA	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
1028	Itil 1970 a	\N	fluphenazine hydrochloride versus fluphenazine decanoate	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1029	Itil 1968	\N	Chlorpromazine versus saline	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
1031	Itil 1971 a	\N	molindone versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1032	Itil 1971 b	\N	fluphenazine hydrochloride dose	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1033	Itoh 1985 a	\N	Bromperidol versus Haloperidol	\N	Japan	\N	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
1034	Itoh 1977	\N	Clozapine versus Haloperidol	\N	Japan	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
1035	Itoh 1986	\N	ceruletide versus Placebo	\N	Japan	\N	\N	\N	\N	\N	265	\N	\N	\N	\N	\N
1038	Borison 1991 a	\N	rimcazole versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	30/32	\N	\N	\N	\N	\N
1039	Brook 1996	\N	zuclopenthixol acetate versus Haloperidol	\N	South Africa	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
1041	Burns 1993	\N	community care versus standard care	\N	United Kingdom	Department of Mental Health Sciences, St George's Hospital Medical School, London.\r\n\r\nU London, St George's Hosp Medical School, England ORIGIN UK\r\n\r\nDepartment of Mental Health Sciences, St George's Hospital Medical School, London. ORIGIN UK	\N	\N	\N	\N	172	\N	\N	\N	\N	\N
1043	Chouinard 1977 b	\N	penfluridol versus Chlorpromazine	\N	Canada	McGill U, Allan Memorial Inst, Montreal, Canada ORIGIN Canada	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
1044	Champney 1992	\N	intensive case management versus nonintensive case management and nonsubsidized housing	\N	United States of America	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
1045	Chien 1968	\N	 CSG No: 2189 	\N	United States of America	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
1046	Chien 1974	\N	 CSG No: 0825 	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
1048	Chiu 1996	\N	 CSG No: 1106 	\N	Hong Kong	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
1049	Chouinard 1984	\N	fluphenazine decanoate versus Haloperidol decanoate	\N	Canada	ORIGIN Canada\r\n\r\nRoyal Victoria Hosp, Allan Memorial Inst Clinical Psychopharmacology Unit, Montreal, PQ, Canada ORIGIN Canada	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
1050	Chouinard 1978 b	\N	pipothiazine palmitate versus fluphenazine enanthate	\N	Canada	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
1051	Chouinard 1987	\N	procyclidine versus Placebo	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
1052	Beal 1977	\N	remotivation therapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
1053	Bishop 1964	\N	Butaperazine versus Placebo//Trifluoperazine versus Placebo//Trifluoperazine versus Butaperazine	\N	United States of America	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
1054	Chouinard 1977 a	\N	rubidum + neuroleptic treatment versus Placebo + neuroleptic treatment	\N	Canada	INRS Research Dept, Hosp Louis-H. Lafontaine, Montreal, Canada ORIGIN Canada	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
1056	Chouinard 1990	\N	remoxipride versus Placebo//Chlorpromazine versus Placebo	\N	Canada	University of Montreal, Psychiatric Research Center, Hospital Louis-H Lafontaine, Quebec, Canada. ORIGIN Canada	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
1057	Chouinard 1976 b	\N	methyldopa-clorpromazine versus Chlorpromazine	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
1059	Chouinard 1980	\N	Chlorpromazine versus neuroleptic withdrawl	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
1060	Chouinard  1982 a	\N	fluphenazine enanthate versus fluphenazine decanoate	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
1061	Chouinard 1979 c	\N	benztropine versus ethopropazine	\N	Canada	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1066	Bergougnan 1996 a	\N	Amisulpride + ethanol versus Placebo	\N	France	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
1067	Bergougnan 1996 b	\N	Amisulpride + ethanol versus Placebo	\N	France	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
1070	Cheng 1981	\N	 CSG No: 561 	\N	Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1073	Chouinard 1976 a	\N	penfluridol versus Placebo//Chlorpromazine versus Placebo	\N	Canada	McGill U, Montreal, Canada ORIGIN Canada	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
1075	Hong 1997 a	\N	 CSG No: 2485 	\N	China	Department of Psychiatry, Veterans Hospital-Taipei, Taiwan, Republic of China.	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1076	Hooper 1983	\N	droperidol versus various dosages	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1078	Horiguchi 1992 a	\N	clonazepam versus antiparkinsonian drug	\N	Japan	Department of Neuropsychiatry, Ehime University School of Medicine, Japan. ORIGIN Mid E./Asia	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
1080	Hormia 1956	\N	Chlorpromazine versus Chlorpromazine + Reserpine	\N	Finland	\N	\N	\N	\N	\N	109	\N	\N	\N	\N	\N
1081	Hornstra 1993	\N	intensive case management versus control group	\N	United States of America	\N	\N	\N	\N	\N	224	\N	\N	\N	\N	\N
1082	Horodnicki 1968	\N	 CSG No: 300 	\N	Poland	ORIGIN Other Europe	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
1083	Huang 1981	\N	 CSG No: 2806 	\N	United States of America	Clin. Pharmacol. Serv., Wood VA Med. Cent., Wood, Wis. 53193,	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1084	Hummer 1996	\N	Clozapine versus Haloperidol	\N	Austria	\N	\N	\N	\N	\N	177	\N	\N	\N	\N	\N
1085	Hurlburt 1996	\N	supportive housing versus homeless	\N	United States of America	\N	\N	\N	\N	\N	361	\N	\N	\N	\N	\N
1086	Ingram 1983	\N	tacrine versus Placebo	\N	Australia	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
1087	Iqbal 1978	\N	penfluridol versus fluphenazine	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
1089	Itil 1978	\N	pipothiazine palmitate versus fluphenazine	\N	United States of America	New York Medical Coll, Div of Biological Psychiatry, Valhalla	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
1090	Jackson 1979	\N	lecithin versus Placebo	\N	United States of America//Australia	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
6218	Kubokura 1971	\N	\N	\N	Japan	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1091	Jacobsson 1974	\N	Chlorpromazine versus Clothiapine	\N	Sweden	ORIGIN Other Europe	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
1092	Jacobsson 1976	\N	penfluridol versus thiothixene	\N	Sweden	ORIGIN Other Europe	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
1094	Jaffe 1960	\N	convulsive group versus control group	\N	United States of America	Hillside Hosp., Long Island, N.Y.	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
1095	Jain 1975	\N	pipothiazine palmitate versus fluphenazine enanthate	\N	Canada	Queen Street Mental Health Ctr, Toronto, Canada	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1096	James 1977	\N	penfluridol versus saline	\N	Australia//New Zealand	ORIGIN Australia/NZ	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
1097	Janakiramiah 1982	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) + Chlorpromazine versus Chlorpromazine	\N	India	ORIGIN Mid E./Asia	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1098	Janicak 1998	\N	verapamil versus Placebo	\N	United States of America	Psychiatric Institute, University of Illinois at Chicago 60612, USA.	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
1099	Jann 1990	\N	Haloperidol dose	\N	United States of America	Mercer U Southern School of Pharmacy, GA, US ORIGIN USA	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
1101	Janowsky 1973 a	\N	methylphenidate versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
1103	Jasovic 1997	\N	antidepressants versus Placebo	\N	SerbiaYugoslavia	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
1104	Jasovic 1996 a	\N	amitriptyline versus Placebo	\N	Yugoslavia	Institute for Psychiatry, Clinical Center of Serbia, School of Medicine, Belgrade, Yugoslavia ORIGIN Other Europe	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
1105	Jasovic 1996 b	\N	brotizolam versus midazolam	\N	Yugoslavia	Institute of Psychiatry, Clinical Center of Serbia, School of Medicine, University of Belgrade, Pasterova 2, 11000 Belgrade, Yugoslavia 1  Department of Psychiatry, General Hospital "Dr Voja Dulic", 12000 Pozarevac, Yugoslavia 2 Boehringer Ingelheim Pharm	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
1106	Jasovic 1995	\N	moclobemide versus Placebo	\N	Yugoslavia	1 Institute for Psychiatry, Clinical Center of Serbia, Belgrade School of Medicine, Pasterova 2, 11000 Belgrade, Yugoslavia 2 General  Hospital "Dr Voja Dulic", Department of Psychiatry, 12000 Pozarevac, Yugoslavia	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
1108	Janicak 1997	\N	Haloperidol dose	\N	United States of America	Psychiatric Inst., Univ. Illinois Chicago, 1601 West Taylor St., Chicago, IL 60612,USA\r\n\r\nIllinois State Psychiatric Inst, Dept of Psychiatry, Chicago, US ORIGIN USA	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
1109	Javed 1991	\N	flupenthixol decanoate versus fluphenazine decanoate	\N	Pakistan	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
1110	Javitt 1994	\N	glycine versus Placebo	\N	United States of America	Department of Psychiatry, Albert Einstein College of Medicine, Bronx Psychiatric Center, NY 10461. ORIGIN USA\r\n\r\nORIGIN USA	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
1111	Jellinek 1981	\N	benztropine + Haloperidol versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
1112	Jensen 1973	\N	cyproterone acetate versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
1113	Jerrell 1989	\N	intensive clinical and case management versus usual care	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
1114	Jerrell 1994	\N	12 step recovery program versus behavioral skills training	\N	United States of America	\N	\N	\N	\N	\N	143	\N	\N	\N	\N	\N
1115	Jeste 1983 a	\N	apomorphine versus Placebo	\N	United States of America	NIMH Adult Psychiatry Branch, St Elizabeths Hosp, Washington, DC ORIGIN USA	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1116	Jimerson 1980	\N	clonidine versus Placebo	\N	United States of America	NIMH Biological Psychiatry Branch, Bethesda, MD ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1117	Jin 1994	\N	open door policy + structured activity program versus control group	\N	China	Yanbian Community Psychiatric Hosp., 114 Ai Guo Road, Yanji City, Jilin 133000, China ORIGIN Mid E./Asia	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
1118	Joergensen 1986	\N	FK 33-824 versus Placebo	\N	Denmark	ORIGIN Other Europe	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
1119	Johns 1984	\N	apomorphine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
1120	Johnson 1973	\N	piperacetazine versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
1121	Johnson 1981 c	\N	orphenadrine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1122	Johnson 1987	\N	flupenthixol decanoate versus half dose//standard dose	\N	United Kingdom	Pastures Hospital. ORIGIN UK	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1124	Johnson 1981 a	\N	regular depot drugs versus control group	\N	United Kingdom	Univ. Hosp. South Manchester, Manchester, M20 8LR, UK ORIGIN UK	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
1125	Johnson 1981 b	\N	regular depot drugs versus control group	\N	United Kingdom	Univ. Hosp. South Manchester, Manchester M20 8LR, UK ORIGIN UK	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1126	Johnson 1960	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) + altropine versus Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1127	Johnson 1965	\N	rehabilitation group versus control group	\N	United States of America	\N	\N	\N	\N	\N	276	\N	\N	\N	\N	\N
1128	Johnstone 1983	\N	flupenthixol + procyclidine versus flupenthixol + Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
1129	Johnstone 1979	\N	flupenthixol versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
1130	Jolley 1989	\N	depot neuroleptic injections versus Placebo	\N	United Kingdom	Department of Psychiatry, Charing Cross and Westminster Medical School, London. ORIGIN UK\r\n\r\nCharing Cross and Westminster Medical School, London, Great Britain; Department of Psychiatry	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
1131	Jones 1970	\N	methylperidol versus trifluoperazine	\N	Australia//New Zealand	ORIGIN Australia/NZ	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
1132	Jones 1971	\N	Chlorpromazine versus trifluoperazine	\N	Australia//New Zealand	ORIGIN Australia/NZ	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
1133	Meder 1996	\N	behavioural education versus control group	\N	Poland	Institute of Psychiatry and Neurology, Department of Rehabilitation, Sobieskiego Street Nr 1/9, Warsaw, 02-957, Poland ORIGIN Other Europe	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
1135	Jonckheere 1966	\N	 CSG No: 425 	\N	Belgium	ORIGIN Other Europe	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1136	Jones 1995	\N	Risperidone versus various doses	\N	Canada	1 McMaster University, Hamilton, Ontario, Canada 2 Janssen Research Foundation, Beerse, Belgium	\N	\N	\N	\N	211	\N	\N	\N	\N	\N
1138	Jørgensen 1982	\N	naloxone versus saline	\N	Norway	U Bergen Inst of Physiology, Neurophysiology Group, Norway ORIGIN Other Europe	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1139	Joshi 1980	\N	vitamin B1 versus Placebo	\N	India	ORIGIN Mid E./Asia	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1140	Joshi 1982	\N	vitamin B1 versus Placebo	\N	India	Dep. Psychiatry, J.J. Hosp. Grant Med. Coll., Bombay, India ORIGIN Mid E./Asia	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1141	Jost 1973	\N	 CSG No: 1263 	\N	Germany	ORIGIN Other Europe	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1142	Jostell 1990	\N	remoxipride versus various dosages	\N	Sweden	Astra Research Centre, Sodertalje, Sweden. ORIGIN Other Europe	\N	\N	\N	\N	171	\N	\N	\N	\N	\N
1143	Judah 1959	\N	mellaril versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1144	Judd 1973	\N	phenothiazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1145	Jus 1974 a	\N	penfluridol versus thioridazine	\N	Canada	Hopital St Michel-Archange, Research Div, Quebec, Quebec, Canada ORIGIN Canada	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
1146	Jus 1975	\N	penfluridol + Chlorpromazine versus penfluridol	\N	Canada	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
1444	Dotti 1979	\N	 CSG No: 3035 	\N	Italy	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1147	Kabes 1981	\N	oxyprothephine decanoate versus fluphenazine decanoate	\N	Czech Republic	Inst of Psychiatry, Prague, Czechoslovakia ORIGIN Other Europe	\N	\N	\N	\N	183	\N	\N	\N	\N	\N
1148	Kahn 1990	\N	carbamazepine + Haloperidol versus Haloperidol	\N	United States of America	Northeast Psychiatric Associates, Nashua, New Hampshire. ORIGIN USA	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
1149	Kahn 1994 a	\N	remoxipride versus Haloperidol	\N	France	ORIGIN Other Europe	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
1150	Kahn 1994 b	\N	m-chlorophenylpiperazine versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
1151	Kahn 1992	\N	m-chlorophenylpiperazine versus Placebo	\N	United States of America	Veterans Affairs Medical Ctr, Dept of Psychiatry, Bronx, NY, US ORIGIN USA	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
1152	Kalinin 1986	\N	intensive insulin coma therapy versus individually adjusted psychopharmacotherapy	\N	Russian Federation	Russian Soviet Federated Socialist Republic Ministry of Health, Moscow Scientific Research Inst of Psychiatry, USSR ORIGIN Other Europe	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
1153	Kalyanasundaram 1981	\N	Chlorpromazine versus Placebo	\N	India	ORIGIN Mid E./Asia	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
1154	Campbell 1976	\N	levodopa versus levoamphetamine	\N	United States of America	New York U, Medical School	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1155	Charalampous 1977	\N	penfluridol versus fluphenazine	\N	United States of America	Baylor U Medical Coll	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
1156	Cheng 1987	\N	 CSG No: 2802 	\N	Sweden	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
1157	Chiu 1976	\N	 CSG No: 2796 	\N	Australia	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
1158	Chouinard 1983 a	\N	piracetam versus Placebo	\N	Canada	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1159	Chouinard 1977 d	\N	benserazinde versus Chlorpromazine	\N	Canada	INRS, Hosp Louis-H.-Lafontaine, Montreal, Canada	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
1160	Chouinard 1978 a	\N	imipramine + fluphenazine de anoate + benzitropine meslyate versus Placebo + fluphenazine de anoate + benzitropine meslyate	\N	Canada	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
1161	Cody 1977	\N	low-cost drugs versus retail drugs	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
1162	Cohen 1987 b	\N	 CSG No: 2746 	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
1164	Corrigan 1995	\N	cognitive rehabilitation + vigilance program versus vigilance and memory training	\N	United States of America	University of Chicago Center for Psychiatric Rehabilitation, Tinley Park, IL 60477, USA.	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1165	Cowden 1956 b	\N	Group Psychotherapy + Reserpine versus Treatment As Usual	\N	United States of America	VA Hosp., Gulfport, Miss.	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
1170	Daniel 1988	\N	apomorphine versus Placebo	\N	Canada	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
1171	Daston 1958	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
1172	Davis 1979	\N	choline chloride versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
1173	de Buck 1973 a	\N	fluphenazine-hci dose	\N	Belgium	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
1175	Baldini 1970	\N	amitriptyline + fluphenazine versus fluphenazine	\N	United States of America	\N	\N	\N	\N	\N	437	\N	\N	\N	\N	\N
1176	Bankier 1968	\N	fluphenazine enanthate versus Placebo//Trifluoperazine versus Placebo//fluphenazine enanthate versus Trifluoperazine	\N	Canada	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
1177	Bechelli 1985	\N	pipotiazine palmitate versus Haloperidol decanoate	\N	Brazil	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1178	Benedict 1994	\N	computer mediated vigilance tasks versus no-treatment control	\N	United States of America	SUNY Buffalo School of Medicine, Dept. of Neurology, Buffalo General Hospital 14203.	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
1179	Bishop 1970	\N	loxapine versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1180	Bogetto 1995	\N	Haloperidol + fluoxetine versus Haloperidol + Amisulpride	\N	Italy	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1181	Bora 1968	\N	carphenazine versus no medication	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
1185	Cooper 1990 a	\N	lumbar punctures versus Haloperidol	\N	United Kingdom	Department of Mental Health, Queen's University of Belfast, Northern Ireland, U.K.	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
1187	Dalack 1997 a	\N	smoking ad libitum versus no smoking	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1188	Daniel 1994 a	\N	Risperidone versus Clozapine	\N	United States of America	Washington Clinical Research Center, Falls Church, VA 22044, USA. ORIGIN USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1190	Daniel 1994 b	\N	fluvoxamine + Haloperidol + benxtropine versus Placebo + Haloperidol + benxtropine	\N	United States of America	Clinical Brain Disorders Branch, NIMH Neuroscience Center at Saint Elizabeths, Washington, D.C.	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
1191	Garver 1991	\N	lithium + Haloperidol versus lithium	\N	United States of America	U Alabama School of Medicine, Birmingham, USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1194	Fleischhacker 1995 a	\N	seroquel versus Placebo	\N	Austria	\N	\N	\N	\N	\N	622	\N	\N	\N	\N	\N
1196	Foss 1983	\N	hemodialysis versus sham	\N	Norway	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
1197	Freeman 1956	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1198	Freeman 1972	\N	EX 10-029 versus trihexyphenidyl hydrochloride	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1199	Gallant 1967 c	\N	trifluperidol versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
1200	Gallhofer 1995 a	\N	Risperidone versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1201	Gallhofer 1996	\N	fluphenazine versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
1202	Gardos 1971	\N	pipothiazine versus fluphenazine	\N	United States of America	\N	\N	\N	\N	\N	3	\N	\N	\N	\N	\N
1203	Gardos 1978	\N	mesoridazine versus thioridazine	\N	United States of America	Boston State Hosp, Inst of Research & Rehabilitation, MA	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
1204	Garver 1984 b	\N	lithium versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
1206	Gelkopf 1994	\N	exposed to comedy films versus exposed to various films	\N	Israel	Lev Hasharon Mental Health Medical Center, Netania, Israel.	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
1208	Glazer 1990	\N	molindone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
1211	Herinckx 1997	\N	assertive community treatment versus standard care	\N	United States of America	Portland State U, Regional Research Inst, Portland, OR, USA	\N	\N	\N	\N	178	\N	\N	\N	\N	\N
1212	Heresco 1997	\N	glycenergic versus Placebo	\N	Israel	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1213	Herz 1978	\N	naloxone versus Placebo	\N	Germany	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1216	Herz 1975	\N	standard inpatient care versus brief hospitalization	\N	United States of America	\N	\N	\N	\N	\N	175	\N	\N	\N	\N	\N
1218	Herz 1971	\N	day care versus inpatient care	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
1219	Herz 1974	\N	individual aftercare versus group aftercare	\N	United States of America	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
1221	Himwich 1997	\N	sodium glutamate versus Placebo	\N	United States of America	Galesburg State Research Hosp., Galesburg, Ill.	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
1222	Hirsch 1975	\N	depot-phenothiaznes versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
1223	Hogarty 1974 a	\N	major role therapy versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	374	\N	\N	\N	\N	\N
1224	Hogarty 1979 b	\N	social therapy + fluphenazine hydrochloride versus fluphenazine hydrochloride	\N	United States of America	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
1226	Holden 1968	\N	chlordiazepoxide + thioridazine versus thioridazine	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1227	Hollister 1955	\N	Reserpine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1228	ELCCT 1997	\N	intensive case management versus standard community care	\N	United Kingdom	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
1231	Kane 1978	\N	fluphenazine enanthate versus fluphenazine decanoate	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
1232	Kane 1983 b	\N	fluphenazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
1233	Kane 1979	\N	fluphenazine decanoate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
1235	Kaplan 1974	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
1236	Kapur 1991	\N	riboflavin versus Placebo	\N	United States of America	University of Pittsburgh, School of Medicine, Western Psychiatric Institute and Clinic, PA 15213-2593. ORIGIN USA	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
1237	Karlsson 1995	\N	N756 versus Placebo	\N	Sweden	Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, Sweden. ORIGIN Other Europe	\N	\N	\N	\N	3	\N	\N	\N	\N	\N
1238	Karniol 1983	\N	 CSG No: 542 	\N	Brazil	ORIGIN South/Central America	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1240	Karsten 1981	\N	cis(z)-clopenthixol versus Haloperidol	\N	Finland	ORIGIN Other Europe	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1241	Katila 1993	\N	onterferon-a versus Placebo	\N	Finland	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
1242	Katz 1996	\N	AIDs counseling versus control group	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
1243	Kaufmann 1994	\N	self help group versus control group	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
1244	Kazamatsuri 1972 a	\N	thiopropazate versus Haloperidol	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1245	Kazdova 1982	\N	lisuride versus Placebo	\N	Czech Republic	Horni Berkovice Psychiatric Hosp, Prague, Czechoslovakia ORIGIN Other Europe	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1246	Keks 1994	\N	remoxipride versus thioridazine	\N	Australia	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
1247	Kellam 1971	\N	thiothixene versus perphenazine	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
1248	Kellner 1975	\N	chlordiazepoxide versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
1249	Kelly 1977	\N	flupenthixol decanoate versus fluphenazine decanoate	\N	United Kingdom	Department of Psychiatry, Hope Hospital, Social Services Department, City of Salford, Salford. ORIGIN UK	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1250	Kelly 1974	\N	Amantadine Hydrochloride versus Benztropine Mesylate	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
1251	Kane 1982 a	\N	fluphenazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
1252	Kelly 1990	\N	family aftercare process health education versus patient health care consumer training	\N	United States of America	Department of Veterans Affairs Medical Center, Perry Point, MD.	\N	\N	\N	\N	418	\N	\N	\N	\N	\N
1253	Kelly 1995b	\N	Game (Educational) versus Study (Non-Directed)	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1254	Kelwala 1984	\N	Haloperidol versus Thiothixene	\N	United States of America	Vanderbilt U ORIGIN USA	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
1255	Kemp 1996	\N	compliance therapy versus control group	\N	United Kingdom	A. Healey, Ctr. for the Economics Mental Hlth., Institute of Psychiatry, De Crespigny Park, London NW3 2QG, United Kingdom	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
1256	Kendrick 1996 a	\N	attitude course for general practice nurses versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1257	Kennedy 1980	\N	experimental ward- group and occupational theapy versus control wards	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	247	\N	\N	\N	\N	\N
1259	Keskiner 1968 a	\N	phenothiazine versus Placebo	\N	United States of America	Department of Psychiatry, Missouri Institute of Psychiatry, University of Missouri School of Medicine, St. Louis, Missouri, U.S.A. ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1260	Keskiner 1971	\N	EEG + fluphenazine enanthate versus EEG + fluphenazine decanoate	\N	United States of America	Department of Psychiatry of the University of Missouri School of Medicine, Missouri Institute of Psychiatry, 5400 Arsenal Street, St. Louis,  Missouri 63139, U.S.A. ORIGIN USA	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1261	Keskiner 1970	\N	Butaperazine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
1262	Keskiner 1968 b	\N	fluphenazine decanoate versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1264	Khorana 1988	\N	penfluridol versus trifluoperazine	\N	United States of America	Department of Psychiatry, Medical College, Baroda.	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
1265	Kidron 1985	\N	carbamazepine versus Placebo	\N	Israel	Jerusalem Mental Health Ctr-Ezrath Nashim, Israel ORIGIN Mid E./Asia	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
1266	Kielhofner 1989	\N	aftercare program versus control group	\N	United States of America	U Illinois, Coll of Associated Health Professions, Chicago, US ORIGIN USA	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
1267	Kiloh 1976	\N	loxapine versus trifluoperazine	\N	Australia//New Zealand	ORIGIN Australia/NZ	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
1269	Kim 1960	\N	Chlorpromazine + aristocort versus Chlorpromazine + Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1270	King 1990	\N	remoxipride versus various dosages	\N	United Kingdom	Queen's U of Belfast, Northern Ireland ORIGIN UK	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
1271	Kern 1996 b	\N	initial error group versus no initial error group	\N	United States of America	Temple University (0225)	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
1272	King 1979	\N	psychotherapy versus phenothiazines	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
1273	King 1994	\N	remoxipride versus Haloperidol	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
1274	King 1992 a	\N	remoxipride versus Placebo	\N	United Kingdom	Queen's U of Belfast, Northern Ireland ORIGIN UK	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
1275	King 1992 b	\N	neuroleptics versus Placebo	\N	United Kingdom	Department of Therapeutics and Pharmacology, Queen's University of Belfast, Northern Ireland. ORIGIN UK	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1277	King 1980	\N	propranolol versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
1278	Kingstone 1970	\N	clopenthixol versus Chlorpromazine	\N	United Kingdom	ORIGIN Canada	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
1279	Kinney 1981	\N	hemoperfusion versus sham	\N	United States of America	Nephrology Research & Education Foundation, Huntington, WV ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1280	Kinon 1993 a	\N	same neuroleptic versus switch to different class of neuroleptic	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
20231	田博 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
1281	Kinon 1993 b	\N	same neuroleptic versus switch to different class of neuroleptic	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
1282	Kinross 1964	\N	fluphenazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1283	Kirli 1997	\N	sertraline versus imipramine	\N	Turkey	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1284	Kissling 1985	\N	fluphenazine decanoate versus Haloperidol decanoate	\N	Germany	ORIGIN Other Europe	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
1285	Kistrup 1991	\N	perphenazine decanoate versus cis(z)-flupentixol decanoate	\N	Denmark	Sct. Hans Hospital, Department P, Roskilde, Denmark. ORIGIN Other Europe	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
1286	Klein 1973	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
1287	Klein 1974	\N	self administered drugs with instructions versus self administered drugs without instructions	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1446	Emrich 1977	\N	naloxone versus Placebo	\N	Germany	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1288	Kleinbloesem 1996	\N	mazapertine versus Placebo	\N	Switzerland	Clin-Pharma Research AG, Birsfelden, Switzerland. ORIGIN Other Europe	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
1289	Kleinman 1982	\N	naloxone versus Placebo	\N	United States of America	NIMH Adult Psychiatry Branch, St Elizabeths Hosp, Washington, DC ORIGIN USA	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
1290	Klett 1972	\N	benztropine mesylate versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	518	\N	\N	\N	\N	\N
1292	Klein 1984	\N	carbamazepine + Haloperidol versus Placebo + Haloperidol	\N	Israel	ORIGIN Mid E./Asia	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
1293	Klieser 1989	\N	trazodone versus Placebo	\N	Germany	ORIGIN Other Europe	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
1297	Kline 1977	\N	pimozide versus trifluoperazine	\N	United States of America	U Southern California Medical School	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
1298	Kline 1967 a	\N	nicotinamide adenine dinucleotide versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1299	Kline 1968	\N	Perphenazine versus Reserpine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1301	Knapen 1976	\N	 CSG No: 450 	\N	Belgium	Inst Psychiatrique Sancta Maria, St-Trond, Belgium ORIGIN Other Europe	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1303	Knight 1979	\N	thiothixene versus tirfuoperazine + Chlorpromazine	\N	Australia//New Zealand	ORIGIN Australia/NZ	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1304	Kobayashi 1980	\N	thyrotropin-releasing hormone versus Placebo	\N	Japan	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
1305	Kochansky 1977	\N	chlordiazepoxide versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
1306	Kogeorgos 1995	\N	sulpiride versus Risperidone	\N	Greece	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
1307	Kojima 1989	\N	ceruletide versus Placebo	\N	Japan	Department of Neuropsychiatry, Tokyo Medical and Dental University Faculty of Medicine, Tokyo, Japan\r\n\r\nNihon U School of Medicine, Tokyo, Japan ORIGIN Mid E./Asia	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
1309	Kolivakis 1974	\N	pimozide versus Chlorpromazine	\N	Canada	Allan Memorial Inst, Montreal, Quebec, Canada ORIGIN Canada	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
1310	Konrad 1996	\N	Clozapine versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
1311	Korner 1990	\N	remoxipride versus Haloperidol	\N	Denmark	Centralsygehuset, Psykiatrisk Afdeling, Hillerod, Denmark ORIGIN Other Europe	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
1312	Kornetsky 1959	\N	Chlorpromazine versus secobarbital	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1313	Korol 1965	\N	Chlorpromazine in sitting position versus Chlorpromazine in standing position	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
1314	Korsgaard 1986	\N	mianserin versus Placebo	\N	Denmark	Sct Hans Hosp, Roskilde, Denmark ORIGIN Other Europe	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
1315	Koshikawa 1991	\N	neuroleptics versus various dosages	\N	Japan	Department of Neuro-psychiatry, Keio University School of Medicine, Tokyo, Japan.	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
1316	Kothari 1960	\N	perphenazine versus MO-482	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1317	Koukkou 1979	\N	Clozapine versus Haloperidol	\N	Switzerland	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
1318	Kovitz 1955	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
1319	Kramer 1975	\N	Chlorpromazine versus Metiapine	\N	United States of America	VA Hosp, Cincinnati, OH ORIGIN USA	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
1320	Kramer 1978	\N	Loxapine versus Thioridazine	\N	United States of America	VA Hosp, Cincinnati, OH	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
1322	Kramer 1988	\N	propranolol versus Placebo	\N	United States of America	Coatesville Veterans Administration Medical Ctr, PA, US ORIGIN USA\r\n\r\nThomas Jefferson U, Jefferson Medical Coll, Philadelphia, PA, US ORIGIN USA	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
1323	Kramer 1997 a	\N	L-745,870 versus Placebo	\N	United States of America	Department of Clinical Neuroscience, Merch & Co Inc., West Point, Pa, USA. ORIGIN USA	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
1325	Kramer 1989	\N	amitriptyline dydroochloride versus Placebo	\N	Canada//United States of America	Department of Psychiatry and Human Behavior Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pa. ORIGIN USA	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
1326	Krawiecki 1957	\N	parentrovite versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
1327	Kreeger 1995	\N	hearing enhancement versus control group	\N	United States of America	Department of Psychiatry, State University of New York at Buffalo 14260. ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1328	Kreisman 1988	\N	low dose neuroleptics versus standard dose neuroleptics	\N	United States of America	New York State Psychiatric Institute, Columbia University, NY 10032.	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
1329	Krus 1963	\N	LSD-25 versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
1330	Krystal 1994	\N	ketamine versus Placebo	\N	United States of America	Department of Psychiatry, Yale University School of Medicine, New Haven, Conn. ORIGIN USA	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
1332	Barchas 1980 b	\N	saline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
1333	Bastecky 1982	\N	clorotepin versus Placebo	\N	Czech Republic	Inst of Physicians & Pharmacists, Psychiatric Dept, Prague, Czechoslovakia	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
1334	Bjerkenstedt 1977	\N	melperone versus thiothixene melperone versus thiothixene	\N	Sweden	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
1335	Bjerkenstedt 1978	\N	melperone versus thiothixene	\N	Sweden	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
1336	Buchkremer 1991	\N	therapeutic relatives groups versus control group	\N	Germany//United States of America	Germany	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
1338	Davies 1991	\N	Clozapine versus Chlorpromazine	\N	United States of America	Case Western Reserve U School of Medicine, Cleveland, OH, US	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1339	Corsini 1978	\N	piribedil versus Haloperidol	\N	Italy	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
1340	Dalack 1997 b	\N	smoking ad libitum versus no smoking	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1341	Davis 1977	\N	naloxone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
1342	de Col 1995	\N	ritanserin versus Placebo	\N	Austria	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1343	De Ronchi 1995	\N	levosulpiride versus pimozide	\N	Italy	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1344	Dean 1958	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
1345	Decina 1994	\N	trazodone versus Placebo	\N	Italy	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
1347	Demerdash 1981	\N	fluspirliene versus flupenthixol decanoate	\N	Kuwait	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
1350	Clark 1977 b	\N	loxapine succinate versus Placebo	\N	United States of America	Central State Griffin Memorial Hosp, Norman, OK	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
1354	Den Boer 1990 b	\N	remoxipride versus Haloperidol	\N	Netherlands	University Hosp, Dept of Biological Psychiatry, Utrecht, Netherlands ORIGIN Other Europe	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
1355	DiGiacomo 1977	\N	lenperone versus Chlorpromazine	\N	United States of America	VA Hosp Psychiatry Dept, Philadelphia, PA	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
1356	Denijs 1973	\N	pimozide versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1357	Diaz Buxo 1980	\N	hemodialysis versus sham	\N	United States of America	\N	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
1358	Dickey 1996	\N	group housing versus independent housing	\N	United States of America	McLean Hospital, 115 Mill Street, Belmont, MA 02178, United States	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
1359	Dillenkoffer 1971	\N	thiothixene versus thioridazine	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
1360	Dilling 1971	\N	work therapy- weekly paid lump sum versus immediately paid piece work	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1361	Dincin 1982	\N	full time rehabilitation program versus part time rehabilitation program	\N	United States of America	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
1362	Dixon 1989	\N	physician training versus control group	\N	United States of America	Payne Whitney Clinic, New York Hospital-Cornell Medical Center, NY 10021.	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1363	Donlon 1976 b	\N	fluphenazine enanthate versus fluphenazine decanoate	\N	United States of America	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
1364	Donnelly 1996	\N	cigarettes versus no intervention	\N	United States of America	Duke U, Medical Ctr, Durham, NC, USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1365	Doran 1990	\N	fluphenazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1366	Dufresne 1988	\N	Bupropion + thiothixene versus Placebo + thiothixene	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
1368	Durell 1968	\N	theraputic community versus control group	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
1369	Dutoit 1995	\N	Haloperidol dose	\N	France	Service de Psychiatrie Generale, Universite de Lille II et CHRU, Lille.	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
1371	Edelstein 1981	\N	physostigmine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
1372	Asher 1981	\N	 CSG No: 2952 	\N	United States of America	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
1373	Breier 1993 c	\N	Clozapine versus Placebo	\N	United States of America	Maryland Psychiatric Research Center, Baltimore 21228.	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1374	Carman 1978	\N	N-(2-chlorophenoxyethyl)-cyclopropylamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
1375	Chouza 1982	\N	 CSG No: 2949 	\N	Uruguay	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
1377	de Cangas 1995	\N	nurse directed assertive case management versus hospital based treatment	\N	Canada	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
1378	Duval 1997	\N	DST versus apomorphine	\N	France	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
1379	Duval 1993	\N	DSDZ HDC-912 versus Amisulpride	\N	France	Section VIII, Centre Hospitalier Specialise, Rouffach, France.	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
1381	Elizur 1980	\N	clonidine versus perphenazine	\N	Israel	\N	\N	\N	\N	\N	2	\N	\N	\N	\N	\N
1382	Ellenor 1995	\N	divalproex versus high//low dosages	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
1383	Emrich 1980 b	\N	DTyE versus Placebo	\N	Germany	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
1384	Emsley 1995	\N	Risperidone versus Haloperidol	\N	South Africa	Department of Psychiatry, University of Stellenbosch, Tygerberg, South Africa.	\N	\N	\N	\N	183	\N	\N	\N	\N	\N
1387	Engelhardt 1978	\N	thiothixene versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
1388	Erlandsen 1977	\N	Clozapine versus Placebo	\N	Norway	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1390	Faretra 1970	\N	fluphenazine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1392	Abuzzahab 1977	\N	penfluridol + trifluoperazine versus penfluridol + Placebo//Penfluridol versus trifluoperazine//trifluoperazine versus Placebo//Penfluridol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
1393	Antun 1971	\N	L-methionine versus glycine	\N	United Kingdom	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
1394	Clark 1986	\N	problem solving program versus skills training program	\N	United States of America	U Mississippi, University, US	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
1395	Crow 1977 b	\N	a-flupenthixol versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
1396	de Cuyper 1984	\N	halopemide versus Placebo	\N	Belgium	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1397	Dim 1968	\N	BL-KR140 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1398	Drake 1996 a	\N	group skills training versus individual placement and support	\N	United States of America	New Hampshire-Dartmouth Psychiatric Research Ctr, Concord, NH, US\r\n\r\nR.E. Clark, Dartmouth Medical School, Department Community Family Medicine, Strasenburgh 7250, Hanover, NH 03755-3862, United  States	\N	\N	\N	\N	143	\N	\N	\N	\N	\N
1399	Ferebee 1963	\N	isoniazid prophylaxis versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	433	\N	\N	\N	\N	\N
1400	Filip 1985	\N	 CSG No: 2825 	\N	Czech Republic	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
1401	Ayd 1972 b	\N	trifluoperazine versus Placebo//trifluoperazine dose	\N	United States of America	912 West Lake Ave., Baltimore, Md	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1404	Falloon 1982	\N	family therapy versus individual therapy	\N	United States of America	Family Project, University of California, Los Angeles 90024-1563. ORIGIN USA\r\nMaudsley and Bethlehem Royal Hospitals, London, England ORIGIN UK	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
1407	Fredericks 1978	\N	drug treatment versus Placebo	\N	United States of America	Chicago Read Mental Health Ctr, IL	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
1408	Fleischhacker 1986	\N	fluperlapine versus Haloperidol	\N	Austria	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1409	Gonzalez 1983	\N	treatment for Spanish speakers versus control groups	\N	United States of America	Stanford U	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
1410	Gaebel 1992	\N	perazine versus Haloperidol	\N	Germany	Germany	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
1411	Garrison 1978	\N	written preparation versus verbal preparation	\N	United Kingdom	Union Hosp-Greater Lynn Community Mental Health Program, MA	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
1412	Goldstein 1969 a	\N	phenothiazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1414	Gordon 1994	\N	Clozapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
1415	Gottschalk 1975	\N	thioridazine versus Placebo	\N	United States of America	U California, Medical Coll, Irvine	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
1416	Drury 1996	\N	cognitive therapy versus control group	\N	United Kingdom	Nottingham Healthcare NHS Trust, UK.	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
1417	Fink 1963	\N	Chlorpromazine versus Placebo	\N	United States of America	Hillside Hosp., Glen Oaks, N.Y.	\N	\N	\N	\N	344	\N	\N	\N	\N	\N
1418	Ferrier 1983	\N	apomorphine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1419	Gagrat 1978	\N	diazepam versus dipenhydramine	\N	United States of America	VA Hosp, Milwaukee, WI	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1422	Alpert 1983	\N	L-DOPA dose	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
1423	Anonymous 1993 a	\N	naltrexone versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1424	Bilone 1988	\N	 CSG No: 3036 	\N	Italy	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
1425	Branchey 1979	\N	lecithin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
1426	Caldarazzo 1980	\N	dipropylacetamide versus Placebo	\N	Italy	L. Bianchi Provincial Psychiatric Hosp, Naples, Italy	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1427	Castellani 1988	\N	 CSG No: 3037 	\N	Italy	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
2918	Watson 1978	\N	 CSG No: 2833 	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
1429	Curry 1979	\N	fluphenazine enanthate versus fluphenazine decanoate	\N	United Kingdom	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
1430	Diamare 1980	\N	dipropylacetamide versus Placebo	\N	Italy	L. Bianchi Provincial Psychiatric Hosp, Naples, Italy	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1431	Falloon 1978 a	\N	pimozide versus fluphenazine decanoate	\N	United Kingdom	ORIGIN UK\r\n\r\nInstitute of Psychiatry, London, England. ORIGIN UK	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
1433	Bastie 1974	\N	 CSG No: 3070 	\N	France	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
1435	Brambilla 1990	\N	thyroliberin versus vasopressin	\N	Italy	Ospedale Psichiatrico Pini, Ctr di Psiconeuroendocrinologia, Milan, Italy	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1437	Clerc 1989 a	\N	Amisulpride Dosage	\N	France	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1441	Digo 1967	\N	 CSG No: 3067 	\N	France	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
1442	Digonnet 1987	\N	psychotropic drugs versus Placebo	\N	France	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
1447	Giannelli 1990	\N	 CSG No: 3033 	\N	Italy	Ospedale Niguarda Ca' Granda, Servizio Psichiatrico "Vergani," Milan, Italy	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
1448	Ferrari 1972	\N	Amantadine versus Placebo	\N	Italy	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1454	Haas 1982 b	\N	pimozide versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1455	Haffmans 1995	\N	Risperidone versus Haloperidol	\N	Netherlands	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
1456	Hamner 1996	\N	seroquel versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	109	\N	\N	\N	\N	\N
1457	Goldwurm 1971	\N	 CSG No: 3029 	\N	Italy	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
1458	Grasso 1974	\N	electic stimuli versus control group	\N	Italy	U Catania, Clinica delle Malattie Nervosa e Mentali, Italy	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
1459	Gravem 1990	\N	zuclopenthixol acetate + zuclopenthixol decanoate versus zuclopenthixol decanoate	\N	Norway	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1460	Greenbaum 1970	\N	niacinamide + tranquilizer versus Placebo	\N	Canada	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
1461	Grinspoon 1967	\N	phenothiazine + psychotherapy versus Placebo + psychotherapy	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1462	Growe 1979	\N	lithium versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
1463	Guazzelli 1995	\N	L-sulpiride versus Haloperidol	\N	Italy	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1464	Gudeman 1981	\N	psychosocial program versus control group	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
1465	Gundlach 1966	\N	diazepam versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1466	Gunther 1995 b	\N	active mental treatment versus unspecific treatment	\N	Germany	Germany	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
1467	Albert 1970	\N	 CSG No: 3089 	\N	Canada	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
1468	Barbier 1984	\N	 CSG No: 3086 	\N	France	Ctr Hospitalier Specialise Sainte-Marie, Privas, France	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1469	Berner 1989 b	\N	 CSG No: 3091\r\nCSG No. 5278 	\N	Austria	Clinique Universitaire de Psychiatrie, Vienne, Autriche.	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1470	Ciurezu 1976	\N	 CSG No: 3106 	\N	Romania	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1472	Costa e Silva 1990	\N	Amisulpride versus Haloperidol	\N	Brazil	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1473	Darondel 1981	\N	 CSG No: 3107 	\N	France	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
1475	Essock 1996	\N	Clozapine versus control group	\N	United States of America	\N	\N	\N	\N	\N	227	\N	\N	\N	\N	\N
1477	Hardeman 1970	\N	thiothixene versus thioridazine	\N	Netherlands	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1478	Harford 1969	\N	reformed sinner strategy versus lapsed saint strategy	\N	United States of America	Massachusetts General Hosp., Boston	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
1479	Harris 1992	\N	thioridazine versus Haloperidol	\N	United States of America	University of California, San Diego.	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
1480	Harris 1997	\N	neuroleptic treatment versus drug free	\N	United States of America	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
1481	Hawkins 1980	\N	biofeedback versus control group	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1482	Hayano 1993	\N	 CSG No: 2295 	\N	Japan	Division of Psychiatry, Goryo Prefectural Hospital, Wakayama, Japan	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1483	Hayes 1995	\N	thorazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
1484	Henley 1976	\N	Chlorpromazine + stimuli versus Placebo + stimuli//Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
1486	Harrow 1951	\N	psychodrama therapy groups versus control group	\N	United States of America	U. Chicago, Ill.	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1489	Glick 1975 a	\N	short hospitalization	\N	United States of America	U California, Langley Porter Inst, San Francisco	\N	\N	\N	\N	141	\N	\N	\N	\N	\N
2919	Watt 1978	\N	 CSG No: 1280 	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1490	Gupta 1995 b	\N	Risperidone versus various doses	\N	United States of America	\N	\N	\N	\N	\N	211	\N	\N	\N	\N	\N
1491	Konig 1996	\N	Amantadine versus Biperiden	\N	Austria	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
1492	Kopell 1968	\N	Chlorpromazine versus methamphetamine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
1494	Kordas 1968	\N	clopenthixol versus Chlorpromazine	\N	Greece	ORIGIN Other Europe	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
1495	Kornetsky 1976	\N	dextroamphetamine versus methylphenidate hydrochloride	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1496	Krebs 1979	\N	methionine-enkephalin versus Placebo	\N	Switzerland	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1497	Krystal 1993 a	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus various dose and elElectro Convulsive Therapy (Electroconvulsive Therapy)rode placements	\N	United States of America	Duke U Medical Ctr, Dept of Psychiatry, Durham, NC, US ORIGIN USA	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
1499	Krystal 1993 c	\N	m-chlorophenylpiperazine versus Placebo	\N	United States of America	Yale U School of Medicine Schizophrenia Biological Research Ctr, Veterans Affairs Medical Ctr, West Haven, CT, US ORIGIN USA	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
1500	Kudo 1997 b	\N	 CSG No: 2428 	\N	Japan	\N	\N	\N	\N	\N	161	\N	\N	\N	\N	\N
1501	Kudo 1972	\N	 CSG No: 963 CSG No: 5348	\N	Japan	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
1502	Kugler 1982	\N	pure tones to left and right ears versus various Hz	\N	United Kingdom	ORIGIN UK\r\n\r\nFriern Hosp, Neuropsychology Research Unit, London, England	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1503	Kugler 1980	\N	Chlorpromazine versus amylobarbitone	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1504	Kuipers 1996	\N	Cognitive Behavioural Training versus normal community care	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1505	Kuipers 1997 b	\N	Cognitive Behavioural Training + standard care versus control group	\N	United Kingdom	Dr. E. Kuipers, Department of Clinical Psychology, Institute of Psychiatry, London SE5 8AF ORIGIN UK\r\n\r\nDepartment of Clinical Psychology, Institute of Psychiatry, London.\r\n\r\nU London, United Medical and Dental Schools of Guy's and St Thomas's Hosps, Dept of Psychology, St Thomas's Hosp, London, England	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1506	Kuipers 1994	\N	structured medication education versus unstructured medication education	\N	United Kingdom	School Nurs, Purdue Univ, West Lafayette IN 47907-1337	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1507	Kuldau 1977	\N	inpatient care versus rapid discharge program	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
1508	Kulkarni 1996	\N	estradiol + neuroleptic treatment versus neuroleptic treatment	\N	Australia	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
1509	Kumari 1997	\N	d-amphetamine versus Haloperidol	\N	United Kingdom	Section of Cognitive Psychopharmacology, University of London, UK. spjtvek@iop.bpuf.ac.uk\r\n\r\nU London, Inst of Psychiatry, Dept of Psychology, London, England UK	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1513	Kurland 1977	\N	naloxone hydrochloride versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1514	Kurland 1981	\N	viloxazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
1515	Kurland 1975	\N	penfluridol versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
1517	Kurland 1966 a	\N	fluphenazine enanthate versus fluphenazine decanoate	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
1518	Kutcher 1989	\N	clonazepam versus Placebo	\N	Canada	Adolescent Inpatient Services, Sunnybrook Medical Centre, Toronto, Ontario, Canada. ORIGIN Canada	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
1519	Lafave 1996	\N	assertive community treatment versus hospital based programs	\N	Canada	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
1520	Lahdelma 1991	\N	remoxipride versus Haloperidol	\N	Finland	Department of Psychiatry, University of Helsinki, Finland.	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1521	Lahti 1995a	\N	(-)3PP versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
1523	Lahti 1997	\N	(-)3PP versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
1524	Lam 1992	\N	Haloperidol dose	\N	United States of America	Department of Pharmacology, University of Texas Health Science Center, San Antonio 78284-6220. ORIGIN USA	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
1525	Lampe 1969	\N	clomacran versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
1527	Kabes 1980 a	\N	oxyprothephine decanoate versus fluphenazine decanoate	\N	Czech Republic	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
1528	Kahn 1993 a	\N	Clozapine versus Placebo	\N	United States of America	Department of Psychiatry, Mount Sinai School of Medicine/Bronx VA Hospital, New York.	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
1529	Kalichman 1995	\N	behavioural skills intervention versus waitlist group	\N	United States of America	Center for AIDS Intervention Research, Medical College of Wisconsin, Milwaukee 53226, USA.	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
1530	Kammerer 1968	\N	 CSG No: 3105 	\N	France	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
1531	Kammerer 1967	\N	 CSG No: 3061 	\N	France	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
1533	Kariya 1983	\N	timiperone versus Haloperidol	\N	Japan	\N	\N	\N	\N	\N	212	\N	\N	\N	\N	\N
1534	Karon 1976	\N	psychologist versus psychiatrist	\N	United States of America	Michigan State U	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
1535	Lam 1994	\N	vitamin E versus Placebo	\N	Hong Kong	Kwai Chung Hosp, Hong Kong, Hong Kong ORIGIN Mid E./Asia	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
1537	Lamontagne 1983	\N	thought stopping technique + Chlorpromazine versus Chlorpromazine	\N	Canada	U Montreal, Canada ORIGIN Canada	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1538	Landis 1960	\N	dornwal dose	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
1539	Landmark 1994	\N	fluphenazine decanoate + fluphenazine HI i.m. versus fluphenazine decanoate	\N	Canada	University of Western Ontario, London. ORIGIN Africa	\N	\N	\N	\N	135	\N	\N	\N	\N	\N
1540	Lange 1980	\N	 CSG No: 2930 	\N	Germany	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1541	Langley 1960	\N	Orphenadrine + Reserpine versus Reserpine + Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1542	Langsley 1978	\N	outpatient family crisis thereapy versus mental hospital admission	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1543	Lapierre 1992	\N	remoxipride versus Haloperidol	\N	Canada	U Ottawa, Royal Ottawa Hosp, ON, Canada ORIGIN Canada	\N	\N	\N	\N	245	\N	\N	\N	\N	\N
1544	Lapierre 1975	\N	pimozide + group psychotherapy versus fluphenazine	\N	Canada	U Ottawa, Canada	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
1545	Lapierre 1990	\N	remoxipride versus Haloperidol	\N	Canada	Royal Ottawa Hospital, Ottawa, Ontario, Canada. ORIGIN Canada	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
1546	LaPorte 1997	\N	monetary reinforcement versus no reinforcement	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
1547	Hollister 1967	\N	Acetophenazine versus Benzquinamide	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1548	Huber 1971	\N	pimozide versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1549	Itil 1969 a	\N	LSD versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
1550	Lascelles 1959	\N	Azacyclonol versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1551	Lasky 1962	\N	Chlorpromazine + thioridazine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	512	\N	\N	\N	\N	\N
1552	Latz 1965	\N	Chlorpromazine versus no drug control	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
1553	Laurell 1970 a	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus flurothyl convulsive therapy (FCT)	\N	Sweden	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
1555	Laurell 1970 c	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus flurothyl convulsive therapy (FCT)	\N	Sweden	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1556	Lawrie 1996	\N	case study of patient with schizophrenia versus case study of patient without schizophrenia	\N	United Kingdom	Edinburgh University Department of Psychiatry, Royal Edinburgh Hospital. ORIGIN UK	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1557	Leblhuber 1987 a	\N	tiaprid versus Placebo	\N	Austria	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1558	Lecrubier 1988	\N	Amisulpride versus Placebo	\N	France	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
1559	Lee 1968	\N	Haloperidol versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
1560	Lee 1992	\N	MK-212 versus Placebo	\N	United States of America	Laboratory of Biological Psychiatry, Case Western Reserve University, University Hospitals of Cleveland, OH 44106. ORIGIN USA	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
1561	Lee 1995	\N	Haloperidol + cyproheptadine versus Haloperidol + Placebo	\N	South Korea	Department of Psychiatry, Yonsei University College of Medicine, Seoul, Korea. ORIGIN Mid E./Asia	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1562	Lee 1974	\N	thiothixene versus various dosages	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
1563	Lee 1994 a	\N	Clozapine versus typical neuroleptics	\N	United States of America	Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio. ORIGIN USA\r\n\r\nDepartment of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37212, USA.\r\n\r\nPsychiatric Hosp at Vanderbilt, Dept of Psychiatry, Nashville, TN, USA	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
1564	Lee 1996 a	\N	carbamazepine + valproic acid versus Haloperidol	\N	South Korea	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
1565	Lee 1996 b	\N	paroxtine + Haloperidol versus paroxtine + Placebo	\N	South Korea	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
1566	Leff 1989	\N	family therapy + education versus relatives group + education	\N	United Kingdom	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1567	Lahti 1994	\N	ketamine + Haloperidol versus Placebo + Placebo	\N	United States of America	\N	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
1568	Lapierre 1976	\N	pimozide + group psychotherapy versus fluphenazine	\N	Canada	Pierre Jaffet Hosp, Hull, Canada	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
1569	Lapierre 1978	\N	penfluridol versus fluphenazine	\N	Canada	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
1570	Lapolla 1965 b	\N	oral stelazine versus IM stalazine	\N	United States of America	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
1571	LaPorte 1996	\N	ketamine injection versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
1572	Leff 1996	\N	capitated program versus fee for service program	\N	United States of America	\N	\N	\N	\N	\N	1734	\N	\N	\N	\N	\N
1574	Lehman 1999	\N	assertive community treatment versus standard care	\N	United States of America	U Maryland, Dept of Psychiatry, Baltimore, MD, USA	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
2920	Weber 1983	\N	 CSG No: 3555 	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
1575	Lehman 1997	\N	assertive community treatment versus standard community treatment	\N	United States of America	Center for Mental Health Services Research, University of Maryland, Baltimore, USA.	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
1576	Lehman 1993	\N	usual community rehabilitation services + innovated group and intensive management versus usual community rehabilitation services	\N	United States of America	Department of Psychiatry, University of Maryland, Baltimore 21201. ORIGIN USA	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
1577	Lehmann 1982	\N	tamitinol dihydrochloride versus Placebo	\N	Germany	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
1579	Lehmann 1980	\N	fluphenazine decanoate versus Placebo	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1580	Lehmann 1967	\N	phenothiazine + butyrophenone versus phenothiazine + Placebo	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1581	Lehmann 1983	\N	Chlorpromazine dose	\N	Canada	McGill U, Div of Psychopharmacology, Montreal, Canada ORIGIN Canada	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
3222	Blanc 1968	\N	 CSG No: 3957 	\N	France	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1582	Leighman 1971	\N	pentylenetetrazol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1583	Leitch 1960	\N	Chlorpromazine versus methotrimeprazine	\N	United Kingdom	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
1584	Lemmens 1998	\N	Risperidone versus Antipsychotics	\N	Belgium	\N	\N	\N	\N	\N	2232	\N	\N	\N	\N	\N
1585	Lemmens 1994	\N	Risperidone versus zuclopenthixol//Risperidone versus Placebo//zuclopenthixol versus Placebo	\N	Belgium	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
1586	Pfefferbaum 1979	\N	beta-endorphin versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1587	Lenzi 1986	\N	carbamazepine + Chlorpromazine versus lithium + Chlorpromazine	\N	Italy	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1590	Leon 1974	\N	Clozapine versus Chlorpromazine	\N	Colombia	ORIGIN South/Central America\r\n\r\nWorld Health Organization Collaborating Ctr for Research & Training in Mental Health, Cali, ColombiaORIGIN South/Central America	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
1591	Leong 1989	\N	pipothiazine palimate versus fluphenazine decanoate	\N	Singapore	ORIGIN Mid E./Asia	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1592	Lepola 1989	\N	sulpiride versus perphenazine	\N	Finland	Harjamaki Mental Hospital, Kuopio, Finland. ORIGIN Other Europe	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
1593	Lerer 1988	\N	fenfluramine versus Placebo	\N	Israel	Jerusalem Mental Health Ctr-Ezrath Nashim Hosp, Israel ORIGIN Mid E./Asia	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1594	Lerner 1979	\N	diazepam versus Haloperidol	\N	Israel	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1595	Lerner 1988	\N	lithium + halopeidol versus Haloperidol + Placebo	\N	Israel	Hadassah Medical School, Hebrew University, Doar Na'Shimshon, Israel. ORIGIN Mid E./Asia	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
1596	Leszek 1991	\N	human leukocyte interferon versus Placebo	\N	Poland	University Medical School, Psychiatric Clinic, Wroclaw, Poland ORIGIN Other Europe	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
1597	Letemendia 1967	\N	Chlorpromazine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
1598	Levin 1959	\N	phenobarbital versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	139	\N	\N	\N	\N	\N
1599	Levin 1990	\N	naloxone + Electro Convulsive Therapy (Electroconvulsive Therapy) versus Electro Convulsive Therapy (Electroconvulsive Therapy) + Placebo	\N	Israel	Tel-Aviv U, Sackler School of Medicine, Ramat-Aviv, Israel ORIGIN Mid E./Asia	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
1600	Levine 1994	\N	inositol dose	\N	Israel	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
1601	Levine 1993 a	\N	inositol dose	\N	Israel	ORIGIN Mid E./Asia	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1602	Levinson 1990	\N	fluphenazine dose	\N	United States of America	Department of Psychiatry, Medical College of Pennsylvania and Hahneman University, Philadelphia 19129, USA. ORIGIN USA	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
1604	Levitt 1975	\N	electrosleep therapy versus simulated treatment	\N	Australia//New Zealand	ORIGIN Australia/NZ	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
1605	Levy 1983 a	\N	Haloperidol dose	\N	United States of America	U Chicago ORIGIN USA	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
1606	Levy 1984	\N	apomorphine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
1607	Levenson 1976	\N	Fluphenazine versus Haloperidol // Fluphenazine versus Thiothixene // Haloperidol versus Thiothixene	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
1608	Levenson 1977	\N	alternative hospitalization versus full time hospitalization	\N	United States of America	Baylor Coll of Medicine, Houston, TX ORIGIN USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1609	Levin 1996	\N	Haloperidol versus Placebo nicatine patches	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
1610	Levine 1997 a	\N	inositol versus Placebo	\N	Israel	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
1612	Levine 1995	\N	inositol + Electroconvulsive Therapy versus Electroconvulsive Therapy + Placebo	\N	Israel	Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev Beersheva Israel.	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
1614	Levine 1993 b	\N	inositol versus Placebo	\N	Israel	Beersheva Mental Health Center, Faculty of Health Sciences, Ben Gurion University, Israel. ORIGIN Mid E./Asia	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1616	Levy 1993	\N	methylphenidate versus apomorphine	\N	United States of America	McLean Hospital, Belmont, MA 02178. ORIGIN USA	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
12590	Hahlweg 1996	\N	\N	\N	Germany	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
1617	Levy 1983 b	\N	GHB + fluphenazine versus Placebo + fluphenazine	\N	United States of America	Bronx VA Medical Ctr, Schizophrenia Biological Research Ctr, NY ORIGIN USA	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
1618	Levy 1983 c	\N	fluotracen versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1619	Lewis 1983	\N	Sulpiride Dosage	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
1620	Lewis 1973	\N	Chlorpromazine versus Haloperidol	\N	Australia//New Zealand	ORIGIN Australia/NZ	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
1621	Leyton 1958	\N	glucose + insulin versus glucose	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1622	Li 1994 a	\N	 CSG No: 327 	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
1623	Liberman 1988	\N	symptom management training versus control group	\N	Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1724	Maletzky 1974	\N	dilantin versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1725	Maley 1973	\N	token economy program versus control group	\N	United States of America	West Virginia U.	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1726	Malfroid 1978	\N	Bromperidol versus Haloperidol	\N	Belgium	ORIGIN Other Europe	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1727	Malik 1980	\N	loxapine versus trifluoperazine	\N	India	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
1728	Malm 1982	\N	group therapy + neuroleptics + social skills training versus neuroleptics + social skills training	\N	Sweden	ORIGIN Other Europe	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
1729	Malm 1974	\N	fluspirilene versus fluphenazine enanthate	\N	Sweden	ORIGIN Other Europe	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
1730	Maloney 1976	\N	neuroleptic treatment versus control group	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1731	Malt 1995	\N	zuclopenthixol versus Haloperidol	\N	Norway	University of Oslo, Department of Psychosomatic and Behavioural Medicine, National Hospital, Norway. ORIGIN Other Europe	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
1733	Mandel 1962	\N	butyrylperazine versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
1734	Mandel 1961	\N	triphenidyl versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
1735	Mangen 1983	\N	community psychiatric nurses versus routine outpatient psychiatrist follow-up	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
1736	Manos 1986	\N	antiparkinson medication versus Placebo	\N	Greece	ORIGIN Other Europe	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
1737	Man 1973	\N	im Chlorpromazine versus im Haloperidol	\N	United States of America	Northville State Hosp., Mich. ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1738	Manchanda 1986	\N	propranolol versus Placebo	\N	United Kingdom // Canada	ORIGIN UK\r\n\r\nU Western Ontario, St Thomas Psychiatric Hosp, Canada ORIGIN Canada	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
1739	Manis 1984	\N	vocabulary definition of high pathology behavior samples versus vocabulary definition of low pathology behavior samples	\N	United States of America	Ann Arbor VA Medical Ctr, MI ORIGIN USA	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
1740	Marais 1971	\N	hydergine versus thioridazine	\N	South Africa	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1741	Marchesi 1992	\N	naltrexone versus Placebo	\N	Italy	Institute of Psychiatry, University of Ancona, Italy. ORIGIN Other Europe	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1742	Marchesi 1995	\N	naltrexone versus Placebo	\N	Italy	ORIGIN Other Europe	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
1743	Marder 1986	\N	fluphenazine decanoate dose	\N	United States of America	West Los Angeles VA Medical Ctr, Brentwood Div, CA ORIGIN USA	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
1744	Marder 1991 a	\N	fluphenazine decanoate dose	\N	United States of America	Veterans Administration Medical Center, West Los Angeles, Brentwood Division, CA 90073. ORIGIN USA	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
1745	Marder 1990	\N	fluphenazine decanoate dose	\N	United States of America	West Los Angeles Veterans Administration Medical Center, Brentwood Division, CA 90073. ORIGIN USA	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
1746	Marder 1989	\N	oral fluphenazine versus depot fluphenazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
1747	Marjerrison 1971	\N	nadolol versus Placebo	\N	Canada	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
1748	Marjerrison 1966 a	\N	butyrophenones versus trifluoperazine	\N	Canada	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
1749	Marjerrison 1975	\N	unilateral Electro Convulsive Therapy (Electroconvulsive Therapy)versus bilateral Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	Canada	U Saskatchewan, Saskatoon, Canada	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
1750	Marjerrison 1969	\N	Chlorpromazine versus chlorprothixene	\N	Canada	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
1751	Marks 1994	\N	home care versus hospital care	\N	United Kingdom	\N	\N	\N	\N	\N	189	\N	\N	\N	\N	\N
1752	Marsálek 1995	\N	pyritinol versus Placebo	\N	Czech Republic	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
1753	Marshall 1989	\N	fenfluramine versus Placebo	\N	United States of America	U California-Los Angeles Clinical Research Unit, Camarillo, US ORIGIN USA	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
1754	Martin 1972	\N	 CSG No: 3072 	\N	France	\N	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
1755	Martin 1975	\N	phenothiazine dose	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
20232	胡亚兰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
1756	Martin 1994	\N	sertindole versus Placebo	\N	United States of America//Canada	\N	\N	\N	\N	\N	205	\N	\N	\N	\N	\N
1757	Angst 1974	\N	 CSG No: 3116 	\N	Switzerland	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1758	Angst 1975	\N	 CSG No: 3149 	\N	Switzerland	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1759	Anonymous 1993 b	\N	pramipexole versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1760	Barnas 1991	\N	zotepine versus Haloperidol	\N	Austria	Arbeitsgruppe fur Biologische Psychiatrie, Universitat Innsbruck Osterreich.	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1762	Bergener 1972	\N	 CSG No: 3150 	\N	Germany	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
1763	Buchkremer 1987	\N	 CSG No: 3163 Biological Abstracts Vol. 84, Iss. 11, Ref. 112939 	\N	Germany	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
1764	Burchard 1972	\N	 CSG No: 3122 	\N	Germany	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
1765	Conley 1995	\N	RWJ-37796 versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1766	D'Orsi 1980	\N	 CSG No: 3114 	\N	Italy	L. Bianchi Provincial Psychiatric Hosp, Naples, Italy	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1767	Hartelius 1968	\N	 CSG No: 3142 	\N	Sweden	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
1768	Heim 1987	\N	 CSG No: 3164 	\N	Germany	\N	\N	\N	\N	\N	135	\N	\N	\N	\N	\N
1769	Hirsch 1989 b	\N	 CSG No: 3133 	\N	Germany	Germany	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
1771	Jonsson 1967	\N	 CSG No: 3143 	\N	Norway	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1772	Arrojo 1978	\N	 CSG No: 3186 	\N	Spain	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
1773	Asada 1976 a	\N	 CSG No: 3168 	\N	Japan	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
1774	Beasley 1997	\N	Olanzapine versus Haloperidol	\N	United States of America//Canada//Germany	\N	\N	\N	\N	\N	431	\N	\N	\N	\N	\N
1777	Bohacek 1975	\N	 CSG No: 3205 	\N	Yugoslavia	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
1778	Bond 1995 a	\N	accelerated approach program versus gradual approach program	\N	United States of America	Indiana U-Purdue U, Dept of Psychology, Indianapolis, US	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
1779	Brzezicki 1965	\N	 CSG No: 3200 	\N	Poland	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1780	Bures 1978	\N	 CSG No: 3198 	\N	Switzerland	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1781	Cocchi 1971	\N	 CSG No: 3182 	\N	Italy	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1782	Degkwitz 1970	\N	 CSG No: 3155 	\N	Germany	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
1783	Dieterle 1991	\N	zotepine versus perazin	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1784	Dohner 1969	\N	 CSG No: 3157 	\N	Germany	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
1785	Doongaji 1982	\N	intravenous metoclopramide versus Placebo	\N	India	Dep. Psychol. Med., King Edward Meml. Hosp., Bombay, India	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
1786	Eckmann 1977	\N	carpipramine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
1787	Etienne 1991	\N	 CSG No: 3117 	\N	France	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1788	Eufe 1979	\N	 CSG No: 3161 	\N	Germany	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
1790	Galfi 1973	\N	fluspirilene + occucatonal therapy versus occucatonal therapy	\N	Hungary	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1791	Goncalves 1976	\N	 CSG No: 3199 	\N	Germany	Germany	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1792	Gonzalez 1985	\N	 CSG No: 3190 	\N	Cuba	Inst Superior de Ciencias Medicas de La Habana, Facultad No. 1, Cuba	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1793	Hadlik 1970	\N	 CSG No: 3203 	\N	Czech Republic	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
1794	Herz 1989 b	\N	intermittent medication protocol versus Placebo	\N	United States of America	State U New York, Buffalo, NY, US	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1795	Freeman 1969	\N	trifluoperazine versus molindone	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
1797	Gallant 1963 d	\N	trifluperidol versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
1799	Goldberg 1986	\N	thiothixene versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
1800	Hogarty 1973	\N	major role therapy versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	374	\N	\N	\N	\N	\N
1801	Hogarty 1986	\N	fluphenazine decanoate versus high//low dosages	\N	United States of America	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
1802	Johnstone 1988	\N	pimozide + lithium versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
1803	Beckmann 1992	\N	remoxipride versus Haloperidol	\N	Germany	Germany	\N	\N	\N	\N	1104	\N	\N	\N	\N	\N
1804	Bellack 1986	\N	 CSG No: 3217 	\N	United States of America	The Medical College of Pennsylvania, Philadelphia, Penn., United States; Department of Psychiatry	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
1805	Buchkremer 1989	\N	 CSG No: 3220 	\N	Germany	Germany	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
1806	Hong 1995 a	\N	Sulpiride + Clozapine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1807	Eckmann 1976	\N	carpipramine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
20233	卢卫红 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
1808	Fischer 1974	\N	Clozapine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	723 217	\N	\N	\N	\N	\N
1810	Haas 1982 c	\N	 CSG No: 3212 	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1811	Heimann 1974 b	\N	 CSG No: 3215\r\nCSG No. 5277 	\N	Switzerland	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
1812	Hirsch 1986	\N	 CSG No: 3221 	\N	United Kingdom	University of London, Great Britain; Charing Cross Hospital Medical School; Department of Psychiatry	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
1813	Awad 1997	\N	remoxipride versus Haloperidol	\N	Canada	Clarke Institute of Psychiatry, Department of Psychiatry, University of Toronto, Ontario, Canada.	\N	\N	\N	\N	205	\N	\N	\N	\N	\N
1814	Bao 1991	\N	flupenthixol decanoate versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1815	Ceskova 1994 a	\N	Risperidone versus perphenazine	\N	Czech Republic	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
1816	Feng 1990	\N	fluphenazine decanoate versus Haloperidol decanoate	\N	China	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
1818	Fleischhauer 1978	\N	pimozide dose	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1819	Goncalves 1972	\N	 CSG No: 3250 	\N	Germany	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
1821	Hornung 1995	\N	psychoeducation medication management versus control group	\N	Germany	\N	\N	\N	\N	\N	191	\N	\N	\N	\N	\N
1822	Jing 1981	\N	Masang (TCM) versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1823	Brambilla 1979	\N	L-dopa + carbodopa versus Placebo	\N	Italy	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
1824	Caffey 1975	\N	 CSG No: 3274 	\N	United States of America	\N	\N	\N	\N	\N	375	\N	\N	\N	\N	\N
1825	Dorevitch 1997 a	\N	vitamin E versus Placebo	\N	Israel	Talbieh Mental Health Center, Jerusalem, Israel.	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1826	Duoshen 1989	\N	Electroconvulsive therapy + Chlorpromazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1827	Elie 1975	\N	 CSG No: 3266 	\N	Canada	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
1828	Foster 1997	\N	As Required (Haloperidol versus Lorazepam)	\N	United States of America	Department of Psychiatry, Medical College of Pennsylvania-Hahnemann University Medical School, Philadelphia, USA.	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
1829	Jungkunz 1984	\N	diazepam versus FK 33-824	\N	Germany	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
1830	Keitner 1985	\N	dexamethasone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
1831	Kern 1995	\N	contingent monetary reinforcement versus enhanced instruction	\N	United States of America	Department of Psychiatry and Behavioral Sciences, University of California, Los Angeles, USA.	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1833	Good 1958	\N	Chlorpromazine dose	\N	United States of America	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
1834	Gottfries 1971	\N	flupenthixol versus flupenthixol decanoate	\N	Sweden	ORIGIN Other Europe	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
1835	Antropov 1981	\N	 CSG No: 3298 	\N	Russian Federation	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
1837	Bakharev 1984	\N	 CSG No: 3309 	\N	Russian Federation	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
1838	Bishop 1967	\N	skf-14336 versus trifluoperazine	\N	United States of America	TULANE U. SCHOOL OF MEDICINE	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
1839	Bloch 1995	\N	counselling intervention versus control group	\N	Australia//United Kingdom	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
1840	Centorrino 1994	\N	Clozapine + fluoxetine versus Clozapine	\N	United States of America	Department of Psychiatry, Harvard Medical School, Boston, MA.	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
1841	Ceskova 1996	\N	Risperidone versus Haloperidol	\N	Czech Republic	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1842	Chen 1995 a	\N	thioridazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	234	\N	\N	\N	\N	\N
1843	Chen 1994	\N	Chlorpromazine versus (three different dosages)	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
1844	Coleman 1974	\N	allopurinol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1845	Delwaide 1979	\N	thioproperazine versus tiapride	\N	Belgium	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
1848	Gardos 1970	\N	trifluoperazine versus thiothixene	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1849	Fenton 1998	\N	Omega-3 Fatty Acid versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
1850	Goldstein 1969 b	\N	perphenazine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
1851	Gryzunov 1994	\N	 CSG No: 3284 	\N	Russian Federation	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
1853	Gui-yun 1988	\N	Thioridazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
1854	Hayano 1992	\N	 CSG No: 3290 	\N	Japan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1855	Hayano 1989	\N	 CSG No: 3310 	\N	Japan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1857	Hollister 1980	\N	apomorphine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
1859	Joe 1985	\N	lecithin versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
20234	陆如平 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
1860	Huang 1995	\N	Flupenthixol versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
1861	Itil 1970 b	\N	fluphenazine hydrochloride dose	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
1862	Kabes 1980 b	\N	 CSG No: 3305 	\N	Czech Republic	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1863	Kawakita 1965	\N	 CSG No: 3279 	\N	Japan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1865	Klieser 1992 a	\N	Haloperidol dose	\N	Germany	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
1867	Klieser 1985	\N	pimozide versus Placebo	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1868	Kluiter 1990	\N	 CSG No: 3232 	\N	Netherlands	Rijksuniversiteit Groningen, Netherlands	\N	\N	\N	\N	159	\N	\N	\N	\N	\N
1869	Knights 1978	\N	brief care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
1870	Ko 1995	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1871	Kohler 1970	\N	 CSG No: 3111 	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1872	Konrad 1997	\N	Clozapine versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
1873	Kornhuber 1985	\N	 CSG No: 3202 	\N	Germany	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
1874	Ladisich 1986	\N	Ziprasidone versus Placebo	\N	Germany	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
1875	Leblhuber 1987 b	\N	tiaprid versus Placebo	\N	Austria	Department of Neurophysiology, Wagner-Jauregg-Krankenhaus, Linz, Austria.	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
1876	Lewandowski 1994	\N	cognitive group therapy versus action oriented group therapy	\N	Germany	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
1877	Shu 1993	\N	Haloperidol versus reduced dose, increased dose	\N	China	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
1879	Linden 1973	\N	 CSG No: 3201 	\N	Germany	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
1880	Liu 1994	\N	Thioridazine versus Clozapine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1881	Mahadevan 1991	\N	zuclopenthixol dihydrochloride versus sulpiride	\N	United Kingdom	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
1882	Martinot 1996 a	\N	Amisulpride versus Placebo	\N	France	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
1883	Martyns 1993	\N	flupenthixol versus clopenthixol	\N	Nigeria	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
1884	Marx 1997	\N	mecamylamine versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
1885	Masiak 1976	\N	 CSG No: 3244 	\N	Poland	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
1886	Masson 1971	\N	 CSG No: 3045 	\N	Switzerland	\N	\N	\N	\N	\N	1041	\N	\N	\N	\N	\N
1887	Mathew 1989	\N	d-amphetamine sulfate versus Placebo	\N	United States of America	Duke U Medical Ctr, Dept of Psychiatry, Durham, NC, US ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1888	Mathew 1986	\N	caffeine versus Placebo	\N	United States of America	Vanderbilt U, School of Medicine, Nashville, TN, US ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1889	Mathur 1981	\N	 CSG No: 1322 	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1890	Matkowski 1979	\N	 CSG No: 3278 	\N	Poland	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1891	Matsunaga 1988	\N	ceruletide versus Placebo	\N	Japan	ORIGIN Mid E./Asia	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
1892	Mattes 1985 a	\N	ceruletide versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
1893	Mattes 1985 b	\N	ceruletide versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
1895	Mattes 1984	\N	lithium versus fluphenazine	\N	United States of America	Carnier Foundation, Belle Mead, NJ ORIGIN USA	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
1897	Mattila 1990	\N	remoxipride + ethanol versus remoxipride	\N	Finland	Department of Clinical Pharmacology, University of Helsinki, Finland. ORIGIN Other Europe	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1898	Matz 1974	\N	Clozapine versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1899	Matzner 1978	\N	Haloperidol versus Placebo	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1900	Mauri 1994	\N	 CSG No: 3044 	\N	Italy	U degli Studi, Istituto di Psichiatria, Pisa, Italy	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2110	Ortega-Soto 1996	\N	trifluoperazine versus various dosages	\N	Mexico	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
3467	Lublin 1991	\N	Haloperidol versus Zuclopenthixol	\N	Denmark	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1901	Mavreas 1992	\N	family intervention + individual care versus control group	\N	Greece	Athens University Medical School, Department of Psychiatry, Eginition Hospital, Greece. ORIGIN Other Europe	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
1902	Mavroidis 1985	\N	Haloperidol dose	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
1903	Mavroidis 1984 a	\N	thiothixene versus various dosages	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1904	Mavroidis 1984 b	\N	fluphenazine dose	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1907	McCall 1992	\N	amobarbital versus Placebo	\N	United States of America	Department of Psychiatry, Duke University School of Medicine, Durham, N.C.	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1909	McClelland 1990	\N	Chlorpromazine versus Haloperidol	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1957	Merskey 1962	\N	pin prick with yes shut versus pin prick with eyes open	\N	United Kingdom	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
1911	McClelland 1976	\N	oral Antipsychotics + Antipsychotics (AP) drugs versus Antipsychotics (AP) drugs oral Antipsychotics + Antipsychotics (AP) drugs versus Antipsychotics (AP) drugs	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
1912	McCord 1981	\N	 CSG No: 1533 	\N	United States of America	\N	\N	\N	\N	\N	650	\N	\N	\N	\N	\N
1913	McCreadie 1982	\N	pimozide versus flupenthixol decanoate	\N	United Kingdom	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
1914	McCreadie 1980	\N	pimozide versus flupenthixol decanoate	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
1915	McCreadie 1979	\N	flupenthixol decanoate dose	\N	United Kingdom	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
1916	McCreadie 1977	\N	Haloperidol versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1917	McCreadie 1978	\N	pimozide versus Chlorpromazine	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1918	McCreadie 1983	\N	pimozide versus flupenthixol decanoate	\N	United Kingdom	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
1919	McCreadie 1986	\N	Haloperidol decanoate versus fluphenazine decanoate	\N	United Kingdom	Crichton Royal Hospital, Dumfries. ORIGIN UK	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
1920	McCreight 1961	\N	pipiridyl phenothiazine 2445 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
1921	McEvoy 1995	\N	Clozapine versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	12 56	\N	\N	\N	\N	\N
1922	McEvoy 1980	\N	flutroline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
1923	McEvoy 1989	\N	benztropine versus glycopyrrolate	\N	United States of America	Western Psychiatric Institute and Clinic, University of Pittsburgh, PA 15213.	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1924	McEvoy 1991	\N	Haloperidol dose	\N	United States of America	Department of Psychiatry, Duke University Medical Center, John Umstead Hospital, Butner, NC 27509. ORIGIN USA	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
1925	McEvoy 1987	\N	Amantadine versus Benztropine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
1928	McEvoy 1997	\N	Haloperidol dose	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1929	McFarlane 1996	\N	assertive community treatment + intensive family involvement versus assertive community treatment + epilsodical family involvement	\N	United States of America	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
1930	McFarlane 1995 a	\N	mulitple family groups + psychoeducation versus mulitple family groups	\N	United States of America	Department of Psychiatry, College of Physicians and Surgeons, Columbia University, USA.	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
1931	McFarlane 1995 b	\N	mulitple family groups + psychoeducation versus single family groups + psychoeducation	\N	United States of America	Department of Epidemiology of Mental Disorders, College of Physicians and Surgeons, Columbia University, USA. ORIGIN USA	\N	\N	\N	\N	172	\N	\N	\N	\N	\N
1933	McGorry 1997 a	\N	early detection and intervention + intensive community based follow up versus early detection and intervention	\N	Australia//New Zealand	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1934	McGorry 1997 b	\N	early detection and intervention + intensive community based follow up versus early detection and intervention	\N	Australia//New Zealand	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1935	McGrath 1974	\N	nicotinamide versus Placebo	\N	Ireland	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
1936	McGrath 1972	\N	nicotinamide versus Placebo	\N	Ireland	\N	\N	\N	\N	\N	265	\N	\N	\N	\N	\N
1938	McIndoo 1971	\N	mesoridazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
1939	McInnes 1972	\N	ketamine + Electro Convulsive Therapy (Electroconvulsive Therapy) versus methohexital + Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	Australia//New Zealand	ORIGIN Australia/NZ	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
1940	McInnes 1978	\N	pimozide versus Placebo	\N	Australia//New Zealand	ORIGIN Australia/NZ	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
1941	McInnis 1985	\N	trihexyphenidyl versus Placebo	\N	Iceland	ORIGIN Other Europe	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
1943	McKenzie 1966	\N	prothipendyl versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1945	Meco 1989	\N	ritanserin versus Placebo	\N	Italy	U degli Studi di Roma "La Sapienza", Italy ORIGIN Other Europe	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1947	Meltzer 1997	\N	Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	277	\N	\N	\N	\N	\N
1949	Meltzer 1979	\N	Clozapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
1950	Meltzer 1996	\N	Clozapine versus typical neuroleptics (Haloperidol)	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
1951	Mena 1966	\N	mesoridazine versus thioridazine	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1952	Mendlewicz 1990	\N	remoxipride versus Haloperidol	\N	Belgium	Hospital Erasme, University Clinics of Brussels, Belgium. ORIGIN Other Europe	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
1953	Menolascino 1985	\N	thiothixene versus thioridazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
1954	Menon 1972	\N	trifluperidol versus Placebo	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1955	Menon 1976	\N	rest during retention interval of a memory task versus acivity during retention interval of a memory task	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1958	Meshel 1967	\N	tybamate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1959	Meshel 1968	\N	tybamate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1960	Messier 1969	\N	thioridazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
1961	Metzer 1993	\N	propranolol versus Placebo	\N	United States of America	Departments of Neurology and Psychiatry (respectively), University of Arkansas for Medical Science, Little Rock, Arkansas, U.S.A. ORIGIN USA	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
1962	Meyendorf 1981	\N	 CSG No: 3194 	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1963	Mezquita 1972 a	\N	 CSG No: 3167 	\N	Spain	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
1964	Midha 1993	\N	loxapine versus Haloperidol	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1965	Mielke 1975	\N	lenperone versus Chlorpromazine	\N	United States of America	Tulane U, Medical School ORIGIN USA	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
1966	Mikheeva 1987	\N	 CSG No: 1227 	\N	Russian Federation	ORIGIN Other Europe	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
1967	Millar 1963	\N	fluphenazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
1968	Miller 1993	\N	Haloperidol versus Placebo	\N	United States of America	Department of Psychiatry, University of Texas Health Science Center at San Antonio 78284-7792.	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
1969	Miller 1997	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
1970	Miller 1974	\N	L-tryptophan + levodopa versus levodopa + Placebo	\N	United States of America	Maimonides Medical Center, Div. of Neurology, Brooklyn, N.Y. ORIGIN USA	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
1971	Miller 1965	\N	hydroxyphenamate versus various dosages	\N	Unclear	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1972	Milne 1960	\N	Chlorpromazine versus methotrimeprazine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
1973	Milner 1963	\N	absorbic acid versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1975	Min 1993	\N	Risperidone versus Haloperidol	\N	South Korea	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
1976	Min 1995	\N	Clozapine versus Haloperidol	\N	South Korea	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
1977	Mindham 1972	\N	Amantadine versus Placebo // Amantadine versus Orphenadrine // Orphenadrine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
1978	Mindham 1977	\N	piribedil versus Placebo	\N	United Kingdom	U Nottingham, Mapperley Hosp, England	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
1979	Minervini 1990	\N	alpidem versus Placebo	\N	Italy	Opera Don Uva Hosp, Dept of Psychiatry, Bisceglie, Italy ORIGIN Other Europe	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
1982	Mitchell 1956	\N	Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
1983	Mitchell 1957	\N	pacatal versus various dosages	\N	United Kingdom	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
1984	Mizuki 1986	\N	DN-1417 versus DTyE	\N	Japan	ORIGIN Mid E./Asia	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1985	Mizuki 1988	\N	ceruletide versus Placebo	\N	Japan	Yamaguchi U School of Medicine, Ube, Japan ORIGIN Mid E./Asia	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
1986	Modrcin 1988	\N	case management versus standard care	\N	United States of America	Portland State U, Graduate School of Social Work, OR, US ORIGIN USA	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
1987	Muller 1997 a	\N	halopoeridol + amitriptylin versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
1989	Modestin 1973	\N	 CSG No: 3245 	\N	Switzerland	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
1990	Modestin 1983	\N	Haloperidol dose	\N	United States of America	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
1991	Moffat 1964	\N	thioproperazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
1992	Mohler 1970	\N	thiothixene versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
1995	Moller 1986	\N	endorphines versus Haloperidol	\N	Germany	ORIGIN Other Europe	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
1996	Moller 1982	\N	oral Haloperidol versus im Haloperidol	\N	Germany	ORIGIN Other Europe	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
1997	Moller 1989	\N	carbamazepine versus Haloperidol	\N	Germany	Psychiatric Hospital, Technical University, Munich, F.R.G.	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
1998	Monteleone 1988 a	\N	baclofen versus Placebo	\N	Italy	Mental Health Service U.S.L. 41, Naples, Italy.	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
1999	Monteleone 1986	\N	sodium valproate versus Placebo	\N	Italy	ORIGIN Other Europe	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
2000	Montero 1971	\N	Chlorpromazine + trifluoperazine hydrochloride versus thioridazine	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2001	Montgomery 1992	\N	desenkephalin endorphin versus Placebo	\N	United Kingdom	St. Mary's Hospital Medical School, London, United Kingdom. ORIGIN UK	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
2002	Moore 1980	\N	physostigmine versus benztropine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2003	Moore 1975	\N	loxapine succinate versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
2921	Weckowicz 1960 a	\N	 CSG No: 814 	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2004	Moore 1983	\N	Communication Skills versus Control Group	\N	United States of America	U Nebraska Coll of Medicine, Nebraska Psychiatric Inst, Omaha ORIGIN USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2005	Morse 1992	\N	continuous treatment team versus outpatient mental health clinic	\N	United States of America	\N	\N	\N	\N	\N	178	\N	\N	\N	\N	\N
2006	Morton 1968	\N	Chlorpromazine versus Placebo//Trifluoperazine versus Placebo//Chlorpromazine versus Trifluoperazine	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2007	Morand 1983	\N	tryptophan versus Placebo	\N	Canada	Inst Philippe Pinel de Montreal, Canada ORIGIN Canada	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2008	Morgan 1968	\N	classroom group versus control group	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
2009	Morphy 1986	\N	alprazolam versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2010	Morris 1970	\N	pimozide versus fluphenazine	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2011	Morrison 1990 a	\N	remoxipride versus Haloperidol	\N	Sweden	Astra Research Centre, Sodertalje, Sweden. ORIGIN Other Europe	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2013	Midha 1994	\N	fluphenazine versus fluphenazine sulfoxide	\N	Canada	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
2014	Morandini 1975	\N	 CSG No: 3113 	\N	Italy	Hosp Neuropsichiatrici Verona, Italy	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2015	Morinigo 1992	\N	carbamazepine versus valproic acid	\N	Spain	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
2016	Morse 1997	\N	broker case management versus assertive community treatment	\N	United States of America	U Missouri, St Louis, MO, USA\r\n\r\nRutgers U, Inst for Health, Health Care Policy, and Aging Research, New Brunswick, NJ, USA	\N	\N	\N	\N	165	\N	\N	\N	\N	\N
2018	Mosher 1995	\N	soteria psychosocial program versus control facility	\N	United States of America	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
2019	Mosnik 1994	\N	phenylalanine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2020	Moss 1958	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
2021	Mouret 1991	\N	insulin versus Placebo	\N	France	Unite Clinique de Psychiatrie Biologique, Ctr Hospitalier Specialise le Vinatier, Lyon-Bron, France ORIGIN Other Europe	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2022	Movin 1994	\N	raclopride versus Placebo	\N	Sweden	Department of Clinical Pharmacology, Astra Arcus AB, Sodertalje, Sweden. ORIGIN Other Europe	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
2023	Moyano 1975	\N	loxapine succinate versus trifluoperazine hydrochloride	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
2024	Muijen 1992	\N	home care versus hospital care	\N	United Kingdom	\N	\N	\N	\N	\N	189	\N	\N	\N	\N	\N
2026	Mulder 1985	\N	assertive community treatment Garbinger program versus control group	\N	United States of America	\N	\N	\N	\N	\N	121	\N	\N	\N	\N	\N
2027	Mulholland 1997 a	\N	sertraline versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
2028	Muller 1992	\N	intermittent medication versus continuous medication	\N	Germany	Germany	\N	\N	\N	\N	365	\N	\N	\N	\N	\N
2030	Munitz 1986	\N	penfluridol versus various dosages	\N	Israel	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2031	Munkvad 1955	\N	suavitil versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
2034	Muyard 1981	\N	 CSG No: 3077 	\N	France	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
2035	Myers 1981	\N	propranolol versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2036	Naber 1997	\N	Olanzapine versus Risperidone // Olanzapine versus Zotepine // Risperidone versus Zotepine	\N	Germany	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
2037	Naber 1983 a	\N	naloxone versus Placebo	\N	Germany	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
2038	Naber 1983 b	\N	naloxone versus Placebo	\N	Germany	ORIGIN Other Europe	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2039	Nachshoni 1994	\N	carbamazepine versus Placebo	\N	Israel	Shalvata Mental Health Center, Kupat-Holim, Hod Hasharon, Israel. ORIGIN Mid E./Asia	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2040	Nagaraja 1977	\N	Haloperidol versus Placebo	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
2184	Petit 1984	\N	Sulpiride Dosage	\N	France	ORIGIN Other Europe	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
6321	Kane 1993 a	\N	Haloperidol dose	\N	United States of America	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
2041	Nahunek 1976	\N	 CSG No: 2828 CSG No: 644	\N	Czech Republic	U Jan Evangelista Purkyne Medical Faculty, Psychiatric Clinic, Brno, Czechoslovakia\r\n\r\nPurkyne U Medical Faculty, Psychiatric Clinic, Brno, Czechoslovakia ORIGIN Other Europe	\N	\N	\N	\N	599	\N	\N	\N	\N	\N
2042	Nahunek 1980	\N	perphenazine versus Placebo	\N	Czech Republic	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
2044	Nahunek 1978	\N	clorothepin versus Clozapine	\N	Czech Republic	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
2045	Nahunek 1982 a	\N	oxyprothepin versus Placebo	\N	Czech Republic	Purkyne U Medical Faculty, Psychiatric Clinic, Brno, Czechoslovakia ORIGIN Other Europe	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
2046	Nahunek 1982 b	\N	oxyprothepin versus Placebo	\N	Czech Republic	Purkyne U Medical Faculty, Psychiatric Clinic, Brno, Czechoslovakia ORIGIN Other Europe	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
2047	Nahunek 1979	\N	oxyprothepin versus Placebo	\N	Czech Republic	ORIGIN Other Europe	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
2048	Nahunek 1975	\N	Clozapine versus Placebo	\N	Czech Republic	ORIGIN Other Europe	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
2049	Nahunek 1968	\N	octoclothepin versus Placebo	\N	Czech Republic	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
2050	Nair 1997	\N	Clozapine versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
2051	Nair 1984	\N	cholecystokinin-octapeptide versus Placebo	\N	Canada	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2052	Naidoo 1956	\N	Reserpine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
2053	Nair 1985	\N	cholecystokinin-octapeptide versus Placebo	\N	Canada	Douglas Hosp Research Ctr, Verdun, Canada ORIGIN Canada	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
2054	Nakazawa 1983	\N	 CSG No: 3015 	\N	Japan	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
2055	Nasrallah 1977	\N	metyrosine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2056	Nasrallah 1984	\N	choline versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
2057	National 1968	\N	phenothiazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	335	\N	\N	\N	\N	\N
2058	Neal 1969	\N	oxypertine versus Placebo//Chlorpromazine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2059	Nedopil 1985 a	\N	benperidol dose	\N	Germany	ORIGIN Other Europe	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
2060	Nedopil 1985 b	\N	benperidol dose	\N	Germany	ORIGIN Other Europe	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
2061	Needham 1969	\N	trifluoperazine versus acridan derivative	\N	Australia//New Zealand	ORIGIN Australia/NZ	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
2062	Negrette 1969	\N	 CSG No: 2817 	\N	Canada	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2063	Nelson 1975	\N	self drug administration versus traditional administration	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
2065	Neppe 1983	\N	carbamazepine versus Placebo	\N	South Africa	ORIGIN Africa	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
2066	Nestoros 1996	\N	cholecystokinin versus Placebo	\N	Greece	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2067	Nestoros 1982	\N	diazepam versus Placebo	\N	Canada	Douglas Hosp Research Ctr, Verdun, Canada ORIGIN Canada	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2068	Nestoros 1978	\N	butaclamol versus fluphenazine	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2069	Netter 1994	\N	malingering condition versus control group	\N	United States of America	California School of Professional Psychology, San Diego 92121. ORIGIN USA	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2070	Netter 1991	\N	L-dopa versus Placebo	\N	Germany	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2071	Neu 1972	\N	benztropine mesylate versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
2072	Neubauer 1966	\N	sernyl versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
2073	Newcomer 1992	\N	Haloperidol dose	\N	United States of America	Washington U School of Medicine, St Louis, MO, US ORIGIN USA	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
2074	Nicholas 1996 b	\N	fenfluramine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2075	Nicolini 1997	\N	Olanzapine versus Risperidone	\N	Mexico	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
2076	Nicolson 1966	\N	penicillamine versus Placebo	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2077	Nienhuis 1991	\N	 CSG No: 3226 	\N	Netherlands	Rijksuniversiteit te Groningen, Netherlands	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
2079	Nisbet 1996	\N	card sorting group versus control group	\N	New Zealand	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
2080	Nishikawa 1989	\N	timiperione versus Placebo	\N	Japan	Department of Pharmacology, Kurume University School of Medicine, Japan. ORIGIN Mid E./Asia	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
2081	Nishikawa 1982	\N	diazepam versus Placebo//Chlorpromazine versus Placebo	\N	Japan	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
2082	Nishikawa 1984	\N	propericiazine versus Placebo	\N	Japan	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
2083	Nishikawa 1985	\N	thioridazine + pimozide, versus Placebo	\N	Japan	ORIGIN Mid E./Asia	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
2084	Nishikawa 1996	\N	naloxone versus Placebo	\N	Japan	ORIGIN Mid E./Asia	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
2087	Nistico 1974 a	\N	penfluridol versus Placebo	\N	Italy	U Naples, IInd Faculty of Medicine, Italy ORIGIN Other Europe	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2089	Norbeck 1983	\N	hemodialysis versus sham	\N	Sweden	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
2090	Nuechterlein 1992	\N	Antipsychotics versus withdraws of Antipsychotics individual placement and support - workplace fundamental module versus vocational rehabilitation	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
2091	Nuechterlein 1994	\N	Antipsychotics versus medication free	\N	United States of America	Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles 90024-6968. ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2093	Nurowska 1980	\N	 CSG No: 2916 	\N	Poland	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
2094	O'Brien 1974	\N	trifluoperazine versus Haloperidol	\N	United States of America	U. Pennsylvania ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2095	O'Brien 1972	\N	group psychotherapy versus individual psychotherapy	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2239	Potkin 1997 a	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	246	\N	\N	\N	\N	\N
2096	O'Connor 1987	\N	confederate labeled as schizophrenic versus confederate labeled as normal	\N	United Kingdom	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
2097	O'Connor 1983	\N	depo-medroxy progesterone acetate versus Placebo	\N	Australia	\N	\N	\N	\N	\N	3	\N	\N	\N	\N	\N
2098	Odejide 1982	\N	fluphenazine versus Placebo	\N	Nigeria	U Ibadan, University College Hosp, Nigeria ORIGIN Africa	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
2099	Oei 1981	\N	companion program versus control group	\N	Australia	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
2100	Offer 1960	\N	music groups versus control group	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
2101	Ogata 1981	\N	 CSG No: 3103 	\N	Japan	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2102	Okasha 1964	\N	Haloperidol versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
2103	Okuma 1989	\N	carbamazepine versus Placebo	\N	Japan	\N	\N	\N	\N	\N	162	\N	\N	\N	\N	\N
2104	Olson 1971	\N	modelling and reinforcement groups versus control group	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
2105	Oltman 1966	\N	perphenazine + amitryiptyline versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
2106	Omerov 1989	\N	perphenazine versus various dosages	\N	Sweden	Danderyd Hosp, Dept of Psychiatry, Sweden ORIGIN Other Europe	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
2107	Ortega 1991	\N	 CSG No: 623 	\N	Mexico	Inst Mexicano de Psiquiatria, Division de Investigaciones Clinicas, Tlalpan, MexicoORIGIN South/Central America	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
6691	Vaglum 2002	\N	\N	\N	Norway	\N	\N	\N	\N	\N	322	\N	\N	\N	\N	\N
2111	Orzack 1969	\N	periodic administration of Chlorpromazine versus sustained rlease form of Chlorpromazine	\N	United States of America	Division of Psychiatry, Boston University School of Medicine, Boston, Massachussetts, U.S.A. ORIGIN USA	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
2112	Marjerrison 1966 b	\N	pheniprazine versus Placebo	\N	Canada	Saskatchewan Hosp., North Battleford, Canada	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2113	May 1985	\N	life skills training versus group counceling	\N	United States of America	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
2114	Mayo 1993	\N	caffeine versus various dosages	\N	United Kingdom	Springfield Hospital, London. ORIGIN UK	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
2115	McAllister 1989	\N	Clozapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2116	Olbrich 1990	\N	cognitive training program versus control group	\N	Germany	Germany	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2117	Os'makova 1972	\N	aminazine versus phenamin	\N	Russian Federation	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2118	Ota 1974 a	\N	Chlorpromazine A versus standard Chlorpromazine (B)	\N	United States of America	Spring Grove Hosp Ctr, Maryland Psychiatric Research Ctr, Catonsville ORIGIN USA	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
2119	Ota 1974 b	\N	penfluridol versus Haloperidol	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2120	Otero 1993	\N	rehabilitation program versus control group	\N	Spain	Ctr de Rehabilitacion Psicosocial Los Carmenes, Madrid, Spain ORIGIN Other Europe\r\n\r\nCtr de Rehabilitacion Psicosocial Los Carmenes, Madrid, Spain	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2122	Ottosson 1960 a	\N	lidocaine + Electroconvulsive Therapy versus Electroconvulsive Therapy + Placebo	\N	Sweden	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2128	Overall 1964	\N	imipramine versus thioridazine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2129	Overall 1969	\N	SK&F 14336 versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
2130	Owen 1981	\N	a-flupenthixol versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
2131	Owen 1993	\N	m-chlorophenylpiperazine versus Placebo	\N	United States of America	NIMH Experimental Therapeutics Branch, Bethesda, MD, US ORIGIN USA	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
2132	Owens 1994	\N	L-dopa + Chlorpromazine versus Chlorpromazine + Placebo//Chlorpromazine versus Placebo	\N	United Kingdom	U Edinburgh, Dept of Psychiiatry, Royal Edinburgh Hosp, Scotland	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
2134	Pai 1982	\N	home care versus hospital care	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
2135	Paillere 1995	\N	Amisulpride versus Placebo	\N	France	Department of Child and Adolescent Psychiatry, Hopital de la Salpetriere, Paris, France. ORIGIN Other Europe\r\n\r\nCNS Development Strategy Department, Synthelabo Groupe, Le Plessis-Robinson, France.	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
2136	Palao 1994	\N	Haloperidol dose	\N	Spain	Department of Psychiatry, Hospital Clinic i Provincial, Barcelona, Spain. ORIGIN Other Europe\r\n\r\nORIGIN Other Europe	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
2139	Palmstierna 1987	\N	neuroleptics versus Placebo	\N	Sweden	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
2140	Panaccio 1972	\N	 CSG No: 3088 	\N	Canada	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
2141	Pancheri 1988	\N	CCK-8 versus Placebo	\N	Italy	U degli Studi di Roma "La Sapienza," Istituto di Psichiatria, Italy ORIGIN Other Europe	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2142	Pandurangi 1989	\N	thiothixene versus Haloperidol	\N	United States of America	Department of Psychiatry, Medical College of Virginia, Virginia Commonwealth University, Richmond. ORIGIN USA	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
2143	Pang 1997	\N	AP medication versus Placebo AP medication versus Placebo	\N	Hong Kong	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
2144	Paprocki 1977	\N	Haloperidol versus Loxapine	\N	United States of America	ORIGIN South/Central America	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
2145	Paredes 1966	\N	Chlorpromazine versus Placebo	\N	United States of America	Jefferson Medical Coll., Philadelphia, Pa.	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
2146	Parent 1974	\N	 CSG No: 3096 	\N	Belgium	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2147	Parent 1982	\N	flupenthixol versus Haloperidol	\N	Belgium	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2148	Park 1965	\N	methionine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
2149	Park 1981	\N	Chlorpromazine + triidothyronine versus Chlorpromazine + Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
2150	Patris 1990	\N	remoxipride versus Haloperidol	\N	France	Ctr Hospitalier Regional et Universitaire, Clinique Psychiatrique, Strasbourg, France ORIGIN Other Europe	\N	\N	\N	\N	186	\N	\N	\N	\N	\N
2151	Pattie 1975	\N	industrial thearpy unit versus control group	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2153	Patterson 1958	\N	insulin coma therapy versus control group	\N	United States of America	Connecticut State Hosp., Middletown	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
2154	Patterson 1981	\N	Chlorpromazine versus Placebo	\N	United States of America	Menninger Foundation, Research Dept, Topeka, KS ORIGIN USA	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2155	Paul 1977	\N	social learning therapy versus milieu therapy	\N	United States of America	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
2156	Paul 1972	\N	drug continuation program versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
2157	Paul 1957	\N	bimedial labotomy versus bilateral lobotomy	\N	United States of America	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
2158	Paulman 1980	\N	induced muscular tension while performing task versus task performed as usual	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
2159	Paulson 1996	\N	consumer assertive community treatments versus usual care	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
2160	Paunovic 1991	\N	Clozapine versus Haloperidol	\N	Yugoslavia	Institute of Psychiatry, University Clinical Centre, Belgrade, Yugoslavia. ORIGIN Other Europe	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
2161	Payne 1974	\N	phenothiazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2162	Payne 1963	\N	proketazine versus Placebo	\N	Canada	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
2163	Pazdirek 1980	\N	chlorprothixen drops versus various dosages	\N	Czech Republic	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
2164	Peak 1957	\N	Azacyclonol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
2165	Pearl 1956	\N	Reserpine Dosage	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
2166	Pecknold 1972	\N	methyldopa versus methotrimeprazine	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2167	Pecknold 1982	\N	pimozide versus Chlorpromazine	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2168	Peet 1981 a	\N	propranolol versus Placebo//Chlorpromazine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
2171	Peet 1996	\N	education group versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
2173	Peniston 1988	\N	group assertive training + contingent time-out versus standard treatment	\N	United States of America	Veterans Affairs Medical Ctr, Psychology Service, Ft Lyon, CO, US ORIGIN USA	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
2174	Penman 1956	\N	Reserpine versus Placebo	\N	Unclear	V.A. Hosp., St. Cloud, Minn.	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
2175	Peppel 1963	\N	phenothiazine therapy versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2176	Perales 1974	\N	Clozapine versus trifluoperazine	\N	Peru	Clinica San Antonio, Lima, PeruORIGIN South/Central America	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2180	Peselow 1987 a	\N	cholecystokinin-octapeptide versus Placebo	\N	United States of America	ORIGIN USA\r\n\r\nNew York VA Medical Ctr, Dept of Psychiatry, NY ORIGIN USA	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
2181	Peselow 1989	\N	GMI versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
7358	Pang 2002 a	\N	\N	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
2187	Petrie 1981	\N	nicotine acid + pyridoxine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2188	Petzel 1972	\N	crowded condition versus uncrowded condition	\N	United States of America	Loyola U., Chicago, Ill. ORIGIN USA	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
2189	Pfeiffer 1965	\N	pentobarbital versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	201	\N	\N	\N	\N	\N
2190	Pfeiffer 1991	\N	neuroleptic treatment versus control group	\N	Germany	Psychiatrische Klinik rechts der Isar der TU, Munchen.	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2191	Pflug 1990	\N	remoxipride versus Haloperidol	\N	Germany	Department of Psychiatry, University of Frankfurt, FRG. ORIGIN Other Europe	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
2192	Pflug 1992	\N	remoxipride versus Haloperidol	\N	Germany	Germany	\N	\N	\N	\N	418	\N	\N	\N	\N	\N
2193	Phanjoo 1990	\N	remoxipride versus thioridazine	\N	United Kingdom	Department of Geriatric Psychiatry, Royal Edinburgh Hospital, United Kingdom. ORIGIN UK	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2194	Pharr 1989	\N	EMG biofeedback group versus control group	\N	United States of America	U Maryland, College Park, US ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2195	Phillips 1965 b	\N	workshop versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
2196	Pi 1990	\N	Chlorpromazine versus Placebo	\N	United States of America	Department of Psychiatry, University of Southern California, Los Angeles. ORIGIN USA	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2197	Pichot 1983	\N	dogmatil versus Chlorpromazine	\N	France	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
2198	Pickar 1987 a	\N	fluphenazine versus Placebo	\N	United States of America	NIMH Clinical Neuroscience Branch, Section on Clinical Studies, Bethesda, MD, US ORIGIN USA	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
2199	Pickar 1989	\N	naloxone versus Placebo	\N	United States of America	Clinical Neuroscience Branch, National Institute of Mental Health, Bethesda, MD 20892. ORIGIN USA	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
2200	Pickar 1981	\N	B-endorphin versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2201	Pickar 1986	\N	neuroleptic treatment versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
2202	Pickar 1994	\N	Clozapine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2203	Pickar 1982	\N	naloxone versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
2204	Pickar 1987 b	\N	verapamil versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
2205	Pietzcker 1985	\N	intermittent treatment versus maintenance treatment	\N	Germany	\N	\N	\N	\N	\N	364	\N	\N	\N	\N	\N
2206	Pigache 1993	\N	Chlorpromazine versus Placebo	\N	United Kingdom	Psychopharmacology Research Unit, Guy's Hospital, London, UK. ORIGIN UK	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2207	Pinard 1971	\N	pimozide versus Placebo	\N	Canada	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
2208	Pinto 1975	\N	diphenylhydantoin + neuroleptics versus diphenylhydantoin	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
2209	Pinto 1979	\N	flupenthixol decanoate versus fluphenazine decanoate	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
2211	Pishkin 1972	\N	imipramine versus nialamide	\N	United States of America	Veterans Administration Hosp., Oklahoma City, Okla. ORIGIN USA	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
2212	Pishkin 1962	\N	imipramine versus nialamide	\N	United States of America	VA Hosp., Tomah, Wisc.	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
2213	Placidi 1986	\N	carbamazepine versus lithium	\N	Italy	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
2214	Platz 1967	\N	carphenazine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	330	\N	\N	\N	\N	\N
2215	Pleasure 1956	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
2216	Prien 1972	\N	Chlorpromazine versus Placebo	\N	United States of America	VA Hosp, Psychiatry Service, Houston, TX ORIGIN USA\r\n\r\nORIGIN USA	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
2217	Polak 1976	\N	community alternative treatment versus psychiatric hospital treatment	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
2219	Pollack 1956	\N	Reserpine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
2220	Pollmacher 1995	\N	Clozapine versus Haloperidol	\N	Germany	ORIGIN Other Europe	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2222	McClelland 1987	\N	ultrasound detector versus clinical rating scale	\N	United Kingdom	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
2224	Merlis 1962	\N	chlordiazepoxide versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
2225	Monteleone 1988 b	\N	sodium valproate versus Placebo	\N	Italy	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
2226	Montigny 1979	\N	deanol versus Placebo	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2227	Munetz 1989	\N	rimcazole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2229	Newton 1989	\N	Haloperidol dose	\N	United States of America	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
2231	Nordic 1986	\N	perphenazine versus Haloperidol	\N	Denmark	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
2232	Ota 1973	\N	oral concentrate Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
2233	Poldinger 1977	\N	Bromperidol versus Haloperidol	\N	Switzerland	Kantonale Psychiatrische Klinik, Wil, Switzerland ORIGIN Other Europe\r\n\r\nORIGIN Other Europe	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2234	Pollack 1964	\N	fluphenazine enanthate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
2235	Portnow 1960	\N	deanol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2236	Posner 1992	\N	family psychoeducational support group versus control group	\N	Canada	U Manitoba Health Sciences Ctr, Dept of Psychiatry, Winnipeg, Canada ORIGIN Canada	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
2237	Potkin 1994 a	\N	sertindole versus Placebo	\N	United States of America//Canada	Department of Psychiatry and Human Behavior, University of California Irvine Medical Center, Orange 92668. ORIGIN USA	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
2238	Potkin 1997 d	\N	 CSG No: 1717 	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
20235	严琦 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
2240	Potkin 1997 b	\N	Clozapine versus Haloperidol	\N	United States of America	Department of Psychiatry, University of California, Irvine 92697, USA.	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2241	Potkin 1985	\N	Haloperidol dose	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
2242	Pool 1976	\N	loxitane versus Placebo	\N	United States of America	Tulane U, Medical School	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
2243	Porot 1980	\N	amineptine versus clomipramine	\N	France	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
2244	Poser 1966	\N	group therapy versus control group	\N	Canada	McGill U., Montreal, Canada	\N	\N	\N	\N	343	\N	\N	\N	\N	\N
2246	Potkin 1995	\N	SDZ MAR 327 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2248	Potkin 1994 b	\N	Clozapine versus Placebo	\N	United States of America	Department of Psychiatry and Human Behavior, University of California, Irvine, Orange 92668. ORIGIN USA	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2249	Potkin 1981	\N	wheat gluten versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2251	Prange 1973	\N	L-tryptophan versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
2252	Prange 1979	\N	protirelin + niacin versus protirelin	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2254	Price 1987 a	\N	verapamil versus Placebo	\N	United States of America	Northeastern Ohio Universities Coll of Medicine, Rootstown, US ORIGIN USA	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2255	Price 1987 b	\N	verapamil versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2257	Prien 1973	\N	intermittent treatment versus continued treatment	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	375	\N	\N	\N	\N	\N
2258	Prien 1969	\N	trifluoperazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	341	\N	\N	\N	\N	\N
2260	Prien 1971	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	840	\N	\N	\N	\N	\N
2261	Van Praag 1970	\N	fluphenazine versus fluphenazine enanthate	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
2262	Perez 1981	\N	lecithin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
2263	Perovich 1989	\N	Bromocriptine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2265	Provenza 1990	\N	reading newspapers rehabilitation versus control group	\N	Italy	U Milan, San Raffaele Hospital Ctr for Rehabilitation & Cognitive Therapy, Italy ORIGIN Other Europe	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
2266	Prusoff 1979	\N	perphenazine + amitriptline hydrochloride versus perphenazine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2267	Pryce 1977	\N	hospital care versus home care	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
2268	Pryce 1978	\N	piracetam versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
2269	Psaras 1984	\N	Bromperidol versus Chlorpromazine	\N	Greece	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2271	Puente 1988	\N	relaxation response training versus control groups	\N	United States of America	U North Carolina, Wilmington, US ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2272	Pugh 1983	\N	propranolol versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
2274	Quinlivan 1995	\N	intensive case management versus control group	\N	United States of America	Mental health case management services, San Diego County Mental Health Services, California 92110, USA. ORIGIN USA	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
2276	Quinn 1984	\N	sulpiride versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2279	Quitkin 1975	\N	penfluridol versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
2280	Rachman 1963	\N	10 minute resting period in between trials versus 21 hour resting period in between trials	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2281	Rackensperger 1974	\N	oxprenolol versus propranolol	\N	Germany	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
2282	Rada 1974	\N	piperacetazine versus various dosages	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2283	Rada 1972	\N	piperacetazine versus thioridazine	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2284	Ragland 1968	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
2285	Rammsayer 1995	\N	remoxipride versus Placebo	\N	Germany	Germany	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
2286	Ramsay 1970 a	\N	molindone versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2287	Ramu 1992	\N	ayurvedic treatment versus Chlorpromazine	\N	India	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
2289	Rama Rao 1981	\N	sulpiride versus Haloperidol	\N	United Kingdom	MRC Neuropsychiatry Lab, West Park Hosp, Epsom, England ORIGIN UK	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2290	Rapisarda 1982 b	\N	supidimid + Haloperidol versus supidimid + Placebo	\N	Italy	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
2292	Rapp 1986	\N	perphenazine enanthate versus Haloperidol decanoate	\N	Sweden	Regionsjuhuset, Umea, Sweden ORIGIN Other Europe	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
3325	Karniol 1982	\N	oxprenolol versus Placebo	\N	Brazil	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
2293	Rappaport 1968	\N	perphenazine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
2294	Rappaport 1967	\N	perphenazine versus sodium pentobarbital	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
2295	Rappaport 1972	\N	phenothiazine medication versus control group	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
2296	Rappaport 1978	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	127	\N	\N	\N	\N	\N
2297	Raptis 1990	\N	beclamide versus Placebo	\N	Germany	Germany	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
2298	Rasch 1966	\N	pericyazine versus Chlorpromazine	\N	Denmark	ORIGIN Other Europe	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
2299	Rasheed 1992	\N	Acetylsalicylic Acid (Aspirin) versus Acetylsalicylic Acid (Aspirin) + Chlorpromazine // Acetylsalicylic Acid (Aspirin) versus Chlorpromazine // Acetylsalicylic Acid (Aspirin) + Chlorpromazine versus Chlorpromazine	\N	Pakistan	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2300	Rasmussen 1976	\N	Chlorpromazine versus thioridazine	\N	Denmark	ORIGIN Other Europe	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2301	Rastogi 1982	\N	hydergine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2302	Rassidakis 1970	\N	Antipsychotics versus control group	\N	Greece	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
2304	Ratey 1992	\N	nadolol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
2305	Rathod 1958	\N	Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2306	Rathod 1961	\N	promazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
2307	Ravaris 1965	\N	fluphenazine enanthate versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
2309	Ravensborg 1972	\N	praise + monetary reward versus praise	\N	United States of America	Fergus Falls State Hosp., Minn. ORIGIN USA	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
2310	Rawitt 1959	\N	equanil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2311	Razali 1995	\N	drug compliance program versus control group	\N	Malaysia	Department of Psychiatry, School of Medical Sciences, Universiti Sains Malaysia, Kelantan.\r\n\r\nU Sains Malaysia, School of Medical Sciences, Dept of Psychiatry, Kelantan, Malaysia	\N	\N	\N	\N	165	\N	\N	\N	\N	\N
2314	Realmuto 1984	\N	thiothixene versus thioridazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
2316	Reardon 1966	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
2317	Rees 1951	\N	desoxycortone acetate + ascorbic acid versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
2318	Rees 1956	\N	cortisone therapy versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2321	Reichert 1976	\N	bilateral Electroconvulsive Therapy versus unilateral Electroconvulsive Therapy	\N	Canada	U Saskatchewan, Saskatoon, Canada	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
2322	Reid 1958	\N	Azacyclonol versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2324	Reinhardt 1959	\N	triflupromazine + iproniazid versus triflupromazine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2325	Reiter 1971	\N	 CSG No: 2366\r\n\r\nAbstract no. 992 	\N	Austria	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2327	Remr 1975	\N	oxypertine versus thioridazine	\N	Czech Republic	Psychiatric Dept, Liberec, Czechoslovakia	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
2328	Remvig 1987	\N	Zuclopenthixol versus Perphenazine	\N	Denmark	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
2329	Ren 1985	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2330	Reschke 1974	\N	Chlorpromazine versus Placebo	\N	United States of America	Los Angeles County Mental Health Services, Long Beach Regional Service, Calif. ORIGIN USA	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
2332	Rice 1979	\N	social skills training versus control treatment	\N	Canada	Mental Health Ctr, Penetanguishene, Canada ORIGIN Canada	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2333	Richardson 1995	\N	RWJ versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2628	Spohn 1977	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2334	Richardson 1982	\N	lecithin versus Placebo	\N	United States of America	Rockland Research Inst, Information Sciences Div, Orangeburg, NY ORIGIN USA	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
2335	Rickels 1978	\N	thiothixene versus Chlorpromazine	\N	United States of America	U Pennsylvania Hosp, Philadelphia, PA ORIGIN USA	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
2336	Rifkin 1991	\N	Haloperidol dose	\N	United States of America	Department of Psychiatry, Long Island Jewish Medical Center, NY. ORIGIN USA\r\n\r\nDepartment of Psychiatry, Our Lady of Mercy Medical Center, Bronx, NY 10466. ORIGIN USA	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
2337	Rifkin 1988	\N	Haloperidol dose	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
2339	Rifkin 1978	\N	AP drugs versus Placebo + procyclidine hydrochloride	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
2340	Rifkin 1976	\N	flulphenazine decanoate versus Placebo	\N	United States of America	ORIGIN USA\r\n\r\nNew York State Psychiatric Inst, New York ORIGIN USA	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
2341	Rifkin 1984	\N	loxapine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
2343	Rinaldi 1956	\N	Azacyclonol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2344	Rinieris 1988	\N	Chlorpromazine + trihexyphenydil versus Chlorpromazine	\N	Greece	Athens U Medical School, Eginition Hosp, Greece ORIGIN Other Europe	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2345	Ritter 1972 a	\N	Chlorpromazine versus Haloperidol	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
2346	Ritter 1971	\N	mesoridazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
2347	Ritter 1972 b	\N	mesoridazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
2348	Robak 1973	\N	pipotiazine palmitate versus control group	\N	Norway	ORIGIN Other Europe	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
2349	Robinson 1996	\N	contiuous fluphenazine decanoate versus intermittent fluphenazine decanoate group	\N	United States of America	Hillside Hospital, Glen Oaks, NY 11004, USA.	\N	\N	\N	\N	528	\N	\N	\N	\N	\N
2350	Robinson 1991	\N	methylphenidate versus Placebo	\N	United States of America	Long Island Jewish Medical Ctr-Hillside Hosp, Dept of Psychiatry, Glen Oaks, NY, US ORIGIN USA	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
2351	Roder 1997	\N	social skills training versus Cognitive Behavioural Therapy (Cognitive Behavioral Therapy)	\N	Switzerland	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
2352	Rodova 1971	\N	clothiapin versus perphenazine	\N	Czech Republic	ORIGIN Other Europe	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
2353	Rodova 1973	\N	Clozapine versus perphenazine	\N	Czech Republic	ORIGIN Other Europe	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
2354	Roelofs 1974	\N	penfluridol versus Placebo	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
2405	Salomon 1972	\N	arginine aspartate versus Placebo	\N	France	Neuropsychiatric Clinic, Grenoble, France	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
2406	Salzman 1991	\N	lorazepam versus Haloperidol	\N	United States of America	Massachusetts Mental Health Ctr, Boston, US ORIGIN USA	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
2407	Sampath 1992	\N	fluphenazine decanoate versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2408	Samuels 1961	\N	Haloperidol versus control group	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
2409	San Miguel 1995	\N	biperiden + Haloperidol versus Haloperidol	\N	Spain	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
2414	Sanfilipo 1996	\N	amphetamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
2415	Santos 1962	\N	norethandrolone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
2416	Sarai 1987	\N	zotepine versus thiothixene	\N	Japan	ORIGIN Mid E./Asia	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
2417	Saretsky 1966	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2418	Sarkar 1994	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) + Haloperidol versus sham + Haloperidol	\N	India	Department of Psychiatry, Command Hospital, Air Force, India.	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2420	Sauter 1991	\N	work skills training versus standard care	\N	United States of America	Rockland Psychiatric Ctr, Orangeburg, NY, US ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2421	Saxena 1996	\N	zuclopenthixol decanoate versus fluphenazine decanoate	\N	Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2422	Schlosberg 1978	\N	pipotiazine palmitate versus Placebo	\N	Israel	Tel Aviv U, Sackler School of Medicine, Beer Ya'acov, Israel	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
2423	Schaffer 1980	\N	amphetamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2424	Scheuing 1964	\N	L-triiodothyronine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2425	Schiele 1975	\N	loxapine succinate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
2426	Schiele 1969 a	\N	trifluperidol versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
2427	Schmauss 1987	\N	buprenorphine versus Placebo	\N	Germany	Max Planck Institute for Psychiatry, Munich.	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2428	Schmidt 1957	\N	Chlorpromazine + Reserpine versus Control Group	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
2429	Schmidt 1982	\N	perazine versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
2431	Schmidt 1991	\N	vitamin E versus Placebo	\N	Switzerland	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2432	Schnetzler 1973	\N	levomepromazine versus perimetazine	\N	France	ORIGIN Other Europe	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
2434	Schooler 1997 b	\N	family management versus control group	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	528	\N	\N	\N	\N	\N
2437	Schulman 1985	\N	Chlorpromazine dose	\N	Denmark	ORIGIN Other Europe	\N	\N	\N	\N	8888	\N	\N	\N	\N	\N
2438	Schulz 1981	\N	dialysis versus sham	\N	United States of America	NIMH Biological Psychiatry Branch, Bethesda, MD ORIGIN USA	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
2439	Schulz 1982	\N	d-amphetamine versus Placebo	\N	United States of America	Virginia Commonwealth U, Medical Coll of Virginia, Schizophrenia Studies Program ORIGIN USA	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
2440	Schut 1955	\N	meratran versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
20236	唐伟 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
2441	Schwartz 1997 a	\N	nifedipine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
2442	Scanlan 1963	\N	taractan versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
2443	Scapicchio 1993	\N	 CSG No: 576 	\N	Italy	Ospedale Psichiatrico S. Maria Immacolata, Guidonia, Italy ORIGIN Other Europe	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
2444	Schoenen 1978	\N	propranolol versus various dosages	\N	Belgium	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
2445	Schonell 1988	\N	Clozapine versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
2450	Schooler 1996	\N	fluphenazine decanoate dose	\N	United States of America	\N	\N	\N	\N	\N	234	\N	\N	\N	\N	\N
2451	Schrut 1955	\N	Reserpine versus Placebo	\N	United States of America	Pontiac State Hosp., Mich.	\N	\N	\N	\N	195	\N	\N	\N	\N	\N
2453	Schulz 1983	\N	plasmapheresis versus sham	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2454	Schulz 1980	\N	beta-endorphin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
2457	Seager 1955	\N	Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
2458	Sebree 1996	\N	sertindole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
2459	Seeman 1978	\N	clinic treatment versus private treatment	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2460	Sehdev 1974	\N	nicotinic acid therapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
2462	Seiler 1994	\N	benperidol- intravenous versus benperidol- tablet	\N	United States of America//Germany	ORIGIN Other Europe	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
2994	Woggon 1986 b	\N	fluperlapine versus Haloperidol	\N	Switzerland	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
2995	Wolkowitz 1988	\N	alprazolam + neuroleptic versus Placebo + neuroleptic	\N	United States of America	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	12	\N	\N	\N	\N	\N
2996	Owen 1996	\N	ketoconazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
2999	Wolk 1967	\N	group psychotherapy versus control	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
3000	Wolkin 1987	\N	d-amphetamine versus Placebo	\N	United States of America	New York U School of Medicine, US	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
3001	Wolkin 1986	\N	essential fatty acid supplementation versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
3002	Wolkin 1994	\N	d-amphetamine versus Placebo	\N	United States of America	Psychiatry Service, New York Veterans Administration Medical Center, NY. ORIGIN USA	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
3004	Wolkowitz 1992	\N	Benzodiazepine + neuroleptic versus Placebo + neuroleptic	\N	United States of America	U California, San Francisco Medical Center Dept of Psychiatry, US ORIGIN USA	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
3005	Wolpert 1968 a	\N	thiothixene versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
3006	Wood 1995	\N	Assertive community treatment versus standard outpatient care	\N	New Zealand	Psychiatric Services, Dunedin Hospital, New Zealand. ORIGIN Australia/NZ	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
3007	Wyant 1990	\N	 CSG No: 1057 	\N	United States of America	Medical Coll of Georgia, Augusta, US ORIGIN USA	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
3008	Xia 1995	\N	Flupentixol versus Sulpiride	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
3009	Xiang 1994	\N	Haloperidol Decanoate + Psychoeducational Family Intervention versus Haloperidol Decanoate	\N	China	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
3010	Xiao 1990	\N	Clozapine, higher dose versus Clozapine, lower dose	\N	China	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
3011	Xiong 1994	\N	Family intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
3015	Yamawaki 1996 a	\N	mianserin versus Placebo	\N	Japan	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
3016	Abse 1956	\N	Reserpine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
3017	Adityanjee 1995	\N	post-synaptic serotonergic agonist versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
3018	Affleck 1966	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
3019	Al-Faris 1997	\N	 CSG No: 3763 	\N	Saudi Arabia	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
3020	Alson 1964	\N	Chlorpromazine versus Placebo	\N	United States of America	VA Hosp., Lyons, N. J.	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
4642	Weldon 1979	\N	 CSG No: 4359 	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4644	Werner 1969	\N	 CSG No: 4487 	\N	United States of America	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
4645	Weinhardt 1998	\N	 CSG No: 4362 	\N	United States of America	Department of Psychology, Syracuse University, New York 13244-2340, USA.	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
4646	Zhang 2000 a	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
4647	Wykes 2000 a	\N	cognitive remediation therapy versus intensive occupational therapy activities	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4648	Yue 1998	\N	behaviour training + standard care versus standard care	\N	China	Hospital for Mental Diseases for Jining City, Shandong 272151 China	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
4649	Wyatt 1999	\N	Placebo versus standard care	\N	United States of America	{a} Neuropsychiatry Branch, NIMH-NIH, 15 North Drive, Suite 203, Bethesda, MD, 20892, USA	\N	\N	\N	\N	157	\N	\N	\N	\N	\N
4650	Yang 1999 a	\N	 CSG No: 4673 	\N	China	Beijing Medical U, Inst of Mental Health, Beijing, China	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
4651	Wykes 1999 a	\N	cognitive remediation therapy versus intensive occupational therapy activities	\N	United Kingdom	Department of Psychology, Institute of Psychiatry, London, UK.	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
4655	Zhang 1999 a	\N	Traditional Chinese Medicine (TCM) Yinxingye + Haloperidol versus Haloperidol + Placebo	\N	China	Z. Xiangyang, Institute of Mental Health, Beijing Medical University, Beijing 100083, China	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
4656	Zhang 1998 b	\N	He-Ne laser irradiation + Antipsychotic medication versus Antipsychotic medication	\N	China	Prof. P.-Y. Zhang, Beijing Huilongguan Hospital, Beijing 100085, China	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
4657	Yang 1998 a	\N	Music therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	Prof. W.-Y. Yang, Beijing Huilongguan Hospital, Beijing 100085, China	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
4660	Yagi 1990 a	\N	Meclofenoxate versus Placebo	\N	Japan	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4661	Wollersheim 1982	\N	psychoanalytic therapy versus behavioral therapy	\N	United States of America	\N	\N	\N	\N	\N	226	\N	\N	\N	\N	\N
4664	Wykes 1998 b	\N	intensive case management versus standard care	\N	United Kingdom	Department of Psychology, Institute of Psychiatry, London.	\N	\N	\N	\N	320	\N	\N	\N	\N	\N
4665	Zwanikken 1976	\N	 CSG No: 4593 	\N	Netherlands	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
4669	Addington 1997	\N	Risperidone versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
4671	Rosen 1971	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	446	\N	\N	\N	\N	\N
4672	Filteau 1995	\N	 CSG No: 3060 	\N	Canada	Universite Laval (Canada) (0726)	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
4673	Abramowitz 1988	\N	educational and support group versus control group	\N	United States of America	University of Maryland College Park (0117)	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
4674	Potterat 1998	\N	modified instructions for the WCST (instructions for verbal expression) versus Standard Heaton instructions for the WCST	\N	United States of America	California School of Professional Psychology - San Diego (0379)	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
4675	Freyslinger 1996	\N	remediation groups- instructional techniques versus control group	\N	Canada	University of Waterloo (Canada) (1141)	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
4676	Nugent 1995	\N	memory training + monetary feedback program versus monetary feedback program	\N	United States of America	Chicago School of Professional Psychology (0971)	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4677	Lomax 1992	\N	collaborative psychoeducational intervention versus control group	\N	United States of America	Saint Louis University (0193)	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
4678	Bronzino 1992	\N	reasoned action intervention versus behavioral tailoring intervention	\N	United States of America	Hofstra University (0086)	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
4679	Arace 1992	\N	 CSG No: 3316 	\N	United States of America	Seton Hall University, School of Education (0869)	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
4680	Buchbauer 1986	\N	positive assertion training versus control group	\N	United States of America	Seton Hall University (0199)	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4681	McCarthy 1985	\N	biofeedback and relaxation training versus control group	\N	United States of America	Kent State University (0101)	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
4682	Streicker 1984	\N	 CSG No: 3064 	\N	United States of America	Northwestern University (0163)	\N	\N	\N	\N	121	\N	\N	\N	\N	\N
4683	Hunter 1984	\N	in center group versus in vivo group	\N	United States of America	University of Massachusetts (0118)	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4684	Mooney 1984	\N	professional interviewers versus paraprofessional interviewers	\N	United States of America	Duke University (0066)	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
2694	Svestka 1973	\N	oxyprothepine versus perphenazine	\N	Czech Republic	ORIGIN Other Europe	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
4685	Green 1984	\N	psychotherapy + medication versus medication	\N	United States of America	Michigan State University (0128)	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
4686	Abston 1984	\N	psychotherapy	\N	United States of America	The University of Southern Mississipg: Pp I (0211)	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
4687	Lancaster 1983	\N	hypnosis versus control group	\N	United States of America	The University of Mississippi (0131)	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
4688	Potelunas 1982	\N	social skills training program versus control groups	\N	United States of America	New York University (0146)	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
4689	Agan 1981	\N	chemotherapy versus control group	\N	United States of America	University of Houston (0087)	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
4690	Wagner 1981	\N	 CSG No: 3071 	\N	United States of America	University of Maine (0113)	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4691	McLatchie 1981	\N	interpersonal problem solving group therapy versus relaxation training group	\N	United States of America	The Pennsylvania State University (0176)	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
4692	Loper 1980	\N	instructional workshop versus control group	\N	United States of America	University of Cincinnati (0045)	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
4693	Denicola 1980	\N	job interview skills group versus control group	\N	United States of America	University of South Florida (0206)	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
5513	Cotes 1977	\N	flupenthixol versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4694	Glover 1980	\N	relaxation training versus drug therapy	\N	United States of America	The Wright Institute (0253)	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
4695	Beckham 1981	\N	lecithin versus Placebo	\N	United States of America	University of North Texas (0158)	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
4696	Pique 1999	\N	assertive community treatment versus standard care	\N	United States of America	California School of Professional Psychology - Berkeley/Alameda (0039)	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
4697	Marshall 1985	\N	skills training + education versus education	\N	United States of America	The University of Arizona (0009)	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4700	Janicak 1999	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
4704	Silver 1996 b	\N	fluvoxamine versus Placebo	\N	Australia	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4705	Matthews 1978	\N	soteria versus no drug	\N	United States of America	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
4706	Prien 1968 b	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4708	Turkington 2000 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus befriending	\N	United Kingdom	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
4709	Karon 1981	\N	psychoanalytic psychotherapy versus ego analytic psychotherapy + phenothiazines	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
4710	Gray 2000	\N	Clozapine + education versus Clozapine	\N	United Kingdom	Tutor-Practitioner, Health Services Research Dept, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
4711	Cohen 1975	\N	social milieu training versus control group	\N	United States of America	U Mississippi	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
4712	Mosko 1972	\N	physical contact psychotherapy versus control group	\N	United States of America	U. Texas	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4720	Warner 2000	\N	Patient Based Shared Record versus Treatment As Usual	\N	United Kingdom	Dr. J.P. Warner, Department of Old Age Psychiatry, Imperial College School of Medicine, St Charles Hospital, Exmoor St, London W10 6DZ, United Kingdom. j.warner@ic.ac.uk	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
4721	Shimodera 2000	\N	single family treatment + standard care versus standard care	\N	Japan	S. Shimodera, Department of Neuropsychiatry, Kochi Medical School, Kohasu, Okoh-cho, Nankoku-shi, Kochi 783-8505, Japan	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
4722	Penn 2000	\N	reinforcement + facial feedback versus repeated practice	\N	United States of America	D.L. Penn, Department of Pschology, Davis Hall, University of North Carolina, Chapel Hill, NC 27599-3270, United States. dpenn@email.unc.edu	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4724	Umbricht 2000	\N	ketamine versus Placebo	\N	Switzerland	Dr. D. Umbricht, Psychiatric University Hospital, Department of Research, PO Box 68, Zurich 8029, Switzerland. umbricht@bli.unizh.ch	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
4725	Raaska 2000	\N	ciprofloxacin versus Placebo	\N	Finland	P.J. Neuvonen, Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, FIN-00290 Helsinki, Finland	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
4727	Shern 2000	\N	psychiatric rehabilitation versus standard care	\N	United States of America	Dr. D.L. Shern, L. de la Parte FL Mental Hlth. Inst., 13301 Bruce B. Downs Blvd, Tampa, FL 33612-3389, United States. shern@fmhi.usf.edu	\N	\N	\N	\N	168	\N	\N	\N	\N	\N
4728	Chu 1966	\N	 CSG No: 3075 	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4730	Schmid 1999	\N	ketamine versus Placebo	\N	Switzerland	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
4732	Dalack 1999 c	\N	smoking ad libitum versus no smoking	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4733	Schultz 1999	\N	phenylalanine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
4734	Sharma 1991	\N	fluphenazine decanoate versus Haloperidol decanoate	\N	United Kingdom	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
4735	Balasubramanian 1991	\N	oral zuclopenthixol versus oral Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
4736	Nedopil 1981	\N	Haloperidol dose	\N	Germany	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
4737	Dimroth 1980	\N	Clozapine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
4738	Maurer 1979	\N	IV fluphenazine dihydrochloride versus oral fluphenazine dihydrochloride	\N	Switzerland	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
4739	Rapp 1972	\N	perphenazine enanthate versus fluphenazine enanthate	\N	Sweden	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
4752	Tyrer 2000 b	\N	internal care management versus external care management	\N	United Kingdom	North West London Mental Health NHS, The Paterson Centre, 20 South Wharf Road, London, W2 1PD, England. Telephone: 0171 886 1655. Fax: 0171 886 1995. E-mail: ptyrer@ic.ac.uk	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4753	NCT00001247	\N	treatment as usual versus Placebo	\N	United States of America	Maryland National Institute of Mental Health (NIMH), 9000 Rockville Pike Bethesda, Maryland, 20892, United States; Recruiting PRPL Warren G. Magnuson Clinical Center National Institutes of Health Bethesda, Maryland, 20892-4754, United States 1-800-411-122	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4754	Woods 2001	\N	Risperidone versus Quetiapine	\N	United States of America	Scott Woods	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
4755	Wallace 2001	\N	 CSG No: 5180\r\n\r\nStart date - 15-SEP-98 - End date - 31-MAY-01	\N	United States of America	University of California Los Angeles 405 Hilgard Ave Los Angeles, Ca 90024	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
3601	Volk 1977	\N	 CSG No: 4001 	\N	Germany	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
4756	Velligan 2001 a	\N	full cognitive adaptation training (CAT) versus treatment as usual	\N	United States of America	University of Texas Hlth Sci Ctr San Ant 7703 Floyd Curl Dr San Antonio, Tx 78224	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
4757	Wilson 2000	\N	neuroleptic + cognitively oriented psychoeducation versus neuroleptic alone	\N	United Kingdom	Consultant Psychiatrist, Riverside Resource Centre, Sandy Road, Partick, Glasgow, G11, Scotland. Telephone: 0141 211 1431	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4758	Turner 2000	\N	Risperidone depot versus Risperidone tablet	\N	United Kingdom	Consultant Psychiatrist, East London &amp; The City Mental Health Trust, Homerton Hospital - East Wing, Homerton Row, London, E9 6SR, UK. Telephone: 020-8510-8857. Fax: 020-8510-8716	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10788	Lidvall 1956	\N	\N	\N	Sweden	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4760	Bentall 2001 a	\N	compliance intervention versus treatment as usual	\N	United Kingdom	Professor Richard Bentall, Psychology Department, University of Manchester, Coupland 1 Building, Oxford Road, Manchester, M13 9PL	\N	\N	\N	\N	228	\N	\N	\N	\N	\N
4762	Berns 2001	\N	electronic assistive device versus control group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4764	Birchwood 2000 c	\N	early detection intervention versus control group	\N	United Kingdom	All Saints Hospital, Lodge Road, Winson Green, Birmingham, B18 5SD, ENGLAND. Telephone: 021 523 5151	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4765	Birchwood 2000 a	\N	early intervention versus control group (psychoeducation)	\N	United Kingdom	North Birmingham Mental Health Trus, Trust Headquarters, 71 Fentham Road, Erdington, Birmingham, B23 6AL, England. Telephone: 0121685 5866. Fax: 0121 623 5770. E-mail: m.j.birchwood.20@bham.ac.uk	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4766	Birchwood 2000 b	\N	early detection intervention versus control group	\N	United Kingdom	Academic Unit, North Birmingham Mental Health Trus, Trust Headquarters, 71 Fentham Road, Erdington, Birmingham, B23 6AL, England. Telephone: 0121 685 5866. Fax: 0121 623 5770. E-mail: m.j.birchwood.20@bham.ac.uk	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
4768	Brownlee 2000	\N	Atypical Antipsychotics versus typical Antipsychotics Clozapine versus second generation Antipsychotics Atypical Antipsychotics versus typical Antipsychotics	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	702	\N	\N	\N	\N	\N
4769	Bullock 2000	\N	SR 31742A versus Haloperidol	\N	United Kingdom	Acute Psychiatry, Ealing, Hammersmith &amp; Fulham NHS Trust, Uxbridge Road, Southall, Middlesex, UB1 3EU. Telephone: 020 8574 2444 x5015. Collaborator: Dr K Wordsall (Ealing, Hammersmith &amp; Fulham Trust)	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4770	Burns 2000 b	\N	intensive case management versus standard case management	\N	United Kingdom	Department of General Psychiatry, Jenner Wing, St Georges Hospital Medical School, Cranmer Terrace, London, SW17 0RE, England. Telephone: 0181 725 5547. Fax: 018 725 3538. E-mail: t.burns@sghms.ac.uk	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
5485	Rist 1988	\N	light sound stimulation versus sound sound stimulation	\N	Germany	Germany	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5487	Gallagher 1995 a	\N	read aloud versus control group	\N	United Kingdom	School of Psychology, Queen's University of Belfast, Northern Ireland, UK.	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
5491	Heimann 1974 a	\N	 CSG No: 3215\r\nCSG No. 5277 	\N	Switzerland	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5492	Berner 1989 a	\N	 CSG No: 3091\r\nCSG No. 5278 	\N	Austria	Clinique Universitaire de Psychiatrie, Vienne, Autriche.	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
5493	Barchas 1980 a	\N	naloxone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5494	Arbitman 1970 a	\N	desmethylimipramine versus protriptyline	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5496	Haas 1988	\N	family intervention versus control group	\N	United States of America	Cornell U Medical Coll, Payne Whitney Clinic, New York, NY, US ORIGIN USA	\N	\N	\N	\N	186	\N	\N	\N	\N	\N
5499	Hassiotis 2001	\N	intensive case management versus control group	\N	United Kingdom	Royal Free and U Coll Medical School, Dept of Psychiatry and Behavioural Sciences, London, England	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
5500	McKenzie 2001	\N	aftrican caribbean case management versus brittish whites case management	\N	United Kingdom	Royal Free and U Coll Medical School, London, England	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
5502	Clark 2001	\N	assertive integrated community treatment versus standard case management	\N	United States of America	Dept. of Community and Family Medicine, Dartmouth Medical School, Strasenburgh 7250, Hanover, NH, 03755-3862: robin.clark@dartmouth.edu, USA	\N	\N	\N	\N	223//203 completed	\N	\N	\N	\N	\N
5503	Hansen 1979	\N	perphenazine + neuroleptic drugs versus neuroleptic drugs	\N	Denmark	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
5504	Crow 1977 a	\N	a-flupenthixol versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
5506	Brown 1979	\N	L- dopa versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
5507	Golightly 2001	\N	tryptophan-amino acid drink versus Placebo	\N	United Kingdom	Prof. A.H. Young, School of Neurosciences/Psychiatry, Division of Psychiatry, Royal Victoria Infirmary, Leazes Wing, Newcastle-upon-Tyne NE1 4LP, United Kingdom	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
5509	Lesem 2001	\N	IM Ziprasidone versus Haloperidol	\N	United States of America	West Oaks Hosp, Houston, TX, US	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
5511	Berk 2001	\N	Risperidone versus Placebo	\N	South Africa	Witwatersrand U Medical School, Dept of Psychiatry, Parktown, South Africa\r\n\r\nDepartments of Psychiatry and Pharmacology, Wits Medical School, Johannesburg, South Africa	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5512	Caspi 2001	\N	pindolol + usual treatment versus Placebo + usual treatment	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
20237	贾艳 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
5520	Miller 2001 b	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
5521	Malla 2001	\N	Risperidone versus Antipsychotics	\N	Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5522	Lam 2001	\N	Clozapine branded versus generic Clozapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5523	Kluznik 2001	\N	clozaril versus generic Clozapine	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
2465	Selman 1976	\N	loxapine succinate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
2466	Semenov 1988	\N	levamisole versus Placebo	\N	Russian Federation	Russian Soviet Federative Socialist Republic Ministry of Health, Moscow Scientific Research Inst of Psychiatry, USSR ORIGIN Other Europe	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
2467	Seppala 1987	\N	buspirone versus sulpiride	\N	Finland	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2469	Serban 1984	\N	thiothixene versus Haloperidol	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
2470	Serok 1984	\N	intensive gestalt group therapy versus control group	\N	Israel	Ben-Gurion U of the Neger, School of Social Work, Beersheva, Israel ORIGIN Mid E./Asia	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
2471	Seth 1979	\N	loxapine versus trifluoperazine	\N	India	National Inst of Nutrition, Hyderabad, India	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
2472	Sethi 1981	\N	naloxone versus Placebo	\N	India	ORIGIN Mid E./Asia	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
2473	Shaskan 1975	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA\r\n\r\nHall-Brooke Hosp, Westport, CT ORIGIN USA\r\n\r\nU Connecticut, Health Ctr ORIGIN USA	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
2474	Shawver 1959	\N	Chlorpromazine versus Reserpine	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
2476	Scheinin 1985	\N	apomorphine versus Placebo	\N	Finland	U Turku, Finland ORIGIN Other Europe	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
2477	Shader 1969	\N	thioridazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
2478	Shader 1971	\N	phenothiazine + psychotherapy versus Placebo + psychotherapy	\N	United States of America	Harvard Medical School, Boston, Mass	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2479	Shalev 1993	\N	levomepromazine versus Haloperidol	\N	Israel	Department of Psychiatry, Hadassah University Hospital, Jerusalem, Israel. ORIGIN Mid E./Asia	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
2480	Shalif 1981	\N	Haloperidol + lithium versus Haloperidol + Placebo	\N	Israel	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
2481	Shanker 1980	\N	horizontal grid matrices versus no grids	\N	Canada	U Winnipeg, Canada ORIGIN USA	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
2482	Sharma 1998	\N	dl-fenfluramine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
10789	Gunne 1957	\N	\N	\N	Sweden	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
2483	Sharma 1990	\N	methylphenidate versus Placebo	\N	United States of America	Illinois State Psychiatric Institute, Chicago 60612.	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2486	Shaw 1974	\N	lithium carbonate versus 2 sustained release forms (priadel and phasal tablets)	\N	United Kingdom	MRC Neuropsychiatry Unit and Area Laboratory, West Park Hospital, Epsom, Surrey. ORIGIN UK	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2487	Shaw 1992	\N	zolpidem versus Placebo	\N	United Kingdom	Department of Psychiatry, Stanley Royd Hospital, Wakefield, UK.	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
2488	Sheldon 1964	\N	day center versus after-care group	\N	United Kingdom	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
2489	Sheldon 1967	\N	day center versus after-care group	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
2490	Shelton 1969	\N	clopenthixol versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
2491	Shenoy 1981	\N	regular medication versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
2493	Shepherd 1956	\N	Chlorpromazine versus Reserpine	\N	United Kingdom	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2494	Shestakov 1979	\N	 CSG No: 3301 	\N	Russian Federation	\N	\N	\N	\N	\N	127	\N	\N	\N	\N	\N
2496	Henry 1996	\N	fluvoxamine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2497	Shiloh 1997	\N	sulpiride versus Placebo	\N	Israel	Geha Psychiatric Hospital, Rabin Medical Center, Petah Tiqva, Israel.	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
2498	Shirvaikar 1966	\N	LSD versus Placebo	\N	India	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2499	Shopsin 1969	\N	Chlorpromazine versus Haloperidol	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
2500	Shopsin 1971	\N	lithium versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
2501	Shopsin 1972	\N	loxapine succinate versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2502	Shriqui 1992	\N	vitamin E versus Placebo	\N	Canada	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
2503	Shvartsburd 1984	\N	 CSG No: 1828 	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	121	\N	\N	\N	\N	\N
2504	Sibilio 1957	\N	 CSG No: 3445 	\N	United States of America	Michigan Department Mental Health, Lansing	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
2505	Silbergeld 1973	\N	 CSG No: 504 	\N	United States of America	Stanford U., Medical School ORIGIN USA	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
12592	Bender 1999	\N	\N	\N	Germany	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
2506	Silver 1991	\N	cyproheptadine versus Placebo	\N	Israel	Flugelman Psychiatric Hosp, Doar Na Ashrat, Israel ORIGIN Mid E./Asia	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2509	Silver 1992	\N	fluvoxamine + Antipsychotics versus Antipsychotics + Placebo	\N	Israel	Flugelman (Mazra) Psychiatric Hospital, Doar Na Ashrat, Israel. ORIGIN Mid E./Asia	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2510	Silverman 1975	\N	subliminal symbiotic stimulation versus control stimulation	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2511	Silverstone 1984 a	\N	pimozide versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
2512	Silverstone 1984 b	\N	zetidoline versus Haloperidol	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
2513	Simpson 1972 a	\N	EX10-029 versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
2514	Simpson 1972 b	\N	biperiden versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
2515	Simpson 1970 a	\N	perphenazine-amitriptyline versus perphenazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2516	Sime 1974	\N	beclamide versus Placebo	\N	United Kingdom	Starcross Hosp, Exeter, England ORIGIN UK	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
2517	Simeon 1975	\N	piperacetazine versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
2519	Simon 1958	\N	Chlorpromazine versus routine care	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
2520	Simopoulos 1971	\N	diphenylhydantoin + traqnquilizers versus diphenylhydantoin	\N	United States of America	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
2521	Simpson 1973 b	\N	Chlorpromazine versus Metiapine	\N	United States of America	Rockland State Hosp., Orangeburg, N.Y. ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2522	Simpson 1970 b	\N	Benztropine Mesylate versus Placebo // Benztropine Mesylate versus Biperiden // Biperiden versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	12 // 8 // 6	\N	\N	\N	\N	\N
2523	Simpson 1972 c	\N	thiothixene versus amitriptyline	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2524	Simpson 1971 a	\N	molindone versus trifluoperazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
2525	Simpson 1970 c	\N	Haloperidol versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
2526	Simpson 1967 a	\N	Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2527	Simpson 1968 a	\N	BC-347 versus Treatment as usual	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2528	Simpson 1980	\N	Chlorpromazine + trihexyphenidyl versus Chlorpromazine + Placebo//Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
2529	Simpson 1967 b	\N	trifluperidol versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2530	Simpson 1976 b	\N	loxapine versus trifluoperazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
2531	Simpson 1966	\N	P-5227 (tricyclic Antipsychotic) versus perphenazine	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
2533	Simpson 1970 d	\N	neuroleptic treatment according to neurpleptic threshold versus neuroleptic treatment according to physician's judgement	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
2534	Simpson 1974	\N	Clozapine branded versus generic Clozapine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
2535	Sims 1975 c	\N	pimozide versus fluphenazine	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2536	Simpson 1976 a	\N	lithium versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
2537	Simpson 1978	\N	intramuscular loxapine versus oral loxapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2538	Simpson 1971 b	\N	neuroleptic treatment once a day versus neuroleptic treatment twice a day	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2539	Simpson 1977	\N	deanol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
2540	Simpson 1988	\N	cardidopa//levodopa versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
2541	Sines 1961	\N	therapeutic intervention by untrained "therapists" versus standard care	\N	United States of America	U. Minnesota	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
2542	Singer 1971 a	\N	thiopropazate hydrochloride versus Placebo	\N	Hong Kong	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
2544	Singer 1974	\N	Clozapine versus Chlorpromazine	\N	Hong Kong	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2545	Singh 1978	\N	trazodone hydrochloride versus Placebo	\N	Canada	Hamilton Psychiatric Hosp, Canada	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
2546	Singh 1979	\N	pipotiazine palmitate versus fluphenazine enanthate	\N	Canada	Hamilton Psychiatric Hosp, Canada	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2547	Singh 1990 a	\N	neuroleptic withdrawal and Placebo preplacement versus usual neuroleptic dose after 2 weeks of Placebo	\N	United States of America	Medical Coll of Pennsylvania, Eastern Pennsylvania Psychiatric Inst, Philadelphia, US ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2548	Singh 1990 b	\N	fluphenazine dose	\N	United States of America	Medical Coll of Pennsylvania, Eastern Pennsylvania Psychiatric Inst, Philadelphia, US ORIGIN USA	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
2696	Svestka 1982 b	\N	 CSG No: 3306 	\N	Czech Republic	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2549	Singh 1973 a	\N	Haloperidol versus anti-parkinsonian drugs	\N	United States of America	Bronx State Hosp., Clinical Psychopharmacology Unit, N.Y. ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2550	Singh 1972	\N	Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2551	Singh 1975	\N	Haloperidol versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2552	Singh 1973 b	\N	Haloperidol versus anti-parkinsonian drugs	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
2557	Siris 1987	\N	fluphenazine + imipramine versus fluphenazine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
2560	Siris 1989	\N	fluphenazine + imipramine versus fluphenazine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2565	Siris 1983 a	\N	fluphenazine + imipramine versus fluphenazine + benztropine + imiprimine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2567	Siris 1983 b	\N	fluphenazine + imipramine versus fluphenazine + benztropine	\N	United States of America	Mt. Sinai Hosp. Med., City New York, New York, NY 10029, United States	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
2569	Sjostrom 1990	\N	 CSG No: 3141 	\N	Finland	Institutionen for psykiatri, Ullerakers sjukhus, Uppsala.	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
2570	Skopova 1985	\N	 CSG No: 2826 	\N	Czech Republic	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
2574	Slotnick 1971	\N	Chlorpromazine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
2575	Sluchevskii 1986	\N	CSG No: 3299	\N	Russian Federation	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
2577	Small 1975	\N	Clozapine + lithium versus Clozapine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
2579	Small 1968	\N	flurothyl convulsive treatment versus Electro Convulsive Therapy(Electroconvulsive Therapy)	\N	United States of America	USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2581	Smith 1996	\N	new Atypical Antipsychotic versus Antipsychotics	\N	Australia	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
2582	Smith 1974	\N	thioridazine versus Haloperidol	\N	United States of America	Meadowbrook Extended Care Facility, Shawsville, VA ORIGIN USA	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
2583	Smith 1965	\N	chlorprothixene versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
2584	Smith 1959 a	\N	SQ 4918 versus Sch-3940	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2585	Smith 1958	\N	triflupromazine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
2586	Smith 1987 a	\N	group workshop (family education) versus educational packet via mail	\N	United Kingdom	Department of Clinical Psychology, All Saints Hospital, Birmingham. ORIGIN UK	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
2587	Smith 1961 a	\N	meprobamate versus tindal	\N	United States of America	\N	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
2588	Smith 1967	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) + Chlorpromazine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2589	Smith 1960 a	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
2590	Smith 1960 b	\N	tetrabenazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
2591	Smith 1984	\N	thioridazine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
2593	Smythies 1974	\N	Reserpine versus Chlorpromazine	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2594	Smythies 1982	\N	molindone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
2595	Soloff 1986	\N	Haloperidol versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
2596	Shu 1987	\N	Haloperidol + insulin shock therapy versus Haloperidol	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
2597	Shu 1983	\N	fluphenazine decanoate versus Placebo	\N	China	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
2598	Soldatos 1986	\N	triazolam versus Placebo	\N	Greece	ORIGIN Other Europe	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
2600	Solomon 1996 b	\N	group workshop (family education) versus waiting list	\N	United States of America	University of Pennsylvania School of Social Work, Phildelphia, 19104, USA.	\N	\N	\N	\N	225	\N	\N	\N	\N	\N
2601	Solomon 1998 c	\N	group workshop (family education) versus waiting list	\N	United States of America	Dr. P. Solomon, School of Social Work, University of Pennsylvania, 3701 Locust Walk, Philadelphia, PA 19104, United States	\N	\N	\N	\N	225	\N	\N	\N	\N	\N
2602	Solomon 1994 a	\N	assertive community treatment versus individual case management	\N	United States of America	Department of Psychiatry, Hahnemann University, Philadelphia, PA 19102. ORIGIN USA\r\n\r\nSchool of Social Work, University of Pennsylvania, 3701 Locust Walk, Philadelphia, PA 19104	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
2603	Solomon 1997 a	\N	group workshop (family education) versus waiting list	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2604	Somerville 1960	\N	phenothiazine versus Chlorpromazine	\N	Australia//New Zealand	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
2606	Sommerness 1957	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
3603	Weiden 1999 a	\N	 CSG No: 4117 	\N	United States of America	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
2607	Song 1993	\N	Pipotiazine palmitate versus Fluphenazine decanoate	\N	China	\N	\N	\N	\N	\N	162	\N	\N	\N	\N	\N
2608	Soni 1986	\N	oxypertine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
2609	Soni 1984	\N	oxypertine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
2610	Soni 1990 a	\N	oral remoxipride versus controlled release remoxipride	\N	United Kingdom	Prestwich Hospital, Salford. ORIGIN UK	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2611	Soni 1990 b	\N	sulpiride versus Placebo	\N	United Kingdom	Hope & Prestwich Hosps, Salford Health Authority, England ORIGIN UK	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2612	Sorgi 1988	\N	nadolol versus Placebo	\N	Canada	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
2613	Soria 1994	\N	 CSG No: 3181 	\N	Spain	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
2614	Soucek 1987	\N	isofloxythepin versus Haloperidol	\N	Czech Republic	Vyzkumny Ustav pro Farmacii a Biochemii, Prague, Czechoslovakia ORIGIN Other Europe	\N	\N	\N	\N	177	\N	\N	\N	\N	\N
2615	South 1961	\N	prochlorperazine versus Placebo//Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
2617	Speer 1997	\N	Risperidone versus medication free	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
2620	Spencer 1992	\N	Haloperidol versus Placebo	\N	United States of America	New York U Medical Ctr, Dept of Psychiatry, US ORIGIN USA\r\n\r\nDepartment of Psychiatry, New York University Medical Center, NY 10016. ORIGIN USA\r\n\r\nNew York U, Medical Ctr, New York, NY, US	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2621	Spencer 1983	\N	social skills training versus remedial drama	\N	United Kingdom	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
2622	Spiegel 1967	\N	carphenazine versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2623	Spina 1992	\N	Bromperidol versus Haloperidol	\N	Italy	ORIGIN Other Europe	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
2624	Spina 1994	\N	fluoxetine versus Placebo	\N	Italy	ORIGIN Other Europe	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
2625	Spohn 1993	\N	neuroleptic treatment versus Placebo	\N	United States of America	Menninger Clinic, Topeka, Kansas 66601-0829. ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2626	Spohn 1986	\N	neuroleptic treatment versus Placebo	\N	United States of America	Menninger Foundation, Research Dept, Topeka, KS ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2627	Spohn 1988	\N	neuroleptic treatment versus Placebo	\N	United States of America	Menninger Foundation, Topeka, KS 66601. ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13121	Wang 2009 a	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
2630	Sramek 1997	\N	rapid titration sertindole versus slow titration sertindole	\N	United States of America	California Clinical Trials, Beverly Hills, USA.	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
2631	Stabenau 1964	\N	thioridazine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
2632	Stahl 1985	\N	fenfluramine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2633	Stanley 1961	\N	trifluoperazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
2635	Stauning 1979	\N	Cis(Z)-flupentixol decanoate in Viscoleo versus 2%, 10%	\N	Denmark	ORIGIN Other Europe	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2636	Stearns 1996	\N	Selegiline versus standard care	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
2637	Steffes 1985	\N	dark colored care-taker uniform versus white care-taker uniform	\N	United States of America	VA Medical Ctr, Intermediate Medical Section, St Cloud, MN ORIGIN USA	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
2638	Steffy 1974	\N	1 second preparatory interval versus 7 second preparatory interval	\N	Canada	U. Waterloo, Ontario, Canada ORIGIN Canada	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
2639	Stein 1984	\N	vasopressin versus Placebo	\N	Israel	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
2640	Stein 1987	\N	community based treatment versus hospital based treatment	\N	United States of America	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
2641	Stein 1975	\N	community based treatment versus hospital based treatment	\N	United States of America	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
2642	Steinberg 1974	\N	moral condition discussion versus neutral condition discussion	\N	United States of America	Philadelphia State Hosp, PA ORIGIN USA	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
2643	Steinbook 1973	\N	loxapine succinate versus Chlorpromazine	\N	United States of America	U. Miami, Medical School ORIGIN USA	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
2644	Steinbook 1975	\N	Chlorpromazine versus Metiapine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
2645	Steiner 1995	\N	structured clinical interview for DSM-II-R versus non-structured psychiatric diagnoses	\N	United States of America	Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2646	Steinert 1986	\N	depot pipothiazine palmitate versus flupenthixol decanoate	\N	United Kingdom	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
2647	Steingard 1994	\N	fluphenazine versus Placebo	\N	United States of America	University of Vermont College of Medicine, Waterbury. ORIGIN USA	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
2697	Swenson 1956	\N	Reserpine versus Placebo	\N	United States of America	St. Peter State Hosp., Minn.	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
20238	周益辉 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
2648	Stenback 1957	\N	usual elElectro Convulsive Therapy (Electroconvulsive Therapy)roconvulsive therapy (Electro Convulsive Therapy (Electroconvulsive Therapy)) versus block elElectro Convulsive Therapy (Electroconvulsive Therapy)roconvulsive therapy (Electro Convulsive Therapy (Electroconvulsive Therapy))	\N	Finland	\N	\N	\N	\N	\N	3	\N	\N	\N	\N	\N
2649	Stenson 1976	\N	Amantadine Hydrochloride versus Benztropine Mesylate	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
2650	Sterlin 1971	\N	doxepin versus amitriptyline	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2651	Stevens 1992	\N	Haloperidol + lorazepam versus Haloperidol	\N	Germany	Germany	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
2652	Stevens 1973	\N	rehabilitation workshop versus standard care	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
2654	Stewart 1969	\N	Haloperidol versus trifluoperazine	\N	Canada	ORIGIN Canada	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
2655	Stewart 1982	\N	baclofen versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
2656	Sterlin 1972	\N	thiothixene versus chlorprothixene	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2657	Sterlin 1970	\N	thiothixene versus Placebo//Chlorpromazine versus Placebo	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2661	St Jean 1964 a	\N	promethazine versus trihexyphenidyl	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2662	St Jean 1964 b	\N	withdrawal of antiparkinsonian medication with Placebo versus continuation of medication	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2663	St Jean 1967	\N	 CSG No: 2786 	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2665	Storms 1982	\N	high cereal diet versus cereal free diet	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
2666	Stotsky 1977	\N	Haloperidol versus Thiothixene	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2667	Straight	\N	group psychotherapy versus standard care	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
2672	Sturm 1974	\N	remotivation technique versus no treatment	\N	United States of America	Veterans Administration Hosp., East Orange, N.J. ORIGIN USA	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
2673	Su 1997	\N	Risperidone versus Clozapine	\N	United States of America	\N	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
2674	Subramaney 1997	\N	lorazepam versus clothiapine	\N	South Africa	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
2675	Suddath 1991	\N	nifedipine versus Placebo	\N	United States of America	NIMH Neuroscience Ctr Neuropsychiatry Branch, St Elizabeths Hosp, Washington, DC, US ORIGIN USA	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
2676	Sugerman 1971	\N	oxypertine winthrop versus chlorothepin	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
2677	Sugerman 1970	\N	adrenochrome semicarbazone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2678	Sugerman 1965	\N	trifluperidol versus trifluperazine	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
2679	Sullivan 1980	\N	presentation of proverbs with negative feedback for wrong response versus presentation of proverbs	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
2680	Sundby 1959	\N	prochlorperazine versus Chlorpromazine	\N	Norway	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
2681	Susser 1998	\N	SexG (sex education) versus control intervention	\N	United States of America	Dr. E. Susser, Columbia University, New York State Psychiatric Institute, Box 24, 722 W 168th St, New York, NY 10032, United States	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
2683	Suzuki 1992	\N	neuroleptic increase by 25% versus neuroleptic decrease by 25%	\N	Japan	Department of Neuro-psychiatry, Keio University School of Medicine, Tokyo, Japan. ORIGIN Mid E./Asia	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
2684	Svestka 1989 a	\N	carbamazepine versus perphenazine	\N	Czech Republic	Dept of Psychiatry, Brno, Czechoslovakia ORIGIN Other Europe	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
2685	Svestka 1990 a	\N	Risperidone versus Haloperidol	\N	Czech Republic	ORIGIN Other Europe	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
2686	Svestka 1982 a	\N	loxapine succinate versus trifluoperazine hydrochloride	\N	Czech Republic	Purkyne U Medical Faculty, Psychiatric Clinic, Brno, Czechoslovakia	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2687	Svestka 1972	\N	pimozide versus perphenazine	\N	Czech Republic	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
2688	Svestka 1970	\N	 CSG No: 3657 	\N	Czech Republic	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
2689	Svestka 1986	\N	oxyprothepine versus clopenthixol decanoate	\N	Czech Republic	University Dept of Psychiatry, Brno, Czechoslovakia ORIGIN Other Europe	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
2690	Svestka 1989 b	\N	isofloxythepin versus perphenazine	\N	Czech Republic	ORIGIN Other Europe	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2691	Svestka 1974	\N	oxypertine versus perphenazine	\N	Czech Republic	ORIGIN Other Europe	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
2692	Svestka 1975	\N	trifluoperazine versus Placebo	\N	Czech Republic	ORIGIN Other Europe	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
2693	Svestka 1987	\N	isofloxythepin versus Haloperidol	\N	Czech Republic	Purkyne U, Faculty of Medicine, Brno, Czechoslovakia ORIGIN Other Europe	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
16503	Malla 2009 a	\N	\N	\N	Canada	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
2698	Syvalahti 1986	\N	intravenous apomorphine versus subcutaneous apomorphine	\N	Finland	ORIGIN Other Europe	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2700	Szmukler 1996	\N	carers' support programme versus standard treatment	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2703	Taiminen 1996	\N	Placebo versus citalopram	\N	Finland	Department of Psychiatry, University of Turku Central Hospital, Turku, Finland.	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
2705	Takahashi 1982	\N	timiperone versus perphenazine	\N	Japan	\N	\N	\N	\N	\N	205	\N	\N	\N	\N	\N
2707	Takeshita 1994	\N	sulpiride versus Placebo	\N	Japan	Department of Neuropsychiatry, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan. ORIGIN Mid E./Asia	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2708	Talbot 1964	\N	tranquilizer combinations versus single tranquilizer	\N	United States of America	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
2709	Tamminga 1992	\N	(-)3PP versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
2710	Tamminga 1986 a	\N	N-Propylnorapomorphine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
2711	Tamminga 1986 b	\N	caerulein versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
2712	Tamminga 1986 c	\N	caerulein versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
2713	Tamminga 1986 d	\N	caerulein versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
2714	Tamminga 1978 a	\N	apomorphine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2715	Tamminga 1994	\N	Clozapine versus Haloperidol	\N	United States of America	Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland Medical School, Baltimore 21228. ORIGIN USA	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
2716	Tamminga 1980	\N	Bromocriptine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2717	Tamminga 1978 b	\N	muscimol versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
2719	Tamminga 1977	\N	physostigmine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2720	Tamminga 1983	\N	 CSG No: 3553 CSG No: 3520 CSG No: 3545	\N	United States of America	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
2723	Tang 1994	\N	Music therapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
2724	Tanghe 1972	\N	fluspririlene versus penfluridol	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2729	Tarsy 1977	\N	deanol acetamidobenzoate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
2733	Taylor 1980	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus sham Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2734	Tegeler 1985	\N	zuclopenthixol decanoate versus zuclopenthixol hydrochloride	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2735	Teja 1975	\N	tranquilizers versus anti-depressants	\N	United States of America	U Virginia Medical School ORIGIN USA	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
2736	Telles 1995	\N	behavioural family management versus standard case management	\N	United States of America	Department of Psychiatry, UCLA 90024, USA. ORIGIN USA	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
2737	Tench 1990	\N	controlled release remoxipride versus immediate release remoxipride	\N	United Kingdom	Prestwich Hospital, Salford, UK.	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2738	Tenenblatt 1956	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2739	Terao 1995	\N	neuroleptics + lithium versus neuroleptics + Placebo	\N	Japan	Hitachi Umegaoka Mental Hospital, Japan. ORIGIN Mid E./Asia	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
2741	Test 1989	\N	community care versus standard care	\N	United States of America	Department of Psychiatry, School of Social Work, University of Wisconsin-Madison 53706.\r\n\r\nWisconsin Office of Mental Health, Madison, WI, US	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
2744	Tetreault 1969 a	\N	Chlorpromazine versus Placebo	\N	Canada	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
2749	Thaker 1990	\N	clonazepam versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
2751	Thaker 1987	\N	GVG versus THIP	\N	United States of America	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
2753	Thorpe 1956	\N	pacatal versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
2754	Tobin 1980	\N	Haloperidol versus thioxene	\N	United States of America	Northwest Psychiatric Clinic, Eau Claire, WS ORIGIN USA	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
2756	Toledo 1972	\N	cinnarizine versus Placebo	\N	Argentina	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2757	Tompkins 1995	\N	cued memory task versus standard memory task	\N	United States of America	Department of Veterans Affairs Medical Center, Ann Arbor, Michigan, USA. ORIGIN USA	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
2758	Toru 1972	\N	sulpride versus Chlorpromazine	\N	Japan	ORIGIN Mid E./Asia	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
2759	Toru 1971	\N	sulpride versus Chlorpromazine	\N	Japan	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
2760	Tourney 1960 a	\N	septal extract versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
12594	Graber 1960	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
2761	Tourney 1960 b	\N	resocialization treatment versus standard care	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2764	Tran 1997 a	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	339	\N	\N	\N	\N	\N
2765	Trandafir 1998	\N	Olanzapine versus Haloperidol	\N	South Africa	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2767	Trichard 1998	\N	Chlorpromazine versus Amisulpride	\N	France	Dr. C. Trichard, Service Hospitalier Frederic Joliot, 4. Place du General Leclerc, 91406 Orsay, France	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2768	Tripodianakis 1986	\N	deanol versus Placebo	\N	Greece	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2769	Troshinsky 1962	\N	maintenance of phenothiazines in aftercare versus replacement of phenothiazines with Placebo in aftercare	\N	United States of America	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
2770	Tuason 1986	\N	loxapine versus Haloperidol	\N	United States of America	Kaseman Presbyterian Hosp, Albuquerque, NM ORIGIN USA	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
2771	Tuason 1984	\N	loxapine versus Chlorpromazine	\N	United States of America	St Paul-Ramsey Medical Ctr, St. Paul, MN ORIGIN USA	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
2772	Tucker 1957	\N	meprobamate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
2773	Tuma 1986	\N	oxyprothepine versus chlorothepine	\N	Czech Republic	Psychiatric Clinic, Hradec Kralove, Czechoslovakia ORIGIN Other Europe	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2774	Turjanski 1998 a	\N	Amisulpride versus Haloperidol	\N	France	1 Synthélabo Groupe, 92350 Le Plessis-Robinson; 2 Synthélabo Recherche, 92200 Bagneux, France	\N	\N	\N	\N	186	\N	\N	\N	\N	\N
2775	Turner 1958	\N	Raunormine versus Reserpine	\N	United States of America	Central Islip State Hosp., N. Y.	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
2776	Sermat 1965	\N	information condition versus punishment condition	\N	Canada	U. Toronto	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
2777	Shutty 1997	\N	 CSG No: 3762 	\N	United States of America	Western State Hosp, Staunton, VA, USA	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
2778	Speller 1997	\N	Amisulpride versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
2779	Strakowski 1997	\N	d-Amphetamine versus Placebo	\N	United States of America	U Cincinnati, Coll of Medicine, Dept of Psychiatry, Psychotic Disorders Research Program, Cincinnati, OH, USA	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
2780	Thorpe 1962	\N	contingenty monetary reinforcement versus non-contingent monetary reinforcement	\N	United Kingdom	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
2781	Turner 1966	\N	Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
2782	Tyrer 1998	\N	community oriented care (intensive case management) versus hospital oriented care (external care management)	\N	United Kingdom	\N	\N	\N	\N	\N	155	\N	\N	\N	\N	\N
2783	Tyrer 1995	\N	intensive case management versus standard case management	\N	United Kingdom	Academic Unit of Psychiatry, St Mary's Hospital Medical School, St Charles Hospital, London, UK. ORIGIN UK	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
2784	Ucer 1969	\N	 CSG No: 1677 	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
2785	Uddyback 1962	\N	thioridazine versus treatment as usual	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
2786	Uhlir 1975	\N	oxypertine winthrop versus chlorothepin	\N	Czech Republic	ORIGIN Other Europe	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
2787	Ulett 1956	\N	convulsive photoshock therapy versus electroshock therapy	\N	United States of America	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
2788	Ullmann 1964	\N	verbal reinforcement of associations to stimulus words versus presentation of stimulus words without reinforcement of associations	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2789	Ungvari 1981	\N	 CSG No: 3228 CSG No: 1506	\N	Hungary	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
2792	Ungvari 1997	\N	citalopram versus Placebo	\N	Hong Kong	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2793	Urquhart 1959	\N	promazine hydrochloride versus acetylpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2795	Vaddadi 1989	\N	DHLA fatty acid suppliment versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
2796	Vaddadi 1986	\N	 CSG No: 2804 	\N	United Kingdom	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
2797	Vagen 1986	\N	procyclidine versus Placebo	\N	Norway	ORIGIN Other Europe	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
2798	Vaisanen 1981	\N	Haloperidol versus Placebo	\N	Finland	ORIGIN Other Europe	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2799	Vallely 1971	\N	nicotinic acide versus nicotinamide	\N	Canada	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
2800	Van Berckel 1996	\N	D- cycloserine versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
2801	Van Berckel 1997	\N	D- cycloserine versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2802	Van Hassel 1982	\N	Anxiety management training versus Applied relaxation training	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
2804	Van Kammen 1985 a	\N	d-amphetamine + lithium versus d-amphetamine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
2806	Van Kammen 1983	\N	hemodialysis versus sham hemodialysis	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
15767	Cabrera 1994 a	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
2807	Van Praag 1975 a	\N	Chlorpromazine versus Placebo	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2809	Van Praag 1971 a	\N	penfluridol versus fluspirilene	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
2810	Van Praag 1982 c	\N	DT-gamma- endorphins versus DE-gamma-endorphins	\N	Netherlands	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
2811	Van Kammen 1985 b	\N	Haloperidol dose	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
2812	Van Ree 1980	\N	synthetic peptides gamma-type endorphins versus Placebo	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
2813	Van Ree 1981	\N	synthetic peptides gamma-type endorphins versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2814	Van Wyk 1972	\N	pimozide versus standard care	\N	South Africa	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2815	Van Wyk 1971 b	\N	Chlorpromazine versus Clothiapine // Chlorpromazine versus Thioridazine // Clothiapine versus Thioridazine	\N	South Africa	ORIGIN Africa	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2816	Van Kammen 1980	\N	lithium versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
2817	Van Kammen 1988	\N	dextro-amphetamine versus Placebo	\N	United States of America	Department of Psychiatry, University of Pittsburgh, PA 15213. ORIGIN USA	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2820	Van Kammen 1987	\N	pimozide versus Placebo	\N	United States of America	Veterans Administration Medical Ctr, Pittsburgh, PA, US ORIGIN USA	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2821	Van Leeuwen 1977 b	\N	droperidol versus Placebo	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
2822	Van Lommel 1974 a	\N	Haloperidol versus penfluridol	\N	Belgium	ORIGIN Other Europe	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
2824	Van Minnen 1997	\N	hospital treatment versus outreach treatment	\N	Netherlands	Department of Clinical Psychology and Personality, University of Nijmegen, The Netherlands. ORIGIN Other Europe	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
2825	Van Praag 1976	\N	Clozapine versus perphenazine	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
2826	Van Putten 1986 a	\N	fluphenazine dose	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
2827	Van Putten 1986 b	\N	fluphenazine dose	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
2828	Van Putten 1992	\N	Haloperidol dose	\N	United States of America	VA, Brentwood Division, Los Angeles, CA. ORIGIN USA	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
2829	Van Putten 1974	\N	phenothiazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
2830	Van Ree 1982	\N	synthetic peptides gamma-type endorphins versus Placebo	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
2833	Vandecasteele 1974	\N	penfluridol versus Placebo	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
2834	VanderZwaag 1996	\N	Clozapine dose	\N	United States of America	John Umstead Hospital, Adult Admission Unit, Butner, NC 27509, USA. ORIGIN USA\r\n\r\nJohn Umstead Hosp, Butner, NC, USA	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
2835	Vanherweghem 1983	\N	hemodialysis versus sham hemodialysis	\N	Belgium	ORIGIN Other Europe	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
2836	Van Dyke 1973	\N	random tone response versus error tone response	\N	United States of America	Pine Rest Christian Hosp., Grand Rapids, Mich. ORIGIN USA	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
2837	Van Kammen 1982 a	\N	 CSG No: 838 CSG No: 2149 CSG No: 549 CSG No: 2738	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
2838	Van Kammen 1989	\N	clonidine versus Placebo	\N	United States of America	Veterans Administration Medical Ctr, Pittsburgh, PA, US ORIGIN USA	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
2839	Van Praag 1973 b	\N	fluphenazine decanoate versus fluphenazine enanthate	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2840	Van Putten 1984	\N	Haloperidol versus thiothixene	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	111	\N	\N	\N	\N	\N
2841	Vangala 1998	\N	Olanzapine versus Haloperidol	\N	Hong Kong	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
2842	Vanherweghem 1979 a	\N	hemodialysis versus sham hemodialysis	\N	Belgium	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2843	Vartiainen 1995	\N	citalopram versus Placebo	\N	Finland	Department of Forensic Psychiatry, Niuvanniemi Hospital, Kuopio, Finland. ORIGIN Other Europe	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
2844	Vasavan 1978	\N	baclofen + Haloperidol versus sodium valproate+ Haloperidol	\N	Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2845	Vaughan 1955	\N	intramuscular Chlorpromazine followed by oral Chlorpromazine versus oral Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
2846	Vaughan 1992	\N	family counseling versus standard care	\N	United Kingdom	Palmerston Unit, Hornsby Hospital, UK. ORIGIN Australia/NZ	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
2847	Velligan 1996	\N	Cognitive Adaptation Training versus standard psychosocial programming	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2848	Venables 1958	\N	 CSG No: 306 	\N	United Kingdom	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
2850	Verhoeven 1981 a	\N	 CSG No: 188 	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
2852	Verhoeven 1982	\N	 CSG No: 307 	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
2856	Van Der Velde 1975 b	\N	loxapine succinate versus Placebo	\N	United States of America	A. Ribicoff Research Center, Norwich Hospital, Norwich, Connecticut 06360, U.S.A. ORIGIN USA	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
2857	Vangtorp 1968	\N	buronil versus promazine	\N	Denmark	ORIGIN Other Europe	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
2859	Vereecken 1972	\N	 CSG No: 2932 	\N	Netherlands	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
2861	Verhoeven 1984 b	\N	 CSG No: 470 	\N	Netherlands	State U of Utrecht, Netherlands ORIGIN Other Europe	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2862	Verhoeven 1981 e	\N	 CSG No: 528 	\N	Netherlands	U Utrecht Hosp, Dept of Psychiatry, Netherlands ORIGIN Other Europe	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2863	Verhoeven 1979	\N	 CSG No: 309 	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
2864	Verhoeven 1986	\N	 CSG No: 328 	\N	Netherlands	ORIGIN Other Europe	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
2866	Versiani 1978	\N	 CSG No: 2525 	\N	Brazil	Federal U of Rio de Janeiro, Inst of Psychiatry, Brazil	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
2867	Vestre 1970	\N	Trifluoperazine versus Placebo//Thioridazine versus Placebo//Trifluoperazine versus Thioridazine	\N	United States of America	\N	\N	\N	Note by Claire: No useable data given in paper	\N	60	\N	\N	\N	\N	\N
2868	Viala 1988	\N	 CSG No: 685 	\N	France	Laboratoire de Toxicologie generale et Biotoxicologie, Faculte de Pharmacie, Marseille, France. ORIGIN Other Europe	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
2869	Vianna 1975	\N	 CSG No: 2559 CSG No: 2169	\N	Brazil	Federal U of Rio de Janeiro, Inst of Psychiatry, Brazil\r\n\r\nORIGIN South/Central America	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
2871	Villeneuve 1972	\N	 CSG No: 3065 	\N	Canada	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
2872	Villeneuve 1980	\N	 CSG No: 3562 	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2873	Vinar 1970	\N	 CSG No: 1253 	\N	Czech Republic	ORIGIN Other Europe	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
2874	Vinar 1976 a	\N	 CSG No: 1335 	\N	Czech Republic	ORIGIN Other Europe	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2875	Vincent 1977	\N	 CSG No: 1268 	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	254	\N	\N	\N	\N	\N
2876	de Vogelaer 1981	\N	carbamazepine versus Placebo	\N	Belgium	Psychiatrische Kliniek Broeders Alexianen, Tienen, Belgium ORIGIN Other Europe	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2877	Vinar 1973	\N	 CSG No: 582 	\N	Czech Republic	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2878	Vinar 1967	\N	 CSG No: 2266 	\N	Czech Republic	ORIGIN Other Europe	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
2880	Vinar 1971	\N	 CSG No: 2968 	\N	Czech Republic	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
2881	Vital 1986	\N	 CSG No: 1679 	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
2882	Viukari 1975	\N	 CSG No: 3549 	\N	Finland	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
2883	Vlissides 1986	\N	 CSG No: 310 	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2889	Volavka 1990	\N	 CSG No: 3385 	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2890	Volavka 1983	\N	 CSG No: 1569 	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2891	Volavka 1977	\N	 CSG No: 586 	\N	United States of America	U Missouri ORIGIN USA	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
2892	Volavka 1986	\N	 CSG No: 3550 	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
2893	Volterra 1996	\N	 CSG No: 1081 CSG No: 862	\N	Italy	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2895	Volterra 1990	\N	 CSG No: 1040 	\N	Italy	U Bologna, Inst of Psychiatry, Italy ORIGIN Other Europe	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2896	Volavka 1997	\N	 CSG No: 2416 	\N	United States of America	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
2899	Vollema 1995	\N	 CSG No: 2728 CSG No: 3128	\N	Netherlands	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
2900	Volz 1994	\N	 CSG No: 2654 	\N	Germany	Germany	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2902	Vyas 1980	\N	 CSG No: 1782 	\N	India	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
2903	Wada 1987	\N	Biperidin versus Placebo	\N	Japan	Department of Neuropsychiatry, Kanazawa University School of Medicine, Japan. ORIGIN Mid E./Asia	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
2904	Wadzisz 1969	\N	 CSG No: 2760 	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2905	Waehrens 1980	\N	 CSG No: 389 	\N	Denmark	ORIGIN Other Europe	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2906	Wagemaker 1983 a	\N	 CSG No: 2509 	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2907	Wagemaker 1984	\N	 CSG No: 313 	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
2909	Wahlund 1983	\N	 CSG No: 2500 	\N	Sweden	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
2911	Walinder 1990	\N	 CSG No: 444 	\N	Sweden	Department of Psychiatry, Linkoping University, Sweden. ORIGIN Other Europe	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
2914	Walsh 1959	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
2915	Wang 1982	\N	Penfluridol versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
2916	Watson 1972	\N	 CSG No: 3436 	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
2917	Watson 1977	\N	 CSG No: 2798 	\N	United States of America	\N	\N	\N	\N	\N	450	\N	\N	\N	\N	\N
2922	Weckowicz 1960 b	\N	Trifluoperazine versus Placebo	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2923	Wehnert 1998	\N	 CSG No: 3139\r\n9th Biennial Winter Workshop on Schizophrenia. Febuary 7-13, 1998. Davos Switzerland 	\N	Denmark	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2924	Weiden 1995	\N	 CSG No: 2951 	\N	United States of America	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
2925	Weingaertner 1971	\N	 CSG No: 3744 	\N	United States of America	1554 Woodruff Ave., Westwood Village, Calif	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
2926	Weinman 1974	\N	 CSG No: 3017 	\N	United States of America	Philadelphia State Hosp, PA	\N	\N	\N	\N	590	\N	\N	\N	\N	\N
2927	Weir 1968	\N	 CSG No: 2057 	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
2929	Welbel 1980	\N	 CSG No: 1375 	\N	Poland	ORIGIN Other Europe	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2930	Welbel 1987	\N	 CSG No: 1324 	\N	Poland	Inst Psychiatrii i Neurologii, Warsaw, Poland ORIGIN Other Europe	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
2931	Wells 1991	\N	 CSG No: 2349 	\N	United States of America	U Tennessee, Coll of Pharmacy, Memphis, USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2935	Weston 1973	\N	 CSG No: 506 	\N	Australia	Royal Brisbane Hosp., U. Queensland, Australia ORIGIN Australia/NZ	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
2936	Wessels 1971	\N	 CSG No: 2377\r\n\r\nAbstract no. 1177 CSG No: 4404	\N	South Africa//Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2937	West 1982	\N	 CSG No: 853 	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
2938	Wetzel 1997	\N	lorazepam versus Placebo	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
2939	Wetzel 1991	\N	 CSG No: 3135 	\N	Germany	Psychiatrische Klinik der Universitat Mainz.	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
2941	Wexler 1997	\N	 CSG No: 3739 	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
2942	Whetstone 1986	\N	 CSG No: 2599 	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
2943	White 1981	\N	 CSG No: 2160 	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
2945	Whiteford 1992	\N	 CSG No: 736 	\N	Australia	Queensland Health Dept Mental Health Branch, Brisbane, Australia ORIGIN Australia/NZ	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
2946	Whitehead 1958	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
2947	Whittaker 1963	\N	 CSG No: 315 	\N	United Kingdom	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
2948	Widerlov 1990 a	\N	 CSG No: 1405 	\N	Sweden	Department of Psychiatry and Neurochemistry, University of Lund, Sweden. ORIGIN Other Europe	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
2952	Wikler 1965	\N	 CSG No: 2897 	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
2954	Wilson 1986	\N	niacin versus Placebo	\N	Canada	U Alberta, Edmonton, Canada ORIGIN Canada	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
19246	刘玉局 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
2955	Wilson 1993	\N	lithium + halopeidol versus Haloperidol + Placebo	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
2956	Walker 1983	\N	 CSG No: 3864 	\N	United Kingdom	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
2957	Wiles 1980	\N	 CSG No: 741 	\N	United Kingdom	U Oxford, Littlemore Hosp Research Unit, England ORIGIN UK	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
2958	Wiles 1990	\N	 CSG No: 2643 	\N	United Kingdom	Department of Clinical Research, Crichton Royal Hospital, Dumfries, Scotland, UK.	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
2959	Wilkins 1987	\N	 CSG No: 2747 	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
2962	Williams 1957	\N	 CSG No: 2606 	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
2964	Wilson 1966	\N	speech training with reinforcement versus no training, no reinforcement	\N	Canada	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2965	Wilson 1961	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
2966	Wilson 1982 a	\N	pimozide versus Chlorpromazine	\N	United States of America	Harborview Medical Ctr, Dept of Psychiatry, Seattle, WA ORIGIN USA	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
2967	Wilson 1982 b	\N	flutroline dose	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
2969	Wing 1956	\N	Reserpine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
2970	Winslow 1986	\N	benztropine + neuroleptic versus Placebo +neuroleptic	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
2971	Winter 1973	\N	fluspirilene versus fluphenazine decanoate	\N	United Kingdom	Barnsley Hall Hospital, Bromsgrove, Worcestershire. ORIGIN UK	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
2972	Winter 1984	\N	Haloperidol versus reduced dose, increased dose	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2973	Winter 1956	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
2975	Wirt 1959	\N	 CSG No: 1477 	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
2976	Wirshing 1995	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
2977	Wirshing 1991	\N	modularized skills training versus supportive group psychotherapy	\N	United States of America	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
2978	Wirshing 1989	\N	trihexyphenidyl hydrochloride versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
2981	Wistedt 1991	\N	zuclopenthixol decanoate versus Haloperidol decanoate	\N	Sweden//Finland//Sweden	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
2983	Wistedt 1983 b	\N	flupenthixol decanoate versus fluphenazine decanoate	\N	Sweden	ORIGIN Other Europe	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
2985	Wittenborn 1975	\N	amitriptyline hydrochloride versus thioridazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	225	\N	\N	\N	\N	\N
2986	Wittenborn 1973	\N	niacin dose	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
2987	Witton 1960	\N	Ritaline HCL	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
2989	Wode-Helgodt 1981	\N	Chlorpromazine dose	\N	Sweden	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
2991	Woggon 1978	\N	bromoperidol, 6mg versus "perphenazine, 20mg"	\N	Switzerland	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
2992	Woggon 1986 a	\N	fluperlapine versus Haloperidol	\N	Switzerland	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
2993	Woggon 1977	\N	 CSG No: 1297 	\N	Switzerland	ORIGIN Other Europe	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
3021	Andersen 1977	\N	interpersonal competititve conditions versus control group	\N	United States of America	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
3023	Cole 1967	\N	Acetophenazine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	529	\N	\N	\N	\N	\N
3024	Anonymous 1972	\N	piperacetazine versus thioridazine	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3025	Anonymous 1966	\N	perphenazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3026	Barsa 1956	\N	Azacyclonol Dosage	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
3028	Bellini 1989	\N	Bromperidol decanoate versus Placebo	\N	Italy	San Raffaele Hosp, Inst of Psychiatry, Milan, Italy ORIGIN Other Europe	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3031	Ben-Dor 1998	\N	vitamin E versus Placebo	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3032	Bennett 1954	\N	isoniazid versus Placebo	\N	United States of America	V. A. Hosp., Coatesville, Pa.	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
3035	Beuzen 1998	\N	Olanzapine versus Clozapine	\N	Unclear	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
3038	Asch 1991	\N	summary letter group versus control group	\N	United Kingdom	Applied Psychology Unit, College of Aeronautics, Cranfield Institute of Technology, Cranfield MK43 0AL, United Kingdom	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
3039	Ascough 1971	\N	validation samples versus cross-validation samples	\N	United States of America	Purdue U	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3041	Baker 1957	\N	mepazine versus Placebo	\N	United Kingdom	Banstead Hosp., Surrey, England.	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
3042	Bizon 1965	\N	 CSG No: 3702 	\N	Poland	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
3043	Blum 1984	\N	naloxone versus Placebo	\N	Israel	\N	\N	\N	\N	\N	2	\N	\N	\N	\N	\N
3044	Blumberg 1964	\N	Chlorpromazine versus Placebo	\N	United States of America	Hillside Hosp., Glen Oaks, N. Y.	\N	\N	\N	\N	168	\N	\N	\N	\N	\N
3045	Blumberg 1961	\N	 CSG No: 3419 	\N	United States of America	U. Texas	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
3049	Brankovic 1998	\N	Clozapine versus fluphenazine	\N	Yugoslavia	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
3050	Braus 1996 b	\N	sertindole versus standard care	\N	Unclear	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
3051	Brecher 1998	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	407	\N	\N	\N	\N	\N
3054	Brill 1964	\N	out-patient treatment versus control group	\N	United States of America	\N	\N	\N	\N	\N	299	\N	\N	\N	\N	\N
3055	Broadhurst 1964	\N	massed pursuit rotor practice versus spaced pursuit rotor practice	\N	United Kingdom	U. London, England	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
3058	Byalin 1985	\N	new treatment gorup versus control group	\N	United States of America	South Beach Psychiatric Ctr, New York, NY	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
3059	Cabrera 1986	\N	oxcarbazepine versus lithium	\N	Germany	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
3060	Casacchia 1989	\N	Bromperidol decanoate versus fluphenazine decanoate	\N	Italy	ORIGIN Other Europe	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3062	Cerniglia 1978	\N	group decision making versus self management	\N	United States of America	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
3063	Aman 1985	\N	methylphenidate versus Placebo	\N	New Zealand	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
3064	Andia 1998	\N	Clozapine versus Haloperidol	\N	Spain	I. Andia, Depto. de Investigacion Neuroquimica, Servicio Vasco de Salud, Bo Arteaga 107, 48016 Zamudio, Vizcaya, Spain	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
3065	Bastecky 1980	\N	clorotepin versus Placebo	\N	Czech Republic	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
3067	Caffey 1964	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	348	\N	\N	\N	\N	\N
3068	Chance 1954	\N	cortisone + potassium chloride versus Placebo + potassium chloride	\N	United States of America	Ohio State U., Columbus.	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
3069	Buruma 1982	\N	tiapride versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3070	Carscallen 1968	\N	trifluoperazine versus phenothiazines	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4564	Schulsinger 1958	\N	 CSG No: 4582 	\N	Norway	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
3072	Chandler 1998	\N	integrated services versus control group	\N	United States of America	\N	\N	\N	\N	\N	516	\N	\N	\N	\N	\N
3073	Chaplin 1998 a	\N	educational intervention versus control group	\N	United Kingdom	Dr. R. Chaplin, Division of Community Psychiatry, Department of Mental Health Sciences, St George's Hospital Medical School, Cranmer  Terrace, London SW17 0RE, United Kingdom	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
3074	Chen 1991	\N	dexetimide versus artane	\N	China	\N	\N	\N	\N	\N	261	\N	\N	\N	\N	\N
3075	Cohen 1968	\N	Chlorpromazine versus Placebo	\N	United States of America	HILLSIDE HOSP., GLEN OAKS, N.Y	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
3076	Collins 1965	\N	morphine sulfate versus Placebo	\N	United States of America	Mental Health Res. Inst., Ft. Steilacoom, Wash.	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
3077	Claghorn 1967 b	\N	Chlorpromazine versus SK & F 14336	\N	United States of America	HOUSTON STATE PSYCHIATRIC INST., BAYLOR U. COLL. OF MEDICINE	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3078	Clark 1968 b	\N	Butaperazine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
3079	Clark 1967	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
3080	Cohen 1972	\N	pre training token group versus no pre training token group	\N	Germany	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
3082	Coryell 1998	\N	Haloperidol versus medium plasma level group	\N	United States of America	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
3083	Costello 1964	\N	d-amphetamine sulphate versus Placebo, no drug	\N	Canada	Regina Psychological Lab., Saskatchewan, Canada	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3088	Davidson 1996	\N	inpatient setting versus day hospital setting	\N	United States of America	\N	\N	\N	\N	\N	197	\N	\N	\N	\N	\N
3090	Alpert 1982	\N	L-DOPA versus control group	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
3091	Anderson 1982 d	\N	lecithin versus Placebo	\N	United States of America	New York U, Manhattan Psychiatric Ctr ORIGIN USA	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
3092	Auberger 1985	\N	tiapride versus Placebo	\N	Germany	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
3093	Blin 1990	\N	apomorphine + domperidone versus Placebo	\N	France	Clinique des Maladies du Systeme Nerveux et de l'Appareil Locomoteur, CHU Timone, Marseille, France.	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
3094	Braden 1980	\N	lithium carbonate versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
3095	de Smedt 1970	\N	dexbenzetimide versus Placebo	\N	Belgium	Mental Hospital of the Brothers of Charity, Antwerp, Belgium	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
3096	de Giacomo 1997	\N	family therapy group versus conventional clinical group	\N	Italy	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
3097	de Jong 1965	\N	trifluoperazine versus thioridazine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3100	Desager 1988	\N	zolpidem + Chlorpromazine versus Chlorpromazine	\N	Belgium	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
3101	Devriese 1994	\N	 CSG No: 3567 	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3102	Arato 1998	\N	Ziprasidone versus Placebo	\N	Hungary	Research, Pharma Projections, Kecskemet U11, Budapest H10 53, Hungary	\N	\N	\N	\N	294	\N	\N	\N	\N	\N
3103	Bouchard 1998	\N	Risperidone versus conventional neuroleptics	\N	Canada	\N	\N	\N	\N	\N	184	\N	\N	\N	\N	\N
3104	Brook 1998 a	\N	Intramuscular Ziprasidone versus Intramuscular Haloperidol	\N	South Africa	Research Unit, Sterkfontein Hospital, Sterkfontain Road, Krugersdorp 1740, South Africa	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
3106	Dickey 1986	\N	inpatient care versus residential program	\N	Canada	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
3107	Dilonardo 1998	\N	prescheduled hospital admissions versus traditional access to hospital care	\N	United States of America	J.D. Dilonardo, 19104 Olney Mill Road, Olney, MD 20832, United States	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
3108	DiMascio 1976	\N	Amantadine versus Benztropine	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
3109	Domino 1985	\N	phosphatidylocholine + psychotropic medication versus Placebo + psychotropic medication	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
3110	Dorevitch 1997 b	\N	vitamin E versus Placebo	\N	Israel	Talbieh Mental Health Ctr, Jerusalem, Israel	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3111	Douglas 1969	\N	mesoridazine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
3113	Wolpert 1969	\N	triiodothyronine + phenothiazine versus Placebo + phenothiazine	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3114	Yamada 1996 a	\N	Nilvadipine versus Placebo	\N	Japan	Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3115	Yamagami 1985	\N	 CSG No: 3011 	\N	Japan	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
3116	Yamagami 1993	\N	Bromperidol versus sulpiride	\N	Unclear	Department of Neuropsychiatry, Osaka Citi University Medical School, Japan.	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
3119	Yan 1984	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3120	Yang 1988	\N	Sulpiride versus Clozapine	\N	China	ORIGIN Mid E./Asia	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
3121	Yisak 1993	\N	Remoxipride versus Biperiden	\N	Sweden	Department of Clinical Pharmacology, Astra Arcus AB, Sodertalje, Sweden. ORIGIN Other Europe	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3122	Yisak 1990	\N	Remoxipride versus remoxipride + warafin, remoxipride + diazepam, remoxipride + ethanol	\N	Sweden	Astra Research Centre, Sodertalje, Sweden. ORIGIN Other Europe	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3124	Yorkston 1977 a	\N	Propranolol versus Placebo	\N	United Kingdom // Austria	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
3125	Yorkston 1981	\N	DL- propranolol versus Chlorpromazine	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
3126	Young 1995	\N	instructional: scaffolding technique versus instructions: basic instructions	\N	Canada	Queen Street Mental Health Centre, Toronto, Ont., Canada.	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
3128	Young 1979	\N	Type A therapist versus Type B therapist	\N	United States of America	U California Medical Ctr, Langley Porter Inst, San Francisco ORIGIN USA	\N	\N	\N	\N	235	\N	\N	\N	\N	\N
3129	Youssef 1987	\N	family-patient education programme versus No family-patient education programme	\N	United States of America	Maymount University, Arlington, Virginia.	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3130	Youssef 1991	\N	Haloperidol decanoate versus Other neuroleptics	\N	Ireland	St. Davnet's Hospital, Monaghan, Ireland. ORIGIN Other Europe	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
3131	Yu 1979	\N	Learning through interactive imagery versus Learning through rote repetition	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
3134	Zann 1986	\N	 CSG No: 3253 	\N	France	Ctr Hospitalier Specialise du Rouvray, Service Hospitalo-Universitaire, Sotteville-les-Rouen, France	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3135	Zapletalek 1984	\N	 CSG No: 3176 	\N	Czech Republic	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
3136	Zapletalek 1975	\N	Sydnocarb versus Placebo	\N	Czech Republic	ORIGIN Other Europe	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
3137	Zapletalek 1986	\N	Glaziovine versus Diazepam	\N	Czech Republic	Psychiatric Clinic, Hradec Kralove, Czechoslovakia ORIGIN Other Europe	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3139	Zapletalek 1981	\N	oxyprothepine decanoate versus fluphenazine decanoate (standard)	\N	Czech Republic	Psychiatric Clinic, Hradec Kralove, Czechoslovakia ORIGIN Other Europe	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3140	Zarranz 1980	\N	 CSG No: 3551 	\N	Spain	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3141	Zastowny 1992	\N	behavioural Therapy versus Inpatient treatment	\N	United States of America	Department of Psychiatry, University of Rochester Medical Center, New York. ORIGIN USA	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
3142	Zeller 1956	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	176	\N	\N	\N	\N	\N
3143	Zemishlany 1991	\N	Alprazolam versus Placebo	\N	Israel	Geha Psychiatric Hosp, Petach Tikva, Israel	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
3145	Zhang 1997 a	\N	Bromocriptine versus Placebo	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3146	Zhang 1991	\N	Laser acupuncture versus Chlorpromazine	\N	China	Psychiatric hospital of kai luan mine bureau, Tangshan.	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
3147	Zhang 1995	\N	Haloperidol, oral versus Haloperidol decanoate	\N	China	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
3148	Zhang 1987 a	\N	Electroacupuncture versus Chloropromazine	\N	China	\N	\N	\N	\N	\N	281	\N	\N	\N	\N	\N
3149	Zhang 1994 a	\N	Family intervention versus Standard care	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
3150	Zhang 1994 b	\N	Guardianship network versus Community follow-up programme 	\N	China	Department of Psychiatry, Shanghai Second Medical University, PRC. ORIGIN Mid E./Asia	\N	\N	\N	\N	656	\N	\N	\N	\N	\N
3151	Zhang 1998 a	\N	Risperidone + Paroxetine versus Haloperidol + Paroxetine	\N	China	Z. Dongfeng, Institute of Mental Health, Beijing Medical University, Beijing 100083, China	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
3152	Daniel 1998	\N	sertindole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	282	\N	\N	\N	\N	\N
3153	Diamond 1960	\N	tranquilizers versus Placebo	\N	United States of America	VA Hosp., American Lake, Wash.	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3154	Velligan 1999 b	\N	Quetiapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3155	Vernallis 1965	\N	 CSG No: 3323 	\N	United States of America	VA Hosp., Topeka, Kan.	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3156	Vestre 1961 a	\N	 CSG No: 3868 	\N	United States of America	U. Minnesota	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3158	Vollenweider 1995	\N	 CSG No: 3908 	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3160	Zimmermann 1970	\N	gamfexine + thioridazine versus Placebo + thioridazine	\N	United States of America	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
3161	Zirkle 1961	\N	 CSG No: 805 	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3162	Zissis 1982	\N	Haloperidol Decanoate versus Placebo	\N	Greece	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
3164	Zohar 1986	\N	 CSG No: 2630 	\N	Israel	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
3167	Zuoze 1986	\N	He-Ne laser irradiation	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
3168	Zuzarte 1997 a	\N	Lorazepam + Antipsychotic medication versus Placebo + Antipsychotic medication	\N	United States of America	\N	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
3169	Zuzarte 1997 b	\N	Lorazepam versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
3170	Zwanikken 1973	\N	Penfluridol versus Placebo	\N	Netherlands	Voorburg Psychiatric Hosp., Vught, Netherlands ORIGIN Other Europe	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
18176	Navidian 2010	\N	\N	\N	Iran	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
3172	Diamond 1986	\N	Clozapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
3173	Downing 1963	\N	Chlorpromazine versus Placebo	\N	United States of America	U. Pennsylvania	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
3174	Downing 1966	\N	phenothiazine versus Placebo	\N	United States of America	U. Pennsylvania	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
3176	Engelhardt 1969 a	\N	Chlorpromazine versus Placebo	\N	United States of America	State U. New York, Downstate Medical Center, Brooklyn\r\n\r\nORIGIN USA\r\n\r\nHILLSIDE HOSP., GLEN OAKS, N.Y	\N	\N	\N	\N	446	\N	\N	\N	\N	\N
3177	Fann 1973 a	\N	methylphenidate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3178	Fann 1976	\N	Amantadine versus Placebo // Amantadine versus Trihexyphenidyl // Trihexyphenidyl versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
3180	Fisk 1987	\N	sodium valproate versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
3181	Frangos 1980	\N	lioresal versus Placebo	\N	Greece	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
3182	Freedman 1965	\N	phenothiazine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	State U. New York	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
3183	Freedman 1967	\N	phenothiazine versus Placebo	\N	United States of America	STATE U. NEW YORK, DOWNSTATE MEDICAL CENTER, BROOKLYN	\N	\N	\N	\N	543	\N	\N	\N	\N	\N
3184	Freedman 1959	\N	group play therapy + psychopharmacological agents versus group play therapy + Placebo	\N	United States of America	State U. New York Downstate Medical Center	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3186	French 1987	\N	computerized assessment versus standard form	\N	United Kingdom	\N	\N	\N	\N	\N	367	\N	\N	\N	\N	\N
3188	Friedhoff 1960	\N	Chlorpromazine versus Placebo	\N	United States of America	New York U. Coll. Medicine	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3189	Friedhoff 1966	\N	dimethoxyphenylethylamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
3190	Fudge 1991	\N	tone contingent feedback versus noncontingent feedbak tones	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3191	Gabrynowicz 1968	\N	leptazole + nicotinic acid versus chloroform water + tartrazine	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3192	Gallagher 1995 b	\N	read aloud versus control group	\N	United Kingdom	School of Psychology, Queen's University of Belfast, Northern Ireland, UK.	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
3193	Gardos 1979	\N	papaverine versus no drug control	\N	United States of America	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
3195	Garfield 1966	\N	ataractic medication withdrawl versus ataractic medication	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
3196	Garry 1966	\N	Chlorpromazine versus benzquinamide	\N	Germany	BRITISCH MILITARY HOSP., MUNSTER, GERMANY	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3197	Geddes 1994	\N	prophylactic neuroleptics versus Placebo	\N	United Kingdom	University Department of Psychiatry, Royal Edinburgh Hospital.	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
3198	George 1998	\N	Clozapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3200	Gerlach 1975 d	\N	lilthium versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3201	Gilbertson 1997	\N	Haloperidol versus drug free	\N	United States of America	Highland Drive Veterans Affairs Medical Center, Pittsburgh, PA 15206, USA.	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3202	Gilgash 1961	\N	thorazine versus Placebo	\N	United States of America	MacMurray Coll.	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
3203	Giordana 1984	\N	 CSG No: 3643 	\N	France	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3204	Goff 1993	\N	selegiline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
3205	Goff 1998 a	\N	D-cycloserine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
3206	Gelenberg 1990	\N	lecithin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
3207	Gelenberg 1989	\N	CDP-Choline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
3208	Goldberg 1970 b	\N	prolixin enanthate versus phenothiazine control	\N	United States of America	Boston State Hosp., West-Ros-Park Mental Health Center, Mass	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
3209	Goldberg 1966	\N	Chlorpromazine versus thioridazine	\N	United States of America	NIMH, Bethesda, Md.	\N	\N	\N	\N	398	\N	\N	\N	\N	\N
3210	Goldman 1965	\N	activating condition versus enervating condition	\N	United States of America	State Hosp., Roosevelt Blvd. and Southhampton Rd., Philadelphia, Pa.	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
3211	Goldstein 1998	\N	switch to Quetiapine versus standard care	\N	United States of America	MRCG, Zeneca Pharmaceuticals, 1800 Concord Pike, Wilmington DE 19850	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
3212	Goldstein 1966 b	\N	tension-arousing movies + thioridazine versus tension-arousing movies + Placebo	\N	United States of America	U. California, Los Angeles	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3213	Goldstein 1972	\N	phenothiazine versus Placebo	\N	United States of America	U. California, Los Angeles	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
3214	Gorelick 1981	\N	B-endorphin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
3215	Gould 1982	\N	Bromperidol versus fluphenazine decanoate	\N	United Kingdom	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
20239	杨绪娜 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
3219	Clark 1970 c	\N	Chlorpromazine hydrochloride versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3220	Allard 1969	\N	occupational therapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
3221	Bjorndal 1980 b	\N	enkephalin versus naloxone	\N	Denmark	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
3225	Cowen 1997	\N	acetazolamide + thiamine versus Placebo	\N	United States of America	Nathan S. Kline Inst for Psychiatric Research, Orangeburg, NY, USA	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
3227	Christensen 1997	\N	 CSG No: 3954 	\N	Denmark	\N	\N	\N	\N	\N	192	\N	\N	\N	\N	\N
3228	Christensen 1992	\N	 CSG No: 3955 	\N	Denmark	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
3229	WR  1961	\N	intensive occupational therapy versus treatment as usual	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3233	Greenberg 1970	\N	referral information versus control group	\N	United States of America	State U. New York, Syracuse	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
3234	Greendyke 1988	\N	pidolol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
3235	Grinspoon 1964	\N	thioridazine versus phenobarbital + atropine sulfate	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3236	Gripp 1971	\N	token economy program versus control group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3237	Gross 1974	\N	pimozide versus Placebo//Trifluoperazine versus Placebo//Trifluoperazine versus pimozide	\N	United States of America	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
3239	Growdon 1977	\N	oral choline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3240	Gu 1992	\N	Metoclopramide versus Haloperidol	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
3241	Guilmot 1971	\N	 CSG No: 3933 	\N	Belgium	2 Chemin prive, Lovenjoel, Belgium	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3242	Grinspoon 1972	\N	phenothiazine + psychotherapy versus Placebo + psychotherapy	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3243	Wirshing 1999 a	\N	Risperidone versus Haloperidol, Clozapine	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
3244	Zhang 1987 b	\N	 CSG No: 4000 	\N	China	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
3246	Yamagami 1988	\N	Haloperidol versus Prolactin	\N	Unclear	Department of Neuropsychiatry, Osaka City University Medical School, Japan.	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
3247	Zernig 1994	\N	Haloperidol + milk versus Haloperidol + water	\N	United States of America	U Michigan Medical School, Dept of Pharmacology, Ann Arbor, USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3248	Anonymous 1997 a	\N	 CSG No: 4004 	\N	Unclear	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
3249	Bagby 1997	\N	 CSG No: 3997 	\N	Canada	U Toronto, Clarke Inst of Psychiatry, Toronto, ON, Canada	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
3250	Baba 1995	\N	 CSG No: 3989 	\N	Japan	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
3251	Beard 1975	\N	group therapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3252	Bell 1996 b	\N	high expectation in work activity program versus self regulation	\N	United States of America	Veterans Affairs Medical Center, West Haven, CT	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
3253	Ezra 1999	\N	long sexual risk reduction session versus brief sexual risk reduction session	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3255	de Ronchi 1997	\N	levosulpiride versus pimozide	\N	Italy	Prof. V. Volterra, Ordinario Istituto di Psichiatria, Universita di Bologna, Bologna, Italy	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3256	Dengler 1969	\N	 CSG No: 3998 	\N	Germany	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
3257	Evans 1996	\N	discussion with health care professional versus fact sheet	\N	United Kingdom	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
3258	Greil 1985	\N	tiapride versus Placebo	\N	Germany	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
3260	Gutierrez 1979	\N	 CSG No: 3468 	\N	Spain	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
3261	Guy 1978	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	342	\N	\N	\N	\N	\N
3262	Hackman 1998	\N	assertive community treatment versus standard care	\N	United States of America	University of MD, 630 W Fayette Street Act Team, Baltimore MD 21201	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
3263	Haider 1966	\N	nortriptyline versus amitriptyline	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3264	Hajioff 1983	\N	co-dergocrine mesylate versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3265	Hall 1962	\N	psychotherapy versus drug therapy	\N	United States of America	VA Hosp., Brockton, Mass.	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
3266	Hanlon 1964	\N	amitriptyline versus perphenazine	\N	United States of America	\N	\N	\N	\N	\N	115	\N	\N	\N	\N	\N
3267	Harrington 1996	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	Unclear	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
3268	Hellerstein 1999	\N	integrated abuse services versus non integrated treatment	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
18766	Caseiro 2010	\N	\N	\N	Spain	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
3269	Hamelin 1998	\N	Ziprasidone under fasting conditions versus Ziprasidone after high fat meal	\N	Canada	Dr. M. LeBel, Anapharm Inc., 250 Rene Levesque Ouest, 5e etage, Ste-Foy, Que. G1V 2K8, Canada	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
3270	Hart 1980	\N	model + reinforcement group versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3271	Hartley 1991	\N	Chlorpromazine versus Placebo	\N	Australia	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
3272	Hartley 1989	\N	Chlorpromazine versus Placebo	\N	Australia	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
3275	Heath 1966	\N	methionine sulfoximine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
3276	Hebenstreit 1986	\N	 CSG No: 3950 	\N	Austria	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
3279	Hesslinger 1998	\N	Haloperidol + carbamazepine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
3280	Hesso 1975	\N	PLP 100-127 versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3281	Hickerson 1956	\N	Reserpine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
3282	Higgins 1978	\N	incentive condition versus no incentive condition	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3283	Hirsch 1989 c	\N	fluphenazine decanoate versus Placebo	\N	United Kingdom	Department of Psychiatry, Charing Cross and Westminster Medical School, London.	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
3284	Hirschowitz 1997	\N	Bromocriptine growth hormone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3285	Hodel 1994	\N	cognitive therapy versus control group	\N	Switzerland	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
3286	Holden 1969 b	\N	perphenazine versus P-5227	\N	United States of America	U. Missouri, School of Medicine, St Louis	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
3287	Hoffer 1962	\N	nicotinic acid versus nicotinamide	\N	Canada	\N	\N	\N	\N	\N	159	\N	\N	\N	\N	\N
3292	Huang 1980	\N	 CSG No: 3475 	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3294	Hymowitz 1980	\N	Antipsychotics versus control group	\N	United States of America	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
3295	Inanaga 1975	\N	L-dopa dose	\N	Japan	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
3296	Ionescu 1983	\N	penfluridol + fluphenazine versus fluphenazine + Placebo	\N	Romania	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
3297	Issakidis 1999	\N	intensive case management versus standard case management	\N	Australia	Clinical Research Unit for Anxiety Disorders, University of New South Wales at St Vincent's Hospital, Sydney, Australia.	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
3298	Itil 1975	\N	fluphenazine versus Haloperidol	\N	United States of America	New York Medical Coll, Div of Biological Psychiatry, NY ORIGIN USA	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
3299	Jackson 1978	\N	deanol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
3301	Jaffe 1976	\N	modelling group versus attention group	\N	Canada	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
3302	Jakobitsch 1996	\N	 CSG No: 3991 	\N	Switzerland	Psychiatrische Universitatsklinik Basel.	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
3303	Jambur 1998	\N	Risperidone versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3304	Jankovic 1982	\N	tetrabenazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3305	Janowsky 1974	\N	methylphenidate versus levamfetamine	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
3306	Janowsky 1972	\N	Amantadine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
3307	Jasovic 1998	\N	mianserin versus Placebo	\N	Yugoslavia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3308	Jensen 1961	\N	tranquilizers versus control group	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
3309	Jeste 1983 b	\N	apomorphine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
3310	Jeste 1977	\N	Chlorpromazine dose	\N	United States of America	\N	\N	\N	\N	\N	3	\N	\N	\N	\N	\N
3311	Johnstone 1998 a	\N	Olanzapine versus Haloperidol	\N	United States of America	Health Services, Eli Lilly and Company, Lilly Corporate Center, Indianapolis IN 46285	\N	\N	\N	\N	814	\N	\N	\N	\N	\N
3314	Jones 1998	\N	Risperidone versus various doses	\N	Canada//United States of America	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
3315	Jus 1978	\N	deanol versus Placebo	\N	Canada	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
3316	Jus 1974 b	\N	benztropine mesylate versus tryptophan	\N	Canada	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
3318	Kahn 1993 b	\N	remoxipride versus Haloperidol	\N	France	\N	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
3320	Kalachnik 1984	\N	neuroleptic reduction versus no neuroleptic history	\N	United States of America	\N	\N	\N	\N	\N	191	\N	\N	\N	\N	\N
3321	Kanas 1980	\N	insight oriented therapy versus non-insight oriented therapy	\N	United States of America	\N	\N	\N	\N	\N	231	\N	\N	\N	\N	\N
3322	Kandel 1981	\N	small group treatment versus control group	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
3323	Kang 1993	\N	Traditional Chinese Medicine (TCM) Suoquan Pills versus Placebo	\N	China	Nanjing Neuropsychiatric Hospital.	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
20240	彭爱琴 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
3326	Karon 1969	\N	experienced therapists versus inexperienced therapists	\N	United States of America	Michigan State U\r\n\r\nORIGIN USA\r\n\r\nMichigan State U	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
3328	Mercer 1997	\N	intensive treatment//Risperidone versus standard group	\N	United Kingdom	G. Mercer, University Department of Psychiatry, Royal Edinburgh Hospital, Edinburgh EH10 5HF	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
3330	Meyer-Lindenberg1997	\N	Clozapine versus zotepine	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
3333	Modai 1996	\N	ART suggestions versus control group	\N	Israel	Open Department, Gehah Psychiatric Hospital, Petah Tiqva, Israel.	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
3334	Monroe 1967	\N	chlordiazepoxide + phenothiazines versus chlordiazepoxide	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3335	Morselli 1985	\N	progabide versus drug treatment for TD	\N	France	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
3336	Mulholland 1998 a	\N	tryptophan versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3338	Cutler 1957	\N	Chlorpromazine versus Placebo	\N	United States of America	Evanston, Ill.	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
3339	Adler 1991	\N	d-proproanolol versus Placebo	\N	United States of America	Psychiatry Service, New York DVAMC, NY 10010.	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
3342	Awad 1998	\N	remoxipride versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	205	\N	\N	\N	\N	\N
3344	Battaglia 1997	\N	Haloperidol versus Haloperidol + lorazepam	\N	United States of America	Alaska Psychiatric Institute, Anchorage, USA.	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
3346	Bellaire 1990	\N	carbamazepine versus lithium	\N	Germany	\N	\N	\N	\N	\N	139	\N	\N	\N	\N	\N
3347	Bieniek 1998	\N	lorazepam versus Haloperidol + lorazepam	\N	United States of America	Department of Psychiatry and Behavioral Sciences, University of Miami, School of Medicine, FL, USA.	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3350	Bastiaens 1999	\N	sample medications versus prescription medications	\N	United States of America	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
3353	Barrowclough 1999	\N	psychosocial intervention+ family support versus psychosocial intervention	\N	United Kingdom	C. Barrowclough, Acad. Dept. of Clinical Psychology, Mental Health Unit, Tameside General Hospital, Ashton-under-Lyne, Lancashire OL6 9RW, United  Kingdom	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
3354	Browne 1996	\N	psychosocial rehabilitation versus conventional rehabilitation program	\N	Ireland	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
3355	Bruns 1992	\N	ambulant group therapy versus control group	\N	Germany	\N	\N	\N	\N	\N	191	\N	\N	\N	\N	\N
3356	Buchanan 1995	\N	mazindol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3357	Buckley 1995	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
3359	Carpenter 1992 b	\N	fluphenazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
3360	Carroll 1998	\N	educational intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
3361	Cassady 1995	\N	amphetamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
3362	Clouth 1999	\N	Olanzapine versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3363	Chanpattana 1999 a	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) + flupenthixol versus Electro Convulsive Therapy (Electroconvulsive Therapy) + Placebo	\N	Thailand	\N	\N	\N	\N	\N	88 114	\N	\N	\N	\N	\N
3364	Carpenter 1999 a	\N	dizepam versus Placebo	\N	United States of America	Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore 21228, USA. wcarpent@mprc.umaryland.edu	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
3365	Breier 1999 c	\N	Clozapine versus Risperidone	\N	United States of America	Experimental Therapeutics Branch, Division of Intramural Research Programs, NIMH, Bethesda, MD, USA. breier_alan@lily.com	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
3367	Cormier 1995	\N	psychoeducation group therapy versus control group	\N	Canada	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
3369	Covi 1971	\N	chlordiazepoxide versus Placebo	\N	Mexico	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3371	Denef 1971	\N	propericiazine versus various dosages	\N	Mexico	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
3372	Dorevitch 1999	\N	intramuscular flunitrazepam versus intramuscular Haloperidol	\N	Israel	Talbieh Mental Health Center, Hebrew University Faculty of Medicine, Jerusalem, Israel.	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
3376	Emsley 1999 b	\N	Quetiapine versus Haloperidol	\N	South Africa	\N	\N	\N	\N	\N	288	\N	\N	\N	\N	\N
3377	Faustman 1995	\N	Quetiapine versus Placebo	\N	United States of America	Vererans Affairs Palo Alto Health Care System, Mental Health Clinical Research Ctr, Palo Alto, CA, USA	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
3378	Fenton 1995	\N	hospital care versus residential care	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3379	Fenton 1999 a	\N	crisis residential alternative program versus hospital care	\N	United States of America	\N	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
3380	Fleischhacker 1996	\N	seroquel versus various dosages	\N	United Kingdom // Australia	\N	\N	\N	\N	\N	448	\N	\N	\N	\N	\N
3381	Friberg 1992	\N	sertindole versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
3382	Gaebel 1995	\N	open treatmtent strategies versus standard prophylactic maintenance	\N	Germany	\N	\N	\N	\N	\N	364	\N	\N	\N	\N	\N
3384	Golightly 1998	\N	tryptophan-amino acid drink versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3385	Goncalves 1985	\N	 CSG No: 4130 	\N	Germany	Germany	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3386	Gottschalk 1978	\N	phenothiazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
3387	Grawe 1998	\N	multimodal treatment versus standard care	\N	Norway	R.W. Grawe, Dept Psychiatry Behavioural Medicine, Norwegian Univ of Science Technology, Box 3008 Lade, N-7002 Trondheim,  Norway	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
3388	Gray 1996	\N	D-amphetamine versus various dosages	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
3389	Green 1998	\N	Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3390	Hampton 1992	\N	assertive case management versus routine discharge planning	\N	United States of America	\N	\N	\N	\N	\N	191	\N	\N	\N	\N	\N
3391	Haverstock 1995	\N	guanabenz versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3392	Hirsch 1999 a	\N	Ziprasidone versus various dosages	\N	United Kingdom	\N	\N	\N	\N	\N	301	\N	\N	\N	\N	\N
3393	Hoffman 1999 a	\N	transcranial magnetic stimulation (Transcranial Magnetic Stimulation) versus sham transcranial magnetic stimulation (Transcranial Magnetic Stimulation)	\N	United States of America	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
3394	Iizuka 1986	\N	 CSG No: 4133 	\N	Germany	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
3395	Ivarson 1998	\N	integrated care versus control group	\N	Sweden	B. Ivarson, Psych. Sces, Boras Mark-Svenljunga-Tranemo, Sweden	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
3397	Junker 1992	\N	alpha-tocopherol versus Placebo	\N	Germany	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
3398	Kazamatsuri 1973	\N	tetrabenazine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
3402	Kelly 1999 a	\N	integrated HIV prevention group versus control group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3403	Kelly 1997	\N	AIDS education session versus cognitive behavioral hiv resk reduction sessions + advocacy training	\N	United States of America	Medical Coll of Wisconsin, Dept of Psychiatry and Behavioral Medicine, Ctr for AIDS Intervention Research, Milwaukee, WI, USA	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
3406	Danion 1999	\N	Amisulpride versus Placebo Amisulpride versus Placebo	\N	France	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	242	\N	\N	\N	\N	\N
3409	Kenny 1992	\N	Clozapine versus typical neuroleptics	\N	United States of America	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
3410	Kenway 1971	\N	pimozide versus fluphenazine	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3412	Kim 1999 a	\N	clonidine + Haloperidol versus Haloperidol + Placebo	\N	Canada	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
3413	Kim 1998 a	\N	Antipsychotics + conjugated estrogen versus no treatment	\N	South Korea	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
3415	King 1991	\N	remoxipride versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
3417	Kinon 1999 a	\N	Olanzapine versus conventional Antipsychotic or Risperidone	\N	United States of America	\N	\N	\N	\N	\N	209	\N	\N	\N	\N	\N
3418	Kitzinger 1949	\N	glutamic acid versus Placebo	\N	United States of America	V.A. Brentwood Hosp., Los Angeles, Calif.	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
3419	Kleinman 1993	\N	single session group versus educational review group	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3421	Klimke 1993	\N	perazin versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
3422	Kline 1967 b	\N	niacin versus niacinamide	\N	United States of America	ROCKLAND STATE HOSP., ORANGEBURG, N.Y	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3423	Knott 1982	\N	fast set stimulus instructions versus neutral stimulus instructions	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3424	Koller 1982	\N	estrogen versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3425	Komori 1995	\N	 CSG No: 3990 	\N	Japan	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
3426	Korinkova 1989	\N	zetidoline versus Haloperidol	\N	Czech Republic	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
3427	Korsgaard 1976	\N	baclofen versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3428	Krystal 1995	\N	ketamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
3429	Krystal 1998	\N	ketamine + lorazepam versus Placebo ketamine + Placebo lorazepam	\N	United States of America	Department of Psychiatry, Yale University School of Medicine, Connecticut, USA.	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3430	Kuang 1988	\N	Thioridazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3431	Kudo 1983 b	\N	 CSG No: 3662 	\N	Japan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3432	Kuipers 1997 a	\N	Cognitive Behavioural Training + standard care versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
3435	Kurland 1966 b	\N	Chlorpromazine + chlordiazepoxide versus Chlorpromazine + imipramine	\N	United States of America	\N	\N	\N	\N	\N	158	\N	\N	\N	\N	\N
3436	Kurland 1962	\N	phenothiazine versus Placebo	\N	United States of America	Spring Grove State Hosp., Baltimore, Md.	\N	\N	\N	\N	238	\N	\N	\N	\N	\N
3437	Kurland 1961	\N	phenothiazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	277	\N	\N	\N	\N	\N
3438	Lahti 1998 a	\N	preclamol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
3439	Lahti 1995 b	\N	ketamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3440	Lal 1974	\N	Trifluoperazine versus Placebo//Thiorpropazate versus Placebo//Trifluoperazine versus Thiorpropazate	\N	Canada	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3442	Lamb 1972	\N	high expectation environment versus low expectation environment	\N	United States of America	San Mateo County Dept. of Public Health and Welfare, San Carlos, Calif	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
3443	Lapierre 1983	\N	pipotiazine palmitate versus fluphenazine decanoate	\N	Canada	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
3444	Lapolla 1967	\N	perphenazine + emitriptyline versus Chlorpromazine	\N	United States of America	CAMARILLO STATE HOSP., CALIF	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
3445	Laurian 1981	\N	Chlorpromazine dose	\N	Switzerland	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3446	Leckman 1971	\N	pentylenetetrazol versus Placebo	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3448	Lee 1994 b	\N	Skill training + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
3449	Lehman 1995 b	\N	assertive community treatment versus control group	\N	United States of America	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
3450	Lehrl 1978	\N	flunarizine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3451	Lejoyeux 1993	\N	Chlorpromazine versus Haloperidol	\N	France	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3452	Leon 1995	\N	Clozapine versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3453	Levita 1961	\N	Chlorpromazine versus Placebo	\N	United States of America	Teachers Coll., Columbia U.	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
3454	Leys 1988	\N	diltiazem versus Placebo	\N	France	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
3455	Li 1995	\N	behaviour therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
3456	Liberman 1998	\N	skills training versus psychosocial occupational therapy	\N	United States of America	West Los Angeles VA Medical Center and the Department of Psychiatry and Biobehavioral Sciences, University of California, USA.  rpl@ucla.edu	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
3457	Lieberman 1988	\N	Bromocriptine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
3458	Lindenmayer 1997 a	\N	oral m-CPP versus Placebo	\N	United States of America	Manhattan Psychiatric Ctr, Psychopharmacology Research Unit, New York, NY, USA	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
3459	Lindenmayer 1988	\N	naloxone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3460	Lindsay 1980	\N	behavioural groups versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3461	Linn 1980	\N	foster care versus inpatient care	\N	United States of America	\N	\N	\N	\N	\N	210	\N	\N	\N	\N	\N
3462	Linnoila 1976	\N	sodium valproate versus Placebo	\N	Austria//Finland	ORIGIN Other Europe	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
3463	Linszen 1997	\N	family intervention versus individual treatment	\N	Netherlands	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
3464	Littrell 1999	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
3465	Lopez 1971	\N	 CSG No: 3188 	\N	Spain	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
3466	Lorr 1961	\N	meprobamate versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
19247	杨老虎 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
3468	Luckey 1967	\N	trifluoperazine versus Placebo//Haloperidol versus Trifluoperazine//Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
3469	Ludatscher 1989	\N	L-dopa versus Placebo	\N	Israel	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
3470	Lynch 1996	\N	Haloperidol + psychotherapy versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
3471	Magner 1974	\N	 CSG No: 3711 	\N	Denmark	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
3473	Mak 1997	\N	family management rehabilitation program versus control group	\N	Hong Kong	Dr. K.-Y. Mak, Department of Psychiatry, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong, Hong Kong	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
3474	Malhotra 1997 a	\N	Clozapine + ketamine versus Clozapine + Placebo	\N	United States of America	National Inst of Mental Health, Experimental Therapeutics Branch, Bethesda, MD, USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3475	Malhotra 1995	\N	ketamine versus drug free	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
3476	Marder 1995	\N	Risperidone versus Clozapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3477	Marjerrison 1967	\N	pheniprazine versus Placebo	\N	Canada	SASKATCHEWAN HOSP., NORTH BATTLEFORD, CANADA	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
3478	Marken 1994	\N	lithium versus Placebo	\N	United States of America	School of Pharmacy and Medicine, University of Missouri-Kansas City, 64108.	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
3479	Marneros 1979	\N	 CSG No: 3642 	\N	Germany	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3480	Marsálek 1997	\N	7-MEOTA versus Placebo	\N	Czech Republic	M. Marsalek, Psychiatric Hospital, Ustavni 91, CZ 181 02 Prague 8	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
3482	Mattila 1994	\N	suriclone + Chlorpromazine versus Placebo + Chlorpromazine//Chlorpromazine versus Placebo	\N	Finland	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3483	Mattke 1971	\N	D-penicillamine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3484	Mattke 1975	\N	loxapine versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3485	McBain 1992	\N	ondansetron versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
3486	McDonald 1956	\N	Reserpine versus Placebo	\N	United States of America	V.A. Hosp., Salt Lake City, Utah.	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
3487	McEvoy 1996 a	\N	Clozapine versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
3488	McEvoy 1992	\N	Haloperidol dose	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3489	McGorry 1999 a	\N	specific treatment + Risperidone versus non specific needs intervention	\N	Australia	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
3490	McGorry 1998	\N	specific treatment + Risperidone versus non specific needs intervention	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
3491	McKeever 1965	\N	psychotherapy versus ataraxic medication	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3493	McLaren 1989	\N	Bromperidol versus fluphenazine	\N	United Kingdom	Royal London Hosp, England ORIGIN UK	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
3494	Medalia 1998	\N	attention training versus control group	\N	United States of America	Dr. A. Medalia, Dept. of Psychiatry, Montefiore Medical Ctr., 111 East 210 St., Bronx, NY 10467, United States	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
3495	Melnyk 1966	\N	Chlorpromazine versus Placebo	\N	Canada	Kingston General Hosp., Canada	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3500	Muller 1978 a	\N	fluphenazine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3503	Murasaki 1998	\N	perospirone versus Haloperidol	\N	Japan	\N	\N	\N	\N	\N	145	\N	\N	\N	\N	\N
3504	Nahunek 1970 a	\N	 CSG No: 3656 	\N	Czech Republic	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
3505	Nahunek 1967	\N	 CSG No: 3658 	\N	Czech Republic	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
3506	Nair 1998 a	\N	Risperidone versus Placebo	\N	Canada	Dr. N.P.V. Nair, Department of Psychiatry, Douglas Hospital, 6875 Lasalle Blvd., Verdun, Que. H4H 1R3, Canada	\N	\N	\N	\N	211	\N	\N	\N	\N	\N
3507	Nasrallah 1983 b	\N	L-dopa versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
3508	Needham 1996	\N	zotepine versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3509	Netz 1963	\N	LSD-25 versus Placebo	\N	Sweden	U. Stockholm, Sweden	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
3510	Nijdam 1992	\N	carbamazepine divitabs versus normal carbamazepine	\N	Netherlands	Psychiatric Hospital Reinier van Arkel, Vught, The Netherlands.	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3511	Nussbaum 1964	\N	modaline sulfate versus Placebo	\N	United States of America	Spring Grove State Hosp., Baltimore, Md.	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
3512	Nutt 1992	\N	buprenorphine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3513	Nuttbrock 1997 b	\N	therapeutic community versus residence community	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3514	O'Hanlon 1998	\N	Amisulpride versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
3515	O'Reilly 1957	\N	perphenazine versus Chlorpromazine	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3516	Offord 1998	\N	M100907 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
3517	Olfson 1998	\N	implementing practice guidelines versus usual care	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3518	Otani 1997	\N	trihexyphenidyl-biperiden versus biperiden-trihexyphenidyl	\N	Japan	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3519	Pach 1998 a	\N	flupenthixol decanoate dose	\N	Germany	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
3521	Parellada 1999	\N	Olanzapine versus Haloperidol	\N	Spain	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
3522	Pathiraja 1995	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
3523	Pecknold 1971	\N	troxonium tosylate versus Placebo	\N	Canada	Douglas Hosp., Verdun, Quebec, Canada	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
3525	Penovich 1978	\N	deanol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
3526	Petit 1996	\N	zotepine versus Haloperidol	\N	France	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
3527	Petit 1993	\N	clonazepam versus Placebo	\N	France	Unite de Psychopharmacologie, Service de Psychologie Medicale, Faculte de Medecine, Montpellier, France	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3528	Phan 1995	\N	community nursing intervention versus control group	\N	Australia	School of Nursing, Faculty of Health Sciences, The University of Sydney, PO Box 170, Lidcombe, NSW 2141, Australia	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
3530	Pinard 1972 b	\N	pimozide versus Placebo	\N	Canada	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
3531	Pishkin 1967	\N	hydroxyzine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
3532	Poyurovsky 1998	\N	mianserin versus Placebo	\N	Israel	Department of Research, Tirat Carmel, PO Box 9, Tirat Carmel 30200, Israel	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3534	Puech 1998	\N	Amisulpride versus Haloperidol	\N	France//Germany	\N	\N	\N	\N	\N	319	\N	\N	\N	\N	\N
3535	Puri 1996	\N	Transcranial Magnetic Stimulation + medication versus Transcranial Magnetic Stimulation	\N	United Kingdom	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
3537	Potkin 1996	\N	sertindole versus Placebo	\N	United States of America//Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3538	Rainaut 1975 a	\N	loxapine versus thioridazine	\N	France	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
3540	Rasmussen 1998	\N	Risperidone versus Haloperidol	\N	Belgium	Department of Psychiatry, Clinical Sciences Building, University of Leicester, Leicester Royal Infirmary, PO BOX 65, LE2 7LX, United Kingdom. Telephone: 0116 252 3242. Fax: 0116 2523293. E-mail: rev@le.ac.uk. Project related web site: n/a. Commercial stud\r\n\r\nJanssen Research Foundation, Turnhoutseweg 30, 2340 Beerse, Belgium	\N	\N	\N	\N	500	\N	\N	\N	\N	\N
3543	Reeves 1998 a	\N	Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
19349	姚兴军 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
3544	Reinstein 1999 a	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	751	\N	\N	\N	\N	\N
3545	Reker 1982	\N	naloxone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
3547	Riemann 1992	\N	cholinergic stimulation versus control group	\N	Germany	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
3548	Rinaldi 1955	\N	Azacyclonol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3549	Ringwald 1978	\N	Bromocriptine versus trihexyphenydil	\N	Switzerland	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
3550	Roback 1972	\N	insight oriented therapy versus non-insight oriented therapy	\N	Canada	Clarke Inst. of Psychiatry, Toronto, Ontario, Canada	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
3551	Rondot 1987	\N	progabide versus Placebo	\N	France	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
3552	Roos 1988	\N	tiapride versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3553	Roos 1982	\N	 CSG No: 3569 	\N	Netherlands	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
3557	Rosenthal 1958	\N	deep coma insulin therapy versus subcoma insulin therapy	\N	United States of America	Boston U. Hosp.	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
3558	Rubin 1971	\N	trifluoperazine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
3559	Saito 1998	\N	Olanzapine versus Placebo	\N	Japan	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3560	Sakurai 1967	\N	Benzodiazepine versus Placebo	\N	Japan	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
3561	Salokangas 1997	\N	citalopram versus Placebo	\N	Finland	Department of Psychiatry, University of Turku, Turku University Central Hospital, Finland.	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
3566	Schultz 1995	\N	fluphenazine + lithium versus fluphenazine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
3568	Schwartz 1990	\N	sulpiride versus Placebo	\N	Israel	Department of Neurology, Bnai-Zion Medical Center, Faculty of Medicine, Technion, Haifa, Israel.	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
3569	Sedman 1990	\N	CI-966 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
3570	Selze 1958	\N	doxylamine versus Placebo	\N	United States of America	Ypsilanti State Hosp., Mich.	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
3571	Sensky 1998	\N	Cognitive Behavioural Training versus befriending	\N	United Kingdom	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
3573	Serafetinides 1971	\N	tybamate versus Placebo	\N	United States of America	U. Oklahoma, Medical Center, Oklahoma City	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
3575	Silver 1996 c	\N	fluvoxamine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
3578	Singer 1978	\N	flunitrazepam versus flurazepam	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
3580	Slavinsky 1982	\N	social support program versus medication clinic without psychosocial support	\N	United States of America	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
3583	Spitzer 1959	\N	L-Glutavite versus vitamins	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3584	Stein 1996	\N	propranolol versus Placebo	\N	Israel	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
3585	Takeshima 1968	\N	 CSG No: 4003 	\N	Japan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3589	Taylor 1987	\N	prochlorperazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
3590	Tetreault 1969 d	\N	 CSG No: 3883 	\N	Canada	U. Montreal, Quebec, Canada	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
3591	Theilemann 1993	\N	integrated psychological therapy versus sociotherapy	\N	Germany	Germany	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
3592	Thomas 1998	\N	Amisulpride versus Haloperidol	\N	Australia//New Zealand	Eli Lilly and Company, Lilly Corporate Center, Indianapolis 46285, USA	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
3596	Tollefson 1996  b	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	1996	\N	\N	\N	\N	\N
3598	Van Praag 1981 b	\N	 CSG No: 3947 	\N	Netherlands	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
3599	Vanherweghem 1980	\N	hemodialysis versus sham hemodialysis	\N	Belgium	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
3600	Velligan 1995	\N	Cognitive Adaptation Training versus standard psychosocial programming	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
19295	唐红 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
3605	Wirshing 1992 b	\N	oral neuroleptic versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
3607	Wykes 1998 a	\N	intensive individual treatment versus standard treatment	\N	United Kingdom	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
3610	Daniel 1999 a	\N	discontinued Olanzapine + Ziprasidone versus control group	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
3611	Daniel 1999 b	\N	discontinued Olanzapine + Ziprasidone versus control group	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
3614	Gerlach 1977 b	\N	AMPT versus baclofen	\N	Denmark	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
3615	Gerlach 1977 c	\N	AMPT versus biperiden	\N	Denmark	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
3618	Glazer 1985 b	\N	baclofen versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3619	Glazer 1985 c	\N	premarin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3624	Hayano 1991 a	\N	 CSG No: 2504\r\nBiological Abstracts Vol. 92, Iss. 10, Ref. 116336 	\N	Japan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3625	Hayano 1991 b	\N	 CSG No: 2360\r\nBiological Abstracts Vol. 92, Iss. 10, Ref. 116337 	\N	Japan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3628	Hogarty 1997 a	\N	personal therapy versus "family therapy, supportive therapy"	\N	United States of America	Department of Psychiatry, University of Pittsburgh School of Medicine, PA, USA.	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
3630	Janowsky 1977 a	\N	naloxone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
3631	Janowsky 1977 b	\N	naloxone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
3633	Jerrell 1995 a	\N	12 step recovery program versus behavioral skills training	\N	United States of America	University of South Carolina School of Medicine, Columbia 29203, USA.	\N	\N	\N	\N	147	\N	\N	\N	\N	\N
3634	King 1959 a	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus regressive Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	United States of America	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
3635	King 1959 b	\N	proclorperazine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
3638	Knudsen 1985 a	\N	perphenazine decanoate versus perphenazine enanthate	\N	Denmark	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
3639	Knudsen 1985 b	\N	perphenazine decanoate dose	\N	Denmark	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
3641	Knudsen 1985 c	\N	perphenazine decanoate + sesame oil versus perphenazine enanthate + sesame oil	\N	Denmark	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
3642	Kocher 1980 a	\N	 CSG No: 3491 CSG No: 3936	\N	Switzerland	Psychiat. Univ. Klin., 4025 Basel, Switzerland	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3644	Lee 1997 a	\N	fluoxetine + Haloperidol versus Haloperidol + Placebo	\N	South Korea	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
3645	Lee 1997 b	\N	sertraline + Placebo versus Haloperidol + Placebo	\N	South Korea	Department of Psychiatry, College of Medicine, Korea University, Seoul. leeminso@unitel.co.kr	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
3652	Mahmoud 1999 a	\N	 CSG No: 4122 	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3654	Munroe 1995 a	\N	group social skills training program versus group psychoeducation	\N	Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3655	Munroe 1995 b	\N	group social skills training program versus group psychoeducation	\N	Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3657	Petit 1995 b	\N	zotepine versus Haloperidol	\N	France	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
3658	Pichot 1988	\N	\N	\N	France	INSERM, Clinique des Maladies Mentales et de l'Encephale, Paris, France ORIGIN Other Europe	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
4138	Nagao 1998	\N	Risperidone versus Haloperidol	\N	Japan	Nagao Hospital, Medical body Ryokuhukai, Kure, Japan	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
3659	Pichot 1988 b	\N	sulpiride versus Chlorpromazine	\N	France	INSERM, Clinique des Maladies Mentales et de l'Encephale, Paris, France ORIGIN Other Europe	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3661	Platt 1981	\N	brief hospitalizaion versus standard hospitalizaion	\N	United Kingdom	\N	\N	\N	\N	\N	224	\N	\N	\N	\N	\N
3667	Sanger 1997	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	1996	\N	\N	\N	\N	\N
3670	Schulman 1983 a	\N	hemodialysis versus sham	\N	Sweden	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3671	Schulman 1983 b	\N	hemodialysis versus sham	\N	Sweden	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3672	Simpson 1973 c	\N	Chlorpromazine versus Metiapine	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
3673	Simpson 1973 a	\N	Butaperazine Route	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
3674	Smith 1977 b	\N	d-Amphetamine versus apomorphine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3675	Smith 1998 a	\N	cigarette with high nicotine versus de-nicotinized cigarette	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3676	Smith 1998 b	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3677	Smith 1977 c	\N	paliperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3678	Solomon 1995 b	\N	consumer case management versus non-consumer case management	\N	United States of America	School Social Work U Pennsylvania, Philadelphia PA 19104	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
3830	Wilner 1997 b	\N	cimetidine + Ziprasidone versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3680	Solomon 1995 d	\N	assertive community treatment versus individual case management	\N	United States of America	U Pennsylvania, School of Social Work, US	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
3681	Spencer 1994 a	\N	Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
3682	Spencer 1994 b	\N	Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
3683	Swift 1998 a	\N	fixed dose intramuscular Ziprasidone versus flexible dose intramuscular Haloperidol	\N	United States of America	Cent Research, Pfizer Inc., Eastern Point Road, Groton CT 06340	\N	\N	\N	\N	306	\N	\N	\N	\N	\N
3684	Swift 1998 d	\N	fixed dose intramuscular Ziprasidone versus flexible dose intramuscular Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	306	\N	\N	\N	\N	\N
3685	Tamminga 1979 a	\N	muscimol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
3686	Tamminga 1979 b	\N	Bromocriptine versus CF 25-397	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3690	Gunderson 1984	\N	therapeutic alliance versus control group	\N	United States of America	Brookside Hospital, Nashua, NH 03063. ORIGIN USA	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
3691	Hall 1955	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3695	Herrmann 1991	\N	maroxepine versus Placebo	\N	Germany	Germany	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
3697	Knights 1979	\N	fluphenazine versus flupenthixol	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
3701	Pickar 1984	\N	ceruletide versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
3702	Hoult 1981	\N	community oriented care versus hospital oriented care	\N	Australia//New Zealand	ORIGIN Australia/NZ\r\n\r\nNorthern Metropolitan Regional Office, Dept of Health, North Ryde, Australia\r\n\r\nORIGIN Australia/NZ	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
3707	Borison 1994b	\N	ICI 204,636 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	109	\N	\N	\N	\N	\N
3708	Johnstone 1978	\N	flupenthixol versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
3709	Johnson 1970 a	\N	lithium versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
3710	Judd 1981	\N	methadone hydrochloride versus Placebo	\N	United States of America	U California-San Diego, School of Medicine, La Jolla ORIGIN USA	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
3711	Kane 1988	\N	Clozapine versus Haloperidol	\N	United States of America	ORIGIN USA\r\n\r\nORIGIN USA\r\n\r\nU California-Irvine Medical Ctr, Dept of Psychiatry, Orange, US ORIGIN USA\r\n\r\nMetropolitan State Hosp, Clinical Research Unit, Norwalk, CA, US ORIGIN USA	\N	\N	\N	\N	268	\N	\N	\N	\N	\N
3713	Kane 1983 a	\N	fluphenazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
3715	Hirsch 1979	\N	brief hospitalizaion versus standard hospitalizaion	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
3716	Kornetsky 1958	\N	Chlorpromazine versus secobarbital	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3717	Kornestsky 1957	\N	meperidine hydrochloride versus Chlorpromazine hydrochloride	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3718	Kulkarni 1972	\N	piperacetazine versus Chlorpromazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	182	\N	\N	\N	\N	\N
3721	Kurland 1982	\N	flutroline dose	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
3722	klieser 1990	\N	remoxipride versus Haloperidol	\N	Germany	Department of Psychiatry, University of Dusseldorf, FRG. ORIGIN Other Europe	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
3723	Leff 1971	\N	fluphenazine decanoate versus Placebo	\N	United Kingdom	ORIGIN UK\r\n\r\nMRC Social Psychiatry Unit, Institute of Psychiatry, London. ORIGIN UK	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
3724	Leff 1982	\N	family therapy + education versus relatives group + education	\N	United Kingdom	Friern Hosp, London, England ORIGIN UK	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
3726	Manos 1981	\N	antiparkinson medication versus Placebo	\N	Greece	ORIGIN Other Europe	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
3727	Marshall 1995	\N	social services case management versus control group	\N	United Kingdom	Oxford University Department of Psychiatry, Warneford Hospital, UK. ORIGIN UK	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
3728	NCT00249132	\N	Risperidone versus Haloperidol//Haloperidol versus Placebo//Risperidone versus Placebo//Risperidone dose//Haloperidol dose	\N	United States of America//Canada	\N	\N	\N	\N	\N	523	\N	\N	\N	\N	\N
3730	Marder 1984	\N	fluphenazine decanoate dose	\N	United States of America	ORIGIN USA\r\n\r\nDepartment of Psychiatry and Behavioral Sciences, UCLA School of Medicine, Neuropsychiatric Institute 90024. ORIGIN USA	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
3733	Munoz 1989	\N	carbamazepine versus Placebo	\N	Spain	Hosp Universitario de Valme, Servicio de Psiquiatria, Seville, Spain ORIGIN Other Europe	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3734	Marchesi 1996	\N	Clozapine versus Haloperidol	\N	Italy	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
3735	Mason-Browne 1957	\N	Azacyclonol versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
3736	May 1965	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus ataraxis drugs	\N	United States of America	\N	\N	\N	\N	\N	228 288	\N	\N	\N	\N	\N
3737	McCreadie 1988	\N	remoxipride versus thioridazine	\N	United Kingdom	Department of Clinical Research, Crichton Royal Hospital, Dumfries, Scotland. ORIGIN UK	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
3740	Merson 1992	\N	multidisciplinary community based team versus conventional hospital based services	\N	United Kingdom	Academic Unit of Psychiatry, St Charles Hospital (St Mary's Hospital Medical School), London. ORIGIN UK	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3742	McCrone 1994	\N	intensive support group versus generic care	\N	United Kingdom	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
3744	Munk 1984	\N	sulpiride versus Haloperidol	\N	Denmark	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
3746	Neborsky 1981	\N	Haloperidol dosage	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3748	Goldberg 1964	\N	Chlorpromazine versus thioridazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	463	\N	\N	\N	\N	\N
6687	Meltzer 2002 e	\N	Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
3751	Nordström 1993	\N	raclopride versus various dosages	\N	Sweden	Karolinska Hosp, Dept of Psychiatry, Stockholm, Sweden ORIGIN Other Europe	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
3757	Pasamanick 1964	\N	hospital care versus home care	\N	United States of America	Miami U	\N	\N	\N	\N	193	\N	\N	\N	\N	\N
3758	Peet 1980	\N	propranolol + Chlorpromazine versus Chlorpromazine	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3759	Petho 1981	\N	B-endorphin versus Placebo	\N	United States of America	ORIGIN Other Europe	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
3762	Pickar 1992	\N	Clozapine versus Placebo	\N	United States of America	Section on Clinical Studies, National Institute of Mental Health, Bethesda, Md. 20892. ORIGIN USA\r\n\r\nExperimental Therapeutics Branch, National Institute of Mental Health, Bethesda, MD 20892.	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
3764	Pigache 1973	\N	Chlorpromazine versus Placebo	\N	United Kingdom	ORIGIN UK	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3765	Heilizer 1959	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
3766	Prien 1968 a	\N	Chlorpromazine versus Placebo//Chlorpromazine dose	\N	United States of America	National Inst. for Mental Health, Bethesda, Md	\N	\N	\N	\N	838	\N	\N	\N	\N	\N
3768	Reeves 1996	\N	Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	302	\N	\N	\N	\N	\N
3769	Remr 1970	\N	Chlorpromazine versus Placebo	\N	Czech Republic	ORIGIN Other Europe	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3772	Schooler 1976	\N	fluphenazine decanoate versus fluphenazine hydrochloride	\N	United States of America	\N	\N	\N	\N	\N	290	\N	\N	\N	\N	\N
3774	Sakalis 1975	\N	Chlorpromazine versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
3775	SSRG 1987	\N	pimozide versus intramuscular flupenthixol decanoate	\N	United Kingdom	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
3779	Kasper 1996	\N	sertindole versus haldol	\N	United States of America	Loma Linda University Medical School, Calif, USA. ORIGIN USA	\N	\N	\N	\N	497	\N	\N	\N	\N	\N
3780	Serafetinides 1972	\N	Chlorpromazine versus Placebo//Loxapine versus Chlorpromazine//Loxapine versus Placebo//zuclopenthixol versus Placebo//Chlorpromazine versus zuclopenthixol//zuclopenthixol versus loxapine//Chlorpromazine versus molindone//molindone versus Placebo//molindone versus loxapine	\N	United States of America	U. California, Center for the Health Sciences, Los Angeles ORIGIN USA	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
3790	Geraisy 1995	\N	Amantadine versus Biperiden	\N	Israel	Flugelman (Mazra) Psychiatric Hospital, Doar Na Ashrat, Israel. ORIGIN Mid E./Asia	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
3791	Simon 1978	\N	evaluation using the Brief Psychiatric Rating Scale (BPRS) versus evaluation using the Nurses' Observation Scale for Inpatient Evaluation (NOSIE)	\N	France	ORIGIN Other Europe	\N	\N	\N	\N	181	\N	\N	\N	\N	\N
3792	Singh 1974	\N	Haloperidol versus benztropine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
3793	Sledge 1996	\N	day hospital care versus inpatient care	\N	United States of America	Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA. ORIGIN USA	\N	\N	\N	\N	197	\N	\N	\N	\N	\N
3795	Solomon 1994 b	\N	consumer case management versus non-consumer case management	\N	United States of America	U Pennsylvania, School of Social Work, Philadelphia, PA, US ORIGIN USA	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
3799	Tarrier 1988	\N	family intervention versus short educational program	\N	United Kingdom	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
3801	Tollefson 1997 HGAJ	\N	Olanzapine versus Haloperidol	\N	United States of America	Health Outcomes Evaluation Group, Lilly USA, Drop Code 1850, Lilly Corporate Center, Indianapolis, IN 46285. E-mail: Tunis_Sandra@Lilly.com	\N	\N	\N	\N	1996	\N	\N	\N	\N	\N
3821	Truax	\N	alternate vicarious therapy versus regular non-vicarious therapy	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3822	Van Putten 1991 a	\N	fluphenazine dose	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
3823	Van Putten 1991 b	\N	Haloperidol dose	\N	United States of America	UCLA School of Medicine.	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
3824	Verhoeven 1981 c	\N	 CSG No: 3276 	\N	Netherlands	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
3825	Wode-Helgodt 1977	\N	Chlorpromazine dose	\N	Sweden	ORIGIN Other Europe\r\n\r\nSt Goran's Hosp, Stockholm, Sweden	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
3826	Wistedt 1984	\N	Haloperidol decanoate versus fluphenazine decanoate	\N	Sweden	Karolinska Inst, Danderyd Hosp, Sweden ORIGIN Other Europe	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
3827	Wistedt 1981	\N	fluphenazine decanoate versus Placebo Flupenthixol decanoate versus Fluphenazine decanoate // Flupenthixol decanoate versus Placebo // Fluphenazine decanoate versus Placebo	\N	Sweden	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	41	\N	\N	\N	\N	\N
3833	Wittenborn	\N	niacin dose	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3834	Uys 1996	\N	zuclopenthixol acetate versus clothiapine	\N	South Africa	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
3835	Van Putten 1990 a	\N	Haloperidol dose	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
3836	Volavka 1992	\N	Risperidone dose//Haloperidol dose//Haloperidol versus Risperidone//Haloperidol versus Placebo//Risperidone versus Placebo	\N	United States of America	Nathan S. Kline Inst for Psychiatric Research, Orangeburg, NY, USA	\N	\N	\N	\N	176	\N	\N	\N	\N	\N
3838	Volavka 1995	\N	 CSG No: 1923 CSG No: 1147 CSG No: 2491 CSG No: 3913	\N	United States of America	\N	\N	\N	\N	\N	111	\N	\N	\N	\N	\N
3842	Wiersma 1991	\N	 CSG No: 625 CSG No: 2124 CSG No: 1692 CSG No: 2445 CSG No: 2489	\N	Netherlands	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
3843	Verhoeven 1981 d	\N	 CSG No: 2876 	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3844	Vernallis	\N	 CSG No: 3373 	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
3845	Villeneuve 1970 a	\N	 CSG No: 3548 	\N	Canada	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
3846	Villeneuve 1970 b	\N	 CSG No: 2852 	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3847	Villeneuve 1970 c	\N	 CSG No: 2862 	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3848	Vinar 1968 a	\N	 CSG No: 3890 	\N	Czech Republic	\N	\N	\N	\N	\N	222	\N	\N	\N	\N	\N
3849	Vinar 1968 b	\N	 CSG No: 3697 	\N	Czech Republic	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
3850	Vinar 1968 c	\N	 CSG No: 2956 	\N	Czech Republic	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3852	Volk 1976 b	\N	 CSG No: 3210 	\N	Germany	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
3854	Aagaard 1959	\N	 CSG No: 4583 	\N	Unclear	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
3860	Agarwal 1992	\N	levamisole versus Placebo//Chlorpromazine versus Placebo	\N	India	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
3861	Akhondzadeh 1999	\N	Haloperidol + cyproheptadine versus Haloperidol + Placebo	\N	Islamic Republic of Iran	Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Iran. s.akhond@neda.net	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3862	Akhtar 1998	\N	propantheline versus trihezyphenydyl	\N	India	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
3864	Allan 1998	\N	Olanzapine versus Haloperidol	\N	United States of America	VA Hudson Valley Health Care System, FDR VA Hospital, Montrose, NY 10548, USA.	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
3866	Anashkina 1990	\N	 CSG No: 4699 	\N	Russian Federation	\N	\N	\N	\N	\N	245	\N	\N	\N	\N	\N
3868	Clark 1973 b	\N	pimozide versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3872	Glick 1997 a	\N	sertindole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	497	\N	\N	\N	\N	\N
3873	Glick 1997 b	\N	sertindole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	462	\N	\N	\N	\N	\N
3874	Goff 1998 b	\N	Ziprasidone versus various dosages	\N	United States of America	Psychotic Disorders Program, Massachusetts General Hospital, Boston, USA.	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
19350	韩永惠 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
3875	Hoffman 1999 b	\N	transcranial magnetic stimulation (Transcranial Magnetic Stimulation) versus sham transcranial magnetic stimulation (Transcranial Magnetic Stimulation)	\N	United States of America	Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.	\N	\N	\N	\N	3	\N	\N	\N	\N	\N
3876	Hoffman 2000	\N	transcranial magnetic stimulation (Transcranial Magnetic Stimulation) versus sham transcranial magnetic stimulation (Transcranial Magnetic Stimulation)	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
3878	Kendrick 1996 b	\N	structured assessment training versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
3880	McGlynn 1993	\N	residential treatment program versus non-residential treatment program	\N	United States of America	\N	\N	\N	\N	\N	276	\N	\N	\N	\N	\N
3881	Nordentoft 1998	\N	optimal treatment program versus standard care	\N	Denmark	M. Nordentoft, Department of Psychiatry, University Hospital, Bispebjerg, Denmark	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3936	Aquila 2000	\N	Olanzapine versus Risperidone	\N	United States of America	Department of Psychiatry, St. Luke's Roosevelt Hospital, New York, NY 10025	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3938	Beasley 2000 c	\N	Olanzapine versus Placebo	\N	United States of America	Eli Lilly and Company, Lilly Corporate Center, Indianapolis, USA	\N	\N	\N	\N	326	\N	\N	\N	\N	\N
3939	Bordeleau 1965	\N	 CSG No: 4708 	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
3940	Burrell 1960	\N	hydroxyzine hydrochloride versus Chlorpromazine	\N	Canada	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
3941	Amin 1977 b	\N	pimozide versus trifluoperazine	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3943	Bitter 2000	\N	Olanzapine versus Clozapine	\N	Austria	Eli Lilly Ges mbH, Wien A-1030, Austria	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
3944	Abel 2000	\N	saline versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3945	Ban 1973	\N	nicotinic acid versus Placebo	\N	Canada	McGill U., Montreal, Quebec, Canada	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3946	Benedict 1989	\N	experimental care versus no-care control	\N	United States of America	Arizona State U, Tempe, US	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4113	Pecknold 1977	\N	trifluoperazine versus pimozide	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
3947	Barak 2000	\N	Risperidone versus typical neuroleptics	\N	Israel	Abarbanel Mental Health Center and Tel-Aviv Community Mental Health Center, Israel	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
3949	Branchey 1978	\N	thioridazine hydorchloride versus fluphenazine hydrochloride	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3951	Aliyev 1999	\N	picrotoxin versus Placebo	\N	Azerbaijan	Dispensary of Mental Hygiene, U.Chagibekov 46/50, F. 1, Baku p.o. 370010, Azerbaijan	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3954	Bredkjær 1999	\N	early integrated treatment versus control group	\N	Denmark	Sct.Hans Hospital, Bistrupvej, 4000 Roskilde, Denmark	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3955	Anker 1958	\N	psychotherapy with trainee-observer versus psychotherapy with supervisor-observer	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3956	Coons 1970	\N	interaction therapy versus insight therapy	\N	Canada	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
3957	Catafau 2000	\N	Ziprasidone versus various dosages	\N	Spain	Nuclear Medicine and Psychiatry Departments, Hospital Sant Pau, Barcelona, Spain	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
3958	Coons 1962	\N	Chlorpromazine versus Placebo//Trifluoperazine versus Placebo//Chlorpromazine versus trifluoperazine	\N	Canada	\N	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
3961	Çetin 2000	\N	Risperidone versus pimozide	\N	Turkey	Dept. of Psychiatry, GATA Haydarpasa Training Hospital Istanbul, Turkey	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3962	Canive 2000	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
3968	Ceron 2000	\N	psychotherapy + auricular acupuncture versus Placebo acupucture	\N	Brazil	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
3972	Clark 1971 a	\N	fluphenazine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
3974	Cooper 1975	\N	penfluridol dose	\N	Canada	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
3978	Currier 2000	\N	Risperidone + lorazepam versus Haloperidol + lorazepam	\N	United States of America	1 University of Rochester Medical Center, 300 Crittenden Boulevards, Rochester, NY 14642, USA	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
3979	Daniel 2000 a	\N	Ziprasidone versus various dosages	\N	United States of America	Clinical Studies Limited, Falls Church, Virginia, USA	\N	\N	\N	\N	196/438	\N	\N	\N	\N	\N
3980	Daniel 2000 b	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	307	\N	\N	\N	\N	\N
3981	Daniel 2000 c	\N	switch from conventional Antipsychotics versus Ziprasidone	\N	United States of America	Clinical Studies Limited, 6066 Leesburg Pike, 6th floor, Falls Church, VA 22041	\N	\N	\N	\N	222	\N	\N	\N	\N	\N
3983	Danion 1992	\N	Chlorpromazine versus lorazepam	\N	France	Department of Psychiatry, Hopitaux Universitaires, Strasbourg, France.	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
3985	Deutsch 1977 b	\N	nicotine acid versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
3986	Deutsch 1976	\N	penfluridol versus Placebo	\N	Canada	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
3991	Eaton 1979	\N	mesoridazine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
3993	Emsley 1999 a	\N	Quetiapine versus Haloperidol	\N	South Africa	Department of Psychiatry, Tygerberg Hospital, 7500 Capetown, South Africa	\N	\N	\N	\N	188	\N	\N	\N	\N	\N
3995	Engelhart 2000	\N	continuous therapy versus low-dose therapy	\N	United States of America	Janssen Pharmaceutica, 1125 Trenton-Harbourton Road, Titusville, NJ 08560	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
3996	Erehefsky 2000	\N	clozarillR versus Clozapine	\N	United States of America	Clinical Pharmacology Dept. Univ. of Texas H.S.C.-S.A., 7703 Floyd Curl Drive, San Antonio, TX 78229-3990	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
3997	Essock 2000 a	\N	assertive community treatment versus control group	\N	United States of America	Department of Psychiatry, Mt. Sinai Medical School, One Gustave Levy Place, Box 1230, New York, NY 10029	\N	\N	\N	\N	262	\N	\N	\N	\N	\N
3999	Fox 1962	\N	amylobarbitone + bemegride versus amylobarbitone	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4001	Gallant 1975	\N	penfluridol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
4002	Gauthier 1972	\N	milieu + psychotherapy versus milieu	\N	Canada	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
4006	Godemann 1999	\N	interval neuroleptic medication versus long term neuroleptic nedication	\N	Germany	Germany	\N	\N	\N	\N	364	\N	\N	\N	\N	\N
4007	Godleski 2000	\N	Olanzapine versus depot Antipsychotic	\N	United States of America	Mental Health Department, VA Medical Center, 800 Zorn Avenue, # 116, Louisville, KY 40206	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
4008	Gouzoulis 1999	\N	psilocybin versus Placebo	\N	Germany	Germany	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
4047	Gross 1998	\N	LU 111995 versus Placebo	\N	Germany	Germany	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
4048	Gunne 1977	\N	naloxone versus saline	\N	Sweden	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
4055	Harvey 2000 b	\N	Ziprasidone versus conventional Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	270	\N	\N	\N	\N	\N
4057	Hellerstein 2000	\N	integrated abuse services versus non integrated treatment	\N	United States of America	Department of Psychiatry, Beth Israel Medical Center, 1st Ave & 16th Street, Pos 2-B, New York, NY 10003-2992	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
4058	Henderson 1960	\N	activity therapy versus control group	\N	Canada	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
20241	谭淑平 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
4201	Behere 1983	\N	AP drugs + Antipsychotics versus Antipsychotics	\N	India	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
19351	李守春 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	318	\N	\N	\N	\N	\N
4059	Hermesh 2000	\N	cyproheptadine versus propranolol	\N	Israel	1 Geha Psychiatric Hospital, Petah Tiqva; 2 School of Mathematical Sciences, Tel Aviv University, Israel	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4060	Hind 1998	\N	zotepine versus 25, 50, 100 mgs	\N	United Kingdom	Knoll Pharmaceuticals, Nottingham, England	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
4061	Hobbs 1960	\N	bilateral lobotomy versus bimedial lobotomy	\N	Canada	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
4062	Hogarty 1974 b	\N	social therapy versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	374	\N	\N	\N	\N	\N
4063	Hranov 1998	\N	fluphenazine versus Haloperidol	\N	Bulgaria	1 Department of Psychiatry of the Medical University, Sofia; 2 Psychiatric Services, Shumen; 3 Psychiatric Service, Blagoevgrad, Bulgaria	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
4068	Jenner 1999	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + neuroleptics versus neuroleptics	\N	Netherlands	Dept. of Psychiatry, University of Groningen, PO Box 30.001, 9700 RB Groningen, Netherlands	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4074	Knegtering 2000	\N	Risperidone versus Olanzapine	\N	Netherlands	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
4075	Koenigsberg 2000 a	\N	Risperidone versus Placebo	\N	United States of America	Department of Psychiatry, Mount Sinai-Bronx VAMC, 130 West Kingsbridge Rd, #116A, Bronx, NY 10468	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
4076	Koenigsberg 2000 b	\N	2-deoxy-D-Glucose versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
4078	Reeves 1998 b	\N	Ziprasidone versus various dosages	\N	United States of America	Central Research Division, Pfizer Inc, Groton, CT, USA	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
4079	Marder 2000	\N	Risperidone versus Haloperidol	\N	United States of America	Department of Psychiatry, West Los Angeles VA Medical Center, 11301 Wilshire Boulevard, Building 210-A, Los Angeles, CA 90073	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
4081	Mintzer 2000	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
4082	Mulqueen 2000	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
4083	Pesco 2000	\N	Risperidone + donepezil versus donepezil	\N	United States of America	Janssen Research Foundation, 1125 Trenton-Harbourton Road, Titusville, NJ 08560	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
4084	Rector 2000	\N	cognitive therapy + standard care versus standard care	\N	Canada	Mood and Anxiety Department, Clarke Institute, 250 College Street, Toronto, ON M5T IR8, Canada	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
4085	Risch 2000 b	\N	donepezil versus Placebo	\N	United States of America	Department of Psychiatry, Medical University of SC, 67 President Street, # 502N, Charleston, SC 29425	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
4088	Sajatovic 2000	\N	Quetiapine versus Risperidone	\N	United States of America	345 Timberidge Trail, Gates Mills, OH 44040	\N	\N	\N	\N	751	\N	\N	\N	\N	\N
4090	Kudo 1999	\N	 CSG No: 4797 	\N	Japan	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
4091	Lemperiere 1999 a	\N	Amisulpride versus Haloperidol	\N	France	, 28, rue des Acacias, 75017 Paris, France	\N	\N	\N	\N	199	\N	\N	\N	\N	\N
4092	Matkovits 1999	\N	iloperidone versus Placebo	\N	United States of America	Novartis Pharma, 59 Route 10 East Hanover, New Jersey, NJ 07936-1080, USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4093	Mergl 1999	\N	Olanzapine versus Clozapine	\N	Germany	Germany	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
4094	Mullen 1999	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	751	\N	\N	\N	\N	\N
4095	Munjiza 1999	\N	group therapy + psychopharmacotherapy versus psychopharmacotherapy	\N	Yugoslavia	Institute for Mental Health Belgrade University, Palmotieva 37, 11000 Belgrade, Yugoslavia	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
4096	Murasaki 1999 b	\N	Quetiapine versus Haloperidol	\N	Japan	\N	\N	\N	\N	\N	197	\N	\N	\N	\N	\N
4097	Nordentoft 1999 OPUS	\N	 CSG No: 4819 CSG No: 5365 CSG No: 4780 CSG No: 4779 integrated treatment versus standard care	\N	Denmark	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	547	\N	\N	\N	\N	\N
4099	Levene 1989	\N	focal family thearpy + neuroleptics versus neuroleptics	\N	Canada	Continuing Care Division, Clarke Institute of Psychiatry, Toronto, Ontario.	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
4100	Perro 1999	\N	Amisulpride versus Olanzapine // Amisulpride versus Quetiapine // Amisulpride versus Risperidone // Amisulpride versus Zotepine // Olanzapine versus Quetiapine // Olanzapine versus Risperidone // Olanzapine versus Zotepine // Quetiapine versus Risperidone // Quetiapine versus Zotepine // Risperidone versus Zotepine	\N	Germany	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
4101	Pushkaryova 1999	\N	efferent therapy versus psychotherapy	\N	Ukraine	Ukranian Scientific Research Institute of Social and Forensic Psychiatry, Frunze 103, 254080 Kiev, Ukraine	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4102	Ramsay 1970 b	\N	nicotinic acid versus Placebo	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4103	Remr 1974	\N	oxypertine versus thioridazine	\N	Czech Republic	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
4104	Rostow 1980	\N	monitoring contitions versus control conditions	\N	United States of America	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
4106	Sirota 1999 a	\N	vitamin E versus Placebo	\N	Israel	Y. Abarbanel Mental Health Center, 15 Keren Kayemet St., 59100 Bat Yam, Israel	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
4110	Lehmann 1977	\N	trazodone	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4112	Paprocki 1976	\N	loxapine versus Haloperidol	\N	Brazil	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
19296	蓝惠燕 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
4114	Quitkin 1977	\N	penfluridol versus Placebo	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4115	Rifkin 1977	\N	procyclidine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
4116	Vergara 1977	\N	 CSG No: 2322 	\N	Panama	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4117	Michael 1985	\N	trihexyphenidyl versus Placebo	\N	India	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4119	Schnore 1961	\N	activity therapy versus control group	\N	Canada	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
4121	Li 1987	\N	Penfluridol versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
4122	Lysaker 1994	\N	paid vocational rehabilitation program versus non paid vocational rehabilitation program	\N	United States of America	West Haven DVA Medical Center, CT 06516.	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
4123	Mokrani 1995	\N	apomorphine versus Placebo	\N	France	Section VIII, Centre Hospitalier Specialise, Rouffach, France.	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
4124	Ranz 1991	\N	training in supportive interaction versus behavioral approach to problem solving	\N	United States of America	Columbia U, New York State Psychiatric Inst, US	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
4125	Riemann 1994	\N	cholinergic stimulation versus control group	\N	Germany	Germany	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
4126	Weiden 1993	\N	 CSG No: 3354 	\N	United States of America	\N	\N	\N	\N	\N	208	\N	\N	\N	\N	\N
4127	Wiedemann 1994	\N	 CSG No: 3338 	\N	Germany	Germany	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
4128	Wu 1995	\N	Day hospital Treatment versus Inpatient treatment	\N	China	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
4129	Kablinger 2000	\N	M100907 versus Placebo	\N	United States of America	LSU Health Sciences Center-Shreveport, Department of Psychiatry, Shreveport, LA, USA	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
4135	Kaleda 2000	\N	Risperidone versus Haloperidol	\N	Russian Federation	Mental Health Research Center, Kashirskoe Shosse 34, 115522, Moscow, Russia	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
4136	Daniel 1991	\N	dextroamphetamine versus Haloperidol	\N	United States of America	Clinical Brain Disorders Branch, NIMH Neurosciences Center at St. Elizabeths, Washington, DC 20032. ORIGIN USA	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
4137	Frazier 1994	\N	Clozapine versus Placebo	\N	United States of America	Child Psychiatry Branch, National Institute of Mental Health, Bethesda, MD 20892.	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
4139	Kolff 2000	\N	Risperidone versus Olanzapine	\N	Netherlands	1 NICI, Department of Psychology, University of Nijmegen, P.O. Box 9104, 6500 HE, Nijmegen, The Netherlands 2 Amsterdam Medical Centre, Tafelbergweg 25, 1105 BC Amsterdam, The Netherlands	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
4140	Lindan 1956	\N	renquel versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
4141	Lee 2000	\N	Risperidone versus various doses	\N	South Korea	1 Dept. of Psychiatry, Yonsei University College of Medicine, Seoul; 2 Dept. of Psychiatry, School of Medicine, Inje University, Pusan; 3 Dept. of Psychiatry, Kyung Hee University College of Medicine, Seoul; 4 Dept. of Psychiatry, College of Medicine, Kor	\N	\N	\N	\N	304	\N	\N	\N	\N	\N
4143	Lasser 2000	\N	iloperidone versus Placebo	\N	United States of America	1 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA 2 Novartis Pharma AG, Basel, Switzerland	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4145	Lam 2000	\N	clorazil versus Clozapine	\N	United States of America	University of Texas Health Science Center San Antonio, Texas, USA	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
4146	Kreitschman 1999	\N	ketamine versus Placebo	\N	Germany	Germany	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
4147	Kulkarni 1999 a	\N	estradiol + Antipsychotic treatment versus Antipsychotic treatment	\N	Australia	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
4148	Martényi 2000	\N	fluphenazine versus Olanzapine	\N	Austria	1 Eli Lilly and Co. Reginal Operations Medical Center, Vienna, Austria 2 Zagreb University, Department Psychiatry, Zagreb, Croatia	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4149	Marjerrison 1964	\N	phenothiazine versus Placebo	\N	Canada	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
4150	Murasaki 2000	\N	Quetiapine versus Haloperidol	\N	Japan	Japanese ICI 204,636 Clinical Evaluation Group, Japan	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4151	McGlashan 1999	\N	Olanzapine dose	\N	United States of America	Yale Psychiatric Institute, 184 Liberty Street, New Haven CT, USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4152	McGorry 1999 b	\N	supportive psychotherapy + Risperidone versus supportive psychotherapy	\N	Australia	Mental Health Services for Kids and Youth, Poplar Road, Parkville, Victoria 3052, Australia	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4153	Mosher 1999	\N	soteria psychosocial program versus control facility	\N	United States of America	Mental Health Services, San Diego County, 2616 Angell Avenue, San Diego, CA 92122, USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4155	Nahunek 1969	\N	 CSG No: 4838 	\N	Czech Republic	U.J.E. Purkyne, Brno, Czechoslovakia	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
4156	Scheepers 2000 a	\N	m-chlorophenylpiperazine versus Placebo	\N	Netherlands	University Medical Center, Department of Psychiatry, P.O. Box 85500, 3508 GA Utrecht, the Netherlands	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
4157	Rajotte 1965	\N	 CSG No: 4707 	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4159	Schooler 2000 b	\N	conventional Antipsychotics + Ziprasidone versus Risperidone Ziprasidone	\N	United States of America	Hillside Hospital, New York, USA	\N	\N	\N	\N	222	\N	\N	\N	\N	\N
4160	Norrie 2000	\N	valproate + Clozapine versus Placebo + Clozapine	\N	Australia	Glenside Hospital, Adelaide, Australia	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
4161	Postma 2000	\N	nicotine versus Placebo	\N	United Kingdom	1 Department of Psychology, Institute of Psychiatry, London; 2 Department of Psychology, City University, London; 3 Section of Cognitive Psychopharmacology, Institute of Psychiatry, London, UK	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
4162	Potkin 2000 a	\N	Clozapine versus Placebo	\N	United States of America	University of California, Irvine, Department of Psychiatry and Human Behavior, Irvine, CA, USA	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
4163	Reuster 1999	\N	occupational therapy versus control group	\N	Germany	Germany	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4164	Schneider 1999	\N	psilocybin versus Placebo	\N	Germany	Germany	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
4166	Yaryura 1972	\N	Levodopa (L-Dopa) versus Placebo	\N	Canada	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
4167	Tetreault 1968	\N	 CSG No: 4715 	\N	Canada	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
4168	Sharpley 2000 a	\N	Olanzapine versus Placebo	\N	United Kingdom	University Department of Psychiatry, Warneford Hospital, Oxford, UK	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
4169	Wright 1964	\N	drug continuation versus transfer to Placebo	\N	Canada	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
4171	Schooler 2000 a	\N	conventional Antipsychotics + Ziprasidone versus Risperidone Ziprasidone	\N	United States of America	Hillside Hospital, New York, NY, USA	\N	\N	\N	\N	222	\N	\N	\N	\N	\N
4172	Smith 2000	\N	cigarette with high nicotine versus de-nicotinized cigarette	\N	United States of America	New York Univ. Medical School, Department of Psychiatry, Hewlett, New York 11557-0316, USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4173	Simons 2000	\N	 CSG No: 4841\r\nAbstracts of the XXIInd CINP Congress, Brussels, Belgium, July 9-13, 2000 	\N	United States of America	Millenium Biostatisics, Inc., Millburn, New Jersey, USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4174	Swift 1998 b	\N	fixed dose intramuscular Ziprasidone versus flexible dose intramuscular Haloperidol	\N	United States of America	1 Central Research Division, Pfizer Inc, Groton, CT; 2 Veterans Affairs Medical Center, Pittsburgh, PA; 3 Veterans Affairs Medical Center, Portland, OR, USA	\N	\N	\N	\N	306	\N	\N	\N	\N	\N
4178	Clark 1970 d	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
4179	Arango 2000	\N	typical Antipsychotics + fluoxetine versus typical Antipsychotics + Placebo	\N	United States of America	U Maryland, Maryland Psychiatric Research Ctr, Baltimore, MD, US	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
4180	Aravagiri 1994	\N	oral Haloperidol versus IM Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
4183	Ascher 1999	\N	experimental patient education group versus control group	\N	United States of America	Psychiatry Service, Roudebush Veterans Affairs Medical Center, Indianapolis, IN 46202, USA. ascher-svanum.haya@indianapolis.va.gov	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
4185	Angunawela 1998	\N	 CSG No: 4194 	\N	United Kingdom	Dr. I.I. Angunawela, Forston Clinic, Herrison, Dorchester DT2 9TB, United Kingdom	\N	\N	\N	\N	249	\N	\N	\N	\N	\N
4186	Aoba 1983	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus Haloperidol	\N	Japan	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
4187	Auriol 1980	\N	disulfiram versus Placebo	\N	France	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4188	Andres 1998	\N	coping therapy versus control group	\N	Switzerland	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
4189	Azrin 1999	\N	education group versus family guideline group	\N	United Kingdom	Sarum Road Hospital, Winchester, UK	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
4190	Azrin 1998	\N	individual mediation compliance instructional sessions versus family mediation compliance instructional sessions	\N	United States of America	Center for Psychological Studies, Nova Southeastern University, Fort Lauderdale, FL 33314, USA.	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
4192	Bark 1996	\N	sertindole versus haldol	\N	United States of America//Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4194	Barker 1998	\N	animal-assisted therapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	313	\N	\N	\N	\N	\N
4196	Becker 1998 a	\N	Individual Placement and Support Program versus Group Skills Training	\N	United States of America	New Hampshire-Dartmouth Psychiatric Research Center, Concord 03301, USA.	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
4197	Bauml 1996	\N	psychoeducation group sessions versus standard care	\N	Germany	\N	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
4198	Beck 1997	\N	Risperidone + psychosocial intervention versus traditional neuroleptic medications + psychosocial intervention	\N	United States of America	Department of Psychiatry and Neurology, University of Missouri School of Medicine, Columbia 65201, USA.	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
19352	周庆华 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
4202	Bhatia 1987	\N	phenothiazine versus Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4203	Bredkjær 2000	\N	early integrated treatment versus control group	\N	Denmark	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4207	Berk 1999	\N	Olanzapine versus Haloperidol	\N	South Africa	Department of Psychiatry, University of the Witwatersrand Medical School, Parktown, South Africa. 039berk@chiron.wits.ac.za	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4208	Bickel 1977	\N	 CSG No: 4403 	\N	Switzerland	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
4210	Bernardi 1975	\N	 CSG No: 4481 	\N	Italy	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
20242	谢琴 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
4211	Buchsbaum 1992 b	\N	Haloperidol versus Placebo	\N	United States of America	Department of Psychiatry and Human Behavior, University of California, Irvine.	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
4212	Callaghan 1997	\N	Olanzapine + imipramine versus Olanzapine	\N	United States of America	{a} Lilly Lab. Clinical Res., Wishard Memorial Hosp., 1001 West 10th St., Indianapolis, IN 46202, USA	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
4213	Byrne 1999	\N	health education versus empowerment education	\N	Canada	System-Linked Research Unit (Health and Social Service Utilization) Faculty of Health Sciences, School of Nursing, Hamilton-Wentworth, Department of Public Health Services Teaching Health Unit, Faculty of Health Sciences, McMaster University, Hamilton, On	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
4214	Buccheri 1996	\N	 CSG No: 4290 	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
4216	Burns 1998 c	\N	structured assessment group versus control group	\N	United Kingdom	St George's Hospital Medical School, London.	\N	\N	\N	\N	169	\N	\N	\N	\N	\N
4218	Buckley 1997	\N	Risperidone versus Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
4219	Burns 1999 a	\N	optimum treatment group versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
4221	Channabasavanna 1987	\N	penfluridol versus Placebo	\N	India	Bangalore U, National Inst of Mental Health & Neurosciences, India ORIGIN Mid E./Asia	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4222	Cetin 1999	\N	Risperidone versus Haloperidol	\N	Turkey	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
4224	Chai 1998	\N	pipothiazine palmitate versus Haloperidol decanoate	\N	China	\N	\N	\N	\N	\N	209	\N	\N	\N	\N	\N
4227	Caracci 1999	\N	Risperidone versus typical neuroleptics	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4228	Carpenter 1999 b	\N	fluphenazine decanoate injections every 2 weeks versus fluphenazine decanoate injections every 6 weeks	\N	United States of America	Maryland Psychiatric Research Center and the Department of Psychiatry, University of Maryland School of Medicine, Baltimore 21228, USA. wcarpent@mprc.umaryland.edu	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
4229	Chang 1998 b	\N	Clozapine + N-oxide versus Clozapine	\N	Taiwan	Laboratory of Biological Psychiatry, Taipei City Psychiatric Center, Taiwan.	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
4231	Calsyn 1998	\N	assertive community treatment versus control group	\N	United States of America	Dr. R.J. Calsyn, University of Missouri-St. Louis, Gerontology Program, 8001 Natural Bridge Road, St. Louis, MO 63121-4499, United States	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4232	Chaplin 1998 b	\N	educational intervention versus control group	\N	United Kingdom	Dr. R. Chaplin, Division of Community Psychiatry, Department of Mental Health Sciences, St. George's Hospital Medical School, Cranmer Terrace, London SW17 ORE, United Kingdom	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
4233	Chouinard 1993 a	\N	clonazepam versus Haloperidol	\N	Canada	Psychiatric Research Centre, Louis-H. Lafontaine Hospital, Montreal, Quebec. ORIGIN Canada	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
4234	Cantell 1980	\N	interferon versus Placebo	\N	Finland	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
4235	Castellani 1978	\N	chlordesmethyldiazepam versus diazepam	\N	Italy	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
4236	Chartier 1974	\N	rewarding model versus non-rewarding model	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
4237	Carroll 1999	\N	educational intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4239	Carpenter 1991 b	\N	continuous medication versus targeted medication	\N	Unclear	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
4241	Chow 2000	\N	Clozapine versus Placebo	\N	Canada	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
4244	Cooper 2000 c	\N	amino acid drink versus tryptophan free drink	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4245	Crawford 1999	\N	lorazepam versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
4248	Chouinard 1992	\N	 CSG No: 4607 CSG No: 2006 CSG No: 4608 CSG No: 4624 CSG No: 4622 CSG No: 1195 CSG No: 2013 CSG No: 3968 CSG No: 4617 CSG No: 4618 CSG No: 4613 CSG No: 4621 CSG No: 3965 CSG No: 4609 CSG No: 2217 CSG No: 2188 Abstract cut short	\N	Canada//United States of America	\N	\N	\N	\N	\N	523	\N	\N	\N	\N	\N
4251	Cramer 1999	\N	medication usage skills for effectiveness program versus control group	\N	United States of America	Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
4252	Coburn 1998	\N	remoxipride versus Haloperidol	\N	United States of America	Department of Psychiatry, Mercer University School of Medicine, Macon, GA 31207-0001, USA.	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
4253	Creed 1999	\N	intensive case management versus standard case management	\N	United Kingdom	\N	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
4255	Colonna 2000	\N	Amisulpride versus Haloperidol	\N	France	\N	\N	\N	\N	\N	488	\N	\N	\N	\N	\N
4256	Christianson 1992	\N	pre-paid plan group versus Medicaid group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4258	Corsini 1976	\N	apomorphine + sulpiride versus apomorphine	\N	Italy	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
4261	Deskmukh 1998	\N	Risperidone versus Haloperidol	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4263	Davis 1985 b	\N	Haloperidol dose	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
4264	Curtis 1995	\N	medication free versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
4563	Schipper 1971	\N	 CSG No: 4478 	\N	Netherlands	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
4265	Csernansky 1999	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	367	\N	\N	\N	\N	\N
4268	Degkwitz 1969	\N	 CSG No: 4371 	\N	Germany	Germany	\N	\N	\N	\N	173	\N	\N	\N	\N	\N
4270	Dalack 1999 b	\N	smoking ad libitum versus no smoking	\N	United States of America	Ann Arbor VA Medical Center, University of Michigan, USA.	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
4272	Delaney 1998	\N	rehabilitation program versus control group	\N	Russian Federation	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4273	Davidoff 1998	\N	experimental video group versus control group	\N	United States of America	Department of Psychiatry, McLean Hospital, Belmont, Massachusetts 02178, USA.	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
4275	Davis 1981	\N	physostigmine + saline versus saline	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
4276	Darby 1970	\N	inkblot cards versus control group	\N	United States of America	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
4278	Den Boer 2000	\N	neuroleptic therapy + ritanserin versus neuroleptic therapy + Placebo	\N	Netherlands	J.A. Den Boer, Grad. Sch. Behav. Cognit. Neurosci., Department of Biological Psychiatry, Academic Hospital, Groningen, Hanzeplein 1, 9713 GZ Groningen, Netherlands. j.a.den.boer@med.rug.nl	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
4280	Dua 1990	\N	Chlorpromazine + impiramine versus Chlorpromazine + Placebo//Chlorpromazine versus Placebo	\N	India	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
4283	Elizur 1979	\N	propranolol versus neuroleptic treatment	\N	Israel	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
4284	Eisler 1978	\N	social skills training with modeling versus social skills training without modeling	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
4285	Earnst 1999	\N	Antipsychotics versus Risperidone	\N	United States of America	U Alabama, Dept of Neurology, Birmingham, AL, US	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4286	Drotts 1999	\N	prochlorperazine versus saline	\N	United States of America	Department of Emergency Medicine, Madigan Army Medical Center, Tacoma, WA, USA.	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
4287	Drake 1999	\N	individual placement and support versus enhanced vocational rehabilitation	\N	United States of America	Dartmouth Medical School, Hanover, NH, USA. Robert.E.Drake@Dartmouth.edu	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
4288	Eranti 1998	\N	Haloperidol + vitamin E versus Haloperidol	\N	India	Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
4289	Elman 1999	\N	Clozapine versus Placebo	\N	United States of America	Experimental Therapeutics Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
4290	Dose 1998	\N	Haloperidol + valproate versus Haloperidol + Placebo	\N	United States of America	Germany	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
4291	Drake 1998	\N	standard case management versus intensive case management	\N	United States of America	Department of Psychiatry, Dartmouth Medical School, Lebanon, N.H., USA. Robert.E.Drake@Dartmouth.edu\r\n\r\nDartmouth Medical School, Department of Community and Family Medicine, Hanover, NH 03755-3862, USA.	\N	\N	\N	\N	223	\N	\N	\N	\N	\N
4292	Eguiluz 1998	\N	psychoeducation group therapy versus control group	\N	Spain	Servicio de Psiquiatra, Hospital de Basurto, Bilbao.	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
4293	Dorfman 1999	\N	vitamin E + neuroleptic treatment versus neuroleptic treatment	\N	Israel	Geha Psychiatric Hospital and Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel.	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
4296	Dyck 2000	\N	multifamily psychoeducation versus control group	\N	United States of America	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
4297	Dixon 1981	\N	fictitious case histories	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
4298	Eklund 1976	\N	penfluridol versus perphenazine	\N	Sweden	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
4299	Eckmann 1970	\N	 CSG No: 4370 	\N	Germany	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
4300	Fischer 2000	\N	zotepine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
4301	Fekete 1998	\N	assertive community treatment versus standard care	\N	United States of America	Indiana U-Purdue U, Clinical Rehabilitation Psychology Program, Indianapolis, IN, USA	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
4302	Fernandez 1998	\N	 CSG No: 4460 	\N	Spain	Hosp Sierrallana, Oviedo, Spain	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
4303	Facciola 1999	\N	Clozapine + valproic acid versus Clozapine	\N	Italy	Institute of Pharmacology, University of Messina, Italy.	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
4304	Essock 1998	\N	assertive community treatment versus control group	\N	United States of America	Department of Psychiatry, Mount Sinai School of Medicine, New York, USA.	\N	\N	\N	\N	262	\N	\N	\N	\N	\N
4305	Evins 2000 a	\N	Bupropion + cognitive behavioral therapy versus Placebo + cognitive behavioral therapy	\N	United States of America	The Psychotic Disorders Unit of the Massachusetts General Hospital, Boston, MA, USA. a_eden_evins@hms.harvard.edu	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4306	Fillatre 1998	\N	incisive neruroleptics versus antidepressant	\N	France	Dr. M. Fillatre, Clinique Psychiatrique Universitaire, rue de Coq, 37541 Saint-cyr-sur-Loire Cedex, France	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4307	Finch 1977	\N	interpersonal skills training versus control group	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
4308	Fink 1980	\N	flutroline versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
4309	Filipova 1978	\N	 CSG No: 4376 	\N	Czech Republic	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4310	Fleischhacker 1991	\N	zotepine versus Haloperidol	\N	Austria	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
4312	Glick 1997 c	\N	sertindole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	282	\N	\N	\N	\N	\N
4313	Gill 1998	\N	consumer administration versus staff administration	\N	United States of America	Chairperson, Department of Psychiatric Rehabilitation and Behavioral Health Care, University of Medicine and Dentistry of New Jersey	\N	\N	\N	\N	375	\N	\N	\N	\N	\N
4314	Glicksohn 2000	\N	elated mood music versus depressed mood music	\N	Israel	Bar-Ilan U, Dept of Criminology, Ramat Gan, Israel	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
4315	Goff 1999 a	\N	D-cycloserine + Clozapine versus D-cycloserine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
4316	Freeman 1998	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	United Kingdom	Department of Psychology, Institute of Psychiatry, Denmark Hill, London, UK.	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4318	Geretsegger 1998	\N	propofol + Electro Convulsive Therapy (Electroconvulsive Therapy) versus methohexital + Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	Austria	Department of Psychiatry, Landesnervenklinik Salzburg, Austria.	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
4319	Fucetola 1999	\N	oral glucose versus Placebo	\N	United States of America	J.W. Newcomer, Department of Psychiatry, Washington University, School of Medicine, 4940 Children's Place, St. Louis, MO 63110-1093, United States. newcomerj@psychiatry.wustl.edu	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4320	Gardos 1974 b	\N	thiothixene versus high//low dosages	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4322	Goldstein 1973	\N	psychotherapy independence modelling versus control group	\N	Netherlands	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
4323	Fishwick 1972	\N	specific work performance feedback versus general work performance feedback	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4324	Goldberg 1981	\N	routine medication versus drug discontinuation	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4326	Garver 1984 c	\N	thiothixene versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
4327	Goodacre 1975	\N	home treatment versus hospital treatment	\N	Canada	\N	\N	\N	\N	\N	212	\N	\N	\N	\N	\N
4329	Griffith 1998	\N	nicotine patch versus Placebo	\N	United States of America	Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, USA.	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
4330	Green 2000	\N	sertraline versus Placebo	\N	United Kingdom	Department of Therapeutics and Pharmacology, The Queen's University of Belfast, UK. Jonathan.Green@nda.n-i.nhs.uk	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4331	Haasen 2000 b	\N	London patient group versus Trinidad patient group	\N	Germany	Germany	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
4332	Gutierrez 1996 a	\N	Risperidone versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	873	\N	\N	\N	\N	\N
4333	Gunter 1983	\N	peer managed small group program versus rehabilitation model	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
4334	Gutride 1973	\N	structured learning thearpy versus control group	\N	United States of America	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
4335	Grunder 1999	\N	Amisulpride versus flupenthixol	\N	Germany	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
4336	Gouzoulis 1998	\N	psilocybin versus Placebo	\N	Germany	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
4337	Guy 1969	\N	psychiatric day hospital versus outpatient clinic	\N	United States of America	\N	\N	\N	\N	\N	137	\N	\N	\N	\N	\N
4338	Hahlweg 1999	\N	behavioural family management + continuous standard dose versus behavioural family management + targeted medication	\N	Germany	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
4339	Hagg 1999	\N	Clozapine + erythromycin versus erythromycin	\N	Sweden	S. Hagg, Division of Clinical Pharmacology, Norrland University Hospital, 901 85 Umea, Sweden	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
4565	Sainz 1955	\N	Chlorpromazine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	425	\N	\N	\N	\N	\N
4340	Haddock 1998	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + neuroleptics versus neuroleptics	\N	United Kingdom	R.P. Bentall, Department of Clinical Psychology, Whelen Building, University of Liverpool, PO Box 147, Liverpool L69 3BX, United Kingdom	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
4342	Hafner 1983	\N	spouse-aided therapy versus individual therapy	\N	Australia	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
4343	Hemnani 1983	\N	metoclopramide versus Placebo	\N	India	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4345	Halperin 2000	\N	cognitive Behavioural group-based intervention versus control group	\N	Australia	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4347	Hellman 1998	\N	enhanced instruction versus "high//low, present//absent"	\N	United States of America	Department of Veteran's Affairs VISN 22 Mental Illness Research Education and Clinical Center (MIRECC), Los Angeles, California, USA.	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
4348	Heresco 1999	\N	glycenergic versus Placebo	\N	Israel	Ezrath Nashim-Herzog Memorial Hospital, Department of Psychiatry, Hadassah Medical School-Hebrew University, Jerusalem, Israel. heresco@md2.huji.ac.il\r\n\r\nEzrath Nashim-Herzog Memorial Hosp, Psychiatry Div, Jerusalem, Israel	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
4349	Hedges 1998	\N	clonidine + neuroleptic treatment versus Placebo + neuroleptic treatment	\N	United States of America	Seven Counties Services, Louisville, Kentucky 40202, USA.	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
4351	Herz 2000	\N	relapse prevention program versus standard care	\N	United States of America	Department of Psychiatry, University of Rochester Medical Center, NY, USA. marvin_herz@urmc.rochester.edu\r\n\r\nDr. M.I. Herz, Strong Ties Community Support Prog., 1650 Elmwood Avenue, Rochester, NY 14620, United States	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
4352	Hassiotis 1999	\N	intensive case management versus standard case management	\N	United Kingdom	A. Hassiotis, Acad. Dept of Psychiatry/Behav. Sci., University College London, Wolfson Building, 48 Riding House Street, London W1N 8AA, United Kingdom	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
4355	Henggeler 1999	\N	home based multisystemic therapy versus psychiatric hospitalization	\N	United States of America	Dr. S.W. Henggeler, Family Services Research Center, Dept. of Psychiatry/Behavioral Sci., Medical University of South Carolina, 67 President Street, Charleston, SC 29425, United States. henggesw@musc.edu	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
4356	Held 1970	\N	phenothiazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
4358	Hirschowitz 1995	\N	Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
4359	Hong 1998	\N	 CSG No: 4334 	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4365	Hicklin 1967	\N	 CSG No: 4453 	\N	Switzerland	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4369	Huttunen 1996	\N	Depot Haloperidol dosage	\N	Finland	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
4370	Johnston 1998	\N	intensive case management versus standard case management	\N	Australia	\N	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
4372	Jin 1998	\N	Clozapine versus Placebo	\N	United States of America	Department of Psychiatry and Human Behavior, College of Medicine, University of California Irvine, USA.	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
4374	Johnstone 1999	\N	pimozide + lithium versus Placebo	\N	United Kingdom	E.C. Johnstone, University Department of Psychiatry, Kennedy Tower Royal Edinburgh Hosp., Edinburgh EH10 5HF, United Kingdom	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
4375	Janowsky 1978	\N	oral methylphenidate versus intravenous methylphenidate	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
4376	Jequier 1976	\N	Benzodiazepine versus Placebo	\N	Canada	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
4387	Kane 1990 a	\N	psychoeducation group versus support group	\N	United States of America	School of Nursing, University of Rochester, NY 14642.	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
4388	Kaiser 1998	\N	care giver interviews versus other provider interviews	\N	Germany	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
4389	Kaiser 1999 a	\N	case manager interviews versus external researcher interviews	\N	Germany	Krankenhaus Spandau, Berlin.	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
4390	Jungerman 1999	\N	deprenyl versus Placebo	\N	Israel	Department of Psychiatry, Rambam Medical Center, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa.	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
4391	Jones 1994	\N	Critical Time Intervention (CTI) versus control group// Intensive case management//Life skills//Supported housing	\N	United States of America	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
4392	Kaneno 1991	\N	 CSG No: 4430 	\N	Japan	\N	\N	\N	\N	\N	259	\N	\N	\N	\N	\N
4393	Kamis 1973	\N	reversal shift versus extradimensional shift	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4394	Kaneko 1969	\N	Chlorpromazine versus Clothiapine	\N	Japan	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
4395	Kaiser 1999 b	\N	BELP interviews versus short form interviews	\N	Germany	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
4397	Keck 1998 a	\N	Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	139	\N	\N	\N	\N	\N
4399	Kapur 1998	\N	Olanzapine dose	\N	Canada	Schizophrenia Division, Clarke Institute of Psychiatry, Toronto, Ont., Canada. kapur@clarke-inst.on.ca	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
4400	Kapur 2000 a	\N	Quetiapine versus various dosages	\N	Canada	Department of Psychiatry, University of Toronto, Ontario. kapur@clarke-inst.on.ca	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
4401	Kapur 2000 b	\N	Haloperidol dose	\N	Canada	Department of Psychiatry, University of Toronto, ON, Canada.	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
4402	Kelly 1995 a	\N	training program versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
4403	Kellam 1967	\N	Chlorpromazine versus thioridazine	\N	United States of America	\N	\N	\N	\N	\N	202	\N	\N	\N	\N	\N
4404	Kato 1985	\N	tiapride versus Placebo	\N	Japan	\N	\N	\N	\N	\N	215	\N	\N	\N	\N	\N
4405	Kato 1989	\N	 CSG No: 4444 	\N	Japan	\N	\N	\N	\N	\N	205	\N	\N	\N	\N	\N
4406	Khanna 1997	\N	Haloperidol versus low//high dosages	\N	India	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
4408	Kern 1997	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4409	Kern 1997 c	\N	initial error group versus no initial error group	\N	United States of America	UCLA Clinical Research Ctr, Camarillo, CA, USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4411	Kirli 1998	\N	sertraline versus imipramine	\N	Turkey	Department of Psychiatry, Uludag University Medical Faculty, Bursa, Turkey.	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4412	Keshavan 1998	\N	conventional Antipsychotic versus Risperidone	\N	United States of America	M.S. Keshavan, Department of Psychiatry, Western Psychiatric Institute/Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213, United States	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
4413	King 1958	\N	Chlorpromazine + group therapy versus Chlorpromazine	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4414	Kendrick 1995	\N	structured assessment training versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
4415	Kemperdick 1967	\N	 CSG No: 4477 	\N	Germany	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
4416	Krystal 2000	\N	ketamine + amphetamine versus Placebo ketamine + Placebo amphetamine	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
4418	Kopelowicz 1998	\N	social skills training versus control group	\N	United States of America	San Fernando Mental Health Ctr, Mission Hills, CA, USA	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
4419	Kramer 1997 b	\N	L-745,870 versus Placebo	\N	United States of America	Merck Research Labs, Dept of Clinical Neuroscience, West Point, PA, USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4420	Kroner 1999	\N	d-amphetamine versus Placebo	\N	Germany	Germany	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
4422	Kopelowicz 1998 b	\N	community re-entry program versus occupational therapy control	\N	United States of America	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
4423	Klinkenberg 1998	\N	interview versus self report	\N	United States of America	Dr. W.D. Klinkenberg, Missouri Institute of Mental Health, University of Missouri, School of Medicine, 5400 Arsenal Street, St. Louis, MO 63139-1361, United States	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
4424	Klein 1999 a	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	Israel	Dr. E. Klein, Department of Psychiatry, Rambam Medical Center, Efron Street, Bat-Galim, Haifa 31096, Israel	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
4425	Kremer 1984	\N	cooking versus sensory awareness	\N	United States of America	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
4426	Kulkarni 2000 a	\N	transdermal estradiol + Antipsychotic treatment versus Antipsychotic treatment + Placebo	\N	Australia	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
4427	Lahti 2000	\N	Olanzapine + ketamine versus Placebo + Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4428	Levine 1997 b	\N	inositol versus Placebo	\N	Israel	Beer-Sheva Mental Health Ctr, Beer-Sheva, Israel	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
4430	Krystal 1999	\N	ketamine + Haloperidol versus Placebo ketamine + Placebo Haloperidol	\N	United States of America	Department of Psychiatry, Yale University School of Medicine, Connecticut, USA. john.krystal@yale.edu	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
4431	Kumra 1999	\N	Atypical nueroleptics versus drug free	\N	United States of America	Child Psychiatry Branch, NIMH, Bethesda, MD 20892-1600, USA.	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
4433	Lapierre 1999 b	\N	remoxipride versus Haloperidol	\N	Canada	Department of Psychiatry, Royal Ottawa Hospital, Ontario, Canada.\r\n\r\nRoyal Ottowa Hosp, Ottawa, ON, Canada	\N	\N	\N	\N	205	\N	\N	\N	\N	\N
4435	Lahti 1998 b	\N	(+)-UH232 versus Placebo	\N	United States of America	Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore 21228, USA.	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
4439	Lavalaye 1999	\N	Olanzapine versus Risperidone	\N	Netherlands	Department of Psychiatry, Academic Medical Centre, Amsterdam, The Netherlands. j.lavalaye@amc.uva.nl	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
4440	Kudo 1987	\N	 CSG No: 4443 	\N	Japan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4442	Lacruz 1999	\N	psychoeducation family intervention versus control group	\N	Spain	M. Lacruz, Departamento de Medicina, Facultad de Medicina, Universidad de Valencia, Avda. Blasco Ibannez, 17, 46010-Valencia, Spain	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
4443	Leese 1998	\N	intensive mental health service versus standard mental health service	\N	United Kingdom	Section of Community Psychiatry, Institute of Psychiatry, London.	\N	\N	\N	\N	320	\N	\N	\N	\N	\N
4444	Lapuc 1970	\N	directions to describe self without comments from therapist versus directions to describe self + reinforcement	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
4445	Kurland 1956	\N	Chlorpromazine versus Reserpine	\N	United States of America	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
4447	Louwerens 2000 a	\N	Clozapine versus classical Antipsychotic	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4449	Lucey 2000	\N	IM Ziprasidone versus IM Haloperidol	\N	Ireland	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4450	Makaric 2000	\N	carbamazepine versus promazine	\N	Croatia	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
4451	Lewis 2000 b	\N	perfenazine versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	702	\N	\N	\N	\N	\N
4452	Louwerens 2000 b	\N	Amisulpride versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4453	Lynch 1997	\N	lorazepam versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
4456	Lui 1993	\N	IV atracurium after Electroconvulsive Therapy versus 0.3mg//kg; 0.5mg//kg	\N	China	Department of Anesthesiology, Veterans General Hospital-Taipei, Taiwan, Republic of China.	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
4457	Liu 1996 b	\N	Clozapine + Sulpiride versus Sulpiride	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
4460	Liu 2000 a	\N	 CSG No: 4562 	\N	Taiwan	Department of Psychiatry, College of Medicine, National Taiwan University, Taipei.	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
4461	Lindholm 1978	\N	perphenazine enanthate dose	\N	Sweden	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4462	Mahal 1976	\N	Chlorpromazine versus Placebo//Ayurvedic medicine//Brahmyadiyoga//Tagara versus Placebo//Chlorpromazine versus Tagara	\N	India	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
4463	Mahal 1975	\N	 CSG No: 4344 	\N	India	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
4464	Manning 1994	\N	capitation versus fee for service	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4466	McGorry 2000 a	\N	supportive case management + Risperidone versus supportive case management	\N	Australia	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4467	Merlo 2000	\N	Risperidone versus various doses	\N	Switzerland	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
4469	Meltzer 2000 b	\N	Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4470	Mitchell 2000	\N	Haloperidol versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
4472	McHugo 1999	\N	assertive community treatment programs- low fidelity versus assertive community treatment programs- high fidelity	\N	United States of America	Research Assistant Professor of Community and Family Medicine, New Hampshire-Dartmouth Psychiatric Research Center, 2 Whipple Place, Suite 202, Lebanon, New Hampshire 03766, e-mail, gregory-mchugo@dartmouth.edu	\N	\N	\N	\N	223	\N	\N	\N	\N	\N
4474	Miceli 2000 a	\N	Ziprasidone versus various dosages	\N	United States of America	{a} Department of Clinical Research, Pfizer Central Research, Groton, CT, 06340, USA	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
4475	Masciocchi 1974	\N	sulpiride versus chlorimipramine	\N	Italy	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4476	McInnis 1967	\N	positive extrinsic reinforcement conditions versus negative extrinsic reinforcement conditions	\N	United States of America	U Illinois, IL, USA	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
4477	Monroe 1965	\N	phenothiazine versus chlordiazepoxide	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
4478	Merinder 1999	\N	psychoeducation intervention versus control group	\N	Denmark	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
4479	Mishory 2000	\N	Haloperidol + phenytoin versus Haloperidol + Placebo//Haloperidol versus phenytoin//Haloperidol versus Placebo//phenytoin versus Placebo	\N	Israel	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
4480	McDougall 1992	\N	6 week nutritional education program versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
4481	Mattke 1976	\N	loxapine versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4482	McCrone 1998	\N	intensive support group versus generic care	\N	United Kingdom	Section of Community Psychiatry (PRiSM), Institute of Psychiatry, London. spjupmc@iop.bpmf.ac.uk	\N	\N	\N	\N	320	\N	\N	\N	\N	\N
4483	Mavroidis 1984 c	\N	fluphenazine dose	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
4484	Mavroidis 1983	\N	Haloperidol dose	\N	United States of America	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
4486	Natani 1983	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) + Haloperidol versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
4487	Naukkarinen 2000	\N	Olanzapine versus perphenazine	\N	Finland	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
4488	Mraz 2000	\N	Olanzapine versus Chlorpromazine	\N	Turkey	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
4489	Mowbray 1997	\N	assertive community treatment versus control group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4490	Montero 1999	\N	behavioural family therapy versus relatives group	\N	Spain	I. Montero, Department of Psychiatry, Faculty of Medicine, 17 Blasco Ibanez, 46010 Valencia, Spain	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
4566	Peet 2001a	\N	Omega-3 Fatty Acid versus Placebo	\N	India	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
20337	董红霞 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4491	Monteleone 1999	\N	D-fenfluramine versus Placebo	\N	Italy	P. Monteleone, Institute of Psychiatry, University of Naples SUN, Largo Madonna dene Grazie, 80138 Napoli, Italy	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
4492	Murasaki 1993	\N	Risperidone versus Haloperidol	\N	Japan	\N	\N	\N	\N	\N	193	\N	\N	\N	\N	\N
4494	Mori 1989	\N	 CSG No: 4437 	\N	Japan	\N	\N	\N	\N	\N	167	\N	\N	\N	\N	\N
4496	Netter 1999	\N	ipsapirone versus Placebo	\N	Germany	Germany	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4497	Newcomer 1999 a	\N	ketamine versus Placebo	\N	United States of America	Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA.	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
4498	Nordström 1998	\N	raclopride versus various dosages	\N	Sweden	Department of Clinical Neuroscience, Karolinska Hospital, Stockholm, Sweden.	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
4499	Newcomer 1998	\N	dexamethasone versus Placebo	\N	United States of America	Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA. newcomerj@psychiatry.wustl.edu	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
4500	Nuttbrock 1997 a	\N	London patients versus Trinidad patients	\N	United States of America	\N	\N	\N	\N	\N	694	\N	\N	\N	\N	\N
4501	Nijman 1997	\N	aggression prevention protocol versus control group	\N	Netherlands	Psychiatric Hospital, Heerlen, The Netherlands.	\N	\N	\N	\N	3	\N	\N	\N	\N	\N
4502	Noorbala 1999	\N	piracetam + Haloperidol versus Haloperidol	\N	Islamic Republic of Iran	Dr. S. Akhondzadeh, No. 29, 39th Street, Gisha Street, Tehran 14479, Iran. s.akhond@neda.net	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
4503	O'Donnell 1999	\N	client focused case management + consumer advocacy versus standard case management	\N	Australia	M. O'Donnell, Psychiatry Unit, Prince of Wales Hospital, Randwick, NSW 2031, Australia. o'donnellmc@sesahs.nsw.gov.au	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
4504	Nigl 1981	\N	electromyograph biofeedback training versus control group	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4505	Nitsun 1974	\N	movement and drama therapy versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
4506	Oliemeulen 2000	\N	Olanzapine versus Clozapine	\N	Netherlands	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
4507	Patra 1998	\N	oral lorazepam versus perenteral lorazepam	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4510	Odhner 1970	\N	verbal task group versus performance task group	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
4511	Petrides 1996	\N	Electro Convulsive Therapy (Electroconvulsive Therapy)- threshhold titration followed by half-age versus Electro Convulsive Therapy (Electroconvulsive Therapy)- half-age followed by threshhold titration	\N	United States of America	Department of Psychiatry, Northport Veterans Admin Med Ctr , 79 Middleville Road, Northport, NY 11768 USA.	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4512	Oranje 2000	\N	ketamine versus Placebo	\N	Netherlands	U Hosp Utrecht, Dept of Psychiatry, Utrecht, Netherlands	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
4513	Pach 1998 b	\N	flupenthixol decanoate dose	\N	Germany	Psychiatrische Klinik, Kliniken Essen-Mitte.	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
4515	Oka 1999	\N	day care therapy versus outpatient therapy	\N	Japan	Department of Neuropsychiatry, Kurume University, Fukuoka, Japan.	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
4516	Pach 1998 c	\N	flupenthixol decanoate dose	\N	Germany	Germany	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
4517	Pach 1998 d	\N	flupenthixol decanoate dose	\N	Germany	Germany	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
4520	Okuma 1988	\N	CSG No: 4440	\N	Japan	\N	\N	\N	\N	\N	283	\N	\N	\N	\N	\N
4521	Perry 1995	\N	amphetamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
4522	Paire 1984	\N	sensory stimulation therapy versus standard hospital treatment	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4523	Parent 1983	\N	flupenthixol versus Haloperidol	\N	Belgium	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4524	Petrioli 1979	\N	 CSG No: 4433 	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
4527	Reeder 2000	\N	cognitive remediation versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
4528	Rachkauskas 1998	\N	 CSG No: 4484 	\N	Russian Federation	\N	\N	\N	\N	\N	143	\N	\N	\N	\N	\N
4531	Poyurovsky 1999	\N	mianserin versus Placebo	\N	Israel	Research Unit, Tirat Carmel Mental Health Center, Israel.	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4532	Pinto 1999	\N	Cognitive Behavioural Training + social skills training versus supportive thearpy	\N	Italy	Department of Mental Health of the Province of Naples, Pollena, Italy.	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
4533	Priebe 1999	\N	inpatient care versus day hospital care	\N	United Kingdom	St. Bartholomew's and the Royal London School of Medicine, Academic Unit, East Ham Memorial Hospital, London, UK.	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
4535	Radant 1998	\N	ketamine versus Placebo	\N	United States of America	Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA.	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4536	Pisvejc 1998	\N	brief pulse stimuli Electroconvulsive Therapy versus ultrabrief pulse stimuli Electroconvulsive Therapy	\N	Czech Republic	Kuffner Sanatorium, Horni Berkovice, Czech Republic.	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
4538	Reinstein 1999 b	\N	benzatropine versus terazosin	\N	United States of America	Dr. M.J. Reinstein, Forest Foundation Inc., Clinical Research Department, 4755 North Kenmore Avenue, Chicago, IL 60640, United States	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4539	Rickard 1993	\N	imaginal relaxation training groups versus progressive relaxation training groups	\N	United States of America	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
4540	Hu 1998 a	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	H. Renwen, Yuanzhou Hosp. of Jiangxi Province, Yichun 336000, China	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
4542	Reyntjens 1986	\N	ritanserin versus Placebo	\N	Belgium	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
4543	Resnick 1984	\N	droperidol versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
4544	Robert 1978	\N	 CSG No: 4369 	\N	France	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
4545	Robin 1976	\N	immediate appointments versus delayed appointments	\N	United Kingdom	\N	\N	\N	\N	\N	234	\N	\N	\N	\N	\N
4546	Roder 2000	\N	new social skills training programs versus control group	\N	Switzerland	\N	\N	\N	\N	\N	143	\N	\N	\N	\N	\N
4547	Scheepers 2000 b	\N	m-chlorophenylpiperazine versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
4549	Schulz 1996	\N	Clozapine versus standard neuroleptic treatment	\N	Germany	Germany	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4550	Sellwood 1999	\N	home based rehabilitation versus outpatient based rehabilitation for schizophrenia whose current state is remission and whose stage of illness is persistent // chronic	\N	United Kingdom	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
4551	Schulz 1999 a	\N	fluphenazine decanoate + lithium versus fluphenazine decanoate + Placebo	\N	United States of America	Department of Psychiatry, Case Western Reserve University, School of Medicine, Cleveland, Ohio 44106, USA.	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
4554	Sajjad 1998	\N	vitamin E versus control group	\N	United Kingdom	Department of Psychiatry, School of Post Graduate Medicine, Keele University, Stoke on Trent, Staffordshire, UK. pca02@keele.ac.uk	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4558	See 1999	\N	Risperidone versus Haloperidol	\N	Kuwait	Department of Psychiatry, Faculty of Medicine, Kuwait University, Safat, Kuwait.	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4560	Salganik 1998	\N	Clozapine versus Haloperidol	\N	Israel	Prof. I. Modai, Sha'ar Menashe Mental Health Center, Mobile Post, Hefer 38814, Israel	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
4561	Schmider 1999	\N	lorazepam versus oxazepam	\N	Germany	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
4562	Schneider 1981	\N	fluphenazine enanthate versus pipothiazine	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
20243	孙志刚 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
4567	Sethi 1983	\N	trifluperazine + benxhexol versus trifluperazine	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4568	Srivastava 1998	\N	centbutindole versus Haloperidol	\N	India	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
4569	Singh 1998	\N	centbutindole versus Haloperidol	\N	India	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
4570	Sim 1989	\N	Haloperidol IM versus "Haloperidol 12mg, 30mg, 60mg"	\N	Taiwan	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
4571	Sovani 1998	\N	performance contingent verbal feedback versus small group interpersonal interaction	\N	India	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
4572	Spooren 1998	\N	fixed aftercare appointment versus motivational counseling	\N	Belgium	\N	\N	\N	\N	\N	647	\N	\N	\N	\N	\N
4573	Sernyak 1998	\N	naltrexone versus Placebo	\N	United States of America	Neuropsychiatry Program, VA Connecticut Health Care System, West Haven Campus 06516, USA.	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
4574	Silver 1998	\N	fluvoxamine versus metaprotiline	\N	Israel	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
4575	Shamir 2000 a	\N	melatonin versus Placebo	\N	Israel	Abarbanel Mental Health Center, Sackler Faculty of Medicine, Tel Aviv University, Israel.	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
4576	Sensky 2000 a	\N	Cognitive Behavioural Training versus befriending	\N	United Kingdom	Division of Neurosciences and Psychological Medicine, Imperial College School of Medicine, London, England. t.sensky@ic.ac.uk	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
4577	Smith 1999 a	\N	community reintegration skills training versus supportive group therapy	\N	United States of America	Weill Medical College of Cornell University, New York Presbyterian Hospital, Westchester Division, White Plains 10605, USA. ths2006@mail.med.cornell.edu	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
4578	Simpson 1999 b	\N	Clozapine versus not stated	\N	United States of America	Medical College of Pennsylvania/Hahnemann University, Philadelphia, USA. gsimpson@hsc.usc.edu	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
4579	Sharma 1999 a	\N	fenfluramine versus Placebo	\N	United States of America	Department of Psychiatry, University of Illinois at Chicago, USA.	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
4580	Sramek 1998	\N	rapid titration fananserin versus intermediate, slow titration fananserin	\N	United States of America	California Clinical Trials, Beverly Hills, CA, USA.	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
4581	Sramek 1999	\N	Clozapine branded versus generic Clozapine	\N	United States of America	Dr. N.R. Cutler, California Clinical Trials, 8500 Wilshire Boulevard, Beverly Hills, CA 90211, United States	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4582	Sharpley 2000 b	\N	Olanzapine versus Placebo	\N	United Kingdom	Dr. A.L. Sharpley, Psychopharmacology Research Unit, Warneford Hospital, Oxford OX3 7JX, United Kingdom	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
4583	Sizaret 1977	\N	 CSG No: 4262 	\N	France	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4586	Suppes 1999	\N	Clozapine versus control group	\N	United States of America	Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas 75235-9070, USA.	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
4588	Svensson 2000	\N	cognitive therapy versus conventional rehabilitation	\N	Sweden	U Hosp, Div of Psychiatry, Dept of Clinical Neuroscience, Lund, Sweden	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
4589	Takahashi 1999	\N	neuroleptic + Risperidone versus neuroleptic + mosaprimine	\N	Japan	Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan.	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4590	Swartz 1999a	\N	Release from Outpatient Commitment versus Undergo Outpatient Commitment	\N	United States of America	\N	\N	\N	\N	\N	331	\N	\N	\N	\N	\N
4592	Sweeney 1997	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4594	Swanson 1998	\N	involuntary outpatient commitment versus release	\N	United States of America	\N	\N	\N	\N	\N	331	\N	\N	\N	\N	\N
4595	Swartz 1998 a	\N	interview by external researcher versus interview by case manager	\N	United States of America	\N	\N	\N	\N	\N	331	\N	\N	\N	\N	\N
4599	Thompson 2000	\N	Chlorpromazine versus Placebo	\N	Australia	Monash University Research Centre for Women's Mental Health, Dandenong Area Mental Health Service, Victoria, Australia.	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
4602	Tegeler 1979	\N	perphenazin-enanthate versus fluspirilene	\N	Germany	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
4603	Taylor 1998	\N	intensive case management versus standard care	\N	United Kingdom	Department of Psychiatry, Institute of Psychiatry, London.\r\n\r\nSection of Community Psychiatry (PRiSM), Institute of Psychiatry, London.	\N	\N	\N	\N	320	\N	\N	\N	\N	\N
4605	Thornicroft1 1998	\N	community oriented care versus hospital oriented care	\N	United Kingdom	Section of Community Psychiatry (PRiSM), Institute of Psychiatry, London.	\N	\N	\N	\N	320	\N	\N	\N	\N	\N
4606	Trotorella 2000	\N	d-fenfluramine versus Placebo	\N	Italy	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
4609	Tyrer 1999	\N	intensive case management versus standard case management	\N	United Kingdom	Department of Public Mental Health, Imperial College School of Medicine, 20 South Wharf Road, Paterson Centre, London, W2 1PD, UK	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
4610	Tollefson 1998 e	\N	Olanzapine versus Haloperidol	\N	United States of America	Eli Lilly and Co, Lilly Research Labs, Indianapolis, IN, USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4932	Chien 1980	\N	 CSG No: 4862 	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
4612	Valencia 1999	\N	psychosocial therapy + pharmacological treatment versus pharmacological treatment	\N	Mexico	Inst Mexicano de Psiquiatria, Div de Investigaciones Epidemiologicas y Sociales, Dept de Investigaciones en Servicios de Salud, Mexico City, Mexico	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
4614	Van-Berckel 1999	\N	D-cycloserine versus Placebo	\N	Netherlands	Department of Psychiatry, University Hospital Utrecht, The Netherlands.	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
4616	Ungvari 1999 a	\N	lorazepam versus Placebo	\N	Hong Kong	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
4617	Ungvari 1999 b	\N	gradual withdrawal of trihexyphenidyl versus treatment as usual	\N	Hong Kong	Department of Psychiatry, Chinese University of Hong Kong, Hong Kong SAR. gsungvari@cuhk.edu.hk	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
4620	Torrey 2000	\N	vocational rehabilitation- individual placement and support versus vocational rehabilitation- integrated supported employment	\N	United States of America	Department of Psychiatry at Dartmouth Medical School in Hanover, New Hampshire, USA.	\N	\N	\N	\N	143	\N	\N	\N	\N	\N
4621	Tsai 1999	\N	Clozapine + D-Serine versus Clozapine + Placebo	\N	United States of America	Laboratory of Molecular and Psychiatric Neuroscience, Mailman Research Center, McLean Hospital, Belmont, MA 02478, USA. Tsaig@McLean.Harvard.edu	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4622	Tollefson 1999 d	\N	conversion of Clozapine to Olanzapine versus conversion of Clozapine to Placebo	\N	United States of America	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
4623	Truffinet 1999	\N	fanaserin versus Placebo	\N	France	CNS Department, Rhone-Poulenc Rorer Research and Development, Antony, France. philippe.truffinet@rp-rorer.fr	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
4624	Turvey 1985	\N	Prompt from Therapist in a Cooperative Game (Delayed) versus Prompt from Therapist in a Cooperative Game (Normal)	\N	United Kingdom	\N	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
4627	Velligan 2000 a	\N	Quetiapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
4628	Wiersma 2000	\N	 CSG No: 4534 CSG No: 5356	\N	Netherlands	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
4629	Velligan 2000 b	\N	Placebo versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
4631	Van-Berckel 1998	\N	D-cycloserine versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4632	Vaughan 1999	\N	multivitamin tablet versus vitamin C Placebo tablet	\N	Australia	Palmerston Centre, Hornsby Hospital, New South Wales, Australia.	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
4633	Wang 1998	\N	Traditional Chinese Medicine (TCM) Huoxue-Huayu versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80 20	\N	\N	\N	\N	\N
4634	Wetzel 1998	\N	 CSG No: 4239 CSG No: 2397 CSG No: 3363 CSG No: 4070	\N	Germany	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
4635	Verster 1998	\N	 CSG No: 4260 	\N	South Africa	Department of Psychiatry, University of the Orange Free State, Bloemfontein.	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4637	Walsh 1999	\N	 CSG No: 4328 	\N	United Kingdom	Department of Psychological Medicine, Institute of Psychiatry, London, UK.	\N	\N	\N	\N	704	\N	\N	\N	\N	\N
4639	Van Berckel 1998	\N	ketamine versus Placebo	\N	Netherlands	B.N.M. Van Berckel, University Hospital Utrecht, Department of Psychiatry, Heidelberglaan 100, 3584 CX Utrecht, Netherlands	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
4640	Volavka 2000	\N	 CSG No: 4669 	\N	United States of America	Dr. J. Volavka, Nathan Kline Institute, 140 Old Orangeburg Road, Orangeburg, NY 10962, United States	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
4641	Wolf 1992	\N	Bromocriptine + Neuroleptic versus Placebo + neuroleptic	\N	Canada	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
4771	Burns 2000 c	\N	intensive case management versus standard case management	\N	United Kingdom	Department of General Psychiatry, Jenner Wing, St Georges Hospital Medical School, Cranmer Terrace, London, SW17 0RE, England. Telephone: 0181 725 5547. Fax: 0181 725 3538. E-mail: t.burns@sghms.ac.uk	\N	\N	\N	\N	700	\N	\N	\N	\N	\N
4772	Burns 2000 d	\N	intensive case management versus standard case management	\N	United Kingdom	Jenner Wing, Cranmer Terrace, Tooting, London, SW17 ORE, ENGLAND. Telephone: 0181 672 9944	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
4773	Bustillo 2001 a	\N	nicotine patch + Antipsychotics versus Placebo patch + Placebo	\N	Mexico	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
4774	Byerly 1999	\N	Clozapine versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4775	Byng 2000	\N	gps services versus secondary services	\N	United Kingdom	UMDS(Guy's and St Thomas'), 80 Kennington Road, London, SE11 6SP. Telephone: 0171 735 8881. Fax: 0171 793 7232	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4777	Carey 2001 b	\N	substance use reduction group versus standard treatment group	\N	United States of America	Syracuse University Syracuse, Ny 13210 Syracuse, Ny 13210	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4778	Centorrino 2001	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4779	Chakos 1999	\N	Antipsychotics + estrogen versus Antipsychotics + Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4780	Chan 2000 b	\N	serindole versus Olanzapine	\N	United Kingdom	St Luke's Woodside Hospital, Woodside Avenue, Muswell Hill, London, N10 3HU. Telephone: 020 8219 1885. Fax: 020 8219 1915. E-mail: sngo@orient.u-net.com	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4781	Chengappa 2001	\N	 CSG No: 5034 	\N	United States of America	University of Pittsburgh at Pittsburgh 4200 5th Ave Pittsburgh, Pa 15260	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
4933	Curry 1988	\N	verbal group versus no reinforcement of movement group	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4784	Day 2000 a	\N	educational intervention versus control group	\N	United Kingdom	Mental Health Services, St Helens &amp; Knowsley Hospital Trust, Whiston Hospital, Prescot, Merseyside, L35 5DR, England. Telephone: 0151 426 1600	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4785	Dick 2000 a	\N	community rehabilitation program versus control group	\N	United Kingdom	Psychiatry, Royal Dundee Liff Hospital, Tayside Primary Care Trust, DUNDEE, DD2 5NF, Scotland UK. Telephone: 01382 580441. Fax: 01382 581329. E-mail: N/A	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
4787	Donnison 2000	\N	cognitive Behavioural group therapy + standard care versus standard care	\N	United Kingdom	Community Health Sheffield NHS Trust, Eastglade Centre, 1 EastGlade Crescent, Sheffield, S12 4QN, UK. Telephone: (0114) 271 6454. Fax: (0114) 271 6450. Proposed study in part-fulfilment of degree	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4788	Drury 2000	\N	cognitive therapy versus control group	\N	United Kingdom	Univeisity of Birmingham, School of Psychology, Edgbaston, Birmingham, B15 2TT, England. Telephone: 0121 414 4932. Fax: 0121 414 4897	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4789	Durham 2000 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	United Kingdom	Psychiatry, Ninewells Hospital and Medical School, University of Dundee, DUNDEE, DD1 9SY, Scotland UK. Telephone: 01382 660111 Ext 32410. Fax: 01382 633923. E-mail: r.c.durham@dundee.ac.uk	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
4790	Durham 2000 b	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	United Kingdom	Department of Psychiatry, University of Dundee, Ninewells Hospital, DUNDEE, DD1 9SY, Scotland. Telephone: 01382 660 111	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4791	Dyck 2001 a	\N	multifamily psychoeducation versus control group	\N	United States of America	Washington State University Pullman, Wa 99164 Pullman, Wa 99164	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
4792	Dye 2000	\N	motivational interview versus control group	\N	United Kingdom	Psychiatry, Ealing, Hammersmith &amp; Fulham NHS Trust, Uxbridge Road, Southall, Middlesex, UB1 3EU. Telephone: 020 8846 7382. Fax: 020 8383 0784. Collaborators: Dr A Montgomery; Dr M Maier (both Ealing, Hammersmith &amp; Fulham Trust); Dr K Dar (Maudsley	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
4794	Essock 2001	\N	assertive community treatment versus control group	\N	United Kingdom	Connecticut St Dept Ment Hlth/Sub Abuse Health and Substance Abuse Hartford, Ct 06105	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
4795	Evans 2000	\N	seroquel versus various dosages	\N	United Kingdom	Psychogeriatrician, EMH Directorate, Clatterbridge Hospital, Bebington, Merseyside, L63 4JY, UK. Telephone: 0151 604 7393	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4796	Evins 2001 a	\N	Bupropion versus Placebo	\N	United States of America	Massachusetts General Hospital 55 Fruit St Boston, Ma 02114	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
4797	Fowler 2000 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	United Kingdom	Psychology Department, Hellesdon Hospital, Drayton High Road, Norwich, Norfolk, NR6 5BE, England. Telephone: 01603 421491	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
4798	Freedman 2000	\N	DMXB-A nicotinic receptor agaonist versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4800	Garety 2000 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	United Kingdom	3rd floor, Adamson Centre for, Mental Health, St Thomas' Hospital, Lambeth Palace Road, London, SE1 7EH. Telephone: 020 7836 5454. E-mail: philippa.garety@kcl.ac.uk	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4802	George 2000 b	\N	typical Antipsychotics + nicotine transdermal patch versus Atypical Antipsychotics + nicotine transdermal patch	\N	United States of America	Dr. T.R. George, Division of Substance Abuse, Department of Psychiatry, Yale University School of Medicine, 34 Park St., New Haven, CT 06519, United States. tony.george@yale.edu	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
4803	Goff 2001 a	\N	D-cycloserine + Clozapine versus Clozapine + Placebo	\N	United States of America	Donald Goff, MD 25 Stanford St. Boston, Massachusetts, 02114, United States 1-617-912-7800 goff@psych.mgh.harvard.edu Study chairs or principal investigators	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
4804	Goff 2001 b	\N	D-cycloserine versus Placebo	\N	United States of America	Donald Goff, MD 25 Stanford St. Boston, Massachusetts, 02114, United States 1-617-912-7800 goff@psych.mgh.harvard.edu	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4806	Golightly 2000	\N	tryptophan-amino acid drink versus Placebo	\N	United Kingdom	Psychiatry, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4809	Greene 1999	\N	operant parent management versus cognitive behavioral therapy (Cognitive Behavioral Therapy)	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4810	Gumley 2000	\N	Psychoeducation (Individualized) + Treatment as Usual versus Treatment as Usual	\N	United Kingdom	Ayrshire and Arran Community Health Care, Ayrshire &amp; Arran Comm. Health Care Trust, North Cunninghame Community Mental Health Team, Administration Block, Ayrshire Central Hospital , IRVINE, KA12 8SS, Scotland. Telephone: 01294274050. Fax: 01294 274112	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
4811	Gumley 2000 b	\N	neruoleptic treatment + individualized psychoeducation versus neuroleptic treatment	\N	United Kingdom	North Community Mental Health Team, Ayrshire &amp; Arran Community Health C, Ayrshire Central Hospital, Irvine, Scotland. Telephone: 01294 274191	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4812	Haddock 2000 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus family intervention	\N	United Kingdom	Dept of Clinical Psychology, Stepping Hill Hospital, Stockport, SK2 7JE, England. Telephone: 0161 331 5095. Collaboration with: Making space, Tameside C &amp; PS Trust, University of Manchester, Manchester, Stockport 7 West Pennine Health Authorities, Old	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4813	Haddock 2000 b	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + family support versus standard care	\N	United Kingdom	Lees Street Centre, Clinical Psychology Therapy Centre, Lees Street, Ashton-under-Lyne, OL6 8NU. Telephone: 0161 330 6947	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4814	Haenschel 2000	\N	EEG versus control group	\N	United Kingdom	Cognitive Behavioural Sciences, Imperial College School of Medicine, 3 North, Charing Cross Hospital, Fulham Palace Road, London, W6 8RF. Telephone: 020 8846 1627. E-mail: c.haenschel@ic.ac.uk. Project related web site: No. Collaborators: Prof S Hirsch; P	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4817	Harvey 2000 d	\N	intensive case management versus standard case management	\N	United Kingdom	Department of General Psychiatry, Jenner Wing, St Georges Hospital Medical School, Cranmer Terrace, London, SW17 0RE, England. Telephone: 0181 725 3522. Fax: 0181 725 3538	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4818	Hasey 2000	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus sham Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	Canada	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4822	Heresco 2000	\N	D-serine + Olanzapine versus D-serine + Placebo	\N	Israel	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4823	Hirsch 2000 a	\N	Ziprasidone versus Olanzapine	\N	United Kingdom	Department of Psychiatry, Imperial College School of Medicine, Charing Cross Hospital, Fulham Palace Road, London, W6 8RF. Telephone: 020 8846 7395. Fax: 020 8846 7372. E-mail: s.hirsch@ic.ac.uk	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4824	Hirsch 2000 b	\N	Ziprasidone versus Risperidone	\N	United Kingdom	Department of Psychiatry, Imperial College School of Medicine, Charing Cross Hospital, Fulham Palace Road, London, W6 8RF. Telephone: 020 8846 7395. Fax: 020 8846 7372. E-mail: s.hirsch@ic.ac.uk	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4825	Hoffman 2001 b	\N	transcranial magnetic stimulation (Transcranial Magnetic Stimulation) versus sham transcranial magnetic stimulation (Transcranial Magnetic Stimulation)	\N	United States of America	Connecticut Yale University School of Medicine, New Haven, Connecticut, 06520-8035, United States; Recruiting Ralph Hoffman 203-785-3259	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4826	Hogarty 2001	\N	enriched supportive therapy versus control group // cognitive enhancement therapy versus enriched supportive therapy	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
4827	Honer 2000	\N	Clozapine + Risperidone versus Clozapine + Placebo	\N	Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4830	Jones 2000 a	\N	care program versus control group	\N	United Kingdom	Division of Psychiatry, Nottingham Healthcare NHS Trust, Duncan Macmillan House, Porchester Road, Mapperley, Nottingham, NG3 6AA, England. Telephone: 0115 969 1300 ext:49106. Fax: 0115 955 5352. E-mail: P.Jones@nottingham.ac.uk. Project related web site: 	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
4831	Jones 2000 b	\N	pharmacology + Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus treatment as usual	\N	United Kingdom	Division of Psychiatry, Nottingham Healthcare NHS Trust, Duncan Macmillan House, Porchester Road, Mapperley, Nottingham, NG3 6AA, England. Telephone: 0115 969 1300 ext:49106. Fax: 0115 955 5352. E-mail: P.Jones@nottingham.ac.uk. Project related web site: 	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
4832	Jones 2000 c	\N	computer based approach versus standard care	\N	United Kingdom	University of Glasgow, Department of Public Health, 2 Lilybank Gardens, Glasgow , G12 8RZ. Telephone: 0141 330 5007. Fax: 0141 330 5018	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
4833	Kane 2001 b	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
4834	Kee 2000	\N	d-cycloserine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
4835	Kelleher 2000	\N	pramipexole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4836	Kelly 1999 b	\N	Quetiapine + Risperidone versus fluphenazine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4837	Kern 2000	\N	errorless learning versus control group	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4840	Kindermann 2001	\N	Aripiprazole versus Olanzapine	\N	United States of America	University of California San Diego Gilman & La Jolla Village Dr San Diego, Ca 92093	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4842	Klein 1999 b	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	Israel	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4844	Kuipers 2000	\N	Cognitive Behavioural Training + medication versus case management + medication	\N	United Kingdom	Dept of Clinical Psychology, Institute of Psychiatry, De Crespigny Park, London, SE5 8AF. Telephone: 071 703 6333	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
4845	Kulkarni 2000 b	\N	estrogen + Antipsychotic treatment versus Antipsychotic treatment + Placebo	\N	Australia	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
4846	Lacro 2001	\N	Risperidone versus Haloperidol	\N	United States of America	Veterans Medical Research Fdn/San Diego Foundation of San Diego San Diego, Ca 92161	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4847	Leavey 2000 a	\N	education and advice package versus control group	\N	United Kingdom	Research Department, Haringey Healthcare NHS Trust, St Anns Road, Haringey, London, N15 3TH. Telephone: 0181 442 6503. Fax: 0181 442 6503. E-mail: gleavey@gleavey.demon.co.uk	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4848	Leavey 2000 b	\N	education and advice package versus control group	\N	United Kingdom	Research Co-ordinator, Haringey Healthcare NHS Trust, St Ann's Hospital, St Ann's Road, London, N15 3TH. Telephone: 020 8442-6503. Fax: 020 8442-6503. E-mail: gerard.leavey@haringey-healthcare.thenhs.com. Project related web site: http://www.doh.gov.uk/nt	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4849	Lester 2000	\N	GP intervention versus control group	\N	United Kingdom	Dept of General Practice, Univ of B, The Medical School, Edgbaston, BIRMINGHAM, B15 2TT. Telephone: 0121 414 3760. Fax: 0121 414 3050	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4851	NCT00628290	\N	cannabidiol versus amisulpiride	\N	Germany	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
19406	王秀芳 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
4853	Lewis 2000 d	\N	Cognitive Behavioural Training versus family support	\N	United Kingdom	South Manchester University Hospitals NHS Trust, University Department of Mental Health, Withington Hospital, Nell Lane, Manchester, M20 2LR. Telephone: 0161 291 4361	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4854	Lewis 2000 e	\N	Cognitive Behavioral Therapy versus Clozapine	\N	United Kingdom	South Manchester University Hospita, University Department of Mental Hea, Withington Hospital, Nell Lane, Manchester, M20 2LR. Telephone: 0161 291 4361	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4858	Lieberman 2001 a	\N	Risperidone versus Clozapine	\N	United States of America	University of North Carolina Chapel Hill Chapel Hill, Nc 27514 Chapel Hill, Nc 27514	\N	\N	\N	\N	224	\N	\N	\N	\N	\N
4859	Lynch 2000	\N	M100907 versus Haloperidol	\N	United Kingdom	Division of Psychiatry and Behavioural Sciences, Clinical Sciences Building, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, England. Telephone: 0113 243 3144. Fax: 0113 206 6772. E-mail: comdhfo@stjames.leeds.ac.uk	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4860	Magnuson 2001	\N	Olanzapine versus Clozapine	\N	United States of America	Maryland National Institute of Mental Health (NIMH), 9000 Rockville Pike Bethesda, Maryland, 20892, United States; Recruiting PRPL  Clinical Center National Institutes of Health Bethesda, Maryland, 20892-4754, United States 1-800-411-1222 prpl@mail.cc.nih	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4862	Marangell 2000	\N	vagal nerve stimulation versus control group	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4863	Marder 2001	\N	Risperidone + individual placement and support versus Olanzapine + psychoeducational skills training	\N	United States of America	University of California Los Angeles 405 Hilgard Ave Los Angeles, Ca 90024	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
4865	Marshall 2000 b	\N	needs feedback groups versus control group	\N	United Kingdom	University of Manchester, Department of Community Psychiatry, Guild Academic Centre, Royal Preston Hospital, PRESTON, PR2 9HT. Telephone: 01772 710477. Fax: 01772 710772. E-mail: max.marshall@man.ac.uk	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
4866	McCreadie 2000	\N	free fruits and vegetables versus treatment as usual	\N	United Kingdom	Department of Clinical Research, Crichton Royal Hospital, Department of Clinical Research , Crichton Royal Hospital , DUMFRIES, DG1 4TG, Scotland. Telephone: 0387 55301	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4869	Mintz 2001	\N	Educational Video about Informed Consent versus Control Group	\N	United States of America	\N	\N	\N	\r\nNotes2\r\neducational video about informed consent versus general control video	\N	83	\N	\N	\N	\N	\N
4870	Newcomer 2001	\N	insulin versus Placebo	\N	United States of America	Washington University Lindell and Skinker Blvd St. Louis, Mo 63130	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4871	Otto 2001 a	\N	education workshops versus control group	\N	United States of America	Medical College of Wisconsin 8701 Watertown Plank Rd Milwaukee, Wi 53226	\N	\N	\N	\N	402	\N	\N	\N	\N	\N
4873	Paykel 2000	\N	lithium versus Placebo	\N	United Kingdom	Box No 189, University Dept of Psychiatry, Addenbrooke's NHS Trust, CB2 2QQ. Telephone: 8436960	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4876	Perkins 2000	\N	modified Cognitive Behavioral Therapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4877	Petch 2000	\N	Cognitive Behavioural Training versus standard care	\N	United Kingdom	Psychology Department, Admissions Building, Springfield University Hospital, 61 Glenburnie Road, London, SW17 7DJ, England. Telephone: 0181 682 6434. Fax: 0181 682 6256	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4878	Purdie 2000	\N	HRT + standard care versus control groups	\N	United Kingdom	Centre for Metabolic Bone Disease, Royal Hull Hospitals (NHS) Trust, Hull Royal Infirmary, Anlaby Road, Hull, HU3 2JZ, UK. Telephone: 01482 675313. Fax: 01482 675301	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4883	Reveley 2000 b	\N	Risperidone versus Olanzapine	\N	United Kingdom	Department of Psychiatry, Clinical Sciences Building, University of Leicester, Leicester Royal Infirmary, PO BOX 65, LE2 7LX, United Kingdom. Telephone: 0116 252 3242. Project related web site: n/a. Commercial study - limited details supplied	\N	\N	\N	\N	Unclear Unclear	\N	\N	\N	\N	\N
4884	Reveley 2000 c	\N	seroquel versus Chlorpromazine	\N	United Kingdom	Department of Psychiatry, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, PO Box 65, LE2 7LX, United Kingdom. Telephone: 0116 252 3242	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4888	Rohriht 2000	\N	body oriented psychological therapy versus supportive councelling	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4889	Rosebush 2000	\N	Olanzapine versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4890	Sackeim 2000	\N	Electro Convulsive Therapy (Electroconvulsive Therapy)- right unilateral versus Electro Convulsive Therapy (Electroconvulsive Therapy)- bilateral	\N	United States of America	Harold A SACKEIM	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4891	Sahakian 2000	\N	Sulpiride versus Placebo // Sulpiride Dosage	\N	United Kingdom	Box 189, Dept. of Psychiatry, Addenbrooke's NHS Trust, CB2 2QQ. Telephone: 2220	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
4893	Sensky 2000	\N	Communication Intervention versus Control Group	\N	United Kingdom	\N	\N	\N	\N	\N	Not Reported	\N	\N	\N	\N	\N
4894	Sensky 2000 c	\N	Cognitive Behavioural Training versus befriending	\N	United Kingdom	Department of Psychiatry, West Middlesex University Hospital, Isleworth, Middlesex, TW7 6AF. Telephone: 020 8565 5052. Fax: 020 8321 5315. E-mail: Not supplied. Project related web site: No. Collaborators:Prof T Barnes (Academic Centre EHF); Dr D Turkingt	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
4899	Sharma 2000 d	\N	rivastigmine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
19407	掌永莉 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
4900	Sharma 2000 e	\N	seroquel versus Chlorpromazine	\N	United Kingdom	Dept of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London, SE5 8AF	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4901	Sharma 2000 b	\N	seroquel versus various dosages	\N	United Kingdom	Dept of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London, SE5 8AF\r\n\r\nForest Healthcare NHS Trust, Whipps Cross Hospital, Whipps Cross Road, London, E11 1NR, England	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4902	Sheitman 2000	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4904	Startup 2000 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	Clinical Psychology, 9/13 Victoria Road, SHOTTON, Wales. Telephone: 01244 811314. Concurrent validity of the Global Assessment of functioning (in preparation)	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4905	Startup 2000 b	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	School of Psychology, University of Wales, Bangor, Bangor, LL57 2DG	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4908	Szmukler 2000	\N	short stay hospitalization versus long stay hospitalization	\N	United Kingdom	Maudsley Hospital; Institute of Psychiatry, Maudsley Hospital, Denmark Hill, London, SE5 8AZ. Telephone: 071 703 6333 ext 2349. Fax: 071 919 2993	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
4909	Szulecka 2000	\N	seroquel versus Risperidone	\N	United Kingdom	Roundhay Wing, St James's Univ Hospital, Beckett Street, LEEDS, LS9 7TF, UK. Telephone: 0113 2433144. Fax: 0113 2347275. No additional information.	\N	\N	\N	\N	380	\N	\N	\N	\N	\N
4910	Tarrier 2000 b	\N	cognitive-behavior therapy + neuroleptics versus Neuroleptics	\N	United Kingdom	South Manchester University Hospitals NHS Trust, University Department of Clinical Psychology, Withington Hospital, Nell Lane, Manchester, M20 2LR. Telephone: 0161 291 4431. Fax: 0161 291 3814. E-mail: ntarrier@fs1.with.man.ac.uk	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5130	Simpson 1999 a	\N	Risperidone versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
20338	顾培 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
4911	Tarrier 2000 c	\N	home based rehabilitation versus hospital rehabilitation	\N	United Kingdom	South Manchester University Hospita, University Department of Clinical, Withington Hospital, Nell Lane, Manchester, M20 2LR. Telephone: 0161 291 4431	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
4912	Tarrier 2000 d	\N	family support + cognitve service versus standard care	\N	United Kingdom	South Manchester University Hospitals NHS Trust, University Department of Clinical Psychology, Withington Hospital, Nell Lane, Manchester, M20 2LR. Telephone: 0161 291 4431. Fax: 0161 291 3814. E-mail: ntarrier@fs1.with.man.ac.uk	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4913	Tarrier 2000 e	\N	family support + psychoeducation versus standard care	\N	United Kingdom	South Manchester University Hospitals NHS Trust, University Department of Clinical Psychology, Withington Hospital, Nell Lane, Manchester, M20 2LR. Telephone: 0161 291 4431. Fax: 0161 291 3814. E-mail: ntarrier@fs1.with.man.ac.uk	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4914	Tarrier 2000 f	\N	psychological intervention versus standard care	\N	United Kingdom	South Manchester University Hospitals NHS Trust, University Department of Clinical Psychology, Withington Hospital, Nell Lane, Manchester, M20 2LR. Telephone: 0161 291 4431. Fax: 0161 291 3814. E-mail: ntarrier@fs1.with.man.ac.uk	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
4915	Tarrier 2000 g	\N	training family support workers to relieve carer burden versus not stated	\N	United Kingdom	South Manchester University Hospitals NHS Trust, University Department of Clinical Psychology, Withington Hospital, Nell Lane, Manchester, M20 2LR. Telephone: 0161 291 4431. Fax: 0161 291 3814. E-mail: ntarrier@fs1.with.man.ac.uk	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4916	Taylor 2000	\N	seroquel versus not stated	\N	United Kingdom	EMI - John Connolly Wing, Ealing, Hammersmith &amp; Fulham NHS Trust, Uxbridge Road, Southall, Middlesex, UB1 3EU. Telephone: 020 8967 5216	\N	\N	\N	\N	500	\N	\N	\N	\N	\N
4917	Theresa 2000	\N	intensive case management versus not stated	\N	United Kingdom	Cedar House, Blackberry Hil Hospital, Manor Road, Fishponds, BRISTOL, BS16 2EW, UK. Telephone: 0117 9186804	\N	\N	\N	\N	158	\N	\N	\N	\N	\N
4918	Trower 2000 a	\N	cognitive therapy versus standard care	\N	United Kingdom	Department of Clinical Psychology, School of Psychology, University of Birmingham, Edgbaston, Birmingham, B15 2TT, England. Telephone: 0121 414 4917. Co researchers: Max Birchwood, Alan Meadan, Sarah Byrne	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4919	Trower 2000 b	\N	cognitive therapy versus standard care	\N	United Kingdom	South B'ham Mental Health NHS Trust, Queen Elizabeth PsychiatricHospital, Mindelsohn Way, Birmingham, B15 2TT. Telephone: 0121 414 4917	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
4920	Turkington 2000 b	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	422	\N	\N	\N	\N	\N
4922	Sharma 2000 a	\N	Risperidone versus Haloperidol	\N	United Kingdom	Dept of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London, SE5 8AF. Telephone: 020 7848 1000. E-mail: spjutos@iop.kcl.ac.uk	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4924	Bauml 1993	\N	psychoeducation group sessions versus standard care	\N	Germany	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
4925	Bauml 1997	\N	psychoeducation group sessions versus standard care	\N	Germany	\N	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
4926	Becker 1980	\N	 CSG No: 4874 	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4927	Boehle 1995	\N	Clozapine versus fluphenazine	\N	Germany	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
4928	Borg 1999	\N	cognitive training program versus cognitive training program + training in cognitive tasks	\N	Norway	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
4930	Campbell 1982	\N	lithium versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
4931	Catlin 1982	\N	B-endorphin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
4934	Fahn 1983	\N	Reserpine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
4935	Fitzgerald 1969	\N	Haloperidol versus Perphenazine	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
4936	Fleming 1982	\N	anger management program versus control group	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
4937	Freeman 1980 c	\N	ozypertine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4938	Gater 1998	\N	psychiatric screening procedure + liason service versus control group	\N	United Kingdom	{a} Rawnsley Build., Manchester Royal Infirm., Oxford Rd., Manchester M13 9WL, UK	\N	\N	\N	\N	218	\N	\N	\N	\N	\N
4939	Goldfinger 1999	\N	individual apartment placement versus staffed group living	\N	United States of America	Department of Psychiatry, Massachusetts Mental Health Center and Harvard Medical School, Boston, USA. steve007ny@aol.com	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
4940	Henggeler 1997	\N	home based multisystemic therapy versus psychiatric hospitalization	\N	United States of America	Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston 29425, USA.	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
4941	Jackson 1991	\N	 CSG No: 4877 	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4942	Kabes 1980 c	\N	Chlorpromazine versus Placebo	\N	Czech Republic	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4943	Lanza 1995	\N	group therapy versus standard care	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
4944	Lecomte 1999	\N	self esteem module versus control group	\N	Canada	Department of Psychology, University of Montreal, Quebec, Canada.	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
4945	MacDonald 2000	\N	telephone reminder 24 hours before appointment time versus no reminder	\N	New Zealand	\N	\N	\N	\N	\N	1053	\N	\N	\N	\N	\N
4946	Mosca 1998	\N	carbamazepine versus valproate	\N	Argentina	Psychiatric Emergency Hospital, "Torcuato de Alvear", Buenos Aires, Argentina	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
4947	Peyman 1956	\N	group psychotherapy + electroshock therapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
4948	Anand 1999 a	\N	lamotrigine + ketamine versus Placebo	\N	United States of America	Yale U School of Medicine, Dept of Psychiatry, New Haven, CT, US	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
4949	Andersen 1999 b	\N	medication versus medication withdrawl	\N	Unclear	\N	\N	\N	\N	\N	339	\N	\N	\N	\N	\N
4950	Arato 1999	\N	Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	294	\N	\N	\N	\N	\N
4951	Barbhaiya 1996	\N	nefazodone + Haloperidol versus nefazodone + Placebo	\N	United States of America	Dept. Metabolism/Pharmacokinetics, Bristol-Myers Squibb, Pharmaceutical Research Institute, PO Box 4000,Princeton, NJ 08543-4000, United States	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
4955	Bradshaw 2000	\N	cognitive Behavioural psychotherapy versus day treatment	\N	United States of America	Dr. W. Bradshaw, School of Social Work, 105 Peters Hall, University of Minnesota, 1404 Gortner Avenue, St. Paul, MN 55108, United States. bbradshaw@che1.che.umn.edu	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
4957	Breier 1999 e	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	526	\N	\N	\N	\N	\N
4958	Brook 1999	\N	Intramuscular Ziprasidone versus Intramuscular Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
4959	Bryson 1999	\N	paid vocational rehabilitation program versus non paid vocational rehabilitation program	\N	United States of America	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
4961	Classen 1989 b	\N	remoxipride versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
4962	Classen 1988	\N	flupenthixol versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
4966	Zelaschi 2000	\N	Clozapine versus Olanzapine	\N	Argentina	Department of Psychiatry, PRA-Korn Hospital, 520 Y 175, LaPlata, BA 1900, Argentina	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
20339	孙洁 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4968	Zimbroff 2000	\N	Ziprasidone IM versus Ziprasidone IM - 2, 10, 20 mg	\N	United States of America	Department of Behavioral Med., Lomalin Dame Medical Center, 710 Barton Road, Redlands, CA 92373	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
4970	Zhu 1996	\N	Traditional Chinese Medicine (TCM) Shuizhi-Dahuang-Heji + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
4971	Conley 1999 a	\N	Atypical neuroleptics versus typical neuroleptics	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
4972	Covell 1999	\N	Clozapine versus conventional Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4973	D'Souza 1999 b	\N	ethanol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
4974	David 1999 b	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4978	Fahy 1999	\N	intensive case management versus standard case management	\N	United States of America	\N	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
4979	Fenton 1999 b	\N	hospital care versus residential care	\N	United States of America	\N	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
4980	Fleming 1999	\N	Olanzapine versus Clozapine	\N	United States of America	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
4981	Fuller 1999	\N	tyrosine + Clozapine versus Placebo + Clozapine	\N	United States of America	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
4982	Glynn 1999	\N	community skills training + individual training versus individual training community skills training + individual training versus individual training	\N	United States of America	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
4983	Goff 1999	\N	Ampakine Dosage // Ampakine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
4985	Good 1999	\N	hormone replacement therapy versus Placebo	\N	Canada	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
4986	Jeppesen 1999 a	\N	integrated treatment versus standard care	\N	Denmark	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
4987	Kim 1999 b	\N	sulpiride versus thioridazine	\N	South Korea	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
4990	Lenert 2000	\N	case study of a mixed race person versus case study of a white person	\N	United States of America	University of California-San Diego, USA. llenert@ucsd.edu	\N	\N	\N	\N	338	\N	\N	\N	\N	\N
4995	Zheng 1992	\N	Haloperidol Decanoate versus Pipotiazine Palmitate	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
4997	Konicki 1999	\N	cocain infusions versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
4999	Kulkarni 1999 b	\N	estradiol + Antipsychotic treatment versus Antipsychotic treatment	\N	Australia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5000	Kurtz 1999	\N	attention process training versus prospective memory training	\N	United States of America	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
5001	Lahti 1999 a	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5002	Lahti 1999 b	\N	Olanzapine + ketamine versus Placebo + Placebo	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
5004	Goldensohn 1979	\N	prepaid group practice plan versus control group	\N	United States of America	\N	\N	\N	\N	\N	466	\N	\N	\N	\N	\N
5005	Krajewski 1993	\N	art + Cognitive Behavioral Therapy versus art therapy	\N	Germany	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
5006	Lancon 1999	\N	sertindole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	197	\N	\N	\N	\N	\N
5007	Lenior 1999	\N	standard intervention + family intervention versus standard intervention	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5009	SOCRATES	\N	Cognitive Behavioural Training + standard care versus standard care Cognitive Behavioural Training versus control group Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	318	\N	\N	\N	\N	\N
5010	Madonick 1999	\N	naltrexone + ketamine versus Placebo + ketamine	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
5013	Miller 1999	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
5014	Mitchell 1999	\N	lorazepam versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
5015	Mockler 1999	\N	Risperidone versus Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
5016	Newcomer 1999 b	\N	guanabanz, ketamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
5017	Nordentoft 1999 a	\N	integrated care versus standard care	\N	Denmark	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
5018	O'Neill 1999	\N	Risperidone versus Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
5021	Phillips 1999 a	\N	prevention program versus control group	\N	Australia	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
5026	Suzuki 1997	\N	guanfacine versus Placebo	\N	Japan	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
5028	Garmezy 1969	\N	Chlorpromazine versus Placebo	\N	United States of America	U. Minnesota	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
5029	Klieser 1992 b	\N	Clozapine versus various dosages	\N	Germany	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
5030	Kuhs 1988	\N	suspension therapy versus standard neuroleptic therapy	\N	Germany	\N	\N	\N	\N	\N	159	\N	\N	\N	\N	\N
5031	Lemmer 1993	\N	pramipexole versus Placebo	\N	Germany	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
5034	Naber 1992	\N	SDZ HDC 912 versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
5036	Perenyi 1989	\N	procyclidine versus Haloperidol	\N	Hungary	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
5037	Peter 1992	\N	cerutil versus Placebo	\N	Germany	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
5038	Preussler 1995	\N	Clozapine versus fluphenazine	\N	Germany	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
5039	Preussler 1997	\N	Clozapine versus fluphenazine	\N	Germany	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
5040	Reeves 1999 a	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
5041	Richardson 1999	\N	Olanzapine versus Clozapine	\N	United States of America	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
5042	Sadik 1999	\N	Risperidone versus Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	684	\N	\N	\N	\N	\N
5043	Schooler 1999	\N	Clozapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
5045	Siris 1999	\N	fluphenazine + imipramine versus fluphenazine + Placebo	\N	United States of America	S. Siris, Hillside Hospital, 75-59 263rd Street, Glen Oaks, NY 11004, United States. siris@lij.edu	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
5046	Swift 1999	\N	Intramuscular Ziprasidone versus Intramuscular Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	306	\N	\N	\N	\N	\N
5434	Beramendi 1980	\N	 CSG No: 5305 	\N	Spain	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
5047	Toney 2000	\N	Clorazil½ Norvatis (branded Clozapine) versus Zenith Goldline (generic Clozapine)	\N	United States of America	University of Texas Health Science Center San Antonio, Texas, USA	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
5048	Umbricht 1999	\N	ketamine versus Placebo	\N	Switzerland	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
5049	Van Bruggen 1999	\N	 CSG No: 4899 	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5050	Vestre 1961 b	\N	Chlorpromazine versus Placebo	\N	United States of America	U. Minnesota	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
5052	Wright 2000 a	\N	intramuscular Olanzapine versus intramuscular Placebo	\N	United Kingdom	Eli Lilly & Co., Lilly, Research Center, Windlesham, UK 1 Eli Lilly & Co., Lilly Research Laboratories, Indianapolis, USA 2 Sterkfontein Hospital, Krugersdorp, South Africa 3 Forest Foundation Inc., Chicago, USA	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
5054	Bauml 1995	\N	psychoeducation group therapy versus control group	\N	Germany	\N	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
5055	Berk 2000 b	\N	Risperidone versus Haloperidol	\N	South Africa	Dr. M. Berk, Dept. of Psychiatry, Univ. of Witwatersrand Medical Sch., 7 York Road, Parktown 2193, South Africa. 039berk@chiron.wits.ac.za	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5056	Carpenter 1982	\N	early intervention versus continuous phamacotherapy	\N	United States of America	Maryland Psychiatr. Res. Cent., Baltimore, MD 21228, United States	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
5057	Cooper 2000 e	\N	zotepine versus Placebo	\N	United Kingdom	S.J. Cooper, Department of Mental Health, Whitla Medical Building, Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom. s.cooper@qub.ac.uk	\N	\N	\N	\N	121	\N	\N	\N	\N	\N
5058	Copolov 2000	\N	Quetiapine versus Haloperidol	\N	Australia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5063	Reeves 1999 b	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
5064	Roder 1999	\N	social skills training versus control group	\N	Switzerland	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
5066	Sharma 1999 b	\N	Risperidone versus Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
5067	Sherr 1999	\N	amphetamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
5068	Spaulding 1999	\N	integrated psychological therapy versus supportive group therapy	\N	United States of America	Department of Psychology, University of Nebraska-Lincoln, 68588-0308, USA.	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5069	Thompson 1999	\N	estrogen versus not stated	\N	Australia	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
5070	Tys 1999	\N	small doses of Risperidone versus Haloperidol	\N	Ukraine	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
5072	Velligan 1999 a	\N	Cognitive Adaptation Training versus standard outpatient treatment	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
5073	Victolo 1999	\N	 CSG No: 4885 	\N	Brazil	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
5074	Wehnert 1999	\N	 CSG No: 4910 	\N	Denmark	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5075	Wirshing 1999 b	\N	 CSG No: 4909 	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
5076	Wykes 1999 b	\N	cognitive remediation therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
5077	Wykes 1999 c	\N	cognitive remediation therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5078	Yurgelun 1999	\N	 CSG No: 4945 	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
5079	Anderson 1983	\N	group psychotherapy versus control group	\N	United States of America	FLORIDA INSTITUTE OF TECHNOLOGY (0473)  DegreePHD  Date1983  pp78	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
5080	Baker 1994	\N	group problem solving versus control group	\N	United States of America	UNIVERSITY OF MISSOURI - COLUMBIA (0133)  DegreePHD  Date1994  pp150	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
5081	Carpenter 1983 d	\N	hemodialysis versus sham	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
5082	Clark 1999	\N	Olanzapine versus Placebo	\N	United States of America	Eli Lilly and Company, Lilly Corporate Center, Indianapolis, USA	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5083	Davidson 2000	\N	Risperidone versus increasing dosages	\N	Israel	Sheba Medical Center, Tel Aviv, Israel. davidson@netvision.net.il	\N	\N	\N	\N	490	\N	\N	\N	\N	\N
5084	Draine 1995	\N	assertive community treatment versus standard community treatment	\N	United States of America	UNIVERSITY OF PENNSYLVANIA (0175)	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
5085	Gallant 2000	\N	GP-45795 versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
5086	Gallant 1971 b	\N	piperacetazine versus thioridazine	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
5087	Gentry 1983	\N	hemodialysis versus sham	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5088	Gershon 1971	\N	A30360 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
5090	Havassy 2000 a	\N	intensive clinical case management versus community based clinical case management	\N	United States of America	Department of Psychiatry, University of California, San Francisco, School of Medicine	\N	\N	\N	\N	268	\N	\N	\N	\N	\N
5092	Lehmann 1971	\N	nicotine acid versus Placebo	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5143	Kasckow 2001	\N	citalopram + Antipsychotics versus Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
20244	王帅 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
5093	Mahmoud 1997 a	\N	 CSG No: 4982 CSG No: 3587 CSG No: 3613 CSG No: 3588 CSG No: 4220	\N	United States of America	M.P.H., Janssen, 1125 Trenton-Harbourton Road, Titusville NJ 08560\r\n\r\nAffiliated Research Inst, 8880 Rio San Diego Dr Ste 1090, San Diego CA 92108\r\n\r\nOutcomes Research, Janssen Pharmaceutica, Inc., Titusville, NJ, USA. rmahmoud@janus.jnj.com	\N	\N	\N	\N	684	\N	\N	\N	\N	\N
5094	Mayang 1990	\N	problem solving skills training groups versus control group	\N	United States of America	WESTERN MICHIGAN UNIVERSITY (0257)  DegreeMA  Date1990  pp63	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
5096	Rossger 1997	\N	Clozapine versus fluphenazine	\N	Germany	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
5097	Schonell 1995	\N	psychoeducation training versus control group	\N	Germany	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
5099	Stankovska 1999	\N	Haloperidol versus Clozapine	\N	Macedonia	Hospital for mental illness, Bulevar III makedonska brigada 27, 91000 Skopje, Macedonia	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5100	Wagemaker 1983 b	\N	 CSG No: 4978 	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
5101	Wetzel 1995	\N	 CSG No: 5199 	\N	Germany	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
5102	Wright 2000 b	\N	intramuscular Olanzapine versus intramuscular Placebo	\N	United Kingdom	Eli Lilly and Company, Windlesham, Surrey GU20 6PH, UK	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
5105	Beasley 1996 c	\N	Olanzapine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	3546	\N	\N	\N	\N	\N
5106	Brecher 1996 a	\N	Risperidone versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
5108	Chouinard 1979 b	\N	pimozide versus Chlorpromazine	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
5110	Dalheim 1997	\N	Olanzapine versus conventional Antipsychotic	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5116	Kohler 2000	\N	Quetiapine versus conventional Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
5117	Levy 1979	\N	dialysis versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5120	Mihara 2000	\N	Bromperidol versus nemonapride	\N	Japan	Department of Neuropsychiatry, Hirosaki University School of Medicine, Japan.	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
5121	O'Connor 1999 a	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	365	\N	\N	\N	\N	\N
5122	Purdon 2000	\N	Quetiapine versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
5123	Razali 2000	\N	cultrually modified family therapy versus behavior family therapy	\N	Malaysia	Dr. S.M. Razali, Department of Psychiatry, School of Medical Sciences, University Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia. mrazali@kb.usm.my	\N	\N	\N	\N	166	\N	\N	\N	\N	\N
5124	Reznik 2000	\N	Fluvoxamine plus Antipsychotic Drug versus Antipsychotic Drug	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5125	Schuld 2000	\N	Clozapine versus Olanzapine	\N	Germany	Germany	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
5126	Shamir 2000 b	\N	melatonin versus Placebo	\N	Israel	Day Hospitalization Department, Abarbanel Mental Health Center, Bat Yam, Israel.	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
5127	Shamir 2000 c	\N	melatonin versus Placebo	\N	Israel	Dr. N. Zisapel, Department of Neurobiochemistry, George S. Wise Fac. of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
5128	Shaw 2000	\N	pharmacy discharge planning versus control group	\N	United Kingdom	C.A. Mackie, University of Strathclyde, Glasgow, United Kingdom. helen.shaw@glacomen.scot.nhs.uk	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
5129	Silver 2000	\N	fluvoxamine + Antipsychotics versus Antipsychotics + Placebo	\N	Israel	H. Silver, Sha'ar Menashe Mental Health Center, Mobile Post, Hefer 38814, Israel. mdsilver@tx.technion.ac.il	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
5131	Simpson 2000	\N	Ziprasidone versus Risperidone	\N	United States of America	University of Southern California School of Medicine, Los Angeles, California, USA\r\n\r\nDepartment of Psychiatry, LAC/USMC Medical Center, 1937 Hospital Place, Grad Hall, Los Angeles, CA 90033	\N	\N	\N	\N	222	\N	\N	\N	\N	\N
5133	Stevens 1993	\N	Haloperidol + lorazepam versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
5134	UK700 2000	\N	intensive case management versus standard case management	\N	United Kingdom // Netherlands	Department of Psychiatry and Neuropsychology, Maastricht University, European Graduate School of Neurosciences, The Netherlands.	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
5135	Velligan 2000 c	\N	Cognitive Adaptation Training versus standard outpatient treatment	\N	United States of America	Department of Psychiatry, University of Texas Health Science Center at San Antonio, 78229-3900, USA. velligand@uthscsa.edu	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
5136	Wassef 2000	\N	 CSG No: 5206 	\N	United States of America	University of Texas Health Sciences Center at Houston-Harris County Psychiatric Center, 77021, USA.	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
5138	Wirshing 2000	\N	Community Re-Entry Program versus Illness Education Classes	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
5140	Zinner 1992	\N	Risperidone versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
5141	Dunn 2001 b	\N	enhanced consent procedure versus routine consent procedure	\N	Unclear	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
5142	Granholm 2001	\N	cognitive Behavioural social skills training + regular pharmacotherapy versus regular pharmacotherapy	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6409	Takahashi 1963	\N	\N	\N	Japan	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
5144	Kinon 2001 d	\N	Haloperidol versus (Lorazepam plus Olanzapine)	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
5145	McQuaid 2001 a	\N	Cognitive Behavioural Training + standard care versus standard care	\N	Unclear	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
5146	Angst 1973	\N	fluspirilene versus fluphenazine decanoate	\N	Switzerland	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5147	Anonymous 1994	\N	 CSG No: 3975 	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5150	Browne 1986	\N	clonidine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
5151	Burns 1997	\N	GP care versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
5152	Carpenter 1987	\N	continuous medication versus targeted medication	\N	United States of America	U Maryland School of Medicine, Maryland Psychiatric Research Ctr, Baltimore, US	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
5153	Chacon 1972	\N	trifluphenazine decanoate versus Placebo//Chlorpromazine versus Placebo	\N	United Kingdom	New Cross Hosp., Wolverhampton, England\r\n\r\nORIGIN UK	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
5159	Fransella 1960	\N	Chlorpromazine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5160	Gater 1997	\N	mulit-disciplinary community team versus traditional psychiatric service	\N	United Kingdom	U Manchester, Mental Illness Research Unit, Withington Hosp, Manchester, England UK	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5161	Gelkopf 1993	\N	exposed to comedy films versus exposed to various films	\N	Israel	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
5162	Glen 1996	\N	niacin flushers versus control group	\N	United Kingdom	Highland Psychiatric Research Group, Craig Dunain Hospital, Inverness, UK.	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
5164	Greendyke 1998	\N	clonidine versus Placebo	\N	United States of America	Department of Pathology and Laboratory Medicine, Veterans Affairs Medical Center, Canadaigua, New York, USA.	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
5165	Greil 1997	\N	lithium versus carbamazepine	\N	Germany	Germany	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
5166	Haase 1974	\N	 CSG No: 563 	\N	Germany	Germany	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
5168	Huang 1984	\N	 CSG No: 3820 	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5169	Jann 1997	\N	Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
5171	Levine 1997 c	\N	Chlorpromazine versus Placebo	\N	Israel	Ben Gurion U of the Negev, Faculty of Medicine, Beersheba Mental Health Ctr, Beersheba, Israel	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5172	Lipska 1986	\N	 CSG No: 683 	\N	Poland	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
5173	Malhotra 1997 b	\N	ketamine versus Placebo	\N	United States of America	National Inst of Mental Health, Experimental Therapeutics Branch, Bethesda, MD, USA	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
5175	Miceli 1998	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
5177	Mosnik 1997	\N	phenylalanine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
5180	Patat 1998	\N	Amisulpride versus Placebo	\N	France	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
5181	Pujalte 1994	\N	clonazepam versus Placebo	\N	France	Unite de Psychopharmacologie, Faculte de Medecine, Montpellier, France.	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
5182	Raaska 1998	\N	itraconazole versus Placebo	\N	Finland	P.J. Neuvonen, Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, FIN-00290 Helsinki, Finland	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
5183	Reeves 1998 c	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
5184	Reeves 1998 d	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
5186	Roitman 1998	\N	DMC versus Placebo	\N	Israel	R.H. Belmaker, Ministry of Hlth. Mental Hlth. Ctr., Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
5187	Ropert 1973	\N	fluphenazine enanthate versus pipothiazine	\N	France	Psychiatric Hosp. of Vaucluse, Epinay-sur-Orge, France	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
5188	Schiele 1963	\N	trifluoperazine + tranylcypromine versus trifluoperazine + Placebo//trifluoperazine versus Placebo//trifluoperazine versus tranylcypromine//tranylcypromine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
5191	Schwartz 1997 c	\N	nifedipine versus Placebo	\N	United States of America	Department of Psychiatry, Veterans Affairs Medical Center and Georgetown University Medical School, Washington, DC 20422, USA.	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
5192	Sharma 1997	\N	TRP depletion dring versus Placebo	\N	United States of America	Psychiatric Institute, University of Illinois at Chicago, 60612, USA.	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
5193	Singer 1973	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
5195	Swanson 1996	\N	neuroleptic medication + anticonvulsive medication versus neuroleptic medication	\N	United States of America	University of California, Child Development Center, 19262 Jamboree, Irvine, CA 92715, United States	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
5196	Swift 1998 c	\N	fixed dose intramuscular Ziprasidone versus flexible dose intramuscular Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	306	\N	\N	\N	\N	\N
5197	Szafranek 1968	\N	 CSG No: 3973 	\N	Poland	\N	\N	\N	\N	\N	185	\N	\N	\N	\N	\N
5370	Petersen 2001	\N	assertive community treatment versus standard care	\N	Denmark	\N	\N	\N	\N	\N	359	\N	\N	\N	\N	\N
5198	Teague 1995	\N	continuous treatment versus standard case management	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5199	Zemishlany 1998	\N	L-deprenyl versus Placebo	\N	Israel	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
5200	Zubenko 1984	\N	Metoprolol versus Propranolol	\N	United States of America	Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA 02178, United States	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
5202	Luo 1997 a	\N	Traditional Chinese Medicine (TCM) Shuxuening + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	545	\N	\N	\N	\N	\N
5333	Jarboe 2001	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	262	\N	\N	\N	\N	\N
5203	Bamrah 2000	\N	seroquel versus various dosages	\N	United Kingdom	CONSULTANT PSYCHIATRIST, MOORSIDE, TRAFFORD GENERAL HOSPITAL, MOORSIDE ROAD, DAVYHULME, M41 5SL, U.K. Telephone: 0161-746-2685	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
5239	Alberti 1999	\N	GBP versus NL	\N	Italy	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
5240	Almond 1999	\N	Haloperidol versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5241	Altamura 1999 b	\N	Clozapine versus Haloperidol decanoate	\N	Italy	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
5242	Altamura 1999 a	\N	Olanzapine versus Haloperidol	\N	Italy	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
5243	Bitter 1999	\N	Olanzapine versus Clozapine	\N	Hungary//South Africa	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
5245	Colonna 1999	\N	Amisulpride versus Haloperidol	\N	France	\N	\N	\N	\N	\N	488	\N	\N	\N	\N	\N
5246	Cosar 1999	\N	Clozapine versus Haloperidol	\N	Turkey	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
5248	Daniel 1999 c	\N	discontinued Risperidone + Ziprasidone versus control group	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
5249	Daniel 1999 d	\N	discontinued Risperidone + Ziprasidone versus control group	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
5250	David 1999 a	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
5251	Diehl 1999	\N	pergolide versus Placebo	\N	Germany	Germany	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5253	Giudicelli 1999	\N	Amisulpride versus Haloperidol	\N	France	\N	\N	\N	\N	\N	828	\N	\N	\N	\N	\N
5255	Hirsch 1999 b	\N	Ziprasidone versus various dosages	\N	United Kingdom	\N	\N	\N	\N	\N	301	\N	\N	\N	\N	\N
5256	Kinon 1999 d	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
5257	Krupitsky 1999	\N	nimodipine + ketamine versus Placebo + Placebo	\N	Russian Federation	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
5258	Lecrubier 1999	\N	Olanzapine versus Placebo	\N	France	\N	\N	\N	\N	\N	244	\N	\N	\N	\N	\N
5259	Lemperiere 1999 b	\N	Amisulpride versus Haloperidol	\N	France	\N	\N	\N	\N	\N	199	\N	\N	\N	\N	\N
5260	Lerner 1999	\N	vitamin B6 versus Placebo	\N	Israel	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
5261	Loza 1999	\N	Olanzapine versus Chlorpromazine	\N	Egypt	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
5262	Malyarov 1999	\N	Atypical Antipsychotics versus Haloperidol	\N	Ukraine	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
5263	Nordström 1999	\N	raclopride versus various dosages	\N	Sweden	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
5264	Rein 1999	\N	Amisulpride versus Haloperidol	\N	France	\N	\N	\N	\N	\N	488	\N	\N	\N	\N	\N
5267	Sirota 1999 b	\N	vitamin E versus Placebo	\N	Israel	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
5268	Snaterse 1999	\N	Risperidone versus Olanzapine	\N	Canada	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
5269	Szafranski 1999	\N	Olanzapine versus perphenazine	\N	Poland	\N	\N	\N	\N	\N	95// 56 completed study	\N	\N	\N	\N	\N
5271	Weiden 1999 b	\N	 CSG No: 5465 Abstracts of the 12th ECNP Congress, London, September 21-25, 1999 	\N	United States of America	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
5274	Cole 1997	\N	exercise versus control group	\N	United States of America	Illinois Institute of Technology (0091)	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
5275	Alter 1993	\N	coping skills training versus control group	\N	United States of America	Fairleigh Dickinson University (0287)	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
5276	Canning 1997	\N	psychotherapy + in-home intervention versus psychotherapy	\N	United States of America	Smith College School for Social Work (0201)	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
5277	Rossi 1994	\N	assignment strategy versus control group	\N	United States of America	United States International University (0239)	\N	\N	\N	\N	308	\N	\N	\N	\N	\N
5278	Hickman 1997	\N	personalized assessment feedback versus control group	\N	United States of America	Indiana University (0093)	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5279	Gary 1990	\N	additional instructions + routine care versus routine care	\N	United States of America	Texas Tech University (0230)	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
5280	Muller-Clemm 1996	\N	assertive case management program versus control group	\N	Canada	University of Victoria (Canada) (0244)	\N	\N	\N	\N	123	\N	\N	\N	\N	\N
5281	Price 1982	\N	lecithin versus Placebo	\N	United States of America	University of North Texas (0158)	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
5282	Cannon 1985	\N	quarterway house care versus traditional inpatient care	\N	United States of America	Brandeis U., The F. Heller Grad. Sch. For Adv. Stud. In Soc. Wel. (0541)	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
5372	Potkin 2001 a	\N	M100907 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	404	\N	\N	\N	\N	\N
5283	Aldavoud 1989	\N	electromyographic biofeedback versus indirect feedback	\N	United States of America	United States International University (0239)	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
5284	Coyle 1988	\N	individual supportive therapy versus medication only	\N	Jamaica	Adelphi University, School of Social Work (0536)	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
5285	Tom 1989	\N	culturally relevant psychoeducation versus standard care	\N	United States of America	City University of New York (0046)	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5287	Kleiser 1990	\N	 CSG No: 5252 	\N	Germany	Germany	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
5288	Koettgen 1988	\N	 CSG No: 5251 	\N	Germany	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
5289	Schubert 1988	\N	 CSG No: 5250 	\N	Austria	Landesnervenkrankenhaus Hall, Austria	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
5290	Muller 1982	\N	 CSG No: 5249	\N	Germany	Germany	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
5291	Addington 2001	\N	setraline versus Placebo	\N	Canada	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
5292	Alva 2001	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5293	Alvarez 2001	\N	Olanzapine + typical Antipsychotics versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	904	\N	\N	\N	\N	\N
5297	Bell 2001 c	\N	neurocognitive enhancement therapy + work therapy versus work therapy	\N	United States of America	Yale University New Haven, Ct 06520 New Haven, Ct 06520	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5298	Bera 2001	\N	seroquel versus risperidal	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5301	Berman 2001	\N	gingko biloba extract versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
5303	Bobes 2001	\N	Olanzapine versus Olanzapine + typical Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	904	\N	\N	\N	\N	\N
5305	Buckley 2001 b	\N	Quetiapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5312	Cucchiaro 2001	\N	iloperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	621	\N	\N	\N	\N	\N
5313	D'Souza 2001	\N	Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5314	David 2001	\N	IM Olanzapine versus IM Haloperidol, Placebo	\N	United States of America	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
5316	Denney 2001	\N	Clozapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5317	Depatie 2001	\N	nicoderm patch versus Placebo	\N	Canada	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
5319	Dittmann 2001 a	\N	Olanzapine versus flupenthixol	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5322	Ereshefsky 2001	\N	name brand Clozapine versus generic Clozapine	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
5324	Friedman 2001 b	\N	donepezil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	38 - 33 completed	\N	\N	\N	\N	\N
5325	Gaebel 2001	\N	early intervention treatment in first episode schizophrenia versus early intervention treatment in multiple episode schizophrenia	\N	Germany	\N	\N	\N	\N	\N	363	\N	\N	\N	\N	\N
5330	Hammond 2001	\N	Quetiapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5560	Kojima 1983	\N	\N	\N	Japan	\N	\N	\N	\N	\N	214	\N	\N	\N	\N	\N
5335	Jenner 2001	\N	hallucinatinon integrated treatment versus usual care	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5338	Kalali 2001	\N	investigational compounds versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5340	Kern 2001	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	256	\N	\N	\N	\N	\N
5342	Kinon 2001 e	\N	Olanzapine dose	\N	United States of America	\N	\N	\N	\N	\N	458	\N	\N	\N	\N	\N
5344	Kristiansen  2001	\N	Risperidone + zuclopenthizol versus yohimbine	\N	Denmark	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5346	Lehman 2001	\N	individual placement and support versus psychosocial program	\N	United States of America	\N	\N	\N	\N	\N	218	\N	\N	\N	\N	\N
5356	McGurk 2001	\N	Clozapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
5357	Medalia 2001 a	\N	problem solving task versus control group	\N	United States of America	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
5358	Meltzer 2001 b	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	301	\N	\N	\N	\N	\N
5359	Miknyak 2001	\N	Risperidone + fluanxol-depot versus fluanxol-depot	\N	Ukraine	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5360	Miller 2001 c	\N	treatment guided by medication algorithms + disorder specific education versus standard care	\N	United States of America	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
5364	Naber 2001 a	\N	Olanzapine versus Clozapine	\N	Germany	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
5365	Nordentoft 2001	\N	integrated care versus standard care	\N	Denmark	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5367	Paquet 2001	\N	Olanzapine versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5373	Purdon 2001	\N	Quetiapine versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
5380	Ritch 2001	\N	Cognitive Adaptation Training versus control groups	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
5383	Sikich 2001 a	\N	 CSG No: 5379 	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
5384	Small 2001	\N	Clozapine + lithium versus Clozapine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
5387	Thaker 2001	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
5389	Velligan 2001 b	\N	Quetiapine versus conventional Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
5390	Ventegodt 2001	\N	 CSG No: 5357 	\N	Denmark	\N	\N	\N	\N	\N	359	\N	\N	\N	\N	\N
5391	Weisman 2001	\N	 CSG No: 5354 	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
5394	Wilner 2001	\N	Ziprasidone IM versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
5396	Wright 2001 b	\N	intramuscular Olanzapine versus intramuscular Placebo	\N	United States of America	\N	\N	\N	\N	\N	270	\N	\N	\N	\N	\N
5400	Arango 1999	\N	depot zuclopenthixol versus oral zuclopenthixol	\N	Spain	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5401	Adityanjee 2000	\N	lamotrigine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
5402	Bellack 2001 b	\N	behavioural therapy versus control group	\N	United States of America	University of Maryland Balt Prof School Professional Schools Baltimore, Md 21201 Fiscal Year: 2000 Dp: Psychiatry	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
5403	Armenteros 2001	\N	Risperidone versus Placebo	\N	United States of America	University of Miami Box 016159 Miami, Fl 33101	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5404	Apicella 2001	\N	Olanzapine versus haldol	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5405	Barnes 2000	\N	Clozapine versus second generation Antipsychotics	\N	United Kingdom	Academic Centre, Trust Headquarters, Uxbridge Road, Southall, Middlesex, UB1 3EU. Telephone: 020 8354 8892. Fax: 020 8354 8952. E-mail: t.r.barnes@ic.ac.uk. Project related web site: No. Collaborators: Prof Shon Lewis (University of Manchester); Prof Robe	\N	\N	\N	\N	702	\N	\N	\N	\N	\N
5406	Barnes 2001 a	\N	cognitive intervention versus psychoeducational intervention	\N	United Kingdom	Professor T R E Barnes, Department of Psychiatry, Charing Cross and Westminster Medical School, St Dunstan's Road, London, W6 8RP	\N	\N	\N	\N	225	\N	\N	\N	\N	\N
5407	Adams 2000	\N	exercise versus control group	\N	United Kingdom	Divisional Research Unit, Royal Cornhill Hospital, Cornhill Road, Aberdeen, AB25 2ZH. Telephone: (01224) 663131 ext 57003. Fax: (01224) 840784	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
5409	Bark 2001	\N	cognitive remediation versus control group	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
5410	Bell 2001 a	\N	neurocognitive enhancement therapy + work therapy versus work therapy	\N	United States of America	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
5411	Brook 2000 b	\N	Intramuscular Ziprasidone versus Intramuscular Haloperidol	\N	South Africa	Sterkfontain Hosp, Research Unit, Krugersdorp, South Africa	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
5412	Rüther 1979	\N	Clozapine versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5415	Tyrer 2000 a	\N	intensive case management versus standard case management	\N	United Kingdom	P. Tyrer, Department of Public Mental Health, Div. of Neurosci./Psychological Med., Imperial College School of Medicine, 20 Wharf Road, London W2 1PD, United Kingdom	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
5416	Murasaki 1999 a	\N	 CSG No: 5288 	\N	Japan	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
5419	Hirose 2000	\N	biperiden intravenous versus biperiden intramuscular	\N	Japan	Dr. S. Hirose, Fukui Prefectural Mental Hospital, 2-12-1 Yotsui Fukuishi, Fukui, Japan	\N	\N	\N	\N	226	\N	\N	\N	\N	\N
5420	Arioni 1971	\N	 CSG No: 5293 	\N	Italy	U. Rome, Inst. of Psychiatry, Italy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
5421	Cohler 1982	\N	infrequent visits versus frequent visits	\N	United States of America	U Chicago	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
5422	D'Urso 1968	\N	 CSG No: 5294 	\N	Italy	Ospedale Psichiatrico Provinciale, Udine, Italy	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5424	Mezquita 1973	\N	 CSG No: 5295 	\N	Spain	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
5425	Jerrell 2000	\N	integrated treatment versus control group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5426	Frojan 1998	\N	 CSG No: 5297 	\N	Spain	U Autonoma de Madrid, Dept de Psicologia Biologica, Madrid, Spain	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5427	Eleazer 1996	\N	community based case management versus control group	\N	United States of America	U South Carolina, School of Medicine, Geriatric Div, Columbia, SC, USA	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
5428	Panteleyeva 1982	\N	naloxone versus Placebo	\N	Russian Federation	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5429	Haran 1960	\N	perphenazine versus Placebo	\N	Ireland	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5430	Vinci 1967	\N	 CSG No: 5301 	\N	Italy	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
5431	Kaden 1997	\N	 CSG No: 5302 	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5432	Bueno 1979	\N	loxapine succinate versus Haloperidol	\N	Brazil	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
5433	Dusek 1967	\N	 CSG No: 5304 	\N	Czech Republic	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
20245	徐晔 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
5436	Pelham 1993	\N	aerobic exercise versus control group	\N	Canada	Dalhousie U School of Recreation, Physical & Health Education, Div of Kinesiology Sport Science & Fitness Lab, Halifax, NS, Canada	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
5561	Kondo 1975	\N	\N	\N	Japan	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
5562	Kudo 1994	\N	\N	\N	Japan	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
5563	Nakazawa 1982	\N	\N	\N	Japan	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
5564	Saito 1981	\N	\N	\N	Japan	\N	\N	\N	\N	\N	145	\N	\N	\N	\N	\N
5565	Shimizu 1984	\N	\N	\N	Japan	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
5568	Nishimatu 1975	\N	\N	\N	Japan	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
5569	Kariya 1981	\N	\N	\N	Japan	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
5570	Murasaki 2001	\N	Quetiapine versus Haloperidol	\N	Japan	\N	\N	\N	\N	\N	197	\N	\N	\N	\N	\N
5437	Rosenheck 1993 b	\N	Clozapine versus Haloperidol	\N	United States of America	Northeast Program Evaluation Center, Veterans Affairs Connecticut Healthcare System, Department of Psychiatry, Yale Medical School,  West Haven 06516, USA. Robert.Rosenheck@Yale.edu\r\n\r\nVA Connecticut Healthcare System, West Haven, 06516-2770, USA. robert.rosenheck@yale.edu\r\n\r\nVA's Northeast Evaluation Center, VA Connecticut Healthcare System, West Haven 06516-2770, USA. Robert.Rosenheck@Yale.edu\r\n\r\nDr. R. Rosenheck, Connecticut Health Care System, 950 Campbell Ave., West Haven, CT 06516-2770, United States. robert.rosenheck@yale.edu	\N	\N	\N	\N	873	\N	\N	\N	\N	\N
5438	Durr 1996	\N	behavioural family management + standard dose neuroleptic treatment versus behavioural family management + intermittend neuroleptic treatment	\N	Germany	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
5439	Kaufmann 1995	\N	self help employment center versus control group	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
5440	Zuoning 1999	\N	Benzamide versus Haloperidol	\N	China	Prof. J. Zuoning, An Ding Hospital, Affiliate Teach. Hosp. Beijing Cap., University of Medical Sciences, 5 An Kang Lane, De Sheng Men Wai, Beijing, China	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
5441	Bond 1986	\N	standard vocational program versus accelerated vocational program	\N	United States of America	Department of Psychology, Indiana University-Purdue University at Indianapolis, Indianapolis, IN 46223, United States	\N	\N	\N	\N	161	\N	\N	\N	\N	\N
5442	Palma 1997	\N	flupenthixol decanoate versus Haloperidol	\N	Chile	Dr. M.I. Palma Wenzel, Napoleon 3565, Oficina 803, Santiago	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
5443	Murow 1997	\N	activity therapy versus control group	\N	Mexico	E. Murow, Instituto Mexicano de Psiquiatria, Calz. Mexico-Xochimilco 101, San Lorenzo Huipulco 14370	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
5444	Meyers 1972	\N	 CSG No: 5315 	\N	Belgium	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
5445	Matthee 1976	\N	 CSG No: 5316 	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5446	Kudo 1997 a	\N	 CSG No: 5319 	\N	Japan	\N	\N	\N	\N	\N	159	\N	\N	\N	\N	\N
5447	Mori 1986	\N	 CSG No: 5320 	\N	Japan	\N	\N	\N	\N	\N	206	\N	\N	\N	\N	\N
5448	Itoh 1985 b	\N	 CSG No: 5321 	\N	Japan	\N	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
5449	Okuma 1987	\N	Haloperidol versus control group	\N	Japan	\N	\N	\N	\N	\N	283	\N	\N	\N	\N	\N
5451	Murasaki 1997	\N	perospirone versus Haloperidol	\N	Japan	\N	\N	\N	\N	\N	145	\N	\N	\N	\N	\N
5452	Itoh 1967	\N	lecithin versus Placebo	\N	Japan	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
5454	Ishimaru 1971 b	\N	 CSG No: 5327 	\N	Japan	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
5456	Tanimukai 1970	\N	 CSG No: 5328 	\N	Japan	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
5457	Kudo 1984	\N	 CSG No: 5329 	\N	Japan	\N	\N	\N	\N	\N	169	\N	\N	\N	\N	\N
5458	Shi 2000 a	\N	Family intervention + standard care versus standard care	\N	China	Mental Health Ctr of Baoshan District, Shanghai, China	\N	\N	\N	\N	213	\N	\N	\N	\N	\N
5460	Yang 1997 a	\N	Clozapine dose	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5461	Mark 1999	\N	Clozapine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	744	\N	\N	\N	\N	\N
5463	Zhao 2000	\N	Family intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	225	\N	\N	\N	\N	\N
5464	Kudo 1990	\N	 CSG No: 5339 	\N	Japan	\N	\N	\N	\N	\N	201	\N	\N	\N	\N	\N
5465	Kudo 1986	\N	 CSG No: 5341	\N	Japan	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
5466	Takahash 1986	\N	 CSG No: 5342 	\N	Japan	\N	\N	\N	\N	\N	127	\N	\N	\N	\N	\N
5467	Shimizu 1985	\N	 CSG No: 5343 	\N	Japan	\N	\N	\N	\N	\N	166	\N	\N	\N	\N	\N
5468	Tanimukai 1973	\N	 CSG No: 5346 	\N	Japan	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
5470	Feng 1999	\N	Intensive rehabilitation + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5471	Li 1992	\N	behaviour therapy versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5472	Anonymous 2000	\N	 CSG No: 5334 	\N	Germany	\N	\N	\N	\N	\N	365	\N	\N	\N	\N	\N
5473	Kokasa 1984	\N	 CSG No: 5332 	\N	Japan	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
5474	Yanai 1972	\N	 CSG No: 5345 	\N	Japan	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
5475	Onodera 1984	\N	 CSG No: 5344 	\N	Japan	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
5477	Kudo 1983 a	\N	 CSG No: 5350 	\N	Japan	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
5478	Kurihara 1983	\N	 CSG No: 5349 	\N	Japan	\N	\N	\N	\N	\N	286	\N	\N	\N	\N	\N
5479	Takesada 1977	\N	 CSG No: 5331 	\N	Japan	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
5480	Gu 1998	\N	Traditional Chinese Medicine (TCM) Moxibustion versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
5481	Gunther 1995 a	\N	monitor training programs versus unspecific treatment	\N	Germany	Germany	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
5484	Florin 1973	\N	 CSG No: 5433 	\N	Germany	Germany	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6410	Itoh 1969 a	\N	\N	\N	Japan	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
5525	Mueser 2001 b	\N	supportive family management + fluphenazine versus applied family management +fluphenazine	\N	United States of America	\N	\N	\N	\N	\N	528	\N	\N	\N	\N	\N
5526	Vinson 2001 b	\N	 CSG No: 5538	\N	United States of America	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
5527	Dixon 2001	\N	vocational interventions	\N	United States of America	\N	\N	\N	\N	\N	218	\N	\N	\N	\N	\N
5528	Medalia 2000 b	\N	problem solving remediation versus control group	\N	United States of America	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
5529	Harvey 2000 a	\N	Risperidone versus Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
5530	Cuesta 2001	\N	Olanzapine versus conventional Antipsychotic	\N	Spain	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
5532	Walsh 2001 b	\N	 CSG No: 5549	\N	United Kingdom	\N	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
5534	Bellack 2000	\N	Applied Family Management + fluphenazine versus Supportive Family Management + Placebo	\N	United States of America	\N	\N	\N	\N	\N	528	\N	\N	\N	\N	\N
5535	Ayd 1972 a	\N	Chlorpromazine dose//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5536	George 2000 a	\N	Olanzapine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5537	Kern 1996 a	\N	AIDs education programs versus control groups	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
5538	Muller 1998 a	\N	halopoeridol + amitriptylin versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	123	\N	\N	\N	\N	\N
5539	Steadman 2001	\N	enhanced services via involuntary outpatient commitment versus enhanced service package only//Intensive case management//Assertive community treatment//Compulsory community and involuntary outpatient treatment	\N	United States of America	\N	\N	\N	\N	\N	142	\N	\N	\N	\N	\N
5541	Rapisarda 1982 a	\N	supidimid + Haloperidol versus supidimid + Placebo	\N	Italy	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5542	Medalia 2000 a	\N	verbal problem solving remediation versus Placebo instruction	\N	United States of America	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
5545	Lehtinen 2000	\N	integrated treatment versus control group	\N	Finland	\N	\N	\N	\N	\N	165	\N	\N	\N	\N	\N
5546	McGeary 2000	\N	modified therapeutic community versus standard care	\N	United States of America	\N	\N	\N	\N	\N	342	\N	\N	\N	\N	\N
5547	Carriere 2000	\N	Amisulpride versus Haloperidol	\N	France	\N	\N	\N	\N	\N	199	\N	\N	\N	\N	\N
5551	Keck 2001	\N	Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	115	\N	\N	\N	\N	\N
5552	Petit 1994	\N	clonazepam versus Placebo	\N	France	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
5554	Ellis 2000	\N	Clozapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5555	Clarke 2000	\N	assertive community treatment versus standard care	\N	United States of America	\N	\N	\N	\N	\N	163	\N	\N	\N	\N	\N
5556	Covington 2000	\N	Clozapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
5558	Kaji 1974	\N	\N	\N	Japan	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
5559	Okada 1980	\N	zotepine versus tiotizene	\N	Japan	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
5572	Leclerc 2000	\N	rehabilitative coping skills module versus control group	\N	Canada	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
5574	Mosolov 1998	\N	lithium carbonate versus contemnol	\N	Russian Federation	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
5576	Vinson 2001a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5577	Tomaras 2000	\N	family intervention + individual psychosocial care versus individual psychosocial care	\N	Greece	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
5578	Basan 2000	\N	psychoeducation intervention versus standard care	\N	Germany	\N	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
5579	Dalack 1999 a	\N	smoking ad libitum versus no smoking	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5580	Chowdhury 1999	\N	Risperidone versus Clozapine	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
5582	Beasley 1996 a	\N	Olanzapine versus Placebo	\N	United States of America//Canada//Germany	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	366	\N	\N	\N	\N	\N
5583	Barsa 1965	\N	fluphenazine enanthate versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
20246	祁玲 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
5584	Gambill 1966	\N	pentothal + chlorperazine versus prochlorperazine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
5585	Herman 1997	\N	integrated treatment program versus standard hospital treatment	\N	United States of America	\N	\N	\N	\N	\N	485	\N	\N	\N	\N	\N
5587	Zito 1984	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
5592	Rees 1965	\N	Haloperidol + AP drug versus Placebo + AP drug	\N	United Kingdom	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
5593	Lapolla 1965 a	\N	tybamate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5595	Tarrier 1993	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
5596	Barrowclough 1990	\N	expressed emotion groups versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5597	Cockburn 1959	\N	Reserpine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5598	Weston 1961	\N	Trifluoperazine versus Placebo	\N	Australia	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
5599	Lamb 1971	\N	high expectation environment versus low expectation environment	\N	United States of America	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
5601	Bellack 1990	\N	standard instructions + contingent reinforcement versus standard instructions + noncontingent reinforcement	\N	United States of America	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
5604	Gray 1958	\N	Azacyclonol versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
5605	Carey 1990	\N	problem solving remediation versus control group	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
5606	Tran 1998 a	\N	Olanzapine versus fluphenazine	\N	Croatia	N. Mimica, Psychiatric Hospital Vrapce, Bolnicka cesta 32, HR-10090 Zagreb, Croatia	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
5610	Toro 1997	\N	intensive case management versus standard care	\N	United States of America	\N	\N	\N	\N	\N	202	\N	\N	\N	\N	\N
5611	Washburn 1976 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
5614	Briggs 1966	\N	vocational advisors versus control group	\N	United States of America	\N	\N	\N	\N	\N	134	\N	\N	\N	\N	\N
5615	Itil 1981	\N	fluphenazine enanthate versus pipothiazine palmitate	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
5616	Hollister 1962	\N	thiopropazate versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5617	Griffiths 1974	\N	rehabilitation program versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
5618	Becker 1967	\N	rehabilitation program versus standard care	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5619	Platt 1980	\N	day hospital care versus inpatient care	\N	United Kingdom	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
5623	Miller 1953	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus pentothal grs	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5624	Leone 1982	\N	loxapine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
5630	Allison 2001	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6384	Breier 2002 a	\N	Olanzapine versus Placebo	\N	Croatia//Italy//Romania//South Africa	\N	\N	\N	\N	\N	270	\N	\N	\N	\N	\N
6386	Chaplin 2002	\N	educational intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
6387	Beebe 2001	\N	community nursing support versus control group	\N	United States of America	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
6388	Barak 2001	\N	animal-assisted therapy versus control group	\N	Israel	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6389	Shrivastava 2000	\N	Risperidone versus Haloperidol	\N	India	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
6391	Ryan 1985	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6392	Grassi 2001	\N	community care versus inpatient services	\N	Italy	\N	\N	\N	\N	\N	195	\N	\N	\N	\N	\N
6394	Blankertz 1997	\N	long term vocational support versus control group	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6395	Anonymous 2001 b	\N	Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6396	Lilburn 1977	\N	ketamine + lorazepam versus ketamine + Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6397	McGorry 2002 b	\N	specific psychosocial intervention + Risperidone + CTB versus needs based intervention	\N	Australia	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
6398	Kazamatsuri 1993	\N	\N	\N	Japan	\N	\N	\N	\N	\N	162	\N	\N	\N	\N	\N
6399	Kudo 1989	\N	\N	\N	Japan	\N	\N	\N	\N	\N	193	\N	\N	\N	\N	\N
6401	Toru 1969	\N	\N	\N	Japan	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
6402	Umene 1972	\N	pimozide versus Chlorpromazine	\N	Japan	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
6404	Muller 2002 b	\N	celecoxib + Risperidone versus Risperidone + Placebo	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
6407	Min 2001	\N	\N	\N	China	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
6408	Wu 1984	\N	Traditional Chinese Medicine (TCM) Huoxue-Huayu + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20247	李育军 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
6411	Macias 2001	\N	assertive community treatment versus vocational program	\N	United States of America	\N	\N	\N	\N	\N	166	\N	\N	\N	\N	\N
6412	Xue 1985	\N	Electroacupuncture versus Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
6413	Cappelen 1961	\N	\N	\N	Norway	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
6415	Volz 2002	\N	\N	\N	Germany//Switzerland	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
6416	Anzai 2002 a	\N	occupational rehabilitation program versus community re-entry program	\N	Japan	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
6417	Woods 2002 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
6419	Samele 2001	\N	intensive case management versus standard case management	\N	United Kingdom	\N	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
6420	Kluger 1983	\N	orientation groups versus control group	\N	United States of America	\N	\N	\N	\N	\N	141	\N	\N	\N	\N	\N
6421	Lingjaerde 1992	\N	Risperidone versus perphenazine	\N	Norway//Denmark	Central Hospital, Department of Psychiatry, Aalesund, Norway. ORIGIN Other Europe	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
6422	Wiedemann 1992	\N	\N	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6424	Dolnak 2000	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
6426	Goldman 1999	\N	Clozapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6431	De Cuyper 1988	\N	Risperidone versus Haloperidol	\N	Belgium//United States of America	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
6432	Kamisada 1988	\N	lithium carbonate versus Placebo	\N	Japan	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6433	Zinner 1991	\N	Risperidone versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
6434	Martinot 1991	\N	neuroleptic treatment versus Placebo	\N	France	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
6437	Beard 1964	\N	rehabilitation program versus control group	\N	United States of America	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
6438	Chouinard 1983 b	\N	fluspirliene versus Chlorpromazine	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
6439	Itoh 1969 c	\N	\N	\N	Japan	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
6441	Heylen 1988	\N	Risperidone versus Haloperidol	\N	Belgium	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
6442	Gerbaldo 1988	\N	OPC-4392 versus Placebo	\N	Germany	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
6445	Clardy 1991	\N	L-dopa versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6446	Mackeprang 2001	\N	Risperidone versus zuclopenthixol	\N	Denmark	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6448	Wessels 1991	\N	\N	\N	South Africa	\N	\N	\N	\N	\N	215	\N	\N	\N	\N	\N
6449	Blin 1991	\N	Risperidone versus Haloperidol	\N	France	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
6454	Ritchie 1999	\N	Olanzapine versus Risperidone	\N	Australia	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
6458	Crosthwaite 2000	\N	Risperidone versus Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6463	Pappas 1997	\N	Risperidone versus Haloperidol	\N	Greece	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
6464	Baumann 1993	\N	Risperidone versus Clozapine	\N	Switzerland	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
6465	Hitzemann 1993	\N	neuroleptic decrease versus standard care	\N	United States of America	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
6471	Gutierrez 1996 b	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	246	\N	\N	\N	\N	\N
6474	Daniel 1995 a	\N	Risperidone versus Clozapine	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6475	Kudo 1994 b	\N	\N	\N	Japan	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
6478	Perro 2000 a	\N	Risperidone versus zotepine	\N	Germany	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
6479	Yagdiran 2000	\N	Amisulpride versus Clozapine // Amisulpride versus Olanzapine // Amisulpride versus Risperidone // Amisulpride versus Zotepine // Clozapine versus Olanzapine // Clozapine versus Risperidone // Clozapine versus Zotepine // Olanzapine versus Risperidone // Olanzapine versus Zotepine // Risperidone versus Zotepine	\N	Germany	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
6484	Burns 2002 a	\N	intensive case management versus standard case management	\N	United Kingdom	\N	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
6485	Morrison 2002 b	\N	early detection inntervention versus Cognitive Behavioural Therapy(Cognitive Behavioral Therapy)	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
6486	Gold 2002	\N	vocational rehabilitation versus control group	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
6488	Roder 2002	\N	new social skills training programs versus control group	\N	Switzerland//Germany//Austria	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
6491	Van Der Gaag 2002	\N	cognitive remediation versus leisure	\N	Netherlands	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
6492	Wilk 2002	\N	Omega-3 Fatty Acid versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	181	\N	\N	\N	\N	\N
6494	Koch 2000	\N	pindolol + fluoxetine versus fluoxetine + Placebo	\N	Germany	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
6497	Kudo 1985	\N	\N	\N	Japan	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
6498	Hirano 1995	\N	Haloperidol versus Placebo	\N	Japan	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
6499	Okubo 1985	\N	Haloperidol dose	\N	Japan	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
6501	Burhan 1969	\N	inpatient care versus outpatient care	\N	United States of America	\N	\N	\N	\N	\N	1169	\N	\N	\N	\N	\N
6502	Suleman 1978	\N	intramuscular Haloperidol with dextrose versus intramuscular Haloperidol with saline	\N	Ireland	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
6504	Adler 1987	\N	propranolol versus benztropine	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
6505	Morozova 2002	\N	Risperidone + amiridin versus Risperidone + Placebo	\N	Russian Federation	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
6506	Lerner 2002 b	\N	vitamin B6 versus Placebo	\N	Israel	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
6507	Haug 2002	\N	short term violence time prediction versus standardized aggression management training	\N	Switzerland	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6509	Naber 2001 b	\N	typical Antipsychotics versus Atypical Antipsychotics	\N	Germany	\N	\N	\N	\N	\N	248	\N	\N	\N	\N	\N
6510	Vichaiya 1971	\N	\N	\N	Thailand	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
6513	Tait 2002	\N	thiothixene versus trifluperazine	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6514	Ayers 1960	\N	thorazine versus Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	United States of America	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
6516	Bishop 1966 b	\N	experimental care versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
6518	Yorkston 1976 a	\N	Propranolol versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
6519	Clark 1970 e	\N	AL-1021 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6520	Itil 1970 c	\N	fluphenazine dose	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
6521	Lehmann 1970	\N	pimozide versus fluphenazine	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6522	Lehmann 1970 b	\N	doxepin versus chlordiazepoxide	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6523	Krumholz 1970 a	\N	pimozide versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
6524	Kurland 1970 a	\N	piperacetazine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
6525	Gallant 1970 b	\N	piperacetazine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
6526	Yaryura 1968	\N	Calcium gluconate iv versus Placebo iv of sterile water	\N	Unclear	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
6527	Schiele 1968	\N	SKF 14336 versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6528	Merlis 1968 a	\N	pimozide versus fluphenazine	\N	United States of America	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
6529	Krumholz 1968 a	\N	tetrabenazine versus promazine	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6530	Krumholz 1968 b	\N	SKF-14336D versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
6531	Clark 1968 c	\N	tybamate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
6532	Wolpert 1968 b	\N	triiodothyronine + phenothiazine versus Placebo + phenothiazine	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6533	Clark 1969 a	\N	fluphenazine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
6534	Krumholz 1968 c	\N	MO-1255 versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
7400	Cai 2000	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
7401	Wang 2000 b	\N	Phenytoin Sodium + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7402	Chen 2000 a	\N	Risperidone versus Placebo	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
7403	Cui 2000	\N	Electroacupuncture + Chlorpromazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7404	Zhou 2000 b	\N	Traditional Chinese Medicine (TCM) Zhenlv Pian versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
7405	Tao 2002	\N	Skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7406	Chen 2002 b	\N	family intervention versus control group	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
7407	Zoccali 2003	\N	mirtazapine + Clozapine versus mirtazapine + Risperidone versus mirtazapine + Olanzapine	\N	Italy	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
7408	Mamo 2004	\N	Ziprasidone versus various dosages	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
7409	Wiersma 2004	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
7410	Chou 2004	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
7411	Gan 2000	\N	Risperidone versus Self-control (Before, during and after treatment)	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
7412	Liu 1995 a	\N	Rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
7413	Jiang 1995	\N	Haloperidol Decanoate versus Penfluridol	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7414	Zhang 2003 c	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	237	\N	\N	\N	\N	\N
7415	Wang 1996 a	\N	Trihexyphenidyl versus Propranolol	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
7416	Huang 1997	\N	Loxapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	205	\N	\N	\N	\N	\N
7417	Sun 1998	\N	Cyproheptadine versus Propranolol	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7420	Fucetola 2000	\N	oral glucose versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
7422	Ritter 2000	\N	nicotine patch versus Placebo patch	\N	United States of America	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
7424	Alphs 1993	\N	remoxipride versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	216	\N	\N	\N	\N	\N
7426	Xiao 2002	\N	Traditional Chinese Medicine (TCM) Huangqi + Care as usual versus Care as usual	\N	China	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
7428	Simpson 1968 b	\N	molidone versus not stated	\N	United States of America	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
7429	Weickert 2003	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
7430	Chen 1995 b	\N	Bromocriptine versus Placebo	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5634	Brandstaetter 2001	\N	celecoxib + Risperidone versus Risperidone + Placebo	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
5635	Brecher 2000	\N	Quetiapine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	427	\N	\N	\N	\N	\N
5636	Breier 2000	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	270	\N	\N	\N	\N	\N
5638	Bustillo 2000	\N	fluoxetine + Olanzapine versus Olanzapine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
5643	Fischer 2001	\N	zotepine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
5644	Friedman 2000 a	\N	donepezil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
5646	Gefvert 2000	\N	OSU6162 versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	4, 3 completed	\N	\N	\N	\N	\N
5648	Glenthoj 2000	\N	Risperidone versus zuclopenthixol	\N	Denmark	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
5655	Hellewell 2000	\N	Quetiapine versus various dosages	\N	United Kingdom	\N	\N	\N	\N	\N	478	\N	\N	\N	\N	\N
5656	Hoffman 2001 a	\N	transcranial magnetic stimulation (Transcranial Magnetic Stimulation) versus sham transcranial magnetic stimulation (Transcranial Magnetic Stimulation)	\N	Unclear	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
5658	Jauhar 2001	\N	structured clinical interveiw versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
5663	Kinon 2001 b	\N	Olanzapine dose	\N	United States of America	\N	\N	\N	\N	\N	480	\N	\N	\N	\N	\N
5664	Lanzaro 2001	\N	Risperidone versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
5665	Lecrubier 2000	\N	Amisulpride versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	310	\N	\N	\N	\N	\N
5666	Lee 2001 a	\N	Quetiapine versus Placebo	\N	Germany//United States of America	\N	\N	\N	\N	\N	1635	\N	\N	\N	\N	\N
5667	Lemmer 2001	\N	zotepine versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
5670	Marques 2001 a	\N	Amisulpride versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	310	\N	\N	\N	\N	\N
5671	Mazian 2001	\N	Olanzapine versus Antipsychotics	\N	Germany	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
5672	McGurk 2000	\N	Clozapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5674	Meltzer 2000 a	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	599	\N	\N	\N	\N	\N
5675	Mullen 2000	\N	Quetiapine versus Risperidone	\N	United States of America//United Kingdom	\N	\N	\N	\N	\N	728	\N	\N	\N	\N	\N
5677	Möller 2001	\N	Amisulpride versus Placebo	\N	Germany	\N	\N	\N	\N	\N	487	\N	\N	\N	\N	\N
5678	Peuskens 2001 b	\N	Amisulpride versus Haloperidol	\N	France	\N	\N	\N	\N	\N	228	\N	\N	\N	\N	\N
5679	Philipps 2001	\N	case management versus control group	\N	Australia	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
5680	Potkin 2001 b	\N	iloperidone versus Placebo	\N	Germany	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
5682	Risch 2000 a	\N	donepezil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5684	Salzman 2000	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
5687	Vasquez-Gomez 2001	\N	midazolam versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5689	Yurgelun-Todd 2001	\N	\N	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5690	Zhong 2001	\N	1- Stepholidine (SPD) versus Perphenazine	\N	Germany	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
5691	Burns 2000 a	\N	intensive case management versus standard case management	\N	United Kingdom	\N	\N	\N	\N	\N	545	\N	\N	\N	\N	\N
5694	Simhandl 1996	\N	carbamazepine versus Placebo	\N	Austria	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
5697	Akhondzadeh 2000	\N	Haloperidol + dipryridamole versus Haloperidol + Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5698	Azorin 2001	\N	Clozapine versus Risperidone	\N	France	\N	\N	\N	\N	\N	273	\N	\N	\N	\N	\N
19408	周益辉 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
5699	Wright 2001 a	\N	Haloperidol versus Haloperidol IM//Haloperidol versus Olanzapine IM// Haloperidol versus Placebo IM//Olanzapine IM versus Haloperidol IM//Olanzapine IM versus Placebo IM//Haloperidol IM versus Haloperidol IM	\N	United States of America	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
5700	Lerner 2001	\N	vitamin B6 versus Placebo	\N	Israel	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
5701	Adler 1994a	\N	vitamin E versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	158	\N	\N	\N	\N	\N
5704	Owens 2001	\N	Trinidad samples versus London African-Caribean samples	\N	United Kingdom	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
5705	Lenior 2001 a	\N	standard intervention + family intervention versus standard intervention	\N	Netherlands	\N	\N	\N	\N	\N	312	\N	\N	\N	\N	\N
5706	Byford 2001	\N	intensive case management versus standard case management	\N	United Kingdom	\N	\N	\N	\N	\N	667	\N	\N	\N	\N	\N
5707	Mattes 1977	\N	short stay hospitalization versus long stay hospitalization	\N	United States of America	\N	\N	\N	\N	\N	173	\N	\N	\N	\N	\N
5709	Esel 2001	\N	Olanzapine versus Haloperidol	\N	Turkey	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
5710	Swoboda 2001	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus standard care	\N	Austria	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
5711	Michaux 1969	\N	psychiatric day hospital treatment versus inpatient treatment	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
5713	Janecek 1963	\N	trifluoperazine + tranycypromine versus tranylcypromine	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5714	Gallant 1963 a	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5715	Gallant 1963 b	\N	trimethoxycinnamamide versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
5716	Bishop 1963 a	\N	benzquinamide versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5719	Summerfelt 1991	\N	monetrary feedback versus standard instructions	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
5720	Raymond 1957	\N	tranquilizers versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
5722	Peet 2001	\N	Omega-3 Fatty Acid versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
5724	Bellack 2001 a	\N	training versus no training	\N	United States of America	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
5726	Odland 1957	\N	Azacyclonol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	171	\N	\N	\N	\N	\N
5727	Langsley 1969	\N	family crisis therapy cases versus hospital care cases	\N	United States of America	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
5728	Rosen 1997	\N	droperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
20340	毕旭军 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
5729	Tsang 2001	\N	work-related social skills training + followup support versus standard care work-related social skills training + followup support versus standard care	\N	Hong Kong	Hong Kong Polytechnic U, Dept of Rehabilitation Sciences, Hung Hom, Hong Kong	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
5734	Langsley 1959	\N	clorpromazine versus EST	\N	United States of America	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
5737	Buitelaar 2001	\N	Risperidone versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
5738	Ishigooka 2001	\N	Olanzapine versus Haloperidol	\N	Japan	National Center of Neurology and Psychiatry, National Institute of Mental Health, Ichikawa 272-0827, Japan	\N	\N	\N	\N	182	\N	\N	\N	\N	\N
5739	Nishizono 1994	\N	zotepine versus Haloperidol	\N	Japan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5740	Phillips 1995	\N	didactic training + physical skills training versus control group	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
5741	Bartels 1981	\N	\N	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5742	Davis 1974	\N	inpatient care versus outpatient care	\N	Unclear	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
5743	Bergemann 1999	\N	estrogen versus Placebo	\N	Germany	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
5745	Anonymous 1979	\N	dialysis versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5746	Gordon 1979	\N	psychosocial program versus control group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5747	Berk 2000 a	\N	mirtazapine versus Placebo	\N	South Africa	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5749	Deberdt 1971	\N	\N	\N	France	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
5752	Godley 1994 a	\N	case management training versus control group	\N	United States of America	\N	\N	\N	\N	\N	234	\N	\N	\N	\N	\N
5753	Lindenmayer 1996	\N	Clozapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5754	Su 1996 a	\N	Risperidone versus Clozapine	\N	Unclear	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
5757	Haffmans 2001	\N	Risperidone versus Haloperidol	\N	Netherlands	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
5760	Duval 2001	\N	Risperidone versus Haloperidol	\N	France	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
5761	Diaz 2001 b	\N	clozepine + glycine versus clozepine + Placebo	\N	Canada	\N	\N	\N	\N	\N	377	\N	\N	\N	\N	\N
5762	Brook 2001 b	\N	Intramuscular Ziprasidone versus Intramuscular Haloperidol	\N	South Africa	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5763	Breier 2001 a	\N	nizatidine + Olanzapine versus Olanzapine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
5764	Bilder 2001	\N	Clozapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	157	\N	\N	\N	\N	\N
5765	Awad 2001	\N	Ziprasidone versus conventional Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	270	\N	\N	\N	\N	\N
5766	Atmaca 2001	\N	Quetiapine versus Haloperidol	\N	Turkey	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
5768	Anil 2001	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	318	\N	\N	\N	\N	\N
5771	Yagdiran 2001	\N	Atypical Antipsychotics versus Amisulprid, Clozapin, Olanzapin, Risperidon, Zotepin	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5773	Turkington 2001 a	\N	psychoeducation + Cognitive Behavioral Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	422	\N	\N	\N	\N	\N
5777	Peuskens 2001 a	\N	Amisulpride versus Risperidone	\N	Belgium	\N	\N	\N	\N	\N	310	\N	\N	\N	\N	\N
5782	Loza 2001	\N	Atypical Antipsychotics versus typical Antipsychotics	\N	Poland	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
5785	Ananth 2001	\N	Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
5787	Breier 2001 c	\N	nizatidine + Olanzapine versus Olanzapine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
5788	Breier 2001 b	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	270	\N	\N	\N	\N	\N
5791	Castle 2001	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	Australia	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
5793	Conde 2001	\N	direct switch to Olanzapine versus tapered switch to Olanzapine	\N	Philippines	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5794	Dunn 2001 c	\N	enhanced consent procedure versus routine consent procedure	\N	United States of America	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
5796	Gabriels 2001	\N	deep brain simulation versus control group	\N	Belgium	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5797	Gefvert 2001	\N	Risperidone versus various doses	\N	Sweden	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
5798	Glick 2001 b	\N	Olanzapine versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	268	\N	\N	\N	\N	\N
5801	Klotz 2001	\N	community reintegration versus standard treatment//assertive community treatment//intensive case management//mulit-disciplinary teams	\N	United States of America	\N	\N	\N	\N	\N	4741	\N	\N	\N	\N	\N
5802	Kolivakis 2001	\N	Risperidone versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
5803	Lehmann 2001	\N	integrated health versus primary care	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5806	Littrell 2001	\N	educational intervention + Olanzapine versus standard care + Olanzapine educational intervention + Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
5808	Martinez 2001	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
5809	McGlashan 2001	\N	Atypical Antipsychotics versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5814	Pai 2001	\N	Risperidone versus Placebo	\N	Taiwan	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
5815	Poyurovsky 2001	\N	Olanzapine + fluoxetine versus Olanzapine + Placebo	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5816	Reinstein 2001	\N	Quetiapine versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5817	Rosenberg 2001 a	\N	sildenafil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
5818	Shamir 2001 a	\N	melatonin versus Placebo	\N	Israel	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
5821	Simpson 2001 a	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	268	\N	\N	\N	\N	\N
5823	Turkington 2001 b	\N	psychoeducation + Cognitive Behavioral Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	422	\N	\N	\N	\N	\N
5824	Turkington 2001 c	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	257	\N	\N	\N	\N	\N
5826	Walsh 2001 c	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
5828	Wirshing 2001 b	\N	Community Re-Entry Program versus Illness Education Classes	\N	United States of America	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
5833	Levine 1998	\N	cognitive group therapy versus supportive group	\N	Israel	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
5834	Schulz 1989	\N	Haloperidol versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
5835	Fenton 2000	\N	crisis residential alternative program versus hospital care	\N	United States of America	Chestnut Lodge Research Institute, Rockville, MD 20850, USA.	\N	\N	\N	\N	185	\N	\N	\N	\N	\N
5836	Okpaku 1997	\N	case management versus control group	\N	United States of America	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
5840	Bagadia 1988	\N	bitemporal Electroconvulsive Therapy versus right temporoparietal Electroconvulsive Therapy	\N	India	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
5842	Bell 1993 a	\N	paid vocational rehabilitation versus non paid vocational rehabilitation	\N	United States of America	Psychology Service, VA Medical Center, West Haven, CT 06516, USA. ORIGIN USA	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
5844	Velasquez 1980	\N	residential treatment program versus non-residential treatment program	\N	United States of America	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
5847	Sheppard 1964	\N	Acetophenazine versus Chlorpromazine // Acetophenazine Dimaleate versus Placebo // Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	170	\N	\N	\N	\N	\N
5848	Wolff 1962	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
5850	Daniels 1998	\N	interactive behavioral training versus control group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5851	Schmidt 1960	\N	bemebride versus Placebo	\N	Malaysia	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
5852	Floru 1974	\N	\N	\N	Germany	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
5853	Engstrand 1969	\N	\N	\N	Norway	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
5854	Funke 1989	\N	\N	\N	Germany	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
5857	Gaertner 1999	\N	Clozapine versus Olanzapine	\N	Germany	\N	\N	\N	\N	\N	233	\N	\N	\N	\N	\N
5859	Pereira 1994	\N	psychoeducation versus control group	\N	Gran Canaria	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
5860	Smeraldi 1991	\N	\N	\N	Italy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
5862	Bandeira 1994	\N	\N	\N	Canada	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
5867	Sittampalam 1962	\N	stemetil versus Placebo	\N	Sri Lanka	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
5868	Solomon 1995 a	\N	consumer case management versus non-consumer case management	\N	United States of America	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
5870	Hayashi 2001	\N	weekly sessions + routine care versus routine care	\N	Japan	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
5872	Bergman 1976	\N	incentive community program versus control group	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
5874	Wolkon 1971	\N	social rehabilitative program versus standard care	\N	United States of America	\N	\N	\N	\N	\N	333	\N	\N	\N	\N	\N
5875	Zwerling 1964	\N	 CSG No: 5531	\N	United States of America	\N	\N	\N	\N	\N	378	\N	\N	\N	\N	\N
5876	King 1960	\N	Chlorpromazine + Electroconvulsive Therapy versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
5878	Vestre 1962	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
5879	Janakiramiah 1981	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) + Chlorpromazine versus Chlorpromazine	\N	India	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
5880	Lecompte 1996	\N	Cognitive Behavioural Training versus control group	\N	Belgium	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
5881	Goldman 1988	\N	patient education program versus control group	\N	United States of America	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
5885	Caffey 1968	\N	standard hospital care versus standard hospital care + aftercare	\N	United States of America	ORIGIN USA	\N	\N	\N	\N	201	\N	\N	\N	\N	\N
5887	Walker 1969	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
5888	Azrin 1979	\N	job club method versus control group	\N	United States of America	\N	\N	\N	\N	\N	154	\N	\N	\N	\N	\N
5890	Keith 1977	\N	job placement training versus control groups	\N	United States of America	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
5891	Bridler 2001	\N	\N	\N	Switzerland	\N	\N	\N	\N	\N	158	\N	\N	\N	\N	\N
5892	Shiloh 2001	\N	\N	\N	Israel	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5894	Blaha 1979	\N	\N	\N	Germany	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
5895	Bomboir 1962	\N	\N	\N	France	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5896	Ishimaru 1971 a	\N	\N	\N	Japan	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
5897	Ruphan 1992	\N	\N	\N	Belgium	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
5898	Lecompte 1997	\N	\N	\N	Germany	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
5899	Borell 1995	\N	\N	\N	Sweden	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
5905	Kodama 1984	\N	\N	\N	Japan	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
5907	Schene 1993	\N	day treatment versus inpatient treatment	\N	Netherlands	\N	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
5908	Sharpley 1964 a	\N	Butaperazine versus perphenazine	\N	United States of America	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
5909	Whittier 1960 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
5910	McEvoy 1993 b	\N	sertindole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
5912	Alfredsson 1984	\N	sulpiride versus Chlorpromazine	\N	Sweden	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
5916	Jones 2001 a	\N	personalized computer education + psychiatric nurse versus computer education	\N	United Kingdom	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
5919	Lahti 2001	\N	ketamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
5922	Carpenter 2000	\N	mazindol + Antipsychotic treatment versus Placebo + Antipsychotic treatment	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5924	Bell 2001 b	\N	neurocognitive enhancement therapy + work therapy versus work therapy	\N	United States of America	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
6356	St Jean 1966	\N	imipramine versus opipramol	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5926	Dunn 2001 a	\N	enhanced consent procedure versus routine consent procedure	\N	United States of America	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
5927	Sumiyoshi 2001 a	\N	neuroleptic + tandospirone versus neuroleptic + Placebo	\N	Japan	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
5928	Barrowclough 2001	\N	motivational interviewing, cogtnitive behavior training, family intervention versus standard care motivational interviewing, cogtnitive behavior training, family intervention versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
5932	Whittier 1960 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
5935	Feldmann 2001	\N	psychoeducation training versus control group	\N	Germany	\N	\N	\N	\N	\N	182	\N	\N	\N	\N	\N
5937	Gillin 1978	\N	pimozide + d-amphetamine versus d-amphetamine	\N	United States of America	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
5938	Smith 1977 a	\N	d-Amphetamine versus apomorphine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5940	McCartan 2001	\N	Chlorpromazine versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
5941	Mueser 2001 a	\N	individual placement and support versus standard services	\N	United States of America	\N	\N	\N	\N	\N	204	\N	\N	\N	\N	\N
5942	Schutz 2001	\N	Haloperidol + reboxetine versus Haloperidol + Placebo	\N	Australia	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5943	Zhang 2001 a	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
5944	Boyer 1989 a	\N	\N	\N	France	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
5945	Estorges 1991	\N	\N	\N	France	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
5946	Monfort 1991	\N	valproate-diazepam versus Chlorpromazine	\N	France	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
5947	Oliveira-Castro 1991	\N	Amisulpride versus Clozapine	\N	France	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
5948	Barrelet 1987	\N	\N	\N	Switzerland	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5949	Lemperiere 1985	\N	\N	\N	France	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
5950	Santiago 1985	\N	integrated services versus control group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5951	Burger 2000	\N	assertive community treatment versus control group	\N	United States of America	\N	\N	\N	\N	\N	165	\N	\N	\N	\N	\N
5955	Alexander 2002	\N	lorazepam versus Haloperidol + promethazine	\N	India	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
5956	Arango 2002 a	\N	depot zuclopenthixol versus oral zuclopenthixol	\N	Spain	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
5957	Baker 2002 a	\N	As Required (Lorazepam versus Olanzapine Dosage) Added to Initial Olanzapine Dosage	\N	United States of America	\N	\N	\N	\N	\N	142	\N	\N	\N	\N	\N
5958	Baker 2002 b	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5960	Battaglia 2002	\N	IM Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5961	Bechdolf 2002	\N	cognitive-oriented group therapy versus psychoeducational program	\N	Germany	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
5964	Brewer 2002	\N	Risperidone versus Haloperidol	\N	Australia	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
5965	Brook 2002	\N	Intramuscular Ziprasidone versus Intramuscular Haloperidol	\N	Germany//Belgium//South Africa//United States of America	\N	\N	\N	\N	\N	567	\N	\N	\N	\N	\N
5966	Castle 2002 a	\N	group-based intervention versus control group	\N	Australia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5967	Cavazzoni 2002 a	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5968	Chue 2002 a	\N	Risperidone microspheres versus Risperidone oral tablets	\N	Canada	\N	\N	\N	\N	\N	640	\N	\N	\N	\N	\N
5970	Cutler 2002	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	269	\N	\N	\N	\N	\N
5971	Czekalla 2002	\N	Olanzapine versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
5972	David 2002 a	\N	IM Olanzapine versus IM Haloperidol, Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5976	Emsley 2002	\N	Omega-3 Fatty Acid versus Placebo	\N	South Africa	\N	\N	\N	\r\nNotes2\r\nPlacebo versus eicosapentaenoic acid for schizophrenia whose current state is acute and whose stage of illness is persistent // chronic with positive symptoms	\N	40	\N	\N	\N	\N	\N
5978	Gharabawi 2002	\N	Risperidone + lorazepam versus Haloperidol + lorazepam	\N	United States of America	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
5988	Keefe 2002	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
5989	Kingdon 2002 a	\N	Cognitive Behavioural Training versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5991	Knegtering 2002 a	\N	Risperidone versus Quetiapine	\N	Netherlands	\N	\N	\N	\N	\N	232	\N	\N	\N	\N	\N
5992	Korell 2002	\N	assertive community treatment versus cognitive adaptation training	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
5995	Kumari 2002	\N	procyclidine + Risperidone versus procyclidine + Quetiapine	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
5998	Linszen 2002 a	\N	sustained intervention programs versus control group	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
5999	Marcelis 2002	\N	2-deoxy-D-Glucose versus Placebo	\N	The Netherlands	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
6000	Maurer 2002	\N	Olanzapine versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
6001	McGlashan 2002 a	\N	Atypical Antipsychotics versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6002	Meehan 2002	\N	im Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
6003	Merlo 2002 a	\N	Risperidone versus various doses	\N	Switzerland	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6004	Morrison 2002 a	\N	early detection inntervention versus Cognitive Behavioural Therapy(Cognitive Behavioral Therapy)	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6005	Muller 2002 a	\N	celecoxib + Risperidone versus Risperidone + Placebo	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
6007	Nienhuis 2002	\N	Cognitive Behavioural Training // Hallucinatinon Integrated Treatment versus Treatment as Usual // EuroQol versus WHOQoL	\N	The Netherlands	\N	\N	\N	\r\n\r\n\r\nNotes2	\N	76	\N	\N	\N	\N	\N
6008	Nikiforova 2002	\N	thymogen + psychopharmacotherapy versus psychopharmacotherapy	\N	Russian Federation	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
6010	O'Donnell 2002	\N	compliance therapy versus non-specific counselling therapy	\N	Ireland	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
6011	Ohlenschlaeger 2002	\N	person continuity treatment groups versus standard treatment	\N	Denmark	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6012	Olié 2002 a	\N	Ziprasidone versus Amisulpride	\N	France	\N	\N	\N	\N	\N	123	\N	\N	\N	\N	\N
6013	Power 2002	\N	assertive community treatment versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
6014	Ritch 2002	\N	Cognitive Adaptation Training versus assertive community treatment	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6015	Sharma 2002 a	\N	Clozapine versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6016	Turkington 2002 a	\N	psychoeducation + Cognitive Behavioral Therapy (Cognitive Behavioral Therapy)	\N	United Kingdom	\N	\N	\N	\N	\N	422	\N	\N	\N	\N	\N
6019	Vangeneugden 2002	\N	\N	\N	Belgium	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6020	Vlokh 2002	\N	\N	\N	Ukraine	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
6021	Walsh 2002	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
6025	Wykes 2002 a	\N	cognitive remediation therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6027	Zachariah 2002	\N	Procyclidine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6028	Brecher 1996 b	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	471	\N	\N	\N	\N	\N
6030	Cheine 1997	\N	Risperidone versus Clozapine	\N	Finland	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6031	Chanpattana 2000	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) + flupenthixol versus Electro Convulsive Therapy (Electroconvulsive Therapy) + Placebo	\N	Thailand	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
6034	Collins 2001	\N	HIV prevention group versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
6035	Blumberg 1965	\N	Chlorpromazine + procyclindine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
6037	Lehman 1995 a	\N	assertive community treatment versus standard care	\N	United States of America	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
6042	Sharpley 2001	\N	Olanzapine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
6048	Blake 1990	\N	alternating treatment design versus control group	\N	United States of America	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
6050	Chanpattana 1999 c	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) + flupenthixol versus Electro Convulsive Therapy (Electroconvulsive Therapy) + Placebo	\N	Thailand	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
6052	Corrigan  2001	\N	depression interview versus psychosis interview	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
6053	Cramer 2001	\N	Clozapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	423	\N	\N	\N	\N	\N
6056	Medalia 2001 b	\N	problem solving remediation versus control group	\N	United States of America	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
6057	Singh 1999	\N	centbutindole versus Haloperidol	\N	India	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
6058	Singh 1981	\N	chlopromazine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6060	Wahass 1997	\N	\N	\N	Saudi Arabia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6061	Chanpattana	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus sham Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	Thailand	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
6062	Small 1981	\N	thiothixene + Electro Convulsive Therapy (Electroconvulsive Therapy) versus thiothixene	\N	United States of America	Larue D. Carter Mem. Hosp., Indiana Univ. Sch. Med., Indianapolis, IN 46202, United States	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
6064	Olié 2002 b	\N	Amisulpride versus Placebo	\N	France	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6065	Lane 2001 a	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
6785	Tandon 2002 b	\N	\N	\N	India	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
6067	Hale 1996	\N	sertindole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	617	\N	\N	\N	\N	\N
6069	Haasen 2000 a	\N	Turkish patient group versus German patient group	\N	Germany	\N	\N	\N	\N	\N	141	\N	\N	\N	\N	\N
6070	Roder 2001	\N	\N	\N	Germany	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
6074	Lindenmayer 2001	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6075	Huxley 2001	\N	intensive case management versus standard case management	\N	United Kingdom	\N	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
6079	Segers 1964	\N	oxymetholone versus Placebo	\N	Belgium	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6080	Gelders 1986	\N	ritanserin versus Placebo	\N	Belgium	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6081	Perry 2001 a	\N	standard instructions + modified instructions versus standard instructions	\N	United States of America	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
6082	Balow 1980	\N	hemodialysis versus sham dialysis	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6083	Imai 1980	\N	\N	\N	Japan	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6085	Corr 2000	\N	d-amphetamine (energetic arousal) versus d-amphetamine (hedonic tone)	\N	United Kingdom	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
6087	Wotman 1999	\N	monaural occlusion versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
6089	Bigelow 1978	\N	propranolol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
6090	Cante 1971	\N	\N	\N	Italy	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
6091	Macmillan 1984	\N	prophylactic neuroleptic medication versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
6093	Tsai 2000	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6094	McFarlane 2000	\N	family aided assertive community treatment + vocational services versus conventional vocational rehabilitation	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6095	Winnik 1962	\N	\N	\N	Israel	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6097	Hochstadt 1980	\N	letter proir to appointment group versus no letter prior to appointment	\N	United States of America	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
6099	Adler 1992a	\N	vitamin E versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
6100	Cavallaro 2001	\N	Risperidone versus Haloperidol	\N	Italy	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
6104	Sacristan 2001	\N	Olanzapine versus Haloperidol	\N	Spain	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
6106	Okuma 1985	\N	\N	\N	Japan	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6107	Bell 1998	\N	paid vocational rehabilitation versus non paid vocational rehabilitation	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
6108	Xu 2001 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
6109	Agelink 2001	\N	Amisulpride versus Clozapine	\N	Germany	\N	\N	\N	\N	\N	131	\N	\N	\N	\N	\N
6110	Diaz 2001 a	\N	Risperidone versus Antipsychotics	\N	United States of America	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	Unclear	\N	\N	\N	\N	\N
6112	Cole 1976	\N	deanol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6117	Ortega-Soto 1994	\N	Haloperidol versus Placebo	\N	Mexico	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
6118	Zimbroff 1997	\N	sertindole versus haldol	\N	United States of America//Canada	\N	\N	\N	\N	\N	497	\N	\N	\N	\N	\N
6119	Gitlin 2001	\N	fluphenazine decanoate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
6122	Kane 2002 b	\N	Haloperidol dose	\N	United States of America	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
6124	Ahmed 2000	\N	thioridazine versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
6127	Bernardo 2001	\N	Olanzapine versus Haloperidol	\N	Spain	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
6128	Daniel 2001 b	\N	Ziprasidone versus 2, 20 mgs	\N	United States of America	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
6129	George 2002 a	\N	nicotine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
6133	Barnas 2001	\N	zotepine versus open monotherapy	\N	Austria	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
6134	Hansson 2001	\N	integrated care program versus control group	\N	Sweden	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
6136	Blumberg 2001	\N	differentiation furthering intervention versus directed problem solving treatment program	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
6137	Sellwood 2001	\N	needs based cognitive behavioral family intervention + family support + standard care versus family support + standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6138	Shamir 2001 b	\N	melatonin versus Placebo	\N	Israel	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
6141	Walsh 2001 d	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
6142	Hadas-Lidor 2001	\N	instumental enrichment versus control group	\N	Israel	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
6146	Tracy 2001	\N	MUSE (medication adherence program) versus treatment as usual	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6151	Bruggeman 2002	\N	9-OH-Risperidone versus Risperidone	\N	Netherlands	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
6152	Holi 2002	\N	transcranial magnetic stimulation (Transcranial Magnetic Stimulation) versus sham transcranial magnetic stimulation (Transcranial Magnetic Stimulation)	\N	Finland	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
6154	Tiihonen 2002	\N	lamotrigine+ Clozapine versus lamatrigine + Risperidone	\N	Finland	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
6155	Addington 2002	\N	Ziprasidone versus Risperidone	\N	Australia	\N	\N	\N	\N	\N	296	\N	\N	\N	\N	\N
6158	Bai 2002 a	\N	Risperidone versus Placebo	\N	Taiwan	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
6160	Bilder 2002	\N	glycine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6162	Brown 2002	\N	discontinued neuroleptics + Quetiapine versus continued neuroleptics	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
6164	Carson 2002 b	\N	Aripiprazole versus Placebo	\N	Japan//United States of America	\N	\N	\N	\N	\N	310	\N	\N	\N	\N	\N
6165	Casey 2002	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
6166	Castilla 2002	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
6168	Conte 2002	\N	Risperidone + mood stabilizers versus Haloperidol + mood stabilizers	\N	Italy	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6172	David 2002 b	\N	IM Olanzapine versus IM Haloperidol, IM lorazepam, Placebo	\N	United States of America	\N	\N	\N	\N	\N	581	\N	\N	\N	\N	\N
6173	Gefvert 2002	\N	OSU6162 versus Placebo	\N	Sweden	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6174	Glaser 2002 a	\N	flupenthixol versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	153	\N	\N	\N	\N	\N
6175	Glaser 2002 b	\N	flupenthixol versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	153	\N	\N	\N	\N	\N
6176	Han 2002	\N	\N	\N	Germany	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
6183	Kinon 2002 a	\N	Olanzapine dose Olanzapine dose	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6184	Knapp 2002	\N	Amisulpride versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	310	\N	\N	\N	\N	\N
6185	Kujawa 2002	\N	Aripiprazole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	1294	\N	\N	\N	\N	\N
6188	Mauri 2002	\N	Olanzapine versus Quetiapine	\N	Italy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6189	McGorry 2002 a	\N	non specific psychosocial intervention + Risperidone versus non specific psychosocial intervention	\N	Australia	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
6190	Miceli 2002	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
6191	Mori 2002	\N	\N	\N	Japan	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
6193	Namjoshi 2002	\N	Olanzapine versus Haloperidol	\N	United States of America//United Kingdom	\N	\N	\N	\N	\N	364	\N	\N	\N	\N	\N
6194	Nasrallah 2002	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6195	Pivac 2002	\N	Olanzapine versus fluphenazine	\N	Croatia	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
6198	Schmidt 2002	\N	iloperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
6200	Sowell 2002	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6201	Young 2002 a	\N	Iloperidone versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6203	Otsuka 1978	\N	promethazine HCl versus methixene HCl	\N	Japan	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
6204	Ito 1974	\N	\N	\N	Japan	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
6205	Yagi 1974	\N	\N	\N	Japan	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
6206	Miyakawa 1973	\N	mesoridazine versus thioridazine	\N	Japan	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
6207	Itoh 1976	\N	\N	\N	Japan	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
6208	Yagi 1976	\N	Carpipramine + Chloropromazine versus Chloropromazine + Placebo//Chlorpromazine versus Placebo	\N	Japan	\N	\N	\N	\N	\N	351	\N	\N	\N	\N	\N
6209	Sugano 1985	\N	Timiperone versus Haloperidol	\N	Japan	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
6210	Okuda 1979 a	\N	CSG 6117	\N	Japan	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
6211	Nakazawa 1985	\N	\N	\N	Japan	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
6212	Itoh 1972	\N	\N	\N	Japan	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
6213	Yagi 1973	\N	\N	\N	Japan	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
6214	Hyugano 1986	\N	\N	\N	Japan	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
6215	Iwanaga 1980 a	\N	\N	\N	Japan	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
6216	Maeda 1972	\N	\N	\N	Japan	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6217	Samejima 1972	\N	Y-4153 versus carpipramine	\N	Japan	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
6219	Montero 2001	\N	behavioural family therapy versus relatives group	\N	Italy and Spain	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	87	\N	\N	\N	\N	\N
6220	Bell 2001 d	\N	paid vocational rehabilitation versus non paid vocational rehabilitation	\N	United States of America	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
6221	Smith 2001 b	\N	cigarette with high nicotine versus de-nicotinized cigarette	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
6222	Matthews 1981	\N	psychotherapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
6223	Cassity 1976	\N	music therapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
6224	Leff 2001	\N	family work package versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6225	Overall 1961	\N	imipramine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	204	\N	\N	\N	\N	\N
6226	Tourlentes  1958	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
6229	Blackburn 1981	\N	prochlorperazine versus Placebo//Chorpromazine versus Placebo//promazine versus Placebo//trifluoperazine versus Placebo//Chorpromazine versus prochlorperazine//promazine versus prochlorperazine// trifluoperazine versus prochlorperazine	\N	United States of America	\N	\N	\N	Note by Claire: Not versus placebo	\N	60	\N	\N	\N	\N	\N
6230	Hordern 1964	\N	thioproperazine versus Placebo	\N	Australia//New Zealand	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
6232	Lee 2001 b	\N	isapirone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
6233	Bertolino 2002	\N	Olanzapine + mirtazapine versus Olanzapine + Placebo	\N	Italy	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6234	Chiu 2002 a	\N	\N	\N	Canada	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
6236	Joffe 2002	\N	Clozapine + orlistat versus "Placebo + Chlorpromazine, Placebo + Clozapine"	\N	Finland	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
6242	Verdoux 2002	\N	\N	\N	France	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
6245	Spiegel 1987	\N	periodic family consultation versus standard care	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
6246	Ro-Trock 1977	\N	family therapy versus individual therapy	\N	United States of America	\N	\N	\N	\N	\N	24/28	\N	\N	\N	\N	\N
6248	Rüther 1988	\N	\N	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6254	Eckmann 1984	\N	perphenazine versus benperidol	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
6255	Ehlert 1988	\N	family education program versus problem solving training	\N	Germany	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
6256	Startup 2001 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
6258	Lunde	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6259	Haddock 1999	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus supporteive counselling//psychoeducation	\N	United Kingdom	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
6260	Rosenthal 2000 c	\N	assertive community treatment versus control group	\N	Israel//Switzerland//United States of America	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
6261	Arvanitis 1998a	\N	seroquel 75,150,300,600,750 mgs versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	169	\N	\N	\N	\N	\N
6263	Goldstein 1998 b	\N	Quetiapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	716	\N	\N	\N	\N	\N
6264	Mueser 2001 c	\N	supportive family management + fluphenazine versus applied family management +fluphenazine	\N	United States of America	\N	\N	\N	\N	\N	313	\N	\N	\N	\N	\N
6266	Marder 2002 a	\N	fluphenazine decanoate dose	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
6267	Chaudhry 2002	\N	cyproheptadine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
6268	Granholm 2002	\N	cognitive Behavioural social skills training + regular pharmacotherapy versus regular pharmacotherapy cognitive Behavioural social skills training + standard care versus standard care	\N	United States of America	\N	\N	\N	\r\nNotes2\r\ngroup cognitive behavioural social skills training versus individual cognitive behavioural social skills training	\N	15	\N	\N	\N	\N	\N
6269	Dahmen 2001	\N	Amisulpride versus flupentixol	\N	Germany	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
6270	Penn 2001	\N	use of politically correct label for schizophrenia versus use of less politically correct label for schizophrenia	\N	United States of America	\N	\N	\N	\N	\N	190	\N	\N	\N	\N	\N
6271	Ihalainen 1973	\N	\N	\N	Finland	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
6273	Kostakoglu 2001	\N	Olanzapine versus Chlorpromazine	\N	Turkey	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
6274	Svestka 1989 c	\N	sulpiride versus perphenazine	\N	Czech Republic	U Jan Evangelista Purkyne, Lekarska Fakulta, Psychiatricka Klinika, Brno, Czechoslovakia ORIGIN Other Europe	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
6279	Weiden 2002	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	270	\N	\N	\N	\N	\N
6283	Rymaszewska 2002	\N	day treatment versus inpatient treatment	\N	Poland	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
6285	Meltzer 2002 a	\N	Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	579	\N	\N	\N	\N	\N
6293	Modai 2002	\N	pindolol versus Placebo	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6296	David 2002 c	\N	IM Olanzapine versus IM Haloperidol, IM lorazepam, Placebo	\N	United States of America	\N	\N	\N	\N	\N	718	\N	\N	\N	\N	\N
6297	Currier 2002	\N	Risperidone + lorazepam versus Haloperidol + lorazepam	\N	United States of America	\N	\N	\N	\N	\N	162	\N	\N	\N	\N	\N
6299	Awad 2002	\N	Ziprasidone versus conventional Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	270	\N	\N	\N	\N	\N
6300	Richmond 2002	\N	zacopride versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
6301	Carpenter 2002	\N	fluphenazine decanoate injections every 2 weeks versus fluphenazine decanoate injections every 6 weeks	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6302	Hirshowitz 2002	\N	fluperlapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
6303	Marder 1993	\N	oral fluphenazine + intensive behavioral skills training versus Placebo + suportive group psychotherapy	\N	United States of America	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
6304	Hirsch 1993	\N	neuroleptic treatment versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
6306	Krystal 1993 b	\N	ketamine + lorazepam versus Placebo ketamine + Placebo lorazepam	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
6307	Potkin 1993 b	\N	Clozapine versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6308	Herz 1988	\N	intermittent medication protocol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
6310	Van Putten 1988	\N	Haloperidol dose	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
6311	Borison 1993	\N	savoxepine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
6312	inderbitzin 1993	\N	fluphenazine decanoate versus control group	\N	United States of America	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
6313	Krystal 1993 d	\N	ketamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
6314	Sharma 1993	\N	fenfluramine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6315	Kane 1993 b	\N	fluphenazine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	166	\N	\N	\N	\N	\N
6316	McEvoy 1993 a	\N	sertindole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
6317	Potkin 1993 a	\N	SDZ HDC 912 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
6318	Munroe-Blum 1993	\N	time-limited group social skills training program versus family group psychoeducation	\N	Canada	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
6319	Schooler 1993	\N	family management versus control group	\N	United States of America	\N	\N	\N	\N	\N	528	\N	\N	\N	\N	\N
6320	Johnston-Cronk 1993	\N	neuroleptic supplements versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
6322	Hirsch 1990	\N	intermittent treatment + depot neruoleptics versus intermittent treatment	\N	United Kingdom	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
6326	Awad 1988	\N	Haloperidol versus Chlorpromazine	\N	Canada	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
6327	Breier 1988 a	\N	neuroleptic treatment versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
6332	Rollnik 2000	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	Germany	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
6333	Fischel 2001	\N	cyproheptadine versus propranolol	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6334	Risch 1981	\N	methscopolamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
6335	Bai 2001	\N	pirenzepine versus Placebo	\N	Taiwan	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6336	Jones 2000 d	\N	quality assurance monitoring program versus control group	\N	United States of America	\N	\N	\N	\N	\N	146	\N	\N	\N	\N	\N
6337	Schooler 1995	\N	Clozapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
6340	Lecrubier 1994	\N	SND 919 versus Haloperidol	\N	France	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6341	Borovicka 2002	\N	Clozapine + phenylpropanolamine versus Clozapine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
6342	Angst 1971	\N	\N	\N	Switzerland	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
6344	George 2002 b	\N	Clozapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
6347	Burke 2002	\N	Risperidone versus Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
6349	Hayashi 2002	\N	group music therapy versus control group	\N	Japan	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
6350	Rosen 2002	\N	active medication versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
6351	Coelho 1993	\N	innovative community treatment model versus control group	\N	United States of America	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
6352	Mortimer 1994	\N	Clozapine versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
6353	Gillis 1981	\N	Chlorpromazine versus fluphenazine decanoate	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
6354	Dehnel 1968	\N	clopenthixol versus perphenazine	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
6355	Gallant 1968 b	\N	thiothixene versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
6357	Wolpert 1967	\N	thiothixene versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
6358	Cooper 1973	\N	Chlorpromazine hydrochloride versus Chlorpromazine embonate	\N	Canada	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
6360	Jones 2001 b	\N	IM Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
6362	Wiedemann 2001	\N	\N	\N	Germany	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
6364	Magliozzi 1985	\N	oral Haloperidol versus im Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
6366	Evins 2001 b	\N	Bupropion + cognitive behavioral therapy versus Placebo + cognitive behavioral therapy	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
6367	Goff 2001	\N	Ampakine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
6368	Potkin 2001 c	\N	Clozapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
6369	Potkin 2002 a	\N	fluoxetine + Quetiapine versus imipramine + Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
6370	Potkin 2002 b	\N	Quetiapine + Risperidone versus Quetiapine + Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
6371	Scheepers 2001	\N	m-chlorophenylpiperazine versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
6374	de Haan 2002	\N	Olanzapine versus Risperidone	\N	Netherlands	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
6375	Fairweather 1969	\N	new community versus usual community	\N	United States of America	\N	\N	\N	\N	\N	338	\N	\N	\N	\N	\N
6379	Iwahashi 1995	\N	carbamazepine versus Haloperidol	\N	Japan	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
6381	Payne  1960	\N	trifluopromazine versus Placebo//Chlorpromazine versus Placebo	\N	Canada	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
6382	McLoughlin 2001	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	United Kingdom	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
6383	Muller 1970	\N	\N	\N	Switzerland	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
6535	Clark 1969 b	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
6536	Clark 1969 c	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
6537	Ko 1989	\N	Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
6538	Hwang 2001	\N	zotepine versus Haloperidol	\N	Taiwan	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
6539	Merlis 1968 b	\N	SU-11279 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6540	Wolpert 1968 c	\N	thiothixene versus chlorprothixene	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6541	Lehmann 1969 a	\N	mandrax versus pentobarbital	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6543	Johnson 1970 b	\N	piperacetazine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
6544	Small 1970	\N	piperacetazine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
6545	Hollister 1970	\N	thiothixene versus oxypertine	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
6546	Hekimian 1970	\N	Butaperazine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6547	Gallant 1971 c	\N	oxilapine versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
6548	Gallant 1970 c	\N	piperacetazine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
6549	Clark 1971 b	\N	pimozide versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6550	Cole 1970 a	\N	Haloperidol versus Thioridazine	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
6551	Clark 1970 f	\N	molindone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
6552	Denber 1970	\N	oxilapine versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
6553	Gallant 1970 d	\N	piperacetazine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
6554	Freeman 1970	\N	Acetophenazine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
6555	Gershon 1970 b	\N	Chlorpromazine versus Lithium	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
6556	Kurland 1970 b	\N	piperacetazine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
6558	Lehmann 1970 d	\N	thiothixene versus clopenthixol	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6559	Lapolla 1969	\N	acetophenazine versus thioridazine hydrochloride	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
6560	Lehmann 1969 b	\N	CI-601 versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6561	Lehmann 1969 c	\N	niacin versus Placebo	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6562	Lehmann 1970 e	\N	thiothixene versus clopenthixol	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6563	Lehmann 1970 f	\N	niacin versus Placebo	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
20248	李育军1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
6565	Denber 1969	\N	acetophenazine versus thioridazine	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
6566	Cole 1970 b	\N	metrazol versus niacin	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
6689	Meisler 2002	\N	assertive community treatment	\N	United States of America	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
6567	Wolpert 1968 d	\N	triiodothyronine + phenothiazine versus Placebo + phenothiazine	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6568	Itil 1969 b	\N	thiothixene versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
6569	Krumholz 1969	\N	LAXX versus carphenazine	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
6572	Harrison-Read 2002	\N	enhanced community management versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	193	\N	\N	\N	\N	\N
6573	Merlo 2002 b	\N	Risperidone versus various doses	\N	Switzerland	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
6574	Javitt 2001	\N	glycine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
6575	Meltzoff 1966	\N	day treatment center versus conventional outpatient treatment	\N	United States of America	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
6578	Yang 2002 a	\N	Haloperidol + Nicotine versus Haloperidol + Placebo	\N	Taiwan//United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6579	Cozolino 1988	\N	educational program versus control group	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
6580	Swift 2002	\N	Ziprasidone Dosage // Haloperidol versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	117 // 79 // 306	\N	\N	\N	\N	\N
6581	Nejtek 2002	\N	Quetiapine versus neuroleptics	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
6584	Smith 2001 a	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
6585	Simopoulos 1974	\N	diphenylhydantoin	\N	United States of America	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
6586	George 2002 c	\N	Bupropion versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
6587	Hirsch 2002	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6588	Shon 2002	\N	Community Re-Entry Program versus Illness Education Classes	\N	South Korea	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
6589	Gensthaler 2001	\N	\N	\N	Germany	\N	\N	\N	\N	\N	153	\N	\N	\N	\N	\N
6590	Basdekis 2000	\N	\N	\N	Germany	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
6592	Amminger 2002	\N	\N	\N	Australia	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
6593	Rosenbaum 2002	\N	supportive psychodynamic psychotherapy + standard care versus standard care	\N	Denmark	\N	\N	\N	\N	\N	563	\N	\N	\N	\N	\N
6596	Kryzhanovskaya 2002	\N	Olanzapine versus conventional Antipsychotic or Risperidone	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6599	Lecomte 2002	\N	group Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus group symptom management	\N	United Kingdom // United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6600	Szmukler 1999	\N	carers' support programme	\N	United Kingdom	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
6601	de Lima 2002	\N	Olanzapine	\N	Brazil	\N	\N	\N	\N	\N	167	\N	\N	\N	\N	\N
6602	Linszen 2002 b	\N	sustained intervention programs	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6603	Baker 2002 e	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy)	\N	Australia	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
6604	McGlashan 2002 b	\N	Olanzapine	\N	Canada//United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6606	Morrison 2002 c	\N	early detection inntervention	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6607	Perro 2002	\N	Amisulpride versus Olanzapine // Amisulpride versus Risperidone // Amisulpride versus Zotepine // Olanzapine versus Risperidone // Olanzapine versus Zotepine // Risperidone versus Zotepine	\N	Germany	\N	\N	\N	\N	\N	123	\N	\N	\N	\N	\N
6608	McGorry 2002 c	\N	Risperidone versus Risperidone + lithium	\N	Australia	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
6609	Lenior 2002 a	\N	standard intervention + family intervention versus standard intervention	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6611	Zimbroff 2002	\N	Ziprasidone IM	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6613	Velligan 2002 a	\N	Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6614	Tandon 2002 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
6615	Shelley 2002	\N	symptom specific group therapy	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6616	Romano 2002	\N	Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6618	Okereke 2002	\N	donepezil HCl	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6620	Meltzer 2002 c	\N	Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6622	Kolivakis 2002	\N	Risperidone	\N	Canada	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6623	Kirwan 2002	\N	Risperidone	\N	New Zealand	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6626	Sirota 2002	\N	fluvoxamine + conventional neuroleptics	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6628	Simpson 2002 c	\N	Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	222	\N	\N	\N	\N	\N
6629	Toprac 2002	\N	intensive case management	\N	United States of America	\N	\N	\N	\N	\N	247	\N	\N	\N	\N	\N
6630	Young 2002 c	\N	Education: intensive education + structured dialogue + consultation + technical assistance	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6632	Wirshing 2002 a	\N	Community Re-Entry Program 	\N	United States of America	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
6635	Druss 2002	\N	integrated care	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6636	Felker 2002	\N	integrated care	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6637	Dixon 2002 a	\N	integrated primary care	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6638	Glick 2002 b	\N	Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6640	Ferenc 2002	\N	fluphenazine	\N	Austria	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6642	Engelhart 2002	\N	Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6643	Duval 2002	\N	Risperidone	\N	France	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
6644	Dunn 2002	\N	enhanced consent procedure	\N	United States of America	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
6648	David 2002 d	\N	IM Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6649	Daniel 2002 a	\N	switch from Olanzapine, and Risperidone	\N	United States of America	\N	\N	\N	\N	\N	222	\N	\N	\N	\N	\N
6650	Daniel 2002 b	\N	oral Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6655	Cavazzoni 2002 b	\N	Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	473	\N	\N	\N	\N	\N
6656	Castle 2002 b	\N	group Cognitive Behavioural Therapy (Cognitive Behavioral Therapy)	\N	Australia	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
6658	Castilla-Puente 2002	\N	therapy group	\N	United States of America	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
6660	Buckley 2002	\N	Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
6661	Breier 2002 b	\N	Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6662	Breier 2002 c	\N	Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6663	Breier 2002 d	\N	nizatidine + Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
6664	Berk 2002 a	\N	mirtazapine + Haloperidol	\N	South Africa	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6665	Bell 2002	\N	neurocognitive enhancement therapy + work therapy	\N	United States of America	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
6666	Aquila 2002	\N	conventional Antipsychotic	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
6667	Ananth 2002	\N	Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6673	Rosenberg 2002 a	\N	sildenafil	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6675	Shamir 2002	\N	melatonin	\N	Israel	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
6676	Schooler 2002	\N	Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	222	\N	\N	\N	\N	\N
6677	Sajatovic 2002	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	751	\N	\N	\N	\N	\N
6678	Sikich 2002 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6684	Risch 2002	\N	donepezil	\N	United States of America	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
6685	Rector 2002	\N	cognitive therapy + standard care	\N	Canada	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
6692	Hoffman 2002	\N	transcranial magnetic stimulation (Transcranial Magnetic Stimulation)	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
6693	Hellerstein 2002	\N	integrated abuse services	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
6694	Harvey 2002 g	\N	Olanzapine, Risperidone	\N	United States of America	\N	\N	\N	\N	\N	222	\N	\N	\N	\N	\N
6695	Keith 2002	\N	fluphenazine decanoate	\N	United States of America	\N	\N	\N	\N	\N	313	\N	\N	\N	\N	\N
6698	Koenigsberg 2002 a	\N	Risperidone	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
6700	Lehman 2002	\N	individual placement and support	\N	United States of America	\N	\N	\N	\N	\N	219	\N	\N	\N	\N	\N
6704	Marder 2002 b	\N	behavioural skills + Risperidone versus group psychotherapy + Haloperidol	\N	United States of America//Canada	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
6705	Marder 2002 c	\N	behavioural skills + Risperidone versus group psychotherapy + Haloperidol	\N	United States of America//Canada	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6708	Masand 2002	\N	Atypical Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6710	McFarlane 2002	\N	family aided assertive community treatment + vocational services	\N	United States of America	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
6714	Heck 2000	\N	Risperidone versus Haloperidol	\N	Netherlands	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
6715	Schooler 1971	\N	Chlorpromazine versus Fluphenazine // Acetophenazine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	480	\N	\N	\N	\N	\N
6717	Jerrell 1995 b	\N	assertive community treatment versus supplemental case management	\N	Colombia	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
6719	Chue 2002 b	\N	oral Risperidone versus IM Risperidone	\N	Belgium	\N	\N	\N	\N	\N	397	\N	\N	\N	\N	\N
6720	Hale 2002	\N	sertindole versus Haloperidol	\N	Denmark//United Kingdom	\N	\N	\N	\N	\N	617	\N	\N	\N	\N	\N
6721	Fairweather 2002	\N	iloperidone versus Haloperidol	\N	Switzerland	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
6723	Azorin 2002	\N	sertindole versus Risperidone	\N	France	\N	\N	\N	\N	\N	186	\N	\N	\N	\N	\N
6724	Auby 2002	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
6726	Veser 2002	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
6728	Strous 2002	\N	Olanzapine+ DHEA versus Olanzapine + Placebo	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6729	Rein 2002	\N	Amisulpride versus Risperidone	\N	France	\N	\N	\N	\N	\N	244	\N	\N	\N	\N	\N
6730	Poyurovsky 2002 b	\N	reboxetine + Olanzapine versus Placebo + Olanzapine	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6731	Poyurovsky 2002 c	\N	mirtazapine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
6733	Murasaki 2002	\N	AD-5423 versus Haloperidol	\N	Japan	\N	\N	\N	\N	\N	265	\N	\N	\N	\N	\N
6736	Martins 2002	\N	Amisulpride versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	377	\N	\N	\N	\N	\N
6737	Loza 2002	\N	Atypical Antipsychotics versus typical Antipsychotics	\N	Poland	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
6739	Jockers-Scherübl2002	\N	paroxetine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
6740	Schiele 1961	\N	thioridazine versus Placebo//Chlorpromazine versus Placebo//Trifluoperazine versus Placebo//thioridazine versus Chlorpromazine//Trifluoperazine versus thioridazine	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
6743	Reynolds 2002 a	\N	transitional discharge versus inpatient and community care overlap	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6748	Azhar 2000	\N	Risperidone versus Haloperidol	\N	Malaysia	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6751	Goldstein 1999	\N	Quetiapine versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	288	\N	\N	\N	\N	\N
6752	O'Connor 1999 b	\N	Ziprasidone versus various dosages	\N	United States of America//United Kingdom	\N	\N	\N	\N	\N	201	\N	\N	\N	\N	\N
6753	Robinson 1999 a	\N	clinician assessments versus independent assessor assessments	\N	United States of America	\N	\N	\N	\N	\N	313	\N	\N	\N	\N	\N
6754	Smith 1999 b	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6755	Buchsbaum 1998	\N	sertindole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
6756	Dalack 1998	\N	smoking ad libitum versus no smoking	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
6757	Lee 1998 b	\N	apomorphine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
6758	Stankovska 2002	\N	Risperidone versus Placebo	\N	Macedonia	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
6759	Soygur 2002	\N	optimal clinical management versus standard care	\N	Turkey	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
6763	Morrison 2002 d	\N	early detection inntervention versus cognitive therapy	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6764	Mizuno 2002	\N	psychoeducation versus control group	\N	Japan	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
6765	Lu 2002 a	\N	\N	\N	China	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
6768	King 2002 b	\N	Olanzapine versus flupenthixol	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6769	Haldun 2002	\N	optimal clinical management versus routine case management	\N	Turkey	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
6770	Gaebel 2002 a	\N	Risperidone versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	809	\N	\N	\N	\N	\N
6772	El-shafei 2002	\N	educational program versus control group	\N	Egypt	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
6773	Dittmann 2002 a	\N	Olanzapine versus flupenthixol	\N	Germany	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6774	Dejanovic 2002	\N	Clozapine versus Haloperidol	\N	Yugoslavia	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
6775	Dan 2002	\N	Cognitive Behavioural Training versus control group	\N	Romania	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
6779	Peuskens 1992	\N	Risperidone versus Haloperidol	\N	Spain	\N	\N	\N	\N	\N	1362	\N	\N	\N	\N	\N
6780	Klieser 1991 a	\N	Risperidone versus Clozapine	\N	Germany	Psychiatrische Klinik der Heinrich Heine Universitat Dusseldorf.\r\n\r\nGermany	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
6781	Borison 1991 b	\N	Risperidone versus Placebo	\N	United States of America//France	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
6782	Wolf 2002	\N	Olanzapine versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
6783	Trivedi 2002	\N	Risperidone versus Haloperidol	\N	India	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
6784	Tang 2002 a	\N	Modified Morita therapy versus Conventional rehabilitation therapy	\N	China	\N	\N	\N	\N	\N	182	\N	\N	\N	\N	\N
6787	Solomon 1963	\N	carphenazine versus phenothiazines	\N	United States of America	\N	\N	\N	\N	\N	457	\N	\N	\N	\N	\N
6788	Druss 2001	\N	integrated care versus general clinic	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
6790	Arvanitis 1998b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	501	\N	\N	\N	\N	\N
6791	Poyurovsky 2003 b	\N	reboxetine + Olanzapine versus Placebo + Olanzapine	\N	Israel	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
6792	de Haan 2003	\N	Olanzapine versus Haloperidol	\N	Netherlands	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
6795	Baymiller 2002	\N	Clozapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
6798	Croudace 2003	\N	primary health care diagnostic and management guidelines versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6799	Kern 2002 a	\N	errorless learning versus conventional instruction	\N	United States of America	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
6800	Moran 2003	\N	intensive case management versus standard case management	\N	United Kingdom	\N	\N	\N	\N	\N	670	\N	\N	\N	\N	\N
6803	Papageorgiou 2002	\N	completion of an advancxe directive + usual care versus usual care	\N	United Kingdom	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
6805	Desta 2002	\N	hydroxychloroquine versus Placebo	\N	Ethiopia	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
6806	Liberman 2002 b	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
6807	Godoy 1990	\N	dichotic listening procedure- signal versus dichotic listening procedure- story	\N	Spain	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
20341	陈时平 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
6809	Richardson 2002 a	\N	interactive art therapy + standard treatment versus standard treatment	\N	United Kingdom	Head of Psychology, The Tavistock Clinic, 120 Belsize Lane, London, NW3 5BA. Telephone: 020 74473834. Project related web site: http://www.doh.gov.uk/ntrd/rd.htm\r\n\r\nCo-ordinated Psychological Treatments Service, Lewisham &amp; Guy's Mental Health NHS Trust, York Clinic, Guy's Hospital, 117 Borough High Street, London. Telephone: 0171 955 4933. Fax: 0171 955 4433\r\n\r\nAdolescent Department, Tavistock &amp; Portman NHS Trust, 120 Belsize Lane, London, NW3 5BA. E-mail: prichardson@tavi-port.org. Project related web site: http://www.tavi-port.org. Updates N0466045336, should replace N0126012252 and F0300311 which are dupl	\N	\N	\N	\N	175	\N	\N	\N	\N	\N
6813	Shiloh 2002	\N	mianserin versus Placebo	\N	Israel	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
6814	Godleski 2003	\N	Olanzapine versus depot Antipsychotic	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
6815	Lee 2002 a	\N	Olanzapine versus typical Antipsychotics	\N	Philippines//Singapore//Taiwan//Thailand//Australia//Hong Kong//Malaysia	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
6816	Goldberg 2000	\N	neuroleptic medications versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
6819	Dixon 2002 b	\N	individual placement and support versus vocational rehabilitation	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
6820	Shin 2002	\N	psychoeducation + supportive thearapy versus supportive thearapy	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
6821	Hoffman 2003	\N	transcranial magnetic stimulation (Transcranial Magnetic Stimulation) versus sham transcranial magnetic stimulation (Transcranial Magnetic Stimulation)	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
6823	Bellucci 2003	\N	computer-assisted cognitive rehabilitation versus control group	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
6824	Lieberman 2003 c	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	164	\N	\N	\N	\N	\N
6825	Moller 1992 a	\N	Risperidone versus Placebo	\N	France	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6827	Pancheri 1992	\N	Risperidone versus Haloperidol	\N	France	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
6828	Andris 1997	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	523	\N	\N	\N	\N	\N
6829	Anonymous a	\N	\N	\N	France	\N	\N	\N	\N	\N	365	\N	\N	\N	\N	\N
6830	Anonymous b	\N	\N	\N	France	\N	\N	\N	\N	\N	407	\N	\N	\N	\N	\N
6833	Szmukler 2003	\N	carers' support programme versus standard treatment	\N	United Kingdom	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
6834	Agib 2002	\N	conventional Antipsychotic versus Atypical Antipsychotic	\N	United Kingdom	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
6835	p	\N	Ziprasidone versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6836	Barker 2001	\N	self-help intervention package versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	800	\N	\N	\N	\N	\N
6837	Barnes 2002	\N	Amisulpride versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
6838	Beer 2002	\N	Clozapine + Amisulpride versus Clozapine + Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
6839	Birchwood 2002	\N	early detection intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
6840	Britto 2002	\N	Ziprasidone versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
6842	Burns 2002 b	\N	cognitive neuroimaging versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
6843	Byng 2002	\N	gps services versus secondary services	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6844	Coburn 2002	\N	flash cards versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6845	Cookson 2002	\N	Ziprasidone versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6846	Craig 2001	\N	assertive outreach versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6847	Drury 2002	\N	cognitive therapy versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6848	Fallon 2002 a	\N	detection and prevention treatment strategies	\N	United Kingdom	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
6849	Wykes 2002 b	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6850	Woodruff 2002	\N	Ziprasidone versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6851	Watson 2002	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
6852	Tyrer 2002	\N	psychiatric services delivered in primary care versus psychiatric services delivered in secondary care	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6853	Turner 2002	\N	Ziprasidone versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6854	Thornicroft 2002 a	\N	dual diagnosis trained case manager versus untrained case managers	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6855	Taylor 2002	\N	typical Antipsychotics versus Atypical Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
6856	Tarrier 2002	\N	group cognitive behavioral therapy (Cognitive Behavioral Therapy) versus not stated	\N	United Kingdom	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
6858	Singh 2002 a	\N	Ziprasidone versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6859	Singh 2002 b	\N	sildenafil versus not stated	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6863	Painter 2001	\N	coping strategy enhancement versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
6866	Meaden 2002	\N	Cognitive Behavioural Training versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6867	McKenna 2002	\N	Risperidone + Clozapine versus Placebo + Clozapine	\N	United Kingdom	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
6868	Lloyd 2002	\N	Risperidone versus neuroleptics	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6869	Lewis 2002 b	\N	Cognitive Behavioural Training versus monitoring only	\N	United Kingdom	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
6870	Kingdon 2002 b	\N	vocational advisors versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
6871	King 2002 c	\N	assertive outreach versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
6872	Kelly 2002	\N	high fruit & vegetable diet versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6873	Joyce 2002	\N	Atypical Antipsychotics versus typical Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	25-50	\N	\N	\N	\N	\N
6875	Hemingway 2002	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6876	Gumley 2002	\N	individualized early signs monitoring versus standard early signs monitoring	\N	United Kingdom	\N	\N	\N	\N	\N	170	\N	\N	\N	\N	\N
6877	Graham 2001	\N	intensive case management versus standard case management	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6878	Godfrey 2002	\N	hormone replacement therapy + treatment as usual versus treatment as usual	\N	United Kingdom	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
6879	George 2001 a	\N	Ziprasidone versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6882	Fowler 2002	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus family intervention	\N	United Kingdom	\N	\N	\N	\N	\N	505	\N	\N	\N	\N	\N
6883	Jackson 2001 b	\N	anger management program versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
6884	Patterson 2003	\N	functional adaptation skills training versus standard care	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
6885	Evins 2000 b	\N	Clozapine + glycine versus Clozapine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
6886	Bechdolf 2000	\N	\N	\N	Germany	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6888	Ohno 2000	\N	\N	\N	Japan	\N	\N	\N	\N	\N	145	\N	\N	\N	\N	\N
6889	Vauth 2001	\N	\N	\N	Switzerland	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
6891	Goswami 2001 a	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus sham Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	India	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6892	Jasovic-Gasic 1991	\N	mianserin versus Placebo	\N	Yugoslavia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6893	Kudoh 2002	\N	ketamine versus fentanyl	\N	Japan	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
6894	French 1999	\N	theraputic community versus standard care	\N	United States of America	\N	\N	\N	\N	\N	342	\N	\N	\N	\N	\N
6897	Finzen 2002	\N	\N	\N	Germany	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6898	Schiller 2000	\N	mandatory drug screening versus standard care	\N	United States of America	\N	\N	\N	\N	\N	392	\N	\N	\N	\N	\N
6899	Harvey 2002 a	\N	intensive case management versus standard case management	\N	United Kingdom	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
19409	王艳 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
6900	Dyck 2002	\N	multifamily psychoeducation versus control group	\N	United States of America	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
6901	Bowen 1994	\N	putative Antipsychotic drug versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
6902	Dekker 2002	\N	assertive community treatment versus control group	\N	Netherlands	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
6903	Barak 2002	\N	Olanzapine versus Haloperidol	\N	Israel	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6904	Klinkenberg 2002	\N	3 month recall condition versus 6 month recall condition	\N	United States of America	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
6906	Risch 2001	\N	donepezil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6907	Sechter 2002	\N	Amisulpride versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	310	\N	\N	\N	\N	\N
6908	Su 2002 a	\N	Sulpiride versus Haloperidol	\N	Taiwan	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6909	Boczkowski 1985	\N	behavioural-tailoring intervention versus psychoeducational intervention	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
6910	Haggstrom 1980	\N	Sulpiride Dosage	\N	Sweden	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
6912	Carranza 1974	\N	sulpiride versus thioridazine	\N	Mexico	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
6913	Benoit 1969	\N	\N	\N	France	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
6914	Kawamura 1972	\N	\N	\N	Japan	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
6915	Schlosser 2002	\N	Amisulpride versus flupenthixol	\N	Germany	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
6917	Rein 1998 a	\N	Amisulpride versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
6918	Rein 1998 b	\N	Amisulpride versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
6919	Rein 1998 c	\N	Amisulpride versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
6921	Pichot 1989	\N	Amisulpride versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
6923	DEFASLP	\N	Amisulpride versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	243	\N	\N	\N	\N	\N
6924	Anonymous 1984 a	\N	Amisulpride versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6925	Anonymous 1984 b	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6928	Rein 1996 a	\N	Amisulpride versus Haloperidol	\N	France	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
6929	Moller 1997 b	\N	Amisulpride versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	228	\N	\N	\N	\N	\N
6930	Patel 1995	\N	sulpiride versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
6931	Daniel 1996	\N	sertindole versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	497	\N	\N	\N	\N	\N
6932	Casey 1979	\N	sulpiride versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
6933	Kallert 2002 a	\N	social integration versus control group	\N	Poland	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6936	DiNitto 2002	\N	integrated treatment versus control group	\N	United States of America	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
6937	Lima 2003	\N	Olanzapine versus typical Antipsychotics	\N	Brazil	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
6938	Swanson 1999	\N	motivational intervention versus standard care	\N	United States of America	\N	\N	\N	\N	\N	121	\N	\N	\N	\N	\N
6940	Bryson 2002	\N	paid vocational rehabilitation program versus non paid vocational rehabilitation program	\N	United States of America	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
6941	Corrigan 2002	\N	stigma conditions questionnaires	\N	United States of America	\N	\N	\N	\N	\N	213	\N	\N	\N	\N	\N
6942	Velligan 2002 b	\N	Cognitive Adaptation Training versus standard outpatient treatment	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
6943	Munjiza 1998	\N	Benzodiazepine group versus classical Antipsychotics group	\N	Yugoslavia	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
6944	Wolkowitz 1993	\N	alprazolam + neuroleptic versus Placebo + neuroleptic	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
6945	Janicak 1993	\N	Haloperidol dose	\N	United States of America	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
6946	Murphree 1967	\N	oral pentobarbital versus intravenous thiopental	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6947	Casey 2003	\N	Antipsychotics + valporate versus Antipsychotic treatment + Placebo	\N	United States of America	\N	\N	\N	\N	\N	249	\N	\N	\N	\N	\N
6948	Tsuang 2002	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
6949	Pesco-Koplowitz 1999	\N	Risperidone + donepezil versus donepezil	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
6950	Friedman 1999	\N	neuroleptics + guanfacine versus neuroleptics + Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
6951	Mullen 1998	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	751	\N	\N	\N	\N	\N
6953	Talbot 2001	\N	tryptophan depletion versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
6954	Anonymous 1993 c	\N	Risperidone versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6955	Mosholder 1996	\N	Quetiapine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	2635	\N	\N	\N	\N	\N
6956	Lahti 2003	\N	Clozapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
6959	Andreason 1996	\N	Olanzapine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
6961	Huttunen 1994	\N	Risperidone versus zuclopenthixol	\N	Finland	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
6965	Gomez 2000	\N	Olanzapine versus typical Antipsychotics	\N	Unclear	\N	\N	\N	\N	\N	904	\N	\N	\N	\N	\N
6968	Lauriello 2001	\N	fluoxetine + Olanzapine versus Olanzapine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
6971	Gumley 2003 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + standard care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
6973	Beasley 2001	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	6374	\N	\N	\N	\N	\N
6980	Castle 2003	\N	group-based intervention versus control group	\N	Australia	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
6981	Morrison 2003 a	\N	early detection inntervention versus cognitive therapy	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
6985	Buchanan 2003	\N	Clozapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
6986	Bryson 2003	\N	individualized computer based cognitive remediation therapy versus cognitive remediation therapy	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
6988	Bennett 2003	\N	supportive therapy group versus control group	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
6989	Benattia 2003	\N	Ziprasidone versus Risperidone	\N	Australia//Canada//United States of America	\N	\N	\N	\N	\N	296	\N	\N	\N	\N	\N
6990	Bell 2003 a	\N	neurocognitive enhancement therapy + work therapy versus work therapy	\N	United States of America	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
6993	Ascher-Svanum 2003	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	1996	\N	\N	\N	\N	\N
6995	O'Keefe 2003	\N	workplace fundamental module- regular attendance versus workplace fundamental module- sporadic attendance	\N	United States of America	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
6996	Ogasa 2003	\N	Lurasidone Dosage // Lurasidone versus Placebo	\N	United States of America // Japan	\N	\N	\N	\N	\N	149	\N	\N	\N	\N	\N
7177	Uzun 2002 c	\N	Ziprasidone versus Risperidone	\N	Croatia	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
6997	Parepally 2003	\N	Quetiapine versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
6998	Perez 2003	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
6999	Pondrom 2003	\N	Ziprasidone versus Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
7000	Potkin 2003 b	\N	Aripiprazole Dosage // Aripiprazole versus Risperidone // Aripiprazole versus Placebo // Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	404	\N	\N	\N	\N	\N
7001	Prentice 2003	\N	interactive educational intervention versus social skill training	\N	United States of America	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7002	Renshaw 2003	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
7004	Rossotto 2003	\N	community re-entry program versus control group	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
7005	Sergi 2003	\N	errorless learning versus conventional instruction	\N	United States of America	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7007	Smelson 2003	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
7008	Smith 2003	\N	training in semantic strategies versus no intervention	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
7009	Stein 2003	\N	customary care with sponsorship versus customary care	\N	United States of America	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
7010	Sumiyoshi 2003 a	\N	buspirone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7012	Weiner 2003	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7015	Wunderink 2003	\N	short Antipsychotic treatment versus sustained Antipsychotic treatment	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7019	Centorrino 2003	\N	Olanzapine versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
7021	Docherty 2003	\N	Risperidone versus Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	675	\N	\N	\N	\N	\N
7022	Edwards 2003	\N	early psychosis prevention intervention versus control group	\N	Australia	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
7024	Farhall 2003	\N	recovery therapy versus control group	\N	Australia	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
7025	Fiszdon 2003	\N	neurocognitive enhancement therapy + work therapy versus work therapy	\N	United States of America	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
7026	Gaither 2003	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
7027	Ganguli 2003	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	123	\N	\N	\N	\N	\N
7028	Gharabawi 2003	\N	oral Risperidone + lorazepam versus IM Haloperidol + lorazepam	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
7097	Chengappa 2003 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
7030	Hoffman 2003  a	\N	transcranial magnetic stimulation (Transcranial Magnetic Stimulation) versus sham transcranial magnetic stimulation (Transcranial Magnetic Stimulation)	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
7032	Jenner 2003	\N	hallucinatinon integrated treatment versus usual care	\N	Netherlands	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7033	Jin 2003 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
7034	Josiassen 2003	\N	Risperidone + Clozapine versus Placebo + Clozapine	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7036	Kelleher 2003	\N	pramipexole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
7037	Kern 2003	\N	errorless learning versus conventional instruction	\N	United States of America	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
7038	Khanna 2003	\N	Ziprasidone versus Chlorpromazine	\N	India//United States of America	\N	\N	\N	\N	\N	307	\N	\N	\N	\N	\N
7040	Kollack-Walker 2003	\N	Olanzapine dose	\N	United States of America	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7043	Lahti 2003 a	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
7044	Lenior 2003	\N	standard intervention + family intervention versus standard intervention	\N	Netherlands	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
7046	Linszen 2003	\N	integrated outpatient treatment program versus control group	\N	Netherlands	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
7047	Marder 2003	\N	Clozapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
7049	Addington 2003	\N	Ziprasidone versus Risperidone	\N	Australia//Canada//Ireland//United States of America	\N	\N	\N	\N	\N	296	\N	\N	\N	\N	\N
7050	Canuso 2003	\N	long acting Risperidone versus oral Risperidone	\N	United States of America	\N	\N	\N	\N	\N	640	\N	\N	\N	\N	\N
7052	Deberdt 2003	\N	Amantadine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
7053	Evins 2003 a	\N	Bupropion versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
7054	Hackman 2003	\N	assertive community treatment versus standard care	\N	United States of America	\N	\N	\N	\N	\N	500+	\N	\N	\N	\N	\N
7055	Kane 2003 b	\N	long acting Atypical antyipsychotics versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7056	Kane 2003 a	\N	Aripiprazole versus perphenazine	\N	United States of America//Canada	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
7059	Kinon 2003 b	\N	Olanzapine versus conventional Antipsychotic	\N	United States of America	\N	\N	\N	\N	\N	293	\N	\N	\N	\N	\N
7068	Motlova 2003	\N	group psychoeducation versus family psychoeducational programs	\N	Czech Republic	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
7069	Poyurovsky 2003 a	\N	reboxetine + Olanzapine versus Placebo + Olanzapine	\N	Israel	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
7070	Renshaw 2003 a	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
7071	Turkington 2003 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus befriending	\N	United Kingdom	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
7072	Ball 2003	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7075	Zhong 2003 a	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	673	\N	\N	\N	\N	\N
7076	de Leon 2003	\N	Clozapine dose	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7077	Brown 2003	\N	discontinued Antipsychotics versus continued Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
7078	Battaglia 2003	\N	IM Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
7079	Montgomery 2003	\N	Olanzapine versus Risperidone	\N	Australia	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
7081	Smelson 2003 a	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
7082	Rodriguez 2003	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	202	\N	\N	\N	\N	\N
7083	McGlashan 2003	\N	Olanzapine versus Placebo	\N	Canada//United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7086	Jones 2003 a	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
7088	Hussain 2003	\N	rivastigmine versus galantamine	\N	Canada	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
7089	Gehrs 2003	\N	assertive community treatment versus intensive case management	\N	Canada	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7090	Bossie 2003 a	\N	long acting Risperidone versus oral Risperidone	\N	United States of America	\N	\N	\N	\N	\N	261	\N	\N	\N	\N	\N
7091	Smith 2003 a	\N	nicotine nasal spray versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7092	Smith 2003 b	\N	rapid dose escalation of Quetiapine in 2, 3 days versus rapid dose escalation of Quetiapine in 3, 5 days	\N	United States of America	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
7179	Jhee 2003	\N	Lurasidone Dosage	\N	United States of America	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
7093	Brook 2003	\N	Intramuscular Ziprasidone versus Intramuscular Haloperidol	\N	South Africa	\N	\N	\N	\N	\N	567	\N	\N	\N	\N	\N
7095	Richardson 2003	\N	branched-chain amino acids versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
7098	O'Donnell 2003 a	\N	compliance therapy versus control group	\N	Republic of Ireland	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
7099	Kumari 2003	\N	procyclidine + Risperidone versus procyclidine + Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
7101	McQuade 2003	\N	Aripiprazole versus Placebo Aripiprazole versus Olanzapine	\N	Japan//United States of America and United States of America	\N	\N	\N	\r\nUser defined 3\r\n	\N	317	\N	\N	\N	\N	\N
7102	Bossie 2003 b	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	695	\N	\N	\N	\N	\N
7103	Poyurovsky 2003 c	\N	mirtazapine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
7104	Taymeeyapradit 2002	\N	Haloperidol versus Zuclopenthixol Acetate	\N	Thailand	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
7106	Al Haddad 1996	\N	Haloperidol versus Zuclopenthixol	\N	Bahrain	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
7107	Nahas 2003	\N	donepezil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
7108	Durham 2003	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + standard care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
7109	CATIE	\N	Clozapine versus Fluphenazine Decanoat // Clozapine versus Olanzapine // Clozapine versus Perphenazine // Clozapine versus Quetiapine // Clozapine versus Risperidone // Clozapine versus Ziprasidone // Fluphenazine Decanoat versus Olanzapine // Fluphenazine Decanoat versus Perphenazine // Fluphenazine Decanoat versus Quetiapine // Fluphenazine Decanoat versus Risperidone // Fluphenazine Decanoat versus Ziprasidone // Olanzapine versus Perphenazine // Olanzapine versus Quetiapine // Olanzapine versus Risperidone // Olanzapine versus Ziprasidone // Perphenazine versus Quetiapine // Perphenazine versus Risperidone // Perphenazine versus Ziprasidone // Quetiapine versus Risperidone // Quetiapine versus Ziprasidone // Risperidone versus Ziprasidone	\N	United States of America // Canada	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	1460	\N	\N	\N	\N	\N
7110	Pickar 2003	\N	Clozapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
7112	Tugal 2003	\N	donepezil adjunctive versus Placebo	\N	Turkey	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
7113	Wright 2003 a	\N	intramuscular Olanzapine versus intramuscular Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
7115	Velligan 2003 a	\N	Quetiapine versus conventional Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7116	Jerrell 2002	\N	Risperidone versus Antipsychotics	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	108	\N	\N	\N	\N	\N
7117	Ritchie 2003 a	\N	Risperidone versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
7118	Swenson 1988	\N	letter proir to appointment group versus no letter prior to appointment	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
7119	Duncan 1990	\N	nifedipine versus 30-60 mgs	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
7120	Beck 1967	\N	one treatment therapist versus two treatment therapists	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
7122	Van Der Gaag 1994	\N	cognitive remediation versus leisure	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
7123	Kris 1965	\N	day hospital treatment versus inpatient treatment	\N	United States of America	\N	\N	\N	\N	\N	141	\N	\N	\N	\N	\N
7124	Drake 1993	\N	social network case management versus control group	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
7125	Claghorn 1969	\N	molindone versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7126	Mielke 1977	\N	molindone versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
7128	Weiden 2003 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	270	\N	\N	\N	\N	\N
7131	Miceli 2003	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
7133	Intersept 2003	\N	Clozapine versus Olanzapine	\N	France	\N	\N	\N	\N	\N	980	\N	\N	\N	\N	\N
7134	Lis 2003	\N	sertindole versus Haloperidol	\N	Denmark//Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7135	Taneli 2003	\N	Quetiapine versus Haloperidol	\N	Turkey	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
7136	Kopala 2003	\N	Risperidone versus Haloperidol	\N	Canada//Israel	\N	\N	\N	\N	\N	555	\N	\N	\N	\N	\N
7137	Sacchetti 2003	\N	Quetiapine versus Risperidone	\N	Italy	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
7139	Davidson 2003	\N	Risperidone versus Haloperidol	\N	Israe//lUnited States of America	\N	\N	\N	\N	\N	533	\N	\N	\N	\N	\N
7140	Chaudhry 2003	\N	Olanzapine versus Haloperidol	\N	Australia//Malaysia//Pakista//Phillipines//Thailand	\N	\N	\N	\N	\N	276	\N	\N	\N	\N	\N
7142	Myers 2001 a	\N	after nicotine versus before nicotine	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
7144	Diamond 1991	\N	Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7145	Sumiyoshi 2003b	\N	Melperone Dosage	\N	United States of America	\N	\N	\N	\N	\N	341	\N	\N	\N	\N	\N
7147	Gaebel 2002 b	\N	intermittent medication strategy versus maintenance medication strategy	\N	Germany	\N	\N	\N	\N	\N	363	\N	\N	\N	\N	\N
7148	Atmaca 2003 a	\N	nizatidine + Olanzapine versus Olanzapine + Placebo	\N	Turkey	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
7149	Wynchank 2003	\N	Haloperidol 10mg+ Nefazodone versus Haloperidol 10mg+ Placebo	\N	South Africa	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
7150	Godemann 2003	\N	interval neuroleptic medication versus long term neuroleptic nedication	\N	Germany	\N	\N	\N	\N	\N	386	\N	\N	\N	\N	\N
7152	Velligan 2002 c	\N	Quetiapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
7153	Malm 2003	\N	integrated care versus community based program	\N	Sweden	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
7154	Bell 2003 b	\N	neurocognitive enhancement therapy + work therapy versus work therapy	\N	United States of America	\N	\N	\N	\N	\N	131	\N	\N	\N	\N	\N
7156	Norman 2002	\N	stress management program versus social activities group	\N	Canada	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
7157	Oosthuizen 2002 a	\N	Risperidone versus Haloperidol	\N	South Africa	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7158	Oosthuizen 2002 b	\N	Risperidone versus Haloperidol	\N	South Africa	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7159	Wuerker 2002	\N	supportive family management versus applied family management	\N	United States of America	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
7160	Chengappa 2003a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	257	\N	\N	\N	\N	\N
7161	Chin 1998	\N	Haloperidol versus Zuclopenthixol	\N	Malaysia	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
7165	Ban 1969	\N	Chlorpromazine versus Haloperidol	\N	United Kingdom // United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7166	Harvey 2003 a	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	176	\N	\N	\N	\N	\N
7167	Tuma 2003	\N	donepezil adjunctive versus Placebo	\N	Czech Republic	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
7168	Rosenheck 2003 a	\N	intensive case management versus standard care	\N	United States of America	\N	\N	\N	\N	\N	460	\N	\N	\N	\N	\N
7169	NCT00007774	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	309	\N	\N	\N	\N	\N
7170	Bai 2003	\N	Risperidone versus Placebo	\N	Taiwan	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
7171	Rector 2003	\N	cognitive therapy + enriched standard care versus enriched standard care	\N	Canada	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
7173	Power 2000 a	\N	assertive community treatment versus control group	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	144	\N	\N	\N	\N	\N
7181	Kinon 2003 c	\N	Olanzapine dose	\N	United States of America	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
7182	Csernansky 2003	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
7183	Adson 2003	\N	Aripiprazole versus Placebo Aripiprazole versus Placebo	\N	Multinational and United States of America	\N	\N	\N	\N	\N	420	\N	\N	\N	\N	\N
7184	Lecrubier 2003	\N	BP 4897 versus Placebo	\N	France	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
7187	Shumeiko 2003	\N	folic acid +pyridoxine + B-12 versus Placebo	\N	Israel	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
7188	Schooler 2003	\N	Risperidone versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	533	\N	\N	\N	\N	\N
7189	Malykhin 2003	\N	Risperidone versus Haloperidol	\N	Belarus	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
7190	Riedel 2003	\N	celecoxib + Risperidone versus Risperidone + Placebo	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
7191	Mitchell 2003	\N	Olanzapine dose	\N	United Kingdom // United States of America	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
7192	Ermilov 2003 a	\N	Olanzapine + glycine versus Placebo + glycine	\N	Israe//lUnited States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
7194	Svestka 2003 a	\N	Olanzapine versus Risperidone	\N	Czech Republic	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
7195	Svestka 2003 b	\N	Olanzapine versus Quetiapine	\N	Czech Republic	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
7196	Rabinowitz 2003	\N	Risperidone versus Haloperidol	\N	Belgium//Israel//United States of America	\N	\N	\N	\N	\N	534	\N	\N	\N	\N	\N
7198	Chan 2003	\N	Risperidone versus Olanzapine	\N	Taiwan	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
7199	Vollenweider 2003	\N	\N	\N	Switzerland	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
7200	Daniel 2003 a	\N	Ziprasidone (2, 20 mgs) versus Haloperidol	\N	South Africa//United States of America	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
7201	Daniel 2003 b	\N	\N	\N	South Africa//United States of America	\N	\N	\N	\N	\N	506	\N	\N	\N	\N	\N
7203	Beasley 2003 b	\N	Olanzapine versus Placebo	\N	United States of America	Eli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana, USA	\N	\N	\N	\N	326	\N	\N	\N	\N	\N
7204	Lin 2003	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
7205	Mortimer 2003 a	\N	Amisulpride versus Olanzapine	\N	France//United Kingdom	\N	\N	\N	\N	\N	377	\N	\N	\N	\N	\N
7207	Dubitsky 2002 a	\N	Aripiprazole Dosage	\N	United States of America	\N	\N	\N	\N	\N	243	\N	\N	\N	\N	\N
7208	Dubitsky 2002	\N	Aripiprazole Dosage // Aripiprazole versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	255	\N	\N	\N	\N	\N
7209	Dubitsky 2002 c	\N	Aripiprazole Dosage	\N	United States of America	\N	\N	\N	\N	\N	143	\N	\N	\N	\N	\N
7210	Dubitsky 2002 d	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	541	\N	\N	\N	\N	\N
7211	Dubitsky 2002 e	\N	famotidine + Aripiprazole versus Aripiprazole	\N	United States of America	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
7212	Dubitsky 2002 f	\N	Aripiprazole versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	631	\N	\N	\N	\N	\N
7213	Dubitsky 2002 g	\N	Aripiprazole Dosage	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
7214	Dubitsky 2002 h	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
7215	Dubitsky 2002 j	\N	Aripiprazole versus perphenazine	\N	United States of America	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
7216	Dubitsky 2002 k	\N	mosapramine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
7217	Dubitsky 2002 l	\N	mosapramine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	207	\N	\N	\N	\N	\N
7218	Dubitsky 2002 m	\N	mosapramine dose	\N	United States of America	\N	\N	\N	\N	\N	704	\N	\N	\N	\N	\N
7219	Dubitsky 2002 n	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
7220	Dubitsky 2002 o	\N	Aripiprazole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	310	\N	\N	\N	\N	\N
7221	Warren 1980	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7222	Bean 1964	\N	music therapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
7224	Mena 1964	\N	tranylcypromine versus trifluoperazine for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	Unclear	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
7228	Abi-Saab 2002	\N	ritanserin + mCPP versus ritanserin + Placebo	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
7229	Akhondzadeh 2003	\N	Haloperidol + ethinyl estraiol versus Haloperidol + Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
7230	Bond 2004	\N	Olanzapine versus first generation Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
7234	Salzer 2004	\N	telephone intervention versus control group	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
7235	Stone 2003	\N	glucose injestion versus saccarine injestion	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
7236	Graeber 2003 a	\N	motivational interviewing versus educational intervention	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7237	Marcelli 2002	\N	valpromide versus neuroleptic	\N	France	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
7238	Akhondzadeh 2002	\N	Haloperidol + diazoxide versus Haloperidol + Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
7239	McDonald 2003	\N	case study of patient with an Antipsychotic prescription versus case study of patient with an alprazolam prescription	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7240	Pantalon 2003	\N	motivational interviewing + standard treatment versus standard care	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7241	Swanson 2003	\N	involuntary outpatient commitment versus release	\N	United States of America	\N	\N	\N	\N	\N	221	\N	\N	\N	\N	\N
7242	Petit 2003	\N	NTLD versus Placebo	\N	France	\N	\N	\N	\N	\N	245	\N	\N	\N	\N	\N
7243	Buchain 2003	\N	Clozapine + occupational therapy versus Clozapine	\N	Brazil	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
7244	Mattejat 2001	\N	inpatient care versus residential program	\N	Germany	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
7245	Engelhardt 1969 b	\N	Chlorpromazine dose	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
7246	Gothelf 2003	\N	Olanzapine versus Haloperidol	\N	Israel	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
7247	Kashner 2003	\N	structured interviews versus control group	\N	United States of America	\N	\N	\N	\N	\N	296	\N	\N	\N	\N	\N
7248	Depla 2003	\N	community integration groups versus control group	\N	Netherlands	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
7250	Seidman 2003	\N	group homes versus independent apartments	\N	United States of America	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
7257	Bark 2003	\N	cognitive remediation versus control group	\N	United States of America	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
7258	Chien 2003	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
7261	Heresco-Levy 2004	\N	glycine + Olanzapine versus glycine + Placebo	\N	Israel	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
7262	Atmaca 2004	\N	Quetiapine + nizatidine versus Quetiapine + Placebo	\N	Turkey	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
7263	Dossenbach 2004	\N	Olanzapine versus fluphenazine	\N	Croatia	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7264	Yen 2004	\N	Haloperidol versus Risperidone	\N	Taiwan	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
7265	Hellewell 1998b	\N	Quetiapine versus Placebo	\N	United States of America//Austria//Canada//New Zealand//United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
7266	Hellewell 1998c	\N	Quetiapine versus Placebo	\N	United States of America//Austria//Canada//New Zealand//United Kingdom	\N	\N	\N	\N	\N	286	\N	\N	\N	\N	\N
7267	Joyce 2003	\N	appraisal and caregiving difficulty support package versus social support care package	\N	United Kingdom	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
7268	Crane 1971	\N	neuroleptic drugs versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
7269	Binkhorst 1963 a	\N	cyclopentolate versus paredrine	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7270	Binkhorst 1963 b	\N	cyclopentolate versus paredrine	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
7271	McKenzie 1964	\N	prefrontal leukotomy versus control group	\N	Canada	\N	\N	\N	\N	\N	141	\N	\N	\N	\N	\N
7272	Kazamatsuri 1972 b	\N	tetrabenazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
7273	Van Meijel 2003	\N	relapse prevention plan versus standard care	\N	Netherlands	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
7275	Arango 2003 b	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
7276	Tsemberis 2003	\N	comsumer driven "Housing First" program versus usual care	\N	United States of America	\N	\N	\N	\N	\N	225	\N	\N	\N	\N	\N
7277	Apiquian 2003	\N	Haloperidol versus Olanzapine	\N	Mexico	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
7278	Kodesh 2003	\N	selegiline versus Placebo	\N	Israel	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
7279	Daniel 2004 a	\N	IM Ziprasidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	306	\N	\N	\N	\N	\N
7280	Ettinger 2003	\N	procyclidine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
7282	Keefe 2003	\N	Risperidone versus Haloperidol	\N	United States of America//Canada	\N	\N	\N	\N	\N	414	\N	\N	\N	\N	\N
7283	Kopelowicz 2003	\N	family assisted skills training versus outpatient care	\N	United States of America	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
7285	Penn 2003	\N	documentary films versus no documentary films	\N	United States of America	\N	\N	\N	\N	\N	163	\N	\N	\N	\N	\N
7287	Sikich 2004	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
7289	Leiguarda 1984	\N	lisuride versus Placebo	\N	Argentina	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
7290	Borison 1984	\N	Amantadine versus Benztropine	\N	United States of America	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
7291	Turrone 2002	\N	Risperidone versus Clozapine	\N	Canada	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
7292	Kelly 2003	\N	Olanzapine versus Clozapine	\N	United States of America	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
7293	Zeng 1995 a	\N	Dexetimide versus Trihexyphenidyl	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
7294	Yi 2000	\N	Venlafaxine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7295	Li 2001 a	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
7296	Zeng 1994	\N	Flunarizine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
7297	Ju 1996	\N	Flupentixol versus Perphenazine	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
7298	Huang 2000	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
7299	Huang 2001 a	\N	Chlorthixol Decanoate versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
7300	Wang 2000 a	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
7301	Schooler 2000 c	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	384	\N	\N	\N	\N	\N
7303	Malla 2000	\N	youth education and support program versus cognitively oriented skills training	\N	Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7304	Mottaghipour 2000	\N	family education group program versus control group	\N	Australia	\N	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
7306	Dahl 2000	\N	TIndividual Placement and Support standard treatment protocol versus control group	\N	Denmark//Norway	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
7307	Opjordsmoen 2000	\N	perphenazine versus Risperidone	\N	Denmark//Norway	\N	\N	\N	\N	\N	134	\N	\N	\N	\N	\N
7309	Avasthi 2001	\N	Olanzapine versus Haloperidol	\N	India	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
7310	Kufferle 1997	\N	Quetiapine versus Haloperidol	\N	Austria	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
7311	Oranje 2003	\N	desipramine + Haloperidol versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
7312	Daskalakis 2003	\N	Haloperidol versus Placebo	\N	Canada	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
7313	Fu 2003 a	\N	ketamine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
7314	Kristiansen 2003	\N	Risperidone versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7315	Heydebrand 2004	\N	Risperidone versus Haloperidol	\N	Canada//United States of America	\N	\N	\N	\N	\N	307	\N	\N	\N	\N	\N
7316	Hodel 2004	\N	emotion management training versus problem solving	\N	Switzerland	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
7317	Louza 2004	\N	Haloperidol + conjugated estrogens versus Haloperidol + Placebo	\N	Brazil	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
7319	Tsai 2004 a	\N	sarcosine (add on) versus Placebo	\N	Taiwan	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
7320	Corrigan 2004	\N	sonepiprazol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	467	\N	\N	\N	\N	\N
7322	Petrakis 2004	\N	naltrexone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
7325	Huber 2004	\N	estradiol versus Placebo	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
7327	Veznedaroglu 2003	\N	\N	\N	Turkey	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7328	Ueland 2004	\N	cognitive remediation versus standard care	\N	Norway	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
7329	Bellack 2004	\N	Clozapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
7330	Tsemberis 2004	\N	comsumer driven "Housing First" program versus treatment as usual	\N	United States of America	\N	\N	\N	\N	\N	225	\N	\N	\N	\N	\N
7331	Trower 2004 a	\N	cognitive therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
7332	Qian 2002 a	\N	Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
7333	Li 2002 a	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
7335	Chen 2002 a	\N	Comprehensive intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
7336	Li 2002 b	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus Modified Electroconvulsive Therapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7337	Lv 2002	\N	Risperidone versus Self-control (Before treatment)	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
7339	Liang 2002 a	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
7340	Zhang 2002 a	\N	Risperidone (First time use) versus Risperidone (Switching from other Antipsychotics)	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7341	Ni 2002	\N	Music therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
7342	Zhu 2002 a	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7343	Ren 2002 a	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7344	Wu 2002 a	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7345	Zhu 2002 b	\N	Pipotiazine + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
7346	Jin 2002	\N	Clozapine + Fluoxetine versus Clozapine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7347	Lu 2002 b	\N	Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
7348	Zhang 2002 b	\N	Olanzapine, higher dosage versus Olanzapine, lower dosage	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
7349	Zhang 2002 c	\N	Clozapine + Paroxetine versus Clozapine + Placebo	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
7350	Liu 2002 a	\N	Nursing intervention + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
7351	Wang 2002 a	\N	Holistic nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7352	Wang 2002 b	\N	Skill training versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7353	Cui 2002	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7355	Zuo 2002	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7356	Pan 2002	\N	Acupuncture point injection of Danshen (TCM) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
7357	Zhang 2002 d	\N	Sulpiride versus Clozapine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7359	Su 2002 b	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
7360	Ren 2002 b	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7361	Zhu 2002 c	\N	Group psychotherapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7362	Anonymous 2002	\N	Pipotiazine Palmitate versus Haloperidol Decanoate	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7363	Cha 2002	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7364	Lin 2002 a	\N	Quetiapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
7365	Li 2002 c	\N	Community based rehabilitation versus Inpatient treatment	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7366	Xiang 2002 a	\N	behaviour therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
7367	Zhu 2002 d	\N	Music therapy + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
7368	Sheng 2002	\N	Singing training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	181	\N	\N	\N	\N	\N
7369	Zhu 2002 e	\N	Light Quantum Therapy + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	145	\N	\N	\N	\N	\N
7371	Xu 2002 a	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7372	Hu 2002 a	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7373	Pang 2002 b	\N	Psychotherapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
7374	Li 2002 d	\N	Community based rehabilitation + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
7376	Lei 2002	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
7377	Wang 2002 d	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
7379	Ban 2001 a	\N	Horticultural therapy + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
7380	Hou 2001 a	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7381	Mei 2001 a	\N	Risperidone versus Risperidone + Alprazolam	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7382	Wu 2001 a	\N	Risperidone, lower dose versus Clozapine	\N	China	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
7383	Ban 2001 b	\N	Horticultural therapy + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
7384	Sun 2001	\N	Dose time: 8:30 and 20:00 versus Dose time: 12:00 and 21:30	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7385	Nan 2001	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
7386	Chen 2001 a	\N	Clozapine versus lithium carbonate	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7387	Peng 2001 a	\N	Risperidone + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
7388	Gao 2001 a	\N	Traditional Chinese Medicine (TCM) Danshen + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7389	Luo 2001 a	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
7390	Xie 2001	\N	Risperidone + Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7391	Xin 2001	\N	Risperidone + Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
7392	Zhang 2001 b	\N	Electroacupuncture + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
7393	Wang 2001 a	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7396	Chen 2001 b	\N	domestic manufactured Quetiapine versus Chlorpromazine Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	221	\N	\N	\N	\N	\N
7397	Yu 2001 a	\N	Clozapine + Qudian Decotion(TCM) versus Clozapine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
7399	Zhou 2000 a	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7431	Xiang 1997	\N	Clonazepam versus Placebo	\N	China	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
7433	Niu 2001 a	\N	Chlorpromazine versus Clozapine	\N	China	\N	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
7434	Liu 2001 a	\N	Citicoline + Glucose injection versus Glucose injection	\N	China	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
7435	Ju 2000	\N	Pipotiazine Palmitate versus Fluphenazine Decanoate	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7436	Chen 1998 a	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7437	Yang 1998 b	\N	Traditional Chinese Medicine (TCM) Shuxuening + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7438	Zhang 1997 b	\N	Traditional Chinese Medicine (TCM) Yinxingye + Haloperidol versus Haloperidol + Placebo versus Haloperidol + ginkgo biloba extract//Haloperidol versus Placebo//Haloperidol versus ginkgo biloba extract//Haloperidol versus Traditional Chinese Medicine (TCM) Yinxingye//chinese herbal medicine	\N	China	\N	\N	\N	\N	\N	109	\N	\N	\N	\N	\N
7439	Zhang 2002 e	\N	Risperidone + Antioxidant versus Risperidone + Placebo	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
7440	Wang 2002 e	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
7441	Qian 2001	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7442	Zhang 2004 a	\N	Risperidone versus various doses	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
7443	Li 2003 g	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
7444	Wu 2003 a	\N	L-Stepholidine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
7445	Ge 1999	\N	Zuclopenthixol versus Perphenazine	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7446	Yang 2002 c	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
7447	Yang 2003 a	\N	Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
7448	Liu 2003 c	\N	Venlafaxine versus Fluoxetine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
7449	Liang 2002 b	\N	Traditional Chinese Medicine (TCM) Dahuang-Yichun-Hu versus Traditional Chinese Medicine (TCM) Fanxieye	\N	China	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
7450	Van Os 2004	\N	Two-Way Communication Checklist (2-COM) versus Treatment as Usual	\N	The Netherlands	\N	\N	\N	\r\nUser defined field 10\r\n	\N	134	\N	\N	\N	\N	\N
7451	Mueller 2004	\N	celecoxib + Risperidone versus Risperidone + Placebo	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
7452	Abbas 2004	\N	saline versus control group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7453	Bersani 2004	\N	Risperidone versus Haloperidol	\N	Italy	\N	\N	\N	\N	\N	594	\N	\N	\N	\N	\N
7454	Bowie 2004	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7455	Ciudad 2004	\N	Olanzapine versus Risperidone	\N	Spain	\N	\N	\N	\N	\N	235	\N	\N	\N	\N	\N
7457	Earley 2004 a	\N	Olanzapine dose	\N	United States of America	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
7458	Emsley 2004 a	\N	Quetiapine versus Haloperidol	\N	South Africa	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
7459	Greenspan 2004	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	194	\N	\N	\N	\N	\N
7460	Hardy 2004 a	\N	Olanzapine versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	548	\N	\N	\N	\N	\N
7461	Harrison 2004 a	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7464	Ellenor 2004	\N	Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7465	Marquez 2004 a	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7466	Marquez 2004 b	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7467	Marquez 2004 c	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7554	Wang 2003 b	\N	Clonazepam + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
7469	Henderson 2004	\N	Olanzapine+Sibutramine versus Olanzapine+Placebo // Sibutramine versus Placebo	\N	United States of America	\N	\N	\N	\r\nUser defined 3\r\n	\N	37	\N	\N	\N	\N	\N
7470	Hussain 2004	\N	rivastigmine versus galantamine	\N	Canada	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
7473	Lysaker 2004	\N	Cognitive Behavioural Training + work placement versus standard services + work placement	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7474	McCreadie 2004	\N	free fruits and vegetables versus treatment as usual	\N	United Kingdom	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
7477	Pandina 2004	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	324	\N	\N	\N	\N	\N
7478	Riedel 2004	\N	Quetiapine versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
7479	Rodriguez 2004	\N	Risperidone versus various doses	\N	United States of America	\N	\N	\N	\N	\N	176	\N	\N	\N	\N	\N
7480	Strejilevich 2004 a	\N	psychoeducation versus Atypical Antipsychotics	\N	Argentina	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
7481	Strejilevich 2004 b	\N	typical Antipsychotic versus Clozapine	\N	Argentina	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7483	Urioste 2004	\N	long acting Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	439	\N	\N	\N	\N	\N
7485	Vreeland 2004	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
7486	Kollack-Walker 2004	\N	Olanzapine versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	346	\N	\N	\N	\N	\N
7488	Akerele 2002	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
7490	Wu 2002 b	\N	Health education + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
7491	Cao 2001	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
7492	Wang 2000 c	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7493	Yu 2002 a	\N	Art therapy + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7494	Zhu 2002 g	\N	He-Ne laser irradiation + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
7495	Fan 1999	\N	Clopenthixol versus Clozapine	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
7496	Liu 1999 a	\N	Flupentixol versus Clozapine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7497	Yang 1999 b	\N	Psychotherapy versus Self-control (Prior to treatment)	\N	China	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
7498	Guan 1999	\N	Naloxone + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
7500	Zhu 1999 a	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7501	Ou 1999	\N	Chlorpromazine versus Clozapine	\N	Hunan	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
7502	Weng 1999	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
7503	Chen 1999 a	\N	Chlorpromazine versus sulpiride	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
7504	Liu 1999 b	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
7505	Chen 1999 b	\N	morita versus Placebo	\N	China	\N	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
7506	Huang 1999 a	\N	Vocational rehabilitation (Cleaning) versus Vocational rehabilitation (Spinning)	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
7507	CHA 1999	\N	Chlorpromazine versus Clozapine	\N	China	\N	\N	\N	\N	\N	115	\N	\N	\N	\N	\N
7508	Lu 1999	\N	Modified morita therapy + Routine Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7509	Gan 1999	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7510	Liu 1999 c	\N	Behaviour therapy (positive enhancement) + standard care versus Clozapine	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
7511	Cui 1999	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
7512	Li 1999 a	\N	Risperidone versus various doses	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7513	He 1999 a	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
7514	Ma 1998	\N	Family intervention versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
7515	Weng 1998	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7516	Wang 1998 a	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7517	Xie 1998	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
7518	Zhu 1998	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
7519	Yang 1998 c	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
7520	Chen 1997 a	\N	Risperidone versus Placebo	\N	China	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
7521	Meng 1996 a	\N	Traditional Chinese Medicine (TCM)// Shuxuening + Antipsychotic medication versus Antipsychotic medication//Ginkgo biloba extract injection versus Placebo//Ginkgo biloba extract injection	\N	China	\N	\N	\N	\r\nUser defined field 10\r\n	\N	36	\N	\N	\N	\N	\N
7522	Yu 1996	\N	Traditional Chinese Medicine (TCM) Shuxuening + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7523	Li 1996 a	\N	Haloperidol decanoate versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	292	\N	\N	\N	\N	\N
7524	Luo 1995	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	210	\N	\N	\N	\N	\N
7526	Wang 1994	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
7527	Wang 1994 a	\N	Sulpiride + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
7530	Zhou 2003 a	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
7531	Liu 2003 a	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
7532	Wang 2003 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	251	\N	\N	\N	\N	\N
7535	Yao 2003 a	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
7536	Chen 2003 a	\N	domestic manufactured Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
7537	He 2003 a	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
7538	Chang 2003 a	\N	Olanzapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
7539	Bian 2003	\N	Chlorpromazine versus Risperidone	\N	China	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
7540	Zhao 2003 b	\N	Risperidone versus Self-control	\N	China	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
7541	Li 2003 a	\N	Family intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	259	\N	\N	\N	\N	\N
7542	Zhang 2003 a	\N	Family intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7543	Huang 2003 a	\N	Fluoxetine + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7544	Xu 2003 a	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7545	Ning 2003 a	\N	Athletic therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
7546	Song 2003	\N	Venlafaxine versus Amitriptyline	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7547	Xu 2003 b	\N	Piracetam + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
7548	Zhan 2003 a	\N	Nursing intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7549	Zhang 2003 b	\N	Music therapy versus Behavior therapy	\N	China	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
7550	Feng 2003 a	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7551	Dong-Qiang 2003	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
7552	Zhong 2003 b	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
7553	Zhang 2003 d	\N	music therapy (active) versus music therapy (passive)	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
7555	Li 2003 b	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
7556	Qiu 2003 a	\N	Quetiapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7557	Wang 2003 c	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
7558	Wang 2003 d	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7559	Liu 2003 b	\N	Clozapine + Imipramine versus Imipramine	\N	China	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
7560	Gan 2003	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
7562	Tang 2003 a	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7565	Li 2003 d	\N	Venlafaxine + Clozapine versus Sulpiride + Clozapine	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
7566	Yang 2003 b	\N	Risperidone + Clonazepam versus Haloperidol	\N	China	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7567	Deng 2003 a	\N	Participative nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	123	\N	\N	\N	\N	\N
7568	Chen 2003 b	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
7569	Yang 2003 c	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
7570	Xu 2003 c	\N	Community based rehabilitation + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7571	Linag 2003	\N	Fluoxetine + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
7572	An 2003 a	\N	quentiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7573	Li 2003 e	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
7576	Huang 2003 b	\N	Group behavior therapy + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
7577	Zheng 2003 a	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
7579	Ma 2003	\N	Skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7580	Chen 2003 c	\N	Skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
7581	Guo 2003 b	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7582	Zhou 2003 b	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
7583	Liu 2004 a	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
7584	Guo 2004	\N	\N	\N	China	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
7585	Zhan 2004 a	\N	Occupation recreational therapy + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
7586	Lu 2004	\N	Skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
7587	Zhou 2004 a	\N	Modified electroconvulsive therapy + routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
7588	Liu 2004 b	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7589	Zhu 2004 a	\N	Community based rehabilitation + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	208	\N	\N	\N	\N	\N
7590	Currier 2004	\N	Risperidone + lorazepam versus Haloperidol + lorazepam	\N	United States of America	\N	\N	\N	\N	\N	162	\N	\N	\N	\N	\N
7594	Zhao 2003 c	\N	Sulpiride + Chlorpromazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7595	Liang 2003 b	\N	Visiting intervention + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7598	Gao 2003 b	\N	Rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
7600	Liu 2000 b	\N	Psychological nursing + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7601	Li 2001 b	\N	Acupuncture versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
7602	Chen 2001 c	\N	Traditional Chinese Medicine (TCM) Shufuning + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
7604	Wang 2002 f 	\N	Risperidone versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7606	Dong 2002	\N	Treatment group versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
7607	Xu 2001 b	\N	Group psychotherapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
7609	Pu 2003 a	\N	Family intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
7610	Zhou 2003 d	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
7612	Pu 2003 b	\N	Nursing intervention + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7613	Sun 2003 a	\N	Psychological nursing + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7614	Ma 2003 b	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
7618	Zhan 2003 b	\N	Skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	146	\N	\N	\N	\N	\N
7619	Zheng 2003 b	\N	Huperzine A + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
7621	Chen 2003 f	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7623	Saren 2003	\N	Skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	148	\N	\N	\N	\N	\N
7626	Zhou 2003 e	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
7628	Xu 2003 d	\N	Psychological therapy + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	287	\N	\N	\N	\N	\N
7632	Ma 2002 a	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
7633	Wang 2000 d	\N	Morita therapy + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
7634	Wang 2002 g	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
7635	Wang 2002 h	\N	Music therapy versus Music therapy	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7640	Li 2004 a	\N	Early intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
7644	Zhang 2003 g	\N	Risperidone versus various doses	\N	China	\N	\N	\N	\N	\N	173	\N	\N	\N	\N	\N
7645	He 2001	\N	Electro Convulsive Therapy (Electroconvulsive Therapy), dominant hemisphere versus Electro Convulsive Therapy (Electroconvulsive Therapy), none-dominant hemisphere	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7646	Gao 2001 b	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
7650	Zhu 2002 h	\N	Morita therapy + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
7654	Yang 2002 d	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
7656	Tang 2002 c	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	162	\N	\N	\N	\N	\N
7658	Tang 2002 d	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
7661	Weng 2002	\N	Skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
7662	Zeng 2002	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7663	Zhang 2002 h	\N	Perphenazine versus Risperidone	\N	China	\N	\N	\N	\N	\N	390	\N	\N	\N	\N	\N
7665	Xiang 2001	\N	Skill training (Medication self-management) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
7749	Zhou 2002 b	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
7667	Wang 2001 d	\N	Psychosocial intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7668	Du 2001 a	\N	Group psychotherapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
7672	Zhang 1999 b	\N	Cognitive therapy + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7675	Guo 1995	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
7676	Sun 1995	\N	Pipotiazine palmintate versus Haloperidol decanoate	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
7677	Liu 1995 b	\N	Thioridazine versus Haloperidol decanoate	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7678	Wang 1997	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
7679	Lu 1998	\N	Diphenhydramine versus Placebo	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7680	Ling 1999	\N	Community based interention + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7681	Wang 1999 a	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
7682	Xu 1997	\N	Diphenhydramine dose	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
7683	Zhang 1998 d	\N	Family health education + Antipsychotic medication versus standard care	\N	China	\N	\N	\N	\N	\N	1048	\N	\N	\N	\N	\N
7684	Lu 2002 c	\N	Anshen-Jianpi Syrup (Traditional Chinese Medicine (TCM))+ Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	143	\N	\N	\N	\N	\N
7685	Meng 2002	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	204	\N	\N	\N	\N	\N
7686	Wang 2002 i	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7687	Wang 2001 e	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
7688	Xu 2001 c	\N	Sultopride injection versus Sulpiride injection	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
7689	Yan 2004 a	\N	Ferrous sulfate + Chlorpromazine versus Chlorpromazine + Placebo//Chlorpromazine versus Placebo//Chlorpromazine versus Ferrous sulfate	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
7690	Zhang 2003 h	\N	Psychological education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7691	Guo 2003 c	\N	Clozapine, higher dose versus Clozapine, lower dose	\N	China	\N	\N	\N	\N	\N	165	\N	\N	\N	\N	\N
7692	Guo 2003 d	\N	Chlorpromazine + Olanzapine versus Olanzapine	\N	China	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
7693	Zeng 2003	\N	Chlorpromazine + Olanzapine versus Olanzapine	\N	China	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
7694	Ma 2003 c	\N	Family health education + Conventional follow-up visit versus Conventional follow-up visit	\N	China	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7695	He 2003 b	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
7696	Bi 1994	\N	Chlorpromazine versus Clozapine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
7698	Liu 1998 a	\N	Zuclopenthixol versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
7699	Zhao 1999	\N	Family intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	186	\N	\N	\N	\N	\N
7700	Su 1999	\N	Dance therapy + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7701	Ma 1999	\N	He-Ne laser irradiation + Chlorpromazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7702	Yao 2000	\N	Modified Electro Convulsive Therapy (MElectroconvulsive Therapy) versus Electro Convulsive therapy (Electroconvulsive Therapy)	\N	China	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
7703	Zhang 2000 b	\N	Insulin + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
7705	Liu 1995 c	\N	Chlorpromazine + Chlorimipramine versus Chlorimipramine	\N	China	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
7706	Wang 2000 e	\N	Chlorpromazine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
7707	Lu 2000	\N	Psychosocial intervention versus Haloperidol	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
7710	Han 2001 a	\N	Family therapy + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
7711	Chen 2001 e	\N	Risperidone versus various doses	\N	China	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
7712	Zeng 2001	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
7713	Chen 2001 f	\N	Risperidone versus Haloperidol Clozapine, Chlorpromazine, sulpiride	\N	China	\N	\N	\N	\N	\N	904	\N	\N	\N	\N	\N
7714	Ma 2001 a	\N	Occupational therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
7715	Yin 2002	\N	Risperidone + Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
7717	Cong 2002	\N	Vinpocetine + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
7719	Zhang 2003 i	\N	Olanzapine, higher dosage versus Olanzapine, lower dosage	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7720	Zhou 2003 f	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7721	Lu 2003 a	\N	Quetiapine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
7722	Li 2003 i	\N	behaviour therapy (positive enhancement) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
7723	Gan 1996	\N	Smoking versus None-smoking	\N	China	\N	\N	\N	\N	\N	167	\N	\N	\N	\N	\N
7724	Liu 1997a	\N	Traditional Chinese Medicine (TCM) Shuxuening + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7725	Lin 1999	\N	behaviour therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7727	Zhang 2000 d	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7730	Ma 2000 a	\N	Chlorpromazine versus Clozapine	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
7732	Chen 2000 b	\N	family intervention versus control group	\N	China	\N	\N	\N	\N	\N	202	\N	\N	\N	\N	\N
7733	Xu 2001 d	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
7734	Zhuang 2001	\N	Community based rehabilitation + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	187	\N	\N	\N	\N	\N
7735	Peng 2001 b	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
7736	Mei 2001 b	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7737	Du 2003 a	\N	Modified Electro Convulsive Therapy (MElectroconvulsive Therapy) versus Clozapine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7738	Lu 2003 b	\N	Occupational therapy + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
7739	Ma 2003 d	\N	Huperzine A versus Placebo	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
7740	Wang 2003 e	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7741	Zheng 2003 c	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
7742	Zheng 2003 d	\N	Horticultural therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	615	\N	\N	\N	\N	\N
7743	Wang 2000 f	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
7744	Shi 2000 b	\N	Clozapine versus Typical Antipsychotics	\N	China	\N	\N	\N	\N	\N	159	\N	\N	\N	\N	\N
7745	Zhou 2000 c	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
7746	Zhang 2001 d	\N	Skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
7747	Wu 2001 b	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7748	Xia 2002	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7750	Ren 2002 c	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7751	Weng 1994	\N	Family health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	408	\N	\N	\N	\N	\N
7752	Li 1996 b	\N	Family health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7753	Chen 1997 b	\N	Traditional Chinese Medicine (TCM) Xingshen-Heji + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7755	He 1999 b	\N	Psychosocial intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
7756	Yue 2002	\N	Physiotherapy and massage versus standard care	\N	China	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
7758	Liu 1998 b	\N	behaviour therapy (positive enhancement) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
7759	Liu 1997b	\N	Clopenthixol (higher dosage) versus Clopenthixol (lower dosage)	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7760	Zhong 1995	\N	Electrode versus Electro-Acupuncture	\N	China	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
7764	Wu 2003 b	\N	music and dance sessions versus treatment as usual	\N	China	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7771	Huang 1998	\N	Chlorpromazine versus Healthy volunteer as control	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7772	Song 1997	\N	Trihexyphenidyl + Chlorpromazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
7774	Yang 2002 f	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
7775	Zhu 2002 i	\N	Haloperidol versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
7780	Lu 2002 d	\N	Shuxuening (Traditional Chinese Medicine (TCM)) + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7783	Xu 2003	\N	Self care nursing based on Orem theory versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	135	\N	\N	\N	\N	\N
7784	Li 2003 j	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7785	Wu 2000 a	\N	Chlorpromazine versus Clozapine	\N	China	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
7787	Ren 2000	\N	Open ward management versus Closed ward management	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
7788	Chen 2003 g	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7789	Gan 1997	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	414	\N	\N	\N	\N	\N
7790	Qiu 2003 b	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
7791	Zhang 2003 j	\N	Occupational therapy + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7792	c	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7793	Gao 2003 e	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7794	Zhu 2003	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
7795	Li 2003 k	\N	Risperidone + Haloperidol versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
7796	Liu 2003 e	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
7797	An 2003 b	\N	quentiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7798	Fang 2003 a	\N	Comprehensive intervention + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
7799	Cao 2003 a	\N	Morita therapy versus rehabilitation therapy	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
7800	Tang 2000 a	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
7801	Liu 2000 d	\N	Flupentixol versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	135	\N	\N	\N	\N	\N
7802	Liu 2000 e	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
7803	Qu 2000	\N	Drama therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7805	Hu 2003 b	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
7806	Guo 2001 b	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
7807	Yu 2001 b	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
7808	Hu 2001	\N	Comprehensive intervention + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7809	Huang 2001 b	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
7810	Wu 2002 d	\N	Risperidone + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
7811	Li 2002 g	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
7812	Zhang 2002 k	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
7813	Zhang 2002 l	\N	Haloperidol + Health education versus Haloperidol	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
7815	Ren 2002 d	\N	Haloperidol versus Risperidone	\N	China	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
7816	Zhou 2002 c	\N	Drama therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
7818	Song 1994	\N	Music therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7820	Wang 1995a	\N	Zuclopenthixol versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
7821	Yu 2002 c	\N	Typical Antipsychotics versus Atypical Antipsychotics	\N	China	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
7822	Yang 1996	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7823	Zhu 1999 b	\N	Clozapine + Chlorimipramine versus Clozapine	\N	China	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
7824	Wang 1999 b	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
7825	Luo 1997 b	\N	Traditional Chinese Medicine (TCM) Shuxuening + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	149	\N	\N	\N	\N	\N
7826	Zhang 1997 c	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
7827	Yang 1997 b	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
7828	Ren 1996	\N	Traditional Chinese Medicine (TCM) Daying Pian + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
7829	Liu 1996 c	\N	Tiapride versus Clozapine	\N	China	\N	\N	\N	\N	\N	153	\N	\N	\N	\N	\N
7830	Zhang 1999 c	\N	Family psychotherapy + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
7831	Yao 1999	\N	Clozapine + Sulpiride versus Clozapine	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
7832	Huang 1999 b	\N	Nemonapride versus Haloperidol	\N	China	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
7833	Lin 1998 b	\N	Community based rehabilitation + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	202	\N	\N	\N	\N	\N
7836	Shen 2004 a	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
7838	Wang 1995 b	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
7840	Li 1998	\N	Family health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
7841	Yi 1996	\N	Traditional Chinese Medicine (TCM) Shuxuening versus Placebo	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
7843	Yao 1997	\N	Family health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
7844	Hu 1994 b	\N	Phenytoin Sodium versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
7845	Gong 1998	\N	Open ward management versus Closed ward management	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7849	Chen 2002 d	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7850	Zhao 1997	\N	Traditional Chinese Medicine (TCM) Shuxuening + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
7929	Beasley 1996 e	\N	Olanzapine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	149	\N	\N	\N	\N	\N
7852	Jia 2000	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) + Chlorpromazine versus control group	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
7853	Yang 2000 a	\N	Acupuncture point injection of sulpiride versus Care as usual	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
7854	郝以辉 2000	\N	He-Ne laser irradiation + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
7855	Qiu 1996	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
7856	Hou 2002	\N	Fluoxetine + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7857	Yu 2002 d	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	135	\N	\N	\N	\N	\N
7858	Chen 2003 h	\N	Comprehensive therapy (package of care including, psychological therapy, behavioural therpay, recreational therpay etc) + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7859	Xiang 2002 b	\N	Skills training + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
7862	Li 2001 d	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7863	Sun 2000 a	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
19410	黄平 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
7864	Tan 1995	\N	Witchcraft versus standard care	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7865	Yang 1998 d	\N	Egb-761 (Ginkgo extract) + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
7866	Chen 1998 b	\N	Clozapine versus (high//low dosages)	\N	China	\N	\N	\N	\N	\N	176	\N	\N	\N	\N	\N
7868	Chen 1999 c	\N	simvastatin versus inositol nicotinate	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7869	Chou 1999	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
7870	Zhang 1999 d	\N	Risperidone versus Risperidone + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
7871	Chen 2000 c	\N	Risperidone versus Placebo	\N	China	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
7872	Zuo 2000	\N	Risperidone	\N	China	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
7873	Zhang 1994 e	\N	Computer controlled electric acupuncture + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
7874	Zhang 2003 f	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
7875	Zhang 1996	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
7876	Yu 2002 e	\N	\N	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
7877	Yue 2004 a	\N	Comprehensive nuring and skills training + routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7878	Han 1997 a	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7880	McGurk 2004	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
7881	Xu 1999	\N	Skill training (Medication self-management) + standard care versus standard care	\N	China	X. Zhida, Beijing An Ding Hospital, Capital Univ. of Medical Sciences, Beijing 100088, China	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
7882	Du 2001 b	\N	Sulpiride + occupational & recreational therapy versus Sulpiride	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7883	Good 2004	\N	Risperidone versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	535	\N	\N	\N	\N	\N
7884	Rogers 2003	\N	psychoeducation intervention versus therapeutic alliance intervention	\N	United Kingdom	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
7885	Timko 2004	\N	community care versus hopsital care	\N	United States of America	\N	\N	\N	\N	\N	230	\N	\N	\N	\N	\N
7886	Ries 2004	\N	contingency management versus noncontingency management	\N	United States of America	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
7887	Leavey 2004	\N	education and advice package versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
7888	Gray 2004	\N	medication management training versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7889	Marshall 2004	\N	feedback from standardized needs assessment versus no feedback from standardized needs assessment	\N	United Kingdom	\N	\N	\N	\N	\N	304	\N	\N	\N	\N	\N
7890	Meltzer 2004	\N	SR compound versus Placebo//Haloperidol versus Placebo//Haloperidol versus Sr compound	\N	United States of America	\N	\N	\N	\N	\N	481	\N	\N	\N	\N	\N
7892	Small 2003	\N	Clozapine + lithium versus Clozapine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
7893	McConville 2003	\N	Quetiapine versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
7894	Power 2003	\N	psychotherapy versus control group	\N	Australia	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
7897	Harrigan 2004	\N	Antipsychotics versus various dosages	\N	China	\N	\N	\N	\N	\N	183	\N	\N	\N	\N	\N
7898	Townsend 2004	\N	fixed dose Olanzapine versus gradual dose escalation Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
7899	Zhang 2004 b	\N	Vitamin E versus Placebo	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
7900	Wonodi 2004 a	\N	naltrexone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
7902	Lopez-Luengo 2003	\N	attention process training versus no training	\N	Spain	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
7903	James 2004	\N	tailored intervention sessions versus single educational session	\N	Australia	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
7904	Chien 2004 a	\N	\N	\N	Hong Kong	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
7905	Stryjer 2004	\N	Clozapine + donepezil versus Clozapine + Placebo	\N	Israel	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
7906	Poyurovsky 2004	\N	famotidine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
7907	Henderson 2004 a	\N	Joint Crisis Plan	\N	United Kingdom	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
7908	Kremer 2004	\N	lamotrigine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
7909	Duncan 2004	\N	D-cycloserine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
7910	Bloch 2004	\N	lidocaine-prilocain cream versus Placebo	\N	Israel	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
7912	Fann 1973 b	\N	Chlorpromazine + antacid versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7913	Janowsky 1973 b	\N	physostigmine versus methylphenidate	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
7914	El-Yousef 1973	\N	physostigmine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	3	\N	\N	\N	\N	\N
7915	Janowsky 1973 c	\N	physostigmine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
7916	Valmaggia 2002	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus supportive counseling	\N	Netherlands//Belgium	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
7917	Janowsky	\N	methylphenidate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
7918	Mueser 2004 a	\N	individual placement and support versus standard services	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	204	\N	\N	\N	\N	\N
7919	Steinberg 2004	\N	motivational interviewing versus psychoeducational intervention	\N	United States of America	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
7922	Rein 1996 b	\N	Amisulpride versus Placebo	\N	France	\N	\N	\N	\N	\N	245	\N	\N	\N	\N	\N
7924	Girish 2003	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) + Placebo versus sham Electro Convulsive Therapy (Electroconvulsive Therapy) + psychotropic drugs	\N	India	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
7925	Cavazzoni 2003	\N	nizatidine + Olanzapine versus Placebo + Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	175	\N	\N	\N	\N	\N
7926	Chang 1991	\N	Haloperidol (10 mg) versus reduced Haloperidol	\N	China	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
7928	Simpson 2004	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	269	\N	\N	\N	\N	\N
20342	于丽 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7930	Turner 1956	\N	Chlorpromazine versus Placebo	\N	Argentina	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
7931	Gaitz 1955	\N	Chlorpromazine with hibernation regime versus Chlorpromazine without hibernation regime	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7932	Tassis 1959	\N	full coma insulin therapy versus electro convulsive therapy (Electroconvulsive Therapy)	\N	Singapore	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
7933	Benaim 1960	\N	Chlorpromazine + insulin versus insulin	\N	United Kingdom	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
7934	Smith 1961 b	\N	Chlorpromazine versus chlordiazepoxide	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
7935	Dalack 1997 d	\N	smoking ad libitum versus no smoking	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7936	Ottosson 1960 b	\N	hexobarbital + Electro Convulsive Therapy versus Electro Convulsive Therapy + Placebo	\N	Sweden	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
7937	Ottosson 1960 c	\N	hexobarbital + lidocaine + Electro Convulsive Therapy versus Electro Convulsive Therapy + Placebo	\N	Sweden	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
7938	Ottosson 1960 d	\N	hexobarbital + lidocaine + Electro Convulsive Therapy versus Electro Convulsive Therapy + Placebo	\N	Sweden	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
7939	Ottosson 1960 e	\N	hexobarbital + lidocaine + Electro Convulsive Therapy versus Electro Convulsive Therapy + Placebo	\N	Sweden	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
7940	Otto 2001 b	\N	smaill group HIV risk reduction intervention versus control group	\N	United States of America	\N	\N	\N	\N	\N	189	\N	\N	\N	\N	\N
7941	Wykes 2002 c	\N	cognitive remediation therapy versus intensive occupational therapy activities	\N	United Kingdom	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
7942	Maratos 2004	\N	music therapy versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
7943	Calsyn 2003 a	\N	assertive community treatment versus modified Acceptance and Commitment Therapy condition	\N	United States of America	\N	\N	\N	\N	\N	178	\N	\N	\N	\N	\N
7944	Calsyn 2003 b	\N	assertive community treatment versus drop-in center	\N	United States of America	\N	\N	\N	\N	\N	207	\N	\N	\N	\N	\N
7945	Marco 2002	\N	ketoconazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
7946	Fahy 2004 a	\N	cognitive skills intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
7950	Ozguven 2004	\N	Olanzapine versus Quetiapine	\N	Turkey	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
7951	Nordentoft 2004 a	\N	integrated care versus standard care	\N	Denmark	\N	\N	\N	\N	\N	547	\N	\N	\N	\N	\N
7952	Appelberg 2004	\N	continued conventional neuroleptics (Chlorpromazine equivalents) versus Olanzapine	\N	Finland	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
7953	Bechdolf 2004 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	Germany	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
7954	Hamann 2004 a	\N	decision aid group versus usual care	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7955	Basi 2004	\N	Risperidone versus Haloperidol	\N	Italy	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
7957	Dal Santo 2004	\N	day hospital versus control group	\N	Italy	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7958	Boulay 2004 a	\N	Olanzapine versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
7959	Brunstein 2004	\N	allopurinol + Antipsychotic treatment versus Placebo + Antipsychotic treatment	\N	Brazil	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
7960	Addington 2004	\N	Ziprasidone versus Risperidone	\N	Australia//Canada//Ireland	\N	\N	\N	\N	\N	256	\N	\N	\N	\N	\N
7961	Anselmetti 2004	\N	cognitive remediation versus control group	\N	Italy	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
7964	Hawkins 2004 a	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7965	Harvey 2004 b	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
7966	Aasen 2004	\N	Rivastigmine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
7968	Hardy 2004 b	\N	Olanzapine dose	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
7969	Emsley 2004 b	\N	Risperidone versus Haloperidol	\N	Israel//South Africa	\N	\N	\N	\N	\N	555	\N	\N	\N	\N	\N
7970	Graham 2004	\N	Amantadine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
7971	Houston 2004	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	548	\N	\N	\N	\N	\N
7973	Jenner 2004	\N	hallucinatinon integrated treatment versus usual care hallucinatinon integrated treatment versus usual care	\N	Netherlands	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
7974	Mahmoud 2004 b	\N	Atypical Antipsychotics versus conventional Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
7975	Hay 2004	\N	Olanzapine versus conventional Antipsychotic	\N	United States of America	\N	\N	\N	\N	\N	293	\N	\N	\N	\N	\N
7978	Kopala 2004	\N	Risperidone versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	555	\N	\N	\N	\N	\N
7979	Horacek 2004	\N	Quetiapine versus conventional Antipsychotics	\N	Czech Republic	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
7980	Kinon 2004 a	\N	Olanzapine versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	394	\N	\N	\N	\N	\N
7981	Keefe 2004 a	\N	Olanzapine versus Haloperidol	\N	Canada//United Kingdom//United States of America	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
7982	Morrison 2004 a	\N	cognitive therapy versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
7983	Mitchell 2004	\N	Olanzapine dose	\N	United States of America	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
7985	Miceli 2004	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
7987	McGlashan 2004 a	\N	Olanzapine versus Placebo	\N	Canada//United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7988	McGlashan 2004 b	\N	Olanzapine versus Placebo	\N	Canada//United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
7989	Mackell 2004	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	138	\N	\N	\N	\N	\N
7991	Power 2004	\N	early detection intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	153	\N	\N	\N	\N	\N
7992	Pagsberg 2004	\N	zuclopenthixol versus Risperidone	\N	Denmark//Netherlands	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
7993	Wong 2004	\N	explanation of psychotic symptoms versus no explanation of psychotic symptoms	\N	China	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
7994	Walsh 2004	\N	\N	\N	Canada//United Kingdom	\N	\N	\N	\N	\N	691	\N	\N	\N	\N	\N
7996	Smelson 2004	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
7997	Riera 2004	\N	Atypical Antipsychotics versus control group	\N	United States of America	\N	\N	\N	\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	1520	\N	\N	\N	\N	\N
7998	Rettenbacher 2004	\N	Clozapine versus Amisulpride	\N	Austria	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
8000	Sharma 2004	\N	revistagmine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8002	Jockers-Scherübl2004	\N	paroxetine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
8003	Sirota 2004	\N	Quetiapine versus Olanzapine	\N	Israel	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8004	Lewis 2004 a	\N	Clozapine versus Atypical Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
8005	Rimon 2004	\N	Olanzapine versus perphenazine	\N	Finland	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
8007	Van Brunt 2004	\N	Olanzapine versus Ziprasidone	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8009	Green 2004 b	\N	Modafinil versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
8012	David 2000 a	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
8015	Nordentoft 2004 b	\N	early detection intervention versus control group	\N	Denmark	\N	\N	\N	\N	\N	578	\N	\N	\N	\N	\N
8016	Bendall 2004	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	Australia	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8110	Ji 1994	\N	Anethole trithione versus Placebo	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
8018	Bertelsen 2004	\N	psychosocial integrated treatment versus standard care	\N	Denmark	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8021	Gleeson 2004	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) (individual) versus family intervention relapse prevention therapy versus standard care family based psychosocial intervention versus standard care	\N	Australia	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
8023	Jackson 2004 a	\N	cognitive therapy recovery intervention versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
8024	Jackson 2004 b	\N	cognitive oriented psychotherapy versus standard care	\N	Australia	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
8139	Niu Yajuan 2003	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8025	ACE	\N	Befriending versus Cognitive Therapy // Befriending versus Control Group // Cognitive Therapy versus Control Group	\N	Australia	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8026	Jenner 2004 b	\N	hallucinatinon integrated treatment versus usual care	\N	Netherlands	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
8028	Lester 2004 a	\N	GP intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8030	McGlashan 2004 c	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8031	Morrison 2004 b	\N	cognitive therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
8032	Petersen 2004	\N	integrated treatment versus standard care	\N	Denmark	\N	\N	\N	\N	\N	547	\N	\N	\N	\N	\N
8036	Stuart 2004	\N	Amisulpride versus Placebo	\N	Australia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8037	Thorup 2004	\N	integrated treatment versus standard care	\N	Denmark	\N	\N	\N	\N	\N	547	\N	\N	\N	\N	\N
8038	Woods 2004 a	\N	Olanzapine + zero duration of untreated psychosis versus Olanzapine + duration of untreated psychosis	\N	United States of America	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
8039	Zipursky 2004	\N	home treatment versus clinic based care	\N	Canada	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
8042	Miller 2004 a	\N	clinical treatment versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
8046	Abdollahian 2004	\N	Risperidone versus Haloperidol	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
8047	Buchsbaum 2004	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
8048	Cavallaro 2004	\N	cognitive enhancement program versus control group	\N	Italy	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
8049	Davidson 2004	\N	Risperidone versus Haloperidol	\N	Israel	\N	\N	\N	\N	\N	535	\N	\N	\N	\N	\N
8050	Dyck 2004	\N	multifamily psychoeducation versus control group	\N	United States of America	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
8051	Earley 2004 b	\N	Olanzapine dose	\N	United States of America	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
8052	Economou 2004	\N	psychoeducation training versus control group	\N	Greece	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8053	Fadden 2004	\N	psychoeducation training versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8054	Honer 2004	\N	Clozapine + Risperidone versus Clozapine + Placebo	\N	Canada	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
8056	Harrison 2004 b	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8057	Kallert 2004 a	\N	augmented psychoedutraining versus routine services	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8061	Magliano 2004	\N	psychoeducation family intervention versus control group	\N	Italy	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8063	Penades 2004	\N	cognitive remediation therapy + standard medication follow-up versus cognitive behavioral therapy + standard medication follow-up	\N	Spain	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
8064	Pioli 2004	\N	rehabilitation program versus control group	\N	Italy	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
8065	Harvey 2004 c	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
8067	Roerig 2004	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
8069	Talwar 2004	\N	music therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8071	Torres-Gonzales 2004	\N	psychoeducation versus standard care	\N	European	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8072	Fiorillo 2004	\N	pschoeducational intervention versus control group	\N	Italy	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8074	Kung 2005	\N	pet therapy versus control group	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8075	Turkoz 2005	\N	long acting Risperidone dose	\N	United States of America	\N	\N	\N	\N	\N	323	\N	\N	\N	\N	\N
8076	Phillips 2005	\N	Antipsychotics versus control group	\N	United States of America	\N	\N	\N	\N	\N	394	\N	\N	\N	\N	\N
8078	Rodriguez 2005	\N	Risperidone versus various doses	\N	United States of America	\N	\N	\N	\N	\N	323	\N	\N	\N	\N	\N
8079	Urioste 2005 a	\N	motivational enhancement therapy (GAIN) versus approach as usual	\N	United States of America	\N	\N	\N	\N	\N	655	\N	\N	\N	\N	\N
8080	Beasley 2005 a	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	304	\N	\N	\N	\N	\N
8081	Walsh 2005	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
8082	Kane 2005 a	\N	Ziprasidone versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
8083	Sun 2000 b	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
8084	Ding 1998	\N	Vitamin B1 + Antipsychotic medication versus Senna mixture + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
8085	Wang 2000 g	\N	Clonazepam versus Artane	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
8086	Chu 1999	\N	Cisapride + Antipsychotic medication versus Vitamin B6 + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
9047	Luo 2003	\N	\N	\N	Singapore	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
8087	Tong  2001	\N	Amitriptyline + Clozapine versus Placebo + Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8088	Wang 2001 f	\N	Traditional Chinese Medicine (TCM) Tongxinluo capsule versus Coenzyme - Q10	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8089	Su Hui 2004	\N	Sorbitol Enema versus Sorbitol Enema	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8090	Zhang Jing 2004	\N	Perphenazine + psychotherapy versus Perphenazine	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
8091	LI Yanxian 2004	\N	Oryzanol + Clozapine versus Placebo + Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8093	Li 1999 c	\N	Traditional Chinese Medicine (TCM) versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	244	\N	\N	\N	\N	\N
8094	Li 2001	\N	Chlorpromazine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	320	\N	\N	\N	\N	\N
8095	Liu Yan 2003	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
8097	Kong 2003	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
8098	Wang 2004 b	\N	Morita therapy + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
8099	Du 2004 b	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
8100	Fang Yunling 1995	\N	Impramine versus Placebo	\N	China	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
8102	Wang Jian 1995	\N	Perphenazine + Alprazolam versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
8103	Bao 2005 a	\N	PDCA family intervention versus Conventional family intervention	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8104	Liu 2004 e	\N	Traditional Chinese Medicine (TCM) Ningxin Anshen Tang + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
8105	Wang 2000 k	\N	Clozapine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	540	\N	\N	\N	\N	\N
8106	Liu 2001 b	\N	Risperidone + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
8107	Fu 2003 b	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
8108	Sheng 2003	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	167	\N	\N	\N	\N	\N
8109	Wei 1995	\N	Propranolol versus Verapamil	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8111	Feng 2002	\N	Tiopronin + Antipsychotic medication versus Placebo + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	287	\N	\N	\N	\N	\N
8112	Huang 2004 b	\N	Systematic rehabilitation therapy + standard care versus standard care 	\N	China	\N	\N	\N	\N	\N	138	\N	\N	\N	\N	\N
8113	Li 2001 e	\N	Anshenjianpi-tang(TCM) +routine Antipsychotic medication versus Placebo + routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	143	\N	\N	\N	\N	\N
8114	Peng 1995	\N	Psychological supportive nursing care + Chlorpromazine versus standard care + Chlorpromazine	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
8115	Dong 1999	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
8116	Wu Haoran 1999	\N	Morita therapy + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
8117	Yu 1999	\N	Ultraviolet blood irradiation and oxygenation + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
8118	Yang Fude 2000	\N	Chlorpromazine versus Clozapine	\N	China	\N	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
8119	Deng 2000	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8120	Zou Jian hua 2002	\N	Sipportive psychotherapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8121	Shi Fuming 2000	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
8122	Zhang Shoulai 2002	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
8123	Zhang 2002	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	320	\N	\N	\N	\N	\N
8124	Ma Wentao 2001	\N	Clozapine + Electroconvulsive Therapy versus Chlorpromazine + Electroconvulsive Therapy	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8125	Liu 2001 e	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
8126	Chen 2002 e	\N	psychosocial intervention versus control group	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
8127	Liang Shaocai 2002	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
8128	Lu 2002 e	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
8129	Wang 2002 l	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
8130	Cao 2002	\N	fluoxetine versus Placebo	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
8131	Wang 1996 b	\N	Loxapine succinate versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8137	Wang 2003 g	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
8138	Lu 2003 c	\N	Loxapine succinate versus Clozapine	\N	China	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
8140	Guo 2003	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	148	\N	\N	\N	\N	\N
8141	Cheng 2003	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
8143	Wang 2003 h	\N	Clozapine + Piracetam versus Clozapine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8144	Li 2003 l	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8145	Chen 2003 i	\N	Skills training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8146	Cao 2003 b	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8147	He 2003	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8148	Zhou 2003 g	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
8149	Mao Yemeng 2000	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
8150	Wang 2000 h	\N	Clonazepami injection into acupuncture point + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
8151	Zhao Jiantong 2001	\N	Fangfeng tongsheng san(TCM) + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	230	\N	\N	\N	\N	\N
8153	Wang 2000 i	\N	Fluoxetine + Clozapine versus Clozapine + Placebo	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8154	Hou Yezhi 2001	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
8155	Huang 2003 c	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
8157	Xing 2002	\N	L-stepholidine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8158	Qing Hai Liu 2003	\N	Individual family intervention versus Group family intervention	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
8159	Hu 2004 b	\N	Congnitive behavioural therapy versus Amitriptyline	\N	China	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
8160	Li 2004 d	\N	Hyperbaric oxygen + Risperidone versus Risperidone only	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
8161	BAO Feng 2004	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8162	Cao 2004	\N	Informed Consent + Treatment as Usual versus Treatment as Usual	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8163	Chang 2004 a	\N	psychiatric rehabilitation versus control group	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
8164	CHEN Rifang 2004	\N	Modern electro convulsive therapy (Electroconvulsive Therapy) versus Conventional electro convulsive therapy (Electroconvulsive Therapy)	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8166	Dai 2004 a	\N	Olanzapine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
8167	Dai 2004 b	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
8168	DingYuanfu 2004	\N	Risperidone versus Quetiapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8169	Du 2004	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
8170	Du 2004 a	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8171	Fan 2004	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
8172	Feng 2004	\N	Rehabilitation training + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
8173	Fu 2004	\N	Modified Electro Convulsive Therapy (MElectroconvulsive Therapy) + Propofol versus Modified Electro Convulsive Therapy (MElectroconvulsive Therapy) + Thiopental sodium	\N	China	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
8174	Ge Qianrong 2004	\N	Risperidone + Clonazepam versus Haloperidol	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
8175	Ge 2004	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	165	\N	\N	\N	\N	\N
8176	Huang 2004 a	\N	behaviour therapy + Antipsychotic medication versus Benzodiazepines + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8177	Hao 2004	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
8178	He 2004 a	\N	Comprehensive intervention + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
8179	Hu 2004	\N	Benzodiazepines + Antipsychotic medication versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	452	\N	\N	\N	\N	\N
8180	Huang 2004 c	\N	Perphenazine + Nimodipine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8181	Huang 2004	\N	Modern electro convulsive therapy (Electroconvulsive Therapy) versus Haloperidol	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8182	Ji 2004	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
8183	Jiang Xingyan 2004	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8184	Jin hong 2004	\N	Traditional Chinese Medicine (TCM) Wulin capsules + Antipsychotic medication versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8185	Shi Tianyuan 2004	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8186	Wang 2004 e	\N	Risperidone + Clonazepam versus Haloperidol	\N	China	\N	\N	\N	\N	\N	254	\N	\N	\N	\N	\N
8188	Li Li 2004	\N	Oral mannitol versus Folium sennae	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
8189	Li 2004 b	\N	Comprehensive rehabilitation training + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
8854	Sankawa 2005	\N	\N	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8190	Li 2004 c	\N	Psychological nursing + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
8191	Li 2004 e	\N	Loxapine versus Clozapine//Loxapine succinate versus Clozapine	\N	China	\N	\N	\N	\r\nUser defined field 10\r\n	\N	60	\N	\N	\N	\N	\N
8192	LI Zhen yu 2004	\N	Clozapine + Doxepin versus Clozapine	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
8193	LI Zheng 2004	\N	Health education for families + standard Care versus standard Care	\N	China	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
8194	Li 2004 g	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
8195	Liang 2004 b	\N	Sodium valproate + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
8196	Liao 2004	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8197	Lin 2004 a	\N	behavioural therapy + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8199	Liu 2004 c	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
8200	Liu Lin 2004 b	\N	Health education + Chloropromazine versus Chloropromazine	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
8201	Liu Weibo 2004	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
8202	Liu Yan  2004	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
8203	Lu  2004 c	\N	\N	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
8204	Lv  2004	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
8205	Ma Xiaozhi 2004	\N	Individual psychoeducation versus Routine health education	\N	China	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
8206	Ma 2004 a	\N	Risperidone versus Chloropromazine	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
8207	Ma 2004 b	\N	Nursing intervention + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
8208	Ma Zheng 2004	\N	Skill training + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
8209	Ma 2004 c	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
8210	Mao Zhengrong 2004	\N	Psychological intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
8211	Min 2004	\N	Family intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	245	\N	\N	\N	\N	\N
8212	Pan Miao 2004	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8213	Pan Miao 2004 b	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8214	Peng 2004 a	\N	Quetiapine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8216	Qi Fusheng 2004	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
8217	Qi Xia Liang 2004	\N	Nursing intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8218	QIAN Dongli 2004	\N	Clozapine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
8219	Ren 2004 a	\N	Open ward management versus Closed ward management	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
8220	Ren Kai 2004	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8221	Ren 2004 b	\N	Clozapine + Fluoxetine versus Clozapine	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
8222	Ren Xianfeng 2004	\N	Amitriptyline + Cognitive therapy versus Amitriptyline	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
8223	Sha 2004	\N	Risperidone versus various doses	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
8225	Sun Dong 2004	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8226	Tan 2004	\N	Outpatient care versus Inpatient care	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8227	Saren 2004	\N	Skill training + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	148	\N	\N	\N	\N	\N
8228	Tang Ying 2004	\N	Olanzapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
8230	Tu 2004	\N	loxapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	226	\N	\N	\N	\N	\N
8231	Wang  2004 f	\N	Cognitive insight therapy + family intervention + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
8232	Wang 2004 g	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
8233	Wang 2004 p	\N	Olanzapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
8234	Wang 2004 h	\N	Clozapine + Compound Diazepam versus Clozapine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8235	Wang 2004 c	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
8236	Wang 2004 i	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
8237	Wang Xianjun 2004	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
8239	Wang 2004 a	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
8240	Wang 2004 o	\N	Risperidone + Mirtazapine versus Mirtazapine	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
8241	Wang 2004 l	\N	Psychological nursing + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
8242	Wang 2004 m	\N	Traditional Chinese Medicine (TCM) Yinxing-Yepian + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
8243	Wang 2004 n	\N	Nursing intervention + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
8244	Wang 2004 d	\N	Quetiapine + Huperzine A versus Quetiapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8245	Wu 2004 a	\N	Traditional Chinese Medicine (TCM) Danshen + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
8246	Wu Haiping 2004	\N	Comprehensive nursing care + Antipsychotic medication versus Conventional nursing + Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
8247	Wu Yi 2004	\N	Risperidone versus Chloropromazine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8248	Wu Yi 2004 b	\N	Risperidone versus Chloropromazine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8250	Xiang 2004	\N	Social skill training versus Conventional intervention	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8251	Xiao Bo 2004	\N	Sulpiride versus Risperidone	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
8252	Xiong 2004	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8254	Xu Chunjun 2004	\N	Clonazepam versus Haloperidol	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8255	Xue 2004	\N	Loxapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8256	Yan 2004 b	\N	Traditional Chinese Medicine (TCM) Jie-jing-decotion versus Trihexyphenidyl	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8257	YANG Bin 2004	\N	Clonazepam versus Haloperidol	\N	China	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
8258	Yang Fude 2004	\N	Chlorpromazine versus Clozapine	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
8259	Yang 2004	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
8260	Yang 2004 a	\N	Clozapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
8261	Yin 2004	\N	Sodium Valproate versus Placebo	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8262	Ying Lishen 2004	\N	Risperidone, 4mg//d versus Risperidone, > 4mg//d	\N	China	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
8263	Yu E Li 2004	\N	Early intervention + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
8265	YUE Shuying 2004	\N	Health education in the form of quiz + routine health education versus Routine health education	\N	China	\N	\N	\N	\N	\N	216	\N	\N	\N	\N	\N
8266	Yue 2004 b	\N	Risperidone versus Risperidone + Clozapine	\N	China	\N	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
8268	Gao 2004	\N	Occupational therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
8269	Zhang Hua 2004	\N	Risperidone versus various doses	\N	China	\N	\N	\N	\N	\N	173	\N	\N	\N	\N	\N
8857	Boyer 1986	\N	\N	\N	France	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8270	Zhang 2004 k	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
8271	ZHANG Li 2004 b	\N	Health education based on health belief model versus Conventional health education	\N	China	\N	\N	\N	\N	\N	176	\N	\N	\N	\N	\N
8272	Zhang 2004 c	\N	Health education for families + standard Care versus standard Care	\N	China	\N	\N	\N	\N	\N	146	\N	\N	\N	\N	\N
8273	Zhang 2004 g	\N	behaviour therapy + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
8274	Zhang Yu 2004	\N	Skill training + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8275	Yueying 2004	\N	Chlorpromazine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
8276	Zhang 2004 h	\N	Antipsychotics + Imipramine versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8277	Zhang 2004 i	\N	Luhui-hu (TCM) versus Fanxieye (TCM)	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
8278	Zhang 2004 d	\N	Rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
8279	Futao 2004	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8280	Yubo 2004	\N	Open ward management versus Closed ward management	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8281	Ma 2004 d	\N	Individual family intervention versus Group family intervention	\N	China	\N	\N	\N	\N	\N	221	\N	\N	\N	\N	\N
8282	Xianzhen 2004	\N	Olanzapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8283	Zheng 2004	\N	Olanzapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20249	李育军2 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
8284	Zhou 2004	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
8285	Zhou 2004 b	\N	Chlorpromazine + Ferrous sulfate versus Chlorpromazine + Trihexyphenidyl	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8787	Brar 2005	\N	behavioural therapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
8790	Gallagher 2005	\N	mifepristone versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
8791	Tugal 2004	\N	donepezil adjunctive versus Placebo	\N	Turkey	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
8792	Turner 2004 a	\N	long acting Risperidone versus conventional depot Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	166	\N	\N	\N	\N	\N
8793	Turner 2004 b	\N	Modafinil versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
8794	Williams 2003 a	\N	\N	\N	Australia	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
8797	Wykes 2003 a	\N	cognitive remediation therapy versus intensive occupational therapy activities	\N	United Kingdom	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
8798	Yagcioglu 2005	\N	Risperidone versus Placebo	\N	Turkey	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
8799	Yamashita 2004	\N	\N	\N	Japan	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
8800	Yasui-Furukori 2002	\N	Bromperidol versus "6, 12, 18mg//day"	\N	Japan	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
8801	Ye 2004 a	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
8802	Yurgelun-Todd 2005	\N	D-cycloserine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
8803	Valmaggia 2005	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus supportive counseling	\N	Netherlands//Belgium	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8804	Zhang 2004 f	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
8805	Van Bruggen 2004	\N	Olanzapine versus Ziprasidone	\N	Netherlands	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
8806	Zoccali 2004	\N	mirtazapine + Clozapine versus Placebo + Clozapine	\N	Italy	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
8807	Zhou 2004 c	\N	Psychodrama therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
8808	Cook 2005 a	\N	supported employment intervention versus standard care	\N	United States of America	\N	\N	\N	\N	\N	1648	\N	\N	\N	\N	\N
8813	Bradshaw 1993	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) (problem solving)	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
8814	Tregellas 2005	\N	nicotine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
8815	Chung 2000	\N	Risperidone versus Haloperidol	\N	South Korea	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
8816	Zeng 1995 b	\N	Buspirone versus Placebo	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8817	Velloso 1965	\N	\N	\N	Brazil	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8818	Thompson 2005	\N	Olanzapine versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
8819	Du 2003 b	\N	Loxapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8820	Wang 2005 a	\N	Loxapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
8821	de Jesus Mari 2004	\N	Antipsychotic Drug versus Olanzapine	\N	Brazil	\N	\N	\N	\N	\N	190	\N	\N	\N	\N	\N
8822	Fitzgerald 2004	\N	Amoxapine versus Olanzapine	\N	Australia//Canada and Australia	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
8823	Ginsberg 2003 	\N	gabapentin versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
8824	Gazdag 2004	\N	etomidate + Electro Convulsive Therapy (Electroconvulsive Therapy) versus propofol + Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	Hungary	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
8825	Elizure 1978 	\N	propranolol versus neuroleptic treatment	\N	Israel	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
8826	Gattaz 2004	\N	Olanzapine versus flupenthixol	\N	Germany	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
8828	Diehl 2003	\N	pergolide versus Placebo	\N	Germany//Brazil	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
8829	de Leon 2004 a	\N	Clozapine dose	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
8830	Schulz 1990	\N	neuroleptic treatment + lithium versus neuroleptic treatment + Placebo	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
8831	Wallace 2004	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
8832	Wolkin 1990	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
8834	Hwang 2003	\N	Amisulpride versus Risperidone	\N	Taiwan	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
8835	Jarema 2003	\N	\N	\N	Poland	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
8837	Hertling 2003	\N	\N	\N	Austria	\N	\N	\N	\N	\N	153	\N	\N	\N	\N	\N
8838	Khazaie 2005	\N	fluphenazine decanoate injections every 2 weeks versus fluphenazine decanoate injections every 6 weeks	\N	Islamic Islamic Republic of Islamic Republic of Iran	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
8839	Goldman 1964	\N	drug treatment versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20250	李玲 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
8840	Goldman 1963	\N	social reward condition versus non reinforcement	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
8841	Goldman 2004	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
8842	Philipp 2003	\N	flupentixol versus Risperidone	\N	Austria//Germany	\N	\N	\N	\N	\N	153	\N	\N	\N	\N	\N
8844	Poplawska 2004	\N	Psychoeducation + Antipsychotic medication versus Antipsychotic medication	\N	Poland	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
8847	Nakajima 2005	\N	Quetiapine versus conventional Antipsychotics	\N	Japan	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
8848	Moller 2004	\N	zotepine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
8849	Newton 1983	\N	day hospital care versus inpatient care	\N	United States of America	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
8850	Schindler 2005	\N	role development program versus control group	\N	United States of America	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
8851	Vittorielli 2003	\N	\N	\N	Italy	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
8852	Valencia 2004 a	\N	psychosocial therapy + pharmacological treatment versus pharmacological treatment	\N	Mexico	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8853	Stock 2005	\N	Aripiprazole versus Antipsychotics	\N	Belgium//United States of America	\N	\N	\N	\N	\N	214	\N	\N	\N	\N	\N
8858	Jia 2004	\N	Traditional Chinese Medicine (TCM) Jianpi-Bushen + Chlorpromazine versus Chlorpromazine + Placebo//Chlorpromazine versus Placebo	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8859	Plesnicar 2003	\N	Risperidone versus Olanzapine	\N	Slovenia	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
8861	Van Putten 1990 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
8862	Vestre 1966	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8863	Boylan 2004	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8864	Williams 2003 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	349	\N	\N	\N	\N	\N
8865	Cada 2004 a	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	640	\N	\N	\N	\N	\N
8867	Cada 2004 b	\N	Risperidone IM versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
8869	Cada 2004 c	\N	Risperidone IM versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	397	\N	\N	\N	\N	\N
8870	Van Nimwegen 2006	\N	Olanzapine versus Risperidone	\N	Netherlands	\N	\N	\N	\N	\N	131	\N	\N	\N	\N	\N
8872	Goff 2005 a	\N	D-cycloserine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
8873	Evins 2004 b	\N	Bupropion + cognitive behavioral therapy versus Placebo + cognitive behavioral therapy	\N	United States of America	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
8874	Levkovitz 2005	\N	ondansetron + Clozapine versus Placebo + Clozapine	\N	Israel	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
8875	de Sena 2003	\N	Risperidone versus Haloperidol	\N	Brazil	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
8876	Brunelleschi 2003	\N	Risperidone versus Placebo	\N	Italy	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
8877	Lee 2005 a	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	South Korea	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
8878	Argo 2004 a	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
8889	Bell 2003 c	\N	vocational rehabilitation + behavioral intervention versus no-pay work activity + behavioral intervention	\N	United States of America	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
8890	Riedel 2005 a	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
8892	Schutzwohl 2005 a	\N	day hospital treatment versus inpatient treatment	\N	Germany//Poland//Czech Republic//Slovak Republic	\N	\N	\N	\N	\N	727	\N	\N	\N	\N	\N
8893	Sibitz 2005	\N	\N	\N	Austria	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
8894	Smith 2005 a	\N	rapid dose escalation of Quetiapine in 2, 3 days versus rapid dose escalation of Quetiapine in 3, 5 days	\N	Unclear	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
8895	Tandon 2005	\N	\N	\N	India	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8896	Cavallaro 2005	\N	computer-aided cognitive training versus control group	\N	Italy	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
8897	Corrigan 2005	\N	education stigma condition versus contact stigma condition	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8898	Herrera 2005	\N	Risperidone versus Placebo//Haloperidol versus Placebo//Haloperidol versus Risperidone	\N	Unclear	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
8899	Glenthoj 2005 a	\N	Risperidone versus zuclopenthixol	\N	Denmark//Netherlands	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
8900	Jurjanz 2005	\N	psychiatric day hospital treatment versus inpatient treatment	\N	Unclear	\N	\N	\N	\N	\N	202	\N	\N	\N	\N	\N
8901	Ko 2005	\N	hormone replacement therapy versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
9208	Zhong 2005 c	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
8903	Khanna 2005	\N	Ziprasidone versus Chlorpromazine	\N	India//United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8906	Arends 2005	\N	Transcranial Magnetic Stimulation (10 Hz) versus sham Transcranial Magnetic Stimulation	\N	Germany	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
8907	Mihai 2005	\N	Psychoeducation + Antipsychotic medication versus Antipsychotic medication	\N	Romania	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8908	Palma 2005	\N	Cognitive Behavioural Training + standard care versus standard care	\N	Spain	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
8909	Levine 2005	\N	B vitamins versus Placebo	\N	Israel	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
8910	Mahmoud 2005	\N	Atypical Antipsychotics versus conventional Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
8911	Mueller 2005 b	\N	COX-2 + reboxetine versus Placebo + reboxetine	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8912	Roncone 2000	\N	single family psychoeducational intervention versus multi family psychoeducational intervention	\N	Italy	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
8913	Brook 2005	\N	Intramuscular Ziprasidone versus Intramuscular Haloperidol	\N	South Africa//United States of America	\N	\N	\N	\N	\N	572	\N	\N	\N	\N	\N
8914	Stone 2005	\N	glucose injestion versus saccarine injestion	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
8915	Dean 1993	\N	community based treatment versus hospital based treatment	\N	United Kingdom	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
8916	Rosenbaum 2005	\N	supportive psychodynamic psychotherapy + standard care versus standard care	\N	Denmark	\N	\N	\N	\N	\N	562	\N	\N	\N	\N	\N
8917	Li 2005 n	\N	\N	\N	China	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
8918	Spence 2005	\N	Modafinil versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
8919	McCreadie 2005	\N	free fruits and vegetables versus treatment as usual	\N	United Kingdom	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
8923	D'Souza 2005 b	\N	spiritually augmented cognitive behavioral therapy versus control group	\N	Australia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8924	Kane 2004	\N	long acting Atypical antyipsychotics versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
8925	Fleischhacker 2003 a	\N	long-acting injectable Atypical Antipsychotics versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	322	\N	\N	\N	\N	\N
8927	Naber 2005 a	\N	Olanzapine versus Clozapine	\N	Germany	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
8928	Bergemann 2005	\N	estrogen + Antipsychotic treatment versus Placebo + Antipsychotic treatment	\N	Germany	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
8929	Naber 2005 b	\N	Olanzapine versus Clozapine	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8930	Mahmoud 1997 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	684	\N	\N	\N	\N	\N
8931	Kluiter 1993	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
8932	Poulet 2005	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	France	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
8933	Cather 2005	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus psychoeducation group	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
8934	Rathod 2005	\N	Cognitive Behavioural Training versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	422	\N	\N	\N	\N	\N
8935	De Luca 2005	\N	Clozapine versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
8936	Barch 2005	\N	D-amphetamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
8937	Rapaport 2005	\N	celecoxib versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
8938	Sartory 2005	\N	computerized cognitive remediation versus standard care	\N	Germany	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
8939	Eerdekens 2004	\N	long-acting Risperidone dose	\N	Belgium	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
8940	Fatemi 2005	\N	Bupropion HCL versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
8286	Zhu 2004 b	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
8287	An 2005 a	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9300	Morrison 1990 b	\N	remoxipride versus Haloperidol	\N	Sweden	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
8288	Nan 2005	\N	Family psychological intervention + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
8289	Chen 2005 a	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8290	Du 2005 a	\N	Health education + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
8291	Jing yi 2005	\N	Social skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
8292	Zhuli 2005	\N	Psychotherapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
8293	Yu 2005 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8294	Li 2005 a	\N	Social skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
8295	Qian 2005 a	\N	Health education + Chlorpromazine versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
8296	Li 2005 b	\N	Health education versus Baseline data (Prior to health education)	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
8297	Xinfeng 2005	\N	Risperidone + Fluoxetine versus Risperidone	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
8298	Li 2005 c	\N	Loxapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
8300	Liu 2005 b	\N	Clozapine dose	\N	China	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
8301	LU Shichen 2005	\N	Risperidone versus Quetiapine	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
8303	Ren 2005 a	\N	Open ward management + Skill training + Antipsychotic medication versus Closed ward management + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
8304	SHENG Weiyue 2005	\N	Recreational and physical activity + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8305	Shun Shuzhen 2005	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
8306	Wan Zhili 2005	\N	Risperidone + Benzodiazepines versus Risperidone	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8307	Wang 2005b	\N	Magnesium Valproate + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8308	Wang Juncheng 2005	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
8309	Wei Chun xiang 2005	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
8310	Xiang 2005	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
8311	Xu 2005 a	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
8312	YANG Bo 2005	\N	Clinical Nursing Pathway versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
8313	Yu 2005 b	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
8314	Yu Jun 2005	\N	\N	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
8315	Yue 2005	\N	Chaihu + Longgu-Muli-decotion (TCM) versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
8316	ZHANG Fuying 2005	\N	Home visit + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
8317	Zhang 2005 b	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
8318	Zhao Lin 2005	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8319	Zhang 2004 e	\N	Participative nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
8320	攣醮 2004	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
8321	抪棄 2004	\N	Chlorpromazine + Cereobiogen versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
8322	曲洪芳1999	\N	Clonazepam versus Haloperidol	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
8323	李英敏 2003	\N	Traditional Chinese Medicine (TCM) Linghuoyin versus Trihexyphenidyl	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8324	温益雄 2004	\N	Traditional Chinese Medicine (TCM) Yeheye-nongsuo-keli versus Trihexyphenidyl	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8325	梁家 1998	\N	Traditional Chinese Medicine (TCM) Kangfuling versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
8326	舒伟洁 1998	\N	Sultopride versus Sulpiride	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8327	鲍文卿 2004	\N	Cognitive insight therapy + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8328	张向阳 1999	\N	Traditional Chinese Medicine (TCM) Yinxingye + Haloperidol versus Haloperidol	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
8329	王宗叶 2004	\N	Atypical Antipsychotics + Skill training versus Typical Antipsychotics + Skill training	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8330	高存友 2004	\N	Piracetam + Hyperbaric oxygen therapy + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
8331	张太泉 2004	\N	Fluoxetine + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8332	卢金山 1997	\N	Chlorpromazine versus Scopolamine	\N	China	\N	\N	\N	\N	\N	340	\N	\N	\N	\N	\N
8333	李光辉 2005	\N	Propranolol versus Trihexyphenidyl	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8334	Wang 1995	\N	Propranolol versus Verapamil	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8335	曾昭祥 1996 a	\N	Dexetimide versus Trihexyphenidyl	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
8337	惠治冬 2001	\N	Nuodikang (TCM) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8338	郑秀霞 2002	\N	Propranolol versus Clonazepam	\N	China	\N	\N	\N	\N	\N	165	\N	\N	\N	\N	\N
8339	郑秀霞 2001	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	271	\N	\N	\N	\N	\N
8340	Wu 2002 e	\N	Psychological nursing + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8341	陈林庆 2002	\N	Psychotherapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
8342	贾裕堂 2002	\N	Trihexyphenidyl versus Placebo	\N	China	\N	\N	\N	\N	\N	142	\N	\N	\N	\N	\N
8343	林小兰 2003	\N	Music therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	202	\N	\N	\N	\N	\N
8344	王志凌 2003	\N	Traditional Chinese Medicine (TCM) Xuefu-Zhuyu-Tang versus Norethisterone + Chlorpromazine or fluoxetine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8345	王素梅 1995	\N	Mannitol versus Rhei And Sodium Bicarbonate Tablets or phenolphthalein	\N	China	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
8346	宋志强 2003	\N	Buspirone + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
8347	李冬梅 2002	\N	Rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8348	王征 2003	\N	Rehabilitation training + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	141	\N	\N	\N	\N	\N
8349	黄书华 1995	\N	Chlorthixol Decanoate versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
8350	吴晓梅 2003	\N	Psychological rehabilitation + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8351	马振武 2003	\N	Fluoxetine versus Amitriptyline	\N	China	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
8352	戴润珠 2003	\N	Traditional Chinese Medicine (TCM) + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8353	常发伟 2003	\N	Quetiapine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8354	杨铭哲 2004	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8356	王昕 1996	\N	Ahylysantinfarctase + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
20343	陈雄 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
8357	石寿森 1997	\N	Ahylysantinfarctase + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
8358	Liang 2001	\N	Traditional Chinese Medicine (TCM) Tianwang-buxin-dan versus Propranolol	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
8359	陈圣祺 2001	\N	Traditional Chinese Medicine (TCM) Shufuning + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
8360	杜宏群 2001	\N	Psychological behavioral therapy + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8361	李淑英 2001	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
8362	郑曾生 2001	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
8363	杨靖 2001	\N	Group psychotherapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8364	徐贵云 2001	\N	Risperidone + Chlorimipramine versus Risperidone + Placebo	\N	China	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
8365	孔庆任 2001	\N	Clozapine + Risperidone versus Risperidone + Sulpiride	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8366	Han 2001	\N	Clozapine + sulpiride versus reduced dose, increased dose	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
8367	孟昭蓉 1998	\N	Traditional Chinese Medicine (TCM) Huanglian-Wendan-Decoction + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
8368	宋茂轩 1997	\N	Traditional Chinese Medicine (TCM) Qingxin-Decoction + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
8369	高树河 2002	\N	Clozapine + Lithium versus Clozapine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8370	白照庆 2003	\N	Paroxetine + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8371	雷光文 2004	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
8372	张海峰 2000	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
8373	李小新 2000	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8374	张彩鸾 2000	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
8375	韩鹏 2000	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
8376	王建军 2003	\N	Risperidone + Sulpiride versus Clozapine + Sulpiride	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8377	陈强 2004	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
8378	李玉 2004	\N	Psychological nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8379	张永华 1998	\N	Clozapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
8380	庄建华 1999	\N	Fluphenazine + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8381	黄玉海 2000	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
8382	李炜东 2000	\N	Traditional Chinese Medicine (TCM) Xiaoyaosan + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
8383	周国权 2000	\N	Antipsychotics + Fluoxetine versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
8384	陈伟钊 2001	\N	Shuxuening (Traditional Chinese Medicine (TCM)) + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
8385	程绍忠 2002	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8386	沐志强 2002	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
8387	朱新国 2002	\N	Antidepressant + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
8388	王宝安 2002	\N	Anshi capsules (TCM) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8389	谭友果 2002	\N	Risperidone versus Clozapine, Chlorpromazine, Haloperidol	\N	China	\N	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
8390	伍毅 2003	\N	Fluoxetine + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
8391	杨九州 2002	\N	Huperzine A + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8392	张曦明 2004	\N	Quetiapine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
8393	郭杰 2004	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8394	李洪祥 2004	\N	Venlafaxine + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
8395	李侠才 1994	\N	Flupentixol versus Sulpiride	\N	China	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
8396	刘庆海 1995	\N	Clozapine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
8398	刘振东 1995	\N	Alprazolam versus Imipramine	\N	China	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
8399	石金钟 1996	\N	Traditional Chinese Medicine (TCM) Shuxuening + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8400	钟红文 1996	\N	Traditional Chinese Medicine (TCM) Shuxuening + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
8401	张淑芹 1996	\N	Traditional Chinese Medicine (TCM) Shuxuening + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
8402	胡文亮 1997	\N	Chlorpromazine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
8403	黄自勇 1997	\N	Chlorpromazine versus Clozapine	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
8404	张淑芹 1997	\N	Traditional Chinese Medicine (TCM) Shuxuening + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
8405	方润领 1997	\N	Imipramine versus Placebo	\N	China	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
8406	王莉 1998	\N	Thioridazine versus Clozapine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8407	孟广彦 1998	\N	Traditional Chinese Medicine (TCM) Kangfuling capsules versus Placebo	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8408	朱美兰 1998	\N	Traditional Chinese Medicine (TCM) Shuxuening + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
8409	张淑芹 1998	\N	Traditional Chinese Medicine (TCM) Shuxuening + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
8410	李永远 2001	\N	Sultopride versus Sulpiride	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8411	施晓辉 2001	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8412	杨永杰 2001	\N	Olanzapine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8413	郭辉荣 2005	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8414	任清涛 2001	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8415	卢白莉 2001	\N	Anshen-Jianpi Syrup (TCM)+ Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	143	\N	\N	\N	\N	\N
8416	王秀英 2001	\N	L-Stopholidine+ Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
8417	张守来 2002	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
8418	万纯 2002	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8419	刘宏林 2001	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	221	\N	\N	\N	\N	\N
8420	肖正军 2001	\N	Risperidone, once daily versus Risperidone, twice daily	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8421	黄群明 2001	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
8422	刘俊彪 2004	\N	Chlorpromazine versus Risperidone	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
8423	李禄斌 1994	\N	Traditional Chinese Medicine (TCM) versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8632	Dunn 2005 a	\N	Ziprasidone versus 10-160 mgs	\N	United States of America	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
8424	吴多琛 1994	\N	Traditional Chinese Medicine (TCM) Mengshi-Guntan Pills + Chlorpromazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8425	王强 1995	\N	Chlorpromazine + Lithium versus Chlorpromazine + Placebo//Chlorpromazine versus Placebo//Chlorpromazine versus lithium	\N	China	\N	\N	\N	\N	\N	miss	\N	\N	\N	\N	\N
8426	王健 1995	\N	Clozapine + Sulpiride versus Sulpiride	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
9209	Cao 2005 b	\N	Chlorpromazine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
8427	范庆祝 1996 a	\N	Traditional Chinese Medicine (TCM) Clozapine + Huangyuansan versus Clozapine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8428	路英智 1996	\N	Morita therapy + Antipsychotic medication versus Occupational therapy + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8429	范庆祝 1996 b	\N	Traditional Chinese Medicine (TCM) Clozapine + Huangyuansan versus Clozapine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8430	张衍军 1996	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
8431	董雪琴 1997	\N	Psychological nursing + Antipsychotic medication versus Conventional nursing + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8432	Ju 1997	\N	Thioridazine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
8433	曹典永 1997	\N	Clozapine + Cerebroprotein hydrolysate versus Clozapine + Ginseng royal jelly	\N	China	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
8434	童伟鹏 1997	\N	Flupentixol versus Fluphenazine	\N	China	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
8435	马起民 1999	\N	Risperidone versus Clozapine or Chlorpromazine	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
8436	钱烈 2000	\N	Psychological rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
8437	刘南华 2004	\N	Risperidone + Clonazepam versus Clozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8438	韩孝龙 1998	\N	Traditional Chinese Medicine (TCM) Yinxingye + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
8439	殷青云 1998	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8440	翁正 1998	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	195	\N	\N	\N	\N	\N
8441	常素兰 1998	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
8442	张利霞 1999	\N	Sulpiride + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8444	王丽娟 1999 a	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8445	许海丽 2002	\N	Chlorpromazine + Sodium Valproate versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8446	Li 2002	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
8447	丁利陆 2002	\N	Psychological intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
8448	孙祺章 2000	\N	Venlafaxine versus Amitriptyline	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8449	孙秀珍 2005	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8450	盖万良 2005	\N	Comprehensive rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8451	文素荣 2005	\N	Music therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
8452	徐美勤 2002	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8453	袁国桢 2002	\N	Chlorpromazine versus Risperidone	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
8454	滕光华 2004	\N	Behaviour nursing + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8455	崔金波 2004	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
8456	张衍军 1999	\N	Levamisole + Haloperidol versus Haloperidol	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
8457	张敬悬 1999	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
8458	余国汉 1999	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	135	\N	\N	\N	\N	\N
8459	姜文成 1999	\N	Sulpiride versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8460	张宝山 1999	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
8461	贾占玲 1999	\N	Pipotiazine + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
8462	司淑玉 1999	\N	Sulpiride + Clozapine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
8463	王丽娟 1999 b	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8464	邵亚琴 1999	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
8465	任进军 2000	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
8466	胡锡澄 2000	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
8467	肖晓梅 2000	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	218	\N	\N	\N	\N	\N
8468	张喆 2000	\N	Health education + Haloperidol versus Haloperidol	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
8469	熊典樟 2000	\N	Thioridazine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8470	蔡铁水 2000	\N	Traditional Chinese Medicine (TCM) Yinxingye + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
8471	王振声 2000	\N	Risperidone versus Haloperidol Decanoate	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
20287	赵业华 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
8472	蒋先胜 2000	\N	Return visit + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
8473	孙树花 2001	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
8474	邹开庆 2001	\N	Adaptive psychotherapy + Care as usual versus Care as usual	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8475	倪建良 2001	\N	Risperidone + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	326	\N	\N	\N	\N	\N
8476	李健芬 2001	\N	alter ego therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8477	楚平华  2001	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
8478	Zheng 2001	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
8479	孙祺章 2001	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
8480	阮鸿杰 2001	\N	Traditional Chinese Medicine (TCM) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
8481	王大华 2000	\N	Traditional Chinese Medicine (TCM) + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
8482	曹静 2001	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8483	宋春爱 2001	\N	Rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
8484	黎丽燕 2001	\N	Psychological intervention + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8485	沈鉴清 2001	\N	Psychological rehabilitation + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
8486	庞道记 2001	\N	Haloperidol Decanoate versus Fluphenazine Decanoate	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
8487	王俊 2001	\N	Psychological intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8488	刘绍梅 2001	\N	Risperidone versus Fluphenazine	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
8489	王胜利 2001	\N	Shuxuening (Traditional Chinese Medicine (TCM)) + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
20344	褚建平 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
8490	龙瑞芳 2001	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8491	何传才 2002	\N	Psychosocial intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
8492	邹国华 2002	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8493	汪金霞 2002	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
8494	吴晓梅 2002	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8495	杨小男 2002	\N	Clozapine + Fluoxetine versus Clozapine	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
8496	谷瑞莲 2002	\N	Risperidone versus Fluphenazine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
8497	王荣芝 2002	\N	Psychotherapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8498	詹来英 2002	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
8499	黄蜀礼 2002	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
8500	蔡志利 2002	\N	Doxepin + Sulpiride versus Sulpiride	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8501	严明 2002	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8502	唐焕英 2002	\N	WL-HA-Z cerebral function therapy machine + Music therapy versus Music therapy	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
8503	解昌国 2002	\N	L-Stepholidine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
8504	Lv 2002 a	\N	Morita therapy + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
8505	李晏 2002	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
8506	李定国 2002	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
8507	王辉 2002	\N	Music therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8508	周一平 2002	\N	Psychological nursing + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8509	梁绮霞 2002	\N	Cognitive therapy + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8510	吴丽荣 2002	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
8511	邱亚锋 2002	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8512	李义明 2002	\N	Psychotherapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8513	邢秀娟 2003	\N	Venlafaxine + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20288	赵雅琴 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
8514	魏德花 2003	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8515	周虎江 2003 a	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	221	\N	\N	\N	\N	\N
8516	周保 2003	\N	Music therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	158	\N	\N	\N	\N	\N
8517	王勇 2003	\N	Cognitive therapy + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
8518	张福英 2003	\N	Nursing intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
8519	邹果果 2003	\N	Clozapine + Sulpiride versus Sulpiride	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
8520	刘锋 2003	\N	Dijia injection (TCM) versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8521	梁芝国 2003	\N	Haloperidol + Clonazepam versus Haloperidol	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8522	周虎江 2003 b	\N	He-Ne laser irradiation versus Trihexyphenidyl	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
8523	周秀华 2003	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8524	任朝晖 2003	\N	Discharge on parole + Care as usual versus Care as usual	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
8525	刘剑涛 2003	\N	Risperidone + Haloperidol versus Clozapine	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
8526	吕兴林 2003	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
8527	刘红兵 2003	\N	Clozapine + Lithium versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8528	周长梅 2003	\N	Health education + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
8529	陈元生 2003	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
8530	杜文佳 2003	\N	Chlorpromazine versus Risperidone	\N	China	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
8531	陈昌钦 2003	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
8532	Liu 2003	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
8533	钟华 2003	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	212	\N	\N	\N	\N	\N
8534	杜晋峰 2003	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8535	冯义萍 2003	\N	behaviour therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
8536	Yan 2003	\N	behaviour therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8537	徐青 2003	\N	Psychological behavioral therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8538	朱倩芸 2003	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
8539	张培新 2003	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
8540	孔令霞 2003	\N	Health education + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	111	\N	\N	\N	\N	\N
8541	李聪慧 2003	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
8542	安宝富 2003	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8543	曹欣冬 2003	\N	Traditional Chinese Medicine (TCM) Shen'an decotion versus Alprazolam	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8544	周保慧 2004	\N	Psychotherapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8545	戴敏誉 2004	\N	Organised psychoeducation versus Routine health education	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
8546	李聪 2004	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
8547	余国汉 2004	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8548	安宝富 2004	\N	Psychosocial intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8549	陈彬 2004	\N	Venlafaxine + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
8550	谌益华 2004	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8551	吴金凤 2004	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
8552	魏爱荣 2004	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8553	冯义萍 2004	\N	Citalopram + Clozapine versus Clozapine + Placebo	\N	China	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
8554	王长奇 2004	\N	Risperidone + Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
8555	杨小男 2004	\N	Quetiapine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
8556	邓炳 2004	\N	Chlorthixol Decanoate versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
8557	李转清 2004	\N	Recreational therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
8558	Zhang 2004 n	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8559	尹浩然 2004	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
8560	汪涛 2004	\N	Buspirone + Risperidone versus Risperidone + Placebo	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
8561	邓云峰 2004	\N	Risperidone + Clonazepam versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
8562	曹永康 2004 a	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	226	\N	\N	\N	\N	\N
8563	曹永康 2004 b	\N	Anle tablets (TCM) versus Diazepam	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
8564	万杰 2004	\N	Skill training + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
8565	张建球 2004	\N	Risperidone + Paroxetine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8566	宋爱美 2004	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
8567	杨玲 2004	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
8569	陈宇晖 2004	\N	Risperidone + Haloperidol versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8570	陈玉广 8505	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8571	丁关元 2005	\N	Acupuncture + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
8572	孙秀娟 2005	\N	Psychological intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	158	\N	\N	\N	\N	\N
8573	Bai 2005a	\N	Aniracetam versus Piracetam	\N	China	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
8574	陶用富 2005	\N	Athletic therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
8575	张志强 2005	\N	Venlafaxine + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
8576	韦强 2005 a	\N	Venlafaxine + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
8577	宋金环 2005	\N	Occupation recreational therapy + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8578	刘桂荣 2005	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8582	McGlashan 2005 b	\N	early detection intervention versus control group	\N	Norway//Denmark	\N	\N	\N	\N	\N	281	\N	\N	\N	\N	\N
8583	Urioste 2005 b	\N	motivational enhancement therapy (GAIN) versus approach as usual	\N	United States of America	\N	\N	\N	\N	\N	650	\N	\N	\N	\N	\N
8584	Jones 2005 a	\N	Atypical Antipsychotics versus typical Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	227	\N	\N	\N	\N	\N
8586	Houston 2005	\N	oral Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
8588	Krystal 2005	\N	ketamine + LY354740 versus Placebo ketamine + Placebo LY354740	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
8589	Mobascher 2005	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	Germany	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
8590	Ganguli 2005 a	\N	behavioural intervention + Antipsychotic treatment versus Antipsychotic treatment	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
8591	Castelein 2005	\N	support group versus control group	\N	Netherlands	\N	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
8592	Bertelsen 2005	\N	psychosocial integrated treatment versus standard care	\N	Denmark	\N	\N	\N	\N	\N	547	\N	\N	\N	\N	\N
8593	Savitz 2005	\N	pregnenolone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
8595	Greig 2005	\N	neurocognitive enhancement therapy + supported employment versus supported employment	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
8596	Summerfelt 2005	\N	glycine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
8598	Gaither 2005	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	United States of America	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
8599	Baker 2005	\N	smoking cessation intervention versus routine care	\N	United Kingdom	\N	\N	\N	\N	\N	298	\N	\N	\N	\N	\N
8600	Reeder 2005	\N	cognitive remediation versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
8601	Bryson 2005	\N	neurocognitive enhancement therapy + work therapy versus work therapy	\N	United States of America	\N	\N	\N	\N	\N	145	\N	\N	\N	\N	\N
8602	Mueller 2005 a	\N	work related social skills training versus unspecific social skills traning	\N	Switzerland	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
8604	Mishara 2005 a	\N	Antipsychotics versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
8605	Tapp 2005	\N	Quetiapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
19411	周继前 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	206	\N	\N	\N	\N	\N
8606	McGurk 2005 a	\N	cognitive skills training versus control group	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
8607	Brown 2005 a	\N	behavioural intervention versus supportive treatment	\N	United Kingdom	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
8608	Kulkarni 2005 a	\N	transdermal estradiol + Antipsychotic treatment versus Antipsychotic treatment + Placebo	\N	Australia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8609	Hunter 2005	\N	Modafinil versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
8610	Benitez 2005	\N	repetitive transcranial magnetic stimulation versus sham	\N	Australia	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
8611	Perry 2005	\N	ketamine versus amphetamine	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
8612	Lauriello 2005	\N	Quetiapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
8613	Gafoor 2005 a	\N	Quetiapine versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8614	Faber 2005	\N	Atypical Antipsychotics versus discontinued medication	\N	Netherlands	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
8615	Pierre 2005	\N	Modafinil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
8616	Thorup 2005	\N	OPUS (integrated treatment including assertive community + family involvement + social skills training) versus standard care	\N	Denmark	\N	\N	\N	\N	\N	547	\N	\N	\N	\N	\N
8617	Rupnow 2005a	\N	Risperidone versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8618	Apiquian 2005	\N	Amoxapine versus Risperidone	\N	Mexico	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
8620	Locklear 2005	\N	Risperidone versus various doses	\N	United States of America	\N	\N	\N	\N	\N	324	\N	\N	\N	\N	\N
8621	Kane 2005 b	\N	sertindole versus Risperidone	\N	United States of America//Canada	\N	\N	\N	\N	\N	321	\N	\N	\N	\N	\N
8622	Schubert 2005	\N	Risperidone + galantamine versus Risperidone + Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
8623	Kinon 2005	\N	Olanzapine versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8624	Kim 2005 a	\N	Haloperidol + donepezil versus Haloperidol + Placebo//Haloperidol versus donepezil//Haloperidol versus Placebo//donepezil versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
8628	Antonova 2005	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
8629	Oren 2005	\N	Aripiprazole versus Placebo//Aripiprazole versus Haloperidol//Haloperidol versus Placebo	\N	Japan//United States of America	\N	\N	\N	\N	\N	448	\N	\N	\N	\N	\N
8630	Abel 2005	\N	saline versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
8631	Zhong 2005 a	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	673	\N	\N	\N	\N	\N
20345	裴双义 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8633	Lindenmayer 2005 a	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
8634	Lasser 2005 a	\N	Antipsychotics + Risperidone versus Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	324	\N	\N	\N	\N	\N
8636	Gopalan 2005	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	339	\N	\N	\N	\N	\N
8637	Joan 2005	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
8640	Zipursky 2005 a	\N	\N	\N	Canada	\N	\N	\N	\N	\N	239	\N	\N	\N	\N	\N
8641	NTR374	\N	short Antipsychotic treatment versus sustained Antipsychotic treatment	\N	Netherlands	\N	\N	\N	\N	\N	131	\N	\N	\N	\N	\N
8642	Lieberman 2005 a	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8643	Harrison 2005	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8644	Gaebel 2005 a	\N	Risperidone versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	271	\N	\N	\N	\N	\N
8645	Bellack 2005 a	\N	behavioural treatment versus standard care	\N	United States of America	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
8647	Bell 2005 a	\N	neurocognitive enhancement therapy + work therapy versus work therapy	\N	United States of America	\N	\N	\N	\N	\N	145	\N	\N	\N	\N	\N
8648	Nuechterlein 2005	\N	individual placement and support - workplace fundamental module versus vocational rehabilitation	\N	United States of America	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
8649	Wykes 2005 a	\N	cognitive remediation therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
8650	McDonell 2005 a	\N	psychoeducation family intervention versus control group	\N	United States of America	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
8651	Alvarez 2005	\N	Risperidone versus Haloperidol	\N	Spain	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
8653	Deberdt 2005 a	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	199	\N	\N	\N	\N	\N
8654	Schulze Monking 1993	\N	\N	\N	Germany	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
8656	Oldham 1963	\N	insulin coma therapy versus control group	\N	Unclear	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
8657	Wu 2002 f	\N	Psychological intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
8658	Liu 2004 d	\N	behaviour training + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
8660	Hogarty 1985	\N	fluphenazine decanoate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	159	\N	\N	\N	\N	\N
8661	Kinon 2004 b	\N	Olanzapine dose	\N	United States of America	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
8662	Adler 2005	\N	ondansetron versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
8663	Atmaca 2003 b	\N	Quetiapine versus control group	\N	Turkey	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
8665	Atmaca 2002 a	\N	Quetiapine versus Haloperidol	\N	Turkey	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
8666	Bechdolf 2004 d	\N	cognitive-oriented group therapy versus psychoeducational program	\N	Germany	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
8667	Feldman 2002	\N	psychoeducation training versus control group	\N	Germany	\N	\N	\N	\N	\N	191	\N	\N	\N	\N	\N
8675	Beebe 2004	\N	telephone intervention versus control group	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
8676	Bodkin 2005	\N	selegiline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
8678	Brunstein 2005	\N	allopurinol + Antipsychotic treatment versus Placebo + Antipsychotic treatment	\N	Brazil	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
8679	Buchanan 2005 a	\N	Clozapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
8680	Chaichan 2004	\N	Olanzapine + fluvoxamine versus Olanzapine	\N	Thailand	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
8681	Evins 2004 a	\N	Bupropion + cognitive behavioral therapy versus Placebo + cognitive behavioral therapy	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
8683	Fiszdon 2004	\N	cognitive remediation therapy + work therapy versus work therapy	\N	United States of America	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
8684	Chinman 2004	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
8685	Diaz 2005 a	\N	Clozapine dose	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
8686	Bhavani 1962	\N	ascorbic acid versus control group	\N	India	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
8688	Han 2004 a	\N	Typical Antipsychotics versus Mood stabilizer	\N	China	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
8689	Frackiewicz 2002	\N	Risperidone versus once daily, twice daily dosages	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
8690	Glick 2005 a	\N	Quetiapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
8692	Higashima 2004	\N	Haloperidol + levomepromazine versus Placebo + Haloperidol	\N	Japan	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
8694	Heresco-Levy 2005	\N	D-serine + Olanzapine versus D-serine + Placebo	\N	Israel	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
8696	Brooks 2003	\N	self management program (12-step condition) versus SMART condition	\N	United States of America	\N	\N	\N	\N	\N	170	\N	\N	\N	\N	\N
8697	Josiassen 2005 a	\N	Risperidone + Clozapine versus Placebo + Clozapine	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8700	Jolley 2003	\N	cognitive therapy + standard care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
8702	Kapur 2005 a	\N	Haloperidol versus Olanzapine versus Placebo//Haloperidol versus Olanzapine//Haloperidol versus Placebo//Olanzapine versus Placebo	\N	Canada	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
8703	Kelly 2005 a	\N	Risperidone versus fluphenazine	\N	United States of America	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	40	\N	\N	\N	\N	\N
8705	Lauriello 2005 b	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	439	\N	\N	\N	\N	\N
8706	Lamure 2003	\N	Haloperidol versus Zuclopenthixol Acetate	\N	France	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
8707	Levkovitz 2003	\N	L-tryptophan versus Placebo	\N	Israel	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
8710	Li 2004 f	\N	Home based psychological intervention + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
8712	Littrell 2003	\N	educational intervention + Olanzapine versus standard care + Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
8714	Lu 2004 b	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
8715	Lerner 2004	\N	vitamin B6 versus Placebo	\N	Israel	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
8716	Lester 2003	\N	GP intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	201	\N	\N	\N	\N	\N
8719	McGurk 2005 b	\N	Clozapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
8720	McIntosh 2004	\N	Transcranial Magnetic Stimulation versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
8722	Mintzer 2004	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	751	\N	\N	\N	\N	\N
8723	Modell 1965	\N	dextroamphetamine sulfate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
8724	Moresco 2004	\N	Olanzapine versus Clozapine	\N	Italy	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
8726	Nasrallah 2004	\N	Risperidone versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	369	\N	\N	\N	\N	\N
8727	Newton 2005	\N	Cognitive Behavioural Training versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
8729	Reynolds 2004	\N	transitional care intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
8730	Oosthuizen 2004	\N	Haloperidol dose	\N	South Africa	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8733	Petrakis 2005	\N	naltrexone + disulfiram versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	254	\N	\N	\N	\N	\N
8735	Papageorgiou 2004	\N	completion of an advancxe directive + usual care versus usual care//advance treatment directives	\N	United Kingdom	\N	\N	\N	\N	\N	161	\N	\N	\N	\N	\N
9155	Li 2005 e	\N	Loxapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
8736	Harris 2004	\N	nicotine gum versus control group	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
8737	Holi 2004	\N	transcranial magnetic stimulation (Transcranial Magnetic Stimulation) versus sham transcranial magnetic stimulation (Transcranial Magnetic Stimulation)	\N	Finland	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
8738	Harvey 2004 d	\N	IM lorazepam versus IM Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
8739	Harrison 2003	\N	day hospital versus home treatment	\N	United Kingdom	\N	\N	\N	\N	\N	187	\N	\N	\N	\N	\N
8741	Hu 2004 a	\N	Music therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
8742	Huber 2003	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus Placebo	\N	Germany	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
8746	Kuipers 2004 a	\N	croydon outreach and assertive support team versus treatment as usual	\N	United Kingdom	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
8748	Kotler 2004	\N	sulpiride + Olanzapine versus Olanzapine	\N	Israel	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
8749	Kingsep 2003	\N	\N	\N	Australia	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
8750	Kern 2005	\N	errorless learning versus symptom management	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8752	Marcus 2005	\N	Aripiprazole versus Placebo Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	367	\N	\N	\N	\N	\N
8753	Mahmoud 2004 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	684	\N	\N	\N	\N	\N
8754	Kenny 2004	\N	assertive community treatment versus brokered case management	\N	United States of America	\N	\N	\N	\N	\N	165	\N	\N	\N	\N	\N
8755	Brook 2001 a	\N	Intramuscular Ziprasidone versus Intramuscular Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	567	\N	\N	\N	\N	\N
8756	Daniel 2001 a	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
8757	Lesem 2001 a	\N	Ziprasidone Dosage	\N	United States of America	\N	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
8758	Brook 2000 a	\N	Intramuscular Ziprasidone versus Intramuscular Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
8759	Swift 1998 e	\N	Intramuscular Ziprasidone versus Intramuscular Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	306	\N	\N	\N	\N	\N
8760	Liberman 2002 a	\N	in vivo amplified skills training versus control group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8761	Rosenfarb 2004	\N	problem solving task versus control group	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
8762	Rutter 2004	\N	internal care management versus external care management	\N	United Kingdom	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
8763	Schooler 2005	\N	Risperidone versus Haloperidol	\N	Israel	\N	\N	\N	\N	\N	559	\N	\N	\N	\N	\N
8764	Sela 2003	\N	vitamins versus Placebo	\N	Israel	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
8765	Sheitman 2004	\N	secretin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
8766	Shin 2004	\N	psychoeducation + supportive thearapy versus supportive thearapy	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
8767	Pandalai 1998	\N	outpatient maintenance pharmacotherapy versus family maintenance therapy	\N	United States of America	\N	\N	\N	\N	\N	313	\N	\N	\N	\N	\N
8770	Souetre 1992	\N	Amisulpride versus Haloperidol	\N	France	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
8774	Tidey 2002	\N	contingent monetary reinforcement + transdermal nicotine patch versus non-contingent monetary reinforcement + sham patch	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
8777	Groff 2004	\N	case management versus control group	\N	United States of America	\N	\N	\N	\N	\N	331	\N	\N	\N	\N	\N
8778	Honer 2005 b	\N	anitpsychotic exposure group versus non exposed group	\N	Canada//Israel	\N	\N	\N	\N	\N	535	\N	\N	\N	\N	\N
8780	Reeder 2004	\N	cognitive remediation versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
8781	Wykes 1999 d	\N	cognitive remediation therapy versus intensive occupational therapy activities	\N	United Kingdom	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
8782	Kane 1990 b	\N	Clozapine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	268	\N	\N	\N	\N	\N
8783	Johns 1990	\N	fluphenazine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
8784	Johnson 2005 a	\N	crisis resolution team versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
8941	Jacobsen 2004	\N	nicotine patch versus Placebo patch	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
8942	Temple 2005	\N	cognitive therapy versus standard care	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
8944	Montero 2005	\N	behavioural family therapy versus relatives group	\N	Spain	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
8945	Dolan 2004	\N	eldepryl versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
8946	Dakhale 2005	\N	Antipsychotics + vitamin C versus Antipsychotics + Placebo	\N	India	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8947	Calsyn 2004	\N	onsite primary care within ATC versus referred to primary care in GIMC	\N	United States of America	\N	\N	\N	\N	\N	720	\N	\N	\N	\N	\N
8948	Sheremata 2004 a	\N	Atypical Antipsychotics + antidepressants versus Atypical Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
8949	Sheremata 2004 b	\N	Atypical Antipsychotics + antidepressants versus Atypical Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
8950	Garver 2005	\N	Risperidone versus no drug control	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
8951	Chibbaro 2005	\N	\N	\N	Italy	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
8952	Bechdolf 2005 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus clinical management	\N	Germany	\N	\N	\N	\N	\N	109	\N	\N	\N	\N	\N
8953	Bechdolf 2005 b	\N	\N	\N	Germany	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
8954	Kulkarni 2005 b	\N	transdermal estradiol + Antipsychotic treatment versus Antipsychotic treatment + Placebo	\N	Australia	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
8955	Kulkarni 2005 c	\N	raloxifen + standard hormone therapy versus Placebo + standard hormone therapy	\N	Australia	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
8956	McCabe 2005	\N	remediation program versus control group	\N	Australia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8957	Smelson 2005 a	\N	Olanzapine versus conventional Antipsychotic	\N	United States of America	\N	\N	\N	\N	\N	632	\N	\N	\N	\N	\N
8959	Toscano 2005	\N	Active Cognitive Therapy for Early Psychosis (ACE) versus befriending	\N	Australia	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
8960	O'Regan 2005 a	\N	depot group (B-complex vitamin) versus oral group	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8961	Rabinowitz 2005	\N	Risperidone versus Olanzapine	\N	Israel	\N	\N	\N	\N	\N	547	\N	\N	\N	\N	\N
8962	Papas 2005	\N	B-complex vitamin versus Placebo	\N	Australia	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
8963	Lee 2005 b	\N	Risperidone versus Haloperidol	\N	South Korea	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
8966	Kumari 2005	\N	rivastigmine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
8967	Belenkaya 2005	\N	Risperidone versus Quetiapine	\N	Russian Federation	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
8970	Lieberman 2005 b	\N	Olanzapine versus Risperidone	\N	United States of America//Canada	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
8971	Sharma 2005 a	\N	revistagmine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
8972	Bai 2005	\N	Olanzapine versus FGA control group Olanzapine versus Placebo	\N	Taiwan	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
8973	Bayar 2005	\N	Olanzapine versus Haloperidol	\N	Turkey	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
8976	Carson 2005	\N	Aripiprazole versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	317	\N	\N	\N	\N	\N
8977	Bombin 2005	\N	depot zuclopenthixol versus oral zuclopenthixol	\N	Spain	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
9156	Liu 2005 c	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
8978	Turczynski 2005	\N	Olanzapine versus conventional Antipsychotic	\N	Poland	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8979	Oleneva 2005	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) + Olanzapine versus Olanzapine	\N	Russian Federation	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
8980	Nachshoni 2005	\N	DHEA versus Placebo	\N	Israel	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
8983	Peuskens 2005	\N	Olanzapine versus Risperidone	\N	Belgium	\N	\N	\N	\N	\N	199	\N	\N	\N	\N	\N
8984	Mattys 2005	\N	Risperidone versus various doses	\N	Belgium	\N	\N	\N	\N	\N	323	\N	\N	\N	\N	\N
8985	Ophir 2005	\N	rivastigmine + Electro Convulsive Therapy (Electroconvulsive Therapy) versus Electro Convulsive Therapy (Electroconvulsive Therapy) + Placebo	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
8986	Modell 2005 a	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	367	\N	\N	\N	\N	\N
8987	Meltzer 2005 a	\N	Clozapine versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	980	\N	\N	\N	\N	\N
8988	Tang 1996	\N	Recreational therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8989	Moller 2005 a	\N	Amisulpride versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
8990	Rubio 2005	\N	\N	\N	Spain	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
8992	Ogasa 2005	\N	Lurasidone Dosage // Lurasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	160 // 132	\N	\N	\N	\N	\N
8993	Ray 2005	\N	Aripiprazole versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
20289	熊明兰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
8994	Seemann 2005 a	\N	quality circle and implementation group versus control group	\N	Germany	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
8995	Seemann 2005 b	\N	quality circle and implementation group versus control group	\N	Germany	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
8996	Tunis 2005	\N	Olanzapine versus conventional Antipsychotic	\N	United States of America	\N	\N	\N	\N	\N	664	\N	\N	\N	\N	\N
8997	L'Italien 2005	\N	Atypical Antipsychotics versus control group	\N	United States of America	\N	\N	\N	\N	\N	1520	\N	\N	\N	\N	\N
8998	Kapur 2005 b	\N	Olanzapine versus Placebo//Haloperidol versus Placebo//Haloperidol versus Olanzapine	\N	Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
8999	Vanelle 2004 a	\N	Amisulpride versus Olanzapine	\N	France//Italy//Tunisia	\N	\N	\N	\N	\N	85 85	\N	\N	\N	\N	\N
9001	Gafoor 2005 c	\N	Quetiapine versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
9002	Sethuraman 2005	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	414	\N	\N	\N	\N	\N
9003	Deberdt 2005 c	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
9004	Deberdt 2005 d	\N	Olanzapine versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	166	\N	\N	\N	\N	\N
9005	Loza 2005	\N	oral Risperidone versus oral Olanzapine	\N	Poland	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
9007	Kim 2005 b	\N	Risperidone versus Quetiapine	\N	South Korea	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
9008	Hamann 2005	\N	Shared Decision Making versus Treatment as Usual	\N	Germany	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
9010	Chabannes 2005	\N	psychoeducation program + Amisulpride versus control group + Amisulpride	\N	France	\N	\N	\N	\N	\N	220	\N	\N	\N	\N	\N
9011	Morken 2005	\N	integrated treatment versus standard care	\N	Norway	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
9013	Pae 2005	\N	rapid titration of Quetiapine versus conventional titration of Quetiapine	\N	South Korea	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9018	Ciliberto 2005	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	439	\N	\N	\N	\N	\N
9019	Hajak 2004	\N	magnetic stimulation (Transcranial Magnetic Stimulation) versus sham	\N	Germany	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
9020	Freudenreich 2005	\N	donepezil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
9021	Corripio 2005	\N	Ziprasidone versus Haloperidol	\N	Spain	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
9022	Evans 2005	\N	nutrition intervetntion + Olanzapine versus Placebo + Olanzapine	\N	Australia	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
9024	Basu 2004	\N	topiramate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
9026	Fleischhacker 2003 b	\N	Risperidone versus various doses	\N	United States of America	\N	\N	\N	\N	\N	725	\N	\N	\N	\N	\N
9027	Akhondzadeh 2005 a	\N	Haloperidol + allopurinol versus Haloperidol + Placebo//Haloperidol versus allopurinol//Haloperidol versus Placebo	\N	Islamic Islamic Republic of Islamic Republic of Iran	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
9028	Hansen 2004	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus befriending	\N	United Kingdom	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
9029	de Lima 2005	\N	Olanzapine versus first generation Antipsychotics	\N	Brazil	\N	\N	\N	\N	\N	197	\N	\N	\N	\N	\N
9030	Barak 2005	\N	Olanzapine versus Haloperidol	\N	Israel	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
9031	Mori 2004	\N	\N	\N	Japan	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
9032	Su 2005 a	\N	Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
9033	Silver 2005	\N	Amantadine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
9034	Weng 2005	\N	\N	\N	China	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
9035	Wagner 2005	\N	\N	\N	Germany	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
9036	Startup 2005	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
9037	Zhang 2005 a	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
9038	de Leon 2005	\N	Clozapine dose	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
9039	Revicki 1999 b	\N	unspecified Antipsychotic medications versus unspecified Antipsychotic medications	\N	United States of America	\N	\N	\N	\N	\N	414	\N	\N	\N	\N	\N
9040	Tait 2005	\N	practitioner receiving education intervention on detecting FEP versus practitioner receiving alternative educational session on Cognitive Behavioural Therapy (Cognitive Behavioral Therapy)	\N	United Kingdom	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
9041	Scherer 2004	\N	Clozapine versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9042	Aasen 2005	\N	Rivastigmine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
9043	Friedman 2005	\N	citalopram versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
9045	Kudoh 2004	\N	Antipsychotic discontinuation during anaesthesia versus antipsychoitc discontinuation after anaesthesia	\N	Japan	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
9046	Lopez-Carrero 2005	\N	electronic case report versus hard copy of case report	\N	Spain	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
9048	Sevy 2005	\N	Modafinil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
9049	Weissman 2005	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
9050	Mihalopoulos 2004	\N	behavioural family management versus multiple familu groups	\N	Australia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9052	Dobmeyer 1990	\N	prepaid health plan versus fee for service plan	\N	United States of America	\N	\N	\N	\N	\N	740	\N	\N	\N	\N	\N
9053	Metcalfe 2005	\N	intensive case management versus standard case management	\N	United Kingdom	\N	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
9054	de Leon 2004 b	\N	Clozapine dose	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9055	Evins 2005 a	\N	Bupropion versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
9056	Larrison-Faucher2004	\N	nicotime gum treatments versus no gum	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
9057	Hordern 1963	\N	trifluoperazine + tranyleypromine versus trifluoperazine	\N	Australia	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
9059	Lipkovich 2005	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	339	\N	\N	\N	\N	\N
9063	Owens 1997	\N	intensive management packages versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
9306	Widerlov 1990 b	\N	\N	\N	Sweden	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
9064	Weckowicz 1960 c	\N	Chlorpromazine versus Placebo//Chlorpromazine versus Ro5-0690//Ro5-0690 versus Placebo	\N	Canada	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
9065	Gerson 1964	\N	diketopiperazine derivative versus control group	\N	United States of America	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
9066	Rush 2003	\N	desease management program versus treatment as usual	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
9067	Wolf 2005	\N	Olanzapine versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
9069	Sun 2005 a	\N	Community based rehabilitation versus Inpatient care	\N	China	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
9070	Tan 2005 a	\N	Community based treatment versus Inpatient care	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
9071	Mathai 2004	\N	intercessory prayer versus standard care	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9072	Martin 2005	\N	assertive community treatment versus standard community treatment	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
9073	Sergi 2005	\N	errorless learning versus conventional instruction	\N	United States of America	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
9074	Vauth 2005	\N	computer assisted cognitive strategy training versus training of self-management skills for negative symptoms	\N	Germany	\N	\N	\N	\N	\N	138	\N	\N	\N	\N	\N
9075	Atmaca 2005	\N	Olanzapine + ginkgo biloba extract versus Olanzapine	\N	Turkey	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
9076	Kraus 2005	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
9078	Dollfus 2005	\N	Olanzapine versus Risperidone	\N	France	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
9079	Brunelin 2006	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus sham Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	France	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
9080	Kumari 2006	\N	rivastigmine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
9082	Hovens 2005	\N	As Required Lorazepam Added to Initial (Risperidone versus Zuclopenthixol)	\N	Netherlands	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
9084	Riedel 2005 b	\N	Quetiapine versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
9086	Keefe 2006 b	\N	Olanzapine versus Haloperidol	\N	United States of America//Canada//United Kingdom//Netherlands	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
9087	Tsai 2006	\N	D-Alanine (add on) versus Placebo	\N	Taiwan	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
9088	Himei 2005	\N	Haloperidol treated group + Risperidone versus untreated group + Risperidone	\N	Japan	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
9091	Ritchie 2006	\N	Risperidone versus Olanzapine	\N	Australia	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
9092	Rohricht 2006	\N	body oriented psychological therapy versus supportive councelling	\N	United Kingdom	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
9093	Rotondi 2005 a	\N	world wide web-based psychoeducation versus standard care	\N	United States of America	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
9094	Strakowski 2005	\N	Haloperidol versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
9095	Zipursky 2005 b	\N	Olanzapine versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
9096	Jhirwal 2006	\N	group cognitive behavioral therapy (Cognitive Behavioral Therapy)versus group psychoeduation	\N	India	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9097	Remillard 2005	\N	Risperidone versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
9098	Forchuk 2005	\N	transitional discharge model- peer support versus ongoing hospital support	\N	Canada	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
9099	Kane 2006 a	\N	Ziprasidone versus Chlorpromazine	\N	India	\N	\N	\N	\N	\N	306	\N	\N	\N	\N	\N
9100	Kozuki 2006	\N	visual feedback therapy versus supportive counselling group	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
9301	Saxena 1990a	\N	remoxipride versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	245	\N	\N	\N	\N	\N
9101	Kreinin 2006	\N	Amisulpride + Clozapine versus Placebo + Clozapine	\N	Israel	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
9104	Lecuona 2004	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus control group	\N	Germany//Switzerland	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
9106	STAR 2006	\N	Aripiprazole versus Risperidone//Aripiprazole versus Quetiapine//Aripiprazole versus Olanzapine Aripiprazole + community-based therapy versus standard-care + community-based therapy Aripiprazole versus Olanzapine Aripiprazole versus standard care	\N	United States of America//Belgium//Finland//United Kingdom//France	\N	\N	\N	\r\nUser defined 3\r\n	\N	555	\N	\N	\N	\N	\N
9109	McQuade 2004 b	\N	Aripiprazole versus Placebo	\N	Belgium//Japan//United States of America	\N	\N	\N	\N	\N	214	\N	\N	\N	\N	\N
9112	Geller 2005	\N	Chlorpromazine versus Clothiapine	\N	Israel	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
9113	Lieberman 2005 c	\N	Olanzapine versus Haloperidol	\N	United States of America//Canada//Netherlands//United Kingdom	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
9116	Loughnan 2004	\N	sevoflurane + Electroconvulsive Therapy versus propofol + Electroconvulsive Therapy	\N	Australia	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
9117	Delay 1959	\N	\N	\N	France	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
9118	Glick 1975 b	\N	short stay hospitalization versus long stay hospitalization	\N	United States of America	\N	\N	\N	\N	\N	235	\N	\N	\N	\N	\N
9119	Goff 2006 a	\N	lamotrigine versus Placebo	\N	United States of America//Canada//United Kingdom	\N	\N	\N	\N	\N	217	\N	\N	\N	\N	\N
9120	Goff 2006 b	\N	lamotrigine versus Placebo	\N	United States of America//Canada//United Kingdom	\N	\N	\N	\N	\N	212	\N	\N	\N	\N	\N
9121	Lewis 2003 b	\N	Clozapine versus conventional treatment	\N	United Kingdom	\N	\N	\N	\N	\N	227	\N	\N	\N	\N	\N
9122	Lewis 2003 c	\N	Clozapine versus conventional treatment	\N	United Kingdom	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
9125	Anzai 2002 b	\N	occupational rehabilitation program versus community re-entry program	\N	Japan	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
9126	Farzin 2005	\N	perphenazine + famotidine versus perfenazine + Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
9127	Generali 2002	\N	metformin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
9128	Kallert 2004 b	\N	day treatment versus inpatient treatment	\N	Germany	\N	\N	\N	\N	\N	191	\N	\N	\N	\N	\N
9130	Kretzschmar 2005	\N	\N	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9131	Langle 2006 a	\N	vocational therapy versus ergotherapy	\N	Germany	\N	\N	\N	\N	\N	227	\N	\N	\N	\N	\N
9132	Nechifor 2004	\N	Risperidone versus Haloperidol	\N	Romania	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
9133	Ukpong 2002	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus sham Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	Nigeria	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
9134	Schulte 2006	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9135	Yamashita 2005	\N	\N	\N	Japan	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
9141	Kavanagh 2004	\N	motivational intervention versus standard care	\N	Australia	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
9142	Scholten 2005	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
9143	Akhondzadeh 2005 b	\N	Risperidone + lamotrigine versus Risperidone + Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
9144	Bazzoni 2003	\N	\N	\N	Italy	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9147	Melle 2006	\N	early detection intervention versus control group	\N	Norway	\N	\N	\N	\N	\N	281	\N	\N	\N	\N	\N
9149	Rosenberg 2001 b	\N	sildenafil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9150	Turkington 2003 b	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus befriending	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9151	Feng 2001	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9152	Fu 2005	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
9153	Jiang 2005 a	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
9154	Li 2005 d	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
9157	Qin 2005	\N	Risperidone + Alprazolam versus Clozapine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9158	Sun 2005 b	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
9159	Ma 2005 a	\N	Antipsychotics versus Self-control (Before treatment of Clozapine)	\N	China	\N	\N	\N	\N	\N	137	\N	\N	\N	\N	\N
9160	Tang 2005 a	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
9161	Wang 2005 b	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
9162	Wang 2005 c	\N	Aripiprazole versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
19412	单美艳 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9163	Xie 2005 a	\N	assertive community treatment versus standard care	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
9164	Yang 2005 a	\N	Venlafaxine + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9165	Ye 2005 a	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
9166	Zhang 2005 c	\N	Quetiapine + Chlorimipramine versus Clozapine + Chlorimipramine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9167	Zhang 2005 d	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
9168	Zhang 2005 e	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
9169	Zhang 2005 f	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9170	Zhao 2005 a	\N	Aripiprazole versus Sulpiride	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9171	Zhou 2005 a	\N	Psychotherapy + Fluoxetine versus Psychotherapy	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
9172	Cao 2005 a	\N	Chlorpromazine versus Olanzapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9173	Chen 2005 b	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	222	\N	\N	\N	\N	\N
9174	Chen 2005 c	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9175	Chen 2005 d	\N	Risperidone + Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9176	Bai 2005 d	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9177	Chen 2005 e	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9178	Gao 2005 a	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
9179	Guan 2005	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9180	Han 2005 a	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
9181	Hao 2005	\N	Quetiapine + niuhuang ninggong tablet (TCM) versus Quetiapine	\N	China	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
9182	Tan 2005 b	\N	Risperidone solution versus Haloperidol	\N	China	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
9183	He 2005 a	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
9184	Jiang 2005 b	\N	Psychoeducation + Antipsychotic medication versus Antipsychotic medication + standard care	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
9185	Li 2005 f	\N	Olanzapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9186	Lin 2005 c	\N	Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
9187	Mai 2005	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
9188	Tang 2005 b	\N	Ziprasidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
9189	Wang 2005 d	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
9190	Wang 2005 e	\N	Risperidone versus Healthy volunteer as control	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
9191	Wang 2005 f	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9192	Wang 2005 g	\N	Risperidone versus Healthy volunteer as control	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
9193	Wang 2005 h	\N	Risperidone versus Healthy volunteer as control	\N	China	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
9194	Wang 2005 i	\N	Quetiapine versus Healthy volunteer as control	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
9195	Wang 2005 j	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9196	Wu 2005 a	\N	Olanzapine + Sulpiride versus Olanzapine	\N	China	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
9197	Wu 2005 b	\N	Open ward management + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
9198	Xia 2005	\N	Aripiprazole versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9199	Yang 2005 b	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9200	Yao 2005 a	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
9201	Yuan 2005 a	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
9202	Zhao 2005 b	\N	Comprehensive rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
9203	Zhai 2005	\N	Health belief therapy (a combination of Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) and psychoeducation) + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
9204	Zhang 2005 g	\N	Olanzapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
9205	Zhu 2005 a	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9206	Zhu 2005 b	\N	Traditional Chinese Medicine (TCM) Shunqidaotan decoction versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9207	Zhong 2005 b	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
19413	陈丽娟 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9210	Cheng 2005 a	\N	Comprehensive rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
9211	Dai 2005	\N	Aripiprazole versus Quetiapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9212	Ding 2005 a	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
9213	Du 2005 b	\N	Skills training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
9214	Du 2005 c	\N	Clozapine versus control group	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
9215	Du 2005 d	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9216	Du 2005 e	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	143	\N	\N	\N	\N	\N
9217	Fan 2005 a	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
9218	Fan 2005	\N	Aniracetam + Quetiapine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
9219	Gao 2005 b	\N	Venlafaxine + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
9220	Guo 2005	\N	Paroxetine + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
9221	Han 2005 b	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
9222	He 2005 b	\N	Music therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9223	Hong 2005	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9224	Huang 2005 a	\N	Tiapride versus Quetiapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9225	Jiang 2005 c	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
9227	Li 2005 h	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9228	Li 2005 i	\N	Humanism nursing management + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9229	Li 2005 j	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
9230	Li 2005 k	\N	Music and sport therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
9231	Liu 2005 d	\N	Cognitive therapy and family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
9232	Liu 2005 e	\N	Low dose Clozapine versus High dose Clozapine	\N	China	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
9234	Luo 2005 a	\N	Acupuncture + Risperidone versus Risperidone Risperidone + Acupuncture versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9235	Luo 2005 b	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9236	Miao 2005	\N	Family-community intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9237	Meng 2005	\N	Art therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9238	Peng 2005	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	191	\N	\N	\N	\N	\N
9239	Qiu 2005 a	\N	Family acompanied open ward management + Clozapine versus Closed ward management + Clozapine	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
9240	Pan 2005	\N	Olanzapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
9241	Shang 2005	\N	stepholidine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
9242	Sheng 2005	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
9243	Shi 2005 a	\N	Cattle encephalon glycoside and ignotin + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9244	Tan 2005 c	\N	Community based rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9245	Tao 2005 a	\N	Cognition behavioural therapy + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	177	\N	\N	\N	\N	\N
9246	Tao 2005 b	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
9247	Wang 2005c	\N	Bibliotherapy versus standard care	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9248	Wang 2005	\N	Quetiapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
9249	Wang 2005 m	\N	Chlorpromazine versus Risperidone	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9250	Wang 2005 n	\N	Risperidone + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
9251	Wang 2005 o	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	123	\N	\N	\N	\N	\N
9252	Wang 2005 p	\N	Acupuncture + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
9253	Wang 2005 q	\N	Imported Risperidone versus Domestic Risperidone	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
9254	Wang 2005 r	\N	Chlorimipramine + routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
9255	Wang 2005 s	\N	Family care sevice intervention (a combination of open ward management with relabilitation therapy) + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
9256	Wang 2005 t	\N	Quetiapine + Clonazepam versus Haloperidol	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
9257	Wang 2005 u	\N	Occupational therapy (craft) + care as usual versus care as usual	\N	China	\N	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
9258	Wang 2005 v	\N	Ziprasidone versus various dosages	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9259	Wu 2005 c	\N	Buflomedil hydrochlorde + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
9261	Xu 2005 b	\N	Insight education therapy + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
9262	Yao 2005 b	\N	Tianeptine versus Placebo // Fluoxetine versus Tianeptine	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
9263	Yuan 2005 b	\N	Shaoyao gancao decoction (TCM) + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
9264	You 2005	\N	Rehabilitation therapy + routine Antipsychotic versus standard care	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9265	Ye 2005 b	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
9266	Yang 2005 c	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9267	Wang 2005 w	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	159	\N	\N	\N	\N	\N
9268	Zhou 2005 b	\N	Cognitivel therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
9269	Zhang 2005 h	\N	Quetiapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
9270	Zhang 2005 i	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
9271	Zhang 2005 j	\N	mianserin versus amitryptiline	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
9272	Zhang 2005 k	\N	Psychoeducation versus Conventional health education	\N	China	\N	\N	\N	\N	\N	111	\N	\N	\N	\N	\N
9273	Zhi 2005	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9274	Zhou 2005 c	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
9275	Tian 2005 a	\N	Family nursing intervention + Risperidone versus Risperidone alone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9276	Sun-ling 2005	\N	Catgut Embedding at Acupoint + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
9277	Huang 2005 b	\N	Psychoeducation + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
9278	Keri 2006	\N	\N	\N	Hungary	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
9279	Li 2005 l	\N	Traditional Chinese Medicine (TCM) Integrated with Western Medicine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
9280	Li 2005 m	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication + standard care	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9282	Su 2005 b	\N	Family intervention versus standard care	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
9284	Ren 2005 b	\N	Simulated family environment + Antipsychotics + comprehensive skills training versus Closed ward management + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9285	Bao 2005	\N	Self-management training + health education + Antipsychotic medication versus health education + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9286	Barnas 1990	\N	zotepine versus Haloperidol	\N	Austria	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
9287	Chang 1990	\N	Haloperidol (10 mg) versus reduced Haloperidol	\N	China//United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
9288	Carpenter 1990 b	\N	continuous medication versus standard dose, targeted neuroleptics	\N	United States of America	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
9289	Cooper 1990 b	\N	remoxipride versus Placebo	\N	Ireland	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
9290	De Cuyper 1990	\N	Risperidone versus Haloperidol	\N	Belgium	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9291	Eklund 1990	\N	Haloperidol decanoate versus Placebo	\N	Sweden	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
9293	Jarema 1990	\N	neuroleptcs versus control group	\N	Poland	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
9294	Jasovic-Gasic 1990	\N	tricyclic antidepressant versus Placebo	\N	Yugoslavia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9295	Kissling 1990 a	\N	flupenthixol decanoate versus Haloperidol decanoate	\N	Germany	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
9296	Kissling 1990 b	\N	SND 919 versus classical neuroleptics	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
9297	Meszaros 1990	\N	carbamazepine versus Placebo	\N	Austria	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
9298	Montgomery 1990	\N	desenkephalin endorphin versus Placebo	\N	United Kingdom // Netherlands // Germany	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
9299	Mori 1990	\N	\N	\N	Japan	\N	\N	\N	\N	\N	167	\N	\N	\N	\N	\N
9302	Saxena 1990b	\N	clopixol versus modecate	\N	Canada	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9303	Strauss 1990	\N	intermittence from neuroleptic therapy versus standard care	\N	Germany	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
9304	Ulmar 1990	\N	trifluperidol versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
9305	Yagi 1990 b	\N	Meclofenoxate versus Placebo	\N	Japan	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9307	Yamagami 1990	\N	Haloperidol versus Prolactin	\N	Japan	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
9308	Hebenstreit 1990 a	\N	controlled release remoxipride versus Haloperidol	\N	Austria	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
9309	Hebenstreit 1990 b	\N	immediate release remoxipride versus Haloperidol	\N	Austria	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
9310	Yang 2005 d	\N	Clozapine + MElectroconvulsive Therapy versus Clozapine alone	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9314	Minami 1990 a	\N	Chlorpromazine versus Haloperidol	\N	Japan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9315	Minami 1990 b	\N	Chlorpromazine versus Haloperidol	\N	Japan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9316	Adams 2005	\N	orientation letter versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	764	\N	\N	\N	\N	\N
9317	Adams 2001	\N	exercise versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
9318	Barnes 2003	\N	Amisulpride versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9319	Barnes 2001 b	\N	Clozapine versus second generation Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	702	\N	\N	\N	\N	\N
9320	Barrowclough 2004 a	\N	motivational intervention versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
9321	Barrowclough 2001 b	\N	group cognitive therapy versus routine care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9322	Bentall 2001 b	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9323	Byng 2001	\N	gps services versus secondary services	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9326	Bebbington 2002	\N	Cognitive Behavioural Training + individual family treatment + standard care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9327	Britto 2001	\N	Ziprasidone versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
9328	Birchwood 2001 a	\N	early intervention versus control group (psychoeducation)	\N	United Kingdom	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
9329	Birchwood 2001 b	\N	early detection intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9330	Burns 2001 a	\N	Risperidone versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9331	Burns 2001 b	\N	work placement training versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	1000	\N	\N	\N	\N	\N
9332	Burns 2001 c	\N	intensive case management versus standard case management	\N	United Kingdom	\N	\N	\N	\N	\N	700	\N	\N	\N	\N	\N
9333	Chambers 2005	\N	Occupational therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9334	Crawford 2004	\N	music therapy + standard care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9335	Cook 2004	\N	Occupational therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
9336	Dye 2001	\N	motivational interview versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
9337	Garety 2001 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9338	Dursun 2002	\N	lamotrigine + standard care versus Placebo + standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9340	Doody 2002	\N	coronary heart risk reduction models	\N	United Kingdom	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
9341	Day 2001	\N	educational intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9342	Dick 2001	\N	community rehabilitation program versus control group	\N	United Kingdom	Royal Dunbdee Liff Hospital, Dundee Healthcare NHS Trust, Royal Dunbdee Liff Hospital, DUNDEE, DD2 5NF, Scotland. Telephone: 01382 580441	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9343	Ebrahim 2006	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus supportive group intervention	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9344	Ebmeier 2001	\N	Transcranial Magnetic Stimulation versus sham	\N	United Kingdom	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
9345	Fahy 2004 b	\N	reasoning and rehabilitation versus control group	\N	United Kingdom // Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9346	Fallon 2002 b	\N	lamotrigine + standard care versus Placebo + standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9347	Fewtrell 2003	\N	ego consilidation methods versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9348	Fowler 2004	\N	social recovery cognitive behavioral therapy versus treatment as usual	\N	United Kingdom	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9351	Francis 2006	\N	Patient Held Medical Records versus Control Group	\N	United Kingdom	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
9352	Garety 2001 b	\N	intensive assertive outreach team versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9353	Guy 2003	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9355	Godfrey 2001	\N	hormone replacement therapy + treatment as usual versus treatment as usual	\N	United Kingdom	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
9358	Gumley 2003 b	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + standard care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9359	Gumley 2001 a	\N	neruoleptic treatment + individualized psychoeducation versus neuroleptic treatment	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9360	Gumley 2001 b	\N	individualized early signs monitoring versus standard early signs monitoring	\N	United Kingdom	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
9361	Hirsch 2001 a	\N	Ziprasidone versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9362	Henderson 2001	\N	Personal Mental Health Records versus Service Information Booklets // Joint Crisis Plan	\N	United Kingdom	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
9365	Harvey 2001	\N	intensive case management versus standard case management	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9366	Haddock 2001	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + family support versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9367	Haddock 2004	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus social activity therapy	\N	United Kingdom	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
9368	Jumnoodoo 2003	\N	interview questionnaire versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9369	Jones 2001 d	\N	computer based approach versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
9370	Jones 2001 e	\N	pharmacology + Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus treatment as usual	\N	United Kingdom	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9371	Jaycock 2001	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9372	Jackson 2001 c	\N	cognitive therapy recovery intervention versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
9373	Hirsch 2001 b	\N	Ziprasidone versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9374	Knapp 2004	\N	early psychosis service versus standard community teams	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9375	Kerwin 2001	\N	Olanzapine versus Clozapine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9376	Jones 2005b	\N	recovery oriented cognitive behavior versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9377	Lewis 2001 c	\N	Cognitive Behavioral Therapy versus Clozapine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9378	Lewis 2001 d	\N	Cognitive Behavioural Training versus family support	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9379	Lewis 2001 e	\N	Cognitive Behavioural Training versus monitoring only	\N	United Kingdom	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
20346	袁月芳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9381	Lynch 2001	\N	M100907 versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9382	McCabe 2004	\N	outcome management versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9383	McCreadie 2001	\N	free fruits and vegetables versus treatment as usual	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9384	McKenna 2004	\N	Risperidone + Clozapine versus Placebo + Clozapine	\N	United Kingdom	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9385	McLoughlin 2004	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9386	Lester 2001	\N	GP intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9387	Lewis 2001 f	\N	Clozapine versus conventional treatment	\N	United Kingdom	\N	\N	\N	\N	\N	359	\N	\N	\N	\N	\N
9388	Morrison 2001	\N	early detection intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9389	Mortimer 2001 a	\N	Ziprasidone versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9390	Mortimer 2003 b	\N	Quetiapine versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	242	\N	\N	\N	\N	\N
9391	Mortimer 2001 b	\N	Clozapine versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9392	Mortimer 2001 c	\N	clozaril-leponex versus zyprexa	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
9394	Michael 2005	\N	social recovery oriented Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard case management	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9398	Petch 2001	\N	Cognitive Behavioural Training versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
20290	于信兵 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9401	Purdie 2001	\N	HRT + standard care versus control groups	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9402	Ramamurthy 2001	\N	Aripiprazole versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9403	Ratna 2003	\N	Quetiapine versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9404	Reveley 2003	\N	Ziprasidone versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9405	Reveley 2001 a	\N	Risperidone versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
9406	Reveley 2001 b	\N	Risperidone versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9407	Reveley 2001 c	\N	seroquel versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9408	Reynolds 2001	\N	Quetiapine versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
9409	Richardson 2001	\N	Omega-3 Fatty Acid versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
9410	Richardson 2001 b	\N	interactive art therapy + standard treatment versus standard treatment	\N	United Kingdom	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
9411	Richardson 2001 c	\N	interactive art therapy + standard treatment versus standard treatment	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9412	Ritchie 2002	\N	pindolol + Olanzapine versus pindolol	\N	United Kingdom	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
9413	Rohriht 2001	\N	body oriented psychological therapy versus supportive councelling	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9414	Gournay 2001	\N	medication management versus patient education training for nurses	\N	United Kingdom	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
9415	Sharma 2001 a	\N	Risperidone versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9416	Sharma 2001 b	\N	seroquel versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9418	Sensky 2001 b	\N	Cognitive Behavioural Training versus befriending	\N	United Kingdom	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
9419	Sahakian 2002	\N	Modafinil versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
9420	Suri 2001	\N	cognitive therapy versus not stated	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9421	Startup 2001 b	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9422	Spurrell 2001	\N	Clozapine versus Atypical Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9423	Singh 2001 a	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9425	Sharma 2001 c	\N	Olanzapine versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9426	Sharma 2002 b	\N	revistagmine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9427	Sharma 2002 c	\N	seroquel versus various dosages	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9428	Leavey 2001	\N	education and advice package versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9429	Tarrier 2004	\N	intensive case management versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9430	Tarrier 2001 b	\N	psychological intervention versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
9431	Tarrier 2001 c	\N	family support + cognitve service versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9432	Tarrier 2001 d	\N	home based rehabilitation versus hospital rehabilitation	\N	United Kingdom	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9433	Tarrier 2001 e	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9434	Tattan 2001	\N	intensive case management versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9435	Taylor 2001	\N	typical Antipsychotics versus Atypical Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
9436	Thornicroft 2002 b	\N	adherence therapy versus health education	\N	United Kingdom // Netherlands // Italy // Germany	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	409	\N	\N	\N	\N	\N
9437	Thornicroft 2004 b	\N	individual placement and support versus standard psychosocial programming	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9438	Thornicroft 2004 c	\N	individual placement and support versus standard psychosocial programming	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9439	Trower 2001 a	\N	cognitive therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9440	Trower 2001 b	\N	cognitive therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
9441	Turkington 2001 d	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
9442	Turner 2001	\N	Risperidone depot versus Risperidone tablet	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9443	Tyrer 2001 a	\N	internal care management versus external care management	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9444	Williams 2005 a	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9445	Warner 2006	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
9446	Wieck 2005	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9447	Williams 2005 b	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9448	Wilson 2001	\N	neuroleptic + cognitively oriented psychoeducation versus neuroleptic alone	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9449	Wright 2005 a	\N	proactive nurse facilitation versus informational packets + standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9450	Wright 2005 b	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9451	Wykes 2001	\N	cognitive remediation therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9452	Szmukler 2001	\N	carers' support programme versus standard treatment	\N	United Kingdom	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9453	Tarrier 2001 f	\N	family support and psycheducation versus not stated	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9454	Thompson 2001	\N	Clozapine versus not stated	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9455	Lester 2004 b	\N	early detection intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
9457	Chapman 2001	\N	behaviour modification training versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9458	Johnson 2004 b	\N	routine research versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9459	Lester 2004 c	\N	NICE guidelines for treatment and management of Schizophrenia versus Alternative NICE guidelines	\N	United Kingdom	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
9460	Drury 2001	\N	cognitive therapy versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9462	McCreadie 2005 b	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
9463	Nothard 2003	\N	safety behaviors prevention program versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9464	Sireling 2003	\N	sertindole versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9466	Chaudhry 2006	\N	Amoxapine versus Haloperidol	\N	Pakistan	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
9467	Beasley 2005 b	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	326	\N	\N	\N	\N	\N
9468	Binder 2006	\N	long acting Risperidone versus Olanzapine	\N	Canada	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
9469	Meyer 2006 a	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	310	\N	\N	\N	\N	\N
9471	Potkin 2005 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	182	\N	\N	\N	\N	\N
9472	Pina 2006	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	367	\N	\N	\N	\N	\N
9473	Marder 2006 a	\N	oral paliperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	444	\N	\N	\N	\N	\N
9477	Conrad 2006	\N	representative payeeship program versus control group	\N	United States of America	\N	\N	\N	\N	\N	184	\N	\N	\N	\N	\N
9479	Grass 2006	\N	Clozapine + Risperidone versus Clozapine	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9480	Gaudiano 2006	\N	acceptance and commitment therapy versus enhanced acceptance and commitment therapy acceptance and commitment therapy versus control group	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n\r\nUser defined 3\r\n	\N	40	\N	\N	\N	\N	\N
9481	Gumley 1997	\N	neruoleptic treatment + individualized psychoeducation versus neuroleptic treatment	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9482	Howell 1961	\N	fluphenazine versus Placebo//Trifluoperazine versus Placebo//fluphenazine versus Trifluoperazine	\N	United States of America	\N	\N	\N	Note by Claire: Not to be included in trifluperazine versus placebo, no data before cross over, no individual group data	\N	56	\N	\N	\N	\N	\N
9483	Kinon 2006 a	\N	Olanzapine versus conventional Antipsychotic or Risperidone	\N	United States of America	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
9484	Stroup 2006 a	\N	discontinuation of previous Atypical Antipsychotic + Olanzapine versus discontinuation of previous Atypical Antipsychotic + ziprazidone	\N	United States of America	\N	\N	\N	\N	\N	444	\N	\N	\N	\N	\N
9485	Scocco 2006	\N	Olanzapine + psychoeducational program versus Olanzapine control	\N	Italy	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
9486	McEvoy 2006 a	\N	Clozapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
9489	Wagner 2003	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	264	\N	\N	\N	\N	\N
9490	Velligan 2006	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
9492	Krakowski 2006	\N	Clozapine versus Haloperidol	\N	United States of America	Nathan S. Kline Institute for Psych Res Psychiatric Research Orangeburg, Ny 10962	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
9493	Harrison-Read 2000	\N	short term intensive case management versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9494	Tyrer 2001 b	\N	internal care management versus external care management	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
9495	Gross 1964	\N	\N	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9496	Carson 2004 a	\N	Aripiprazole versus Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	1119	\N	\N	\N	\N	\N
9497	Carson 2004 b	\N	Aripiprazole versus Placebo	\N	Japan//United States of America	\N	\N	\N	\N	\N	306	\N	\N	\N	\N	\N
9498	Casey 2004	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9500	Jody 2004 b	\N	Aripiprazole versus safety control group	\N	United States of America	\N	\N	\N	\N	\N	1599	\N	\N	\N	\N	\N
9503	Casey 2003 a	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	314	\N	\N	\N	\N	\N
9516	Bhaskaran 1958	\N	meratran versus ritalin	\N	India	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
9517	Matheu 1961	\N	fluphenazine dihydrochloride versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
9518	Ray 1962	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) + Chlorpromazine versus Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9519	Roncone 2004	\N	rehabilitation program versus control group	\N	Italy	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
9520	Scharfstein 2001	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9522	Archie 2006	\N	integrated care program versus control group	\N	Denmark	\N	\N	\N	\N	\N	547	\N	\N	\N	\N	\N
9523	Awad 2006	\N	Olanzapine versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
9524	Emsley 2006 b	\N	Risperidone versus Haloperidol	\N	Israel	\N	\N	\N	\N	\N	522	\N	\N	\N	\N	\N
9525	Gopalakrishnan 2006	\N	sildenafil versus Placebo	\N	India	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
9526	Miodownik 2006	\N	vitamin B6 versus Placebo	\N	Israel	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9527	Mauri 2006	\N	Olanzapine dose	\N	Italy	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
9528	Lencz 2006	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
9529	Lee 2006 a	\N	Olanzapine versus typical Antipsychotics	\N	South Korea//Taiwan//Malaysia	\N	\N	\N	\N	\N	898	\N	\N	\N	\N	\N
9530	Kim 2006 a	\N	topiramate + Olanzapine versus Olanzapine	\N	South Korea	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9531	Jandl 2006	\N	Transcranial Magnetic Stimulation versus sham	\N	Germany	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
9533	Heresco-Levy 2006 a	\N	sarcosine + Risperidone versus sarcosine + Placebo	\N	Taiwan	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
9534	Haddock 2006	\N	Cognitive Behavioural Training versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	309	\N	\N	\N	\N	\N
9535	Christensen 2006 a	\N	free recall words versus control group	\N	Canada	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
9536	Gumley 2006	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + standard care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
9537	Poyurovsky 2006	\N	mirtazapine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
9539	Sharma 2006	\N	revistagmine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9540	Wu 2006 a	\N	Clozapine versus sulpride	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
9542	Bresee 2006	\N	celecoxib versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
9543	Emsley 2005 a	\N	Quetiapine versus Haloperidol	\N	South Africa	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
9544	Timko 2006	\N	community care versus hopsital care	\N	United States of America	\N	\N	\N	\N	\N	230	\N	\N	\N	\N	\N
9545	Cui 2004	\N	Social skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9546	Jiang 2004 a	\N	Psychoeducation + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
9713	Eli Lilly 2003 c	\N	Olanzapine versus Aripiprazole	\N	Unclear	\N	\N	\N	\N	\N	560	\N	\N	\N	\N	\N
9547	Li 2004 h	\N	Mutual participation nursing care + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9548	Liu 2004 f	\N	Supportive psychological therapy + routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
9549	Ren 2004 c	\N	Comprehensive rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
9550	Wei 2005	\N	Morita therapy + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
9551	Zhong 2006	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
9553	Bellack 2006	\N	behavioural treatment versus control group	\N	United States of America	\N	\N	\N	\N	\N	175	\N	\N	\N	\N	\N
9554	Citrome 2006 a	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	572	\N	\N	\N	\N	\N
9555	Soo Kwon 2006	\N	weight management + Olanzapine versus Olanzapine	\N	South Korea	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
9556	McGurk 2005 c	\N	cognitive training + supported employment versus supported employment	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
9558	Shaw 2006	\N	Olanzapine versus Clozapine	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
9559	Olincy 2006	\N	nicotine agonist versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
9560	Dickey 2003	\N	medicaide managed care versus fee for service plan	\N	United States of America	\N	\N	\N	\N	\N	420	\N	\N	\N	\N	\N
9561	Mitchell 2006	\N	Olanzapine dose	\N	United States of America	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
9563	Van Meijel 2006 a	\N	relapse prevention plan versus standard care	\N	Netherlands	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
9564	Berkman 2006	\N	behavioural treatment for substance abuse versus supportive treatment for addiction recovery	\N	United States of America	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
9565	Bradley 2006	\N	multi-family group treatment versus control group	\N	Australia	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
9566	Mir 2006	\N	Aripiprazole versus Antipsychotics	\N	Unclear	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
9567	Valencia 2004 b	\N	\N	\N	Mexico	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9568	Grecu 2006	\N	Atypical drugs versus typical drugs	\N	Romania	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
9569	Loebel 2006 a	\N	Ziprasidone versus various dosages	\N	United States of America//Canada	\N	\N	\N	\N	\N	186	\N	\N	\N	\N	\N
9570	Schlogelhofer 2006	\N	Clozapine versus Quetiapine	\N	Australia//Austria	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
9571	Vasquez 2006	\N	Ziprasidone versus Haloperidol	\N	Peru	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
9572	Ascher-Svanum 2006 a	\N	Olanzapine versus typical Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	664	\N	\N	\N	\N	\N
9573	Bilder 2006	\N	Risperidone versus various doses	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9574	Boidi 2006	\N	rapid dose escalation with Quetiapine versus conventional dose escalation with Quetiapine	\N	Italy	\N	\N	\N	\N	\N	269	\N	\N	\N	\N	\N
9575	Bossie 2006	\N	long-acting Risperidone dose	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9576	Byerly 2006 a	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
9577	Canas 2006	\N	Quetiapine versus Risperidone	\N	Spain	\N	\N	\N	\N	\N	466	\N	\N	\N	\N	\N
9579	Citrome 2006 c	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	572	\N	\N	\N	\N	\N
9581	Cottingham 2006	\N	metformin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
9582	Currier 2006 a	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	445	\N	\N	\N	\N	\N
9584	Daniel 2006	\N	IM Aripiprazole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
9585	Faries 2006 a	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	218	\N	\N	\N	\N	\N
9586	Faries 2006 b	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9588	Gaebel 2006	\N	Risperidone versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	302	\N	\N	\N	\N	\N
9592	Jean-Baptiste 2006	\N	weight management program + Antipsychotics versus Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
9597	Kim 2006 b	\N	citalopram + Antipsychotics versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
9598	Kim 2006 c	\N	topiramate + Olanzapine versus Olanzapine	\N	South Korea	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9599	Kryzhanovskaya 2006a	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
9600	Lewis 2006 a	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9602	Loebel 2006 b	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	186	\N	\N	\N	\N	\N
9603	Potkin 2006 b	\N	Asenapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
9604	Penades 2006 a	\N	cognitive remediation therapy + standard medication follow-up versus cognitive behavioral therapy + standard medication follow-up	\N	Spain	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9605	Newcomer 2006	\N	Aripiprazole versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	290	\N	\N	\N	\N	\N
9607	Meyer 2006 d	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	306	\N	\N	\N	\N	\N
9608	Davidson 2006 b	\N	oral paliperidone extended release tablets versus Placebo	\N	Israel//South Africa	\N	\N	\N	\N	\N	618	\N	\N	\N	\N	\N
9609	McEvoy 2006 b	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
9610	McEvoy 2006 c	\N	Clozapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
9613	Rathod 2006	\N	Cognitive Behavioural Training versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	422	\N	\N	\N	\N	\N
9614	Rodriguez 2006	\N	Risperidone versus various doses	\N	United States of America	\N	\N	\N	\N	\N	323	\N	\N	\N	\N	\N
9615	Rubio 2006	\N	Risperidone versus zuclopenthixol Risperidone versus zuclopenthixol	\N	Spain	\N	\N	\N	\N	\N	115	\N	\N	\N	\N	\N
9618	Strom 2006	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	17000	\N	\N	\N	\N	\N
19414	熊辉 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
9620	Sacchetti 2006	\N	Ziprasidone versus Clozapine	\N	Italy	\N	\N	\N	\N	\N	146	\N	\N	\N	\N	\N
9622	Warrington 2006 a	\N	\N	\N	Canada//United States of America	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
9623	Zelaschi 2006	\N	Clozapine versus Olanzapine	\N	Argentina	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
9624	Bai 2006 a	\N	long-acting injectable Risperidone versus Risperidone oral tablets	\N	Taiwan	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
9625	Baloescu 2006	\N	Olanzapine versus Quetiapine, Risperidone, Amisulpride, Ziprasidone	\N	Romania	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
9626	Bosia 2006	\N	COMT gene + cognitive therapy versus Cognitive Behavioral Therapy	\N	Italy	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
9627	Castrogiovanni 2006	\N	psychoeducation program + Olanzapine versus Olanzapine	\N	Italy	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
9628	Chaudhry 2006 b	\N	Risperidone versus Quetiapine	\N	Pakistan	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
9631	Ertugrul 2006	\N	Risperidone versus Olanzapine	\N	Turkey	\N	\N	\N	\N	\N	123	\N	\N	\N	\N	\N
9632	Farzin 2006	\N	perphenazine + famotidine versus perfenazine + Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
9634	Gharabawi 2006	\N	Risperidone versus various doses Risperidone versus various doses Risperidone versus various doses Risperidone versus Haloperidol	\N	United States of America // France	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9635	Giaquinto 2006	\N	Olanzapine + diet therapy versus Olanzapine	\N	Italy	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
9636	Keefe 2006 a	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	1460	\N	\N	\N	\N	\N
9637	Kelemen 2006	\N	first generation Antipsychotics versus second generation Antipsychotics	\N	Hungary	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
9638	Kim 2006 d	\N	Aripiprazole versus Haloperidol	\N	South Korea	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
9640	Parellada 2006	\N	Quetiapine versus Olanzapine	\N	Spain	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
9641	Musil 2006	\N	Risperidone versus Quetiapine	\N	Germany	\N	\N	\N	\N	\N	474	\N	\N	\N	\N	\N
9642	Mossaheb 2006	\N	Clozapine + Haloperidol versus Clozapine + Placebo//Clozapine versus Haloperidol//Clozapine versus Placebo//Haloperidol versus Placebo	\N	Austria	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
9643	Mechri 2006	\N	Chlorpromazine versus Haloperidol	\N	Tunisia	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9645	Marinkovic 2006	\N	Risperidone versus various doses	\N	Serbia	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
9646	Mantua 2006	\N	non pharmacological interventions + oral medications versus non pharmacological interventions	\N	United Kingdom	\N	\N	\N	\N	\N	177	\N	\N	\N	\N	\N
9647	Lasic 2006	\N	Risperidone versus Haloperidol	\N	Croatia	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9648	Lin 2006 a	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
9650	Plesnicar 2006	\N	Risperidone versus Olanzapine	\N	Slovenia	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
9651	Ko 2006 a	\N	testosterone versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
9652	Klaras 2006	\N	lifestyle intervention + Atypical Antipsychotics versus Atypical Antipsychotics	\N	Sweden	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
9653	Prikryl 2006	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	Czech Republic	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
9654	Rappard 2006 a	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	186	\N	\N	\N	\N	\N
9655	Robles 2006	\N	Quetiapine versus Olanzapine	\N	Spain	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
9656	Ryu 2006	\N	leptin gene polymorphism versus Antipsychotics	\N	South Korea	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
9658	Shim 2006 a	\N	Aripiprazole versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
9659	Strous 2006	\N	Olanzapine+ DHEA versus Olanzapine + Placebo	\N	Israel	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9660	Su 2006 a	\N	Olanzapine versus Risperidone	\N	Taiwan	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
9661	Tudor 2006	\N	Olanzapine versus Ziprasidone	\N	Romania	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
9663	Lewis 2006 b	\N	Clozapine versus second generation Antipsychotics	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	136	\N	\N	\N	\N	\N
9665	Lewis 2006 c	\N	Atypical Antipsychotics versus conventional Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	227	\N	\N	\N	\N	\N
9666	Lewis 2006 d	\N	Clozapine versus conventional treatment	\N	United Kingdom	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
9667	Morrens 2006	\N	Atypical Antipsychotics versus conventional neuroleptics	\N	Belgium	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
9669	Addington 2006	\N	psychosocial treatment versus control group	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
9670	Alaghband-rad 2006 a	\N	pharmalogical treatment versus control group	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9671	Alaghband-rad 2006 b	\N	pharmalogical treatment versus control group	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
9673	Bechdolf 2006 a	\N	Olanzapine, cognitive bahavioral therapy (Cognitive Behavioral Therapy) + Risperidone versus cognitive bahavioral therapy (Cognitive Behavioral Therapy)	\N	Germany	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
9674	Castelein 2006	\N	self-help group versus control group	\N	Netherlands	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
9675	Crespo-Facorro 2006a	\N	Olanzapine versus Haloperidol	\N	Spain	\N	\N	\N	\N	\N	172	\N	\N	\N	\N	\N
9676	Dittmann 2006	\N	Olanzapine versus Placebo	\N	United States of America//Canada//Germany	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
9677	Gafoor 2006	\N	Quetiapine versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
9678	Hoffman 2006	\N	Olanzapine versus Placebo	\N	United States of America//Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9679	Jackson 2006	\N	cognitive therapy recovery intervention versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
9681	Keet 2006	\N	psychoeducation versus motivational interviewing	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9682	Killackey 2006	\N	vocational rehabilitation versus control group	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9684	Leclerc 2006	\N	Cognitive Behavioural Training versus control group	\N	Canada	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
9685	Lecomte 2006 a	\N	group Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus skills training	\N	Canada	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
9686	Linszen 2006	\N	critical peridod intervention (CPI) versus control group	\N	Netherlands	\N	\N	\N	\N	\N	183	\N	\N	\N	\N	\N
9687	Lester 2006	\N	GP intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
9689	Bertelsen 2006	\N	psychosocial integrated treatment versus standard care	\N	Denmark	\N	\N	\N	\N	\N	578	\N	\N	\N	\N	\N
9690	Hodgekins 2006 a	\N	employment and education group versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9691	Hodgekins 2006 b	\N	employment and education group versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
9692	Mottaghipour 2006	\N	home based family education versus hospital based family groups	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
9693	Nienhuis 2006	\N	targeted treatment versus maintenance treatment	\N	Netherlands	\N	\N	\N	\N	\N	131	\N	\N	\N	\N	\N
9694	Newton 2006	\N	cognitive remediation therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9695	Nordentoft 2006 a	\N	integrated care versus standard care	\N	Denmark	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
9697	Power 2006	\N	early intervention + GE education versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
9698	Ruhrmann 2006 a	\N	needs focused intervention + Amisulpride versus needs focused intervention	\N	Germany	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
9699	Ruhrmann 2006 b	\N	needs focused intervention + Amisulpride versus needs focused intervention	\N	Germany	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
9700	Sharifi 2006	\N	first episode psychosis program versus control group	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
9701	Srihari 2006	\N	Specialized Treatment Early in Psychosis (STEP) versus usual community care	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9702	Stain 2006	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus not stated	\N	Australia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9703	Verhaegh 2006	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9704	Wunderink 2006	\N	guided discontinuation of medication versus maintenance treatment	\N	Netherlands	\N	\N	\N	\N	\N	131	\N	\N	\N	\N	\N
9705	Duval 2006	\N	oral Risperidone + neuroleptic treatment versus long-acting Risperidone + neuroleptic treatment	\N	France	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
9706	Wyszogrodzka 2006 a	\N	Olanzapine versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
9707	Morrison 2006 a	\N	cognitive therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
9708	Eli Lilly 2006 a	\N	Olanzapine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
9709	Eli Lilly 2003 a	\N	Olanzapine versus Risperidone	\N	Unclear	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
9710	Eli Lilly 2004 a	\N	intramuscular Olanzapine depot versus oral Olanzapine	\N	Unclear	\N	\N	\N	\N	\N	1250	\N	\N	\N	\N	\N
9711	Eli Lilly 2006 b	\N	Olanzapine pamoate depot versus Olanzapine	\N	Unclear	\N	\N	\N	\N	\N	520	\N	\N	\N	\N	\N
9712	Eli Lilly 2003 b	\N	Olanzapine versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
9714	Eli Lilly 2003 d	\N	Olanzapine dose	\N	Unclear	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
9715	NCT00103571	\N	Aripiprazole versus Olanzapine	\N	United States of America//Pureto Rico and United States of America and United States of America	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
9716	Eli Lilly 2005 a	\N	LY2140023 versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
9718	NCT00337662	\N	Olanzapine versus Risperidone	\N	United States of America//Argentina//Russian Federation	\N	\N	\N	\N	\N	628	\N	\N	\N	\N	\N
9719	Eli Lilly 2006 e	\N	oral Olanzapine versus orodispersible tablet	\N	Unclear	\N	\N	\N	\N	\N	284	\N	\N	\N	\N	\N
9721	Eli Lilly 2004 c	\N	Olanzapine versus Quetiapine	\N	Unclear	\N	\N	\N	\N	\N	340	\N	\N	\N	\N	\N
9722	Reilly 2006	\N	behavioural therapy versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9723	Ascher-Svanum 2005 a	\N	Olanzapine versus Placebo//Haloperidol versus Placebo//Haloperidol versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	248	\N	\N	\N	\N	\N
9724	Caplan 2006	\N	group home living versus independent living	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
9725	Chien 2005	\N	\N	\N	Hong Kong//China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
9727	Green 2006	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
9728	Lane 2006 a	\N	sarcosine + Clozapine versus Placebo + Clozapine	\N	Taiwan	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
9729	Levine 2006	\N	B vitamins versus Placebo	\N	Israel	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
9730	Hasson-Ohayon 2006	\N	psychoeducatinal intervention versus control arobic exercises	\N	Israel	\N	\N	\N	\N	\N	145	\N	\N	\N	\N	\N
9731	Killaspy 2006 b	\N	assertive community treatment versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	251	\N	\N	\N	\N	\N
9732	McEvoy 2006 f	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	251	\N	\N	\N	\N	\N
9735	Perkins 2006	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
9736	Schubert 2006	\N	Risperidone + galantamine versus Risperidone + Placebo	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
9738	Kryzhanovskaya 2006b	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
9739	Wonodi 2006	\N	amphetamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
9741	Chrzanowski 2006	\N	Aripiprazole versus Olanzapine biperiden + Haloperidol versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	214	\N	\N	\N	\N	\N
9742	Farrow 2006	\N	Modafinil versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
9743	Lambert 2006	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
9745	McCue 2006	\N	second generation Antipsychotics versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	368	\N	\N	\N	\N	\N
9746	Alvarez 2006	\N	Risperidone versus Olanzapine	\N	Spain	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
9747	Kinon 2006 b	\N	Olanzapine versus conventional Antipsychotic or Risperidone	\N	United States of America	\N	\N	\N	\N	\N	394	\N	\N	\N	\N	\N
9748	Azorin 2006	\N	sertindole versus Risperidone	\N	France	\N	\N	\N	\N	\N	187	\N	\N	\N	\N	\N
9749	Lal 2006	\N	levomepromazine versus Chlorpromazine	\N	Canada	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
9750	McDonell 2006	\N	multiple family group treatment versus standard care	\N	United States of America	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
9751	Ritsner 2006 a	\N	dehydroepiandrosterone versus Placebo	\N	Israel	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
9752	Uchida 2006	\N	reduced, increased dose of Antipsychotics versus standard care	\N	Japan	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
9753	Weber 2006	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
9754	Vanherweghem 1979 b	\N	hemodialysis versus sham hemodialysis	\N	Belgium	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
9755	Bai 2002 b	\N	Risperidone + acupuncture versus Risperidone + sham acupuncture	\N	China	\N	\N	\N	\N	\N	230	\N	\N	\N	\N	\N
9756	Berger 2003	\N	epicallocatechin gallate + Antipsychotic treatment versus Antipsychotic treatment + Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9757	Berger 2006	\N	lithium versus Placebo	\N	Australia	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
9758	Buchanan 2005 b	\N	rasagiline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9759	NCT00916461	\N	lamotrigine versus Placebo	\N	Brazil//Pakistan	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	51	\N	\N	\N	\N	\N
9760	Chengappa 2003 c	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
9761	Chiu 2006 a	\N	\N	\N	Canada//United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9762	Drake 2003	\N	cognitive rehabilitation versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
9763	Evins 2003 b	\N	nicotine transdermal patch versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9764	Fitzgerald 2000	\N	magnetic stimulation (Transcranial Magnetic Stimulation) versus sham	\N	Australia	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
9765	Fleming 2003	\N	memantine + donepezil versus memantine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9766	Gallo 2006	\N	trimethoprim-sulfamethoxazole versus 160, 800 mgs	\N	Peru	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
9767	Greenberg 2003	\N	folic acid versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
9768	Gross 2004	\N	simvastatin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19415	王新法 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
9769	Hashimoto 2005	\N	tropisetron versus Placebo	\N	Japan	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9770	Jaskiw 2003	\N	tyrosine versus control group	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
9771	Jin 2003 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
9772	Johnstone 2002	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	United Kingdom	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
9773	Kelleher 2004	\N	pramipexole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9774	Kern 2002 b	\N	errorless learning versus symptom management	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9775	Keshavan 2003	\N	psychoeducation intervention versus collaboration enhancement	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9776	Kulkarni 2005 d	\N	estradiol + Antipsychotic treatment versus Placebo + Antipsychotic treatment	\N	Australia	\N	\N	\N	\N	\N	375	\N	\N	\N	\N	\N
9777	Leweke 2004	\N	cannabidiol versus Placebo	\N	Germany	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
9778	McNeil 2005	\N	valacyclovir versus Placebo	\N	Sweden	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
9779	Muller 2004 a	\N	celecoxib + Amisulpride versus Amisulpride + Placebo	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
9780	NCT00483964	\N	Olanzapine + herbal extracts versus Olanzapine	\N	India	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
9781	O'Donnell 2003 b	\N	bitamins B12, B6, and folic acid versus Placebo	\N	Australia	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
9782	Penn 2004	\N	Cognitive Behavioural Training versus group supportive therapy	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9783	Potkin 2000 b	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
9784	Prasad 2005	\N	valacyclovir versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
9785	Savitz 2004	\N	pregnenolone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20347	袁国锋 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9786	Schneider 2001	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	United States of America	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
9787	Simonsen 2000	\N	health care in an area with an early detection program versus health care in an area with standard care	\N	Denmark	\N	\N	\N	\N	\N	281	\N	\N	\N	\N	\N
9788	Smith 2004	\N	pioglitazone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9789	Tamminga 2005	\N	BF2.649 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9790	NCT01041092	\N	raloxifene versus Placebo	\N	Spain	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
9791	Wang 2003 i	\N	Risperidone + Valproate versus Risperidone	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
9792	Weiser 2003	\N	\N	\N	Israel	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
9793	Wuliji 2003	\N	sulpiride + shuangzao versus sulpiride + Placebo//Sulpiride versus shuangzao// sulpiride versus Placebo//shuangzao versus Placebo	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
9794	Zhang 2003 k	\N	Haloperidol + Ondansetron versus Haloperidol	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
9795	Zhang 2003 l	\N	Risperidone + Celecoxib versus Risperidone	\N	China	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
9796	Zhang 2005 l	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
9797	de Lima 2004	\N	\N	\N	Brazil	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9798	Holt 2006	\N	Atypical Antipsychotics versus conventional Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
9799	刘成霞 2005	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9800	庞胜芝 2005	\N	Personalized nursing intervention + routine care versus Routine care	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
9801	张艳秋 2005	\N	Aripiprazole versus Sulpiride	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9803	胡铜森 2005	\N	Risperidone versus Clozapine or Chlorpromazine or perphenazine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
9804	李敏 2005	\N	Occupational therapy + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9805	汤剑平 2005	\N	MElectroconvulsive Therapy + unilateral electrode versus MElectroconvulsive Therapy + bilateral electrode	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
9807	刘桂芳 2005	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9808	吕纪珍 2005	\N	Psychological nursing + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
9810	何蕊芳 2005	\N	Family education + cognitive therapy + routine care versus Drug thrapy + standard care	\N	China	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
9811	Yang 2005	\N	Group psychological rehabilitation therapy versus rehabilitation therapy//Chlorpromazine versus Placebo	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
20291	魏维 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9812	贾太莲 2005	\N	Traditional Chinese Medicine (TCM) A versus Traditional Chinese Medicine (TCM) B	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
9813	王汉婵 2005	\N	Nursing intervention + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
9814	李轶群 2005	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9815	苏慧 2005	\N	Comprehensive rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9816	陈元堂 2005	\N	Venlafaxine + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
9817	范建华 2005	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
9818	肖莉蓉 2005	\N	Comprehensive rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
9819	王大开 2005	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9820	梁峻铭 2005	\N	Aripiprazole versus Haloperidol	\N	China	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
9821	童寿明 2005	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9822	周志英 2005 a	\N	supportive psychotherapy + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
9823	王树阳 2005	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
9824	赵业华 2005	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
9825	杨俊义 2005	\N	Risperidone in various dosages versus Risperidone in various dosages	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
9826	王立杰 2005	\N	Clozapine + Sulpiride versus Chlorpromazine Clozapine + Sulpiride versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
9827	汪宏才 2005	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
9828	刘启珍 2005	\N	Clopenthixol versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
9829	沈秀梅 2005	\N	Early intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9830	张子平 2005	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9831	黄金茹 2005	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9832	肖琳 2005	\N	Traditional Chinese Medicine (TCM) Xuesaitong capsule + routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9833	栗大顺 2005	\N	Risperidone,Clonazepam versus "Perphenazine,Clonazepam"	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9834	马兆峰 2005	\N	Olanzapine versus Haloperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9835	王宏林 2005	\N	Loxapine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
9836	田瑞芳 2005	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9837	韩中媛 2005	\N	Risperidone + Clonazepam versus Clozapine Risperidone + Clonazepam versus Clozapine	\N	China	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
9838	Quan 2005	\N	Nursing intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
9839	朱良君 2005 a	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9840	连文仙 2005	\N	Holistic nursing versus standard care	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9841	张冬红 2005 a	\N	Behavioural therapy + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9842	张冬红 2005 b	\N	Nursing intervention + Antipsychotic medication versus Antipsychotic medication + standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
9843	朱逸人 2005	\N	Cognitive psychological nursing intervention + care as usual versus Care as usual	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
9844	周志英 2005 b	\N	Psychological intervention versus Routine guidance	\N	China	\N	\N	\N	\N	\N	142	\N	\N	\N	\N	\N
9845	于得霞 2005	\N	Psychoeducation + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
9846	朱良君 2005 b	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9847	蒋菊芳 2005	\N	Cognitive behavioural therapy + routine Antipsychotic medication versus Conventioanl health education + routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9848	高月云 2005	\N	Post-discharge follow-up + standard care versus standard care Nursing follow-up versus conventional follow-up	\N	China	\N	\N	\N	\r\nUser defined field 10\r\n	\N	168	\N	\N	\N	\N	\N
9849	张海风 2005	\N	Loxapine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	134	\N	\N	\N	\N	\N
9850	丁志杰 2005	\N	Risperidone + Buspirone versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9851	王秀芳 2005	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20468	刘洪刚 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
9852	陈蕊 2005	\N	Psychoeducation + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
9853	Zhi 2005a	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
9854	麻赤贞 2005	\N	Traditional Chinese Medicine (TCM) + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9855	张跃兵 2005	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
9856	樊凌姿 2005	\N	Risperidone versus Quetiapine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
9857	王相立 2005	\N	Psychoeducation for family members + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9858	张金钊 2005	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
9860	孙花 2005	\N	Psychoeducation + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	230	\N	\N	\N	\N	\N
9861	赵成香 2005	\N	Nursing intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
9862	陈洪辉 2005	\N	Psychological intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9863	安新发 2005	\N	Psychoeducation + Chlorpromazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
9864	刘春仙 2005 a	\N	Quetiapine + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9865	张海燕 2005	\N	Clozapine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9866	高俊霞 2005	\N	Open ward management versus Closed ward management	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
9867	延英芹 2005	\N	Health education + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
9868	褚会英 2006	\N	Psychological nursing versus standard care	\N	China	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
9869	文胜惠 2006	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9870	Pan 2006	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9871	吴军 2006	\N	Traditional Chinese Medicine (TCM) Xing nao fu shen tang + Chlorpromazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
9872	钟薇 2005	\N	Olanzapine + Fluvoxamine versus Olanzapine	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
9873	殷俊凤 2005	\N	Flupenthixol versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	153	\N	\N	\N	\N	\N
9874	章浩明 2005	\N	Psychoeducation + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
9875	李秀英 2005	\N	Cognitive psychological therapy + family intervention + routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9876	张海杰 2005	\N	Music sports therapy + routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
9877	韦强 2005 b	\N	Psychological therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
9878	黄英 2005	\N	Cognitive Behavioural nursing intervention + routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9879	刘琳 2005	\N	Health education for family members + Antipsychotic versus Antipsychotic	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
9880	朱春红 2005	\N	Sodium valproate + Risperidone versus Clonazepam, Risperidone	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
9881	刘雪萍 2005	\N	Flexible ward management versus Conventioanl closed ward management	\N	China	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
9882	Ucok 2006 a	\N	Problem solving remediation versus Standard care	\N	Turkey	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
9883	Arango 2006	\N	depot zuclopenthixol versus oral zuclopenthixol	\N	Spain	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
9884	Ascher-Svanum 2005 b	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	1996	\N	\N	\N	\N	\N
9886	王秋燕 2005	\N	Music therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
9887	余洁 2005	\N	Comprehensive social skills training + care as usual versus Care as usual	\N	China	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
9888	刘春仙 2005 b	\N	Loxapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9889	梁在益 2005	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9890	刘可智 2005	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9891	Zhou 2005	\N	Informed Consent (with Treatment) + Treatment as Usual versus Treatment as Usual	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9892	郑永梅 2005	\N	Skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
9893	王立娥 2005	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
9894	Cosden 2005	\N	assertive community treatment versus standard care	\N	United States of America	\N	\N	\N	\N	\N	235	\N	\N	\N	\N	\N
9895	Gold 2005 a	\N	music therapy + standard care versus standard care	\N	Norway	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
9897	Lenert 2005	\N	Risperidone versus various doses	\N	United States of America	\N	\N	\N	\N	\N	725	\N	\N	\N	\N	\N
9899	Rossi 2006	\N	modified verbalization trategy versus standard verbalization trategy	\N	Italy	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
9900	Tunis 2006	\N	Olanzapine versus conventional Antipsychotic	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	664	\N	\N	\N	\N	\N
9902	Guillem 2006	\N	rivastigmine + Antipsychotics versus Antipsychotics	\N	Canada	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
9903	Kim 2006 e	\N	Clozapine versus Risperidone	\N	South Korea	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
9904	张长军 2005	\N	System health education versus Conventional health education	\N	China	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
9905	Tassaneeyakul 2005	\N	Clorazil ½ (Clozapine) versus Cloril ½ (Clozapine)	\N	Thailand	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
9906	Naeem 2006 a	\N	Cognitive Behavioural Training versus befriending	\N	United Kingdom	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
9907	Naeem 2006 b	\N	Cognitive Behavioural Training versus befriending	\N	United Kingdom	\N	\N	\N	\N	\N	257	\N	\N	\N	\N	\N
9908	Taira 2006	\N	questionnaire about neuroleptic side effects versus routine care	\N	Japan	\N	\N	\N	\N	\N	210	\N	\N	\N	\N	\N
9909	Knegtering 2006	\N	Risperidone versus Olanzapine	\N	Netherlands	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
9912	Gold 2006	\N	supported employment and assertive community treatment versus traditional vocational rehabilitation	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	177	\N	\N	\N	\N	\N
9913	Grawe 2006	\N	integrated psychosocial treatment versus standard pharmacotherapy treatment	\N	Norway	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
9914	Martino 2006	\N	motivational interviewing versus standard psychiatric interview	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
9915	Petrakis 2006	\N	naltrexone + disulfiram versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	254	\N	\N	\N	\N	\N
9917	Brenner 1987	\N	\N	\N	Switzerland	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9918	Kraemer 1987	\N	\N	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9919	Neumann 1988	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) +neruoleptics versus Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	Austria	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9920	Scheidhacker 1991	\N	\N	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9923	Sayers 2005	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
9924	Simpson 2006 a	\N	long acting Risperidone dose	\N	United States of America//Canada//Argentina//Chile	\N	\N	\N	\N	\N	324	\N	\N	\N	\N	\N
9925	Zhong 2006 b	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	673	\N	\N	\N	\N	\N
9926	Vreeland 2006	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
9927	Hemingway 1999	\N	GP services versus general services	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9928	Kitchener 2004	\N	mental health first aid training versus wait list	\N	Australia	\N	\N	\N	\N	\N	301	\N	\N	\N	\N	\N
9929	Sugar 2004	\N	Clozapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	423	\N	\N	\N	\N	\N
9930	Boulay 2002	\N	Olanzapine versus control group	\N	Canada	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
9931	Morrison 2004 e	\N	cognitive therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9933	Hall 2003	\N	cognitive Behavioural treatment + standard care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
9934	Saba 2006	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	France	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
9935	Wang 2006 a	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
9936	Maoz 2000	\N	(Haloperidol plus Propranolol) versus (Haloperidol plus Placebo)	\N	Israel	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
9937	Baker 2006 a	\N	smoking cessation intervention versus routine care	\N	Australia	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	298	\N	\N	\N	\N	\N
9938	Baker 2006b	\N	motivational interview + cognitive behavior therapy versus routine care	\N	Australia	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
9939	Bustillo 2002	\N	Quetiapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
9940	Emsley 2007	\N	Risperidone versus Haloperidol	\N	Israel	\N	\N	\N	\N	\N	509	\N	\N	\N	\N	\N
9943	McKibbin 2006	\N	diabetes awareness and rehabilitation program versus usual care//Dietary advice//exercise therapy	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
9944	Patterson 2006	\N	functional adaptation skills training versus attention control group	\N	United States of America	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
9945	Swanson 2006 b	\N	psychiatric advanced directive session versus written information regarding psychiatric advanced directives//Advance treatment directives	\N	United States of America	\N	\N	\N	\N	\N	469	\N	\N	\N	\N	\N
9946	Zhang 2006 a	\N	Haloperidol + ondansetron versus Haloperidol + Placebo//Haloperidol versus Placebo//ondansetron versus Placebo	\N	China	\N	\N	\N	\N	\N	121	\N	\N	\N	\N	\N
9947	Fowler 2007a	\N	social recovery cognitive behavioral therapy versus treatment as usual	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
9948	EDIE-2	\N	Cognitive Therapy + Monitoring Mental State versus Monitoring Mental State // Cognitive Therapy + Monitoring Mental State versus Treatment As Usual // Cognitive Therapy versus Treatment As Usual // Monitoring Mental State versus versus Treatment As Usual	\N	United Kingdom	\N	\N	\N	\N	\N	320	\N	\N	\N	\N	\N
9949	Esfahani 2002	\N	Bromocriptine versus Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
9951	Muhlack 2006	\N	rescue remedy versus Placebo	\N	Germany	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
9952	Kinon 2006 c	\N	Olanzapine versus Quetiapine	\N	Unclear	\N	\N	\N	\N	\N	346	\N	\N	\N	\N	\N
9953	Janssen-Ortho 2006	\N	risperidal consta versus oral Atypical Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
9954	Chiu 2006 b	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
9955	Van Meijel 2006 b	\N	early intervention versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
9956	Bjorkman 2002	\N	trenghts model case management versus standard care	\N	Sweden	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
9957	Hu 1998 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
9958	Baymiller 2002 c	\N	Clozapine versus Placebo//Clozapine versus Haloperidol//Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
9959	Zhang 2006 b	\N	Haloperidol + ginkgo biloba extract versus Haloperidol + Placebo//ginkgo biloba extract versus Placebo//Haloperidol versus Placebo	\N	China	\N	\N	\N	\N	\N	109	\N	\N	\N	\N	\N
9960	Salkever 1999	\N	assertive community treatment programs versus usual care	\N	United States of America	\N	\N	\N	\N	\N	173	\N	\N	\N	\N	\N
9961	Akdede 2006	\N	Clozapine + Risperidone versus Clozapine + Placebo	\N	Turkey	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
9962	Crespo-Facorro 2006b	\N	Olanzapine versus Haloperidol Haloperidol versus Risperidone//Haloperidol versus Olanzapine//Olanzapine versus Risperidone	\N	Spain	\N	\N	\N	\r\nUser defined field 10\r\n	\N	182	\N	\N	\N	\N	\N
9963	Farhady 2000	\N	Clozapine versus multiple dosages	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9964	Zadeh 2006	\N	Clozapine + Electroconvulsive Therapy versus Clozapine + Sham // Clozapine + Electroconvulsive Therapy versus Electroconvulsive Therapy + Placebo // Electroconvulsive Therapy + Placebo versus Clozapine + Sham	\N	Iran	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
9965	Shafti 2006 a	\N	clomipramine versus citalopram	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9966	Shafti 2006 b	\N	Bromocriptine versus nortriptyline	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
9967	Shafti 2006 c	\N	fluvoxamine versus maprotiline	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
9968	Ren 2001	\N	Doxepin + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
9969	Knott 2006	\N	\N	\N	Australia	\N	\N	\N	\N	\N	170	\N	\N	\N	\N	\N
9970	Choi 2006	\N	\N	\N	South Korea	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
9971	Harvey 2006 b	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
9973	Haug 1959	\N	\N	\N	Norway	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
9974	Langle 2006 b	\N	manualized procedure versus control group	\N	Germany	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
9975	Mozes 2006	\N	Olanzapine versus Risperidone	\N	Israel	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
9976	Sells 2006	\N	peer based management versus regular case management	\N	United States of America	\N	\N	\N	\N	\N	137	\N	\N	\N	\N	\N
9977	Veser 2006	\N	Oral Haloperidol + lorazepam IM versus Oral Risperidone + lorazepam IM versus Lorazepam IM + Placebo//Oral Haloperidol versus lorazepam IM//Oral Risperidone versus lorazepam IM//Oral Haloperidol versus Placebo//Oral Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
9978	Veltro 2006	\N	\N	\N	Italy	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
9979	Morse 2006	\N	integrated assertive community treatment versus control group	\N	United States of America	\N	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
9981	Eli Lilly HGDV 2002	\N	Olanzapine versus Chlorpromazine	\N	Morocco	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
9983	Chan 2007 a	\N	Aripiprazole versus Risperidone	\N	Taiwan	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
9985	Lasser 2004 b	\N	conventional depot Antipsychotics + Risperidone versus conventional depot Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	188	\N	\N	\N	\N	\N
9986	Mosolov 2000	\N	Haloperidol versus zuclopenthixol	\N	Russia	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
9989	Depatie 2002	\N	nicoderm patch versus Placebo	\N	Canada	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
9990	Kane 2007	\N	paliperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	630	\N	\N	\N	\N	\N
9991	Suresh Kumar 2007	\N	melatonin versus Placebo	\N	India	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9992	Pae 2007 a	\N	rapid titration of Quetiapine versus conventional titration of Quetiapine	\N	South Korea	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
9993	Lindenmayer 2007 a	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
9994	Caroff 2007	\N	galantamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
9995	Barretto 2006	\N	\N	\N	Brazil	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
9996	Peng 2006 a	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
9997	An 2006 a	\N	olanzipine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
20292	黄卫东 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
9998	An 2006 b	\N	Olanzapine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
9999	Ao 2006	\N	Aripiprazole versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
10000	Bai 2000 c	\N	drug + cognitive therapy group versus drug therapy group	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10002	Cao 2006 a	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
10004	Chen 2006 b	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
10005	Chen 2004 b	\N	Haloperidol versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
10007	Chen 2006 c	\N	Community nursing versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10008	Chen 2006 d	\N	Chlorpromazine versus Clozapine	\N	China	\N	\N	\N	\N	\N	161	\N	\N	\N	\N	\N
10009	Chen 2006 e	\N	Rifampicin versus Rifapentine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10010	Cheng 2006 a	\N	Sulpiride versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10011	Cheng 2006 b	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
10013	Dai 2003	\N	Paired recovery + Antipsychotic medication versus standard care + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	230	\N	\N	\N	\N	\N
10014	Deng 2006 a	\N	Paired recovery + Antipsychotic medication versus standard care + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
10015	Deng 2003 b	\N	Family intervation + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
10016	Deng 2006 b	\N	Comprehensive early intervention versus standard care	\N	China	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
10017	Ding 2000 a	\N	Half dose stimulation of Electro Convulsive Therapy(Electroconvulsive Therapy) versus Whole dose stimulation of Electro Convulsive Therapy(Electroconvulsive Therapy)	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10018	Ding 2006 a	\N	Imitating social life + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
10019	Ding 2006 b	\N	Traditional Chinese Medicine (TCM) Jiawei lingguizhugan tang versus Placebo	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10020	Du 2006	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10021	Du 2005 f	\N	Family intervention + Antipsychotic medication versus health education + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	143	\N	\N	\N	\N	\N
10022	Fan 2006 a	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
10023	Fan 2005 c	\N	Community nursing intervention + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
10024	Gong 2003	\N	Quentinpine + Paroxetine versus Quentinpine	\N	China	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
10025	Guo 2003 e	\N	Commuinty intervention versus care as usual	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
10026	Gao 2003 f	\N	Commuinty intervention versus care as usual	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
10027	Guo 2006 a	\N	Chlorpromazine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
10029	He 2006	\N	Promethazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10030	Hou 2006	\N	Psychoeducation + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
10031	Hu 2003 c	\N	Militarised therapy + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	166	\N	\N	\N	\N	\N
10032	Hu 2006	\N	Behavioural nursing intervention + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
10033	Lin 2006 b	\N	Aripiprazole versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
10034	Huang 2006 a	\N	Patient education + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10036	Huang 2006 c	\N	Clozapine versus Quetiapine fumarate	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
10037	Huang 2006 d	\N	Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10038	Ji 2006	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
10039	Jia 2005	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10040	Jiang 2006 a	\N	Huperzine + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
10041	Jiang 2006 b	\N	Clinical pathway versus Traditional health education	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
10042	Kong 2006	\N	Traditional Chinese Medicine (TCM) Kaiqiao ling + Sulpiride versus Sulpiride	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10043	Kuang 2006 a	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10044	Lai 2006	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
10045	Lan 2006 a	\N	Citalopram + Clozapine versus Clozapine + Placebo	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
10046	Lei 2006	\N	Health education + psychological intervention versus standard care	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10047	Liu 2005 g	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10048	Li 2005 o	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
10049	Li 2006 a	\N	Ziprasidone + Placebo versus Chlorpromazine + Placebo//Chlorpromazine versus Placebo//Ziprasidone versus Placebo//Chlorpromazine versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
10050	Li 2006 b	\N	Ziprasidone versus various dosages	\N	China	\N	\N	\N	\N	\N	231	\N	\N	\N	\N	\N
10052	Li 2006 c	\N	Nursing intervention versus standard care	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10053	Li 2005 p	\N	Ginkgo Biloba Leaf Preparation + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10054	Li 2006 d	\N	Family education + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
10055	Li 2006 e	\N	Risperidone + Venlafaxine versus Risperidone	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10058	Li 2006 f	\N	Humanism nursing management + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10060	Liang 2006 a	\N	Social skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10061	Lin 2006 c	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10062	Lin 2005 d	\N	Nursing intervention + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	168	\N	\N	\N	\N	\N
10064	Liu 2006 a	\N	Aripiprazole versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
10065	Liu 2004 g	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
10067	Liu 2006 b	\N	Holistic nursing + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
10069	Liu 2006 c	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10070	Liu 2006 d	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10071	Liu 2006 e	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10072	Liu 2006 f	\N	Aripiprazole versus No treatment (healthy population as control)	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
10074	Liu 2003 h	\N	Clozapine versus Risperidone or Quetiapine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10075	Liu 2006 g	\N	Traditional Chinese Medicine (TCM) Xing-nao decoction + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
10076	Liu 2004 h	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
10077	Liu 2006 h	\N	Quetiapine fumarate versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10078	Liu 2004 i	\N	Traditional Chinese Medicine (TCM) Ningxin Anshen Tang + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
10079	Lu 2006 a	\N	Loxapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
10081	Lu 2006 c	\N	Ziprasidone versus various dosages	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10082	Lu 2006 d	\N	Zipraside injection versus Haloperidol injection	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10084	Lu 2006 e	\N	Pipotiazine palmitate injection versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
10086	Lu 2006 f	\N	Sodium valproate + Atypical Antipsychotic versus Atypical Antipsychotic	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10087	Lu 2006 g	\N	Aripiprazole versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
10088	Luo 2006 a	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
10089	Ma 2005 b	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
10090	Ma 2001 b	\N	Clozapine + Electroconvulsive Therapy versus Chlorpromazine + Electroconvulsive Therapy	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10091	Ma 2006 a	\N	Morita therapy + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
10095	Pan 2003	\N	Acupuncture + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
10096	Pang 2000	\N	Cognitive behavioural therapy + family intervention + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10097	Qi 2006 a	\N	Health education + Antipsychotic medication versus control group	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
10098	Qin 2006 a	\N	Olanzapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10099	Qu 2005	\N	Chlorpromazine versus Risperidone	\N	China	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
10100	Ren 2004 d	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
10101	Ren 2005 c	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
20293	黄卫东1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10102	Shen 2004 b	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10103	Shi 2006	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
10104	Song 2001	\N	Comprehensive rehabilitation therapy + Antipsychotic medication versus Antipsychotic medications	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
10106	Sun 2006 a	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
10107	Sun 2003 c	\N	Paired rehabilitation therapy versus standard care	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
10108	Sun 2006 b	\N	Citalopram + Perphenazine versus Perphenazine + Placebo	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10109	Sun 2006 c	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10110	Sun 2006 d	\N	Venlafaxin + Chlorpromazine versus Chlorpromazine + Placebo//Chlorpromazine versus Placebo//Venlafaxin versus Chlorpromazine//Venlafaxin versus Placebo	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10111	Sun 2006 e	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
10114	Tang 2006 a	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
10115	Tang 2005 c	\N	Traditional Chinese Medicine (TCM) Jianpi-Bushen + Chlorpromazine versus Chlorpromazine + Placebo//Chlorpromazine versus Placebo//Chlorpromazine versus jian-pi bu-shen(ctm)//jian-pi bu-shen(ctm) versus Chlorpromazine//Traditonal chinese medicine	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10116	Tang 2006 b	\N	Traditional Chinese Medicine (TCM) Jianpi-Bushen + Chlorpromazine versus Chlorpromazine + Placebo//Chlorpromazine versus Placebo//Chlorpromazine versus jian-pi bu-shen(ctm)//jian-pi bu-shen(ctm) versus Chlorpromazine//Traditonal chinese medicine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10117	Tao 2006 a	\N	Aripiprazole Dosage	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
10118	Tian 2006 a	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10119	Tian 2006 b	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
10120	Wan 2006 a	\N	Homely environment and humanism nursing care + Antipsychotic medications versus Antipsychotic treatment + standard care	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10121	Wang 2006 b	\N	Chlorpromazine versus Risperidone	\N	China	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
10122	Wang 2003 j	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	251	\N	\N	\N	\N	\N
10123	Wang 2006 c	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
10124	Wang 2006 d	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10125	Wang 2003 k	\N	Haloperidol + Liniment Levamisole versus Haloperidol + distilled water	\N	China	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
10126	Wang 2006 e	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
10127	Wang 2005 x	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10129	Wang 2006	\N	Magnesium Valproate + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
10130	Wang 2006 g	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10131	Wang 2003	\N	Interpersonal Communication Skills Training + Treatment as Usual versus Treatment as Usual	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10132	Wang 2006 h	\N	Music therapy + Antipsychotic medication versus Antipsychotic medication + standard care	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
10133	Wang 2006 i	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10134	Wang 2006 j	\N	Aripiprazole versus Haloperidol	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
10135	Wang 2006 k	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10136	Wang 2001 g	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10137	Wang 2004 q	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	204	\N	\N	\N	\N	\N
10138	Wang 2006 l	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10139	Wang 2004 r	\N	Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
10140	Wang 2003 m	\N	Intravascular low level laser radiation + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10141	Wang 2006 m	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
10142	Wang 2006 n	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10143	Wei 2006 a	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
10144	Wei 2006 b	\N	Aripiprazole versus Quetiapine	\N	China	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
10145	Wei 2006 c	\N	Aripiprazole versus Quetiapine	\N	China	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
10146	Wen 2006 a	\N	Group Counseling + Antipsychotic medication versus standard care + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10147	Wu 2006 b	\N	Open ward management + Antipsychotic medication versus Close ward management + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
10148	Xie 2006 a	\N	Yoga exercise + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10149	Xie 2002 a	\N	Comprehesive psychological nursing intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
10152	Xu 2001 e	\N	Risperidone + Placebo versus Risperidone + Clomipramine	\N	China	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
10790	Guz 2002	\N	Risperidone versus Olanzapine	\N	Turkey	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10153	Xu 2005 c	\N	Clozapine + recreational therapy versus Clozapine	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
10155	Gong 2001	\N	Clozapine versus Clozapine + Sulpiride	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10156	Xu 2003 f	\N	Piracetam + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
10157	Xu 2006 a	\N	Alpha electroencephalogram-guided transcranial magnetic stimulation therapy versus Sham alpha electroencephalogram-guided transcranial magnetic stimulation therapy	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
10158	Xun 2006 a	\N	Risperidone versus Penflurido	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
10159	Yan 2004 c	\N	Traditional Chinese Medicine (TCM) Jie-jing Decoction versus Artane	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10160	Yan 2004 d	\N	Ferrous sulfate + Chlorpromazine versus Chlorpromazine + Placebo//Chlorpromazine versus Placebo//Ferrous sulfate versus Chlorpromazine//Ferrous sulfate versus Placebo	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10161	Yang 2006 a	\N	Psychological nursing + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
10162	Yang 2000 b	\N	Chlorpromazine versus Clozapine	\N	China	\N	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
10163	Yang 2001	\N	Chlorpromazine versus Clozapine	\N	China	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
10165	Yang 2004 c	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
10166	Yang 2006 b	\N	Aripiprazole versus Haloperidol	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10167	Yang 2006 c	\N	Psychoeducation + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
10168	Yang 2006 d	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10169	Yang 2005 e	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
10170	Yang 2005 f	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
10171	Yang 2005 g	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
10172	Yang 2005 h	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
10173	Yang 2004 d	\N	Quetiapine(produced in China) versus Sulpiride	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
10174	Yang 2006 e	\N	Systemic psychsocial and family intervention + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
10175	Yang 2006 f	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
10176	Yang 2006 g	\N	Olanzapine(domestic) versus Olanzapine(imported)	\N	China	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
10177	Yao 2003 b	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
10179	Ye 2005 c	\N	Aripiprazole versus Olanzapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10181	Ying 2006	\N	Psychoeducation for family members + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
10182	Yu 2006 a	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
10183	Yu 2006 b	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
10184	Yuan 2003	\N	Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10185	Zeng 2006 a	\N	Whole course intervention + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
10186	Zhang 2006 c	\N	Psychological nursing + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10187	Zhang 2006 d	\N	Insight education + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10188	Zhang 2006 e	\N	Behaviour rElectro Convulsive Therapy (Electroconvulsive Therapy)ification + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10189	Zhang 2006 f	\N	Psychological nursing + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
10190	Zhang 2006 g	\N	cessation of Antipsychotics versus continuation of Antipsychotics	\N	China	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
10191	Zhang 2006 h	\N	Antipsychotics + family intervention versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	188	\N	\N	\N	\N	\N
10192	Zhang 2006 i	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
10193	Zhang 2006 j	\N	Comprehensive rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
10194	Zhang 2006 k	\N	Comprehensive rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
20294	马新莲 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
10195	Zhang 2006 l	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10196	Zhan 2000	\N	Haloperidol versus Placebo + Levamisole ointment//Haloperidol versus levamisole ointment//levamisole ointment versus Placebo//Haloperidol versus Placebo	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10197	Zhang 2006 m	\N	Aripiprazole versus Olanzapine	\N	China	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
10198	Zhang 2006 n	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
10199	Zhang 2006 o	\N	Psychological intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10200	Zhang 2004 j	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10201	Zhao 2004 a	\N	Psychoeducatiaon +Antipsychotic medication versus Conventional health education + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
10202	Zhao 2006 a	\N	Aripiprazole versus Quetiapine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
10203	Chu 2006	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10204	Zhi 2006	\N	Self-efficacy training + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
10205	Zhong 2003 c	\N	Systematic rehabilitation therapy versus standard care 	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10206	Zhou 2005 d	\N	Cognitive therapy + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
10208	Zou 2006 a	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
10210	Zhou 2006 a	\N	Music therapy (audio only) + Antipsychotic medication versus Music therapy (audio + visual) + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10211	Zhou 2006 b	\N	Nursing intervention+ Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
10212	Zhou 2004 d	\N	Bilateral brain stereotactic anterior destruction tactics + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
10213	Zhu 2001 b	\N	Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
10214	Zhu 2004 c	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
10215	Zhu 2006 a	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10216	Zhu 2006 b	\N	Trazodone + Antipsychotic medication (Chlorpromazine or sulpiride) versus Oryzanol + Antipsychotic (Chlorpromazine or sulpiride)	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
10217	Li 2003 o	\N	Loxapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10220	Killaspy 2006 c	\N	interactive group art therapy + standard care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	376	\N	\N	\N	\N	\N
10221	Bell 2005 b	\N	neurocognitive enhancement therapy + work therapy versus work therapy	\N	United States of America	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
10222	Lysaker 2005	\N	cobnitive behavioral program versus standard support services	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10224	Ramu 1999	\N	brahmyadiyoga//Chlorpromazine versus Placebo	\N	India	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
20469	陈凤仙 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
10226	McLeod 2007 a	\N	Cognitive Behavioural Training versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
10227	Akhondzadeh 2007	\N	Risperidone + celecoxib versus Risperidone + Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10228	Baptista 2007 a	\N	Olanzapine versus Risperidone	\N	Venezuela	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
10229	Combs 2006	\N	attentional prompt versus repeated practice	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
10230	Eack 2007	\N	cognitive enhancement therapy versus enriched supportive therapy	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
10231	Rosenheck 2004	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10232	Keefe 2005	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
10233	Khazaal 2007	\N	Cognitive Behavioural Training versus control group	\N	Switzerland	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
10234	Kurtz 2007	\N	computer assisted cognitive remediation versus computer skills training control	\N	United States of America	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
10235	Lindenmayer 2007 b	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
10236	Penades 2006 b	\N	cognitive remediation therapy + standard medication follow-up versus cognitive behavioral therapy + standard medication follow-up	\N	Spain	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10237	Strous 2007 a	\N	Olanzapine+ DHEA versus Olanzapine + Placebo	\N	Israel	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10238	NCT00034801	\N	Olanzapine versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	378	\N	\N	\N	\N	\N
10239	Xiang 2006	\N	Community Re-Entry Module versus standard group psychoeducation	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
10240	Beebe 2005	\N	exercise versus control group	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
10498	NCT00305474	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10241	Turkington 2006	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus befriending	\N	United Kingdom	\N	\N	\N	\N	\N	422	\N	\N	\N	\N	\N
10242	Slade 2006	\N	questionnaires about needs and quality of life + feedback versus Treatment as usual	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	160	\N	\N	\N	\N	\N
10243	Rabinowitz 2006	\N	Risperidone versus Haloperidol	\N	Israel	\N	\N	\N	\N	\N	559	\N	\N	\N	\N	\N
10245	Latimer 2006	\N	supported employment group versus traditional vocational services	\N	Canada	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
10246	Das 2006	\N	educational intervention versus control group	\N	India	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10247	McLeod 2007 b	\N	Cognitive Behavioural Training versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10249	Costa 2007	\N	Antipsychotic Drug versus Olanzapine	\N	Brazil	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
10250	Talwar 2006	\N	music therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
10251	Gray 2006 a	\N	adherence therapy versus health education	\N	Netherlands//Germany//United Kingdom//Italy	\N	\N	\N	\N	\N	409	\N	\N	\N	\N	\N
10252	Barrowclough 2006 a	\N	behavioural therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
10253	Barnett 1978	\N	Group Encounters Program versus Hobbies and Games	\N	United States of America	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
10254	Ehrenreich 2007	\N	erythropoietin versus Placebo	\N	Germany	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
10256	McEvoy 2005	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
10257	Harvey 2005 b	\N	long acting Risperidone versus Antipsychotic treatment	\N	United States of America	\N	\N	\N	\N	\N	282	\N	\N	\N	\N	\N
10258	Lin 2002 d	\N	Chenxia Liujunzi Wan (TCM) versus Artane or Phenergan	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
10259	Fei 2004	\N	Antipsychotics + Ziyintang (Traditional Chinese Medicine (TCM)) versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
10260	Li 2006 g	\N	Rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10261	Xu 2006 b	\N	Immediate switch to Aripiprazole (from routine Antipsychotics) versus Graduale switch to Aripiprazole (from routine Antipsychotics)	\N	China	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
10262	Yang 2005 i	\N	Amitriptyline versus Atropine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10263	Yang 2006 h	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10265	Goswami 2001 b	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus sham Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	India	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10266	Ettinger 2002	\N	procyclidine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
10267	Kabanov 2002	\N	Risperidone versus Haloperidol	\N	Russia	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
10268	Chandra 2002	\N	centbutindole versus Risperidone	\N	India	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
10269	Agarwal 2001	\N	Risperidone versus Placebo	\N	India	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
10270	Goswami 2003	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus sham Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	India	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
10271	Ulrich 2005	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
10272	Harrison 2006	\N	cognitive Behavioural case management versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
10273	NTR405	\N	Aripiprazole versus Risperidone	\N	Netherlands	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10274	Klingberg 2005 a	\N	Cognitive Behavioural Training versus cognitive remediation	\N	Germany	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
10277	Burns 2004 a	\N	work placement training versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10278	Lewis 2003 d	\N	Clozapine versus conventional treatment	\N	United Kingdom	\N	\N	\N	\N	\N	227	\N	\N	\N	\N	\N
10279	Burns 2004 b	\N	teaching practice nurses group versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10280	Kumani 2005	\N	Cognitive Behavioural Training versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10281	Lester 2004d	\N	Patient Held Medical Records versus Control Group	\N	United Kingdom	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	500	\N	\N	\N	\N	\N
10282	Fahy 2006	\N	reasoning and rehabilitation versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
10283	Harrison-Read 2004	\N	short term intensive case management versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10284	Van Nimwegen 2005	\N	Olanzapine versus Risperidone	\N	Netherlands	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10285	Huf 2002 b	\N	Haloperidol + promethazine versus midazolam	\N	Brazil	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
10286	Barrowclough 2004 c	\N	Psychosocial intervention + standard care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10287	Jackson 2004 d	\N	cognitive therapy recovery intervention versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10288	Kuipers 2004 b	\N	Cognitive Behavioural Training versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10289	ISRCTN37811364	\N	self-help training package versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	1600	\N	\N	\N	\N	\N
10290	Wykes 2004	\N	cognitive remediation therapy versus standard care	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	85	\N	\N	\N	\N	\N
10291	Johnson 2005 b	\N	specialist services + standard care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
10292	ISRCTN54567688	\N	Modafinil versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
11012	NCT00237939	\N	Aripiprazole Dosage	\N	Belgium	\N	\N	\N	\N	\N	1200	\N	\N	\N	\N	\N
10293	Richardson 2004	\N	interactive art therapy + standard treatment versus standard treatment	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10294	Trower 2004 b	\N	cognitive therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10295	Tyrer 2004 a	\N	psychiatric services delivered in primary care versus psychiatric services delivered in secondary care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10296	Castelein 2006 b	\N	support group versus control group	\N	Netherlands	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
10297	Barrowclough 2003	\N	motivational interviewing + cogtnitive behavior training versusstandard care	\N	United Kingdom	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
10298	Byng 2004 a	\N	gps services versus secondary services	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10300	NTR443	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	147	\N	\N	\N	\N	\N
10301	Ngan 2003	\N	Antipsychotics study group versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10302	Craig 2005	\N	NICE schizophrenia guideline program versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10303	Craig 2004 c	\N	early psychosis service versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10304	Guy 2004	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10305	Kingdon 2003	\N	vocational advisors versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10306	Joffe 2006 a	\N	mirtazapine versus Placebo	\N	Finland	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
10307	NTR179	\N	cessation of Antipsychotics versus continuation of Antipsychotics	\N	Netherlands	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
10308	Busschbach 2005	\N	supported employment versus standard rehabilitation	\N	Netherlands	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
10309	NCT00514423	\N	psychoeducation group therapy versus control group	\N	Germany	\N	\N	\N	\N	\N	896	\N	\N	\N	\N	\N
10310	Howard 2007	\N	womens crisis house versus psychiatric hospital admission	\N	United Kingdom	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
10312	Van Gestel 2006	\N	mental health recovery course versus waiting list	\N	Netherlands	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
10313	NTR226	\N	Cognitive Behavioural Training versus control group	\N	Netherlands	\N	\N	\N	\N	\N	230	\N	\N	\N	\N	\N
10314	Becker 2005 a	\N	planning and monitoring intervention versus control group	\N	Germany	\N	\N	\N	\N	\N	490	\N	\N	\N	\N	\N
10315	Brown 2006	\N	health promotion interventions versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10316	Lewis 2000 h	\N	cognitive realignment therapy versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
10318	Gray 2003	\N	concordance skills training versus assessment skills control	\N	United Kingdom	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
10319	Ritchie 2003 b	\N	pindolol + Olanzapine versus pindolol	\N	United Kingdom	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
10321	Loebel 2005	\N	Ziprasidone versus various dosages	\N	Canada//United States of America	\N	\N	\N	\N	\N	599	\N	\N	\N	\N	\N
10322	Marder 2005 a	\N	oral paliperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	444	\N	\N	\N	\N	\N
10323	Osborn 2005	\N	nurse led intervention versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10325	Szmukler 2004	\N	carers' support programme versus standard treatment	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10326	Ngan 2005	\N	Antipsychotics study group versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10327	Hunter 2003	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
10328	Lewis 2004 c	\N	computerized support system versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10329	Hirsch 2004	\N	mental health treatment in general practice setting versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10330	Thornicroft 2003	\N	adherence therapy versus health education	\N	United Kingdom	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
10331	Tyrer 2003	\N	neuroleptic drugs versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10332	Tyrer 2004 b	\N	internal care management versus external care management	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
10333	Tyrer 2007	\N	nidotherapy versus assertive standard care	\N	United Kingdom	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
10335	Wykes 2006	\N	cognitive remediation therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10336	Hemingway 2004	\N	GP + mental health worker versus GP	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10337	Thornicroft 2007	\N	trained case managers versus untrained case managers	\N	United Kingdom	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
10339	NCT00175513	\N	valtrex + Antipsychotics versus Antipsychotics	\N	Canada	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10340	NCT00206115	\N	Quetiapine fumarate versus various dosages for schizophrenia or//and serious mental illness whose current state is not described and whose stage of illness is not described	\N	Bulgaria//Greece	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10341	NCT00237848	\N	D-serine + cognitive retraining versus Placebo + cognitive retraining	\N	India	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
10342	NCT00237809	\N	D-serine + cognitive retraining versus Placebo + cognitive retraining	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
10343	NCT00237796	\N	cognitive Behavioural social skills training versus supportive contact Cognitive Behavioral Social Skills Training versus Goal-Focused Supportive Contact	\N	United States of America	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	150	\N	\N	\N	\N	\N
10344	NCT00232687	\N	Aripiprazole versus Risperidone	\N	Austria//Belgium	\N	\N	\N	\N	\N	450	\N	\N	\N	\N	\N
10345	NCT00231933	\N	person centered planning + community integration versus person centered planning	\N	United States of America	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
10346	NCT00231894	\N	piglitazone + life style diet group versus Placebo + life style diet group	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10347	NCT00231335	\N	escitalopram versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
10348	NCT00145847	\N	naltrexone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
10349	NCT00148083	\N	long acting Risperidone versus continuation of medication	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10350	NCT00261716	\N	motivational interviewing + supported employment versus illness education + supported employment	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10351	NCT00261794	\N	computer assisted cognitive remediation versus computerized control task	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10352	NCT00269035	\N	Risperidone versus various doses	\N	Spain	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
10353	NCT00272168	\N	Maryland program of vocational effectiveness versus control group	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10354	NCT00276263	\N	sarcosine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10355	NCT00280813	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
10356	NCT00260273	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus supportive therapy	\N	Canada	\N	\N	\N	\N	\N	208	\N	\N	\N	\N	\N
10358	NCT00412373	\N	paliperidone ER versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
10359	NCT00412620	\N	ABT-925 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	225	\N	\N	\N	\N	\N
10360	NCT00259870	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	338	\N	\N	\N	\N	\N
10361	NCT00257192	\N	Ziprasidone versus Placebo	\N	United States of America//Malaysia//Singapore	\N	\N	\N	\N	\N	276	\N	\N	\N	\N	\N
11676	Zhang 2007 b	\N	Aripiprazole versus Perphenazine	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
10362	NCT00256997	\N	Risperidone long acting injection versus oral Antipsychotics	\N	Australia//Canada//Ireland//United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	260	\N	\N	\N	\N	\N
10363	NCT00255515	\N	Quetiapine fumarate + cognitive remediation therapy versus Quetiapine fumarate	\N	Sweden	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
10364	AstraZeneca 2005 c	\N	Quetiapine (fast tiration) versus Quetiapine (currently approved tiration)	\N	Norway	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
10365	NCT00249288	\N	folate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10366	NCT00248794	\N	cognitive rehabilitation versus control group	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10367	NCT00246259	\N	long acting Risperidone versus Antipsychotic treatment	\N	Canada	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
10368	NCT00140179	\N	valnoctamide versus Placebo	\N	Israel	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
10369	NCT00206544	\N	tamoxifen versus Placebo	\N	Australia	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10370	NCT00245206	\N	Aripiprazole versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	450	\N	\N	\N	\N	\N
10371	NCT00202293	\N	Olanzapine + lithium versus Chlorpromazine + lithium	\N	Australia	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
19416	杨如良 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10372	NCT00161031	\N	atomoxetine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
10373	NCT00167310	\N	Omega-3 Fatty Acid versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10374	NCT00167934	\N	valproate + Antipsychotic thereapy versus Antipsychotic thereapy	\N	United States of America	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
10375	NCT00168311	\N	magnetic stimulation (Transcranial Magnetic Stimulation) versus sham	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10376	NCT00169689	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus Placebo	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10377	NCT00169702	\N	weight management program + Olanzapine versus Olanzapine	\N	Germany	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10378	NCT00169988	\N	Risperidone + sertraline versus sertraline + Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10379	NCT00174889	\N	pregnenolone versus Placebo	\N	Israel	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10380	NCT00176423	\N	galantamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10381	NCT00158366	\N	behavioural training versus behavioural training bosster sessions	\N	United States of America	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
10382	NCT00176436	\N	atomoxetine + group counceling and exercise versus control group	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10383	NCT00176449	\N	Aripiprazole versus standard care	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10384	NCT00179465	\N	Tiagabine 16mg + Antipsychotics versus Placebo + Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
10385	NCT00177905	\N	behavioural treatment versus social skills training	\N	United States of America	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
10386	NCT00177177	\N	L-carnosine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
10387	NCT00177580	\N	pravastatin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
10388	NCT00190749	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
10389	NCT00189995	\N	Clozapine versus Placebo//Clozapine versus Haloperidol//Haloperidol versus Placebo	\N	Israel	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
10390	NCT00186771	\N	Transcranial Magnetic Stimulation versus Placebo	\N	Canada	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
10391	NCT00183443	\N	divalproex ER versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
10392	NCT00192751	\N	pyschoeducational group versus control group	\N	Israel	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
10393	NCT00182494	\N	diabetes prevention program + metformin versus diabetes prevention program + Placebo	\N	Canada	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
10394	NCT00192582	\N	motivational interview versus control group	\N	Australia	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10395	NCT00192855	\N	entacopone versus Placebo	\N	Israel	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10396	NCT00202280	\N	folic acid, vitamin B12, vitamin B6 + Antipsychotics versus Antipsychotics + Placebo	\N	Australia	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10397	NCT00203788	\N	Risperidone + individual placement and support versus Risperidone + workplace fundamentals module	\N	United States of America	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
10398	NCT00205660	\N	Aripiprazole versus Atypical Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
10399	NCT00206102	\N	Quetiapine fumarate versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	1000	\N	\N	\N	\N	\N
10400	NCT00132314	\N	Risperidone LAI + individual placement and support versus Risperidone LAI + workplace fundamentals module	\N	United States of America	\N	\N	\N	\N	\N	369	\N	\N	\N	\N	\N
10401	NCT00136760	\N	Bupropion versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
10402	NCT00137189	\N	music therapy + standard care versus standard care	\N	Norway	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
10406	NCT00137280	\N	collaborative chronic illness care model versus control group	\N	United States of America	\N	\N	\N	\N	\N	1040	\N	\N	\N	\N	\N
10407	NCT00138021	\N	computerized cognitive training program + suppported employment servies versus supported employment services	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10408	NCT00139919	\N	Bifeprunox versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
10848	Potkin 2007 a	\N	Ziprasidone versus various dosages	\N	United States of America//Canada	\N	\N	\N	\N	\N	599	\N	\N	\N	\N	\N
10849	Strom 2007	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	18,094	\N	\N	\N	\N	\N
10850	Talbott 2007	\N	Aripiprazole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	1290	\N	\N	\N	\N	\N
10852	Collins 2007	\N	cognitive Behavioural social skills training versus standard care	\N	United States of America	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
19417	潘志芳 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10853	Daniel 2007 a	\N	IM Aripiprazole versus IM Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
10854	Goldstein 2007	\N	Atypical drugs versus perphenazine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10855	Haut 2007	\N	cognitive remediation versus group skills training	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10856	Ibrahim 2007 a	\N	Quetiapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
10857	Kaushik 2007	\N	computerized cognitive skills training versus control group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10858	Perez-Iglesias 2007a	\N	Olanzapine versus Haloperidol	\N	Spain	\N	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
10859	Van Os 2007	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10860	Allen 2007	\N	Aripiprazole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	1290	\N	\N	\N	\N	\N
10862	NCT00396643	\N	Omega-3 Fatty Acid versus Placebo	\N	Austria	\N	\N	\N	\r\n\r\n\r\n\r\n\r\n\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	81	\N	\N	\N	\N	\N
10863	Arnt 2007	\N	sertindole versus Haloperidol	\N	Denmark	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
10864	Ascher-Svanum 2007 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10865	Baker 2007	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	306	\N	\N	\N	\N	\N
10866	Barr 2007	\N	nicotine versus healthy and schizophrenic controls	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10867	Baskak 2007	\N	Biperiden versus Placebo	\N	Turkey	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
20470	唐再胜 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10868	Bell 2007 a	\N	neurocognitive enhancement therapy + supported employment versus supported employment	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
10869	Bennett 2007	\N	behavioural treatment versus control group	\N	United States of America	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
10870	Bertelsen 2007 a	\N	psychosocial integrated treatment versus standard care	\N	Denmark	\N	\N	\N	\N	\N	578	\N	\N	\N	\N	\N
10872	Jensen 2007	\N	Risperidone versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
10873	Holland 2007	\N	Cognitive Training (Targeted) versus Games (Computer)	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
10874	Haupt 2007 a	\N	divalproex + Antipsychotic treatment versus Antipsychotic treatment + Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10875	Harvey 2007 a	\N	Ziprasidone versus Clozapine	\N	Italy	\N	\N	\N	\N	\N	147	\N	\N	\N	\N	\N
10876	Harris 2007	\N	computer assisted cognitive remediation versus control group	\N	Australia	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
10878	Hale 2007	\N	sertindole versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	295	\N	\N	\N	\N	\N
10879	Greig 2007 a	\N	neurocognitive enhancement therapy + supported employment versus supported employment	\N	United States of America	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
10880	Green 2007 a	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
10881	Granholm 2007	\N	cognitive Behavioural social skills training + standard care versus standard care	\N	United States of America	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
10882	Fahnestock 2007	\N	Olanzapine versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10883	d'Souza 2007	\N	alcohol versus control group	\N	United States of America	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
10884	Canuso 2007	\N	paliperidone extended release versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	285	\N	\N	\N	\N	\N
10885	Buchanan 2007 a	\N	galantamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
10886	Brecher 2007	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10888	Jessani 2007	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10889	Jeste 2007	\N	cognitive enhancing drug versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	145	\N	\N	\N	\N	\N
10890	Josiassen 2007	\N	tolvaptan versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
10891	Jung 2007	\N	Aripiprazole + Haloperidol versus Haloperidol + Placebo	\N	South Korea	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
10892	Khan 2007 a	\N	computerized neurocognitive skills training versus control group	\N	United States of America	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
10893	Killackey 2007	\N	individual placement and support + standard care versus standard care	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10894	Kim 2007 a	\N	Aripiprazole versus non- Aripiprazole	\N	South Korea	\N	\N	\N	\N	\N	270	\N	\N	\N	\N	\N
10895	Kollack-Walker 2007	\N	Olanzapine versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
10896	Kramer 2007 a	\N	paliperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	530	\N	\N	\N	\N	\N
19489	Lindenmayer 2008 a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
10897	Kujawa 2007	\N	Risperidone versus various doses	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10898	Kulkarni 2007	\N	transdermal estradiol + Antipsychotic treatment versus Antipsychotic treatment + Placebo	\N	Australia	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10899	Lahti 2007	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
10900	Allison 2007	\N	Ziprasidone versus Placebo//Olanzapine versus Placebo//Risperidone versus Placebo//Haloperidol versus Placebo//Olanzapine versus Ziprasidone//Risperidone versus Ziprasidone//Haloperidol versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	294	\N	\N	\N	\N	\N
10901	Fioritti 2007	\N	individual placement and support versus control group	\N	Italy	\N	\N	\N	\N	\N	312	\N	\N	\N	\N	\N
10902	Daskalakis 2007	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
10903	Davis 2007 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus work outcome	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
10904	de Castella 2007	\N	raloxifene versus Placebo	\N	Australia	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
10905	Diamond 2007	\N	cognitive adaption training versus standard care	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10906	Drake 2007	\N	cognitive remediation group versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
10907	Boonstra 2007	\N	withdrawl of Antipsychotics versus continuation of Antipsychotics	\N	Netherlands	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
10910	Leweke 2007	\N	cannabidiol versus amisulpiride	\N	Germany	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
10911	Lysaker 2007 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10912	Luthringer 2007 a	\N	paliperidone ER versus Placebo	\N	France//Poland//Romania	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
10913	Loebel 2007	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	186	\N	\N	\N	\N	\N
10914	Lecomte 2007	\N	group Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	Canada	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
10915	Lesem 2007	\N	SGS518 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
10916	Linszen 2007	\N	specialized care and parent groups versus standard care	\N	Netherlands	\N	\N	\N	\N	\N	188	\N	\N	\N	\N	\N
10917	Marder 2007 a	\N	Risperidone + supported employment (with and without skills training model versus Olanzapine + supported employment (with and without skills training model	\N	United States of America	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
10918	McCabe 2007	\N	proprioception retraining versus face perception retraining	\N	Australia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11556	Peng 2006 b	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
11557	Pu 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
11558	Qin 2006 b	\N	Home visit + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11559	Qin 2007	\N	Traditional Chinese Medicine (TCM) Jieyu-Anshen-decotion + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11560	Qiu 2007 a	\N	Quetiapine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	191	\N	\N	\N	\N	\N
11561	Qiu 2007 b	\N	Cognitive education for families + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11562	Qu 2006 a	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	213	\N	\N	\N	\N	\N
11563	Qu 2006 b	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
11564	Sha 2006	\N	Psychotherapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11565	Shen 2006	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
11566	Shen 2007	\N	Initiative training + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11567	Song 2006 c	\N	Loxapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11568	Song 2006 d	\N	Nursing intervention + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11569	Song 2006 e	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
11570	Su 2006 c	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11571	Sun 2007 a	\N	Quetiapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11897	Parsons 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	239	\N	\N	\N	\N	\N
11572	Sun 2007 b	\N	Olanzapine + Ranitidine versus Olanzapine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
11573	Sun 2007 c	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
11574	Sun 2006 i	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
11575	Sun 2007 d	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
11576	Tan 2006 b	\N	Divisional service + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
20251	易著英 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
11577	Tan 2007	\N	Home based intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
11578	Tang 2006 c	\N	Open management versus Closed management	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
11579	Tang 2007 a	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13494	Evins 2005 c	\N	Bupropion versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
13497	Lane 2005	\N	sarcosine versus Placebo	\N	Taiwan	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
13498	Lenior 2001 b	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13501	Hoffman 2005	\N	transcranial magnetic stimulation (Transcranial Magnetic Stimulation) versus sham transcranial magnetic stimulation (Transcranial Magnetic Stimulation)	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
13504	Gillis 1977 b	\N	\N	\N	Finland	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13505	Kern 2006	\N	Aripiprazole versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	255	\N	\N	\N	\N	\N
13507	Ko 2005 b	\N	topiramate versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
13510	Kretschmar 1971	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13512	Solomon 1995 e	\N	assertive community treatment versus individual case management	\N	United States of America	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
13515	Finnell 1997	\N	Recreational Therapy // Vocational Rehabilitation	\N	United States of America	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
13520	Kalali 2000	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13521	Warawat 2001	\N	Olanzapine + fluoxamine versus Olanzapine	\N	Thailand	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
13522	Amann 2005	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
13523	Fries 2003	\N	psychoeducation group therapy versus control group	\N	Unclear	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13524	Klingberg 1997	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
13525	Koch 2003	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
13526	Rappold 2005	\N	IFN alpha-2b versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
13528	Takats 1999	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13529	Wiebel 1995	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13533	Greenfield 2008	\N	crisis residential program versus locked inpatient psychiatric facility	\N	United States of America	\N	\N	\N	\N	\N	393	\N	\N	\N	\N	\N
13534	Siris 1993	\N	fluphenazine + imipramine versus fluphenazine + Placebo	\N	United States of America	Hillside Hospital, Glen Oaks, NY 11004. ORIGIN USA\r\n\r\nLong Island Jewish Medical Ctr, Hillside Hosp, Glen Oaks, NY, US ORIGIN USA	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
13536	Ban 1975 d	\N	thiothixene versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13537	Fleischhacker 1995 b	\N	seroquel versus various dosages	\N	Austria	\N	\N	\N	\N	\N	448	\N	\N	\N	\N	\N
13538	Ogunmefun 2009	\N	donepezil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
10409	NCT00140166	\N	niacinamide versus ascorbate	\N	Israel	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
10410	NCT00210717	\N	paliperidone palmitate versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	700	\N	\N	\N	\N	\N
10411	NCT00212836	\N	Asenapine versus Olanzapine	\N	Australia	\N	\N	\N	\N	\N	444	\N	\N	\N	\N	\N
10412	NCT00401089	\N	panax ginseng + Antipsychotics versus Antipsychotics	\N	Canada//United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10413	NCT00328978	\N	Quetiapine 800mgs versus Quetiapine >800mgs	\N	Canada	\N	\N	\N	\N	\N	330	\N	\N	\N	\N	\N
10414	NCT00138775	\N	D-serine versus Placebo D-serine dose	\N	Israel	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined field 10\r\n	\N	200	\N	\N	\N	\N	\N
10415	NCT00140192	\N	creatine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10416	NCT00144027	\N	Antipsychotic medication adherence intervention versus usual care	\N	United States of America	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
10417	NCT00145496	\N	Asenapine versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	444	\N	\N	\N	\N	\N
10418	NCT00148564	\N	Olanzapine versus Ziprasidone	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10419	NCT00148447	\N	escitalopram versus Placebo	\N	Israel	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10420	NCT00148590	\N	memantine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10421	NCT00148616	\N	memantine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10422	NCT00149734	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10423	NCT00149955	\N	Clozapine versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10424	NCT00150176	\N	Asenapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
10425	NCT00156065	\N	Asenapine + Haloperidol versus Placebo + Haloperidol//Asenapine versus Haloperidol//Asenapine versus Placebo//Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
10426	NCT00156091	\N	Asenapine versus Placebo	\N	United States of America//Russian Federation//Ukraine	\N	\N	\N	\N	\N	662	\N	\N	\N	\N	\N
10427	NCT00158223	\N	pimozide + Clozapine versus Placebo + Clozapine	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
10428	NCT00206128	\N	seroquel SR versus seroquel IR	\N	Germany	\N	\N	\N	\N	\N	630	\N	\N	\N	\N	\N
10429	NCT00206557	\N	Antipsychotics + raloxifene versus Antipsychotics + Placebo	\N	Australia	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10430	NCT00206570	\N	Antipsychotics + estradiol versus Antipsychotics + Placebo	\N	Australia	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
10431	NCT00210548	\N	paliperidone palmitate versus Placebo	\N	South Korea//Malaysia//Ukraine//United States of America//Taiwan	\N	\N	\N	\N	\N	376	\N	\N	\N	\N	\N
10432	NCT00215917	\N	D-serine versus Risperidone	\N	Israel	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10433	NCT00216281	\N	Clozapine + atomoxetine versus Clozapine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
10434	NCT00216671	\N	Risperidone + Antipsychotics versus Antipsychotics	\N	Denmark//Finland	\N	\N	\N	\N	\N	220	\N	\N	\N	\N	\N
10435	NCT00220714	\N	Risperidone long acting injection versus oral Antipsychotics//Monetary incentives//	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10436	NCT00218231	\N	Bupropion versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10437	NCT00223418	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10438	NCT00044083	\N	tolcapone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
10439	NCT00044655	\N	Risperidone versus Haloperidol//Switching	\N	United States of America	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
10440	NCT00048828	\N	Olanzapine versus Clozapine	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10441	NCT00056498	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10442	NCT00057707	\N	Modafinil versus Placebo	\N	United States of America	\N	\N	\N	\r\nUser defined 3\r\n\r\nUser defined field 10\r\n	\N	180	\N	\N	\N	\N	\N
10443	NCT00071604	\N	medication adherence therapy versus friendly support group	\N	United States of America	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
10444	NCT00088049	\N	Olanzapine versus Aripiprazole Olanzapine versus dosage of drug + versus Aripiprazole for schizophrenia whose current state is acute and whose stage of illness is not described Olanzapine versus Aripiprazole	\N	United States of America	\N	\N	\N	\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	566	\N	\N	\N	\N	\N
10445	NCT00088491	\N	Olanzapine depot versus oral Olanzapine	\N	Finland//India//Turkey//United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	1250	\N	\N	\N	\N	\N
10446	NCT00090324	\N	Quetiapine fumarate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	249	\N	\N	\N	\N	\N
10447	NCT00100165	\N	nicotine agonist versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
10448	NCT00124683	\N	Bupropion + nicotine patch versus nicotine patch + Placebo	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10449	NCT00111189	\N	paliperidone palmitate versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	640	\N	\N	\N	\N	\N
10450	NCT00129441	\N	merck L-830982 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
10451	NCT00130923	\N	long acting Risperidone versus oral Risperidone	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10452	NCT00352339	\N	Aripiprazole versus Risperidone	\N	South Korea	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10453	NCT00357006	\N	estradiol versus Placebo	\N	Australia	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
10454	NCT00361166	\N	Risperidone dose//Haloperidol low dose + pimavanserin versus Haloperidol + Placebo//Haloperidol low dose versus Risperidone low dose + pimavanserin//Haloperidol low dose + pimavanserin versus Risperidone + Placebo//Haloperidol + Placebo versus Haloperidol low dose//Haloperidol + Placebo versus Risperidone low dose + pimavanserin//Haloperidol + Placebo versus Risperidone + Placebo//Risperidone low dose + pimavanserin versus Risperidone + Placebo//	\N	United States of America//Brazil	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined field 10\r\n	\N	423	\N	\N	\N	\N	\N
10455	NCT00361543	\N	raloxifene + Antipsychotic treatment versus Placebo + Antipsychotic treatment	\N	Australia	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10456	NCT00362804	\N	tetrabenazine versus Placebo	\N	Canada	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10457	NCT00373321	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10458	NCT00373126	\N	transdermal nicotine patch versus Placebo patch	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10459	NCT00372151	\N	L-theonine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10460	NCT00369577	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
20252	张青磊 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10461	NCT00366704	\N	Bifeprunox versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
10462	NCT00374777	\N	zolpidem MR versus Placebo	\N	Japan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10463	NCT00374244	\N	pimozide + Clozapine versus Placebo + Clozapine	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10464	NCT00373672	\N	Modafinil versus Placebo // Armodafinil versus Placebo	\N	United States of America	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	60	\N	\N	\N	\N	\N
10465	NCT00375050	\N	Riluzole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
10466	NCT00380224	\N	Bifeprunox versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10467	NCT00363376	\N	zonisamide + Olanzapine versus Placebo + Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10468	NCT00391677	\N	attention shaping procedures versus control group	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10469	NCT00392249	\N	supervised treatment + Antipsychotics versus control group + Antipsychotics	\N	Pakistan	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
10470	NCT00395915	\N	Aripiprazole + Clozapine versus Clozapine + Placebo	\N	Italy	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
10471	NCT00396214	\N	Bifeprunox versus Quetiapine	\N	Sweden	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10472	NCT00396565	\N	ER oros paliperidone versus Placebo	\N	Japan	\N	\N	\N	\N	\N	329	\N	\N	\N	\N	\N
10473	NCT00397033	\N	paliperidone ER versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	315	\N	\N	\N	\N	\N
10474	NCT00400166	\N	recovery guide services versus control group	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10475	NCT00401973	\N	Amantadine versus Metformin // Amantadine + Olanzapine versus Olanzapine // Metformin + Olanzapine versus Olanzapine	\N	Russia and Unclear	\N	\N	\N	\r\nUser defined 3\r\n	\N	200	\N	\N	\N	\N	\N
10476	NCT00403247	\N	capsule with folate, vitamin B12, & pyridoxine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10477	NCT00403546	\N	Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10478	NCT00404573	\N	RGH-188 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	375	\N	\N	\N	\N	\N
10479	NCT00406718	\N	med-emonoitor device versus pharmcat therapy Electronic Medication Monitor versus PharmCAT Therapist // Electronic Medication Monitor // PharmCAT Therapist	\N	United States of America	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	150	\N	\N	\N	\N	\N
10480	NCT00407277	\N	nicotine patch versus Placebo patch	\N	Canada	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10481	NCT00409201	\N	reboxetine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
10482	NCT00303602	\N	under the toungue Olanzapine versus swallowed Olanzapine	\N	Canada//United States of America//Netherlands//Mexico	\N	\N	\N	\N	\N	149	\N	\N	\N	\N	\N
10483	NCT00338598	\N	glycine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
10486	NCT00334035	\N	\N	\N	Hong Kong	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined field 9\r\n	\N	130	\N	\N	\N	\N	\N
10487	NCT00333970	\N	cognitive remediation therapy versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
10488	NCT00333177	\N	psychosocial therapy + Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
10489	NCT00330863	\N	Atypical Antipsychotics (Oral) versus Risperidone (Long Acting Injection)	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	304	\N	\N	\N	\N	\N
10490	NCT00330551	\N	oral Risperidone versus injectable Risperidone	\N	United States of America	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
10491	NCT00325689	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	338	\N	\N	\N	\N	\N
10492	NCT00324051	\N	conventional oral Olanzapine versus Olanzapine orodispersible tablets	\N	Brazil	\N	\N	\N	\N	\N	284	\N	\N	\N	\N	\N
10493	NCT00320697	\N	Bupropion + cognitive behavioral therapy versus Placebo + cognitive behavioral therapy	\N	United States of America	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
10494	NCT00320671	\N	Aripiprazole versus Risperidone	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	242	\N	\N	\N	\N	\N
10495	NCT00320489	\N	Olanzapine pamoate depot versus Olanzapine Clozapine versus memantine versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic	\N	United States of America // Brazil // Multicentre // Australia // France	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	520	\N	\N	\N	\N	\N
10496	NCT00308997	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10497	NCT00306475	\N	divalproex sodium ER versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10499	NCT00307216	\N	graduated recovery intervention program versus control group	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10571	Chen 2005 g	\N	Self-confidence training + routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10500	NCT00312962	\N	Cognitive Training (Computerized Neuroplasticity-Based) versus Games (Computer)	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	80	\N	\N	\N	\N	\N
10501	NCT00312949	\N	interactive educational website versus control group	\N	United States of America	\N	\N	\N	\N	\N	288	\N	\N	\N	\N	\N
10502	NCT00309452	\N	\N	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined field 9\r\n	\N	200	\N	\N	\N	\N	\N
10503	NCT00309413	\N	connabidiol versus Placebo	\N	Germany	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
10504	NCT00316238	\N	Olanzapine-RAIM versus control group	\N	Japan	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
10505	NCT00314639	\N	Modafinil versus Placebo	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
10506	NCT00338949	\N	Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
10507	NCT00349973	\N	dipyridamole versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
10508	NCT00347425	\N	bofeprunox versus Atypical Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10509	NCT00345033	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
10510	NCT00338975	\N	standard care + cognitive behavioral social skills training versus standard care + supportive contact Cognitive Behavioral Social Skills Training versus Goal-Focused Supportive Contact	\N	United States of America	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	240	\N	\N	\N	\N	\N
10511	NCT00338832	\N	lifestyle intervention versus control group	\N	United States of America	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
10512	NCT00345982	\N	Clozapine + sertindole versus Clozapine + Placebo	\N	Denmark	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10513	NCT00350467	\N	ER oros paliperidone versus Olanzapine	\N	China	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
10514	NCT00350883	\N	cognitive therapy versus standard care	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10515	NCT00351936	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
10516	NCT00356317	\N	Culturally Informed Therapy versus Psychoeducation	\N	United States of America	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
10517	NCT00344500	\N	behavioural weight loss program versus standard care	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10518	NCT00281320	\N	Asenapine Dosage	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10519	NCT00225498	\N	Olanzapine or risperidol versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10520	NCT00231101	\N	Quetiapine + Risperidone versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10521	NCT00282165	\N	nartriptan versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
10522	NCT00287820	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
10523	NCT00288353	\N	Ziprasidone versus Aripiprazole	\N	United States of America	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
10524	NCT00288366	\N	Ziprasidone versus Aripiprazole	\N	United States of America	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
10525	NCT00289861	\N	Clozapine + Risperidone versus Clozapine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10526	NCT00295048	\N	computer assisted cognitive remediation versus computerized control task	\N	United States of America	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
10527	NCT00295139	\N	behavioural treatment versus control group	\N	United States of America	\N	\N	\N	\N	\N	307	\N	\N	\N	\N	\N
10528	NCT00297947	\N	Quetiapine versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10530	NCT00300651	\N	Cognitive Behavioural Training versus standard care	\N	Germany	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	70	\N	\N	\N	\N	\N
10531	NCT00300846	\N	Aripiprazole + Clozapine versus Clozapine	\N	Austria//Czech Republic	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
10532	NCT00291226	\N	glycine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
10533	曹新妹 2002	\N	Psychoeducation for patients and family members + routine care versus Psychoeducation for patients only + routine care	\N	China	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
10534	Jia 2002	\N	Psychological therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
10535	Li 2002 h	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
10536	Li 2002 i	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
10537	Liu 2002 b	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10538	Ma 2002 b	\N	Antipsychotics and Zao-bai-ning-shen-tang (Traditional Chinese Medicine (TCM)) versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	244	\N	\N	\N	\N	\N
10539	Wang 2002 m	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	146	\N	\N	\N	\N	\N
10540	Wang 2002 n	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
10542	Xu 2002 b	\N	Ginkgo tablet + routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10543	Yang 2002 e	\N	Risperidone versus Risperidone + Clozapine	\N	China	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
10544	Yang 2002 g	\N	Traditional Chinese Medicine (TCM) + western medicine versus Western medicine	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
10545	Zhang 2002 m	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
10547	Zhao 2002 b	\N	Family intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	226	\N	\N	\N	\N	\N
10548	Zhao 2002 c	\N	Risperidone versus Clozapine + sulpiride	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10549	Zhu 2002 j	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
10552	Ye 2006 a	\N	Clozapine + Loxapine versus Loxapine 	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10553	Zhou 2005 e	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10554	阿怀红 2006 a	\N	Aripiprazole versus Sulpiride	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10555	阿怀红 2006 b	\N	Aripiprazole versus Sulpiride	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10556	Bai 2005 e	\N	Huperzine A versus Placebo	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10557	Bi 2000	\N	Holistic nursing versus standard care	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10558	Cai 2006 a	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	197	\N	\N	\N	\N	\N
10559	Cai 2005	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
10560	Cao 2006 b	\N	Ziprasidone versus Placebo//Ziprasidone versus Haloperidol//Haloperidol versus Placebo	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10561	Cao 2004 b	\N	Risperidone + Venlafaxine versus Risperidone 	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
10562	Chang 2003 b	\N	Olanzapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
10563	Chang 2004 b	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
10564	Chen 2003 k	\N	Risperidone + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
10565	Chen 2006 g	\N	Olanzapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
10566	Chen 2005 f	\N	Psychological educational + family intervention versus standard care	\N	China	\N	\N	\N	\N	\N	357	\N	\N	\N	\N	\N
10567	Chen 2006 h	\N	Clozapine + Venlafaxine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10568	Chen 2006 i	\N	Aripiprazole versus Risperidone 	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10569	Chen 2004 d	\N	Recreation therapy versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10570	Chen 2006 j	\N	Antipsychotics and modified electroconvulsive therapy versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
10639	Lu 2006 h	\N	Risperidone versus Quetiapine	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
10572	Chen 2004 e	\N	Risperidone + Chlorimipramine versus Clozapine + Chlorimipramine	\N	China	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
10573	Chen 2006 k	\N	Quetiapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10574	Chen 2003 l	\N	Modern electro convulsive therapy (Electroconvulsive Therapy) versus Traditional electro convulsive therapy (Electroconvulsive Therapy)	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
10575	Chen 2006 l	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10576	Chen 2006 m	\N	Electroacupuncture + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
10577	Cheng 2005 b	\N	Systematic psychoeducation + psychoeducation versus psychoeducation only	\N	China	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
10578	Cheng 2006 c	\N	Aripiprazole versus Perphenazine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10579	Cui 2001	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10580	Deng 2006 c	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
10581	Ding 2000 b	\N	Comprehensive life skills training + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
10582	Ding 2003 a	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10583	Ding 2006 c	\N	Clozapine combined with Paroxetine versus Clozapine combined with Placebo	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
10584	Dong 2006	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20253	樊增华 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10585	Du 2000	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
10586	Fan 2005 d	\N	Olanzapine + Nursing intervention versus Olanzapine + standard care	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10587	Fan 2000	\N	Holistic nursing + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10588	Gan 2004	\N	Fufang Shenhuai Fen + Olanzapine versus Olanzapine	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
10589	Gao 2006 a	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
10590	Gao 2006 b	\N	Social skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10591	Gao 2005 c	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	224	\N	\N	\N	\N	\N
10592	Gao 2002	\N	Huperzine + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10593	Guo 2006 b	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	115	\N	\N	\N	\N	\N
10594	Han 2006 a	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
10595	Hang 2006	\N	behaviour therapy + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10596	He 2003 d	\N	Olanzapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10597	He 2004 b	\N	Open ward versus Closed ward	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10598	He 2003 e	\N	Family intervention with psychoeducation + Antipsychotic medication versus psychoeducation + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
10599	Hou 2004	\N	Traditional Chinese Medicine (TCM) Huoxue Huayu + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
10600	Huang 2005 c	\N	Group recovery + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10601	Huang 2006 e	\N	Comprehensive rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication Social worker intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
10602	Huang 2006 f	\N	Aripiprazole versus Risperidone 	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10603	Huang 2005 d	\N	Traditional Chinese Medicine (TCM) Wendan Tang + Antipsychotic medication versus estazolam + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10604	Huang 2006 g	\N	Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
10605	Huang 2006 h	\N	Aripiprazole versus Sulpiride	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
10606	Ji 2005 a	\N	Holistic nursing + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10607	Jiang 2006 c	\N	Aripiprazole versus Olanzapine	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
10608	Jiang 2006	\N	Self-management education + Antipsychotic medication versus Routine health education + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10609	Kuang 2006 b	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10610	Lei 2005	\N	Occupational therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
10611	Li 2004 i	\N	Loxapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10612	Li 2006 i	\N	Risperidone versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10613	Li 2006 j	\N	Electric stimulation + Sulpiride versus Sulpiride	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10614	Li 2005 r	\N	Risperidone + Medical automatic oxygen-rich device versus Risperidone	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
10615	Li 2005 s	\N	Tiapride versus Haloperidol	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10616	Li 2003 p	\N	Community family intervention + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	343	\N	\N	\N	\N	\N
10617	Li 2006 k	\N	Nursing intervention versus standard care	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
10618	Li 2006 l	\N	Humanism Nursing Management + Antipsychotic medication versus standard care + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
10619	Li 2000	\N	Risperidone + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10620	Li 2004 j	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
10621	Li 2006 m	\N	Aripiprazole versus Clozapine 	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
10622	Li 2006 n	\N	Aripiprazole versus Clozapine 	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10623	Li 2006 o	\N	Cognitive therapy + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10624	Li 2006 p	\N	Social skill training + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
10625	Li 2006 q	\N	Sulpiride + Haloperidol versus Sulpiride	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
10626	Liang 2006 b	\N	Quetiapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20254	段文涛 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
10627	Liang 2005 a	\N	Clozapine versus Risperidone 	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10628	Lin 2006 d	\N	Sit-ups + care as usual versus care as usual	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10629	Lin 2005 a	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
10630	Lin 2005 e	\N	Risperidone + Sertraline versus Risperidone 	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
10631	Lin 2005 f	\N	Quetiapine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10632	Liu 2003 i	\N	Clozapine + Sodium valproate versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10633	Liu 2006 i	\N	Holistic nursing + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
10634	Liu 2003 j	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10635	Liu 2003 k	\N	Quetiapine versus Risperidone 	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10636	Liu 2006 j	\N	Occupational therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10637	Liu 2005 i	\N	Clozapine versus other Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10638	Liu 2006 k	\N	Health education versus standard care	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
10640	Lv 2005	\N	Open ward magnement + Antipsychotic medication versus Closed ward management + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10641	Ma 2001 c	\N	Chlorpromazine versus Clozapine 	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
10642	Mei 2006 b	\N	Quetiapine combined with Clonazepam versus Haloperidol + Scopolamine	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
10643	Qi 2006 b	\N	Comprehensive rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10644	Qian 2005 b	\N	Quetiapine versus Sulpiride Quetiapine versus sulpride	\N	China	\N	\N	\N	\r\nUser defined field 10\r\n	\N	60	\N	\N	\N	\N	\N
10645	Ren 2006	\N	Risperidone versus Loxapine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
10646	Rosenheck 2005	\N	Olanzapine versus Haloperidol 	\N	China	\N	\N	\N	\N	\N	309	\N	\N	\N	\N	\N
10647	Ruan 2005	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10648	Sheng 2006 a	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
10649	Sheng 2006 b	\N	Morita therapy + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
10650	Song 2006 a	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10651	Song 2006 b	\N	Aripiprazole versus Risperidone 	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
10652	Su 2006 b	\N	Comprehensive rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10653	Sun 2000 c	\N	psychoeducation versus Routine review	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10654	Sun 2006 f	\N	Aripiprazole versus Risperidone 	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
10655	Sun 2006 g	\N	Quetiapine versus Risperidone 	\N	China	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
10656	Sun 2006 h	\N	Rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
10657	Sun 2000 d	\N	Clozapine versus Clozapine combined with Perphenazine	\N	China	\N	\N	\N	\N	\N	153	\N	\N	\N	\N	\N
10658	Tan 2005 f	\N	Rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
10659	Tang 2005 d	\N	Acupuncture + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
10660	Tang 2005 e	\N	Venlafaxine versus Chlorimipramine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
10661	Tang 2005 f	\N	Risperidone + fluoxetine versus Risperidone 	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
10662	Tang 2004	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10663	Tao 2004	\N	Psychological intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
10664	Tao 2001 b	\N	Psychological intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10665	Tian 2005 b	\N	Risperidone + Chlorpromazine versus Risperidone + Benzodiazepines	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
10666	Wang 2006 o	\N	Quetiapine versus Risperidone 	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10667	Wang 2006 p	\N	Aripiprazole versus Risperidone 	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10668	Wang 2006 q	\N	Traditional Chinese Medicine (TCM) Shuxue ning + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
10669	Wang 2004 s	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20255	武建斌 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
10670	Wang 2006 r	\N	Acupuncture + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
10671	Wang 2005 z	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10672	Wang 2004 t	\N	Traditional Chinese Medicine (TCM) Quanxi Kangshen Koufu Ye + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10674	Wang 2000 l	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10675	Wang 2006 s	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
10676	Wang 2001 h	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10677	Wang 2006 t	\N	Traditional Chinese Medicine (TCM) Risperidone + Dian-meng-xing-decoction + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
10678	Wang 2005 ab	\N	Adjunctive treatment with divalproex sodium ER versus Placebo	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
10679	Wang 2005 ac	\N	Sulpiride + Sertraline versus Sulpiride	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10680	Wei 2006 d	\N	Therapeutic community versus standard care	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10681	Wei 2006 e	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10682	Wen 2006 b	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10683	Wen 2005	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10684	Wu 2006 c	\N	Risperidone + Clonazepam injection versus Haloperidol 	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10686	Xiao 2006 a	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
10687	Xie 2004 a	\N	Clozapine + Haloperidol decanoate injection versus Clozapine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
10688	Xie 2004 b	\N	Health education by clinical nursing pathway versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	111	\N	\N	\N	\N	\N
10689	Xu 2006 c	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
10690	Xu 2006 d	\N	Clozapine + Sulpiride versus Clozapine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
10691	Xu 2006 e	\N	Aripiprazole versus Haloperidol	\N	China	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
10692	Xu 2005 e	\N	Comprehensive training + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
10693	Xu 2006 f	\N	Health education + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
10694	Xu 2006 g	\N	Home based psychotherapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10695	Xun 2006 b	\N	Risperidone oral solution versus Penfluridol	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10696	Yang 2006 i	\N	Holistic nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10697	Yang 2006 j	\N	Risperidone + Baizi-Yangxin-Pills (TCM) versus Risperidone	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
10698	Yang 2006 k	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10699	Yang 2003 e	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
10700	Yang 2005 j	\N	Risperidone + Venlafaxine versus Risperidone	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
10701	Yang 2006 l	\N	Traditional Chinese Medicine (TCM) Shu-xue-ning + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10703	Yi 2005	\N	Loxapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10704	Yin 2000	\N	Traditional Chinese Medicine (TCM) Shengmaiyin, as needed versus West medicine, as needed	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
10705	You 2006	\N	behaviour training + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10706	Yu 2005 c	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
10707	Yu 2006 c	\N	Risperidone + Clonazepam versus Haloperidol	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
10708	Yu 2006 d	\N	Quetiapine versus Loxapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10709	Yuan 2006	\N	Aripiprazole + Paroxetine versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10710	Zhan 2004 b	\N	Risperidone in various dosages versus Risperidone in various dosages	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
10711	Zhang 2005 m	\N	Home based psychotherapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
10712	Zhang 2006 p	\N	Psychotherapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10713	Zhang 2006 q	\N	Health education + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10714	Zhang 2006 r	\N	Psychological nursing + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
10715	Zhang 2006 s	\N	Family intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
10716	Zhang 2006 t	\N	Family therapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
10717	Zhang 2006 u	\N	Family therapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10718	Zhang 2005 n	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
10719	Zhang 2006 v	\N	Rehabilitation training + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
10720	Zhang 2006 w	\N	Loxapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10721	Zhang 2006 x	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10722	Zhang 2006 y	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
10723	Zhang 2004 l	\N	behaviour training + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
10724	Zhang 2005 o	\N	Aripiprazole versus Haloperidol	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10725	Zhang 2006 z	\N	Aripiprazole versus Haloperidol	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10726	Zhao 2003 d	\N	Loxapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
10727	Zheng 2006 a	\N	Nursing intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10728	Zheng 2003 e	\N	Olanzapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
10729	Zheng 2006 b	\N	Biofeedback therapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10730	Zhou 2006 c	\N	Aripiprazole versus Sulpiride	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10732	Zhou 2005 g	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10733	Zhou 2000 d	\N	Chlorpromazine versus Clozapine	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
10734	Zhu 2006 c	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
10735	Zhu 2006 d	\N	Health education + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10736	Zhu 2001 c	\N	Cognitive therapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10737	Zhuang 2006	\N	Aripiprazole versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10738	Cao 2005 c	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
10739	Han 2006 b	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Paroxetine versus Paroxetine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
10740	Li 2006 r	\N	Family therapy + Quetiapine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10741	Yang 2006 m	\N	Quetiapine + Clonazepam versus Haloperidol	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10742	Chen 2005 h	\N	Social support versus None	\N	China	\N	\N	\N	\N	\N	244	\N	\N	\N	\N	\N
10743	Guo 2006 c	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
10745	Fei 2002	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
10746	Huang 2002	\N	Community based intervention versus None	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
10747	Li 2002 j	\N	Specific rehabilition nursing versus Conventional rehabilition nursing	\N	China	\N	\N	\N	\N	\N	141	\N	\N	\N	\N	\N
10748	Liu 2002 c	\N	Venlafaxine versus Chlorimipramine	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
10749	Lu 2002 f	\N	Vocational rehabilitation + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
10750	Luo 2002	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
10751	Wang 2002 o	\N	Community based intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
10752	Wang 2002 p	\N	Health care team + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
10753	Xiang 2002 c	\N	Skill training + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
10754	Xiang 2002 d	\N	Skill training + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
10755	Zhang 2002 o	\N	Levamisole embrocation + Haloperidol versus Haloperidol	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10756	Zou 2002	\N	Supportive psychotherapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
10757	Block 2006	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10758	Baptista 2007 b	\N	Olanzapine versus Placebo	\N	Venezuela	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10759	Baptista 2006	\N	metformin + Olanzapine versus Olanzapine + Placebo	\N	Venezuela	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10760	Andrezina 2006	\N	Aripiprazole versus Placebo//Aripiprazole versus Haloperidol//Haloperidol versus Placebo	\N	Latvia	\N	\N	\N	\N	\N	325	\N	\N	\N	\N	\N
10761	Carpenter 2006	\N	Risperidone + olanzapilne versus Quetiapine + Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	333	\N	\N	\N	\N	\N
10762	Donaldson 2006	\N	suicidal support team + treatment as usual versus treatment as usual	\N	United States of America	\N	\N	\N	\N	\N	289	\N	\N	\N	\N	\N
20256	柴艳丽 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
10763	Essock 2006 b	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	1432	\N	\N	\N	\N	\N
10765	Jackson 2007	\N	integrated care versus standard care	\N	United States of America	\N	\N	\N	\N	\N	199	\N	\N	\N	\N	\N
10766	Macias 2006	\N	assertive community treatment versus supported employment services	\N	United States of America	\N	\N	\N	\N	\N	177	\N	\N	\N	\N	\N
10767	Hogarty 2006	\N	cognitive enhancement therapy versus enriched supportive therapy	\N	United States of America	\N	\N	\N	\N	\N	121	\N	\N	\N	\N	\N
10768	Schutzwohl 2007 a	\N	\N	\N	Germany	\N	\N	\N	\N	\N	191	\N	\N	\N	\N	\N
10769	Morken 2007	\N	integrated treatment versus standard care	\N	Norway	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10770	Marder 1991 b	\N	Risperidone versus Placebo//Risperidone versus Haloperidol//Haloperidol versus Placebo	\N	Canada//United States of America	\N	\N	\N	\N	\N	523	\N	\N	\N	\N	\N
10771	Solomon 1990	\N	Haloperidol versus lorazipam	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10772	Arranz 2007	\N	orally disintegrated Olanzapine versus standard Olanzapine tablet	\N	Spain	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
10773	Bernardo 2006	\N	Ziprasidone versus Placebo	\N	Spain	\N	\N	\N	\N	\N	218	\N	\N	\N	\N	\N
10775	Bell 1995	\N	paid vocational rehabilitation versus non paid vocational rehabilitation	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10777	Gang 1997	\N	Electroacupuncture + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10778	Fagerlund 2007	\N	donepezil + Ziprasidone versus Placebo + Ziprasidone	\N	Denmark	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
10779	Emsley 2004 d	\N	Quetiapine versus Haloperidol	\N	South Africa	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10780	de Leon 2007	\N	Clozapine dose	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10782	Alverson 1998	\N	vocational rehabilitation programs	\N	United States of America	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
10784	Miodownik 2003	\N	vitamin B6 adjunctive versus Placebo	\N	Israel	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
10785	Meltzer 2006 a	\N	Atypical Antipsychotics versus conventional Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	1460	\N	\N	\N	\N	\N
10786	McCay 2006 a	\N	healthy self concept group versus control group	\N	Canada	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
10787	Lee 2006 c	\N	stress management program + vocational training versus vocational training	\N	Taiwan	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
10791	Frangou 2001	\N	electronic telemonitoring versus control group electronic telemonitoring versus control group electronic telemonitoring versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
10792	Jager 2006	\N	\N	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10793	Smelson 2006 a	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
10794	Smelson 2006 b	\N	Olanzapine versus conventional Antipsychotic	\N	United States of America	\N	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
10796	Startup 2006 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10797	Skrinar 2005	\N	organized exercise + log of workouts versus no organized execise program + log of workouts	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
10798	Mueser 2004 b	\N	individual placement and support versus standard services	\N	United States of America	\N	\N	\N	\N	\N	204	\N	\N	\N	\N	\N
10800	Wunderink 2007 a	\N	Dose Reduction-Discontinuation (DR) versus Maintenance Treatment	\N	The Netherlands	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
10801	Jenner 2006	\N	hallucinatinon integrated treatment versus usual care	\N	Netherlands	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
10802	Lee 2007 a	\N	galantamine versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
10803	McGurk 2007	\N	cognitive training + supported employment versus supported employment	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
10804	Mortimer 2004 b	\N	Aripiprazole versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	310	\N	\N	\N	\N	\N
10805	Pierson 2006	\N	sertraline versus Placebo	\N	Canada	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
10806	Reimold 2007	\N	flupentixol versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
10807	Robinson 2006	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10808	Rosenheck 2006 a	\N	perphenazine versus second generation Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	1493	\N	\N	\N	\N	\N
10810	Stroup 2007 a	\N	discontinuation of perphenazine + Olanzapine versus discontinuation of perphenazine + Risperidone	\N	United States of America	\N	\N	\N	\N	\N	115	\N	\N	\N	\N	\N
10813	Li 2005 t	\N	Systemic health education versus Conventional health education	\N	China	\N	\N	\N	\N	\N	286	\N	\N	\N	\N	\N
20257	杨苏萍 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
10814	Shi 2002	\N	Risperidone + Clozapine versus Risperidone	\N	New Zealand//Spain//United States of America	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
10815	Zhang 2002 p	\N	Risperidone + Comprehensive rehabilitation nursing versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10816	Fagerlund 2004	\N	Risperidone versus zuclopenthixol	\N	Denmark	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
10817	Zhang 2006 aa	\N	Antipsychotics versus withdraws of Antipsychotics	\N	China	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
10818	MATISSE	\N	Art Therapy (Interactive Group) + Treatment As Usual versus Treatment As Usual	\N	United Kingdom	\N	\N	\N	\N	\N	376	\N	\N	\N	\N	\N
10819	Muller 2004 b	\N	COX-2 versus Placebo	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10823	EMEA 2007 c	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	404	\N	\N	\N	\N	\N
10824	EMEA 2007 d	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10825	EMEA 2007 e	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10826	EMEA 2007 f	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	297	\N	\N	\N	\N	\N
10827	EMEA 2007 h	\N	Aripiprazole versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	270	\N	\N	\N	\N	\N
10828	EMEA 2007 i	\N	Aripiprazole versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
10829	EMEA 2007 j	\N	Olanzapine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
10830	EMEA 2007 k	\N	Olanzapine versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	431	\N	\N	\N	\N	\N
10831	EMEA 2007 l	\N	Olanzapine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	355	\N	\N	\N	\N	\N
10832	EMEA 2007 m	\N	Olanzapine versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	1996	\N	\N	\N	\N	\N
10833	EMEA 2007 n	\N	Olanzapine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
10834	Ahmed 2007	\N	Bifeprunox Dosage // Bifeprunox versus Placebo // Bifeprunox versus Olanzapine // Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\r\nUser defined 3\r\n	\N	604	\N	\N	\N	\N	\N
10836	Boggs 2007	\N	galantamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
10837	Casey 2007	\N	Bifeprunox Dosage // Bifeprunox versus Placebo // Bifeprunox versus Risperidone // Risperidone versus Placebo	\N	United States of America // Canada	\N	\N	\N	\N	\N	589	\N	\N	\N	\N	\N
10838	Kane 2007 a	\N	Quetiapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	588	\N	\N	\N	\N	\N
10839	Keefe 2007	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
10840	Heisterberg 2007	\N	Risperidone versus Placebo	\N	Denmark//United States of America	\N	\N	\N	\N	\N	599	\N	\N	\N	\N	\N
10841	Lazarus 2007	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
10843	Marcus 2007	\N	Aripiprazole versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	173	\N	\N	\N	\N	\N
10844	Meltzer 2007	\N	Bifeprunox Dosage // Bifeprunox versus Placebo // Bifeprunox versus Risperidone // Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	599	\N	\N	\N	\N	\N
10847	Peuskens 2007 a	\N	Quetiapine versus Placebo	\N	Belgium	\N	\N	\N	\N	\N	197	\N	\N	\N	\N	\N
10919	McGorry 2007	\N	Cognitive Behavioural Training + befriending + Risperidone versus Cognitive Behavioural Training + befriending + Placebo	\N	Australia	\N	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
10921	Meltzer 2007 b	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	186	\N	\N	\N	\N	\N
10922	Mueser 2007	\N	cognitive training + supported employment versus supported employment	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
10923	Miller 2007	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
10924	Minzenberg 2007 a	\N	Modafinil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
10926	Moser 2007	\N	hypothetical cognitive anhancing agent versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
10927	Nienhuis 2007	\N	targeted treatment versus maintenance treatment	\N	Netherlands	\N	\N	\N	\N	\N	131	\N	\N	\N	\N	\N
10928	Nelson 2007 a	\N	Risperidone + Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	Australia	\N	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
10929	Newcomer 2007 a	\N	Olanzapine versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10930	Nyhuis 2007	\N	early response patients on Antipsychotics versus early non responders on Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	497	\N	\N	\N	\N	\N
10931	O'Donnell 2007	\N	bitamins B12, B6, and folic acid versus Placebo	\N	Australia	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10932	Ogasa 2007	\N	Lurasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
10933	Oren 2007	\N	Aripiprazole versus Placebo//Aripiprazole versus Haloperidol//Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	448	\N	\N	\N	\N	\N
10934	Papas 2007 a	\N	B-complex vitamin versus Placebo	\N	Australia	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
10936	Peters 2007	\N	Cognitive Behavioural Training versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
10937	Petersen 2007 a	\N	integrated treatment versus standard care	\N	Denmark	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10938	Phillips 2007 b	\N	neuroleptic medication and cognitively oriented psychotherapy versus supportive psychotherapy	\N	Australia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
20471	艾春启 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
10939	Prikryl 2007	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	Czech Republic	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
10940	Procyshyn 2007	\N	Clozapine + Risperidone versus Clozapine + Placebo	\N	Canada	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
10941	Ritch 2007	\N	Cognitive Adaptation Training versus standard care	\N	United States of America	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
10942	Robinson 2007	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
10943	Aranda 2007	\N	Quetiapine versus Olanzapine	\N	Spain	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
10944	Reeder 2007	\N	cognitive remediation versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
10945	Roder 2007	\N	integrated psychological therapy versus treatment as usual	\N	Germany//Switzerland	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
10946	Sartory 2007	\N	visualization group versus rehersal group	\N	Germany	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
10947	Sanchez-Cubillo 2007	\N	Risperidone versus Haloperidol	\N	Spain	\N	\N	\N	\N	\N	131	\N	\N	\N	\N	\N
10948	Savitz 2007	\N	pregnenolone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
10949	Sergi 2007	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10950	Shapira 2007	\N	Bifeprunox Dosage // Bifeprunox versus Placebo // Bifeprunox versus Haloperidol // Bifeprunox versus Olanzapine // Bifeprunox versus Risperidone // Haloperidol versus Placebo // Haloperidol versus Olanzapine // Haloperidol versus Risperidone // Olanzapine versus Placebo // Olanzapine versus Risperidone // Risperidone versus Placebo	\N	United States of America // Denmark // France	\N	\N	\N	\r\nUser defined 3\r\n	\N	497	\N	\N	\N	\N	\N
10951	Shibre 2007	\N	trimethoprim versus Placebo	\N	Ethiopia	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
10953	Silverstein 2007	\N	Basic Conversation Skills Module (BCSM) with attention shaping versus BCSM in standard format	\N	United States of America	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
10954	Smith 2007	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
10955	Tzimos 2007	\N	oral paliperidone versus Placebo	\N	Greece	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
10956	NCT00455663	\N	cognitive adaptive training versus standard care	\N	United States of America	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
10957	NCT00472862	\N	oral paliperidone extended release tablets versus Placebo	\N	Denmark	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	120	\N	\N	\N	\N	\N
10958	Warrington 2007 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	158	\N	\N	\N	\N	\N
10960	Weiden 2007 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
10961	Wunderink 2007 b	\N	guided discontinuation of medication versus maintenance treatment	\N	Netherlands	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
10962	Wykes 2007	\N	cognitive remediation therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10963	Zipursky 2007	\N	home treatment versus hospital-based outpatient treatment	\N	Canada	\N	\N	\N	\N	\N	155	\N	\N	\N	\N	\N
10964	Maples 2007	\N	medication managemet versus congnitive adaptive training	\N	United States of America	\N	\N	\N	\N	\N	257	\N	\N	\N	\N	\N
10968	Huang 2006 i	\N	Quetiapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10969	Lang 2004	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
10970	Wang 2006 u	\N	Home based nursing intervention versus Conventional medication instruction	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10971	Wang 2004 u	\N	Risperidone versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
10972	Wang 2006 v	\N	Nursing intervention + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
10973	Yang 2003 f	\N	Antipsychotics + ElElectro Convulsive Therapy (Electroconvulsive Therapy)roacupuncture (Yintang, Baihui) versus Antipsychotic + ElElectro Convulsive Therapy (Electroconvulsive Therapy)roacupuncture (Baihui, psychomotor zone)	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10974	Anon a	\N	occupational therapy versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
10975	Yazici 2002	\N	\N	\N	Turkey	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
10976	Sivasankaran 1974	\N	trifluperidol versus prochlorperazine	\N	India	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
10978	NCT00018642	\N	Quetiapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10979	NCT00018668	\N	Risperidone versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
10982	NCT00036088	\N	Olanzapine versus active comparator	\N	United States of America	\N	\N	\N	\N	\N	530	\N	\N	\N	\N	\N
10983	NCT00044187	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
10984	NCT00051298	\N	Olanzapine versus Placebo	\N	United States of America//Russian Federation	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
10985	NCT00073164	\N	divalproex sodium versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
10986	NCT00080327	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	370	\N	\N	\N	\N	\N
10987	NCT00085748	\N	paliperidone versus Placebo	\N	Canada//Greece	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
10988	NCT00085891	\N	Quetiapine fumarate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	535	\N	\N	\N	\N	\N
10989	NCT00088478	\N	Olanzapine long acting injection versus Placebo//Olanzapine versus Placebo//Olanzapine dose	\N	croatia//Russian Federation//United States of America	\N	\N	\N	\N	\N	404	\N	\N	\N	\N	\N
10990	NCT00095524	\N	Aripiprazole versus Placebo	\N	Brazil//United Kingdom//United States of America	\N	\N	\N	\N	\N	173	\N	\N	\N	\N	\N
10991	NCT00097942	\N	memantine hcl versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
10992	NCT00100776	\N	Olanzapine dose	\N	United States of America	\N	\N	\N	\N	\N	599	\N	\N	\N	\N	\N
10993	NCT00108368	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
10994	NCT00114595	\N	Omega-3 Fatty Acid versus Placebo	\N	South Africa	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
10995	NCT00149292	\N	LY2140023 versus Placebo	\N	Russian Federation	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
10996	NCT00159081	\N	Risperidone versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	159	\N	\N	\N	\N	\N
10997	NCT00159120	\N	Risperidone versus Haloperidol	\N	Germany	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	71	\N	\N	\N	\N	\N
10998	NCT00159133	\N	Risperidone versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
10999	Bartels 2005	\N	healthcare management and supported rehabilitation versus routine care	\N	United States of America	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
11001	NCT00175955	\N	levetiracetam versus Placebo	\N	Belgium//Bulgaria	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
11002	NCT00191555	\N	Olanzapine versus Haloperidol	\N	France	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
11003	NCT00191828	\N	Olanzapine + psychoeducational treatment versus Olanzapine	\N	Italy	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11004	NCT00204087	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Amisulpride versus clinical management	\N	Germany	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
11006	NCT00214578	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	510	\N	\N	\N	\N	\N
11007	NCT00222235	\N	d-cycloserine versus Placebo	\N	United States of America//Israel	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
11008	NCT00161018	\N	Quetiapine + Risperidone versus fluphenazine	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
11009	NCT00164242	\N	galantamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
11010	NCT00222794	\N	atomoxetine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
11013	NCT00239122	\N	recovery therapy versus control group	\N	Australia	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
11014	NCT00254241	\N	seroquel versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11015	NCT00254787	\N	rapid dose Quetiapine fumarate versus conventional esalation Quetiapine fumarate	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
11016	NCT00304473	\N	Quetiapine fumarate versus various dosages	\N	Taiwan	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11017	NCT00305422	\N	Quetiapine fumarate versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
11018	NCT00307203	\N	Bupropion + Cognitive Behavioral Therapy versus Placebo + Cognitive Behavioral Therapy	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11020	NCT00320736	\N	galantamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
11021	NCT00331825	\N	Risperidone versus Olanzapine	\N	Taiwan	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
11022	NCT00339170	\N	neurocognitive enhancement therapy + vocational services versus vocational services	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	72	\N	\N	\N	\N	\N
11023	NCT00383747	\N	transdermal nicotine patch versus Placebo patch	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11025	NCT00419146	\N	Omega-3 Fatty Acid versus Placebo // Omega-3 Fatty Acid versus Vitamins EC // Vitamins EC versus Placebo	\N	Norway	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	99	\N	\N	\N	\N	\N
11026	NCT00430560	\N	work therapy + cognitive rehabilitation versus work therapy	\N	United States of America	\N	\N	\N	\N	\N	145	\N	\N	\N	\N	\N
11029	NCT00435721	\N	psychoeducation versus control group	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11030	NCT00440843	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
11031	NCT00449397	\N	Quetiapine fumarate versus various dosages	\N	Australia	\N	\N	\N	\N	\N	141	\N	\N	\N	\N	\N
11032	NCT00453804	\N	injectable naltrexone versus oral naltrexone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11033	NCT00455650	\N	mecamylamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11034	NCT00457899	\N	rapid titration of Quetiapine versus conventional titration of Quetiapine	\N	United Kingdom	\N	\N	\N	\N	\N	234	\N	\N	\N	\N	\N
11035	NCT00461318	\N	individual placement and support versus standard services	\N	United Kingdom	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
11036	NCT00465920	\N	modified Cognitive Behavioral Therapy versus control group	\N	Germany	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
11037	NCT00466323	\N	family member provider outreach versus enhanced standard care	\N	United States of America	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
11038	NCT00469664	\N	guanfacine + Atypical Antipsychotics versus Placebo + Atypical Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11039	NCT00485498	\N	Olanzapine hydrochloride versus Risperidone	\N	China	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
11040	NCT00485810	\N	Olanzapine hydrochloride versus various dosages	\N	Japan	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
11041	NCT00485823	\N	Olanzapine hydrochloride + weight management program versus control group	\N	South Korea	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
11042	NCT00485901	\N	Olanzapine hydrochloride versus IM Haloperidol	\N	Taiwan	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11043	NCT00486005	\N	Olanzapine hydrochloride + nizatidine versus Placebo + nizatidine	\N	Brazil	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
11044	NCT00487942	\N	Armodafinil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
11045	NCT00488163	\N	atomoxetine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
11046	NCT00492336	\N	rasagiline + Antipsychotic medication versus Placebo Rasagiline versus Placebo Rasagiline versus Placebo	\N	United States of America	\N	\N	\N	\r\nUser defined field 10\r\n	\N	60	\N	\N	\N	\N	\N
11047	NCT00492349	\N	varenicline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11048	NCT00495911	\N	Cognitive Behavioural Training versus standard care	\N	Canada	\N	\N	\N	\N	\N	309	\N	\N	\N	\N	\N
11049	NCT00320723	\N	Bupropion + cognitive behavioral therapy + nicotine transdermal patch versus nicotine transdermal patch + + cognitive behavioral therapy + Placebo	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11050	NCT00506909	\N	oxycotin + Antipsychotics versus Placebo + Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11051	NCT00509067	\N	galantamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11052	NCT00255918	\N	dimethoxbenzylidene anabaseine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
11053	NCT00423943	\N	Modafinil versus Placebo	\N	United States of America	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	70	\N	\N	\N	\N	\N
11054	NCT00481026	\N	transcranial direct current stimulation versus Placebo	\N	Australia	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11056	NCT00083668	\N	ER oros paliperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	595	\N	\N	\N	\N	\N
11057	NCT00078039	\N	paliperidone versus Placebo	\N	Bulgaria//Croatia//Estonia//France	\N	\N	\N	\N	\N	595	\N	\N	\N	\N	\N
11058	NCT00077727	\N	ER galantamine hydrobromide versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11059	NCT00077714	\N	ER oros paliperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	440	\N	\N	\N	\N	\N
11060	NCT00074477	\N	E092670 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	210	\N	\N	\N	\N	\N
11061	NCT00073320	\N	paliperidone palmitate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
11062	NCT00071747	\N	lamotrigine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	176	\N	\N	\N	\N	\N
11063	NCT00071591	\N	functional adaptation skills training versus control group	\N	United States of America	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
11064	NCT00069433	\N	skills training versus control group	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11065	NCT00063349	\N	Clozapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
11066	NCT00063297	\N	R209130 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
11068	NCT00053690	\N	Cognitive Behavioural Training + Treatment as Usual versus Treatment as Usual	\N	United States of America	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
11069	NCT00300963	\N	talnetant versus Risperidone versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	275	\N	\N	\N	\N	\N
11070	NCT00046085	\N	family psychoeducational program versus standard care	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
11071	NCT00043693	\N	family intervention versus control group	\N	United States of America	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
11072	NCT00042224	\N	Clozapine + Electroconvulsive Therapy versus Clozapine	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
11073	NCT00042159	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11074	NCT00018629	\N	Cognitive Behavioural Training versus control group	\N	United States of America	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
11075	NCT00001768	\N	IV immunoglobulin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11076	NCT00088075	\N	Risperidone versus Placebo	\N	United States of America//India//Russian Federation//Ukraine	\N	\N	\N	\N	\N	159	\N	\N	\N	\N	\N
11077	NCT00101634	\N	R092670 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	518	\N	\N	\N	\N	\N
11079	NCT00119756	\N	paliperidone palmitate versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	282	\N	\N	\N	\N	\N
11080	NCT00153959	\N	psychiatric day hospital treatment versus inpatient treatment	\N	Germany	\N	\N	\N	\N	\N	1117	\N	\N	\N	\N	\N
11081	NCT00157313	\N	integrated treatment, family involvement versus social skills training	\N	Denmark	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
11082	NCT00157378	\N	Risperidone versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
11083	NCT00161408	\N	Cognitive Behavioural Training versus psychoeducation	\N	Germany	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
11084	NCT00167362	\N	cognitive enhancement therapy + enriched supportive therapy versus enriched supportive therapy	\N	United States of America	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
11085	NCT00169026	\N	Clozapine versus typical and Atypical drugs	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
11087	NCT00169039	\N	Clozapine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
11088	NCT00169065	\N	Clozapine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
11089	NCT00169091	\N	Clozapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
11090	NCT00178971	\N	buspirone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11091	NCT00179062	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
11092	NCT00179231	\N	Olanzapine versus Clozapine	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11093	NCT00183625	\N	individual placement and support + Risperidone or Olanzapine versus social skills training + Risperidone or Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
11094	NCT00184509	\N	integrated psychosocial treatment versus control group	\N	Norway	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11095	NCT00190008	\N	piracetam versus Placebo	\N	Israel	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11097	NCT00197093	\N	SB-773812 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11098	NCT00202007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
11099	NCT00203775	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11100	NCT00204061	\N	clinical management + Amisulpride versus clinical manangement	\N	Germany	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
11101	NCT00206947	\N	donepezil versus Ziprasidone	\N	Denmark	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11102	NCT00206960	\N	zuclopenthixol versus Risperidone	\N	Denmark	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
11103	NCT00206986	\N	clonidine versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11104	NCT00216476	\N	Risperidone long acting injection versus Aripiprazole//Risperidone long acting injection versus Quetiapine oral//Quetiapine oral versus Aripiprazole//	\N	Germany and United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	710	\N	\N	\N	\N	\N
11105	NCT00220870	\N	decision aid versus control group	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11106	NCT00222495	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
11107	NCT00235352	\N	Ampakine versus Placebo	\N	United States of America	\N	\N	\N	\r\nUser defined 3\r\n	\N	105	\N	\N	\N	\N	\N
11108	NCT00236379	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11109	NCT00236457	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	560	\N	\N	\N	\N	\N
11111	NCT00240708	\N	long acting Risperidone versus oral Risperidone	\N	Japan	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
11112	NCT00249119	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	1510	\N	\N	\N	\N	\N
20258	杨建华 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11114	NCT00249223	\N	long acting Risperidone versus oral Risperidone	\N	Belgium	\N	\N	\N	\N	\N	670	\N	\N	\N	\N	\N
11115	NCT00253110	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	414	\N	\N	\N	\N	\N
11116	NCT00253136	\N	long acting Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	416	\N	\N	\N	\N	\N
11117	NCT00261430	\N	long acting injectable Risperidone + acceptance approach versus long acting injectable Risperidone + approach as usual	\N	United States of America	\N	\N	\N	\N	\N	688	\N	\N	\N	\N	\N
11118	NCT00272584	\N	Risperidone + Clozapine versus Placebo + Clozapine	\N	Canada	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11119	NCT00283179	\N	Aripiprazole + Risperidone versus Risperidone	\N	Taiwan	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
11120	NCT00297388	\N	Risperidone versus various doses	\N	United States of America	\N	\N	\N	\N	\N	320	\N	\N	\N	\N	\N
11121	NCT00286299	\N	Aerobic Exercise (Physical Interventions) versus Games (Computer)	\N	Norway	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	40	\N	\N	\N	\N	\N
11122	NCT00300404	\N	daraprim versus Placebo	\N	Germany	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11124	NCT00304616	\N	Aripiprazole versus Risperidone	\N	South Korea	\N	\N	\N	\N	\N	500	\N	\N	\N	\N	\N
11125	NCT00328276	\N	sarcosine versus various dosages	\N	Taiwan	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
11126	NCT00328367	\N	Aripiprazole versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
11127	NCT00337350	\N	rosiglitazone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
11128	Liang 2003 d	\N	Clozapine versus Clozapine 	\N	China	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
11129	NCT00512070	\N	Olanzapine + melatonin versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
11130	NCT00508560	\N	contingency management versus control group	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11131	NCT00508157	\N	Aripiprazole versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	258	\N	\N	\N	\N	\N
11132	NCT00506077	\N	MK0249 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11133	NCT00505765	\N	AL-108 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11134	NCT00505076	\N	MK-0777 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11135	NCT00495352	\N	Bupropion + nicotine replacement therapy versus nicotine replacement therapy	\N	Taiwan	\N	\N	\N	\N	\N	500	\N	\N	\N	\N	\N
11136	NCT00494650	\N	Cognitive Behavioural Training versus control group	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	200	\N	\N	\N	\N	\N
11137	NCT00493233	\N	Antipsychotics versus Placebo	\N	Canada	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11138	NCT00491569	\N	sarcosine + D-serine versus Placebo	\N	Taiwan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11139	NCT00358709	\N	skills training approach versus control group	\N	Canada	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
11140	NCT00378183	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11141	NCT00423878	\N	Risperidone versus Aripiprazole//Quetiapine versus Aripiprazole//Olanzapine versus Aripiprazole//Antipsychotic switching	\N	United States of America	\N	\N	\N	\N	\N	187	\N	\N	\N	\N	\N
11142	NCT00425815	\N	Ampakine Dosage // Ampakine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
11143	NCT00428168	\N	betahistine + Olanzapine versus Placebo + Olanzapine	\N	Canada	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
11144	NCT00431184	\N	pentazocine versus lorazepam	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
11145	NCT00431223	\N	cognitive remediation therapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
11146	NCT00435370	\N	tropisetron + Risperidone versus Placebo + Risperidone	\N	China//United States of America	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
11147	NCT00456976	\N	selegiline versus Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
11218	NCT00224315	\N	Clozapine + Ziprasidone versus Clozapine + Risperidone	\N	Germany	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
20472	刘铭涛 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
11148	NCT00465283	\N	donepezil + Electro Convulsive Therapy (Electroconvulsive Therapy) versus Placebo + Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	Israel	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11149	NCT00466310	\N	Aripiprazole versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11150	NCT00468533	\N	Aripiprazole Dosage	\N	Taiwan	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11151	NCT00481156	\N	Traditional Chinese Medicine (TCM) versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
11152	NCT00482430	\N	MK0557 versus Placebo	\N	Malaysia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11154	NCT00484302	\N	Cognitive Behavioural Training with motivational interviewing versus standard care Specialized Psychosocial Treatment	\N	Denmark	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	140	\N	\N	\N	\N	\N
11155	NCT00469365	\N	pharmacist telephone contact versus usual care	\N	United States of America	\N	\N	\N	\N	\N	3048	\N	\N	\N	\N	\N
11156	NCT00000374	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
11157	NCT00000387	\N	self management therapy versus intervention therapy	\N	United States of America	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	30	\N	\N	\N	\N	\N
11158	NCT00013000	\N	enhanced education versus basic education	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11159	NCT00044005	\N	Lurasidone Dosage	\N	United States of America	\N	\N	\N	\N	\N	98 OR 150	\N	\N	\N	\N	\N
11160	NCT00044044	\N	Lurasidone Dosage // Lurasidone versus Placebo // Haloperidol versus Lurasidone // Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	330 OR 356	\N	\N	\N	\N	\N
11161	NCT00046813	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11162	NCT00047450	\N	citalopram versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
11163	NCT00102479	\N	Aripiprazole Dosage	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11164	NCT00102063	\N	Aripiprazole versus Placebo	\N	United States of America//Puerto Rico	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
11165	NCT00088634	\N	Lurasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	160 OR 180	\N	\N	\N	\N	\N
11166	NCT00057135	\N	pharmacy based intervention versus standard care	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
11167	NCT00053703	\N	Risperidone versus molindone//Olanzapine versus Molindone//Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
11168	NCT00051740	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11169	NCT00051233	\N	world wide web-based psychoeducation versus standard care	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11170	NCT00048269	\N	mifepristone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11171	NCT00105326	\N	ER oros paliperidone versus Placebo	\N	France//Poland//Romania	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11172	NCT00105794	\N	psychiatric advance directives intervention versus control group//Advance treatment directives	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11173	NCT00139906	\N	Bifeprunox versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
11174	NCT00141479	\N	Bifeprunox versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11175	NCT00145444	\N	Olanzapine versus Ziprasidone	\N	Belgium//Netherlands	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11176	NCT00159770	\N	Ziprasidone versus Quetiapine	\N	Denmark//Finland//Iceland//Switzerland	\N	\N	\N	\N	\N	290	\N	\N	\N	\N	\N
11177	NCT00119574	\N	Treatment plan: Collaborative Chronic Illness Model versus Treatment plan: Standard EQUIP model	\N	United States of America	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
11178	NCT00151424	\N	Asenapine versus Placebo	\N	United States of America//Russian Federation//Ukraine	\N	\N	\N	\N	\N	277	\N	\N	\N	\N	\N
11179	NCT00156104	\N	Asenapine versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	460	\N	\N	\N	\N	\N
11180	NCT00156117	\N	Asenapine versus Placebo	\N	United States of America//Russian Federation//Ukraine	\N	\N	\N	\N	\N	450	\N	\N	\N	\N	\N
11181	NCT00156637	\N	team based quality improvement intervention versus opinion leader intervention	\N	United States of America	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
11182	NCT00223535	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11183	NCT00218218	\N	transdermal nicotine patch versus Placebo patch	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11185	NCT00212771	\N	Asenapine versus Olanzapine	\N	Australia//Belgium//Czech Republic//France//Germany//Poland//Rusiia//South Africa//Spain	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
11186	NCT00208143	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
11187	NCT00193713	\N	Bifeprunox versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11188	NCT00182442	\N	Olanzapine versus Quetiapine	\N	Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11189	NCT00177983	\N	world wide web-based psychoeducation versus standard care	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11190	NCT00174200	\N	Risperidone versus Placebo	\N	Canada//Russian Federation	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
11191	NCT00507988	\N	complex problem solving training versus basic cognitive training	\N	Germany	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11192	NCT00500695	\N	motivational interviewing versus psychoeducational intervention	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11193	NCT00498550	\N	Clozapine versus control group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11194	NCT00498004	\N	quetipine versus Risperidone	\N	South Korea	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11195	NCT00490516	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
11196	NCT00480844	\N	\N	\N	Israel	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11197	NCT00486798	\N	rapid titration of Quetiapine versus conventional titration of Quetiapine	\N	Sweden	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11198	NCT00470106	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
11199	NCT00463372	\N	PF-02545920 versus various dosages	\N	South Africa	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11200	NCT00463346	\N	acamprosate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
11204	NCT00431574	\N	regular daily Antipsychotic dosing versus active medication same daily dose every 2nd day	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11205	NCT00420823	\N	taurine versus Placebo	\N	Australia	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
11206	NCT00420498	\N	atomoxetine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11207	NCT00419653	\N	Amisulpride versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
11208	NCT00418873	\N	zotepine versus Risperidone Risperidone versus Zotepine	\N	Taiwan	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	160	\N	\N	\N	\N	\N
11209	NCT00418171	\N	Olanzapine versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	18000	\N	\N	\N	\N	\N
11210	NCT00310661	\N	sarizotan versus Placebo	\N	Canada//India	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11211	NCT00291213	\N	levetiracetam versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11212	NCT00265551	\N	SCA-136 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
11214	NCT00239109	\N	Ziprasidone versus Olanzapine	\N	Spain	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
11215	NCT00237861	\N	Risperidone versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11216	NCT00235274	\N	subvutaneous secretin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
11217	NCT00224380	\N	medication adherence therapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
11219	NCT00455715	\N	sildenafil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
11220	NCT00455702	\N	D-cycloserine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11221	NCT00463879	\N	galantamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
11222	NCT00499044	\N	cognitive drug research versus matrics consensus cognitive battery	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
11224	Zhou 1998	\N	Psychological treatment + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
11225	Zhao 1996	\N	He-Ne laser versus None	\N	China	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
11226	Brewer 2007	\N	Risperidone versus Haloperidol	\N	Australia	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
11228	Davidson 2007	\N	paliperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	618	\N	\N	\N	\N	\N
11229	Davies 2007	\N	first generation Antipsychotics versus second generation Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	227	\N	\N	\N	\N	\N
11230	Freudenreich 2007	\N	Risperidone + Clozapine versus Placebo + Clozapine	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
11231	Mackin 2007	\N	mifepristone versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
11233	Mogg 2007	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	United Kingdom	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
11234	Strous 2007 b	\N	typical Antipsychotics + Risperidone versus typical Antipsychotics	\N	Israel	\N	\N	\N	\N	\N	121	\N	\N	\N	\N	\N
11235	Wu 2007 a	\N	diet and exercise versus treatment as usual	\N	Taiwan	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
11236	Xiang 2007	\N	Community Re-Entry Module versus standard group psychoeducation	\N	China	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
11237	Weinberger 2007	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11238	Akerele 2007	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
11239	Baptista 2007 c	\N	metformin + Olanzapine versus Olanzapine + Placebo	\N	Venezuela	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11240	Boidi 2007	\N	rapid dose initiation with Quetiapine versus conventional dose initiation with Quetiapine	\N	Italy	\N	\N	\N	\N	\N	271	\N	\N	\N	\N	\N
11241	Buchsbaum 2007 a	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
11242	Carra 2007	\N	informative program versus additonal support program	\N	Italy	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	101	\N	\N	\N	\N	\N
11243	George 2007 b	\N	dihydrexidine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
11244	Kohler 2007	\N	donepezil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
20259	李少梅 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
11245	Keks 2007	\N	Risperidone versus Olanzapine	\N	Australia//United States of America	\N	\N	\N	\N	\N	629	\N	\N	\N	\N	\N
11246	Lee 2007 b	\N	donepezil + Haloperidol versus Haloperidol + Placebo//Donepezil versus Haloperidol//Donepezil versus Placebo//Haloperidol versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
11247	Sumiyoshi 2007	\N	buspirone versus Placebo	\N	Japan//United States of America	\N	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
11248	Ohlmeier 2007	\N	perazine + carbamazepine versus Olanzapine	\N	Germany	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
11249	Poyurovsky 2007	\N	reboxetine + Olanzapine versus Placebo + Olanzapine	\N	Israel	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
11250	Riedel 2007 a	\N	Quetiapine versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
11251	Risch 2007	\N	donepezil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
11252	Wynn 2007	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11253	Zoccali 2007	\N	lamotrigine + Clozapine versus Placebo + Clozapine	\N	Italy	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11254	Nakonezny 2007	\N	Risperidone versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
11255	Richardson 2007	\N	interactive art therapy + standard treatment versus standard treatment	\N	United Kingdom	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11256	Lu 2005 b	\N	Pipotiazine palmitate injection versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
11257	Lu 2005 c	\N	Sodium valproate + Atypical Antipsychotic versus Atypical Antipsychotic	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11258	Ma 2002 c	\N	Antipsychotics + ElElectro Convulsive Therapy (Electroconvulsive Therapy)roacupuncture (Yintang, Baihui) versus Antipsychotic + ElElectro Convulsive Therapy (Electroconvulsive Therapy)roacupuncture (Baihui, psychomotor zone)	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11259	Peng 2004 b	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	257	\N	\N	\N	\N	\N
11260	Shan 2002	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
11261	Wang 2003 n	\N	Antipsychotics + Bushen-Jiannao-Heji (TCM ) versus Antipsychotic	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11262	Wang 2002 q	\N	Traditional Chinese Medicine (TCM) Qinggan-Huayu-decotion versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11264	Zhang 2004 m	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
11265	Xu 2004	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	204	\N	\N	\N	\N	\N
11266	Zhang 2005 p	\N	Antipsychotics + Ziyin (TCM) versus Antipsychotic	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
11267	Zhu 2004 d	\N	Risperidone versus Clozapine	\N	India	\N	\N	\N	\N	\N	187	\N	\N	\N	\N	\N
11268	Yuan 2005 c	\N	Quetiapine versus Risperidone	\N	Canada	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11269	Ma 2004 f	\N	Electroacupuncture (Baihui, Shenting) + Antipsychotic versus Antipsychotic	\N	Canada	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
11270	Chen 2003 m	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11271	Chen 2005 i	\N	Risperidone + Clozapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
11272	Chi 2005	\N	Aniracetam + Chlorimipramine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
11273	Ding 2003 b	\N	Antipsychotics + TCM versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11274	Huang 2005 e	\N	Electro Convulsive Therapy (Electroconvulsive Therapy), half dose versus Electro Convulsive Therapy (Electroconvulsive Therapy), full dose	\N	United States of America	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
11275	Jiang 2004 b	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	293	\N	\N	\N	\N	\N
11276	Jiang 2005 d	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Pharmacotherapy versus Pharmacotherapy	\N	Germany	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11277	Jin 2005	\N	Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11278	Li 2002 k	\N	Anshen-Jianpi-Syrup (TCM) versus Syrup Placebo	\N	China	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
11279	Li 2001 f	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
11280	Menzies 2007	\N	lorazepam + flumazenil versus lorazepam + Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
11281	Hang 2004	\N	Rehabilitation training + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
11282	Li 2002 l	\N	Clinical Nursing Pathway versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
11283	Dunn 2006	\N	routine explanation of Placebos versus educational model explanation of Placebos	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
11284	Duraiswamy 2007	\N	Antipsychotics + yoga therapy versus Antipsychotic treatment	\N	India	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
11285	England 2007	\N	cognitive nursing intervention + usual care versus usual care	\N	Canada	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
11286	Henderson 2007	\N	Olanzapine+Sibutramine versus Olanzapine+Placebo // Sibutramine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
11287	Jin 2006	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
11288	Lecrubier 2006	\N	Amisulpride versus Placebo	\N	France	\N	\N	\N	\N	\N	245	\N	\N	\N	\N	\N
11289	Schonebaum 2006	\N	clubhouse program versus control group	\N	United States of America	\N	\N	\N	\N	\N	177	\N	\N	\N	\N	\N
11290	Patterson 2005	\N	group therapy versus friendly support group	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
11292	Bauml 2006	\N	psychoeducation- obligatory exercise program versus routine care	\N	Germany	\N	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
11293	Patel 2006	\N	cognitive remediation therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
11294	Lenior 2005	\N	standard intervention + family intervention versus standard intervention	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11295	Sytema 2007	\N	assertive community treatment versus standard community treatment	\N	Netherlands	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
11296	Valencia 2006	\N	psychosocial therapy versus standard care	\N	Mexico	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
11297	Martinez 2005	\N	integral rehabilitation program + psychiatric management versus psychiatric management	\N	Mexico	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
11298	Bai 2007 a	\N	long-acting injectable Risperidone versus Risperidone oral tablets	\N	Taiwan	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11299	Bauml 2007	\N	psychoeducation versus standard care	\N	Germany	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
11300	Gigantesco 2006	\N	skills assessment and definition of goals + standard care versus standard care	\N	Italy	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
11302	Kaptsan 2007	\N	creatine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
11303	Kashner 2006	\N	algorithm based care versus usual care	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
11305	Magliano 2006	\N	psychoeducation family intervention versus control group	\N	Italy	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
11306	McHugo 2004	\N	integrated housing services versus parallel housing services	\N	United States of America	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
11307	Miller 2004 b	\N	treatment guided by medication algorithms + disorder specific education versus standard care	\N	United States of America	\N	\N	\N	\N	\N	512	\N	\N	\N	\N	\N
11309	Reeder 2006	\N	cognitive remediation versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
11310	Tracy 2007	\N	contingency management versus assesment only	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
11311	Ciudad 2007	\N	Olanzapine versus Risperidone	\N	Spain	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11312	Elbogen 2007	\N	facilitated decision making versus control group//advance treatment directives	\N	United States of America	\N	\N	\N	\N	\N	419	\N	\N	\N	\N	\N
11313	Bosia 2007	\N	standard rehabilitation treatment + cognitive exercise versus standard rehabilitation treatment	\N	Italy	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11314	Maneesakorn 2007	\N	adherence therapy versus control group	\N	Thailand	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
11315	McMahon 2005	\N	Olanzapine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
11316	Milas 1999	\N	Olanzapine versus fluphenazine	\N	Croatia	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
11317	Beasley 2006	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	326	\N	\N	\N	\N	\N
11318	Canas 2007	\N	Ziprasidone versus various dosages	\N	Spain	\N	\N	\N	\N	\N	325	\N	\N	\N	\N	\N
11319	Brunelin 2007	\N	metabolic stressor versus Placebo	\N	France	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
11320	Corrigan 2007	\N	education anti-stigma video versus contact anti-stigma video	\N	United States of America	\N	\N	\N	\N	\N	244	\N	\N	\N	\N	\N
11321	Evins 2007	\N	Bupropion + cognitive behavioral therapy + nicotine transdermal patch versus nicotine transdermal patch + + cognitive behavioral therapy + Placebo	\N	United States of America	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
11322	Manchanda 2007	\N	Risperidone versus Olanzapine	\N	United Kingdom // Canada	\N	\N	\N	\N	\N	193	\N	\N	\N	\N	\N
11323	Stant 2007	\N	guided discontinuation of medication versus maintenance treatment	\N	Netherlands	\N	\N	\N	\N	\N	157	\N	\N	\N	\N	\N
11324	Wu 2007 b	\N	Atypical Antipsychotic medication versus Typical Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
11325	Zhang 2006 ab	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
11326	Ng 2006	\N	social skills training versus supportive group discussion	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
11327	Stefancic 2007	\N	assertive community treatment versus standard care	\N	United States of America	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
11328	Agid 2007	\N	Olanzapine versus Risperidone	\N	Canada	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
11329	Chan 2007 b	\N	psychoeducation program versus vocational therapy	\N	China	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
11330	D'Souza 2006	\N	alcohol versus control group	\N	United States of America	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
11331	Samarasekera 2007	\N	befriending + routine care versus Cognitive Behavioral Therapy + routine care	\N	United Kingdom	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
11377	Bernardo 2007	\N	Ziprasidone versus Placebo	\N	Spain	\N	\N	\N	\N	\N	293	\N	\N	\N	\N	\N
11332	Smith 2005 d	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11333	Robinson 2005	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	112	\N	\N	\N	\N	\N
11334	Potkin 2005 c	\N	Asenapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
11336	Neale 2005	\N	SGS518 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
11337	Malhotra 2005	\N	Aripiprazole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	1281	\N	\N	\N	\N	\N
11338	Lieberman 2005 d	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	599	\N	\N	\N	\N	\N
11339	Kane 2005 c	\N	paliperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	630	\N	\N	\N	\N	\N
11340	Jayathilake 2005	\N	Clozapine versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
11341	Lewis 2005 b	\N	first generation Antipsychotics versus second generation Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	227	\N	\N	\N	\N	\N
11342	Lewis 2005 c	\N	first generation Antipsychotics versus second generation Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
11344	Smith 2006	\N	nicotine nasal spray versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
11345	Mata 2006	\N	Risperidone versus Haloperidol	\N	Spain	\N	\N	\N	\N	\N	154	\N	\N	\N	\N	\N
11346	Yi 2006 a	\N	Psychotherapy + Pharmacotherapy versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
11347	Wu 2003 c	\N	family education about mental illness versus no education	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11348	Wang 2002 r	\N	Olanzapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11349	Lee 2005 c	\N	galantamine versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
11351	Aguglia 2007	\N	psychosocial//psychoeducational interventions versus control group	\N	Italy	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
11352	Sumic 2007	\N	Antipsychotic + antidepressant versus Antipsychotic	\N	Croatia	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
11353	Grant 1965	\N	pericyazine versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
11354	Heller 1965	\N	pericyazine versus phenothiazine	\N	United Kingdom	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
11355	Leitch 1965	\N	pericyazine versus trifluoperazine	\N	United Kingdom	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
11356	Fowler 2007b	\N	social recovery cognitive behavioral therapy versus treatment as usual	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
20473	安孝群 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11358	Birchwood 2007	\N	cognitive therapy versus standard care	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	180	\N	\N	\N	\N	\N
11359	Pilowsky 2007	\N	cannabis + dopamine versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11360	Joffe 2006 b	\N	Clozapine + orlistat versus "Placebo + Chlorpromazine, Placebo + Clozapine"	\N	Finland	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
11361	Michon 2005	\N	individual placement and support versus standard services	\N	Netherlands	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
11362	Lester 2004 e	\N	GP intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
11363	Lee 2007 c	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	United Kingdom	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
11364	Priebe 2004	\N	inpatient care versus day hospital care	\N	United Kingdom	\N	\N	\N	\N	\N	209	\N	\N	\N	\N	\N
11365	Eli Lilly 2007 f	\N	LY2140023 versus Placebo	\N	Austria//Croatia//Germany//Mexico//Portugal//Romania//Russia//South Africa	\N	\N	\N	\N	\N	870	\N	\N	\N	\N	\N
11366	Eli Lilly 2002 c	\N	weight management program + Olanzapine versus control group + Olanzapine	\N	South Korea	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
11367	Eli Lilly 2004 g	\N	Olanzapine hydrochloride versus Haloperidol	\N	Taiwan	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11368	Eli Lilly 2004 h	\N	intramuscular Olanzapine depot versus Placebo	\N	Croatia//Russian Federation//United States of America	\N	\N	\N	\N	\N	402	\N	\N	\N	\N	\N
11369	Eli Lilly 2004 i	\N	Olanzapine hydrochloride dose	\N	Japan	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
11370	Eli Lilly 2002 d	\N	Olanzapine versus Placebo	\N	Russian Federation//United States of America	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
11372	Thornicroft 2004 d	\N	individual placement and support versus standard psychosocial programming	\N	United Kingdom	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
11373	Kim 2007 b	\N	Amisulpride versus Risperidone	\N	South Korea	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
11374	Jakovljevic 2007	\N	Olanzapine versus fluphenazine	\N	Croatia	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
11375	Goldberg 2007 a	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
11376	Eklund 2004	\N	competative work versus community-based activities	\N	Sweden	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
20260	夏仲 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11378	Anchor 1972	\N	discussion groups	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
11379	Lee 2007 d	\N	Risperidone versus Haloperidol	\N	Taiwan	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
11380	Lopez-Luengo 2005	\N	attention process training versus control group	\N	Spain	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
11381	Mamo 2007 b	\N	Aripiprazole Dosage	\N	Canada	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
11382	Ruhrmann 2007 a	\N	flupentixol versus Risperidone	\N	Germany//Austria	\N	\N	\N	\N	\N	153	\N	\N	\N	\N	\N
11383	Thorup 2006	\N	OPUS (integrated treatment including assertive community + family involvement + social skills training) versus standard care	\N	Denmark	\N	\N	\N	\N	\N	547	\N	\N	\N	\N	\N
11385	Landeen 2007	\N	Cognitive Behavioural Training versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	422	\N	\N	\N	\N	\N
11386	Guthrie 2003	\N	psychotherapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
11387	Burns 2003	\N	intensive case management versus standard case management	\N	United Kingdom	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
11388	Birchwood 2003	\N	early detection intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11389	Chipchase 2003	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11390	Startup 2003	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11391	Ai 2007	\N	seroquel versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
11392	An 2006 c	\N	Risperidone versus Olanzapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11393	Ao 2007	\N	Traditional Chinese Medicine (TCM) Shuangzao Heji versus Sulpiride	\N	China	\N	\N	\N	\N	\N	195	\N	\N	\N	\N	\N
11394	Bai 2006 b	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
11395	Bai 2007 b	\N	Loxapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
11396	Bai 2007 c	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
11397	Bao 2007	\N	Aripiprazole + clonazepam versus clonazepam	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
11398	Cai 2007	\N	Loxapine versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
11399	Cai 2006 b	\N	Risperidone + sertraline versus Risperidone + Placebo	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11400	Chang 2007	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
11401	Chang 2006	\N	loxapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
11402	Chen 2007 a	\N	Nursing intervention versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11403	Chen 2007 b	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
11404	Chen 2007 c	\N	Aripiprazole + Sulpiride versus Sulpiride	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
11405	Chen 2007 d	\N	Quetiapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
11406	Chen 2007 e	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
11407	Chen 2007 f	\N	Occupation recreational therapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11408	Chen 2007 g	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
11409	Chen 2007 h	\N	Fluoxetine + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11410	Chen 2007 i	\N	Community based prevention + Psychological consult via internet versus Community based prevention	\N	China	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
11411	Chen 2007 j	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11412	Chen 2006 n	\N	Venlafaxine + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
11413	Chen 2006 o	\N	Psychotherapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
11414	Chen 2007 k	\N	Rehabilitation training versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
11415	Chen 2007 l	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11416	Chen 2007 m	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
11417	Cheng 2007 b	\N	Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11418	Dai 2007	\N	Early comprehensive intervention + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
11419	Dai 2006 a	\N	Society-based theory rehabilitation versus Conventional rehabilitation	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11420	Dang 2007	\N	Mental health education versus Conventional rehabilitation	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11421	Deng 2007 a	\N	Social skill training + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11422	Deng 2007 b	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
11515	Lin 2006 e	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
11423	Deng 2006 d	\N	Clozapine + inosine oral solution versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11424	Deng 2006 e	\N	Clozapine + inosine oral solution versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
11425	Diao 2006	\N	Health education + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
11426	Diao 2007	\N	Intensive education + Care as usual versus Care as usual	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11427	Ding 2007	\N	Reading therapy + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
11428	Du 2007	\N	Art therapy + Care as usual versus Care as usual	\N	China	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
11429	Fan 2006 b	\N	Anshen-decoction (TCM) + Antipsychotic versus Antipsychotic	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11430	Feng 2006 a	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
11431	Feng 2006 b	\N	Clozapine + Lithium versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11432	Gan 2007	\N	Psychological treatment + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
11433	Gao 2007	\N	Orem Self-care Model Training versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
11434	Gao 2007 b	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
11435	Gao 2007 c	\N	Piracetam + Hyperbaric oxygen therapy + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
11436	Gao 2006 c	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
11437	Gong 2007 a	\N	Home based intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	166	\N	\N	\N	\N	\N
11438	Gong 2007 b	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
11439	Guan 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
11440	Guo 2007	\N	Haloperidol versus Magnesium Valproate + Quetiapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11441	Guo 2006 d	\N	Sulpiride + Sertraline versus Risperidone	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
11442	Guo 2007 b	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
11443	Guo 2007 c	\N	Art therapy + Care as usual versus Care as usual	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11444	Guo 2006 e	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
11445	Guo 2007 d	\N	Home based intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11446	Han 2007	\N	Skill training (Medication self-management) + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11447	Han 2006 c	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11448	Han 2007 b	\N	Olanzapine versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
11449	Hao 2007	\N	Quetiapine (Seroquel) versus Quetiapine (Qiwei)	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11450	He 2007 a	\N	Aripiprazole versus Sulpiride	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11451	He 2007 b	\N	Home visit + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
11452	He 2007 c	\N	Health education + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	220	\N	\N	\N	\N	\N
11453	He 2007 d	\N	Risperidone + Clonazepam versus Clozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11454	Hou 2007 a	\N	Training for insight and confidence + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
11455	Hou 2007 b	\N	Haloperidol + Citalopram versus Haloperidol	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
11456	Hu 2007 a	\N	Antipsychotics + Mengshi-Ditan-decotion (TCM ) versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
11457	Hu 2007 b	\N	Care nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	184	\N	\N	\N	\N	\N
11459	Huang 2007 a	\N	Quetiapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
11460	Huang 2007 b	\N	Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
11461	Huang 2007 c	\N	Aripiprazole versus Perphenazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11462	Huang 2006 k	\N	Risperidone + Venlafaxine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11463	Huo 2007	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11464	Ji 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
11465	Jia 2007	\N	Sodium valproate + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11466	Jiang 2006 e	\N	Risperidone + Cattle Encephalon Glycoside And Ignotin Injection versus Risperidone	\N	China	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
11467	Jiang 2006 f	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	191	\N	\N	\N	\N	\N
11468	Jiang 2007 a	\N	Family-based supportive psychotherapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11469	Jiang 2007 b	\N	Chlorprothixene injection versus Haloperidol injection	\N	China	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
11470	Jiang 2007 c	\N	Occupation recreational therapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11471	Jiang 2006 g	\N	Clozapine + Mirtazapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
11473	Jiang 2007 d	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11474	Jiang 2006 i	\N	Aripiprazole versus Quetiapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11475	Jin 2007	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11476	Kang 2006	\N	Quetiapine + Clonazepam versus Clozapine	\N	China	\N	\N	\N	\N	\N	182	\N	\N	\N	\N	\N
11477	Kong 2007 a	\N	Music therapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
11478	Kong 2007 b	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11479	Kuang 2006 c	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11480	Kuang 2007 a	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11481	Kuang 2007 b	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11482	Lan 2006 b	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
11483	Li 2007 a	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
11484	Li 2007 b	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11485	Li 2007 c	\N	Early intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	568	\N	\N	\N	\N	\N
11486	Li 2006 s	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
11487	Li 2007 d	\N	Aripiprazole versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
11488	Li 2007 e	\N	Ziprasidone versus various dosages	\N	China	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
11489	Li 2006 t	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11490	Li 2007 f	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
11491	Li 2007 g	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11492	Li 2007 h	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
11493	Li 2007 i	\N	Psychological intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11494	Li 2006 u	\N	Health education + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11495	Li 2006 v	\N	Aripiprazole versus Olanzapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11496	Li 2007 j	\N	Olanzapine versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11497	Li 2006 w	\N	Paroxetine + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11498	Li 2006 x	\N	Emotion expression + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
11499	Li 2007 k	\N	Group psychotherapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
11500	Li 2006 y	\N	Open management versus Closed management	\N	China	\N	\N	\N	\N	\N	131	\N	\N	\N	\N	\N
11501	Li 2006 z	\N	Aripiprazole versus Haloperidol	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
11502	Li 2007 l	\N	Family psychotherapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11503	Li 2007 m	\N	music therapy + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20474	朱琼 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11504	Li 2007 n	\N	Traditional Chinese Medicine (TCM) Huangqi-Kongxian-capsules versus Cyproheptadine	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
11505	Li 2007 o	\N	Haloperidol + Placebo versus Haloperidol + Clonazepam versus Clonazepam + Placebo//Haloperidol versus Placebo//Haloperidol versus clonazepam//clonazepam versus Placebo	\N	China	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
11506	Li 2007 p	\N	Chlorpromazine versus Risperidone	\N	China	\N	\N	\N	\N	\N	213	\N	\N	\N	\N	\N
11507	Li 2007 q	\N	Aripiprazole versus None	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
11508	Li 2007 r	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11509	Liang 2007 a	\N	Follow-up psychological nursing versus Conventional follow-up	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11510	Liang 2006 c	\N	Aripiprazole versus Haloperidol	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11511	Liang 2007 b	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11512	Liang 2006 d	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
11513	Liang 2006 e	\N	Home based skill training + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11514	Lin 2007 a	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
11516	Lin 2007 b	\N	Discharge on parole + Care as usual versus Care as usual	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11517	Lin 2007 c	\N	Chlorpromazine versus Risperidone	\N	China	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
11518	Lin 2007 d	\N	Open management versus Closed management	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11519	Lin 2006 f	\N	Occupational and recreational therapy (Yoga) versus Conventional Occupational and recreational therapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11520	Ling 2007	\N	Aripiprazole versus Perphenazine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
11521	Liu 2007	\N	Aniracetam + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11522	Liu 2007 b	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11523	Liu 2007 c	\N	Traditional Chinese Medicine (TCM) Daotan-decotion + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
11524	Liu 2007 d	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
11525	Liu 2007 e	\N	Clinical Nursing Pathway versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
11526	Liu 2007 f	\N	behaviour therapy versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
11527	Liu 2006 l	\N	Norethisterone versus Lithium	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
11528	Liu 2007 g	\N	Home based intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11529	Liu 2007 h	\N	behaviour therapy + Citalopram versus Citalopram	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
11530	Liu 2006 m	\N	Psychotherapy + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
11531	Liu 2007 i	\N	Health education based on clinical pathway versus Conventional health education	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11532	Liu 2007 j	\N	Antipsychotics + Sodium valproate versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
11533	Lou 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
11534	Lu 2007 b	\N	Psychological nursing based on social theory versus Conventional psychological nursing	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11536	Luo 2006 c	\N	Antipsychotics + Acupuncture versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
11537	Lv 2006 a	\N	Home based nursing + standard care versus standard care Family nursing + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
11538	Lv 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
11539	Lv 2006 b	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11540	Ma 2006 b	\N	Antipsychotics + Clonazepam injection(Tinggong acupoin) versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11541	Ma 2007 a	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
11542	Ma 2007 b	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
11543	Ma 2006 c	\N	Psychological intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
11544	Ma 2007 c	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11545	Ma 2007	\N	Aniracetam + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11546	Mei 2007	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
11547	Ming 2007	\N	Psychological intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11548	Mu 2007 a	\N	Perphenazine + Venlafaxine versus Perphenazine + Placebo	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
11549	Nai 2007 a	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
11550	Nai 2007 b	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11551	Ou 2007 a	\N	Citalopram + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
11552	Ou 2007 b	\N	Risperidone + Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
11553	Pan 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11554	Peng 2007 a	\N	Aripiprazole versus Quetiapine	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
11555	Peng 2007 b	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
11580	Tang 2007 b	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
11581	Tang 2007 c	\N	Risperidone + Clonazepam versus Haloperidol	\N	China	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
11582	Tang 2007 d	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11583	Tang 2007 e	\N	Acupuncture + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
11584	Tao 2007 a	\N	Clozapine + Sulpiride versus Clozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11585	Tao 2007 b	\N	Sertraline + Sulpiride versus Sulpiride	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
11586	Tian 2007 a	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11587	Tian 2007 b	\N	Incentive nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11588	Tian 2006 c	\N	Health education + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11589	Tong 2006	\N	Fluoxetine + Sulpiride versus Sulpiride	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
11590	Tong 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
11591	Tu 2007	\N	Aripiprazole versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	187	\N	\N	\N	\N	\N
11592	Wan 2007	\N	Sertraline + Sulpiride versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11593	Wan 2006 b	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11595	Wang 2006 x	\N	Flunarizine + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
11596	Wang 2007 a	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
11597	Wang 2006 y	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11598	Wang 2007 b	\N	Aripiprazole versus Risperidone	\N	Unclear	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
11599	Wang 2006 z	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11600	Wang 2006 aa	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11602	Wang 2007 c	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
11603	Wang 2006 ac	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11604	Wang 2006 ad	\N	Intravenous infusion via dorsal ulnar veins versus Intravenous infusion via dorsal radial veins	\N	China	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
11605	Wang 2007 d	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
11606	Wang 2007 e	\N	Loxapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11607	Wang 2006 ae	\N	behaviour therapy + Citalopram versus Citalopram	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11608	Wang 2007 f	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11609	Wang 2007 g	\N	Home based intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	204	\N	\N	\N	\N	\N
11610	Wang 2006 af	\N	Health education + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	220	\N	\N	\N	\N	\N
11611	Wang 2006 ag	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
11612	Wang 2007 h	\N	Family-type care versus Closed management	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
11613	Wang 2006 ah	\N	Health education + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11614	Wang 2007 i	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11615	Wang 2006 ai	\N	Home based intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11616	Wang 2007 j	\N	Home based intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11617	Wang 2007 k	\N	Antipsychotics + Venlafaxine versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11618	Wang 2007 l	\N	Music therapy + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11619	Wei 2007	\N	Self-management + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
11620	Wei 2006 f	\N	Painting therapy + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
11621	Wei 2006 g	\N	Aripiprazole versus Sulpiride	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11622	Wen 2007	\N	Clozapine + Dingkuang Zhuyu decotion (TCM) versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11623	Wu 2006 d	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11624	Wu 2006 e	\N	Aripiprazole versus Haloperidol Aripiprazole versus Haloperidol//Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11625	Wu 2007 c	\N	Physical exercise therapy + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
11626	Wu 2007 d	\N	Rehabilitation nursing therapy versus Conventional nursing care	\N	China	\N	\N	\N	\N	\N	211	\N	\N	\N	\N	\N
11627	Wu 2006 f	\N	Antidepressant + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	146	\N	\N	\N	\N	\N
11628	Wu 2006 g	\N	Psychological nursing + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
11629	Wu 2006 h	\N	Risperidone + Clonazepam versus Haloperidol	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11630	Xia 2007	\N	Aripiprazole versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20261	闾金杰1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11631	Xiao 2007 a	\N	Psychological intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11632	Xiao 2007 b	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
11633	Xiao 2006 b	\N	Health education + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11634	Xie 2006 b	\N	Health education for families + standard Care versus standard Care	\N	China	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
11635	Xiong 2006	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11636	Xu 2007 a	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11637	Xu 2006 h	\N	Aripiprazole + Antipsychotics versus Antipsychotics + Placebo	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11638	Xu 2007 b	\N	Antipsychotics + Personalized nursing versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	172	\N	\N	\N	\N	\N
11639	Xu 2007 c	\N	Citalopram versus Chlorimipramine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11640	Xu 2007	\N	Skill training (self medication management) versus standard care	\N	China	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
11641	Xu 2007 e	\N	Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11642	Xu 2007 f	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
11643	Xu 2007 g	\N	Traditional Chinese Medicine (TCM) Wendan-decotion + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
11644	Xu 2007 h	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11645	Xuan 2007	\N	Risperidone + Benzodiazepines versus Risperidone	\N	China	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
11646	Yan 2006	\N	Coupling nursing + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
11647	Yang 2006 n	\N	Quetiapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11648	Yang 2006 o	\N	Risperidone (Zhuofu) versus Risperidone (Risperdal)	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11649	Yang 2007 a	\N	Risperidone versus Quetiapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11650	Yang 2007 b	\N	Skill training (Table Tennis) + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11651	Yang 2007 c	\N	Conventional nursing + Skill training versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11652	Yang 2006 p	\N	Quetiapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
11653	Yang 2007 d	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
11654	Yang 2007 e	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11655	Yang 2007 f	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11656	Yang 2007 g	\N	Psychological intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
11657	Ye 2006 c	\N	Pipotiazine palmitate injection versus Fluphenazine decanoate	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11658	Yi 2007 a	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11659	Yi 2006 b	\N	Psychological intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
11660	Yi 2006 c	\N	Quetiapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
11661	Yi 2007 b	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11662	Yu 2007 a	\N	Humanistic nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
11663	Yu 2007 b	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11664	Yu 2007 c	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
11665	Yue 2007	\N	Specific nursing intervention versus Conventional nursing intervention	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11666	Yue 2006	\N	Constraint as per protocal versus Constraint as needed	\N	China	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
11667	Zeng 2006 b	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11668	Zeng 2006 c	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11669	Zeng 2007 a	\N	Risperidone + Paroxetine versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11670	Zeng 2007 b	\N	Aripiprazole + Jieyu Anshen Decotion (TCM) versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11671	Zeng 2007 c	\N	Home visit + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11672	Zeng 2007 d	\N	Health education + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
11673	Zeng 2006 d	\N	Quetiapine versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11674	Zhan 2007	\N	Home based nursing + Pharmacotherapy versus Conventional nursing + Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
11675	Zhang 2007 a	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11677	Zhang 2007 c	\N	Community based intervention versus standard care	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
11678	Zhang 2006 ac	\N	Antipsychotics + Qingkailing (TCM) versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
11679	Zhang 2006 ad	\N	Family comprehensive intervention versus standard care	\N	China	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
11680	Zhang 2007 d	\N	Olanzapine + Clonazepam versus Haloperidol	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
11681	Zhang 2006 ae	\N	Olanzapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
11682	Zhang 2007 e	\N	Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
11683	Zhang 2007 f	\N	Loxapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11684	Zhang 2007 g	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
11685	Zhang 2006 af	\N	Home based intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
11686	Zhang 2006 ag	\N	Home based intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
11687	Zhang 2006 ah	\N	Physical exercise therapy + Antipsychotics versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
11688	Zhang 2007 h	\N	Risperidone + Sodium valproate versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11689	Zhang 2007 i	\N	Skill training + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
11690	Zhang 2007 j	\N	Accompanying rehabilitation training + Care as usual versus Care as usual	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11691	Zhang 2007 k	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11692	Zhang 2007 l	\N	Antipsychotics + Meridian oxygen therapy versus Antipsychotic	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11693	Zhang 2007 m	\N	Psychoeducation + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
11694	Zhang 2007 n	\N	Psychoeducation + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11695	Zhang 2006 ai	\N	Open management versus Closed management	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
11696	Zhang 2007 o	\N	Antipsychotics + TCM versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11697	Zhang 2007 p	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11698	Zhao 2007 a	\N	Community based nursing intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
11699	Zhao 2006 b	\N	Nursing intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11700	Zhao 2007 b	\N	Quetiapine + Sulpiride versus Quetiapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
11701	Zhao 2007 c	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11702	Zhao 2007 d	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
11703	Zhao 2006 c	\N	Risperidone Oral Solution versus Olanzapine Tablets	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11704	Zhe 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
11705	Zheng 2006 c	\N	Skill training + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11706	Zheng 2007 a	\N	Home visit + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11707	Zheng 2007 b	\N	Home visit + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11708	Zheng 2007 c	\N	Traditional Chinese Medicine (TCM) Ningxin-Kaiqiao-capsules versus Fluphenazine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
11709	Zhong 2007	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
11710	Zhong 2006 c	\N	Risperidone + Clonazepam versus Haloperidol	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11712	Zhou 2007 a	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11713	Zhou 2007 b	\N	Health education based on clinical pathway versus Conventional health education	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11714	Zou 2007	\N	Quetiapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
11715	Zhou 2006 d	\N	Quetiapine + Sulpiride versus Quetiapine	\N	China	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
11716	Zhou 2007 c	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
11717	Zhou 2007 d	\N	Health education + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11718	Zhou 2007 e	\N	Health education + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11719	Zhou 2006 e	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
11720	Zhou 2006 f	\N	Traditional Chinese Medicine (TCM) Hugan decotion versus Tiopronin Tablets	\N	China	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
20262	李巧 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
11721	Zhou 2007 f	\N	Olanzapine versus None	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11722	Zhou 2006 g	\N	Antipsychotics + Extract of St.John's wort tablets versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11723	Zhu 2006 e	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11724	Zhu 2006 f	\N	Home based intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
11725	Zong 2007	\N	Psychological intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11726	Zhou 2007 g	\N	Home based medication intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	286	\N	\N	\N	\N	\N
11727	Zou 2006 b	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
11728	Zou 2006 c	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11729	Zuo 2007	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus Antidepressants	\N	China	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
11730	Wang 2006 aj	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11731	Yang 2007 h	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
11732	Wu 2007 e	\N	Aripiprazole versus Perphenazine	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
11733	Eli Lilly 2007 g	\N	Olanzapine versus Quetiapine	\N	Unclear	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
11735	Chien 2007	\N	\N	\N	Hong Kong	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
11736	Goldberg 2007 b	\N	medial emergency department versus control group	\N	United States of America	\N	\N	\N	\N	\N	142	\N	\N	\N	\N	\N
11737	Rivera 2007	\N	consumer assisted intensive case management versus standard care	\N	United States of America	\N	\N	\N	\N	\N	255	\N	\N	\N	\N	\N
11738	Rowe 2007	\N	group and peer support + standard treatment versus standard treatment	\N	United States of America	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
11739	Hanlon 1966	\N	phenothiazine + benztropine mesylate versus phenothiazine	\N	United States of America	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
11740	Barbui 2007	\N	Risperidone versus Haloperidol	\N	Spain	\N	\N	\N	\N	\N	182	\N	\N	\N	\N	\N
11741	Bond 2007	\N	individual placement and support versus diversified placement approach	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	200	\N	\N	\N	\N	\N
11742	Buchanan 2007 b	\N	glycine versus Placebo	\N	United States of America//Israel	\N	\N	\N	\N	\N	171	\N	\N	\N	\N	\N
11743	Buchanan 2008	\N	galantamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
11744	Byerly 2007	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus health education	\N	Netherlands//United Kingdom//Italy//Germany	\N	\N	\N	\N	\N	409	\N	\N	\N	\N	\N
11745	NCT00308360	\N	risperione + valproate versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
11746	Gold 2007 a	\N	music therapy + standard care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
12188	NCT00788970	\N	shiatsu versus Placebo	\N	Israel	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
11747	Greig 2007 b	\N	neurocognitive enhancement therapy + vocational program versus vocational program	\N	United States of America	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
11748	Honer 2006 b	\N	Risperidone + Clozapine versus Placebo + Clozapine	\N	Canada//Germany//China//United Kingdom	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
11750	Jean-Baptiste 2007	\N	weight loss program versus treatment as usual	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
11751	Johnson 2007	\N	case management training versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11752	Lane 2008	\N	sarcosine versus various dosages	\N	China	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
11753	Marder 2007 c	\N	oral paliperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	444	\N	\N	\N	\N	\N
11754	McCann 2007	\N	Cognitive Behavioural Training versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	422	\N	\N	\N	\N	\N
11755	McCue 2007	\N	second generation Antipsychotics versus Clozapine	\N	United Kingdom	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
11756	Heres 2007	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	673	\N	\N	\N	\N	\N
11757	Mortimer 2007	\N	Amisulpride versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	377	\N	\N	\N	\N	\N
11758	Munro 2007	\N	nurse training program versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
11761	Sacchetti 2008	\N	Quetiapine versus Risperidone	\N	Italy	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
11762	Suzuki 2007	\N	Quetiapine versus Risperidone	\N	Japan	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
11763	Taylor 2007	\N	Haloperidol versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	327	\N	\N	\N	\N	\N
11764	Turkington 2008	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus befriending	\N	United Kingdom	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11765	Valencia 2007	\N	psychosocial skills training versus standard care	\N	Mexico	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
11768	Lapidus 2001	\N	stress coping intervention versus problem solving treatment control	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11770	Gaebel 2007	\N	Risperidone versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	158	\N	\N	\N	\N	\N
11771	Hasson-Ohayon 2007	\N	illness management and recovery program versus treatment as usual	\N	Israel	\N	\N	\N	\N	\N	210	\N	\N	\N	\N	\N
11772	Lerner 2007 a	\N	vitamin B6 versus Placebo	\N	Israel	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11774	Potkin 2007 c	\N	Asenapine versus Placebo	\N	United States of America//Russian Federation//Ukraine	\N	\N	\N	\N	\N	182	\N	\N	\N	\N	\N
11775	Rosa 2007	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	Brazil	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
11776	Saddichha 2007 a	\N	Olanzapine versus Haloperidol	\N	India	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
11777	Schutt 2007	\N	empowerment oriented group home versus independent apartments	\N	United States of America	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
11778	Ulrich 2007	\N	music therapy versus treatment as usual	\N	Germany	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
11779	Rahav 1994	\N	therapeutic community versus community residence	\N	United States of America	\N	\N	\N	\N	\N	410	\N	\N	\N	\N	\N
11780	Chan 2007 c	\N	supported group residence versus control group	\N	Japan	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
11781	Ohlenschlaeger 2008	\N	integrated treatment versus standard care	\N	Denmark	\N	\N	\N	\N	\N	328	\N	\N	\N	\N	\N
11783	Ohlenschlaeger 2007	\N	assertive community treatment versus standard care	\N	Denmark	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
11784	Sullivan 2007	\N	modified therapeutic community versus standard care	\N	United States of America	\N	\N	\N	\N	\N	139	\N	\N	\N	\N	\N
11786	NCT00334126	\N	Paliperidone ER versus Placebo // Paliperidone ER versus Quetiapine // Quetiapine versus Placebo	\N	United States of America // Russian Federation // Ukraine// India	\N	\N	\N	\N	\N	399	\N	\N	\N	\N	\N
11787	Carson 2008	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	302	\N	\N	\N	\N	\N
11788	Castelein 2008 a	\N	support group versus control group	\N	Netherlands	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11789	Cavezian 2008	\N	chess playing versus treatment as usual	\N	France	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
11790	Chen 2008 a	\N	\N	\N	China	\N	\N	\N	\N	\N	178	\N	\N	\N	\N	\N
11791	Emsley 2008 a	\N	Asenapine versus Olanzapine	\N	Germany//Netherlands//SouthAfrica	\N	\N	\N	\N	\N	1219	\N	\N	\N	\N	\N
11792	Frommann 2008 a	\N	training of affect recognition versus cognitive remediation training	\N	Germany	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
11793	Frommann 2008 b	\N	training of affect recognition (pre treatment) versus training of affect recognition (post treatment)	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11794	Grenier 2008	\N	magnetic stimulation versus Placebo	\N	France	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
11795	Han 2008 a	\N	\N	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11797	Hui 2008 a	\N	Quetiapine versus Placebo	\N	China	\N	\N	\N	\N	\N	178	\N	\N	\N	\N	\N
11798	Juckel 2008	\N	Quetiapine fumarate after light meal versus Quetiapine fumarate after fasting	\N	Germany//Sweden//United States of America	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
11799	Kalali 2008	\N	XR Quetiapine fumarate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	588	\N	\N	\N	\N	\N
11800	Kane 2008 a	\N	Asenapine versus Placebo//Haloperidol versus Placebo//Haloperidol versus Asenapine	\N	United States of America//Russian Federation//Ukraine	\N	\N	\N	\N	\N	458	\N	\N	\N	\N	\N
11802	Kulkarni 2008 b	\N	transdermal estradiol + Antipsychotic treatment versus Antipsychotic treatment + Placebo	\N	Australia	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
11803	Kulkarni 2008 c	\N	transdermal estradiol + Antipsychotic treatment versus Antipsychotic treatment + Placebo	\N	Australia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11804	Levkovitz 2008 a	\N	minocycline versus Placebo	\N	Israel	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
11805	Meltzer 2008	\N	Risperidone + Placebo versus Haloperidol + Placebo versus Risperidone + pimavanserine, Haloperidol + pimavanserine//Risperidone versus Placebo//Haloperidol versus Placebo//Haloperidol versus Risperidone//Risperidone versus pimavanserine//Haloperidol versus pimavanserine//pimavanserine versus Placebo	\N	Brazil//United States of America	\N	\N	\N	\N	\N	412	\N	\N	\N	\N	\N
11806	Pajonk 2008	\N	cycle ergometry versus tabletop football	\N	Germany	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
11807	Peuskens 2008 a	\N	Quetiapine versus Placebo	\N	Belgium	\N	\N	\N	\N	\N	197	\N	\N	\N	\N	\N
11808	Rossenu 2008	\N	paliperidone versus Placebo	\N	Belgium//Croatia//United States of America	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
11809	Sushko 2008	\N	Aircryotherapy + Aripiprazole versus Aripiprazole	\N	Ukraine	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
11811	Harvey 2008 a	\N	Ziprasidone versus various dosages	\N	United States of America//Canada	\N	\N	\N	\N	\N	186	\N	\N	\N	\N	\N
11812	Kramer 2008	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	247	\N	\N	\N	\N	\N
11813	Jackson 2003 a	\N	cognitive therapy recovery intervention versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11815	Morrison 2003 b	\N	early detection intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11816	Mortimer 2003 d	\N	HRT + Antipsychotics versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11817	Cowen 2003	\N	chromium + Antipsychotics versus Placebo + Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11818	Laugharne 2003	\N	joint crisis plan versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
11819	Jackson 2003 b	\N	cognitive therapy recovery intervention versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11820	Austwick 2003	\N	intensive case management versus standard case management	\N	United Kingdom	\N	\N	\N	\N	\N	700	\N	\N	\N	\N	\N
20475	杨显东 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
11821	Wykes 2003 b	\N	cognitive remediation therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11822	Gumley 2003 c	\N	cognitive early signs monitoring versus standardized early signs monitoring	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
11823	Goeroecs 2004	\N	Aripiprazole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	1294	\N	\N	\N	\N	\N
11824	Daniel 2004 b	\N	Aripiprazole Dosage // Aripiprazole versus Placebo // Haloperidol versus Placebo // Aripiprazole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	414\r\nAbstracts of the XXIInd CINP Congress, Brussels, Belgium, July 9-13, 2000 400	\N	\N	\N	\N	\N
11825	Hansen 2007	\N	sertindole versus Risperidone	\N	Poland	\N	\N	\N	\N	\N	187	\N	\N	\N	\N	\N
11826	Linne 2008	\N	sertindole versus Olanzapine	\N	Sweden	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
11827	Naber 2008	\N	Asenapine versus Olanzapine	\N	Germany//Netherlands//South Africa	\N	\N	\N	\N	\N	1225	\N	\N	\N	\N	\N
11828	Peuskens 2007 b	\N	sertindole versus Risperidone	\N	Germany//France	\N	\N	\N	\N	\N	261	\N	\N	\N	\N	\N
11829	Awad 2003	\N	Ziprasidone versus various dosages	\N	Canada//United States of America	\N	\N	\N	\N	\N	567	\N	\N	\N	\N	\N
11830	Kinon 2003 e	\N	Olanzapine versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	346	\N	\N	\N	\N	\N
11831	Harrison 2004 c	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	269	\N	\N	\N	\N	\N
11832	Nyilas 2007 a	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	302	\N	\N	\N	\N	\N
11839	Anon 2005 b	\N	Risperidone - Consta versus "Risperidone, olansapine, Quetiapine, Aripiprazole, Amisulpride"	\N	United Kingdom	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
11840	Stock 2004	\N	Aripiprazole versus Haloperidol	\N	Japan//United States of America	\N	\N	\N	\N	\N	1294	\N	\N	\N	\N	\N
11841	DelBello 2006	\N	Ziprasidone versus low//high dosage	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
11842	Roychowdhury 2004 a	\N	Olanzapine versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
11843	Roychowdhury 2004 b	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	546	\N	\N	\N	\N	\N
11844	Roychowdhury 2004 c	\N	Olanzapine versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	346	\N	\N	\N	\N	\N
11846	Gilaberte 2006	\N	Olanzapine versus Risperidone	\N	Spain	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
11847	Keks 2006	\N	Risperidone versus Olanzapine	\N	Australia//Belgium//Israel//United States	\N	\N	\N	\N	\N	629	\N	\N	\N	\N	\N
11848	Uzun 2006	\N	Risperidone versus Clozapine	\N	Croatia	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11849	Santa Ana 2007	\N	group motivational interviewing + standard care versus standard care + therapist activity control	\N	United States of America	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
11851	Wu 2008 a	\N	Olanzapine 15mg + metformin 750mg versus Olanzapine 15mg + Placebo	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
11852	Amiri 2008	\N	Risperidone + selegiline versus Risperidone + Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11853	Baptista 2008	\N	metformin + sibutramine versus metformin + Placebo	\N	Venezuela	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
11854	Byerly 2008	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
11855	Bergemann 2008 a	\N	estradiol + norethisterone acetate versus Placebo	\N	Germany	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
11857	Ellett 2008	\N	urban environment versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
11858	George 2008 a	\N	Bupropion + transdermal nicotine patch versus Placebo + transdermal nicotine patch	\N	Canada	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
11860	Wu 2008 b	\N	Olanzapine 15mg + metformin 750mg versus Olanzapine 15mg + Placebo	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11861	Saddichha 2008 a	\N	Olanzapine versus Haloperidol	\N	India	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
11862	Kumra 2008 a	\N	Clozapine versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11863	Jackson 2008	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus befriending	\N	Australia	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
11864	Johnson 2008	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
11866	Perlick 2008	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	309	\N	\N	\N	\N	\N
11951	NCT00535574	\N	bexarotene versus Placebo	\N	Israel	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11867	Poulin 2007	\N	supervised exercise program + Antipsychotic treatment versus Antipsychotic treatment	\N	Canada	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
11868	Assion 2008	\N	Clozapine + Amisulpride (400,600 mgs) versus Clozapine + Placebo	\N	Germany	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
11869	Cook 2007	\N	supported employment intervention versus standard care	\N	United States of America	\N	\N	\N	\N	\N	1648	\N	\N	\N	\N	\N
11870	Cortese 2008	\N	Quetiapine versus 400, 800 mgs	\N	Canada	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
11871	NCT00254202	\N	iloperidone versus Placebo	\N	United States of America//India	\N	\N	\N	\N	\N	606	\N	\N	\N	\N	\N
11872	Friedman 2008	\N	atomoxetine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
11873	Gallhofer 2007	\N	sertindole versus Haloperidol	\N	Estonia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11874	Goff 2007 d	\N	lamotrigine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	217	\N	\N	\N	\N	\N
11875	Goff 2007 e	\N	lamotrigine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	212	\N	\N	\N	\N	\N
11876	Goldstein 2005	\N	cognitive training program versus control group	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11877	Goyal 2007	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	India	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
11878	Kluge 2007	\N	Clozapine versus Olanzapine	\N	Germany	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	30	\N	\N	\N	\N	\N
11879	Riedel 2007 b	\N	Olanzapine versus Quetiapine	\N	Germany	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
11880	Weinberger 2008	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
11882	Kelleher 2008	\N	galantamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
11883	Sapra 2008	\N	long acting Atypical Antipsychotic versus oral Atypical Antipsychotic	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
11884	Bobo 2008	\N	Clozapine versus typical neuroleptics	\N	United States of America	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
11885	Thyssen 2008	\N	deltoid muscle injection of long-acting-Risperidone versus gluteal muscle injection of long-acting-Risperidone	\N	Belgium	\N	\N	\N	\N	\N	170	\N	\N	\N	\N	\N
11886	Hough 2008	\N	paliperidone palmitate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	410	\N	\N	\N	\N	\N
11887	Mandel 2008	\N	im Ziprasidone versus im Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	572	\N	\N	\N	\N	\N
11888	Hill 2008 a	\N	iloperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
11889	Hamilton 2008	\N	iloperidone versus Placebo	\N	United States of America//India	\N	\N	\N	\N	\N	597	\N	\N	\N	\N	\N
11890	Cazorla 2008 a	\N	Asenapine versus Olanzapine	\N	United States of America//Russian Federation//Ukraine	\N	\N	\N	\N	\N	481	\N	\N	\N	\N	\N
11891	Whitehead 2008	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	314	\N	\N	\N	\N	\N
11892	Medori 2008	\N	conventional neuroleptics versus Quetiapine	\N	Belgium	\N	\N	\N	\N	\N	710	\N	\N	\N	\N	\N
11893	Prescorn 2008	\N	Asenapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	148	\N	\N	\N	\N	\N
11895	Shen 2008 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	313	\N	\N	\N	\N	\N
11896	Simonson 2008	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	355	\N	\N	\N	\N	\N
11899	Gopal 2008	\N	paliperidone injection- deltoid versus paliperidone injection- gluteus	\N	United States of America	\N	\N	\N	\N	\N	252	\N	\N	\N	\N	\N
11901	Macfadden 2008	\N	Risperidone versus various doses	\N	Germany//United States of America	\N	\N	\N	\N	\N	323	\N	\N	\N	\N	\N
11902	Greenberg 2008	\N	vitamin B supplement versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
11903	Cassella 2008	\N	loxapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
11904	Lavedan 2008	\N	iloperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	407	\N	\N	\N	\N	\N
11905	Bogeum 2008	\N	Aripiprazole + Haloperidol versus Haloperidol + Placebo//Aripiprazole versus Haloperidol//Haloperidol versus Placebo//Aripiprazole versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
11906	Lee 2008 a	\N	memantine versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
11907	Chiu 2008	\N	\N	\N	Canada	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
11908	Cordes 2008 a	\N	magnetic stimulation (Transcranial Magnetic Stimulation) versus sham	\N	Germany	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
11909	Ereshefsky 2008 a	\N	RGH-188 versus Placebo	\N	Hungary//United States of America	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
11910	NCT00034749	\N	Risperidone versus various doses	\N	Belgium	\N	\N	\N	\N	\N	279	\N	\N	\N	\N	\N
11911	NCT00323193	\N	psychoeducation intervention versus control group	\N	United States of America	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
11952	NCT00534898	\N	bexarotene versus Placebo	\N	Israel	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11912	NCT00356291	\N	skill building + motivational interviewing versus skill building	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11913	NCT00380536	\N	peer led health education versus control group	\N	United States of America	\N	\N	\N	\N	\N	111	\N	\N	\N	\N	\N
11914	NCT00514449	\N	Antipsychotic + valocyclovir versus Antipsychotic + Placebo	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
11915	NCT00392236	\N	2-way pager + treatment as usual versus treatment as usual	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11916	NCT00435903	\N	palm pilot versus control group	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
11917	NCT00447720	\N	case manager HIV education versus control group	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
11918	NCT00458094	\N	pysical activity intervention + peer support versus pysical activity intervention	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11919	NCT00496691	\N	HIV prevention group versus control group	\N	United States of America	\N	\N	\N	\N	\N	750	\N	\N	\N	\N	\N
11920	NCT00515671	\N	illness management and recovery training versus control group	\N	United States of America	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
11921	NCT00515723	\N	Risperidone versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11922	NCT00517075	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
11923	NCT00518323	\N	paliperidone ER versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	200	\N	\N	\N	\N	\N
11924	NCT00520728	\N	occupational time use intervention versus control group	\N	Canada	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
11925	NCT00523445	\N	champix versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11926	NCT00524043	\N	paliperidone ER versus Placebo	\N	United States of America//India//Taiwan	\N	\N	\N	\N	\N	201	\N	\N	\N	\N	\N
11927	NCT00525304	\N	self management program versus control group Self-Management	\N	United States of America	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	60	\N	\N	\N	\N	\N
11928	NCT00525863	\N	oxygen therapy versus Placebo	\N	Israel	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
11929	NCT00528905	\N	AZD3480 versus Placebo	\N	United States of America//Canada	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
11930	NCT00531518	\N	psychoeducation multifamily group treatment versus supported employment and education	\N	United States of America	\N	\N	\N	\N	\N	900	\N	\N	\N	\N	\N
11931	NCT00535132	\N	Risperidone versus paliperidone	\N	United States of America	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
11932	NCT00570063	\N	PF-02545920 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
11933	NCT00567710	\N	BL-1020 versus Placebo	\N	Israel	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
11934	NCT00567203	\N	PF-3463275 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
11935	NCT00567034	\N	zyprexa + naltrexone versus zyprexa + Placebo	\N	United States of America	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
11936	NCT00565175	\N	famotidine versus Placebo	\N	Finland	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11937	NCT00564096	\N	Transcranial magnetic stimulation (Transcranial Magnetic Stimulation)	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
11938	NCT00560937	\N	pregnenolone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
11939	NCT00559572	\N	motivational group sessions versus time and attention control group sessions	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11940	NCT00554840	\N	varenicline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
11941	NCT00552500	\N	valproate + Atypical Antipsychotics versus Atypical Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11942	NCT00549718	\N	Lurasidone Dosage // Lurasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	480 OR 489	\N	\N	\N	\N	\N
11943	NCT00548327	\N	atomoxetine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
11944	NCT00547118	\N	rimonabant versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11945	NCT00546403	\N	Modafinil versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	26	\N	\N	\N	\N	\N
11946	NCT00545467	\N	Aripiprazole versus Antipsychotics	\N	Taiwan	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
11947	NCT00541398	\N	behavioural implementation of guideline versus control group	\N	Denmark	\N	\N	\N	\N	\N	222	\N	\N	\N	\N	\N
11948	NCT00539071	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
11949	NCT00538642	\N	Ziprasidone versus current Antipsychotic	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
11950	NCT00538070	\N	sarcosine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
11953	NCT00534183	\N	Olanzapine versus Haloperidol	\N	India	\N	\N	\N	\N	\N	2006	\N	\N	\N	\N	\N
11954	NCT00573287	\N	Clozapine + Electroconvulsive Therapy versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
11955	NCT00573417	\N	Modafinil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
11956	NCT00567281	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus one//two sites in the temporal lobes	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11957	NCT00575666	\N	intranasal insulin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11958	NCT00575848	\N	glycine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
11959	NCT00580125	\N	PF-0217830 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
11960	NCT00585390	\N	Omega-3 Fatty Acid versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11961	NCT00587561	\N	social cognition training versus wait list control	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
11962	NCT00588731	\N	cannabidiol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
11963	NCT00589914	\N	paliperidone palmitate versus risperdal consta	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	700	\N	\N	\N	\N	\N
11964	NCT00590577	\N	paliperidone palmitate versus various dosages	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	644	\N	\N	\N	\N	\N
11965	NCT00591318	\N	ceftriaxone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
11966	NCT00595504	\N	ramelteon adjunct versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11967	NCT00600756	\N	Quetiapine XR versus Risperidone	\N	Belgium//Brazil//Bulgaria//Denmark//Finland//Germany//Italy//Mexico//Portugal//Romania//Russia//Spain//Switzerland//Turkey	\N	\N	\N	\N	\N	732	\N	\N	\N	\N	\N
11968	NCT00601224	\N	social cognitiona and interaction training + treatment as usual versus treatment as usual	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
11979	NCT00653406	\N	Risperidone versus various doses	\N	Unclear	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
11980	NCT00646256	\N	psychoeducation + standard treatment versus standard treatment	\N	Germany	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
11981	NCT00686998	\N	AZD2624 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
11982	NCT00604760	\N	MEM 3454 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
11983	NCT00621634	\N	Omega-3 Fatty Acid versus Placebo	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11984	NCT00637234	\N	oxcarbazepine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
11985	NCT00657631	\N	acceptance and commitment therapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
11987	NCT00694707	\N	RGH-188 versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	675	\N	\N	\N	\N	\N
11988	NCT00605995	\N	simvastatin versus Placebo	\N	United States of America//Israel	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
11989	NCT00640510	\N	Olanzapine versus Placebo	\N	Japan	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
11990	NCT00645944	\N	eszopiclone versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	80	\N	\N	\N	\N	\N
11991	NCT00646581	\N	intranasal insulin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
11992	NCT00688259	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus support therapy	\N	United States of America	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
11994	NCT00615511	\N	pregnenolone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
11995	NCT00621777	\N	varenicline + cognitive behavioral therapy versus Placebo + cognitive behavioral therapy	\N	United States of America	\N	\N	\N	\N	\N	274	\N	\N	\N	\N	\N
11996	NCT00663039	\N	oxytocin nasal spray versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
11997	NCT00690235	\N	pramlintide versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
11998	NCT00690274	\N	BF2.649 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
11999	NCT00604279	\N	\N	\N	China	\N	\N	\N	\N	\N	420	\N	\N	\N	\N	\N
12000	NCT00618280	\N	nicotine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
12001	NCT00628394	\N	atomoxetine + cognitive remediation versus cognitive remediation + Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
12002	NCT00635700	\N	Ziprasidone versus Placebo	\N	United States of America//Canada	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
12003	NCT00639886	\N	pregnenolone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
12004	NCT00789698	\N	Lurasidone versus Quetiapine	\N	Multi-Center // Colombia // Germany // India // Philippines // Romania // Russia // Ukraine // United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n\r\n\r\n\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 9\r\n\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	240	\N	\N	\N	\N	\N
12006	NCT00658645	\N	Bifeprunox versus Placebo // Bifeprunox versus Quetiapine // Quetiapine versus Placebo	\N	Multi-Center	\N	\N	\N	\N	\N	227	\N	\N	\N	\N	\N
12007	NCT00686699	\N	P04628 versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
12008	NCT00686153	\N	nicotine nasal spray versus Placebo nasal spray	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
12009	Chanpattana 1999 b	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) + flupenthixol versus Electro Convulsive Therapy (Electroconvulsive Therapy) + Placebo	\N	Thailand	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
12010	Wykes 1994	\N	Chlorpromazine versus Placebo//Chlorpromazine dose	\N	United Kingdom	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
12011	Pae 2006	\N	rapid titration of Quetiapine versus conventional titration of Quetiapine	\N	South Korea	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
12012	Penades 2006 c	\N	cognitive remediation therapy + standard medication follow-up versus cognitive behavioral therapy + standard medication follow-up	\N	Spain	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
12013	Jenner 1994	\N	integrated treatment versus standard care	\N	Netherlands	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
12014	Faber 2006	\N	Atypical Antipsychotics versus discontinued medication	\N	Netherlands	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
12015	Pampoulova 2006	\N	Quetiapine versus Placebo	\N	Canada	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
12017	Ruhrmann 1994	\N	flupentixol versus Risperidone	\N	Germany//Austria	\N	\N	\N	\N	\N	153	\N	\N	\N	\N	\N
12018	Schliefer 2003	\N	Chlorpromazine versus Clothiapine	\N	Israel	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
12019	Simpson 2003 b	\N	IM lorazepam versus oral Risperidone	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
12020	Simpson 2003 c	\N	IM lorazepam versus oral Risperidone	\N	United States of America	\N	\N	\N	\N	\N	162	\N	\N	\N	\N	\N
12021	Simpson 2003 d	\N	IM lorazepam versus oral Risperidone	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
12022	Thompson 2006	\N	Clozapine versus Haloperidol	\N	United Kingdom	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
12023	Nyberg 1994	\N	ACR16 versus Placebo	\N	Sweden	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
12024	NCT00611806	\N	folate + vitamin B12 versus folate + Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	144	\N	\N	\N	\N	\N
12025	NCT00640562	\N	Quetiapine (Extended Release) versus Risperidone	\N	Italy	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	216 // 290	\N	\N	\N	\N	\N
12026	NCT00644969	\N	varenicline tartrate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
12027	NCT00654706	\N	Quetiapine versus Sertindole	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	260	\N	\N	\N	\N	\N
12028	NCT00655239	\N	Cognitive Training versus Games (Computer)	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
12029	NCT00660595	\N	Quetiapine versus Risperidone	\N	Finland	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
12030	NCT00672464	\N	Olanzapine + metformin and//or simvastatin versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
12031	NCT00677898	\N	adherence program versus enhanced treatment as usual	\N	United States of America	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
12032	NCT00685321	\N	H1-coil deep Transcranial Magnetic Stimulation versus sham	\N	Israel	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
12033	NCT00694889	\N	Cognitive Training (Computerized) versus Games (Computer)	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n	\N	80	\N	\N	\N	\N	\N
12034	ISRCTN02658871	\N	clinical management + Aripiprazole versus clinical manangement + Placebo	\N	Germany	\N	\N	\N	\N	\N	380	\N	\N	\N	\N	\N
12035	Jumnoodoo 2006	\N	relapse prevention program versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
12191	Rouillon 2008	\N	Olanzapine dose	\N	France	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
12036	Thornicroft 2008	\N	joint crisis plan versus treatment as usual joint crisis plan versus standard treatment for psychotic whose current state is not described and whose stage of illness is not described//crisis intervention	\N	United Kingdom	\N	\N	\N	\N	\N	540	\N	\N	\N	\N	\N
12039	Gouzoulis 2006	\N	Ziprasidone versus Clozapine	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
12040	NCT00615433	\N	Lurasidone Dosage // Lurasidone versus Placebo // Lurasidone versus Olanzapine // Olanzapine versus Placebo	\N	Bulgaria//Colombia//India//Lithuania//Peru//Philippines//Serbia//Montenegro//United States of America	\N	\N	\N	\N	\N	478 OR 480	\N	\N	\N	\N	\N
12041	ISRCTN44218911	\N	Omega-3 Fatty Acid versus Placebo // Omega-3 Fatty Acid Dosage	\N	United Kingdom	\N	\N	\N	\r\nUser defined field 10\r\n\r\nNotes2\r\nfish oil versus Placebo ethyl-eicosapentaenoic acid versus Placebo EPA versus Placebo EPA versus Placebo Ethyl-eicosapentaenoate acid versus Placebo//Ethyl-eicosapentaenoate acid dose	\N	115 // 120 // 122	\N	\N	\N	\N	\N
12311	Malm 2000	\N	\N	\N	Sweden	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12044	Grodner 1982	\N	art//movement therapy versus no treamtment	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
12045	NCT00581243	\N	SLV-313 ST versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
12046	Birchwood 2008	\N	cognitive therapy for command hallucinations + standard care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
12047	Jones 2004	\N	personalized computer education + psychiatric nurse versus computer education	\N	United Kingdom	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
12049	NCT00572247	\N	psychiatric rehabilitation approach to weight loss versus control group	\N	United States of America	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
12050	Moritz 2007 a	\N	metacognitive training versus control group	\N	Germany	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
12051	Garety 2003	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + standard care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	301	\N	\N	\N	\N	\N
12052	Gournay 2005	\N	adherence therapy versus control group	\N	Thailand	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
12053	Gray 2006 b	\N	adherence therapy versus control group	\N	Thailand	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
12054	NCT00563706	\N	vibicaserin versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	450	\N	\N	\N	\N	\N
12056	Mak 2007	\N	psychological treatment versus control group	\N	Hong Kong	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
12057	So 2006	\N	family psychoeducation versus waiting list	\N	Hong Kong	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
12059	Chabannes 2008	\N	psychoeducation program + Amisulpride versus control group + Amisulpride	\N	France	\N	\N	\N	\N	\N	220	\N	\N	\N	\N	\N
12060	Golden 2008	\N	Clozapine orally disintegrating tablets versus Clozapine solid oral tablets	\N	South Africa	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
12061	Glenthoj 2007 b	\N	Risperidone versus zuclopenthixol	\N	Denmark	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
12062	McClellan 2007	\N	Risperidone versus molindone	\N	United States of America	\N	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
12063	Craig 2008	\N	case managers with training versus case managers control	\N	United Kingdom	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
12064	Bressi 2008	\N	systematic family therapy versus control group	\N	Italy	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
12065	Whitten 2006	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12066	Pickett-Schenk 2008	\N	family education intervention versus control group	\N	United States of America	\N	\N	\N	\N	\N	462	\N	\N	\N	\N	\N
12067	Lindenmayer 2008	\N	cognitive remediation versus control group	\N	United States of America	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
12068	Wong 2008	\N	supported employment program versus conventional vocational rehabilitation program	\N	Hong Kong	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
12069	Sefasi 2008	\N	group caregiver education versus control group	\N	Malawi	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
12070	Kongsakon 2006	\N	Olanzapine versus Haloperidol	\N	Thailand	\N	\N	\N	\N	\N	276	\N	\N	\N	\N	\N
12071	Kageyama 2007	\N	family group versus control group	\N	Japan	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
12072	Heim 1989	\N	\N	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12075	Schneider 2007	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12083	Peacock 1996	\N	Clozapine versus typical Antipsychotics	\N	Denmark	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
12086	Trueman 1974	\N	flupenthixol decanoate	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
12105	Astrup 1974	\N	flupenthixol decanoate versus pipotiazine undecyclenate	\N	Norway	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
12106	Green 2001 a	\N	Clozapine versus Risperidone	\N	United States of America	Harvard University (Medical School) Medical School Campus Boston, Ma 02115	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12109	Hamilton 1999b	\N	copy of referral letter versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	1961	\N	\N	\N	\N	\N
12110	Hildebrandt 1975	\N	Home Visit	\N	United States of America	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
12114	Margo 1981	\N	auditory input from earphones versus no auditiory input from earphones	\N	United Kingdom	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
12115	Marx 1973	\N	on the spot treatment versus progressive treatment	\N	United States of America	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
12118	Pfeiffer 1987	\N	Music therapy	\N	Germany	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
12121	Brotons 1987	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12122	Pavlicevic 1994	\N	music therapy versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
12124	Rosenheck 1998	\N	intensive case management versus standard care	\N	United States of America	\N	\N	\N	\N	\N	873	\N	\N	\N	\N	\N
12135	Immich 1970	\N	\N	\N	China	\N	\N	\N	\N	\N	159	\N	\N	\N	\N	\N
12141	Bucci 1985	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12149	Zhu 2005 c	\N	sodium valproate versus Clonazepam	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
12151	Agius 2007	\N	psychosocial intervention versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
12157	Jackson 2005 a	\N	cognitive oriented psychotherapy versus standard care	\N	Australia	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	91	\N	\N	\N	\N	\N
12162	Ray 1964	\N	nuvon versus Placebo	\N	India	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
12163	Bustillo 2001 c	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12167	NCT00455234	\N	intramuscular Olanzapine versus intramuscular Haloperidol + promethazine	\N	India	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
12170	Meco 1987	\N	\N	\N	Japan	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12173	Hogarty 1997 b	\N	personal therapy versus supportive therapy	\N	United States of America	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
12174	Barton 2008	\N	writing about psychotic experiences versus writing about time management	\N	United Kingdom	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
12175	Berk 2008 a	\N	N-acetyl cysteine versus Placebo	\N	Australia//Switzerland	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
12176	Castelein 2008 b	\N	support group versus control group	\N	Netherlands	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
12178	Chen 2008 b	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
12179	England 2008	\N	cognitive nursing intervention + usual care versus usual care	\N	Canada	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
12180	Fletcher 2008	\N	integrated assertive community treatment versus standard care	\N	United States of America	\N	\N	\N	\N	\N	191	\N	\N	\N	\N	\N
12181	Gallagher 2008	\N	mifepristone versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
12183	Hatta 2008	\N	Olanzapine versus Risperidone	\N	Japan	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
12184	Hong 2008	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
12185	Keefe 2008	\N	donepezil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	251	\N	\N	\N	\N	\N
12187	Lavoie 2008	\N	N-acetyl cysteine versus Placebo	\N	Switzerland	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
20476	薛蓉 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
12194	Wood 1998	\N	comprehensive case management versus standard case management	\N	United States of America	\N	\N	\N	\N	\N	362	\N	\N	\N	\N	\N
12195	Agid 2008	\N	Ziprasidone versus 2, 20 mgs	\N	Canada	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
12196	Barbui 2008 a	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
12197	Brunelin 2008	\N	homavanillic acid versus Placebo	\N	France	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
12198	Dyer 2008	\N	galantamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
12199	Foster 2008	\N	relapse prevention program versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
12202	Jubelt 2008	\N	nicotine patch versus Placebo patch	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
12205	Killackey 2008 a	\N	individual placement and support + standard care versus standard care	\N	Australia	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
12206	Latimer 2008	\N	individual placement and support versus traditional vocational services	\N	Canada	\N	\N	\N	\N	\N	312	\N	\N	\N	\N	\N
12209	Rami 2008	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus control group	\N	Spain	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
12210	Russell 2008	\N	active training versus repeated exposure	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
12211	Sartory 2008	\N	cognitive remediation therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
12212	Shekhar 2008 a	\N	xanomeline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
12214	Thompson 2008	\N	educational Cognitive Behavioural Therpay (Cognitive Behavioral Therapy) workbook + educational visit to consultants + reminder system on medication charts versus guidelines alone	\N	United Kingdom	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
12215	Tremeau 2008	\N	purchasing of a mug scenario versus selling of a mug scenario	\N	United States of America	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
12216	Velligan 2008 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
12219	Sharpley 1964 c	\N	Tranylcypromine + trifluoperazine, pargyline + Placebo versus Tranylcypromine + Placebo versus Pargyline + trifluoperazine// trifluoperazine versus Placebo//Pargyline versus trifluoperazine//Tranylcypromine versus Placebo//	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
12220	Lin 2006 g	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
12221	Taemeeyapradit 1994	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12222	Intoh 1990	\N	Trifluoperazine versus Placebo//Penfluridol versus Placebo//Trifluoperazine versus Penfluridol	\N	Thailand	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
12224	Rosoiu 2006	\N	\N	\N	Romania	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12225	Mohr 2006	\N	repetitive Transcranial Magnetic Stimulation // Cognitive Training versus repetitive Transcranial Magnetic Stimulation	\N	Czech	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
12226	Kim 2005 c	\N	Reality Therapy	\N	Korea	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
12227	Liang 2005 c	\N	Health education + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
12229	Tamrakar 2006	\N	Risperidone versus Haloperidol	\N	Nepal	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
12230	Keisar 2007	\N	\N	\N	Israel	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12231	Kopelowicz 2006	\N	work skills training versus occupational therapy	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
12232	Chouinard 2007	\N	rivastigmine + Antipsychotics	\N	Canada	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
12234	Daniel 2007 b	\N	Aripiprazole versus Placebo // Aripiprazole versus Haloperidol // Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	448	\N	\N	\N	\N	\N
12235	Genc 2007	\N	Clozapine + Amisulpride versus Clozapine + Quetiapine	\N	Turkey	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
12236	Doering 1998	\N	\N	\N	Austria	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12237	Rupnow 2007	\N	 for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is persistent // chronic	\N	United States of America	\N	\N	\N	\N	\N	382	\N	\N	\N	\N	\N
12238	Kemp 2007	\N	Cognitive Behavioural Training versus standard care	\N	Australia	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
12239	Perham 2007	\N	Exercise	\N	United States of America	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
12240	Klein 1998	\N	peer social support versus control group	\N	United States of America	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
12242	Cheng 2005 c	\N	psychoeducation versus control groups for lay carers//family whose current state is not described and whose stage of illness is not described	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
12243	Wolf 2007	\N	Aripiprazole versus Placebo Aripiprazole versus safety control group Aripiprazole versus safety control group	\N	United States of America // Japan // France// Switzerland	\N	\N	\N	\r\nUser defined 3\r\n	\N	833	\N	\N	\N	\N	\N
12244	Fuentes 2007	\N	\N	\N	Spain	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
12246	Padgett 2006	\N	housing program versus standard care	\N	United States of America	\N	\N	\N	\N	\N	225	\N	\N	\N	\N	\N
12251	Salize 2007 a	\N	\N	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12254	Schafer 2007	\N	\N	\N	Germany	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
12255	Milano 2007	\N	Olanzapine + diet and exercise routine versus Olanzapine	\N	Italy	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
12256	Chiappelli 2001	\N	\N	\N	Italy	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12257	Tang 2002 e	\N	Piracetam versus Placebo	\N	China	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
12259	Shoja 2004	\N	Alprazolam versus Citalopram // Alprazolam versus Clomipramine // Alprazolam versus Placebo // Citalopram versus Clomipramine // Citalopram versus Placebo // Clomipramine versus Placebo	\N	Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
12261	Tunis 2007	\N	Olanzapine versus Risperidone versus conventional Antipsychotic drugs for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	China	\N	\N	\N	\N	\N	664	\N	\N	\N	\N	\N
12263	Ahmadi 2000	\N	Famotidine versus Haloperidol	\N	Iran	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
12265	Karahmadi 2002	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12266	Singh 2007	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12267	Delva 2007	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12268	Humphrey-Beebe 2000	\N	Telephone nursing intervention versus control//Nursing support//Information and communication technology based prompting for treatment compliance	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
12270	Weinberg 1968	\N	Workshop Program	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
12279	Field 2001	\N	Intensive community treatment versus Intensive hospital treatment + community aftercare//intensive case management	\N	United States of America	\N	\N	\N	\N	\N	154	\N	\N	\N	\N	\N
12281	Bond 2000	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12283	Morice 1996	\N	Neurocognitive Rehabilitation	\N	Australia	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
12284	Gervey 1994	\N	\N	\N	Denmark//France//United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
12285	Durost 1964	\N	Haloperidol versus Placebo	\N	Canada	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
12288	Vosseler 1959	\N	Megaphen shock treatment	\N	Belgium//Germany//United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
12290	Souto 1971	\N	\N	\N	Canada	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12291	Ayuso-Gutierrez 1973	\N	\N	\N	Nigeria//United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12292	Suwa 1963	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12296	Naoki 2003	\N	\N	\N	Japan	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
12297	Sungur 2003	\N	optimal case management versus routine case management	\N	Turkey	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
12298	Isawa 1999	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12299	Jensen 2003	\N	Body awareness therapy	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
12300	Svestka 2003 c	\N	\N	\N	Czech Republic	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12304	Chen 2002 f	\N	\N	\N	United Kingdom // United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12307	Kim 1998 b	\N	Haloperidol versus Haloperidol+Methylphenidate	\N	Korea	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
12310	Han 2000	\N	Paroxetine versus Placebo	\N	Korea	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
12316	Cho-Boon 1989	\N	Haloperidol Dosage // Haloperidol versus Placebo	\N	Taiwan	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
12319	Inoue 1974	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12324	Sorgi 1992	\N	nadolol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
12326	Mair 1990	\N	\N	\N	Germany	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12327	Brown 1993	\N	Cognitive Rehabilitation versus Occupational Therapy	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
12328	Kline 1981	\N	work exploration discussion group versus control group	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
12329	Brook 1998 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
12330	Curtis 1998	\N	outreach case management versus standard aftercare	\N	United States of America	\N	\N	\N	\N	\N	292	\N	\N	\N	\N	\N
12333	Liang 1987	\N	Haloperidol (low dose) versus Insulin shock therapy + Placebo versus Haloperidol (high dose)//Haloperidol dose//Haloperidol versus Placebo//Haloperidol versus Insulin shock therapy	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
12334	Santos 1989	\N	Haloperidol dose	\N	Spain	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
12335	Smith 1987 b	\N	Haloperidol versus dosage of drug + for schizophrenia whose current state is acute and whose stage of illness is persistent // chronic	\N	Unclear	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
12336	Sharma 1995	\N	predischarge intervention versus control group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12337	Vora 1977	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
12339	Lindberg 1981 b	\N	group psychotherapy versus individual psychotherapy	\N	Sweden	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12340	Lindberg 1981 c	\N	group psychotherapy versus individual psychotherapy	\N	Sweden	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
12341	Baker 2002	\N	motivational interview versus control group motivational interview versus self-help booklet	\N	Australia	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
12343	Chandler 2006	\N	integrated treatment versus standard care	\N	United States of America	\N	\N	\N	\N	\N	182	\N	\N	\N	\N	\N
12345	Carey 2004	\N	HIV prevention group versus control group	\N	United States of America	\N	\N	\N	\N	\N	408	\N	\N	\N	\N	\N
12346	Drake 2006	\N	care management versus standard case management	\N	United States of America	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
12347	Hulse 2002	\N	motivational interview versus informational package	\N	Australia	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
12348	Mangrum 2006	\N	integrated treatment versus parallel treatmtment	\N	United States of America	\N	\N	\N	\N	\N	216	\N	\N	\N	\N	\N
12349	Mowbray 1999	\N	integrated program versus standard care	\N	United States of America	\N	\N	\N	\N	\N	535	\N	\N	\N	\N	\N
12350	Sacks 2004	\N	modified therapeutic community treatment program versus mental health treatment program	\N	United States of America	\N	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
12351	Xie 2005 b	\N	assertive community treatment versus standard care	\N	United States of America	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
12352	Barrowclough 2006 b	\N	motivational strategies + Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus motivational strategies	\N	United Kingdom	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
12353	Sitharthan 1999	\N	itegrated drug and alcohol intervention versus minimal intervention	\N	Australia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12355	Baro 1972	\N	pimozide versus Haloperidol	\N	Belgium	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
12360	Zhang 1999	\N	Thioridazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12361	Yuan 2000 a	\N	Doxepin versus TCM (suoquan pills)//Chinese medicine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
12363	Lin 1999 a	\N	Propantheline versus Placebo	\N	China	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
12364	Zhou 1996	\N	Propantheline versus doxepine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
12367	Yang 1997 c	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12370	Yao 1994	\N	Hismanal versus Propantheline	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
12371	Li 1993	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12376	Lewandowski 1988	\N	Group Therapy	\N	Germany	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
12378	Ping 1994	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12380	Rifang 2001	\N	sodium valproate + Chlorpromazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
12381	Ushakov 1990	\N	\N	\N	Russia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12384	Bailine 1981	\N	Haloperidol - intramuscular versus Chlorpromazine for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
12386	Van Kammen 1982 b	\N	 for schizophrenia whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
12387	Anon 1994	\N	\N	\N	Canada//United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12388	Mausbach 2008	\N	culturally tailored skills intervention versus community based support group	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
12392	Yoon 2002	\N	\N	\N	South Korea	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
12393	Park 1997	\N	Zolpidem versus Triazolam//Triazolam versus Placebo//Zolpidem versus Placebo	\N	Thailand	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
12394	Lee 1997 c	\N	sertraline versus Haloperidol versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described	\N	South Korea	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
12395	Lee 2002 b	\N	\N	\N	South Korea	\N	\N	\N	\N	\N	218	\N	\N	\N	\N	\N
12396	Kim 2006 h	\N	\N	\N	South Korea	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
12397	Ahn 2002	\N	Switching to Olanzapine	\N	Korea	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
12398	Lifschitz 2005	\N	\N	\N	South Africa	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12399	Hotz 2005	\N	\N	\N	South Africa	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12401	Feng-Ju 2006	\N	Clozapine + Electroacupuncture versus Clozapine	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
12406	Jacobs 1964	\N	ci- 383 versus Placebo versus ci- 381 for schizophrenia or//and psychotic whose current state is not described and whose stage of illness is persistent // chronic	\N	Unclear	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
12411	Yang 1994	\N	\N	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
12414	Dong 1997	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
12415	Martyn 1994	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12417	Kumar 1974	\N	tentex forte versus Placebo	\N	India	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
12418	ISRCTN38856272	\N	Community Mental health teams	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12419	Kabes 1984 b	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12420	Hofmann 1979	\N	\N	\N	Austria	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12421	Grandmontagne 1979	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12422	Cullerre 1980	\N	\N	\N	France	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
12423	Crosse 1974	\N	\N	\N	Spain	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12425	Balanchandran 1997	\N	\N	\N	Israel	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12426	Korsgaard 1982	\N	\N	\N	Israel	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12427	Heikkila 1992 b	\N	\N	\N	Finland	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12428	O'Krent 1985	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12429	Lin 1999 b	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12430	del Giudice 1970	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12432	Schooler 1975	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12438	Hirsch 1999 c	\N	Haloperidol versus Ziprasidone	\N	\N	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
12444	McGowan 1995	\N	Intergrated rehabilitation services//intensive case management	\N	United States of America	\N	\N	\N	\N	\N	439	\N	\N	\N	\N	\N
12446	Campbell 1984	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12447	Okuda 1979 b	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12450	Wang 2004 j	\N	Social skill training + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
12451	Li 2004 k	\N	Comprehensive intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
12456	Akerele 2003	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12457	Qiu 2005 b	\N	Family intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
12458	Ries 2000	\N	Cash versus Voucher // Contingent Management of Reward System versus Non-Contingent Management of Reward System	\N	United States of America	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
12459	Belmaker 1988	\N	demethylchlortetracycline + haliperidol versus Placebo + haliperidol	\N	Israel	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
12460	Havassy 2000 b	\N	Case Management	\N	United States of America	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
12461	Evins 2003 c	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12462	Cao 2003 c	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
12463	Byrne 1996	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12464	Richmond 2004	\N	Cognitive Behavioral Therapy+Nicotine Replacement Therapy	\N	Australia	\N	\N	\N	\N	\N	298	\N	\N	\N	\N	\N
12467	Ziegler 1989 b	\N	Amisulpride versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
12470	Stant 2002	\N	\N	\N	Russia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12471	Xue 1987	\N	Electroacupunctureversus Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
12473	Madalena 1964	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12474	Garciaruiz 1964	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12475	Deberdt 1964	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12477	Akerele 2004	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12480	Tuma 2004	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12485	Ding 2005 b	\N	Traditional Chinese Medicine (TCM) Ling Gui Zhu Gan Tang Mixture + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
12490	Zhong 2004	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	673	\N	\N	\N	\N	\N
12515	Clerc 1981	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12516	Clerc 1989 b	\N	Amisulpride Dosage	\N	France	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
12521	Ebrinc 2004	\N	Amisulpride versus Haloperidol	\N	Turkey	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
12538	NCT00707382	\N	genotyping for CYP450 polymorphisms versus intense clinical monitoring	\N	Denmark	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
12540	Wu 2008 c	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
12543	NCT00645502	\N	oral Risperidone versus tablets of Risperidone	\N	Unclear	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
12544	Fitzgerald 2008	\N	bilateral Transcranial Magnetic Stimulation versus sham	\N	Australia	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
12546	Uzenoff 2008	\N	adherence-coping-education (ACE) versus supportive counseling	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
12547	Owen 2008	\N	enhanced educational implementation strategy versus basic educational implementation strategy	\N	United States of America	\N	\N	\N	\N	\N	349	\N	\N	\N	\N	\N
12548	NCT00711464	\N	Modafinil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
12549	NCT00649844	\N	Ziprasidone versus Clozapine	\N	Italy	\N	\N	\N	\N	\N	147	\N	\N	\N	\N	\N
12550	NCT00634348	\N	Ziprasidone versus Aripiprazole Ziprasidone versus Aripiprazole	\N	United States of America	\N	\N	\N	\N	\N	256	\N	\N	\N	\N	\N
12551	NCT00723606	\N	Ziprasidone versus various dosages	\N	China	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	364	\N	\N	\N	\N	\N
12552	NCT00639483	\N	celecoxib + Risperidone versus Risperidone + Placebo	\N	Argentina//Brazil//Germany//Mexico//Philippines//Taiwan	\N	\N	\N	\N	\N	270	\N	\N	\N	\N	\N
12553	NCT00705783	\N	IM Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	403	\N	\N	\N	\N	\N
12554	NCT00706654	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	1000	\N	\N	\N	\N	\N
12555	NCT00650611	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
12556	NCT00725855	\N	MEM 3454 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
12557	NCT00645372	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	242	\N	\N	\N	\N	\N
12558	NCT00727103	\N	varenicline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
12559	NCT00566735	\N	razadyne + Electro Convulsive Therapy (Electroconvulsive Therapy) versus Placebo + Electro Convulsive Therapy (Electroconvulsive Therapy)	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
12561	NCT00733057	\N	minocycline versus Placebo	\N	Israel	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
12562	NCT00712270	\N	Aripiprazole versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
12563	NCT00728195	\N	JNJ 37822681 versus Placebo	\N	Bulgaria//Estonia//India//Korea//Republic of Lithuania//Malaysia//Romania//Russia//South Africa//Taiwan//Ukraine	\N	\N	\N	\N	\N	475	\N	\N	\N	\N	\N
12564	NCT00725075	\N	Org 25935 versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	246	\N	\N	\N	\N	\N
12565	NCT00672373	\N	Gingko biloba extract versus Placebo	\N	China	\N	\N	\N	\N	\N	157	\N	\N	\N	\N	\N
12568	Ganguli 2008	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
12570	NCT00645515	\N	Ziprasidone versus Risperidone	\N	Spain	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
12571	NCT00268749	\N	glycine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
12572	NCT00628420	\N	ACP-104 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
12573	NCT00712660	\N	IT-Aided Preventative Program of Relapse Prevention (mobile phone based relapse prevention program questionnaire + feeback) versus Questionnaire alone	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
12574	NCT00725270	\N	mifepristone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
12576	Strous 2008	\N	Olanzapine+ DHEA versus Olanzapine + Placebo	\N	Israel	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
12577	NCT00695708	\N	cognitive auditory training-brain fitness program versus cognitive auditory training-cogpack	\N	Germany	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	60	\N	\N	\N	\N	\N
12578	NCT00722176	\N	BI-1020 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	220	\N	\N	\N	\N	\N
12579	NCT00704509	\N	Bifeprunox versus Placebo // Bifeprunox versus Quetiapine // Quetiapine versus Placebo	\N	Multi-Center	\N	\N	\N	\N	\N	346	\N	\N	\N	\N	\N
12580	Kopecek 2007	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12581	Baeuml 1997	\N	Group psychoeducation	\N	Germany	\N	\N	\N	\N	\N	111	\N	\N	\N	\N	\N
12582	Jennings 1981	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12583	Anand 1999 b	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12584	Brinkman 1989	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12586	Ropert 1963	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12588	Nguyen 1984	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12589	Pichot 1986	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12595	Malaspina 1997	\N	\N	\N	United Ststes of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
12596	Klingberg 2001	\N	Cognitive behavior therapy versus Intensive psychoeducation//Cognitive behavior therapy versus Treatment as usual//Intensive psychoeducation versus Treatment as usual	\N	Germany	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
12597	Gabbard 2001	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12598	Messotten 1991	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12603	Svendsen 1961	\N	thioridazine versus Chlorpromazine	\N	Denmark	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
12604	Wang 2005 ad	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20477	李晓玲 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
12606	Mazeh 2006	\N	donepezil versus Placebo	\N	Israel	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
12608	Habib 1961	\N	\N	\N	Lebanon	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12613	Alphs 2008	\N	paliperidone ER versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	399	\N	\N	\N	\N	\N
12615	Davis 2008 b	\N	Benzodiazepine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
12616	Detke 2008 a	\N	Olanzapine long-acting injection versus Placebo	\N	Australia//United States of America	\N	\N	\N	\N	\N	404	\N	\N	\N	\N	\N
12617	Detke 2008 b	\N	Olanzapine long-acting injection versus Placebo	\N	Germany//United States of America	\N	\N	\N	\N	\N	1075	\N	\N	\N	\N	\N
12618	Dodd 2008	\N	mitazapine + Atypical Antipsychotic treatment versus Placebo + Atypical Antipsychotic treatment	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
12620	Forbes 2008	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	302	\N	\N	\N	\N	\N
12621	Glenthoj 2008	\N	Risperidone versus zuclopenthixol	\N	Denmark	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
12622	Gulliver 2008 a	\N	Olanzapine long-acting injection versus oral Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	1065	\N	\N	\N	\N	\N
12623	Gulliver 2008 b	\N	Olanzapine long-acting injection versus oral Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	921	\N	\N	\N	\N	\N
12624	Han 2008 c	\N	\N	\N	China	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12625	Chetvertnykh 2008	\N	\N	\N	Russian Federation	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
12627	Jensen 1964	\N	UK-738 versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
12629	Buckley 2005	\N	ready for discharge questionnaire	\N	Georgia	\N	\N	\N	\N	\N	382	\N	\N	\N	\N	\N
12632	Duffy 2004	\N	Support intervention for carers versus support as normal//family intervention	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12633	Zimmer 2007	\N	\N	\N	Brazil	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
12634	Agara 2007	\N	group psychoeducation versus control group	\N	Nigeria	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
12635	Sibitz 2007	\N	\N	\N	Austria	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
12636	Berkman 2007	\N	N-acetyl cysteine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	149	\N	\N	\N	\N	\N
12637	Feng 2003 b	\N	Antipsychotics + Tiopronin versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	287	\N	\N	\N	\N	\N
12639	Anon 2007 b	\N	Clozapine versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
12640	Kin Wong 2008	\N	supported employment program versus conventional vocational rehabilitation program	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
12641	Assuncao 2006	\N	Olanzapine + nizatidine versus Olanzapine + Placebo	\N	Brazil	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
12642	NCT00090012	\N	Olanzapine versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	340	\N	\N	\N	\N	\N
12644	Han 2008 d	\N	\N	\N	China	\N	\N	\N	\N	\N	204	\N	\N	\N	\N	\N
12648	Turkington 2002 b	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	not clear	\N	\N	\N	\N	\N
12655	Yoon 2008	\N	\N	\N	South Korea	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
12656	Wolwer 2008 a	\N	Risperidone versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	159	\N	\N	\N	\N	\N
12657	Weiser 2008	\N	\N	\N	Germany//United States of America	\N	\N	\N	\N	\N	195	\N	\N	\N	\N	\N
12664	Mosolov 2001	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12666	Pinto 1972	\N	\N	\N	Brazil	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12667	Price 1986	\N	verapamil versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
12668	Iancu 2008	\N	escitalopram versus Placebo	\N	Israel	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
12671	Prikryl 2008 a	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	Czech Republic	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
12672	Potapov 2008	\N	Risperidone versus Olanzapine	\N	Russian Federation	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
12674	Olincy 2008 b	\N	nicotine agonist versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
12676	Miyake 2008	\N	Blonanserin versus Risperidone	\N	Japan	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
12677	Saito 2008	\N	Risperidone versus dopamine	\N	Japan	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
12679	Lee 2008 b	\N	memantine versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
12680	Lee 2008 c	\N	Aripiprazole versus Antipsychotics	\N	South Korea	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
12682	Klein 2008	\N	metformin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
12683	Kinon 2008 b	\N	LY2140023 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12684	Kapur 2008	\N	Olanzapine versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
12685	Inada 2008	\N	Blonanserin versus Haloperidol	\N	Japan	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
12687	Siu 2008	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12689	Twamley 2008 a	\N	cognitive training versus standard pharmacotherapy	\N	United States of America	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	38	\N	\N	\N	\N	\N
12690	Velligan 2008 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
12692	Peuskens 2008 b	\N	sertindole versus Risperidone for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Belgium	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12693	Bayer 2008	\N	\N	\N	Germany	\N	\N	\N	\N	\N	227	\N	\N	\N	\N	\N
12695	Remillard 2008	\N	Risperidone versus Haloperidol	\N	Canada	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
12697	Wang 1998 c	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12698	Chafetz 2008	\N	active health promotion + basic primary care versus basic primary care	\N	United States of America	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	309	\N	\N	\N	\N	\N
12699	Faries 2008	\N	 for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	221	\N	\N	\N	\N	\N
12700	Hill 2008 b	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
12701	Qian 1996	\N	Wu-dan-san (TCM) versus Placebo//Chinese medicine//chinese medicine versus Placebo	\N	China	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
12702	Drake 1996 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12704	Gabor 2007	\N	ect + etomidate versus ect + propofol for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Hungary	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
12707	McCay 2007	\N	stigma group intervention + standard care versus standard care	\N	Canada	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
12708	Barr 2008	\N	nicotine versus healthy and schizophrenic controls	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
12710	Berget 2008	\N	control groups versus animal-assisted therapy for schizophrenia or//and schizotypal whose current state is not described and whose stage of illness is persistent // chronic with negative symptoms	\N	Norway	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
12712	Bell 2008 a	\N	neurocognitive enhancement therapy + vocational services versus vocational services	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
12715	Ruhrmann 2007 b	\N	needs focused intervention + Amisulpride versus needs focused intervention	\N	Germany	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
12717	NCT00621998	\N	Risperidone versus Olanzapine	\N	Taiwan	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
12718	NCT00722163	\N	Cognitive Behavioural Training versus befriending	\N	Canada	\N	\N	\N	\N	\N	330	\N	\N	\N	\N	\N
12719	NCT00654576	\N	psychosocial intervention versus control group	\N	China	\N	\N	\N	\N	\N	1400	\N	\N	\N	\N	\N
12720	NCT00714818	\N	genetic counseling versus control group	\N	Canada	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
12721	NCT00713804	\N	genetic counseling versus control group	\N	Canada	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
12722	NCT00659919	\N	trazodone versus Placebo	\N	Israel	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
12723	NCT00709202	\N	betahistine + Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
12724	NCT00737256	\N	Aripiprazole versus perphenazine	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
12726	NCT00686140	\N	celecoxib + Risperidone versus Risperidone + Placebo	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
12728	NCT00563550	\N	sertindole versus Risperidone	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
12729	NCT00711269	\N	Lurasidone versus Placebo // Lurasidone versus Risperidone // Risperidone versus Placebo	\N	Japan // South Korea // Taiwan	\N	\N	\N	\N	\N	440	\N	\N	\N	\N	\N
12730	NCT00718510	\N	L-arginine + standard care versus Placebo + standard care	\N	Canada	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
12731	NCT00089869	\N	Atypical Antipsychotics + atomoxetine versus Atypical Antipsychotics + Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12732	NCT00736710	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
12733	NCT00712075	\N	computer assisted cognitive behavioral social skills training + usual care versus computer assisted supportive contact control	\N	United States of America	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
12734	NCT00522613	\N	supportive care versus control group	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
20263	王志强 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
12735	NCT00712686	\N	Aripiprazole versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	703	\N	\N	\N	\N	\N
12736	Hyde 1987	\N	hostel ward versus general hospital	\N	United Kingdom	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
12737	Creed 1996	\N	day hospital care versus inpatient care	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12743	Puschner 2008	\N	needs oriented discharge planning and monitoring versus control group	\N	Germany	\N	\N	\N	\N	\N	490	\N	\N	\N	\N	\N
12745	Wolford 2008	\N	interviewer assessment versus computer-assisted assessment	\N	United States of America	\N	\N	\N	\N	\N	245	\N	\N	\N	\N	\N
12746	Chien 2008 b	\N	\N	\N	Hong Kong	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
12747	Sikich 2008 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
12748	Gallagher 2007	\N	contingent reinforcement versus control group	\N	United States of America	\N	\N	\N	\N	\N	181	\N	\N	\N	\N	\N
12749	Patil 2007	\N	Olanzapine + LY2140023 versus Olanzapine + Placebo	\N	Russian Federation	\N	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
12751	Yuan 2008 a	\N	\N	\N	China	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
12753	Popov 2008	\N	\N	\N	Russia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12754	Halbreich 2008	\N	second generation Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
12755	Findling 2008	\N	oral Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	302	\N	\N	\N	\N	\N
12757	Arman 2008	\N	metformin versus Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
12758	Sacco 2008	\N	galantamine versus Placebo	\N	Canada//United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
12759	Kim 2006 i	\N	Recovery Education Program	\N	Korea	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
12760	Vaz-Leal 2008 a	\N	metaformin + life intervention versus life intervention	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
12761	Van Nimwegen 2008	\N	Olanzapine versus Risperidone	\N	Netherlands	\N	\N	\N	\N	\N	138	\N	\N	\N	\N	\N
12765	Chen 2008 c	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
12767	Yao 2008	\N	Risperidone, Risperdal versus Risperidone, Danke	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12768	Twamley 2008 b	\N	supported employment (Individual Placement Support) versus Conventional vocational Rehabilitation	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
12769	Salimi 2008	\N	Risperidone versus Olanzapine	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
12771	Schneider 2008	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	United States of America	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
12773	Moxon 2008	\N	community treatment group versus control group	\N	New Zealand	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
12774	Cook 2008	\N	standard treatment versus supported employment program for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	1273	\N	\N	\N	\N	\N
12776	Moller 2008 a	\N	immediate release Quetiapine versus extended release Quetiapine fumarate	\N	Germany	\N	\N	\N	\N	\N	497	\N	\N	\N	\N	\N
12777	Combs 2008	\N	attentional shaping intervention versus repeated practice	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
12778	Zanjani 2008	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
12779	Luty 2008	\N	description of a fictional patient versus photo of a man in a business suit	\N	United Kingdom	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
12781	So 2008	\N	anxiety induction versus anxiety reduction	\N	Hong Kong	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
12782	Ascher-Svanum 2008 a	\N	 for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	664	\N	\N	\N	\N	\N
12786	Bisol 2008 a	\N	flunarizine versus Haloperidol	\N	Brazil	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
12790	Harvey 2008 b	\N	Ziprasidone versus Clozapine	\N	Italy	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
12793	Moller 2008 b	\N	Risperidone versus Haloperidol	\N	Germany	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	296	\N	\N	\N	\N	\N
12794	Rusch 2008	\N	stigma reduction program versus psychoeducation	\N	United States of America	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
12795	Van Dorn 2008	\N	psychiatric advanced directives treatment versus psychiatric advanced directives information packet//Advance treatment directives	\N	United States of America	\N	\N	\N	\N	\N	469	\N	\N	\N	\N	\N
12796	Bergemann 2008 b	\N	estradiol versus Placebo	\N	Germany	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
12797	Deberdt 2008	\N	Olanzapine versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
12798	Jensen 2008	\N	Risperidone versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
12800	Ader 2008	\N	Risperidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
20264	周芳珍 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
12801	Fakra 2008	\N	Risperidone versus Haloperidol	\N	France	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
12802	Dunn 2008	\N	education intervention versus control group	\N	United States of America	\N	\N	\N	\N	\N	178	\N	\N	\N	\N	\N
12803	Bustillo 2008	\N	Quetiapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
12816	Raweh 1999	\N	perphenazine versus second generation Antipsychotics	\N	Israel	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
12817	Haggarty 2008	\N	Shared Care (Transition into Primary Care Psychiatry) versus Treatment as Usual	\N	Canada	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
12819	Bechdolf 2007 b	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus support therapy	\N	Germany	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
12822	Lysaker 2006 b	\N	cobnitive behavioral program versus standard support services	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
12826	Apiquian 2008	\N	\N	\N	Mexico	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
12828	Kinon 2008 c	\N	Olanzapine dose	\N	United States of America	\N	\N	\N	\N	\N	599	\N	\N	\N	\N	\N
14103	Luo Cheng 2007	\N	Olanzapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
12831	Davis 2008 c	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + work therapy versus work therapy	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
12832	Ko 2008	\N	testosterone versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
12833	Doruk 2008	\N	Clozapine + ginkgo biloba extract versus Clozapine + Placebo	\N	Turkey	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
12834	Pratt 2008	\N	integrated social rehabilitation versus control group	\N	United States of America	\N	\N	\N	\N	\N	183	\N	\N	\N	\N	\N
12836	Velligan 2001 c	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12841	NCT00768612	\N	vabicaserin versus Risperidone	\N	Unclear	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
12848	Shafti 2005 a	\N	clomipramine versus citalopram	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
12850	Schrock 2006	\N	Bupropion versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
12852	NCT00781794	\N	NSA-789 versus Placebo	\N	France//United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
12853	NCT00255879	\N	Quetiapine versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
12854	NCT00791440	\N	Cognitive Behavioural Training versus control group	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
12855	NCT00631722	\N	Quetiapine fumarate versus Haloperidol	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
12856	NCT00786318	\N	Ziprasidone versus standard therapy	\N	United States of America	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
12857	NCT00772005	\N	Armodafinil versus Placebo // Armodafinil Dosage	\N	United States of America	\N	\N	\N	\r\nUser defined field 10\r\n	\N	287	\N	\N	\N	\N	\N
12858	NCT00798109	\N	motivational therapy versus standard care	\N	France	\N	\N	\N	\N	\N	330	\N	\N	\N	\N	\N
12859	NCT00791882	\N	social skills training versus control group	\N	Brazil	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
12860	NCT00761670	\N	Amisulpride versus Risperidone	\N	Hungary	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
12861	NCT00783120	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus Placebo	\N	Germany	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	140	\N	\N	\N	\N	\N
12862	NCT00790517	\N	Premier lifestyle intervention with DASH diet versus standard care	\N	United States of America	\N	\N	\N	\N	\N	280	\N	\N	\N	\N	\N
12863	NCT00797277	\N	Olanzapine versus Haloperidol + lorazepam	\N	Taiwan	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
12864	NCT00621465	\N	Critical Time Intervention (CTI) versus usual care// Intensive case management//Life skills//Supported housing Critical Time Intervention	\N	United States of America	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	150	\N	\N	\N	\N	\N
12865	NCT00794963	\N	integrated care versus standard care	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
12866	NCT00770744	\N	Lu 31-130 versus Olanzapine	\N	Czech Republic//France//Hong Kong//Indonesia//Philippines//Poland//Spain//Thailand	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
12867	NCT00770237	\N	smoking cues versus natural cues	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
12868	NCT00757497	\N	transcranial direct current stimulation versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
12870	NCT00753051	\N	Clozapine + Electroconvulsive Therapy versus Clozapine + Haloperidol	\N	Thailand	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
12872	NCT00783185	\N	specialized treatment versus control group	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
12873	NCT00781079	\N	intensive case management + consumer providers teams versus control group	\N	United States of America	\N	\N	\N	\N	\N	329	\N	\N	\N	\N	\N
12874	NCT00790192	\N	Lurasidone Dosage // Lurasidone versus Quetiapine // Lurasidone versus Placebo // Quetiapine versus Placebo	\N	Multi-Center // India // Romania // Russia // Ukraine // United States of America	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	488	\N	\N	\N	\N	\N
12875	NCT00641745	\N	Lurasidone versus Risperidone	\N	Multi-Center // Argentina // Brazil // Chile // Croatia // Israel //South Africa // Thailand // United States of America	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	600 OR 611 OR 629	\N	\N	\N	\N	\N
12876	NCT00793780	\N	naltrexone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
12877	Lichtenberg 2008 b	\N	clinical management group versus standard care	\N	Israel	\N	\N	\N	\N	\N	217	\N	\N	\N	\N	\N
12878	NCT00645099	\N	paliperidone ER versus Olanzapine	\N	Argentina//Brazil//Egypt//Estonia//France//Greece//Jordan//Lebanon//Lithuania//Romania//Slovakia//South Africa//Spain//Turkey//United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12879	NCT00693472	\N	PO5145AM1 versus Placebo	\N	South Africa	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
12883	Spaulding 1998	\N	integrated psychological therapy versus supportive group therapy	\N	United States of America	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
12884	Sensky 2000 e	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12887	Startup 2004 b	\N	Cognitive Behavioral Therapy	\N	Australia	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
12889	Gong 1998 c	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12905	Imai 1982	\N	\N	\N	Japan	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12910	Zhang 1997 d	\N	Traditional chinese medicine versus routine Antipsychotics//Traditional chinese medicine	\N	China	\N	\N	\N	\N	\N	123	\N	\N	\N	\N	\N
12914	Bellomo 1972 a	\N	\N	\N	Brazil	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12917	Drake 1994	\N	rehabilitative day treatment versus supported employment	\N	United States of America	\N	\N	\N	\N	\N	183	\N	\N	\N	\N	\N
12931	Kubacki 1984	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12933	Caranza 1973	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
12936	Kinross 1963	\N	fluphenazine enanthate versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	147	\N	\N	\N	\N	\N
12939	Rupnow 2005b	\N	Risperidone versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	308	\N	\N	\N	\N	\N
12940	Riedel 2005 c	\N	Quetiapine versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
12941	Lasser 2005 b	\N	Atypical Antipsychotics + Risperidone versus Atypical Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	323	\N	\N	\N	\N	\N
12942	Cavazzoni 2004	\N	Olanzapine dose	\N	United Kingdom // United States of America	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
12944	Dunn 2005 b	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	206	\N	\N	\N	\N	\N
12945	de Lima 2007	\N	Olanzapine versus first generation Antipsychotics	\N	Brazil	\N	\N	\N	\N	\N	197	\N	\N	\N	\N	\N
12946	Shim 2007 d	\N	Aripiprazole + Haloperidol versus Haloperidol + Placebo//Aripiprazole versus Haloperidol//Haloperidol versus Placebo//Aripiprazole versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
12947	Preskorn 2007	\N	Asenapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	148	\N	\N	\N	\N	\N
12948	Nyilas 2007 b	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	302	\N	\N	\N	\N	\N
12950	Buchsbaum 2007 b	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12952	Eerdekens 2007	\N	paliperidone ER versus Placebo	\N	Belgium//United States of America	\N	\N	\N	\N	\N	109	\N	\N	\N	\N	\N
12953	Fleming 2007	\N	Asenapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
12954	Harvey 2007 b	\N	Ziprasidone versus Clozapine	\N	Italy	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
12955	Izakova 2007	\N	Risperidone versus Haloperidol + sertraline	\N	Slovak Republic	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
12957	Kim 2007 c	\N	Risperidone versus Haloperidol	\N	South Korea	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
12958	Kim 2007 d	\N	Risperidone versus Amisulpride	\N	South Korea	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
12959	Lee 2007 g	\N	Bromocriptine versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
13120	Morozova 2009	\N	Risperidone + amiridin versus Risperidone + Placebo	\N	Russian Federation	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
12961	Gwynne 1962	\N	trifluoperazine versus Placebo//Chlorpromazine versus Placebo//Chlorpromazine versus Trifluoperazine	\N	Unclear	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
12963	Holden 1971	\N	thiothixene versus trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
12964	Wijsenbeek 1974	\N	\N	\N	Israel	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
12966	Gerlach 1977	\N	G 31.406 versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
12975	Sherr 2002	\N	nicotine spray versus control group	\N	United States of America	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
12980	Jarema 2000	\N	\N	\N	Poland	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
12982	Callahan 2004	\N	Vignette Inmate	\N	United States of America	\N	\N	\N	\N	\N	1877	\N	\N	\N	\N	\N
12990	Colombo 2008	\N	Aripiprazole versus Olanzapine	\N	Italy	\N	\N	\N	\N	\N	314	\N	\N	\N	\N	\N
12991	Sells 2008	\N	peer based management versus regular case management	\N	United States of America	\N	\N	\N	\N	\N	137	\N	\N	\N	\N	\N
12993	Josiassen 2008	\N	tolvaptan versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
13105	Brown 2006 a	\N	brief health promotion interevntion versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
12994	Safa 2008	\N	Olanzapine versus Risperidone for schizophrenia or//and schizophreniform whose current state is not described and whose stage of illness is not described	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
12995	Goff 2008 c	\N	D-cycloserine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
12996	Lan 2008	\N	Antipsychotic drugs for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	China	\N	\N	\N	\N	\N	220	\N	\N	\N	\N	\N
12997	Forsberg 2008	\N	lifestyle program versus control group	\N	Sweden	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
12999	ISRCTN25455020	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus Cognitive Remediation Cognitive behavioural therapy versus Cognitive remediation//Cognitive behaviour therapy versus other psychosocial treatments	\N	Germany	\N	\N	\N	\r\nNotes2\r\nCognitive Behavioural Training versus cognitive remediation	\N	49	\N	\N	\N	\N	\N
13006	Perez 2008	\N	Olanzapine versus Haloperidol	\N	Spain	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
13007	Han 2008	\N	Movies (Video) versus Games (Video)	\N	South Korea // United States of America	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
13008	Gutierrez 2007	\N	psychoeducation intervention versus control group	\N	Chile	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
13009	An 2007	\N	Nursing intervention versus control group	\N	South Korea	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
13010	Goder 2008	\N	Olanzapine + Amisulpride versus Amisulpride + Placebo	\N	Germany	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
13017	Hemnani 1982	\N	metoclopramide versus Placebo	\N	India	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
13019	Eack 2008	\N	cognitive enhancement therapy versus control group	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
13023	Abderhalden 2008	\N	risk assessment versus control group	\N	Switzerland	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
13026	Gunby 1966	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13039	Angst 1970	\N	2- chlor-11(4'-methylpiperazino)-dibenzo-(b,f)(1-4)-oxazepin (sum3170) for psychotic whose current state is acute and whose stage of illness is not described with agitation	\N	Unclear	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
13045	Anon 2002	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13048	Anon 2003 c	\N	Aripiprazole (15mgs) versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	1294	\N	\N	\N	\N	\N
13050	Swartz 2006	\N	Facilitated Psychiatric Advance Directive	\N	United States of America	\N	\N	\N	\N	\N	469	\N	\N	\N	\N	\N
13051	Hanlon 1969	\N	thioridazine + phenothiazines versus thioridazine	\N	United States of America	\N	\N	\N	\N	\N	190	\N	\N	\N	\N	\N
13053	Hankoff 1962	\N	meprobamate versus Placebo//Chlorpromazine versus Placebo//Chlorpromazine versus meprobamate//chlordiazepoxide versus Placebo//chlordiazepoxide versus meprobamate	\N	United States of America	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
13055	Azima 1962 a	\N	chlordiazepoxide versus Placebo	\N	Canada	\N	\N	\N	\N	\N	199	\N	\N	\N	\N	\N
13059	Yue 2002 a	\N	Morita Therapy + Risperidone versus Risperidone + care as usual	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
13060	Wang 2002 s	\N	Morita Therapy versus control group	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
13067	NCT00734435	\N	Olanzapine + zonisamide SR versus Olanzapine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
13068	Ding 2008	\N	Traditional Chinese Medicine (TCM) Tongda decotion versus Placebo	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
13070	Lecomte 2008	\N	group Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus social skills training//group Cognitive Behavioural Therapy (Cognitive Behavioral Therapy)//social skills programmes	\N	Canada	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
13071	Gutierrez-Suela 2008	\N	\N	\N	Spain	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13072	Lewis 2008	\N	MK-0777 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
13073	Akhondzadeh 2008 a	\N	donepezil + Risperidone versus Risperidone + Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13075	Akhondzadeh 2008 b	\N	 for schizophrenia whose current state is acute and whose stage of illness is persistent // chronic with negative symptoms	\N	Islamic Republic of Iran	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	40	\N	\N	\N	\N	\N
13076	Strous 2009 a	\N	S-andenosyl-Methionine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
13079	DelBello 2008	\N	Ziprasidone versus low//high dosage	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
13080	Barbui 2008 b	\N	intramuscular Haloperidol + promethazine versus Haloperidol	\N	Brazil	\N	\N	\N	\N	\N	316	\N	\N	\N	\N	\N
13082	Bylund 2008	\N	computer mediated structured process + usual care versus usual care	\N	United States of America	\N	\N	\N	\N	\N	507	\N	\N	\N	\N	\N
13088	Ben Hadj 1995	\N	\N	\N	Tunisia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13091	Purvis 1970	\N	community followup program versus control group	\N	United States of America	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
13103	Rotatori 1980	\N	behavioural self control program versus control group	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
13104	Archie 2003	\N	Olanzapine + fitness program versus Olanzapine	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
20265	张子平 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
13106	Weiden 2005 a	\N	Sibutramine + Haloperidol, Olanzapine, Risperidone versus Placebo + Antipsychotics//Sibutramine versus Placebo//Sibutramine versus Antipsychotic//Haloperidol versus Placebo//Risperidone versus Placebo//Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
13108	Kryzhanovskaya  2009	\N	Olanzapine versus Placebo	\N	United States of America//Russian Federation	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
13109	Bilder 2001 a	\N	Clozapine versus Haloperidol // Clozapine versus Olanzapine // Clozapine versus Risperidone // Haloperidol versus Olanzapine // Haloperidol versus Risperidone // Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	157	\N	\N	\N	\N	\N
13111	Mulholland 1997 b	\N	sertraline versus Placebo	\N	Ireland	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
13112	Nobay 2004	\N	midazolam versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	111	\N	\N	\N	\N	\N
13114	Lieb 2003	\N	\N	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13115	Fleming 2009	\N	AIT-82 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
13116	Dickerson 2009 a	\N	allopurinol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
13118	Haro 2009	\N	Amisulpride + Quetiapine versus Clozapine	\N	Spain	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13119	Kapur 2009	\N	Amoxapine versus Risperidone	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13122	Tamminga 2009	\N	Aripiprazole + atomoxetine versus Aripiprazole + Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13123	Dickerson 2009 b	\N	azithromycin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
13124	Cai 2009	\N	bezoar xiexin tang + Haloperidol versus Haloperidol + Placebo//Bezoar xiexin tang versus Placebo//Haloperidol versus Placebo//Haloperidol versus bezoar xiexin tang//chinese herbal medicine	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
13125	Norman 2009	\N	Buspirone versus Placebo	\N	Australia	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
13126	Muller 2009 a	\N	COX-2 versus Placebo	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13127	Dolnak 2009	\N	celecoxib + Antipsychotics versus Placebo + Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
13128	Xiao 2009 a	\N	Cerebrolysin 30 ml versus Placebo	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
13129	Popovic 2009	\N	Risperidone versus Clozapine	\N	Spain	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
13130	Cowen 2009	\N	chromium picolinate + Antipsychotics versus Placebo + Antipsychotics	\N	United Kingdom	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
13131	Belmaker 2009 a	\N	Chlorpromazine versus Clothiapine	\N	Israel	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
13133	Vinogradov 2009 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
13135	Jarskog 2009 a	\N	dehydroepiandrosterone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13136	Muller 1998 b	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13137	Lun 2009	\N	dihydroateannuin versus Risperidone	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
13138	Thaker 2009	\N	dipyridamole versus not stated	\N	United States of America	\N	\N	\N	\N	\N	138	\N	\N	\N	\N	\N
13139	Kohler 2009	\N	donepezil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
13140	Lara 2009	\N	allopurinol versus Placebo	\N	Brazil	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
13141	Conley 2009 a	\N	atomoxetine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13142	Muller 2009 b	\N	COX-2 versus Placebo	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
13144	Emsley 1999 c	\N	Haloperidol versus fluphenazine versus Quetiapine for schizophrenia whose current state is partial remission and whose stage of illness is not described with positive symptoms	\N	United Kingdom	\N	\N	\N	\N	\N	288	\N	\N	\N	\N	\N
13145	Wieck 2009	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
13146	Brusov 2009	\N	Olanzapine + famciclovir versus Olanzapine	\N	Russian Federation	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13147	Desta 2009	\N	hydroxychloroquine versus Placebo	\N	Ethiopia	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
13148	Cheung 2009	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
13149	Belmaker 2009 b	\N	folic acid versus Placebo	\N	Israel	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
13150	Fenton 2009	\N	Omega-3 Fatty Acid versus Placebo	\N	United States of America	\N	\N	\N	\r\nUser defined 3\r\n	\N	87	\N	\N	\N	\N	\N
13151	Bahn 2009 a	\N	exenatide versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13152	Bahn 2009 b	\N	insulin versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13153	Bustillo 2009	\N	lamotrigine + Clozapine versus Placebo + Clozapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13154	Xu 2009	\N	LDGXW+Risperidone (3-6mg, <rmg) versus Placebo	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
13156	Hadley 2009	\N	metformin versus Standard Care	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13157	Young 2009 a	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
13158	Poyurovsky 2009 a	\N	mirtazapine + propranolol versus Placebo + propranolol	\N	Israel	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
13159	Joffe 2009 a	\N	mirtazapine versus Placebo	\N	Finland	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13161	Berk 2009 a	\N	N-acetyl cysteine versus Placebo	\N	Australia	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
13162	NCT01066403	\N	pergolide versus Placebo	\N	Germany	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
13163	Savitz 2009	\N	pregnenolone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
13164	O'Callaghan 2009	\N	psychoeducation versus standard care	\N	Ireland	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
13165	Klushnik 2009	\N	Risperidone versus Placebo	\N	Russia	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
13166	Ritsner 2009 a	\N	dehydroepiandrosterone versus Placebo	\N	Israel	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
13167	Poyurovsky 2009 b	\N	reboxetine + Olanzapine versus Placebo + Olanzapine	\N	Israel	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13168	Zhang 2009a	\N	\N	\N	China	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
13169	Rujescu 2009	\N	riluzole versus Placebo	\N	Germany	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
13170	Juckel 2009	\N	rimonabant versus Placebo	\N	Germany	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
13171	Anil 2009	\N	Clozapine versus Placebo	\N	Turkey	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13172	McClellan 2009	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
13173	Potkin 2009 a	\N	rivastigmine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
13174	Strous 2009 b	\N	S-andenosyl-Methionine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13175	Xiao 2009 b	\N	Sarsarpogenin versus Placebo	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
13176	Lieberman 2009 a	\N	secretin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
13177	Spivak 2009	\N	sibutramine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13178	Potkin 2009 b	\N	suberoylanilide hydroxamic acid versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
13179	Lieberman 2009 b	\N	tamoxifen versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
13180	Ma 2009	\N	Sulpiride + tianma versus Sulpiride + Placebo//Sulpiride versus tianma//Sulpiride versus Placebo// tianma versus Placebo	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
13181	Tiihonen 2009 a	\N	topiramate versus Placebo	\N	Finland	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
13182	Alem 2009	\N	trimethoprim versus Placebo	\N	Ethiopia	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
13183	Li 2009 a	\N	\N	\N	China	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
13184	Dickerson 2009 c	\N	valacyclovir versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
13185	Lerner 2009	\N	vitamin B6 versus Placebo	\N	Israel	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
13186	Wang 2009 b	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
13187	Thomas 1992	\N	droperidol versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
13190	Smulevitch 1974	\N	lithium versus Placebo	\N	Russian Federation	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
13191	Nasrallah 1986	\N	5-hydroxytryptophan versus Alpha-methyl-p-tyrosine // 5-hydroxytryptophan versus Choline Chloride // 5-hydroxytryptophan versus Levodopa // 5-hydroxytryptophan versus Valproic Acid // 5-hydroxytryptophan versus Placebo // Alpha-methyl-p-tyrosine versus Choline Chloride // Alpha-methyl-p-tyrosine versus Levodopa // Alpha-methyl-p-tyrosine versus Valproic Acid // Alpha-methyl-p-tyrosine versus Placebo // Choline Chloride versus Levodopa // Choline Chloride versus Valproic Acid // Choline Chloride versus Placebo // Levodopa versus Valproic Acid // Levodopa versus Placebo // Valproic Acid versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
13193	Lundbeck 2006 a	\N	sertindole versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13202	Gruzelier 1980	\N	propranolol + neruoleptics versus propranolol	\N	United Kingdom	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
13207	Ratey 1991	\N	nadolol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13208	Mata 2008	\N	Risperidone versus Haloperidol	\N	Spain	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
13217	Fleischhacker  2008	\N	Aripiprazole + Clozapine versus Clozapine + Placebo	\N	Austria//Finland	\N	\N	\N	\N	\N	207	\N	\N	\N	\N	\N
20478	李巧爱 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
13222	Buchsbaum 2007	\N	sertindole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
13224	Ono 2008	\N	Olanzapine versus Placebo	\N	Japan	\N	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
13225	Atsushi 2008	\N	Risperidone versus perospirone	\N	Japan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13226	Behdani 2008	\N	Risperidone + ethinyl estradiol versus Risperidone + Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
13227	Hebrani 2008	\N	topiramate + Clozapine versus Placebo + Clozapine	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
13229	Kapas 2008	\N	RGH-188 versus Placebo	\N	Hungary//United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
13230	Detke 2008 c	\N	Olanzapine long-acting injection versus Placebo	\N	Germany//United States of America	\N	\N	\N	\N	\N	1065	\N	\N	\N	\N	\N
13232	Detke 2008 d	\N	Olanzapine long-acting injection versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	264	\N	\N	\N	\N	\N
13234	Lan 2008 a	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
13237	Tsai 1998	\N	Antipsychotics + D-serine versus Antipsychotics + Placebo	\N	Taiwan	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
13239	Wei 2006 h	\N	Risperidone 2mg//d versus Risperidone 4mg//d	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
13240	McDonel 1997	\N	assertive community treatment versus control group	\N	United States of America	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
13241	Barrett 1957	\N	Chlorpromazine + Reserpine versus Reserpine	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13242	Byerly 2003	\N	clinician monitoring versus electronic monitoring	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
13243	Lundbeck 2004	\N	Bifeprunox versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13251	NCT00034905	\N	Quetiapine fumarate versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13252	NCT00843687	\N	gluteal IM Risperidone versus deltoid IM Risperidone	\N	Unclear	\N	\N	\N	\N	\N	188	\N	\N	\N	\N	\N
13257	NCT00796081	\N	ER oros paliperidone versus various dosages	\N	Unclear	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
13258	NCT00845026	\N	LY2140023 versus Atypical Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
13259	NCT00791232	\N	D-cycloserine + Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus Placebo + Cognitive Behavioural Therapy (Cognitive Behavioral Therapy)	\N	Unclear	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
13261	NCT00791622	\N	paliperidone versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
13262	NCT00791349	\N	paliperidone versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
13267	NCT00817648	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
13268	NCT00827918	\N	MK8998 versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	205	\N	\N	\N	\N	\N
13269	NCT00819689	\N	Aripiprazole versus perphenazine	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
13270	NCT00796185	\N	paliperidone ER versus Risperidone	\N	Unclear	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
13271	NCT00817336	\N	AQW051 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
13272	NCT00759993	\N	chromium piccolinate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13273	NCT00810355	\N	Cognitive Behavioural Training + cognitive remediation versus support services	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
13274	NCT00832845	\N	cognitive Behavioural social skills training + standard care versus standard care	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13275	NCT00829400	\N	cognitive training + VA work program versus VA work program	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
13276	NCT00802100	\N	Antipsychotics + behavioral treatment versus Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13277	NCT00809770	\N	contingency management + standard care versus standard care	\N	United States of America	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
13278	NCT00753506	\N	artemisinin versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
13279	NCT00826202	\N	D-serine versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	72	\N	\N	\N	\N	\N
13280	NCT00816894	\N	D-serine versus Olanzapine	\N	Israel	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13281	NCT00833547	\N	eszopiclone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
13282	NCT00740259	\N	flunarizine versus Haloperidol	\N	Brazil	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
13283	NCT00768326	\N	Lu 31-130 versus Olanzapine	\N	Unclear	\N	\N	\N	\N	\N	210	\N	\N	\N	\N	\N
13284	NCT00810667	\N	Lu AE58054 + Risperidone versus Placebo + Risperidone	\N	France	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
13285	NCT00759421	\N	sertindole versus Olanzapine	\N	Unclear	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
13286	NCT00006195	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
13287	NCT00817154	\N	individually based rehabilitative program versus control group	\N	Unclear	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
13288	NCT00757978	\N	memantine versus Placebo	\N	Brazil	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
13289	NCT00827840	\N	paliperidone ER versus Risperidone	\N	South Korea	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
13290	NCT00825539	\N	AQW051 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
13291	NCT00838032	\N	Quetiapine fumarate versus Haloperidol	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
13292	NCT00806234	\N	Aripiprazole versus second generation Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
13293	NCT00759460	\N	sertindole versus Olanzapine	\N	China	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
13294	NCT00813436	\N	intranasal oxytocin versus Placebo	\N	Israel	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
13295	NCT00816907	\N	metformin + behavioral therapy versus Placebo + behavioral therapy	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
13296	NCT00763841	\N	Transcranial Magnetic Stimulation versus Placebo	\N	Australia	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
13297	NCT00742079	\N	D-cycloserine + Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus Placebo + Cognitive Behavioural Therapy (Cognitive Behavioral Therapy)	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
13298	NCT00802919	\N	carenicline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13303	Lemperiere 1962 a	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13305	Potter 1989 a	\N	Clozapine + Chlorpromazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
13310	Meltzer 2009	\N	Risperidone + buspirone versus Placebo + buspirone	\N	United States of America	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
13311	NCT00197483	\N	pergolide + Risperidone versus Placebo + Risperidone	\N	Japan	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13316	Dencker 1973	\N	fluphenazine decanoate versus pipotiazine	\N	Sweden	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
13318	Acil 2008	\N	aerobic exercise versus control group	\N	Turkey	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13319	Akhapkin 2008	\N	Risperidone//Generic rileptid versus original rispolet	\N	Russia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13320	Shen 2008 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	313	\N	\N	\N	\N	\N
13321	Gold 2007 b	\N	supported employment versus traditional vocational rehabilitation	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13324	Pollard 2008	\N	Rehabilitation therapy versus standard care	\N	Israel	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
13325	Choi 2009 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
13326	Goff 2009 b	\N	sildenafil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
13327	Akhondzadeh 2009 a	\N	ondansetron + Risperidone versus Risperidone + Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13330	Dickerson 2009 d	\N	valacyclovir versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
20479	武翠凤 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
13331	Byerly 2009	\N	Aripiprazole + Risperidone versus Aripiprazole	\N	United States of America	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
13332	Sacco 2009	\N	atomoxetine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
13334	Lysaker 2009	\N	cobnitive behavioral program versus standard support services	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
13335	Mossner 2009	\N	Risperidone versus Haloperidol for schizophrenia whose current state is not described and whose stage of illness is first episode	\N	Germany	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
13337	Cook 2009	\N	standard treatment versus occupational therapy for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	United Kingdom	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
13338	Horan 2009	\N	social cognitive skills training versus control group	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
13340	Moritz 2007 b	\N	metacognitive training versus control group	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13342	Sacks 2008	\N	therapeutic community versus intensive outreach program for serious mental illness whose current state is not described and whose stage of illness is not described with substance abuse	\N	United States of America	\N	\N	\N	\N	\N	314	\N	\N	\N	\N	\N
13343	Duncan 1997	\N	ketamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13344	Sandlund 2008	\N	study circles versus control group	\N	Sweden	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
13345	Pilling 2009	\N	whole team training approach versus dual diagnosis intervention	\N	United Kingdom	\N	\N	\N	\N	\N	159	\N	\N	\N	\N	\N
13346	Cordes 2008 b	\N	weight management program + standard therapy versus standard therapy	\N	Germany	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
13347	Hiller 2007	\N	cognitive Behavioural intervention versus control group	\N	Germany	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
13348	Van Der Gaag 2008	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus treatment as usual	\N	Netherlands	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
13349	Remington	\N	Ziprasidone versus Quetiapine	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
13350	Potter 1989 b	\N	Clozapine + Chlorpromazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
13351	Meszaros 1991	\N	carbamazepine versus Placebo	\N	Austria	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
13352	Potkin 2008 b	\N	Asenapine versus Placebo	\N	United States of America//Russian Federation//Ukraine	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
13353	Mulholland 1998 b	\N	sertraline versus Placebo	\N	Ireland	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
20266	王发兵 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	287	\N	\N	\N	\N	\N
13355	Lohr 1998	\N	vitamin E versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
13359	Schutzwohl 2005 b	\N	day hospital treatment versus inpatient treatment	\N	Germany	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
13362	Waldrop 1961	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
13367	Steadman 2005	\N	jail diversion versus non- diversion of jail	\N	United States of America	\N	\N	\N	\N	\N	1612	\N	\N	\N	\N	\N
13368	Reiter 1987	\N	atenolol versus propranolol	\N	United States of America	\N	\N	\N	\N	\N	7	\N	\N	\N	\N	\N
13370	Weickert 2004	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
13377	Ruiz 1981	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13378	Wirshing 2006 b	\N	Community Re-Entry Program versus Social Independen Living Skills	\N	United States of America	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
13379	Philipp 2002	\N	\N	\N	Germany	\N	\N	\N	\N	\N	153	\N	\N	\N	\N	\N
13381	Patel 1996 b	\N	sulpiride versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13383	Vallina 2001	\N	Integrated Psychological Intervention	\N	Spain	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
13388	Silverstein 2005 b	\N	attention process training versus intensive behavioral rehabilitation	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
13389	Weiden 1999 c	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13390	Ralevski 2006 b	\N	Naltrexone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13391	Tsurumaru 1972	\N	Clocapramine versus Chlorpromazine	\N	Japan	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
13392	Rubin 2005	\N	inpatients psychiatry team with internist versus usual care	\N	United States of America	\N	\N	\N	\N	\N	139	\N	\N	\N	\N	\N
13394	Motlova 2002	\N	Family Psychoeducation	\N	Czech	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n	\N	25	\N	\N	\N	\N	\N
13396	Torres 2002	\N	Occupational Therapy + Psychomotor Skills Training + Social Skills Training versus Occupational Therapy + Psychomotor Skills Training + Social Skills Training + The Train Game	\N	Spain	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
13397	Munetz 1985	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
13398	Moriana 2006	\N	psychosocial skills training versus control group	\N	Spain	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
13401	Perry 2004	\N	Mazindol versus placbo	\N	United States of America	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
13402	Shumway 2005	\N	time tradeoff methods	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13405	Williams 2007	\N	Nicotine Dosage	\N	United States of America	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
13406	Mihara 2001	\N	Bromperidol versus nemonapride	\N	Japan	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
13407	Tohen 2001	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	177	\N	\N	\N	\N	\N
13409	Wunderink 2005	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	131	\N	\N	\N	\N	\N
13412	Venegas 2006	\N	pyridoxine versus Placebo for schizophrenia whose current state is acute and whose stage of illness is not described with tardive dyskinesia	\N	China	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
13415	Smith 2005 e	\N	rapid dose escalation of Quetiapine in 2, 3 days versus rapid dose escalation of Quetiapine in 3, 5 days	\N	United States of America	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
13419	Small 2002	\N	low dose Quetiapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
13420	Yildiz 2003	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
13421	Rubioz 2006	\N	Risperidone versus zuclopenthixol	\N	Unclear	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
13422	Roder 2006	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
13423	Mosher 1974	\N	soteria psychosocial program versus usual treatment	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
13425	Mueser 2005	\N	workplace fundamentals program versus standard care	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
13426	Tsang 2005	\N	compliance therapy versus standard treatment for schizophrenia whose current state is acute and whose stage of illness is not described	\N	China	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
13429	Nair 1998 b	\N	Clozapine versus various dosages	\N	Unclear	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
13430	Tiihonen 2005	\N	\N	\N	Finland	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13431	Sheidow 2004	\N	multisystemic therapy versus inpatient care	\N	United States of America	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
13432	Munnich 1966	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13433	Shoja-Shafti 2006	\N	nortriptyline versus Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
13434	Wykes 2005 b	\N	cognitive remediation therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
13435	Murray 2003	\N	Risperidone versus Ziprasidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13438	Prior 1998	\N	anxiety management course versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
13442	Millar 2008 a	\N	Aripiprazole + Clozapine versus Clozapine + Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	207	\N	\N	\N	\N	\N
13443	Millar 2008 b	\N	Aripiprazole versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
13446	Morozova 2008	\N	Risperidone + Placebo versus Risperidone + neuromidin treatment//Risperidone versus neuromidin treatment//Risperidone versus Placebo	\N	Russia	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
13447	Fraser 2008 b	\N	resilience-based intervention versus control group	\N	Australia	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
13448	DeMarce 2008	\N	continued behavioral care versus standard care	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
13450	Gandelman 2009	\N	Ziprasidone versus fasting	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
13451	Figueroa 2009	\N	extended release Quetiapine fumarate versus immediate release Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
13455	Addington 2009	\N	Ziprasidone versus Risperidone	\N	Canada	\N	\N	\N	\N	\N	139	\N	\N	\N	\N	\N
13456	Vickar 2009	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
13457	Van Orden 2009	\N	collaborative mental health care versus treatment as usual	\N	Netherlands	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
13459	Pioli 2006	\N	rehabilitation for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is persistent // chronic	\N	Italy	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
13461	Krakowski 2008	\N	Clozapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
13462	Takeuchi 2008	\N	medication switching strategy of stopping previous Antipsychotic after 4 weeks of taking it concurrently with Aripiprazole versus medication switching strategy of simultaneous tapering previous Antipsychotic while taking it concurrently with Aripiprazole	\N	Japan	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
13463	Koshino 1983	\N	\N	\N	Japan	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
13465	Evins 2006 e	\N	Bupropion versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13466	Eyler 2005	\N	errorless learning versus standard administration of consent form	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
13467	Kim 2004	\N	Olanzapine versus Risperidone	\N	South Korea	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
13468	Hodel 1996	\N	\N	\N	Switzerland	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
13469	Greenspan 2005 b	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	382	\N	\N	\N	\N	\N
13473	Harvey 2005 c	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	673	\N	\N	\N	\N	\N
13475	Kallert 2007	\N	\N	\N	Germany	\N	\N	\N	\N	\N	191	\N	\N	\N	\N	\N
13477	Kallert 2005 b	\N	day treatment versus inpatient treatment	\N	Germany	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
13478	Koshino 1979	\N	\N	\N	Japan	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
13480	Ko 2006 b	\N	hormone replacement therapy versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
13481	Lee 2008 d	\N	Risperidone versus Haloperidol	\N	Taiwan	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
13482	Erickson 2005	\N	donepezil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
13488	Evins 2005 b	\N	Bupropion versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
13489	Lane 2001 b	\N	grapefruit juice + Clozapine versus ketoconazole + Clozapine	\N	Taiwan//United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
13490	Kumar 2003	\N	\N	\N	Italy	\N	\N	\N	\N	\N	980	\N	\N	\N	\N	\N
13492	Goncalves 1973	\N	\N	\N	Brazil	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13493	Kudoh 2003	\N	epidural anethiesia versus no epidural anethesia	\N	Japan	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
13542	Crespo-Facorro 2008	\N	Risperidone versus Olanzapine versus Haloperidol for schizophrenia or//and schizophreniform whose current state is not described and whose stage of illness is first episode	\N	Spain	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
13543	Silverstein 2009	\N	Basic Conversation Skills Module (BCSM) with attention shaping versus BCSM in standard format	\N	United States of America	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
13544	de Oliveira 2009	\N	Aripiprazole versus Haloperidol	\N	Brazil	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
13545	Baptista 2009 a	\N	rosiglitazone + Olanzapine versus Olanzapine + Placebo	\N	Venezuela	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13546	Farhall 2009	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	Australia	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
13549	Eklund 2008	\N	Standard assessment occupational therapy versus Activity based assessment//occupational therapy	\N	Sweden	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
13550	Bagati 2009	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) treatment + Antipsychotics versus Antipsychotics	\N	India	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13551	Chan 2009	\N	psychoeducation intervention versus control group	\N	Hong Kong	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
13553	Riedel 2009	\N	Amisulpride versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
13554	Wiersma 2009	\N	routine outcome measurement versus control group for serious mental illness whose current state is not described and whose stage of illness is not described	\N	Germany//Netherlands//Sweden//Switzerland//Spain//United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	320	\N	\N	\N	\N	\N
13555	Lieberman 2009 c	\N	memantine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	138	\N	\N	\N	\N	\N
13556	Dickerson 2009 e	\N	allopurinol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
13557	Casey 2009	\N	divalproex ER + Olanzapine versus divalproex ER + Risperidone	\N	United States of America	\N	\N	\N	\N	\N	402	\N	\N	\N	\N	\N
13558	Penn 2009 a	\N	group Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus enhanced supportive thearpy	\N	United States of America	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
13560	Harris 2009	\N	medication management training program versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
13561	Potkin 2008 c	\N	iloperidone versus Placebo//Risperidone versus Placebo//Haloperidol versus Placebo//Risperidone versus iloperidone//Haloperidol versus iloperidone	\N	United States of America	\N	\N	\N	\N	\N	616	\N	\N	\N	\N	\N
13562	Kurt 2007	\N	\N	\N	Turkey	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
13565	Uzenoff 2007	\N	adherence-coping-education (ACE) versus supportive counseling	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
13568	Crespo Iglesias 2006	\N	telephoned group versus control group//Prompts to encourage appointment attendance	\N	Spain	\N	\N	\N	\N	\N	214	\N	\N	\N	\N	\N
13569	Germana 1990	\N	Bromperidol versus Haloperidol	\N	Italy	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
13572	Tang 2003 b	\N	Electroacupuncture + Antipsychotic medication versus Antipsychotic medication	\N	Hong Kong	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13573	Gangadhar 2000	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) versus BLElectroconvulsive Therapy	\N	India	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13575	Szmukler 2003 a	\N	carers' support programme versus standard treatment	\N	United Kingdom	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
13576	Garety 2000 b	\N	intensive assertive outreach team versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13577	Nahunek 1970 b	\N	flupenthixol versus perphenazine	\N	Czech Republic	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
13578	Bertensen 2009	\N	psychosocial integrated treatment versus standard care	\N	Denmark	\N	\N	\N	\N	\N	547	\N	\N	\N	\N	\N
13579	Mathew 2009	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	302	\N	\N	\N	\N	\N
13601	Karagianis 2009 a	\N	oral Olanzapine versus Placebo	\N	Canada//United States of America	\N	\N	\N	\N	\N	931	\N	\N	\N	\N	\N
13602	Sharifi 2009	\N	home aftercare service versus standard care	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
13603	Kwon 2009	\N	sertindole versus Olanzapine	\N	China//South KoreaTaiwan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13604	Fawzi 2009	\N	Aripiprazole versus Olanzapine + clomipramine	\N	Egypt	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
13605	McDonnell 2009 a	\N	Olanzapine versus Placebo	\N	France//United States of America	\N	\N	\N	\N	\N	404	\N	\N	\N	\N	\N
13606	Montes 2009	\N	monthly nurse telephone followup versus standard clinical followup//prompts	\N	Spain	\N	\N	\N	\N	\N	928	\N	\N	\N	\N	\N
20480	朱蔼 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
13607	Katz 2009	\N	occupational goal intervention versus control group	\N	Israel	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
13610	Sacchetti 2009 a	\N	Ziprasidone versus Clozapine	\N	Italy	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
13611	Klingberg 2009 a	\N	psychological intervention versus control group	\N	Germany	\N	\N	\N	\N	\N	111	\N	\N	\N	\N	\N
13612	Erinfolami 2009	\N	Risperidone versus Haloperidol	\N	Nigeria	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
13613	Fleischhacker 2009b	\N	Aripiprazole + Clozapine versus Clozapine + Placebo	\N	Austria//Finland//France	\N	\N	\N	\N	\N	207	\N	\N	\N	\N	\N
13614	Wirshing 2009	\N	behavioural weight loss program versus standard care	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
13617	Piegari 2009	\N	cognitive training program versus social skills training program	\N	Italy	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
13618	Gigantesco 2009	\N	skills assessment and definition of goals + standard care versus standard care	\N	Italy	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
13619	Burns 2009 a	\N	individual placement and support versus standard services	\N	United Kingdom	\N	\N	\N	\N	\N	302	\N	\N	\N	\N	\N
13621	Zahn 1993	\N	Fluphenazine versus Placebo//Clozapine versus Fluphenazine//Fluphenazine versus Clozapine	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
13623	Morrison 2008	\N	cognitive therapy versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	320	\N	\N	\N	\N	\N
13635	Haddock 2009	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus social activity therapy	\N	United Kingdom	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
13637	Drebing 2007	\N	contingency management vocational rehabilitation versus vocational rehabilitation	\N	United States of America	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
14255	Zhang Jing 2008	\N	Family intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14256	Zhang Jie 2007	\N	Nursing intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14257	Zhang Jin 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14258	Zhang Jin 2008-1	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14259	Zhang RenKai 2008	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
14260	Zhang RenKai 2008-1	\N	Clozapine + Paroxetine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14261	Zhang Rong 2008	\N	Quetiapine (Shusi) versus Quetiapine (Seroquel)	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14262	Zhang RuiXia 2007	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
14263	Zhang ShaoLi 2008	\N	Modified Electro Convulsive Therapy (MElectroconvulsive Therapy) versus Risperidone + Clonazepam	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14264	Zhang ShengLi 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
14265	Zhang ShuJie 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14266	Zhang WenMin 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
14267	Zhang Yi 2008	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
14268	Zhang XinJun 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
14269	Zhang XiaoYan 2007	\N	Family intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
14270	Zhang XiaoLing 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
14271	Zhang 2008a	\N	Magnesium Valproate + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14272	Zhang 2008	\N	Quetiapine + Clonazepam versus Haloperidol	\N	China	\N	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
14273	Zhang YiZhong 2007	\N	Cerebroprotein Hydrolysate For Injection versus Piracetam	\N	China	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
14274	Zhang YongShui 2008	\N	Haloperidol decanoate versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14275	Zhang YueKun 2008	\N	Olanzapine + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
14276	Zhang YuMei 2008	\N	Encouragement nursing + Routine Antipsychotic medcation versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14277	Zhang ZhanChou 2008	\N	Health education for family members + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	157	\N	\N	\N	\N	\N
15194	汪周兵 2009	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15196	温广妹 2009	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15200	王相立 2009	\N	Metformin + Lifestyle Intervention versus Lifestyle Intervention	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15201	王秀丽 2009	\N	Aripiprazole versus Chlorpromazine	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15202	王茂萍 2009	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15204	田梅 2009	\N	Mental health education versus No mental health education	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15205	田红梅 2009	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + standard care versus standard care//Cognitive function training + conventional training versus Conventional training	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15208	皇甫丽 2009	\N	Ziprasidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15209	程均 2009	\N	Ziprasidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15210	程平 2009 a	\N	Ziprasidone versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15217	罗来兴 2009 b	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15220	肖勃 2009	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15221	肖攀攀 2009	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15222	肖敏 2009	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15223	苏京利 2009	\N	Community based rehabilitation versus standard care	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15225	莫春娥 2009	\N	Health education + Antipsychotic medication versus Antipsychotic medication + standard care	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15227	董汉振 2009	\N	Modified morita therapy + Routine Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15230	蔡云帆 2009	\N	Skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
15231	蔡进伟 2009	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15235	覃松 2009	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15238	许玉梅 2009	\N	Clozapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15240	谢红武 2009	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15241	谭会 2009	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15243	赵侠 2009	\N	Risperidone, imported versus Risperidone, domestic	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16535	Yue 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	3000	\N	\N	\N	\N	\N
16536	ISRCTN50487713	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
16548	MO2-547	\N	depakote ER + Olanzapine or Risperidone versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	402	\N	\N	\N	\N	\N
16555	Newcomer 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
16563	Valencia 2010	\N	\N	\N	Mexico	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
16566	Anderson 2010	\N	adherence therapy versus standard treatment for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	Multicentre//United States of America//United Kingdom	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
16853	Gafoor 2010 a	\N	Risperidone versus Quetiapine	\N	United Kingdom	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
16569	NCT01157351	\N	\N	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 9\r\n	\N	442	\N	\N	\N	\N	\N
16573	NCT01136772	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
16575	NCT01149655	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	340	\N	\N	\N	\N	\N
16576	NCT01129674	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	1210	\N	\N	\N	\N	\N
16587	NCT01143077	\N	Lurasidone Dosage	\N	United States of America	\N	\N	\N	\N	\N	244	\N	\N	\N	\N	\N
16588	NCT01125358	\N	\N	\N	Japan	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
16595	NCT01192880	\N	Bitopertin Dosage // Bitopertin versus Placebo	\N	\N	\N	\N	\N	\N	\N	630	\N	\N	\N	\N	\N
16597	NCT01116830	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
16601	NCT01193153	\N	\N	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 9\r\n	\N	520	\N	\N	\N	\N	\N
16602	NCT01122927	\N	Aripiprazole Dosage	\N	United States of America	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
16606	NCT01189006	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	161	\N	\N	\N	\N	\N
16608	Weiner 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
16612	NCT01175135	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
16621	NCT01173874	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
16622	NCT01164059	\N	\N	\N	Germany	\N	\N	\N	\N	\N	630	\N	\N	\N	\N	\N
16626	NCT01139502	\N	\N	\N	Norway	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
16627	NCT01175642	\N	\N	\N	Canada	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
16628	Pinninti 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
16632	NCT01213836	\N	seroquel XR versus seroquel IR	\N	Multicentre//Austria//Germany//Italy//Spain	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	90	\N	\N	\N	\N	\N
16635	Poletti 2010	\N	\N	\N	Italy	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
16644	NCT01163227	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
16667	NCT00845507	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
16669	NCT01167556	\N	\N	\N	Netherland	\N	\N	\N	\N	\N	147	\N	\N	\N	\N	\N
16670	NCT01190254	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
16681	NCT01172106	\N	\N	\N	Uganda	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
16695	NCT01142596	\N	\N	\N	Japan	\N	\N	\N	\N	\N	264	\N	\N	\N	\N	\N
16700	NCT00682448	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
16701	NCT01206153	\N	metformin versus Placebo	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
16702	NCT01192594	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
16703	NCT01133080	\N	\N	\N	Israel	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
16704	Terevnikov 2010	\N	mirtazapine versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is partial remission and whose stage of illness is not described	\N	Multicentre//Russia//Finland	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	41	\N	\N	\N	\N	\N
16705	NCT01196286	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
16710	NCT01202357	\N	\N	\N	Hong Kong	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
16715	NCT01133587	\N	\N	\N	Norway	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
16722	NCT00728728	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
16729	Thyssen 2010	\N	Risperidone long acting injection for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Belgium	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
16737	NCT01214005	\N	smoking abstinence versus smoking	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
16744	NCT00086593	\N	\N	\N	Multicentre//United States of America//Canada//United Kingdom	\N	\N	\N	\N	\N	210	\N	\N	\N	\N	\N
16747	NCT01169142	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
16748	NCT00669903	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
16755	NCT01207414	\N	iloperidone versus Aripiprazole	\N	United States of America	\N	\N	\N	\N	\N	500	\N	\N	\N	\N	\N
16759	NCT01137799	\N	JNJ-39393406 versus Placebo	\N	Germany	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n	\N	39	\N	\N	\N	\N	\N
16760	NCT01165294	\N	\N	\N	Belgium	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
16761	NCT01186471	\N	\N	\N	Belgium	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
16762	NCT01167348	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
16765	NCT01139099	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
16770	NCT01119014	\N	\N	\N	Denmark	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 9\r\n	\N	300	\N	\N	\N	\N	\N
16772	NCT01176721	\N	\N	\N	Germany	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
16775	ISRCTN11501328	\N	Joint Crisis Plans	\N	UK	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n	\N	\N	\N	\N	\N	\N	\N
16780	NCT01207219	\N	Yoga Therapy versus Waitlist // Aerobic Exercise versus Yoga Therapy // Aerobic Exercise versus Waitlist	\N	Hong Kong, China	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	120	\N	\N	\N	\N	\N
16782	NCT01161277	\N	Aripiprazole versus Placebo//Haloperidol versus Placebo//Haloperidol versus Aripiprazole	\N	Norway	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
16784	Zuardi 1983	\N	Haloperidol Decanoate versus Oral Haloperidol	\N	Brazil	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
16786	Kong 2001	\N	Sulpiride Dosage	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
16796	Lin 2010	\N	Risperidone versus Risperidone + Haloperidol for schizophrenia whose current state is acute and whose stage of illness is persistent // chronic with negative symptoms	\N	Taiwan	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
16797	Pandina 2010 c	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	1220	\N	\N	\N	\N	\N
16799	Dulude 2010	\N	nicotine versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic	\N	Canada	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
16800	Feifel 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
16804	Brown 2010	\N	stimulation versus no intervention versus filmed contact for schizophrenia whose current state is partial remission and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	143	\N	\N	\N	\N	\N
16805	Karagianis 2010	\N	Olanzapine orally distintegrating + Placebo versus standard Olanzapine tablet + Placebos for schizophrenia or//and psychotic whose current state is partial remission and whose stage of illness is not described with weight gain	\N	Multicentre//Canada//United Sates of America//Mexico//Netherlands	\N	\N	\N	\N	\N	149	\N	\N	\N	\N	\N
16808	Fijal 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
16824	Morrison 2009	\N	cognitive therapy + mental state monitoring versus mental state monitoring for psychotic whose current state is not described and whose stage of illness is not described	\N	United Kingdom	\N	\N	\N	\N	\N	288	\N	\N	\N	\N	\N
16828	Fiszdon 2010	\N	cognitive remediation therapy (crt) versus standard treatment for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is persistent // chronic	\N	United States of America	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
16834	Wittorf 2010	\N	cognitive behavioral therapy (cbt) versus supportive therapy for schizophrenia or//and schizophreniform whose current state is not described and whose stage of illness is persistent // chronic with positive symptoms	\N	Germany	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
16845	Fleischhacker 2010	\N	 for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic with weight gain	\N	Multicentre//Austria//France//Belgium//Finland//United States of America//South Africa	\N	\N	\N	\N	\N	207	\N	\N	\N	\N	\N
16847	Lee 2010 c	\N	Aripiprazole versus non Aripiprazole group for schizophrenia or//and schizoaffective disorders whose current state is partial remission and whose stage of illness is persistent // chronic	\N	South Korea	\N	\N	\N	\N	\N	292	\N	\N	\N	\N	\N
16854	Carpenter-Song 2010	\N	vocational rehabilitation versus psychosocial rehabilitation versus individual placement and support for serious mental illness whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	204	\N	\N	\N	\N	\N
16857	Penadas 2010	\N	cognitive behavioral therapy (cbt) versus cognitive remediation therapy (crt) for schizophrenia whose current state is not described and whose stage of illness is not described with negative symptoms	\N	Spain	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
16873	Feifel 2010 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
16882	Stryjer 2010	\N	trazodone versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is not described with akathisia	\N	Israel	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
16892	Villeneuve 2010 a	\N	\N	\N	Canada	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
16903	Wilder 2010	\N	medication preference versus prescribed medication for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described//Advance treatment directives	\N	United States of America	\N	\N	\N	\N	\N	469	\N	\N	\N	\N	\N
16906	Bakali 2009	\N	Group Psychotherapy Duration	\N	Norway	\N	\N	\N	\N	\N	167	\N	\N	\N	\N	\N
16913	Giakoumaki 2010 a	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
16915	Woltmann 2010	\N	Shared Decision Making versus Treatment as Usual	\N	United States of America	\N	\N	\N	\N	\N	Not Reported	\N	\N	\N	\N	\N
16919	Thomas 2010	\N	\N	\N	Multicentre//United Kingdom//France//Belgium//Netherlands//Denmark//Italy	\N	\N	\N	\N	\N	9895	\N	\N	\N	\N	\N
13682	Breier 2005	\N	Olanzapine versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	548	\N	\N	\N	\N	\N
20267	祝敬溪 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
16926	Ascher-Svanum 2010	\N	Risperidone versus Olanzapine for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is persistent // chronic	\N	Multicentre//United States of America//Russia//Brazil	\N	\N	\N	\N	\N	596	\N	\N	\N	\N	\N
16937	Canuso 2010 d	\N	paliperidone extended release versus Placebo for schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	Multicentre//United States of America//Romania//India//Philippines//Malaysia//South Korea	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
16939	Pedersen 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
16945	Tsai 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
16948	Savitz 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
16957	Simpson 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
16958	Pandina 2010 d	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	1220	\N	\N	\N	\N	\N
16959	Harvey 2010	\N	Lurasidone Dosage	\N	Japan	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
16960	Barak 2010	\N	\N	\N	State of Israel	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
16961	Gulliver 2010 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	318	\N	\N	\N	\N	\N
16962	Kern 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	636	\N	\N	\N	\N	\N
13639	Zhang 2009b	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
13640	Weaver 2009	\N	Integrated care versus treatment as usual//	\N	United States of America	\N	\N	\N	\N	\N	431	\N	\N	\N	\N	\N
13641	Tsang 2009	\N	integrated supported employment versus traditional vocational rehabilitation	\N	Hong Kong	\N	\N	\N	\N	\N	163	\N	\N	\N	\N	\N
13642	Sacchetti 2009 b	\N	Ziprasidone versus Clozapine	\N	Italy	\N	\N	\N	\N	\N	147	\N	\N	\N	\N	\N
13644	McGurk 2009	\N	cognitive remediation + vocational rehabilitation versus vocational rehabilitation	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
13645	Marzolini 2009	\N	group based risistance and aerobic program versus usual care	\N	United States of America	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
13646	Lecardeur 2009	\N	cognitive remediation therapy versus control group	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13650	Barbie 2009	\N	recovery workbook training + standard care versus standard care	\N	Canada	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
13651	Arango 2009	\N	Quetiapine versus Olanzapine	\N	Spain	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
13653	Kukla 2009	\N	individual placement and support versus diversified placement approach	\N	United States of America	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
13654	Gutierrez 2009	\N	psychoeducation intervention versus control group	\N	Chile	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
13656	Conley 2009 b	\N	galantamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
13657	Chabannes 2009	\N	psychoeducation program + Amisulpride versus control group + Amisulpride	\N	France	\N	\N	\N	\N	\N	220	\N	\N	\N	\N	\N
13660	Fang 2003 b	\N	Early intervention + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
13666	NCT00864045	\N	sertindole versus Olanzapine	\N	Sweden	\N	\N	\N	\N	\N	394	\N	\N	\N	\N	\N
13667	NCT00876304	\N	PS-04802540 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13668	NCT00864825	\N	\N	\N	Israel	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
13669	NCT00848432	\N	Risperidone versus various doses	\N	China	\N	\N	\N	\N	\N	404	\N	\N	\N	\N	\N
13670	NCT00859872	\N	Risperidone + clonazepam versus Haloperidol	\N	China	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
13671	NCT00857818	\N	Aripiprazole versus Quetiapine	\N	Denmark	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
13672	NCT00847600	\N	pregnenolone versus Placebo	\N	Israel	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13673	NCT00870909	\N	transcranial direct current stimulation versus sham transcranial direct current stimulation	\N	France//Tunisia	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13674	NCT00856583	\N	sertindole versus Risperidone	\N	Sweden	\N	\N	\N	\N	\N	9858	\N	\N	\N	\N	\N
13675	NCT00861796	\N	CYR-101 versus Placebo	\N	France	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
13676	NCT00866645	\N	IM levosulpiride versus Haloperidol	\N	China	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
13677	NCT00862992	\N	cariprazine versus various dosages	\N	Japan	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13678	NCT00875498	\N	intermittent theta burst stimulation versus Placebo	\N	France	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
13679	NCT00848484	\N	MK5757 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
13680	EUFEST	\N	Amisulpride versus Haloperidol//Olanzapine versus Haloperidol//Quetiapine versus Haloperidol//Ziprasidone versus Haloperidol Amisulpride versus Haloperidol	\N	Israel//Netherlands//Germany//European countries//United Kingdom//Switzerland//Poland and Austria	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	498	\N	\N	\N	\N	\N
13681	Xie 2003 c	\N	Medication management skill training + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20268	刘桂芳 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13683	Tao 2006 b	\N	behavioural therapy + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	206	\N	\N	\N	\N	\N
13684	Cao 2006 d	\N	Chlorpromazine versus Olanzapine	\N	China	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
13685	Korr 1995	\N	assertive case management program versus routine services	\N	United States of America	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
13687	Gulcur 2007	\N	community integration model versus services as usual	\N	United States of America	\N	\N	\N	\N	\N	225	\N	\N	\N	\N	\N
13689	Gulcur 2003	\N	experimental housing program versus continuum of care control program	\N	United States of America	\N	\N	\N	\N	\N	225	\N	\N	\N	\N	\N
13690	Dixon 1997	\N	assertive community treatment versus standard care	\N	United States of America	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
13691	Obenchain 1999	\N	Olanzapine versus Haloperidol	\N	Multinational	\N	\N	\N	\N	\N	1996	\N	\N	\N	\N	\N
13699	Meyer 2002	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13706	Tohen 2000 c	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13708	Hong 2001	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
13710	Kinon 2002 b	\N	Olanzapine versus conventional Antipsychotic or Risperidone	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
13711	Kinon 2001 a	\N	Olanzapine versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
13717	Remington 2009 a	\N	Aripiprazole versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
13718	Lauber 2009	\N	individual placement and support + standard care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
13719	Lambert 2009	\N	Olanzapine versus Aripiprazole	\N	Australia	\N	\N	\N	\N	\N	173	\N	\N	\N	\N	\N
13720	Durham 2009	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	301	\N	\N	\N	\N	\N
13721	Crespo-Facorro 2009a	\N	transdermal oestradiol versus transdermal Placebo	\N	Australia	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
13725	Rogers 2007	\N	consumer-operated service program versus control group	\N	United States of America	\N	\N	\N	\N	\N	1827	\N	\N	\N	\N	\N
13726	Okugawa 2009	\N	perospirone versus Risperidone	\N	Japan	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
13727	Newcomer 2009	\N	Olanzapine versus Ziprasidone	\N	Unclear	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
13728	Kulhara 2009	\N	pyschoeducational program versus standard care	\N	India	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
13732	Henderson 2009	\N	Clozapine+Rosiglitazone versus Clozapine+Placebo // Rosiglitazone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
13734	Avital 2009	\N	zolmitriptan versus propranolol	\N	Israel	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
13735	Algul 2009	\N	propofol + remifentanil versus propofol	\N	Turkey	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
13736	Potkin 2003 d	\N	Haloperidol dose//Iloperidone dose//Risperidone dose//Haloperidol versus Placebo//Iloperidone versus Placebo//Risperidone versus Placebo//Haloperidol versus Iloperidone//Haloperidol versus Risperidone//Risperidone versus Iloperidone	\N	United States of America	\N	\N	\N	\N	\N	706	\N	\N	\N	\N	\N
13739	Dai 2006 b	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
13740	Chen 2005 j	\N	Social skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
13741	Gao 2005 d	\N	Health education + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
13742	Zhao 2004 b	\N	Nursing intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
13743	Zhao 2006 d	\N	Olanzapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
13744	Li 2006 aa	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
13752	Demily 2009	\N	Game of Chess versus Treatment As Usual	\N	France	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
13757	Cleton 2007	\N	paliperidone extended release versus Placebo	\N	Belgium	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
13759	Su 2000	\N	Sulpiride versus Haloperidol	\N	Taiwan	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
13760	Miller 2001 a	\N	Risperidone versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
13761	ACTRN12608000188336	\N	CD ROM learning versus printed manual learning	\N	Australia	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
13762	ACTRN12608000475347	\N	Omega-3 Fatty Acid versus Placebo	\N	Australia	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	320	\N	\N	\N	\N	\N
13763	NCT00884897	\N	oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13764	NCT00882518	\N	\N	\N	China	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
13765	NCT00878462	\N	unflavored Asenapine versus raspberry Asenapine	\N	United States of America	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
13766	Weickert 2008	\N	\N	\N	Australia	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
13767	Swadi 2003	\N	seroquel versus Risperidone	\N	New Zealand	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13812	NCT00893256	\N	citalopram + Risperidone versus Placebo + Risperidone	\N	India	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
20269	赵蓓 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
13768	Startup 2006 b	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus Non-DirElectro Convulsive Therapy (Electroconvulsive Therapy)ive ReflElectro Convulsive Therapy (Electroconvulsive Therapy)ive Listening	\N	Australia	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
13769	Guastella 2009	\N	oxytocin versus Placebo	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13771	ACTRN12608000472370	\N	group music therapy versus control group	\N	Australia	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
13772	NCT00892528	\N	RGH-188 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	675	\N	\N	\N	\N	\N
13773	NCT00892021	\N	NSA-789 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
13774	NCT00940394	\N	\N	\N	Hong Kong	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
13775	NCT00885716	\N	Cognitive Training versus Shared Decision Making	\N	Germany	\N	\N	\N	\r\nUser defined field 10\r\n	\N	80	\N	\N	\N	\N	\N
13777	Moore 2006	\N	Aripiprazole versus Atypical Antipsychotics	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13778	McGorry 2000 b	\N	psychological treatment + Risperidone versus psychological treatment + Placebo	\N	Australia	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
13779	NCT00929370	\N	GSK1018921 versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
13780	NCT00914238	\N	extended specialized assertive intervention versus standard care	\N	Denmark	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
13783	NCT00917293	\N	avastrem versus Placebo	\N	Canada	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
13784	NCT00924976	\N	educational intervention versus standard care	\N	United States of America	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
13785	NCT00937261	\N	Risperidone versus paliperidone	\N	United States of America	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
13786	NCT00936351	\N	Mindfulness Meditation versus Support Program	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13787	NCT00934908	\N	green tea versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
13789	NCT00932529	\N	Olanzapine versus Ziprasidone	\N	Norway	\N	\N	\N	\N	\N	226	\N	\N	\N	\N	\N
13790	NCT00930150	\N	Cognitive Training (Brain Fitness) (Computerized) versus Games (Computer)	\N	United States of America	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
13791	NCT00919607	\N	\N	\N	China	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
13792	NCT00926965	\N	Amisulpride versus conventional Antipsychotics	\N	Taiwan	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
13793	NCT00919620	\N	Case Management + Treatment As Usual versus Treatment As Usual // Time of Administration - Early Intervention	\N	China	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	500	\N	\N	\N	\N	\N
13794	NCT00923078	\N	cognitive training program versus control group	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13795	NCT00922272	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
13796	NCT00921804	\N	AZD8529 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
13797	NCT00905307	\N	OPC-34712 versus Placebo	\N	India	\N	\N	\N	\N	\N	450	\N	\N	\N	\N	\N
13798	Harris 2003	\N	cognitive remediation versus control group	\N	Australia	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
13799	ACTRN12605000267651	\N	Omega-3 Fatty Acid versus Placebo	\N	Australia	\N	\N	\N	\r\nNotes2\r\nethyl-eicosapentaenoic acid versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is first episode	\N	80	\N	\N	\N	\N	\N
13800	NCT00929955	\N	\N	\N	Pakistan	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
13801	Killackey 2005	\N	vocational rehabilitation versus control group	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13802	ACTRN12609000421235	\N	Omega-3 Fatty Acid versus Placebo	\N	Australia	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
13803	Castle 2008	\N	risperdal consta + psychoeducational therapy versus risperdal consta	\N	Australia	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14105	Luo Xin 2008	\N	Quetiapine versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
13804	ACTRN12605000594628	\N	Cognitive Analytic Therapy + Treatment as Usual versus Treatment as Usual	\N	Australia	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
13805	Croft 2009	\N	glycine + Antipsychotics versus Placebo + Antipsychotics	\N	Australia	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
13806	Dodd 2004	\N	mitazapine + Atypical Antipsychotic treatment versus Placebo + Atypical Antipsychotic treatment	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13807	Farhall 2001	\N	recovery therapy versus control group	\N	Australia	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
13808	ACTRN12608000210370	\N	acceptance and commitment therapy versus control group Acceptance and Commitment Therapy versus Befriending	\N	Australia	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	106	\N	\N	\N	\N	\N
13809	NCT00888693	\N	ABT-288 Dosage // ABT-288 versus Placebo	\N	United States of America	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	81	\N	\N	\N	\N	\N
13810	NCT00895258	\N	cognitive training versus enhanced support	\N	United States of America	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
20270	卓子禄 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
13813	Francey 2007	\N	psychosocial treamtment + Antipsychotics versus psychosocial treamtment + Placebo	\N	Australia	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
13814	NCT00885690	\N	sertindole versus Olanzapine	\N	Denmark//Sweden	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
13815	ACTRN12609000064202	\N	problem solving based Bibliotherapy via a self help manual versus standard care Bibliotherapy Bibliotherapy Bibliotherapy Bibliotherapy Bibliotherapy Individual placement support + treatment as usual versus treatment as usual Bibliotherapy	\N	Australia	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 10\r\n	\N	124	\N	\N	\N	\N	\N
13816	NCT00894842	\N	\N	\N	Singapore	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
13817	Jorm 2008 b	\N	first aid training versus no treatment	\N	Australia	\N	\N	\N	\N	\N	540	\N	\N	\N	\N	\N
13818	Killackey 2008 b	\N	individual placement and support + standard care versus standard care	\N	Australia	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	360	\N	\N	\N	\N	\N
13819	Berk 2002 b	\N	N-acetyl cysteine + standard careversus Placebo	\N	Australia	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
13820	NCT00918021	\N	Olanzapine + Clozapine versus Placebo + Clozapine	\N	Finland	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13821	Arvanitis 1993	\N	seroquel versus various dosages	\N	United States of America//Canada	\N	\N	\N	\N	\N	301	\N	\N	\N	\N	\N
13822	Chiesa 2009	\N	\N	\N	Italy	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
13823	Smith 2009 a	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13824	Pappa 2009	\N	Amantadine versus Placebo	\N	Greece	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	22	\N	\N	\N	\N	\N
13825	Bush 2009	\N	N-acetyl cysteine + standard careversus Placebo + standard therapy	\N	Australia	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
13826	Abdollahian 2009	\N	selegiline + Clozapine versus selegiline + Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
13827	Yoon 2009 b	\N	\N	\N	South Korea	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
13828	Chesnoy 2009	\N	\N	\N	France	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
13829	Lehrer 2009	\N	Aripiprazole versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13832	McDonnell 2009 b	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	931	\N	\N	\N	\N	\N
13833	Rubio 2009	\N	Amisulpride versus zuclopenthixol	\N	Spain	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
13834	Cazorla 2009	\N	Asenapine versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	349	\N	\N	\N	\N	\N
13835	Pajonk 2009	\N	cycle ergometry versus tabletop football	\N	Germany	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
13836	Haznedar 2009	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
13837	Hazlett 2009	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
13838	Muller 2009 c	\N	COX-2 versus Placebo	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13839	Wykes 2009 a	\N	cognitive remediation therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13840	Maples 2009	\N	cognitive adaptive training versus standard care	\N	United States of America	\N	\N	\N	\N	\N	245	\N	\N	\N	\N	\N
13841	Brecher 2006	\N	Quetiapine versus Placebo	\N	United States of America//Canada	\N	\N	\N	\N	\N	532	\N	\N	\N	\N	\N
13843	Reinke 2004	\N	Contact Methods	\N	United States of America	\N	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
13844	Newcomer 1999 c	\N	anhydrous dextrose + sodium saccharin versus saccharin	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
13845	Nieves 2002	\N	assertive community treatment model versus control group	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13846	Niznikiewicz 2005	\N	Clozapine versus Chlorpromazine	\N	United States of America	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
13847	O'Brien 2003	\N	vocational training versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
13851	Penn 2002	\N	viewing a video of a person with schizophrenia twice	\N	United States of America	\N	\N	\N	\N	\N	215	\N	\N	\N	\N	\N
13853	Pope 2005	\N	Errorless Learning versus Symptom Management Training	\N	United States of America	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
13854	Postel 1971	\N	\N	\N	France	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13855	Postma 2006 a	\N	nicotine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
13856	Poyurovsky 2003 d	\N	mianserin versus Placebo	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13859	Zipursky 2005 c	\N	\N	\N	Canada	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
13860	Lerner 2007 e	\N	Vitamin B6 versus Placebo	\N	Israel	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
13864	Luengo 2002	\N	cancellation listening task versus dichotic listening task	\N	Spain	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
13868	Reza 2004	\N	pyschoeducational group versus control group	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	244	\N	\N	\N	\N	\N
14024	Dickerson 2009 f	\N	azithromycin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
13869	McDonell 2005 b	\N	Cognitive therapy versus standard care//Intensive case management//Assetive community treatment	\N	United States of America	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
13870	McDonell 2007	\N	multiple family group treatment versus standard care	\N	United States of America	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
13872	Meltzer 2005 e	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
13879	Tanabe 2006	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
13881	Twamley 2005	\N	supported employment (Individual Placement Support) versus Conventional vocational Rehabilitation	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
13885	Sramek 2003	\N	Olanzapine versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	183	\N	\N	\N	\N	\N
13886	Voss 2003	\N	Multi-Family Group	\N	United States of America	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
13887	Wells 2003	\N	Interventions for smoking cessation	\N	United States of America	\N	\N	\N	\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	145	\N	\N	\N	\N	\N
13888	Wolwer 2005	\N	tackling affect recognition versus standard care 	\N	Germany	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
13889	Woods 2004 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
13893	Risch 2006	\N	donepezil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
13898	Stengard 2003	\N	oral educational intervention versus video educational intervention	\N	Finland	\N	\N	\N	\N	\N	197	\N	\N	\N	\N	\N
13899	Schmidt 2006	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	142	\N	\N	\N	\N	\N
13901	Shahar 2006	\N	Consumer Partner versus Non-Consumer Partner	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14099	Sarita 1998	\N	 for schizophrenia whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
13907	Schimmelmann 2005	\N	Amisulpride versus Olanzapine // Amisulpride versus Risperidone // Amisulpride versus Zotepine // Olanzapine versus Risperidone // Olanzapine versus Zotepine // Risperidone versus Zotepine	\N	Germany	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
13911	Castiello 2007	\N	schizophrenic group versus depression group	\N	Italy	\N	\N	\N	\N	\N	445	\N	\N	\N	\N	\N
13912	Chengappa 2007	\N	dosage of drug + versus topiramate versus Placebo for schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
13914	Chung 2005	\N	antistigma seminar versus control group	\N	Hong Kong	\N	\N	\N	\N	\N	166	\N	\N	\N	\N	\N
13915	Collie 2006	\N	Clozapine versus Olanzapine	\N	Australia	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
13916	Bressi 2004	\N	\N	\N	Italy	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13918	Cook 2005 b	\N	supported employment intervention versus standard care	\N	United States of America	\N	\N	\N	\N	\N	1648	\N	\N	\N	\N	\N
13923	Chung 2004	\N	antistigma seminar versus control group	\N	Hong Kong	\N	\N	\N	\N	\N	314	\N	\N	\N	\N	\N
13924	Bellack 2005 b	\N	computer assisted cognitive remediation program versus control group	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
13927	Arato 2002	\N	Ziprasidone versus Placebo	\N	Hungary//United States of America	\N	\N	\N	\N	\N	294	\N	\N	\N	\N	\N
13929	Bai 2006 c	\N	long-acting injectable Risperidone versus Risperidone oral tablets	\N	Taiwan	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
13935	Birchwood 2006	\N	cognitive therapy versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
13936	Boulay 2004 b	\N	Haloperidol versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
13937	Broerse 2002	\N	Olanzapine versus Risperidone	\N	Netherlands	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
13938	Bechdolf 2005 d	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus clinical management + Amisulpride	\N	Germany	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
13939	Kisely 2006	\N	Anti-Smoking Programme	\N	Australia	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
13942	Hitsman 2003	\N	tryptophan-depleting mixture versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
13944	Hoptman 2006	\N	Clozapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
13946	Huang 2005 f	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	185	\N	\N	\N	\N	\N
13947	Dippenaar 2005	\N	Omega-3 Fatty Acid versus Placebo	\N	South Africa	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
13952	Kwon 2006	\N	Olanzapine versus control group	\N	South Korea	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
13953	Lane 2002	\N	Olanzapine versus Haloperidol	\N	Taiwan	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
13954	Lasser 2007	\N	Antipsychotics + Risperidone versus Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
13956	Ginsberg 2004 a	\N	lamotrigine + Clozapine versus Placebo + Clozapine	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
13957	Evins 2002	\N	Risperidone + D-cycloserine versus Risperidone + Placebo	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
13960	Fonder 2005	\N	mecamylamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
13964	Henquet 2006	\N	THC versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
20271	徐鹏 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
13965	Ginsberg 2004 b	\N	Olanzapine + sibutramine versus Olanzapine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
13969	Drake 2009	\N	cognitive remediation group versus cognitive behavioral therapy	\N	United Kingdom	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
13970	ISRCTN77769281	\N	financial incentive group versus treatment as usual Financial Incentives	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	136	\N	\N	\N	\N	\N
13971	Jones 2009	\N	liaison + education group versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
13974	Canuso 2008 c	\N	paliperidone extended release versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	316	\N	\N	\N	\N	\N
13975	Canuso 2008 d	\N	paliperidone extended release versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
13976	Kane 2008a	\N	Armodafinil versus Placebo // Armodafinil Dosage	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13977	Loebel 2008	\N	Lurasidone versus Ziprasidone	\N	United States of America	\N	\N	\N	\N	\N	234 // 307	\N	\N	\N	\N	\N
13980	Roberts 2009	\N	social cognition interaction training + treatment as usual versus treatment as usual	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
13983	Na 2009	\N	Music therapy versus usual care	\N	South Korea	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
13984	Gil Sanz 2009	\N	Emotion recognition + social cognition versus control	\N	Spain	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
13987	Velligan 2009 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
13988	Shafti 2007	\N	escitalopram versus Placebo for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic with negative symptoms	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
13990	Pae 2009 a	\N	immediate suspension of previous treatments during switch to Aripiprazole versus gradual suspension of previous treatments during switch to Aripiprazole	\N	South Korea	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
13993	Glick 2009	\N	lamotrigine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
13995	Cheng 2009	\N	electroacupuncture versus sham electroacupuncture for schizophrenia whose current state is not described and whose stage of illness is not described with auditory halluciantions	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13997	ACTRN12609000603213	\N	acceptance and commitment therapy versus treatment as usual	\N	Australia	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
13998	NCT00946348	\N	dronabinol + Placebo versus cannabis + Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
13999	NCT00018850	\N	ondansetron versus Placebo//Nicotine versus Placebo//Haloperidol versus Placebo//Ondansetron versus nicotine//Ondansetron versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	936	\N	\N	\N	\N	\N
14000	NCT00956189	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
14001	NCT00960219	\N	DAAOI-1 versus Placebo	\N	Taiwan	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14002	NCT00960375	\N	smoking cessation program versus control group	\N	United States of America	\N	\N	\N	\N	\N	210	\N	\N	\N	\N	\N
14003	ISRCTN11889976	\N	extended specialized early intervention service versus standard care	\N	Canada	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	240	\N	\N	\N	\N	\N
14006	Johnson 2003	\N	assertive community treatment versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	251	\N	\N	\N	\N	\N
14007	Afshar 2009	\N	Clozapine + topiramate versus Clozapine + Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
14008	Almomani 2009	\N	motivational interviewing versus oral health education	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
14009	Fisher 2009	\N	auditory training versus control group	\N	United States of America	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
14010	Henderson 2009a	\N	Aripiprazole+Olanzapine versus Olanzapine+Placebo // Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
14012	Kern 2009	\N	errorless learning versus conventional instruction	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
14013	Lindenmayer 2009 a	\N	Olanzapine versus dosage of drug + for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	599	\N	\N	\N	\N	\N
14101	Tran 1999 c	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
20481	吴盛荧 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14015	Ryckmans 2009	\N	switch of medication versus Aripiprazole titrated arm versus Aripiprazole fixed arm dose for schizophrenia whose current state is acute and whose stage of illness is persistent // chronic	\N	Belgium	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
14016	Salmasi 2009	\N	vitamin E versus Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
14017	Tonge 2009	\N	psychoanalytic psychotherapy versus standard care	\N	Australia	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14020	Barton 2009	\N	Cognitive Behavioural Training versus case management	\N	United Kingdom	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
14021	Borras 2009	\N	group intervention versus control group	\N	Switzerland	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
14023	Carrizo 2009	\N	Clozapine + extended release metformin versus Clozapine + Placebo	\N	Venezuela	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
14025	Garcia 2009	\N	Blonanserin versus Placebo // Blonanserin versus Haloperidol // Haloperidol versus Placebo	\N	Japan	\N	\N	\N	\N	\N	307	\N	\N	\N	\N	\N
14026	Guo 2007 e	\N	 for schizophrenia or//and schizophreniform whose current state is partial remission and whose stage of illness is persistent // chronic	\N	China	\N	\N	\N	\N	\N	1400	\N	\N	\N	\N	\N
14030	Luty 2009	\N	motivational interview versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14032	Mueser 2009	\N	family behavior based program versus family psychoeducational program	\N	United States of America	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
14034	Ravanic 2009 a	\N	 for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	Serbia	\N	\N	\N	\N	\N	325	\N	\N	\N	\N	\N
14037	Sonmez 2009	\N	Ziprasidone versus Risperidone	\N	Turkey	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
14038	Hatta 2009	\N	Risperidone versus Aripiprazole	\N	Japan	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14039	Cuesta 2009	\N	Olanzapine versus Risperidone	\N	Spain	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14040	Chanpattana 2001	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) (thymatrol instrument) versus Electro Convulsive Therapy (Electroconvulsive Therapy) (MElectro Convulsive Therapy (Electroconvulsive Therapy)A SR1 instrument)	\N	Thailand	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
14041	Broadhurst 1958 b	\N	sodium amytal versus dexedrine	\N	United Kingdom	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
14042	Brockington 1978 b	\N	amitriptyline + Chlorpromazine versus Chlorpromazine	\N	United Kingdom	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
14044	NCT00963846	\N	Huperzine A versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
14045	NCT00977522	\N	PF-03463275 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14046	NCT00975611	\N	Amantadine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
14047	NCT00964041	\N	D-cycloserine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
14048	NCT00963924	\N	D-cycloserine + cognitive remeidation versus Placebo + cognitive remeidation	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14049	NCT00968851	\N	EVP-6124 versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	225	\N	\N	\N	\N	\N
14050	NCT00970281	\N	Olanzapine versus Placebo	\N	Japan	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	91	\N	\N	\N	\N	\N
14052	Yang 2008	\N	Ziprasidone versus Risperidone	\N	china	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
14053	Xu 2008 b	\N	Sertraline + Sulpiride versus Risperidone	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
14054	Yang 2008 a	\N	Aripiprazole versus Risperidone	\N	china	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
14055	Dickerson 2009 g	\N	valacyclovir versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
14056	Garry 1962 c	\N	SKF 7261 versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
14060	Xu 2008 a	\N	Social skill training + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
14061	Xu 2008 c 	\N	Citalopram versus Venlafaxine	\N	china	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14062	Yang 2008 b	\N	Aripiprazole versus Sulpiride	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14064	Liu BaiCong 2007	\N	Quetiapine versus Clozapine	\N	china	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
14066	Liu QingLian 2007	\N	Health education + Pharmacotherapy versus Pharmacotherapy	\N	china	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14067	Liu Qin 2007	\N	Risperidone + Brainwave therapy versus Risperidone	\N	china	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14068	Liu MingShan 2007	\N	Loxapine versus Aripiprazole	\N	china	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
14069	Liu JiaSheng 2008	\N	Aripiprazole versus Chlorpromazine	\N	china	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
14070	Liu HuanZhong 2008	\N	Aripiprazole versus Risperidone	\N	china	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
14071	Liu ZhengRong 2008	\N	Risperidone versus Olanzapine	\N	china	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14072	Liu ZhengRong 2008-1	\N	Aripiprazole versus Risperidone	\N	china	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
14073	Liu QingHai 2008	\N	Olanzapine versus Clozapine	\N	china	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
14074	Liu XiaoHong 2008	\N	Ziprasidone versus Risperidone	\N	china	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14075	Liu Jie 2008	\N	Psychosocial intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
14076	Liu ShuHua 2008	\N	Aripiprazole versus Perphenazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14077	Liu QingLian 2008	\N	Family intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14078	Liu JingNian 2008	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
14079	Liu CongMin 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
14080	Liu WeiFeng 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
14081	Liu Yong 2008	\N	Perphenazine + Health education versus Perphenazine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14082	Liu GuoXiong 2007	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
14083	Liu BoCong 2007	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
14084	Liu GuoYou 2008	\N	Family intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
14085	Liu HuaLi 2008	\N	Aripiprazole versus Haloperidol	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
14086	Liu YouDuo 2008	\N	Clozapine + Fluphenazine decanoate versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14087	Liu TongZhou 2008	\N	Modified Electro Convulsive Therapy (MElectroconvulsive Therapy) versus Risperidone	\N	China	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
14088	Liu XiFen 2008	\N	Conventional health education versus Health education by clinical pathway	\N	China	\N	\N	\N	\N	\N	220	\N	\N	\N	\N	\N
14089	Liu XiuQing 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
14090	Liu LiFang 2008	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
14091	Liu Wei 2008	\N	Ziprasidone versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
14092	Liu YunHua 2008	\N	Health education + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14093	Liu Rui 2008	\N	Transcranial repeated magnetic stimulation (TRMS) versus Sham repeated transcranial magnetic stimulation (TRMS)	\N	China	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
14095	Lu ChunAi 2008	\N	behavioural therapy + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
14096	Liu Hao 2008	\N	Repetitive transranial magnetic stimulation (repetitive Transcranial Magnetic Stimulation) versus Repetitive transranial magnetic stimulation (repetitive Transcranial Magnetic Stimulation) - Sham	\N	China	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
14097	Lu ChunPei 2007	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14098	Lu YanChun 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14102	Falloon 1978 b	\N	paracetamol versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
14107	Luo YuLing 2008	\N	Comprehensive nursing intervention + routine antispsychotic versus standard care + routine Antipsychotic	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14108	Lv BinJun 2008	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14109	Lin Hui 2007	\N	Traditional Chinese Medicine (TCM) XieXinTang + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	135	\N	\N	\N	\N	\N
14110	Zhou HaoTian 2008	\N	Menghan-Heji(TCM ) + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14111	Zhu YiRen 2008	\N	Health education + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14112	Yuan 2008 b	\N	Sertraline + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14113	Zhang ChuanHai 2007	\N	Sertraline versus Venlafaxine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14114	Zhang YueLan 2007	\N	Evidence-based nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
14115	Yan MeiYing 2007	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
14116	Yan FengJuan 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14117	Yan BaoChang 2008	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14118	Xue ZhiQiang 2007	\N	Individual rehabilitation therapy versus standard care	\N	China	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
14119	Xu Ying 2008 -1	\N	Risperidone + Citalopram versus Risperidone	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
14120	Xu RuJin 2008	\N	Risperidone + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
14121	Xu Miao 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14122	Xu MeiQin 2007	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14123	Xu JianXiong 2008	\N	Clozapine + Huperzine-A versus Clozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14124	Xu 2008	\N	Aniracetam + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
14125	Xiong YingJu 2007	\N	Enhanced psychoeducation + care as usual versus Conventional health education + care as usual	\N	China	\N	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
14126	Xin Gang 2008	\N	Aripiprazole versus Perphenazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14127	Xie ZhongYing 2008	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14128	Xie 2008	\N	Hexagram boxing exercise therapy + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20272	庞可可 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14129	Yang Ping 2008	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14130	Wei YueLing 2007	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
14131	Wu WenLi 2008	\N	Open ward management versus Closed ward management	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14132	Wu Sai 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
14133	Wu NingQiang 2008	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Antipsychotic medication versus Conventional psychological intervention + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14134	Wen YiXiong 2008 -1	\N	Lian-zi qing-xin Tang (TCM) + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
14135	Wen YiXiong 2008	\N	Lian-zi qing-xin Tang (TCM) + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14136	Wen NaiYi 2008	\N	behaviour therapy + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
14137	Wei XuHua 2008	\N	Traditional Chinese Medicine (TCM) Qingxin Guntan Wan combined with Chlorpromazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
14138	Wei YouFang 2008 - 1	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
14139	Wei Wei 2008	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14140	Wei RanJing 2008	\N	Home nursing service + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14141	Wei PingXiang 2008	\N	Sulpiride + Nimodipine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14142	Wei Jun 2008	\N	Domestic Risperidone versus Joint venture Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14143	Wang ZhengHua 2008	\N	Aripiprazole versus Haloperidol	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14144	Wang ZaoLan 2008	\N	Health education + Antipsychotic medication versus Antipsychotic medication + standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14145	Wang YunGang 2008	\N	Aripiprazole versus Sulpiride	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14146	Wang YuLing 2008	\N	Comprehensive nursing intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	147	\N	\N	\N	\N	\N
14147	Wang YuanChang 2008 	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14150	Wang YuanChang2008-1	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14151	Wang YuMei 2008	\N	Family Nursing + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
14152	Xie XinNian 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
14153	Xie WenJiao 2008	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14155	Xia JinXiao 2008	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
14156	Wu YuanFang 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
14157	Wu Yi 2008	\N	Olanzapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14158	Wang Yi 2008	\N	Metoprolol versus Propranolol	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
14159	Wang Yi 2008-1	\N	Aripiprazole Route	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14160	Wang Ying 2007	\N	Nursing intervention versus No nursing intervention	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14161	Wang Ying 2008	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14163	Wang XiangYang2008-1	\N	Humanism Nursing Management + Antipsychotic medication versus standard care + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14164	Mi GuoLin 2008	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
14165	Liang Yan 2008	\N	Comprehensive nursing intervention (package of care including psychoeducation, Cognitive Behavioral Therapy etc) + routine care versus Routine care	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
14166	Sha Rong 2008	\N	Social and independent living skills training + Antipsychotic medication versus Antipsychotic medication + care as usual	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14167	Shuai HongLi 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14168	He ChuanCai 2008	\N	Comprehensive intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14169	Ha Si 2008	\N	Group psychotherapy + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14170	He ShuFen 2008	\N	Health education (goal attainment) versus Conventional health education	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
14171	Liu XiYing 2008	\N	Humanistic nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14172	Lv JinJie 2007	\N	Psychotherapy via illness playback + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14173	Wang XiaoQuan 2008	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
14174	Wang Yang 2007	\N	Risperidone versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20273	李双 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
14175	Lu AiYi 2008	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
14176	Chen JingYu 2008	\N	Intramuscular Ziprasidone versus Intramuscular Haloperidol	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14178	Chen Kai 2008	\N	Electric acupuncture + Aripiprazole versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
14179	Chen PengYue 2008	\N	Self-confidence training + routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14180	Chen QingSong 2007	\N	Risperidone + Fluoxetine versus Risperidone + Placebo	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
14181	Chen QingSong 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14182	Chen Song 2008	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14183	Chen XiangLi 2008	\N	Traditional Chinese Medicine (TCM) Wuling Capsule and Ginkgo extract Tablet versus Wuling Capsule	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14184	Chen XiaoHan 2008	\N	Community nursing intervention versus standard care	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
14185	Chen Yong 2008	\N	Risperidone capsule versus Risperidone tablet	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
14186	Chen ZhenLei 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14187	Cheng XiaoChun 2008	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
14188	Cui JieFeng 2008	\N	Traditional Chinese Medicine (TCM) + Clozapine versus Clozapine + Placebo	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
14189	Cui Meng 2008	\N	Risperidone versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14190	Dai SuPing 2008	\N	Psychological intervention + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14191	Dai XinGuo 2008	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14192	Deng Hua 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
14193	Deng KeWen 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
14194	Deng LiangHua 2008	\N	Cognitive behavioral therapy + routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
14195	Ding YongHong 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14196	Ding YuanFu 2007	\N	Modified Electro Convulsive Therapy (MElectroconvulsive Therapy) versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14197	Ding ZhiJie 2008	\N	Ziprasidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
14198	Dong RuiLan 2008	\N	Social function training + Routine Antipsychotic medication + traditional nursing versus Routine Antipsychotic medication + traditional nursing	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14199	Dong TaiXin 2007	\N	Ziprasidone + Clozapine versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
14200	Dong TaiXin 2007-1	\N	Ziprasidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	191	\N	\N	\N	\N	\N
14201	Dong Wei 2008	\N	Ziprasidone versus Quetiapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14202	Du Biao 2007	\N	Aripiprazole versus Haloperidol 	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14203	Fan BeiFang 2008	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
14204	Fan JianHua 2007	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
14205	Fu CanLi 2008	\N	Ziprasidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14206	Fu ChunHong 2007	\N	Comprehensive intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
14207	Fu GuoZhu 2008	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
14208	Gan JingLi 2007	\N	Hexagram boxing + Routine Antipsychotic medication versus Antipsychotic drugs therapy	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14209	Gao CunYou 2007	\N	Piracetam + Hyperbaric oxygen therapy + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
14210	Gao CunYou 2008	\N	Fuzheng Kaiqiao Oral Liquid + Risperidon versus Risperidone alone	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
14211	Gao Hui 2007	\N	behaviour therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
14212	Gao ShiQing 2008	\N	Occupational therapy + Antipsychotic medication versus standard care	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14213	Gao XingHai 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14214	Gao XinHua 2008	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
14215	Gao ZhenBo 2008	\N	Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
14216	Geng YuChen 2008	\N	Olanzapine versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14217	Gong DeXuan 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
14218	Gong GaoQin 2007	\N	Quetiapine + Chlorpromazine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14219	Gong Qian 2008	\N	Clozapine combined with sertraline versus Clozapine alone	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
14220	Kou GuiMin 2008	\N	Ziprasidone versus various dosages	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
14221	Guo Li 2008	\N	Loxapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
14222	Guo YanQiao 2008	\N	Clinical nursing pathway versus Care as usual	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14223	Guo ZhenYu 2008	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
14224	Han Bai 2007	\N	Traditional Chinese Medicine (TCM) Qingxin Chongji ?+ Risperidone + Olanzapine versus Qingxin Chongji ?+ Chlorpromazine + Clozapine	\N	China	\N	\N	\N	\N	\N	404	\N	\N	\N	\N	\N
14225	Han Bai 2008	\N	Traditional Chinese Medicine (TCM) Qingxin Chongji I + Risperidone + Olanzapine versus Risperidone + Olanzapine	\N	China	\N	\N	\N	\N	\N	406	\N	\N	\N	\N	\N
14226	Han Peng 2007	\N	Ziprasidone versus Chlorpromazine 	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14227	Han XueFeng 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
14228	He RunFang 2008	\N	Systematic psychoeducation versus Conventional health education	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
14229	He MinHui 2008	\N	Community individualized intervention + Care as usual versus Care as usual	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14230	He XingMei 2007	\N	Quetiapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14231	He YiQun 2007	\N	Quetiapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
14232	Yang XiuShuang 2008	\N	Traditional Chinese Medicine (TCM) Jian-pi Hua-tain Xiao-zhi Fa versus Flurastatin	\N	China	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
14233	Yang ShunCai 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
14235	Yang XiaoMei 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14236	Yao MingRong 2008	\N	Risperidone (Danke) versus Risperidone (Risperdal)	\N	China	\N	\N	\N	\N	\N	205	\N	\N	\N	\N	\N
14237	Xu ChengMin 2008	\N	Risperidone versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14238	Yi HuanWen 2008	\N	Risperidone (Ketong) versus Risperidone (Risperdal)	\N	China	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
14239	Yi XiaoRong 2008	\N	Health education + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	142	\N	\N	\N	\N	\N
14240	Yin JunXian 2008	\N	Clinical pathway versus Conventional care	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
14241	Yin JunXian 2008-1	\N	Aripiprazole versus Typical Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
14242	Yu AiZhen 2008	\N	Olanzapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
14243	Yu JunTao 2008	\N	Psychological intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
14244	Yu Lin 2007	\N	Ziprasidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
14246	Yu RuiYan 2008	\N	Nursing intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60 60	\N	\N	\N	\N	\N
14248	Yu YongTao 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14249	Yu ZhiGang 2007	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14250	Zeng GuiE 2007	\N	Health education + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14251	Zhang ChangJun 2008	\N	Psychological intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
14252	Zhang DaWen 2007	\N	Risperidone + Sodium valproate versus Risperidone	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
14253	Zhang Feng 2008	\N	Ziprasidone versus various dosages	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14254	Zhang HaiTao 2007	\N	Citalopram + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
14278	Zhang ZhenDong 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14279	Zhang ZhiFeng 2008	\N	Family intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
14280	Zhang ZhongShan 2008	\N	Cyproheptadine versus Propranolol	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14281	Zhao CuiPing 2007	\N	Living skills training versus standard care	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
14282	Zhao GuiXia 2008	\N	Psychoeducation versus No intervention	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14283	Zhao LuPing 2008	\N	Ziprasidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
14284	Zhao QingLian 2007	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14285	Zhao Shan 2007	\N	Comprehensive rehabilitation therapy + routine Antipsychotic medication versus standard care	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14286	Zhao Zheng 2007	\N	Psychoeducation + Antipsychotic medication versus follow-up visit + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
14287	Zheng JingLi 2007	\N	Quetiapine + Clozapine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
14288	Zheng QingMei 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14289	Zheng WanLing 2008	\N	Family health education versus standard care	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
14290	Zheng XiaoRong 2008	\N	\N	\N	China	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
14291	Zheng XiuXia 2007	\N	Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14292	Zheng XueBao 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
14294	Zhong XiaoBing 2008	\N	Quetiapine versus Sulpiride	\N	China	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
14295	Zhou Ping 2007	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
14296	Zhou WeiChun 2007	\N	Psychological intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14297	Zhou WeiDong 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
14298	Zou XiaoHua 2008	\N	Ziprasidone versus Olanzapine	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
14299	Zhou Yong 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
14300	Zhou YuanJia 2008	\N	Aripiprazole versus Sulpiride	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
14301	Zhou YuLin 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14302	Zhou Zhen 2008	\N	Health education + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
14303	Zhu ManLian 2008	\N	Aripiprazole versus Quetiapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14304	Xu YuFang 2008	\N	Programming training + Antipsychotic medication versus Conventional rehabilitation therapy + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14305	Hou HongBo 2008	\N	Psychological intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14306	Hu GuoHua 2008	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
14307	Hu JingRong 2008	\N	Health education pathway versus Conventional health education	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14308	Hua Ting 2008	\N	Health education + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14310	Huang ChangHuang2007	\N	Clozapine combined + Huperzine-A versus Clozapine alone	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
14311	Huang JinRu 2007	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14312	Huang JiWei 2007	\N	Aripiprazole versus Perphenazine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14314	Huang XingBing 2008	\N	Ziprasidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
14315	Huang Xiong 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14316	Huang Ying 2008	\N	Health education + holistic nursing versus holistic nursing	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14317	Huang ZhiYong 2008	\N	Olanzapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14318	Huang ZiQiong 2007	\N	Holistic nursing + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
14319	Jiang CuiMei 2008	\N	Ziprasidone versus CLozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14320	Jiang CuiMei 2008-1	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
14321	Cheng MingJun 2007	\N	Quetiapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
14322	Dai JunQiu 2007	\N	Healthy education and nursing + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
14323	Fan JiMei 2008	\N	Family intervention + drug treatment versus drug treatment	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14324	Gan JiXing 2008	\N	Lian-zi Qing-xin Tang (TCM) + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14325	Li CongHui 2007	\N	Aripiprazole versus Perphenazine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14326	Li Jing 2008	\N	Aripiprazole versus Haloperidol	\N	China	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
14327	Li Xi 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
14328	Li XiaoJun 2008	\N	Rispeidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
14329	Luo JianHua 2008	\N	Quetiapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14330	Mu DeJun 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14331	Song GuiQing 2008	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14332	Song GuangMing 2008	\N	Rispeidone versus Quetiapine	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
14333	Wang CuiMin 2007	\N	Flunarizine versus Placebo	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14334	Wang GangPing 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
14335	Wang JingBo 2008	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
14336	Wang MingTao 2008	\N	Aripiprazole versus Sulpiride	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
14337	Wang QingGong 2008	\N	Olanzapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	237	\N	\N	\N	\N	\N
14338	Xu ZhiPing 2008	\N	Ziprasidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14339	Yang Juan 2008	\N	Ziprasidone versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14340	Yang Lian 2007	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
14341	Zhang ShengLi 2008-1	\N	Quetiapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14342	Zhou YuanDong 2003	\N	Risperidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
14343	Jiang GuoQing 2008	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20482	周梦煜 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
14344	Jiang JuFang 2008	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Routine antispsychotic medication versus Conventional health education + routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
14345	Jiang ZeYu 2008	\N	Ziprasidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
14346	Jie Rui 2008	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
14347	Jin JianFeng 2008	\N	Chlorpromazine + Aripiprazole versus Chlorpromazine + Placebo//Chlorpromazine versus Placebo//Chlorpromazine versus Aripiprazole//Aripiprazole versus Placebo	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14348	Jin LuPing 2007	\N	Role playing + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
14349	Jin Xin 2008	\N	Aripiprazole versus Perphenazine	\N	China	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
14350	Jin Ying 2007	\N	Rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14351	Jing 2008	\N	Aripiprazole versus Perphenazine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
14352	Kang HongYing 2008	\N	Loxapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14353	Kong LingFang 2007	\N	Painting therapy + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
14354	Kong SuLi 2007	\N	Piracetam + Hyperbaric oxygen therapy + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
14355	Kong Yuan 2007	\N	Family intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14356	Kou GuiMin 2007	\N	Ziprasidone versus various dosages	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14357	Lai ShuZhen 2008	\N	Brain modulating-order therapy versus Risperidone	\N	China	\N	\N	\N	\N	\N	109	\N	\N	\N	\N	\N
14358	Lei JinMei 2007	\N	Risperidone versus Clozapine 	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
14359	Lei QingHua 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14360	Li DengMing 2008	\N	Risperidone versus Quetiapine	\N	China	\N	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
14361	Li DengMing 2008-1	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14362	Li Gang 2008	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
14363	Li GuoRong 2007	\N	Demonstration therapy (package of care involving handcraft, day trips, reading, listening to music etc) + care as usual versus Care as usual 	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14364	Li HaiGen 2008	\N	Nursing intervention + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14365	Li JianHua 2008	\N	Fee-free Antipsychotic medication versus General outpatient treatment	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14366	Li JinBo 2008	\N	Aripiprazole versus Perphenazine 	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14367	Li JinBo 2008-1	\N	Quetiapine versus Perphenazine 	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14368	Li Jing 2008-1	\N	Quetiapine fumarate versus Sulpiride	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
14369	Li JunHua 2008	\N	Health education + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
14370	Li JunHua 2008-1	\N	Follow-up visit + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
14371	Li JunHua 2008-2	\N	Family intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
14372	Li LiYan 2008	\N	Comprehensive rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14373	Li MeiHua 2007	\N	Aripiprazole versus Quetiapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14374	Li MeiJuan 2007	\N	Insight education + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
14375	Li MeiJuan 2008	\N	Socail skill training + Antipsychotic medication versus Antipsychotic medications only	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14376	Li Min 2008	\N	Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
14377	Li QiaoMin 2007	\N	Guidance of family care + care as ususal versus Care as usual 	\N	China	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
14378	Li QiBin 2007	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14379	Li QiBin 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14380	Li RuYu 2008	\N	Sertraline + Sulpiride versus Sulpiride	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14381	Li ShuiChao 2007	\N	Cognitive behavioural therapy + routine Antipsychotic medications versus Routine psychological therapy + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14382	Li ShuMin 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14738	連文仙 2005	\N	Holistic nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14383	Li SuRong 2008	\N	Psychological therapy + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14384	Li SuRong 2008-1	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14385	Li SuYin 2007	\N	Han ethnic population versus Other minority ethic population	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14386	Li SuYin 2008	\N	Olanzapine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
14387	Li 2008a	\N	Magnesium Valproate + Olanzapine versus Olanzapine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
14388	Li WanXiu 2008	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
14389	Tao JianQing 2007	\N	Group psychotherapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
14390	Tao JianQing 2008-2	\N	Open management versus Closed management	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
14391	Tao JianQing 2008-3	\N	Quetiapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
14392	Tao JianQing 2008-4	\N	Gastrodin Injection + routine Antipsychotic medication versus Routine Antipsychotics	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
14393	Tao ShiWu 2007	\N	Tiapride versus Perphenazine	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
14394	Li XiaoHong 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
14395	Li XiPo 2008	\N	Reboxetine + Clozapine versus Clozapine + Placebo	\N	China	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
14396	Li XiPo 2008-1	\N	Reboxetine + Clozapine versus Clozapine + Placebo	\N	China	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
14397	Li Yong 2008	\N	Traditional Chinese Medicine (TCM) Daying Tang + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14398	Lian ShuKui 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
14399	Liang GuiFang 2007	\N	Family nursing + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
14400	Liang Jia 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14401	Liang Liang 2008	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14403	Wang Jie 2007	\N	Risperidone + Mirtazapin versus Risperidone + Paroxetine	\N	China	\N	\N	\N	\N	\N	120 80	\N	\N	\N	\N	\N
14405	Wang JiCai 2007	\N	Intramuscular Ziprasidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
14406	Wang JiFeng 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14407	Wang JiHong 2008	\N	Psychoeducation + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
14408	Wang JiHong 2008-1	\N	Psychological nursing + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14410	Wang Jing 2008	\N	Psychoeducation + Antipsychotic medication versus Conventional health education + standard care	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14820	许洪伟 2002	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
14411	Wang KaiWu 2008	\N	Psychological intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14412	Wang LiLi 2007	\N	Olanzapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14413	Wang LiLi 2008	\N	Risperidone oral solution versus Risperidone tablets	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
14414	Wang LiZhi 2008	\N	Traditional Chinese Medicine (TCM) + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14415	Wang Ling 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14416	Wang LiSha 2008	\N	Open ward management + standard care versus Closeward management + standard care	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
14417	Wang RenFeng 2008	\N	Olanzapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14418	Wang RenChang 2008	\N	Traditional Chinese Medicine (TCM) Wendan Tang + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14419	Wang TianLong 2008	\N	Ziprasidone versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
14420	Wang XiangYang2008	\N	psychoeducation versus standard care	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14421	Wang XiaoDong 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14422	Wang XiaoHong 2008	\N	Quetiapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14423	Wang XiaoLong 2008	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14424	Wang XiaoQuan 2008-1	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14425	Wang XueBin 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14426	Wang YanHua 2008	\N	Community nursing intervention versus standard care	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14427	Wang YanJun 2007	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14428	Wang YanZhi 2007	\N	New model of health education versus Conventional health education	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14429	Tao ShiWu 2008	\N	Risperidone versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
15039	Lan 2009	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
14430	Tao YongFu 2008	\N	Group psychotherapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
14431	Tian Hong 2008	\N	Clozapine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
14432	Zou Xun 2008	\N	Traditional Chinese Medicine (TCM) intergrated with western medicine + Antipsychotic medication versus Western medicine + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
14433	Zhong GuoJian 2008	\N	Homelike wards + standard care versus Closed wards + standard care	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
14434	Wan Hao 2007	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14436	Wan ZhengYan 2008	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14437	Wang BaoHong 2008	\N	Behavioural intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14438	Wang BingHua 2008	\N	Aripiprazole versus Sulpiride	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14439	Wang BingHua 2008-1	\N	Modified Electro Convulsive Therapy (MElectroconvulsive Therapy) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
14440	Wang CaiRong 2008	\N	Community Health Education + care as usual versus Care as usual 	\N	China	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
14441	Wang ChunYang 2008	\N	Psychological intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
14442	Wang DeGang 2008	\N	Cognitive behavioural Therapy + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
14443	Wang GangPing 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14444	Wang GuiYing 2008	\N	Rehabilitation therapy versus standard care	\N	China	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
14445	Wang GuoFu 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14446	Wang JianRong 2007	\N	Traditional Chinese Medicine (TCM) Shun qi dao tan tang + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14447	Song ZhenHua 2007	\N	Antipsychotics + Huperzine A versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	107 117	\N	\N	\N	\N	\N
14449	Song ZiXiang 2008	\N	Aripiprazole + Risperidone versus Risperidone + Placebo	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14450	Su KeYu 2007	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
14451	Su Mian 2008	\N	Community comprehensive rehabilitation programme + routine Antipsychotic medication versus Care as usual + Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14452	Su Qin 2008	\N	Olanzapine versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14453	Sun FuGen 2008	\N	behaviour therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	123	\N	\N	\N	\N	\N
14454	Sun Hui 2008	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
14455	Sun Hui 2008-1	\N	Clozapine + Lithium versus Clozapine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
14456	Sun MeiLing 2007	\N	Quetiapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14457	Sun 2008	\N	Magnesium Valproate versus Placebo	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14458	Sun ShuMin 2007	\N	Social support + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14459	Sun Yi 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
14460	Tang BenLing 2008	\N	Risperidone versus Sulpiride	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14461	Tang ChunGuang 2008	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
14462	Tang Hong 2007	\N	Skill training + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14463	Tang Wei 2008	\N	Ziprasidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14464	Tang ZhenKun 2007	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
14465	Lv ChunMei 2007	\N	Health education + Conventional follow-up versus Conventional follow-up	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
14466	Ma Li 2008	\N	Acupuncture + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14467	Ma LiXia 2008	\N	Aripiprazole versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14468	Ma Qi 2007	\N	Aripiprazole + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
14469	Ma XiaoGuang 2008	\N	Ziprasidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14470	Mao XiXiang 2007	\N	Risperidone (16-25years old patients) versus Risperidone (40-50 years old patients).	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
14471	Mei 2008	\N	Y-tyrosine + Antipsychotic medication versus Placebo + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
14472	Meng JianFeng 2008	\N	Health education + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
14473	Meng YueLan 2007	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
15040	Si 2009b	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14474	Mo WeiJing 2007	\N	Health education + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14475	Nai XiaoZhen 2008	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14476	Ni YuLan 2008	\N	Skill training + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14477	Nie SuoCheng 2007	\N	Ziprasidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14478	Ning ZhengYuan 2008	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20483	龚飞中 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
14479	Pan LiMei 2008	\N	Comprehensive psychological behavior intervention + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	131	\N	\N	\N	\N	\N
14480	Pan TianWei 2008	\N	Ziprasidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14481	Pan WenYan 2008	\N	Ziprasidone versus Chlorpromazine 	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14482	Pei JinYu 2008	\N	Systematic health education versus Health instruction by nurse	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14483	Peng DongYing 2007	\N	Risperidone (Suole) versus Risperidone (Risperdal)	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
14484	Peng WeiZhen 2008	\N	Family intervention + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
14485	Peng YongHong 2008	\N	Antipsychotics + Fangfeng Tongshen pills (TCM ) versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
14486	Qin AiLing 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14487	Qiu YuZhu 2007	\N	Olanzapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14488	Qu JianXin 2008	\N	Risperidone versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
14489	Ru BaoJian 2008	\N	Living skills training + Antipsychotic medication versus Antipsychotic medication and traditional nursing mode	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14490	Ruan ShuiYing 2008	\N	Clozapine + supportive psychotherapy + fluoxetine versus Clozapine + supportive psychotherapy	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14491	Shan HongFu 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14492	Shang XiuZhen 2007	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	80 80	\N	\N	\N	\N	\N
14494	Shen Feng 2007	\N	Group Cognitive behavioural Therapy (Cognitive Behavioral Therapy) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
14495	Shi DongQing 2008	\N	Olanzapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14496	Shi YuZhong 2007	\N	Risperidone versus Chlorpromazine 	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
14497	Shuai HongLi 2008-1	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
14498	Song ChunLian 2008	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14499	Song JianZhu 2008	\N	Traditional Chinese Medicine (TCM) Niuhuang Ninggong tablets + Loxapine versus Loxapine	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
14500	Song WenYing 2008	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14501	Song YanPing 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14502	Ai ChunQi 2008	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14503	An ChengGe 2008	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
14504	An HongWei 2008	\N	Antipsychotics + paroxetine versus Placebo	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
14505	Bai ShuYing 2007	\N	Sanwei-tanxiang tang (TCM) versus Propranolol	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
14506	Ban Na 2008	\N	Aripiprazole versus Quetiapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14507	Bu Ru 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14508	Cai JinWei 2008	\N	Quetiapine versus Chlorpromazine hydrochloride	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14509	Cai QingQi 2007	\N	Quetiapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
14510	Cai XiongYing 2008	\N	MElectroconvulsive Therapy + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14512	Cao Jiang 2007	\N	zipraside versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14513	Cao YongKang 2007	\N	Antipsychotics + family treatment versus Antipsychotic treatment group	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14514	Chang FaWei 2008	\N	Aripiprazole versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
14515	Chang ShuangHai 2007	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14516	Chang YuShan 2008	\N	Risperidone versus Quetiapine	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
14518	Chen Fei 2007-1	\N	Olanzapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
14519	Chen Fei 2007	\N	Aripiprazole versus Quetiapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14520	Chen FengXian 2007	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
14521	Chen HanBo 2008	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14523	Chen JingQing 2007	\N	Group psychological therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
14524	Wang WenLin 2008	\N	Aripiprazole versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
14525	NCT00983476	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
14526	NCT00980252	\N	Cognitive Behavioural Training versus psychoeducation	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
14527	NCT00990925	\N	lifestyle modification group versus usual care	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
14528	NCT00988728	\N	SCH 900435 versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14529	NCT00996242	\N	L-lysine versus Placebo	\N	Sweden	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
14530	NCT00995553	\N	compuer skills training versus cogntive remediation	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14531	NCT00998608	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
14532	NCT00982020	\N	oral Olanzapine versus intense weight intervention	\N	United States of America	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14533	NCT00960024	\N	supported employment versus control group	\N	Sweden	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14534	NCT00992407	\N	long acting Risperidone versus oral Risperidone	\N	South Korea	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
14535	NCT00986531	\N	AZD8529 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
14536	NCT00981526	\N	telmisartan versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14538	NCT00947375	\N	Haloperidol deaconate + lamotrigine versus Haloperidol deaconate + Placebo//Haloperidol deaconate versus lamotrigine//Haloperidol deaconate versus Placebo//lamotrigine versus Placebo	\N	Azerbaijan	\N	\N	\N	\N	\N	350	\N	\N	\N	\N	\N
14539	Aleman 2009	\N	group therapy versus control group	\N	Netherlands	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
14540	Thornicroft 2009	\N	community oriented care versus facility oriented care	\N	India	\N	\N	\N	\N	\N	327	\N	\N	\N	\N	\N
14541	Conus 2009	\N	N-acetyl cysteine versus Placebo	\N	Switzerland//United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
14542	Zuo 2009	\N	 for schizophrenia whose current state is acute and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	181	\N	\N	\N	\N	\N
14543	Vinogradov 2009 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
14547	Lipkovich 2009	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	414	\N	\N	\N	\N	\N
14549	Kim 2009	\N	Aripiprazole versus switch of medication versus non Aripiprazole oral Antipsychotics for schizophrenia or//and schizoaffective disorders whose current state is partial remission and whose stage of illness is not described	\N	South Korea	\N	\N	\N	\N	\N	292	\N	\N	\N	\N	\N
14550	Berwaerts 2009	\N	paliperidone extended release versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
14552	Nagel 2009	\N	motivational care planning versus treatment as usual	\N	Australia	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
14553	Moss 2009	\N	Bupropion + nicotine patch versus Bupropion + Placebo patch	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
14816	王萍 2007	\N	Risperidone + Citalopram versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14817	秦天星 2005	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14555	Hough 2009	\N	switch of medication versus paliperidone palmitate versus dosage of drug + for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic	\N	United States of America	\N	\N	\N	\N	\N	252	\N	\N	\N	\N	\N
14557	Vercammen 2009	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
14559	Ritsner 2009 b	\N	dehydroepiandrosterone versus Placebo	\N	Israel	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
14560	Nemoto 2009	\N	divergent thinking versus convergent thinking control program for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	Unclear	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
14561	McKee 2009	\N	mecamylamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
14562	Manuel 2009	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14567	Choi 2009b	\N	Math Game versus Math Game (Motivational) // Math Game versus Control Group // Math Game (Motivational) versus Control Group	\N	United States of America	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
14568	Chen 2009 b	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
14569	Buchsbaum 2009	\N	sertindole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
14573	Sockalingam 2009	\N	ipratropium versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described with hypersalivation	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
14574	Magliano 2009	\N	test-retest of questionnaire versus face validity of questionnaire	\N	Italy	\N	\N	\N	\N	\N	149	\N	\N	\N	\N	\N
14575	Kumari 2009	\N	Cognitive Behavioural Training + standard care versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
14577	Burns 2009 b	\N	individual placement and support versus standard services	\N	Germany//United Kingdom	\N	\N	\N	\N	\N	312	\N	\N	\N	\N	\N
14581	Huang Sheng 2003	\N	Risperidone versus Haloperidol	\N	China	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
14582	Smith 2002	\N	nicotine nasal spray versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
14584	McEvoy 2003	\N	galantamine + Risperidone versus Placebo + Risperidone	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
14586	Ricbmond 2005	\N	Cognitive Behavioural Training + nicotine replacement therapy versus standard care	\N	Australia	\N	\N	\N	\N	\N	298	\N	\N	\N	\N	\N
14591	Nishimatsu 1991	\N	\N	\N	Japan	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
14594	AstraZeneca 2007 a	\N	Quetiapine fumarate 200 mgs versus Quetiapine fumarate 400 mgs	\N	Unclear	\N	\N	\N	\N	\N	141	\N	\N	\N	\N	\N
14595	AstraZeneca 2005 L	\N	Quetiapine fumarate versus Chlorpromazine	\N	Canada//United States of America	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
14596	AstraZeneca 1998	\N	Quetiapine versus Risperidone	\N	Unclear	\N	\N	\N	\N	\N	408	\N	\N	\N	\N	\N
14597	AstraZeneca 2001	\N	Quetiapine versus Placebo//Haloperidol versus Placebo//Haloperidol versus Quetiapine	\N	Unclear	\N	\N	\N	\N	\N	381	\N	\N	\N	\N	\N
14598	AstraZeneca 2000	\N	Quetiapine versus Chlorpromazine	\N	Unclear	\N	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
14599	AstraZeneca 2005 m	\N	Quetiapine fumarate versus standard care	\N	United States of America	\N	\N	\N	\N	\N	449	\N	\N	\N	\N	\N
14602	Bristol-Myers 2005	\N	Aripiprazole versus Olanzapine	\N	Argentina//Brazil//Canada//United States of America	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
14604	Bristol-Myers 2001	\N	Aripiprazole versus Placebo	\N	Canada//United States of America	\N	\N	\N	\N	\N	420	\N	\N	\N	\N	\N
14605	Bristol-Myers 2005 a	\N	Aripiprazole versus Placebo	\N	Canada//United States of America	\N	\N	\N	\N	\N	176	\N	\N	\N	\N	\N
14606	Bristol-Myers 2004 d	\N	Aripiprazole versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	214	\N	\N	\N	\N	\N
14607	Bristol-Myers 2004 e	\N	Aripiprazole versus standard care	\N	Unclear	\N	\N	\N	\N	\N	1599	\N	\N	\N	\N	\N
14608	Bristol-Myers 2004 f	\N	Aripiprazole versus Placebo//Haloperidol versus Placebo//Aripiprazole versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	448	\N	\N	\N	\N	\N
14609	Bristol-Myers 2004 g	\N	Aripiprazole (conventio) versus Aripiprazole (oral disintegrating tablets)	\N	United States of America	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
14610	Bristol-Myers 2005 b	\N	Aripiprazole versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	357	\N	\N	\N	\N	\N
14611	Bustillo 2003	\N	fluoxetine + Olanzapine versus Olanzapine + Placebo	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
14614	Dietrich 2006	\N	news articles	\N	Germany	\N	\N	\N	\N	\N	206	\N	\N	\N	\N	\N
14615	Eisai 2005	\N	donepezil hydrochloride versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	251	\N	\N	\N	\N	\N
14616	Eli lilly 2005 g	\N	Olanzapine versus Placebo//Haloperidol versus Placebo//Olanzapine versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	270	\N	\N	\N	\N	\N
14617	Eli lilly 2005 h	\N	Olanzapine versus Placebo//Haloperidol versus Placebo//Olanzapine versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
14618	Eli lilly 2004 l	\N	Olanzapine versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	431	\N	\N	\N	\N	\N
14619	Eli Lilly 2008 a	\N	Olanzapine depot versus single//multiple dosages	\N	Unclear	\N	\N	\N	\N	\N	314	\N	\N	\N	\N	\N
14620	Eli lilly 2006 m	\N	Olanzapine versus Risperidone	\N	Unclear	\N	\N	\N	\N	\N	664	\N	\N	\N	\N	\N
14621	Eli Lilly 2004 m	\N	Olanzapine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
14622	Eli Lilly 2006 n	\N	fluoxetine + Olanzapine versus Olanzapine + Placebo	\N	Unclear	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
14623	Eli Lilly 2006 o	\N	oral Olanzapine versus oral Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
14624	Eli lilly 2005 i	\N	Olanzapine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	326	\N	\N	\N	\N	\N
14625	Eli Lilly 2004 n	\N	Olanzapine versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	1996	\N	\N	\N	\N	\N
14626	Eli Lilly 2004 o	\N	Olanzapine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	335	\N	\N	\N	\N	\N
14627	Eli Lilly 2007 h	\N	Olanzapine depot versus "lots x, y, z"	\N	Unclear	\N	\N	\N	\N	\N	165	\N	\N	\N	\N	\N
14628	Eli Lilly 2006 p	\N	Olanzapine versus conventional neuroleptics	\N	Unclear	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
14629	Elman 2002	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
14631	GlaxoSmithKline 2005	\N	Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
14632	Hafner 2004 a	\N	Cognitive Behavioural Training + Amisulpride versus Cognitive Behavioural Training	\N	Germany	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14640	Touma 2002	\N	\N	\N	Japan	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
14642	Pfizer 2007 f	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
14643	Pfizer 2006 a	\N	Ziprasidone + Amisulpride versus various dosages	\N	France	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
14644	Pfizer 2005 h	\N	Ziprasidone versus Olanzapine	\N	Germany	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
14645	Pfizer 2005 i	\N	Ziprasidone versus various dosages	\N	Unclear	\N	\N	\N	\N	\N	256	\N	\N	\N	\N	\N
14648	Sumiyoshi 2004	\N	Buspirone versus Placebo	\N	Japan	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
14658	刘小玉 2006	\N	Risperidone versus Olanzapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14660	劉桂芳 2005	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14661	劉自力 2005	\N	Haloperidol Decanoate + Clozapine versus Risperidone + Clozapine Haloperidol Decanoate + Clozapine versus Risperidone + Clozapine	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
14664	呂紀珍 2005	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14665	呂靜芹 2005	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14666	周小东 2004	\N	Modified electro convulsive therapy (Electroconvulsive Therapy) + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14667	周素芝 2005	\N	Modified limbs bracer versus Traditional limbs bracer	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14818	耿玉辰 2008	\N	Citalopram versus Fluoxetine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14672	姚寧 2005	\N	Health belief therapy (package of care including Cognitive Behavioural Therapy (Cognitive Behavioral Therapy), psychoeducation etc) + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14676	孫全新 2005 a	\N	\N	\N	China	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
14677	孫秀珍 2005	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14678	孫立華 2005	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14681	張金釗 2005	\N	Cognitive Behavioural nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14682	徐天朝 2004	\N	Acupuncture + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14683	成愛萍 2005	\N	Systematic health education versus Conventional health education	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14685	文素榮 2005	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14686	施劍飛 2005	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14687	无 2006	\N	Risperidone + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14688	朱桂兰 2000	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14689	朱毅平 2005	\N	TCM Composite Danshen Dropping Pill + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14690	朱毅平 2005 a	\N	TCM Compound Danshen pill + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14691	朱毅平 2003	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14692	朱良君 2005 c	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14693	朱良君 2005 d	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14694	朱逸人 2005 a	\N	Cognitive therapy + routine care versus routine care//Cognitive therapy	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14696	李剛 2005 a	\N	Quetiapine + Sulpiride versus Quetiapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14698	李軼群 2005	\N	Chlorpromazine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
14699	林勁松 2005	\N	Haloperidol + Alprazolam + Carbamazepine versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14705	樊凌姿 2005 a	\N	Risperidone versus Quetiapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14706	樊愛珍 2005	\N	Nursing intervention + routine drug therapy versus routine drug therapy//Nursing intervention	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14709	汪宏才 2005 a	\N	Risperidone versus sulpride	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
14713	潘艷芬 2005	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14714	王以云 2005 a	\N	Music therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
14716	王樹陽 2005	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
14717	王漢嬋 2005	\N	Outpatient support + routine care versus routine care//Outpatient support	\N	China	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
14718	Wang 2005a	\N	Amfebutamone versus Placebo	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14719	王立 2005	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14720	王立娥 2005 a	\N	Cognitive Behavioural nursing + Routine Antipsychotic medication versus Routine Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14724	祝书文 2006	\N	Performance planning therapy (including skills training, role play etc) + Antipsychotic medication versus Routine psychological support + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14727	胡明月 2006	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14728	蓋萬良 2005	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14729	蘇華龍 2005	\N	Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14730	袁杰 2006	\N	Chlorpromazine versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14731	褚建平 2005	\N	Quetiapine versus Perphenazine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14732	許麗榮 2005	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14735	趙利國 2005 a	\N	Rehabilitation therapy + routine Antipsychotic versus routine Antipsychotic//Rehabilitation therapy	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
14737	趙長印 2005	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14739	Xing 2005	\N	Post-discharge guidance + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
14740	鄒清蘭 2005	\N	Risperidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14743	钟镭勇 2006	\N	Buflomedil Hydrochloride + Antipsychotic medication versus Antipsychotic medication + Placebo	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14745	陈启豹 2004	\N	Olanzapine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14746	陳情 2005	\N	Clozapine + Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14747	陳玉廣 2004	\N	Risperidone versus perhenazine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14748	陶建青 2006	\N	long acting Risperidone versus oral Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14750	韋強 2005	\N	Venlafaxine + Clozapine versus Clozapine//Venlafaxine versus Clozapine	\N	China	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
14753	馬繼東 2005	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14758	龐勝芝 2005	\N	Individualized nursing intervention + Conventional nursing versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14759	นงเยาว์ พ 2542	\N	Haloperidol versus Risperidone	\N	Thailand	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
14762	วรวัฒน์ 2544	\N	\N	\N	Thailand	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14763	任清涛 2002	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14764	冯雪雁 2002	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14765	刘晋洪 2002	\N	\N	\N	China	\N	\N	\N	\N	\N	220	\N	\N	\N	\N	\N
14767	刘英江 2002	\N	Magnetic pillow versus sham magnetic pillow	\N	China	\N	\N	\N	\N	\N	436	\N	\N	\N	\N	\N
14771	周秀华 2002	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14772	唐永怡 2005	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14775	孙轻骑 2007	\N	Olanzapine + Penfluridol versus Olanzapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14776	宋艳萍 2006	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14778	崔隽 2007	\N	Ziprasidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14779	张东卫 2008	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14780	张守来 2002 a	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14781	张建 2008	\N	Aripiprazole versus perphenazine	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14782	张文敏 2008	\N	Loxapine succinate capsules versus Risperidone	\N	China	\N	\N	\N	\N	\N	134	\N	\N	\N	\N	\N
14784	张登科 2002	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14785	徐丽珍 2002	\N	Quetiapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14787	支勝利 2005	\N	\N	\N	China	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
14788	施剑飞 2005	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14789	曾为群 2002	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14790	朱丽萍 2002	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14791	朱乐信 2002	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14792	朱华芳 2007	\N	Risperidone versus Haloperidone	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
14799	李紅 2005	\N	Systematic health education versus general health education	\N	China	\N	\N	\N	\N	\N	286	\N	\N	\N	\N	\N
14801	林福荣 2008	\N	Olanzapine versus Haloperidol	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14805	梁绍材 2002	\N	\N	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
14806	梅桂森 2005	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14808	汤启芳 2002	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14810	沈爱新 2007	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14815	王精 2007	\N	Health education + routine care versus routine care alone//Health education	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14821	许玉芳 2008	\N	Programtic training versus Conventional training	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14824	郑桂芝 2006	\N	Psychoeducation//Psychoeducation + routine care versus routine care only	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14826	鄧炳煙 2004	\N	Chlorpromazine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
14827	闫俊英 2005	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14829	韦有芳 2008	\N	Risperidone versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
14830	顾桂英 2006	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14831	高金香 2005	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
14833	Liu 2005 h	\N	Clozapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14838	McCrone 2009	\N	assertive community treatment versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	251	\N	\N	\N	\N	\N
14845	Velligan 2009 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	148	\N	\N	\N	\N	\N
20274	汤庆军 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14848	Nasr 2009	\N	pheyshoeducation + psychotropic drugs versus psychotropic drugs	\N	Pakistan	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
14849	Miyaoka 2009	\N	Yi-Gan versus Placebo	\N	Japan	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
14850	Mittal 2009	\N	Antipsychotic adherence intervention versus usual care for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
14852	Chadwick 2009	\N	group mindfulness therapy versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
14853	Cavallaro 2009	\N	computer-aided cognitive training versus control group	\N	Italy	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14855	Hamann 2004 b	\N	psychoeducation groups	\N	Germany	\N	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
14856	Green 2007 c	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	224	\N	\N	\N	\N	\N
14857	Goldstein 1970	\N	phenothiazine (thioridazine) versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
14863	Buchanan 2006	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
14867	Potkin 2009 d	\N	Ziprasidone versus various dosages	\N	Canada//United States of America	\N	\N	\N	\N	\N	599	\N	\N	\N	\N	\N
14877	Haller 2009	\N	psychoeducation and coping with illness therapy versus supportive dialogues or vocational rehabilitation	\N	Austria	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
14878	ISRCTN74919979	\N	Conventional education group versus IT education group//IT education group versus Education group + standard care//Conventional education group versus Education group + standard care	\N	Finland	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
14879	Matsui 2009	\N	standard treatment versus cognitive rehabilitation + treatment as usual for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	Japan	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
14880	Modabber 2009	\N	allopurinol versus Placebo for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
14882	NCT01003132	\N	acceptance and commitment therapy + treatment as usual versus treatment as usual Acceptance and Commitment Therapy	\N	United Kingdom and UK and United Kingdom	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	24	\N	\N	\N	\N	\N
14883	NCT01003379	\N	TC-5619 versus Placebo	\N	United States of America//India	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
14884	NCT01009047	\N	paliperidone versus Aripiprazole	\N	Czech Republic//India//Russia//Slovakia//Spain//Ukraine//United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	228	\N	\N	\N	\N	\N
14885	NCT01009060	\N	GSK239512 versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	120	\N	\N	\N	\N	\N
14886	NCT00999505	\N	Amantadine versus Placebo	\N	Brazil	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
14887	NCT01012167	\N	oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
14888	Smith 2009 b	\N	pioglitazone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
14889	Ganguli 2009	\N	behavioural training bosster sessions versus standard care	\N	Canada//United States of America	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
14890	Meyer 2009 b	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
14893	Richardson 2009	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
14895	Harvey 2007 c	\N	Ziprasidone versus Clozapine	\N	Italy	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
14897	Findling 2007	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	302	\N	\N	\N	\N	\N
14898	Potkin 2007 d	\N	Asenapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
14906	Ascher-Svanum 2007 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
14907	Gandelman 2007	\N	Ziprasidone versus fasting	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
14908	Sapra 2007	\N	long acting Atypical Antipsychotic versus oral Atypical Antipsychotic	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
14909	Uzcategui 2007	\N	Olanzapine versus Placebo	\N	Venezuela	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
14910	Wu 2007 f	\N	nicotine replacement therapy versus high dose (30.2mg), low dose (20.8mg)	\N	Taiwan	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
14911	Haas 2007	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
14913	Schulz 2007 b	\N	Quetiapine SR versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	588	\N	\N	\N	\N	\N
14914	Sacchetti 2007 b	\N	Ziprasidone versus Clozapine	\N	Italy	\N	\N	\N	\N	\N	147	\N	\N	\N	\N	\N
14917	Ibrahim 2007 b	\N	Quetiapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
14918	Stahl 2007	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	599	\N	\N	\N	\N	\N
14920	Corey-Lisle 2007	\N	Aripiprazole versus standard therapy	\N	United States of America	\N	\N	\N	\N	\N	544	\N	\N	\N	\N	\N
14921	Pae 2007 b	\N	Aripiprazole versus Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
14922	Kim 2007 e	\N	topiramate + Atypical Antipsychotics versus Atypical Antipsychotics	\N	South Korea	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
14923	Weiden 2007 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
14925	Weiden 2007 c	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
14927	Klieser 1991 b	\N	zotepine versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
14929	Klieser 1994	\N	remoxipride versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
14930	Mei 2005	\N	Zaorenanshen decoction + Chlorpromazine versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14931	Yan 2005	\N	Traditional Chinese Medicine (TCM) Jie-jing decoction versus Benzhexol hydrochloride 	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14932	Wang 2005 ae	\N	A large dose of traditional Chinese medicine versus A normal dose of traditional Chinese medicine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
14933	Tang 2005 g	\N	Traditional Chinese Medicine (TCM) Jian-Pi-Bu-Shen + Chlorpromazine versus Chlorpromazine + Placebo//Chlorpromazine versus Placebo//Jian-pi-bu-shen (tcm) versus Chlorpromazine//Jian-pi-bu-shen (tcm) versus Placebo//traditonal chinese medicine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14934	Shi 2005 b	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
14935	Svestka 2005	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
14936	Shopsin 1978	\N	Clozapine versus Placebo//Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
20484	王素红 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
14937	Kramer 2009	\N	paliperidone palmitate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	247	\N	\N	\N	\N	\N
14938	Yang 2006 q	\N	Olanzapine + Ginkgo bilola versus Olanzapine only	\N	Turkey	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
14940	Gallinat 2001	\N	Clozapine versus Olanzapine	\N	Germany	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
14941	Postma 2006 b	\N	nicotine versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
14942	Tamminga 1997 a	\N	sertindole versus Olanzapine	\N	United States of America//Canada	\N	\N	\N	\N	\N	205	\N	\N	\N	\N	\N
14943	Tamminga 1997 b	\N	sertindole versus Olanzapine	\N	United States of America//Canada	\N	\N	\N	\N	\N	462	\N	\N	\N	\N	\N
14944	Krakowski 2009	\N	Clozapine versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
14945	Schreiner 2009 c	\N	paliperidone ER versus oral Olanzapine	\N	Argentina//Belgium//Estonia//France//Germany//Greece//Netherlands//Slovakia//South Africa//Spain//Turkey	\N	\N	\N	\N	\N	462	\N	\N	\N	\N	\N
14946	Saddichha 2009	\N	Olanzapine versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
14947	Letourneau 2009	\N	Quetiapine versus Olanzapine	\N	Unclear	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
14949	Wunderink 2009	\N	guided discontinuation of medication versus maintenance treatment	\N	Unclear	\N	\N	\N	\N	\N	131	\N	\N	\N	\N	\N
14951	Stenberg 2009	\N	mirtazapine versus Placebo	\N	Finland	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
14953	Noordsy 2009	\N	Clozapine with and without cannabis versus Risperidone with and without cannabis	\N	Unclear	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
14955	Tereynikov 2009	\N	adjunctive mirtazapine versus not stated	\N	Unclear	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
14957	Vita 2009	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
14960	Goff 2009 e	\N	D-cycloserine + Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus Placebo + Cognitive Behavioural Therapy (Cognitive Behavioral Therapy)	\N	Spain	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
14965	Adrianzen 2008	\N	Haloperidol versus Olanzapine	\N	Venezuela	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
14966	Hawthorne 2009	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
14967	Shafti 2009	\N	Fluphenazine decanoate versus Olanzapine + Placebo//Fluphenazine decanoate versus Olanzapine//Fluphenazine decanoate versus Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
14970	Ingole 2009	\N	Olanzapine versus Risperidone	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14972	Beebe 2009	\N	 for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14974	Howard 2009	\N	hospital admission versus women's crisis house admission for schizophrenia whose current state is acute and whose stage of illness is not described	\N	United Kingdom	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
14977	Chapel 2009	\N	Asenapine versus Placebo	\N	United States of America//South Africa	\N	\N	\N	\N	\N	148	\N	\N	\N	\N	\N
14980	Cordes 2009	\N	magnetic stimulation (Transcranial Magnetic Stimulation) versus sham	\N	Germany	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
14982	Lahti 2009	\N	Olanzapine versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
14984	Schuhmacher 2009	\N	Haloperidol versus Risperidone versus dosage of drug + for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Germany	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
20275	杨如良 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
14986	Chen 2009 c	\N	warm-supplementing kidney yang (wsky) versus Placebo versus Risperidone for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic with negative symptoms	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
14987	Eack 2009	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
14989	Brown 2009 b	\N	brief health promotion interevntion versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
14990	Weiden 2009 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
14991	Kane 2009 c	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	323	\N	\N	\N	\N	\N
14992	Faith 2009	\N	probiotic organisms versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
14993	Jayashri 2009	\N	ondansetron versus Placebo	\N	Australia	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
14994	David 2009	\N	pravastatin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14995	Baker 2009 a	\N	smoking cessation intervention versus control group	\N	Australia	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
14996	NCT01022489	\N	magnetic stimulation versus Placebo	\N	France	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
14997	NCT01016145	\N	first generation Antipsychotics versus second generation Antipsychotics	\N	Brazil	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
14998	NCT01027962	\N	Intensive Computerised Brain Training versus Games (Computer)	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
14999	NCT01028677	\N	oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
15000	NCT01029769	\N	Amisulpride versus Olanzapine	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15001	Lee 2009	\N	mirtazapine + Risperidone versus Placebo + Risperidone	\N	South Korea	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
15003	Chan 2000 a	\N	caes management versus routine community care	\N	Hong Kong	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
15004	Nicholls 2002	\N	Amisulpride versus Risperidone	\N	United Kingdom	\N	\N	\N	\N	\N	310	\N	\N	\N	\N	\N
15007	Swadi 2010	\N	Quetiapine versus Risperidone	\N	New Zealand	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
15008	Leutwyler 2009 a	\N	health promoting intervention versus control group	\N	Unclear	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
15009	Stauffer 2009	\N	switch to Olanzapine versus continuation on Risperidone	\N	Unclear	\N	\N	\N	\N	\N	630	\N	\N	\N	\N	\N
15010	Pappadopulos 2009	\N	Ziprasidone versus Olanzapine	\N	Unclear	\N	\N	\N	\N	\N	18,154	\N	\N	\N	\N	\N
15012	Robb 2009	\N	Aripiprazole versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	302	\N	\N	\N	\N	\N
15014	Carothers 2009	\N	paliperidone extended release versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15015	Canuso 2009 a	\N	paliperidone extended release versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
15016	Samochowiec 2009	\N	Ziprasidone versus perazine	\N	Unclear	\N	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
15017	Alphs 2009	\N	paliperidone palmitate versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	408	\N	\N	\N	\N	\N
15018	Fleischhacker 2009c	\N	IM paliperidone palmitate in deltoid versus IM paliperidone palmitate in gluteal	\N	Unclear	\N	\N	\N	\N	\N	570	\N	\N	\N	\N	\N
15019	Baptista 2009 b	\N	metformin + Olanzapine versus Olanzapine + Placebo	\N	Unclear	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15020	Nicol 2009 a	\N	Olanzapine versus Aripiprazole	\N	Unclear	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
15021	Grinspan 2009	\N	paliperidone ER + Risperidone versus Risperidone	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15024	Gopal 2009	\N	paliperidone palmitate versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	388	\N	\N	\N	\N	\N
15025	Hardy 2009	\N	Olanzapine versus Risperidone	\N	Unclear	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
15026	Cassella 2009	\N	loxapine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	344	\N	\N	\N	\N	\N
15027	Moghadam 2009	\N	Risperidone versus Aripiprazole	\N	Unclear	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
15029	Hamilton 2009	\N	iloperidone versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15030	Damsa 2009	\N	nicotine replacement versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15032	Kollack-Walker 2009	\N	Olanzapine versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	225	\N	\N	\N	\N	\N
15033	Correll 2009	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	294	\N	\N	\N	\N	\N
15034	Nicol 2009 b	\N	Aripiprazole versus Antipsychotics	\N	Unclear	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
20485	成军	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
15035	Hoffmann 2009	\N	Olanzapine + amantadine versus Olanzapine + zonisamide	\N	Unclear	\N	\N	\N	\N	\N	199	\N	\N	\N	\N	\N
15037	Pandina 2009	\N	paliperidone palmitate versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	636	\N	\N	\N	\N	\N
15038	Johnsen 2009	\N	Risperidone versus Ziprasidone	\N	Unclear	\N	\N	\N	\N	\N	213	\N	\N	\N	\N	\N
20276	陈宇晖 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
15043	Lothringer 2009	\N	HIV prevention group versus control group	\N	Brazil	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
15045	Edwards 2008	\N	cognitive Behavioural case management + standard care versus standard care	\N	Australia	\N	\N	\N	\N	\N	235	\N	\N	\N	\N	\N
15046	Yung 2008	\N	\N	\N	Australia	\N	\N	\N	\N	\N	115	\N	\N	\N	\N	\N
15047	Francey 2008	\N	psychosocial treamtment + Antipsychotics versus psychosocial treamtment + Placebo	\N	Australia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15048	Malla 2008	\N	extended specialized early intervention service versus standard care	\N	Canada and Unclear	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	200	\N	\N	\N	\N	\N
15050	Chen 2008 d	\N	\N	\N	Hong Kong	\N	\N	\N	\N	\N	178	\N	\N	\N	\N	\N
15052	Hui 2008 b	\N	Quetiapine versus Placebo	\N	Hong Kong	\N	\N	\N	\N	\N	178	\N	\N	\N	\N	\N
15053	Leweke 2008 b	\N	cannabidiol versus amisulpiride	\N	Germany	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
15054	Mottaghipour 2008	\N	home based family education versus hospital based family groups	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
15055	Bechdolf 2008 a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus support therapy	\N	Germany	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
15056	Fowler 2008	\N	Cognitive Behavioural Training + standard care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
15057	Santos 2008	\N	cognitive Behavioural case management versus control group	\N	Portugal	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15058	Gafoor 2008	\N	early intervention versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15059	Alvarez-Jimenez 2008	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	Australia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15061	Sharifi 2008	\N	home care versus standard care//Prompts to encourage appointment attendance	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
15062	Nyilas 2008	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	302	\N	\N	\N	\N	\N
15067	Ritsner 2008	\N	pregnenolone versus Placebo	\N	Israel	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
15068	Bechdolf 2008 b	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Aripiprazole, Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Placebo versus clinical management + Aripiprazole, clinical management + Placebo	\N	Australia//Germany	\N	\N	\N	\N	\N	380	\N	\N	\N	\N	\N
15070	Killackey 2008 c	\N	individual placement and support + standard care versus standard care	\N	Australia	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
15072	Bertelsen 2008	\N	psychosocial integrated treatment versus standard care	\N	Denmark	\N	\N	\N	\N	\N	547	\N	\N	\N	\N	\N
15073	Chong 2008	\N	\N	\N	Singapore	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15074	Nordentoft 2008	\N	two years of early intensive intervention versus five years of early intensive intervention	\N	Denmark	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
15075	Amini 2008	\N	Atypical Antipsychotics versus treatment as usual	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
15077	Kumar 2010	\N	Modafinil versus Placebo	\N	India	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
15079	于兆阳 2009	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15082	任列 2009	\N	Ziprasidone + Clozapine versus Clozapine	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15089	侯雪玲 2009 a	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15093	兰琳 2009	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15094	刘从敏 2009	\N	Tandospirone versus Buspirone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15096	刘俊彪 2009	\N	Quetiapine versus Haloperidol 	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15097	刘勇 2009	\N	Open ward management + pharmacotherapy versus Closed ward management + pharmacotherapy	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15099	刘志东 2009	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15100	刘昊 2009 a	\N	Venlafaxine + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15103	刘晓红 2009	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15117	吴晓梅 2009	\N	Skill training + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15122	周云 2009 a	\N	Propantheline versus Doxepine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15123	周云 2009 b	\N	Ziprasidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15127	周海晓 2009	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15128	夏静 2009	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15130	姚明荣 2009	\N	Setraline + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15135	孟庆珍 2009	\N	Aripiprazole versus Haloperidol	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20277	耿在香 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15139	宋春联 2009	\N	Ziprasidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15141	寻知元 2009	\N	Quetiapine + Sulpiride versus Sulpiride	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15142	尤晓莉 2009	\N	Health education + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15145	常蔚 2009	\N	Chlorpromazine + Wendantang versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15146	张丽 2009	\N	Family-centered nursing intervention + Antipsychotic medication versus Routine outpatient care + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15147	张亚红 2009	\N	Psychosocial intervention versus standard care	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15155	张洪秋 2009	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication Comprehensive family intervention + pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15156	张瑞芬 2009	\N	Home nursing service + Antipsychotic medication versus Antipsychotic medication only//Community based nursing intervention + pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15159	彭汝春 2009	\N	Ziprasidone versus Risperidone Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15160	彭燕 2009	\N	Targeted health education + Antipsychotic medication versus Conventional health education + Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15161	彭瑛 2009	\N	Health education versus standard care// Home based nursing education + pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15164	徐娟 2009	\N	Ziprasidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15169	方政华 2009	\N	Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15170	施泉惠 2009	\N	Open ward management versus Closed ward management	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15172	曲万仁 2009	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15173	朱建忠 2009	\N	Aripiprazole versus Sulpiride	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15174	朱玉星 2009	\N	Rehabilitation performance plan + Antipsychotic medication versus psychological therapy + Antipsychotic medication//Performance Plan + conventional psychotherapy versus Conventional psychotherapy	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15175	朱颖 2009	\N	behavioural intervention + Metformin versus behavioural intervention + Placebo	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15184	李英 2009	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15189	杨雀屏 2009	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15190	林云 2009	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15191	林卓毅 2009	\N	Ziprasidone versus Clozapine	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15193	汪卫华 2009	\N	Clozapine versus Olanzapine//Clozapine + Risperidone + Olanzapine versus Clozapine	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15244	赵晶媛 2009 a	\N	Psychosocial intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15246	赵晶媛 2009 c	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15250	邓春继 2009	\N	Rehabilitation therapy + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15251	邓梅 2009	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15253	邱学文 2009	\N	Clozapine versus control	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15254	郑春 2009	\N	Family intervention + Antipsychotic medication versus Antipsychotic medication// Family intervention + pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15255	郝广义 2009	\N	Traditional Chinese Medicine (TCM) Yiqi-Huoxue-Yao + Antipsychotic medication versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15259	陆爱益 2009	\N	Ziprasidone versus Quetiapine Ziprasidone versus Quetiapine	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15260	陈仁念 2009	\N	Estazolam + Risperidone versus Clonazepam + Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15262	Chen 2009a	\N	Aripiprazole versus Perphenazine	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15263	陈晓晟 2009	\N	Nursing intervention + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15265	陈汝兰 2009	\N	Healing training + Antipsychotic medication versus Antipsychotic medication only	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15267	陈远岭 2009	\N	Aripiprazole versus Olanzapine Aripiprazole versus Olanzapine	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15269	鞠康 2009	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15272	马忠智 2009	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15276	高丽红 2009	\N	Sulpiride + Venlafaxine versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15278	高志勤 2009 a	\N	Active rapid repetitive transcranial magnetic stimulation (repetitive Transcranial Magnetic Stimulation) + Risperidone versus Sham repetitive Transcranial Magnetic Stimulation + Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15280	魏丽霞 2009	\N	Olanzapine versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15281	魏绪华 2009	\N	Traditional Chinese Medicine (TCM)//Huanglian-Jiedu decotion +Clozapine versus Clozapine Traditional Chinese Medicine (TCM)//Huanglian Jiedu Decoction + Clozapine versus Clozapine	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15282	黄承繁 2009	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15285	黄群明 2009	\N	Motivational interview therapy (package of care including Cognitive Behavioral Therapy, skills training etc) + routine rehabilitation therapy versus Routine rehabilitation therapy	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15290	李宏 2009	\N	Fluoxertine hydrochloride + Sulpiride versus Sulpiride Fluoxetine + Sulpiride	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	\N	\N	\N	\N	\N	\N
15291	Wang 2009	\N	Aripiprazole versus Aripiprazole + Magnesium Valproate	\N	China	\N	\N	\N	\r\nCountry of origin\r\n	\N	60	\N	\N	\N	\N	\N
15293	Basu 2009	\N	topiramate versus Placebo for schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
15294	Delahaye 2009	\N	\N	\N	Belgium	\N	\N	\N	\N	\N	301	\N	\N	\N	\N	\N
15296	Williams 2008 b	\N	Nicotine patch versus Nicotine nasal spray//Smoking cessation	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
15297	Alvarez-Jimenez 2009	\N	cognitive behavioral therapy versus standard treatment + for psychotic whose current state is partial remission and whose stage of illness is first episode	\N	Australia	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
15299	Koletsi 2009	\N	individual placement and support versus vocational rehabilitation	\N	Netherlands	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
15300	Velligan 2009 c	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	445	\N	\N	\N	\N	\N
15301	Akhondzadeh 2009 b	\N	Risperidone + propentofylline versus Risperidone + Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
15302	Lin 2009 c	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15303	Mackle 2009	\N	Asenapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	386	\N	\N	\N	\N	\N
15304	Akhondzadeh 2009 c	\N	Risperidone + rianserin versus Risperidone + Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
15309	Haas 2009	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
15310	Villalta-Gil 2009	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
15311	Smith 2009 c	\N	Olanzapine versus Risperidone for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is persistent // chronic with hypersalivation	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
15312	Park 2009	\N	Aripiprazole versus Risperidone versus dosage of drug + for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	South Korea	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
15313	Lucena 2009	\N	memantine versus Placebo versus Clozapine for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Brazil	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
15314	Stewart 2009	\N	low dose Ziprasidone (10-40mg titration) versus high dose Ziprasidone (20-80mg titration)	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
15315	Levitt 2009	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
15316	Dewa 2009	\N	clinic intervention versus home treatment intervention for schizophrenia or//and schizophreniform whose current state is not described and whose stage of illness is first episode	\N	Canada	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
15317	Premkumar 2009	\N	Cognitive Behavioural Training + standard care versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15318	Chu 2009	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
15320	海燕 2009	\N	Second-generation Antipsychotic medication versus First-generation Antipsychotic medication	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15321	AstraZeneca 2009	\N	Quetiapine prolong versus oral Risperidone	\N	Finland	\N	\N	\N	\N	\N	3	\N	\N	\N	\N	\N
15322	Anon 2010 a	\N	Org 5222 versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
15324	NCT01047592	\N	sarcosine + DAAOI-1 versus sarcosine + Placebo	\N	Taiwan	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15325	NCT01045720	\N	Traditional Chinese Medicine (TCM)//TCM (suoquan pills) versus TCM (wuling powder)//TCM (wuling powder) versus Placebo//TCM (suoquan pills) versus Placebo	\N	Taiwan	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
15326	NCT01041976	\N	supported employment versus control group	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
15327	NCT01052389	\N	Aripiprazole versus Haloperidol	\N	Italy	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
20486	张磊 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
15328	NCT01043458	\N	ABT-126 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
15329	NCT01052714	\N	behavioural weight loss program versus standard care	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
15330	NCT01041053	\N	niacin dose	\N	Canada	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
15331	NCT01041274	\N	citalopram versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
15332	NCT01036282	\N	computer cognitive skills training versus control group	\N	United States of America	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
15333	NCT01052103	\N	LY2140023 + standard care versus standard care	\N	United States of America	\N	\N	\N	\N	\N	280	\N	\N	\N	\N	\N
15334	Geddes 2010	\N	mirtazapine versus Placebo	\N	UK // Finland // Italy // China	\N	\N	\N	\N	\N	330	\N	\N	\N	\N	\N
15335	Burns 2010	\N	community treatment order versus traeatment on leave	\N	United Kingdom	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
15336	Valimaki 2010	\N	internet based patient support system training versus no IT- educational information session	\N	Finland	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
15337	McCabe 2010 a	\N	training program versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
15339	Kovitz 1956 a	\N	Chlorpromazine versus Reserpine // Chlorpromazine versus Placebo // Reserpine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
15342	陶建青 2007	\N	Aripiprazole versus Risperidone	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15345	天龙王 2007	\N	behaviour therapy + Citalopram versus Citalopram	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15347	Schtzwohl 2002	\N	inpatient setting versus day hospital setting	\N	Unclear	\N	\N	\N	\N	\N	500	\N	\N	\N	\N	\N
15350	Hanlon 1959	\N	perphenazine versus perphenazine-benztropine mesylate	\N	Unclear	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
15352	Martens 1960	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15356	Nieznanski 2000	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15358	Morgenstern 1960	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
15359	Gauthier 1967	\N	Trifluoperazine versus Trifluperidol	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
15360	学军王 2007	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15361	Wang 2007 m	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15362	Loza 2004	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15365	Saygilarli 1960	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15367	Lee 1999	\N	Cognitive Differentiation Training versus Psychoeducation	\N	Korea	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
15369	Morrison 2002 e	\N	Cognitive Therapy	\N	UK	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15370	Chung 2001	\N	Cognitive Behavioral Therapy versus Supportive Psychotherapy	\N	Korea	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
15371	Supczynska 2001	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15372	Lee 1998 a	\N	Cognitive Differentiation Training versus Psychoeducation	\N	Korea	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
15375	Kein 1991	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15377	Mallinckrodt 1999	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15383	Kageyama 2002	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15385	Kiejna 2002 a	\N	inpatient care versus day hospital care	\N	Unclear	\N	\N	\N	\N	\N	338	\N	\N	\N	\N	\N
15386	Atmaca 2002 b	\N	dosage of drug + versus Quetiapine versus Haloperidol for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Turkey	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
15390	Sun 2007	\N	Magnesium Valproate + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
15393	Kircher 2002	\N	old age psychiatric care versus control group	\N	Germany	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
15394	Kim 1997 b	\N	\N	\N	South Korea	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
15395	Burns 1999 b	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15397	Kiejna 2002 b	\N	day hospital treatment versus inpatient treatment for serious mental illness whose current state is partial remission and whose stage of illness is persistent // chronic	\N	Czech//Poland//United Kingdom//Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15398	Eckmann 1971	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15399	Acosta 1971	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15401	Momolov 2000	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15402	Carson 2002 a	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15403	Wong 1999	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15406	Kinon 2000	\N	Olanzapine versus conventional Antipsychotic or Risperidone	\N	Unclear	\N	\N	\N	\N	\N	176	\N	\N	\N	\N	\N
15412	Levkovitz 2009	\N	minocycline versus Placebo	\N	Israel	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
15413	Lecrubier 2004	\N	Amisulpride versus Olanzapine	\N	France	\N	\N	\N	\N	\N	377	\N	\N	\N	\N	\N
15414	McCay 2006 b	\N	stigma group intervention + standard care versus standard care	\N	Canada	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15416	Braga 2009	\N	Clozapine + Electroconvulsive Therapy versus Clozapine	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
15417	Rotondi 2005 c	\N	world wide web-based psychoeducation versus standard care	\N	United States of America	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
15419	George 2006	\N	Bupropion + transdermal nicotine patch versus Placebo + transdermal nicotine patch	\N	Canada	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
15421	Mauri 2004	\N	Olanzapine dose	\N	Italy	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
15422	Vanelle 2004 b	\N	Amisulpride versus Olanzapine	\N	Unclear	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
15501	Anon 2003 e	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	255	\N	\N	\N	\N	\N
15423	Li 2009 c	\N	Bupropion versus Placebo	\N	China	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n	\N	80	\N	\N	\N	\N	\N
15424	Lieberman 2003 a	\N	Haloperidol versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15425	Potkin 2006 a	\N	Asenapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
15427	Loza 2006	\N	Olanzapine versus Risperidone	\N	Poland	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
15431	Meyer 2006 c	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15432	Rappard 2006 b	\N	Ziprasidone versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15433	Sacchetti 2004	\N	Quetiapine versus Risperidone	\N	Italy	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
15435	Kramer 2006	\N	paliperidone versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	530	\N	\N	\N	\N	\N
15437	Ratner 2006	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15438	Joyce 2004	\N	Amisulpride versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
15439	Chen 2008 e	\N	Traditional Chinese Medicine (TCM) Zhuangyang capsule + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15440	Malhotra 2004	\N	donepezil versus Placebo	\N	Canada//United States of America	\N	\N	\N	\N	\N	251	\N	\N	\N	\N	\N
15442	Chakos 2006	\N	Antipsychotics + estrogen versus Antipsychotics + Placebo estrogen replacement therapy (ert) versus augmentation therapy versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\r\nUser defined 3\r\n\r\nNotes2\r\nfirst and second generation antipsychotics + estrogen versus (first and second generation) antipsychotics + placebo	\N	22	\N	\N	\N	\N	\N
15443	Suzuki 2006	\N	Quetiapine versus Risperidone	\N	Japan	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
15444	de Lucena 2009 b	\N	memantine + Clozapine versus Clozapine + Placebo	\N	Australia//Brazil//United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
15445	Weiden 2006	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
15450	Kane 2006 b	\N	Aripiprazole versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	1281	\N	\N	\N	\N	\N
15453	Olivares 2004	\N	Olanzapine versus Risperidone	\N	Spain	\N	\N	\N	\N	\N	235	\N	\N	\N	\N	\N
15454	Cuidad 2004	\N	Olanzapine versus Risperidone	\N	Spain	\N	\N	\N	\N	\N	235	\N	\N	\N	\N	\N
15455	Ono 2006	\N	Olanzapine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
15460	McCabe 2009	\N	visual scanpath versus emotion perception	\N	Australia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15461	Fakra 2004	\N	Risperidone versus Haloperidol	\N	France	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
15464	John 2006	\N	Risperidone + citalopram versus Risperidone	\N	India	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
15465	Tsai 2004 b	\N	sarcosine (add on) versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
15467	Boonstra 2006	\N	withdrawl of Antipsychotics versus continuation of Antipsychotics	\N	Netherlands	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
15468	Kinon 2006 d	\N	Olanzapine dose	\N	United States of America	\N	\N	\N	\N	\N	599	\N	\N	\N	\N	\N
15470	Sumiyoshi 2001 b	\N	Tandospirone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
15471	Gurpegui 2005	\N	Risperidone versus Olanzapine	\N	Spain	\N	\N	\N	\N	\N	235	\N	\N	\N	\N	\N
15473	McLoughlin 2006	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	United Kingdom	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
15475	Stahl 2004	\N	Risperidone versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15480	Schutt 2009	\N	independent apartment versus group home versus housing for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
15483	Hayward 2009	\N	cognitive therapy + psychoeducation versus psychoeducation for schizophrenia whose current state is acute and whose stage of illness is not described	\N	United Kingdom	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
15484	Kopelowicz 2009	\N	 for schizophrenia or//and schizoaffective disorders whose current state is partial remission and whose stage of illness is persistent // chronic	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
15489	Liberman 2009	\N	Olanzapine versus Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
15495	McClure 2009	\N	Risperidone versus Placebo for schizotypal whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
15496	Kaizl 2007	\N	\N	\N	Germany	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
15499	Schutzwohl 2007 b	\N	\N	\N	Germany	\N	\N	\N	\N	\N	202	\N	\N	\N	\N	\N
15500	Anon 2003 d	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	310	\N	\N	\N	\N	\N
20278	和西波 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
15502	Goff 2009 g	\N	D-cycloserine + Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus Placebo + Cognitive Behavioural Therapy (Cognitive Behavioral Therapy)	\N	Spain	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
15503	Organon 2009 b	\N	Asenapine versus Olanzapine	\N	Unclear	\N	\N	\N	\N	\N	306	\N	\N	\N	\N	\N
15504	Fleischhacker 2009d	\N	Risperidone versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	636	\N	\N	\N	\N	\N
15505	Shafti 2005 b	\N	Bromocriptine versus nortriptyline	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
15506	Shafti 2005 c	\N	fluvoxamine versus maprotiline	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
15507	Kaplan 1985	\N	subliminal symbiotic stimulation versus various messages	\N	United States of America	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
15508	Druss 2010	\N	medical care management versus usual care	\N	United States of America	\N	\N	\N	\N	\N	407	\N	\N	\N	\N	\N
15509	Giron 2010	\N	psychosocial family intervention versus care	\N	Spain	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
15511	Becker 2005 b	\N	outcome monitoring versus outcome management	\N	Germany	\N	\N	\N	\N	\N	294	\N	\N	\N	\N	\N
15513	Poyurovsky 2009 c	\N	reboxetine versus Placebo for schizophrenia or//and schizophreniform whose current state is partial remission and whose stage of illness is not described	\N	Israel	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
15517	Waldo 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
15518	Chan 2010	\N	Risperidone versus Olanzapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
15519	Dickinson 2010	\N	computer-assisted cognitive remediation versus control group	\N	United States of America	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
15524	Bloch 2010	\N	Bupropion + Cognitive Behavioral Therapy versus Placebo + Cognitive Behavioral Therapy	\N	Israel	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
15525	Langley 2009	\N	Assertive community treatment versus Intensive case management	\N	Canada	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
15527	Burti 2009	\N	adherence therapy versus control group	\N	Netherlands	\N	\N	\N	\N	\N	179	\N	\N	\N	\N	\N
15529	Lee 2010 a	\N	Bromocriptine versus Placebo	\N	South Korea	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15531	De Lucena 2010	\N	Clozapine versus Placebo versus memantine for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Brazil	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
15535	NCT01055509	\N	cognitive adaptive training versus standard care	\N	Denmark	\N	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
15538	Woolderink 2009	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	214	\N	\N	\N	\N	\N
15539	Zoeteman 2006	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
15540	Kho 2008	\N	Cognitive Behavioural Training + work thearpy versus control condition	\N	Netherlands	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
15541	de Haan 2008	\N	Clozapine versus Olanzapine	\N	Netherlands	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
15542	de Haan 2009	\N	Clozapine versus Risperidone	\N	Netherlands	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
15543	Verstappen 2007	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
15544	Dragt 2007	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus control group	\N	Netherlands	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
15545	Staring 2007	\N	treatment adherence therapy versus standard care	\N	Netherlands	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
15546	NTR1166	\N	Crisis Plan	\N	Netherlands and The Netherlands and Netherlands	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	240	\N	\N	\N	\N	\N
15547	Dlabac-de Lange 2008	\N	magnetic stimulation versus Placebo	\N	Netherlands	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
15548	NTR1325	\N	Digital Communication Device (Computer) + Treatment as Usual versus Treatment as Usual	\N	The Netherlands	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
15549	Sun 2005 c	\N	Risperdone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15551	Hodge 2010	\N	cognitive remediation versus control group	\N	Unclear	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
15552	Hodgekins 2010	\N	recovery oriented versus social recovery focused cognitive behavioral therapy (srcbt) versus standard treatment for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	Unclear	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
15553	Hafner 2004 b	\N	Cognitive Behavioural Training versus case management	\N	Germany	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
15554	Steinlechner 2010	\N	Botulinum toxin B versus Placebo	\N	Germany	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
15557	Byerly 2010	\N	Risperidone versus Quetiapine//Antipsychotic switching//Management of sexual dysfunction	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
15558	Izakova 2009	\N	Risperidone versus Haloperidol + sertraline	\N	United States of America	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
15561	MacFadden 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	323	\N	\N	\N	\N	\N
15562	Fakra 2009	\N	Risperidone versus Haloperidol	\N	France	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
15563	Lublin 2009	\N	Ziprasidone versus Olanzapine//Ziprasidone versus Risperidone//Ziprasidone versus Quetiapine	\N	Denmark/Finland/Iceland/Switzerland	\N	\N	\N	\N	\N	293	\N	\N	\N	\N	\N
15564	Biegel 2009	\N	volunteer partern with history of spychiatric disability versus vonlunteer partner	\N	United States of America	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
15789	Chouinard 1987 a	\N	remoxipride versus 75-500 mgs	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
15568	Lloyd 2000	\N	intensive home treatment versus control group	\N	United Kingdom	\N	\N	\N	\N	\N	209	\N	\N	\N	\N	\N
15569	Chen 2008 f	\N	\N	\N	China	\N	\N	\N	\N	\N	178	\N	\N	\N	\N	\N
15570	Hui 2008 c	\N	Quetiapine versus Placebo	\N	China	\N	\N	\N	\N	\N	178	\N	\N	\N	\N	\N
15579	Byford 2000	\N	intensive case management versus standard case management	\N	United Kingdom	\N	\N	\N	\N	\N	708	\N	\N	\N	\N	\N
15581	Kabes 1985 a	\N	piracetam versus Placebo	\N	Czech Republic	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
15582	Sikich 2002 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
15584	Byng 2004 b	\N	mental health link program versus service development as usual	\N	United Kingdom	\N	\N	\N	\N	\N	335	\N	\N	\N	\N	\N
15588	Nordentoft 2007 b	\N	integrated care versus standard care	\N	Denmark	\N	\N	\N	\N	\N	547	\N	\N	\N	\N	\N
15589	Nordentoft 2000	\N	integrated care versus standard care	\N	Denmark	\N	\N	\N	\N	\N	312	\N	\N	\N	\N	\N
15591	Janicak 1994	\N	Haloperidol dose	\N	United States of America	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
15593	Canuso 2009 b	\N	paliperidone extended release versus Placebo versus dosage of drug + for schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	317	\N	\N	\N	\N	\N
15595	Kabes 1985 b	\N	piracetam versus Placebo	\N	Czech Republic	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
15597	Nordontoft 2007 c	\N	integrated care versus standard care	\N	Denmark	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
15599	Chengappa 2002 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
15600	Conley 2002	\N	Olanzapine versus Clozapine	\N	United States of America	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
15601	Johnson 1981 d	\N	fluphenazine versus control group	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
15602	Johnson 1981 e	\N	flupenthixol versus control group	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
15603	Klein 2006	\N	metformin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
15604	Nahas 2001	\N	donepezil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	6	\N	\N	\N	\N	\N
15605	Pickett-Schenk 2006	\N	family education intervention versus control group	\N	United States of America	\N	\N	\N	\N	\N	462	\N	\N	\N	\N	\N
15606	Abbasi 2010	\N	mirtazapine + Risperidone versus Placebo + Risperidone	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
15607	Hough 2010	\N	paliperidone palmitate versus Placebo//paliperidone palmitate dose	\N	Belgium//Russia//United States of America and Multicentre//Ukraine//Taiwan//South Africa//Russia//Romania//Republic of Korea//Mexico//Costa Rica//United States of America	\N	\N	\N	\N	\N	410	\N	\N	\N	\N	\N
15609	Osborn 2010	\N	nurse led intervention + education pack versus education pack	\N	United Kingdom	\N	\N	\N	\N	\N	121	\N	\N	\N	\N	\N
15610	Kane 2010 b	\N	Asenapine versus Placebo//Haloperidol versus Placebo//Haloperidol versus Asenapine	\N	United States of America	\N	\N	\N	\N	\N	458	\N	\N	\N	\N	\N
15611	Krakowski 2010	\N	Clozapine versus Haloperidol	\N	Hungary//United States of America	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
15614	Gray 2005	\N	adherence councelling versus control training intervention	\N	United Kingdom	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
15615	Lerner 2000	\N	vitamin B6 versus Placebo	\N	Israel	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
15617	Giakoumaki 2010	\N	tolcapone versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
15618	Findling 2010	\N	oral Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	284	\N	\N	\N	\N	\N
15619	Honer 2010	\N	Quetiapine versus Placebo	\N	Canada//United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15620	Kumra 2010	\N	Clozapine versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
15621	Letourneau 2010	\N	Quetiapine versus Olanzapine	\N	Canada	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
15622	Mueser 2010	\N	family behavior based program versus family psychoeducational program	\N	United States of America	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
15624	Nuechterlein 2010	\N	individual placement and support - workplace fundamental module versus vocational rehabilitation	\N	United States of America	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
15625	Pelayo-Teran 2010	\N	Olanzapine versus Haloperidol	\N	Spain	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
15626	Rushby 2010	\N	tDCS versus sham	\N	Australia	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
15627	Shu 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	376	\N	\N	\N	\N	\N
15628	Liebman 2010	\N	tiagabine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
15629	Roder 2010	\N	integrated neurocognitive therapy versus standard care	\N	Switzerland//Austria//Germany	\N	\N	\N	\N	\N	161	\N	\N	\N	\N	\N
15630	Shim 2010	\N	varenicline versus Placebo	\N	South Korea//United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
15631	Stahl 2010	\N	Ziprasidone versus various dosages	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
15632	Van Der Gaag 2010	\N	Competitive memory training (COMET) versus Treatment As Usual	\N	Netherlands	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
15633	Zhou 1989	\N	TCM (daying tablets) versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15634	Zhang 1993	\N	TCM (xuefu zhuyu decotion) + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
15635	Classen 1993	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
15637	Hornung 1993	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
15640	Eberhard 2009	\N	telephone intervention- immediate advice versus control group	\N	Sweden	\N	\N	\N	\N	\N	344	\N	\N	\N	\N	\N
15641	Anon 2009 g	\N	 for schizophrenia whose current state is partial remission and whose stage of illness is not described with cognitive impairment	\N	Unclear	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
15643	Agid 2010	\N	Ziprasidone versus Olanzapine	\N	Italy//United States of America	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
15644	Apud 2010	\N	tolcapone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
15645	Biedermann 2010	\N	sibutramine versus Placebo	\N	Austria	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
15647	Dubovsky 2010	\N	Asenapine Dosage	\N	United States of America	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
15648	Geffen 2010	\N	BL-1020 versus Placebo	\N	Israel//Switzerland//United States of America	\N	\N	\N	\N	\N	363	\N	\N	\N	\N	\N
15649	Genevsky 2010	\N	cognitive training program versus control group	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
15650	Matsui 2010	\N	explicit instruction versus normal instruction	\N	Japan	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
15651	McCabe 2010 b	\N	emotion recognition treatment program versus biofeedback treatment	\N	Australia	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
15652	Noordsy 2010	\N	Clozapine with and without cannabis versus Risperidone with and without cannabis	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
15653	Velligan 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
15654	McGorry 2010	\N	psychological therapy + Quetiapine versus psychological therapy + Placebo	\N	Australia	\N	\N	\N	\N	\N	163	\N	\N	\N	\N	\N
15655	Tan 2009	\N	\N	\N	China	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
15656	Xu 2008 d	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
15657	Alwi 2010 a	\N	remediation program versus control group	\N	Malaysia	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
15658	Alwi 2010 b	\N	remediation program versus control group	\N	Malaysia	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
15659	Adamowski 2009	\N	day care versus inpatient care	\N	Poland	\N	\N	\N	\N	\N	238	\N	\N	\N	\N	\N
15661	Yasui-Furukori 2010	\N	Risperidone versus Olanzapine for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Japan	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
15662	Leontieva 2009	\N	naltrexone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
16357	Williams 2010a	\N	Treatment of Addiction to Nicotine in Schizophrenia (TANS) versus Medication Management (MM)	\N	United States of America	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
15663	Chien 2010	\N	care management versus support versus family psychoeducation for lay carers//family whose current state is not described and whose stage of illness is not described	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
15664	Janssen 2010 a	\N	computerized guideline implementation versus control group	\N	Germany	\N	\N	\N	\N	\N	522	\N	\N	\N	\N	\N
15665	Ji 2005 b	\N	Chlorpromazine versus Clozapine	\N	China	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
15666	NCT01010477	\N	nicotine nasal spray + behavioral intervention versus Placebo + behavioral intervention for schizophrenia whose current state is remission and whose stage of illness is persistent // chronic	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15667	NCT01015001	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	Brazil	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
15668	NCT01029067	\N	metacognitive skills training versus cognitive remediation	\N	Germany	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15670	NCT01075295	\N	behavioural intervention for the prevention of weight gain + standard care versus standard care	\N	Canada	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15671	NCT01077700	\N	ABT-288 Dosage // ABT-288 versus Placebo	\N	United States of America	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	214	\N	\N	\N	\N	\N
15674	NCT01077791	\N	behavioural cognitive therapy versus control group	\N	France	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
15675	NCT01078129	\N	cognitive remediation therapy versus control group	\N	France	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
15676	NCT01078870	\N	escitalopram versus Placebo	\N	Taiwan	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
15677	NCT01081769	\N	injectable paliperidone palmitate versus oral antipschotics	\N	United States of America	\N	\N	\N	\N	\N	766	\N	\N	\N	\N	\N
15678	NCT01082250	\N	Lurasidone Dosage	\N	United States of America	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
15680	NCT01082588	\N	pravastatin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
15681	NCT01083381	\N	MS14 + Risperidone versus Placebo + Risperidone	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
15682	NCT01086748	\N	Risperidone versus ly2140023 versus Placebo for schizophrenia whose current state is acute and whose stage of illness is persistent // chronic	\N	Multicentre//United States of America//Germany//Croatia//Puerto Rico//Russian Federation	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	880	\N	\N	\N	\N	\N
15683	NCT01091506	\N	L-methylfolate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
15684	NCT01093365	\N	varenicline versus Placebo	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
15685	NCT01095562	\N	ABT-126 Dosage // ABT-126 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	207	\N	\N	\N	\N	\N
15686	NCT01098110	\N	Asenapine versus Placebo	\N	Japan	\N	\N	\N	\N	\N	528	\N	\N	\N	\N	\N
15687	NCT01101464	\N	Asenapine Dosage	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
15689	NCT01104766	\N	cariprazine versus Placebo Cariprazine Dosage // Cariprazine versus Placebo // Cariprazine versus Aripiprazole // Aripiprazole versus Placebo	\N	United States of America and Multi-Center	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	600	\N	\N	\N	\N	\N
15690	NCT01104779	\N	Electro Convulsive Therapy (Electroconvulsive Therapy) + Haloperidol versus Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	450	\N	\N	\N	\N	\N
15691	Miceli 2010	\N	Ziprasidone versus various dosages	\N	Unclear	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
15692	Klingberg 2010	\N	Cognitive Behavioural Training versus standard care	\N	Unclear	\N	\N	\N	\N	\N	169	\N	\N	\N	\N	\N
15693	Hallak 2010	\N	cannabidiol versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
15694	Ritchie 2010	\N	Risperidone versus Olanzapine	\N	Unclear	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
15695	Loo 2010	\N	repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation) versus sham repetitive Transcranial Magnetic Stimulation (repetitive Transcranial Magnetic Stimulation)	\N	Unclear	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
15696	EDIE-NL	\N	Cognitive Behavioral Therapy + Treatment As Usual versus Treatment As Usual	\N	The Netherlands	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 10\r\n	\N	\N	\N	\N	\N	\N	\N
15697	Wang 2010	\N	smoking for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic	\N	Unclear	\N	\N	\N	\N	\N	374	\N	\N	\N	\N	\N
15698	Oluboka 2010	\N	clozaril versus generic Clozapine	\N	Unclear	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
15699	Gleeson 2010	\N	standard treatment versus relapse prevention program for psychotic or//and noáminority whose current state is not described and whose stage of illness is first episode	\N	Unclear	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
15700	McCormack 2010	\N	Olanzapine versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
15704	Almomani 2007	\N	Motivational Interviewing	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15721	Andrade 2007	\N	first generation Antipsychotics versus second generation Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
15729	ISRCTN42305247	\N	citalopram versus Placebo for schizophrenia or//and schizophreniform whose current state is partial remission and whose stage of illness is not described with negative symptoms	\N	United Kingdom	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
15732	Bas Oosterhout 2010	\N	metacognitive training versus standard care	\N	Unclear	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
15734	Bechdolf 2010	\N	group Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) versus group psychoeducation	\N	Unclear	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
15736	Bechdolf 2006 b	\N	cognitive behavioral therapy (cbt) versus supportive counseling for psychotic whose current state is not described and whose stage of illness is prodromal illness	\N	Unclear	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
15744	Berwaerts 2009 a	\N	paliperidone extended release versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
15745	Bhowmick 2010	\N	Amisulpride versus Olanzapine	\N	Unclear	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
15747	Bloemers 2005	\N	standard treatment versus assertive community treatment for serious mental illness whose current state is not described and whose stage of illness is not described	\N	Netherlands	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
15757	Braga 2009 a	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
15763	ISRCTN28876952	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
15764	Bushe 2007	\N	Olanzapine versus Quetiapine versus dosage of drug + for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described with negative symptoms	\N	Unclear	\N	\N	\N	\N	\N	346	\N	\N	\N	\N	\N
15772	Canuso 2009 c	\N	dosage of drug + versus paliperidone extended release versus Placebo for schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
15775	Carothers 2009 a	\N	dosage of drug + versus Placebo versus paliperidone extended release for schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	316	\N	\N	\N	\N	\N
15783	Chan 2009 a	\N	virtual reality cognitive training versus control group	\N	Hong Kong	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
15785	Chandler 2000	\N	social skills training + Acceptance and Commitment Therapy versus Acceptance and Commitment Therapy	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20487	马云 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
15806	Crespo-Facorro 2009b	\N	Olanzapine versus Haloperidol versus Risperidone for schizophrenia whose current state is not described and whose stage of illness is first episode	\N	Unclear	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
15810	Davidson 2004 a	\N	supported socialization- matched with partner without psychiatric history versus supported socialization- matched with a volunteer partner	\N	United States of America	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
15822	Dieterle 1987	\N	perazine versus dosage of drug + versus aminosultoprid for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
15825	Dixon 2009 a	\N	critical time interventiaon (CTI) versus usual care	\N	United States of America	\N	\N	\N	\N	\N	135	\N	\N	\N	\N	\N
15827	D'Souza 2002 a	\N	spiritually augmented cognitive behavioral therapy versus supportive case management therapy	\N	Australia	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
15836	Fagerlund 2006	\N	donepezil + Ziprasidone versus Placebo + Ziprasidone	\N	Denmark	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
15838	NCT01111149	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15842	Fleischhacker  2008a	\N	Aripiprazole + Clozapine versus Clozapine + Placebo	\N	France 	\N	\N	\N	\N	\N	207	\N	\N	\N	\N	\N
15844	Forchuk 2008	\N	immediate housing assistance versus standard care	\N	Canada//United Kingdom	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
15846	Foster 2010	\N	cognitive Behavioural worry intervention versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
15850	Freeman 2009	\N	IM Olanzapine versus IM Haloperidol	\N	United States of America	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
15857	Galderisi 2009	\N	social skills training versus individualized training for schizophrenia or//and schizoaffective disorders whose current state is partial remission and whose stage of illness is persistent // chronic	\N	Italy	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15868	ISRCTN79497236	\N	smoking cessation intervention versus group support versus counseling for serious mental illness whose current state is not described and whose stage of illness is not described	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	100	\N	\N	\N	\N	\N
15869	Gilmore 2002	\N	Haloperidol versus dosage of drug + versus Olanzapine for schizophrenia whose current state is acute and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
15877	Goodchild 1969	\N	trifluoperazine versus Placebo versus trifluperidol//Trifluperidol versus Placebo//Trifluoperazine versus Placebo//Trifluoperazine versus Trifluperidol	\N	Unclear	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15883	Gray 2006 c	\N	adherence therapy versus control training for psychotic whose current state is not described and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15884	Grebb 1986	\N	verapamil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
15888	NCT01118208	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	419	\N	\N	\N	\N	\N
15894	Hargarter 2007	\N	\N	\N	Germany	\N	\N	\N	\N	\N	530	\N	\N	\N	\N	\N
15897	Hegde 2009	\N	psychoeducation versus drug therapy for schizophrenia or//and lay carers//family whose current state is not described and whose stage of illness is first episode	\N	Unclear	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
15911	Hough 2008 a	\N	paliperidone palmitate injection versus Placebo versus dosage of drug + for schizophrenia whose current state is partial remission and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	312	\N	\N	\N	\N	\N
15914	ISRCTN83261243	\N	Haloperidol - intramuscular versus Haloperidol - intramuscular + promethazine for serious mental illness whose current state is acute and whose stage of illness is not described with agitation	\N	Brazil	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
15932	Kabes 1985 c	\N	oxyprothepine decanoate maintenance therapy versus not stated	\N	Czech Republic	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
15933	Kahn 2005	\N	Quetiapine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	588	\N	\N	\N	\N	\N
15934	Kahn 2007 a	\N	Quetiapine versus Placebo	\N	Bulgaria//Netherlands//Philippines//Sweden//United States of America	\N	\N	\N	\N	\N	588	\N	\N	\N	\N	\N
15935	Kahn 2007 b	\N	 for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	588	\N	\N	\N	\N	\N
15937	Kane 2004 a	\N	dosage of drug + versus Aripiprazole versus perphenazine for schizophrenia whose current state is not described and whose stage of illness is not described with treatment resistant	\N	Unclear	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
20279	李志文 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
15939	Kane 2004 b	\N	Asenapine versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	386	\N	\N	\N	\N	\N
15943	Keefe 2006 c	\N	 for psychotic whose current state is not described and whose stage of illness is first episode	\N	Unclear	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
15952	Khodabakhshi 2009	\N	behavioural family management versus standard case management	\N	Unclear	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
15955	ISRCTN25898179	\N	Staff Training (GetREAL)	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n	\N	900	\N	\N	\N	\N	\N
15956	Kim 2006 j	\N	Olanzapine monotherapy versus Olanzapine + topiramate for schizophrenia whose current state is not described and whose stage of illness is not described with weight gain	\N	Unclear	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15972	Kryzhanovskaya 2006c	\N	Placebo versus Olanzapine versus dosage of drug + for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
15973	Kryzhanovskaya 2006d	\N	dosage of drug + versus Placebo versus Olanzapine for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
15975	Kryzhanovskaya 2006e	\N	Olanzapine versus Placebo versus dosage of drug + for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Germany//United States of America	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
15976	NTR1318	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
15977	NCT01121042	\N	odansetron versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is persistent // chronic	\N	United States of America	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
15981	Kungel 2007	\N	\N	\N	Germany	\N	\N	\N	\N	\N	232	\N	\N	\N	\N	\N
15984	Lachler 2007	\N	\N	\N	Switzerland	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
15987	Lane 2009a	\N	sarcosine + D-serine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
15999	Levkovitz 2009b	\N	minocycline versus Placebo for schizophrenia whose current state is acute and whose stage of illness is early illness	\N	Unclear	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
16009	Lieberman 2006	\N	Ziprasidone versus dosage of drug + versus Haloperidol for schizophrenia whose current state is remission and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	186	\N	\N	\N	\N	\N
16017	Lobban 2010	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
16019	Loebel 2007a	\N	Haloperidol versus Ziprasidone for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	186	\N	\N	\N	\N	\N
16020	Loebel 2006 c	\N	dosage of drug + versus Ziprasidone versus Haloperidol for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	186	\N	\N	\N	\N	\N
16359	Kavanagh 2004a	\N	motivational intervention versus standard care	\N	Unclear	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
20488	陈日访1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
16023	Lomena 1999	\N	Haloperidol versus Olanzapine for schizophrenia or//and schizophreniform whose current state is not described and whose stage of illness is not described	\N	Spain	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
16025	Lung 2007	\N	Olanzapine dose	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
16026	ISRCTN47146067	\N	hyoscine hydrobromide versus Clozapine versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described with sialorrhea	\N	United Kingdom	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
16034	McEvoy 2006 e	\N	 for schizophrenia or//and schizophreniform whose current state is not described and whose stage of illness is first episode	\N	Unclear	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
16037	McLoughlin 2006a	\N	sham transcranial magnetic stimulation versus repetitive transcranial magnetic stimulation (rtms) for schizophrenia whose current state is not described and whose stage of illness is not described with negative symptoms	\N	Unclear	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
16038	McQuade 2006	\N	Haloperidol IM versus Aripiprazole im//Aripiprazole im versus Placebo//Haloperidol IM versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	448	\N	\N	\N	\N	\N
16040	Meehan 2001	\N	im Olanzapine versus Placebo//Haloperidol versus Placebo//Haloperidol versus im Olanzapine	\N	Unclear	\N	\N	\N	\N	\N	311	\N	\N	\N	\N	\N
16045	Meyer 2006 b	\N	Ziprasidone versus Olanzapine for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	228	\N	\N	\N	\N	\N
16048	Miceli 2010a	\N	Haloperidol versus dosage of drug + versus Ziprasidone for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
16050	Milstein 1994	\N	iloperidone versus Placebo//Chlorpromazine versus Placebo//Chlorpromazine versus Iloperidone	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
16059	Mueller 2008	\N	integrated neurocognitive and social cognitive group therapy versus standard care	\N	Switzerland	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
16066	Newcomer 2009a	\N	 for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
16070	Niknam 2009	\N	donepezil + Antipsychotics versus Antipsychotics	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
16071	Nordentoft 2009a	\N	standard treatment versus intensive early intervention for psychotic whose current state is not described and whose stage of illness is first episode	\N	Unclear	\N	\N	\N	\N	\N	547	\N	\N	\N	\N	\N
16073	Nordentoft 2006 b	\N	 for psychotic whose current state is not described and whose stage of illness is first episode	\N	Unclear	\N	\N	\N	\N	\N	547	\N	\N	\N	\N	\N
16074	Nyberg 2004	\N	ACR16 versus Placebo	\N	Sweden	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
16078	Oliveira 2005	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16080	Oren 2007a	\N	Aripiprazole versus Placebo//Aripiprazole versus Haloperidol//Haloperidol versus Placebo	\N	Czech Republic//United States of America	\N	\N	\N	\N	\N	232	\N	\N	\N	\N	\N
16083	Pae 2010	\N	Aripiprazole versus switch of medication for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
16086	Paillot 2009	\N	cognitive therapy versus psychotherapy versus listen empathize agree partner (leap) therapy for schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
16087	Pajonk 2010	\N	cycle ergometry versus tabletop football	\N	Germany	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
16088	Pandina 2009a	\N	paliperidone palmitate versus Placebo versus dosage of drug + for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	636	\N	\N	\N	\N	\N
16089	Patel 2010	\N	cognitive remediation therapy + usual care versus usual care	\N	United kingdom	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
16090	ISRCTN42412532	\N	pergolide versus tolcapone versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described with cognitive impairment	\N	Germany	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
16091	Penades 2006 d	\N	cognitive remediation therapy + standard medication versus cognitive behavioral therapy + standard medication for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic with negative symptoms	\N	Unclear	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
16092	Peralta 2010	\N	Risperidone versus Haloperidol	\N	Unclear	\N	\N	\N	\N	\N	173	\N	\N	\N	\N	\N
16101	Peuskens 2007 c	\N	Quetiapine versus Placebo	\N	Belgium//India//Sweden//Ukraine//United States of America	\N	\N	\N	\N	\N	327	\N	\N	\N	\N	\N
16106	Pickett-Schenk 2006a	\N	family education intervention versus control group	\N	United States of America	\N	\N	\N	\N	\N	462	\N	\N	\N	\N	\N
16114	Poyurovsky 2007a	\N	reboxetine versus Olanzapine versus Placebo for schizophrenia whose current state is not described and whose stage of illness is first episode	\N	Unclear	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
16116	ISRCTN84216587	\N	Physical Activities versus Psychotherapy	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 9\r\n\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	256	\N	\N	\N	\N	\N
16121	Raaska 2004	\N	caffeinated coffee versus decaffeinated coffee	\N	Finland	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
16123	Randal 2003	\N	multimodal psychotherapy + standard care versus standard care	\N	Australia	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
16134	Robb 2010	\N	Aripiprazole versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	302	\N	\N	\N	\N	\N
16136	ACTRN12610000241033	\N	rehabilitation versus standard treatment + versus peer support + for psychotic whose current state is not described and whose stage of illness is first episode	\N	Australia	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
16138	Rogers 2006	\N	psychiatric vocational rehabilitation versus enhanced state vocational rehabilitation	\N	United States of America	\N	\N	\N	\N	\N	242	\N	\N	\N	\N	\N
16142	Rupnow 2005 c	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	255	\N	\N	\N	\N	\N
16153	Sandison 1960 a	\N	thioridazine versus Placebo versus dosage of drug + for schizophrenia whose current state is acute and whose stage of illness is persistent // chronic	\N	Unclear	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
16161	Schooler 2003a	\N	Clozapine versus Risperidone for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is persistent // chronic	\N	Unclear	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
16162	Schuhmacher 2009a	\N	Haloperidol versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
16163	Schultz 2007	\N	\N	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
16168	Sevy 2009	\N	dosage of drug + versus Risperidone versus Olanzapine for schizophrenia or//and schizophreniform whose current state is not described and whose stage of illness is first episode with cannabis use disorder	\N	Unclear	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
16180	Silverman 2009	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
16193	Smeerdijk 2009	\N	psychoeducation versus family motivational intervention for psychotic whose current state is not described and whose stage of illness is early illness	\N	Unclear	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
16195	ISRCTN67096137	\N	cognitive behavioral therapy (cbt) versus standard psychiatric care for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United Kingdom	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
16198	Stenberg 2009a	\N	mirtazapine versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
16204	Sumiyoshi 2008	\N	buspirone versus Placebo	\N	Japan//United States of America	\N	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
16207	Swildens 2005	\N	psychiatric rehabilitation versus rehabilitation for serious mental illness whose current state is not described and whose stage of illness is not described	\N	Netherlands	\N	\N	\N	\N	\N	1507	\N	\N	\N	\N	\N
17258	于席丽 2009	\N	Risperidone versus Quetiapine 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16211	NCT01100775	\N	galantamine versus galantamine or Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
16223	Tregellas 2010	\N	DMXB-A versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
16224	Tsang 2010	\N	integrated supported employment versus traditional vocational rehabilitation	\N	China	\N	\N	\N	\N	\N	189	\N	\N	\N	\N	\N
16234	Valmaggia 2003	\N	supportive counseling + psychoeducation versus cognitive behavioral therapy (cbt) for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic with positive symptoms	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
16236	Van Nimwegen 2006a	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	131	\N	\N	\N	\N	\N
16237	Van Nimwegen 2006b	\N	Olanzapine versus Risperidone versus dosage of drug + for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	131	\N	\N	\N	\N	\N
16245	Vanweringh 1994	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
16248	Vercammen 2009a	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
16258	ISRCTN03613183	\N	home treatment intervention versus standard treatment for serious mental illness whose current state is not described and whose stage of illness is not described	\N	United Kingdom	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
16263	Whitehead 2009	\N	Aripiprazole versus Placebo versus dosage of drug + for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
16265	ACTRN12610000249055	\N	standard treatment + versus group therapy versus care management for schizophrenia whose current state is not described and whose stage of illness is not described with substance related disorder	\N	Australia	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
16267	Wilson 1994	\N	Haloperidol versus Placebo//Haloperidol versus Lithium//Lithium versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
16269	Wisniewski 2009	\N	Aripiprazole versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	302	\N	\N	\N	\N	\N
16270	Wisted 1990	\N	zuclopenthixol decanoate versus Haloperidol decanoate	\N	Sweden	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
16271	Woods 2009a	\N	standard treatment versus systematic treatment for early psychosis (step) for psychotic whose current state is not described and whose stage of illness is first episode	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
16273	ISRCTN55488371	\N	standard treatment versus computer-assisted cognitive remediation versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described with cognitive impairment	\N	United Kingdom	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
16281	Luo Xin 2008 a	\N	Ziprasidone versus Olanzapine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16282	Wang JiHong 2008 a	\N	Comprehensive nursing intervention + standard care versus standard care	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16286	Canuso 2010a	\N	\N	\N	Multicentre//United States of America//Canada//Argentina//Columbia//Czech Republic//Slovakia//Ukraine	\N	\N	\N	\N	\N	201	\N	\N	\N	\N	\N
16287	Canuso 2010b	\N	paliperidone extended release versus dosage of drug + versus Placebo for schizoaffective disorders or//and schizophrenia whose current state is acute and whose stage of illness is not described	\N	Multicentre//India//Russia//Ukraine//United States of America	\N	\N	\N	\N	\N	316	\N	\N	\N	\N	\N
16289	Cordes 2010	\N	magnetic stimulation (Transcranial Magnetic Stimulation) versus sham	\N	Germany	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
16290	Johnsen 2010	\N	Risperidone versus Ziprasidone	\N	Norway	\N	\N	\N	\N	\N	213	\N	\N	\N	\N	\N
16293	ISRCTN27745631	\N	Acetylsalicylic Acid (Aspirin) versus Placebo	\N	The Netherlands	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	70	\N	\N	\N	\N	\N
16295	Meltzer 2010	\N	Clozapine versus typical neuroleptics	\N	United States of America	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
16296	Peuskens 2010	\N	Quetiapine versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic	\N	Sweden//Belgium	\N	\N	\N	\N	\N	197	\N	\N	\N	\N	\N
16306	Choi 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
16312	Lee 2010 b	\N	Risperidone versus standard care	\N	Republic of Korea	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
16313	Mirabella 2009	\N	Group cognitive behavioural therapy	\N	Italy	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
16316	Aghotor 2010a	\N	metacognitive training versus control group	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
16317	Eack 2010	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16323	Berwaerts 2010	\N	paliperidone extended release versus Placebo	\N	Multicentre//Europe	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
16325	Bushe 2010	\N	Olanzapine versus Quetiapine	\N	Multicentre	\N	\N	\N	\N	\N	340	\N	\N	\N	\N	\N
16326	Butler 2010	\N	supported employment program for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	United Kingdom	\N	\N	\N	\N	\N	203	\N	\N	\N	\N	\N
16328	Ceccato 2009	\N	\N	\N	Italy	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
16330	Finding 2010	\N	molindone versus Olanzapine versus Risperidone for schizophrenia or//and schizophreniform whose current state is acute and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
19875	NCT01714661	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16334	Howard 2010	\N	supported employment versus treatment as usual	\N	United Kingdom	\N	\N	\N	\N	\N	219	\N	\N	\N	\N	\N
16335	Hsu 2010	\N	IM Olanzapine versus IM Haloperidol	\N	Taiwan	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
16337	Kinon 2010a	\N	Risperidone versus various doses	\N	Unclear	\N	\N	\N	\N	\N	628	\N	\N	\N	\N	\N
16338	Kramer 2010	\N	paliperidone palmitate versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	197	\N	\N	\N	\N	\N
16341	Li 2008	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
16342	Liang 2010	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
16343	Maurel 2010	\N	control program versus pharmaceutical education for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	France	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
16344	McClure 2010	\N	pergolide versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
16345	McCrone 2010	\N	early intervention service versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
16346	Mittrach 2010a	\N	repetitive transcranial magnetic stimulation (rtms) versus sham transcranial magnetic stimulation for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is persistent // chronic	\N	Germany	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
16348	Narula 2010	\N	tipiramate + Olanzapine versus Placebo + Olanzapine	\N	India	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
16349	Pandina 2010	\N	paliperidone palmitate versus Placebo	\N	Multicentre//Asia//Europe//United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	652	\N	\N	\N	\N	\N
16353	Stenberg 2010	\N	mirtazapine versus Placebo	\N	Russian Federation	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
16355	Vernon 2010a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	191	\N	\N	\N	\N	\N
16356	Wang 2010b	\N	Risperidone versus maintenance therapy versus dose reduction for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic	\N	China	\N	\N	\N	\N	\N	404	\N	\N	\N	\N	\N
16360	Emmanuel 2002	\N	enhanced key-worker liaison versus normal care	\N	United Kingdom	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
16361	Engelhardt 1994	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16362	Maosheng 2002	\N	family intervention + medication versus control group	\N	China	\N	\N	\N	\N	\N	357	\N	\N	\N	\N	\N
16363	Pandina 2010a	\N	paliperidone palmitate versus Risperidone	\N	Multicentre	\N	\N	\N	\N	\N	1220	\N	\N	\N	\N	\N
16364	Gulliver 2010	\N	Olanzapine long-acting injection versus low//medium//high dosages	\N	Canada	\N	\N	\N	\N	\N	599	\N	\N	\N	\N	\N
16365	Alphs 2010	\N	paliperidone palmitate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	312	\N	\N	\N	\N	\N
16366	Schoemaker 2010	\N	Asenapine versus Olanzapine	\N	United Kingdom	\N	\N	\N	\N	\N	440	\N	\N	\N	\N	\N
16370	Ananth 1975	\N	Amantadine Hydrochloride versus Benztropine Mesylate // Amantadine Hydrochloride versus Ethopropazine // Benztropine Mesylate versus Ethopropazine	\N	Canada	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
16371	Roberts 2010	\N	Olanzapine versus dosage of drug + versus Quetiapine for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is persistent // chronic with negative symptoms	\N	United States of America	\N	\N	\N	\N	\N	223	\N	\N	\N	\N	\N
16372	Claghorn 1970 b	\N	Chlorpromazine versus Oxypertine	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
16375	Holden 1971a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16376	Deutsch 1971a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16377	Guirguis 1977a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16380	McLaughlin 1973	\N	Chlorpromazine // Piperacetazine	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
16383	Ghaeli 2001	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16386	Merrick 1973	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16388	Froemming 1988	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16392	Kramer 1975a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16395	Cold 1989	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16396	Garcia 1992	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16397	Lampe 1969a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16398	Beebe 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
16400	Borges 2010	\N	dosage of drug + versus Clozapine for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Brazil	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
16402	Forsberg 2010	\N	lifestyle program versus control group	\N	Sweden	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
16403	Mielke 1975a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16405	Jus 1975a	\N	penfluridol versus thioridazine	\N	Canada	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
16413	Lim 2010	\N	Risperidone orodispersible tablet versus IM Haloperidol	\N	Republic of Korea	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
16414	Levine 2010a	\N	Olanzapine versus Haloperidol	\N	North America//Western Europe	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
16416	Minzenberg 2010	\N	Modafinil versus Placebo // Modafinil Dosage	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
16418	Fisher 2010	\N	auditory training versus control group	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
16422	Lak 2010	\N	chinese basic conversation skill module (cbcsm) versus Placebo versus social skills training for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	Hong Kong	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
16427	Mueser 2010a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	183	\N	\N	\N	\N	\N
16428	Linnoila 1976a	\N	Sodium Valproate versus Placebo	\N	\N	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
16430	Robinson 2010a	\N	peer support intervention versus specialist treatment care	\N	Austrialia	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
16432	Jones 1995a	\N	Risperidone Once-Daily versus Risperidone Twice-Daily	\N	Multi-Center	\N	\N	\N	\N	\N	211	\N	\N	\N	\N	\N
16433	Dufresne 1992	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16436	Pietrzak 2010	\N	d-amphetamine versus Placebo	\N	Multicentre//United States of America//Australia	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
16437	Reyntens 1998	\N	Anticholinergic medication versus Placebo	\N	Belgium	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
16441	Diaz 2010	\N	Haloperidol versus Risperidone	\N	Multicentre//Spain//United States of America	\N	\N	\N	\N	\N	111	\N	\N	\N	\N	\N
16442	Fernandez 2010	\N	metformin versus Placebo	\N	Venezuela	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
16443	Francey 2010 a	\N	psychosocial treamtment + Antipsychotics versus psychosocial treamtment + Placebo	\N	Australia	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
16445	Muller 2010	\N	\N	\N	Germany	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
16447	Smith 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
16448	Srinath 2010	\N	Haloperidol + promethazine versus Lorazepam injection//Lorazepam for aggression//Haloperidol for aggression//promethazine for aggression	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
16449	Stahl 2010 a	\N	\N	\N	Multicentre//United States of America	\N	\N	\N	\N	\N	599	\N	\N	\N	\N	\N
16450	Stip 2010 a	\N	Ziprasidone versus switch of medication versus dosage of drug + for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is persistent // chronic	\N	Canada	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
16451	Van Veelen 2010	\N	\N	\N	Multicentre//Belgium//Netherland	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
16453	Xiong 2010	\N	Electroacupuncture + Clozapine versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
16457	Shinde 2005	\N	family psychoeducation group versus control group	\N	Republic of India	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
16459	Anon 2010 d	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
16462	Barrio 2010	\N	family based intervention versus life skills training versus support for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
16469	Choi 2010 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
16472	Day-Poulsen 2009	\N	\N	\N	European Multicentre	\N	\N	\N	\N	\N	258	\N	\N	\N	\N	\N
16473	De Las Cuevas 2006	\N	video conference telepsychiatry versus face to face conventional treatment for psychotic whose current state is not described and whose stage of illness is not described	\N	Multicentre//Spain//Australia	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
16485	Gopal 2010	\N	\N	\N	Multicentre//United States of America//Malaysia//Republic of Korea//Taiwan//Ukraine	\N	\N	\N	\N	\N	388	\N	\N	\N	\N	\N
16487	Guo 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	1268	\N	\N	\N	\N	\N
16489	Han 2009	\N	\N	\N	China	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
16490	Iancu 2010	\N	escitalopram versus Placebo	\N	Israel	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
16491	Kasckow 2010	\N	 for lay carers//family or//and schizoaffective disorders whose current state is not described and whose stage of illness is persistent // chronic with subsyndromal depression	\N	United States of America	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
16494	Klrov 2009	\N	repetitive Transcranial Magnetic Stimulation Route	\N	Czech	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
16495	Koethe 2009	\N	\N	\N	Germany	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
16496	Kramer 2010 b	\N	Paliperidone versus Placebo ER oros paliperidone versus Placebo	\N	India // Latvia // Lithuania // Romania // Turkey // United States of America // Multi-Center and United States of America	\N	\N	\N	\r\nUser defined 3\r\n	\N	207	\N	\N	\N	\N	\N
16497	Kuwilsky 2010	\N	Clozapine versus Ziprasidone versus Risperidone for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is not described with treatment resistant	\N	Germany	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
16499	Lencz 2010	\N	Olanzapine versus dosage of drug + versus Risperidone for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is first episode	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
16504	Mittal 2009 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
16505	Miller 2009	\N	\N	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
16506	Montero 2006 a	\N	family intervention versus relatives' group for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Spain	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
16507	Nasrallah 2010	\N	\N	\N	Multicentre//United States of America//South Africa//Romania//Russia//Bulgaria	\N	\N	\N	\N	\N	514	\N	\N	\N	\N	\N
16509	Nomoto 2006	\N	\N	\N	Japan	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
16511	Novak 2006	\N	repetitive transcranial magnetic stimulation (rtms) versus sham transcranial magnetic stimulation for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic with negative symptoms	\N	Czech Republic	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
16513	Peters 2010	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
16514	Prakash 2006	\N	electroconvulsive therapy + donepezil versus electroconvulsive therapy + Placebos for schizophrenia whose current state is not described and whose stage of illness is not described	\N	India	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
16518	Salyers 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	324	\N	\N	\N	\N	\N
16519	Schoemaker 2010 a	\N	Asenapine versus Olanzapine for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	Multicentre//United States of America//Spain//Netherlands//Russia//Spain//Germany//United Kingdom//Australia//South Africa//Belgium//Czech Republic//France//Poland	\N	\N	\N	\N	\N	1225	\N	\N	\N	\N	\N
16522	Shiina 2010	\N	tropisetron versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic	\N	Japan	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
16524	Stinson 2010	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
16526	Tondora 2010	\N	illness management versus peer support versus standard care for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is persistent // chronic with negative symptoms	\N	United States of AmericA	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
16530	Van Der Feltz 2006	\N	psychiatric consultation versus care as usual for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Netherlands	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
16533	Yang 2010	\N	Blonanserin versus Risperidone	\N	South Korea	\N	\N	\N	\N	\N	206	\N	\N	\N	\N	\N
16534	Zisook 2010	\N	citalopram versus Placebo versus augmentation therapy for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described with depression	\N	United States of America	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
16963	Singh 2010 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	201	\N	\N	\N	\N	\N
16964	Cazorla 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
16965	Joep 2010	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	440	\N	\N	\N	\N	\N
16969	Chiu 2010 a	\N	\N	\N	Multisite	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
16970	Baptista 2010	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
16972	Dubovsky 2010 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
16973	Witte 2010	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	1064	\N	\N	\N	\N	\N
16975	Slotema 2010	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
16976	Litman 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
16977	Stahl 2010 c	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
16978	Alphs 2010 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	146	\N	\N	\N	\N	\N
16980	Chan 2010 d	\N	Olanzapine versus Risperidone for schizophrenia or//and schizophreniform whose current state is not described and whose stage of illness is not described with tardive dyskinesia	\N	Taiwan	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
16984	Xiang 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	404	\N	\N	\N	\N	\N
16988	Zhang 2010	\N	Haloperidol versus Quetiapine fumarate for schizophrenia whose current state is acute and whose stage of illness is not described	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
16989	Li 2010 a	\N	Risperidone long acting injection versus dosage of drug + versus paliperidone palmitate for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Multicentre//United States of America//China	\N	\N	\N	\N	\N	452	\N	\N	\N	\N	\N
16993	Takekita 2010	\N	Aripiprazole versus Perospirone	\N	Japan	\N	\N	\N	\r\nNotes2\r\ndosage of drug + versus Aripiprazole versus perospirone for schizophrenia whose current state is not described and whose stage of illness is not described	\N	62	\N	\N	\N	\N	\N
16994	Pandina 2010 e	\N	dosage of drug + versus paliperidone palmitate versus Placebo for schizophrenia whose current state is acute and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	636	\N	\N	\N	\N	\N
17003	Mohammadi 2010	\N	estrogen versus Placebo for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
17007	Chaudhry 2010	\N	minocycline versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described with negative symptoms	\N	Multicentre//Brazil//Pakistan	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
17015	Iglesias-Garcia 2010	\N	\N	\N	Spain	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
17032	Kane 2010 d	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	386	\N	\N	\N	\N	\N
17038	Granholm 2010 a	\N	Cognitive Behavioral Therapy	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
17048	ACTRN12610000954022	\N	Haloperidol versus Olanzapine//Haloperidol versus Quetiapine//Haloperidol versus Risperidone//Haloperidol versus Ziprasidone//Olanzapine versus Quetiapine// Olanzapine versus Risperidone//Olanzapine versus Ziprasidone//Quetiapine versus Risperidone//Quetiapine versus Ziprasidone//Risperidone versus Ziprasidone	\N	Spain	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
17049	ChiCTR-TRC-10000934	\N	\N	\N	China	\N	\N	\N	\N	\N	3000	\N	\N	\N	\N	\N
17052	NTR747	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
17053	NTR2350	\N	\N	\N	Netherland	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 9\r\n	\N	168	\N	\N	\N	\N	\N
17054	NTR1799	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
17055	NTR1787	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
17056	Turner 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	312	\N	\N	\N	\N	\N
17060	NCT00137267	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	nclear	\N	\N	\N	\N	\N
17061	NCT00439634	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	700	\N	\N	\N	\N	\N
17062	NCT00227305	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	1000	\N	\N	\N	\N	\N
17063	NCT00299702	\N	Aripiprazole versus Risperidone long acting injection	\N	United States of America//Argentina//Chile//India	\N	\N	\N	\N	\N	316	\N	\N	\N	\N	\N
17064	NCT00642369	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
17069	Chandler 1999	\N	standard treatment versus capitatted assertive community treatment for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
17072	Faries 2009a	\N	switch of medication versus conventional Antipsychotic drugs versus Atypical Antipsychotic for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is persistent // chronic	\N	United States of America	\N	\N	\N	\N	\N	664	\N	\N	\N	\N	\N
17078	Koolaee 2010	\N	 for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
17079	Schepp 2009	\N	Multifamily Group Psychoeducation	\N	United States of America	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
17080	NCT01251055	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
17081	NCT01246232	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	230	\N	\N	\N	\N	\N
17082	NCT01244854	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
17083	NCT01242371	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
17085	NCT01234454	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
17086	Ereshefsky 2010	\N	Lurasidone Dosage // Lurasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
17087	Garcia 2010	\N	\N	\N	Spain	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
17088	Johnsen 2010a	\N	\N	\N	Norway	\N	\N	\N	\N	\N	226	\N	\N	\N	\N	\N
17090	Kim 2010 e	\N	Blonanserin versus Risperidone	\N	South Korea	\N	\N	\N	\N	\N	212	\N	\N	\N	\N	\N
17091	Kinon 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	669	\N	\N	\N	\N	\N
17092	Marsh 2010	\N	Mental State Reasoning Training versus Social Activities	\N	Australia	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
17094	Rodewald 2010a	\N	\N	\N	Multicentre//Switzerland//Germany	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
17096	Segarra 2010	\N	\N	\N	Spain	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
17097	Slotema 2010a	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
17098	Stauffer 2010a	\N	Continuing Risperidone versus Switching to Olanzapine	\N	\N	\N	\N	\N	\N	\N	628	\N	\N	\N	\N	\N
17101	Tsapakis 2010	\N	\N	\N	Multicentre//United Kingdom//United States of America//Greece	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
17104	Filia 2010a	\N	control groups versus healthy life style intervention for serious mental illness whose current state is not described and whose stage of illness is not described	\N	Australia	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
17106	Guastella 2010	\N	oxytocin versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
17108	Marsh 2010a	\N	social activity group versus mental state reasoning for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Australia	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
17109	McCabe 2010	\N	emotion recognition versus biofeedback for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Australia	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
17110	Reece 2010	\N	memory training for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic with memory dysfunction	\N	Australia	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
17111	Robinson 2010b	\N	standard treatment versus peer support for psychotic whose current state is not described and whose stage of illness is first episode	\N	Australia	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
17112	Saddichha 2010	\N	Risperidone versus Olanzapine versus Haloperidol for schizophrenia whose current state is not described and whose stage of illness is first episode	\N	India	\N	\N	\N	\N	\N	161	\N	\N	\N	\N	\N
17208	Schepp 2010	\N	Symptom Management	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21009	李燕 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
17113	Stain 2010	\N	cognitive behavioral therapy (cbt) versus non-directive reflective listening (ndrl) for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Multicentre//Australia//United Kingdom	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
17114	Vercammen 2010	\N	repetitive transcranial magnetic stimulation (rtms) versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described with treatment resistant	\N	Netherlands	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
17116	Weickert 2010	\N	transcranial direct current stimulation versus sham tms for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Australia	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
17118	Crocq 2010	\N	\N	\N	Multicentre//France//Denmark//Turkey//Belgium//Netherland//United Kingdom//Germany//Netherlands//Italy//Hong Kong//India//Taiwan//Thailand//South Korea//Singapore//Philippines	\N	\N	\N	\N	\N	9809	\N	\N	\N	\N	\N
17119	Grootens 2010	\N	\N	\N	Multicentre//Netherlands//Belgium	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
17120	Anon 2010a	\N	supportive therapy versus cognitive enhancement therapy for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is persistent // chronic	\N	Unclear	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
17122	Ciorabai 2010	\N	Olanzapine conventional oral tablet (oct) versus Olanzapine orodispersible tablet (odt) for schizophrenia whose current state is partial remission and whose stage of illness is not described	\N	Multicentre//Turkey//Romania//Israel//Brazil//Mexico	\N	\N	\N	\N	\N	265	\N	\N	\N	\N	\N
17124	De 2010	\N	\N	\N	Multicentre//Belgium//Denmark	\N	\N	\N	\N	\N	261	\N	\N	\N	\N	\N
17125	Gaebel 2010a	\N	Risperidone long acting injection versus Quetiapine for schizophrenia or//and schizoaffective disorders whose current state is partial remission and whose stage of illness is not described	\N	Multicentre//Spain//France//Italy//Germany//Sweden	\N	\N	\N	\N	\N	710	\N	\N	\N	\N	\N
17127	Nelleman 2010	\N	Olanzapine versus sertindole for psychotic whose current state is acute and whose stage of illness is not described	\N	Multicentre//Taiwan//South Korea//Singapore//Denmark//China	\N	\N	\N	\N	\N	389	\N	\N	\N	\N	\N
17130	Haut 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
17133	Shibre 2010	\N	trimethoprim versus Placebo for schizophrenia whose current state is acute and whose stage of illness is persistent // chronic	\N	Multicentre//United Kingdom//Ethiopia	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
17134	Vercammen 2010a	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
17141	Eack 2010b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
17143	Malchow 2010	\N	Aerobic exercise versus table football//exercise therapy	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
17149	Botha 2010a	\N	\N	\N	South Africa	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
17152	Nyhuis 2010a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	664	\N	\N	\N	\N	\N
17153	Tiwari 2010	\N	\N	\N	Multicentre//United States of America//Canada	\N	\N	\N	\N	\N	154	\N	\N	\N	\N	\N
17162	Cotton 2010a	\N	\N	\N	Australia	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
17178	NCT00212784	\N	\N	\N	Australia	\N	\N	\N	\N	\N	1225	\N	\N	\N	\N	\N
17179	NCT00061802	\N	\N	\N	United States of America//India//Romania	\N	\N	\N	\N	\N	225	\N	\N	\N	\N	\N
17180	NCT00946985	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	163	\N	\N	\N	\N	\N
17183	NCT01051531	\N	\N	\N	Multicentre//Australia//Hong Kong//Taiwan//China//New Zealand//South Korea//Thailand//Malaysia	\N	\N	\N	\N	\N	587	\N	\N	\N	\N	\N
17184	Potkin 2006 c	\N	Quetiapine versus Placebo // Quetiapine versus Risperidone // Risperidone versus Placebo	\N	United States of America//India//Romania	\N	\N	\N	\N	\N	382	\N	\N	\N	\N	\N
17185	Greenspan 2005a	\N	\N	\N	United States of America//India//Romania	\N	\N	\N	\N	\N	382	\N	\N	\N	\N	\N
17186	Greenspan 2005 d	\N	\N	\N	United States of America//India//Romania	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17187	Potkin 2005a	\N	\N	\N	United States of America//India//Romania	\N	\N	\N	\N	\N	382	\N	\N	\N	\N	\N
17188	Alvarez 2006 a	\N	\N	\N	Spain	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
17190	Chaplin 2007	\N	\N	\N	United States of America//India//Romania	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17191	Alvarez 2010	\N	\N	\N	Spain	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
17196	ISRCTN22581937	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
17197	ISRCTN03732457	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
17198	ISRCTN16939126	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
17199	ISRCTN02507940	\N	Recovery intervention versus treatment as usual	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n	\N	420	\N	\N	\N	\N	\N
17200	ISRCTN29607432	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
17201	ISRCTN60687844	\N	Modafinil versus Placebo	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n	\N	40	\N	\N	\N	\N	\N
17203	ISRCTN68824876	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	230	\N	\N	\N	\N	\N
17204	ISRCTN95603741	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
17205	ISRCTN71943786	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
21010	李永强 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
17209	Scheppp 2010	\N	Psychoeducation	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
17210	NCT01259427	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	276	\N	\N	\N	\N	\N
17211	NCT01266174	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
17213	Tenhula 2007	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
17214	Pierce 2004	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
17218	Cusack 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	134	\N	\N	\N	\N	\N
17223	Kender 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
17227	Addington 2011	\N	cognitive behavioral therapy (cbt) versus supportive therapy for schizophrenia whose current state is acute and whose stage of illness is prodromal illness	\N	Multicentre//Canada//United Kingdom	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
17229	Daumit 2010	\N	group exercise versus group exercise + peer support for serious mental illness whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
17230	Kaplan 2011	\N	internet peer support for schizophrenia whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
17231	Tregellas 2011	\N	dosage of drug + versus Placebo versus dmxb-a for schizophrenia whose current state is acute and whose stage of illness is persistent // chronic	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
17232	Pietrzak 2010 a	\N	amphetamine versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic	\N	Multicentre//United States of America//Australia	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
17233	Bose 2010	\N	 for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Hungary	\N	\N	\N	\N	\N	732	\N	\N	\N	\N	\N
17234	Cassella 2010 a	\N	dosage of drug + versus loxapine versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described with agitation	\N	United States of America	\N	\N	\N	\N	\N	344	\N	\N	\N	\N	\N
17236	Dubovsky 2010 b	\N	Asenapine sublingual versus Asenapine versus dosage of drug + for psychotic whose current state is acute and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
17237	Fricchione 2010	\N	zuclopenthixol versus depot preparations versus zuclopenthixol for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	Multicentre//Australia//Italy	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
17238	Ghaleiha 2010	\N	 for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
17239	Istikoglou 2010	\N	Haloperidol - intramuscular versus Aripiprazole for psychotic whose current state is acute and whose stage of illness is not described with agitation	\N	Greece	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
17240	Klirova 2010	\N	sham transcranial magnetic stimulation versus repetitive transcranial magnetic stimulation (rtms) for schizophrenia whose current state is partial remission and whose stage of illness is not described with auditory halluciantions	\N	Czech Republic	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
17241	Marque 2010 a	\N	minocycline versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic	\N	Multicentre//Canada//Brazil	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
17243	Pandina 2010 b	\N	 for schizophrenia whose current state is not described and whose stage of illness is not described for schizophrenia whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	1220	\N	\N	\N	\N	\N
17244	Perez 2010	\N	Haloperidol versus Olanzapine versus Risperidone for psychotic whose current state is acute and whose stage of illness is first episode	\N	Spain	\N	\N	\N	\N	\N	145	\N	\N	\N	\N	\N
17246	Schmidt 2010	\N	Olanzapine versus Placebo versus jnj-37822681 for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Belgium	\N	\N	\N	\N	\N	498	\N	\N	\N	\N	\N
17247	Sliwa 2010	\N	dosage of drug + versus paliperidone palmitate versus Placebo for schizophrenia whose current state is acute and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	625	\N	\N	\N	\N	\N
17248	Staring 2010	\N	standard treatment versus adherence therapy versus motivational interviewing for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	Netherlands	\N	\N	\N	\N	\N	109	\N	\N	\N	\N	\N
17250	Tessier 2010	\N	paliperidone extended release versus Olanzapine versus dosage of drug + for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Multicentre//France//Spain//Germany//Greece//South Africa//Belgium//Turkey//Argentina//Slovakia Republic//Netherlands	\N	\N	\N	\N	\N	459	\N	\N	\N	\N	\N
17251	Zhang 2010 a	\N	Haloperidol versus Quetiapine fumarate for schizophrenia whose current state is acute and whose stage of illness is not described	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
17252	Genevsky 2010a	\N	Cognitive Training (Computerized) versus Games (Computer)	\N	United States of America	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
17254	Ritsner 2010 a	\N	 for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is persistent // chronic	\N	Israel	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
17256	丁兆生2010	\N	Aripiprazole + Clozapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17257	于伟文 2010	\N	Comprehensive nursing intervention + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17259	于文斗 2010	\N	Psychosocial intervention + drug therapy versus drug therapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17260	付华秀 2009	\N	Family nursing versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17262	任春生 2009	\N	Modified electroconvulsive therapy (MElectroconvulsive Therapy) + Clorpromazine versus Electroconvulsive therapy (Electroconvulsive Therapy)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17263	任祥艳 2010	\N	Psychological intervention versus Routine supply of information	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17264	任艳萍 2010	\N	Repetitive transranial magnetic stimulation (repetitive Transcranial Magnetic Stimulation) versus Repetitive transranial magnetic stimulation (repetitive Transcranial Magnetic Stimulation) - Sham	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17265	伍群萍 2010	\N	Continuous nursing service + periodic follow-up visits versus Periodic follow-up visits	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17266	伏彩霞 2010 a	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17267	伏彩霞 2010 b	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17268	但雪姣 2010	\N	Quetiapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17269	何凤叶 2010	\N	Psychological nursing + Risperidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17270	何凤叶 2009	\N	Health education + Risperidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17271	He 2009	\N	Self-care theory intervention + holistic nursing versus Holistic nursing	\N	\N	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
17272	何燕飞 2010	\N	Risperidone + Lithium versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17273	何玲 2010	\N	Home visit versus No visit	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17274	He Ruirong 2009	\N	Risperidone microsphere for injection versus Haloperidol tablets	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17275	何香娟 2010	\N	Open ward management + pharmacotherapy versus Closed ward management + pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17276	余成国 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17277	余瑞高 2009	\N	Aripiprazole versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17278	余英仪 2010	\N	Day hospital workshop rehabilitation + regular follow-up visits versus Regular follow-up visits	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17279	侯占岭1 2009	\N	Risperidone orally disintegrating tablets versus Risperidone tablets	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17280	侯占岭 2010	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17281	侯雪玲 2009 b	\N	Health education + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17282	傅深省 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17283	Fu 2010	\N	Quantitative self-management + Behavioural therapy versus Behavioural therapy	\N	\N	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
17284	党亚军 2010	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17285	全瑞国 2009	\N	Traditional Chinese Medicine (TCM) Huangqi injection + Antipsychotic versus Antipsychotic	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17286	冒雷明 2010	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17287	农秋燕 2010	\N	Holistic nursing + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17288	冯宝珍 2009	\N	Rational emotion guidance therapy + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17289	冯龙喜 2010	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17290	刘井华 2009	\N	Social skill training + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17292	刘卉兰 2010	\N	Clozapine versus Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17293	刘华 2010	\N	Systemic rehabilitation intervention + standard care versus standard care 	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17294	刘发强 2010	\N	Modified Electro Convulsive Therapy (MElectroconvulsive Therapy) + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17295	刘国友 2010	\N	Vocational rehabilitation + social skill training versus Social skill training	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17296	刘国友 2009	\N	Skill training + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17297	刘国斌 2010	\N	Olanzapine versus Haloperidol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17298	刘增龙 2010	\N	Medicated oxygen therapy (TCM) + Risperidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17299	刘娟 2009	\N	Aripiprazole versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17300	刘守梅 2009	\N	Duloxetine + Antipsychotic versus Fuloxetine + Antipsychotic	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17301	刘少华 2009	\N	Venlafaxine + Aripiprazole versus Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17302	刘庆军 2010	\N	Aripiprazole versus Haloperidol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17304	刘忠 2009 a	\N	Ziprasidone versus Baseline data (Prior to use of Ziprasidone)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17305	刘忠 2009 b	\N	Quetiapine versus Ziprasidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17306	刘新发 2010	\N	Acupuncture + Risperidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17307	刘昊 2009 c	\N	Aripiprazole versus Quetiapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17308	刘昊 2009 b	\N	Venlafaxine + Aripiprazole versus Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17309	刘春平 2009	\N	Skill training (paper folding) + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21011	李永强1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
17310	刘智 2009	\N	Quetiapine versus Chlorpromazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17311	刘朝军 2009	\N	Aripiprazole versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17312	刘杜娟 2009	\N	Systemic skill training + conventional nursing versus Conventional nursing	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17313	刘永忠 2010	\N	Psychological and behavior intervention versus None (healthy population as control)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17314	刘汝震 2010	\N	Modified Electro Convulsive Therapy (MElectroconvulsive Therapy) versus Chloropromazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17315	刘洪秋 2010	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17316	刘清连 2009	\N	Health education + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17317	刘献标 2010 a	\N	Comprehensive psychological and behavioral intervention + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17318	刘献标 2010 b	\N	Quetiapine versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17319	刘献标 2010 v	\N	Ziprasidone versus various dosages	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17320	刘磊 2010	\N	Tropisetron + Risperidone versus Risperidone + Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17321	刘秀珍 2009	\N	Interactive health education versus Conventional health education	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17322	刘翔宇 2009	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17323	刘胜皇 2010	\N	Olanzapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17324	刘艳芳 2009	\N	None versus None	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17325	刘金光 2010	\N	Olanzapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17326	华芳 2010	\N	Token economy + Care as usual versus Care as usual	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17327	单美艳 2009	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17328	单金凤 2010	\N	Exercise therapy + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17329	占归来 2009	\N	Risperidone microspheres versus Risperidone oral tablets	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17330	卢世臣 2009	\N	Comprehensive intervention + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17331	卢伟 2010 a	\N	Clozapine versus Baseline data (Prior to drug use)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17332	卢伟 2010 b	\N	Pharmacotherapy (male) versus Pharmacotherapy (female)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17333	卢春爱 2010	\N	Social skill training + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17334	卢桂华 2010	\N	Risperidone microspheres versus Risperidone oral tablets	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17335	印文娜 2010	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17336	原富强 2010	\N	Traditional Chinese Medicine (TCM) Jieyu Huatan Anshen Heji + Loxapine versus Loxapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17337	史晓慧 2010	\N	Nursing intervention + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17338	Shi 2010	\N	Haloperidol versus Magnesium Valproate + Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17339	史良荣 2010	\N	Traditional Chinese Medicine (TCM) (Jiawei Wendan decoction) + Sulpiride versus Haloperidol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17340	叶萌 2009	\N	Ziprasidone injection versus Haloperidol injection	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17341	叶飞 2009	\N	Modified Electro Convulsive Therapy (MElectroconvulsive Therapy) + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17342	叶飞英 2010	\N	Positive reinforcement + occupational and recreational therapy versus Occupational and recreational therapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17343	吕斌军 2009	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17344	吴延海 2010	\N	Loxapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17345	吴建杰 2009	\N	Social skill training + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17346	吴晓虹 2009	\N	Modified morita therapy + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17347	吴永辉 2009	\N	Olanzapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17349	吴碧兰 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17350	吴秀光 2010	\N	Nursing intervention + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17351	吴胜 2009	\N	Psychosocial intervention + Risperidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17352	吴莉珍 2009	\N	Ziprasidone versus Chlorpromazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17353	周串莲 2010	\N	Olanzapine + Sulpiride versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17354	周云 2009 d	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17355	周云 2009 c	\N	Ziprasidone versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17356	周仁义 2009	\N	Traditional Chinese Medicine (TCM) Jieyu Huatan Anshen Heji + Risperidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17357	周宝卿 2009	\N	Olanzapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17358	周庆华 2009	\N	Positive reinforcement + occupational and recreational therapy versus Occupational and recreational therapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17359	周建初 2009	\N	Psychosocial training + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21012	李梅英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
17360	周秀芳 2010	\N	Clozapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17361	周立发 2010	\N	Second generation Antipsychotics(Olanzapine, Quetiapine, Ziprasidone) versus Baseline data (Prior to drug use)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17362	周维春 2009	\N	Psychological intervention + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17363	唐嵩 2010	\N	Levofloxacin + Azithromycin versus Levofloxacin	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17365	唐茂芹 2009	\N	Quetiapine versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17366	唐静 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17368	奈效祯 2009	\N	Aripiprazole versus Chlorpromazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17369	姚华华 2010	\N	Quantitative health education + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17370	姜小琴 2009	\N	Risperidone + modified Electro Convulsive Therapy (Electroconvulsive Therapy) versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17371	Jiang 2009	\N	Magnesium Valproate + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
17372	孔国强 2009	\N	Antipsychotics versus Baseline data (Prior to drug use)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17373	孙东 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17374	孙付根 2009a	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17375	孙付根 2009b	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17376	孙凤环 2009	\N	Comprehensive rehabilitation therapy + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17377	孙德生 2009	\N	Quetiapine versus Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17378	孙爱民 2010	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17379	Sun Xiuqi 2009	\N	Protoporphrin disodium (PD) + Chloropromazine versus Chloropromazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17380	孙群星 2010	\N	Venlafaxine ER + Perphenazine versus Perphenazine + Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17381	孙静 2010	\N	Aripiprazole + Perphenazine versus Aripiprazole + Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17382	孙鹏 2009	\N	Quetiapine versus Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17383	孟彬 2009	\N	Traditional Chinese Medicine (TCM) Shumian Capsules versus Clonazepam	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17384	孟江 2010	\N	Occupational therapy versus Conventional nursing	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17385	季显琼 2010	\N	Health education for families versus None	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17386	季林影 2009	\N	Ziprasidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17387	安孝群 2009	\N	Skill training + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17388	安琼 2010	\N	Occupational and recreational therapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17389	宋丽 2009	\N	Olanzapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17390	宋军平 2010	\N	Ziprasidone versus Chlorpromazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17391	宋喜霞 2009	\N	Psychological therapy + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17392	宋新虹 2010	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17393	宋燕 2009	\N	Olanzapine versus Haloperidol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17394	宋芳 2010	\N	Olanzapine versus Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17395	宋长惠 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17396	寇桂敏 2009	\N	Ziprasidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17397	展咏1 2009	\N	Group psychotherapy + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17398	岳德华 2009	\N	Aripiprazole versus Haloperidol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17399	岳英 2010	\N	Community individual case management versus Conventional out-patient follow-up visits	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17400	崔开艳 2010	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17401	庄华 2010	\N	Aripiprazole versus Haloperidol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17402	齐波 2009	\N	Aripiprazole versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17403	龙复青 2009	\N	Aripiprazole versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17404	庞良俊 2010	\N	Ziprasidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17405	康建华 2010	\N	Social skill training versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17406	廖更生 2010	\N	Comprehensive rehabilitation therapy + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17407	张东卫 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17408	张丽 2009a	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
17409	张丽娜 2010	\N	Psychological nursing + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17410	张云芳 2010	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17411	张亚红 2009a	\N	Psychosocial intervention + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17412	Zhang Baoli 2009	\N	Aripiprazole versus Haloperidol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17413	张军勐 2010	\N	Community based rehabilitation + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17414	Zhang 2009c	\N	Game Play + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
17415	张冬敏 2010	\N	Group therapy + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17416	张加明 2010	\N	Risperidone + Mirtazapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17417	张启林 2010	\N	Aripiprazole versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17418	张小智 2010	\N	Ziprasidone + Clozapine versus Ziprasidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17419	张展筹 2010	\N	Psychoeducation + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17420	张峻岭1 2009	\N	Quetiapine versus Perphenazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17421	张帆 2009	\N	Aripiprazole versus Quetiapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17422	Zhang Ping 2009	\N	Risperidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17423	张怀伦 2010	\N	Risperidone + Mirtazapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17424	张怀惠 2009	\N	Skill training + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17425	张敏 2010	\N	Health education pathway versus Conventional health education	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17426	张文顺 2009	\N	Continuous performance test (CPT) versus Contiunous performance test (CPT)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17427	张新平 2009	\N	Traditional Chinese Medicine (TCM) Shunqi Jieyu decoction versus Amitriptyline	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17428	张明松 2009	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17429	张映虹 2010	\N	Risperidone versus Haloperidol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17430	张景崴 2009	\N	Venlafaxine + Quetiapine versus Quetiapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17431	张树龙 2010	\N	Olanzapine versus Haloperidol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17432	张毅 2009	\N	Olanzapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17433	张毅 2010	\N	Olanzapine versus Clozapine + Chlorpromazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17435	张海杰 2009	\N	Comprehensive Community-based intervention + conventional health education versus Conventional health education	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17436	张海燕 2010	\N	Olanzapine versus Serenelfi	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17437	张淑芬 2010	\N	Risperidone + Sertraline versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17438	张深山 2009	\N	Risperidone + Sertraline versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17439	张灵娥 2009	\N	Risperidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17440	张灵娥 2009a	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17441	张炜 2009	\N	Health education + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17442	张玉清 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17443	张玖龙 2010	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17444	Zhang 2009	\N	Medication self-management training + pharmacotherapy versus Pharmacotherapy Medication self-management training + pharmacotherapy versus Pharmacotherapy Medication self-management training + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
17448	张疆莉 2010a	\N	Ziprasidone injection versus Haloperidol injection	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17449	张疆莉 2010b	\N	Aripiprazole versus Haloperidol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17451	Zhang 2010a	\N	Aniracetam + Risperidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17452	张红英 2010	\N	Solution focused health education versus Conventional health education	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17453	张艳杰 2010	\N	Evidence-based nursing versus Conventional nursing	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17454	张艳琦 2009	\N	Aripiprazole versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17455	张艳琦 2010a	\N	Aripiprazole versus Perphenazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17456	张艳琦 2010b	\N	Ziprasidone versus Perphenazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17457	张艳琦 2010	\N	Ziprasidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17458	张莉 2010	\N	Comprehensive nursing intervention + pharmacotherapy versus Conventional nursing + pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17459	张轶杰 2010	\N	Modified Electro Convulsive Therapy (MElectroconvulsive Therapy) + Clozapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17460	张长军 2009	\N	Mixed-sex living + Risperidone versus Single-sex living + Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17461	张雪静 2009	\N	Nursing visits + conventional rehabilitation service versus Conventional rehabilitation service	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17462	张香芝 2009	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17463	张鸿 2010	\N	Community nursing intervention + conventional health education versus Conventional health education	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17464	彭乐存 2010	\N	Modified morita therapy + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17465	彭亮 2010	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17468	彭红艳 2010	\N	Rehabilitation therapy + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17469	彭萍1 2009	\N	Family psychotherapy + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21013	李树敏 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
17470	徐丽红1 2009	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17471	徐国洪 2010	\N	Ziprasidone versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17472	徐文炜 2010	\N	Individual cognitive rehabilitation versus None	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17473	徐斐康 2009	\N	Olanzapine versus Quetiapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17475	徐松 2010	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17476	徐清 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17477	徐清芝 2010	\N	Health education + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17478	徐秀梅 2010	\N	Aripiprazole + Yinao capsules (TCM ) versus Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17479	徐筠 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17480	徐裕 2009	\N	Sertraline + Quetiapine versus Sertraline + Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17481	徐鹏 2010	\N	Aripiprazole versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17482	支胜利 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17483	文丽 2010	\N	PDCA community-based nursing intervention + pharmacotherapy versus Conventional PDCA community-based nursing intervention + pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17484	文启琴 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17485	文家松 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17486	方亚明 2009	\N	Group psychotherapy + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17487	方传荣 2010	\N	Ziprasidone versus Quetiapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17488	施万平 2010	\N	Lamotrigine + routine Antipsychotic medication versus Routine Antipsychotic medication	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17489	施季华 2010	\N	Combined intervention + pharmacotherapy versus Conventional pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17490	易世国 2009	\N	Traditional Chinese Medicine (TCM) Qingxin decoction + Ziprasidone versus Ziprasidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17491	易元平 2009	\N	Systemic health education + conventional management versus Conventional management	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17492	晏桂萍 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17493	曾兆圣 2010	\N	Olanzapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17494	曾庆翰 2010	\N	Olanzapine versus Perphenazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17495	曾祥刚 2010	\N	Olanzapine versus Chlorpromazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17496	朱宛平 2010	\N	Ziprasidone versus Perphenazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17498	朱志高 2010	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17499	朱晓芬 2009	\N	Sertraline + Sulpiride versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17500	朱玉星 2009b	\N	Psychological nursing + Perphenazine versus Perphenazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17502	Zhu Hongmei 2010	\N	Ziprasidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17503	朱逸溪 2010	\N	Olanzapine versus Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17504	李万秀 2009	\N	Risperidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17505	李义会 2009	\N	Health education + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17506	李代秀 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17507	李作珍 2010	\N	Ziprasidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17508	李倦国 2010	\N	Quetiapine + Venlafaxine versus Quetiapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17509	李健 2009	\N	Relaxation training + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17667	程平-雷志豪-邱堂威 2009	\N	Ziprasidone versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17510	李军 2010	\N	Venlafaxine + routine Antipsychotic medication versus Placebo + routine Antipsychotic medication	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17511	李凡 2010	\N	Risperidone + Clozapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17513	李启斌 2010	\N	Ziprasidone versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17514	李国兰 2010	\N	Quetiapine versus Perphenazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17515	李国胜 2010	\N	Ziprasidone versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17516	李守春 2010	\N	Community based comprehensive intervention + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17518	李幼灵 2010	\N	Community based nursing intervention + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17519	李志雄 2009	\N	Venlafaxine + Sulpiride versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17520	李春燕 2010	\N	Olanzapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17521	李春芳 2009a	\N	Community based intervention versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17522	李春芳 2009b	\N	Supportive group therapy versus Routine occupational therapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17523	李昱 2010	\N	Ziprasidone versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17524	李晓华1 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17525	李晓玲 2009	\N	Cognitive intervention versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17526	李晓英 2009	\N	Aripiprazole versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17527	李晓菊 2009	\N	Olanzapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17528	李杰 2009	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17529	李杰 2010b	\N	Video playback + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17530	李松林 2010	\N	Quetiapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17531	李松林1 2010	\N	Risperidone + Clozapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17532	Li 2009	\N	Aripiprazole versus Aripiprazole + Magnesium Valproate	\N	\N	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
17533	李树霞 2010	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17534	李梁 2009	\N	Risperidone versus Ziprasidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17535	李海军 2010	\N	Cerebralvascular function therapy + Risperidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17536	李海涛 2010	\N	Aripiprazole versus Quetiapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17537	李淑华 2010	\N	Rehabilitation nursing therapy versus Conventional nursing care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17538	李烽 2009	\N	Risperidone (Zhuofu) versus Risperidone (Risperdal)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17539	李玉凤 2010	\N	Interactive health education versus Conventional health education	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17540	李益群 2010	\N	Quetiapine versus Chlorpromazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17541	Li 2009a	\N	Orem Self-care Model Training versus Conventional nursing	\N	\N	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
17542	李莹 2010a	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + Pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17543	李莹 2010b	\N	Quetiapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17544	李萍 2010	\N	Systematic health education + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17545	李超 2010b	\N	Aripiprazole versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17546	李轶琛 2009	\N	Aripiprazole versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17547	李轶群1 2009	\N	Ziprasidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17548	李鑫 2009	\N	Psychological therapy + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17549	杜俊林 2010	\N	Tanreqing Injectioin (TCM) versus Cefazolin sodium	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17550	杜淑艳 2010	\N	Quetiapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17551	杜玉杰 2010	\N	Aripiprazole versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17552	杜秀蓉 2010	\N	Follow visit (via telephone) + conventional discharge instruction versus Conventional discharge instruction	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17553	Du 2010	\N	Self-management focused group education + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
17554	杜荣荣 2010	\N	Open ward management versus Closed ward management	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17555	Yang 2009	\N	Physical exercise + Pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17556	杨光 2009	\N	None versus None	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17557	杨彩儒 2010	\N	Systematic cognitive therapy + Care as usual versus Care as usual	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17558	杨春强 2009a	\N	Aripiprazole versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17559	杨春强 2009b	\N	Ziprasidone versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17560	杨玲 2010	\N	Comprehensive nursing therapy + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17561	杨甫德 2009	\N	Risperidone (Domestic) versus Risperidone (Imported)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17562	Yang Xiucheng 2009	\N	Ziprasidone versus Chlorpromazine Ziprasidone versus Chlorpromazine	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17563	杨老虎 2010b	\N	Olanzapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17564	杨老虎 2009	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17565	杨菊琼 2010	\N	Daytop mode rehabilitation + Antipsychotic medication versus Conventional rehabilitation + Antipsychotic medication	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17566	杨雀屏 2010	\N	Aripiprazole versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17570	林升 2010	\N	Traditional Chinese Medicine (TCM) Wendan decoction + Risperidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17572	林文 2009	\N	Risperidone in various dosages versus Risperidone in various dosages	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17573	林素兰 2010	\N	Diverse health education versus Conventional health education intervention	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17574	林纯玲 2010	\N	Follow-up visits (via telephone) + conventional community rehabilitation versus Conventional community rehabilitation	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17575	林跃泉 2010	\N	Mirtazapine + Guipi Pills (TCM ) versus Mirtazapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17577	梁国英 2009	\N	Community nursing intervention versus Conventional nursing	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17578	梁润娣 2010	\N	Community nursing intervention versus Conventional nursing	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17579	梁素霞 2010	\N	Olanzapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17580	梁红 2009	\N	Community nursing instruction versus Conventional nursing	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17581	欧学军 2010	\N	Quetiapine versus conventional Antipsychotics	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17582	欧阳杏娟 2010	\N	Olanzapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17583	段武刚 2010	\N	Ziprasidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17584	段武钢 2010b	\N	Ziprasidone versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17585	段武钢 2010c	\N	Traditional Chinese Medicine (TCM) Anshen decoction + Ziprasidone versus Ziprasidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17586	段武钢-曾德志-罗建武-1 201	\N	Traditional Chinese Medicine (TCM) Ningxin decoction + Ziprasidone versus Ziprasidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17587	段武钢-曾德志-罗建武-2 201	\N	Ziprasidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17588	毛星-刘洪秋-陈玉辉 2010	\N	Olanzapine versus Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17589	Tang Qingping 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17668	程燕 2009	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20489	钱丹红 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
17590	汤景文-何东东-刘建明- 2010	\N	Farming intervention + conventional rehabilitation therapy versus Conventional rehabilitation therapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17593	汪波-刘智-付以蓉-宁洁 2009	\N	Pharmacotherapy + psychosocial training versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17594	汪波-周建初-刘智-宁洁 2009	\N	Pharmacotherapy + psychosocial training versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17595	汪磊萍-魏爱荣-周艾英- 2010	\N	cognitive remediation versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17596	汪莉-张斌-徐乐平-施建 2009	\N	Aripiprazole + Haloperidol versus Haloperidol + Placebo//Aripiprazole versus Haloperidol//Haloperidol versus Placebo//Aripiprazole versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17597	沈丽华-沈菊梅 2010	\N	Nursing intervention + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17598	沈婷-李朝-王飚-王慧芳 2010	\N	Etomidate versus Propofol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17599	沈婷-王飚-王慧芳-江开 2010	\N	Etomidate versus Propofol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17600	沈峰-王玲芝-李敏慧-梁 2010	\N	Group psychotherapy + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17601	沐志强-杨顺英-李弼 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17602	洪娜 2010	\N	Chlorpromazine + Qingxin Guntan Pills (Traditional Chinese Medicine (TCM)) versus Chloropromazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17603	涂国和-胡有平-周学儿 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17604	温云辉-李惠仙-康建华- 2010	\N	Modified Morita therapy + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17605	温广妹-何燕丰-王美-王 2009	\N	Health education + conventional nursing versus Conventional nursing	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17606	潘勇-庞波 2010	\N	Risperidone + Sertraline versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17607	潘朝霞-尹定富-刘宁汉 2010	\N	Clozapine + Sodium valproate versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17610	熊剑-钟志兵 2010	\N	Quetiapine versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17611	熊昆武-黄朝红-周莉 2009	\N	Psychological intervention + pharmacotherapy versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17612	熊骊龙1 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17613	王万章-张晓斌-杨兆正- 2009	\N	Olanzapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17614	王丽君-张静 2010	\N	Antipsychotic + Sodium valproate versus Antipsychotic	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17615	王俊仙-高平来 2009	\N	Risperidone versus Quetiapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17616	王兴元-张帆-康建华 2009	\N	Aripiprazole versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17618	王勇-陈祖金-袁洪彬 2010	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17619	王吉祥 2010	\N	Antipsychotic + TCM versus Antipsychotic	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17620	王善松-王翠芳-张岿-曹 2010	\N	Modified electro convulsive therapy (MElectroconvulsive Therapy) + Etomidate versus electro convulsive therapy (Electroconvulsive Therapy) + Aripiprazole + Etomidate	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17621	王学军-马富晓 2009	\N	Ziprasidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17622	王学文-李宝珠 2010	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17623	王宪琴-张程赪 2010	\N	Psychoeducation + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17624	王延祜-唐济生-柴新生- 2009	\N	Community based comprehensive rehabilitation therapy versus Outpatient follow up visit	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17625	王彩虹-杨永杰 2010	\N	Risperidone + Outpatient comprehensive nursing intervention versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17626	王慧芳-张红霞-杨晓敏- 2009	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17627	王敏-付艳菊-侯晓梅 2010	\N	Open ward management versus Closed ward management	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17628	王敬龙-王建平 2010	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17629	王方国-陈慧芹-王胜 2010	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17630	王晓平-崔亚男-王勇 2009	\N	Aripiprazole versus Self-control	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17631	王景丽-袁俊梅 2009	\N	Risperidone versus Haloperidol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17632	王洁萍-刘诏薄-饶文康 2010	\N	Ziprasidone versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17633	王淑芳-邢君 2010	\N	Risperidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17634	王祥 2009	\N	Olanzapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17636	王秀梅-李刚-李忠义 2010	\N	Quetiapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17637	王素芬-王琼秀-李小玲- 2010	\N	Olanzapine + Trazodone versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17638	王红志-王成芳-乔义俊 2010	\N	Psychological intervention + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17639	王绍昌 2010	\N	Ziprasidone versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17640	王继红-宋新勤-李莹-曹 2010	\N	Health education + conventional instrution versus Conventional instrution	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17641	Wang 2010c	\N	Self-care education + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
17642	王莹-陈清刚-李涛 2010	\N	Smoking + Olanzapine versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17643	王远昶 2009	\N	Risperidone + Paroxetine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17644	王锐成-孙洪刚-杨波 2010	\N	Ziprasidone versus Chlorpromazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17645	王长虹-李晏-苏林雁-马 2009	\N	Olanzapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17646	王闻 2009	\N	Quetiapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17647	王闻1 2009	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17648	王静 2009	\N	Atypical Antipsychotic + Shuxuening (TCM) versus Atypical Antipsychotic	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17649	王鹤秋-许本键-马永春- 2009	\N	Traditional Chinese Medicine (TCM) Shu-xue-ning (Ginkgo extract) + other Atypical-Antipsychotic versus Atypical Antipsychotic	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17650	王龙书 2010	\N	Olanzapine + Venlafaxine versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17653	由炜-付崇铭-米国琳 2009	\N	Risperidone in various dosages versus Risperidone in various dosages	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17654	白云1 2009	\N	Occupational therapy + Antipsychotic medication versus Antipsychotic medication	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17655	白剑文1 2009	\N	Ziprasidone versus Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17656	白慧丽-颜淑环-郑素娟- 2010	\N	Risperidone versus Perphenazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17657	白红娟-马军-周丽红 2010	\N	Risperidone + Citalopram versus Citalopram	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17658	白锦波-黄海燕-陶世武- 2010	\N	Risperidone versus Ziprasidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17659	皮玥玥 2010	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17660	盛民生-胡军-欧阳海兰 2010	\N	Ziprasidone versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17661	石夏明-朱凤艳-张向阳- 2009	\N	Melatonin + original pharmacotherapy versus Original pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17662	石建喜-赵建龙-岳华-张 2010	\N	Traditional Chinese Medicine (TCM) Yangxin formula 2 + Risperidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17664	石雪丽 2010	\N	Aripiprazole versus Chlorpromazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17665	祖晓雪-孙仲秋 2009	\N	Quetiapine versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17669	穆世铭-简天容 2010	\N	Psychoeducation + Antipsychotic medication versus Standard package of education + Antipsychotic medication	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17670	穆莉莉 2010	\N	Individual nursing intervention versus Conventional nursing	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17672	童梓顺-赵素华-蒋泽宇 2010	\N	Chlorpromazine, sulpiride, Clozapine, Risperidone, Olanzapine, Quetiapine, Aripiprazole versus Chlorpromazine, sulpiride, Clozapine, Risperidone, Olanzapine, Quetiapine, Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17673	符爱琴 2010	\N	Nursing intervention + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17674	管銮友 2009	\N	Ziprasidone versus Quetiapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17675	米国琳-唐茂芹-王远玉- 2009	\N	Quetiapine versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17676	米国琳-蒋燕敏-栾习云- 2009	\N	Risperidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17677	米瑛1 2009	\N	Community based nursing intervention + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17678	纪红玉-张鸿-傅列云 2010	\N	Comprehensive psychological intervention + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17679	缪海燕-徐健 2009	\N	Comprehensive psychological intervention + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17680	罗亨全 2010	\N	Olanzapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17681	罗俊明-胡曦 2009	\N	Integrated health education versus Conventional health education	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17682	罗慧芳 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17683	罗来兴 2009	\N	Risperidone (Risperdal) versus Risperidone (Zhuofei)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17684	罗琦-陈筱章-熊典樟-邹 2010	\N	Paliperidone versus Perphenazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17685	Luo Yu 2009	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17687	罗红梅 2010	\N	Health education for families + standard Care versus standard Care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17688	罗维肖-林汉-孙志国-谭 2009	\N	Play back intervention + Care as usual versus Care as usual	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17689	耿寒松-刘荣芹-边辛丑- 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17690	肖勃-谢文娇-丘春柳-林 2009	\N	Olanzapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17692	胡亚湘-崔炳喜-于浚玫- 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17693	胡海燕-朱未名-王文花- 2010	\N	Mengshi Ditan decoction (TCM) + Antipsychotic versus Antipsychotic	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17694	艾芳-张宇 2010	\N	Home based nursing intervention + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17695	苏勉-苏天勋-梁艳-叶健 2010	\N	Health education for families + standard Care versus standard Care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17696	苏爱东-李军花-李晓芳 2010	\N	Health education for family members + Antipsychotic versus Antipsychotic	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17697	苏雪萍 2009	\N	Comprehensive rehabilitation therapy (including psychoeducation, occupational therapy, social skills training) + routine Antipsychotic medication versus Routine Antipsychotic medication	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17698	Su 2009	\N	Life skills and self-management training + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
17699	苏鸣新1 2009	\N	Comprehensive nursing intervention + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17700	苏鸣新 2010	\N	Psychological intervention + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17701	范建华-覃宗厚-吴国伟 2010	\N	Olanzapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17702	范文澜-余成民-李正发 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17703	莫亚莉 2010	\N	Ziprasidone + Clozapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17704	葛传惠-孙凤霞-骆祥芬 2010	\N	Nursing intervention + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17706	葛淑君-王春艳-朱丹 2010	\N	Aripiprazole versus Quetiapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17707	董伟-顾卫霞 2010	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17708	董晓茹-孙利-武晓杰 2009	\N	Olanzapine versus Chlorpromazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17709	董汉振-蒲金玉-孙梦月- 2009	\N	Modified Morita therapy versus Conventional rehabilitation therapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17710	董继承-席巧真-缪竞诚 2009	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17711	蒋军生-许美园 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17712	蒋合萍-罗毅平 2009	\N	Olanzapine versus Haloperidol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17713	蒋国庆-罗捷 2009	\N	Aripiprazole versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17714	蒋幸衍-黄寅平-徐清-陆 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17715	蒋廷云-张文蔚-石福强 2010	\N	Individualized rehabilitation + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17716	蒋德政-易崇贵-王世荣- 2010	\N	Social skill training + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17717	蒋海潮-金凤仙 2010	\N	Paliperidone versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17718	蔡广超-李朝晖 2010	\N	Farming therapy + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17719	蔡海英 2010	\N	Open ward management versus Closed ward management	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17720	蔡连秀 2010	\N	Interactive health education versus Conventional health education	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17721	薛僖峰-孙晓刚 2010	\N	Quetiapine + Sulpiride versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17722	袁纯玲1 2009	\N	Quetiapine versus Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17723	Yuan 2009	\N	Medication self-management + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
17724	Pei 2009	\N	Medication self-management versus standard care	\N	\N	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
17725	Pei 2010	\N	Medication self-management versus standard care	\N	\N	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
17726	裴树景-杨红卫 2009	\N	Risperidone oral solution versus Haloperidol oral solution	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17727	解克平-韩莹 2009	\N	Traditional Chinese Medicine (TCM) Yimucao Extract, Wuji Baifu Pills, etc (TCM ) versus Diethylstilbestrol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17728	詹兆能 2009	\N	Ziprasidone versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17729	许宏伟-蔡晖-杨桂芝 2009	\N	Rehabilitation therapy + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17730	许若煌 2009	\N	Psychological intervention + Aripiprazole versus Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17731	诸春明 2010	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17732	诸春明-彭光海-朱培俊- 2010	\N	Quetiapine versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17733	谢子任 2009	\N	Chlorpromazine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17734	谢守付-董晔-李奕-乔晶 2010	\N	Comprehensive supportive intervention + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17735	谢根生-赵新蕾-钱国平- 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17736	谢淑娟-黎群 2010	\N	Comprehensive psychological therapy + routine Antipsychotic medication versus Conventional health education + routine Antipsychotic medication	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17737	谢炜麟1 2009	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17738	谢育南-邝云航-刘献标- 2010	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17739	谢舟明-龚毅 2010	\N	Ziprasidone versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17741	谭柏坚-叶飞英-叶百维- 2009	\N	Comprephensive rehabilitation therapy + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17742	谭茂玉 2010	\N	Individualised Family intervention//psychoeducation + standard care versus Family intervention + standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17743	谭莉-金圭星-王学义-尤 2010	\N	Club model psychoeducation//rehabilitation versus Conventional rehabilitation	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17744	Gong 2010	\N	Magnesium Valproate versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17745	贾敏 2010	\N	Painting therapy + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17746	贾永涛-张海燕-展咏 2010	\N	Risperidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17747	贾秋梅 2010	\N	Risperidone + Rifampicin versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17748	贾秋梅1 2010	\N	Aripiprazole versus Perphenazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17750	赵明丽-常余善 2010	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17751	赵晋娴-杨轲馨 2010	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17752	赵晶媛-张红星-郭素芹- 2009	\N	Skill training + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17754	赵洪祖-杜好瑞-崔二龙 2009	\N	Etomidate versus Propofol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17755	赵素萍-马超-于朋永-李 2009	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17756	赵贵文 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17757	赵青霞-胡海涛-张丽霞 2009	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17758	路光晖-韩英 2009	\N	Venlafaxine + Sulpiride versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17759	邓文-徐彩霞-祁富生-陈 2010	\N	Risperidone versus Quetiapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17760	邢秀娟 2010	\N	Aripiprazole + Sertraline versus Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17761	邬素萍-黄群明-朱伟芳 2009	\N	Psychological nursing + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17762	郎春英-唐莉莉-付萍萍- 2009	\N	Psychological intervention + Risperidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17763	郑惊涛 2009	\N	Psychosocial intervention + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17764	郑昌爱 2010	\N	Ziprasidone versus Chlorpromazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17766	郑艳梅 2009	\N	Open ward management + skill training + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17767	郑蓉-刘幸全 2010	\N	Occupational therapy + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17768	郝广义-张万红-李春来- 2009	\N	Traditional Chinese Medicine (TCM) Drugs for nourishing qi and activating blood versus Chlorpromazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17769	郭平-李转 2009	\N	Quetiapine + Sertraline versus Quetiapine + Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17770	郭桂胜-刘丽 2010	\N	Risperidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17771	郭永清-张必然-晏迎春 2010	\N	Community nursing intervention + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17772	郭赛玲1 2009	\N	Antipsychotic + sertraline versus Antipsychotic + Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17773	鄢爱平-曾德志-樊学文- 2009	\N	Anshen decoction (TCM) + Risperidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17774	钟小兵-林志雄 2009	\N	Risperidone versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17775	钟智勇-王相兰-王厚亮- 2009	\N	Buflomedil + Antipsychotics versus Antipsychotics	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17776	钟潇琦-孙祺章-卢芸凌 2010	\N	Paliperidone versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17777	钟潇琦-郑建玲-黄雄 2010	\N	Olanzapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17778	钱文胜 2009	\N	Aripiprazole versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17779	闾金杰-拜有根-黄胜华- 2010	\N	Modified Morita therapy + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17780	闾金杰-黄胜华-拜有根- 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17781	阚瑞云 2010	\N	Group health education + Traditional health education versus Traditional health education	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17782	阿怀红-沈君-廖东升-屠 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17783	陆爱军-王永强 2010	\N	Farming therapy + conventional rehabilitative treatment versus Conventional rehabilitative treatment	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17786	陈世珍-蔡卓珊 2010	\N	Skill training + conventional rehabilitation therapy + pharmacotherapy versus Conventional rehabilitation therapy + pharmacotherapy	\N	China	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	160	\N	\N	\N	\N	\N
17787	陈丽-朱凤艳 2009	\N	Quetiapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17788	陈丽娟 2009	\N	Clinical Nursing Pathway versus Conventional nursing	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17789	陈丽霞-田常青 2010	\N	Risperidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17790	陈光财-邓方渝-王德燧- 2010	\N	Ziprasidone injection versus Haloperidol injection	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17791	陈克彦 2009	\N	Traditional Chinese Medicine (TCM) (Shenqi Wuweizi Tablets) + sulpiride versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17792	Chen 2009	\N	Oxcarbazepine + Antipsychotic versus Antipsychotic monotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17793	Chen Yan 2010	\N	Skill training + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17794	陈常云-李守春-陈维香 2009	\N	Life skill training + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17795	陈平勋-罗建慈-刘桃芳 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17797	陈恩民 2010	\N	Ziprasidone versus Quetiapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17798	陈恩民1 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17799	陈恩民2 2010	\N	Cognitive therapy + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17800	陈春梅 2010	\N	Switch to Ziprasidone from Risperidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17801	陈永红 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17802	陈永红1 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17803	陈汝兰-江连娣-招用燕- 2009	\N	Skill training + standard care versus Skill training	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17804	陈玲-王俊超 2010	\N	Aripiprazole versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17805	陈红英-张郦-付迎春-季 2009	\N	Aripiprazole versus Quetiapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17806	陈莉晶 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17808	陈鸾凤 2010	\N	Nursing intervention + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17809	陶世武-杨诚-陈强-潘润 2009	\N	Risperidone versus Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17810	陶庆兰-邓红-张树森-沈 2009	\N	Social skill training + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17811	靳西龙 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17812	鞠康-费玥-季卫东-高运 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17813	韦盛中 2010	\N	Olanzapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17814	韩伟 2010	\N	Vocational skill training versus Conventional nursing	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17815	韩卫军-孙桂荷 2009	\N	Sulpiride versus Alprazolam+ Buspirone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17816	韩惠芬 2010	\N	Risperidone versus Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17817	韩树华 2010	\N	Aripiprazole versus Quetiapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17818	顾秀华 2010	\N	Programmed training + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17819	颜淑环-程荣玉-王玉丽- 2010	\N	Family intervention versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17820	马丽波-姜平平-王旸-张 2009	\N	Psychological therapy + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17821	马俊国-徐富玲-谭余龙 2009	\N	Anle pills (TCM) versus Wuji Baifeng pills (TCM)	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17822	马兆峰1 2009	\N	Ziprasidone versus Quetiapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17823	马军-刘永义-殷朝辉-张 2010	\N	Escitalopram versus Maprotiline	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17824	Ma 2010	\N	Magnesium Valproate + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
17825	马廷斌-宁志军 2010	\N	Quetiapine versus Sulpiride	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17826	马明 2009	\N	Family intervention + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17827	马明1 2009	\N	Periodic health education for outpatient service + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17828	马明2 2009	\N	Intensive comprehensive intervention + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17829	马洪涛-程丽华-许家泉 2010	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17830	马贵君 2009	\N	Rehabilitation therapy + standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17831	马迅 2010	\N	Olanzapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17832	马闯胜-马玲-张淑芳 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17833	高丽红-路光辉 2009	\N	Venlafaxine + Sulpiride versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17834	高伟-王瑞-徐学兵 2009	\N	Risperidone + Tandospirone versus Risperidone + alprazolam	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17835	高军-张伟 2009	\N	Modified Electro Convulsive Therapy (MElectroconvulsive Therapy) + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17836	高军-张伟 2010	\N	Olanzapine versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17837	高宏强-陈冬-常余善-张 2010	\N	Risperidone + Mirtazapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21014	李杰 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
17838	高式兰1 2009	\N	Comprehensive nursing intervention + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18421	NCT01412060	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	700	\N	\N	\N	\N	\N
18422	NCT01412866	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
18423	NCT01420575	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
18424	NCT01422902	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
18425	NCT01423916	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
18427	NCT01431092	\N	\N	\N	Denmark	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
18428	ACTRN12611000849998	\N	\N	\N	Australia	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
18429	CTRI-2011-08-00	\N	\N	\N	India	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
18430	IRCT13870605110	\N	\N	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
18431	ACTRN1261100091	\N	\N	\N	Australia	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
18432	Castro 2011	\N	melatonin versus Placebo for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic with tardive dyskinesia	\N	Venezuela	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
18443	Bechdolf 2011a	\N	Motivational interviewing versus Supportive therapy	\N	Germany	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n	\N	60	\N	\N	\N	\N	\N
18449	Chavda 2004	\N	\N	\N	India	\N	\N	\N	\N	\N	249	\N	\N	\N	\N	\N
18453	Crespo 2011 a	\N	\N	\N	Spain	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
18458	Drummond 1998	\N	\N	\N	Multicentre	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
18460	Druss 2010 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
18462	Eldred 1960	\N	Pineal extract versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
18463	Faber 2011	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
18465	Gallant 1963	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18466	Gallant 1965	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18470	Hekimian 1963	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18475	Horan 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
18479	Jeri 1957	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18482	Koike 2011	\N	\N	\N	Japan	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
18486	Laan 2006 a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18487	Lafave 1995	\N	\N	\N	Canada	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
18497	Mises 1963	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18502	Philipp 2003 a	\N	\N	\N	Austria	\N	\N	\N	\N	\N	153	\N	\N	\N	\N	\N
18504	Portela 1961	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18511	Sarin 2004	\N	\N	\N	India	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
18525	Woltmann 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
18527	Zhang 2011 a	\N	\N	\N	China	\N	\N	\N	\N	\N	239	\N	\N	\N	\N	\N
18528	Zillinger 1955	\N	Electroshock therapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18530	Pfizer 2006 b	\N	\N	\N	Austria//Germany	\N	\N	\N	\N	\N	276	\N	\N	\N	\N	\N
18533	Borba 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
18536	Palma 2011	\N	Cognitive-Motivational Therapy	\N	Spain	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
18538	Raposo 2011	\N	\N	\N	Brazil	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
18540	Tidey 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
18543	Zhang 2011 b	\N	Paliperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
18551	Pedersen 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
18553	Lee 2011	\N	Mirtazapine versus Placebo	\N	Korea	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
18556	Silverman 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
18558	Maurino  2010 a	\N	\N	\N	Spain	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
18560	De 2011	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
18562	Ascher 2010	\N	\N	\N	Croatia//Russia//United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n	\N	233	\N	\N	\N	\N	\N
18565	Hanrahan 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	238	\N	\N	\N	\N	\N
18566	Eack 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
18568	IRCT20110718704	\N	\N	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
18569	ISRCTN18240558	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
18570	ISRCTN46241817	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
18572	NCT01436331	\N	First episode//cbt//psyhcosocial//assertive community treatment//family intervention//early intervention//	\N	Italy	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
18574	NCT01446328	\N	\N	\N	Norway	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
18575	NCT01448499	\N	\N	\N	Israel	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
18576	Tanasiewicz 2011	\N	\N	\N	Poland	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
18579	ISRCTN58667926	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
18580	10714 2001	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
18581	Mesotten 1991	\N	\N	\N	Belgium	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18582	Morgan 2011	\N	\N	\N	Australia	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18586	Birchwood 2011 a	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
18593	Fung 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
18594	Girgis 2011 b	\N	\N	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
18598	Hsiao 2011	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
18599	Jin 2011	\N	\N	\N	China/United States of America	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
18605	Mico 2011	\N	\N	\N	Italy	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
18608	Ozguven 2011	\N	\N	\N	Turkey	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
18609	Park 2011	\N	\N	\N	Republic of Korea	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
18611	Saddichha 2011	\N	Olanzapine versus Risperidone//Olanzapine versus Haloperidol//Risperidone versus Haloperidol	\N	India	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
18612	Tessier 2011	\N	Paliperidone er versus Olanzapine oral	\N	France	\N	\N	\N	\N	\N	459	\N	\N	\N	\N	\N
18613	Veltro 2011	\N	\N	\N	Italy	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
18616	Williams 1962	\N	Intensive Group Leaving	\N	United States of America	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
18618	NCT01457339	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
18619	NCT01458379	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
18620	NCT01451164	\N	\N	\N	Japan	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
18621	NCT01459029	\N	\N	\N	Israel	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
18623	NCT01451736	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
18624	NCT01452919	\N	\N	\N	Argentina//Brazil//Greece//United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
18625	NCT01450514	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19795	Raniwallal 1996	\N	Zotepine versus Haloperidol	\N	Unlcear	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
19796	NCT00558298	\N	Risperidone long acting injection dose	\N	Unclear	\N	\N	\N	\N	\N	811	\N	\N	\N	\N	\N
19798	Chen 2012 b	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19803	Su 2012 a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19804	Ge 2010	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19805	Roache 2011	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19812	Rezaee 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19816	Niitsu 2012	\N	Fluvoxamine + Atypical antispsychotics versus Placebo + Atypical Antipsychotic treatment	\N	Japan	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
19817	Ory 2012	\N	Amantadine versus Placebo	\N	France	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
19819	Zhang 2012	\N	Risperidone + Oral tropisetron versus Risperidone + Placebo//tropisetron versus Placebo	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
19824	Wettermann 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19826	Nielsen 2012 b	\N	Venous blood sampling versus Capillary blood sampling//Physical health care monitoring	\N	Denmark	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
19828	Rascol 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19836	Hwang 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19843	Harmell 2012	\N	Web consent versus Routine consent procedure	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
19849	Wing 2012	\N	Repetitive transcranial magnetic stimulation + transdermal nicotine versus Sham repeated transcranial magnetic stimulation + transdermal nicotine//smoking cessation	\N	Canada	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
19855	Center for Drug 2012	\N	Risperidone depot versus Placebo//Risperidone depot dose//	\N	Unclear	\N	\N	\N	\N	\N	416	\N	\N	\N	\N	\N
19856	Quinn 2012	\N	Risperidone long acting injection versus oral Antipsychotics//Risperidone long acting injection versus Oral Risperidone//Risperidone long acting injection versus oral Olanzapine//Risperidone long acting injection versus oral Quetiapine	\N	Canada	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
19862	Cheng 2008	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19863	Dixon 2011 a	\N	Family-to-Family Education Program	\N	United States of America	\N	\N	\N	\N	\N	318	\N	\N	\N	\N	\N
19866	Kroon 2011 b	\N	Comprehensive user-run recovery programme + care as usual	\N	Unclear	\N	\N	\N	\N	\N	175	\N	\N	\N	\N	\N
19867	Kroon 2011 c	\N	User-run recovery course versus wait list	\N	Unclear	\N	\N	\N	\N	\N	333	\N	\N	\N	\N	\N
19869	ACTRN1261200105	\N	Brief Intervention versus Brief Intervention+Family Support // Brief Intervention // Brief Intervention+Family Support	\N	Thailand	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n	\N	180	\N	\N	\N	\N	\N
19870	ACTRN1261200111	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19871	NCT01699997	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19872	NCT01701609	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19873	NCT01704833	\N	Cognitive Behavioral Therapy versus treatment as usual	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
19874	NCT01712646	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21015	李晶武 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
21020	Li 2013a	\N	Magnesium Valproate + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21021	李彩玲 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21022	李广玉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
21023	李巧波 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
21024	李守春 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
21025	李宁 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21026	李国珍 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
21027	李嘉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21028	李卫军 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21029	李华 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
21030	李剑 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
21031	李刚 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21032	李冬梅 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
21033	李健 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21034	李伟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
21035	李于林 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
21036	李于林1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21037	李于林 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
21038	朱琳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21039	朱明蓉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
21040	朱慧 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
21041	朱巧玲 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21042	朱士皊 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
21043	朱国辉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21044	曾默 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21045	曾德志 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
17839	高彩虹 2010	\N	Risperidone versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17840	高志勤-余海鹰-崔雪莲- 2010	\N	Low frequency repeated transcranial magnetic stimulation versus Sham repeated transcranial magnetic stimulation	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17841	高志勤-余海鹰-崔雪莲- 2009	\N	Low frequency repeated transcranial magnetic stimulation versus Sham repeated transcranial magnetic stimulation	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17842	高志勤-余海鹰-金梅-邱 2009	\N	Low frequency repeated transcranial magnetic stimulation versus Sham repeated transcranial magnetic stimulation	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17843	高慧-戴晶景-朱岚 2010	\N	Occupational therapy + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17844	高长青 2010	\N	Aripiprazole versus Clozapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17845	魏书红 2009	\N	Nursing intervention + routine nursing versus Routine nursing	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17846	魏波-黄健-肖忠承 2010	\N	Life skill training + routine nursing versus Routine nursing	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17847	魏秋菊-魏春香-楚平华 2010	\N	Group education intervention + Care as usual versus Care as usual	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17849	鲍丽萍-潘晋-崔晓青-程 2010	\N	Holistic nursing + Standard care versus standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17850	麻显娇-卢喜金-邹晓华 2009	\N	Aripiprazole versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17851	黄凌霜-梅红彬-李勇 2010	\N	Traditinal Chinese Medicine (TCM) Formula activating blood circulation to dissipate blood stasis + Metformin versus Metformin	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17852	黄婷-李丽娟 2010	\N	Comprehensive skill training + nursing versus nursing	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17853	黄峰 2010	\N	Ziprasidone versus Perphenazine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17854	黄峰1 2010	\N	Ziprasidone versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17855	黄河亮-孙艳惠-吕明玉 2010	\N	Risperidone versus Aripiprazole	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17856	黄河亮-王桂香 2009	\N	Aripiprazole versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17857	黄河香-黄淼 2010	\N	Community based therapy versus Inpatient therapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17858	黄祖荣-林家幸-余木英 2009	\N	Risperidone + Clozapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17859	黄粱镔-龙欣-王臬茂 2010	\N	Quetiapine versus None	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17860	黄芳 2010	\N	Cognitive therapy + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17861	黄芹2010 a	\N	Group psychotherapy + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17862	黄芹2010 b	\N	behaviour therapy + Citalopram versus Citalopram	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17863	黄金茹2010	\N	Cognitive Behavioural Therapy (Cognitive Behavioral Therapy) + routine nursing versus Routine nursing	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17864	黎举红2009	\N	Free medication versus Payable medication	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17865	黎举红200	\N	Free medication versus Payable medication	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17866	陈常云 2009 a	\N	Life skill training + pharmacotherapy versus Pharmacotherapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17867	Brandon 1985	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
17868	Stone 1995	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
17869	Leung 1998	\N	\N	\N	Hong Kong	\N	\N	\N	\N	\N	unclear	\N	\N	\N	\N	\N
17999	Redhead 2011	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
20280	寇根生	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
17872	Levine 2010	\N	Risperidone versus Haloperidol for schizophrenia or//and schizophreniform whose current state is acute and whose stage of illness is early illness	\N	Israel	\N	\N	\N	\N	\N	491	\N	\N	\N	\N	\N
17876	Detke 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	1065	\N	\N	\N	\N	\N
17878	Hough 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
17881	Leutwyler 2010	\N	diabetes awareness and rehabilitation training (dart) versus usual care + information for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
17883	NCT01281527	\N	dosage of drug + versus paliperidone palmitate for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	1000	\N	\N	\N	\N	\N
17884	NCT01280305	\N	raloxifene versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	Multicentre//Israel//Romania	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
17885	NCT01279213	\N	 for schizophrenia whose current state is not described and whose stage of illness is not described with treatment resistant	\N	Argentina	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
17886	NCT01279070	\N	no training versus cognitive training for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is persistent // chronic	\N	Spain	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
17887	NCT01272765	\N	 for serious mental illness whose current state is partial remission and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
17888	NCT01272752	\N	ihbg - 10 versus Placebo for serious mental illness whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
17894	Simon 2010 a	\N	sensitized gp group versus non sensitized gp group for schizophrenia whose current state is not described and whose stage of illness is prodromal illness	\N	Switzerland	\N	\N	\N	\N	\N	1171	\N	\N	\N	\N	\N
17895	Pandina 2011	\N	dosage of drug + versus paliperidone palmitate + Placebo versus Risperidone long acting injection + oral Risperidone for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Multicentre//Belgium//United States of America//Bulgaria//Estonia//Hungary//Lithuania//Czech Republic//Poland//Russia//Ukraine//India//Spain//Germany//France//Austria	\N	\N	\N	\N	\N	1220	\N	\N	\N	\N	\N
17896	Cho 2011	\N	 for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic	\N	South Korea	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
17897	Behere 2011	\N	waiting lists versus exercise therapy versus yoga therapy for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	India	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
17900	Stobbe 2010 a	\N	assertive community treatment versus standard treatment for serious mental illness whose current state is acute and whose stage of illness is not described with neurocognition	\N	Netherlands	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
17901	Kusumi 2010	\N	Risperidone standard tablet versus Risperidone oral solution for schizophrenia whose current state is acute and whose stage of illness is persistent // chronic	\N	Japan	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
17902	Catty 2010	\N	Individual Placement and Support versus Vocational Rehabilitation // Individual Placement and Support versus Treatment as Usual	\N	The Netherlands // United Kingdom // Italy // Bulgaria // Germany // Switzerland	\N	\N	\N	\r\n\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	312	\N	\N	\N	\N	\N
17904	Crook 2011	\N	normal teaching versus e learning + standard cp2 teaching for health care professionals whose current state is not described and whose stage of illness is not described	\N	United Kingdom	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
17905	NCT00103727	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	275	\N	\N	\N	\N	\N
17906	NCT00049946	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	231	\N	\N	\N	\N	\N
17910	Ahn 2011	\N	lomazeni versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic	\N	United States of America	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
17916	Mintzer 2001	\N	Quetiapine versus Risperidone for psychotic whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
17917	Barak 2001 a	\N	Olanzapine versus Haloperidol for schizophrenia whose current state is acute and whose stage of illness is persistent // chronic	\N	Israel	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
17918	Sutton 2001	\N	Olanzapine versus Risperidone for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	339	\N	\N	\N	\N	\N
17919	Sandison 1960 b	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
17920	Sandison 1960 c	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
17921	Sandison 1960 d	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
17923	Lai 2010a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17925	IRCT201011085133N1	\N	physical exercise versus behavior therapy versus no intervention for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic with negative symptoms	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
18002	Blumberger 2011	\N	\N	\N	Multicentre//Canada//United States of America	\N	\N	\N	\N	\N	228	\N	\N	\N	\N	\N
20281	翟江 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
17926	IRCT201010042935N4	\N	leponex versus iranian Clozapine for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
17927	IRCT201009112181N5	\N	Olanzapine versus Placebo versus ranitidine for schizophrenia whose current state is not described and whose stage of illness is not described with weight gain	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18352	NCT01393600	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
18353	NCT01391390	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
17928	IRCT138903254191N1	\N	theta burst versus sham transcranial magnetic stimulation versus repetitive transcranial magnetic stimulation (rtms) for schizophrenia whose current state is partial remission and whose stage of illness is not described	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
17929	IRCT138902113843N1	\N	citalopram versus Placebo versus augmentation therapy for schizophrenia whose current state is acute and whose stage of illness is not described with negative symptoms	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
17930	IRCT138811022935N3	\N	Omega-3 Fatty Acid versus Placebo	\N	Iran	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
17931	IRCT138809201457N7	\N	Haloperidol + ascorbic acid versus Haloperidol + Placebo//Haloperidol versus ascorbic acid//Haloperidol versus Placebo//ascorbic acid versus Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
17932	IRCT138809201457N6	\N	Haloperidol + celecoxib versus Haloperidol + Placebo//Haloperidol versus celecoxib//Haloperidol versus Placebo//celecoxib versus Placebo	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
17933	IRCT138801241457N4	\N	Risperidone + d- pencillamine and priridoxine versus priridoxine and Risperidone + Placebos for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
17934	JPRN-UMIN000004931	\N	algorithm-guided medication management versus standard treatment for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Japan	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
17936	JPRN-UMIN000004398	\N	Aripiprazole versus Perospirone	\N	Japan	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n\r\n\r\n\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 10\r\n	\N	100	\N	\N	\N	\N	\N
17939	ISRCTN60855021	\N	cognitive behavioral therapy (cbt) for psychotic whose current state is not described and whose stage of illness is not described with anxiety	\N	United Kingdom	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
17941	125152891 2010	\N	Asenapine versus Risperidone for schizophrenia whose current state is acute and whose stage of illness is not described	\N	India	\N	\N	\N	\N	\N	280	\N	\N	\N	\N	\N
17942	123158394 2007	\N	dosage of drug + versus paliperidone palmitate versus Placebo for schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	Multicentre//India//United States of America//Bulgaria//Malaysia//philippines//Romania//Russia//Ukraine//South Africa	\N	\N	\N	\N	\N	520	\N	\N	\N	\N	\N
17943	110253575 2010	\N	Quetiapine versus Quetiapine fumarate for schizophrenia whose current state is not described and whose stage of illness is not described	\N	India	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
17944	033115352 2010	\N	dosage of drug + versus iloperidone versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is not described	\N	India	\N	\N	\N	\N	\N	710	\N	\N	\N	\N	\N
17945	CTRI-2011-091-000140	\N	Blonanserin versus Haloperidol	\N	India	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
17946	A1281039	\N	Clozapine versus dosage of drug + versus Ziprasidone for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Italy	\N	\N	\N	\N	\N	147	\N	\N	\N	\N	\N
17947	AstraZeneca 2008	\N	Risperidone versus Quetiapine for schizophrenia whose current state is acute and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	672	\N	\N	\N	\N	\N
17949	F1D-MC-HGMF S	\N	Olanzapine versus dosage of drug + for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
17950	AstraZeneca 2006	\N	Quetiapine versus dosage of drug + versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	Canada	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
17951	AstraZeneca 2006 a	\N	Quetiapine fumarate versus dosage of drug + versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic	\N	Unclear	\N	\N	\N	\N	\N	171	\N	\N	\N	\N	\N
17953	AstraZeneca 2007	\N	titration schedule versus Quetiapine - immediate release versus dosage of drug + for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is not described with neurocognition	\N	United Kingdom	\N	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
17954	D1441C00112	\N	dosage of drug + versus Placebo versus Quetiapine for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
17955	AstraZeneca 2005 a	\N	 for schizophrenia whose current state is acute and whose stage of illness is not described with treatment resistant	\N	Unclear	\N	\N	\N	\N	\N	242	\N	\N	\N	\N	\N
17956	AstraZeneca 2006 c	\N	Quetiapine - immediate release versus Placebo versus dosage of drug + for schizophrenia whose current state is acute and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	535	\N	\N	\N	\N	\N
17957	Anon 2006	\N	 for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	United Kingdom	\N	\N	\N	\N	\N	1225	\N	\N	\N	\N	\N
20282	杨迎兰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
17958	AstraZeneca 2009 a	\N	Quetiapine versus Risperidone for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	Finland	\N	\N	\N	\N	\N	3	\N	\N	\N	\N	\N
17959	AstraZeneca 2001a	\N	Haloperidol versus Quetiapine versus dosage of drug + for schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	381	\N	\N	\N	\N	\N
17961	NCT01300637	\N	metformin versus Placebo versus Clozapine for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	Taiwan	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
17962	NCT01300364	\N	reboxetine versus citalopram versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is not described with negative symptoms	\N	Spain	\N	\N	\N	\N	\N	249	\N	\N	\N	\N	\N
17964	NCT01295372	\N	Risperidone versus zicronapine for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Multicentre//Czech Republic//Finland//Estonia//Poland//France	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
17965	NCT01291511	\N	iloperidone versus Placebo versus dosage of drug + for schizophrenia whose current state is acute and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	710	\N	\N	\N	\N	\N
17966	NCT01282307	\N	guided self determination versus standard treatment for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described Guided Self-Determination	\N	Denmark	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	101	\N	\N	\N	\N	\N
17967	NCT01267019	\N	augmentation therapy versus non social skills training versus social cognitive training with invivo exercises for schizophrenia or//and schizoaffective disorders whose current state is partial remission and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
17968	NCT01258920	\N	dosage of drug + versus paliperidone palmitate for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Japan	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
18100	Nicol 2011	\N	Antipsychotics for serious mental illness whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
17969	NCT01248195	\N	Amisulpride versus Olanzapine versus Clozapine for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Multicentre//Austria//Belgium//Czech Republic//Denmark//France//Germany//Israel//Italy//Germany//Israel//Italy//Netherlands//Poland//Romania//Spain//Switzerland//United Kingdom	\N	\N	\N	\N	\N	350	\N	\N	\N	\N	\N
17970	NCT01235585	\N	Bitopertin Dosage // Bitopertin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
17971	NCT01235559	\N	dosage of drug + versus Placebo versus spd489 for schizophrenia whose current state is partial remission and whose stage of illness is not described with negative symptoms	\N	United States of America	\N	\N	\N	\N	\N	507	\N	\N	\N	\N	\N
17972	NCT01235520	\N	Bitopertin Dosage // Bitopertin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
17973	NCT01234298	\N	spd489 versus Placebo versus dosage of drug + for schizophrenia whose current state is partial remission and whose stage of illness is not described with negative symptoms	\N	United States of America	\N	\N	\N	\N	\N	507	\N	\N	\N	\N	\N
17974	NCT01216891	\N	behavioral therapy for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is first episode	\N	United States of America	\N	\N	\N	\N	\N	370	\N	\N	\N	\N	\N
17975	NCT01213524	\N	nicotine replacement therapy (nrt) versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
17976	Van 2011	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	216	\N	\N	\N	\N	\N
17978	Lesem 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	344	\N	\N	\N	\N	\N
17981	Bhurgri 2010	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
17984	Penn 2011	\N	\N	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n	\N	46	\N	\N	\N	\N	\N
17986	Kulkarni 2011	\N	\N	\N	Australia	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
17988	D'Amato 2011	\N	\N	\N	France	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
17990	Breitborde 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
17991	Beauchamp 2011	\N	Cognitive Behavioral Therapy versus Skills Training for Symptom Management	\N	Canada	\N	\N	\N	\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	129	\N	\N	\N	\N	\N
17992	Si 2011	\N	dosage of drug + versus Quetiapine fumarate for schizophrenia whose current state is not described and whose stage of illness is not described	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
17993	Kam 2010	\N	horticultural therapy versus conventional workshop training for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	Hong Kong	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
17994	Chatterjee 2011	\N	Collaborative Community-Based Care+Facility-Based Care versus Facility-Based Care	\N	India	\N	\N	\N	\r\nUser defined field 9\r\n	\N	36	\N	\N	\N	\N	\N
17995	Bhathena 2011	\N	abt-925 versus Placebo versus dosage of drug + for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
17996	Koivunen 2010	\N	leaflet comparison group versus web based support system for health care professionals whose current state is not described and whose stage of illness is not described	\N	Multicentre//Finland//United Kingdom	\N	\N	\N	\N	\N	149	\N	\N	\N	\N	\N
17998	Muscatello 2011	\N	\N	\N	Italy	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
18004	Ritsner 2011	\N	l- theanine versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	Israel	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18013	Akhondzadeh 2011	\N	\N	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
18015	Buchanan 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18017	Popov 2011	\N	\N	\N	Germany	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
18018	Rosenheck 2011	\N	oral Antipsychotic versus dosage of drug + versus Risperidone long acting injection for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	369	\N	\N	\N	\N	\N
18019	Scoriels 2011	\N	Modafinil versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
18020	Slotema 2011	\N	\N	\N	Multicentre//Netherlands//United States of America	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
18021	Eack 2011	\N	cognitive enhancement therapy versus enriched supportive therapy (est) for schizophrenia or//and schizoaffective disorders whose current state is partial remission and whose stage of illness is early illness	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
18022	Stant 2011	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
18031	ISRCTN41137900	\N	Health Improvement Profile versus Treatment As Usual	\N	United Kingdom	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
18032	ISRCTN49454276	\N	seclusion versus restraints versus Olanzapine for serious mental illness whose current state is not described and whose stage of illness is not described	\N	Brazil	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
18033	ISRCTN96754763	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
18034	NCT01307800	\N	\N	\N	Multicentre//Romania//Russia//United States of America//Croatia	\N	\N	\N	\N	\N	950	\N	\N	\N	\N	\N
18035	NCT01312272	\N	\N	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 9\r\n	\N	24	\N	\N	\N	\N	\N
18036	NCT013126491	\N	\N	\N	France	\N	\N	\N	\N	\N	370	\N	\N	\N	\N	\N
18037	NCT01313052	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
18038	NCT01315002	\N	\N	\N	Germany	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
18039	NCT01315587	\N	\N	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
18040	NCT013188501	\N	\N	\N	Spain	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 9\r\n	\N	45	\N	\N	\N	\N	\N
18041	NCT01323205	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
18042	NCT01324297	\N	\N	\N	Canada	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
18043	NCT01324973	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
18044	U1111-1119-5851	\N	\N	\N	Germany	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
18045	Barbui 2011	\N	Clozapine + Aripiprazole versus Clozapine + Haloperidol versus augmentation therapy for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic with treatment resistant	\N	Italy	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
18047	Griswold 2010	\N	care navigators versus usual care for psychotic whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	175	\N	\N	\N	\N	\N
18051	Watzke 2010	\N	systematic treatment selection (sts) versus random treatment selection for serious mental illness whose current state is not described and whose stage of illness is not described	\N	Germany	\N	\N	\N	\N	\N	291	\N	\N	\N	\N	\N
18053	Bio 2011	\N	vocational rehabilitation versus waiting lists for schizophrenia whose current state is partial remission and whose stage of illness is not described	\N	Brazil	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
18056	Kane 2011	\N	 for schizophrenia whose current state is not described and whose stage of illness is not described with treatment resistant	\N	Multicentre//United States of America//Canada	\N	\N	\N	\N	\N	321	\N	\N	\N	\N	\N
18057	Mann 2011	\N	Placebo versus Bupropion sr for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
18235	Dutra 2011	\N	varenicline for schizophrenia whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
18058	Combs 2011	\N	attention training for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of AmerIca	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
18060	Hill 2011	\N	folate versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
18061	Grootens 2011	\N	Olanzapine versus Ziprasidone for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is persistent // chronic	\N	Multicentre//Netherlands//Belgium	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
18063	Robles 2011	\N	Olanzapine versus Quetiapine for schizophrenia or//and psychotic whose current state is not described and whose stage of illness is not described	\N	Spain	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
18064	Ross 2011	\N	attention control activity versus reasoning therapy for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described with delusions	\N	United Kingdom	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
18065	Toozandehjani 2011	\N	\N	\N	Iran	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
18066	Vesterager 2011	\N	psychosocial program versus cognitive training + comphrensive psychosocial programme for schizophrenia or//and schizotypal whose current state is early post-acute and whose stage of illness is first episode	\N	Denmark	\N	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
18067	Decot 2011	\N	standard Antipsychotics versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
18068	Detke 2011a	\N	Olanzapine oral versus Olanzapine long acting injection for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Multicentre//United States of America//France	\N	\N	\N	\N	\N	524	\N	\N	\N	\N	\N
18069	Dickerson 2011	\N	Placebo versus artemisinin for schizophrenia whose current state is partial remission and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
18071	Falkai 2011	\N	table football versus aerobic exercise for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	Multicentre//Germany//Canada//United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
18072	Ferziger 2011	\N	paliperidone palmitate versus oral Antipsychotic for schizophrenia whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
18073	Goetz 2011	\N	recovering energy through nutrition and exercise for ther weight loss program + versus control groups for schizophrenia whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
18074	Granholm 2011	\N	cognitive behavioral social skills training versus goal focused supportive contact grouo therapy intervention for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
18075	Gupta 2011	\N	functional adaptation skills training versus control groups for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Canada	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
18076	Hill 2011b	\N	folate versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is not described with negative symptoms	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
18079	Kaushik 2011	\N	cognitive remediation therapy (crt) versus control groups for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
18080	Kayo 2011	\N	first generation Antipsychotics versus second generation Antipsychotics for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Brazil	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
18081	Kelly 2011a	\N	rimonabant versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is partial remission and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
18082	Keshavan 2011	\N	enriched supportive therapy (est) versus cognitive enhancement therapy for schizophrenia or//and schizoaffective disorders whose current state is partial remission and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
18083	Kinon 2011	\N	ly 2140023 monohydrate versus standard care for schizophrenia whose current state is acute and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	261	\N	\N	\N	\N	\N
18084	Kosten 2011	\N	 for schizophrenia whose current state is not described and whose stage of illness is not described	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
18085	Krakowski 2011	\N	Clozapine versus Haloperidol versus Olanzapine for schizophrenia whose current state is not described and whose stage of illness is not described with aggression	\N	United States of America	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
18086	Kulkarni 2011b	\N	raloxifene versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	Australia	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
18087	Kulkarni 2011a	\N	adjunctive transderaml estradiol versus Placebo for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Australia	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
18088	Landa 2011	\N	paranoia focused cognitive behavioural therapy + standard care versus standard care	\N	Multicentre // United States of America // China // United Kingdom	\N	\N	\N	\r\nNotes2\r\nCognitive Behavioral Therapy versus standard care//Cognitive Behavioral Therapy\r\nUser defined field 10\r\n	\N	24	\N	\N	\N	\N	\N
18089	Lin 2011	\N	yoga therapy versus waiting lists versus physical exercise for psychotic whose current state is not described and whose stage of illness is not described	\N	Hong Kong	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18091	Machielsen 2011	\N	Clozapine versus Risperidone for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Netherlands	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
18092	Markus 2011	\N	cannabidiol versus dopamine d2//d3 receptor antagonist Amisulpride for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Germany	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
18093	McCabe 2011	\N	bio feedback based treatment versus emotion recognition for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Australia	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
18094	McFarlane 2011	\N	family aided assertive community treatment versus family crisis therapy cases for psychotic whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20283	胡琼英 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
18095	Melau 2011	\N	intensive assertive treatment program versus standard treatment for schizophrenia whose current state is not described and whose stage of illness is first episode	\N	Denmark	\N	\N	\N	\N	\N	547	\N	\N	\N	\N	\N
18098	Mueller 2011	\N	integrated neurocognitive therapy (int) versus treatment as usual for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Multicentre//Switzerland//Germany//Austria	\N	\N	\N	\N	\N	169	\N	\N	\N	\N	\N
18101	Nordentoft 2011	\N	psychosocial intervention versus computer assisted cognitive training + psychosocial intervention for schizophrenia whose current state is not described and whose stage of illness is first episode	\N	Denmark	\N	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
18102	Nugent 2011	\N	early intensive program versus standard treatment for psychotic whose current state is not described and whose stage of illness is not described	\N	Denmark	\N	\N	\N	\N	\N	578	\N	\N	\N	\N	\N
18103	Prasad 2011	\N	valacyclovir versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
18104	Radhakrishnan 2011	\N	Placebo d-serine + control cognitive retraining versus Placebo versus d-serine + computerized cognitive retraining for schizophrenia whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
18105	Rotondi 2011	\N	tele health versus usual care for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
18107	Schooler 2011	\N	oral therapy versus Risperidone long acting injection for schizophrenia whose current state is not described and whose stage of illness is first episode	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
18108	Shim 2011	\N	varenicline versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is not described	\N	Republic of Korea	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18110	Sliwa 2011	\N	paliperidone palmitate versus Risperidone long acting injection for schizophrenia whose current state is not described and whose stage of illness is early illness	\N	United States of America	\N	\N	\N	\N	\N	276	\N	\N	\N	\N	\N
18111	Somers 2011	\N	 for schizophrenia whose current state is partial remission and whose stage of illness is first episode	\N	Netherlands	\N	\N	\N	\N	\N	350	\N	\N	\N	\N	\N
18113	Stain 2011	\N	non directive reflective listening versus cognitive behavioral therapy (cbt) for psychotic whose current state is not described and whose stage of illness is not described	\N	Multicentre//Australia//United Kingdom	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
18114	Stentebjerg 2011	\N	Quetiapine versus Aripiprazole for psychotic whose current state is not described and whose stage of illness is first episode	\N	Denmark	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
18115	Subotnik 2011	\N	Risperidone long acting injection versus Risperidone oral for schizophrenia whose current state is not described and whose stage of illness is early illness	\N	United States of America	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
18117	Twamley 2011	\N	cognitive training versus standard pharmacotherapy for schizophrenia whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
18118	Twamley 2011a	\N	standard pharmacotherapy versus cognitive training for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
18119	Umbricht 2011	\N	rg 1678 versus dosage of drug + versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is not described with negative symptoms	\N	Switzerland	\N	\N	\N	\N	\N	323	\N	\N	\N	\N	\N
18120	Vanover 2011	\N	iti-007 versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is partial remission and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
18121	Warren 2011	\N	rimonabant versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is partial remission and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
18122	Allott 2011	\N	befriending versus cognitive behavioral therapy for psychotic whose current state is not described and whose stage of illness is not described	\N	Australia	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
18123	Ascher 2011a	\N	discontinuers versus switch of medication for schizophrenia whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	344	\N	\N	\N	\N	\N
18124	Attux 2011	\N	 for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Brazil	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
18125	Audier 2011	\N	money for medication versus control groups for psychotic whose current state is not described and whose stage of illness is not described with substance abuse	\N	Netherlands	\N	\N	\N	\N	\N	168	\N	\N	\N	\N	\N
18126	Austin 2011	\N	standard community treatment versus intensive early intervention for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Multicentre//Denmark//Norway	\N	\N	\N	\N	\N	547	\N	\N	\N	\N	\N
18127	Ballon 2011	\N	metformin versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	146	\N	\N	\N	\N	\N
18129	Beebe 2011	\N	motivational intervention versus time and attention control for schizophrenia whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
18130	Bell 2011	\N	work therapy versus work therapy + cognitive remediation therapy for psychotic whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
18131	Bennett 2011	\N	behavioral treatment for substance abuse versus supportive group for serious mental illness whose current state is not described and whose stage of illness is not described with substance abuse	\N	United States of America	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
18132	Bowie 2011	\N	cognitive remediation therapy for schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	Canada	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
18133	Brunette 2011	\N	other oral Antipsychotics versus Clozapine for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
18134	Buchanan 2011a	\N	rimonabant versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is partial remission and whose stage of illness is prodromal illness	\N	United States of America	\N	\N	\N	\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	15	\N	\N	\N	\N	\N
18135	Buller 2011	\N	Quetiapine versus sertindole for schizophrenia whose current state is partial remission and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	264	\N	\N	\N	\N	\N
18136	Chaves 2011	\N	minocycline versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is early illness	\N	Multicentre//Brazil//Canada	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
18141	Li 2011	\N	 for schizophrenia whose current state is acute and whose stage of illness is not described	\N	China	\N	\N	\N	\N	\N	452	\N	\N	\N	\N	\N
18142	Brown 2011	\N	behavioural treatment of substance abuse in schizophrenia (btsas) versus supportive tretment in addiction recovery (star) for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described with substance abuse	\N	United States of America	\N	\N	\N	\N	\N	175	\N	\N	\N	\N	\N
18350	IRCT20110328393	\N	\N	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
18351	ACTRN12611000731998	\N	\N	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
18143	Moritz 2011	\N	waiting lists versus metacognitive training for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic	\N	Multicentre//Germany//Canada	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
18144	Stenberg 2011	\N	mirtazapine versus Placebo for schizophrenia whose current state is not described and whose stage of illness is persistent // chronic	\N	Finland	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
18146	Fan 2011	\N	insulin versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is persistent // chronic	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
18147	Hong 2011	\N	nicotine versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
18148	Lindenmayer 2011a	\N	Quetiapine versus dosage of drug + for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is persistent // chronic	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18149	Redden 2011	\N	abt-925 versus dosage of drug + versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	Multicentre//Argentina//United States of America//Mexico	\N	\N	\N	\N	\N	155	\N	\N	\N	\N	\N
18156	Manuel 2011	\N	standard clinical use management versus assertive community treatment for psychotic whose current state is acute and whose stage of illness is not described with substance abuse	\N	United States of America	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
18157	NCT01339858	\N	acetylcysteine versus Placebo for schizophrenia or//and schizophreniform whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18158	NCT01338298	\N	Aripiprazole versus dosage of drug + versus Placebo for schizophrenia or//and schizoaffective disorders whose current state is partial remission and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
18159	ISRCTN28632626	\N	transdiagnostic internet based maintenance treatment versus treatment as usual for serious mental illness whose current state is acute and whose stage of illness is not described	\N	Germany	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
18160	ISRCTN23197625	\N	Cognitive Behavioral Therapy versus Standard Psychiatric Care // Worry Induction versus Worry Reduction	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	150	\N	\N	\N	\N	\N
18161	Akbarpour 2010	\N	\N	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
18162	Ball 2011	\N	Atomoxetine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
18166	Campbell 2011	\N	Workshop Program	\N	UK	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
18172	Jahn 2011	\N	psychoeducation versus routine occupational therapy versus computerized cognitive training for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is persistent // chronic	\N	Germany	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
18173	Kane 2011b	\N	Asenapine versus Placebo versus switch of medication for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is persistent // chronic	\N	Multicentre//United States of America//Ukraine//India//Latvia//Craotia//Russian Federation	\N	\N	\N	\N	\N	386	\N	\N	\N	\N	\N
18177	Schennach 2011	\N	Risperidone versus Haloperidol for schizophrenia whose current state is acute and whose stage of illness is first episode	\N	Germany	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
18178	Segal 2010	\N	\N	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 9\r\n	\N	505	\N	\N	\N	\N	\N
18180	Stauffer 2011	\N	Olanzapine versus Haloperidol versus dosage of drug + for schizophrenia or//and schizophreniform whose current state is not described and whose stage of illness is first episode	\N	United States of America	\N	\N	\N	\N	\N	225	\N	\N	\N	\N	\N
18199	Allen 2011	\N	nicotine replacement therapy versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described with agitation	\N	Switzerland	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
18200	Baldacara 2011	\N	 for psychotic whose current state is acute and whose stage of illness is not described with agitation	\N	Brazil	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
18202	Friedman 2011 a	\N	 for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
18204	Kinon 2011 a	\N	Ly 2140023 versus Olanzapine//Ly 2140023 dose	\N	Russia	\N	\N	\N	\N	\N	669	\N	\N	\N	\N	\N
18206	Muscatello 2011 a	\N	 for schizophrenia whose current state is not described and whose stage of illness is not described with treatment resistant	\N	Italy	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18208	Wass 2011	\N	l-lysine versus Placebo for schizophrenia whose current state is partial remission and whose stage of illness is persistent // chronic	\N	Multicentre//Sweden//Canada	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
18210	NCT01354132	\N	n-acetyl-cysteine versus Placebo for schizophrenia or//and schizophreniform whose current state is partial remission and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
18211	NCT01364792	\N	valaciclovir versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Netherlands	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
18212	NCT01363349	\N	Risperidone versus Placebo versus bl-1020 for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Romania	\N	\N	\N	\N	\N	435	\N	\N	\N	\N	\N
18213	NCT01359293	\N	oral Antipsychotic versus paliperidone palmitate injection for schizophrenia or//and schizophreniform whose current state is not described and whose stage of illness is first episode	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
18214	NCT01368406	\N	standard care versus weight management program for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	Brazil	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
18215	NCT01361698	\N	illness management and recovery versus treatment as usual for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Denmark	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
18220	Klein 1985	\N	Amisulpride versus Haloperidol	\N	Germany	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
18222	Catty 2011	\N	individual placement and support versus traditional vocation rehabilation for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Multicentre//Germany//Italy//Netherlands//Belgium//Switzerland	\N	\N	\N	\N	\N	312	\N	\N	\N	\N	\N
18224	Kent 2011	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	498	\N	\N	\N	\N	\N
18227	Tek 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
18229	Crespo 2011	\N	 for schizophrenia or//and schizophreniform whose current state is not described and whose stage of illness is first episode	\N	Spain	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
18230	Girgis 2011	\N	Haloperidol versus Aripiprazole for schizophrenia whose current state is acute and whose stage of illness is early illness	\N	United States of America	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
18232	Yung 2011	\N	\N	\N	Australia	\N	\N	\N	\N	\N	115	\N	\N	\N	\N	\N
18233	Woolley 2011	\N	oxytocin versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
19243	Sun 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	212	\N	\N	\N	\N	\N
18238	Mobascher 2011	\N	nicotine versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
18240	Gopal 2011a	\N	\N	\N	Belgium	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
18243	Boonstra 2011	\N	Continuing Antipsychotic Drug versus Withdrawal of Antipsychotic Drug	\N	The Netherlands	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
18244	Hatta 2011	\N	 for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	Japan	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
18245	Silverman 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
18246	Sungur 2011	\N	Case Management Methods	\N	Turkey	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
18247	Huguelet 2011a	\N	\N	\N	Switzerland	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
18249	Salkever 2011	\N	Individual Placement and Support Supported Employment+Medication Management	\N	United States of America	\N	\N	\N	\N	\N	1121	\N	\N	\N	\N	\N
18250	Mosolov 2010a	\N	Ly 2140023 versus Placebo//Olanzapine versus Ly 2140023//Olanzapine versus Placebo	\N	Russia	\N	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
20284	刘臣2012	\N	\N	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
18254	Stroth 2011	\N	training of affect recognition versus waiting lists for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Germany	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
18255	Stone 2011	\N	Placebo versus Risperidone for schizophrenia whose current state is not described and whose stage of illness is not described	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
18256	Smith 2011	\N	Cognitive Behavioral Therapy+Motivational Interviewing	\N	UK	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18257	Sharifi 2011	\N	home after care versus treatment as usual for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
18258	Shafiei 2011	\N	cognitive behavioral therapy and social skill training versus cognitive behavioral group-based intervention for schizophrenia whose current state is acute and whose stage of illness is not described with negative symptoms	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
18259	Ranjbar 2011	\N	augmentation therapy versus Placebo versus selegiline for schizophrenia whose current state is acute and whose stage of illness is not described with negative symptoms	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
18260	Piegari 2011	\N	computerised cognitive training versus social skills training for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	Italy	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
18261	Montes 2011	\N	sms reminder on their cell phone versus standard of care for schizophrenia whose current state is partial remission and whose stage of illness is not described	\N	Spain	\N	\N	\N	\N	\N	254	\N	\N	\N	\N	\N
18265	Farshidfar 2011	\N	metformin versus Placebo versus Risperidone for schizophrenia whose current state is not described and whose stage of illness is not described with weight gain	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
18268	Bose 2011	\N	cariprazine versus dosage of drug + versus Placebo for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Hungary	\N	\N	\N	\N	\N	732	\N	\N	\N	\N	\N
18271	Alphs 2011	\N	paliperidone palmitate versus Placebo versus dosage of drug + for schizophrenia whose current state is acute and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	312	\N	\N	\N	\N	\N
18279	NCT01386918	\N	\N	\N	Canada	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
18281	NCT01378078	\N	\N	\N	Germany	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
18282	NCT01377233	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
18283	NCT01376596	\N	\N	\N	Canada	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
18284	NCT01376076	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
18285	NCT01370291	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18286	NCT01365299	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18287	IRCT13880124145	\N	\N	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
18289	IRCT20110610155	\N	\N	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
18290	CTRI-2011-06-001792	\N	\N	\N	India	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
18291	IRCT20110603155	\N	\N	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
18293	Vancampfort 2011	\N	resting control condition versus progressive muscle relaxation treatment for schizophrenia whose current state is acute and whose stage of illness is not described	\N	Belgium	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
18294	Vancampfort 2011a	\N	Yoga//exercise therapy	\N	Netherlands	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
18295	Rodewald 2011 a	\N	planning and problem solving intervention versus basic cognition versus work therapy for schizophrenia or//and schizoaffective disorders whose current state is not described and whose stage of illness is not described	\N	Germany	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	89	\N	\N	\N	\N	\N
18298	Ralevski 2011	\N	Acamprosate + Antipsychotic medication versus Placebo + Antipsychotic medication//Acamprosate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
18299	Ren 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
18300	Weiner 2011	\N	varenicline versus Placebo for schizophrenia whose current state is not described and whose stage of illness is not described	\N	Unclear	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
18301	Liemburg 2011	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
18302	Ghaleiha 2011	\N	Risperidone versus Clozapine versus Haloperidol for schizophrenia whose current state is acute and whose stage of illness is persistent // chronic	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
18304	Tchoukhine 2011	\N	\N	\N	Finland	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
18306	Zhang 2010 b	\N	\N	\N	China	\N	\N	\N	\N	\N	245	\N	\N	\N	\N	\N
18307	Fardig 2011	\N	Illness management and recovery versus treatment as usual	\N	Sweden	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
18309	Lassen 2011a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18313	Crespo 2011a	\N	Haloperidol versus Risperidone versus Olanzapine for schizophrenia or//and schizophreniform whose current state is not described and whose stage of illness is first episode	\N	Spain	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
18325	Klein 1993	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18326	Rüther 1989	\N	\N	\N	France	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18415	Rotondi 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
18328	Edgelow 2011	\N	Assertive community treatment versus Assertive community treatment + occupational therapy//Assertive community treatment//Supported employment	\N	Canada	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
18329	Katz 2011	\N	Occupational goal intervention versus Neurocognitive rehabilitation//Occupational goal intervention versus Activity training//Neurocognitive rehabilitation versus Activity training	\N	Israel	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
18332	MHRN 2011	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	766	\N	\N	\N	\N	\N
18337	ISRCTN69299093	\N	Supported Self-Management	\N	United Kingdom and UK	\N	\N	\N	\r\nUser defined field 9\r\n	\N	100	\N	\N	\N	\N	\N
18339	Worrell 2011	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	135	\N	\N	\N	\N	\N
18340	OCTET	\N	Community Treatment Orders versus Leave of Abstence // Community Treatment Orders versus Section 17	\N	United Kingdom	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
18342	ISRCTN96677673	\N	Supported employment//Individual placement and support//monetary incentives	\N	United Kingdom	\N	\N	\N	\N	\N	219	\N	\N	\N	\N	\N
18343	Birchwood 2011	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
18349	JPRN-JapicCTI-101175	\N	\N	\N	Japan	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 9\r\n	\N	410	\N	\N	\N	\N	\N
18354	NCT01394471	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
18355	NCT01400477	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
18356	NCT01390376	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18358	NCT01391403	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
18360	NCT01393613	\N	\N	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 9\r\n	\N	660	\N	\N	\N	\N	\N
18361	NCT01396421	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	630	\N	\N	\N	\N	\N
18362	NCT01410357	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	212	\N	\N	\N	\N	\N
18367	Segal 2011	\N	Community mental health agencies (cmha) versus Consumer-operated service program + community mental health agencies	\N	United States of America	\N	\N	\N	\N	\N	139	\N	\N	\N	\N	\N
18368	Tas 2011	\N	\N	\N	Turkey	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
18369	De Jesus 2011	\N	\N	\N	Brazil	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
18370	Dickerson 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
18371	Essock 2011	\N	\N	\N	Multicentre	\N	\N	\N	\N	\N	127	\N	\N	\N	\N	\N
18373	Ralevski 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
18374	Terevnikov 2011	\N	\N	\N	Finland	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
18378	Barr 2011	\N	\N	\N	Canada	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
18379	Bhugra 2011	\N	Assertive outreach versus treatment as usual//Assertive outreach	\N	United Kingdom	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
18382	Hardy 2011	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
18383	Hashimoto 2011	\N	\N	\N	Japan	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
18387	Keshavan 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
18390	Methapatara 2011	\N	\N	\N	Thailand	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
18392	Rosenheck 2011 a	\N	Risperidone versus Antipsychotic Drug	\N	United States of America	\N	\N	\N	\N	\N	382	\N	\N	\N	\N	\N
18393	Sturz 2011	\N	Computer-assisted cognitive training versus Paper and pencil cognitive training	\N	Germany	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
18394	Visceglia 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
18399	Case 2010	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	628	\N	\N	\N	\N	\N
18401	Hasan 2010	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18402	Malchow 2010 a	\N	\N	\N	Germany	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
18403	Ganguli 2011	\N	Behavioural therapy versus Behavioural treatment + enhancing social skills//Behavioural therapy versus treatment as usual//Behavioural treatment + enhancing social skills versus treatment as usual	\N	Unclear	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
18408	Bonsack 2011	\N	\N	\N	Switzerland	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
18410	Schmechtig 2010	\N	Amisulpride versus Nicotine // Amisulpride versus Risperidone // Amisulpride versus Placebo // Nicotine versus Risperidone // Nicotine versus Placebo // Risperidone versus Placebo	\N	UK	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n	\N	240	\N	\N	\N	\N	\N
18413	Kasckow 2011	\N	tele health versus intensive case management for schizophrenia or//and schizoaffective disorders whose current state is acute and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
18414	Kreyenbuhl 2011	\N	printed information versus health technology intervention for psychotic whose current state is not described and whose stage of illness is not described	\N	United States of America	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
18765	Bruxner 2010	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
18417	Umbricht 2011 a	\N	\N	\N	Switzerland	\N	\N	\N	\N	\N	323	\N	\N	\N	\N	\N
18418	IRCT20110714393	\N	\N	\N	Islamic Republic of Iran	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18419	ISRCTN27704027	\N	Prompts to encourage appointment attendance	\N	Finland	\N	\N	\N	\N	\N	3100	\N	\N	\N	\N	\N
18420	JPRN-UMIN000006011	\N	\N	\N	Japan	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 9\r\n	\N	60	\N	\N	\N	\N	\N
18626	NCT00902694	\N	Weight-Loss Intervention (Behavioral) versus Treatment As Usual	\N	United States of America	\N	\N	\N	\r\nUser defined field 9\r\n	\N	320	\N	\N	\N	\N	\N
18629	ISRCTN33576045	\N	Psychoeducation//token economy//Monetary incentives//Psychoeducation versus contingency management	\N	United Kingdom	\N	\N	\N	\N	\N	544	\N	\N	\N	\N	\N
18630	NCT01478815	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
18631	ISRCTN63382258	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
18632	NCT01465074	\N	\N	\N	Canada	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
18633	NCT01478880	\N	\N	\N	Germany	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
18635	NCT01473550	\N	Patient Held Medical Records versus Waitlist	\N	Canada	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n	\N	450	\N	\N	\N	\N	\N
18638	NCT01481883	\N	\N	\N	Australia	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
18639	NCT01469039	\N	Aripiprazole Dosage // Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	690	\N	\N	\N	\N	\N
18640	Dazzan 2011	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
18641	Dazzan 2011 b	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	210	\N	\N	\N	\N	\N
18642	Dazzan 2011 a	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	245	\N	\N	\N	\N	\N
18689	Beebe 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 9\r\n	\N	97	\N	\N	\N	\N	\N
18690	Aho 2011 a	\N	Group psychoeducation versus treatment as usual//psychoeducation	\N	Finland	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
18696	Bartzokis 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
18698	Slotema 2011 a	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
18703	Potkin 2011	\N	Lurasidone versus Ziprasidone	\N	Multicentre // United States of America // Japan	\N	\N	\N	\r\nNotes2\r\nZiprasidone versus lurasidone Ziprasidone versus lurasidone for schizophrenia or//and schizoaffective disorders whose current state is partial remission and whose stage of illness is not described	\N	301	\N	\N	\N	\N	\N
18718	Arbour 2011 a	\N	\N	\N	Canada	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
18720	Bouhlel 2011	\N	\N	\N	Tunisia	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
18723	Novick 2011	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	1064	\N	\N	\N	\N	\N
18727	JPRN-UMIN000006685	\N	\N	\N	Japan	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
18728	Bitter 2010	\N	Olanzapine conventional oral tablet (oct) versus Olanzapine orodispersible tablet (odt)	\N	Brazil//Israel//Mexico//Romania//Turkey	\N	\N	\N	\N	\N	175	\N	\N	\N	\N	\N
18730	NCT00316303	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
18731	NCT01491490	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18732	NCT01493726	\N	Aripiprazole Dosage // Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
18733	NCT01499563	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	320	\N	\N	\N	\N	\N
18734	NCT01490086	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	228	\N	\N	\N	\N	\N
18735	NCT01496690	\N	\N	\N	Denmark	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
18736	NCT01435928 (PEARL)	\N	Lurasidone versus Placebo	\N	Multi-Center // France // Italy // Russia // Serbia // Slovakia // South Africa // United States of America	\N	\N	\N	\N	\N	676 (Pearl)	\N	\N	\N	\N	\N
18738	NCT01487668	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
18739	NCT01488929	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	456	\N	\N	\N	\N	\N
18740	IRCT20111018783	\N	\N	\N	Iran	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
18741	NCT01492439	\N	\N	\N	Canada	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
18743	IRCT20100905255	\N	\N	\N	Iran	\N	\N	\N	\N	\N	280	\N	\N	\N	\N	\N
18744	NCT01503359	\N	\N	\N	Poland	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
18745	NCT01494623	\N	\N	\N	Canada	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18746	IRCT20110822393	\N	\N	\N	Iran	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18750	Van 2011 a	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	597	\N	\N	\N	\N	\N
18751	Johnson 2008 a	\N	\N	\N	UK	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
18753	De 2011 b	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
18758	Tang 2011 a	\N	\N	\N	Taiwan	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
18759	Umbricht 2011 b	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	323	\N	\N	\N	\N	\N
18763	Birchwood 2010	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
18764	Bonsack 2010	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
18768	Chen 2010 b	\N	\N	\N	Hong Kong	\N	\N	\N	\N	\N	178	\N	\N	\N	\N	\N
18769	Chen 2010 a	\N	\N	\N	Hong Kong	\N	\N	\N	\N	\N	1000	\N	\N	\N	\N	\N
18770	Eack 2011 b	\N	Cognitive enhancement therapy - computer based versus Enriched supportive therapy//Information and communication technology-based cognitive remediation	\N	United States of America	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
18773	Gaebel 2010	\N	\N	\N	Germany	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
18775	Hinton 2010	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
18777	Killackey 2010	\N	\N	\N	Australia	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
18779	Meister 2010	\N	\N	\N	Germany/Switzerland	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
18784	Pelayo 2010	\N	\N	\N	Spain	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
18785	Perez 2010 a	\N	\N	\N	Spain	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
18788	Shahrivar 2010 a	\N	\N	\N	Iran	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
18789	Simon 2010 b	\N	\N	\N	Switzerland	\N	\N	\N	\N	\N	591	\N	\N	\N	\N	\N
18790	Smeerdijk 2010	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
18791	Stain 2010 a	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
18792	Tessier 2010 a	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	179	\N	\N	\N	\N	\N
18794	Van Der Krieke 2010	\N	Self-Management (Internet Application)	\N	The Netherlands	\N	\N	\N	\N	\N	Not Reported	\N	\N	\N	\N	\N
18795	Vesterager 2010	\N	\N	\N	Copenhagen	\N	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
18796	Xiao 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
18805	Firestone 2011	\N	Lifestyle intervention versus treatment as usual//dietary advice//exercise therapy	\N	Unclear	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
18829	Cook 2011 b	\N	Building Recovery of Individual Dreams and Goals through Education and Support (BRIDGES) versus wait list control	\N	United States of America	\N	\N	\N	\N	\N	428	\N	\N	\N	\N	\N
18830	Gleeson 2011 a	\N	\N	\N	Austrialia	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
18837	Brown 2011 b	\N	Weight Loss Intervention	\N	United States of America	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
18839	Guan 2011	\N	Remifentanil + electroconvulsive therapy versus Esmolol + electroconvulsive therapy	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
18842	Jonikas 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	519	\N	\N	\N	\N	\N
18843	Kelleher 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
18845	Redden 2011 a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18846	Schlosser 2011	\N	Family intervention versus psychoeducation//family intervention (18 sessions)//Brief psychoeducation//psychoeducation	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
18847	ACTRN12605000440628	\N	\N	\N	Australia	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
18850	Nischk 2011	\N	Brief Psychoeducation versus treatment as usual	\N	Germany	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
18852	Ruiz 2011	\N	\N	\N	Spain	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
18853	Kusumi 2011 a	\N	\N	\N	Japan	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
18855	Fiorillo 2011	\N	\N	\N	Italy	\N	\N	\N	\N	\N	324	\N	\N	\N	\N	\N
18857	Dunbar 2011	\N	\N	\N	India//United States of America	\N	\N	\N	\N	\N	185	\N	\N	\N	\N	\N
18859	Hopkins 2011	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	323	\N	\N	\N	\N	\N
18860	Loza 2011	\N	\N	\N	Poland	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
18861	Loza 2011 a	\N	\N	\N	Poland	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
18862	Nisenbaum 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
18866	NCT01506765	\N	N-acetyl cysteine versus Placebo	\N	Switzerland	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
18867	NCT01512290	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18868	NCT01514682	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18869	NCT01515423	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	1288	\N	\N	\N	\N	\N
18870	NCT01516424	\N	Blonanserin versus Risperidone	\N	China	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
18871	NCT01517360	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
18872	NCT01518894	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
18873	NCT01519557	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
18874	NCT01521026	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
18876	NCT01523730	\N	\N	\N	Canada	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
18877	NCT01524380	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
18878	ISRCTN74054823	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
18879	ISRCTN34900108	\N	\N	\N	Iran	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
18883	CTRI-2012-01-00	\N	\N	\N	India	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
18891	Vita 2011	\N	\N	\N	Italy	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
18895	Blank 2011	\N	Monetary incentives//Advance practice nurse versus treatment as usual	\N	United States of America	\N	\N	\N	\N	\N	238	\N	\N	\N	\N	\N
18899	Van Gestel 2012	\N	Peer-Run Intervention	\N	The Netherlands	\N	\N	\N	\N	\N	333	\N	\N	\N	\N	\N
18900	Wolwer 2011	\N	\N	\N	Germany	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
18905	Chao 2011	\N	Exercise therapy	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
18910	Zhang 2011 c	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
18911	Bajaj 2012	\N	\N	\N	Europe//United States of America	\N	\N	\N	\N	\N	273	\N	\N	\N	\N	\N
18912	Jamora 2012	\N	\N	\N	Philippines	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
18914	Swildens 2011	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
18921	Hoffmann 2012	\N	\N	\N	Switzerland	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
18923	Remington 2012	\N	\N	\N	Canada	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
18929	Chen 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	632	\N	\N	\N	\N	\N
18930	Davis 2011 b	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
18931	Deutsch 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
18932	Feifel 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
18935	Hong 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
18936	Hosford 2011 a	\N	\N	\N	India//United States of America	\N	\N	\N	\N	\N	185	\N	\N	\N	\N	\N
18937	Lasser 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
18940	Mathalon 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
18941	Oranje 2011 a	\N	\N	\N	Denmark	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
18942	Pedersen 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
18943	Potkin 2011a	\N	Lurasidone Dosage	\N	United States of America	\N	\N	\N	\r\nUser defined field 9\r\n	\N	24 OR 25	\N	\N	\N	\N	\N
18944	Prasad 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
18945	Robinson 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
18946	Roffman 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
18948	Shen 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	313	\N	\N	\N	\N	\N
18950	Szegedi 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	215	\N	\N	\N	\N	\N
18952	Ibrahim 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
18953	Agam 2011	\N	\N	\N	Israel	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
18955	Woolley 2011 a	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
18956	Buchsbaum 2010	\N	Aripiprazole versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18957	Bunney 2010 a	\N	Ziprasidone Dosage	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
18958	Chen 2010 c	\N	Atypical Antipsychotic Drug versus Typical Antipsychotic Drug	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18959	Feifel 2010 b	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18960	Ferziger 2010	\N	Oral Antipsychotic Drug versus Paliperidone Palmitate	\N	Multi-Center	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18961	Garcia 2010 a	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
18962	Keefe 2010	\N	CYP-1020 versus Placebo//CYP-1020 versus Risperidone//CYP-1020 dose	\N	India/Romania/United States of America	\N	\N	\N	\N	\N	363	\N	\N	\N	\N	\N
18963	Leweke 2010	\N	Cannabidiol versus Placebo	\N	Germany	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
19244	范春云 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
18964	Lieberman 2010	\N	Meformin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	148	\N	\N	\N	\N	\N
18965	Lieberman 2010 a	\N	Davunetide Dosage // Davunetide versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
18967	Minzenberg 2010 b	\N	Modafinil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
18969	Pedersen 2010 a	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
18970	Prasad 2010	\N	Valacyclovir versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
18972	Smith 2010 a	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18974	Tregellas 2010 a	\N	DMXB-A Dosage // DMXB-A versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
18975	Umbricht 2010 a	\N	RG1678 Dosage // RG1678 versus Placebo	\N	Switzerland	\N	\N	\N	\N	\N	323	\N	\N	\N	\N	\N
18976	Vanover 2010	\N	ITI-007 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
18977	Wing 2010	\N	repetitive Transcranial Magnetic Stimulation	\N	Canada	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
18981	Bergk 2011	\N	seclusion versus restraints	\N	Germany	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n	\N	102	\N	\N	\N	\N	\N
18982	NCT01529515	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	500	\N	\N	\N	\N	\N
18983	ISRCTN76324634	\N	\N	\N	Germany/Switzerland	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
18984	ACTRN1261200021	\N	\N	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
18985	ACTRN1261200019	\N	\N	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
18986	ISRCTN61109178	\N	\N	\N	Switzerland	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
18987	ISRCTN75675072	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
18990	Deakin 2012	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	170	\N	\N	\N	\N	\N
18992	Gelkopf 2012	\N	Smoking Reduction Intervention	\N	Israel	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
18993	Rabovsky 2012	\N	\N	\N	Switzerland	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
18994	Vazquez 2012	\N	Coping with Stress Training	\N	Spain	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
18999	Shifu 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	109	\N	\N	\N	\N	\N
19001	Tempier 2012	\N	Specialized Early Intervention	\N	UK	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
19004	Fang 2012	\N	Haloperidol im versus Risperidone oral//Antipsychotic switching	\N	China	\N	\N	\N	\N	\N	205	\N	\N	\N	\N	\N
19006	Fleischhacker 2012 b	\N	\N	\N	Australia/Europe/New Zealand/United States of America	\N	\N	\N	\N	\N	747	\N	\N	\N	\N	\N
19008	Royer 2012	\N	\N	\N	France	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
19009	Silverman 2011 b	\N	Music therapy	\N	United States of America	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
19011	Bechdolf 2011	\N	\N	\N	Germany	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
19014	Gassmann 2011	\N	\N	\N	Germany	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
19018	Klingberg 2011 a	\N	\N	\N	Germany	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
19019	NCT01123408	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
19020	Lincoln 2011	\N	\N	\N	Germany	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19022	Malchow 2011 a	\N	\N	\N	Germany	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
19023	McCabe 2011 a	\N	\N	\N	Australia	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
19025	Ojeda 2011	\N	Occupational therapy versus Cognitive remediation	\N	Spain	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n	\N	72	\N	\N	\N	\N	\N
19027	Quisenaerts 2011	\N	\N	\N	Belgium	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
19028	Scheewe 2011	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
19029	Scheewe 2011 a	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
19031	Shaygan 2011	\N	\N	\N	Iran	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
19033	Van 2011 b	\N	\N	\N	Netherlands	\N	\N	\N	\N	\N	201	\N	\N	\N	\N	\N
19037	Coppola 2011	\N	Paliperidone versus Placebo // Paliperidone Dosage	\N	Taiwan // India // United States of America // Multi-Center	\N	\N	\N	\N	\N	201	\N	\N	\N	\N	\N
19042	Langer 2012	\N	\N	\N	Spain	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
19047	Tomita 2011	\N	Critical Time Intervention	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
19058	Rosenheck 1998 a	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	423	\N	\N	\N	\N	\N
19059	NCT01567124	\N	\N	\N	Australia	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
19060	NCT01555697	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19061	NCT01561859	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
19062	NCT01567943	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19063	NCT01566513	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	320	\N	\N	\N	\N	\N
19064	NCT01563016	\N	\N	\N	Hong Kong	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19066	NCT01569659	\N	Lurasidone Dosage	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19068	NCT01561742	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19070	NCT01568528	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
19072	CTRI-2012-03-00	\N	\N	\N	India	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19073	NCT01556763	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
19074	NCT01547026	\N	\N	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
19075	NCT01559272	\N	\N	\N	Croatia/Spain/United States of America	\N	\N	\N	\N	\N	224	\N	\N	\N	\N	\N
19076	NCT01551979	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
19078	DRKS00003623	\N	\N	\N	Germany	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
19079	IRCT20120206729	\N	Atorvastin + Risperidone versus Placebo + Risperidone//Atorvastin versus Placebo//Risperidone versus Atorvastin//Risperidone versus Placebo	\N	Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
19081	IRCT20120224155	\N	Risperidone + minocycline versus Risperidone + Placebo//minocycline versus Placebo//Risperidone versus Placebo//Risperidone versus minocycline	\N	Iran	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
19082	ISRCTN32545295	\N	\N	\N	Spain	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
19083	ISRCTN79584912	\N	Eye Movement Desentizational and Reprocessing versus Waitlist	\N	The Netherlands	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nUser defined field 9\r\n	\N	240	\N	\N	\N	\N	\N
19084	James 2012	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19085	McGuire 2012	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	350	\N	\N	\N	\N	\N
19086	Jones 2012	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
19087	IRCT201202117373N2	\N	Omega-3 Fatty Acid versus Placebo	\N	Iran	\N	\N	\N	\r\nUser defined field 9\r\n	\N	60	\N	\N	\N	\N	\N
19089	Behdani 2011	\N	\N	\N	Iran	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19090	Nielsen 2012	\N	\N	\N	Denmark	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
19097	Xiang 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	404	\N	\N	\N	\N	\N
19098	Averbeck 2012	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
19104	Raven 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19105	Wang 2012 a	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
19107	Cullen 2012	\N	Reasoning and rehabilitation versus treatment as usual	\N	United Kingdom	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
19108	Hatta 2012	\N	\N	\N	Japan	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
19110	Bechi 2012	\N	\N	\N	Italy	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
19115	Mattai 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
19120	Bagoien 2011	\N	Motivational interviewing + treatment as usual versus treatment as usual	\N	Unclear	\N	\N	\N	\N	\N	135	\N	\N	\N	\N	\N
19122	Berti 2011	\N	dietary advice//Exercise therapy//Health promotion interventions versus treatment as usual	\N	Italy	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
19125	Johnson 2011	\N	Assertive community treatment//early intervention//Community Mental health Services versus Specialist team	\N	United Kingdom	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
19126	Kroon 2011	\N	Recovery training programme	\N	Unclear	\N	\N	\N	\N	\N	210	\N	\N	\N	\N	\N
19127	Kroon 2011 a	\N	Recovery group + care as usual versus wait list control	\N	Netherlands	\N	\N	\N	\N	\N	175	\N	\N	\N	\N	\N
19128	Latimer 2011	\N	Housing first + assertive community treatment//Housing first + intensive case management//assertive community treatment//intensive case management	\N	Canada	\N	\N	\N	\N	\N	2300	\N	\N	\N	\N	\N
19245	刁端忠 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19130	Michon 2011	\N	Vocational rehabilitation//Individual placement and supporrt (ips)//Vocational rehabilitation versus Individual placement and supporrt (ips)	\N	Netherfields	\N	\N	\N	\N	\N	151	\N	\N	\N	\N	\N
19131	Puschner 2011	\N	Outcome monitoring & management	\N	Bavaria	\N	\N	\N	\N	\N	294	\N	\N	\N	\N	\N
19133	Roosenschoon 2011	\N	Illness management and recovery training	\N	Unclear	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
19135	Schmechtig 2011	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	233	\N	\N	\N	\N	\N
19136	Schulze 2011	\N	Psychoeducation coping skills training	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
19137	Hansen 2012	\N	\N	\N	Denmark	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
19141	McElroy 2012	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
19142	Perlick 2011	\N	Clinician-Led Intervention versus Peer-Led Intervention	\N	United States of America	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
19143	Ratliff 2011	\N	Weight loss program + monetary incentitives versus Weight loss program + contingency management + monetary incentitives//Exercise therapy//monetary incentives//Weight loss program versus contingency management	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
19145	Tek 2011 a	\N	Naltrexone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
19146	Twamley 2012	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
19147	Younis 2012	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
19148	Burton 2011	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
19152	Kopelowicz 2012	\N	\N	\N	United States of America	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
19153	Chen 2012	\N	Olanzapine versus first generation Antipsychotics//Risperidone versus first generation Antipsychotics//Olanzapine versus Haloperidol//Olanzapine versus trifluoperazine//Risperidone versus Haloperidol//Risperidone versus trifluoperazine//Olanzapine versus Risperidone	\N	Taiwan	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
19156	Na 2011	\N	Paliperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19157	Schneiderhan 2011	\N	Medication therapy management	\N	United States of America	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
19158	Stone 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
19159	Tangu 2011	\N	Medication instructions	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
19166	Arbabi 2012	\N	Modafinil versus Placebo	\N	Iran	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
19171	2011-005138-21	\N	Tc-5619 versus Placebo	\N	Romania//Russia//Serbia//Ukraine//United States of America	\N	\N	\N	\N	\N	456	\N	\N	\N	\N	\N
19172	NCT01570712	\N	Housing first program versus treatment as usual//Supported housing	\N	France	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
19173	NCT01573637	\N	Raloxifene versus Placebo	\N	Spain	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19178	McDonnell1 2011	\N	Olanzapine long acting injection versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	931	\N	\N	\N	\N	\N
19179	Schepp 2011	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19181	李杰 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
19182	沙蓉 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19184	彭渝 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
19185	赵肖霞 2011	\N	Chlorpromazine versus Risperidone//Chlorpromazine versus Quetiapine//Risperidone versus Quetiapine	\N	China	\N	\N	\N	\N	\N	168	\N	\N	\N	\N	\N
19186	兰庆榜 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	270	\N	\N	\N	\N	\N
19187	杨诚 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
19188	Wang 2010a	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
19189	薛蓉 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19190	Xie 2011	\N	Aripiprazole versus Aripiprazole + Magnesium Valproate	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
19191	杨迎兰 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
19192	解克平 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
19193	彭东阳 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
19194	刘琼华 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
19195	蒋菊芳 2011	\N	Clinical nursing pathway versus conventional nursing	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19196	陈俊雄 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19197	蒋红 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
19198	刘翠欣 2011	\N	Excellence nursing management + Pharmacotherapy verus Pharmacotherapy//Excellence nursing management	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19199	高志勤 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
19200	刘晓军 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
19201	徐亚秋 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
19202	翁深宏 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
19203	梅映台 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19204	方崇芳 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
19205	卢爱莲 2011	\N	Intensive health education versus routine health education//Health education	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
19206	胡光涛 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
19207	杨健 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
19208	焦薇 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
19209	王玲 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
19210	杨梅 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
19211	马迅 2010 a	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
19212	谢育南 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
19213	侯春兰 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
19214	李智强 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
19215	王丽莉 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
19216	陈正 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
19217	陈庆红 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
19218	肖世富 2011	\N	Sarsasapogenin (TCM) + Risperidone versus Risperidone//Sarsasapogenin (TCM) versus Risperidone	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
19219	温盛霖 2011	\N	Risperidone versus Olanzapine	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
19220	顾广善 2010	\N	Risperidone versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
19221	李永红 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
19222	Yao 2010	\N	Magnesium Valproate + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
19223	刘纪猛 2011	\N	Risperidone + Clozapine versus Clozapine// Risperidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
19224	唐爱珠 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19225	李广田 2011	\N	Risperidone + sertraline versus Risperidone//Risperidone versus sertraline	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
19226	左潇 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
19227	林虹 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19228	寇金爱 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
19229	吴德华 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
19230	高海江 2011	\N	Risperidone versus Quetiapine	\N	China	\N	\N	\N	\N	\N	210	\N	\N	\N	\N	\N
19231	陈平勋 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
19232	张谦 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
19233	陈勇 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19234	杜永慧 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19235	刘显阳 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
19236	成为荣 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
19237	陶世武 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
19238	褚梅林 2011	\N	Group psychotherapy + Conventional nursing versus Conventional nursing// Group psychotherapy versus Conventional nursing	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
20285	吕振雷 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19239	陈绪焕 2010	\N	Olanzapine (domestic) versus Olanzapine (imported)	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
19240	余雪芹 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
19241	谢国建 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
19242	侯锐钢 2010	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19248	刘晓军 2011 a	\N	Haloperidol versus Olanzapine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
19249	刘海瑶 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19250	梁勇 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
19251	张超 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19252	余雪虎 2011	\N	Comprehensive intervention + pharmacotherapy versus pharmacotherapy	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
19253	钟如青 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19254	周永静 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
19255	孙桂兰 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
19256	Tang 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19257	魏玉莲 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19258	宋红 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	216	\N	\N	\N	\N	\N
19259	高班玲 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	263	\N	\N	\N	\N	\N
19260	任智勇 2011	\N	Family intervention + pharmacotherapy versus pharmacotherapy// Family intervention	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
19261	赵云 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19262	苏京利 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19263	李广田 2011 a	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19264	姜俊哲 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
19265	曹经纬 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
19266	李西敏 2011	\N	Family comprehensive intervention + Pharmacotherapy versus pharmacotherapy//Family comprehensive intervention	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
19267	段武钢 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
19268	黄志茹 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
19269	丁宁 2011	\N	Occupation recreational therapy + pharmacotherapy versus pharmacotherapy//Occupation recreational therapy	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
19270	吴开文 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19271	刘月芬 2011	\N	Occupation recreational therapy + pharmacotherapy versus pharmacotherapy//Occupation recreational therapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19272	成为荣 2010 a	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19273	唐建良 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
19274	周平 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
19275	曹国兴 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
19276	徐莉萍 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
19277	罗燕 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	399	\N	\N	\N	\N	\N
19278	刘建君 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
19279	周广玉 2011	\N	Paroxetine + Lithium versus Paroxetine//Paroxetine versus Lithium	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
19280	黄玉琴 2011	\N	Suicide intervention + Pharmacotherapy versus Pharmacotherapy//Suicide intervention	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
19281	翟乃霞 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
19282	罗颖 2011	\N	Rehabilitation nursing versus conventional nursing	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
19283	张莉 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19284	司丽华 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
19285	侯玉玲 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
19286	何丽婵 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
19287	谷德康 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19288	胡立红 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
19289	肖凤新 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
19290	杨英 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
19291	王英群 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19292	徐燕川 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
19293	涂亚莉 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19294	苏勉 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
19297	张献强 2011	\N	Occupational therapy + pharmacotherapy versus pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19298	刘建金 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19299	段武钢 2010 a	\N	\N	\N	China	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
19300	张玉海 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
19301	张华坤 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
19302	Xie 2011a	\N	Nurse-Patient Communication + Pharmacotherapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19303	杨云秀 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
19304	Teng 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
19305	陈幼然 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
19306	齐巧玲 2010	\N	Nursing intervention + conventional treatment versus conventional treatment//Nursing intervention	\N	China	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
19307	Nong 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	188	\N	\N	\N	\N	\N
19308	傅慕君 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
19309	汪正华 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
19310	陈刚伟 2011	\N	Relaxation therapy + Pharmacotherapy versus Pharmacotherapy// Relaxation therapy versus Pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19311	李兰芳 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19312	宋丽 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
19313	梁玉婵 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
19314	于瑞丽 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
19315	王振华 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
19316	侯月红 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
19317	王艳 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
19318	张学民 2011	\N	Aripiprazole + Clozapine versus Clozapine//Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	168	\N	\N	\N	\N	\N
19319	颜建辉 2011	\N	Ziprasidone + Clozapine versus Clozapine//Ziprasidone versus Clozapine	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
19320	柳贵明 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
19321	何震 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19322	刘林晶 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
19323	贾竑晓 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19324	高海江 2011 a	\N	\N	\N	China	\N	\N	\N	\N	\N	278	\N	\N	\N	\N	\N
19325	黄志茹 2010 a	\N	\N	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
19326	王学升 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
19327	周清清 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19328	孙宏俊 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
19329	胥德广 2011	\N	Risperidone + Shengmai capsules (TCM) versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
19330	罗世芳 2011	\N	Quetiapine + Shugan decotion (TCM) versus Quetiapine	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19331	张子梅 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19332	卢殿军 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19333	樊献丽 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19334	唐仕友 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
19335	姜俊哲 2010 a	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
19336	Liu 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
19337	张永俐 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
19338	余学 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
19339	张明兰 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
19340	汤景文 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
19341	邓方渝 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
19342	Zhu 2011	\N	Health education + conventional care versus conventional care// Health education	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19343	冯亚芬 2011	\N	Health education + pharmacotherapy versus pharmacotherapy// Health education	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19344	刘根凤 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19345	张瑞芬 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
19346	余海鹰 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
19347	赵占宏 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
19348	王红艳 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19353	刘明辉 2011	\N	Comprehensive psychological intervention + pharmacotherapy versus pharmacotherapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19354	王怀静 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
19355	乔金荣 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19356	马秋 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
19357	董汉振 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	189	\N	\N	\N	\N	\N
19358	任杰 2011	\N	Clozapine versus Thioridazine	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
19359	刘丽微 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19360	Huang 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
19361	郭全芳 2011	\N	Insight education + pharmacotherapy versus pharmacotherapy//Insight education	\N	China	\N	\N	\N	\N	\N	217	\N	\N	\N	\N	\N
19362	周广玉 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
19363	陈华云 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19364	代嘉庚 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
19365	张玲 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
19366	庞铁良 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
19367	张莉 2010 a	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19368	穆世铭 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
19369	郑樱 2011	\N	Behavior training + conventional nursing versus conventional nursing//Behavior training versus conventional nursing	\N	China	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
19370	刘国霞 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19371	皮玥玥 2010 a	\N	\N	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
19372	莫迪 2011	\N	Citalopram + Antipsychotics versus Antipsychotics//Citalopram versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
19373	谢鸿珍 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19374	余亚珍 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19375	蒋燕 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
19376	陶敏 2011	\N	Social skills training + Conventional nursing versus Conventional nursing//Social skills training	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
19377	汪艳 2011	\N	Acupuncture + pharmacotherapy versus pharmacotherapy//Acupuncture	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
19378	陈海莹 2011	\N	Repetitive transcranial magnetic stimulation versus sham Repetitive transcranial magnetic stimulation	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
19379	徐天朝 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19380	杜玉杰 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19381	尹道亮 2011	\N	Risperidone + yinxingye tablets (TCM) versus Risperidone//Yinxingye tablets (TCM) versus Risperidone	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
19382	张晓阳 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19383	戚惠娟 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19384	张述杰 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19385	赵青霞 2010	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
19386	于艳华 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
19387	李祥 2011	\N	Risperidone versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
19388	陈刚伟 2011 a	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19389	李鹰 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
19390	石保青 2011	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
19391	张咏梅 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19392	孙艳 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
19393	Liu 2011a	\N	Aripiprazole versus Perospirone	\N	China	\N	\N	\N	\N	\N	278	\N	\N	\N	\N	\N
19394	张保利 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
19395	周天红 2011	\N	Aripiprazole versus Olanzapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19396	李晓一 2011	\N	Olanzapine versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
19397	张静 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
19398	李超 2011	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19399	朱凤宜 2011	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
19400	易峰 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19401	杨明华 2011	\N	Aripiprazole versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
19402	张恒 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
19403	王昉 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19404	罗玲玲 2011	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19405	李超 2010	\N	Aripiprazole versus Clozapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19418	马树芝 2011	\N	Open versus closed ward management	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
19419	贾竑晓 2010 a	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
19420	朱玉梅 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19421	刘彩兴 2011	\N	Quetiapine versus Olanzapine or Aripiprazole//Quetiapine versus Olanzapine//Aripiprazole versus Quetiapine	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19422	哈秀英 2011	\N	Risperidone versus Quetiapine	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
19423	李建峰 2011	\N	Music therapy + pharmacotherapy versus pharmacotherapy// Music therapy	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19424	张红旗 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
19425	罗慧芳 2010 a	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
19426	杨杰 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
19427	任艳萍 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
19428	张峰 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19429	温占红 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
19430	陈慧 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
19431	熊辉 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
19432	孙平 2011	\N	Risperidone versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
19433	冉昌华 2011	\N	Risperidone versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
19434	黄智辉 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19435	林敏 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19436	胡华廷 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
19437	赵敬平 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
19438	何文刚 2011	\N	Risperidone versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19439	王金堂 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
19440	宋丽 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19441	崔明伟 2011	\N	Ziprasidone versus Perphenazine	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
19442	杨仁登 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
19443	卢殿军 2011 a	\N	Quetiapine versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19444	王体宾 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	187	\N	\N	\N	\N	\N
19445	王永学 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19446	李仕军 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19447	王刚平 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
19448	邓广 2011	\N	Aripiprazole versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
19449	喻志敏 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19450	邢香然 2011	\N	Aripiprazole versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19451	李春花 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19452	许亚平 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
19453	吕长波 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
19454	秦捷 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19455	阿怀红 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
19456	张鸿燕 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	239	\N	\N	\N	\N	\N
19457	李培轩 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
19458	黄峰 2010 a	\N	Ziprasidone versus sulpride	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
19459	何淑芬 2011	\N	Health education pathway versus Health education	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20490	韦强 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19460	徐丽芬 2011	\N	skills training + conventional treatment versus conventional treatment// skills training	\N	China	\N	\N	\N	\N	\N	199	\N	\N	\N	\N	\N
19461	Li 2010	\N	Conventional health education + Medication education Versus Conventional health education	\N	China	\N	\N	\N	\N	\N	281	\N	\N	\N	\N	\N
19463	张志娟 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
19464	叶百维 2011	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19465	殷月珍 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19466	Prasad 2012	\N	Valacyclovir versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
19477	Morrison 2012	\N	Cognitive therapy versus Monitoring of mental state//Cognitive therapy	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n	\N	288	\N	\N	\N	\N	\N
19479	Sulaiman 2012	\N	Aripiprazole versus Placebo	\N	Malaysia	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
19480	Vita 2011 a	\N	\N	\N	Italy	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
19481	Weiser 2012	\N	\N	\N	Unclear	\N	\N	\N	\N	\N	248	\N	\N	\N	\N	\N
19488	Honarmand 2012	\N	Electroconvulsive Therapy + magnesium sulfate versus Electroconvulsive Therapy + Placebo//Electroconvulsive Therapy + magnesium sulfate dose	\N	Iran	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
19493	Edwards 2011	\N	Clozapine versus Thioridazine // Clozapine versus Clozapine+Cognitive Behavioral Therapy // Clozapine versus Cognitive Behavioral Therapy+Thioridazine // Clozapine+Cognitive Behavioral Therapy versus Cognitive Behavioral Therapy+Thioridazine // Clozapine+Cognitive Behavioral Therapy versus Thioridazine // Cognitive Behavioral Therapy+Thioridazine versus Thioridazine	\N	Australia	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
19496	Liang 2011	\N	Paliperidone sustained release tablets versus Olanzapine (domestic)	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
19497	Mahmoud 2011	\N	First generation Antipsychotics versus Second generation Antipsychotics//	\N	United Kingdom	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
19498	Nuijten 2012	\N	Inpatient Integrated Treatment versus Outpatient Integrated Treatment 	\N	The Netherlands	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
19500	DeMartinis 2012	\N	Pf-02545920 dose//Pf-02545920 versus Placebo//Risperidone versus Placebo//Risperidone versus Pf-02545920	\N	Unclear	\N	\N	\N	\N	\N	259	\N	\N	\N	\N	\N
19501	Hegde 2012	\N	Home-based cognitive training + psychoeduction versus psychoeduction//psychoeduction	\N	India	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
19502	Jarskog 2012	\N	Gsk239512 versus Placebo//Gsk239512 dose	\N	Unclear	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
19503	Jaugey 2012	\N	Cognitive Remediation (Computer-Assisted) versus Games (Computer)	\N	Switzerland	\N	\N	\N	\r\nCountry of origin\r\n	\N	32	\N	\N	\N	\N	\N
19505	Leweke 2012 a	\N	Cannabidiol versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
19507	Nasrallah 2012	\N	Olanzapine + Placebo versus Olanzapine + lisdexamfetamine dimesylate//Olanzapine versus Placebo//Olanzapine versus lisdexamfetamine dimesylate//lisdexamfetamine dimesylate versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
19508	Rakesh 2012	\N	Ect//EcT versus full dose anticonvulsants//Ect versus half dose anticonvulsants//EcT + full dose anticonvulsants versus Ect + half dose anticonvulsants	\N	India	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
19509	Sanchez 2011	\N	Panax ginseng + Antipsychotics versus Placebo + Antipsychotic medication//Panax ginseng dose//Panax ginseng versus Placebo//Panax ginseng versus Antipsychotics	\N	Canada	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
19510	王 1997	\N	Cutgut embedding therapy	\N	China	\N	\N	\N	\N	\N	216	\N	\N	\N	\N	\N
19511	Fan 2002	\N	Morita therapy + routine Antipsychotic medication versus routine Antipsychotic medication//Morita therapy	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19512	黄振英 2010	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19517	David 2012	\N	Video self-observations versus video control	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
19518	Dawes 2012	\N	Citalopram + Antipsychotics versus Placebo + Antipsychotic medication//Citalopram versus Placebo//Citalopram versus Antipsychotics//	\N	United States of America	\N	\N	\N	\N	\N	198	\N	\N	\N	\N	\N
19522	Chaudhry 2012	\N	Minocycline + treatment as usual versus Placebo + treatment as usual//Minocycline versus Placebo	\N	Brazil//Pakistan	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
19524	Steinwachs 2011	\N	Communication skills//Information and communication technology in patient education and support	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
19531	Phutane 2012	\N	ect//Bifrontal ect versus Bitemporal ect	\N	India	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
19533	Yalcin 2012	\N	Electroconvulsive Therapy//Propofol + ect versus Ketamine + ect///Propofol + ect versus Ketofol + ect//Ketamine + ect versus Ketofol + ect Ect + propofol versus Ect + ketamine//Ect + propofol versus Ect + ketofol//Ect + ketamine versus Ect + ketofol	\N	Turkey	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n	\N	90	\N	\N	\N	\N	\N
19535	Faber 2012 a	\N	Maintance treatment versus Guided discontinuation of medication//Intermittent drug techniques//Maintance treatment	\N	Netherlands	\N	\N	\N	\N	\N	53	\N	\N	\N	\N	\N
19537	Kelleher 2012	\N	Risperidone versus placbo// Olanzapine versus Placebo//Quetiapine versus Placebo//Clozapine versus Placebo//Ziprasidone versus Placebo//Risperidone versus Pramipexole//Olanzapine versus Pramipexole//Quetiapine versus Pramipexole//Clozapine versus Pramipexole//Ziprasidone versus Pramipexole	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
19539	Zhu 2012	\N	Paliperidone sustained release tablets versus Olanzapine (domestic)	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
19552	Wu 2012	\N	Olanzapine versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
19554	Yanos 2012	\N	Stigma group intervention versus treatment as usual//Interventions to reduce experiences of stigma and discrimination of people//cognitive therapy versus treatment as usual	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
19555	Chang 2012	\N	Aripiprazole versus Clozapine	\N	South Korea	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
19571	Yang  2011 a	\N	Olanzapine versus Risperidone//Olanzapine versus Aripiprazole//Risperidone versus Aripiprazole//	\N	China	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
19573	NCT01598623	\N	Oxytocin + non specific counselling versus Placebo + non specific counselling//Oxytocin + non specific counselling versus Oxytocin + social skills training//Oxytocin + non specific counselling versus Placebo + social skills training//Placebo + non specific counselling versus Oxytocin + social skills training//Placebo + non specific counselling versus Placebo + social skills training//Oxytocin versus Placebo//social skills training//counselling	\N	Israel	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
19574	NCT01598896	\N	Dronabinol versus Placebo//Dronabinol versus Clonidine//Clonidine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
19575	IRCT20120513155	\N	Risperidone + raloxifene versus Risperidone + Placebo//raloxifene versus Placebo//Risperidone versus raloxifene//Risperidone versus Placebo	\N	Iran	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
20286	谢明华 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19577	NCT01607840	\N	Transcranial direct current stimulation//Transcranial direct current stimulation anodal versus Transcranial direct current stimulation sham//Transcranial direct current stimulation anodal versus Transcranial direct current stimulation cathodol//Transcranial direct current stimulation sham versus Transcranial direct current stimulation cathodol	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
19578	NCT01601587	\N	Psychoeducation	\N	Norway	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
19579	NCT01609153	\N	Olanzapine versus Amisulpride//Olanzapine versus Olanzapine + Amisulpride//Amisulpride versus Olanzapine + Amisulpride	\N	Germany	\N	\N	\N	\N	\N	399	\N	\N	\N	\N	\N
19581	NCT01593774	\N	Melatonin versus Placebo	\N	Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
19582	NCT01597141	\N	Family-aided assertive community treatment versus Enhanced standard treatment//Family intervention//psychoeducation//supported employment//assertive community treatment//Crisis intervention//Individual case management	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19583	NCT01602029	\N	Ondansetron versus Placebo//Ondansetron versus Simvastatin//Simvastatin versus Placebo	\N	Pakistan	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
19584	DRKS00003603	\N	Olanzapine + Placebo versus Olanzapine + Amisulpride//Olanzapine + Placebo versus Amisulpride + Placebo//Olanzapine + Amisulpride versus Amisulpride + Placebo//Amisulpride versus Placebo//Olanzapine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	399	\N	\N	\N	\N	\N
19585	NCT01606254	\N	Paliperidone palmitate IM dose	\N	Unclear	\N	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
19586	NCT01607424	\N	Cognitive remediation versus Computerised cognitive remediation//Information and communication technology-based cognitive remediation	\N	France	\N	\N	\N	\N	\N	151	\N	\N	\N	\N	\N
19587	NCT01606436	\N	Ly 2140023 versus Placebo//Moxifloxacin versus Placebo//Ly 2140023 versus Moxifloxacin	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19588	ISRCTN82129964	\N	Supported discharge services versus Usual inpatient treatment//Intensive case management//	\N	United Kingdom	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
19589	NCT01595503	\N	Repetitive transcranial magnetic stimulation with fMRI-based targeting versus Repetitive transcranial magnetic stimulation with landmark-based targeting//Repetitive transcranial magnetic stimulation	\N	United States of America	\N	\N	\N	\N	\N	5	\N	\N	\N	\N	\N
19592	Pelosi 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19593	Chung 2012	\N	Olanzapine versus Risperidone//Olanzapine versus paliperidone//Risperidone versus paliperidone	\N	Taiwan	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19606	Gurvich 2011 a	\N	Estradiol versus Placebo//Estradiol dose	\N	Austrailia	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
19610	Nielsen 2012 a	\N	Sertindole versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
19613	Jarrett 2012	\N	Critical Time Intervention	\N	UK	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19615	Sachs 2012	\N	Training of affect recognition versus Occupational therapy + treatment as usual	\N	Austria	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
19616	Valencia 2012	\N	Intergrated treatment versus treatment as usual//pharmacotherapy + psychosocial + psychoeducation versus treatment as usual	\N	Mexico	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
19626	Medalia 2012	\N	Monetary incentives//Brief Psychoeducation//Psychoeducation	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19629	Won 2012	\N	Emotion management nursing program	\N	South Korea	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
19634	Pandina 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19638	Morozova 2012	\N	Dimebon versus Placebo	\N	Russia	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
19640	Taylor 2012	\N	Negative information + appraisal manipulation versus Neutral information + appraisal manipulation	\N	United Kingdom	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
19641	NCT01635075	\N	Exercise	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
19642	NCT01634373	\N	Quetiapine Brand	\N	India	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19643	NCT01626872	\N	MP-214 Dosage // MP-214 versus Risperidone // MP-214 versus Placebo // Risperidone versus Placebo	\N	Japan	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
19644	NCT01626859	\N	MP-214 Dosage	\N	Japan	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
19645	NCT01626456	\N	Aripiprazole Dosage	\N	Multi-Center	\N	\N	\N	\N	\N	500	\N	\N	\N	\N	\N
19646	NCT01625897	\N	MP-214 Dosage // MP-214 versus Risperidone	\N	Japan	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19647	NCT01625000	\N	MP-214 Dosage // MP-214 versus Risperidone	\N	Japan	\N	\N	\N	\N	\N	480	\N	\N	\N	\N	\N
19648	NCT01623726	\N	transcranial Direct Current Stimulation	\N	Brazil	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
19649	NCT01623713	\N	Iloperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
19650	NCT01622166	\N	Art Therapy	\N	Germany	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n	\N	60	\N	\N	\N	\N	\N
19651	NCT01621737	\N	Asenapine versus Placebo	\N	Croatia // Ukraine // Multi-Center	\N	\N	\N	\N	\N	354	\N	\N	\N	\N	\N
19652	NCT01620086	\N	repetitive Transcranial Magnetic Stimulation	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
19653	NCT01619319	\N	Cognitive Remediation versus Games (Computer)	\N	Canada	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
19654	NCT01617187	\N	Asenapine versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19724	Tregellas 2010 b	\N	DMXB-A versus Placebo//DMXB-A dose	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
19656	NCT01614899	\N	Lurasidone Dosage // Lurasidone versus Placebo	\N	Multi-Center // Taiwan // Korea // Japan	\N	\N	\N	\r\nUser defined field 9\r\n	\N	435	\N	\N	\N	\N	\N
19657	JPRN-UMIN000008201	\N	Yoga	\N	Japan	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
19659	ISRCTN61621571	\N	Cognitive Behavioral Therapy	\N	UK	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
19660	ISRCTN34145189	\N	Structured Communication Approach versus Treatment as Usual	\N	UK	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	96	\N	\N	\N	\N	\N
19661	ChiCTR-TRC-12002273	\N	Olanzapine versus Paliperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19662	UKCRNID9332	\N	Bitopertin versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
19663	UKCRNID9544	\N	Bitopertin versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
19668	Yasui 2012	\N	Aripiprazole versus Placebo	\N	Japan	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
19669	Castilla 2004	\N	Music therapy	\N	United States of America	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
19671	Gurvich 2011 b	\N	Raloxifen versus Placebo//Raloxifen versus Hormone replacement therapy//Hormone replacement therapy versus Placebo	\N	Australia	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
19672	NCT01639872	\N	Clozapine//substance abuse	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19673	ISRCTN06118265	\N	Self confidence Cognitive Behavioral Therapy	\N	UK	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	30	\N	\N	\N	\N	\N
19674	JapicCTI-101175	\N	Aripiprazole Route	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19676	Bowie 2012	\N	Cognitive remediation + functional skills training versus Cognitive remediation//Cognitive remediation + functional skills training versus functional skills training//Cognitive remediation//sociall skills	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19677	Brunelin 2012 a	\N	transcranial direct-current stimulation versus sham transcranial direct-current stimulation	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19681	Rass 2012	\N	Information and communication technology-based cognitive remediation//cognitive remediation versus treatment as usual//cognitive remediation versus watching television	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19688	Chang 2012 a	\N	Unclear	\N	Republic of Korea	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
19689	Hjorth 2012	\N	Physical health education//Physical health care monitoring	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19692	Montes 2012 a	\N	prompts//Information and communication technology based prompting for treatment compliance//Sms prompt versus treatment as usual	\N	Spain	\N	\N	\N	\N	\N	254	\N	\N	\N	\N	\N
19693	Quisenaerts 2012	\N	nicotine versus Placebo//nicotine dose	\N	Belgium	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
19694	Sharif 2012	\N	family psychoeducation(10 sessions)	\N	Iran	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	70	\N	\N	\N	\N	\N
19696	Chen 2010	\N	maintenance treatment + Quetiapine versus maintenance treatment + Placebo//Quetiapine versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19698	Eack 2012	\N	Cognitive enhancement therapy versus Enriched supportive therapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19701	Buchsbaum 2010 a	\N	Aripiprazole versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
19702	Bunney 2010 b	\N	Ziprasidone dose	\N	United States of America	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
19926	McCrone 2009 a	\N	Crisis Resolution Service	\N	UK	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
19704	Chen 2010 d	\N	typical Antipsychotics versus Atypical Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	389	\N	\N	\N	\N	\N
19705	Cutler 2011a	\N	Quetiapine xr versus Quetiapine - immediate release//Quetiapine dose//Quetiapine versus Placebo//Quetiapine xr versus Placebo//Quetiapine - immediate release versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19706	Feifel 2010 c	\N	Intranasal oxytocin + Antipsychotics versus Placebo + Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
19707	Ferziger 2010 a	\N	paliperidone palmitate versus oral Antipsychotics (Aripiprazole, Haloperidol, Olanzapine, paliperidone, perphenazine, Quetiapine, or Risperidone)//paliperidone palmitate versus Aripiprazole//paliperidone palmitate versus Haloperidol//paliperidone palmitate versus Olanzapine//paliperidone palmitate versus paliperidone//paliperidone palmitate versus perphenazine//paliperidone palmitate versus Quetiapine//paliperidone palmitate versus Risperidone	\N	Unclear	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
19709	Garcia 2010 b	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
19712	Leweke 2010 a	\N	Cannabidiol versus Placebo//cannabis	\N	Germany	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
19713	Lieberman 2010 c	\N	Davunetide dose//Davunetide versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
19714	Lieberman 2010 b	\N	metformin versus Placebo//exercise therapy//dietary advice	\N	United States of America	\N	\N	\N	\N	\N	148	\N	\N	\N	\N	\N
19717	PEARL 2	\N	Lurasidone Dosage // Lurasidone versus Olanzapine // Lurasidone versus Placebo // Olanzapine versus Placebo	\N	Multi-Center // United States of America // Colombia // India // Lithuania // Philippines	\N	\N	\N	\N	\N	473 OR 475	\N	\N	\N	\N	\N
19718	Pedersen 2010 b	\N	oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
19719	Prasad 2010 a	\N	Valacyclovir + Antipsychotics versus Placebo + Antipsychotics	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
19720	Schmechtig 2010 b	\N	Risperidone versus Placebo//Risperidone versus nicotine//Risperidone versus Amisulpride//nicotine versus Placebo//nicotine versus Amisulpride//Amisulpride versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	233	\N	\N	\N	\N	\N
19722	Smith 2010 b	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
19908	Barr 2012 a	\N	\N	\N	Canada	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
19725	Umbricht 2010 b	\N	RG1678 versus Placebo//RG1678 dose	\N	United States of America	\N	\N	\N	\N	\N	323	\N	\N	\N	\N	\N
19727	Vanover 2010 a	\N	ITI-007 versus Placebo//ITI-007 dose	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
19728	Vinogradov 2010	\N	computerized cognitive training	\N	United States of America	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
19729	Wing 2010 a	\N	Repetitive transcranial magnetic stimulation//Smoking cessation	\N	Canada	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
19733	Jianjun 2012	\N	Health and safety education	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19740	Sharifi 2012	\N	home aftercare versus treatment as usual	\N	Iran	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
19748	Yi 2012	\N	Rosiglitazone versus Placebo	\N	United States of America	\N	\N	\N	\r\nUser defined field 9\r\n	\N	19	\N	\N	\N	\N	\N
19750	Smeerdijk 2012	\N	family Motivational interviewing versus routine family support//family intervention	\N	Netherlands	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
19751	Li 2012	\N	Oral paliperidone extended release tablets versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19752	Meszaros 2012 a	\N	varenicline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
19753	Spaniel 2012	\N	Information and communication technology based prompting for treatment compliance//prompts	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19754	Stryjer 2012	\N	Electroconvulsive Therapy + rivastigmine versus Electroconvulsive Therapy + Placebo//rivastigmine versus Placebo//ect	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19756	Barr 2012	\N	Repetitive transcranial magnetic stimulation versus sham Repetitive transcranial magnetic stimulation	\N	Canada	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
19757	Li 2012 a	\N	Ziprasidone versus Olanzapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19760	Chen 2012 a	\N	HT100 (Ginseng extract) + pharmocology versus Placebo + pharmocology HT1001 versus Placebo	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
19761	Gholipour 2012	\N	exercise therapy//token economy	\N	Iran	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
19763	Mohammadi 2012	\N	Music therapy	\N	Iran	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
19764	Egerton 2011	\N	Bolus (Placebo) versus Metoclopramide	\N	Australia	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
19765	Kim 2012	\N	Paliperidone er versus Risperidone	\N	Korea	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n	\N	58	\N	\N	\N	\N	\N
19766	Wu 2012 a	\N	metformin versus Placebo//Metformin + Clozapine, Olanzapine, Risperidone, sulpiride versus Placebo + Clozapine, Olanzapine, Risperidone, sulpiride//	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
19772	Kay 2011	\N	Computer based versus clincian therapy//Information and communication technology in patient education and support	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19776	Montes 2012 b	\N	prompts//Information and communication technology based prompting	\N	Spain	\N	\N	\N	\N	\N	286	\N	\N	\N	\N	\N
19781	Clayton 2012	\N	Citizenship intervention versus usual services	\N	United States of America	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
19782	Roiz 2012	\N	Risperidone versus Haloperidol low dose//Olanzapine versus Haloperidol low dose//Risperidone versus Olanzapine	\N	Spain	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
19783	NCT01688037	\N	\N	\N	\N	\N	\N	\N	\r\nUser defined field 9\r\n	\N	\N	\N	\N	\N	\N	\N
19784	NCT01682161	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19786	ISRCTN45593573	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19787	ISRCTN98067793	\N	Critical Time Intervention	\N	UK	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
19788	ACTRN12612000974808	\N	Peer Delivered Support	\N	Australia	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
19789	ACTRN12612000963820	\N	Self-Help	\N	Australia	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19790	JPRN-UMIN000008818	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19793	Radulovic 2002	\N	Sibutramine + Antipsychotic medication versus Placebo + Antipsychotic medication	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
19794	Mohr 2007	\N	Repetitive transcranial magnetic stimulation versus Sham repeated transcranial magnetic stimulation	\N	Czech Republic	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
19876	NCT01714713	\N	evp-6124 (alpha-7 nachr) dose	\N	United States of America	\N	\N	\N	\N	\N	1000	\N	\N	\N	\N	\N
19877	NCT01716975	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19878	UKCRN ID 11514	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19889	Zheng 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19891	Geffen 2012	\N	BL-1020 Dosage//Risperidone versus BL-1020//BL-1020 versus Placebo//Risperidone versus placebi	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19892	Kupsch 2013	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19893	Tomita 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19894	Twamley 2012 a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19897	Kwon 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19899	O'Brien 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19900	He 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19901	Xie 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19902	Morthorst 2012	\N	Assertive Intervention	\N	Denmark	\N	\N	\N	\N	\N	243	\N	\N	\N	\N	\N
19903	Perry 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19904	Sato 2012	\N	Community rehabilitation program versus waitlist	\N	Japan	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
19905	Weiss 2012 a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19910	Kilian 2012	\N	Individual placement and support//Individual placement and support versus Vocational rehabilitation	\N	United Kingdom // Netherlands // Germany // Italy // Bulgaria // Switzerland	\N	\N	\N	\N	\N	312	\N	\N	\N	\N	\N
19915	Schonebaum 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19916	Zarafonitis 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19921	Scheewe 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19929	O'Reilly 2007	\N	Telepsychiatry clinic versus face to face clinic	\N	Canada	\N	\N	\N	\N	\N	495	\N	\N	\N	\N	\N
19935	Davies 2007 a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19937	Torres-Carbajo 2005	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19938	Sudaporn 2009	\N	\N	\N	Thailand	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
19939	NCT01729650	\N	Physical activity intervention versus diet	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19940	NCT01729572	\N	Remote monitoring	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19941	NCT01724476	\N	b12 + Antipsychotic medication versus Placebo + Antipsychotic medication	\N	Ethiopia	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
19942	NCT01738698	\N	Spd489 + Antipsychotic medication versus Placebo + Antipsychotic medication //Spd489 dose	\N	United States of America	\N	\N	\N	\N	\N	380	\N	\N	\N	\N	\N
19943	NCT01733121	\N	Nbi-98854	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19944	NCT01731977	\N	Family psychoeducation	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19945	NCT01733602	\N	Tdcs	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19946	NCT01724372	\N	Antidepressants	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19947	NCT01722344	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19948	NCT01731171	\N	Probiotics	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19949	ISRCTN99672552	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19950	ISRCTN17160673	\N	cognitive remediation	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19951	IRCT201109287660N1	\N	Acetylsalicylic Acid (Aspirin) versus Placebo	\N	Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
19952	JPRN-UMIN000009239	\N	Shared Decision Making versus Treatment as Usual	\N	Japan	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
19955	UKCRN ID 13062	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19956	UKCRN ID 12951	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19958	Pikalov 2012	\N	Lurasidone versus Placebo // Lurasidone versus Quetiapine // Quetiapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Not Reported	\N	\N	\N	\N	\N
19960	Koychev 2012	\N	Risperidone versus Placebo//Amisulpride versus Placebo//Nicotine versus Placebo//Risperidone versus Amisulpride//Amisulpride versus nicotine//Risperidone versus nicotine	\N	United Kingdom	\N	\N	\N	\N	\N	248	\N	\N	\N	\N	\N
19961	Weissman 2012	\N	Olanzapine + sertraline versus Olanzapine + Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19962	Mandel 1961 a	\N	Antiparkinson medication versus Placebo	\N	Unclear	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
19964	McDonell 2012	\N	Contingency management + treatment as usual versus treatment as usual	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19965	Perez 2012	\N	Risperidone versus Olanzapine//Risperidone versus Haloperidol//Haloperidol versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19966	Sukegawa 2012	\N	Chlorpromazine dose	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19970	Mamah 2012	\N	Haloperidol versus Olanzapine	\N	Canada//Netherlands//United Kingdom//United States of America	\N	\N	\N	\N	\N	185	\N	\N	\N	\N	\N
19974	Jin 2012	\N	Transcranial magnetic stimulation	\N	China//United States of America	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
19975	Slotema 2012	\N	Repetitive transcranial magnetic stimulation versus Repetitive transcranial magnetic stimulation with priming	\N	Netherlands	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
19976	Baker 2012 a	\N	Health advice versus smoking advice	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19977	NCT00616798	\N	Bitopertin Dosage // Bitopertin versus Placebo	\N	Multi-Center // Switzerland // Austria // Brazil // France // Germany // Hungary // Japan // Mexico // Poland // United States of America	\N	\N	\N	\r\nUser defined 3\r\n	\N	323	\N	\N	\N	\N	\N
19978	Chaudhry 2009	\N	Risperidone versus Quetiapine//Risperidone versus Olanzapine//Olanzapine versus Quetiapine	\N	Pakistan	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
19979	Findling 2012	\N	Quetiapine versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19981	Fricchione 2012	\N	Monotherapy versus polypharmacy//Switch of medication	\N	Italy	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19984	Hwang 2012 a	\N	Olanzapine IM versus Haloperidol IM + lorazepam IM	\N	Taiwan	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
19985	Jia 2009	\N	Haloperidol versus Quetiapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
19988	Keshavan 2012	\N	Cognitive enhancement therapy versus Enriched supportive therapy	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
19989	Kinon 2009 a	\N	Risperidone versus Olanzapine//Switch of medication	\N	United States of America	\N	\N	\N	\N	\N	630	\N	\N	\N	\N	\N
19990	Kong 2009	\N	Haloperidol IM versus Olanzapine IM//Haloperidol IM versus Haloperidol IM + lorazepam IM//Olanzapine IM versus Haloperidol IM + lorazepam IM	\N	South Korea	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
19991	Lan 2009 a	\N	Aripiprazole versus Aripiprazole + Risperidone//Aripiprazole dose	\N	Taiwan	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
19992	Li 2012 b	\N	Risperidone versus Quetiapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
19993	Loze 2012	\N	Aripiprazole intramuscular depot versus Placebo//Maintance treatment	\N	France	\N	\N	\N	\N	\N	403	\N	\N	\N	\N	\N
19995	Meltzer 2009 a	\N	Asenapine dose//Asenapine versus Haloperidol//Asenapine versus Placebo//Haloperidol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	187	\N	\N	\N	\N	\N
19996	Oosthuizen 2009	\N	1 comcomitant medication + Antipsychotics versus 2 comcomitant medication + Antipsychotics	\N	South Africa	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
19998	Pelayo 2009	\N	Haloperidol versus Olanzapine//Haloperidol versus Risperidone//Risperidone versus Olanzapine	\N	Spain	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
20001	Schreiner 2009	\N	Oral paliperidone extended release	\N	Germany	\N	\N	\N	\N	\N	294	\N	\N	\N	\N	\N
20002	Shimada 2009	\N	Social skills training versus control	\N	Japan	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
20003	Suzana 2009	\N	Haloperidol, Risperidone, Clozapine (monotherapy) versus Valproate, carbamazepine (adjuctive)//(monotherapy versus combination therapy//Haloperidol versus valproate//Haloperidol versus carbamazepine//Risperidone versus carbamazepine//Risperidone versus valproate//Clozapine versus carbamazepine//Clozapine versus valproate	\N	Serbia	\N	\N	\N	\N	\N	Unclear	\N	\N	\N	\N	\N
20005	Turncliff 2012	\N	Aripiprazole Dosage // Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
20010	Alphs 2012	\N	Risperidone long acting injection	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20012	Jerrell 2012	\N	Conventional Antipsychotics versus Second generation Antipsychotics	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20013	Zhang 2012 a	\N	Paliperidone er versus Aripiprazole//Paliperidone er versus Ziprasidone//Aripiprazole versus Ziprasidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20014	IRCT138712231764N1	\N	Omega-3 Fatty Acid versus Placebo	\N	Iran	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
20015	Stant 2012	\N	Individual placement and support versus vocational rehabilitation	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20020	Gharaeipour 2012	\N	Cognitive remediation therapy versus supportive therapy	\N	Taiwan	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
20023	Magliano 2000	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20024	Mobascher 2012	\N	Nasal nicotine versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20025	Wustenberg 2011 a	\N	Erythropoietin + Antipsychotic medication versus Placebo + Antipsychotic medication	\N	Germany	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
20026	Abhishekh 2012	\N	bifrontal electrode placement versus Bitemporal ect	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20027	Takao 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20028	Jochems 2012	\N	Motivation feedback + treatment as usual versus treatment as usual Feedback	\N	The Netherlands	\N	\N	\N	\r\nUser defined field 9\r\n	\N	350	\N	\N	\N	\N	\N
20030	Madigan 2012	\N	Group cognitive behavioral therapy + motivational interviewing versus treatment as usual//Group cognitive behavioral therapy versus treatment as usual//motivational interviewing versus treatment as usual	\N	Ireland	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	88	\N	\N	\N	\N	\N
20031	Anandarajan 2012	\N	Aripiprazole versus Risperidone depot	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20035	Guse 2013	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20037	Kinter 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20038	Parsons 2009	\N	Ziprasidone oral or Ziprasidone IM versus Haloperidol oral or Haloperidol IM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20040	Shim 2009	\N	Olanzapine IM	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20042	Van 2012 b	\N	Cbt + treatment as usual versus treatment as usual	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20043	Haimov 2012	\N	Acupuncture therapy//music therapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20044	Kaushal 2012	\N	Risperidone versus Olanzapine	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20045	Schreiner 2012	\N	Paliperidone extended release versus Olanzapine oral	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20046	Varambally 2012	\N	yoga versus exercise//yoga//exercise therapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20047	Zincir 2011	\N	Music therapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20048	Allott 2012	\N	Individual placement and support versus treatment as usual	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20050	Bartzokis 2012	\N	Risperidone oral versus Risperidone long acting injection	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20051	Bechdolf 2012	\N	cognitive behavioral therapy versus supportive counselling//skills training versus supportive counselling//cognitive remediation versus supportive counselling//multifamily psychoeducation versus supportive counseling	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20053	Castle 2012	\N	Healthy diet versus treatment as usual	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20054	Chan 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20055	Chang 2012 b	\N	Early intervention	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20056	Chaudhry 2012 a	\N	Cognitive behavioural therapy + social skills versus treatment as usual	\N	South Korea	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
20057	Christensen 2012	\N	Individual placement and support + cognitive remediation + social skills training versus Standard care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20061	Farreny 2012 a	\N	Problem Solving and Cognitive Flexibility training versus Leisure activities	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20062	Francey 2012	\N	Intensive psychosocial intervention + Antipsychotic medication versus Intensive psychosocial intervention + Placebo//Antipsychotic medication versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20063	Gleeson 2012 a	\N	Relapse prevention therapy + specialist first-episode treatment versus specialist first-episode treatment	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20066	Killackey 2012	\N	Individual placement and support + treatment as usual versus treatment as usual	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20154	Davis 2012	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
20068	Lawlor 2012	\N	Motivational interviewing + cognitive behavioural therapy + psychoeducation versus treatment as usual//Motivational interviewing versus treatment as usual//cognitive behavioural therapy versus treatment as usual//psychoeducation versus treatment as usual//	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20070	Malla 2012	\N	Risperidone long acting injection versus Oral Antipsychotics	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20071	Malla 2012 a	\N	Early intervention	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20072	Marvin 2012	\N	Family intervention	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20074	Moran 2012	\N	Nicotine patch versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
20076	Nishida 2012	\N	Early intervention	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20077	Nordt 2012	\N	Individual placement and supporrt (ips) versus treatment duration	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20078	Nuechterlein 2012 b	\N	Risperidone long acting injection versus Risperidone oral	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20079	Nuechterlein 2012 a	\N	Individual placement and support versus Vocational rehabilitation	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20080	Piskulic 2012	\N	Cognitive Remediation (Brain Fitness) versus Games (Computer)	\N	Australia	\N	\N	\N	\r\nUser defined field 9\r\n	\N	32	\N	\N	\N	\N	\N
20081	Rohleder 2012	\N	Amisulpride versus cannabidiol	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20082	Rondeau 2012	\N	Early intervention versus regular care	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20083	Rosenbaum 2012	\N	Aerobic exercise versus table football	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20085	Saija 2012	\N	Social cognition training program + oxytcoin nasal spray versus Social cognition training program + Placebo nasal spray	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20087	Smith 2012	\N	Olanzapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20088	Srihari 2012	\N	early intervention	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20089	Srihari 2012 a	\N	Early Intervention Service	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20090	Subotnik 2012 a	\N	Risperidone Route	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
20093	Weiden 2012	\N	Risperidone long acting injection versus oral Antipsychotics	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20094	Woods 2012	\N	glycine versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20095	Woolley 2012	\N	oxytocin versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20096	Yung 2012	\N	Cognitive therapy + Risperidone versus Cognitive therapy + Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20097	De 2011 a	\N	Paliperidone extended release	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20101	Vayisoglu 2012	\N	 lamotrigine versus Placebo	\N	\N	\N	\N	\N	\r\nNotes2\r\n	\N	\N	\N	\N	\N	\N	\N
20103	Lee 2012	\N	Amisulpride Dosage	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20106	NCT01749124	\N	Telephone intervention	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20107	NCT01752465	\N	Health coaching	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20108	NCT01752712	\N	Oxytocin	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20109	ISRCTN01416694	\N	Psychoeducation sibling	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20111	ISRCTN34757603	\N	Structured Communication Approach versus Treatment as Usual	\N	UK	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n	\N	180	\N	\N	\N	\N	\N
20112	IRCT20111009301	\N	naltrexone	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20118	Ferraz 2012	\N	Training staff for psychocial rehabilitation services versus treatment as usual	\N	Portugal	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
20119	Garber 2012	\N	Illness management and recovery program versus treatment as usual	\N	Israel	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
20123	Rogers 2012	\N	Peer support versus control	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
20124	Penades 2012	\N	Cognitive remediation therapy versus Psychoeducation	\N	Spain	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
20125	Stognone 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20126	Rogers 2012 a	\N	Peer support + vocational support versus control	\N	United States of America	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
20128	Lu 2004 c	\N	Clozapine + paroxetine versus Clozapine + Placebo	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
20130	Lin 2002 b	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20131	EUCTR2012 2013	\N	Bydureon versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20133	NCT01760889	\N	SPD489 Dosage // SPD489 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20137	NCT01779700	\N	Fingolimod versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
20138	NCT01768000	\N	Family Cognitive Adaptation Training	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
20139	NCT01780116	\N	Adherence Therapy	\N	China	\N	\N	\N	\N	\N	134	\N	\N	\N	\N	\N
20140	NCT01779440	\N	Decision Support System	\N	United States of America	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
20141	NCT01765829	\N	Continuation // Discontinuation	\N	Spain	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
20146	Ratliff 2012	\N	Lifestyle Modification versus Lifestyle Modification+Payment // Contingency Management	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
20149	Palmier 2013	\N	Software Application for Android Smartphones versus Text-Messages	\N	UK	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
20153	Citrome 2012	\N	Switching to Iloperidone	\N	Multi-Center	\N	\N	\N	\N	\N	500	\N	\N	\N	\N	\N
20155	Fleischhacker 2012 a	\N	Aripiprazole Dosage // Aripiprazole Route	\N	\N	\N	\N	\N	\N	\N	662	\N	\N	\N	\N	\N
20156	Gallego 2012 a	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
20158	Kelly 2012	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
20159	Keshavan 2012 a	\N	Cognitive Enhancement Therapy versus Enriched Supportive Therapy	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
20160	Kochunov 2012	\N	Nicotine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
20161	Leweke 2012	\N	Cannabidiol versus Placebo	\N	Germany	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
20164	Meltzer 2012	\N	Risperidone Dosage	\N	United States of America	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
20165	Rasetti 2012	\N	Tolcapone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
20166	Reichenberg 2012	\N	Modafinil versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20169	Turncliff 2012 a	\N	ALKS 9070 Dosage // ALKS 9070 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
20170	Vanover 2012	\N	ITI-007 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20171	Wang 2010 a	\N	Paliperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
20172	Weiser 2012a	\N	Acetylsalicylic Acid (Aspirin) + Pantoprazole versus Minocycline // Acetylsalicylic Acid (Aspirin) + Pantoprazole versus Pramipexole // Acetylsalicylic Acid (Aspirin) + Pantoprazole versus Placebo // Minocycline versus Pramipexole // Minocycline versus Placebo // Pramipexole versus Placebo	\N	Multi-Center // Israel	\N	\N	\N	\r\nNotes2\r\nAspirin versus Minocycline // Aspirin versus Pramipexole // Aspirin versus Placebo // Minocycline versus Pramipexole // Minocycline versus Placebo // Pramipexole versus Placebo\r\nUser defined field 9\r\n	\N	400	\N	\N	\N	\N	\N
20173	Woolley 2012 a	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
20174	Zukin 2012	\N	Cariprazine versus Placebo // Cariprazine Dosage	\N	Multi-Center	\N	\N	\N	\N	\N	446	\N	\N	\N	\N	\N
20176	Dixon 2012	\N	Family Member Provider Outreach	\N	United States of America	\N	\N	\N	\N	\N	222	\N	\N	\N	\N	\N
20177	Ho 2012	\N	Tai-Chi	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
20178	Marcus 2012	\N	Housing Voucher	\N	United States of America	\N	\N	\N	\N	\N	460	\N	\N	\N	\N	\N
20182	Kasthurip 2012	\N	Haloperidol versus Olanzapine	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20183	Kumar 2012	\N	Olanzapine versus Quetiapine	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20186	Rosenbaum 2012 a	\N	Supportive Psychodynamic Psychotherapy	\N	Denmark	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20187	Sahoo 2012	\N	Haloperidol versus Olanzapine // Haloperidol versus Risperidone // Olanzapine versus Risperidone	\N	India	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20189	Smith 2013	\N	Pioglitazone versus Placebo Pioglitazone versus Placebo	\N	China // United States of America // Multi-Center	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n	\N	56	\N	\N	\N	\N	\N
20191	Gu 2012	\N	Magnesium Valproate versus Magnesium Valproate + Quetiapine	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
20192	Kusumi 2012	\N	Olanzapine Route	\N	Japan	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
20193	Pandina 2013	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20196	Echeburua 2011	\N	Cognitive Behavioral Therapy	\N	Spain	\N	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
20200	Rathod 2013	\N	Cognitive Behavioral Therapy	\N	UK	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
20201	Rus 2013	\N	Social Skills Training	\N	Spain	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
20202	Conde 2011	\N	Haloperidol versus Risperidone	\N	Philippines	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
20204	Baksheev 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20206	ISRCTN00721331	\N	mirtazapine versus Placebo Mirtazapine versus Placebo	\N	Russia	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n	\N	37	\N	\N	\N	\N	\N
20207	孙平 2012 a	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20208	闾金杰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20209	侯正华 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20210	郑艳明 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20211	刘娜 2012 b	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20212	刘洁 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20213	李四冬 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20214	李媛媛 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20215	徐成敏 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20216	吴美娟 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20217	吴慧 2012 a	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20218	梁家騋 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20219	盛嘉玲 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20220	顾小静 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20221	周玉梅 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20222	冯宝珍 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20223	刘芳 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20224	向应强 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20225	欧阳杏娟 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20226	刘晓伟 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20227	高红锐 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20228	陈健华 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20229	张丽英 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
20295	静 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
20296	雷远严 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
20297	陈胜华 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
20298	金建烽 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
20299	郭金宏 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
20300	邓小娟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
20301	辛一帆 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20302	赵雅琴 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
20303	许爱琴 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
20304	许晓英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20305	许兰花 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20306	胡君 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20307	耿寒松 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
20308	祖鑫 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20309	王秀莉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
20310	王文骁 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
20311	曹书改 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20312	张红旗 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
20313	张伟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	185	\N	\N	\N	\N	\N
20314	廖东升 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	190	\N	\N	\N	\N	\N
20315	寇根生 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20316	孙洪祥 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20317	娟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20318	姚丰菊 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
20319	周长凤 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20320	周彩莲 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20321	Liu 2013	\N	Magnesium Valproate + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
20322	刘彩秀 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20323	刘彩秀 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20324	余利国 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20325	付春红 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20326	满孝琴 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20327	巨怀林 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20328	吴海龙 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
20329	张长春 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
20330	陈俊雄 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
20331	王敬龙 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
20332	王宏林 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20333	刘延永 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20334	屈艳妮 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
20335	谢杰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
20336	柳贵明 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
20348	Fan 2013a	\N	Donepezil versus Donepezil + Magnesium Valproate	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20349	王宇峰 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20350	王云红 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
20351	杨润康 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
20352	杜剑峰 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
20353	李素君 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
20354	徐爱群 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20355	徐敬文 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20356	徐优明 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20357	张薇薇 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
20358	张洪亮 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
20359	孙长军 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
20360	刘宗和 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
20361	张继聪 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
20362	柳宏宇 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20363	柳宏宇1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20364	李良 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20365	朱肖飞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20366	马彩娥 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
20367	吴慧 2012 b	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20368	张睿 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	162	\N	\N	\N	\N	\N
20369	丁宁 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20370	齐红梅 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20371	邹凯 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20372	熊桂兰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20373	刘军 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
20374	张加强 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
20375	刘振英 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20376	闫少校 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
20377	李和军 2012 b	\N	\N	\N	China	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
20378	李宁 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	131	\N	\N	\N	\N	\N
20379	黄艳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20380	黄碧琴 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20381	魏明琼 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20382	颜为轩 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
20383	陈红梅 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
20384	赵树霞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
20385	苏嵘 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20386	Wang 2013a	\N	\N	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
20387	王海渊 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20388	杨玉清 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
20389	张月恒 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20390	张景彦 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20391	张景彦 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20392	张传海 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20393	回秀清 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20394	周怀忠 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
20395	凌卫明 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
20396	王永柏 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
20397	马雁冰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
20398	韩桂玲 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
20399	韩文艳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
20400	董亚辉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20401	石广念 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20402	汪津洋 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20403	杜春燕 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20404	成军 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
20405	陈春红 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20406	汪东明 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20408	梁映 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
20409	马清 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
20410	曾新平 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
20411	李东美 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
20412	许方义 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
20413	杨卫东 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	178	\N	\N	\N	\N	\N
20414	孙平 2012 b	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
20415	范成 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20416	寇根生 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20417	穆朝娟 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
20418	高粉霞 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20419	贾敏 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
20420	王健	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20421	纪芳 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20422	周小青 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
20423	王敬龙1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
20424	胡祖林 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
20425	王宏林1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20426	刘娜 2012 a	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20427	孙润珠 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
20428	李延红 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20429	潘振山 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
20430	刘向阳 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20431	赵和丹 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20432	王海燕 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
20433	吴翠杰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20434	宋传福 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20435	张俊峰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20436	夏庆润 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20437	段兴斌 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20438	赵学庆 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
20439	廖春平 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
20440	张恒 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20441	沈丽珍 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20442	尹烈虎 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
20443	白慧丽 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20444	王彩虹 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
20445	周会爽 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20446	肖师惠 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	197	\N	\N	\N	\N	\N
20447	陈日访 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
20448	李四冬1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	153	\N	\N	\N	\N	\N
20449	辛一帆 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20450	张加明 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
20451	汪富军 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20452	李冰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
20453	杨静娟 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
20454	邓春江 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20455	张星亮 2012 a	\N	\N	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
20456	何海霞 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20457	王鹏 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20458	周长凤 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20459	黄朝华 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20460	吕晓静 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
20461	宋奕 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
20462	孙淑云 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20463	王延鹤 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
20464	崔菁 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
20465	苏邹 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20466	赵桂军 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20467	范成1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20491	杨小曲 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
20492	尹雪冰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20493	宣彩英 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
20494	唐艳 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
20495	关伟 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
20496	罗娴 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
20497	许庆文 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20498	顾曙光 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
20499	王鹤秋 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
20500	龙珊珊 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20501	张丽 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
20502	杨立身 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
20503	杨立身1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
20504	刘从敏 2012 a	\N	\N	\N	China	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
20505	陈燕 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
20506	李晓琼 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20507	Chen 2012a	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
20508	Li 2012a	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20509	王红尔 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
20510	孔鑫 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
20511	封蕴 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20512	付慧鹏 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20513	张燕锋 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
20514	王洪娟 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20515	劳恩荣 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
20516	郑宏 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
20517	徐枝楼 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20518	崔中兰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20519	徐春花 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
20520	马久华 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
20521	时德菊 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	137	\N	\N	\N	\N	\N
20522	李和军 2012 a	\N	\N	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
20523	冯艾群 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20524	申振可 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20525	许婷 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20526	郭献锋 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
20527	马效芝 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
20528	黄发妮 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20529	戴晶璟 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
20530	鲍丽萍 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
20531	王文君 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
20532	崔凤琢 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20533	李振超 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20534	高瑛 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20535	李萍 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
20536	张莉 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20537	顾桂英 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
20538	陈瑞芳 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
20539	周丹 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20540	李耀东 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
20541	杨伟芳 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
20542	马婉 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
20543	李萍1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20544	孙蔚华 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
20545	赵业华1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20546	李冰1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20547	张星亮 2012 b	\N	\N	\N	China	\N	\N	\N	\N	\N	154	\N	\N	\N	\N	\N
20548	王祖森 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	111	\N	\N	\N	\N	\N
20549	李皖生 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	131	\N	\N	\N	\N	\N
20550	段妮 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20551	刘林晶 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
20552	陈进东 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
20553	徐德会 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20554	汪艳 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	372	\N	\N	\N	\N	\N
20555	邹宏涛 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20556	张尚荣 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
20557	王有斌 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
20558	李耀东1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20559	李凯杰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
20560	罗俊蓉 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
20561	查智群 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20562	Xiao 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	149	\N	\N	\N	\N	\N
20563	林涛 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
20564	华彩霞 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	168	\N	\N	\N	\N	\N
20565	左彥 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20566	张玉娥 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20567	刘付敏 2012 b	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20568	黄冬琳 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20569	许艳红 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
20570	张红 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
20571	王文君1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
20572	陈永刚 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
20573	周锦 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20574	王娜娜 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
20575	徐莉 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20576	许本健 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
20577	陈钊 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20578	姚凤云 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
20579	方喜玲 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20580	胡美玉 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
20581	林丽霞 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20582	庞月萍 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20583	林连英 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20584	黄玉英 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20585	姜欢 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20586	胡卫群 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20587	黄晓芳 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
20588	李东美1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
20589	刘美玲 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
20590	甄莉丽 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
20591	罗世芳 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20592	张晓明 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20593	朱倩芸 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
20594	瞿波 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
20595	刘庆奇 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
20596	宋艳萍 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20597	周怀忠 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
20598	刘海军 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
20599	赵亚明 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
20600	杨逢润 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
20601	林文 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
20602	张洪亮 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20603	戴涛 2012 a	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20604	杨凌雪 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20605	陈秀珍 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20606	张朝峰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20607	孙亚军 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20608	徐严秀 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	485	\N	\N	\N	\N	\N
20609	马效芝1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
20610	程菊英 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20611	肖师惠1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	175	\N	\N	\N	\N	\N
20612	王尚红 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20613	黄丽宏 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20614	王玉玲 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	163	\N	\N	\N	\N	\N
20615	韩树华 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	289	\N	\N	\N	\N	\N
20616	竹道平 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
20617	王飞 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20618	梁金梅 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20619	江学锋 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20620	王志 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
20621	赵涛 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
20622	刘伟 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
20623	范祚君 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
20624	兰开荣 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20625	易东晓 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	196	\N	\N	\N	\N	\N
20626	朱倩芸1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20627	王艳红 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20628	于志淼 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
20629	杨显东1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20630	李冰2 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
20631	任尚 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
20632	朱宛平 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20633	张香云 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20634	徐彩霞 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20635	苏庆伟 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20636	王新春 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
20637	韩兴玲 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
20638	赵永厚 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20639	赵永厚1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
20640	蒋军生 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
20641	郑友玲 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20642	张冬敏 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20643	戴涛 2012 b	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20644	严叶良 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20645	李小莲 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20646	胡海霞 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
20647	陈勇华 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20648	梁文石 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20649	梁宏光 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
20650	林树冲 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20651	王仁峰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	123	\N	\N	\N	\N	\N
20652	陶金梅 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20653	Wang 2012	\N	Magnesium Valproate + Quetiapine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
20654	李海云 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
20655	马海霞 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
20656	黄河 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
20657	潘淑先 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20658	宋宝华 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20659	Chang 2012a	\N	Aripiprazole versus Perospirone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20660	陈汉华 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
20661	马元业 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20662	胡亚兰1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
20663	陶锋 2012 b	\N	\N	\N	China	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
20664	曹德 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
20665	巩秀芹 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20666	巩秀芹	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20667	鞠红珍 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20668	胡红霞 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	178	\N	\N	\N	\N	\N
20669	赵永红 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20670	刘锟 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
20671	王继丰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20672	蒋卫平 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20673	张庆娥 2012 a	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20674	张庆娥 2012 b	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20675	蒋幸衍 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20676	赵新苗 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
20677	曹伟 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20678	陆燕华 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20679	张泽栋 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20680	岳丽萍 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
20681	许洁 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
20682	王晓捷 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20683	葛霞 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
20684	权文香 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
20685	龚发金 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20686	何杰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	155	\N	\N	\N	\N	\N
20687	张生翠 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	720	\N	\N	\N	\N	\N
20688	Zhang 2012a	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20689	李春 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20690	梁皓明 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
20691	陶锋 2012 a	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20692	刘飞 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20693	邹义 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20694	黄佩珊 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
20695	姚自强 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
20696	郭艳梅 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20697	张素琼 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	350	\N	\N	\N	\N	\N
20698	崔虹 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
20699	林晓兰 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
20700	Fan 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20701	Liu 2012	\N	Magnesium Valproate + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20702	马廷斌 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20703	邓文 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	165	\N	\N	\N	\N	\N
20704	李璐 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
20705	耿磊 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
20706	罗世芳1 2012	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20707	龚士虎 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
20708	齐俊茹 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
20709	黎赛英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
20710	黎华柱 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
20711	黄萍 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20712	黄继伟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20713	黄秀芳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20714	黄海涛 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
20715	黄桥生 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
20716	黄杏娟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
20717	黄晓慧 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
20718	黄春艳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
20719	黄娟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20720	Huang 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
20721	鲁国芬 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	280	\N	\N	\N	\N	\N
20722	魏荣国 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
20723	魏维 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20724	高良会 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20725	高红锐 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20726	高玉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
20727	高湘 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
20728	高平来 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20729	高孟英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	121	\N	\N	\N	\N	\N
20730	马金芳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
20731	马筠 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
20732	马秀青 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20733	马春燕 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
20734	马建华 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	178	\N	\N	\N	\N	\N
20735	马云 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
20736	额尔敦 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
20737	顾桂英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
20738	顾桂英1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
20739	顾桂英2 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
20740	雷田香 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20741	雷田香1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
20742	雷志洁 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
20743	雷小燕 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20744	雷佳峰 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20745	陶用富 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	204	\N	\N	\N	\N	\N
20746	陶建青 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20747	陈香 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20748	陈飞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20749	陈雪晶 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20750	陈雄 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
20751	陈雄1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20752	陈钰 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20753	陈艳波 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
20754	陈筱章 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
20755	陈泽 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
20756	陈智敏 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20757	陈宇晖 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20758	Chen 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
20759	陈亚萍 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
20760	陈云芳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20761	陈丽香 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
20762	陈丽香 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20763	陈一郡 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20764	陆雪山 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20765	闾金杰 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20766	闫爱国 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20767	闫明贵 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
20768	闫丽华 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
20769	钟爱红 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20770	钟文凯 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
20771	钟古华 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20772	金鑫 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
20773	Jin 2013a	\N	Magnesium Valproate + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
20774	郭育君 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
20775	郭细先 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
20776	郭献锋 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
20777	郭新聊 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20778	郭建雄 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
20779	郭侠 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20780	郭会霞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
20781	郭云龙 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
20782	Chi 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20783	郑梅 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20784	郑杏珊 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
20785	郑昌爱 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	2000	\N	\N	\N	\N	\N
20786	郑宏 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
20787	郁莉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
20788	邹灵芳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20789	邹海欧 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
20790	邹凯 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20791	邹凯1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20792	邵阁忠 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	184	\N	\N	\N	\N	\N
20793	邵平 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
20794	邵平1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
20795	邵国艳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20796	邬东红 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
20797	邢锋 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20798	邢锋1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20799	邓良华 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
20800	邓广 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20801	邓娟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20802	辛春萍 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20803	赵龙 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
20804	赵静 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
20805	赵青霞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
20806	赵红梅 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
20807	赵淑琴 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
20808	赵春海 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
20809	赵成清 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20810	赵小荣 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20811	赵小玲 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
20812	赵小玲1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20813	赖飞翔 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
20814	谷士军 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20815	谭颖芬 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
20816	谢秀钦 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	102	\N	\N	\N	\N	\N
20817	谢文娇 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20818	谢振强 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20819	谢友许 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
20820	许锦泉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	93	\N	\N	\N	\N	\N
20821	许锦泉1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
20822	Xu 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20823	许志平 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20824	许志平1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20825	许子明 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
20826	许勤伟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
20827	解小永 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20828	袁日强 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
20829	袁日强1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20830	薛雷 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	138	\N	\N	\N	\N	\N
20831	薛爱兰 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20832	薛文 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	471	\N	\N	\N	\N	\N
20833	蔡长源 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20834	蔡艳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20835	蔡经宇 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20836	蔡琳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20837	蔡军 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
20838	蒲金玉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20839	蒲绮霞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20840	蒲绮霞1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20841	蒙莉莉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
20842	蒋燕升 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20843	蒋永红 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20844	蒋正伟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	162	\N	\N	\N	\N	\N
20845	蒋丽红 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
20846	蒋丽红 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20847	董雪刚 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20848	董自强 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
20849	菅彩霞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
20850	菅彩霞1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
20851	范洁 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
20852	苏柯羽 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20853	苏卫东 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
20854	芈志勇 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
20855	臧秀萍 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
20856	胡雪梅 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20857	胡长霞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
20858	胡春丽 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
20859	胡怡 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20860	胡学慧 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20861	胡孝芬 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
20862	胡君1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
20863	胡光涛 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
20864	胡义思 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20865	肖群林 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20866	Xiao 2013	\N	Magnesium Valproate + Risperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	282	\N	\N	\N	\N	\N
20867	聂文燕 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
20868	耿在香 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20869	罗汝琴 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20870	罗晓东 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
20871	罗伟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20872	等 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
20873	符巍 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
20874	童小均 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
20875	章珠妃 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
20876	穆慧 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
20877	程闯 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20878	程敏锋 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
20879	秦春红 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
20880	秦培云 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20881	石森 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20882	石岩 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20883	盛嘉玲 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
20884	皮峻峰 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20885	申文武 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
20886	甄莉丽 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20887	甄庆伟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	324	\N	\N	\N	\N	\N
20888	璩宪法 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
20889	琳等 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20890	王鸿雁 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
20891	王飞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20892	王静波 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20893	王锦芬 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
20894	王进祥 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
20895	王菲 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20896	王茜 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20897	王自强 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20898	王翠英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
20899	王维强 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20900	王维强1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20901	王红艳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20902	王立志 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20903	王秀芳 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20904	王秀芳 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20905	王琦 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
20906	王珊 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
20907	王玉翠 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20908	王爱青 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	212	\N	\N	\N	\N	\N
20909	王洪明 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
20910	王泽民 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20911	王汉婵 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20912	王桂珍 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
20913	王格斐 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20914	王晓璇 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20915	王文英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
20916	王成芳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20917	王成艳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
20918	王慢利 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20919	王建波 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20920	王小红 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
20921	王小红1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
20922	王小丽 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20923	王宇 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20924	王娣 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20925	王天明 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20926	Wang 2013d	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20927	王双凤 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20928	王双凤1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
20929	Wang 2013c	\N	Magnesium Valproate + Olanzapine versus Olanzapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20930	王凤英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20931	王军 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	220	\N	\N	\N	\N	\N
20932	王健 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20933	王俊 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20934	王伯军 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
20935	王伟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20936	王任昌 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
20937	王东平 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
20938	狄邦成 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20939	狄邦成1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20940	牛轶 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
20941	牛慧明 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20942	潘燕 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20943	潘殊 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
20944	潘国良 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
20945	满孝琴1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
20946	Wen 2013	\N	Magnesium Valproate + Quetiapine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20947	洪梅 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	138	\N	\N	\N	\N	\N
20948	洪巧丽 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20949	沈君 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
20950	沈君 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
20951	汤耀明 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
20952	江永 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20953	毛智群 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
20954	殷朝辉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20955	段瑞瑞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
20956	段惠峰 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
20957	Wu 2013	\N	Magnesium Valproate + Quetiapine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
20958	欧小春 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20959	欧九娣 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20960	樊凌姿 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
20961	梁识崇 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20963	梁航 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20964	梁翠英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
20965	梁松新 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20966	梁映 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
20967	柴萌 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
20968	林连英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	155	\N	\N	\N	\N	\N
20969	林昭宇 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20970	杨靖 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
20971	杨铭哲 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
20972	杨薇 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
20973	杨艳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	168	\N	\N	\N	\N	\N
20974	杨翠英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
20975	杨维林 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
20976	杨玲 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
20977	杨淼 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20978	杨淼1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
20979	杨润康1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
20980	杨永秀 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	212	\N	\N	\N	\N	\N
20981	杨新 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20982	杨斌 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
20983	杨彩霞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
20984	杨建华1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
20985	杨建华 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
20986	杨安军 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
20987	杨国平 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20988	杨和增 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
20989	杨修来 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
20990	杨亚妮 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
20991	李鹏程 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20992	李雪晶 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20993	李雅忠 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20994	李金惠 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
20995	李达 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20996	李辉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
20997	李言禹 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
20998	李萌 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
20999	李莉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
21000	李美艳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
21001	李红远 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	142	\N	\N	\N	\N	\N
21002	李红英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
21003	李立群 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21004	李秀美 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
21005	李福英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
21006	李祥 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21007	李祥 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
21008	李玉英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
21046	曹民佑 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21047	曹志良 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21048	曹志良1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21049	曹德 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21050	易著英 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	518	\N	\N	\N	\N	\N
21051	易峰 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21052	时林 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21053	方美华 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
21054	方竞红 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21055	斌 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21056	房海英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
21057	戚惠娟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
21058	成芝花 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
21059	成岗 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
21060	成军1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
21061	成军2 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21062	徐雪梅 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21063	徐维斌 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
21064	徐红霞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
21065	徐红霞1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
21066	徐淑敏 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
21067	徐开营 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
21068	徐勇 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
21069	徐健康 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21070	徐世超 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
21071	彭红波 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21072	彭红波1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
21073	Peng 2013	\N	Magnesium Valproate + Antipsychotics versus Antipsychotics	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21074	彭星 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
21075	彭保全 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
21076	强瑞香 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	322	\N	\N	\N	\N	\N
21077	张静静 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21078	张英辉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
21079	张翔 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
21080	张红军 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
21081	张紫娟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
21082	张玉敏 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
21083	张玉娥 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21084	张焱 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21085	张淑云 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21086	张涛 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21087	张海华 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21088	张洪新 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
21089	张永超 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21090	张毓茂 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
21091	张桂平 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21092	张春锋 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
21093	张文蔚 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
21094	张改兰 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	190	\N	\N	\N	\N	\N
21095	张懿 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21096	张懿1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
21097	张慧芳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
21098	张建 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21099	张尚坤 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
21100	张国富 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21101	张变梅 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
21102	张华 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21103	张冬敏 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21104	张俊青 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21105	张仁凯 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21106	廖之明 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
21107	庞铁良 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
21108	庞波 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21109	庆雷 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21110	常超华 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
21111	常俊华 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
21112	嵇迎春 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
21113	岳莉莉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21114	居丽晶 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
21115	宋珀槿 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
21116	宋洁 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
21117	宋桂清 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21118	宋来云 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
21119	宋丽娜 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21120	安琦 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21121	安晓东 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
21122	季锦毅 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
21123	孟月兰 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21124	孙飞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21125	孙霞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
21126	孙淑红 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	336	\N	\N	\N	\N	\N
21127	孙本树 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21128	孙晓丹 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
21129	孙文欣 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21130	孙国胜 2013a	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
21131	孙国胜 2013b	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21132	娄渊敏 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
21133	姜诚勇 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21134	姜明霞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
21135	姚玲玲 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
21136	夏荷秀 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21137	喻晓 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
21138	唐岩 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
21139	唐兢 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21140	唐义莲等 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
21141	周龙川 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
21142	周颖 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21143	周赟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21144	周芳珍 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
21145	周芳珍 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
21146	周立发 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21147	周浩 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
21148	周新英 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
21149	周慧民 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
21150	周丽芳 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
21151	周丽芳 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
21152	周丽芳 2013 c	\N	\N	\N	China	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
21153	吴辉霞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21154	Wu X 2013	\N	Magnesium Valproate + Olanzapine versus Olanzapine	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21155	吴殿龙 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
21156	吴桂华 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21157	吴志雄 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
21158	吴开文 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21159	吴奕珉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
21160	吴仁刚 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
21161	吴丽 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
21162	吴东 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	170	\N	\N	\N	\N	\N
21163	吕伟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
21164	向道华 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	167	\N	\N	\N	\N	\N
21165	向永红 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21166	叶渊 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21167	史丽娜 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21168	卢琦 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21169	卢春爱 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
21170	卢慧贤 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21171	卢慧贤 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21172	Lu 2013a	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
21173	卢喜金 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
21174	南晓荣 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21175	刘香凤 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
21176	刘顺发 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
21177	刘顺兰 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
21178	刘锐 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
21179	刘西俊 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
21180	刘蕴霞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
21181	刘荣芹 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21182	刘胜利 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21183	刘璇 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
21184	刘玉芝 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21185	刘期文 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	138	\N	\N	\N	\N	\N
21186	刘期文 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	332	\N	\N	\N	\N	\N
21187	刘晖 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21188	刘旭 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
21189	刘国强 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
21190	刘利平 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
21191	刘其贵 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21192	刘俐芬 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21193	刘仰 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21194	刘仰1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
21195	刘书君 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21196	凌秾喜 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21197	凌洁 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
21198	冯锦妹 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
21199	冯莹 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21200	冯茹 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
21201	兰滨 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
21202	何芳梅 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21203	何娟儿 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
21204	何堂礼 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	148	\N	\N	\N	\N	\N
21205	伍建辛 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
21206	伍卫 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	135	\N	\N	\N	\N	\N
21207	任俊赏 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
21208	任会蓉 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
21209	付金芳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	296	\N	\N	\N	\N	\N
21210	付文娟 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21211	付拥军 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21212	亓高超 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	172	\N	\N	\N	\N	\N
21213	于青 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21214	于瑞 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
21215	于瑞1 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21216	乔颖 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21217	乔屹 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
21218	严芳 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21219	丁振江 2013 a	\N	\N	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21220	丁振江 2013 b	\N	\N	\N	China	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
21221	丁婷 2013	\N	\N	\N	China	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
21222	Brown 2014	\N	Wight Management Package	\N	United States of America	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
21223	Cai 2014	\N	Handwork versus Humor Skills Training	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21224	Fleischhacker  2014	\N	Aripiprazole versus Placebo // Aripiprazole Dosage // Aripiprazole Route	\N	Multi-Center	\N	\N	\N	\N	\N	403 // 662	\N	\N	\N	\N	\N
21225	Green 2014	\N	Wight Management Package	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	200	\N	\N	\N	\N	\N
21226	Happell 2014 b	\N	Cardiometabolic Health Nurse	\N	Australia	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
21227	Ho 2014	\N	Exercise versus Tai-Chi // Tai-Chi // Exercise	\N	China	\N	\N	\N	\N	\N	153	\N	\N	\N	\N	\N
21230	Perez 2014	\N	Aripiprazole versus Quetiapine // Aripiprazole versus Ziprasidone // Quetiapine versus Ziprasidone	\N	Spain	\N	\N	\N	\N	\N	202	\N	\N	\N	\N	\N
21231	NCT00968513	\N	Brief Nicotine Replacement Therapy versus Extended Nicotine Replacement Therapy // Nicotine Replacement Therapy	\N	United States of America	\N	\N	\N	\N	\N	956	\N	\N	\N	\N	\N
21232	Waghorn 2014	\N	Individual Placement and Support	\N	Australia	\N	\N	\N	\N	\N	208	\N	\N	\N	\N	\N
21340	NCT02294409	\N	Cognitive Behavioral Therapy versus Cognitive Remediation	\N	Canada	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21233	Chow 2014	\N	Nurse-Led Case Management Programme // Nurse-Led Case Management Programme versus Phone Call // Phone Call	\N	China	\N	\N	\N	\N	\N	312	\N	\N	\N	\N	\N
21234	Reeder 2014	\N	Cognitive Remediation	\N	UK	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
21235	Weisman 2014	\N	Culturally Informed Therapy versus Psychoeducation 	\N	United States of America	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
21236	Abu 2014	\N	Oxytocin versus Placebo	\N	Israel // UK // Multi-Center	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
21239	Aho 2011 b	\N	Psychoeducation (Group)	\N	Finland	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
21242	Amiaz 2014	\N	Varenicline versus Placebo	\N	Israel // United States of America // China // Multi-Center	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
21245	Bademli 2014	\N	Family to Family Support	\N	Turkey	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
21247	Bais 2014	\N	repetitive Transcranial Magnetic Stimulation // repetitive Transcranial Magnetic Stimulation Location	\N	The Netherlands	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
21250	Barbeito 2014	\N	Psychoeducation	\N	Spain	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21251	Baumgartner 2012	\N	Critical Time Intervention	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21254	Caponnetto 2014	\N	Electronic Cigarette	\N	Italy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21256	Carta 2014	\N	Sailing	\N	Italy	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	40	\N	\N	\N	\N	\N
21257	Casas 2014	\N	Psycheducation Route	\N	Mexico	\N	\N	\N	\N	\N	127	\N	\N	\N	\N	\N
21259	Clark 1970	\N	Chlorpromazine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
21262	Del 2014	\N	Semantic Priming Groups	\N	Multi-Center	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
21263	Detke 2014 b	\N	Weight Intervention	\N	Multi-Center	\N	\N	\N	\N	\N	203	\N	\N	\N	\N	\N
21264	Dlabac 2014	\N	repetitive Transcranial Magnetic Stimulation	\N	The Netherlands	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
21265	Ebrahimi 2014	\N	Supportive Nursing Care	\N	Iran	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
21267	Finnegan 2014	\N	Critical Proxy versus Neutral Proxy	\N	UK	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
21270	Gaikwad 2014	\N	repetitive Transcranial Magnetic Stimulation	\N	India	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21271	Gerlach 1978	\N	Biperiden+Haloperidol versus Clozapine // Biperiden+Haloperidol versus Haloperidol // Biperiden+Haloperidol versus Thioridazine // Clozapine versus Haloperidol // Clozapine versus Thioridazine // Haloperidol versus Thioridazine	\N	Denmark	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
21272	Ghanizadeh 2014 b	\N	Minocycline versus Placebo	\N	Iran	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
21273	Griffin 2014	\N	Opioid Dependence Counseling+Standard Medical Management versus Standard Medical Management	\N	United States of America	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
21274	Hanrahan 2014	\N	Transitional Care Model	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21276	Hautamaki 2013	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21278	Hindocha 2014	\N	Cannabidiol versus Cannabidiol+Delta-9-tetrahydrocannabinol // Cannabidiol versus Delta-9-tetrahydrocannabinol // Cannabidiol versus Placebo // Cannabidiol+Delta-9-tetrahydrocannabinol versus Delta-9-tetrahydrocannabinol // Cannabidiol+Delta-9-tetrahydrocannabinol versus Delta-9-tetrahydrocannabinol // Delta-9-tetrahydrocannabinol versus Placebo	\N	UK	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
21279	Hjorth 2014	\N	Active Awareness	\N	Denmark	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
21280	Hosford 2014 b	\N	TC-5619 versus Placebo	\N	Russia // Ukraine // Hungry // Romania // Serbia // United States of America // Multi-Center	\N	\N	\N	\N	\N	477	\N	\N	\N	\N	\N
21281	Ikai 2014	\N	Yoga Therapy	\N	Japan	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
21282	Ising 2014	\N	Cognitive Behavioral Therapy	\N	The Netherlands	\N	\N	\N	\N	\N	201	\N	\N	\N	\N	\N
21283	Kedare 2014	\N	Psychoeducation	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21284	Khazaie 2013	\N	Olanzapine versus Risperidone	\N	Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21286	Kontio 2014	\N	eLearning	\N	Finland	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
21287	Laties 2014	\N	Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	1098	\N	\N	\N	\N	\N
21290	Litman 2014 b	\N	AZD8529 versus Risperidone // AZD8529 versus Placebo // Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	151	\N	\N	\N	\N	\N
21292	Lu 2012	\N	Cognitive Remediation	\N	China	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
21293	Marx 2014	\N	Pregnenolone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21295	Mondino 2014	\N	transcranial Direct Current Stimulation	\N	France	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
21296	NCT01474395	\N	D-Serine versus Placebo	\N	United States of America	\N	\N	\N	\r\nUser defined 3\r\n	\N	16	\N	\N	\N	\N	\N
21298	Novak 2014	\N	repetitive Transcranial Magnetic Stimulation	\N	Czech	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
21299	Oertel 2014	\N	Aerobic Exercise versus Relaxation Training	\N	Germany	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
21303	Percell 1974	\N	Assertive Training versus Relationship-Control Therapy	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
21304	NCT01781000	\N	Cognitive Training versus Facial Affect Training // Cognitive Training versus Treatment As Usual // Facial Affect Training versus Treatment As Usual	\N	Germany	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n	\N	80	\N	\N	\N	\N	\N
21305	Poulton 2014	\N	Multidimensional Treatment Foster Care	\N	United States of America	\N	\N	\N	\N	\N	166	\N	\N	\N	\N	\N
21306	Ritsner 2014 b	\N	L-theanine+Pregnenolone versus Placebo	\N	Israel	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21307	Rosenblum 2014	\N	Dual-Focus 12-Step Group (Double Trouble in Recovery; DTR)	\N	United States of America	\N	\N	\N	\N	\N	349	\N	\N	\N	\N	\N
21308	Rouillon 2013	\N	Risperidone versus Quetiapine	\N	Multi-Center	\N	\N	\N	\N	\N	666	\N	\N	\N	\N	\N
21310	Shoja 2014	\N	Olanzapine versus Risperidone	\N	Iran	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21311	Singh 2014	\N	Haloperidol versus Levosulpiride	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21312	Sinha 2014	\N	Cognitive Training	\N	India	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21313	Smith 2014 b	\N	Virtual Reality Job Interview Training	\N	United States of America	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
21314	Solomon 2014	\N	Transitional Care	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21316	Stauffer 2014	\N	Pomaglumetad Methionil versus Placebo	\N	The Netherlands	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
21317	Steibliene 2014	\N	L-triiodothyronine versus Placebo	\N	Lithuania	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
21319	Sukegawa 2008	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21323	Tan 2011	\N	Cognitive Remediation versus Physical Exercise	\N	Singapore	\N	\N	\N	\r\nUser defined field 9\r\n	\N	70	\N	\N	\N	\N	\N
21324	Tandon 2014	\N	Continuing Lurasidone versus Switching to Placebo	\N	United States of America	\N	\N	\N	\N	\N	285	\N	\N	\N	\N	\N
21326	Tantirangsee 2014	\N	Brief Intervention versus Brief Intervention+Family Support // Brief Intervention // Brief Intervention+Family Support	\N	UK	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	169	\N	\N	\N	\N	\N
21329	Tek 2014 b	\N	Naltrexone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
21330	Turncliff 2014	\N	Aripiprazole Injection Location	\N	United States of America	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
21331	Ungvari 2012	\N	Amineptine versus Placebo	\N	Hungary	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
21332	Vincenzi 2014	\N	Pravastatin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21336	Yassini 2014	\N	Bupropion versus Placebo	\N	Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21337	NCT02261519	\N	Sodium Benzoate versus Placebo	\N	Taiwan	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
21338	NCT02274558	\N	NBI-98854 Dosage // NBI-98854 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
21339	NCT02302209	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21699	Chen Hsing 2013	\N	Nicotine Dosage	\N	Taiwan	\N	\N	\N	\N	\N	184	\N	\N	\N	\N	\N
21341	NCT02283437	\N	Bibliotherapy versus Psychoeducation // Bibliotherapy // Psychoeducation	\N	China	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
21342	NCT02258737	\N	Case Management	\N	Switzerland	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
21343	NCT02281773	\N	Dosage - BI 409306 // BI409306 versus Placebo	\N	Multi-Center	\N	\N	\N	\N	\N	516	\N	\N	\N	\N	\N
21344	NCT02282761	\N	ITI-007 Dosage // ITI-007 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	440	\N	\N	\N	\N	\N
21345	NCT02291861	\N	SD-809 - Dosage // SD-809 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
21346	NCT02245607	\N	Cognitive Training versus Recreational Therapy	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21347	NCT02264327	\N	Motivational Interviewing Route	\N	United States of America	\N	\N	\N	\N	\N	3780	\N	\N	\N	\N	\N
21348	NCT02246426	\N	Plasticity-Based Software Programs	\N	United States of America	\N	\N	\N	\N	\N	154	\N	\N	\N	\N	\N
21349	NCT02298985	\N	Curcumin versus Placebo	\N	Israel	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21350	NCT02282085	\N	Continuing Oral Antipsychotic Drug versus Switching to Aripiprazole	\N	United States of America	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
21351	NCT02276469	\N	Peer Support	\N	Germany	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
21352	NCT02287584	\N	DSP-5423P - Dosage // DSP-5423P versus Placebo	\N	Multi-Center // China // Japan // Korea // Philippines // Taiwan // Malaysia	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
21353	NCT02299492	\N	Person Centered Care Planning	\N	United States of America	\N	\N	\N	\N	\N	476	\N	\N	\N	\N	\N
21354	NCT02275390	\N	Psychoeducation	\N	China	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
21355	ISRCTN20328848	\N	Prodromal Detection and Treatment	\N	Norway	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
21356	NCT02242578	\N	repetitive Transcranial Magnetic Stimulation	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
21357	ISRCTN43816889	\N	Eye Movement Desensitisation and Reprocessing Therapy	\N	UK	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
21358	DRKS00006878	\N	Continuation of Antipsychotic Drug versus Discontinuation of Antipsychotic Drug	\N	Germany	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
21360	ChiCTR-COC-14005301	\N	Neuropsychological test	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21361	ChiCTR-OPC-14005339	\N	M-E-C-T versus Music Therapy	\N	China	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
21362	JPRN-JapicCTI-142688	\N	Blonanserin versus Placebo	\N	Japan	\N	\N	\N	\N	\N	360	\N	\N	\N	\N	\N
21363	CTRI-2014-10-005144	\N	Iloperidone versus Olanzapine	\N	India	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21364	Hollister 1960	\N	Chlorpromazine versus Phenobarbital // Chlorpromazine versus Trifluoperazine // Phenobarbital versus Trifluoperazine	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21366	McNair 1965	\N	Chlordiazepoxide versus Meprobamate // Chlordiazepoxide versus Placebo // Meprobamate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
21367	Dinitz 1965	\N	Home-care versus Hospitalization // Drug+Homecare versus Homecare+Placebo	\N	United States of America	\N	\N	\N	\N	\N	163	\N	\N	\N	\N	\N
21369	Buchan 1969	\N	FR 33 versus Vitamin B	\N	Zimbabwe	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
21370	Baker 1971	\N	Operant Conditioning	\N	UK	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
21374	Steuber 1978	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21798	NCT01941251 2013	\N	navigated Transcranial Magnetic Stimulation	\N	Finland	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
21799	NCT01945333 2013	\N	Cognitive Remediation	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21800	NCT01946295 2013	\N	Famotidine versus Placebo	\N	Finland	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
21801	NCT01948024 2013	\N	Asenapine Brand	\N	United States of America	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
21802	NCT01964092 2013	\N	Individual Placement and Support versus Ordinary Employment Schemes	\N	Norwey	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	800	\N	\N	\N	\N	\N
21803	NCT01967420 2013	\N	Social Cognition Training	\N	UK	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
21804	NCT01969500	\N	Mobile System for Self-management	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21805	NCT01971073 2013	\N	transcranial Direct Current Stimulation	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21806	NCT01971307	\N	Supporting Primary Care in Diagnosis and Choice of Treatment (Internet Application) versus Treatment as Usual	\N	The Netherlands	\N	\N	\N	\N	\N	648	\N	\N	\N	\N	\N
21807	NCT01973270 2013	\N	Cognitive Exercises (General) versus Cognitive Training (Targeted)	\N	United States of America	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
21808	NCT01992393	\N	Targeted Self-Management	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
21809	Von 2013	\N	Post-Discharge Network Coordination Program	\N	Switzerland	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
21814	Ozkan 2013	\N	Psychoeducation	\N	Turkey	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
21817	Fernandez 2013	\N	Cognitive rehabilitation computarized program	\N	Spain	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
21818	Tsotsi 2013	\N	Attention to Facial Features Intervention versus Facial Emotion Intervention	\N	Greece	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
21822	Kidorf 2013	\N	Reinforced on-site integrated care+vouchers versus Standard on-site integrated care+vouchers	\N	United States of America	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
21824	Chung 2013	\N	repetitive Transcranial Magnetic Stimulation // repetitive Transcranial Magnetic Stimulation Frequency	\N	Korea	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
21825	Fleischhacker W 2013	\N	Aripiprazole Dosage // Aripiprazole Route	\N	\N	\N	\N	\N	\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	662	\N	\N	\N	\N	\N
21828	Kane 2013	\N	Cariprazine versus Placebo // Cariprazine Dosage	\N	Multi-Center	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	446	\N	\N	\N	\N	\N
21829	Kocyigit 2013	\N	L-arginine versus Placebo	\N	Turkey	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
21834	Maat 2013	\N	Aripiprazole versus Risperidone	\N	The Netherlands	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21835	Miyaoka 2013	\N	Yokukansan versus Placebo	\N	Japan	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21836	Peters 2013	\N	Aripiprazole Dosage // Aripiprazole Route	\N	\N	\N	\N	\N	\N	\N	662	\N	\N	\N	\N	\N
21837	Puig 2013	\N	Cognitive Remediation	\N	Spain	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
21838	Rapado 2013	\N	N-Acetyl Cysteine versus Placebo	\N	\N	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
21840	Steibliene 2013	\N	L-triiodothyronine+Risperidone versus Risperidone+Placebo	\N	Lithuania	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
21842	Wakamatsu 2013	\N	Paliperidone Palmitate versus Placebo	\N	Japan // Korea // Taiwan // Multi-Center	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21845	NCT01074632	\N	Lurasidone Meal Type	\N	United States of America	\N	\N	\N	\N	\N	16 // 26	\N	\N	\N	\N	\N
21849	Lee3 2013	\N	Assertiveness Training	\N	Taiwan	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
21851	Valencia 2013	\N	Social Skills Training+Family Psychoeducation	\N	Mexico	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
21854	Sanada 2013	\N	Blonanserin versus Paliperidone	\N	Japan	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
21857	Walther 2013	\N	Haloperidol versus Olanzapine // Haloperidol versus Risperidone // Olanzapine versus Risperidone Haloperidol versus Olanzapine // Haloperidol versus Risperidone // Olanzapine versus Risperidone	\N	Switzerland	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
21861	Barkhof 2013	\N	Health Education versus Health Education	\N	The Netherlands	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	114	\N	\N	\N	\N	\N
21865	Hjorth 2013a	\N	Cognitive Behavioral Therapy+Motivational Interviewing	\N	Denmark	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	103	\N	\N	\N	\N	\N
21456	Hui 2010	\N	Early Intervention	\N	China	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21868	Meskanen 2013	\N	Femotidine versus Placebo	\N	Finland	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21869	Morrison 2013	\N	Cognitive Therapy	\N	UK	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
21870	Kemp 2013	\N	Olanzapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
21871	Patterson1 2013	\N	Art Therapy	\N	\N	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
21872	Areberg 2013	\N	Individual Placement and Support versus Traditional Vocational Rehabilitation	\N	Sweden	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	120	\N	\N	\N	\N	\N
21874	Malla 2013	\N	Atypical Antipsychotic Drug versus Risperidone	\N	Canada	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
21877	Daly 2013	\N	JNJ-37822681 versus Olanzapine // JNJ-37822681 versus Placebo // Olanzapine versus Placebo // JNJ-37822681 Dosage	\N	Multi-Center	\N	\N	\N	\N	\N	498	\N	\N	\N	\N	\N
21880	Schneider 2013	\N	Flupentixol versus Quetiapine	\N	Germany	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
21882	Chien2 2013	\N	Peer Support versus Psychoeducation // Peer Support // Psychoeducation	\N	China	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
21884	Green 2013	\N	Intervention Led Jointly by Peer and Professional Counselors	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
21890	Baumgarten 2013	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21891	Liang 2013	\N	Haloperidol versus Quetiapine	\N	China	\N	\N	\N	\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	80	\N	\N	\N	\N	\N
21892	Li 2013 a	\N	Paliperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21893	Gibson 2013	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
21894	Cavallo 2013	\N	Intensive Computerized Cognitive Training	\N	Italy	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
21898	Shen W 2013	\N	Hospital-Community-Family Rehabilitation versus Rehabilitation	\N	China	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
22793	Berry 2014	\N	integrated motivational interview and cognitive behavioural therapy versus standard care for schizophrenia or//and schizophreniform whose current state is not described and whose stage of illness is not described	\N	United Kingdom	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 10\r\n	\N	327	\N	\N	\N	\N	\N
22797	Eack 2014	\N	Cognitive Enhancement Therapy	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
22800	Woolley 2014	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
22802	Takeuchi 2014b	\N	Dosage Maintenance versus Dosage Reduction // Olanzapine versus Risperidone Dosage Maintenance versus Dosage Reduction // Olanzapine versus Risperidone	\N	Japan	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	61	\N	\N	\N	\N	\N
22803	Medlin 2014	\N	Experimental Paranoia Induction versus Experimental Stress Induction	\N	United States of America	\N	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
22805	de Macedo 2014	\N	Oxytocin versus Placebo	\N	Brazil	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22806	de 2014a	\N	Repetitive Transcranial Magnetic Stimulation Dosage	\N	The Netherlands	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
22807	Nurenberg 2015	\N	Animal-Assisted Therapy // Canine-Assisted Psychotherapy versus Equine-Assisted Psychotherapy// Animal-Assisted Therapy versus Enhanced Social Skills Psychotherapy	\N	United States of America	\N	\N	\N	\r\nUser defined 3\r\n	\N	90	\N	\N	\N	\N	\N
22808	Luciano 2014	\N	Assertive Community Treatment	\N	United States of America	\N	\N	\N	\N	\N	205	\N	\N	\N	\N	\N
22810	Rapado 2015	\N	N-Acetyl Cycteine versus Placebo	\N	Australia	\N	\N	\N	\N	\N	121	\N	\N	\N	\N	\N
22813	Stockings 2014	\N	Smoking cessation//nicotine replacement therapy//brief motivational interviewing	\N	Austrailia	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
22814	Quan 2015	\N	Repetitive Transcranial Magnetic Stimulation	\N	China	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
22815	Taylor 2014	\N	Lorazepam versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
22817	Rosell  2015	\N	DAR-0100A versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
22818	Unterrainer 2014	\N	Meditation versus Walking	\N	Austria	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
22820	Lee 2014	\N	Pedometer + Phone Calls versus Written Information about Physical Activity	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
22821	Garcia 2014	\N	Education	\N	Spain	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22822	Tomita 2015	\N	Critical Time Intervention	\N	United States of America	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
22823	McClure 2009a	\N	Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
22824	Martin 2014	\N	Lisdexamfetamine Dimesylate versus Placebo // + Antipsychotic Drug	\N	Canada	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
22827	Kane 2014a	\N	Aripiprazole versus Placebo	\N	Croatia // United States of America // Latvia // Multi-Centre	\N	\N	\N	\N	\N	340	\N	\N	\N	\N	\N
22828	Gross 2014	\N	Loxapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	52 // 53	\N	\N	\N	\N	\N
22829	Sarpal 2015	\N	Aripiprazole versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
21375	Dencker1 1980	\N	Clopenthixol Decanoate // Flupenthixol Palmitate	\N	Sweden	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21377	Cooper 1981	\N	Fluphenazine versus Pipotiazine Pahnitate	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21380	Silver 1995	\N	Amantadine versus Biperiden // Amantadine versus Placebo // Biperiden versus Placebo	\N	Israel	\N	\N	\N	\r\nUser defined 3\r\n	\N	32	\N	\N	\N	\N	\N
21383	NCT01936220 1997	\N	Continuity of Specialized Care versus Continuity of Specialized Care+Parent Groups // Continuity of Specialized Care+Parent Groups // Continuity of Specialized Care	\N	The Netherlands	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
21385	MÃ¼ller1 1998	\N	Amisulpride versus Flupentixol	\N	Germany	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	126	\N	\N	\N	\N	\N
21386	Hellewell 1998	\N	Quetiapine Dosage // Haloperidol versus Quetiapine // Quetiapine versus Placebo // Haloperidol versus Placebo	\N	Multi-Center	\N	\N	\N	\N	\N	1361	\N	\N	\N	\N	\N
21387	Schmidt 1998	\N	Clinical Team Model versus Intensive Broker Model // Clinical Team Model versus PACT Adaptation Model // Intensive Broker Model versus PACT Adaptation Model	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21388	Nair 1999	\N	Clozapine Dosage	\N	United States of America	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
21389	Ogrodniczuk 2000	\N	Interpretive Therapy versus Supportive Therapy	\N	Canada	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
21390	Feldmann 2000	\N	Psychoeducational Psychotherapeutic Intervention	\N	Germany	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
21392	Dittmann 2002 b	\N	Flupenthixol versus Olanzapine	\N	Germany	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
21393	Ahn 2002 c	\N	Switching to Olanzapine	\N	Korea	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
21394	Kageyama 2002a	\N	Self-Help (Promoting the Partnership)	\N	Japan	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
21395	Chengappa 2002 b	\N	Once Daily Quetiapine versus Twice Daily Quetiapine	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
21396	Simons 2002	\N	Quetiapine versus Risperidone	\N	Multi-Center	\N	\N	\N	\N	\N	725	\N	\N	\N	\N	\N
21397	Smith1 2002	\N	Quetiapine Dosage Escalation // Quetiapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
21398	Khazaie 2003	\N	Fluphenazine Decanoate Dosage	\N	Iran	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
21400	Sacchetti1 2003	\N	Olanzapine versus Quetiapine // Olanzapine versus Risperidone // Quetiapine versus Risperidone	\N	Multi-Center	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21401	van 2003	\N	Relapse Prevention Plans	\N	The Netherlands	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21402	TREC 2003	\N	Haloperidol+Promethazine versus Midazolam Haloperidol + promethazine versus midazolam	\N	Brazil	\N	\N	\N	\r\nUser defined 3\r\n	\N	301	\N	\N	\N	\N	\N
21403	NCT01989728 2004	\N	Psychiatric Examination and Feedback	\N	Denmark	\N	\N	\N	\N	\N	1121	\N	\N	\N	\N	\N
21404	Craig 2004	\N	Case Management+Health Care Assistant versus Standard Case Management	\N	London	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
21405	ISRCTN20556456	\N	Relapse prevention therapy	\N	UK	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21407	NCT00287352	\N	Amantadine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21408	Lin 2005	\N	Continuing Clozapine versus Switching to Zotepine	\N	Taiwan	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
21409	Drebing 2005	\N	Enhanced Incentives	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
21410	NCT01926613 2006	\N	Supported Employment versus Thinking Skills for Work Program	\N	United States of America	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
21418	John 2007	\N	Citalopram versus Placebo	\N	India	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
21420	Daneshmand 2007	\N	Haloperidol versus Risperidone	\N	Iran	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
21421	NCT01915017 2008	\N	Cognitive Behavioral Therapy versus Cognitive Adaptation Training // Cognitive Behavioral Therapy versus Multi-modal Cognitive Therapy // Cognitive Behavioral Therapy // Cognitive Adaptation Training versus Multi-modal Cognitive Therapy // Cognitive Adaptation Training // Multi-modal Cognitive Therapy	\N	United States of America	\N	\N	\N	\N	\N	178	\N	\N	\N	\N	\N
21422	Sudhakar 2008	\N	Modafinil versus Placebo	\N	India	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
21427	Hoffman 2008	\N	repetitive Transcranial Magnetic Stimulation	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
21431	Villari 2008	\N	Haloperidol versus Olanzapine // Haloperidol versus Quetiapine // Haloperidol versus Risperidone // Olanzapine versus Quetiapine // Olanzapine versus Risperidone // Quetiapine versus Risperidone	\N	Italy	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
21432	Rouillon 2009	\N	Quetiapine versus Risperidone	\N	Multi-Center	\N	\N	\N	\N	\N	666	\N	\N	\N	\N	\N
21433	Gao 2009	\N	repetitive Transcranial Magnetic Stimulation	\N	China	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
21434	Kim 2009a	\N	Methods - Contact // Educational Lecture versus Video-Based Contact	\N	Korea	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
21435	Loze 2009	\N	Aripiprazole Dosage	\N	\N	\N	\N	\N	\N	\N	302	\N	\N	\N	\N	\N
21437	Wass 2009	\N	L-Lysine versus Placebo	\N	Sweden	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
21438	NCT01942382 2009	\N	Paliperidone Palmitate Dosage // Paliperidone Palmitate Injection Location	\N	United States of America	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
21439	NCT01988714	\N	Cognitive Training (Targeted) versus Games (Computer)	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21440	Shokraneh 2009	\N	Family Cognitive Training	\N	Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21441	NCT02105779 2009	\N	Cognitive Remediation // Social Cognitive Training versus Targeted Cognitive Training	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21443	Haas1 2009	\N	Risperidone Dosage	\N	Multi-Center // Belgium // Bulgaria // Czech // Estonia // Germany // Poland // Romania // United States of America	\N	\N	\N	\N	\N	279	\N	\N	\N	\N	\N
21444	Emmerson 2009	\N	Cognitive Behavioral Social Skills Training	\N	United States of America	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
21446	Graff 2009	\N	Pramipexole Dihydrochloride versus Placebo	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
21447	Yu 2010	\N	repetitive Transcranial Magnetic Stimulation	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
21448	Zhijuan 2010	\N	repetitive Transcranial Magnetic Stimulation	\N	China	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21449	NCT01907282 2010	\N	Enhanced Care versus Family Focused Treatment	\N	United States of America	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
21451	NCT01942161 2010	\N	Aripiprazole Dosage	\N	Japan	\N	\N	\N	\N	\N	99	\N	\N	\N	\N	\N
21452	Mohammadi1 2010	\N	Ondansetron versus Placebo	\N	Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21455	Chan 2010 c	\N	Psychoeducation	\N	China	\N	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
21457	Cassella 2010 b	\N	Loxapine Dosage // Loxapine versus Placebo	\N	\N	\N	\N	\N	\N	\N	314	\N	\N	\N	\N	\N
21459	NCT02201888 2010	\N	Cognitive Training	\N	Spain	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
21460	ISRCTN59501939	\N	Manipulating Anxiety versus Thinking Styles (Computer Package)	\N	UK	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n	\N	200	\N	\N	\N	\N	\N
21461	ISRCTN70185866	\N	High intensity strategy referrals versus Low intensity strategy for referrals	\N	UK	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
21462	Weng 2010	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21463	Xu 2010	\N	Acupuncture	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21464	Isbister 2010	\N	Droperidol versus Midazolam // Droperidol versus Droperidol+Midazolam // Droperidol+Midazolam versus Midazolam	\N	Australia	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
21465	Rosenberg 2010	\N	Public Health Model	\N	United States of America	\N	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
21467	Chen 2011	\N	repetitive Transcranial Magnetic Stimulation	\N	China	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
21468	Tatsumi 2011	\N	Occupational Therapy	\N	Japan	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
21469	Liu 2011	\N	Atypical Antipsychotic Drug versus Typical Antipsychotic Drug // repetitive Transcranial Magnetic Stimulation // Atypical Antipsychotic Drug versus repetitive Transcranial Magnetic Stimulation // repetitive Transcranial Magnetic Stimulation versus Typical Antipsychotic Drug	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21470	Xu 2011	\N	repetitive Transcranial Magnetic Stimulation	\N	China	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
21471	Gao 2011	\N	repetitive Transcranial Magnetic Stimulation	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
21474	NCT02140788	\N	Metformin versus Metformin + Omega-3 Fatty Acid // Metformin versus Omega-3 Fatty Acid // Metformin versus Treatment as Usual // Metformin + Omega-3 Fatty Acid versus Omega-3 Fatty Acid // Metformin + Omega-3 Fatty Acid versus Treatment as Usual // Omega-3 Fatty Acid versus Treatment as Usual	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
21476	NCT02210962	\N	Omega-3 Fatty Acid versus Placebo	\N	Poland	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21479	Sledge 2011	\N	Peer Support	\N	United States of America	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
21480	Rosenheck1 2011	\N	Risperidone versus Antipsychotic Drug	\N	United States of America	\N	\N	\N	\N	\N	382	\N	\N	\N	\N	\N
21483	Eisen 2012	\N	Clinician-Led Recovery Group versus Recovery-Oriented Peer-Led Group	\N	United States of America	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
21484	NCT01024569	\N	Self-Management	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	555	\N	\N	\N	\N	\N
21485	Repo 2012	\N	Continiuing Olanzapine versus Switching Olanzapine	\N	Finland	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
21486	Shahrivar 2012	\N	Integrated Treatment	\N	Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21487	Omranifard 2012	\N	Compliance Therapy versus Supportive Counseling	\N	Iran	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	76	\N	\N	\N	\N	\N
21488	Navidian 2012	\N	Psychoeducation (Group)	\N	Iran	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
21489	Omranifard1 2012	\N	Sertraline versus Placebo	\N	Iran	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21492	Ihm 2012	\N	Listen-Empathize-Agree-Partner	\N	United States of America	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
21493	ISRCTN42520374	\N	Housing First	\N	Canada	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n	\N	103	\N	\N	\N	\N	\N
21494	Sato1 2012	\N	Aripiprazole versus Risperidone	\N	Japan	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
21495	Alvarez 2012	\N	Olanzapine versus Ziprasidone	\N	Spain	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
21496	Georgiev 2012	\N	Progressive Muscle Relaxation	\N	Bulgaria	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
21498	Killackey1 2012	\N	Individual Placement and Support	\N	Australia	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
21499	Glue 2012	\N	Clozapine Dosage // Clozapine Route	\N	New Zealand	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21500	Grupp 2012	\N	Health Service Engagement Intervention	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
21501	Williams 2012	\N	Varenicline versus Placebo	\N	United States of America // Canada // Multi-Center	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
21502	Katagiri 2012	\N	Olanzapine versus Placebo	\N	Japan	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21504	Fadaii 2012	\N	Donepezil versus Placebo	\N	Iran	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
21505	Vadas 2012	\N	Acupuncture Therapy versus Music Therapy // Acupuncture Therapy // Music Therapy	\N	Israel	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
21506	NCT02110771 2012	\N	Cognitive Remediation	\N	France	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21507	NCT02128919 2012	\N	transcranial Direct Current Stimulation Duration	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
21508	NCT02137993 2012	\N	A-prexa versus Zyprexa	\N	Korea	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
21509	NCT02144155 2012	\N	Oxytocin Dosage	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
21510	NCT02167347 2012	\N	Family Intervention	\N	Pakistan	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
21511	Riedel 2012	\N	Quetiapine Route	\N	\N	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
21512	Thienel 2012	\N	Haloperidol versus Risperidone	\N	Germany	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
21514	Carson 2012	\N	Aripiprazole versus Placebo	\N	\N	\N	\N	\N	\N	\N	403	\N	\N	\N	\N	\N
21515	Ma 2012	\N	Cognitive Behavioral Therapy versus Supportive Psychotherapy	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21516	Ricarte 2012	\N	Event-Specific Memory Training versus Social Skills and Occupational Therapy	\N	Spain	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
21517	Kane1 2012	\N	Aripiprazole versus Placebo	\N	\N	\N	\N	\N	\N	\N	403	\N	\N	\N	\N	\N
21519	Baker 2012	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21520	Bersudsky 2012	\N	Oxytocin versus Placebo	\N	Israel	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21521	Tsai1 2012	\N	Benzoate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21522	Pedersen 2012	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
21524	Sanchez 2012	\N	Aripiprazole versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21525	Potkin 2012	\N	Asenapine versus Olanzapine	\N	Multi-Center	\N	\N	\N	\N	\N	949	\N	\N	\N	\N	\N
21528	Chirita 2012	\N	L-lysine versus Placebo	\N	Romania	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21529	Prikrylova 2012	\N	repetitive Transcranial Magnetic Stimulation	\N	Czech	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21530	NCT02192723 2012	\N	Aripiprazole versus Haloperidol+Perphenazine // Aripiprazole versus Olanzapine // Aripiprazole versus Quetiapine // Aripiprazole versus Risperidone // Aripiprazole versus Ziprasidone // Haloperidol+Perphenazine versus Olanzapine // Haloperidol+Perphenazine versus Quetiapine // Haloperidol+Perphenazine versus Risperidone // Haloperidol+Perphenazine versus Ziprasidone // Olanzapine versus Quetiapine // Olanzapine versus Risperidone // Olanzapine versus Ziprasidone // Quetiapine versus Risperidone // Quetiapine versus Ziprasidone // Risperidone versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	550	\N	\N	\N	\N	\N
21531	ISRCTN33695128	\N	Cognitive Behavioral Therapy	\N	UK	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21533	ISRCTN47998710	\N	Cognitive Behavioral Therapy	\N	UK	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21534	ISRCTN88275061	\N	Cognitive Behavioral Therapy	\N	UK	\N	\N	\N	\N	\N	135	\N	\N	\N	\N	\N
21535	NCT01568229 2012	\N	AMG 747 Dosage // AMG 747 versus Placebo	\N	United States of America // Czech // France // Malaysia // Poland // UK // Multi-Center	\N	\N	\N	\N	\N	111	\N	\N	\N	\N	\N
21536	NCT01655680	\N	ABT-126 Dosage // ABT-126 versus Placebo	\N	United States of America // Russia // UK // Multi-Center	\N	\N	\N	\N	\N	432	\N	\N	\N	\N	\N
21537	Paikkatt 2012	\N	Yoga Therapy	\N	India	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21545	Prikryl 2012	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21547	Walker 2012	\N	Psychoeducation	\N	UK	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
21551	Chen 2013 a	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21552	van 2013	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21553	Tenjin 2013	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21554	Koren 2013	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21555	McGinley 2013	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21558	ISRCTN17801606	\N	Acceptance and Commitment Therapy versus Cognitive Behavioral Therapy	\N	UK and United Kingdom	\N	\N	\N	\r\nNotes2\r\n	\N	61	\N	\N	\N	\N	\N
21559	ISRCTN13762819	\N	Prediction and Management of Cardiovascular Risk	\N	UK	\N	\N	\N	\N	\N	398	\N	\N	\N	\N	\N
21560	CTRI-2013-02-00	\N	Aripiprazole versus Placebo	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21561	SLCTR-2013-008	\N	Eenhancing Social and Communication Skills and Self-Confidence (Dance, Yoga, Drama)	\N	Sri Lanka	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21562	NCT01804582 2013	\N	Family Navigator Consultation	\N	United States of America	\N	\N	\N	\N	\N	1200	\N	\N	\N	\N	\N
21563	NCT01794429 2013	\N	Exenatide versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
21564	NCT01793220 2013	\N	SMS Reminder	\N	UK	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
21565	NCT01801787 2013	\N	transcranial Direct Current Stimulation	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21566	NCT01795547 2013	\N	Aripiprazole versus Paliperidone Palmitate	\N	United States of America	\N	\N	\N	\N	\N	286	\N	\N	\N	\N	\N
21567	NCT01794897 2013	\N	Valacyclovir versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
21568	NCT01793935 2013	\N	Sensoril versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21569	NCT01788774 2013	\N	Risperidone Dosage	\N	Multi-Center // Croatia // South Africa // Russia	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
21570	NCT01804920 2013	\N	D-Serine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21571	Penades 2013	\N	Cognitive Remediation versus Social Skills Training	\N	Spain	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21572	Stroup 2013	\N	Switching to Aripiprazole	\N	United States of America	\N	\N	\N	\N	\N	215	\N	\N	\N	\N	\N
21573	Fischer 2013	\N	Oxytocin versus Placebo	\N	Israel	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
21574	Fatemi 2013	\N	Bupropion versus Varenicline // Bupropion versus Placebo // Varenicline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21575	Li 2013	\N	Insulin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
21576	Schulz 2013	\N	Adherence Therapy	\N	Switzerland // Germany // Multi-Center	\N	\N	\N	\N	\N	161	\N	\N	\N	\N	\N
21578	Egan 2013	\N	MK-8998 versus Olanzapine // MK-8998 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	216	\N	\N	\N	\N	\N
21581	Bosch 2013	\N	Acupuncture	\N	\N	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
21583	Abhishekh 2013	\N	ECT Location	\N	India	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
21584	Brunelin 2013	\N	transcranial Direct Current Stimulation	\N	France	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21585	Hajebi 2013	\N	Aftercare Services	\N	Iran	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
21586	Manoach 2013	\N	Eszopiclone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
21587	Marx 2013	\N	Pregnenolone Dosage // Pregnenolone versus Placebo	\N	Singapore	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21588	Mathalon 2013	\N	Cognitive Training (Computer-Based) versus Games (Computer)	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
21589	Sikich 2013	\N	Cognitive Remediation (Computer Games, Neuroplasticity-Based) versus Games (Computer)	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
21590	Sun 2013	\N	Asenapine Dosage	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
21592	Nisenbaum 2013	\N	Dosage LY2140023 // LY2140023 versus Risperidone // LY2140023 versus Placebo // Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21593	Yi 2013	\N	Paliperidone Palmitate versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21596	Bais 2013	\N	repetitive Transcranial Magnetic Stimulation	\N	The Netherlands	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
21598	Wunderink 2013	\N	Guided Discontinuation versus Maintenance Treatment	\N	The Netherlands	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	128	\N	\N	\N	\N	\N
21599	Woolley 2013	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
21603	Vesterager 2013	\N	Cognitive Remediation	\N	Denmark	\N	\N	\N	\N	\N	117	\N	\N	\N	\N	\N
21604	Van1 2013	\N	Lifestyle Intervention	\N	The Netherlands	\N	\N	\N	\N	\N	130	\N	\N	\N	\N	\N
21605	Van2 2013	\N	Cognitive Behavioral Therapy	\N	The Netherlands	\N	\N	\N	\N	\N	201	\N	\N	\N	\N	\N
21606	Ulloa 2013	\N	Guideline	\N	Mexico	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
21607	Takeuchi 2013 a	\N	Dosage Maintenance versus Dosage Reduction // Olanzapine versus Risperidone	\N	\N	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
21608	Szeszko 2013	\N	Aripiprazole versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
21609	Su 2013	\N	Chlorpromazine versus Clozapine // Chlorpromazine versus Chlorpromazine+Valproate // Chlorpromazine versus Clozapine+Valproate // Clozapine versus Chlorpromazine+Valproate // Clozapine versus Clozapine+Valproate // Chlorpromazine+Valproate versus Clozapine+Valproate	\N	China	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
21610	Subotnik 2013	\N	Risperidone Dosage // Risperidone Route	\N	United States of America	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
21611	CHANGE	\N	Health Promoting Program // Health Promoting Program versus Care Coordinator // Care Coordinator	\N	Denmark	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	450	\N	\N	\N	\N	\N
21613	Siever 2013	\N	Guanfacine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
21614	Siever1 2013	\N	DAR-0100A versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
21615	Baker 2013 a	\N	Aripiprazole versus Placebo	\N	\N	\N	\N	\N	\N	\N	403	\N	\N	\N	\N	\N
21616	Robinson 2013	\N	Olanzapine versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
21617	Reeder 2013	\N	Cognitive Remediation	\N	UK	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
21619	Pijnenborg 2013	\N	Metacognitive Group Treatment	\N	The Netherlands	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21621	Oranje 2013	\N	Clonidine Dosage // Clonidine versus Placebo	\N	Denmark	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n	\N	20	\N	\N	\N	\N	\N
21622	Nunes 2013	\N	Lodenafil Carbonate versus Placebo	\N	Brazil	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
21623	Nuechterlein KH 2013	\N	Risperidone Dosage // Risperidone Route	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21624	Nuechterlein KH1 201	\N	Cognitive Remediation versus Healthy Behavior Training	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21625	Rotondi 2013	\N	Family Psychoeducation	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
21626	Nienow 2013	\N	Cognitive Remediation versus Computer Skills Training	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
21627	Bartzokis 2013	\N	Risperidone Dosage // Risperidone Route	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
21628	Mueser 2013	\N	Supportive Employment+Thinking Skills for Work versus Thinking Skills for Work	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
21630	McGurk 2013	\N	Supportive Employment	\N	United States of America	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
21631	Ahmed 2013	\N	Cognitive Remediation	\N	United States of America	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
21632	Marder 2013	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
21633	Malchow 2013	\N	Aerobic Exercise (Cycling) versus Table Football	\N	Germany	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
21634	Lystad 2013	\N	Cognitive Behavioral Therapy versus Cognitive Remediation	\N	Norway // Austria // Australia // Multi-Center	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21635	Loewy 2013	\N	Cognitive Training (Brain Fitness) (Computerized) versus Games (Computer)	\N	United States of America	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
21637	Bell 2013	\N	Cognitive Remediation	\N	United States of America	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
21638	Leweke 2013	\N	Cannabidiol versus Placebo	\N	Germany	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
21639	Kurtz 2013	\N	Cognitive Remediation versus Computer Skills	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
21640	ISRCTN29242879	\N	Cognitive Behavioral Therapy versus Supportive Therapy Cognitive Behavioural Training versus attention control group	\N	Germany	\N	\N	\N	\r\nUser defined 3\r\n	\N	330	\N	\N	\N	\N	\N
21641	Killackey 2013 a	\N	Individual Placement and Support	\N	Australia	\N	\N	\N	\N	\N	146	\N	\N	\N	\N	\N
21642	Kern 2013	\N	Errorless Learning+Supported Employment versus Supported Employment	\N	United States of America	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
21643	Kasckow 2013	\N	Telehealth Monitoring	\N	United States of America	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
21644	Jorgensen 2013	\N	Guided Self-Determination	\N	Denmark	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
21645	Jorg 2013	\N	Lifestyle Intervention	\N	The Netherlands	\N	\N	\N	\N	\N	900	\N	\N	\N	\N	\N
21646	Chang 2013	\N	Case Management	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
21977	Parke 2013	\N	Minimum Effective Dosage Designs // Dosage versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21647	Christensen 2013	\N	Cognitive Remediation+Individual Placement and Support+Social Skills Training versus Individual Placement and Support // Individual Placement and Support // Cognitive Remediation+Individual Placement and Support+Social Skills Training	\N	Denmark	\N	\N	\N	\N	\N	750	\N	\N	\N	\N	\N
21650	Goff 2013	\N	D-cycloserine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
21652	Wolfgang Fleisc 2013	\N	Aripiprazole Dosage // Aripiprazole Route	\N	United States of America	\N	\N	\N	\N	\N	662	\N	\N	\N	\N	\N
21653	Ermer 2013	\N	Lisdexamfetamine Dimesylate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
21654	Eack 2013 a	\N	Enriched Supportive Therapy versus Cognitive Enhancement Therapy	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
21655	Drake 2013	\N	Cognitive Remediation versus Social Contact	\N	UK	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
21656	Dlabac 2013	\N	repetitive Transcranial Magnetic Stimulation	\N	The Netherlands	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
21657	Dixon 2013	\N	Family-to-Family Education Program	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21658	Dirks 2013	\N	Lisdexamfetamine Dimesylate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21659	De 2013	\N	Metacognitive Reflection and Insight Therapy	\N	The Netherlands	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
21660	Davis 2013	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
21661	Chan 2013	\N	Droperidol versus Olanzapine // Droperidol versus Placebo // Olanzapine versus Placebo	\N	Australia	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n	\N	336	\N	\N	\N	\N	\N
21662	Lee 2013 a	\N	Aripiprazole versus Placebo	\N	Korea	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
21665	Lee1 2013	\N	Cognitive Rehabilitation	\N	Korea	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
21669	Caballero 2013	\N	TV Series	\N	Spain	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
21670	Eack 2013 b	\N	Cognitive Enhancement Therapy versus Enriched Supportive Therapy	\N	United States of America	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
21671	Eramo 2013	\N	Aripiprazole versus Placebo	\N	Multi-Center	\N	\N	\N	\N	\N	403	\N	\N	\N	\N	\N
21673	Hansen 2013	\N	Assertive Community Treatment	\N	Denmark	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
21674	Hu 2013	\N	Olanzapine versus Paliperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21676	Kindler 2013	\N	repetitive Transcranial Magnetic Stimulation versus Theta burst protocols	\N	Switzerland	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
21677	Viering 2013	\N	Individual Placement and Support	\N	Switzerland	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
21683	Sofronov 2013	\N	Fluvoxamine+Zuclopenthixole versus Paliperidone // Fluvoxamine+Zuclopenthixole versus Sertindole // Paliperidone versus Sertindole	\N	Russia	\N	\N	\N	\N	\N	167	\N	\N	\N	\N	\N
21687	Wang 2013	\N	Aripiprazole versus Olanzapine // Aripiprazole versus Risperidone // Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21688	Ainsworth 2013	\N	Smartphone App versus Text-Messaging	\N	UK	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
21689	ISRCTN33306437	\N	Acceptance and Commitment Therapy	\N	UK	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21694	CTRI-2013-06-00	\N	Clozapine Brand	\N	India	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
21695	CTRI-2013-05-00	\N	Metformin versus Placebo	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21696	Patel 2013	\N	Adherence Therapy versus Health Education	\N	Italy // Germany // UK // The Netherlands // Multi-Center	\N	\N	\N	\N	\N	409	\N	\N	\N	\N	\N
21698	Herbild 2013	\N	Pharmacogenetic Testing	\N	Denmark	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
21701	ISRCTN37178153	\N	Cognitive Behavioral Program	\N	Switzerland	\N	\N	\N	\N	\N	166	\N	\N	\N	\N	\N
21702	Loftis 2013	\N	Epigallocatechin Gallate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
21703	IRCT201210163014N6	\N	Vitamin D	\N	Iran	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21704	Jayaram 2013	\N	Yoga Therapy	\N	India	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
21705	Ghanizadeh 2013	\N	Zonisamide versus Placebo	\N	Iran	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
21708	Cavezza 2013	\N	Adherence Therapy versus Health Education	\N	Australia	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
21711	Manjunath 2013	\N	Exercise versus Yoga Therapy	\N	India	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
21712	Boyer 2013	\N	Quality of Life Assessment versus Quality of Life Feedback	\N	France	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
21713	Braehler 2013	\N	Compassion Focused Therapy	\N	United Kingdom	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21716	Neunhauserer D  2013	\N	Hiking	\N	Austria	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
21719	Tybura 2013	\N	Olanzapine versus Perazine // Olanzapine versus Ziprasidone // Perazine versus Ziprasidone	\N	Poland	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
21720	ISRCTN26099032	\N	Supported Employment versus Traditional Vocational Rehabilitation	\N	Switzerland	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	100	\N	\N	\N	\N	\N
21722	Adams 2013	\N	Metformin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	148	\N	\N	\N	\N	\N
21724	Pitschel 2013	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21726	Foruzandeh 2013	\N	Occupational Therapy	\N	Iran	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21728	Jones 2013	\N	Oral Health Intervention	\N	UK	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	800	\N	\N	\N	\N	\N
21729	Wang 2013b	\N	Psychosocial Rehabitation Training	\N	China	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
21731	Wang2 2013	\N	Olanzapine versus Placebo	\N	China	\N	\N	\N	\N	\N	261	\N	\N	\N	\N	\N
21733	Battaglia 2013	\N	Soccer Training	\N	Italy	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
21735	Potkin 2013	\N	Iloperidone Dosage // Iloperidone versus Quetiapine // Iloperidone versus Ziprasidone // Quetiapine versus Ziprasidone	\N	\N	\N	\N	\N	\N	\N	188	\N	\N	\N	\N	\N
21738	ISRCTN44114663	\N	Relating Therapy	\N	UK	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	30	\N	\N	\N	\N	\N
21739	ISRCTN65314790	\N	Avatar Therapy versus Supportive Counselling	\N	UK	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	142	\N	\N	\N	\N	\N
21740	Stip 2013	\N	Electronic Pill Dispenser	\N	Canada	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
21741	ChiCTR-TRC-13003263	\N	Case Management	\N	China	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
21742	Pontes 2013	\N	Cognitive Training versus Reading Training	\N	Brazil	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
21743	Holt 2013	\N	Lifestyle Education Programme	\N	UK	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21744	Usher 2013	\N	Healthy Lifestyle Booklet versus Nurse-Led Weight Management Program	\N	Australia	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
21745	Bakker 2013	\N	Integrative Reactivation and Rehabilitation	\N	The Netherlands	\N	\N	\N	\N	\N	168	\N	\N	\N	\N	\N
21746	Hinkelmann 2013	\N	Citalopram versus Reboxetine // Citalopram versus Placebo // Reboxetine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
21749	Chien 2013	\N	Mindfullness-Based Psychoeducation	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
21751	Deen 2013	\N	Telepsychotherapy	\N	United States of America	\N	\N	\N	\N	\N	179	\N	\N	\N	\N	\N
21752	Goldberg 2013	\N	Weight Loss Program	\N	United States of America	\N	\N	\N	\N	\N	109	\N	\N	\N	\N	\N
21753	Slade 2013	\N	Public Health Mode	\N	United States of America	\N	\N	\N	\N	\N	202	\N	\N	\N	\N	\N
21756	Johnson 2013	\N	Broad-Minded Affective Coping	\N	UK	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
21757	Varambally 2013	\N	Yoga Therapy	\N	India	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
21759	Petry1 2013	\N	Contingency Management	\N	United States of America	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
21760	Terevnikov 2013	\N	Mirtazapine versus Placebo	\N	Finland	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
21762	Lieberman 2013	\N	TC-5619 versus Placebo	\N	India // United States of America	\N	\N	\N	\N	\N	185	\N	\N	\N	\N	\N
21763	Ghafari 2013	\N	Estrogen versus Placebo	\N	Iran	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
21764	Hansson 2013	\N	Feedback	\N	Sweden	\N	\N	\N	\N	\N	374	\N	\N	\N	\N	\N
21765	Gold 2013	\N	Individual Music Therapy	\N	Norway // Austria // Australia // Multi-Center	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
21766	ACTRN1261300097a	\N	Melatonin versus Placebo // Cognitive Behavioral Therapy	\N	Australia	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
21767	ACTRN1261300097b	\N	Emotion Recognition Training versus Mental-State Reasoning Training	\N	Australia	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
21768	ACTRN1261300112 2013	\N	Metacognitive Training Program	\N	Australia	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
21769	ACTRN12613001217796	\N	Lifestyle Intervention	\N	Australia	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21770	ChiCTR-TRC-13003407	\N	Assertive Community Treatment	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21771	CTRI-2013-10-00	\N	Valacyclovir versus Placebo	\N	India	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
21772	DRKS00005200 2013	\N	transcranial random noise stimulation	\N	Germany	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21773	DRKS00005346 2013	\N	Kinesitherapy versus Motor-Cognitive Therapy	\N	Germany	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
21774	EUCTR2013 2013	\N	Genetic Test	\N	Spain	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21775	IRCT20130819123 2013	\N	Crocin versus Placebo	\N	Iran	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
21776	ISRCTN08387324	\N	Peer-Led Self-Management Programme Peer-Led Self-Management Programme Peer-Led Self-Management Programme Peer-Led Self-Management Program versus Control Group	\N	UK and Singapore and Singapore	\N	\N	\N	\N	\N	242	\N	\N	\N	\N	\N
21778	JPRN-JapicCTI-111627	\N	Bitopertin Dosage	\N	Japan	\N	\N	\N	\N	\N	165	\N	\N	\N	\N	\N
21780	JPRN-UMIN000011194	\N	Aripiprazole versus Blonanserin	\N	Japan	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21781	JPRN3 2013	\N	Social cognition and Interaction Training	\N	Japan	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21782	JPRN4 2013	\N	Risperidone	\N	Japan	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
21783	KCT0000873 2013	\N	Exercise Therapy versus Occupational Therapy	\N	Korea	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
21784	NTR4172	\N	Game (Computer)	\N	The Netherlands	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21785	NCT01903707 2013	\N	Cognitive Remediation versus Placebo	\N	Ireland	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21786	NCT01903837 2013	\N	Samidorphan versus Placebo // Samidorphan Dosage	\N	United States of America // Bulgaria // Czech // Multi-Center	\N	\N	\N	\N	\N	350	\N	\N	\N	\N	\N
21787	NCT01905605 2013	\N	Phosphatidylcholine Supplementation versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	162	\N	\N	\N	\N	\N
21788	NCT01908192 2013	\N	Sodium Benzoate versus Placebo	\N	Taiwan	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
21789	NCT01909466 2013	\N	Injection Location of Aripiprazole	\N	United States of America	\N	\N	\N	\N	\N	141	\N	\N	\N	\N	\N
21790	NCT01911429	\N	Lurasidone Dosage // Lurasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	249	\N	\N	\N	\N	\N
21791	NCT01911676 2013	\N	PF-03463275 versus Placebo // PF-03463275 Dosage	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
21792	NCT01913327	\N	Aripiprazole versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21793	NCT01927276 2013	\N	Gluten Free Flour versus Wheat Flour	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
21794	NCT01934023 2013	\N	Varenicline versus Placebo	\N	Canada	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
21795	NCT01939548 2013	\N	PF-02545920 versus Placebo // PF-02545920 Dosage	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	230	\N	\N	\N	\N	\N
21796	NCT01940159 2013	\N	SEP-363856 versus Placebe	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
21797	NCT01940939 2013	\N	repetitive Transcranial Magnetic Stimulation	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
21900	Takahashi 2013	\N	Paliperidone Palmitate versus Placebo	\N	Japan	\N	\N	\N	\N	\N	324	\N	\N	\N	\N	\N
21902	Ma 2013	\N	Cognitive Behavioral Therapy versus Supportive Psychotherapy	\N	China	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
21903	NCT02023736 2013	\N	Feedback	\N	United States of America	\N	\N	\N	\N	\N	1000	\N	\N	\N	\N	\N
21905	NCT02001103 2013	\N	Memantine versus Placebo // Memantine Dosage	\N	Taiwan	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21907	NCT02019329 2013	\N	RO5545965 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
21908	JPRN5 2013	\N	Risperidone Injection Depth	\N	Japan	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21909	JPRN-UMIN000012729	\N	Aripiprazole versus Blonanserin	\N	Japan	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
21910	IRCT2013091414499N3	\N	Occupational therapy versus Social living skills training Package	\N	Iran	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
21912	IRCT20130622208 2013	\N	Group Hiking	\N	Iran	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
21913	ChiCTR-TRC-13003929	\N	Cognitive Behavioral Therapy	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
21914	ISRCTN09150095	\N	Exercise	\N	UK	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21915	ISRCTN78084871	\N	Psychoeducational intervention	\N	Jordan	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	144	\N	\N	\N	\N	\N
21919	NCT01234779	\N	Bitopertin Dosage // Bitopertin versus Placebo // Bitopertin versus Olanzapine	\N	Multi-Center // United States of America // Switzerland // Romania // Ukraine // Russia // Slovakia	\N	\N	\N	\r\nNotes2\r\n	\N	301	\N	\N	\N	\N	\N
21920	Capdevielle 2013	\N	Semantic Priming Groups	\N	France	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
21923	Dlabac1 2013	\N	repetitive Transcranial Magnetic Stimulation	\N	The Netherlands	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
21924	Farreny 2013	\N	Cognitive Remediation versus Leisure Activities	\N	Spain	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
21925	Kos 2013	\N	repetitive Transcranial Magnetic Stimulation	\N	The Netherlands	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
21927	Lay 2013	\N	Psychoeducation	\N	Switzerland	\N	\N	\N	\N	\N	238	\N	\N	\N	\N	\N
21929	Linke 2013	\N	Computer-Assisted Cognitive Training versus Relaxation+Social Integration	\N	Poland	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
21930	Lorente 2013	\N	Cognitive Behavioral Therapy versus Antipsychotic Drug	\N	Spain	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
21932	Malda 2013	\N	Befriending versus Behavioral Activation for Negative Symptoms	\N	The Netherlands	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21935	Schmidt 2013	\N	Amisulpride versus Olanzapine // Amisulpride versus Amisulpride+Olanzapine // Amisulpride+Olanzapine versus Olanzapine	\N	Germany	\N	\N	\N	\N	\N	303	\N	\N	\N	\N	\N
21937	Watkins 2013	\N	Aerobic Exercise (Stationary Bike) versus Table Football	\N	Australia	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
21938	Moritz1 2013	\N	Metacognitive Training versus Computerized Cognitive Training	\N	Germany	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
21939	Barch 2013	\N	AQW051	\N	United States of America	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
21940	Davis2 2013	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
21941	Evins 2013	\N	Varenicline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
21942	Feifel 2013	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21943	Fleischhacker W1 201	\N	Aripiprazole Dosage	\N	Austria	\N	\N	\N	\N	\N	841	\N	\N	\N	\N	\N
21944	Ghahremani 2013	\N	Modafinil versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
21945	Haig1 2013	\N	Placebo Dosage // Placebo	\N	United States of America	\N	\N	\N	\N	\N	420	\N	\N	\N	\N	\N
21948	Marx1 2013	\N	Pregnenolone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
21950	Smith1 2013	\N	Varenicline versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21951	Stan 2013	\N	Atomoxetine versus Placebo // Atomoxetine versus Cognitive Remediation // Cognitive Remediation versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21952	Stroup1 2013	\N	Insulin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21953	Trampush 2013	\N	Aripiprazole versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	169	\N	\N	\N	\N	\N
21955	Turncliff 2013	\N	Aripiprazole Injection Location	\N	United States of America	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
21959	Wolf1 2013	\N	AZD8529 versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n	\N	26	\N	\N	\N	\N	\N
21960	Woolley1 2013	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
21961	Youngstrom 2013	\N	Colombia Suicide Severity Rating Scale (C-SSRS) versus Sheehan Suicide Tracking Scale (S-STS)	\N	United States of America	\N	\N	\N	\N	\N	199	\N	\N	\N	\N	\N
21962	de Beurs 2013	\N	Application of Guideline Training	\N	The Netherlands	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
21964	Fleischhacker W2 201	\N	Aripiprazole versus Placebo	\N	Multi-Center	\N	\N	\N	\N	\N	403	\N	\N	\N	\N	\N
21965	Walker 2013	\N	Psychoeducation (Coping With Mental Illness)	\N	UK	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
21967	Vadhan 2013	\N	Marijuana versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
21970	van3 2013	\N	Immediate Feedback	\N	The Netherlands	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
21978	IRCT201203112085N7	\N	Purslane+Risperidone versus Risperidone Biperiden versus Biperiden+Purslane	\N	Iran	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21979	HernÃ¡ndez 2013	\N	Life Therapy Review	\N	Spain	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
21980	Park 2013	\N	Cognitive Behavioral Social Skills Training	\N	Korea	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
21982	Kageyama 2013	\N	Remifentanil Dosage // Remifentanil versus Placebo	\N	Japan	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
21983	Stant 2013	\N	Individual Placement and Support versus Regular Vocational Rehabilitation	\N	The Netherlands	\N	\N	\N	\N	\N	151	\N	\N	\N	\N	\N
21984	Mousavi 2013	\N	Haloperidol versus Olanzapine // Haloperidol versus Risperidone // Haloperidol versus Thiothixene // Olanzapine versus Risperidone // Olanzapine versus Thiothixene // Risperidone versus Thiothixene	\N	Iran	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
21985	Nag 2013	\N	Haloperidol versus Olanzapine // Haloperidol versus Risperidone // Haloperidol versus Thioridazine // Olanzapine versus Risperidone // Olanzapine versus Thioridazine // Risperidone versus Thioridazine	\N	Nepal	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
21986	Konnopka 2013	\N	Cognitive Behavioral Therapy versus Supportive Therapy	\N	Germany	\N	\N	\N	\N	\N	330	\N	\N	\N	\N	\N
21988	Saleem 2013	\N	Cognitive Remediation (Computer Game) versus Treatment As Usual	\N	UK	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
21989	ISRCTN84658943	\N	Tweeting	\N	UK	\N	\N	\N	\N	\N	166	\N	\N	\N	\N	\N
21990	NCT02072954 2013	\N	Asenapine Dosage // Asenapine Duration // Asenapine Brand	\N	India	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
21991	NCT02121106 2013	\N	Cognitive Remediation	\N	Canada	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
21992	NCT02149823 2013	\N	Oxytocin Dosage // Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
21993	Fleischhacker W3 201	\N	Aripiprazole Dosage // Aripiprazole Route	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
21994	Dean 2013	\N	Reasoning and Rehabilitation	\N	Australia	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
21996	Tsang 2013	\N	Self-Stigma Reduction Programme	\N	China	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
21999	Winseck 2013	\N	Switching to Iloperidone	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22000	Weiden 2013	\N	Switching to Iloperidone	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22001	Alva 2013	\N	Switching to Iloperidone	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22002	Daskalakis 2013	\N	repetitive Transcranial Magnetic Stimulation	\N	Canada	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
22006	De3 2013	\N	Trial-Based Cognitive Therapy Formats	\N	\N	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
22008	da 2013	\N	Alpha-Methylparatyrosine versus Placebo	\N	The Netherlands	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
22009	Bramesfeld 2013	\N	Assertive Outreach	\N	Germany	\N	\N	\N	\N	\N	536	\N	\N	\N	\N	\N
22010	Baker 2013 b	\N	Aripiprazole versus Placebo	\N	\N	\N	\N	\N	\N	\N	394	\N	\N	\N	\N	\N
22014	Warman 2013	\N	JTC Discussion	\N	United States of America	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
22015	Rocha 2013	\N	Metacognitive and Social Cognition Training	\N	Portugal	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
22017	Drake1 2013	\N	Cognitive Remediation versus Social Contact	\N	UK	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
22019	Battersby 2013	\N	Flinders Program	\N	Australia	\N	\N	\N	\N	\N	77	\N	\N	\N	\N	\N
22020	Kindler1 2013	\N	Transcranial Magnetic Stimulation	\N	Switzerland	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22021	Farreny1 2013	\N	Cognitive Remediation versus Leisure Activities	\N	Spain	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
22022	de Bont 2013	\N	Eye Movement Desensitization and Reprocessing versus Prolonged Exposure	\N	The Netherlands	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22023	Cohen 2013	\N	Patient-Facing Kiosks	\N	United States of America	\N	\N	\N	\N	\N	571	\N	\N	\N	\N	\N
22024	NCT02199743	\N	Haloperidol versus Lurasidone // Haloperidol versus Perphenazine // Lurasidone versus Perphenazine	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
22025	NCT02202213 2013	\N	Lu AF11167 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
22026	NCT02202226 2013	\N	Lu AF35700 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
22027	ISRCTN12055530	\N	Medication Review Form	\N	UK	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22028	ISRCTN66900787	\N	Modafinil versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
22029	NCT01834638	\N	ABT-126 Dosage	\N	United States of America // Russia // UK // Multi-Center	\N	\N	\N	\N	\N	268	\N	\N	\N	\N	\N
22030	Sukegawa 2013	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22033	Lerner 2013	\N	Bexarotene versus Placebo	\N	Israel	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
22036	Ozkan1 2013	\N	Psychoeducation+Telephone Follow-Up	\N	Turkey	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
22038	Cook 2013	\N	Nutrition Education Course versus Wellness Recovery Action Planning	\N	United States of America	\N	\N	\N	\N	\N	143	\N	\N	\N	\N	\N
22039	Lin 2013	\N	Adapted Illness Management and Recovery	\N	Taiwan	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
22040	Amr 2013	\N	Haloperidol versus Quetiapine	\N	Jordan	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
22042	Lu 2013	\N	Music Intervention Group	\N	Taiwan	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
22043	Fekadu 2013	\N	Minocycline versus Placebo	\N	Ethiopia	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
22044	Terzian 2013	\N	Social Activities	\N	Italy	\N	\N	\N	\N	\N	357	\N	\N	\N	\N	\N
22046	Farokhnia 2013	\N	N-Acetylcysteine versus Placebo	\N	Iran	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
22047	Quisenaerts 2013	\N	Nicotine versus Placebo	\N	Belgium	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
22049	O'Brien 2013	\N	Enhanced Care versus Family Focused Therapy	\N	United States of America	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
22053	Jager 2013	\N	Individual Placement and Support	\N	Multi-Center	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22054	Palepu 2013	\N	Assertive Community Treatment+Hosing First versus Congregate Housing with On-site Support // Assertive Community Treatment+Hosing First // Congregate Housing with On-site Support // Hosing First+Intensive Case Management	\N	Canada	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	288	\N	\N	\N	\N	\N
22057	Dwinger 2013	\N	Telephone-Based Health Coaching	\N	Germany	\N	\N	\N	\N	\N	12000	\N	\N	\N	\N	\N
22058	Gaughran 2013	\N	Health Promotion Intervention	\N	UK	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22060	Caforio 2013	\N	Mirtazapine versus Placebo	\N	Italy	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
22061	Findling 2013	\N	Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	283	\N	\N	\N	\N	\N
22063	Owen 2013	\N	Evidence-Based Quality Improvement Plus Facilitation	\N	United States of America	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
22065	NTR10340	\N	Web-Based Shared Decision-Making Tool versus Treatment as Usual	\N	The Netherlands	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
22066	Petretto 2013	\N	Psychoeducation // Family Supportive Therapy versus Psychoeducation	\N	Italy	\N	\N	\N	\N	\N	340	\N	\N	\N	\N	\N
22067	Ermilov 2013 b	\N	D-serine versus Olanzapine	\N	Israel	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
22068	JPRN-UMIN000007942	\N	Aripiprazole versus Blonanserin // Aripiprazole versus Paliperidone // Blonanserin versus Paliperidone	\N	Japan	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
22069	Lane 2013	\N	Sodium Benzoate versus Placebo	\N	Taiwan	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	52	\N	\N	\N	\N	\N
22071	Johnsen 2013	\N	Olanzapine versus Quetiapine // Olanzapine versus Risperidone // Olanzapine versus Ziprasidone // Quetiapine versus Risperidone // Quetiapine versus Ziprasidone // Risperidone versus Ziprasidone	\N	\N	\N	\N	\N	\N	\N	226	\N	\N	\N	\N	\N
22075	Tinland 2013	\N	Housing First	\N	France	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
22076	Hori 2013	\N	Continuing Polypharmacy versus Switching to Monotherapy	\N	Japan	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
22077	Stauffer 2013	\N	LY2140023 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	167	\N	\N	\N	\N	\N
22078	Garrido 2013	\N	Cognitive Remediation	\N	Spain	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
22080	Wang3 2013	\N	Social Cognition and Interaction Training	\N	China	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
22081	Agnihotri 2013	\N	Ayurvedic Medicine versus Placebo	\N	India	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22082	McGuire 2013	\N	Illness Management and Recovery versus Problem Solving Groups	\N	United States of America	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
22083	Komatsu 2013	\N	Information Technology Aided Relapse Prevention Programme	\N	Japan	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
22087	Ranjbar 2013	\N	Ranitidine versus Placebo	\N	Iran	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
22089	Browning 2013	\N	Cognitive Behavioral Therapy versus Family Intervention // Cognitive Behavioral Therapy // Family Intervention	\N	UK	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22090	Kelly 2013	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22091	Bucci 2013	\N	Neurocognitive Individualized Training versus Social Skills Individualized Training	\N	Italy	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
22092	Bartels 2013	\N	Integrated Skills Training and Preventive Healthcare	\N	United States of America	\N	\N	\N	\N	\N	183	\N	\N	\N	\N	\N
22093	Naber 2013 a	\N	Quetiapine versus Risperidone	\N	Multi-Center	\N	\N	\N	\N	\N	798	\N	\N	\N	\N	\N
22094	Boggs 2013	\N	Nicotine versus Placebo // Nicotine // Dosage	\N	United States of America	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
22095	Reeves 2013	\N	Antipsychotic Drug Switching+Healthy Lifestyle Education versus Healthy Lifestyle Education+Metformin // Antipsychotic Drug Switching+Healthy Lifestyle Education versus Healthy Lifestyle Education // Healthy Lifestyle Education versus Healthy Lifestyle Education+Metformin	\N	United States of America	\N	\N	\N	\N	\N	132	\N	\N	\N	\N	\N
22097	Ikai 2013	\N	Yoga Therapy	\N	Japan	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
22098	Saeko 2013	\N	Yoga Therapy	\N	Japan	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
22099	Drake2 2013	\N	Individual Placement and Support+Supported Employment+Systematic Medication Management+Behavioral Health Services+Health Insurance	\N	United States of America	\N	\N	\N	\N	\N	2238	\N	\N	\N	\N	\N
22100	Hatta 2013	\N	Olanzapine versus Risperidone	\N	Japan	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
22102	Sigrunarson 2013	\N	Integrated Treatment	\N	Norway	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22104	McEvoy 2013 b	\N	Aripiprazole versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22105	Mallikaarjun 2013	\N	Aripiprazole Dosage	\N	\N	\N	\N	\N	\N	\N	89	\N	\N	\N	\N	\N
22108	Sanz 2013	\N	Clozapine versus Risperidone	\N	Spain	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
22109	Perez 2013	\N	Postal Information versus Theory-based Educational Intervention // Contact Intensity between Primary care and Secondary care	\N	UK	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	62	\N	\N	\N	\N	\N
22110	Park1 2013	\N	Olanzapine versus Ziprasidone	\N	Korea	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22112	Wing1 2013	\N	Varenicline versus Placebo	\N	Canada	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22113	Killackey 2013 b	\N	Individual Placement and Support	\N	Australia	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	146	\N	\N	\N	\N	\N
22115	Jarskog 2013	\N	Metformin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	148	\N	\N	\N	\N	\N
22116	Freeman 2013 a	\N	Cognitive Behavioral Therapy	\N	UK	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22118	Fischer1 2013	\N	Clinical Trial-Related Consent Form	\N	Multi-Center	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
22120	Amrami 2013	\N	Reboxetine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
22121	Vahia 2013	\N	Citalopram versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	187	\N	\N	\N	\N	\N
22124	Roldan 2013	\N	Personalized In-Home Nursing Care Plan	\N	Spain	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
22126	Prikryl 2013	\N	repetitive Transcranial Magnetic Stimulation	\N	Czech	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
22127	Tek 2013	\N	Naltrexone versus Placebo // Naltrexone Dosage	\N	United States of America	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
22129	Best 2013	\N	Awareness of Diagnosis versus Not Aware of Diagnosis	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22132	Lin 2013 a	\N	Amisulpride+Sulpiride versus Amisulpride	\N	Taiwan	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	96	\N	\N	\N	\N	\N
22135	Goff1 2013	\N	Ziprasidone Dosage // Ziprasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
22136	Cipriani 2013	\N	Aripiprazole versus Haloperidol	\N	Italy	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
22137	Putkonen 2013	\N	Seclusion and Restraint Prevention Training	\N	Finland	\N	\N	\N	\N	\N	4	\N	\N	\N	\N	\N
22138	Deutsch 2013	\N	Galantamine+CDP-choline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
22139	Meskanen1 2013	\N	Famotidine versus Placebo	\N	Finland	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22141	Chen 2013 b	\N	Metformin versus Placebo	\N	Taiwan	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
22142	Lasser 2013	\N	Lisdexamfetamine Dimesylate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
22143	Gohar 2013	\N	Illness Management Training versus Social Cognitive Skills Training	\N	Egypt	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
22144	Hoeben 2013	\N	JNJ-37822681 // Placebo	\N	Belgium	\N	\N	\N	\N	\N	498	\N	\N	\N	\N	\N
22146	Brooner 2013	\N	Integrated On-Site Substance Abuse and Psychiatric Care versus Non-Integrated Off-Site Substance Abuse and Psychiatric Care	\N	United States of America	\N	\N	\N	\N	\N	316	\N	\N	\N	\N	\N
22149	Brunette 2013	\N	Motivational Intervention	\N	United States of America	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
22151	Hallak 2013	\N	Sodium Nitroprusside versus Placebo	\N	Brazil	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22154	Shao 2013	\N	Olanzapine versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
22155	Crespo 2013 a	\N	Aripiprazole versus Quetiapine // Aripiprazole versus Ziprasidone // Quetiapine versus Ziprasidone	\N	Spain	\N	\N	\N	\N	\N	202	\N	\N	\N	\N	\N
22158	Krakvik 2013	\N	Cognitive Behavioral Therapy	\N	Norway	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
22159	Sin 2013	\N	Peer Support versus Psychoeducation // Peer Support // Psychoeducation // Peer Support versus Peer Support+Psychoeducation // Peer Support+Psychoeducation versus Psychoeducation // Peer Support+Psychoeducation	\N	UK	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
22160	Mantovani 2013	\N	Haloperidol+Midazolam versus Haloperidol+Promethazine // Haloperidol+Midazolam versus Olanzapine // Haloperidol+Midazolam versus Ziprasidone // Haloperidol+Promethazine versus Olanzapine // Haloperidol+Promethazine versus Ziprasidone // Olanzapine versus Ziprasidone	\N	Brazil	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
22162	Rezaei 2013	\N	Memantine versus Placebo	\N	Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22164	Franck 2013	\N	Individualized Cognitive Remediation Therapy versus General Cognitive Remediation Therapy	\N	Sweden // France // Multi-Center	\N	\N	\N	\N	\N	138	\N	\N	\N	\N	\N
22167	Marsteller 2013	\N	Guided Care	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
22168	Hu1 2013	\N	Paliperidone versus Olanzapine	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
22172	Kukla1 2013	\N	Illness Management and Recovery	\N	United States of America	\N	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
22176	Egan 2013 b	\N	MK-0249 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
22177	Matthews 2013	\N	Galantamine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
22178	Bagoien 2013	\N	Motivational Interviewing	\N	Norway	\N	\N	\N	\N	\N	135	\N	\N	\N	\N	\N
22180	Noroozian 2013	\N	Tropisetron versus Placebo	\N	Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22181	McGinty 2013	\N	News Media Messages	\N	United States of America	\N	\N	\N	\N	\N	1797	\N	\N	\N	\N	\N
22182	Hoffman 2013	\N	repetitive Transcranial Magnetic Stimulation	\N	United States of America	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
22186	Ayesa 2013	\N	Haloperidol versus Olanzapine // Haloperidol versus Risperidone // Olanzapine versus Risperidone	\N	Spain	\N	\N	\N	\N	\N	79	\N	\N	\N	\N	\N
22189	Chien3 2013	\N	Mutual Support versus Psychoeducation // Psychoeducation // Mutual Support	\N	China	\N	\N	\N	\N	\N	135	\N	\N	\N	\N	\N
22190	Leff 2013	\N	Avatar Therapy	\N	UK	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	26	\N	\N	\N	\N	\N
22191	Chien4 2013	\N	Nurse-Led Psychoeducation	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
22192	Meszaros 2013	\N	Varenicline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
22193	Fan 2013	\N	Insulin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
22194	Lin 2013 b	\N	Clozapine versus Zotepine // Switching to Zotepine	\N	Taiwan	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
22196	Crespo 2013 b	\N	Aripiprazole versus Quetiapine // Aripiprazole versus Ziprasidone // Quetiapine versus Ziprasidone	\N	Spain	\N	\N	\N	\N	\N	249	\N	\N	\N	\N	\N
22197	Nasrallah 2013	\N	Lurasidone Dosage // Lurasidone versus Placebo	\N	Multi-Center // India // United States of America // Russia // Ukraine // Romania // Malaysia // France	\N	\N	\N	\r\nNotes2\r\n	\N	500	\N	\N	\N	\N	\N
22198	Attux 2013	\N	Lifestyle Wellness Program	\N	Brazil	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
22199	Lee4 2013	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
22201	Lozano 2013	\N	Motivational Feedback	\N	United States of America	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
22202	Janney1 2013	\N	Wight Management	\N	United States of America	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
22203	Hoshii 2013	\N	Subject-Chosen Occupational Therapy versus Therapist-Chosen Occupational Therapy	\N	Japan	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
22204	Petrovsky 2013	\N	Nicotine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
22205	Bechi 2013	\N	Cognitive Remediation versus Theory of Mind	\N	Italy	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22206	Khodaie 2013	\N	Granisetron versus Placebo	\N	Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22207	Tsang1 2013	\N	Therapist-Administered Treatment versus Virtual Reality-Based Vocational Training // Therapist-Administered Treatment // Virtual Reality-Based Vocational Training	\N	China	\N	\N	\N	\N	\N	95	\N	\N	\N	\N	\N
22209	Nunes1 2013	\N	Lodenafil Carbonate versus Placebo	\N	Brazil	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22210	Jarskog1 2013	\N	Davunetide Dosage // Davunetide versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
22214	Naber 2013 b	\N	Risperidone Dosage	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22215	Warren 2013	\N	Rimonabant versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
22216	Poyurovsky 2013	\N	Betahistine+Reboxetine versus Placebo	\N	Israel	\N	\N	\N	\N	\N	43	\N	\N	\N	\N	\N
22217	Lee 2013 b	\N	Cognitive Remediation	\N	Australia	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
22218	Modabbernia 2013	\N	Oxytocin versus Placebo	\N	Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22219	Gunduz 2013	\N	Pimozide versus Placebo Pimozide versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n	\N	32	\N	\N	\N	\N	\N
22220	Jin 2013	\N	Aripiprazole versus Olanzapine // Aripiprazole versus Quetiapine // Aripiprazole versus Risperidone // Olanzapine versus Quetiapine // Olanzapine versus Risperidone // Quetiapine versus Risperidone	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	332	\N	\N	\N	\N	\N
22221	McGorry 2013	\N	Cognitive Therapy+Placebo versus Risperidone+Cognitive Therapy // Cognitive Therapy+Placebo versus Supportive therapy+Placebo // Risperidone+Cognitive Therapy versus Supportive therapy+Placebo	\N	Australia	\N	\N	\N	\N	\N	115	\N	\N	\N	\N	\N
22223	Chukhin 2013	\N	Orlistat versus Placebo	\N	Finland	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
22224	Falkai 2013	\N	Aerobic Exercise (Cycling) versus Table Football	\N	Germany	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
22226	Leshner 2013	\N	Errorless Learning versus Symptom Management Training	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22228	McClure 2013	\N	Haloperidol versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	238	\N	\N	\N	\N	\N
22229	Lindenmayer 2013	\N	Social Cognition Training	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
22230	Sousa 2013	\N	Communication Intervention versus Control Group	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n	\N	90	\N	\N	\N	\N	\N
22232	Scheewe 2013	\N	Exercise Therapy versus Occupational Therapy	\N	The Netherlands	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
22233	D'Souza 2013	\N	Cognitive Retraining versus D-serine // Cognitive Retraining versus D-serine+Cognitive Retraining // Cognitive Retraining versus Placebo // Cognitive Retraining versus D-serine // D-serine versus D-serine+Cognitive Retraining // D-serine versus Placebo // D-serine+Cognitive Retraining versus Placebo	\N	United States of America // India // Multi-Center	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
22234	Woods 2013	\N	Glycine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
22237	Hansen1 2013	\N	Cognitive Adaptation Training	\N	Denmark	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
22240	Scheewe1 2013	\N	Exercise Therapy versus Occupational Therapy	\N	The Netherlands	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	63	\N	\N	\N	\N	\N
22241	Kahn 2013	\N	Exercise Therapy versus Occupational Therapy	\N	The Netherlands	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
22242	Georgieva 2013	\N	Involuntary Medication versus Seclusion	\N	The Netherlands	\N	\N	\N	\N	\N	520	\N	\N	\N	\N	\N
22243	Fan1 2013	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
22244	Ou 2013	\N	Olanzapine versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
22247	Ghiasi 2013	\N	Nicotine Patch versus Smoking	\N	Iran	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
22248	Oranje1 2013	\N	Clonidine versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22252	Jindal 2013	\N	Aripiprazole versus Olanzapine	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22254	Chaudhry 2013	\N	Ondansetron versus Simvastatin // Ondansetron versus Placebo // Simvastatin versus Placebo	\N	UK	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	216	\N	\N	\N	\N	\N
22255	Lam 2014	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22256	Semenikhin 2014	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22258	Zarea 2014	\N	Family-Centered Empowerment Training	\N	Iran	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
22259	NCT01964404 2014	\N	Dronabinol versus Marijuana // Dronabinol versus Placebo // Marijuana versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
22260	NCT01992913 2014	\N	Cognitive Behavioral Therapy+Cognitive Remediation versus Psychoeducation	\N	United States of America	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
22261	NCT01995864 2014	\N	Critical Time Intervention	\N	United States of America	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
22262	Kukla 2014	\N	Cognitive Behavioral Therapy	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22263	NCT02032680 2014	\N	E-health Family Psychoeducation versus In-person Family Psychoeducation	\N	United States of America	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
22264	NCT02008773 2014	\N	 Valacyclovir versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	175	\N	\N	\N	\N	\N
22265	NCT02006628 2014	\N	GWP42003 versus Placebo	\N	Poland // UK // Multi-Center	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
22267	NCT02034474 2014	\N	 Tocilizumab versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22268	NCT02019459 2014	\N	Low Nicotine Cigarettes versus Standard Nicotine Cigarettes	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
22271	Hou 2014	\N	Mindfulness-Based Stress Reduction Program versus Self-Help Health Education Booklet	\N	China	\N	\N	\N	\N	\N	141	\N	\N	\N	\N	\N
22274	Economou 2014	\N	Anti-Stigma Education	\N	Greece	\N	\N	\N	\N	\N	1081	\N	\N	\N	\N	\N
22276	van Oosterhout 2014	\N	Metacognitive Group Training	\N	The Netherlands	\N	\N	\N	\N	\N	154	\N	\N	\N	\N	\N
22277	Bratu 2014	\N	Acamprosate versus Counseling // Acamprosate versus Naltrexone // Counseling versus Naltrexone	\N	\N	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
22280	Denia 2014	\N	Clozapine versus Risperidone	\N	Spain	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
22282	PRIME	\N	Personalized Real-time Intervention for Motivational Enhancement	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n	\N	40	\N	\N	\N	\N	\N
22283	Rosenheck 2014	\N	Antipsychotic Drug versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	369	\N	\N	\N	\N	\N
22284	Pijnenborg 2014	\N	Group Wise Drill and Practice Cognitive Remediation Training versus Metacognitive Group Training	\N	The Netherlands	\N	\N	\N	\N	\N	121	\N	\N	\N	\N	\N
22286	McEvoy 2014	\N	Haloperidol Decanoate versus Paliperidone Palmitate	\N	United States of America	\N	\N	\N	\N	\N	290	\N	\N	\N	\N	\N
22287	Adams 2014a	\N	Physical Restraints versus Seclusion Room	\N	Brazil	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
22288	Csipke 2014	\N	Evidence-Based Therapies	\N	UK	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
22289	Crivelaro 2014	\N	Cognitive Remediation versus Recreational Activities	\N	Brazil	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
22291	Smith 2014 a	\N	Virtual Reality Job Interview Training	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
22292	Choi 2014	\N	Extrinsic Reward versus Intrinsic Reward	\N	United States of America	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
22293	Takeuchi 2014	\N	Perphenazine Dosage	\N	Multi-Center	\N	\N	\N	\N	\N	267	\N	\N	\N	\N	\N
22294	Schreiner 2014	\N	Long-Acting Antipsychotic Drug versus Paliperidone Palmitate	\N	Multi-Center	\N	\N	\N	\N	\N	769	\N	\N	\N	\N	\N
22297	Ganguli 2014	\N	Stepped Behavioral Treatment	\N	Canada	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22298	Cella 2014 b	\N	Social Cognition and Interaction Training	\N	UK	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
22300	Sanz 2014	\N	Clozapine versus Risperidone	\N	Spain	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22301	MÃ¼ller 2014	\N	Integrated Neurocognitive Therapy	\N	Switzerland	\N	\N	\N	\N	\N	91	\N	\N	\N	\N	\N
22302	Burshtein 2014	\N	Riloxifene versus Placebo	\N	Israel	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
22303	Hosford 2014 a	\N	TC-5619 versus Placebo	\N	United States of America // Russia // Ukraine // Hungry // Romania // Serbia // Multi-Center	\N	\N	\N	\N	\N	477	\N	\N	\N	\N	\N
22304	Rabinowitz 2014	\N	CYP-1020 versus Risperidone	\N	Israel	\N	\N	\N	\N	\N	269	\N	\N	\N	\N	\N
22305	Girgis 2014 a	\N	DAR-0100A Dosage // DAR-0100A versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
22307	Killackey 2014	\N	Individual Placement and Support	\N	Australia	\N	\N	\N	\N	\N	146	\N	\N	\N	\N	\N
22310	Yu 2014	\N	OMS643762 Dosage	\N	\N	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
22313	NCT01192867	\N	Bitopertin Dosage // Bitopertin versus Placebo	\N	Multi-Center	\N	\N	\N	\r\nNotes2\r\n	\N	627	\N	\N	\N	\N	\N
22314	Nuechterlein KH 2014	\N	Cognitive Remediation versus Healthy Behavior Training	\N	\N	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
22315	Reeder1 2014	\N	Cognitive Remediation	\N	UK	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
22317	Cantillon 2014	\N	RP5063 Dosage // RP5063 versus Placebo // Aripiprazole versus RP5063 // Aripiprazole versus Placebo	\N	\N	\N	\N	\N	\N	\N	234	\N	\N	\N	\N	\N
22319	Garrido 2014	\N	Cognitive Remediation	\N	Spain	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
22320	Vizzotto 2014	\N	Craft Activities versus Occupational Therapy	\N	Brazil	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
22321	Vanover1 2014	\N	ITI-007 Dosage // Risperidone versus Placebo // ITI-007 versus Placebo // ITI-007 versus Risperidone	\N	\N	\N	\N	\N	\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	\N	\N	\N	\N	\N	\N
22325	Michalopoulou 2014	\N	Modafinil versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
22327	Pijnenborg1 2014	\N	Cognitive Remediation Training versus Metacognitive Group Treatment	\N	The Netherlands	\N	\N	\N	\N	\N	134	\N	\N	\N	\N	\N
22328	Yuan 2014	\N	Aripiprazole versus Olanzapine // Aripiprazole versus Risperidone // Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
22329	Li 2014	\N	RBP-7000 Dosage	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
22330	Bhatia 2014	\N	Physical Exercise versus Yoga Training	\N	India	\N	\N	\N	\N	\N	234	\N	\N	\N	\N	\N
22332	Cacciotti 2014	\N	Oxytocin versus Placebo	\N	Australia	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
22333	CTRI-2014-07-004712	\N	Haloperidol+Promethazine versus Zuclopenthixol Acetate	\N	India	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	350	\N	\N	\N	\N	\N
22334	Puig 2014	\N	Cognitive Remediation	\N	Spain	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
22335	Ghanizadeh 2014	\N	Lovastatin versus Placebo	\N	Iran	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
22336	Birchwood 2014	\N	Cognitive Behavioral Therapy	\N	UK	\N	\N	\N	\N	\N	197	\N	\N	\N	\N	\N
22337	Mirabzadeh 2014	\N	Haloperidol versus Risperidone	\N	Iran	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
22339	NCT02098408	\N	Cognitive Remediation	\N	Denmark	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	126	\N	\N	\N	\N	\N
22341	NCT02091388 2014	\N	LY03004 versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
22342	NCT02090335	\N	Fitness Club Membership versus Health Promotion and Fitness	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	210	\N	\N	\N	\N	\N
22343	NCT02088983 2014	\N	CDP-Choline versus Placebo	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22344	NCT02086786 2014	\N	Risperidone Injection Location	\N	United States of America	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
22345	NCT02086162	\N	Educational Pamphlet versus Motivational Decision Support System	\N	United States of America	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
22346	NCT02085421 2014	\N	transcranial Direct Current Stimulation	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22347	NCT02079844 2014	\N	Roflumilast versus Placebo // Roflumilast Dosage	\N	UK	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
22348	NCT02074319	\N	Methotrexate versus Placebo	\N	Pakistan	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	100	\N	\N	\N	\N	\N
22349	NCT020370741 2014	\N	EVP-6308 versus Placebo // EVP-6308 Dosage	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22350	NCT02069392 2014	\N	Nicotine	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22351	NCT02067975 2014	\N	Tryptophan versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22352	NCT02062190 2014	\N	Resveratrol versus Placebo	\N	Brazil	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22353	NCT02054702	\N	Brexpiprazole	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	81	\N	\N	\N	\N	\N
22354	NCT02049021 2014	\N	ECT	\N	Brazil	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22355	NCT02047539	\N	Acetylsalicylic Acid (Aspirin) versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22356	NCT02040883 2014	\N	Tandospirone	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
22357	NCT02037581	\N	Integrated Care	\N	Germany	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
22358	JPRN-UMIN000012949	\N	Sensory Modulation Room	\N	Japan	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
22359	JPRN-JapicCTI-121929	\N	Bitopertin Dosage	\N	Japan	\N	\N	\N	\N	\N	165	\N	\N	\N	\N	\N
22361	IRCT2013102915206N1	\N	Herbal Medicine versus Placebo	\N	Iran	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22362	CTRI-2014-03-00	\N	Quetiapine Brand // Quetiapine Route	\N	India	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
22363	ChiCTR-TRC-14004160	\N	Oxytocin versus Placebo	\N	China	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
22364	ChiCTR-TRC-14004186	\N	Aripiprazole+Risperidone versus Aripiprazole+Paliperidone // Paliperidone versus Risperidone // Aripiprazole+Risperidone versus Paliperidone // Aripiprazole+Paliperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22365	ChiCTR-TRC-14004187	\N	Cognitive Behavioral Therapy	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
22366	ACTRN12614000175673	\N	Early Intervention	\N	Australia	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
22367	ACTRN1261400012 2014	\N	repetitive Transcranial Magnetic Stimulation Route	\N	Australia	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
22368	ISRCTN99485756	\N	Positive Memory Training	\N	UK	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
22369	ISRCTN19447796	\N	Structured lifestyle education	\N	UK	\N	\N	\N	\N	\N	412	\N	\N	\N	\N	\N
22370	ISRCTN06022197	\N	Cognitive Behavioral Therapy versus Antipsychotic Drug	\N	UK	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22371	ISRCTN23930628	\N	Neurofeedback	\N	Switzerland	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22372	Gumley 2014	\N	Early Signs Scale versus Fear of Recurrence Scale	\N	UK	\N	\N	\N	\N	\N	169	\N	\N	\N	\N	\N
22373	ISRCTN34871361	\N	Cognitive skills program	\N	Canada	\N	\N	\N	\N	\N	108	\N	\N	\N	\N	\N
22374	ISRCTN06180958	\N	Dimensions of Health-Depression-Drugs	\N	UK	\N	\N	\N	\N	\N	1383	\N	\N	\N	\N	\N
22375	ISRCTN06815355	\N	Attention Control Training	\N	UK	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22376	ISRCTN88145142	\N	Enhanced Management	\N	UK	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
22377	ISRCTN16488358	\N	Care Planning Training	\N	UK	\N	\N	\N	\N	\N	480	\N	\N	\N	\N	\N
22378	ISRCTN34966555	\N	Cognitive Behavioral Therapy versus Monitoring Symptoms App	\N	UK	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
22379	ACTRN1261400037 2014	\N	Dancing Therapy versus Exercise Training	\N	Greece	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
22380	ACTRN12614000457640	\N	Mental Health Experience Co-design	\N	Australia	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	342	\N	\N	\N	\N	\N
22381	CTRI-2014-04-004521	\N	Lurasidone Dosage // Lurasidone versus Quetiapine	\N	India	\N	\N	\N	\N	\N	192	\N	\N	\N	\N	\N
22382	ChiCTR-TRC-14004451	\N	repetitive Transcranial Magnetic Stimulation	\N	China	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
22383	ChiCTR-TRC-14004854	\N	Olanzapine versus Paliperidone	\N	China	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
22384	CTRI-2014-04-00 b	\N	Clozapine Brand	\N	India	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
22385	DRKS00006091 2014	\N	Medication training programme	\N	Germany	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
22387	IRCT201203129267N1	\N	Psychosocial intervention	\N	Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22388	IRCT20140312110 2014	\N	Ondanstrone versus Placebo	\N	Iran	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
22389	IRCT20140323170 2014	\N	Aromatherapy	\N	Iran	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
22390	IRCT2014041317246N1	\N	Typical Antipsychotic Drug versus Placebo	\N	Iran	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22391	JPRN-UMIN000013746	\N	Exercise versus Yoga Therapy	\N	Japan	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22392	JPRN4 2014	\N	Nutrition education	\N	Japan	\N	\N	\N	\N	\N	540	\N	\N	\N	\N	\N
22393	ISRCTN43548483	\N	Motivational Intervention	\N	UK	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
22395	NCT02088060 2014	\N	Cannabidiol versus Placebo // Cannabidiol versus Olanzapine // Olanzapine versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
22396	NCT02095457 2014	\N	Frequent monitoring and feedback versus Infrequent monitoring and feedback 	\N	Israel	\N	\N	\N	\N	\N	900	\N	\N	\N	\N	\N
22397	NCT02097563 2014	\N	High Intensity Family-Focused Therapy versus Low Intensity Family-Focused Therapy	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
22398	NCT02101372 2014	\N	Psychoeducation	\N	Spain	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22399	NCT02102113 2014	\N	delta 9-tetrahydrocannabinol Dosage // delta 9-tetrahydrocannabinol versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
22400	NCT02104752 2014	\N	Curcumin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
22401	NCT02109562 2014	\N	RBP-7000 versus Placebo // RBP-7000 Dosage // RBP-7000 versus Risperidone // Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	339	\N	\N	\N	\N	\N
22402	NCT02114593 2014	\N	Parent support program	\N	Sweden	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
22403	NCT02118610 2014	\N	L-tetrahydropalmatine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22404	NCT02124811 2014	\N	Minocycline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
22405	NCT02127879 2014	\N	repetitive Transcranial Magnetic Stimulation	\N	Czech	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22407	NCT02130596 2014	\N	Behavioral Intervention versus Nutritional Counselling 	\N	Canada	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
22408	NCT02131116 2014	\N	Metacognitive Therapy	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22409	NCT02131129 2014	\N	repetitive Transcranial Magnetic Stimulation	\N	United States of America	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22410	NCT02134418 2014	\N	Cognitive Behavioral Therapy	\N	Israel	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
22411	NCT02146547 2014	\N	Aripiprazole versus Aripiprazole Depot // Aripiprazole versus Paliperidone // Aripiprazole versus Paliperidone Palmitate // Aripiprazole Depot versus Paliperidone // Aripiprazole Depot versus Paliperidone Palmitate // Paliperidone versus Paliperidone Palmitate	\N	The Netherlands	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
22412	NCT02151656 2014	\N	F17464 versus Placebo	\N	France // Hungary // Latvia // Romania // Multi-Center	\N	\N	\N	\N	\N	142	\N	\N	\N	\N	\N
22413	NCT02155699 2014	\N	Exercise Intensity	\N	United States of America	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
22414	NCT02156908 2014	\N	D-Serine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
22415	NCT02159001 2014	\N	Delayed ECT versus Immadiate ECT	\N	Finland	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22416	NCT02161718 2014	\N	Olanzapine+Samidorphan (ALKS 3831) versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	450	\N	\N	\N	\N	\N
22417	NCT02164981 2014	\N	Sodium Nitroprusside versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22418	NCT02167620 2014	\N	Metformin versus Placebo	\N	Canada	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
22419	NCT02168166 2014	\N	Executive Function Training	\N	Canada	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22420	NCT02170051	\N	Cognitive Behavioral Social Skills Training-Compensatory Cognitive Training // Cognitive Behavioral Social Skills Training-Compensatory Cognitive Training versus Goal focused supportive contact	\N	United States of America	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
22421	NCT02174510	\N	Lurasidone Dosage // Lurasidone versus Placebo	\N	China	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
22422	NCT02174523	\N	Lurasidone versus Placebo	\N	China	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
22423	NCT02175251 2014	\N	repetitive Transcranial Magnetic Stimulation Frequency	\N	France	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
22424	NCT02176044 2014	\N	Sodium Nitroprusside versus Placebo	\N	UK	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22425	NCT02181777 2014	\N	Group Training for Social Skills	\N	UK	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22426	NCT02181803 2014	\N	MK-8189 Dosage // MK-8189 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
22427	NCT02186769 2014	\N	LY03004 versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
22428	NCT02188121 2014	\N	Atorvastatin+Valsartan	\N	United States of America	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
22429	Moritz 2014	\N	Group Metacognitive Training versus Neuropsychological Training Group	\N	Germany	\N	\N	\N	\N	\N	150	\N	\N	\N	\N	\N
22430	Salman 2014	\N	Collaborative Care	\N	Pakistan	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
22431	Palm 2014	\N	transcranial Direct Current Stimulation	\N	Germany	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22432	Nordentoft 2014	\N	Care Coordinator // Life Style Change Team // Care Coordinator versus Life Style Change Team	\N	Denmark	\N	\N	\N	\N	\N	450	\N	\N	\N	\N	\N
22433	NCT01981356	\N	Acceptance and Commitment Therapy	\N	United States of America	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
22434	Kawanishi 2014	\N	Assertive Case Management	\N	Japan	\N	\N	\N	\N	\N	914	\N	\N	\N	\N	\N
22436	Chaudhry 2014	\N	Ondansetron versus Simvastatin // Ondansetron versus Placebo // Simvastatin versus Placebo	\N	Pakistan	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
22437	NCT01192906	\N	Bitopertin Dosage // Bitopertin versus Placebo	\N	Multi-Center // United States of America	\N	\N	\N	\r\nNotes2\r\n	\N	605	\N	\N	\N	\N	\N
22440	Jahanian 2014	\N	Rivastigmine versus Placebo	\N	Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22441	Zeinoddini 2014	\N	L-lysine versus Placebo	\N	Iran	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
22442	Zhu 2014	\N	Donepezil versus Placebo	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
22443	Barekatain 2014	\N	Aftercare Services	\N	Iran	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
22444	Kantrowitz 2014	\N	D-Serine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22445	Hatta 2014	\N	Augmentation with Risperidone versus Switching to Risperidone // Augmentation with Olanzapine versus Switching to Olanzapine	\N	Japan	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
22447	Fleischhacker W 2014	\N	Aripiprazole Dosage // Aripiprazole Route	\N	\N	\N	\N	\N	\N	\N	662	\N	\N	\N	\N	\N
22449	Sytema 2014	\N	Assertive Community Treatment versus Evidence-Based Interventions	\N	The Netherlands	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	159	\N	\N	\N	\N	\N
22450	Jerome 2014	\N	Weight Loss Program	\N	United States of America	\N	\N	\N	\N	\N	291	\N	\N	\N	\N	\N
22452	Muller 2014	\N	Music (Classical) versus Music (Adapted to Brain Rhythm Anomalies)	\N	Germany	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22453	Davis 2014 a	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
22454	Mayabhate 2014	\N	Aripiprazole versus Paliperidone // Aripiprazole versus Placebo // Paliperidone versus Placebo	\N	India	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
22455	Siever 2014	\N	DAR-0100A versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
22456	Rabany 2014	\N	Deep-Transcranial Magnetic Stimulation	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22457	Lopez 2014	\N	Multimodal Intervention	\N	Colombia	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
22458	Fu 2014	\N	Paliperidone Palmitate versus Placebo	\N	\N	\N	\N	\N	\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	334	\N	\N	\N	\N	\N
22459	Ganguli1 2014	\N	Stepped Behavioral Treatment	\N	Canada	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22460	Filho 2014	\N	repetitive Transcranial Magnetic Stimulation	\N	Brazil	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22461	Angelo 2014	\N	Contingency Management	\N	United States of America	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
22462	Morozova 2014	\N	CD-008-0173 versus Placebo	\N	Russia	\N	\N	\N	\N	\N	47	\N	\N	\N	\N	\N
22463	Gerretsen 2014	\N	Caloric Vestibular Stimulation	\N	Canada	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22464	Demanuele 2014	\N	Eszopiclone versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n	\N	21	\N	\N	\N	\N	\N
22466	Liang 2014	\N	Aripiprazole versus Placebo	\N	China	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
22467	Chen 2014 a	\N	Aripiprazole versus Placebo	\N	China	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
22468	Tarrier 2014	\N	Cognitive Behavioural Treatment	\N	UK	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
22469	Ostergaard 2014	\N	Cognitive Remediation versus Early Intervention	\N	Denmark	\N	\N	\N	\N	\N	98	\N	\N	\N	\N	\N
22470	Kidd 2014	\N	Cognitive Remediation	\N	Canada	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
22471	Patterson 2014	\N	Housing First	\N	Canada	\N	\N	\N	\N	\N	497	\N	\N	\N	\N	\N
22474	Detke 2014 a	\N	Olanzapine Route	\N	\N	\N	\N	\N	\N	\N	524	\N	\N	\N	\N	\N
22475	Beebe 2014	\N	Telephone versus Text Message // Telephone versus Telephone+Text Message // Telephone+Text Message versus Text Message 	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22476	Zhang 2014	\N	Psychosocial Intervention	\N	China	\N	\N	\N	\N	\N	1268	\N	\N	\N	\N	\N
22477	Krakowski 2014	\N	Clozapine versus Olanzapine // Clozapine versus Haloperidol // Haloperidol versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
22478	Tjia 2014	\N	Dissemination Intensity of Evidence-Based Antipsychotic Prescribing Guidelines	\N	United States of America	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
22480	Usall 2014	\N	Citalopram versus Reboxetine // Citalopram versus Placebo // Reboxetine versus Placebo	\N	Spain	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
22481	Rabany1 2014	\N	Deep-Transcranial Magnetic Stimulation	\N	Israel	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22482	Chan 2014 a	\N	Haloperidol versus Olanzapine	\N	Taiwan	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
22484	Hori 2014	\N	Blonanserin versus Risperidone	\N	Japan	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
22487	Malm 2014	\N	Integrated Care versus Rational Rehabilitation	\N	Sweden	\N	\N	\N	\N	\N	84	\N	\N	\N	\N	\N
22488	Khaleghparast 2014	\N	Discharge Planning	\N	Iran	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
22489	Michon 2014	\N	Individual Placement and Support versus Traditional Vocational Rehabilitation	\N	The Netherlands	\N	\N	\N	\N	\N	151	\N	\N	\N	\N	\N
22491	Zhou 2014	\N	Self-Management Intervention Self-Management Training versus Treatment As Usual	\N	China	\N	\N	\N	\r\nUser defined 3\r\n	\N	201	\N	\N	\N	\N	\N
22492	NCT01667601	\N	Conventional Psychoeducation versus Mindfulness-Based Psychoeducation // Conventional Psychoeducation // Mindfulness-Based Psychoeducation	\N	China	\N	\N	\N	\N	\N	107	\N	\N	\N	\N	\N
22493	Yao 2014	\N	Day Nursing Care	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
22494	Nemoto 2014	\N	Escitalopram versus Paroxetine	\N	Japan	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
22495	Gobbi 2014	\N	Olanzapine versus Quetiapine	\N	Canada	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
22496	Matsuda 2014	\N	Neurocognitive Rehabilitation	\N	Japan	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
22498	Smith1 2014	\N	transcranial Direct Current Stimulation	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
22499	de 2014	\N	Tadalafil versus Placebo	\N	The Netherlands	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
22500	Lovell 2014	\N	Healthy Living	\N	UK	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
22502	Marvin 2014	\N	Family Focused Therapy versus Enhanced Care	\N	United States of America	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
22503	Miklowitz 2014	\N	Family Focused Therapy versus Enhanced Care	\N	United States of America	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
22504	Grocke 2014	\N	Group Music Therapy	\N	Australia	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
22505	Tek 2014 a	\N	Eszopiclone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
22508	Leung 2014	\N	Depletion versus Non-Depletion // Glucose versus Placebo	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22509	Quee 2014	\N	Cognitive Adaptation Training	\N	The Netherlands	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22510	Kinon 2014	\N	Antipsychotic Drug versus Olanzapine	\N	United States of America	\N	\N	\N	\N	\N	293	\N	\N	\N	\N	\N
22512	Calvo 2014	\N	Nonstructured Group versus Psychoeducational Problem-Solving Group	\N	Spain	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	55	\N	\N	\N	\N	\N
22514	Cella 2014 a	\N	Cognitive Remediation	\N	UK	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
22515	Vanover2 2014	\N	ITI-007 Dosage // ITI-007 versus Risperidone // ITI-007 versus Placebo // Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22516	Bartzokis 2014	\N	Risperidone Route	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
22517	Girgis 2014 b	\N	DAR-0100A Dosage // DAR-0100A versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
22518	Brunelin 2014	\N	transcranial Direct Current Stimulation	\N	France	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
22519	O'Brien 2014	\N	NBI-98854 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22522	Van1 2014	\N	Metacognitive Reflection and Insight Therapy	\N	The Netherlands	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22523	Salzer 2014	\N	Interviewer-administrated Data Collection versus Self-administered Data Collection	\N	United States of America	\N	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
22524	Romo 2014	\N	Melatonin versus Placebo	\N	Mexico	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
22525	Woods 2014	\N	D-Serine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
22529	Tybura 2012	\N	Olanzapine versus Perazine // Olanzapine versus Ziprasidone // Perazine versus Ziprasidone	\N	Poland	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	191	\N	\N	\N	\N	\N
22530	Li 2014 a	\N	Quetiapine Fumarate ER Dosage	\N	China	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
22531	Davis 2014 b	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
22532	Barrowclough 2014	\N	Motivational Interviewing (Brief) versus Motivational Interviewing (Long)	\N	UK	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
22533	Dang 2014	\N	Cognitive Training	\N	China	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22534	Graham 2014	\N	Motivational Intervention	\N	UK	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
22537	Kianimehr 2014	\N	Raloxifene versus Placebo	\N	Iran	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
22538	Liu 2014	\N	Quetiapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
22539	Zhao 2014	\N	repetitive Transcranial Magnetic Stimulation // repetitive Transcranial Magnetic Stimulation Frequency	\N	China	\N	\N	\N	\N	\N	96	\N	\N	\N	\N	\N
22540	Oshima 2014	\N	Conventional Vocational Services versus Individual Placement and Support	\N	Japan	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
22541	Umbricht 2014 a	\N	RG3487 versus Placebo // RG3487 Dosage	\N	\N	\N	\N	\N	\N	\N	215	\N	\N	\N	\N	\N
22542	Wolwer 2014	\N	repetitive Transcranial Magnetic Stimulation	\N	Germany	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
22543	Prikryl 2014	\N	repetitive Transcranial Magnetic Stimulation	\N	Czech	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
22544	Salyers 2014	\N	Illness Management and Recovery versus Problem Solving Groups	\N	United States of America	\N	\N	\N	\N	\N	118	\N	\N	\N	\N	\N
22546	Cleton 2014	\N	Paliperidone Palmitate Injection Location	\N	\N	\N	\N	\N	\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	201	\N	\N	\N	\N	\N
22547	Fadai 2014	\N	Saffron Aqueous Extract versus Placebo	\N	Iran	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
22549	Pratts 2014	\N	Asenapine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
22550	Kilbourne 2014	\N	Life Goals Collaborative Care // Collaborative Care	\N	United States of America	\N	\N	\N	\N	\N	284	\N	\N	\N	\N	\N
22552	Favrod 2014	\N	Metacognitive Training	\N	Switzerland	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
22554	Craig 2014	\N	Motivational Interviewing	\N	UK	\N	\N	\N	\N	\N	159	\N	\N	\N	\N	\N
22555	Schrank 2014	\N	Positive Psychotherapy	\N	UK	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n	\N	80	\N	\N	\N	\N	\N
22557	Ma 2014	\N	Paliperidone Palmitate versus Risperidone	\N	China	\N	\N	\N	\N	\N	147	\N	\N	\N	\N	\N
22558	Humm 2014	\N	Job Interview Training	\N	United States of America	\N	\N	\N	\N	\N	37	\N	\N	\N	\N	\N
22560	Rosell 2014	\N	DAR-0100A versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	16	\N	\N	\N	\N	\N
22561	Velligan 2014	\N	Cognitive Adaptation Training versus Cognitive Behavioral Therapy // Cognitive Adaptation Training versus Multi-modal Cognitive Therapy // Cognitive Adaptation Training // Cognitive Behavioral Therapy versus Multi-modal Cognitive Therapy // Cognitive Behavioral Therapy // Multi-modal Cognitive Therapy	\N	UK	\N	\N	\N	\N	\N	166	\N	\N	\N	\N	\N
22562	NCT02194933 2014	\N	Brexpiprazole Dosage	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22563	NCT02195700 2014	\N	SD-809 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
22564	NCT02197286	\N	Vitamin D versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
22565	NCT02204787 2014	\N	transcranial Direct Current Stimulation	\N	France	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22566	NCT02204956	\N	Brief Education versus Extended Care	\N	United States of America	\N	\N	\N	\N	\N	422	\N	\N	\N	\N	\N
22567	NCT02205099 2014	\N	SKL15508 versus Placebo // SKL15508 Dosage	\N	United States of America	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
22747	Kilian 2015	\N	Agomelatine	\N	South Africa	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22568	NCT02205684	\N	Aerobic Exercise (Physical Interventions) versus Game (Computer)	\N	Norway	\N	\N	\N	\N	\N	110	\N	\N	\N	\N	\N
22569	NCT02222909 2014	\N	Community-based organizations+Co-developed IT intervention versus Community-based organizations	\N	United States of America	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
22570	NCT02227160	\N	Outpatient Counseling and Support Groups versus Psychosocial Group Intervention	\N	United States of America	\N	\N	\N	\N	\N	190	\N	\N	\N	\N	\N
22571	NCT02230384 2014	\N	JNJ versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22573	NCT02237235 2014	\N	Magnesium Threonate versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22574	NCT02237417 2014	\N	Aripiprazole	\N	United States of America	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
22575	NCT02240173 2014	\N	Sorghum Bicolor (JOBELYN) versus Placebo	\N	Nigeria	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
22576	NCT02240446 2014	\N	transcranial Direct Current Stimulation	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22577	NCT02188732	\N	Community Based Health Home+Self-Management Training versus Community Based Health Home // Community Based Health Home+Telehealth versus Community Based Health Home // Community Based Health Home+Self-Management Training versus Community Based Health Home+Telehealth	\N	United States of America	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
22578	ACTRN1261400095 2014	\N	PULSAR (Principles Unite Local Services Assisting Recovery)	\N	Australia	\N	\N	\N	\N	\N	756	\N	\N	\N	\N	\N
22579	CTRI-2014-07-00 b	\N	Ranitidine Dosage	\N	India	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	75	\N	\N	\N	\N	\N
22580	CTRI-2014-07-002 201	\N	Continuing Anticonvulsant therapy versus Stopping Anticonvulsant therapy	\N	India	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
22582	IRCT20140715155 2014	\N	Cilostazol versus Placebo	\N	Iran	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22583	ISRCTN02672532	\N	Being treated at home	\N	Germany	\N	\N	\N	\N	\N	292	\N	\N	\N	\N	\N
22584	ISRCTN12929657	\N	Virtual Reality	\N	The Netherlands	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
22585	ISRCTN47185233	\N	CORE Crisis Resolution Teams Resource Kit	\N	UK	\N	\N	\N	\N	\N	1265	\N	\N	\N	\N	\N
22587	JPRN6 2014	\N	Paliperidome Palmitate versus Risperidone	\N	Japan	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
22588	JPRN7 2014	\N	Metacognitive Training	\N	Japan	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22589	NCT01920685 2014	\N	Delayed Computerised Reasoning and Anxiety Intervention versus Immediate Computerised Reasoning and Anxiety Intervention	\N	UK	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
22590	NTR4716 2014	\N	Clonidine versus Placebo	\N	The Netherlands	\N	\N	\N	\N	\N	75	\N	\N	\N	\N	\N
22591	Silverstein 2014	\N	Attention Shaping Precedures versus UCLA Basic Conversations Skills Module	\N	United States of America	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
22592	Garety 2014	\N	Computerized Reasoning Training	\N	UK	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
22593	Pagsberg 2014	\N	Aripiprazole versus Quetiapine	\N	Denmark	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
22595	Emsley 2014	\N	Omega-3 Fatty Acid versus Placebo	\N	South Africa	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
22596	Li 2014 b	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	279	\N	\N	\N	\N	\N
22597	Kaplan 2014	\N	Healthy Lifestyle Education versus Parental Education	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22598	Waller 2014	\N	Cognitive Behavioral Therapy	\N	UK	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	66	\N	\N	\N	\N	\N
22599	Briki 2014	\N	Metacognitive Training versus Supportive Therapy	\N	France	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
22600	Dickerson 2014	\N	Probiotic Supplementation // Placebo	\N	United States of America	\N	\N	\N	\N	\N	65	\N	\N	\N	\N	\N
22601	Miyaoka 2014	\N	Yokukansan versus Placebo	\N	Japan	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
22603	McEvoy 2014a	\N	Haloperidol Decanoate versus Paliperidone Palmitate	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	311	\N	\N	\N	\N	\N
22604	Gibson 2014	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
22605	Adams 2014b	\N	Aripiprazole versus Pomaglumetad Methionil (LY2140023 Monohydrate)	\N	Multi-Center	\N	\N	\N	\N	\N	678	\N	\N	\N	\N	\N
22606	Kulkarni 2014	\N	Estradiol versus Placebo // Estradiol Dosage	\N	Australia	\N	\N	\N	\N	\N	183	\N	\N	\N	\N	\N
22608	NCT01869660	\N	Shared Decision Making versus Treatment as Usual	\N	Japan	\N	\N	\N	\N	\N	58	\N	\N	\N	\N	\N
22612	JPRN-UMIN000004511	\N	Continuing Regimen versus Dosage Reduction	\N	Japan	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n\r\nUser defined field 9\r\n\r\nUser defined field 10\r\n	\N	163	\N	\N	\N	\N	\N
22613	Abhishekh 2014	\N	ECT Location	\N	India	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
22614	von 2014	\N	Adherence Therapy	\N	Thailand	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
22615	Hasson 2014	\N	Social Cognition and Interaction Training versus Social Mentoring	\N	Israel	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
22617	Larsen 2014	\N	Liraglutide versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
22619	Wang 2014	\N	Artemether versus Placebo	\N	China	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
22620	Hosseini 2014	\N	Desmopressin versus Palcebo	\N	Iran	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
22621	Meltzer 2014	\N	Risperidone Dosage	\N	United States of America	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
22622	Schnell 2014	\N	Clozapine versus Ziprasidone	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22623	Kuokkanen 2014	\N	Metacognitive Group Training	\N	Finland	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22690	Kelly 2014	\N	Peer Navigatation	\N	United States of America	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
22624	Shen 2014	\N	Vabicaserin Dosage // Olanzapine versus Vabicaserin // Vabicaserin versus Placebo // Olanzapine versus Placebo	\N	United States of America // India // Multi-Center	\N	\N	\N	\N	\N	313	\N	\N	\N	\N	\N
22625	Modabbernia 2014	\N	Melatonin versus Placebo	\N	Iran	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
22626	Si 2014	\N	Paliperidone Palmitate Dosage Paliperidone Palmitate Dosage	\N	China	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
22628	Rui 2014	\N	Paliperidone Extended Release versus Placebo	\N	China	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
22629	Botha 2014	\N	Assertive Community Treatment	\N	South Africa	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22630	NCT01297985	\N	Illness Self-management	\N	United States of America	\N	\N	\N	\N	\N	428	\N	\N	\N	\N	\N
22633	Szeszko 2014	\N	Aripiprazole versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
22634	Ritsner 2014 a	\N	Pregnenolone versus Placebo	\N	Israel	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22635	Weiden 2014	\N	Switching to Iloperidone	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	500	\N	\N	\N	\N	\N
22636	Stobbe 2014	\N	Assertive Community Treatment	\N	The Netherlands	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
22637	Schoemaker 2014	\N	Org 25935 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	215	\N	\N	\N	\N	\N
22638	Litman 2014 a	\N	AZD2624 versus Placebo // Olanzapine versus Placebo // AZD2624 versus Olanzapine	\N	Canada	\N	\N	\N	\N	\N	106	\N	\N	\N	\N	\N
22640	Mosolov 2014	\N	Olanzapine versus Risperidone // Atypical Antipsychotic Drug versus Typical Antipsychotic Drug	\N	Russia	\N	\N	\N	\N	\N	104	\N	\N	\N	\N	\N
22641	Morrison 2014	\N	Cognitive therapy	\N	UK	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
22642	Gold 2014	\N	Facility-Based Clubhouse versus Program of Assertive Community Treatment	\N	United States of America	\N	\N	\N	\N	\N	167	\N	\N	\N	\N	\N
22643	Liu1 2014	\N	Minocycline versus Placebo	\N	China	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
22644	Happell 2014 a	\N	Cardiometabolic Health Nurse	\N	Australia	\N	\N	\N	\N	\N	155	\N	\N	\N	\N	\N
22645	Ernst Nielsen 2014	\N	Olanzapine versus Sertindole	\N	Denmark	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
22646	Cain 2014	\N	D-Cycloserine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22647	Khodaie 2014	\N	Minocycline versus Placebo	\N	Iran	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22649	Bogenschutz 2014	\N	Facilitation Therapy	\N	United States of America	\N	\N	\N	\N	\N	121	\N	\N	\N	\N	\N
22651	Druss 2014	\N	Electronic Personal Health Record	\N	United States of America	\N	\N	\N	\N	\N	170	\N	\N	\N	\N	\N
22652	Gong 2014	\N	Village Doctor-Assisted Case Management	\N	China	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22654	Preskorn 2014	\N	EVP-6124 Dosage // EVP-6124 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
22655	Maat 2014	\N	Aripiprazole versus Risperidone	\N	The Netherlands	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
22656	Roberts 2014	\N	Social Cognition and Interaction Training	\N	United States of America	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
22657	Durgam1 2014	\N	Cariprazine Dosage // Cariprazine versus Placebo // Cariprazine versus Risperidone // Risperidone versus Placebo	\N	United States of America // India // Russia // Ukraine // Malaysia // Multi-Center	\N	\N	\N	\N	\N	732	\N	\N	\N	\N	\N
22658	Ishoy 2014	\N	Glucagon-like peptide-1 (GLP-1) versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22659	Evins 2014	\N	Varenicline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
22660	Leatherman 2014	\N	Oral Antipsychotic Drug versus Risperidone	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	382	\N	\N	\N	\N	\N
22662	Boege 2014	\N	Home Treatment (BeZuHG)	\N	Germany	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
22664	Huerta 2014	\N	Raloxifene versus Placebo	\N	Spain	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
22667	Kluge 2014	\N	Clozapine versus Olanzapine	\N	Germany	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22668	Zhou1 2014	\N	Aripiprazole versus Olanzapine // Aripiprazole versus Risperidone // Olanzapine versus Risperidone	\N	China	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
22669	Biedermann 2014	\N	Sibutramine versus Placebo	\N	Austria	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
22670	Bartels 2014	\N	Integrated Illness Management and Recovery	\N	United States of America	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
22671	ACTRN12609001039279	\N	Contingency Management+Motivational Interviewing and Cognitive Behavioral Therapy	\N	Australia	\N	\N	\N	\N	\N	236	\N	\N	\N	\N	\N
22672	Kaphzan 2014	\N	Entacapone versus Placebo	\N	Israel	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22675	Taveira 2014	\N	Naltrexone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22676	Smeerdijk 2014	\N	Family Motivational Intervention versus Routine Family Support	\N	The Netherlands	\N	\N	\N	\N	\N	97	\N	\N	\N	\N	\N
22677	Muscatello 2014	\N	Ziprasidone versus Placebo	\N	Italy	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22680	Roh 2014	\N	Mecamylamine versus Varenicline	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22684	Quisenaerts 2014	\N	Nicotine versus Placebo	\N	Belgium	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
22685	Farokhnia 2014	\N	Riluzole versus Placebo	\N	Iran	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	50	\N	\N	\N	\N	\N
22686	Fallahi 2014	\N	Group Psychoeducational Programme	\N	Iran	\N	\N	\N	\N	\N	71	\N	\N	\N	\N	\N
22687	Crespo 2014	\N	Aripiprazole versus Quetiapine // Aripiprazole versus Ziprasidone // Quetiapine versus Ziprasidone	\N	Spain	\N	\N	\N	\N	\N	202	\N	\N	\N	\N	\N
22688	Happell1 2014	\N	Cardiometabolic Health Nurse	\N	Australia	\N	\N	\N	\N	\N	154	\N	\N	\N	\N	\N
22689	Rakesh 2014	\N	ECT Location	\N	India	\N	\N	\N	\N	\N	114	\N	\N	\N	\N	\N
22691	Sanchez 2014	\N	Neuropsychological Rehabilitation	\N	Spain	\N	\N	\N	\N	\N	92	\N	\N	\N	\N	\N
22692	Chen 2014 b	\N	Implementation Intention Condition versus Typical Instruction Condition	\N	China	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
22694	Pelayo 2014	\N	Haloperidol versus Olanzapine // Haloperidol versus Risperidone // Olanzapine versus Risperidone	\N	Spain	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
22697	Arvidsson 2014	\N	Two-Way Communication Checklist (2-COM) versus Treatment as Usual	\N	Sweden	\N	\N	\N	\N	\N	191	\N	\N	\N	\N	\N
22698	Cordes 2014	\N	Weight Management Program	\N	Germany	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
22699	NCT02160249 2015	\N	Community Based Rehabilitation versus Family Based Care	\N	Ethiopia	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
22700	NCT02214667 2015	\N	Motivational Interviewing+Group Therapy	\N	United States of America	\N	\N	\N	\N	\N	72	\N	\N	\N	\N	\N
22701	NCT02234258 2015	\N	Cognitive Behavioral Social Skills Training versus Psychoeducation	\N	United States of America	\N	\N	\N	\N	\N	225	\N	\N	\N	\N	\N
22702	Huang 2005	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22703	Granholm 2008	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22704	Jeppesen 2001	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22705	Petersen 2005	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22706	Liang 2007	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22707	Marder 1994	\N	Risperidone Dosage // Haloperidol versus Risperidone // Haloperidol versus Placebo // Risperidone versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n	\N	523	\N	\N	\N	\N	\N
22708	NCT01193166	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22710	Wynn 2014	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
22712	Weickert 2014	\N	Raloxifene versus Placebo	\N	Australia	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	93	\N	\N	\N	\N	\N
22713	Vanover 2014	\N	ITI-007 versus Placebo // ITI-007 versus Risperidone // Risperidone versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22714	Takeuchi 2014a	\N	Olanzapine or Risperidone Dosage Maintenance versus Olanzapine or Risperidone Dosage Reduction	\N	Canada	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
22715	Szeszko 2012	\N	Aripiprazole versus Risperidone	\N	United States of America	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
22717	Smit 2008	\N	Omega-3 Fatty Acid	\N	South Africa	\N	\N	\N	\N	\N	Not Reported	\N	\N	\N	\N	\N
22718	Silverman 2013	\N	Education versus Educational Music Therapy // Education versus Music Activity // Educational Music Therapy versus Music Activity	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
22719	Silverman 2012	\N	Group Songwriting versus Psychoeducation // Group Songwriting versus Recreational Music Therapy // Psychoeducation versus Recreational Music Therapy	\N	United States of America	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
22720	Shuang 2014	\N	Iloperidone versus Risperidone	\N	China	\N	\N	\N	\N	\N	260	\N	\N	\N	\N	\N
22721	Shrestha 2007	\N	Esmolol versus Labetalol // Esmolol versus Placebo // Labetalol versus Placebo	\N	Nepal	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
22723	Schobel 2012	\N	Gabapentin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22724	Roffman 2014	\N	5-MTG versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22725	Prinsloo 2007	\N	LY2140023 Dosage // LY2140023 versus Olanzapine // LY2140023 versus Placebo	\N	South Africa	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22726	NCT02349880	\N	Cognitive Training versus Shared Decision Making Training	\N	Germany	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
22727	NCT02342210	\N	Mindfulness Ambassador Council for Early Psychosis	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22728	NCT02341131 2015	\N	Cognitive Remediation Therapy versus Psychoeducation	\N	Spain	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22729	NCT02340559 2015	\N	Metacognitive Training versus Psychoeducation	\N	Spain	\N	\N	\N	\N	\N	122	\N	\N	\N	\N	\N
22730	NCT02337439 2015	\N	Visual Information Processing Training	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22731	NCT02336581	\N	Acceptance and Commitment Therapy	\N	United States of America	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22732	NCT02334228 2015	\N	Lifestyles	\N	United States of America	\N	\N	\N	\N	\N	133	\N	\N	\N	\N	\N
22733	NCT02332798 2014	\N	PF04958242 versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
22734	NCT02329431 2014	\N	Activation curriculum (Parents) versus Support Group	\N	United States of America	\N	\N	\N	\N	\N	270	\N	\N	\N	\N	\N
22735	NCT02326389 2014	\N	Cognitive Remediation versus Exercise	\N	United States of America	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22736	NCT02322437 2014	\N	Home Treatment	\N	Switzerland	\N	\N	\N	\N	\N	500	\N	\N	\N	\N	\N
22737	NCT02320032 2014	\N	Aripiprazole	\N	United States of America	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
22738	NCT02319746 2014	\N	Cognitive Behavioural Therapy versus Psychoeducation	\N	Spain	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
22739	NCT02313493 2014	\N	Baby Triple P	\N	Germany	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
22740	NCT02308956 2014	\N	Integrated Mental Health in Primary Care // Psychiatric Nurse-Led Specialist Care	\N	United Kingdom	\N	\N	\N	\N	\N	324	\N	\N	\N	\N	\N
22741	NCT02305823 2014	\N	Aripiprazole versus Quetiapine // Aripiprazole versus Ziprasidone // Quetiapine versus Ziprasidone	\N	Spain	\N	\N	\N	\N	\N	203	\N	\N	\N	\N	\N
22742	NCT02304432 2014	\N	D-Cycloserine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	2	\N	\N	\N	\N	\N
22743	Marenco 2014	\N	Antipsychotic Drug versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
22745	Kriel 2006	\N	Aripiprazole versus Placebo	\N	South Africa	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22746	Kothari 2013	\N	Olanzapine versus Zotepine	\N	India	\N	\N	\N	\N	\N	112	\N	\N	\N	\N	\N
22748	Kelly 2014a	\N	Minocycline versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
22750	JPRN 2014	\N	Yokukansan versus Placebo	\N	Japan	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22751	ISRCTN14760638 2014	\N	Memantine versus Placebo	\N	The Netherlands	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
22752	IRCT20130907145 2014	\N	Aripiprazole versus Olanzapine	\N	Iran	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
22753	Hussain 2006	\N	Quetiapine versus Placebo	\N	South Africa	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22754	Holtzhausen 2008	\N	Aripiprazole	\N	South Africa	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22755	Holtzhausen 2008a	\N	Aripiprazole	\N	South Africa	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22756	HKCTR 2014	\N	Cognitive Behavioural Therapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22757	HKCTR-1781	\N	Mindfulness?Based Therapy	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22758	HKCTR 2012	\N	Exercise versus Tai Chi	\N	China	\N	\N	\N	\N	\N	135	\N	\N	\N	\N	\N
22759	HKCTR-1438	\N	Omega-3 Fatty Acid versus Placebo	\N	China	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22760	HKCTR 2009	\N	Early Intervention	\N	China	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22761	Haslett 2014	\N	Engagement Intervention for Individual Placement and Support (Brochure) versus Engagement Intervention for Individual Placement and Support (Mobile Computer-Based)	\N	United States of America	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
22762	Hard 2014	\N	Aripiprazole Brand // Aripiprazole versus Placebo	\N	\N	\N	\N	\N	\N	\N	622	\N	\N	\N	\N	\N
22763	Grunder 2014	\N	Atypical Antipsychotic Drug versus Typical Antipsychotic Drug	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22764	Girgis 2014	\N	DAR-0100A Dosage // DAR-0100A versus Placebo	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	49	\N	\N	\N	\N	\N
22765	Gioia 2014	\N	Recovery Oriented Decisions for Relatives’ Support	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22766	Gerretsen 2014a	\N	Caloric Vestibular Simulation	\N	Canada	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22768	Fleischhacker  2014a	\N	Aripiprazole versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22769	Fleischhacker 2014b	\N	Cariprazine Dosage // Cariprazine versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22770	Evins 2012	\N	D-Cycloserine versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22771	EUCTR2014 2014	\N	SD-809 (Deutetrabenazine) versus Placebo	\N	Czech // Germany // Hungary // Poland // Slovakia // United States of America // Multi-Centre	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
22773	Davis 2014	\N	N-Acetylcysteine versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
22774	Davis1 2014	\N	Oxytocin versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
22775	CTRI 2014	\N	Transcranial Direct Current Stimulation	\N	India	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
22776	CTRI 2014a	\N	Repetitive Transcranial Magnetic Stimulation	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22777	Correll 2014	\N	Aripiprazole versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	146	\N	\N	\N	\N	\N
22778	Correll 2014a	\N	Brexpiprazole Dosage // Brexpiprazole versus Placebo	\N	Multi-Centre	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22780	Cho 2014	\N	DAR-0100A Dosage // DAR-0100A versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
22783	Botha 2013	\N	Revolving Door Phenomenon	\N	South Africa	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22784	Botha 2013a	\N	Affordable Assertive Intervention	\N	South Africa	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22786	ACTRN1261400131 2014	\N	Recovery Oriented Training	\N	Australia	\N	\N	\N	\N	\N	900	\N	\N	\N	\N	\N
22789	Shoja 2014a	\N	Olanzapine versus Risperidone	\N	Iran	\N	\N	\N	\N	\N	268	\N	\N	\N	\N	\N
22790	McGinty 2015	\N	Vignette	\N	United States of America	\N	\N	\N	\N	\N	3940	\N	\N	\N	\N	\N
22830	Perez 20141	\N	Haloperidol versus Olanzapine // Haloperidol versus Risperidone // Olanzapine versus Risperidone	\N	Spain	\N	\N	\N	\N	\N	170	\N	\N	\N	\N	\N
22831	Kilbourne 2014a	\N	Enhanced Replicating Effective Programs versus Standard Replicating Effective Programs	\N	United States of America	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	88	\N	\N	\N	\N	\N
22833	Welch 2014	\N	Vignette	\N	\N	\N	\N	\N	\N	\N	256	\N	\N	\N	\N	\N
22834	Moscovice 1993	\N	Fee for Service Plan versus Prepayment Plan	\N	United States of America	\N	\N	\N	\N	\N	739	\N	\N	\N	\N	\N
22836	ISRCTN63162737	\N	Psychoeducation	\N	Switzerland	\N	\N	\N	\r\nCountry of origin\r\n\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	38	\N	\N	\N	\N	\N
22837	Fornells 2014	\N	specialized care versus standard care	\N	United Kingdom	\N	\N	\N	\N	\N	144	\N	\N	\N	\N	\N
22838	NCT01057849	\N	Risperidone versus Aripiprazole	\N	China	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
22840	Katz 2014	\N	Family-to-Family Education Program	\N	United States of America	\N	\N	\N	\N	\N	318	\N	\N	\N	\N	\N
22842	Kim 2014	\N	Repetitive Transcranial Magnetic Stimulation // Repetitive Transcranial Magnetic Stimulation Dosage // Repetitive Transcranial Magnetic Stimulation Placement	\N	Korea	\N	\N	\N	\N	\N	23	\N	\N	\N	\N	\N
22843	Fitzgerald 2014	\N	Transcranial Direct Current Stimulation	\N	\N	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
22844	Wusthoff 2014	\N	Integrated Treatment	\N	Norway	\N	\N	\N	\N	\N	55	\N	\N	\N	\N	\N
22847	Looijmans 2014	\N	Healthy Lifestyle	\N	The Netherlands	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22849	Ayoughi 2012	\N	Counselling	\N	Afghanistan	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
22852	Lam 2015	\N	Metacognitive Training	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
22854	Lee 2014a	\N	Haloperidol Continuation versus Haloperidol Withdrawal	\N	\N	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
22855	Petrides 2015	\N	Electroconvulsive Therapy	\N	United States of America	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
22931	Falkai 2014	\N	N-Acetyl Cysteine versus Psychotherapy for Social Cognition	\N	Germany	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22857	Aschbrenner 2014	\N	Motivational Decision Support System (Electronic)	\N	United States of America	\N	\N	\N	\N	\N	124	\N	\N	\N	\N	\N
22861	Marder 1994a	\N	Fluphenazine versus Placebo	\N	\N	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
22862	Marder 1996	\N	\N	\N	\N	\N	\N	\N	\N	\N	66	\N	\N	\N	\N	\N
22863	Zhao 2012a	\N	Clozapine versus Risperdal // Clozapine versus Ziprasidone // Risperdal versus Ziprasidone	\N	China	\N	\N	\N	\N	\N	187	\N	\N	\N	\N	\N
22864	Abhishekh 2012a	\N	Electroconvulsive Therapy Placement	\N	India	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
22865	Adams 2014	\N	Restraint versus Seclusion	\N	Brazil	\N	\N	\N	\N	\N	105	\N	\N	\N	\N	\N
22868	Alphs 2015	\N	Continuing Paliperidone Extended-Release versus Switching To Oral Antipsychotics	\N	USA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22869	Alptekin 2012	\N	Switching to Sertindole	\N	Turkey	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
22870	Alvarez 2014	\N	Early Intervention	\N	Australia	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22872	Ando 2014	\N	Early Intervention	\N	Japan	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
22875	Averbeck 2012a	\N	Oxytocin versus Placebo	\N	USA	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
22876	Baandrup 2015	\N	Melatonin versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
22878	Baker 2012a	\N	Healthy Lifestyle	\N	\N	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
22882	Bartzokis 2014a	\N	Risperidone Route	\N	United States	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
22883	Bechdolf 2012a	\N	Aripiprazole + Clinical Management + Cognitive Behavioral Therapy versus Clinical Management + Placebo // Aripiprazole + Clinical Management versus Cognitive Behavioral Therapy	\N	Germany	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
22884	Beebe 2015	\N	Telephone Intervention Problem-Solving versus Treatment As Usual	\N	USA	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
22885	Bell 2015	\N	Nintendo BrainAge (Cognitive Training) versus PositScience (Cognitive Training)	\N	USA	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
22886	Berwaerts 2015	\N	Paliperidone Palmitate (Long-Acting) // Placebo	\N	USA	\N	\N	\N	\N	\N	305	\N	\N	\N	\N	\N
22887	Best 2015a	\N	Working Memory Training versus Control Group	\N	Canada	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
22888	Best 2015	\N	Working Memory Training with Difficulty Increase versus Working Memory Training with Sham Difficulty Increase	\N	Canada	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
22889	Bhatia 2015	\N	Physical Exercise versus Yoga Training // Physical Exercise versus Treatment As Usual // Yoga Training versus Treatment As Usual	\N	USA	\N	\N	\N	\N	\N	340	\N	\N	\N	\N	\N
22892	Bogers 2015	\N	Blood Sampling Methods	\N	The Netherlands	\N	\N	\N	\N	\N	73	\N	\N	\N	\N	\N
22894	Broussard 2014	\N	Anti-Stigma Messages	\N	United States	\N	\N	\N	\N	\N	414	\N	\N	\N	\N	\N
22895	Brown 2015	\N	BI409306 Dosage // BI409306 versus Placebo	\N	USA	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22896	Brown 2015a	\N	BI409306 Dosage // BI409306 versus Placebo	\N	USA	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22897	Brunelin 2014a	\N	transcranial Direct current Stimulation	\N	France	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22899	Buchanan 2015	\N	Oxytocin (Intranasal) versus Placebo // Galantamine versus Oxytocin (Intranasal) // Galantamine versus Placebo	\N	USA	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
22901	Burshtein 2012	\N	Allopurinol versus Placebo	\N	Israel	\N	\N	\N	\N	\N	248	\N	\N	\N	\N	\N
22902	Cadenhead 2015	\N	Omega-3 Fatty Acid versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	109	\N	\N	\N	\N	\N
22903	Calver 2015	\N	Droperidol versus Haloperidol	\N	USA	\N	\N	\N	\N	\N	228	\N	\N	\N	\N	\N
22904	Cantero 2012	\N	Cognitive Behavioural Therapy versus Supportive Therapy	\N	Multi-Center	\N	\N	\N	\N	\N	330	\N	\N	\N	\N	\N
22906	Chan 2012a	\N	Case Management	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
22907	Chen 2014	\N	Aerobic Exercise versus Yoga // Aerobic Exercise versus Control // Yoga versus Control	\N	China	\N	\N	\N	\N	\N	85	\N	\N	\N	\N	\N
22908	Chen 2012b	\N	Aerobic Exercise versus Yoga // Aerobic Exercise versus Control // Yoga versus Control	\N	China	\N	\N	\N	\N	\N	61	\N	\N	\N	\N	\N
22909	Chisholm 2014	\N	Contact and Education versus Education	\N	United Kingdom	\N	\N	\N	\N	\N	657	\N	\N	\N	\N	\N
22910	Choi 2014a	\N	Processing Speed Training versus Control	\N	United States	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
22911	Choi 2015	\N	Processing Speed Training versus Control Group	\N	USA	\N	\N	\N	\N	\N	39	\N	\N	\N	\N	\N
22912	Christensen 2014	\N	Individual Placement and Support versus Individual Placement and Support + Cognitive Remediation + Social Skills Training // Individual Placement and Support versus TAU // Individual Placement and Support + Cognitive Remediation + Social Skills Training versus TAU	\N	Denmark	\N	\N	\N	\N	\N	750	\N	\N	\N	\N	\N
22913	Cihakova 2015	\N	Gluten-Free Diet	\N	USA	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22916	Cotton 2014	\N	Individual Placement Support	\N	Australia	\N	\N	\N	\N	\N	146	\N	\N	\N	\N	\N
22921	Davis 2015	\N	N-Acetylcysteine versus Placebo	\N	USA	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
22922	Davis 2015a	\N	N-Acetylcysteine versus Placebo	\N	USA	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
22923	De 2012	\N	Befriending versus Metacognitive Therapy	\N	The Netherlands	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
22924	DeMartinis 2012a	\N	PF-02545920 Dosage // PF-02545920 versus Risperidone // PF-02545920 versus Placebo	\N	United States	\N	\N	\N	\N	\N	259	\N	\N	\N	\N	\N
22926	Duncan 2015	\N	Exercise versus Sitting	\N	Canada	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22927	Dunn 2015	\N	Transcranial Direct Current Stimulation (tDCS) versus Sham // Transcranial Direct Current Stimulation (tDCS) Placement	\N	USA	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
22928	Dutta 2014	\N	Asenapine versus Clozapine // Asenapine versus Ziprasidone // Clozapine versus Ziprasidone	\N	India	\N	\N	\N	\N	\N	119	\N	\N	\N	\N	\N
22929	Eack 2015	\N	Cognitive Enhancement Therapy versus TAU	\N	USA	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
23169	Subotnik 2015	\N	Risperidone Route	\N	USA	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
22932	Falkai 2012	\N	Physical Exercise (Physical Intervention) versus Control // Cognitive Remediation versus Control	\N	Multi-Center // Germany // Canada	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22933	Falkai 2012a	\N	Cycling (Physical Intervention) versus Control // Cognitive Remediation versus Control	\N	Multi-Center // Germany // Canada	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22934	Feifel 2012	\N	Intranasal Oxytocin versus Placebo	\N	USA	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
22935	Fisher 2012	\N	Cognitive Training (Computerized) (Targeted) versus Computer Games	\N	USA	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
22938	Frohlich 2015	\N	\N	\N	USA	\N	\N	\N	\N	\N	26	\N	\N	\N	\N	\N
22940	Gaebel 2012	\N	Quetiapine (Oral) versus Risperidone (LAI)	\N	Germany	\N	\N	\N	\N	\N	666	\N	\N	\N	\N	\N
22941	Giesbrecht 2015	\N	Confirmatory Factor Analysis versus Exploratory Factor Analysis	\N	Canada	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
22944	Gleeson 2014	\N	Online Social Therapy versus Treatment As Usual	\N	Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22945	Glenthoj 2014	\N	Cognitive Remediation Therapy (Intensive) + Treatment As Usual versus Treatment As Usual	\N	Denmark	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
22947	Goldsmith 2015	\N	Cognitive Behavioral Therapy versus Supportive Counseling // Cognitive Behavioral Therapy versus Treatment As Usual // Supportive Counseling versus Treatment As Usual	\N	United Kingdom	\N	\N	\N	\N	\N	308	\N	\N	\N	\N	\N
22948	Haig 2015	\N	ABT-126 Dosage // ABT-126 versus Placebo	\N	USA	\N	\N	\N	\N	\N	157	\N	\N	\N	\N	\N
22949	Hallak 2014	\N	Sodium Nitroprusside versus Placebo	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22950	Harris 2015	\N	Cognitive Remediation (Internet-Based) versus Control Group	\N	Australia	\N	\N	\N	\N	\N	86	\N	\N	\N	\N	\N
22951	Hassan 2014	\N	Cognitive-Behavioral Intervention versus Treatment As Usual	\N	\N	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
22953	Hjorth 2015	\N	Psychotropic Pharmacotherapy Training versus Control Group	\N	Denmark	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
22954	Hjorthoj 2014	\N	OPUS Early Intervention versus Treatment As Usual	\N	Denmark	\N	\N	\N	\N	\N	547	\N	\N	\N	\N	\N
22955	Hjorthoj 2012	\N	Cognitive Behavior Therapy + Motivational Interviewing + Treatment As Usual versus Treatment As Usual	\N	Denmark	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
22956	Ho 2015	\N	Integrated Care versus Treatment As Usual	\N	USA	\N	\N	\N	\N	\N	363	\N	\N	\N	\N	\N
23032	Maples 2012	\N	Electronic Medication Monitor (Med-eMonitor) versus Home-Delivered Treatment (PharmCAT) // Electronic Medication Monitor (Med-eMonitor) versus Treatment As Usual // Home-Delivered Treatment (PharmCAT) versus Treatment As Usual	\N	USA	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
22957	Horan 2012	\N	Social Cognitive Skills Training versus Neurocognitive Remediation (Computerized) // Social Cognitive Skills Training versus Standard Illness Management Skills Training // Social Cognitive Skills Training versus Social Cognitive Skills Training + Neurocognitive Remediation // Neurocognitive Remediation (Computerized) versus Standard Illness Management Skills Training // Neurocognitive Remediation (Computerized) versus Social Cognitive Skills Training + Neurocognitive Remediation // Standard Illness Management Skills Training versus Social Cognitive Skills Training + Neurocognitive Remediation	\N	USA	\N	\N	\N	\N	\N	68	\N	\N	\N	\N	\N
22958	Hoy 2014	\N	Transcranial Direct Current Stimulation (tDCS) Dosage // Transcranial Direct Current Stimulation (tDCS) versus Sham	\N	Australia	\N	\N	\N	\N	\N	18	\N	\N	\N	\N	\N
22959	Hsih 2015	\N	Oxytocin versus Placebo	\N	USA	\N	\N	\N	\N	\N	38	\N	\N	\N	\N	\N
22961	Ibrahim 2012	\N	Cognitive Behavior Therapy versus Control Group	\N	Egypt	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22962	Iizuka 2014	\N	Cognitive Training (Video Games-Based) versus Visuospatial Puzzle Games	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22963	Ikai 2015	\N	Yoga versus Control Group	\N	Japan	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
22964	ISRCTN11422802	\N	Worry Intervention (Group) versus TAU	\N	United Kingdom	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
22965	ISRCTN12424842	\N	\N	\N	United Kingdom	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
22966	ISRCTN58327365	\N	Video-Feedback Intervention to Promote Positive Parenting and Sensitive Discipline versus TAU	\N	United Kingdom	\N	\N	\N	\N	\N	300	\N	\N	\N	\N	\N
22967	ISRCTN86762253	\N	Exercises and Mindfulness Self-Help Manual versus Progressive Muscle Relaxation Self-Help Manual	\N	Germany	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22968	Johannesen 2015	\N	D-Serine versus Placebo // Glycine Transporter Inhibition (GlyTI) Dosage // Glycine Transporter Inhibition (GlyTI) versus Placebo	\N	USA	\N	\N	\N	\N	\N	104 // 9	\N	\N	\N	\N	\N
22969	Johnsen 2012	\N	Olanzapine versus Quetiapine // Olanzapine versus Risperidone // Olanzapine versus Ziprasidone // Quetiapine versus Risperidone // Quetiapine versus Ziprasidone // Risperidone versus Ziprasidone	\N	Norway	\N	\N	\N	\N	\N	171	\N	\N	\N	\N	\N
22970	Jorgensen 2015	\N	Guided Self-Determination versus Control Group	\N	Denmark	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22971	Kahn 2012	\N	Exercise Therapy versus Occupational Therapy	\N	The Netherlands	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
22972	Kaiser 2015	\N	Risperidone Route	\N	USA	\N	\N	\N	\N	\N	83	\N	\N	\N	\N	\N
22973	Kane 2012	\N	Asenapine versus Placebo // Asenapine versus Haloperidol // Haloperidol versus Placebo	\N	USA	\N	\N	\N	\N	\N	458	\N	\N	\N	\N	\N
22977	Kane 2015a	\N	Lurasidone Dosage // Lurasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	213 (Analysis)	\N	\N	\N	\N	\N
22979	Kantrowitz 2012	\N	D-Serine versus Placebo	\N	USA	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
22981	Kato 2012	\N	Lurasidone Dosage	\N	Japan	\N	\N	\N	\N	\N	208	\N	\N	\N	\N	\N
22982	Keks 2012	\N	Olanzapine (Oral) versus Risperidone (Long-Acting Injectable)	\N	Australia	\N	\N	\N	\N	\N	377	\N	\N	\N	\N	\N
22983	Kelly 2014b	\N	Minocycline versus Placebo	\N	USA	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
22984	Kern 2015	\N	Errorless Learning versus Supportive Employment	\N	USA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
22985	Kertchok 2015	\N	Promoting Functioning and Therapeutic Relationship Program versus TAU	\N	Thailand	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
22986	Kidorf 2015	\N	Financial Incentive versus Treatment As Usual	\N	USA	\N	\N	\N	\N	\N	125	\N	\N	\N	\N	\N
22987	Killackey 2014a	\N	Individual Placement and Support versus Treatment As Usual	\N	Australia	\N	\N	\N	\N	\N	146	\N	\N	\N	\N	\N
22990	Kim 2012c	\N	Weight Management Program versus Control Group	\N	Korea	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
22991	Kim 2014a	\N	Retention Strategies	\N	USA	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
22992	Kim 2014b	\N	Aerobic Exercise versus Control Group	\N	Korea	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
22993	Kimhy 2015	\N	Aerobic Exercise versus Treatment As Usual	\N	USA	\N	\N	\N	\N	\N	33	\N	\N	\N	\N	\N
22994	Kishore 2015	\N	Vitamin D versus Placebo	\N	India	\N	\N	\N	\N	\N	10	\N	\N	\N	\N	\N
22995	Knegtering 2014	\N	repetitive Transcranial Magnetic Stimulation versus Sham	\N	The Netherlands	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
22996	Kontis 2012	\N	Cognitive Remediation Therapy versus Treatment As Usual	\N	UK	\N	\N	\N	\N	\N	134	\N	\N	\N	\N	\N
22997	Koolaee 2014	\N	Communal Living Skills Training versus Treatment As Usual	\N	Iran	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
22998	Koren 2014	\N	Vignettes	\N	Israel	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
22999	Kuipers 2012	\N	Cognitive Behaviour Therapy for Psychosis versus Treatment As Usual	\N	UK	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23001	Kumar 2015	\N	Electroconvulsive Therapy Placement	\N	India	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
23002	Kurtz 2012	\N	Cognitive Remediation Program + Social Skills Training // Control Group	\N	USA	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
23003	Kurtz 2015a	\N	Verbal Episodic Memory Improving Strategies	\N	USA	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
23004	Laffont 2015	\N	Risperidone Dosage	\N	USA	\N	\N	\N	\N	\N	90	\N	\N	\N	\N	\N
23005	Larr 2012	\N	Betahistine versus Placebo	\N	USA	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
23006	Lassen 2011	\N	Acceptance and Commitment Therapy (Group) + Treatment As Usual versus Treatment As Usual	\N	USA	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
23007	Lasser 2012	\N	Lisdexamfetamine Dimesylate Withdrawal // Lisdexamfetamine Dimesylate versus Placebo	\N	USA	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n	\N	69	\N	\N	\N	\N	\N
23008	Lavania 2015	\N	Haloperidol (Intramuscular Injection) versus Levosulpiride (Intramuscular Injection)	\N	India	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
23010	Lees 2014	\N	Modafinil versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
23012	Levy 2015	\N	Glycine versus Placebo	\N	USA	\N	\N	\N	\N	\N	2	\N	\N	\N	\N	\N
23013	Leweke 2014	\N	Cannabidiol versus Placebo	\N	Germany	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
23014	Leweke 2014a	\N	Cannabidiol versus Placebo	\N	Germany	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
23017	Lin 2015	\N	Aerobic Exercise versus Yoga // Aerobic Exercise versus Waitlist // Yoga versus Waitlist	\N	China	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
23018	Lindenmayer 2015	\N	Brain Fitness versus COGPACK // Brain Fitness versus COGPACK + Mind Reading // Brain Fitness versus Brain Fitness + Mind Reading // Brain Fitness + Mind Reading versus COGPACK // Brain Fitness + Mind Reading versus COGPACK + Mind Reading versus COGPACK versus COGPACK + Mind Reading	\N	USA	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
23019	Lindenmayer 2012	\N	Cognitive Remediation (COGPACK) versus Mind Reading - an Interactive Guide to Emotions (Multimedia Program Of Social Cognition)	\N	USA	\N	\N	\N	\N	\N	59	\N	\N	\N	\N	\N
23020	Lisiecka 2015	\N	Minocycline versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	226	\N	\N	\N	\N	\N
23021	Litman 2014	\N	AZD8529 versus Risperidone // AZD8529 versus Placebo // Risperidone versus Placebo	\N	\N	\N	\N	\N	\N	\N	152	\N	\N	\N	\N	\N
23022	Liu 2014a	\N	Social Cognition and Interaction Training-Tablet (Computerized)	\N	USA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23026	Loewy 2015	\N	Cognitive Auditory Training versus Games (Computer)	\N	USA	\N	\N	\N	\N	\N	103	\N	\N	\N	\N	\N
23028	Lombardo 2015	\N	Encenicline versus Placebo	\N	USA	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n	\N	319	\N	\N	\N	\N	\N
23029	Madigan 2012a	\N	Psychological Intervention (Group) (Cognitive Behavioural Therapy + Motivational Interviewing) versus Treatment As Usual	\N	Ireland	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23030	Malhotra 2015	\N	Aripiprazole versus Risperidone	\N	USA	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
23031	Malla 2014	\N	Extension of Early Intervention versus Treatment As Usual // Length of Early Intervention	\N	Canada	\N	\N	\N	\N	\N	220	\N	\N	\N	\N	\N
23033	Marder 2015	\N	Oxytocin (Intranasal) versus Placebo	\N	USA	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
23034	Marder 2014	\N	Oxytocin (Intranasal) versus Placebo	\N	USA	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
23035	Marder 2015a	\N	Oxytocin (Intranasal) versus Placebo	\N	USA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23036	Marsh 2012	\N	Social Cognitive Training Program (SoCog) versus Treatment As Usual	\N	Australia	\N	\N	\N	\N	\N	34	\N	\N	\N	\N	\N
23037	Matsuda 2015	\N	Cognitive Rehabilitation versus Waitlist	\N	Japan	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
23038	McEwen 2015	\N	Cognitive Training // Cognitive Training + Exercise (Physical Intervention)	\N	USA	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
23040	McGorry 2012	\N	Cognitive Therapy + Low-Dose Risperidone versus Cognitive Therapy + Placebo // Cognitive Therapy + Low-Dose Risperidone versus Supportive Therapy + Placebo // Cognitive Therapy + Placebo versus Supportive Therapy + Placebo	\N	Australia	\N	\N	\N	\N	\N	115	\N	\N	\N	\N	\N
23041	McGurk 2015	\N	COGPACK Instruction versus COGPACK Instruction + Strategy Coaching	\N	USA	\N	\N	\N	\N	\N	78	\N	\N	\N	\N	\N
23042	Melzer 2015	\N	Electroconvulsive Therapy versus Sham	\N	Brazil	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
23043	Michalopoulou 2015	\N	Oxytocin (Intranasal) versus Placebo	\N	UK	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
23047	Morrison 2012a	\N	Cognitive Therapy + Monitoring versus Monitoring	\N	UK	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n	\N	288	\N	\N	\N	\N	\N
23049	Morrison 2014a	\N	Cognitive Therapy + Treatment As Usual versus Treatment As Usual	\N	\N	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
23050	Moun 2015	\N	Home-Based Cognitive Training Program + Treatment As Usual versus Treatment As Usual	\N	India	\N	\N	\N	\N	\N	74	\N	\N	\N	\N	\N
23053	Muller 2014a	\N	Cognitive Training (Auditory or Visual) versus Treatment As Usual	\N	Germany	\N	\N	\N	\N	\N	46	\N	\N	\N	\N	\N
23054	Muser 2014	\N	Oral Antipsychotic Drug versus Paliperidone Palmitate	\N	\N	\N	\N	\N	\r\nUser defined 3\r\n\r\nNotes2\r\n	\N	451	\N	\N	\N	\N	\N
23055	Nalesnik 2015	\N	transcranial Direct current Stimulation versus Sham	\N	United Kingdom	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
23057	NCT02354001	\N	Raloxifene Hydrochloride versus Placebo	\N	USA	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
23058	NCT02357797	\N	Vortioxetine versus Placebo	\N	USA	\N	\N	\N	\N	\N	88	\N	\N	\N	\N	\N
23059	ditory 2015	\N	Transcranial Alternating Current Stimulation versus Transcranial Direct Current Stimulation	\N	USA	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
23060	NCT02360319	\N	Aripiprazole (Long Acting Injectable) versus Antipsychotic Medication (Long Acting Injectable)	\N	USA	\N	\N	\N	\N	\N	500	\N	\N	\N	\N	\N
23061	NCT02360566	\N	Participatory Video Intervention versus Control Group	\N	Canada	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
23062	NCT02360813	\N	Cognitive Remediation Therapy versus TAU	\N	Ireland	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
23063	NCT02366117	\N	Training // Control Group	\N	Portugal	\N	\N	\N	\N	\N	240	\N	\N	\N	\N	\N
23064	NCT02377505	\N	Deep Brain Stimulation versus Sham	\N	Spain	\N	\N	\N	\N	\N	8	\N	\N	\N	\N	\N
23065	NCT02380885	\N	Social Cognition and Interaction Training versus Therapeutic Alliance Focused Therapy // Social Cognition and Interaction Training versus TAU // Therapeutic Alliance Focused Therapy versus TAU	\N	Israel	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
23066	NCT02383095	\N	Art Therapy versus Metacognitive Therapy	\N	France	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
23067	NCT02386605	\N	Motivational Interviewing versus Relaxation Skills	\N	USA	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
23068	NCT02390557	\N	Quality Monitoring Intervention versus TAU	\N	USA	\N	\N	\N	\N	\N	480	\N	\N	\N	\N	\N
23069	NCT02391649	\N	Bibliotherapy versus Psychoeducation // Bibliotherapy versus TAU // Psychoeducation versus TAU	\N	China	\N	\N	\N	\N	\N	129	\N	\N	\N	\N	\N
23070	NCT02392468	\N	BI409306 Dosage // BI409306 versus Placebo	\N	USA	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
23071	NCT02396797	\N	New atWork Intervention versus Original atWork Intervention	\N	Norway	\N	\N	\N	\N	\N	1500	\N	\N	\N	\N	\N
23072	NCT02398279	\N	L-Arginine versus Placebo	\N	Turkey	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
23073	NCT02404194	\N	Cognitive Training (Targeted) versus Computer Game	\N	USA	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
23074	NCT02407808	\N	Delta-9-Tetrahydrocannabinol (THC) versus Placebo	\N	USA	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
23075	NCT02408198	\N	Anxiety Intervention versus Waitlist	\N	United Kingdom	\N	\N	\N	\N	\N	35	\N	\N	\N	\N	\N
23076	NCT02413164	\N	Physiotherapy Programme + Deep Water Running versus Control Group	\N	Spain	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
23077	NCT02417142	\N	Exenatide versus Placebo	\N	USA	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
23078	NCT02418819	\N	PF-06412562 Dosage // PF-06412562 versus Placebo	\N	USA	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
23079	NCT02420015	\N	Stay Quit Coach (Mobile App) versus Control Group	\N	USA	\N	\N	\N	\N	\N	36	\N	\N	\N	\N	\N
23080	NCT02421146	\N	Transcranial Direct Current Stimulation versus Sham	\N	USA	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
23081	NCT02421237	\N	Narrative Enhancement and Cognitive Therapy versus Supportive Therapy (Group)	\N	USA	\N	\N	\N	\N	\N	175	\N	\N	\N	\N	\N
23082	NCT02421965	\N	Mobile Health (Mobile App) versus Wellness Recovery Action Planning	\N	USA	\N	\N	\N	\N	\N	174	\N	\N	\N	\N	\N
23083	NCT02424188	\N	Integrated Intervention versus TAU	\N	USA	\N	\N	\N	\N	\N	220	\N	\N	\N	\N	\N
23084	NCT02426983	\N	Transcranial Direct Current Stimulation versus Sham // Dextromethorphan versus Placebo	\N	USA	\N	\N	\N	\N	\N	12	\N	\N	\N	\N	\N
23085	NCT02427542	\N	Cognitive Behavioural Therapy for Depersonalisation-Derealisation versus TAU	\N	United Kingdom	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
23086	NCT02430935	\N	Cognitive Adaptation Training versus Cognitive Remediation (Action-Based)	\N	Canada	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
23087	NCT02431702	\N	Paliperidone Palmitate Route // Switching to Paliperidone Palmitate // Switching from Paliperidone Palmitate // Paliperidone Palmitate versus Oral Antipsychotics	\N	USA	\N	\N	\N	\N	\N	275	\N	\N	\N	\N	\N
23088	NCT02435095	\N	Intermittent Treatment versus Maintenance Treatment	\N	Germany	\N	\N	\N	\N	\N	666	\N	\N	\N	\N	\N
23089	NCT02435784	\N	Two-Way Communication Checklist (2-COM) versus Treatment as Usual	\N	China	\N	\N	\N	\N	\N	80	\N	\N	\N	\N	\N
23090	Nelson 2015	\N	Transcranial Direct Current Stimulation versus Sham // Transcranial Random Noise Stimulation versus Sham // Transcranial Direct Current Stimulation versus Transcranial Random Noise Stimulation	\N	USA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23091	Nemoto 2014a	\N	Cognitive Training Program for Convergent Thinking versus Cognitive Training Program for Divergent Thinking	\N	Japan	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
23092	Newcomer 2014a	\N	Aripiprazole versus Olanzapine // Aripiprazole versus Risperidone // Olanzapine versus Risperidone	\N	USA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23094	Nieman 2014	\N	Cognitive Behavioural Therapy versus Treatment As Usual	\N	The Netherlands	\N	\N	\N	\N	\N	201	\N	\N	\N	\N	\N
23095	Nienow 2015	\N	Transcranial Direct Current Stimulation versus Sham	\N	USA	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
23100	Nuechterlein 2012	\N	Conventional Vocational Rehabilitation versus Individual Placement and Support + Group Skills Training	\N	USA	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
23101	Nuechterlein 2014	\N	Cognitive Training versus Cognitive Training + Aerobic Exercise	\N	USA	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
23102	O'Brien 2014a	\N	Nicotine Route // Nicotine versus Placebo	\N	Australia	\N	\N	\N	\N	\N	657	\N	\N	\N	\N	\N
23103	O'Connor 2007	\N	Attention Placebo Control versus Cognitive Behavioral Therapy	\N	Canada	\N	\N	\N	\N	\N	24	\N	\N	\N	\N	\N
23105	Oranje 2015	\N	Clonidine versus Placebo	\N	Denmark	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
23106	Owen 2015	\N	Cognitive Behavior Therapy (Group) // Treatment As Usual	\N	UK	\N	\N	\N	\N	\N	113	\N	\N	\N	\N	\N
23108	Pajonk 2012	\N	Cycle Ergometry (Physical Intervention) versus Tabletop Football (Physical Intervention)	\N	Germany	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
23109	Palm 2015	\N	Transcranial Direct Current Stimulation versus Sham	\N	Germany	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
23112	Park 2015	\N	Healthy Lifestyle	\N	Canada	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23113	Patino 2015	\N	Exenatide versus Placebo	\N	USA	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
23114	Pedersen 2012a	\N	Oxytocin (Intranasal) versus Placebo	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23116	Penades 2012a	\N	Cognitive Remediation Therapy versus Psychological Control Therapy	\N	Spain	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
23118	Petrides 2012	\N	Clozapine versus Clozapine + Electroconvulsive Therapy	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23119	Petrides 2015a	\N	Clozapine versus Clozapine + Electroconvulsive Therapy	\N	USA	\N	\N	\N	\N	\N	20	\N	\N	\N	\N	\N
23120	Picco 2014	\N	Vignettes	\N	Singapore	\N	\N	\N	\N	\N	123	\N	\N	\N	\N	\N
23123	Pikalov 2012a	\N	Haloperidol versus Lurasidone // Lurasidone versus Olanzapine // Lurasidone versus Risperidone // Lurasidone versus Quetiapine // Lurasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Not Reported	\N	\N	\N	\N	\N
23124	Pikalov 2014a	\N	Lurasidone versus Placebo	\N	United States of America	\N	\N	\N	\N	\N	Not Reported	\N	\N	\N	\N	\N
23125	Piskulic 2012a	\N	Cognitive Remediation (Brain Fitness) versus Video Games	\N	Canada	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n	\N	36	\N	\N	\N	\N	\N
23127	Pontes 2012	\N	Cognitive Training versus Control Group	\N	Brazil	\N	\N	\N	\N	\N	17	\N	\N	\N	\N	\N
23129	Ramsay 2014	\N	Cognitive Remediation Training versus Computer Skills Training	\N	USA	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n	\N	26	\N	\N	\N	\N	\N
23131	Rapp 2012	\N	Vignettes	\N	Germany	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
23132	Redmeijer 2014	\N	Cognitive Adaptation Training + Treatment As Usual versus Treatment As Usual	\N	The Netherlands	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
23133	Rinaldi 2014	\N	Motivational Training for Clinicians + Supported Employment versus Supported Employment	\N	UK	\N	\N	\N	\N	\N	159	\N	\N	\N	\N	\N
23134	Roberts 2015	\N	Bias Activation Training versus Non-Bias Activation Training // Debiasing Training versus Game (Computer)	\N	USA	\N	\N	\N	\N	\N	26 // 36	\N	\N	\N	\N	\N
23135	Roder 2015	\N	Neurocognitive Therapy (Integrated) versus Treatment As Usual	\N	Switzerland	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
23136	Roffman 2014a	\N	Folic Acid + Vitamin B12 versus Placebo	\N	USA	\N	\N	\N	\N	\N	140	\N	\N	\N	\N	\N
23137	Ruhrmann 2014	\N	Cognitive Behavioral Intervention + Social Cognitive Intervention versus N-acetylcysteine // Integrated Preventive Psychological Intervention versus N-acetylcysteine // N-acetylcysteine versus Placebo	\N	Germany	\N	\N	\N	\N	\N	200	\N	\N	\N	\N	\N
23138	Russinova 2014	\N	Peer-Run Antistigma Photovoice Intervention versus Waitlist	\N	USA	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
23140	Sab 2015	\N	Cognitive Remediation Therapy + Educational Session + Social Skills versus Cooking	\N	France	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
23141	Saddichha 2012	\N	Haloperidol versus Olanzapine // Haloperidol versus Risperidone // Olanzapine versus Risperidone	\N	India	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23142	Sato 2015	\N	Cognitive Remediation (COGPACK) + Supportive Employment versus Vocational Services	\N	Japan	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23144	Savitz 2015	\N	Pregnenolone versus Placebo	\N	USA	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
23145	Scheewe 2012a	\N	Exercise Therapy versus Occupational Therapy	\N	The Netherlands	\N	\N	\N	\N	\N	63	\N	\N	\N	\N	\N
23148	RAISE-ETP	\N	Community Care versus Integrated Treatment (NAVIGATE)	\N	United States	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n	\N	404	\N	\N	\N	\N	\N
23152	Schulz 2012	\N	Tropisetron versus Placebo	\N	USA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23153	Shaygan 2013	\N	Psychoeducation versus Treatment As Usual	\N	Iran	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
23154	Sheikhmoonesi 2015	\N	Buspirone versus Placebo	\N	Iran	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
23156	Siever 2015	\N	Guanfacine versus Placebo	\N	USA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23157	Siever 2015a	\N	Guanfacine versus Placebo	\N	USA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23159	Silbert 2015	\N	ABT-128 Dosage // ABT-288 versus Placebo	\N	USA	\N	\N	\N	\N	\N	207	\N	\N	\N	\N	\N
23160	Silverstein 2015	\N	Cash Payment // Intrinsically Rewarding Learning Cues	\N	USA	\N	\N	\N	\N	\N	82	\N	\N	\N	\N	\N
23163	Smith 2015	\N	Virtual Reality Job Interview Training versus Waitlist	\N	USA	\N	\N	\N	\N	\N	30	\N	\N	\N	\N	\N
23164	Sommer 2015	\N	Theta Burst repetitive Transcranial Magnetic Stimulation versus Placebo	\N	USA	\N	\N	\N	\N	\N	76	\N	\N	\N	\N	\N
23166	Stain 2014	\N	Cognitive Behavioral Therapy versus Non-Directive Reflective Listening (NDRL)	\N	Australia	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
23168	Steinberg 2015	\N	Interactive Education versus Motivational Interviewing with Personalized Feedback	\N	USA	\N	\N	\N	\N	\N	101	\N	\N	\N	\N	\N
23171	Sullivan 2015	\N	Minocycline versus Placebo	\N	USA	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
23172	Takano 1995	\N	Day Care	\N	Japan	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23173	Takeuchi 2015	\N	Clozapine Discontinuation (Gradual) versus Clozapine Discontinuation (Immediate)	\N	Canada	\N	\N	\N	\N	\N	32	\N	\N	\N	\N	\N
23175	Tanner 2015	\N	Folic Acid and Vitamin B12 versus Placebo	\N	USA	\N	\N	\N	\N	\N	22	\N	\N	\N	\N	\N
23176	Tecic 2012	\N	Cognitive Behavioral Therapy (Modified) + Treatment As Usual versus Treatment As Usual	\N	Germany	\N	\N	\N	\N	\N	49	\N	\N	\N	\N	\N
23177	Thorndike 2015	\N	Varenicline versus Placebo	\N	USA	\N	\N	\N	\N	\N	87	\N	\N	\N	\N	\N
23178	Tikka 2015	\N	repetitive Transcranial Magnetic Stimulation versus Sham	\N	India	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23179	Tuchman 2015	\N	Health Care Transition Care Coordination versus Control Group	\N	USA	\N	\N	\N	\N	\N	210	\N	\N	\N	\N	\N
23181	Twamley 2015	\N	Cognitive Training (Compensatory) + Supported Employment versus Supported Employment	\N	USA	\N	\N	\N	\N	\N	136	\N	\N	\N	\N	\N
23182	Uher 2014	\N	Cognitive Behavioral Intervention (Skills for Wellness) // Control Group	\N	Canada	\N	\N	\N	\N	\N	100	\N	\N	\N	\N	\N
23183	Umbricht 2012	\N	RG1678 Dosage // RG1678 versus Placebo	\N	\N	\N	\N	\N	\N	\N	323	\N	\N	\N	\N	\N
23187	Van Der Meer 2015	\N	Cognitive Adaptation Training versus Treatment As Usual	\N	The Netherlands	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23189	Van Lutterveld 2014	\N	repetitive Transcranial Magnetic Stimulation (Theta-Burst) versus Sham	\N	The Netherlands	\N	\N	\N	\r\nCountry of origin\r\n\r\nNotes2\r\n	\N	41	\N	\N	\N	\N	\N
23191	Vasfi 2015	\N	Aftercare Services versus Treatment As Usual	\N	Iran	\N	\N	\N	\N	\N	120	\N	\N	\N	\N	\N
23192	Velden 2014	\N	Individual Placement and Support versus Treatment As Usual	\N	Norway	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
23193	Velligan 2015	\N	Social Cognition and Interaction Training versus Waitlist	\N	USA	\N	\N	\N	\N	\N	28	\N	\N	\N	\N	\N
23194	Velligan 2015a	\N	Motivation Enhancement versus TAU	\N	USA	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
23196	Vinogradov 2012	\N	Cognitive Training versus Computer Games	\N	USA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23197	Vinogradov 2014	\N	Cognitive Training versus Cognitive Training + Social Cognitive Training	\N	USA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23198	Vizzotto 2015	\N	Occupational Goal Intervention versus Control Group	\N	Brazil	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
23199	Vyas 2015	\N	Minocycline versus Placebo	\N	USA	\N	\N	\N	\N	\N	52	\N	\N	\N	\N	\N
23200	Walther 2015	\N	Stop-Distance Paradigms	\N	Switzerland	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
23201	Ward 2012	\N	Bike Training versus Playing Tabletop Football	\N	Australia	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23203	Warren 2015	\N	Oxytocin (Intranasal) // Placebo	\N	USA	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
23204	Wehring 2015	\N	\N	\N	USA	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
23205	Wehring 2012	\N	Oxytocin (Intranasal) versus Placebo	\N	USA	\N	\N	\N	\N	\N	21	\N	\N	\N	\N	\N
23206	Weickert 2015	\N	Raloxifene versus Placebo	\N	Australia	\N	\N	\N	\N	\N	19	\N	\N	\N	\N	\N
23209	Weiser 2015	\N	Oxytocin versus Placebo	\N	Israel	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
23210	Wenneberg 2014	\N	Cognitive Remediation Therapy (Computerized) versus Treatment As Usual	\N	Denmark	\N	\N	\N	\N	\N	126	\N	\N	\N	\N	\N
23211	Woelwer 2014	\N	Integrated Social Cognitive and Behavioral Skills Therapy versus Neurocognitive Remediation Therapy	\N	Germany	\N	\N	\N	\N	\N	180	\N	\N	\N	\N	\N
23308	Uher 2014a	\N	Early Interventions (Pre-Emptive)	\N	USA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23212	Wojtalik 2015	\N	Cognitive Enhancement Therapy versus Treatment As Usual	\N	USA	\N	\N	\N	\N	\N	14	\N	\N	\N	\N	\N
23213	Woolley 2015	\N	Oxytocin (Intranasal) versus Placebo	\N	USA	\N	\N	\N	\N	\N	29	\N	\N	\N	\N	\N
23214	Wu 2012a	\N	Lifestyle Intervention versus Lifestyle Intervention + Metformin // Lifestyle Intervention versus Metformin // Lifestyle Intervention versus Placebo // Lifestyle Intervention + Metformin versus Metformin // Lifestyle Intervention + Metformin versus Placebo // Metformin versus Placebo	\N	\N	\N	\N	\N	\N	\N	128	\N	\N	\N	\N	\N
23216	Yamaguchi 2014	\N	Filmed Social Contact versus Internet Self-Learning // Filmed Social Contact versus Game // Internet Self-Learning versus Game	\N	Japan	\N	\N	\N	\N	\N	250	\N	\N	\N	\N	\N
23217	Zvonkovic 2015	\N	Anti-Stigma Education versus Control Group	\N	USA	\N	\N	\N	\N	\N	94	\N	\N	\N	\N	\N
23218	Stralia 2015	\N	Sodium Benzoate versus Placebo	\N	Australia	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
23219	ChiCTR-IOR-15006278	\N	Aripiprazole versus Risperidone	\N	China	\N	\N	\N	\N	\N	13	\N	\N	\N	\N	\N
23220	ChiCTR-IPR-15006246	\N	Integrated Community Intervention	\N	China	\N	\N	\N	\N	\N	1200	\N	\N	\N	\N	\N
23221	CTRI-2015-01-005438	\N	Clozapine versus Risperidone	\N	India	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
23222	CTRI-2015-01-005448	\N	Theta Burst Repetitive Transcranial Magnetic Stimulation versus Sham	\N	India	\N	\N	\N	\N	\N	45	\N	\N	\N	\N	\N
23223	CTRI-2015-02-005575	\N	Haloperidol versus Olanzapine	\N	India	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
23224	CTRI 2015b	\N	Repetitive Transcranial Magnetic Stimulation versus Sham	\N	India	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
23225	Gaweda 2015	\N	Metacognitive Training versus TAU	\N	Poland	\N	\N	\N	\N	\N	44	\N	\N	\N	\N	\N
23226	Harder 2014	\N	Supportive Psychodynamic Psychotherapy (SPP) + Treatment As Usual versus Treatment As Usual	\N	Denmark	\N	\N	\N	\N	\N	269	\N	\N	\N	\N	\N
23228	Jones 2013a	\N	Oral Health Intervention versus TAU	\N	United Kingdom	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23230	Polo 2015	\N	Cognitive Behavioral Therapy versus Control Group	\N	Spain	\N	\N	\N	\N	\N	50	\N	\N	\N	\N	\N
23232	Schrijver 2014	\N	Haloperidol versus Placebo	\N	The Netherlands	\N	\N	\N	\N	\N	780	\N	\N	\N	\N	\N
23233	Stevenson 2014	\N	Part D Prescription Drug Plans (Medicare)	\N	USA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23235	EUCTR2014-001968-35	\N	Spironolactone Dosage // Spironolactone versus Placebo	\N	Germany	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23236	EUCTR2014-002765-30	\N	Aripiprazole Route // Paliperidone Route // Aripiprazole versus Paliperidone	\N	Multi-Center // Austria // Belgium // Bulgaria // Czech Republic // Denmark // Germany // Greece // Hungary // Israel // Italy // Netherlands // Norway // Poland // Romania // Spain // United Kingdom	\N	\N	\N	\N	\N	600	\N	\N	\N	\N	\N
23237	DRKS00007888	\N	Intervention for Depression (Web-Based) versus Waitlist	\N	Germany	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
23238	DRKS00008018	\N	Treatment for at Least 12 Months (Intermittent Treatment) versus Treatment for Only First Episode or As Required	\N	Germany	\N	\N	\N	\N	\N	666	\N	\N	\N	\N	\N
23239	JPRN 2015	\N	ME2112 versus Placebo	\N	Japan	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
23240	JPRN-UMIN000017047	\N	Blonanserin versus Olanzapine	\N	Japan	\N	\N	\N	\N	\N	60	\N	\N	\N	\N	\N
23241	Bendall 2015	\N	Befriending // Cognitive Behaviour Therapy	\N	Australia	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
23243	Chen 2015	\N	Case Management versus TAU	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
23244	Deane 2015	\N	Family Interventions (Correspondence Based)	\N	Australia	\N	\N	\N	\N	\N	81	\N	\N	\N	\N	\N
23248	Habib 2015	\N	Cognitive Behavioral Therapy (Culturally-Adopted) versus Treatment As Usual	\N	Pakistan	\N	\N	\N	\N	\N	42	\N	\N	\N	\N	\N
23251	Hindocha 2015	\N	Cannabidiol versus Delta-9-Tetrahydrocannabinol // Cannabidiol versus Cannabidiol + Delta-9-Tetrahydrocannabinol // Cannabidiol versus Placebo // Delta-9-Tetrahydrocannabinol versus Cannabidiol + Delta-9-Tetrahydrocannabinol // Delta-9-Tetrahydrocannabinol versus Placebo // Cannabidiol + Delta-9-Tetrahydrocannabinol versus Placebo	\N	United Kingdom	\N	\N	\N	\N	\N	48	\N	\N	\N	\N	\N
23254	Kane 2015b	\N	Community Care versus Integrated Treatment	\N	USA	\N	\N	\N	\N	\N	400	\N	\N	\N	\N	\N
23258	Lahti 1995	\N	Ketamine Dosage // Ketamine versus Placebo	\N	USA	\N	\N	\N	\N	\N	9	\N	\N	\N	\N	\N
23260	Meltzer 2001	\N	Apomorphine versus Placebo	\N	USA	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
23261	Mueller 2015	\N	Integrated Neurocognitive Therapy versus Treatment As Usual	\N	\N	\N	\N	\N	\N	\N	156	\N	\N	\N	\N	\N
23262	Naeem 2015	\N	Cognitive Behavioral Therapy (Culturally Adopted) versus TAU	\N	Pakistan	\N	\N	\N	\N	\N	116	\N	\N	\N	\N	\N
23263	Nottage 2015	\N	Delta-9-Tetrahydrocannabinol (THC) versus Placebo	\N	UK	\N	\N	\N	\N	\N	15	\N	\N	\N	\N	\N
23264	Othman 2014	\N	ABT-288 Dosage // ABT-288 versus Placebo	\N	USA	\N	\N	\N	\N	\N	67	\N	\N	\N	\N	\N
23267	Rapaport 1993	\N	Nalmefene versus Placebo	\N	USA	\N	\N	\N	\N	\N	11	\N	\N	\N	\N	\N
23270	Schirmer 2015	\N	Medication Training Program (Skills Based) versus Control Group	\N	Germany	\N	\N	\N	\N	\N	141	\N	\N	\N	\N	\N
23271	Stiekema 2015	\N	Cognitive Adaptation Training (Nursing Intervention) versus TAU	\N	The Netherlands	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23273	Volpe 2015	\N	Structured Group Reading Program versus Control Group	\N	Italy	\N	\N	\N	\N	\N	41	\N	\N	\N	\N	\N
23274	Wang 2015	\N	Education versus Progressive Muscle Relaxation // Education versus Education + Progressive Muscle Relaxation // Education versus Control Group // Education + Progressive Muscle Relaxation versus Progressive Muscle Relaxation // Progressive Muscle Relaxation versus Control Group // Education + Progressive Muscle Relaxation versus Control Group	\N	China	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
23275	Wani 2015	\N	Continuing Olanzapine // Switching To Aripiprazole	\N	India	\N	\N	\N	\N	\N	62	\N	\N	\N	\N	\N
23276	Xia 2014	\N	Aripiprazole versus Wuji Powder (TCM)	\N	China	\N	\N	\N	\N	\N	70	\N	\N	\N	\N	\N
23278	Yang 2012	\N	Vignettes	\N	China	\N	\N	\N	\N	\N	160	\N	\N	\N	\N	\N
23279	Zhang 2014a	\N	Aripiprazole versus Olanzapine // Aripiprazole versus Quetiapine // Olanzapine versus Quetiapine	\N	China	\N	\N	\N	\N	\N	164	\N	\N	\N	\N	\N
23283	Woolley 2015a	\N	Oxytocin (Intranasal) versus Placebo	\N	USA	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
23284	Zhang 2015	\N	Part D Prescription Drug Plans (Medicare)	\N	USA	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N	\N
23285	Ray 2015	\N	Repetitive Transcranial Magnetic Stimulation versus Sham // Repetitive Transcranial Magnetic Stimulation Dosage	\N	India	\N	\N	\N	\N	\N	40	\N	\N	\N	\N	\N
23286	NTR5135	\N	Trained Nurse versus TAU	\N	The Netherlands	\N	\N	\N	\N	\N	16	\N	\N	\N	\N	\N
23287	Berry 2015	\N	Psychological Intervention (Ward Based) versus TAU	\N	United Kingdom	\N	\N	\N	\N	\N	51	\N	\N	\N	\N	\N
23288	Buonocore 2015	\N	Cognitive Remediation Therapy + Metacognitive Training versus Cognitive Remediation Therapy + Control Group	\N	Italy	\N	\N	\N	\N	\N	57	\N	\N	\N	\N	\N
23291	Jenkins 2014	\N	Atypical Antipsychotics versus Placebo	\N	USA	\N	\N	\N	\N	\N	54	\N	\N	\N	\N	\N
23294	Kasckow 2015	\N	Telehealth Monitoring + Treatment As Usual versus Treatment As Usual	\N	USA	\N	\N	\N	\N	\N	25	\N	\N	\N	\N	\N
23296	Koren 2015	\N	Psychosocial Therapy (Group) versus Control Group	\N	Russia	\N	\N	\N	\N	\N	56	\N	\N	\N	\N	\N
23297	Kurtz 2015b	\N	Cognitive Remediation Program (Computer-Assisted) + Social Skills Training versus Computer Skills + Social Skills Training	\N	USA	\N	\N	\N	\N	\N	64	\N	\N	\N	\N	\N
23299	Lee 2015	\N	MK-212 versus Placebo	\N	USA	\N	\N	\N	\N	\N	69	\N	\N	\N	\N	\N
23300	Li 2014a	\N	Cognitive-Behavioral Therapy versus Supportive Therapy	\N	China	\N	\N	\N	\N	\N	192	\N	\N	\N	\N	\N
23302	Mendella 2015	\N	Compensatory Cognitive Training versus Treatment As Usual	\N	Canada	\N	\N	\N	\N	\N	27	\N	\N	\N	\N	\N
23307	Ran 2015	\N	Medication + Psychoeducation (Family) versus Medication // Medication + Psychoeducation (Family) versus Control Group // Medication versus Control Group	\N	China	\N	\N	\N	\N	\N	306	\N	\N	\N	\N	\N
23309	Veldhuizen 2015	\N	Housing First versus TAU	\N	Canada	\N	\N	\N	\N	\N	1158	\N	\N	\N	\N	\N
23311	Peet 2002	\N	Omega-3 Fatty Acid versus Placebo // Omega-3 Fatty Acid Dosage	\N	United Kingdom	\N	\N	\N	\N	\N	31	\N	\N	\N	\N	\N
\.


--
-- Data for Name: trial2condition; Type: TABLE DATA; Schema: clean; Owner: postgres
--

COPY trial2condition (trial_id, condition_id) FROM stdin;
138	1183
138	1188
138	1198
138	1206
138	45548
139	1183
139	1188
139	1198
139	1206
139	45548
140	1179
140	1188
140	1197
140	1201
140	45318
142	1183
142	1188
142	1218
142	1232
142	1233
143	1183
143	1188
143	1200
143	1206
143	1218
144	1183
144	1188
144	1206
144	1218
144	1229
145	1183
145	1188
145	1200
145	1206
145	1218
146	1183
146	1188
146	1198
146	1206
146	1211
147	1183
147	1188
147	1198
147	1206
147	1218
149	1183
149	1188
149	1200
149	1206
149	1218
150	1183
150	1188
150	1200
150	1206
150	1218
151	1183
151	1188
151	1206
151	1218
151	1229
152	1195
152	1198
152	1206
152	1218
152	45236
153	1183
153	1188
153	1198
153	1206
153	1218
154	1183
154	1188
154	1206
154	1218
154	1229
155	1180
155	1188
155	1197
155	1201
155	1277
156	1183
156	1188
156	1206
156	1222
156	1232
157	1183
157	1188
157	1206
157	1218
157	1232
158	1183
158	1188
158	1206
158	1218
158	1232
160	1183
160	1194
160	1206
160	1218
160	1232
162	1183
162	1188
162	1198
162	1206
162	1218
163	1183
163	1188
163	1198
163	1206
163	1218
164	1183
164	1191
164	1198
164	1206
164	1218
165	1183
165	1188
165	1206
165	1218
165	1229
166	1183
166	1198
166	1204
166	1218
166	1239
168	1183
168	1188
168	1198
168	1206
168	1213
168	1218
169	1183
169	1188
169	1206
169	1218
169	1232
170	1183
170	1188
170	1198
170	1206
170	1220
171	1183
171	1198
171	1206
171	1239
171	45539
172	1183
172	1199
172	1204
172	1218
172	1239
173	1183
173	1188
173	1194
173	1206
173	1218
173	1229
173	45134
174	1188
174	1198
174	1206
174	1211
174	45238
176	1183
176	1188
176	1206
176	1218
176	1229
177	1183
177	1188
177	1198
177	1206
177	1217
178	1183
178	1188
178	1198
178	1206
178	1218
179	1183
179	1188
179	1198
179	1206
179	1218
180	1183
180	1198
180	1206
180	1210
180	1239
181	1183
181	1194
181	1200
181	1206
181	1218
182	1183
182	1194
182	1198
182	1206
182	45134
185	1183
185	1188
185	1198
185	1206
185	1220
186	1183
186	1188
186	1198
186	1206
186	1218
187	1183
187	1188
187	1198
187	1206
187	45317
188	1183
188	1193
188	1218
188	1232
188	1233
189	1183
189	1188
189	1218
189	1232
189	1233
190	1183
190	1188
190	1206
190	1218
190	1232
191	1188
191	1218
191	1232
191	1233
191	45238
192	1183
192	1196
192	1232
192	1233
192	45014
196	1183
196	1188
196	1198
196	1206
196	1218
197	1183
197	1188
197	1198
197	1206
197	1218
198	1183
198	1188
198	1198
198	1206
198	1218
199	1183
199	1188
199	1198
199	1206
199	1218
200	1183
200	1188
200	1198
200	1204
200	1218
201	1183
201	1198
201	1206
201	1218
201	1239
202	1183
202	1188
202	1198
202	1206
202	1218
203	1183
203	1188
203	1194
203	1200
203	1206
203	1218
203	1229
204	1183
204	1188
204	1206
204	1218
204	1232
205	1183
205	1188
205	1198
205	1206
205	1218
207	1183
207	1188
207	1218
207	1229
207	1233
208	1183
208	1188
208	1198
208	1206
208	1213
209	1183
209	1188
209	1198
209	1206
209	1220
210	1183
210	1188
210	1198
210	1206
210	1220
211	1183
211	1188
211	1206
211	1232
211	45128
212	1183
212	1188
212	1206
212	1218
212	1232
215	1183
215	1188
215	1198
215	1206
215	1218
216	1183
216	1188
216	1218
216	1232
216	1233
218	1183
218	1188
218	1198
218	1206
218	1218
219	1188
219	1218
219	1232
219	1233
219	45236
220	1183
220	1188
220	1198
220	1206
220	1218
224	1183
224	1188
224	1206
224	1218
224	1232
225	1183
225	1188
225	1206
225	1218
225	1229
226	1188
226	1211
226	1232
226	1233
226	45236
227	1183
227	1188
227	1206
227	1218
227	1229
228	1183
228	1188
228	1198
228	1206
228	1218
229	1183
229	1194
229	1217
229	1232
229	1233
231	1183
231	1188
231	1198
231	1206
231	1218
232	1183
232	1188
232	1206
232	1218
232	1232
234	1183
234	1188
234	1198
234	1206
234	1218
235	1183
235	1188
235	1218
235	1232
235	1233
236	1183
236	1188
236	1198
236	1206
236	45134
237	1183
237	1188
237	1198
237	1206
237	1218
238	1183
238	1198
238	1206
238	1220
238	1239
239	1188
239	1218
239	1232
239	1233
239	45236
240	1183
240	1196
240	1198
240	1206
240	1218
241	1183
241	1188
241	1198
241	1206
241	1218
242	1188
242	1213
242	1232
242	1233
242	45238
243	1183
243	1188
243	1206
243	1218
243	1229
244	1183
244	1196
244	1198
244	1206
244	1218
245	1183
245	1196
245	1198
245	1206
245	1218
246	1183
246	1188
246	1200
246	1206
246	1218
247	1183
247	1188
247	1198
247	1206
247	1218
249	1183
249	1188
249	1198
249	1206
249	1218
252	1183
252	1188
252	1198
252	1206
252	1218
253	1183
253	1188
253	1206
253	1218
253	1232
254	1183
254	1188
254	1206
254	1218
254	1229
255	1183
255	1188
255	1206
255	1218
255	1229
256	1183
256	1188
256	1206
256	1218
256	1229
257	1183
257	1188
257	1206
257	1218
257	1229
258	1183
258	1193
258	1206
258	1218
258	1229
259	1183
259	1188
259	1206
259	1218
259	1229
261	1183
261	1193
261	1198
261	1206
261	1218
262	1183
262	1188
262	1206
262	1218
262	1229
263	1183
263	1194
263	1198
263	1206
263	1218
264	1183
264	1188
264	1206
264	1218
264	1229
265	1183
265	1188
265	1218
265	1232
265	1233
268	1183
268	1188
268	1206
268	1218
268	1229
269	1183
269	1188
269	1206
269	1218
269	1229
270	1183
270	1196
270	1206
270	1218
270	1229
271	1183
271	1196
271	1206
271	1218
271	1229
273	1188
273	1200
273	1206
273	1213
273	45238
274	1183
274	1188
274	1198
274	1206
274	1218
275	1183
275	1188
275	1205
275	1218
275	1232
276	1183
276	1188
276	1218
276	1232
276	1233
278	1183
278	1188
278	1206
278	1218
278	1229
279	1188
279	1206
279	1218
279	1229
279	45236
280	1195
280	1206
280	1218
280	1232
280	45238
281	1195
281	1206
281	1218
281	1232
281	45238
282	1183
282	1188
282	1206
282	1218
282	1229
283	1183
283	1188
283	1198
283	1206
283	1218
284	1183
284	1188
284	1198
284	1206
284	1218
285	1195
285	1206
285	1218
285	1232
285	45238
286	1195
286	1206
286	1219
286	1232
286	45238
287	1183
287	1188
287	1206
287	1218
287	1229
288	1188
288	1218
288	1232
288	1233
288	45238
289	1183
289	1188
289	1198
289	1206
289	1218
290	1183
290	1188
290	1198
290	1206
290	1218
291	1188
291	1206
291	1211
291	1232
291	45238
293	1183
293	1196
293	1206
293	1229
293	1257
294	1179
294	1191
294	1197
294	1201
294	1257
297	1183
297	1188
297	1206
297	1218
297	1232
298	1188
298	1206
298	1218
298	1232
298	45238
299	1183
299	1188
299	1206
299	1218
299	1232
300	1183
300	1188
300	1206
300	1213
300	1232
301	1183
301	1188
301	1206
301	1218
301	1232
302	1183
302	1188
302	1206
302	1218
302	1232
303	1183
303	1188
303	1206
303	1218
303	1229
304	1183
304	1194
304	1206
304	1218
304	1232
306	1183
306	1188
306	1206
306	1218
306	1232
307	1183
307	1188
307	1206
307	1218
307	1232
308	1183
308	1188
308	1206
308	1232
308	1246
309	1183
309	1188
309	1218
309	1232
309	1233
310	1183
310	1188
310	1206
310	1218
310	1229
311	1182
311	1188
311	1206
311	1218
311	1229
312	1188
312	1206
312	1218
312	1229
312	45238
313	1183
313	1194
313	1206
313	1218
313	1229
314	1183
314	1188
314	1206
314	1218
314	1229
316	1183
316	1188
316	1198
316	1206
316	1218
317	1183
317	1188
317	1218
317	1232
317	1233
318	1183
318	1188
318	1198
318	1206
318	1217
319	1183
319	1188
319	1198
319	1206
319	1218
320	1183
320	1188
320	1198
320	1206
320	1217
322	1183
322	1194
322	1198
322	1206
322	1218
323	1188
323	1200
323	1206
323	1218
323	45238
324	1183
324	1194
324	1206
324	1218
324	1229
325	1183
325	1188
325	1198
325	1206
325	1219
326	1183
326	1188
326	1206
326	1218
326	1229
329	1183
329	1188
329	1206
329	1218
329	1229
330	1188
330	1218
330	1232
330	1233
330	45238
332	1183
332	1188
332	1206
332	1218
332	1229
333	1183
333	1188
333	1198
333	1206
333	1218
334	1188
334	1206
334	1218
334	1229
334	45238
336	1195
336	1206
336	1218
336	1229
336	45238
337	1188
337	1206
337	1209
337	1229
337	45236
338	1183
338	1188
338	1206
338	1218
338	1229
339	1183
339	1188
339	1218
339	1232
339	1233
340	1183
340	1188
340	1200
340	1206
340	1218
342	1183
342	1188
342	1206
342	1220
342	1229
343	1183
343	1188
343	1200
343	1206
343	1218
346	1183
346	1188
346	1198
346	1206
346	1218
348	1183
348	1188
348	1206
348	1217
348	1229
352	1195
352	1206
352	1218
352	1229
352	45236
353	1183
353	1188
353	1206
353	1218
353	1229
355	1183
355	1188
355	1218
355	1232
355	1233
356	1183
356	1188
356	1206
356	1218
356	1229
357	1183
357	1188
357	1218
357	1232
357	1233
358	1183
358	1188
358	1198
358	1206
358	1209
359	1183
359	1188
359	1206
359	1218
359	1232
360	1183
360	1188
360	1206
360	1218
360	1229
361	1183
361	1188
361	1206
361	1218
361	1229
362	1183
362	1188
362	1198
362	1206
362	1217
363	1183
363	1188
363	1206
363	1218
363	1229
364	1183
364	1188
364	1206
364	1218
364	1229
365	1183
365	1188
365	1206
365	1218
365	1229
366	1183
366	1188
366	1206
366	1218
366	1229
367	1188
367	1218
367	1232
367	1233
367	45238
369	1183
369	1188
369	1218
369	1232
369	1233
370	1183
370	1188
370	1218
370	1232
370	1233
371	1183
371	1188
371	1206
371	1213
371	1229
372	1182
372	1188
372	1218
372	1232
372	1233
373	1183
373	1194
373	1218
373	1232
373	1233
374	1183
374	1188
374	1198
374	1206
374	1218
375	1183
375	1188
375	1206
375	1218
375	1229
377	1182
377	1188
377	1218
377	1232
377	1233
378	1183
378	1188
378	1200
378	1206
378	1218
379	1183
379	1188
379	1206
379	1218
379	1229
380	1183
380	1188
380	1206
380	1218
380	1232
382	1183
382	1188
382	1206
382	1218
382	1229
383	1183
383	1188
383	1198
383	1206
383	1218
384	1183
384	1188
384	1218
384	1232
384	1233
385	1183
385	1188
385	1206
385	1219
385	1229
386	1183
386	1188
386	1206
386	1220
386	1229
387	1183
387	1188
387	1206
387	1218
387	1229
388	1183
388	1194
388	1206
388	1218
388	1229
390	1183
390	1188
390	1206
390	1229
390	45134
391	1188
391	1218
391	1232
391	1233
391	45238
392	1183
392	1188
392	1206
392	1218
392	1229
393	1183
393	1188
393	1198
393	1206
393	1218
393	1232
393	1233
393	45236
394	1183
394	1196
394	1220
394	1232
394	1233
395	1183
395	1188
395	1206
395	1218
395	1229
396	1188
396	1206
396	1218
396	1229
396	45238
399	1183
399	1196
399	1218
399	1232
399	1233
401	1183
401	1188
401	1206
401	1218
401	1229
404	1188
404	1206
404	1218
404	1229
404	45238
405	1183
405	1188
405	1206
405	1220
405	1232
405	1233
405	45238
406	1183
406	1188
406	1206
406	1216
406	1229
407	1183
407	1188
407	1206
407	1218
407	1229
408	1183
408	1188
408	1206
408	1220
408	1229
409	1183
409	1188
409	1206
409	1218
409	1229
410	1183
410	1188
410	1206
410	1218
410	1229
411	1183
411	1196
411	1198
411	1206
411	1218
412	1183
412	1196
412	1198
412	1206
412	1218
414	1183
414	1188
414	1206
414	1218
414	1229
415	1183
415	1188
415	1206
415	1218
415	1229
416	1183
416	1188
416	1206
416	1218
416	1229
417	1183
417	1194
417	1206
417	1218
417	1229
418	1183
418	1194
418	1200
418	1206
418	1218
419	1183
419	1188
419	1206
419	1218
419	1229
420	1183
420	1194
420	1200
420	1206
420	1218
421	1183
421	1194
421	1200
421	1206
421	1218
422	1183
422	1188
422	1200
422	1206
422	1218
423	1183
423	1188
423	1198
423	1206
423	1218
424	1183
424	1188
424	1206
424	1220
424	1229
425	1183
425	1188
425	1198
425	1206
425	1218
426	1183
426	1188
426	1206
426	1218
426	1229
427	1183
427	1188
427	1198
427	1206
427	1218
428	1183
428	1188
428	1200
428	1218
428	1233
429	1183
429	1194
429	1206
429	1218
429	1229
430	1183
430	1188
430	1206
430	1220
430	1229
431	1183
431	1188
431	1206
431	1218
431	1229
433	1183
433	1188
433	1217
433	1232
433	1233
435	1183
435	1188
435	1206
435	1218
435	1229
436	1183
436	1194
436	1198
436	1206
436	1218
438	1183
438	1188
438	1199
438	1205
438	1218
439	1183
439	1188
439	1206
439	1218
439	1229
440	1183
440	1188
440	1198
440	1206
440	1218
441	1183
441	1188
441	1198
441	1206
441	1218
442	1183
442	1188
442	1200
442	1206
442	1218
443	1183
443	1196
443	1198
443	1218
443	1233
444	1188
444	1206
444	1220
444	1229
444	45238
445	1183
445	1188
445	1198
445	1206
445	1218
446	1188
446	1198
446	1210
446	1233
446	45238
447	1188
447	1198
447	1233
447	45019
447	45238
449	1188
449	1200
449	1206
449	1213
449	45236
450	1183
450	1188
450	1198
450	1206
450	1210
452	1183
452	1188
452	1218
452	1232
452	1233
453	1183
453	1188
453	1198
453	1206
453	1209
454	1194
454	1198
454	1206
454	1217
454	45238
455	1183
455	1188
455	1198
455	1206
455	45548
457	1183
457	1196
457	1218
457	1229
457	1233
458	1188
458	1218
458	1232
458	1233
458	45238
459	1188
459	1206
459	1218
459	1229
459	45238
460	1183
460	1188
460	1206
460	1218
460	1229
462	1183
462	1188
462	1206
462	1218
462	1229
463	1179
463	1188
463	1197
463	1201
463	1218
464	1183
464	1188
464	1206
464	1218
464	1229
465	1183
465	1194
465	1206
465	1211
465	1229
466	1183
466	1188
466	1198
466	1218
466	1233
467	1183
467	1188
467	1200
467	1206
467	1218
471	1183
471	1188
471	1218
471	1232
471	1233
473	1183
473	1188
473	1206
473	1218
473	1229
475	1183
475	1188
475	1198
475	1206
475	1218
478	1183
478	1188
478	1206
478	1218
478	1232
479	1179
479	1188
479	1197
479	1201
479	1218
480	1183
480	1194
480	1206
480	1218
480	1229
481	1183
481	1188
481	1232
481	1233
481	45134
482	1183
482	1188
482	1198
482	1206
482	1218
483	1183
483	1188
483	1198
483	1206
483	1218
486	1183
486	1188
486	1206
486	1218
486	1229
487	1183
487	1188
487	1206
487	1218
487	1229
488	1183
488	1188
488	1198
488	1206
488	1218
489	1183
489	1194
489	1206
489	1209
489	1229
490	1183
490	1188
490	1206
490	1218
490	1229
491	1183
491	1188
491	1200
491	1206
491	1218
492	1183
492	1188
492	1206
492	1218
492	1229
493	1183
493	1188
493	1206
493	1218
493	1229
494	1183
494	1188
494	1206
494	1218
494	1229
495	1183
495	1188
495	1198
495	1206
495	1218
496	1183
496	1188
496	1206
496	1218
496	1229
497	1183
497	1188
497	1198
497	1206
497	1218
498	1183
498	1188
498	1206
498	1220
498	1229
500	1183
500	1188
500	1218
500	1232
500	1233
501	1183
501	1188
501	1218
501	1232
501	1233
503	1183
503	1188
503	1206
503	1218
503	1229
504	1183
504	1188
504	1206
504	1218
504	1229
505	1188
505	1218
505	1232
505	1233
505	45238
507	1183
507	1188
507	1206
507	1218
507	1229
508	1183
508	1188
508	1218
508	1232
508	1233
509	1183
509	1188
509	1218
509	1232
509	1233
510	1183
510	1188
510	1218
510	1232
510	1233
511	1183
511	1188
511	1206
511	1218
511	1229
512	1183
512	1188
512	1206
512	1218
512	1229
513	1183
513	1188
513	1206
513	1218
513	1229
514	1183
514	1188
514	1206
514	1218
514	1229
515	1183
515	1188
515	1198
515	1206
515	1218
517	1179
517	1188
517	1197
517	1201
517	1218
518	1183
518	1188
518	1198
518	1206
518	1218
519	1183
519	1193
519	1198
519	1206
519	1218
520	1188
520	1218
520	1232
520	1233
520	45238
521	1183
521	1188
521	1206
521	1218
521	1229
522	1183
522	1188
522	1206
522	1218
522	1229
523	1183
523	1188
523	1200
523	1206
523	1218
525	1183
525	1188
525	1206
525	1218
525	1229
526	1183
526	1188
526	1206
526	1218
526	1229
527	1188
527	1206
527	1218
527	1229
527	45238
528	1183
528	1188
528	1206
528	1218
528	1229
529	1183
529	1188
529	1206
529	1218
529	1229
530	1183
530	1194
530	1232
530	1233
530	45545
531	1183
531	1188
531	1206
531	1218
531	1229
535	1183
535	1194
535	1206
535	1218
535	1229
536	1183
536	1194
536	1206
536	1218
536	1229
537	1183
537	1188
537	1206
537	1218
537	1229
538	1183
538	1188
538	1206
538	1218
538	1229
539	1183
539	1188
539	1206
539	1218
539	1229
540	1183
540	1188
540	1206
540	1218
540	1229
543	1183
543	1188
543	1206
543	1218
543	1229
544	1183
544	1188
544	1198
544	1206
544	1218
545	1188
545	1206
545	1218
545	1229
545	45238
547	1183
547	1194
547	1198
547	1206
547	1218
548	1183
548	1188
548	1198
548	1206
548	1218
549	1183
549	1188
549	1198
549	1206
549	1218
551	1183
551	1188
551	1206
551	1218
551	1229
552	1183
552	1188
552	1206
552	1220
552	1229
553	1195
553	1218
553	1232
553	1233
553	45236
554	1183
554	1188
554	1206
554	1218
554	1229
557	1183
557	1188
557	1198
557	1206
557	1218
559	1188
559	1206
559	1218
559	1229
559	45238
560	1183
560	1188
560	1206
560	1219
560	1229
561	1183
561	1188
561	1198
561	1206
561	1218
563	1183
563	1188
563	1206
563	1217
563	1229
564	1183
564	1188
564	1218
564	1232
564	1233
565	1183
565	1188
565	1206
565	1218
565	1229
566	1183
566	1188
566	1206
566	1218
566	1229
567	1188
567	1200
567	1206
567	1218
567	45238
568	1183
568	1188
568	1206
568	1218
568	1229
569	1183
569	1188
569	1198
569	1206
569	1218
571	1183
571	1188
571	1206
571	1218
571	1229
572	1183
572	1188
572	1198
572	1206
572	1218
574	1188
574	1218
574	1232
574	1233
574	45238
575	1183
575	1194
575	1200
575	1206
575	1218
576	1183
576	1188
576	1206
576	1216
576	1229
577	1188
577	1206
577	1218
577	1229
577	45238
578	1183
578	1188
578	1206
578	1218
578	1229
579	1183
579	1188
579	1218
579	1232
579	1233
582	1183
582	1188
582	1218
582	1232
582	1233
585	1183
585	1194
585	1200
585	1206
585	1218
586	1183
586	1188
586	1198
586	1206
586	1222
586	45548
587	1183
587	1188
587	1206
587	1218
587	1229
589	1183
589	1188
589	1206
589	1218
589	1229
590	1183
590	1188
590	1206
590	1218
590	1229
591	1183
591	1188
591	1206
591	1218
591	1229
593	1183
593	1188
593	1206
593	1218
593	1229
594	1183
594	1188
594	1206
594	1218
594	1229
595	1183
595	1188
595	1218
595	1232
595	1233
596	1188
596	1218
596	1232
596	1233
596	45238
597	1188
597	1222
597	1232
597	1233
597	45238
598	1183
598	1188
598	1198
598	1206
598	1218
599	1183
599	1188
599	1204
599	1218
599	1232
601	1183
601	1188
601	1206
601	1218
601	1229
602	1188
602	1198
602	1206
602	1218
602	45236
604	1188
604	1206
604	1218
604	1229
604	45238
605	1183
605	1188
605	1206
605	1218
605	1229
607	1188
607	1206
607	1220
607	1229
607	45238
608	1183
608	1188
608	1206
608	1218
608	1229
609	1183
609	1188
609	1206
609	1218
609	1229
611	1183
611	1188
611	1206
611	1218
611	1229
612	1183
612	1188
612	1206
612	1218
612	1232
613	1183
613	1188
613	1206
613	1218
613	1229
615	1188
615	1209
615	1232
615	1233
615	45238
617	1183
617	1188
617	1200
617	1206
617	1218
618	1188
618	1206
618	1218
618	1229
618	45236
619	1188
619	1218
619	1232
619	1233
619	45238
620	1183
620	1188
620	1206
620	1218
620	1229
621	1183
621	1188
621	1206
621	1220
621	1229
623	1183
623	1188
623	1206
623	1218
623	1229
624	1183
624	1198
624	1206
624	1218
624	1239
625	1183
625	1188
625	1198
625	1206
625	1218
626	1188
626	1206
626	1218
626	1229
626	45238
628	1183
628	1188
628	1206
628	1218
628	1229
629	1183
629	1188
629	1206
629	1218
629	1229
630	1183
630	1188
630	1206
630	1218
630	1229
632	1188
632	1218
632	1232
632	1233
632	45236
633	1183
633	1188
633	1198
633	1206
633	1218
634	1183
634	1188
634	1198
634	1206
634	1218
635	1183
635	1196
635	1198
635	1206
635	1218
636	1183
636	1188
636	1206
636	1218
636	1229
637	1183
637	1194
637	1206
637	1218
637	1229
638	1183
638	1194
638	1206
638	1218
638	1229
639	1183
639	1188
639	1200
639	1206
639	1218
640	1188
640	1218
640	1232
640	1233
640	45238
641	1183
641	1188
641	1206
641	1218
641	1229
642	1188
642	1200
642	1206
642	1218
642	45238
643	1183
643	1188
643	1206
643	1218
643	1229
644	1188
644	1218
644	1232
644	1233
644	45238
646	1183
646	1188
646	1206
646	1217
646	1229
648	1183
648	1188
648	1206
648	1218
648	1229
649	1183
649	1188
649	1206
649	1218
649	1229
650	1183
650	1188
650	1206
650	1218
650	1229
652	1183
652	1188
652	1206
652	1218
652	1229
653	1188
653	1206
653	1232
653	45019
653	45236
656	1188
656	1206
656	1218
656	1219
656	1229
656	45236
657	1183
657	1188
657	1206
657	1218
657	1229
658	1183
658	1188
658	1206
658	1218
658	1229
660	1188
660	1206
660	1218
660	1229
660	45238
661	1195
661	1206
661	1218
661	1229
661	45238
662	1179
662	1188
662	1197
662	1201
662	1218
663	1183
663	1188
663	1206
663	1218
663	1229
664	1183
664	1188
664	1198
664	1206
664	1218
665	1183
665	1188
665	1198
665	1206
665	1218
666	1183
666	1188
666	1206
666	1218
666	1229
667	1183
667	1188
667	1206
667	1218
667	1229
668	1183
668	1188
668	1198
668	1206
668	1218
669	1183
669	1188
669	1206
669	1218
669	1229
670	1183
670	1194
670	1198
670	1206
670	1218
671	1188
671	1206
671	1218
671	1229
671	45238
672	1188
672	1206
672	1218
672	1229
672	45238
673	1195
673	1206
673	1218
673	1229
673	45236
674	1183
674	1195
674	1206
674	1218
674	1229
676	1183
676	1188
676	1198
676	1206
676	1218
677	1188
677	1198
677	1206
677	1218
677	45238
678	1183
678	1188
678	1206
678	1218
678	1229
679	1188
679	1198
679	1206
679	1218
679	45238
680	1188
680	1198
680	1206
680	1218
680	45236
681	1183
681	1188
681	1206
681	1218
681	1229
682	1183
682	1188
682	1206
682	1217
682	1229
683	1183
683	1188
683	1206
683	1211
683	1229
685	1183
685	1188
685	1206
685	1218
685	1229
686	1183
686	1194
686	1206
686	1218
686	1229
687	1183
687	1188
687	1218
687	1232
687	1233
688	1183
688	1188
688	1206
688	1218
688	1229
689	1183
689	1188
689	1206
689	1218
689	1229
690	1188
690	1218
690	1232
690	1233
690	45238
691	1188
691	1206
691	1220
691	1229
691	45238
694	1183
694	1188
694	1200
694	1206
694	1218
696	1183
696	1188
696	1206
696	1219
696	1229
697	1183
697	1188
697	1206
697	1218
697	1229
698	1183
698	1194
698	1206
698	1218
698	1229
699	1183
699	1194
699	1206
699	1220
699	1229
700	1188
700	1206
700	1229
700	45238
700	45337
702	1188
702	1218
702	1232
702	1233
702	45238
703	1183
703	1188
703	1206
703	1218
703	1229
704	1183
704	1188
704	1206
704	1218
704	1229
705	1183
705	1188
705	1218
705	1232
705	1233
706	1183
706	1188
706	1198
706	1206
706	1218
707	1183
707	1188
707	1198
707	1206
707	1218
708	1188
708	1200
708	1206
708	1218
708	45238
709	1183
709	1188
709	1206
709	1218
709	1229
710	1183
710	1188
710	1206
710	1218
710	1229
712	1183
712	1194
712	1198
712	1206
712	1218
713	1183
713	1188
713	1198
713	1206
713	1218
714	1183
714	1194
714	1206
714	1218
714	1229
715	1183
715	1188
715	1206
715	1218
715	1229
716	1183
716	1188
716	1206
716	1218
716	1229
717	1183
717	1188
717	1206
717	1218
717	1232
718	1179
718	1188
718	1197
718	1201
718	1218
719	1183
719	1188
719	1200
719	1206
719	1218
720	1183
720	1188
720	1218
720	1232
720	1233
721	1183
721	1188
721	1206
721	1218
721	1229
722	1183
722	1194
722	1200
722	1206
722	1218
723	1179
723	1188
723	1197
723	1201
723	1218
725	1183
725	1194
725	1206
725	1220
725	1229
726	1183
726	1194
726	1206
726	1211
726	1229
727	1183
727	1194
727	1206
727	1218
727	1229
728	1188
728	1218
728	1232
728	1233
728	45238
729	1183
729	1196
729	1206
729	1218
729	1229
730	1188
730	1198
730	1206
730	1218
730	45238
731	1188
731	1206
731	1218
731	1229
731	45238
732	1183
732	1196
732	1218
732	1232
732	1233
733	1183
733	1188
733	1205
733	1218
733	1232
734	1188
734	1206
734	1218
734	1229
734	45238
735	1188
735	1206
735	1218
735	1229
735	45238
736	1188
736	1198
736	1206
736	45238
736	45548
737	1183
737	1188
737	1206
737	1218
737	1229
738	1183
738	1188
738	1206
738	1218
738	1229
739	1183
739	1188
739	1206
739	1218
739	1229
740	1183
740	1188
740	1216
740	1232
740	1233
741	1188
741	1200
741	1206
741	1218
741	45238
742	1183
742	1188
742	1218
742	1232
742	1233
744	1188
744	1218
744	1232
744	1233
744	45238
746	1183
746	1188
746	1206
746	1218
746	1229
747	1183
747	1188
747	1206
747	1218
747	1229
748	1183
748	1188
748	1206
748	1218
748	1229
749	1183
749	1188
749	1206
749	1218
749	1229
750	1188
750	1218
750	1232
750	1233
750	45238
751	1179
751	1188
751	1197
751	1201
751	1218
752	1183
752	1188
752	1206
752	1218
752	1229
753	1183
753	1188
753	1206
753	1218
753	1229
755	1188
755	1206
755	1218
755	1229
755	45238
758	1183
758	1188
758	1218
758	1232
758	1233
759	1183
759	1188
759	1198
759	1206
759	1218
762	1183
762	1188
762	1206
762	1218
762	1229
763	1183
763	1188
763	1206
763	1211
763	1229
765	1183
765	1194
765	1206
765	1218
765	1229
766	1183
766	1188
766	1206
766	1218
766	1229
767	1183
767	1188
767	1198
767	1206
767	1218
768	1183
768	1188
768	1206
768	1220
768	1229
769	1183
769	1188
769	1206
769	1218
769	1229
770	1179
770	1188
770	1197
770	1201
770	1218
771	1188
771	1206
771	1218
771	1229
771	45238
772	1188
772	1218
772	1232
772	1233
772	45238
773	1188
773	1206
773	1211
773	1229
773	45238
774	1183
774	1188
774	1198
774	1206
774	1218
775	1183
775	1188
775	1206
775	1213
775	1229
776	1188
776	1206
776	1218
776	1229
776	45238
777	1183
777	1188
777	1198
777	1206
777	1210
778	1195
778	1198
778	1206
778	1218
778	45236
779	1183
779	1188
779	1198
779	1206
779	1218
780	1183
780	1188
780	1206
780	1218
780	1229
782	1183
782	1188
782	1198
782	1206
782	1218
783	1183
783	1188
783	1206
783	1218
783	1229
784	1183
784	1188
784	1206
784	1218
784	1229
785	1183
785	1188
785	1206
785	1218
785	1229
786	1183
786	1188
786	1206
786	1218
786	1229
788	1183
788	1188
788	1206
788	1218
788	1229
789	1183
789	1188
789	1206
789	1218
789	1229
790	1183
790	1188
790	1206
790	1218
790	1229
791	1183
791	1188
791	1206
791	1218
791	1229
792	1188
792	1206
792	1218
792	1229
792	45236
793	1183
793	1188
793	1206
793	1218
793	1229
796	1183
796	1188
796	1206
796	1218
796	1229
797	1183
797	1188
797	1206
797	1218
797	1229
798	1183
798	1188
798	1206
798	1218
798	1229
799	1183
799	1188
799	1206
799	1218
799	1229
800	1183
800	1196
800	1218
800	1232
800	1233
801	1183
801	1188
801	1206
801	1218
801	1229
802	1183
802	1188
802	1206
802	1218
802	1229
804	1183
804	1188
804	1206
804	1220
804	1229
805	1188
805	1206
805	1218
805	1229
805	45236
807	1183
807	1188
807	1206
807	1218
807	1229
808	1183
808	1188
808	1206
808	1218
808	1229
809	1183
809	1188
809	1198
809	1206
809	1218
810	1188
810	1198
810	1206
810	1210
810	45236
811	1183
811	1188
811	1198
811	1206
811	1218
812	1183
812	1188
812	1206
812	1218
812	1229
813	1183
813	1188
813	1198
813	1206
813	1218
814	1183
814	1188
814	1198
814	1206
814	1218
815	1188
815	1206
815	1220
815	1229
815	45238
816	1183
816	1188
816	1206
816	1218
816	1229
818	1183
818	1188
818	1206
818	1218
818	1229
819	1183
819	1188
819	1200
819	1206
819	1218
820	1183
820	1188
820	1218
820	1232
820	1233
822	1183
822	1188
822	1198
822	1206
822	1216
824	1183
824	1188
824	1206
824	1218
824	1229
825	1183
825	1188
825	1198
825	1206
825	1218
827	1183
827	1196
827	1198
827	1206
827	1218
829	1188
829	1198
829	1206
829	1218
829	45238
830	1188
830	1206
830	1218
830	1229
830	45238
831	1183
831	1188
831	1206
831	1218
831	1229
833	1183
833	1188
833	1206
833	1218
833	1229
834	1183
834	1194
834	1200
834	1205
834	1218
836	1188
836	1200
836	1206
836	1218
836	45238
837	1183
837	1194
837	1206
837	1218
837	1229
838	1183
838	1194
838	1218
838	1232
838	1233
839	1183
839	1196
839	1206
839	1218
839	1229
840	1188
840	1206
840	1220
840	1229
840	45238
841	1183
841	1188
841	1200
841	1206
841	1218
842	1183
842	1188
842	1198
842	1206
842	1218
843	1183
843	1194
843	1200
843	1206
843	1218
844	1183
844	1188
844	1200
844	1206
844	1218
845	1183
845	1188
845	1206
845	1218
845	1229
846	1183
846	1188
846	1198
846	1206
846	1218
847	1183
847	1188
847	1206
847	1218
847	1229
848	1183
848	1188
848	1198
848	1206
848	1218
849	1183
849	1188
849	1206
849	1218
849	1229
850	1183
850	1188
850	1218
850	1232
850	1233
851	1183
851	1188
851	1206
851	1218
851	1229
852	1183
852	1188
852	1206
852	1218
852	1229
854	1195
854	1198
854	1206
854	1218
854	45238
855	1183
855	1188
855	1206
855	1218
855	1229
856	1183
856	1188
856	1200
856	1206
856	1222
857	1182
857	1188
857	1206
857	1218
857	1229
858	1188
858	1206
858	1218
858	1229
858	45236
859	1183
859	1188
859	1206
859	1218
859	1229
861	1188
861	1206
861	1218
861	1229
861	45238
862	1183
862	1188
862	1206
862	1218
862	1229
863	1188
863	1218
863	1232
863	1233
863	45236
864	1188
864	1206
864	1218
864	1229
864	45236
865	1179
865	1188
865	1197
865	1201
865	1218
866	1183
866	1193
866	1198
866	1206
866	1218
867	1183
867	1193
867	1206
867	1218
867	1229
869	1183
869	1188
869	1206
869	1218
869	1229
870	1183
870	1188
870	1206
870	1220
870	1229
871	1183
871	1188
871	1198
871	1206
871	1218
873	1183
873	1188
873	1206
873	1218
873	1229
874	1183
874	1188
874	1206
874	1219
874	1229
875	1183
875	1196
875	1206
875	1218
875	1229
876	1188
876	1200
876	1206
876	1218
876	45236
877	1188
877	1200
877	1206
877	1218
877	45236
878	1183
878	1188
878	1198
878	1206
878	1218
879	1183
879	1188
879	1206
879	1218
879	1229
881	1183
881	1188
881	1206
881	1218
881	1229
882	1183
882	1188
882	1198
882	1206
882	1218
883	1183
883	1188
883	1198
883	1206
883	1218
884	1183
884	1188
884	1206
884	1218
884	1229
885	1183
885	1188
885	1218
885	1232
885	1233
886	1183
886	1194
886	1218
886	1232
886	1233
887	1183
887	1188
887	1218
887	1232
887	1233
888	1183
888	1196
888	1198
888	1206
888	1218
890	1179
890	1188
890	1197
890	1201
890	1218
891	1183
891	1188
891	1206
891	1218
891	1229
892	1183
892	1188
892	1206
892	1218
892	1229
893	1183
893	1194
893	1198
893	1205
893	1218
894	1183
894	1188
894	1200
894	1206
894	1218
895	1183
895	1194
895	1200
895	1206
895	1218
896	1183
896	1188
896	1206
896	1218
896	1229
898	1183
898	1188
898	1206
898	1218
898	1229
899	1183
899	1188
899	1206
899	1218
899	1229
900	1183
900	1188
900	1206
900	1218
900	1229
901	1183
901	1188
901	1198
901	1206
901	1218
902	1183
902	1188
902	1198
902	1206
902	1218
903	1183
903	1188
903	1206
903	1218
903	1229
904	1183
904	1188
904	1206
904	1218
904	1229
905	1183
905	1188
905	1206
905	1218
905	1229
906	1183
906	1188
906	1206
906	1218
906	1229
907	1183
907	1188
907	1206
907	1218
907	1229
908	1183
908	1188
908	1218
908	1232
908	1233
909	1183
909	1188
909	1200
909	1206
909	1218
911	1183
911	1196
911	1198
911	1206
911	1218
912	1188
912	1198
912	1206
912	1218
912	45238
913	1183
913	1188
913	1206
913	1218
913	1229
914	1183
914	1188
914	1218
914	1232
914	1233
915	1183
915	1188
915	1206
915	1218
915	1229
916	1183
916	1188
916	1198
916	1218
916	1233
917	1183
917	1188
917	1206
917	1218
917	1229
918	1183
918	1188
918	1206
918	1218
918	1229
919	1183
919	1188
919	1206
919	1218
919	1229
920	1188
920	1218
920	1232
920	1233
920	45238
921	1188
921	1218
921	1232
921	1233
921	45238
922	1183
922	1188
922	1206
922	1218
922	1229
923	1188
923	1218
923	1232
923	1233
923	45238
924	1179
924	1188
924	1197
924	1201
924	1218
925	1179
925	1188
925	1197
925	1201
925	1218
926	1179
926	1188
926	1197
926	1201
926	1218
927	1179
927	1188
927	1197
927	1201
927	1218
928	1179
928	1188
928	1197
928	1201
928	1218
929	1179
929	1188
929	1197
929	1201
929	1218
930	1179
930	1188
930	1218
930	1232
930	1233
931	1183
931	1188
931	1198
931	1206
931	1218
932	1183
932	1188
932	1206
932	1218
932	1229
933	1183
933	1188
933	1206
933	1218
933	1229
934	1188
934	1206
934	1218
934	1229
934	45238
935	1183
935	1188
935	1218
935	1232
935	1233
936	1183
936	1188
936	1206
936	1218
936	1229
937	1183
937	1188
937	1206
937	1218
937	1229
938	1183
938	1218
938	1232
938	1233
938	1239
939	1183
939	1188
939	1198
939	1206
939	1218
940	1183
940	1188
940	1206
940	1218
940	1229
941	1183
941	1188
941	1206
941	1218
941	1229
943	1183
943	1188
943	1198
943	1206
943	1218
944	1183
944	1188
944	1206
944	1218
944	1229
946	1183
946	1188
946	1206
946	1218
946	1229
947	1183
947	1188
947	1222
947	1232
947	1233
948	1183
948	1188
948	1198
948	1206
948	1218
949	1183
949	1188
949	1206
949	1218
949	1229
950	1183
950	1188
950	1206
950	1218
950	1229
951	1183
951	1188
951	1206
951	1216
951	1229
952	1183
952	1188
952	1200
952	1203
952	1218
953	1183
953	1188
953	1200
953	1206
953	1218
954	1183
954	1188
954	1206
954	1218
954	1229
955	1183
955	1188
955	1206
955	1218
955	1229
956	1183
956	1188
956	1206
956	1217
956	1229
957	1183
957	1188
957	1206
957	1219
957	1229
958	1183
958	1188
958	1206
958	1218
958	1229
959	1183
959	1188
959	1198
959	1206
959	1218
960	1183
960	1188
960	1206
960	1218
960	1229
964	1183
964	1188
964	1206
964	1218
964	1229
966	1183
966	1194
966	1200
966	1206
966	1218
967	1183
967	1188
967	1198
967	1206
967	1218
968	1183
968	1188
968	1198
968	1206
968	1247
969	1183
969	1188
969	1198
969	1206
969	1218
970	1183
970	1196
970	1198
970	1218
970	1233
971	1188
971	1198
971	1206
971	1218
971	45238
972	1183
972	1188
972	1198
972	1206
972	1218
973	1188
973	1198
973	1206
973	1217
973	45236
974	1183
974	1188
974	1198
974	1206
974	1218
975	1183
975	1188
975	1206
975	1218
975	1229
977	1183
977	1188
977	1200
977	1206
977	1218
978	1183
978	1188
978	1218
978	1232
978	1233
979	1183
979	1194
979	1200
979	1206
979	1218
981	1183
981	1188
981	1206
981	1220
981	1229
982	1183
982	1188
982	1198
982	1206
982	1217
983	1188
983	1206
983	1218
983	1229
983	45236
984	1183
984	1188
984	1206
984	1218
984	1232
987	1183
987	1188
987	1206
987	1218
987	1229
988	1183
988	1188
988	1206
988	1218
988	1229
989	1183
989	1188
989	1198
989	1206
989	1218
991	1183
991	1188
991	1206
991	1218
991	1229
992	1179
992	1188
992	1197
992	1201
992	1218
993	1183
993	1188
993	1206
993	1218
993	1229
994	1188
994	1206
994	1218
994	1229
994	45238
995	1188
995	1218
995	1232
995	1233
995	45238
996	1183
996	1188
996	1206
996	1218
996	1229
997	1188
997	1218
997	1232
997	1233
997	45238
998	1188
998	1206
998	1218
998	1229
998	45238
999	1188
999	1206
999	1218
999	1229
999	45238
1000	1183
1000	1188
1000	1206
1000	1218
1000	1229
1001	1183
1001	1188
1001	1206
1001	1218
1001	1229
1004	1183
1004	1188
1004	1206
1004	1218
1004	1229
1006	1183
1006	1188
1006	1206
1006	1218
1006	1229
1007	1183
1007	1188
1007	1206
1007	1218
1007	1229
1008	1188
1008	1206
1008	1218
1008	1229
1008	45236
1010	1183
1010	1188
1010	1206
1010	1218
1010	1229
1011	1188
1011	1206
1011	1218
1011	1229
1011	45236
1012	1188
1012	1232
1012	1233
1012	45238
1012	45549
1013	1183
1013	1188
1013	1198
1013	1206
1013	1221
1014	1183
1014	1194
1014	1218
1014	1232
1014	1233
1015	1183
1015	1188
1015	1200
1015	1206
1015	1218
1016	1183
1016	1188
1016	1198
1016	1206
1016	1218
1017	1188
1017	1206
1017	1218
1017	1229
1017	45236
1019	1188
1019	1206
1019	1218
1019	1229
1019	45236
1021	1183
1021	1188
1021	1206
1021	1218
1021	1229
1022	1183
1022	1188
1022	1206
1022	1218
1022	1229
1023	1183
1023	1188
1023	1206
1023	1222
1023	1229
1024	1183
1024	1188
1024	1206
1024	1218
1024	1229
1025	1183
1025	1188
1025	1206
1025	1218
1025	1229
1026	1183
1026	1188
1026	1200
1026	1206
1026	1218
1027	1183
1027	1188
1027	1206
1027	1211
1027	1229
1028	1183
1028	1188
1028	1206
1028	1218
1028	1229
1029	1183
1029	1188
1029	1218
1029	1232
1029	1233
1031	1183
1031	1188
1031	1198
1031	1206
1031	1218
1032	1183
1032	1188
1032	1206
1032	1218
1032	1229
1033	1183
1033	1188
1033	1206
1033	1218
1033	1229
1034	1183
1034	1188
1034	1206
1034	1218
1034	1229
1035	1183
1035	1188
1035	1206
1035	1218
1035	1229
1038	1183
1038	1188
1038	1198
1038	1206
1038	1218
1039	1183
1039	1198
1039	1206
1039	1218
1039	1239
1041	1183
1041	1188
1041	1198
1041	1206
1041	1218
1043	1183
1043	1188
1043	1206
1043	1219
1043	1229
1044	1188
1044	1218
1044	1232
1044	1233
1044	45238
1045	1188
1045	1199
1045	1206
1045	1218
1045	45236
1046	1183
1046	1196
1046	1218
1046	1229
1046	1233
1048	1183
1048	1188
1048	1232
1048	1233
1048	1258
1049	1183
1049	1188
1049	1206
1049	1218
1049	1229
1050	1183
1050	1188
1050	1206
1050	1218
1050	1229
1051	1183
1051	1188
1051	1206
1051	1219
1051	1229
1052	1183
1052	1188
1052	1200
1052	1206
1052	1218
1053	1183
1053	1188
1053	1198
1053	1206
1053	1218
1054	1183
1054	1188
1054	1206
1054	1218
1054	1229
1056	1183
1056	1188
1056	1198
1056	1206
1056	1218
1057	1183
1057	1188
1057	1206
1057	1218
1057	1229
1059	1183
1059	1188
1059	1206
1059	1218
1059	1229
1060	1183
1060	1188
1060	1206
1060	1216
1060	1229
1061	1183
1061	1188
1061	1206
1061	1219
1061	1229
1066	1179
1066	1191
1066	1197
1066	1201
1066	1218
1067	1179
1067	1191
1067	1197
1067	1201
1067	1218
1070	1183
1070	1188
1070	1206
1070	1232
1070	1258
1073	1183
1073	1188
1073	1206
1073	1218
1073	1229
1075	1183
1075	1188
1075	1198
1075	1206
1075	1218
1076	1183
1076	1188
1076	1198
1076	1206
1076	1218
1078	1183
1078	1188
1078	1206
1078	1219
1078	1229
1080	1188
1080	1206
1080	1218
1080	1229
1080	45238
1081	1183
1081	1188
1081	1206
1081	1218
1081	1229
1083	1188
1083	1200
1083	1220
1083	1233
1083	45238
1084	1188
1084	1206
1084	1218
1084	1229
1084	45238
1085	1183
1085	1196
1085	1206
1085	1218
1085	1229
1086	1183
1086	1188
1086	1206
1086	1220
1086	1229
1087	1183
1087	1188
1087	1200
1087	1206
1087	1218
1089	1183
1089	1188
1089	1206
1089	1218
1089	1229
1090	1183
1090	1188
1090	1206
1090	1220
1090	1229
1091	1183
1091	1188
1091	1198
1091	1206
1091	1218
1092	1183
1092	1188
1092	1206
1092	1218
1092	1229
1094	1188
1094	1218
1094	1232
1094	1233
1094	45238
1095	1183
1095	1188
1095	1206
1095	1218
1095	1229
1096	1183
1096	1188
1096	1206
1096	1218
1096	1229
1097	1183
1097	1188
1097	1198
1097	1206
1097	1218
1098	1188
1098	1198
1098	1206
1098	1218
1098	45238
1099	1183
1099	1188
1099	1218
1099	1232
1099	1233
1101	1183
1101	1194
1101	1198
1101	1206
1101	1218
1103	1183
1103	1188
1103	1213
1103	1232
1103	1233
1104	1183
1104	1188
1104	1213
1104	1232
1104	1233
1105	1183
1105	1188
1105	1206
1105	1218
1105	1229
1106	1183
1106	1188
1106	1213
1106	1232
1106	1233
1108	1183
1108	1194
1108	1198
1108	1206
1108	1218
1109	1183
1109	1188
1109	1206
1109	1218
1109	1229
1110	1183
1110	1188
1110	1206
1110	1218
1110	1229
1111	1183
1111	1188
1111	1206
1111	1219
1111	1229
1112	1188
1112	1218
1112	1232
1112	1233
1112	45238
1113	1188
1113	1206
1113	1218
1113	1229
1113	45238
1114	1188
1114	1200
1114	1206
1114	1218
1114	45238
1115	1183
1115	1188
1115	1206
1115	1218
1115	1229
1116	1183
1116	1194
1116	1206
1116	1218
1116	1229
1117	1183
1117	1188
1117	1206
1117	1218
1117	1229
1118	1183
1118	1188
1118	1206
1118	1218
1118	1229
1119	1183
1119	1188
1119	1206
1119	1220
1119	1229
1120	1183
1120	1188
1120	1198
1120	1206
1120	1218
1121	1183
1121	1188
1121	1198
1121	1206
1121	1213
1122	1183
1122	1188
1122	1200
1122	1206
1122	1218
1124	1183
1124	1188
1124	1198
1124	1206
1124	1213
1125	1183
1125	1188
1125	1198
1125	1206
1125	1213
1126	1183
1126	1194
1126	1206
1126	1218
1126	1229
1127	1183
1127	1188
1127	1206
1127	1218
1127	1229
1128	1183
1128	1188
1128	1198
1128	1206
1128	1218
1129	1183
1129	1194
1129	1198
1129	1206
1129	1218
1130	1183
1130	1188
1130	1200
1130	1206
1130	1218
1131	1183
1131	1188
1131	1206
1131	1218
1131	1229
1132	1183
1132	1188
1132	1206
1132	1218
1132	1229
1133	1183
1133	1188
1133	1206
1133	1218
1133	1229
1136	1183
1136	1188
1136	1198
1136	1206
1136	1218
1137	1183
1137	1188
1137	1206
1137	1218
1137	1229
1138	1183
1138	1188
1138	1206
1138	1218
1138	1229
1139	1183
1139	1188
1139	1198
1139	1206
1139	1218
1140	1183
1140	1188
1140	1198
1140	1206
1140	1218
1142	1183
1142	1188
1142	1198
1142	1206
1142	1218
1143	1183
1143	1188
1143	1218
1143	1232
1143	1233
1144	1183
1144	1188
1144	1198
1144	1206
1144	1218
1145	1183
1145	1188
1145	1206
1145	1218
1145	1229
1146	1183
1146	1188
1146	1206
1146	1218
1146	1229
1147	1183
1147	1188
1147	1218
1147	1232
1147	1233
1148	1183
1148	1188
1148	1198
1148	1206
1148	1218
1149	1188
1149	1198
1149	1206
1149	1219
1149	45236
1150	1183
1150	1188
1150	1206
1150	1218
1150	1229
1151	1183
1151	1188
1151	1218
1151	1232
1151	1233
1152	1183
1152	1188
1152	1218
1152	1232
1152	1233
1153	1188
1153	1198
1153	1206
1153	1218
1153	45238
1154	1183
1154	1196
1154	1198
1154	1206
1154	1218
1155	1183
1155	1194
1155	1206
1155	1218
1155	1229
1156	1183
1156	1194
1156	1218
1156	1232
1156	1233
1157	1183
1157	1188
1157	1198
1157	1218
1157	1233
1158	1183
1158	1194
1158	1200
1158	1206
1158	1218
1159	1183
1159	1188
1159	1206
1159	1218
1159	1229
1160	1183
1160	1188
1160	1206
1160	1218
1160	1229
1161	1183
1161	1188
1161	1206
1161	1218
1161	1229
1162	1183
1162	1188
1162	1206
1162	1218
1162	1232
1164	1183
1164	1194
1164	1206
1164	1218
1164	1229
1165	1183
1165	1188
1165	1198
1165	1206
1165	1218
1170	1183
1170	1188
1170	1218
1170	1232
1170	1233
1171	1183
1171	1188
1171	1206
1171	1218
1171	1229
1172	1183
1172	1188
1172	1206
1172	1218
1172	1229
1173	1188
1173	1198
1173	1206
1173	1218
1173	45238
1175	1188
1175	1206
1175	1218
1175	1229
1175	45238
1176	1183
1176	1188
1176	1206
1176	1218
1176	1232
1177	1183
1177	1188
1177	1198
1177	1206
1177	1218
1178	1183
1178	1188
1178	1206
1178	1218
1178	1229
1179	1183
1179	1188
1179	1198
1179	1206
1179	1218
1180	1183
1180	1188
1180	1206
1180	1218
1180	1229
1181	1183
1181	1188
1181	1206
1181	1218
1181	1232
1182	1183
1182	1188
1182	1206
1182	1218
1182	1229
1184	1188
1184	1206
1184	1219
1184	1229
1184	45238
1185	1183
1185	1188
1185	1205
1185	1218
1185	1232
1187	1183
1187	1188
1187	1206
1187	1218
1187	1229
1188	1183
1188	1194
1188	1206
1188	1218
1188	1229
1190	1183
1190	1188
1190	1206
1190	1218
1190	1229
1191	1183
1191	1194
1191	1206
1191	1218
1191	1229
1194	1183
1194	1188
1194	1198
1194	1206
1194	45548
1196	1183
1196	1188
1196	1218
1196	1232
1196	1233
1197	1183
1197	1188
1197	1198
1197	1206
1197	1218
1198	1183
1198	1188
1198	1206
1198	1219
1198	1229
1199	1183
1199	1188
1199	1198
1199	1206
1199	1218
1200	1183
1200	1188
1200	1206
1200	1218
1200	1229
1201	1183
1201	1188
1201	1206
1201	1218
1201	1229
1202	1183
1202	1188
1202	1198
1202	1206
1202	1218
1203	1183
1203	1188
1203	1206
1203	1218
1203	1229
1204	1183
1204	1194
1204	1198
1204	1206
1204	1218
1206	1183
1206	1188
1206	1206
1206	1218
1206	1229
1208	1188
1208	1200
1208	1206
1208	1220
1208	45238
1211	1183
1211	1194
1211	1206
1211	1218
1211	1229
1212	1183
1212	1188
1212	1206
1212	1218
1212	1229
1213	1183
1213	1188
1213	1218
1213	1232
1213	1233
1216	1188
1216	1198
1216	1206
1216	1218
1216	45238
1218	1183
1218	1188
1218	1198
1218	1206
1218	1218
1219	1188
1219	1200
1219	1206
1219	1218
1219	45238
1221	1183
1221	1188
1221	1206
1221	1218
1221	1229
1222	1183
1222	1188
1222	1206
1222	1218
1222	1229
1223	1183
1223	1188
1223	1200
1223	1206
1223	1218
1224	1183
1224	1188
1224	1206
1224	1218
1224	1229
1226	1183
1226	1188
1226	1206
1226	1218
1226	1229
1227	1183
1227	1188
1227	1206
1227	1218
1227	1229
1228	1183
1228	1194
1228	1206
1228	1218
1228	1229
1231	1183
1231	1188
1231	1200
1231	1206
1231	1216
1232	1183
1232	1188
1232	1206
1232	1218
1232	1229
1233	1183
1233	1188
1233	1200
1233	1206
1233	1218
1235	1183
1235	1188
1235	1206
1235	1218
1235	1229
1236	1183
1236	1188
1236	1200
1236	1206
1236	1218
1237	1179
1237	1188
1237	1197
1237	1201
1237	1218
1240	1188
1240	1218
1240	1232
1240	1233
1240	45238
1241	1183
1241	1188
1241	1206
1241	1218
1241	1229
1242	1188
1242	1206
1242	1218
1242	1229
1242	45238
1243	1188
1243	1218
1243	1232
1243	1233
1243	45238
1244	1188
1244	1206
1244	1220
1244	1229
1244	45238
1245	1188
1245	1206
1245	1219
1245	1229
1245	45236
1246	1183
1246	1218
1246	1232
1246	1233
1246	1239
1247	1183
1247	1188
1247	1206
1247	1218
1247	1229
1248	1183
1248	1194
1248	1218
1248	1232
1248	1233
1249	1183
1249	1188
1249	1200
1249	1206
1249	1218
1250	1183
1250	1188
1250	1198
1250	1206
1250	1219
1251	1183
1251	1188
1251	1200
1251	1204
1251	1218
1252	1183
1252	1188
1252	1200
1252	1206
1252	1218
1253	1179
1253	1188
1253	1197
1253	1201
1253	1218
1254	1183
1254	1188
1254	1198
1254	1206
1254	1218
1255	1188
1255	1198
1255	1206
1255	1218
1255	45236
1256	1179
1256	1188
1256	1197
1256	1201
1256	1218
1257	1188
1257	1206
1257	1218
1257	1229
1257	45238
1259	1183
1259	1188
1259	1200
1259	1206
1259	1218
1260	1183
1260	1188
1260	1206
1260	1218
1260	1229
1261	1183
1261	1188
1261	1206
1261	1218
1261	1229
1262	1188
1262	1218
1262	1232
1262	1233
1262	45236
1264	1183
1264	1188
1264	1206
1264	1218
1264	1229
1265	1183
1265	1188
1265	1206
1265	1218
1265	1229
1266	1188
1266	1200
1266	1206
1266	1218
1266	45238
1267	1183
1267	1188
1267	1198
1267	1206
1267	1218
1269	1183
1269	1188
1269	1206
1269	1218
1269	1229
1270	1183
1270	1188
1270	1206
1270	1218
1270	1229
1271	1183
1271	1196
1271	1206
1271	1218
1271	1229
1272	1183
1272	1188
1272	1198
1272	1206
1272	1218
1273	1179
1273	1188
1273	1197
1273	1201
1273	1218
1274	1183
1274	1188
1274	1206
1274	1218
1274	1229
1275	1179
1275	1188
1275	1197
1275	1201
1275	1218
1277	1183
1277	1188
1277	1206
1277	1218
1277	1229
1278	1183
1278	1188
1278	1198
1278	1206
1278	1218
1279	1183
1279	1188
1279	1206
1279	1218
1279	1229
1280	1183
1280	1194
1280	1198
1280	1206
1280	1218
1281	1183
1281	1194
1281	1198
1281	1206
1281	1218
1282	1183
1282	1188
1282	1206
1282	1218
1282	1229
1283	1183
1283	1188
1283	1213
1283	1232
1283	1233
1284	1183
1284	1188
1284	1200
1284	1206
1284	1218
1285	1183
1285	1188
1285	1200
1285	1206
1285	1218
1286	1183
1286	1188
1286	1206
1286	1218
1286	1229
1287	1188
1287	1206
1287	1218
1287	1229
1287	45238
1288	1179
1288	1188
1288	1197
1288	1201
1288	1218
1289	1183
1289	1188
1289	1206
1289	1218
1289	1229
1290	1183
1290	1188
1290	1206
1290	1219
1290	1229
1292	1183
1292	1194
1292	1198
1292	1206
1292	1218
1293	1183
1293	1188
1293	1198
1293	1206
1293	1213
1297	1183
1297	1188
1297	1200
1297	1206
1297	1218
1298	1183
1298	1188
1298	1198
1298	1206
1298	1218
1299	1183
1299	1188
1299	1206
1299	1218
1299	1229
1303	1183
1303	1188
1303	1206
1303	1218
1303	1229
1304	1183
1304	1188
1304	1206
1304	1218
1304	1229
1305	1188
1305	1218
1305	1232
1305	1233
1305	45238
1306	1183
1306	1188
1306	1218
1306	1232
1306	1233
1307	1188
1307	1206
1307	1220
1307	1229
1307	45238
1309	1183
1309	1188
1309	1200
1309	1206
1309	1218
1310	1183
1310	1188
1310	1206
1310	1218
1310	1229
1311	1183
1311	1218
1311	1232
1311	1233
1311	1239
1312	1183
1312	1188
1312	1198
1312	1206
1312	1218
1313	1183
1313	1188
1313	1206
1313	1218
1313	1229
1314	1195
1314	1206
1314	1219
1314	1229
1314	45238
1315	1183
1315	1188
1315	1200
1315	1206
1315	1218
1316	1183
1316	1188
1316	1206
1316	1218
1316	1229
1317	1183
1317	1188
1317	1198
1317	1206
1317	1218
1318	1183
1318	1188
1318	1206
1318	1218
1318	1229
1319	1183
1319	1188
1319	1198
1319	1206
1319	1218
1320	1183
1320	1188
1320	1198
1320	1206
1320	1218
1322	1183
1322	1188
1322	1206
1322	1211
1322	1229
1323	1183
1323	1188
1323	1198
1323	1206
1323	1218
1325	1183
1325	1188
1325	1206
1325	1213
1325	1229
1326	1188
1326	1198
1326	1206
1326	1218
1326	45236
1327	1183
1327	1194
1327	1200
1327	1206
1327	1218
1328	1183
1328	1194
1328	1200
1328	1206
1328	1218
1329	1183
1329	1188
1329	1218
1329	1232
1329	1233
1330	1179
1330	1188
1330	1197
1330	1201
1330	1218
1332	1183
1332	1188
1332	1206
1332	1218
1332	1229
1333	1183
1333	1188
1333	1206
1333	1218
1333	1229
1334	1183
1334	1188
1334	1198
1334	1206
1334	1218
1335	1183
1335	1188
1335	1198
1335	1206
1335	1218
1336	1183
1336	1188
1336	1200
1336	1206
1336	1218
1338	1183
1338	1188
1338	1206
1338	1218
1338	1229
1339	1183
1339	1188
1339	1198
1339	1206
1339	1219
1340	1183
1340	1188
1340	1206
1340	1218
1340	1229
1341	1183
1341	1188
1341	1206
1341	1218
1341	1229
1342	1188
1342	1211
1342	1232
1342	1233
1342	45238
1343	1183
1343	1188
1343	1206
1343	1217
1343	1229
1344	1183
1344	1188
1344	1206
1344	1218
1344	1229
1345	1183
1345	1188
1345	1206
1345	1218
1345	1229
1347	1183
1347	1188
1347	1206
1347	1218
1347	1229
1350	1183
1350	1188
1350	1206
1350	1218
1350	1229
1354	1183
1354	1198
1354	1206
1354	1218
1354	1239
1355	1183
1355	1188
1355	1206
1355	1218
1355	1229
1356	1183
1356	1188
1356	1206
1356	1218
1356	1229
1357	1183
1357	1188
1357	1206
1357	1218
1357	1229
1358	1188
1358	1206
1358	1218
1358	1229
1358	45238
1359	1183
1359	1188
1359	1206
1359	1218
1359	1229
1360	1183
1360	1188
1360	1200
1360	1206
1360	1218
1361	1188
1361	1206
1361	1218
1361	1229
1361	45238
1362	1183
1362	1188
1362	1206
1362	1216
1362	1229
1363	1183
1363	1188
1363	1198
1363	1206
1363	1218
1364	1183
1364	1188
1364	1206
1364	1218
1364	1229
1365	1183
1365	1188
1365	1206
1365	1218
1365	1229
1366	1183
1366	1188
1366	1206
1366	1213
1366	1229
1368	1183
1368	1188
1368	1206
1368	1218
1368	1229
1369	1183
1369	1188
1369	1198
1369	1206
1369	1218
1371	1183
1371	1194
1371	1206
1371	1218
1371	1229
1372	1188
1372	1220
1372	1232
1372	1233
1372	45238
1373	1183
1373	1188
1373	1206
1373	1218
1373	1229
1374	1183
1374	1194
1374	1206
1374	1218
1374	1229
1377	1183
1377	1194
1377	1198
1377	1206
1377	1218
1378	1188
1378	1206
1378	1213
1378	1229
1378	45236
1379	1183
1379	1188
1379	1206
1379	1218
1379	1229
1381	1183
1381	1188
1381	1198
1381	1206
1381	1218
1382	1183
1382	1196
1382	1218
1382	1232
1382	1233
1383	1183
1383	1188
1383	1198
1383	1206
1383	1218
1384	1188
1384	1199
1384	1204
1384	1218
1384	44936
1387	1183
1387	1188
1387	1206
1387	1218
1387	1229
1388	1183
1388	1188
1388	1218
1388	1232
1388	1233
1390	1183
1390	1188
1390	1218
1390	1232
1390	1233
1392	1183
1392	1188
1392	1198
1392	1206
1392	1218
1393	1183
1393	1188
1393	1206
1393	1218
1393	1229
1394	1183
1394	1188
1394	1206
1394	1218
1394	1229
1395	1183
1395	1188
1395	1198
1395	1206
1395	1218
1396	1188
1396	1206
1396	1218
1396	1229
1396	45238
1397	1183
1397	1188
1397	1200
1397	1206
1397	1218
1398	1195
1398	1206
1398	1218
1398	1229
1398	45238
1399	1188
1399	1206
1399	1218
1399	1229
1399	45238
1401	1183
1401	1188
1401	1198
1401	1206
1401	1218
1404	1183
1404	1188
1404	1218
1404	1232
1404	1233
1407	1183
1407	1188
1407	1206
1407	1218
1407	1229
1408	1183
1408	1188
1408	1198
1408	1206
1408	1218
1409	1188
1409	1206
1409	1218
1409	1229
1409	45238
1410	1183
1410	1188
1410	1198
1410	1206
1410	1218
1411	1188
1411	1200
1411	1206
1411	1218
1411	45238
1412	1183
1412	1188
1412	1198
1412	1206
1412	1218
1414	1183
1414	1188
1414	1205
1414	1218
1414	1232
1415	1183
1415	1188
1415	1206
1415	1218
1415	1229
1416	1188
1416	1198
1416	1206
1416	1218
1416	45238
1417	1188
1417	1206
1417	1218
1417	1229
1417	45238
1418	1183
1418	1188
1418	1198
1418	1206
1418	1218
1419	1188
1419	1198
1419	1206
1419	1211
1419	45238
1422	1188
1422	1198
1422	1206
1422	1218
1422	45236
1423	1183
1423	1188
1423	1206
1423	1218
1423	1232
1425	1183
1425	1188
1425	1206
1425	1218
1425	1229
1426	1183
1426	1188
1426	1200
1426	1206
1426	1218
1429	1188
1429	1206
1429	1218
1429	1229
1429	45238
1430	1183
1430	1188
1430	1218
1430	1232
1430	1233
1431	1183
1431	1188
1431	1198
1431	1206
1431	1218
1435	1183
1435	1188
1435	1218
1435	1232
1435	1233
1437	1183
1437	1188
1437	1218
1437	1232
1437	1233
1442	1188
1442	1218
1442	1232
1442	1233
1442	45238
1446	1183
1446	1188
1446	1198
1446	1206
1446	1218
1448	1188
1448	1216
1448	1232
1448	1233
1448	45238
1454	1183
1454	1194
1454	1198
1454	1206
1454	1218
1455	1183
1455	1188
1455	1200
1455	1206
1455	1218
1456	1183
1456	1188
1456	1198
1456	1206
1456	1218
1458	1183
1458	1188
1458	1204
1458	1218
1458	1232
1459	1183
1459	1193
1459	1206
1459	1218
1459	1229
1460	1183
1460	1188
1460	1206
1460	1218
1460	1229
1461	1183
1461	1188
1461	1206
1461	1218
1461	1229
1462	1183
1462	1194
1462	1206
1462	1218
1462	1229
1463	1183
1463	1188
1463	1198
1463	1206
1463	1218
1464	1183
1464	1188
1464	1206
1464	1218
1464	1229
1465	1183
1465	1188
1465	1206
1465	1218
1465	1229
1466	1183
1466	1194
1466	1198
1466	1206
1466	1218
1472	1188
1472	1198
1472	1206
1472	1218
1472	45236
1475	1183
1475	1194
1475	1206
1475	1218
1475	1229
1477	1183
1477	1188
1477	1206
1477	1218
1477	1229
1478	1183
1478	1188
1478	1206
1478	1218
1478	1229
1479	1188
1479	1206
1479	1218
1479	1229
1479	45238
1480	1183
1480	1188
1480	1200
1480	1206
1480	1218
1481	1183
1481	1188
1481	1206
1481	1218
1481	1229
1483	1183
1483	1188
1483	1206
1483	1218
1483	1229
1484	1183
1484	1188
1484	1206
1484	1218
1484	1229
1486	1183
1486	1188
1486	1218
1486	1232
1486	1233
1489	1183
1489	1188
1489	1206
1489	1218
1489	1229
1490	1188
1490	1218
1490	1232
1490	1233
1490	45238
1491	1183
1491	1188
1491	1206
1491	1216
1491	1229
1492	1183
1492	1188
1492	1206
1492	1218
1492	1229
1494	1183
1494	1188
1494	1206
1494	1218
1494	1229
1495	1183
1495	1188
1495	1198
1495	1206
1495	1218
1496	1179
1496	1188
1496	1197
1496	1201
1496	1218
1497	1195
1497	1218
1497	1232
1497	1233
1497	45238
1499	1183
1499	1188
1499	1218
1499	1232
1499	1233
1500	1183
1500	1188
1500	1218
1500	1232
1500	1233
1501	1183
1501	1188
1501	1199
1501	1206
1501	1218
1502	1183
1502	1188
1502	1206
1502	1218
1502	1229
1503	1179
1503	1188
1503	1197
1503	1201
1503	1218
1504	1188
1504	1218
1504	1232
1504	1233
1504	45238
1505	1188
1505	1206
1505	1218
1505	1229
1505	45238
1506	1188
1506	1206
1506	1218
1506	1229
1506	45238
1507	1188
1507	1206
1507	1218
1507	1229
1507	45238
1508	1188
1508	1198
1508	1206
1508	1218
1508	45236
1509	1179
1509	1188
1509	1197
1509	1201
1509	1218
1513	1183
1513	1188
1513	1198
1513	1206
1513	1218
1514	1183
1514	1188
1514	1198
1514	1206
1514	1213
1515	1183
1515	1188
1515	1198
1515	1206
1515	1218
1517	1183
1517	1188
1517	1198
1517	1206
1517	1218
1518	1188
1518	1206
1518	1211
1518	1229
1518	45238
1519	1188
1519	1218
1519	1232
1519	1233
1519	45238
1520	1183
1520	1198
1520	1206
1520	1218
1520	1239
1521	1183
1521	1188
1521	1206
1521	1218
1521	1229
1521	1232
1521	1233
1523	1183
1523	1188
1523	1218
1523	1232
1523	1233
1524	1183
1524	1188
1524	1218
1524	1232
1524	1233
1525	1183
1525	1188
1525	1206
1525	1218
1525	1229
1527	1183
1527	1188
1527	1218
1527	1232
1527	1233
1528	1183
1528	1188
1528	1206
1528	1218
1528	1229
1529	1188
1529	1206
1529	1218
1529	1229
1529	45238
1533	1183
1533	1188
1533	1206
1533	1218
1533	1229
1534	1183
1534	1188
1534	1206
1534	1218
1534	1229
1535	1183
1535	1188
1535	1206
1535	1218
1535	1229
1537	1183
1537	1188
1537	1206
1537	1218
1537	1229
1538	1183
1538	1188
1538	1198
1538	1206
1538	1218
1539	1183
1539	1188
1539	1206
1539	1218
1539	1229
1541	1188
1541	1218
1541	1232
1541	1233
1541	45238
1542	1183
1542	1188
1542	1206
1542	1218
1542	1229
1543	1183
1543	1188
1543	1198
1543	1206
1543	1218
1544	1183
1544	1188
1544	1206
1544	1218
1544	1229
1545	1183
1545	1188
1545	1206
1545	1218
1545	1229
1546	1183
1546	1188
1546	1218
1546	1232
1546	1233
1547	1183
1547	1188
1547	1198
1547	1206
1547	1218
1548	1183
1548	1188
1548	1206
1548	1218
1548	1229
1549	1183
1549	1188
1549	1206
1549	1218
1549	1229
1550	1183
1550	1188
1550	1206
1550	1218
1550	1229
1551	1183
1551	1188
1551	1198
1551	1206
1551	1218
1552	1183
1552	1188
1552	1206
1552	1218
1552	1229
1553	1194
1553	1206
1553	1218
1553	1229
1553	45238
1555	1194
1555	1206
1555	1218
1555	1229
1555	45238
1556	1178
1556	1188
1556	1197
1556	1201
1556	1218
1557	1188
1557	1206
1557	1220
1557	1229
1557	45238
1558	1183
1558	1188
1558	1200
1558	1206
1558	1217
1559	1183
1559	1188
1559	1206
1559	1218
1559	1229
1560	1183
1560	1188
1560	1206
1560	1218
1560	1229
1561	1183
1561	1188
1561	1206
1561	1218
1561	1229
1562	1183
1562	1188
1562	1206
1562	1218
1562	1229
1563	1183
1563	1188
1563	1206
1563	1218
1563	1229
1564	1183
1564	1188
1564	1206
1564	1217
1564	1229
1565	1183
1565	1188
1565	1206
1565	1218
1565	1229
1566	1183
1566	1188
1566	1200
1566	1206
1566	1218
1567	1183
1567	1188
1567	1198
1567	1206
1567	1218
1568	1183
1568	1188
1568	1206
1568	1218
1568	1229
1569	1183
1569	1188
1569	1206
1569	1218
1569	1229
1570	1188
1570	1206
1570	1218
1570	1229
1570	45238
1571	1183
1571	1188
1571	1200
1571	1206
1571	1218
1572	1188
1572	1218
1572	1232
1572	1233
1572	45238
1574	1183
1574	1194
1574	1200
1574	1206
1574	1218
1575	1183
1575	1194
1575	1206
1575	1218
1575	1229
1576	1183
1576	1194
1576	1218
1576	1232
1576	1233
1577	1183
1577	1188
1577	1206
1577	1218
1577	1229
1579	1183
1579	1188
1579	1218
1579	1232
1579	1233
1580	1183
1580	1188
1580	1206
1580	1218
1580	1229
1581	1183
1581	1194
1581	1200
1581	1206
1581	1218
1582	1188
1582	1206
1582	1218
1582	1229
1582	45238
1583	1183
1583	1188
1583	1206
1583	1218
1583	1229
1584	1183
1584	1188
1584	1198
1584	1206
1584	1218
1585	1183
1585	1198
1585	1206
1585	1218
1585	1239
1586	1183
1586	1188
1586	1213
1586	1232
1586	1233
1587	1188
1587	1198
1587	1206
1587	1218
1587	45238
1590	1183
1590	1188
1590	1198
1590	1206
1590	1218
1591	1183
1591	1188
1591	1200
1591	1206
1591	1218
1592	1183
1592	1188
1592	1198
1592	1206
1592	1218
1593	1183
1593	1188
1593	1206
1593	1218
1593	1229
1594	1183
1594	1188
1594	1198
1594	1206
1594	1218
1595	1183
1595	1194
1595	1198
1595	1206
1595	1218
1596	1183
1596	1188
1596	1206
1596	1218
1596	1229
1597	1183
1597	1188
1597	1206
1597	1218
1597	1229
1598	1183
1598	1188
1598	1206
1598	1218
1598	1229
1599	1183
1599	1188
1599	1206
1599	1218
1599	1229
1600	1183
1600	1188
1600	1206
1600	1218
1600	1229
1601	1183
1601	1188
1601	1206
1601	1213
1601	1229
1602	1183
1602	1194
1602	1198
1602	1206
1602	1218
1604	1188
1604	1206
1604	1218
1604	1229
1604	45238
1605	1183
1605	1188
1605	1218
1605	1232
1605	1233
1606	1183
1606	1188
1606	1220
1606	1232
1606	1233
1607	1183
1607	1188
1607	1198
1607	1206
1607	1218
1608	1183
1608	1188
1608	1198
1608	1206
1608	1218
1609	1183
1609	1188
1609	1206
1609	1218
1609	1229
1610	1183
1610	1188
1610	1206
1610	1213
1610	1229
1612	1183
1612	1194
1612	1206
1612	1213
1612	1229
1614	1183
1614	1188
1614	1206
1614	1218
1614	1229
1616	1183
1616	1194
1616	1205
1616	1218
1616	1232
1617	1183
1617	1188
1617	1218
1617	1232
1617	1233
1618	1183
1618	1194
1618	1218
1618	1232
1618	1233
1619	1183
1619	1188
1619	1206
1619	1218
1619	1229
1620	1188
1620	1218
1620	1232
1620	1233
1620	45238
1621	1183
1621	1188
1621	1218
1621	1232
1621	1233
1622	1183
1622	1188
1622	1206
1622	1218
1622	1229
1623	1183
1623	1188
1623	1200
1623	1206
1623	1218
1626	1183
1626	1188
1626	1200
1626	1206
1626	1218
1626	1229
1626	1232
1626	1233
1627	1183
1627	1188
1627	1206
1627	1213
1627	1229
1628	1183
1628	1188
1628	1206
1628	1218
1628	1229
1630	1183
1630	1188
1630	1200
1630	1206
1630	1220
1631	1183
1631	1194
1631	1198
1631	1206
1631	1220
1634	1188
1634	1198
1634	1206
1634	1218
1634	45236
1635	1183
1635	1188
1635	1206
1635	1218
1635	1229
1636	1183
1636	1188
1636	1206
1636	1218
1636	1229
1637	1183
1637	1188
1637	1198
1637	1206
1637	1218
1638	1183
1638	1188
1638	1206
1638	1218
1638	1229
1639	1188
1639	1206
1639	1218
1639	1229
1639	45238
1640	1183
1640	1188
1640	1206
1640	1218
1640	1229
1641	1183
1641	1188
1641	1206
1641	1218
1641	1229
1642	1188
1642	1198
1642	1206
1642	1218
1642	45238
1643	1183
1643	1188
1643	1206
1643	1218
1643	1229
1644	1183
1644	1188
1644	1198
1644	1206
1644	1218
1649	1183
1649	1188
1649	1218
1649	1232
1649	1233
1650	1183
1650	1188
1650	1218
1650	1232
1650	1233
1651	1183
1651	1188
1651	1206
1651	1218
1651	1229
1652	1183
1652	1188
1652	1206
1652	1213
1652	1229
1653	1188
1653	1218
1653	1232
1653	1233
1653	45238
1654	1188
1654	1218
1654	1232
1654	1233
1654	45238
1655	1183
1655	1188
1655	1218
1655	1232
1655	1233
1656	1183
1656	1188
1656	1200
1656	1205
1656	1218
1657	1183
1657	1194
1657	1206
1657	1218
1657	1229
1658	1195
1658	1206
1658	1218
1658	1229
1658	45238
1659	1183
1659	1188
1659	1206
1659	1218
1659	1229
1661	1183
1661	1188
1661	1206
1661	1218
1661	1229
1663	1183
1663	1188
1663	1198
1663	1206
1663	1218
1664	1183
1664	1188
1664	1206
1664	1218
1664	1229
1665	1183
1665	1188
1665	1206
1665	1218
1665	1229
1666	1183
1666	1188
1666	1198
1666	1206
1666	1218
1667	1183
1667	1188
1667	1206
1667	1220
1667	1229
1669	1183
1669	1188
1669	1206
1669	1220
1669	1229
1670	1183
1670	1194
1670	1206
1670	1218
1670	1229
1671	1188
1671	1206
1671	1220
1671	1229
1671	45238
1672	1183
1672	1188
1672	1206
1672	1218
1672	1229
1674	1188
1674	1206
1674	1220
1674	1229
1674	45238
1675	1188
1675	1206
1675	1229
1675	45236
1675	45430
1676	1183
1676	1188
1676	1198
1676	1206
1676	1218
1677	1183
1677	1188
1677	1206
1677	1218
1677	1229
1678	1183
1678	1196
1678	1200
1678	1206
1678	1216
1679	1183
1679	1188
1679	1206
1679	1218
1679	1229
1680	1179
1680	1188
1680	1197
1680	1201
1680	1217
1681	1183
1681	1194
1681	1198
1681	1206
1681	1218
1682	1188
1682	1200
1682	1206
1682	1218
1682	45238
1683	1183
1683	1196
1683	1200
1683	1206
1683	1218
1685	1183
1685	1188
1685	1206
1685	1218
1685	1229
1687	1188
1687	1198
1687	1206
1687	1218
1687	45236
1688	1183
1688	1188
1688	1200
1688	1206
1688	1218
1690	1188
1690	1200
1690	1206
1690	1218
1690	45238
1691	1188
1691	1198
1691	1206
1691	1218
1691	45236
1692	1188
1692	1198
1692	1206
1692	1218
1692	45236
1693	1188
1693	1218
1693	1232
1693	1233
1693	45238
1694	1183
1694	1188
1694	1198
1694	1206
1694	1218
1695	1183
1695	1188
1695	1217
1695	1232
1695	1233
1696	1179
1696	1188
1696	1197
1696	1201
1696	1218
1697	1188
1697	1206
1697	1218
1697	1229
1697	45238
1698	1183
1698	1188
1698	1206
1698	1218
1698	1229
1699	1183
1699	1196
1699	1200
1699	1206
1699	1218
1700	1183
1700	1188
1700	1200
1700	1206
1700	1218
1701	1183
1701	1188
1701	1218
1701	1232
1701	1233
1702	1183
1702	1196
1702	1218
1702	1232
1702	1233
1703	1188
1703	1206
1703	1220
1703	1229
1703	45238
1704	1183
1704	1188
1704	1206
1704	1218
1704	1229
1705	1183
1705	1188
1705	1218
1705	1232
1705	1233
1706	1183
1706	1188
1706	1206
1706	1218
1706	1229
1707	1188
1707	1206
1707	1218
1707	1229
1707	45238
1708	1188
1708	1206
1708	1218
1708	1229
1708	45238
1709	1183
1709	1188
1709	1206
1709	1218
1709	1229
1710	1183
1710	1188
1710	1206
1710	1218
1710	1229
1711	1183
1711	1188
1711	1206
1711	1218
1711	1229
1712	1183
1712	1188
1712	1198
1712	1206
1712	1218
1713	1188
1713	1206
1713	1219
1713	1229
1713	45238
1714	1183
1714	1188
1714	1206
1714	1218
1714	1229
1715	1183
1715	1188
1715	1206
1715	1218
1715	1229
1717	1183
1717	1188
1717	1206
1717	1218
1717	1229
1718	1188
1718	1206
1718	1218
1718	1229
1718	45236
1719	1183
1719	1188
1719	1200
1719	1206
1719	1218
1720	1183
1720	1188
1720	1206
1720	1218
1720	1229
1721	1183
1721	1188
1721	1218
1721	1232
1721	1233
1722	1179
1722	1188
1722	1197
1722	1201
1722	1218
1723	1183
1723	1188
1723	1206
1723	1218
1723	1229
1724	1188
1724	1218
1724	1232
1724	1233
1724	45238
1725	1183
1725	1188
1725	1206
1725	1218
1725	1229
1726	1188
1726	1206
1726	1218
1726	1229
1726	45236
1727	1183
1727	1188
1727	1206
1727	1218
1727	1229
1728	1183
1728	1188
1728	1218
1728	1232
1728	1233
1729	1183
1729	1188
1729	1206
1729	1218
1729	1229
1730	1183
1730	1188
1730	1198
1730	1206
1730	1218
1731	1188
1731	1206
1731	1218
1731	1229
1731	45238
1733	1183
1733	1188
1733	1206
1733	1218
1733	1229
1734	1183
1734	1188
1734	1206
1734	1219
1734	1229
1735	1188
1735	1206
1735	1218
1735	1229
1735	45238
1736	1183
1736	1194
1736	1206
1736	1219
1736	1229
1737	1188
1737	1198
1737	1206
1737	1210
1737	45238
1738	1183
1738	1188
1738	1198
1738	1206
1738	1218
1739	1183
1739	1188
1739	1200
1739	1206
1739	1218
1740	1188
1740	1218
1740	1232
1740	1233
1740	45238
1741	1183
1741	1188
1741	1206
1741	1217
1741	1229
1742	1183
1742	1188
1742	1206
1742	1217
1742	1229
1743	1183
1743	1188
1743	1200
1743	1206
1743	1218
1744	1183
1744	1188
1744	1200
1744	1206
1744	1218
1745	1183
1745	1188
1745	1200
1745	1206
1745	1218
1746	1183
1746	1188
1746	1198
1746	1206
1746	1218
1747	1188
1747	1206
1747	1209
1747	1229
1747	45238
1748	1183
1748	1188
1748	1206
1748	1218
1748	1229
1749	1188
1749	1198
1749	1206
1749	45238
1749	45450
1750	1183
1750	1188
1750	1198
1750	1206
1750	1218
1751	1188
1751	1206
1751	1218
1751	1229
1751	45238
1752	1183
1752	1194
1752	1220
1752	1232
1752	1233
1753	1183
1753	1188
1753	1206
1753	1218
1753	1229
1755	1183
1755	1188
1755	1219
1755	1232
1755	1233
1756	1183
1756	1188
1756	1200
1756	1206
1756	1218
1756	1221
1756	1232
1756	1233
1759	1179
1759	1191
1759	1197
1759	1201
1759	1218
1760	1183
1760	1188
1760	1206
1760	1217
1760	1229
1765	1183
1765	1188
1765	1206
1765	1218
1765	1229
1774	1183
1774	1188
1774	1218
1774	1232
1774	1233
1778	1188
1778	1206
1778	1218
1778	1229
1778	45238
1783	1183
1783	1188
1783	1206
1783	1218
1783	1229
1785	1188
1785	1206
1785	1220
1785	1229
1785	45238
1786	1188
1786	1206
1786	1218
1786	1229
1786	45236
1790	1183
1790	1188
1790	1206
1790	1218
1790	1229
1794	1183
1794	1194
1794	1200
1794	1206
1794	1218
1795	1183
1795	1188
1795	1198
1795	1206
1795	1218
1797	1183
1797	1188
1797	1206
1797	1218
1797	1229
1799	1183
1799	1188
1799	1200
1799	1206
1799	1218
1800	1183
1800	1188
1800	1200
1800	1206
1800	1218
1801	1183
1801	1188
1801	1206
1801	1218
1801	1229
1802	1188
1802	1198
1802	1206
1802	1218
1802	45236
1803	1188
1803	1220
1803	1232
1803	1233
1803	45238
1806	1183
1806	1188
1806	1217
1806	1232
1806	1233
1807	1183
1807	1188
1807	1206
1807	1218
1807	1229
1808	1183
1808	1188
1808	1198
1808	1206
1808	1218
1813	1183
1813	1188
1813	1198
1813	1206
1813	1217
1814	1183
1814	1188
1814	1206
1814	1218
1814	1229
1814	1232
1815	1183
1815	1194
1815	1198
1815	1206
1815	1218
1816	1183
1816	1188
1816	1206
1816	1218
1816	1232
1818	1183
1818	1188
1818	1218
1818	1232
1818	1233
1821	1183
1821	1188
1821	1200
1821	1206
1821	1218
1822	1183
1822	1188
1822	1218
1822	1232
1822	1233
1823	1183
1823	1188
1823	1206
1823	1218
1823	1229
1825	1183
1825	1188
1825	1206
1825	1220
1825	1229
1826	1183
1826	1188
1826	1218
1826	1232
1826	1233
1828	1188
1828	1198
1828	1206
1828	1218
1828	45238
1829	1183
1829	1188
1829	1218
1829	1232
1829	1233
1830	1183
1830	1194
1830	1206
1830	1218
1830	1229
1831	1183
1831	1188
1831	1206
1831	1218
1831	1229
1833	1183
1833	1188
1833	1206
1833	1218
1833	1229
1834	1183
1834	1188
1834	1206
1834	1218
1834	1229
1838	1183
1838	1188
1838	1198
1838	1206
1838	1218
1839	1183
1839	1194
1839	1198
1839	1206
1839	1218
1840	1183
1840	1193
1840	1206
1840	1218
1840	1229
1841	1183
1841	1188
1841	1218
1841	1232
1841	1233
1842	1183
1842	1188
1842	1206
1842	1218
1842	1229
1843	1183
1843	1188
1843	1218
1843	1232
1843	1233
1844	1183
1844	1188
1844	1218
1844	1232
1844	1233
1845	1188
1845	1220
1845	1232
1845	1233
1845	45238
1848	1183
1848	1188
1848	1206
1848	1218
1848	1229
1849	1183
1849	1194
1849	1218
1849	1232
1849	1233
1850	1188
1850	1198
1850	1206
1850	1218
1850	45238
1853	1183
1853	1188
1853	1206
1853	1218
1853	1232
1857	1183
1857	1188
1857	1206
1857	1218
1857	1232
1859	1183
1859	1188
1859	1206
1859	1220
1859	1229
1860	1183
1860	1188
1860	1206
1860	1217
1860	1232
1861	1183
1861	1194
1861	1206
1861	1218
1861	1229
1865	1183
1865	1188
1865	1198
1865	1206
1865	1218
1867	1188
1867	1206
1867	1218
1867	1229
1867	45238
1869	1188
1869	1206
1869	1218
1869	1229
1869	45236
1870	1179
1870	1188
1870	1197
1870	1201
1870	1218
1872	1183
1872	1188
1872	1206
1872	1218
1872	1229
1874	1183
1874	1194
1874	1198
1874	1206
1874	1218
1875	1183
1875	1188
1875	1206
1875	1220
1875	1229
1876	1183
1876	1188
1876	1218
1876	1232
1876	1233
1877	1183
1877	1188
1877	1206
1877	1218
1877	1232
1880	1183
1880	1188
1880	1204
1880	1205
1880	1218
1880	1232
1881	1183
1881	1188
1881	1198
1881	1206
1881	1218
1882	1183
1882	1188
1882	1218
1882	1232
1882	1233
1883	1183
1883	1188
1883	1206
1883	1218
1883	1229
1884	1183
1884	1188
1884	1218
1884	1232
1884	1233
1887	1183
1887	1188
1887	1198
1887	1206
1887	1218
1888	1183
1888	1188
1888	1206
1888	1218
1888	1229
1889	1183
1889	1188
1889	1206
1889	1229
1889	1258
1891	1183
1891	1188
1891	1206
1891	1220
1891	1229
1892	1183
1892	1188
1892	1206
1892	1218
1892	1229
1893	1183
1893	1188
1893	1206
1893	1218
1893	1229
1895	1183
1895	1194
1895	1206
1895	1218
1895	1229
1897	1179
1897	1188
1897	1197
1897	1201
1897	1218
1898	1183
1898	1188
1898	1198
1898	1206
1898	1218
1899	1188
1899	1218
1899	1232
1899	1233
1899	45238
1901	1183
1901	1188
1901	1206
1901	1218
1901	1229
1902	1183
1902	1198
1902	1206
1902	1218
1902	1239
1903	1183
1903	1188
1903	1206
1903	1218
1903	1229
1904	1183
1904	1188
1904	1206
1904	1218
1904	1229
1907	1188
1907	1206
1907	1218
1907	1229
1907	45238
1909	1179
1909	1188
1909	1197
1909	1201
1909	1218
1911	1183
1911	1188
1911	1206
1911	1219
1911	1229
1912	1188
1912	1218
1912	1232
1912	1233
1912	45238
1913	1183
1913	1188
1913	1206
1913	1218
1913	1229
1914	1183
1914	1188
1914	1206
1914	1218
1914	1229
1915	1183
1915	1188
1915	1206
1915	1218
1915	1229
1916	1183
1916	1188
1916	1206
1916	1218
1916	1229
1917	1183
1917	1188
1917	1206
1917	1218
1917	1229
1918	1183
1918	1188
1918	1206
1918	1218
1918	1229
1919	1183
1919	1188
1919	1206
1919	1218
1919	1229
1920	1183
1920	1188
1920	1206
1920	1218
1920	1229
1921	1183
1921	1188
1921	1206
1921	1218
1921	1229
1922	1183
1922	1188
1922	1198
1922	1206
1922	1218
1923	1183
1923	1194
1923	1200
1923	1206
1923	1218
1924	1183
1924	1194
1924	1198
1924	1206
1924	1218
1925	1183
1925	1188
1925	1200
1925	1206
1925	1218
1928	1183
1928	1188
1928	1206
1928	1218
1928	1229
1929	1183
1929	1188
1929	1206
1929	1218
1929	1229
1930	1183
1930	1188
1930	1206
1930	1218
1930	1229
1931	1183
1931	1188
1931	1206
1931	1218
1931	1229
1933	1188
1933	1204
1933	1218
1933	1232
1933	45238
1934	1188
1934	1204
1934	1218
1934	1232
1934	45238
1935	1183
1935	1188
1935	1206
1935	1218
1935	1229
1936	1183
1936	1188
1936	1206
1936	1218
1936	1229
1938	1183
1938	1188
1938	1206
1938	1218
1938	1229
1939	1183
1939	1188
1939	1206
1939	1218
1939	1229
1940	1188
1940	1206
1940	1218
1940	1229
1940	45238
1941	1188
1941	1206
1941	1218
1941	1229
1941	45238
1943	1188
1943	1206
1943	1218
1943	1229
1943	45238
1945	1188
1945	1206
1945	1220
1945	1229
1945	45238
1947	1183
1947	1188
1947	1200
1947	1206
1947	1217
1949	1183
1949	1188
1949	1206
1949	1218
1949	1229
1950	1183
1950	1188
1950	1205
1950	1218
1950	1232
1951	1188
1951	1206
1951	1218
1951	1229
1951	45238
1952	1183
1952	1206
1952	1218
1952	1229
1952	1239
1953	1183
1953	1196
1953	1206
1953	1218
1953	1229
1954	1183
1954	1188
1954	1206
1954	1218
1954	1229
1955	1183
1955	1191
1955	1200
1955	1206
1955	1218
1956	1183
1956	1188
1956	1206
1956	1219
1956	1229
1957	1183
1957	1188
1957	1200
1957	1206
1957	1218
1958	1188
1958	1206
1958	1218
1958	1229
1958	45238
1959	1183
1959	1188
1959	1206
1959	1218
1959	1229
1960	1183
1960	1188
1960	1206
1960	1218
1960	1229
1961	1183
1961	1188
1961	1206
1961	1219
1961	1229
1964	1188
1964	1218
1964	1232
1964	1233
1964	45238
1965	1183
1965	1188
1965	1206
1965	1218
1965	1229
1967	1183
1967	1188
1967	1206
1967	1218
1967	1229
1968	1183
1968	1188
1968	1198
1968	1206
1968	1218
1969	1183
1969	1188
1969	1205
1969	1218
1969	1232
1970	1188
1970	1206
1970	1219
1970	1229
1970	45238
1971	1183
1971	1188
1971	1206
1971	1218
1971	1229
1972	1183
1972	1188
1972	1206
1972	1218
1972	1232
1973	1183
1973	1188
1973	1206
1973	1218
1973	1232
1975	1183
1975	1188
1975	1206
1975	1218
1975	1232
1976	1183
1976	1188
1976	1206
1976	1218
1976	1232
1977	1188
1977	1206
1977	1219
1977	1229
1977	45238
1978	1183
1978	1188
1978	1206
1978	1219
1978	1229
1979	1183
1979	1188
1979	1206
1979	1218
1979	1229
1982	1183
1982	1188
1982	1198
1982	1206
1982	1218
1983	1188
1983	1206
1983	1218
1983	1229
1983	45236
1984	1183
1984	1188
1984	1206
1984	1218
1984	1229
1985	1183
1985	1188
1985	1206
1985	1218
1985	1229
1986	1188
1986	1206
1986	1218
1986	1229
1986	45238
1987	1183
1987	1194
1987	1198
1987	1206
1987	1213
1990	1183
1990	1188
1990	1198
1990	1206
1990	1218
1991	1183
1991	1188
1991	1206
1991	1218
1991	1229
1992	1183
1992	1188
1992	1206
1992	1218
1992	1229
1995	1183
1995	1196
1995	1206
1995	1218
1995	1229
1996	1183
1996	1194
1996	1198
1996	1206
1996	1218
1997	1183
1997	1188
1997	1206
1997	1218
1997	1229
1998	1183
1998	1188
1998	1206
1998	1218
1998	1229
1999	1183
1999	1188
1999	1206
1999	1218
1999	1229
2000	1183
2000	1188
2000	1206
2000	1218
2000	1229
2001	1183
2001	1188
2001	1206
2001	1218
2001	1229
2002	1188
2002	1200
2002	1206
2002	1220
2002	45238
2003	1183
2003	1188
2003	1198
2003	1206
2003	1218
2004	1183
2004	1188
2004	1206
2004	1218
2004	1229
2005	1195
2005	1218
2005	1232
2005	1233
2005	45238
2006	1183
2006	1188
2006	1206
2006	1218
2006	1229
2007	1183
2007	1188
2007	1206
2007	1209
2007	1229
2008	1183
2008	1188
2008	1206
2008	1218
2008	1229
2009	1183
2009	1188
2009	1200
2009	1206
2009	1218
2010	1183
2010	1188
2010	1206
2010	1218
2010	1229
2011	1183
2011	1188
2011	1206
2011	1218
2011	1229
2013	1183
2013	1188
2013	1206
2013	1218
2013	1229
2015	1188
2015	1218
2015	1232
2015	1233
2015	45238
2016	1195
2016	1218
2016	1232
2016	1233
2016	45238
2018	1183
2018	1188
2018	1218
2018	1232
2018	1233
2019	1183
2019	1188
2019	1206
2019	1220
2019	1229
2020	1183
2020	1188
2020	1206
2020	1218
2020	1229
2021	1183
2021	1188
2021	1200
2021	1206
2021	1220
2022	1188
2022	1206
2022	1211
2022	1229
2022	45238
2023	1183
2023	1188
2023	1206
2023	1218
2023	1229
2024	1183
2024	1194
2024	1206
2024	1218
2024	1229
2026	1188
2026	1206
2026	1218
2026	1229
2026	45238
2027	1183
2027	1188
2027	1200
2027	1206
2027	1213
2028	1188
2028	1218
2028	1232
2028	1233
2028	45238
2030	1183
2030	1188
2030	1198
2030	1206
2030	1218
2031	1183
2031	1188
2031	1206
2031	1218
2031	1229
2035	1183
2035	1188
2035	1206
2035	1218
2035	1229
2036	1183
2036	1188
2036	1217
2036	1232
2036	1233
2037	1183
2037	1188
2037	1218
2037	1232
2037	1233
2038	1183
2038	1188
2038	1198
2038	1206
2038	1218
2039	1183
2039	1188
2039	1206
2039	1217
2039	1229
2040	1188
2040	1200
2040	1206
2040	1218
2040	45238
2042	1183
2042	1188
2042	1206
2042	1218
2042	1229
2044	1183
2044	1188
2044	1206
2044	1218
2044	1229
2045	1183
2045	1188
2045	1206
2045	1218
2045	1229
2046	1183
2046	1188
2046	1206
2046	1218
2046	1229
2047	1183
2047	1188
2047	1206
2047	1218
2047	1229
2048	1188
2048	1218
2048	1232
2048	1233
2048	45238
2049	1183
2049	1188
2049	1206
2049	1218
2049	1229
2050	1183
2050	1188
2050	1206
2050	1220
2050	1229
2051	1183
2051	1188
2051	1206
2051	1218
2051	1229
2052	1183
2052	1188
2052	1198
2052	1206
2052	1218
2053	1183
2053	1188
2053	1206
2053	1218
2053	1229
2054	1183
2054	1188
2054	1199
2054	1206
2054	1218
2055	1183
2055	1188
2055	1198
2055	1206
2055	1218
2056	1188
2056	1220
2056	1232
2056	1233
2056	45238
2057	1183
2057	1188
2057	1198
2057	1206
2057	1218
2058	1183
2058	1188
2058	1206
2058	1218
2058	1229
2059	1183
2059	1188
2059	1198
2059	1206
2059	1218
2060	1183
2060	1188
2060	1198
2060	1206
2060	1218
2061	1183
2061	1188
2061	1206
2061	1218
2061	1229
2063	1183
2063	1188
2063	1206
2063	1218
2063	1229
2065	1188
2065	1206
2065	1218
2065	1229
2065	45238
2066	1183
2066	1188
2066	1200
2066	1206
2066	1218
2067	1183
2067	1188
2067	1206
2067	1218
2067	1229
2068	1183
2068	1188
2068	1198
2068	1206
2068	1218
2069	1179
2069	1188
2069	1197
2069	1201
2069	1218
2070	1179
2070	1188
2070	1197
2070	1201
2070	1218
2071	1183
2071	1188
2071	1206
2071	1219
2071	1229
2072	1194
2072	1206
2072	1218
2072	1229
2072	45238
2073	1183
2073	1188
2073	1200
2073	1206
2073	1218
2074	1188
2074	1218
2074	1232
2074	1233
2074	45238
2075	1183
2075	1188
2075	1206
2075	1218
2075	1229
2076	1183
2076	1188
2076	1206
2076	1218
2076	1229
2079	1183
2079	1188
2079	1206
2079	1218
2079	1229
2080	1183
2080	1188
2080	1200
2080	1206
2080	1218
2081	1183
2081	1188
2081	1200
2081	1206
2081	1218
2082	1183
2082	1188
2082	1200
2082	1206
2082	1218
2083	1183
2083	1188
2083	1200
2083	1206
2083	1218
2084	1183
2084	1188
2084	1206
2084	1218
2084	1229
2087	1183
2087	1188
2087	1206
2087	1218
2087	1229
2089	1183
2089	1188
2089	1206
2089	1218
2089	1229
2090	1183
2090	1188
2090	1200
2090	1205
2090	1206
2090	1218
2091	1183
2091	1188
2091	1200
2091	1206
2091	1218
2094	1188
2094	1206
2094	1209
2094	1229
2094	45238
2095	1183
2095	1188
2095	1200
2095	1206
2095	1218
2096	1178
2096	1191
2096	1197
2096	1201
2096	1218
2097	1183
2097	1188
2097	1206
2097	1209
2097	1229
2098	1183
2098	1188
2098	1206
2098	1218
2098	1229
2099	1183
2099	1188
2099	1206
2099	1218
2099	1229
2100	1183
2100	1188
2100	1218
2100	1232
2100	1233
2102	1183
2102	1188
2102	1198
2102	1206
2102	1218
2103	1183
2103	1194
2103	1198
2103	1206
2103	1218
2104	1183
2104	1188
2104	1206
2104	1218
2104	1229
2105	1183
2105	1188
2105	1206
2105	1218
2105	1229
2106	1183
2106	1188
2106	1198
2106	1206
2106	1218
2110	1183
2110	1188
2110	1198
2110	1206
2110	1218
2111	1183
2111	1188
2111	1206
2111	1218
2111	1229
2112	1183
2112	1188
2112	1206
2112	1218
2112	1229
2113	1183
2113	1194
2113	1200
2113	1206
2113	1218
2114	1183
2114	1188
2114	1206
2114	1218
2114	1229
2115	1183
2115	1188
2115	1206
2115	1218
2115	1229
2116	1183
2116	1188
2116	1206
2116	1218
2116	1229
2117	1183
2117	1188
2117	1218
2117	1232
2117	1233
2118	1188
2118	1206
2118	1218
2118	1229
2118	45236
2119	1183
2119	1188
2119	1218
2119	1232
2119	1233
2120	1183
2120	1188
2120	1206
2120	1218
2120	1229
2122	1183
2122	1188
2122	1206
2122	1218
2122	1229
2128	1183
2128	1188
2128	1206
2128	1213
2128	1229
2129	1183
2129	1188
2129	1198
2129	1206
2129	1218
2130	1183
2130	1188
2130	1198
2130	1206
2130	1218
2131	1183
2131	1188
2131	1206
2131	1218
2131	1229
2132	1183
2132	1188
2132	1206
2132	1218
2132	1229
2134	1183
2134	1188
2134	1206
2134	1218
2134	1229
2135	1183
2135	1188
2135	1206
2135	1218
2135	1229
2136	1183
2136	1188
2136	1198
2136	1206
2136	1218
2139	1183
2139	1188
2139	1200
2139	1206
2139	1218
2141	1183
2141	1188
2141	1206
2141	1218
2141	1229
2142	1183
2142	1194
2142	1198
2142	1206
2142	1218
2143	1183
2143	1188
2143	1206
2143	1219
2143	1229
2144	1183
2144	1188
2144	1198
2144	1206
2144	1218
2145	1183
2145	1188
2145	1206
2145	1218
2145	1229
2147	1183
2147	1188
2147	1198
2147	1206
2147	1218
2148	1183
2148	1188
2148	1206
2148	1218
2148	1229
2149	1183
2149	1188
2149	1198
2149	1206
2149	1218
2150	1183
2150	1188
2150	1198
2150	1206
2150	1218
2151	1188
2151	1218
2151	1232
2151	1233
2151	45238
2153	1188
2153	1206
2153	1218
2153	1229
2153	45238
2154	1179
2154	1188
2154	1197
2154	1201
2154	1218
2155	1188
2155	1206
2155	1218
2155	1229
2155	45238
2156	1188
2156	1206
2156	1218
2156	1229
2156	45238
2157	1188
2157	1206
2157	1218
2157	1229
2157	45236
2158	1183
2158	1188
2158	1206
2158	1218
2158	1229
2159	1183
2159	1188
2159	1218
2159	1232
2159	1233
2160	1183
2160	1188
2160	1206
2160	1218
2160	1229
2161	1183
2161	1188
2161	1206
2161	1218
2161	1229
2162	1183
2162	1188
2162	1206
2162	1218
2162	1229
2163	1183
2163	1188
2163	1213
2163	1232
2163	1233
2164	1183
2164	1188
2164	1198
2164	1206
2164	1218
2165	1183
2165	1188
2165	1206
2165	1218
2165	1229
2166	1188
2166	1198
2166	1206
2166	1218
2166	45236
2167	1183
2167	1188
2167	1198
2167	1206
2167	1218
2168	1183
2168	1188
2168	1206
2168	1218
2168	1229
2171	1183
2171	1188
2171	1200
2171	1206
2171	1218
2173	1183
2173	1188
2173	1206
2173	1218
2173	1229
2174	1183
2174	1188
2174	1198
2174	1206
2174	1218
2175	1183
2175	1188
2175	1206
2175	1218
2175	1229
2176	1188
2176	1218
2176	1232
2176	1233
2176	45238
2180	1183
2180	1188
2180	1206
2180	1218
2180	1229
2181	1183
2181	1188
2181	1206
2181	1220
2181	1229
2184	1183
2184	1188
2184	1206
2184	1217
2184	1229
2187	1183
2187	1188
2187	1206
2187	1218
2187	1229
2188	1183
2188	1188
2188	1206
2188	1218
2188	1229
2189	1183
2189	1188
2189	1206
2189	1218
2189	1229
2190	1188
2190	1200
2190	1206
2190	1218
2190	45238
2191	1183
2191	1206
2191	1218
2191	1229
2191	1239
2192	1183
2192	1188
2192	1198
2192	1206
2192	1218
2193	1188
2193	1218
2193	1232
2193	1233
2193	45238
2194	1183
2194	1188
2194	1206
2194	1218
2194	1229
2195	1183
2195	1188
2195	1206
2195	1218
2195	1229
2196	1183
2196	1188
2196	1198
2196	1206
2196	1218
2197	1188
2197	1198
2197	1206
2197	1218
2197	45238
2198	1183
2198	1188
2198	1206
2198	1218
2198	1229
2199	1183
2199	1188
2199	1206
2199	1218
2199	1229
2200	1183
2200	1188
2200	1198
2200	1206
2200	1213
2201	1183
2201	1188
2201	1206
2201	1218
2201	1229
2202	1183
2202	1188
2202	1206
2202	1218
2202	1229
2203	1183
2203	1188
2203	1206
2203	1218
2203	1229
2204	1183
2204	1188
2204	1206
2204	1218
2204	1229
2205	1183
2205	1188
2205	1200
2205	1206
2205	1218
2206	1183
2206	1188
2206	1206
2206	1218
2206	1229
2207	1183
2207	1188
2207	1206
2207	1218
2207	1229
2208	1183
2208	1188
2208	1206
2208	1218
2208	1229
2209	1183
2209	1188
2209	1200
2209	1206
2209	1218
2211	1183
2211	1188
2211	1206
2211	1213
2211	1229
2212	1183
2212	1188
2212	1206
2212	1213
2212	1229
2213	1183
2213	1194
2213	1198
2213	1206
2213	1218
2214	1183
2214	1188
2214	1206
2214	1218
2214	1229
2215	1183
2215	1188
2215	1206
2215	1213
2215	1229
2216	1183
2216	1188
2216	1206
2216	1218
2216	1229
2217	1188
2217	1206
2217	1218
2217	1229
2217	45238
2219	1183
2219	1188
2219	1206
2219	1218
2219	1229
2220	1188
2220	1206
2220	1218
2220	1229
2220	45238
2222	1183
2222	1188
2222	1206
2222	1219
2222	1229
2224	1188
2224	1206
2224	1218
2224	1229
2224	45238
2225	1183
2225	1188
2225	1206
2225	1220
2225	1229
2226	1183
2226	1188
2226	1206
2226	1220
2226	1229
2227	1183
2227	1188
2227	1200
2227	1206
2227	1218
2229	1183
2229	1188
2229	1206
2229	1218
2229	1229
2231	1188
2231	1206
2231	1220
2231	1229
2231	45238
2232	1183
2232	1188
2232	1206
2232	1218
2232	1229
2233	1183
2233	1188
2233	1206
2233	1218
2233	1229
2234	1183
2234	1188
2234	1206
2234	1218
2234	1229
2235	1183
2235	1188
2235	1206
2235	1218
2235	1229
2236	1183
2236	1188
2236	1200
2236	1206
2236	1218
2237	1183
2237	1188
2237	1218
2237	1232
2237	1233
2238	1183
2238	1188
2238	1232
2238	1233
2238	1244
2239	1183
2239	1188
2239	1218
2239	1232
2239	1233
2240	1183
2240	1188
2240	1218
2240	1232
2240	1233
2241	1183
2241	1206
2241	1218
2241	1229
2241	1239
2242	1183
2242	1188
2242	1198
2242	1206
2242	1218
2243	1194
2243	1206
2243	1218
2243	1229
2243	45238
2244	1183
2244	1188
2244	1206
2244	1218
2244	1229
2246	1183
2246	1188
2246	1206
2246	1218
2246	1229
2248	1183
2248	1188
2248	1200
2248	1206
2248	1218
2249	1183
2249	1188
2249	1206
2249	1218
2249	1229
2251	1183
2251	1188
2251	1220
2251	1232
2251	1233
2252	1183
2252	1188
2252	1218
2252	1232
2252	1233
2254	1183
2254	1188
2254	1198
2254	1206
2254	1218
2255	1183
2255	1188
2255	1217
2255	1232
2255	1233
2257	1183
2257	1188
2257	1200
2257	1206
2257	1218
2258	1183
2258	1188
2258	1206
2258	1218
2258	1229
2260	1183
2260	1188
2260	1206
2260	1218
2260	1229
2261	1183
2261	1188
2261	1198
2261	1206
2261	1218
2262	1188
2262	1206
2262	1220
2262	1229
2262	45238
2263	1188
2263	1200
2263	1206
2263	1218
2263	45238
2265	1183
2265	1188
2265	1206
2265	1218
2265	1229
2266	1183
2266	1188
2266	1206
2266	1213
2266	1229
2267	1183
2267	1188
2267	1206
2267	1218
2267	1229
2268	1183
2268	1188
2268	1206
2268	1218
2268	1229
2269	1183
2269	1188
2269	1198
2269	1206
2269	1218
2271	1183
2271	1188
2271	1198
2271	1206
2271	1218
2272	1183
2272	1188
2272	1206
2272	1209
2272	1229
2274	1188
2274	1206
2274	1218
2274	1229
2274	45238
2276	1188
2276	1206
2276	1220
2276	1229
2276	45238
2279	1183
2279	1188
2279	1206
2279	1218
2279	1229
2280	1183
2280	1188
2280	1206
2280	1229
2280	45168
2281	1183
2281	1188
2281	1198
2281	1206
2281	1218
2282	1183
2282	1188
2282	1200
2282	1206
2282	1218
2283	1183
2283	1188
2283	1200
2283	1206
2283	1218
2284	1183
2284	1188
2284	1206
2284	1218
2284	1229
2285	1179
2285	1188
2285	1197
2285	1201
2285	1218
2286	1183
2286	1188
2286	1206
2286	1218
2286	1229
2287	1183
2287	1188
2287	1206
2287	1218
2287	1232
2289	1183
2289	1188
2289	1206
2289	1218
2289	1229
2290	1183
2290	1188
2290	1206
2290	1218
2290	1229
2292	1183
2292	1188
2292	1206
2292	1218
2292	1229
2293	1183
2293	1188
2293	1198
2293	1206
2293	1218
2294	1183
2294	1188
2294	1198
2294	1206
2294	1218
2295	1183
2295	1188
2295	1206
2295	1218
2295	1229
2296	1183
2296	1188
2296	1198
2296	1206
2296	1218
2297	1183
2297	1188
2297	1198
2297	1206
2297	1218
2298	1183
2298	1188
2298	1206
2298	1218
2298	1229
2299	1179
2299	1188
2299	1197
2299	1201
2299	1218
2300	1188
2300	1218
2300	1232
2300	1233
2300	45238
2301	1183
2301	1196
2301	1206
2301	1220
2301	1229
2302	1188
2302	1206
2302	1218
2302	1229
2302	45238
2304	1183
2304	1188
2304	1206
2304	1209
2304	1229
2305	1188
2305	1198
2305	1206
2305	1218
2305	45238
2306	1188
2306	1206
2306	1218
2306	1229
2306	45238
2307	1183
2307	1188
2307	1206
2307	1218
2307	1229
2309	1183
2309	1188
2309	1206
2309	1218
2309	1229
2310	1188
2310	1218
2310	1232
2310	1233
2310	45238
2311	1183
2311	1188
2311	1206
2311	1218
2311	1229
2314	1183
2314	1188
2314	1206
2314	1218
2314	1229
2316	1183
2316	1188
2316	1198
2316	1206
2316	1218
2317	1183
2317	1188
2317	1206
2317	1218
2317	1229
2318	1183
2318	1188
2318	1206
2318	1218
2318	1229
2321	1183
2321	1188
2321	1206
2321	1213
2321	1229
2322	1183
2322	1188
2322	1206
2322	1218
2322	1229
2324	1183
2324	1188
2324	1206
2324	1218
2324	1229
2327	1183
2327	1188
2327	1206
2327	1218
2327	1229
2328	1188
2328	1198
2328	1206
2328	1218
2328	45236
2329	1183
2329	1188
2329	1218
2329	1232
2329	1233
2330	1183
2330	1188
2330	1198
2330	1206
2330	1218
2332	1188
2332	1206
2332	1218
2332	1229
2332	45238
2333	1183
2333	1188
2333	1206
2333	1218
2333	1229
2334	1183
2334	1188
2334	1206
2334	1220
2334	1229
2335	1183
2335	1188
2335	1198
2335	1206
2335	1218
2336	1183
2336	1188
2336	1198
2336	1206
2336	1218
2337	1183
2337	1188
2337	1206
2337	1218
2337	1229
2339	1183
2339	1188
2339	1206
2339	1218
2339	1229
2340	1183
2340	1188
2340	1206
2340	1218
2340	1229
2341	1183
2341	1188
2341	1206
2341	1218
2341	1229
2343	1188
2343	1206
2343	1218
2343	1229
2343	45236
2344	1183
2344	1188
2344	1198
2344	1206
2344	1218
2345	1183
2345	1188
2345	1198
2345	1206
2345	1210
2346	1183
2346	1188
2346	1206
2346	1218
2346	1229
2347	1183
2347	1188
2347	1206
2347	1218
2347	1229
2348	1188
2348	1206
2348	1218
2348	1229
2348	45238
2349	1183
2349	1194
2349	1200
2349	1206
2349	1218
2350	1183
2350	1194
2350	1200
2350	1206
2350	1218
2351	1183
2351	1188
2351	1218
2351	1232
2351	1233
2352	1183
2352	1188
2352	1198
2352	1206
2352	1218
2353	1183
2353	1188
2353	1206
2353	1218
2353	1229
2354	1188
2354	1206
2354	1218
2354	1229
2354	45236
2355	1183
2355	1188
2355	1206
2355	1218
2355	1229
2356	1183
2356	1188
2356	1206
2356	1218
2356	1229
2358	1183
2358	1188
2358	1206
2358	1218
2358	1229
2360	1188
2360	1198
2360	1206
2360	1218
2360	45238
2361	1183
2361	1188
2361	1206
2361	1217
2361	1229
2363	1183
2363	1188
2363	1200
2363	1206
2363	1218
2364	1183
2364	1188
2364	1206
2364	1218
2364	1229
2365	1183
2365	1188
2365	1206
2365	1218
2365	1229
2368	1183
2368	1188
2368	1200
2368	1206
2368	1218
2370	1195
2370	1206
2370	1218
2370	1229
2370	45236
2371	1188
2371	1198
2371	1206
2371	1218
2371	45238
2372	1183
2372	1188
2372	1198
2372	1206
2372	1218
2373	1183
2373	1188
2373	1198
2373	1206
2373	1218
2375	1179
2375	1188
2375	1197
2375	1201
2375	1218
2376	1188
2376	1206
2376	1220
2376	1229
2376	45238
2377	1183
2377	1188
2377	1218
2377	1232
2377	1233
2379	1183
2379	1188
2379	1206
2379	1218
2379	1229
2380	1183
2380	1188
2380	1218
2380	1232
2380	1233
2381	1183
2381	1188
2381	1206
2381	1218
2381	1229
2382	1183
2382	1188
2382	1218
2382	1232
2382	1233
2383	1188
2383	1218
2383	1232
2383	1233
2383	45238
2384	1183
2384	1188
2384	1206
2384	1218
2384	1229
2385	1183
2385	1188
2385	1200
2385	1206
2385	1218
2386	1183
2386	1188
2386	1206
2386	1218
2386	1229
2387	1188
2387	1206
2387	1220
2387	1229
2387	45238
2388	1183
2388	1188
2388	1206
2388	1218
2388	1229
2389	1188
2389	1206
2389	1220
2389	1229
2389	45238
2390	1183
2390	1196
2390	1198
2390	1206
2390	1211
2391	1188
2391	1198
2391	1206
2391	1211
2391	45238
2393	1183
2393	1188
2393	1206
2393	1218
2393	1229
2394	1188
2394	1206
2394	1218
2394	1229
2394	45238
2395	1188
2395	1206
2395	1218
2395	1229
2395	45238
2396	1188
2396	1200
2396	1206
2396	1218
2396	45238
2398	1179
2398	1188
2398	1197
2398	1201
2398	1218
2399	1183
2399	1188
2399	1206
2399	1218
2399	1229
2400	1179
2400	1188
2400	1197
2400	1201
2400	1218
2401	1183
2401	1188
2401	1200
2401	1206
2401	1218
2402	1183
2402	1188
2402	1198
2402	1206
2402	1218
2403	1183
2403	1188
2403	1206
2403	1218
2403	1229
2404	1183
2404	1188
2404	1200
2404	1206
2404	1218
2405	1188
2405	1218
2405	1232
2405	1233
2405	45238
2406	1183
2406	1196
2406	1198
2406	1206
2406	1218
2407	1183
2407	1188
2407	1200
2407	1206
2407	1218
2408	1183
2408	1188
2408	1198
2408	1206
2408	1218
2409	1183
2409	1188
2409	1206
2409	1218
2409	1229
2414	1183
2414	1188
2414	1198
2414	1206
2414	1217
2415	1188
2415	1206
2415	1218
2415	1229
2415	45236
2416	1183
2416	1188
2416	1206
2416	1218
2416	1229
2417	1183
2417	1188
2417	1206
2417	1218
2417	1229
2418	1183
2418	1204
2418	1218
2418	1232
2418	1239
2420	1183
2420	1188
2420	1206
2420	1218
2420	1229
2421	1183
2421	1188
2421	1206
2421	1218
2421	1229
2422	1183
2422	1188
2422	1206
2422	1218
2422	1229
2423	1183
2423	1188
2423	1206
2423	1213
2423	1229
2424	1183
2424	1188
2424	1206
2424	1218
2424	1229
2425	1183
2425	1188
2425	1206
2425	1218
2425	1229
2426	1183
2426	1188
2426	1198
2426	1206
2426	1218
2427	1183
2427	1206
2427	1218
2427	1229
2427	1239
2428	1183
2428	1188
2428	1206
2428	1218
2428	1229
2429	1188
2429	1198
2429	1206
2429	1218
2429	45238
2431	1188
2431	1206
2431	1220
2431	1229
2431	45238
2432	1183
2432	1188
2432	1206
2432	1218
2432	1229
2434	1183
2434	1194
2434	1198
2434	1206
2434	1218
2437	1183
2437	1188
2437	1198
2437	1206
2437	1218
2438	1183
2438	1188
2438	1206
2438	1218
2438	1229
2439	1183
2439	1188
2439	1218
2439	1232
2439	1233
2440	1188
2440	1206
2440	1213
2440	1229
2440	45238
2441	1183
2441	1188
2441	1206
2441	1220
2441	1229
2442	1183
2442	1188
2442	1206
2442	1218
2442	1229
2444	1188
2444	1219
2444	1232
2444	1233
2444	45238
2445	1183
2445	1188
2445	1206
2445	1218
2445	1229
2450	1183
2450	1194
2450	1198
2450	1206
2450	1218
2451	1188
2451	1198
2451	1206
2451	1218
2451	45236
2453	1183
2453	1194
2453	1206
2453	1218
2453	1229
2454	1183
2454	1188
2454	1218
2454	1232
2454	1233
2457	1188
2457	1206
2457	1218
2457	1229
2457	45236
2458	1183
2458	1188
2458	1218
2458	1232
2458	1233
2459	1183
2459	1188
2459	1200
2459	1206
2459	1218
2460	1183
2460	1188
2460	1206
2460	1218
2460	1229
2462	1183
2462	1188
2462	1198
2462	1206
2462	1218
2465	1183
2465	1188
2465	1198
2465	1206
2465	1218
2466	1183
2466	1196
2466	1218
2466	1232
2466	1233
2467	1179
2467	1188
2467	1197
2467	1201
2467	1218
2469	1183
2469	1194
2469	1206
2469	1218
2469	1229
2470	1183
2470	1188
2470	1206
2470	1218
2470	1229
2471	1183
2471	1188
2471	1206
2471	1218
2471	1229
2472	1183
2472	1188
2472	1206
2472	1218
2472	1229
2473	1183
2473	1188
2473	1200
2473	1206
2473	1213
2474	1183
2474	1188
2474	1206
2474	1218
2474	1229
2476	1183
2476	1188
2476	1206
2476	1218
2476	1229
2477	1183
2477	1188
2477	1198
2477	1206
2477	1218
2478	1183
2478	1188
2478	1198
2478	1206
2478	1218
2479	1183
2479	1188
2479	1198
2479	1206
2479	1218
2480	1182
2480	1188
2480	1218
2480	1232
2480	1233
2481	1183
2481	1188
2481	1206
2481	1218
2481	1229
2482	1183
2482	1194
2482	1218
2482	1232
2482	1233
2483	1183
2483	1188
2483	1198
2483	1206
2483	1218
2486	1183
2486	1188
2486	1206
2486	1218
2486	1229
2487	1183
2487	1188
2487	1206
2487	1218
2487	1229
2488	1183
2488	1188
2488	1200
2488	1206
2488	1213
2489	1183
2489	1188
2489	1200
2489	1206
2489	1213
2490	1183
2490	1188
2490	1206
2490	1218
2490	1229
2491	1183
2491	1188
2491	1200
2491	1206
2491	1220
2493	1183
2493	1188
2493	1206
2493	1218
2493	1229
2496	1183
2496	1188
2496	1217
2496	1232
2496	1233
2497	1183
2497	1194
2497	1206
2497	1218
2497	1229
2498	1183
2498	1188
2498	1206
2498	1218
2498	1229
2499	1188
2499	1198
2499	1206
2499	1218
2499	45236
2500	1183
2500	1194
2500	1198
2500	1206
2500	1218
2501	1183
2501	1188
2501	1198
2501	1206
2501	1218
2502	1183
2502	1196
2502	1200
2502	1206
2502	1220
2503	1183
2503	1194
2503	1199
2503	1233
2503	45060
2504	1183
2504	1188
2504	1198
2504	1206
2504	1218
2505	1183
2505	1194
2505	1206
2505	1232
2505	45194
2506	1183
2506	1188
2506	1200
2506	1206
2506	1218
2509	1183
2509	1188
2509	1206
2509	1217
2509	1229
2510	1183
2510	1188
2510	1206
2510	1218
2510	1229
2511	1183
2511	1188
2511	1198
2511	1206
2511	1218
2512	1183
2512	1188
2512	1198
2512	1206
2512	1218
2513	1183
2513	1188
2513	1200
2513	1206
2513	45019
2514	1183
2514	1188
2514	1200
2514	1206
2514	45019
2515	1183
2515	1188
2515	1200
2515	1206
2515	45019
2516	1188
2516	1206
2516	1229
2516	45014
2516	45238
2517	1183
2517	1188
2517	1198
2517	1206
2517	1209
2519	1183
2519	1188
2519	1198
2519	1206
2519	1218
2520	1183
2520	1188
2520	1198
2520	1206
2520	1209
2521	1183
2521	1188
2521	1206
2521	1218
2521	1229
2522	1183
2522	1188
2522	1200
2522	1206
2522	45019
2523	1188
2523	1198
2523	1206
2523	45238
2523	45429
2524	1183
2524	1188
2524	1198
2524	1206
2524	1218
2525	1183
2525	1188
2525	1200
2525	1206
2525	1218
2526	1183
2526	1188
2526	1200
2526	1206
2526	1218
2527	1183
2527	1188
2527	1200
2527	1206
2527	1218
2528	1183
2528	1188
2528	1200
2528	1206
2528	1218
2529	1183
2529	1188
2529	1200
2529	1206
2529	45425
2530	1183
2530	1188
2530	1198
2530	1205
2530	1218
2531	1183
2531	1188
2531	1200
2531	1206
2531	1218
2533	1183
2533	1188
2533	1200
2533	1206
2533	1218
2534	1183
2534	1188
2534	1200
2534	1206
2534	1218
2535	1183
2535	1188
2535	1200
2535	1206
2535	1217
2536	1188
2536	1200
2536	1206
2536	1220
2536	45238
2537	1183
2537	1188
2537	1206
2537	1218
2537	1229
2538	1183
2538	1188
2538	1200
2538	1206
2538	1218
2539	1183
2539	1188
2539	1206
2539	1220
2539	1229
2540	1188
2540	1200
2540	1206
2540	1220
2540	45236
2541	1192
2541	1206
2541	1218
2541	1229
2541	45238
2542	1188
2542	1206
2542	1220
2542	1229
2542	45236
2544	1183
2544	1188
2544	1198
2544	1206
2544	1218
2545	1183
2545	1188
2545	1200
2545	1206
2545	1213
2546	1183
2546	1188
2546	1200
2546	1206
2546	1218
2547	1183
2547	1188
2547	1200
2547	1206
2547	1258
2548	1183
2548	1194
2548	1198
2548	1206
2548	1218
2549	1183
2549	1188
2549	1198
2549	1206
2549	1218
2550	1183
2550	1188
2550	1198
2550	1206
2550	1218
2551	1183
2551	1188
2551	1200
2551	1206
2551	1218
2552	1183
2552	1188
2552	1198
2552	1206
2552	45430
2557	1183
2557	1194
2557	1199
2557	1206
2557	45356
2560	1183
2560	1194
2560	1199
2560	1206
2560	45356
2565	1183
2565	1194
2565	1199
2565	1206
2565	45356
2567	1183
2567	1188
2567	1194
2567	1199
2567	1206
2567	1218
2567	1232
2567	1233
2567	45356
2574	1188
2574	1198
2574	1206
2574	1218
2574	45236
2577	1183
2577	1194
2577	1206
2577	1218
2577	1229
2579	1183
2579	1196
2579	1198
2579	1206
2579	1218
2581	1183
2581	1188
2581	1206
2581	1229
2581	45435
2582	1188
2582	1198
2582	1206
2582	1218
2582	45236
2583	1188
2583	1206
2583	1218
2583	1229
2583	45236
2584	1188
2584	1206
2584	1218
2584	1229
2584	45238
2585	1183
2585	1188
2585	1206
2585	1221
2585	1229
2586	1180
2586	1188
2586	1197
2586	1201
2586	1218
2587	1183
2587	1188
2587	1200
2587	1206
2587	45434
2588	1183
2588	1188
2588	1198
2588	1206
2588	1218
2589	1183
2589	1188
2589	1206
2589	1218
2589	1229
2590	1183
2590	1188
2590	1200
2590	1206
2590	1218
2591	1183
2591	1194
2591	1198
2591	1206
2591	1218
2593	1183
2593	1188
2593	1198
2593	1206
2593	1218
2594	1183
2594	1188
2594	1198
2594	1206
2594	1218
2595	1196
2595	1206
2595	1218
2595	1229
2595	1237
2596	1183
2596	1188
2596	1218
2596	1232
2596	1233
2597	1188
2597	1206
2597	1218
2597	1229
2597	45238
2598	1183
2598	1193
2598	1206
2598	1218
2598	1229
2600	1188
2600	1200
2600	1206
2600	1218
2600	45238
2601	1188
2601	1200
2601	1206
2601	1218
2601	45238
2602	1195
2602	1200
2602	1206
2602	45238
2602	45421
2603	1188
2603	1200
2603	1206
2603	1218
2603	45238
2604	1188
2604	1206
2604	1218
2604	1229
2604	45238
2606	1183
2606	1188
2606	1198
2606	1206
2606	45562
2607	1183
2607	1188
2607	1218
2607	1232
2607	1233
2608	1188
2608	1200
2608	1206
2608	1218
2608	45238
2609	1188
2609	1200
2609	1206
2609	1218
2609	45238
2610	1183
2610	1188
2610	1200
2610	1206
2610	1218
2611	1183
2611	1188
2611	1206
2611	1218
2611	1229
2612	1188
2612	1198
2612	1206
2612	1209
2612	45238
2614	1183
2614	1188
2614	1198
2614	1206
2614	1218
2615	1183
2615	1188
2615	1206
2615	1218
2615	1229
2617	1183
2617	1188
2617	1200
2617	1206
2617	1218
2620	1183
2620	1188
2620	1203
2620	1218
2620	1238
2621	1183
2621	1188
2621	1206
2621	1218
2621	1229
2622	1183
2622	1188
2622	1206
2622	1218
2622	1229
2623	1183
2623	1188
2623	1200
2623	1206
2623	1218
2624	1183
2624	1188
2624	1200
2624	1206
2624	1218
2625	1183
2625	1188
2625	1200
2625	1206
2625	1220
2626	1183
2626	1188
2626	1200
2626	1206
2626	1220
2627	1183
2627	1188
2627	1200
2627	1206
2627	1220
2628	1183
2628	1188
2628	1200
2628	1206
2628	1218
2630	1183
2630	1188
2630	1200
2630	1206
2630	1218
2631	1188
2631	1198
2631	1206
2631	1218
2631	45236
2632	1183
2632	1188
2632	1200
2632	1206
2632	1218
2633	1183
2633	1188
2633	1200
2633	1206
2633	1218
2635	1183
2635	1194
2635	1200
2635	1206
2635	1218
2636	1183
2636	1188
2636	1200
2636	1206
2636	1220
2637	1188
2637	1206
2637	1218
2637	1232
2637	45238
2638	1183
2638	1188
2638	1200
2638	1206
2638	1218
2639	1183
2639	1188
2639	1200
2639	1206
2639	1218
2640	1183
2640	1188
2640	1200
2640	1206
2640	1218
2641	1183
2641	1188
2641	1200
2641	1206
2641	1218
2642	1183
2642	1188
2642	1206
2642	1218
2642	1229
2643	1183
2643	1188
2643	1198
2643	1206
2643	1218
2644	1183
2644	1188
2644	1198
2644	1206
2644	1218
2645	1183
2645	1196
2645	1198
2645	1206
2645	1218
2646	1183
2646	1188
2646	1200
2646	1206
2646	1218
2647	1183
2647	1188
2647	1206
2647	1218
2647	1229
2648	1188
2648	1206
2648	1218
2648	1229
2648	45238
2649	1188
2649	1200
2649	1206
2649	45019
2649	45238
2650	1183
2650	1188
2650	1200
2650	1206
2650	1218
2651	1183
2651	1188
2651	1198
2651	1206
2651	1218
2652	1188
2652	1206
2652	1218
2652	1229
2652	45236
2654	1183
2654	1188
2654	1200
2654	1206
2654	1218
2655	1188
2655	1200
2655	1206
2655	1220
2655	45238
2656	1183
2656	1188
2656	1206
2656	1218
2656	1229
2657	1183
2657	1188
2657	1206
2657	1218
2657	1229
2661	1183
2661	1196
2661	1200
2661	1206
2661	1218
2662	1183
2662	1196
2662	1200
2662	1206
2662	1218
2663	1183
2663	1188
2663	1198
2663	1206
2663	1218
2665	1183
2665	1191
2665	1206
2665	1218
2665	1229
2666	1188
2666	1198
2666	1204
2666	1218
2666	45236
2667	1183
2667	1188
2667	1206
2667	1218
2667	1229
2672	1183
2672	1188
2672	1198
2672	1206
2672	1218
2673	1183
2673	1188
2673	1218
2673	1232
2673	1233
2674	1188
2674	1198
2674	1206
2674	1218
2674	45236
2675	1183
2675	1188
2675	1200
2675	1206
2675	1220
2676	1183
2676	1188
2676	1198
2676	1206
2676	1218
2677	1183
2677	1188
2677	1200
2677	1206
2677	45450
2678	1183
2678	1188
2678	1198
2678	1206
2678	1218
2679	1183
2679	1188
2679	1200
2679	1206
2679	1218
2680	1183
2680	1188
2680	1206
2680	1218
2680	1229
2681	1196
2681	1200
2681	1206
2681	45236
2681	45545
2683	1183
2683	1188
2683	1200
2683	1206
2683	1218
2684	1183
2684	1188
2684	1198
2684	1206
2684	1218
2685	1183
2685	1194
2685	1198
2685	1206
2685	1218
2686	1183
2686	1188
2686	1206
2686	1218
2686	1229
2687	1183
2687	1188
2687	1198
2687	1206
2687	1218
2689	1183
2689	1194
2689	1198
2689	1206
2689	1218
2690	1183
2690	1188
2690	1198
2690	1206
2690	1218
2691	1183
2691	1188
2691	1198
2691	1206
2691	1218
2692	1183
2692	1194
2692	1198
2692	1206
2692	1218
2693	1183
2693	1194
2693	1198
2693	1206
2693	1218
2694	1183
2694	1188
2694	1206
2694	1218
2694	1229
2697	1188
2697	1206
2697	1218
2697	1229
2697	45238
2698	1183
2698	1188
2698	1206
2698	1218
2698	1229
2700	1188
2700	1200
2700	1206
2700	1218
2700	45238
2703	1183
2703	1188
2703	1200
2703	1206
2703	1218
2705	1183
2705	1188
2705	1200
2705	1206
2705	1218
2707	1183
2707	1188
2707	1200
2707	1206
2707	1218
2708	1183
2708	1188
2708	1198
2708	1206
2708	1218
2709	1183
2709	1188
2709	1200
2709	1206
2709	1218
2710	1183
2710	1188
2710	1198
2710	1206
2710	1218
2711	1183
2711	1188
2711	1200
2711	1206
2711	1218
2712	1183
2712	1188
2712	1200
2712	1206
2712	1218
2713	1183
2713	1188
2713	1200
2713	1206
2713	1218
2714	1183
2714	1188
2714	1198
2714	1206
2714	1221
2715	1188
2715	1200
2715	1206
2715	1220
2715	45238
2716	1183
2716	1188
2716	1200
2716	1206
2716	1220
2717	1183
2717	1188
2717	1200
2717	1206
2717	1220
2719	1183
2719	1188
2719	1200
2719	1206
2719	1220
2720	1183
2720	1188
2720	1206
2720	1220
2720	1229
2723	1183
2723	1188
2723	1206
2723	1218
2723	1232
2724	1183
2724	1188
2724	1200
2724	1206
2724	1218
2729	1188
2729	1200
2729	1206
2729	1216
2729	45238
2733	1183
2733	1188
2733	1198
2733	1206
2733	1218
2734	1179
2734	1183
2734	1188
2734	1206
2734	1218
2734	1229
2735	1183
2735	1188
2735	1206
2735	1218
2735	1229
2736	1183
2736	1193
2736	1206
2736	1218
2736	1229
2737	1183
2737	1188
2737	1200
2737	1206
2737	1218
2738	1183
2738	1188
2738	1200
2738	1206
2738	1218
2739	1183
2739	1188
2739	1200
2739	1206
2739	1218
2741	1183
2741	1194
2741	1203
2741	1229
2741	45380
2744	1183
2744	1188
2744	1200
2744	1206
2744	1218
2749	1188
2749	1200
2749	1206
2749	1220
2749	45238
2751	1183
2751	1188
2751	1200
2751	1206
2751	1220
2753	1183
2753	1188
2753	1198
2753	1206
2753	1218
2754	1183
2754	1188
2754	1200
2754	1206
2754	1218
2756	1183
2756	1196
2756	1206
2756	1229
2756	45560
2757	1183
2757	1196
2757	1200
2757	1206
2757	1218
2758	1183
2758	1188
2758	1200
2758	1206
2758	1218
2759	1183
2759	1188
2759	1200
2759	1206
2759	1218
2760	1183
2760	1188
2760	1200
2760	1206
2760	1218
2761	1183
2761	1188
2761	1200
2761	1206
2761	1218
2764	1183
2764	1188
2764	1198
2764	1206
2764	1218
2765	1188
2765	1198
2765	1201
2765	45236
2765	45561
2767	1183
2767	1188
2767	1200
2767	1206
2767	1218
2768	1188
2768	1206
2768	1220
2768	1229
2768	45236
2769	1183
2769	1188
2769	1200
2769	1206
2769	1218
2770	1183
2770	1188
2770	1198
2770	1206
2770	1209
2771	1183
2771	1188
2771	1198
2771	1206
2771	1218
2772	1183
2772	1188
2772	1200
2772	1206
2772	1218
2773	1188
2773	1200
2773	1206
2773	1218
2773	45238
2774	1183
2774	1188
2774	1198
2774	1206
2774	1218
2775	1183
2775	1188
2775	1200
2775	1206
2775	1218
2776	1183
2776	1188
2776	1206
2776	1218
2776	1229
2777	1183
2777	1188
2777	1206
2777	1232
2777	45564
2778	1183
2778	1188
2778	1206
2778	1218
2778	1229
2779	1183
2779	1188
2779	1198
2779	1204
2779	1218
2780	1183
2780	1188
2780	1200
2780	1206
2780	1218
2781	1188
2781	1218
2781	1232
2781	1233
2781	45238
2782	1196
2782	1200
2782	1206
2782	45236
2782	45373
2783	1188
2783	1200
2783	1206
2783	1218
2783	45238
2784	1183
2784	1196
2784	1198
2784	1233
2784	45556
2785	1183
2785	1188
2785	1198
2785	1206
2785	1218
2786	1183
2786	1188
2786	1198
2786	1206
2786	1218
2787	1183
2787	1188
2787	1200
2787	1206
2787	1218
2788	1183
2788	1188
2788	1200
2788	1206
2788	1218
2789	1183
2789	1188
2789	1198
2789	1206
2789	1218
2792	1183
2792	1188
2792	1200
2792	1206
2792	1218
2793	1183
2793	1188
2793	1200
2793	1206
2793	1218
2795	1183
2795	1188
2795	1206
2795	1220
2795	1229
2796	1183
2796	1188
2796	1199
2796	1206
2796	45563
2797	1188
2797	1200
2797	1206
2797	1218
2797	45236
2798	1188
2798	1200
2798	1206
2798	45238
2798	45556
2799	1183
2799	1188
2799	1200
2799	1206
2799	1218
2800	1179
2800	1188
2800	1197
2800	1201
2800	1218
2801	1179
2801	1188
2801	1197
2801	1201
2801	1218
2802	1183
2802	1188
2802	1200
2802	1206
2802	1218
2804	1183
2804	1188
2804	1198
2804	1206
2804	1246
2806	1183
2806	1188
2806	1206
2806	1218
2806	1229
2807	1183
2807	1193
2807	1198
2807	1218
2807	1233
2809	1188
2809	1198
2809	1218
2809	1233
2809	45236
2810	1183
2810	1194
2810	1198
2810	1218
2810	1233
2811	1183
2811	1188
2811	1198
2811	1218
2811	1233
2812	1183
2812	1188
2812	1199
2812	1218
2812	1233
2813	1183
2813	1188
2813	1199
2813	1218
2813	1233
2814	1183
2814	1188
2814	1206
2814	1218
2814	1229
2815	1183
2815	1193
2815	1198
2815	1218
2815	1233
2816	1183
2816	1188
2816	1199
2816	1206
2816	45356
2817	1183
2817	1188
2817	1206
2817	1217
2817	1229
2820	1183
2820	1188
2820	1206
2820	1217
2820	1229
2821	1183
2821	1188
2821	1198
2821	1206
2821	1218
2822	1183
2822	1193
2822	1206
2822	1218
2822	1229
2824	1188
2824	1200
2824	1206
2824	45238
2824	45556
2825	1188
2825	1198
2825	1218
2825	1233
2825	45236
2826	1183
2826	1188
2826	1198
2826	1206
2826	1218
2827	1183
2827	1188
2827	1198
2827	1206
2827	1218
2828	1183
2828	1188
2828	1206
2828	1218
2828	1229
2829	1183
2829	1188
2829	1200
2829	1206
2829	45350
2830	1183
2830	1188
2830	1199
2830	1218
2830	1233
2833	1183
2833	1188
2833	1200
2833	1206
2833	1218
2834	1183
2834	1188
2834	1206
2834	1221
2834	1229
2835	1183
2835	1188
2835	1206
2835	1218
2835	1229
2836	1183
2836	1191
2836	1200
2836	1206
2836	1218
2837	1183
2837	1194
2837	1206
2837	1218
2837	1229
2838	1183
2838	1188
2838	1198
2838	1206
2838	1218
2839	1188
2839	1198
2839	1218
2839	1233
2839	45236
2840	1183
2840	1194
2840	1206
2840	1211
2840	1229
2841	1183
2841	1194
2841	1206
2841	1218
2841	1229
2842	1183
2842	1188
2842	1206
2842	1218
2842	1229
2843	1183
2843	1188
2843	1206
2843	1209
2843	1229
2844	1183
2844	1188
2844	1200
2844	1206
2844	1220
2845	1183
2845	1193
2845	1198
2845	1206
2845	1218
2846	1180
2846	1188
2846	1197
2846	1201
2846	1218
2847	1183
2847	1188
2847	1199
2847	1206
2847	1218
2848	1183
2848	1188
2848	1218
2848	1232
2848	1233
2850	1183
2850	1188
2850	1218
2850	1232
2850	1233
2852	1183
2852	1188
2852	1218
2852	1232
2852	1233
2853	1183
2853	1188
2853	1206
2853	1218
2853	1232
2856	1183
2856	1188
2856	1198
2856	1206
2856	1218
2857	1196
2857	1218
2857	1229
2857	1233
2857	45236
2859	1183
2859	1188
2859	1198
2859	1206
2859	1218
2861	1183
2861	1194
2861	1206
2861	1218
2861	1229
2862	1183
2862	1188
2862	1218
2862	1232
2862	1233
2863	1183
2863	1194
2863	1198
2863	1206
2863	1218
2864	1183
2864	1194
2864	1198
2864	1206
2864	1218
2866	1183
2866	1188
2866	1218
2866	1232
2866	1233
2867	1183
2867	1188
2867	1206
2867	1218
2867	1232
2868	1183
2868	1193
2868	1199
2868	1218
2868	1233
2869	1183
2869	1188
2869	1198
2869	1206
2869	1218
2872	1183
2872	1196
2872	1206
2872	1220
2872	1232
2873	1183
2873	1188
2873	1206
2873	1218
2873	1232
2874	1183
2874	1188
2874	1206
2874	1218
2874	1232
2875	1183
2875	1188
2875	1218
2875	1229
2875	1233
2876	1183
2876	1188
2876	1218
2876	1232
2876	1233
2877	1183
2877	1188
2877	1206
2877	1218
2877	1232
2878	1183
2878	1193
2878	1206
2878	1218
2878	1232
2880	1183
2880	1188
2880	1218
2880	1232
2880	1233
2881	1183
2881	1188
2881	1206
2881	1232
2881	45060
2882	1188
2882	1206
2882	1220
2882	1232
2882	45238
2883	1183
2883	1193
2883	1198
2883	1206
2883	1218
2889	1183
2889	1196
2889	1199
2889	1206
2889	1209
2890	1183
2890	1188
2890	1198
2890	1206
2890	1218
2891	1183
2891	1188
2891	1206
2891	1218
2891	1232
2892	1188
2892	1206
2892	1220
2892	1232
2892	45238
2893	1183
2893	1188
2893	1205
2893	1218
2893	1232
2895	1183
2895	1188
2895	1198
2895	1206
2895	45019
2896	1183
2896	1194
2896	1198
2896	1206
2896	1218
2899	1183
2899	1188
2899	1218
2899	1232
2899	1233
2900	1183
2900	1188
2900	1198
2900	1206
2900	1218
2902	1183
2902	1188
2902	1198
2902	1206
2902	1218
2903	1183
2903	1188
2903	1206
2903	1232
2903	1258
2904	1183
2904	1196
2904	1198
2904	1218
2904	1233
2905	1183
2905	1188
2905	1206
2905	1218
2905	1229
2906	1183
2906	1188
2906	1206
2906	1218
2906	1229
2907	1183
2907	1188
2907	1206
2907	1218
2907	1232
2909	1183
2909	1188
2909	1206
2909	1218
2909	1229
2911	1183
2911	1194
2911	1218
2911	1232
2911	1233
2914	1183
2914	1188
2914	1199
2914	1206
2914	1218
2915	1183
2915	1188
2915	1206
2915	1221
2915	1232
2916	1183
2916	1188
2916	1198
2916	1206
2916	1218
2917	1183
2917	1188
2917	1206
2917	1218
2917	1232
2918	1183
2918	1188
2918	1232
2918	1233
2918	45181
2919	1183
2919	1188
2919	1198
2919	1218
2919	1233
2920	1188
2920	1206
2920	1220
2920	1232
2920	45238
2921	1183
2921	1188
2921	1198
2921	1206
2921	1218
2922	1183
2922	1188
2922	1206
2922	1218
2922	1229
2923	1183
2923	1188
2923	1218
2923	1232
2923	1233
2924	1183
2924	1194
2924	1198
2924	1218
2924	1233
2925	1183
2925	1188
2925	1232
2925	1233
2925	45181
2926	1188
2926	1199
2926	1206
2926	1218
2926	45236
2927	1188
2927	1232
2927	1233
2927	45238
2927	45562
2931	1183
2931	1194
2931	1198
2931	1206
2931	1211
2935	1183
2935	1188
2935	1199
2935	1206
2935	1218
2936	1183
2936	1188
2936	1198
2936	1204
2936	1218
2937	1195
2937	1218
2937	1232
2937	1233
2937	45238
2938	1188
2938	1198
2938	1206
2938	1218
2938	45238
2939	1183
2939	1188
2939	1218
2939	1232
2939	1233
2941	1183
2941	1188
2941	1206
2941	1218
2941	1229
2942	1183
2942	1196
2942	1199
2942	1206
2942	1218
2943	1183
2943	1188
2943	1198
2943	1205
2943	1218
2945	1183
2945	1188
2945	1218
2945	1229
2945	1233
2946	1183
2946	1193
2946	1198
2946	1206
2946	45317
2947	1183
2947	1188
2947	1199
2947	1206
2947	1258
2948	1183
2948	1188
2948	1206
2948	1218
2948	1232
2952	1183
2952	1191
2952	1206
2952	1218
2952	1232
2954	1183
2954	1191
2954	1206
2954	1229
2954	1277
2955	1183
2955	1188
2955	1206
2955	1221
2955	1229
2956	1183
2956	1188
2956	1206
2956	1218
2956	1229
2957	1183
2957	1188
2957	1206
2957	1218
2957	1232
2958	1183
2958	1188
2958	1206
2958	1218
2958	1232
2959	1182
2959	1188
2959	1232
2959	1233
2959	45548
2962	1183
2962	1188
2962	1206
2962	1232
2962	1258
2964	1183
2964	1188
2964	1200
2964	1206
2964	1218
2965	1183
2965	1188
2965	1206
2965	1218
2965	1229
2966	1183
2966	1188
2966	1200
2966	1206
2966	1218
2967	1183
2967	1188
2967	1199
2967	1206
2967	1218
2969	1183
2969	1193
2969	1198
2969	1206
2969	1218
2970	1188
2970	1198
2970	1218
2970	1233
2970	45236
2971	1183
2971	1188
2971	1206
2971	1218
2971	1229
2972	1183
2972	1188
2972	1198
2972	1206
2972	1218
2973	1188
2973	1198
2973	1218
2973	1233
2973	45238
2975	1183
2975	1188
2975	1205
2975	1218
2975	1232
2976	1183
2976	1188
2976	1206
2976	1221
2976	1229
2977	1183
2977	1188
2977	1200
2977	1206
2977	1218
2978	1188
2978	1200
2978	1206
2978	1220
2978	45238
2981	1183
2981	1188
2981	1200
2981	1206
2981	1218
2983	1183
2983	1188
2983	1198
2983	1206
2983	1218
2985	1188
2985	1206
2985	1213
2985	1229
2985	45236
2986	1183
2986	1188
2986	1200
2986	1206
2986	1218
2987	1183
2987	1188
2987	1200
2987	1206
2987	1218
2989	1183
2989	1188
2989	1198
2989	1206
2989	1218
2991	1183
2991	1188
2991	1198
2991	1206
2991	1218
2992	1183
2992	1196
2992	1206
2992	1218
2992	1229
2993	1183
2993	1196
2993	1232
2993	1233
2993	45128
2994	1183
2994	1196
2994	1206
2994	1218
2994	1229
2995	1183
2995	1194
2995	1206
2995	1221
2995	1229
2996	1183
2996	1188
2996	1213
2996	1232
2996	1233
2999	1183
2999	1188
2999	1200
2999	1206
2999	1218
3000	1183
3000	1191
3000	1200
3000	1206
3000	1218
3001	1188
3001	1200
3001	1206
3001	1220
3001	45238
3002	1183
3002	1196
3002	1198
3002	1206
3002	1218
3004	1183
3004	1194
3004	1206
3004	1221
3004	1229
3005	1183
3005	1188
3005	1200
3005	1206
3005	1218
3006	1188
3006	1200
3006	1206
3006	1218
3006	45238
3007	1183
3007	1188
3007	1198
3007	1210
3007	1233
3008	1183
3008	1188
3008	1206
3008	1217
3008	1232
3009	1183
3009	1194
3009	1206
3009	1218
3009	1229
3010	1183
3010	1188
3010	1205
3010	1218
3010	1232
3011	1183
3011	1188
3011	1206
3011	1218
3011	1232
3011	1233
3015	1183
3015	1188
3015	1206
3015	1213
3015	1218
3015	1229
3016	1188
3016	1198
3016	1206
3016	45134
3016	45236
3017	1183
3017	1188
3017	1206
3017	1218
3017	1232
3018	1188
3018	1218
3018	1232
3018	1233
3018	45238
3019	1178
3019	1188
3019	1197
3019	1201
3019	1218
3020	1188
3020	1206
3020	1218
3020	1229
3020	45236
3021	1183
3021	1188
3021	1217
3021	1232
3021	1233
3023	1183
3023	1188
3023	1198
3023	1206
3023	1218
3024	1183
3024	1188
3024	1206
3024	1218
3024	1232
3025	1183
3025	1188
3025	1218
3025	1232
3025	1233
3026	1183
3026	1188
3026	1206
3026	1218
3026	1232
3028	1183
3028	1188
3028	1200
3028	1206
3028	1218
3031	1183
3031	1188
3031	1206
3031	1218
3031	1232
3032	1183
3032	1188
3032	1206
3032	1218
3032	1232
3035	1183
3035	1188
3035	1206
3035	1218
3035	1229
3038	1188
3038	1200
3038	1206
3038	1218
3038	45238
3039	1183
3039	1188
3039	1218
3039	1232
3039	1233
3041	1188
3041	1206
3041	1218
3041	1229
3041	45236
3043	1183
3043	1188
3043	1206
3043	1218
3043	1232
3044	1188
3044	1232
3044	1233
3044	45029
3044	45236
3045	1183
3045	1188
3045	1218
3045	1232
3045	1233
3049	1183
3049	1188
3049	1206
3049	1218
3049	1229
3050	1183
3050	1188
3050	1218
3050	1232
3050	1233
3051	1183
3051	1194
3051	1218
3051	1232
3051	1233
3054	1183
3054	1188
3054	1200
3054	1206
3054	1218
3055	1183
3055	1188
3055	1206
3055	1218
3055	1229
3058	1183
3058	1188
3058	1206
3058	1218
3058	1229
3059	1194
3059	1206
3059	1218
3059	1229
3059	45238
3060	1183
3060	1188
3060	1218
3060	1232
3060	1233
3062	1188
3062	1206
3062	1218
3062	1229
3062	45238
3063	1188
3063	1198
3063	1206
3063	1217
3063	45238
3064	1183
3064	1188
3064	1220
3064	1232
3064	1233
3065	1183
3065	1188
3065	1206
3065	1218
3065	1229
3067	1183
3067	1188
3067	1206
3067	1218
3067	1229
3068	1188
3068	1218
3068	1232
3068	1233
3068	45238
3069	1188
3069	1220
3069	1232
3069	1233
3069	45238
3070	1183
3070	1188
3070	1206
3070	1218
3070	1229
3072	1188
3072	1218
3072	1232
3072	1233
3072	45238
3073	1195
3073	1220
3073	1232
3073	1233
3073	45238
3074	1183
3074	1188
3074	1191
3074	1218
3074	1232
3074	1233
3074	1277
3075	1183
3075	1188
3075	1206
3075	1209
3075	1229
3076	1183
3076	1188
3076	1206
3076	1218
3076	1232
3077	1183
3077	1188
3077	1206
3077	1218
3077	1229
3078	1183
3078	1188
3078	1206
3078	1218
3078	1229
3079	1183
3079	1188
3079	1206
3079	1218
3079	1229
3080	1183
3080	1188
3080	1206
3080	1218
3080	1229
3082	1183
3082	1194
3082	1198
3082	1206
3082	1218
3083	1179
3083	1188
3083	1197
3083	1201
3083	1218
3088	1188
3088	1198
3088	1206
3088	1218
3088	45238
3090	1188
3090	1198
3090	1206
3090	1218
3090	45236
3091	1183
3091	1188
3091	1198
3091	1206
3091	1218
3092	1183
3092	1196
3092	1198
3092	1206
3092	1220
3093	1179
3093	1191
3093	1197
3093	1201
3093	1218
3094	1183
3094	1194
3094	1206
3094	1218
3094	1229
3095	1188
3095	1206
3095	1219
3095	1229
3095	45238
3096	1183
3096	1188
3096	1206
3096	1218
3096	1229
3097	1183
3097	1188
3097	1206
3097	1218
3097	1229
3100	1179
3100	1188
3100	1197
3100	1201
3100	1218
3102	1183
3102	1188
3102	1206
3102	1209
3102	1218
3102	1229
3103	1183
3103	1188
3103	1206
3103	1218
3103	1232
3104	1183
3104	1198
3104	1206
3104	1218
3104	1239
3106	1183
3106	1188
3106	1206
3106	1218
3106	1229
3107	1188
3107	1206
3107	1218
3107	1229
3107	45238
3108	1183
3108	1188
3108	1206
3108	1216
3108	1229
3109	1183
3109	1196
3109	1206
3109	1220
3109	1229
3110	1183
3110	1194
3110	1206
3110	1220
3110	1229
3111	1188
3111	1206
3111	1218
3111	1229
3111	45238
3113	1183
3113	1188
3113	1200
3113	1206
3113	1218
3114	1183
3114	1188
3114	1206
3114	1218
3114	1229
3115	1183
3115	1188
3115	1198
3115	1206
3115	1218
3116	1183
3116	1188
3116	1199
3116	1206
3116	1218
3119	1183
3119	1188
3119	1206
3119	1218
3119	1232
3120	1183
3120	1188
3120	1206
3120	1218
3120	1232
3121	1179
3121	1188
3121	1197
3121	1201
3121	1218
3122	1179
3122	1188
3122	1197
3122	1201
3122	1218
3124	1183
3124	1188
3124	1198
3124	1206
3124	1218
3124	1220
3125	1183
3125	1188
3125	1198
3125	1206
3125	1218
3126	1183
3126	1188
3126	1200
3126	1206
3126	1218
3128	1183
3128	1196
3128	1206
3128	1219
3128	1229
3129	1182
3129	1188
3129	1199
3129	1206
3129	1218
3130	1188
3130	1200
3130	1206
3130	1218
3130	45236
3131	1183
3131	1188
3131	1206
3131	1218
3131	1229
3136	1195
3136	1206
3136	1218
3136	1229
3136	45238
3137	1196
3137	1200
3137	1206
3137	1218
3137	45236
3139	1183
3139	1194
3139	1200
3139	1206
3139	1218
3141	1183
3141	1196
3141	1200
3141	1206
3141	1218
3142	1195
3142	1206
3142	1218
3142	1229
3142	45238
3143	1179
3143	1188
3143	1197
3143	1201
3143	1218
3145	1183
3145	1188
3145	1232
3145	1233
3145	1263
3146	1183
3146	1188
3146	1206
3146	1218
3146	1232
3147	1183
3147	1191
3147	1218
3147	1232
3147	1233
3148	1183
3148	1188
3148	1206
3148	1218
3148	1232
3148	1233
3149	1183
3149	1188
3149	1218
3149	1232
3149	1233
3150	1183
3150	1196
3150	1206
3150	1218
3150	1232
3151	1183
3151	1188
3151	1206
3151	1218
3151	1232
3152	1183
3152	1188
3152	1200
3152	1206
3152	1218
3153	1183
3153	1188
3153	1206
3153	1218
3153	1229
3154	1183
3154	1188
3154	1200
3154	1206
3154	1218
3155	1183
3155	1188
3155	1198
3155	1206
3155	1218
3156	1183
3156	1188
3156	1199
3156	1233
3156	45317
3158	1183
3158	1188
3158	1232
3158	1233
3158	45565
3160	1183
3160	1188
3160	1200
3160	1206
3160	1218
3161	1183
3161	1188
3161	1198
3161	1206
3161	1218
3162	1183
3162	1188
3162	1198
3162	1206
3162	1218
3164	1183
3164	1194
3164	1198
3164	1218
3164	1233
3167	1183
3167	1188
3167	1198
3167	1206
3167	1218
3168	1183
3168	1188
3168	1218
3168	1232
3168	1233
3169	1183
3169	1188
3169	1200
3169	1206
3169	1213
3170	1195
3170	1206
3170	1218
3170	1229
3170	45238
3172	1183
3172	1188
3172	1200
3172	1206
3172	1218
3173	1183
3173	1188
3173	1198
3173	1206
3173	1218
3174	1183
3174	1188
3174	1198
3174	1206
3174	1218
3176	1183
3176	1188
3176	1206
3176	1218
3176	1229
3177	1188
3177	1206
3177	1220
3177	1229
3177	45238
3178	1183
3178	1194
3178	1206
3178	1219
3178	1229
3180	1188
3180	1206
3180	1220
3180	1229
3180	45238
3181	1183
3181	1188
3181	1206
3181	1220
3181	1229
3182	1183
3182	1188
3182	1206
3182	1218
3182	1229
3183	1183
3183	1188
3183	1206
3183	1218
3183	1229
3184	1183
3184	1188
3184	1206
3184	1218
3184	1229
3186	1188
3186	1206
3186	1218
3186	1229
3186	45238
3188	1183
3188	1188
3188	1206
3188	1218
3188	1229
3189	1183
3189	1188
3189	1218
3189	1232
3189	1233
3190	1188
3190	1206
3190	1220
3190	1229
3190	45238
3191	1183
3191	1196
3191	1218
3191	1232
3191	1233
3192	1183
3192	1188
3192	1206
3192	1218
3192	1229
3193	1183
3193	1188
3193	1206
3193	1220
3193	1229
3195	1183
3195	1188
3195	1206
3195	1218
3195	1229
3196	1183
3196	1188
3196	1206
3196	1218
3196	1229
3197	1183
3197	1188
3197	1204
3197	1218
3197	1232
3198	1183
3198	1188
3198	1206
3198	1218
3198	1229
3200	1188
3200	1206
3200	1220
3200	1229
3200	45238
3201	1183
3201	1188
3201	1218
3201	1232
3201	1233
3202	1183
3202	1188
3202	1218
3202	1232
3202	1233
3204	1188
3204	1200
3204	1206
3204	1220
3204	45238
3205	1183
3205	1188
3205	1200
3205	1206
3205	1218
3206	1188
3206	1206
3206	1220
3206	1229
3206	45238
3207	1183
3207	1194
3207	1206
3207	1220
3207	1229
3208	1183
3208	1188
3208	1206
3208	1218
3208	1229
3209	1183
3209	1188
3209	1198
3209	1206
3209	1218
3210	1183
3210	1188
3210	1206
3210	1218
3210	1229
3211	1183
3211	1194
3211	1200
3211	1206
3211	1218
3212	1183
3212	1188
3212	1206
3212	1218
3212	1229
3213	1183
3213	1188
3213	1206
3213	1218
3213	1232
3214	1183
3214	1194
3214	1206
3214	1218
3214	1229
3215	1188
3215	1218
3215	1232
3215	1233
3215	45238
3219	1188
3219	1218
3219	1232
3219	1233
3219	45238
3220	1183
3220	1188
3220	1198
3220	1206
3220	1218
3221	1183
3221	1188
3221	1206
3221	1218
3221	1229
3225	1188
3225	1206
3225	1220
3225	1229
3225	45238
3229	1183
3229	1188
3229	1200
3229	1206
3229	1218
3233	1188
3233	1206
3233	1218
3233	1229
3233	45238
3234	1188
3234	1206
3234	1220
3234	1229
3234	45238
3235	1183
3235	1188
3235	1206
3235	1218
3235	1229
3236	1183
3236	1188
3236	1206
3236	1218
3236	1229
3237	1183
3237	1188
3237	1200
3237	1206
3237	1218
3239	1183
3239	1188
3239	1206
3239	1220
3239	1229
3240	1183
3240	1188
3240	1206
3240	1218
3240	1232
3242	1183
3242	1188
3242	1206
3242	1218
3242	1229
3243	1183
3243	1188
3243	1200
3243	1206
3243	45339
3244	1183
3244	1188
3244	1206
3244	1232
3244	44979
3246	1183
3246	1188
3246	1206
3246	1218
3246	1229
3247	1179
3247	1188
3247	1197
3247	1201
3247	1218
3249	1183
3249	1191
3249	1213
3249	1232
3249	1233
3251	1183
3251	1188
3251	1200
3251	1206
3251	1218
3252	1183
3252	1194
3252	1200
3252	1206
3252	1218
3253	1188
3253	1200
3253	1206
3253	1218
3253	45238
3255	1183
3255	1188
3255	1206
3255	1217
3255	1229
3257	1183
3257	1188
3257	1206
3257	1218
3257	1229
3258	1183
3258	1188
3258	1206
3258	1220
3258	1229
3261	1183
3261	1188
3261	1218
3261	1232
3261	1233
3262	1188
3262	1218
3262	1232
3262	1233
3262	45238
3263	1183
3263	1188
3263	1206
3263	1218
3263	1229
3264	1183
3264	1188
3264	1206
3264	1220
3264	1229
3265	1183
3265	1188
3265	1206
3265	1218
3265	1229
3266	1188
3266	1206
3266	1218
3266	1229
3266	45236
3267	1183
3267	1196
3267	1218
3267	1232
3267	1233
3268	1183
3268	1188
3268	1218
3268	1232
3268	1233
3269	1179
3269	1188
3269	1197
3269	1201
3269	1218
3270	1183
3270	1188
3270	1206
3270	1218
3270	1229
3271	1179
3271	1188
3271	1197
3271	1201
3271	1218
3272	1179
3272	1188
3272	1197
3272	1201
3272	1218
3275	1183
3275	1188
3275	1206
3275	1218
3275	1229
3279	1183
3279	1194
3279	1206
3279	1218
3279	1229
3280	1183
3280	1188
3280	1206
3280	1218
3280	1229
3281	1188
3281	1200
3281	1206
3281	1218
3281	45236
3282	1183
3282	1188
3282	1206
3282	1218
3282	1229
3283	1183
3283	1188
3283	1200
3283	1206
3283	1218
3284	1183
3284	1188
3284	1206
3284	1218
3284	1229
3285	1183
3285	1188
3285	1218
3285	1232
3285	1233
3286	1183
3286	1188
3286	1206
3286	1218
3286	1229
3287	1183
3287	1188
3287	1206
3287	1218
3287	1229
3292	1188
3292	1220
3292	1232
3292	1233
3292	45238
3294	1183
3294	1188
3294	1206
3294	1218
3294	1229
3295	1183
3295	1188
3295	1206
3295	1218
3295	1229
3296	1183
3296	1188
3296	1200
3296	1206
3296	1218
3297	1183
3297	1196
3297	1206
3297	1218
3297	1229
3298	1183
3298	1188
3298	1206
3298	1218
3298	1229
3299	1183
3299	1188
3299	1206
3299	1220
3299	1229
3301	1188
3301	1206
3301	1218
3301	1229
3301	45238
3303	1183
3303	1188
3303	1218
3303	1232
3303	1233
3304	1188
3304	1206
3304	1216
3304	1229
3304	45238
3305	1183
3305	1188
3305	1198
3305	1206
3305	1218
3306	1188
3306	1206
3306	1220
3306	1229
3306	45238
3307	1183
3307	1188
3307	1213
3307	1232
3307	1233
3308	1183
3308	1188
3308	1206
3308	1218
3308	1229
3309	1183
3309	1188
3309	1206
3309	1220
3309	1229
3310	1183
3310	1188
3310	1200
3310	1206
3310	1220
3311	1183
3311	1188
3311	1218
3311	1232
3311	1233
3314	1183
3314	1188
3314	1198
3314	1206
3314	1218
3315	1183
3315	1188
3315	1206
3315	1220
3315	1229
3316	1188
3316	1206
3316	1220
3316	1229
3316	45238
3318	1188
3318	1198
3318	1206
3318	1219
3318	45238
3320	1188
3320	1206
3320	1220
3320	1229
3320	45238
3321	1188
3321	1198
3321	1206
3321	1218
3321	45238
3322	1183
3322	1188
3322	1206
3322	1218
3322	1229
3323	1183
3323	1188
3323	1206
3323	1232
3323	1271
3325	1183
3325	1188
3325	1206
3325	1220
3325	1229
3326	1183
3326	1188
3326	1206
3326	1218
3326	1229
3328	1183
3328	1188
3328	1200
3328	1206
3328	1218
3330	1183
3330	1188
3330	1206
3330	1218
3330	1229
3333	1195
3333	1206
3333	1213
3333	1229
3333	45238
3334	1183
3334	1188
3334	1206
3334	1218
3334	1229
3335	1188
3335	1200
3335	1206
3335	1220
3335	45238
3336	1183
3336	1188
3336	1200
3336	1206
3336	1213
3338	1183
3338	1188
3338	1206
3338	1218
3338	1229
3339	1183
3339	1188
3339	1206
3339	1218
3339	1232
3342	1183
3342	1188
3342	1198
3342	1206
3342	1217
3344	1188
3344	1206
3344	1218
3344	1232
3344	45236
3346	1182
3346	1188
3346	1218
3346	1232
3346	1233
3347	1188
3347	1198
3347	1206
3347	1218
3347	45238
3350	1188
3350	1218
3350	1232
3350	1233
3350	45238
3353	1183
3353	1194
3353	1206
3353	1218
3353	1229
3354	1183
3354	1188
3354	1218
3354	1232
3354	1233
3355	1183
3355	1188
3355	1200
3355	1206
3355	1218
3356	1183
3356	1188
3356	1217
3356	1232
3356	1233
3357	1183
3357	1188
3357	1206
3357	1218
3357	1229
3359	1183
3359	1188
3359	1203
3359	1218
3359	1232
3360	1183
3360	1188
3360	1206
3360	1218
3360	1229
3361	1183
3361	1188
3361	1218
3361	1232
3361	1233
3362	1183
3362	1188
3362	1218
3362	1232
3362	1233
3363	1183
3363	1194
3363	1198
3363	1206
3363	1218
3364	1183
3364	1194
3364	1199
3364	1203
3364	1218
3365	1183
3365	1188
3365	1206
3365	1218
3365	1229
3367	1183
3367	1188
3367	1218
3367	1232
3367	1233
3369	1188
3369	1218
3369	1232
3369	1233
3369	45238
3371	1188
3371	1198
3371	1206
3371	1218
3371	45236
3372	1183
3372	1194
3372	1198
3372	1206
3372	1209
3376	1183
3376	1188
3376	1206
3376	1218
3376	1229
3377	1183
3377	1188
3377	1218
3377	1232
3377	1233
3378	1188
3378	1198
3378	1206
3378	1218
3378	45238
3379	1188
3379	1198
3379	1206
3379	1218
3379	45238
3380	1183
3380	1188
3380	1198
3380	1233
3380	45548
3381	1179
3381	1188
3381	1197
3381	1201
3381	1218
3382	1183
3382	1188
3382	1218
3382	1232
3382	1233
3384	1183
3384	1188
3384	1206
3384	1218
3384	1229
3386	1183
3386	1188
3386	1198
3386	1206
3386	1218
3387	1183
3387	1188
3387	1200
3387	1204
3387	1218
3388	1183
3388	1188
3388	1218
3388	1232
3388	1233
3389	1179
3389	1188
3389	1197
3389	1201
3389	1218
3390	1188
3390	1200
3390	1206
3390	1218
3390	45238
3391	1183
3391	1188
3391	1218
3391	1232
3391	1233
3392	1183
3392	1188
3392	1200
3392	1206
3392	1218
3393	1183
3393	1188
3393	1206
3393	1218
3393	1229
3395	1183
3395	1188
3395	1205
3395	1218
3395	1232
3397	1188
3397	1220
3397	1232
3397	1233
3397	45238
3398	1188
3398	1206
3398	1220
3398	1229
3398	45238
3402	1188
3402	1218
3402	1232
3402	1233
3402	45238
3403	1188
3403	1218
3403	1232
3403	1233
3403	45238
3406	1183
3406	1188
3406	1206
3406	1217
3406	1229
3409	1183
3409	1188
3409	1205
3409	1218
3409	1232
3410	1183
3410	1188
3410	1218
3410	1232
3410	1233
3412	1183
3412	1188
3412	1206
3412	1218
3412	1229
3413	1183
3413	1188
3413	1206
3413	1218
3413	1229
3415	1183
3415	1188
3415	1206
3415	1218
3415	1229
3417	1183
3417	1194
3417	1200
3417	1206
3417	1218
3418	1183
3418	1188
3418	1218
3418	1232
3418	1233
3419	1183
3419	1188
3419	1200
3419	1206
3419	1220
3421	1183
3421	1188
3421	1198
3421	1206
3421	1218
3422	1183
3422	1188
3422	1198
3422	1206
3422	1218
3423	1183
3423	1188
3423	1206
3423	1220
3423	1229
3424	1188
3424	1220
3424	1232
3424	1233
3424	45238
3426	1183
3426	1188
3426	1206
3426	1218
3426	1229
3427	1188
3427	1206
3427	1220
3427	1229
3427	45238
3428	1183
3428	1188
3428	1218
3428	1232
3428	1233
3429	1179
3429	1188
3429	1197
3429	1201
3429	1218
3430	1183
3430	1206
3430	1218
3430	1232
3430	1239
3432	1188
3432	1206
3432	1218
3432	1229
3432	45238
3435	1188
3435	1198
3435	1206
3435	1218
3435	45238
3436	1183
3436	1188
3436	1198
3436	1206
3436	1218
3437	1183
3437	1188
3437	1198
3437	1206
3437	1218
3438	1183
3438	1188
3438	1218
3438	1232
3438	1233
3439	1183
3439	1188
3439	1198
3439	1206
3439	1218
3440	1188
3440	1218
3440	1232
3440	1233
3440	45238
3442	1188
3442	1200
3442	1206
3442	1218
3442	45238
3443	1183
3443	1188
3443	1206
3443	1218
3443	1229
3444	1183
3444	1188
3444	1206
3444	1218
3444	1229
3445	1179
3445	1188
3445	1197
3445	1201
3445	1218
3446	1183
3446	1194
3446	1206
3446	1218
3446	1229
3448	1188
3448	1206
3448	1218
3448	1232
3448	45238
3449	1183
3449	1196
3449	1218
3449	1232
3449	1233
3450	1188
3450	1218
3450	1232
3450	1233
3450	45238
3451	1183
3451	1188
3451	1206
3451	1216
3451	1229
3452	1188
3452	1206
3452	1211
3452	1229
3452	45238
3453	1183
3453	1188
3453	1200
3453	1206
3453	1218
3454	1188
3454	1220
3454	1232
3454	1233
3454	45238
3455	1183
3455	1188
3455	1206
3455	1218
3455	1232
3456	1183
3456	1188
3456	1200
3456	1206
3456	1218
3457	1188
3457	1198
3457	1206
3457	1220
3457	45238
3458	1183
3458	1188
3458	1206
3458	1218
3458	1229
3459	1183
3459	1188
3459	1206
3459	1220
3459	1229
3460	1183
3460	1188
3460	1200
3460	1206
3460	1218
3461	1188
3461	1218
3461	1232
3461	1233
3461	45238
3462	1188
3462	1206
3462	1220
3462	1229
3462	45238
3463	1183
3463	1188
3463	1205
3463	1218
3463	1232
3464	1183
3464	1188
3464	1206
3464	1218
3464	1229
3466	1188
3466	1200
3466	1206
3466	1218
3466	45238
3467	1188
3467	1206
3467	1220
3467	1229
3467	45238
3468	1183
3468	1188
3468	1200
3468	1206
3468	1218
3469	1183
3469	1188
3469	1206
3469	1220
3469	1229
3470	1188
3470	1206
3470	1218
3470	1229
3470	45238
3473	1183
3473	1188
3473	1200
3473	1206
3473	1218
3474	1183
3474	1194
3474	1206
3474	1218
3474	1229
3475	1183
3475	1188
3475	1218
3475	1232
3475	1233
3476	1183
3476	1188
3476	1200
3476	1206
3476	1218
3477	1183
3477	1188
3477	1206
3477	1218
3477	1229
3478	1188
3478	1206
3478	1218
3478	1229
3478	45238
3480	1183
3480	1194
3480	1220
3480	1232
3480	1233
3482	1179
3482	1188
3482	1197
3482	1201
3482	1218
3483	1183
3483	1188
3483	1206
3483	1218
3483	1229
3484	1183
3484	1188
3484	1198
3484	1206
3484	1216
3485	1183
3485	1188
3485	1198
3485	1206
3485	1218
3486	1183
3486	1188
3486	1206
3486	1218
3486	1229
3487	1183
3487	1188
3487	1206
3487	1218
3487	1229
3488	1183
3488	1194
3488	1198
3488	1206
3488	1218
3489	1183
3489	1188
3489	1203
3489	1218
3489	1232
3490	1183
3490	1188
3490	1203
3490	1218
3490	1232
3491	1183
3491	1188
3491	1204
3491	1218
3491	1229
3493	1183
3493	1188
3493	1200
3493	1206
3493	1218
3494	1183
3494	1188
3494	1206
3494	1218
3494	1229
3495	1183
3495	1188
3495	1206
3495	1218
3495	1229
3500	1183
3500	1188
3500	1218
3500	1232
3500	1233
3503	1183
3503	1188
3503	1218
3503	1232
3503	1233
3506	1183
3506	1188
3506	1198
3506	1206
3506	1218
3507	1188
3507	1220
3507	1232
3507	1233
3507	45238
3508	1188
3508	1218
3508	1232
3508	1233
3508	45238
3509	1179
3509	1188
3509	1197
3509	1201
3509	1218
3510	1188
3510	1206
3510	1218
3510	1232
3510	45238
3511	1183
3511	1188
3511	1206
3511	1218
3511	1229
3512	1183
3512	1188
3512	1198
3512	1206
3512	1218
3513	1188
3513	1218
3513	1232
3513	1233
3513	45238
3514	1179
3514	1188
3514	1197
3514	1201
3514	1218
3515	1183
3515	1188
3515	1218
3515	1232
3515	1233
3516	1183
3516	1188
3516	1218
3516	1232
3516	1233
3517	1183
3517	1188
3517	1200
3517	1206
3517	1218
3518	1183
3518	1188
3518	1206
3518	1218
3518	1229
3519	1183
3519	1188
3519	1200
3519	1206
3519	1218
3521	1183
3521	1218
3521	1232
3521	1233
3521	1239
3522	1183
3522	1188
3522	1218
3522	1232
3522	1233
3523	1188
3523	1206
3523	1219
3523	1229
3523	45238
3525	1188
3525	1206
3525	1220
3525	1229
3525	45238
3526	1183
3526	1188
3526	1198
3526	1206
3526	1218
3527	1183
3527	1188
3527	1206
3527	1211
3527	1229
3528	1188
3528	1218
3528	1232
3528	1233
3528	45238
3530	1183
3530	1188
3530	1206
3530	1218
3530	1229
3531	1188
3531	1198
3531	1206
3531	1218
3531	45238
3532	1188
3532	1198
3532	1206
3532	1211
3532	45238
3534	1183
3534	1188
3534	1198
3534	1206
3534	1218
3535	1183
3535	1188
3535	1218
3535	1232
3535	1233
3537	1183
3537	1188
3537	1200
3537	1206
3537	1217
3537	1218
3537	1229
3538	1183
3538	1188
3538	1206
3538	1218
3538	1229
3540	1183
3540	1194
3540	1205
3540	1218
3540	1232
3543	1183
3543	1188
3543	1198
3543	1206
3543	1218
3544	1188
3544	1200
3544	1206
3544	1218
3544	45238
3545	1183
3545	1194
3545	1206
3545	1220
3545	1229
3547	1183
3547	1188
3547	1213
3547	1232
3547	1233
3548	1188
3548	1198
3548	1206
3548	1218
3548	45238
3549	1188
3549	1206
3549	1220
3549	1229
3549	45238
3550	1183
3550	1188
3550	1206
3550	1218
3550	1229
3551	1188
3551	1206
3551	1220
3551	1229
3551	45238
3552	1188
3552	1206
3552	1220
3552	1229
3552	45238
3557	1183
3557	1188
3557	1206
3557	1218
3557	1229
3558	1183
3558	1188
3558	1198
3558	1206
3558	1218
3559	1179
3559	1188
3559	1197
3559	1201
3559	1218
3560	1188
3560	1218
3560	1232
3560	1233
3560	45238
3561	1183
3561	1188
3561	1200
3561	1206
3561	1218
3566	1183
3566	1194
3566	1200
3566	1206
3566	1218
3568	1188
3568	1206
3568	1220
3568	1229
3568	45238
3569	1183
3569	1188
3569	1218
3569	1232
3569	1233
3570	1183
3570	1188
3570	1206
3570	1218
3570	1229
3571	1183
3571	1188
3571	1206
3571	1218
3571	1229
3573	1183
3573	1188
3573	1206
3573	1218
3573	1229
3575	1183
3575	1188
3575	1200
3575	1206
3575	1217
3578	1188
3578	1206
3578	1229
3578	45238
3578	45430
3580	1183
3580	1196
3580	1200
3580	1206
3580	1218
3583	1188
3583	1200
3583	1206
3583	1218
3583	45236
3584	1183
3584	1188
3584	1206
3584	1209
3584	1229
3589	1179
3589	1188
3589	1197
3589	1201
3589	1218
3591	1183
3591	1194
3591	1206
3591	1218
3591	1229
3592	1183
3592	1200
3592	1206
3592	1218
3592	1239
3596	1183
3596	1200
3596	1206
3596	1218
3596	1239
3599	1183
3599	1188
3599	1206
3599	1218
3599	1229
3600	1183
3600	1188
3600	1199
3600	1206
3600	1218
3601	1183
3601	1188
3601	1232
3601	1233
3601	45555
3603	1183
3603	1188
3603	1218
3603	1232
3603	1233
3605	1183
3605	1188
3605	1206
3605	1218
3605	1229
3607	1183
3607	1188
3607	1206
3607	1218
3607	1229
3610	1183
3610	1194
3610	1206
3610	1218
3610	1229
3611	1183
3611	1194
3611	1206
3611	1218
3611	1229
3614	1188
3614	1206
3614	1216
3614	1229
3614	45238
3615	1188
3615	1206
3615	1216
3615	1229
3615	45238
3618	1188
3618	1200
3618	1206
3618	1220
3618	45238
3619	1188
3619	1220
3619	1232
3619	1233
3619	45238
3628	1183
3628	1194
3628	1200
3628	1206
3628	1218
3630	1183
3630	1194
3630	1200
3630	1206
3630	1218
3631	1183
3631	1194
3631	1198
3631	1206
3631	1218
3633	1188
3633	1200
3633	1206
3633	1218
3633	45238
3634	1183
3634	1188
3634	1198
3634	1206
3634	1218
3635	1183
3635	1188
3635	1206
3635	1218
3635	1229
3638	1183
3638	1188
3638	1206
3638	1218
3638	1229
3639	1183
3639	1188
3639	1206
3639	1218
3639	1229
3641	1183
3641	1188
3641	1206
3641	1218
3641	1229
3644	1183
3644	1188
3644	1206
3644	1218
3644	1229
3645	1183
3645	1188
3645	1206
3645	1218
3645	1229
3652	1183
3652	1188
3652	1232
3652	1233
3652	44970
3654	1183
3654	1188
3654	1218
3654	1232
3654	1233
3655	1183
3655	1188
3655	1218
3655	1232
3655	1233
3657	1183
3657	1188
3657	1198
3657	1206
3657	1218
3658	1183
3658	1188
3658	1206
3658	1217
3658	1229
3659	1183
3659	1188
3659	1206
3659	1217
3659	1229
3661	1188
3661	1198
3661	1206
3661	1218
3661	45238
3667	1183
3667	1204
3667	1218
3667	1232
3667	1239
3670	1183
3670	1188
3670	1206
3670	1218
3670	1229
3671	1183
3671	1188
3671	1206
3671	1218
3671	1229
3672	1183
3672	1188
3672	1206
3672	1218
3672	1229
3673	1183
3673	1188
3673	1200
3673	1206
3673	1218
3674	1183
3674	1188
3674	1200
3674	1206
3674	1220
3675	1183
3675	1188
3675	1206
3675	1218
3675	1229
3676	1183
3676	1188
3676	1206
3676	1221
3676	1229
3677	1183
3677	1188
3677	1206
3677	1218
3677	1229
3678	1188
3678	1200
3678	1206
3678	1218
3678	45238
3680	1195
3680	1200
3680	1206
3680	45238
3680	45421
3681	1183
3681	1188
3681	1203
3681	1218
3681	1238
3682	1183
3682	1188
3682	1203
3682	1218
3682	1238
3683	1188
3683	1198
3683	1206
3683	1218
3683	45236
3684	1188
3684	1198
3684	1206
3684	1218
3684	45236
3685	1183
3685	1188
3685	1200
3685	1206
3685	1220
3686	1183
3686	1188
3686	1200
3686	1206
3686	1218
3690	1183
3690	1188
3690	1206
3690	1218
3690	1229
3691	1183
3691	1188
3691	1206
3691	1218
3691	1229
3695	1179
3695	1188
3695	1197
3695	1201
3695	1218
3697	1183
3697	1188
3697	1206
3697	1213
3697	1229
3701	1183
3701	1188
3701	1206
3701	1218
3701	1229
3702	1183
3702	1188
3702	1206
3702	1218
3702	1229
3707	1183
3707	1188
3707	1198
3707	1206
3707	45548
3708	1183
3708	1188
3708	1198
3708	1206
3708	1218
3709	1183
3709	1194
3709	1198
3709	1206
3709	1218
3710	1183
3710	1188
3710	1198
3710	1206
3710	1218
3711	1183
3711	1188
3711	1206
3711	1218
3711	1229
3713	1183
3713	1188
3713	1206
3713	1218
3713	1229
3715	1188
3715	1206
3715	1218
3715	1229
3715	45238
3716	1179
3716	1188
3716	1197
3716	1201
3716	1218
3717	1179
3717	1188
3717	1197
3717	1201
3717	1218
3718	1183
3718	1194
3718	1206
3718	1210
3718	1229
3721	1183
3721	1188
3721	1198
3721	1206
3721	1218
3722	1183
3722	1188
3722	1198
3722	1206
3722	1218
3723	1183
3723	1188
3723	1206
3723	1218
3723	1229
3724	1183
3724	1188
3724	1200
3724	1206
3724	1218
3726	1183
3726	1188
3726	1206
3726	1219
3726	1229
3727	1188
3727	1200
3727	1206
3727	1218
3727	45238
3728	1183
3728	1188
3728	1206
3728	1217
3728	1229
3728	45019
3730	1183
3730	1188
3730	1200
3730	1206
3730	1218
3733	1188
3733	1206
3733	1218
3733	1229
3733	45238
3734	1183
3734	1188
3734	1198
3734	1206
3734	1218
3735	1183
3735	1188
3735	1206
3735	1218
3735	1229
3736	1183
3736	1188
3736	1218
3736	1232
3736	1233
3737	1183
3737	1198
3737	1206
3737	1218
3737	1239
3740	1188
3740	1200
3740	1206
3740	1218
3740	45238
3742	1188
3742	1206
3742	1218
3742	1229
3742	45236
3744	1183
3744	1188
3744	1206
3744	1218
3744	1229
3746	1188
3746	1198
3746	1206
3746	1218
3746	45236
3748	1183
3748	1188
3748	1198
3748	1206
3748	1218
3751	1183
3751	1198
3751	1206
3751	1218
3751	1239
3757	1183
3757	1188
3757	1206
3757	1218
3757	1229
3758	1183
3758	1188
3758	1206
3758	1218
3758	1229
3759	1183
3759	1188
3759	1198
3759	1206
3759	1218
3762	1183
3762	1194
3762	1206
3762	1218
3762	1229
3764	1183
3764	1188
3764	1206
3764	1218
3764	1229
3765	1183
3765	1188
3765	1206
3765	1222
3765	1229
3766	1183
3766	1188
3766	1206
3766	1218
3766	1229
3768	1183
3768	1188
3768	1198
3768	1206
3768	1218
3769	1183
3769	1188
3769	1206
3769	1218
3769	1229
3772	1183
3772	1188
3772	1198
3772	1206
3772	1218
3774	1183
3774	1188
3774	1198
3774	1206
3774	1218
3775	1183
3775	1188
3775	1198
3775	1204
3775	1218
3779	1183
3779	1188
3779	1200
3779	1206
3779	1218
3779	1232
3779	1233
3780	1183
3780	1188
3780	1206
3780	1218
3780	1229
3790	1183
3790	1188
3790	1206
3790	1218
3790	1229
3791	1183
3791	1188
3791	1200
3791	1206
3791	1218
3792	1183
3792	1188
3792	1200
3792	1206
3792	1218
3793	1193
3793	1198
3793	1206
3793	1218
3793	45238
3795	1188
3795	1200
3795	1206
3795	1218
3795	45238
3799	1183
3799	1188
3799	1200
3799	1206
3799	1218
3801	1183
3801	1188
3801	1200
3801	1206
3801	1213
3821	1188
3821	1206
3821	1218
3821	1229
3821	45238
3822	1183
3822	1188
3822	1206
3822	1218
3822	1229
3823	1183
3823	1188
3823	1206
3823	1218
3823	1229
3825	1183
3825	1188
3825	1198
3825	1206
3825	1218
3826	1183
3826	1188
3826	1200
3826	1206
3826	1218
3827	1183
3827	1188
3827	1200
3827	1206
3827	1218
3827	1232
3827	1258
3827	45604
3830	1179
3830	1188
3830	1197
3830	1201
3830	1218
3833	1183
3833	1188
3833	1200
3833	1206
3833	1218
3834	1195
3834	1198
3834	1206
3834	1218
3834	45236
3835	1183
3835	1188
3835	1206
3835	1218
3835	1229
3836	1183
3836	1194
3836	1198
3836	1206
3836	1213
3836	45060
3836	45450
3838	1183
3838	1194
3838	1198
3838	1206
3838	1217
3842	1183
3842	1194
3842	1198
3842	1205
3842	1206
3842	45549
3843	1183
3843	1194
3843	1198
3843	1218
3843	1233
3844	1188
3844	1199
3844	1206
3844	1218
3844	45236
3845	1188
3845	1220
3845	1232
3845	1233
3845	45238
3846	1183
3846	1188
3846	1206
3846	1218
3846	1232
3847	1183
3847	1188
3847	1206
3847	1232
3847	1258
3848	1183
3848	1188
3848	1206
3848	1218
3848	1232
3849	1183
3849	1188
3849	1206
3849	1218
3849	1232
3850	1183
3850	1188
3850	1198
3850	1206
3850	1218
3852	1183
3852	1193
3852	1232
3852	1233
3852	45554
3860	1183
3860	1188
3860	1198
3860	1206
3860	1218
3861	1183
3861	1188
3861	1206
3861	1218
3861	1229
3862	1183
3862	1188
3862	1206
3862	1218
3862	1232
3864	1183
3864	1188
3864	1206
3864	1218
3864	1232
3868	1183
3868	1188
3868	1206
3868	1218
3868	1229
3872	1183
3872	1188
3872	1206
3872	1216
3872	1229
3873	1183
3873	1188
3873	1206
3873	1216
3873	1229
3874	1183
3874	1194
3874	1198
3874	1206
3874	1218
3875	1183
3875	1194
3875	1206
3875	1218
3875	1229
3876	1183
3876	1194
3876	1206
3876	1218
3876	1229
3878	1179
3878	1188
3878	1197
3878	1201
3878	1218
3880	1188
3880	1206
3880	1232
3880	45238
3880	45337
3881	1183
3881	1188
3881	1203
3881	1218
3881	1232
3936	1183
3936	1194
3936	1218
3936	1229
3936	1233
3938	1183
3938	1194
3938	1200
3938	1206
3938	1218
3940	1188
3940	1198
3940	1206
3940	1218
3940	45238
3941	1183
3941	1188
3941	1218
3941	1232
3941	1233
3943	1183
3943	1188
3943	1206
3943	1218
3943	1229
3944	1179
3944	1188
3944	1197
3944	1201
3944	1218
3945	1183
3945	1188
3945	1206
3945	1218
3945	1229
3946	1183
3946	1188
3946	1206
3946	1218
3946	1229
3947	1183
3947	1188
3947	1206
3947	1218
3947	1229
3949	1183
3949	1188
3949	1206
3949	1218
3949	1229
3951	1183
3951	1188
3951	1206
3951	1218
3951	1232
3954	1188
3954	1204
3954	1218
3954	1232
3954	45238
3955	1183
3955	1196
3955	1218
3955	1232
3955	1233
3956	1188
3956	1206
3956	1218
3956	1229
3956	45238
3957	1183
3957	1194
3957	1218
3957	1232
3957	1233
3958	1183
3958	1196
3958	1198
3958	1206
3958	1218
3961	1188
3961	1218
3961	1232
3961	1233
3961	45238
3962	1183
3962	1188
3962	1206
3962	1218
3962	1229
3968	1183
3968	1188
3968	1218
3968	1232
3968	1233
3972	1183
3972	1188
3972	1198
3972	1206
3972	1218
3974	1183
3974	1188
3974	1206
3974	1218
3974	1229
3978	1188
3978	1198
3978	1206
3978	1210
3978	45236
3979	1183
3979	1188
3979	1198
3979	1206
3979	1218
3980	1183
3980	1194
3980	1198
3980	1206
3980	1218
3981	1183
3981	1188
3981	1200
3981	1206
3981	1218
3983	1179
3983	1188
3983	1197
3983	1201
3983	1218
3985	1183
3985	1188
3985	1206
3985	1218
3985	1229
3986	1183
3986	1188
3986	1206
3986	1218
3986	1229
3991	1183
3991	1188
3991	1206
3991	1218
3991	1229
3993	1183
3993	1188
3993	1206
3993	1218
3993	1229
3995	1183
3995	1188
3995	1198
3995	1206
3995	1218
3996	1188
3996	1218
3996	1232
3996	1233
3996	45238
3997	1183
3997	1194
3997	1206
3997	1218
3997	1229
3999	1188
3999	1213
3999	1232
3999	1233
3999	45238
4001	1183
4001	1188
4001	1206
4001	1218
4001	1229
4002	1183
4002	1188
4002	1206
4002	1218
4002	1229
4006	1183
4006	1188
4006	1218
4006	1232
4006	1233
4007	1188
4007	1218
4007	1232
4007	1233
4007	45238
4008	1179
4008	1188
4008	1197
4008	1201
4008	1218
4047	1183
4047	1188
4047	1206
4047	1218
4047	1229
4048	1183
4048	1188
4048	1206
4048	1218
4048	1229
4055	1183
4055	1188
4055	1200
4055	1206
4055	1218
4057	1183
4057	1188
4057	1218
4057	1232
4057	1233
4058	1183
4058	1188
4058	1200
4058	1206
4058	1218
4059	1188
4059	1198
4059	1206
4059	1211
4059	45238
4060	1179
4060	1188
4060	1197
4060	1201
4060	1218
4061	1183
4061	1188
4061	1206
4061	1218
4061	1229
4062	1183
4062	1188
4062	1206
4062	1218
4062	1229
4063	1183
4063	1188
4063	1206
4063	1218
4063	1229
4068	1188
4068	1206
4068	1218
4068	1229
4068	45236
4074	1188
4074	1218
4074	1232
4074	1233
4074	45238
4075	1183
4075	1188
4075	1218
4075	1232
4075	1233
4076	1183
4076	1188
4076	1218
4076	1232
4076	1233
4078	1183
4078	1188
4078	1198
4078	1206
4078	1210
4079	1183
4079	1188
4079	1206
4079	1218
4079	1229
4081	1183
4081	1194
4081	1200
4081	1206
4081	1216
4082	1183
4082	1188
4082	1205
4082	1222
4082	1232
4083	1179
4083	1188
4083	1197
4083	1201
4083	1218
4084	1183
4084	1188
4084	1218
4084	1232
4084	1233
4085	1183
4085	1188
4085	1200
4085	1206
4085	1218
4088	1188
4088	1200
4088	1206
4088	1218
4088	45238
4090	1183
4090	1188
4090	1206
4090	1218
4090	1232
4091	1183
4091	1218
4091	1232
4091	1233
4091	1239
4092	1188
4092	1218
4092	1232
4092	1233
4092	45238
4093	1183
4093	1188
4093	1206
4093	1218
4093	1229
4094	1188
4094	1200
4094	1206
4094	1218
4094	45238
4095	1183
4095	1188
4095	1218
4095	1232
4095	1233
4096	1183
4096	1188
4096	1218
4096	1232
4096	1233
4097	1183
4097	1194
4097	1199
4097	1204
4097	1218
4097	1232
4097	45380
4099	1183
4099	1188
4099	1206
4099	1218
4099	1229
4100	1183
4100	1188
4100	1218
4100	1232
4100	1233
4101	1188
4101	1218
4101	1232
4101	1233
4101	45238
4102	1183
4102	1188
4102	1198
4102	1206
4102	1218
4103	1183
4103	1188
4103	1206
4103	1218
4103	1229
4104	1183
4104	1188
4104	1206
4104	1218
4104	1229
4106	1183
4106	1191
4106	1206
4106	1218
4106	1229
4110	1183
4110	1188
4110	1206
4110	1218
4110	1229
4112	1183
4112	1188
4112	1198
4112	1206
4112	1218
4113	1183
4113	1188
4113	1200
4113	1206
4113	1218
4114	1183
4114	1188
4114	1206
4114	1218
4114	1229
4115	1183
4115	1188
4115	1206
4115	1218
4115	1229
4116	1183
4116	1188
4116	1206
4116	1218
4116	1229
4117	1183
4117	1188
4117	1206
4117	1219
4117	1229
4119	1183
4119	1188
4119	1200
4119	1206
4119	1218
4121	1183
4121	1188
4121	1205
4121	1218
4121	1232
4122	1183
4122	1188
4122	1200
4122	1206
4122	1218
4123	1183
4123	1194
4123	1206
4123	1218
4123	1229
4124	1188
4124	1218
4124	1232
4124	1233
4124	45238
4125	1183
4125	1188
4125	1213
4125	1232
4125	1233
4126	1183
4126	1188
4126	1199
4126	1218
4126	1233
4127	1183
4127	1194
4127	1198
4127	1205
4127	1218
4128	1183
4128	1188
4128	1206
4128	1218
4128	1232
4129	1183
4129	1194
4129	1218
4129	1232
4129	1233
4135	1183
4135	1194
4135	1218
4135	1232
4135	1233
4136	1183
4136	1188
4136	1218
4136	1232
4136	1233
4137	1183
4137	1188
4137	1205
4137	1218
4137	1232
4138	1183
4138	1188
4138	1218
4138	1232
4138	1233
4139	1183
4139	1188
4139	1218
4139	1232
4139	1233
4140	1183
4140	1188
4140	1206
4140	1218
4140	1229
4141	1183
4141	1188
4141	1218
4141	1232
4141	1233
4143	1183
4143	1194
4143	1198
4143	1206
4143	1218
4145	1188
4145	1218
4145	1232
4145	1233
4145	45238
4146	1179
4146	1188
4146	1197
4146	1201
4146	1218
4147	1183
4147	1188
4147	1198
4147	1206
4147	1218
4148	1183
4148	1188
4148	1198
4148	1206
4148	1218
4149	1188
4149	1206
4149	1218
4149	1229
4149	45238
4150	1183
4150	1188
4150	1206
4150	1218
4150	1229
4151	1188
4151	1203
4151	1218
4151	1232
4151	45238
4152	1183
4152	1188
4152	1203
4152	1218
4152	1232
4153	1183
4153	1188
4153	1218
4153	1232
4153	1233
4156	1183
4156	1194
4156	1206
4156	1218
4156	1229
4159	1183
4159	1188
4159	1198
4159	1200
4159	1206
4159	1247
4160	1183
4160	1188
4160	1206
4160	1218
4160	1229
4161	1183
4161	1188
4161	1218
4161	1232
4161	1233
4162	1183
4162	1188
4162	1218
4162	1232
4162	1233
4163	1188
4163	1218
4163	1232
4163	1233
4163	45238
4164	1179
4164	1188
4164	1197
4164	1201
4164	1218
4166	1183
4166	1193
4166	1206
4166	1220
4166	1229
4168	1179
4168	1188
4168	1197
4168	1201
4168	1218
4169	1183
4169	1196
4169	1200
4169	1206
4169	1218
4171	1183
4171	1188
4171	1198
4171	1200
4171	1206
4171	1247
4172	1183
4172	1188
4172	1206
4172	1218
4172	1229
4173	1183
4173	1193
4173	1229
4173	1233
4173	45549
4174	1188
4174	1198
4174	1206
4174	1218
4174	45236
4178	1183
4178	1188
4178	1206
4178	1218
4178	1229
4179	1183
4179	1188
4179	1206
4179	1218
4179	1229
4180	1183
4180	1188
4180	1218
4180	1232
4180	1233
4183	1183
4183	1194
4183	1206
4183	1218
4183	1232
4185	1188
4185	1198
4185	1206
4185	1218
4185	1229
4185	45238
4186	1183
4186	1188
4186	1218
4186	1232
4186	1233
4187	1183
4187	1188
4187	1218
4187	1232
4187	1233
4188	1183
4188	1194
4188	1218
4188	1232
4188	1233
4189	1183
4189	1196
4189	1206
4189	1218
4189	1229
4190	1183
4190	1196
4190	1200
4190	1206
4190	1218
4192	1183
4192	1188
4192	1200
4192	1206
4192	1218
4192	1229
4194	1188
4194	1198
4194	1206
4194	1218
4194	45238
4196	1183
4196	1196
4196	1206
4196	1218
4196	1232
4197	1183
4197	1188
4197	1206
4197	1220
4197	1222
4197	1229
4198	1183
4198	1194
4198	1206
4198	1218
4198	1229
4201	1188
4201	1218
4201	1232
4201	1233
4201	45238
4202	1183
4202	1188
4202	1206
4202	1218
4202	1229
4203	1188
4203	1204
4203	1218
4203	1232
4203	45238
4207	1188
4207	1218
4207	1232
4207	1233
4207	45236
4211	1183
4211	1188
4211	1206
4211	1229
4211	45134
4212	1179
4212	1188
4212	1197
4212	1201
4212	1218
4213	1188
4213	1206
4213	1218
4213	1229
4213	45238
4214	1183
4214	1188
4214	1206
4214	1229
4214	45181
4216	1188
4216	1206
4216	1218
4216	1229
4216	45238
4218	1183
4218	1194
4218	1209
4218	1232
4218	1233
4219	1188
4219	1206
4219	1218
4219	1229
4219	45238
4221	1183
4221	1188
4221	1200
4221	1206
4221	1218
4222	1183
4222	1188
4222	1218
4222	1232
4222	1233
4224	1183
4224	1188
4224	1218
4224	1232
4224	1233
4227	1183
4227	1194
4227	1206
4227	1218
4227	1229
4228	1183
4228	1194
4228	1200
4228	1206
4228	1218
4229	1183
4229	1188
4229	1218
4229	1232
4229	1233
4231	1188
4231	1218
4231	1232
4231	1233
4231	45238
4232	1195
4232	1200
4232	1206
4232	1220
4232	45238
4233	1183
4233	1188
4233	1198
4233	1206
4233	1218
4234	1183
4234	1196
4234	1218
4234	1232
4234	1233
4235	1188
4235	1218
4235	1232
4235	1233
4235	45238
4236	1183
4236	1188
4236	1206
4236	1218
4236	1229
4237	1183
4237	1188
4237	1218
4237	1232
4237	1233
4239	1183
4239	1188
4239	1200
4239	1206
4239	1218
4241	1183
4241	1188
4241	1199
4241	1204
4241	1218
4244	1183
4244	1188
4244	1218
4244	1232
4244	1233
4245	1179
4245	1188
4245	1197
4245	1201
4245	1218
4248	1183
4248	1188
4248	1198
4248	1206
4248	1217
4248	1220
4248	45549
4251	1183
4251	1196
4251	1206
4251	1218
4251	1229
4252	1183
4252	1188
4252	1206
4252	1218
4252	1229
4253	1188
4253	1206
4253	1218
4253	1229
4253	45236
4255	1183
4255	1188
4255	1198
4255	1206
4255	1218
4256	1195
4256	1218
4256	1232
4256	1233
4256	45238
4258	1191
4258	1219
4258	1232
4258	1233
4258	45238
4261	1183
4261	1188
4261	1218
4261	1232
4261	1233
4263	1183
4263	1188
4263	1198
4263	1206
4263	1218
4264	1183
4264	1188
4264	1200
4264	1206
4264	1218
4265	1183
4265	1194
4265	1200
4265	1206
4265	1218
4270	1183
4270	1194
4270	1206
4270	1218
4270	1229
4272	1183
4272	1188
4272	1206
4272	1218
4272	1229
4273	1188
4273	1198
4273	1206
4273	1218
4273	45236
4275	1179
4275	1188
4275	1197
4275	1201
4275	1220
4276	1183
4276	1188
4276	1206
4276	1218
4276	1229
4278	1183
4278	1188
4278	1206
4278	1218
4278	1229
4280	1183
4280	1188
4280	1206
4280	1213
4280	1229
4283	1183
4283	1188
4283	1198
4283	1206
4283	1218
4284	1183
4284	1188
4284	1206
4284	1218
4284	1229
4285	1183
4285	1188
4285	1206
4285	1218
4285	1229
4286	1188
4286	1206
4286	1211
4286	1229
4286	45238
4287	1195
4287	1206
4287	1218
4287	1229
4287	45238
4288	1188
4288	1198
4288	1206
4288	1218
4288	45238
4289	1183
4289	1188
4289	1218
4289	1232
4289	1233
4290	1183
4290	1194
4290	1198
4290	1206
4290	1218
4291	1188
4291	1206
4291	1218
4291	1229
4291	45238
4292	1183
4292	1188
4292	1204
4292	1218
4292	1232
4293	1183
4293	1188
4293	1206
4293	1220
4293	1229
4296	1183
4296	1188
4296	1218
4296	1232
4296	1233
4297	1179
4297	1188
4297	1197
4297	1201
4297	1218
4298	1183
4298	1188
4298	1198
4298	1206
4298	1218
4300	1183
4300	1188
4300	1206
4300	1217
4300	1229
4301	1188
4301	1206
4301	1218
4301	1229
4301	45238
4303	1183
4303	1194
4303	1206
4303	1218
4303	1229
4304	1183
4304	1194
4304	1206
4304	1218
4304	1229
4305	1183
4305	1188
4305	1218
4305	1232
4305	1233
4306	1183
4306	1188
4306	1204
4306	1218
4306	1232
4307	1183
4307	1188
4307	1206
4307	1218
4307	1229
4308	1179
4308	1188
4308	1197
4308	1201
4308	1218
4310	1183
4310	1188
4310	1198
4310	1206
4310	1218
4312	1183
4312	1188
4312	1206
4312	1216
4312	1229
4313	1188
4313	1200
4313	1206
4313	1218
4313	45238
4314	1183
4314	1194
4314	1218
4314	1232
4314	1233
4315	1183
4315	1188
4315	1200
4315	1206
4315	1217
4316	1183
4316	1194
4316	1206
4316	1218
4316	1229
4318	1183
4318	1196
4318	1218
4318	1232
4318	1233
4319	1183
4319	1188
4319	1218
4319	1232
4319	1233
4320	1183
4320	1188
4320	1206
4320	1218
4320	1229
4322	1188
4322	1200
4322	1206
4322	1218
4322	45238
4323	1183
4323	1188
4323	1198
4323	1206
4323	1218
4324	1183
4324	1188
4324	1206
4324	1220
4324	1229
4326	1188
4326	1198
4326	1206
4326	1218
4326	45236
4327	1188
4327	1198
4327	1206
4327	1218
4327	45238
4329	1183
4329	1188
4329	1218
4329	1232
4329	1233
4330	1179
4330	1188
4330	1197
4330	1201
4330	1218
4331	1183
4331	1188
4331	1205
4331	1218
4331	1232
4332	1183
4332	1188
4332	1206
4332	1218
4332	1229
4333	1183
4333	1188
4333	1206
4333	1218
4333	1229
4334	1188
4334	1206
4334	1218
4334	1229
4334	45238
4335	1183
4335	1188
4335	1198
4335	1206
4335	1218
4336	1179
4336	1188
4336	1197
4336	1201
4336	1218
4337	1183
4337	1188
4337	1206
4337	1218
4337	1229
4338	1183
4338	1194
4338	1206
4338	1218
4338	1229
4339	1179
4339	1188
4339	1197
4339	1201
4339	1218
4340	1183
4340	1188
4340	1206
4340	1218
4340	1232
4342	1195
4342	1200
4342	1206
4342	1218
4342	45238
4343	1188
4343	1206
4343	1220
4343	1229
4343	45238
4345	1183
4345	1188
4345	1218
4345	1232
4345	1233
4347	1183
4347	1188
4347	1206
4347	1218
4347	1229
4348	1183
4348	1188
4348	1206
4348	1218
4348	1229
4349	1183
4349	1193
4349	1206
4349	1218
4349	1229
4351	1183
4351	1188
4351	1200
4351	1206
4351	1218
4352	1188
4352	1218
4352	1232
4352	1233
4352	45238
4355	1188
4355	1206
4355	1218
4355	1229
4355	45238
4356	1183
4356	1188
4356	1206
4356	1218
4356	1229
4358	1183
4358	1188
4358	1206
4358	1218
4358	1229
4359	1183
4359	1188
4359	1218
4359	1232
4359	1233
4369	1183
4369	1188
4369	1206
4369	1218
4369	1229
4370	1188
4370	1218
4370	1232
4370	1233
4370	45238
4372	1183
4372	1188
4372	1206
4372	1218
4372	1229
4374	1188
4374	1198
4374	1206
4374	1218
4374	45236
4375	1183
4375	1194
4375	1200
4375	1206
4375	1218
4376	1183
4376	1188
4376	1218
4376	1232
4376	1233
4387	1183
4387	1188
4387	1206
4387	1218
4387	1229
4388	1188
4388	1218
4388	1232
4388	1233
4388	45238
4389	1188
4389	1200
4389	1206
4389	1218
4389	45238
4390	1183
4390	1188
4390	1206
4390	1217
4390	1229
4391	1188
4391	1218
4391	1232
4391	1233
4391	45238
4393	1183
4393	1188
4393	1206
4393	1218
4393	1229
4394	1183
4394	1188
4394	1206
4394	1218
4394	1229
4395	1188
4395	1200
4395	1206
4395	1218
4395	45238
4397	1183
4397	1194
4397	1198
4397	1206
4397	1218
4399	1183
4399	1188
4399	1218
4399	1232
4399	1233
4400	1183
4400	1188
4400	1206
4400	1218
4400	1229
4401	1183
4401	1204
4401	1218
4401	1232
4401	1239
4402	1179
4402	1188
4402	1197
4402	1201
4402	1218
4403	1183
4403	1188
4403	1198
4403	1206
4403	1218
4404	1183
4404	1188
4404	1206
4404	1220
4404	1229
4406	1188
4406	1198
4406	1206
4406	1218
4406	45236
4408	1183
4408	1188
4408	1206
4408	1218
4408	1229
4409	1183
4409	1196
4409	1206
4409	1218
4409	1229
4411	1183
4411	1188
4411	1213
4411	1232
4411	1233
4412	1188
4412	1204
4412	1218
4412	1232
4412	45238
4413	1183
4413	1188
4413	1206
4413	1218
4413	1229
4414	1188
4414	1218
4414	1232
4414	1233
4414	45238
4416	1179
4416	1188
4416	1197
4416	1201
4416	1218
4418	1183
4418	1188
4418	1200
4418	1206
4418	1218
4419	1183
4419	1188
4419	1198
4419	1206
4419	1218
4420	1179
4420	1188
4420	1197
4420	1201
4420	1218
4422	1188
4422	1206
4422	1218
4422	1229
4422	45238
4423	1188
4423	1218
4423	1232
4423	1233
4423	45238
4424	1183
4424	1188
4424	1206
4424	1218
4424	1229
4425	1183
4425	1188
4425	1206
4425	1218
4425	1229
4426	1183
4426	1188
4426	1198
4426	1206
4426	1218
4427	1183
4427	1188
4427	1218
4427	1232
4427	1233
4428	1183
4428	1188
4428	1206
4428	1218
4428	1229
4430	1179
4430	1188
4430	1197
4430	1201
4430	1218
4431	1183
4431	1188
4431	1206
4431	1218
4431	1229
4433	1183
4433	1188
4433	1206
4433	1217
4433	1229
4435	1183
4435	1188
4435	1206
4435	1218
4435	1229
4439	1183
4439	1188
4439	1206
4439	1218
4439	1229
4442	1183
4442	1188
4442	1218
4442	1232
4442	1233
4443	1188
4443	1206
4443	1218
4443	1229
4443	45236
4444	1183
4444	1188
4444	1200
4444	1206
4444	1218
4445	1183
4445	1188
4445	1206
4445	1218
4445	1229
4447	1183
4447	1188
4447	1206
4447	1218
4447	1229
4449	1188
4449	1198
4449	1206
4449	1210
4449	45236
4450	1183
4450	1188
4450	1198
4450	1206
4450	1210
4451	1188
4451	1218
4451	1232
4451	1233
4451	45238
4452	1179
4452	1188
4452	1197
4452	1201
4452	1217
4453	1179
4453	1188
4453	1197
4453	1201
4453	1218
4456	1183
4456	1196
4456	1198
4456	1206
4456	1221
4457	1183
4457	1188
4457	1206
4457	1217
4457	1232
4460	1183
4460	1194
4460	1198
4460	1229
4460	1233
4460	45448
4461	1183
4461	1188
4461	1206
4461	1218
4461	1229
4462	1183
4462	1188
4462	1205
4462	1218
4462	1232
4463	1183
4463	1188
4463	1206
4463	1218
4463	1232
4464	1183
4464	1188
4464	1218
4464	1232
4464	1233
4466	1188
4466	1203
4466	1218
4466	1232
4466	45238
4467	1183
4467	1194
4467	1204
4467	1218
4467	1232
4469	1183
4469	1188
4469	1200
4469	1206
4469	1218
4470	1179
4470	1188
4470	1197
4470	1201
4470	1218
4472	1188
4472	1200
4472	1206
4472	1218
4472	45238
4474	1179
4474	1188
4474	1197
4474	1201
4474	1218
4475	1183
4475	1188
4475	1206
4475	1218
4475	1229
4476	1183
4476	1188
4476	1206
4476	1218
4476	1229
4477	1183
4477	1188
4477	1206
4477	1218
4477	1229
4478	1183
4478	1188
4478	1206
4478	1218
4478	1232
4479	1194
4479	1206
4479	1218
4479	1229
4479	45238
4480	1183
4480	1188
4480	1200
4480	1206
4480	1218
4481	1183
4481	1188
4481	1198
4481	1206
4481	1218
4482	1188
4482	1206
4482	1218
4482	1229
4482	45236
4483	1183
4483	1188
4483	1206
4483	1218
4483	1229
4484	1183
4484	1188
4484	1206
4484	1218
4484	1229
4486	1183
4486	1188
4486	1206
4486	1218
4486	1229
4487	1183
4487	1188
4487	1198
4487	1206
4487	1218
4488	1188
4488	1218
4488	1232
4488	1233
4488	45238
4489	1188
4489	1206
4489	1218
4489	1229
4489	45238
4490	1183
4490	1188
4490	1218
4490	1232
4490	1233
4491	1183
4491	1188
4491	1206
4491	1218
4491	1229
4492	1183
4492	1188
4492	1218
4492	1232
4492	1233
4496	1179
4496	1188
4496	1197
4496	1201
4496	1218
4497	1179
4497	1188
4497	1197
4497	1201
4497	1218
4498	1183
4498	1198
4498	1206
4498	1218
4498	1239
4499	1183
4499	1188
4499	1206
4499	1218
4499	1229
4500	1183
4500	1188
4500	1205
4500	1218
4500	1232
4501	1188
4501	1198
4501	1206
4501	1209
4501	45238
4502	1183
4502	1188
4502	1206
4502	1218
4502	1229
4503	1183
4503	1194
4503	1200
4503	1206
4503	1218
4504	1183
4504	1188
4504	1198
4504	1206
4504	1218
4505	1183
4505	1188
4505	1206
4505	1218
4505	1229
4506	1183
4506	1188
4506	1206
4506	1218
4506	1229
4507	1188
4507	1218
4507	1232
4507	1233
4507	45238
4510	1183
4510	1188
4510	1206
4510	1218
4510	1229
4511	1188
4511	1206
4511	1213
4511	1229
4511	45238
4512	1179
4512	1188
4512	1197
4512	1201
4512	1218
4513	1183
4513	1188
4513	1200
4513	1206
4513	1218
4515	1183
4515	1188
4515	1200
4515	1206
4515	1218
4516	1183
4516	1188
4516	1200
4516	1206
4516	1218
4517	1183
4517	1188
4517	1200
4517	1206
4517	1218
4521	1179
4521	1188
4521	1197
4521	1201
4521	1218
4522	1188
4522	1206
4522	1218
4522	1229
4522	45238
4523	1183
4523	1188
4523	1198
4523	1206
4523	1218
4527	1183
4527	1188
4527	1218
4527	1232
4527	1233
4531	1188
4531	1206
4531	1211
4531	1229
4531	45238
4532	1183
4532	1188
4532	1206
4532	1218
4532	1229
4533	1183
4533	1188
4533	1206
4533	1218
4533	1229
4535	1179
4535	1188
4535	1197
4535	1201
4535	1218
4536	1183
4536	1188
4536	1206
4536	1213
4536	1229
4538	1183
4538	1194
4538	1206
4538	1218
4538	1229
4539	1188
4539	1206
4539	1218
4539	1229
4539	45238
4540	1183
4540	1188
4540	1232
4540	1233
4540	44974
4542	1183
4542	1188
4542	1206
4542	1218
4542	1229
4543	1183
4543	1188
4543	1198
4543	1206
4543	1210
4545	1188
4545	1200
4545	1206
4545	1218
4545	45238
4546	1183
4546	1194
4546	1218
4546	1232
4546	1233
4547	1183
4547	1194
4547	1206
4547	1218
4547	1229
4549	1183
4549	1194
4549	1205
4549	1218
4549	1232
4550	1183
4550	1188
4550	1200
4550	1206
4550	1218
4551	1183
4551	1194
4551	1206
4551	1218
4551	1229
4554	1188
4554	1206
4554	1220
4554	1229
4554	45238
4558	1183
4558	1188
4558	1206
4558	1218
4558	1229
4560	1183
4560	1188
4560	1206
4560	1218
4560	1229
4561	1188
4561	1206
4561	1218
4561	1229
4561	45238
4562	1183
4562	1188
4562	1206
4562	1218
4562	1229
4565	1183
4565	1188
4565	1206
4565	1218
4565	1229
4566	1183
4566	1188
4566	1218
4566	1232
4566	1233
4567	1183
4567	1188
4567	1206
4567	1218
4567	1229
4568	1183
4568	1188
4568	1206
4568	1218
4568	1229
4569	1183
4569	1188
4569	1206
4569	1218
4569	1229
4570	1183
4570	1188
4570	1198
4570	1206
4570	1218
4571	1183
4571	1188
4571	1206
4571	1218
4571	1229
4572	1188
4572	1206
4572	1218
4572	1229
4572	45236
4573	1183
4573	1188
4573	1200
4573	1206
4573	1218
4574	1183
4574	1188
4574	1200
4574	1206
4574	1217
4575	1183
4575	1188
4575	1206
4575	1218
4575	1229
4576	1183
4576	1188
4576	1206
4576	1218
4576	1229
4577	1188
4577	1206
4577	1218
4577	1229
4577	45236
4578	1183
4578	1188
4578	1194
4578	1200
4578	1206
4578	1218
4578	1221
4578	1229
4579	1183
4579	1194
4579	1198
4579	1206
4579	1217
4580	1183
4580	1188
4580	1200
4580	1206
4580	1218
4581	1183
4581	1188
4581	1206
4581	1218
4581	1229
4582	1179
4582	1188
4582	1197
4582	1201
4582	1218
4586	1182
4586	1196
4586	1206
4586	1221
4586	1229
4588	1183
4588	1188
4588	1200
4588	1206
4588	1218
4589	1183
4589	1188
4589	1206
4589	1218
4589	1229
4590	1188
4590	1206
4590	1218
4590	1229
4590	1232
4590	1233
4590	45238
4592	1183
4592	1188
4592	1205
4592	1232
4592	45435
4594	1188
4594	1206
4594	1218
4594	1229
4594	45238
4595	1183
4595	1188
4595	1200
4595	1206
4595	1218
4599	1183
4599	1188
4599	1206
4599	1221
4599	1229
4602	1183
4602	1188
4602	1200
4602	1206
4602	1218
4603	1188
4603	1206
4603	1218
4603	1229
4603	45236
4605	1188
4605	1218
4605	1229
4605	1233
4605	45236
4606	1183
4606	1188
4606	1200
4606	1206
4606	1218
4609	1188
4609	1200
4609	1206
4609	1218
4609	45236
4610	1188
4610	1218
4610	1232
4610	1233
4610	45238
4612	1183
4612	1188
4612	1200
4612	1206
4612	1218
4614	1183
4614	1188
4614	1206
4614	1218
4614	1229
4616	1183
4616	1188
4616	1200
4616	1206
4616	1218
4617	1183
4617	1188
4617	1200
4617	1206
4617	1216
4620	1188
4620	1200
4620	1206
4620	1218
4620	45238
4621	1183
4621	1188
4621	1206
4621	1221
4621	1229
4622	1188
4622	1200
4622	1206
4622	1218
4622	45236
4623	1183
4623	1188
4623	1206
4623	1221
4623	1229
4624	1183
4624	1188
4624	1200
4624	1206
4624	1218
4627	1183
4627	1188
4627	1200
4627	1206
4627	1218
4628	1183
4628	1188
4628	1206
4628	1232
4628	45181
4629	1183
4629	1188
4629	1200
4629	1206
4629	1218
4631	1179
4631	1188
4631	1197
4631	1201
4631	1218
4632	1183
4632	1188
4632	1206
4632	1218
4632	1229
4633	1183
4633	1188
4633	1205
4633	1218
4633	1232
4634	1183
4634	1188
4634	1198
4634	1206
4634	1213
4634	1217
4634	1262
4635	1183
4635	1188
4635	1206
4635	1218
4635	1232
4637	1188
4637	1206
4637	1232
4637	45238
4637	45380
4639	1179
4639	1188
4639	1197
4639	1201
4639	1218
4640	1183
4640	1194
4640	1198
4640	1218
4640	1233
4641	1183
4641	1188
4641	1206
4641	1221
4641	1229
4642	1183
4642	1188
4642	1199
4642	1218
4642	1233
4644	1188
4644	1206
4644	1218
4644	1229
4644	45238
4645	1188
4645	1206
4645	1229
4645	45238
4645	45545
4646	1183
4646	1188
4646	1206
4646	1218
4646	1232
4646	1233
4647	1183
4647	1188
4647	1200
4647	1206
4647	1218
4648	1188
4648	1209
4648	1232
4648	1233
4648	45238
4649	1183
4649	1188
4649	1200
4649	1206
4649	1218
4650	1183
4650	1188
4650	1206
4650	1220
4650	1232
4651	1183
4651	1188
4651	1200
4651	1206
4651	1218
4655	1183
4655	1188
4655	1206
4655	1218
4655	1232
4656	1183
4656	1188
4656	1206
4656	1218
4656	1232
4657	1183
4657	1188
4657	1206
4657	1218
4657	1232
4660	1183
4660	1196
4660	1206
4660	1218
4660	1229
4661	1195
4661	1206
4661	1218
4661	1229
4661	45238
4664	1188
4664	1206
4664	1218
4664	1229
4664	45236
4665	1183
4665	1196
4665	1206
4665	1218
4665	1232
4669	1183
4669	1188
4669	1206
4669	1218
4669	1229
4671	1183
4671	1188
4671	1206
4671	1218
4671	1229
4673	1183
4673	1188
4673	1218
4673	1232
4673	1233
4674	1183
4674	1188
4674	1206
4674	1218
4674	1229
4675	1183
4675	1188
4675	1206
4675	1218
4675	1229
4676	1183
4676	1194
4676	1218
4676	1232
4676	1233
4677	1183
4677	1188
4677	1198
4677	1206
4677	1218
4678	1183
4678	1188
4678	1200
4678	1206
4678	1218
4679	1178
4679	1188
4679	1197
4679	1201
4679	1218
4680	1183
4680	1188
4680	1200
4680	1206
4680	1218
4681	1183
4681	1188
4681	1206
4681	1218
4681	1229
4682	1193
4682	1218
4682	1229
4682	1233
4682	45238
4683	1183
4683	1188
4683	1218
4683	1232
4683	1233
4684	1183
4684	1188
4684	1206
4684	1218
4684	1229
4685	1183
4685	1188
4685	1206
4685	1218
4685	1229
4686	1188
4686	1218
4686	1232
4686	1233
4686	45238
4687	1188
4687	1206
4687	1218
4687	1229
4687	45238
4688	1183
4688	1188
4688	1200
4688	1206
4688	1218
4689	1183
4689	1188
4689	1200
4689	1206
4689	1218
4690	1196
4690	1218
4690	1232
4690	1233
4690	45236
4691	1188
4691	1200
4691	1206
4691	1218
4691	45238
4692	1183
4692	1188
4692	1206
4692	1218
4692	1229
4693	1183
4693	1188
4693	1200
4693	1206
4693	1218
4694	1188
4694	1198
4694	1206
4694	1216
4694	45238
4695	1188
4695	1206
4695	1220
4695	1229
4695	45238
4696	1188
4696	1206
4696	1218
4696	1229
4696	45238
4697	1188
4697	1218
4697	1232
4697	1233
4697	45238
4700	1182
4700	1188
4700	1218
4700	1232
4700	1233
4704	1183
4704	1188
4704	1200
4704	1206
4704	1217
4705	1183
4705	1188
4705	1218
4705	1232
4705	1233
4706	1183
4706	1188
4706	1206
4706	1218
4706	1229
4708	1183
4708	1188
4708	1198
4708	1206
4708	1218
4709	1183
4709	1188
4709	1198
4709	1206
4709	1218
4710	1183
4710	1188
4710	1218
4710	1232
4710	1233
4711	1183
4711	1188
4711	1206
4711	1218
4711	1229
4712	1183
4712	1188
4712	1206
4712	1218
4712	1229
4720	1183
4720	1196
4720	1199
4720	1218
4720	1233
4721	1183
4721	1188
4721	1206
4721	1218
4721	1229
4722	1183
4722	1194
4722	1206
4722	1218
4722	1229
4724	1179
4724	1188
4724	1197
4724	1201
4724	1218
4725	1183
4725	1188
4725	1206
4725	1218
4725	1229
4727	1188
4727	1218
4727	1232
4727	1233
4727	45238
4728	1183
4728	1188
4728	1198
4728	1206
4728	1218
4730	1179
4730	1188
4730	1197
4730	1201
4730	1218
4732	1183
4732	1188
4732	1206
4732	1218
4732	1229
4733	1183
4733	1188
4733	1206
4733	1220
4733	1229
4734	1183
4734	1188
4734	1206
4734	1218
4734	1229
4735	1188
4735	1198
4735	1206
4735	1218
4735	45236
4736	1183
4736	1194
4736	1198
4736	1206
4736	1218
4737	1188
4737	1198
4737	1206
4737	1218
4737	45236
4738	1183
4738	1188
4738	1206
4738	1218
4738	1229
4739	1183
4739	1188
4739	1206
4739	1218
4739	1229
4752	1183
4752	1196
4752	1206
4752	1218
4752	1229
4753	1183
4753	1193
4753	1200
4753	1206
4753	1218
4754	1183
4754	1188
4754	1200
4754	1206
4754	1218
4755	1188
4755	1218
4755	1232
4755	1233
4755	45238
4756	1183
4756	1188
4756	1218
4756	1232
4756	1233
4757	1183
4757	1188
4757	1200
4757	1206
4757	1218
4758	1183
4758	1188
4758	1200
4758	1206
4758	1218
4760	1183
4760	1194
4760	1206
4760	1218
4760	1232
4762	1183
4762	1194
4762	1218
4762	1232
4762	1233
4764	1183
4764	1188
4764	1203
4764	1218
4764	1229
4765	1183
4765	1188
4765	1203
4765	1218
4765	1229
4766	1183
4766	1188
4766	1203
4766	1218
4766	1229
4768	1183
4768	1188
4768	1206
4768	1218
4768	1229
4768	1232
4768	1233
4769	1183
4769	1188
4769	1217
4769	1232
4769	1233
4770	1188
4770	1206
4770	1218
4770	1229
4770	45238
4771	1188
4771	1206
4771	1218
4771	1229
4771	45238
4772	1188
4772	1206
4772	1218
4772	1229
4772	45238
4773	1183
4773	1188
4773	1218
4773	1232
4773	1233
4774	1183
4774	1188
4774	1218
4774	1232
4774	1233
4775	1188
4775	1218
4775	1232
4775	1233
4775	45238
4777	1188
4777	1206
4777	1218
4777	1229
4777	45238
4778	1183
4778	1194
4778	1218
4778	1232
4778	1233
4779	1183
4779	1188
4779	1218
4779	1232
4779	1233
4780	1188
4780	1218
4780	1232
4780	1233
4780	45238
4781	1188
4781	1218
4781	1232
4781	1233
4781	45238
4784	1183
4784	1188
4784	1206
4784	1218
4784	1229
4785	1188
4785	1218
4785	1232
4785	1233
4785	45238
4787	1188
4787	1198
4787	1206
4787	1218
4787	45238
4788	1188
4788	1198
4788	1206
4788	1218
4788	45238
4789	1183
4789	1188
4789	1206
4789	1218
4789	1229
4790	1183
4790	1188
4790	1206
4790	1218
4790	1229
4791	1188
4791	1218
4791	1232
4791	1233
4791	45238
4792	1183
4792	1188
4792	1218
4792	1232
4792	1233
4794	1188
4794	1206
4794	1218
4794	1229
4794	45238
4795	1188
4795	1218
4795	1232
4795	1233
4795	45238
4796	1183
4796	1188
4796	1218
4796	1232
4796	1233
4797	1188
4797	1198
4797	1206
4797	1218
4797	45236
4798	1183
4798	1188
4798	1218
4798	1232
4798	1233
4800	1188
4800	1205
4800	1218
4800	1232
4800	45238
4802	1183
4802	1194
4802	1218
4802	1232
4802	1233
4803	1183
4803	1188
4803	1217
4803	1232
4803	1233
4804	1183
4804	1188
4804	1200
4804	1206
4804	1217
4806	1183
4806	1188
4806	1206
4806	1218
4806	1229
4809	1188
4809	1218
4809	1232
4809	1233
4809	45238
4810	1188
4810	1206
4810	1218
4810	1229
4810	45238
4811	1183
4811	1188
4811	1218
4811	1232
4811	1233
4812	1183
4812	1188
4812	1205
4812	1218
4812	1232
4813	1183
4813	1194
4813	1205
4813	1218
4813	1232
4814	1183
4814	1188
4814	1206
4814	1218
4814	1232
4817	1188
4817	1218
4817	1232
4817	1233
4817	45238
4818	1188
4818	1218
4818	1232
4818	1233
4818	45238
4822	1183
4822	1188
4822	1218
4822	1232
4822	1233
4823	1183
4823	1188
4823	1206
4823	1218
4823	1229
4824	1183
4824	1188
4824	1206
4824	1217
4824	1229
4825	1183
4825	1188
4825	1206
4825	1218
4825	1229
4826	1183
4826	1188
4826	1194
4826	1200
4826	1206
4826	1218
4826	1229
4827	1183
4827	1188
4827	1218
4827	1232
4827	1233
4830	1183
4830	1194
4830	1218
4830	1232
4830	1233
4831	1188
4831	1218
4831	1232
4831	1233
4831	45238
4832	1183
4832	1188
4832	1218
4832	1232
4832	1233
4833	1183
4833	1188
4833	1218
4833	1232
4833	1233
4834	1183
4834	1188
4834	1218
4834	1232
4834	1233
4835	1183
4835	1194
4835	1218
4835	1232
4835	1233
4836	1188
4836	1218
4836	1232
4836	1233
4836	45238
4837	1183
4837	1188
4837	1218
4837	1232
4837	1233
4840	1183
4840	1194
4840	1200
4840	1206
4840	1218
4842	1188
4842	1206
4842	1213
4842	1229
4842	45238
4844	1188
4844	1218
4844	1232
4844	1233
4844	45238
4845	1183
4845	1188
4845	1218
4845	1232
4845	1233
4846	1183
4846	1188
4846	1218
4846	1232
4846	1233
4847	1188
4847	1204
4847	1218
4847	1232
4847	45236
4848	1188
4848	1204
4848	1218
4848	1232
4848	45236
4849	1183
4849	1188
4849	1206
4849	1218
4849	1229
4851	1183
4851	1198
4851	1218
4851	1233
4851	1239
4853	1183
4853	1188
4853	1205
4853	1218
4853	1232
4854	1183
4854	1188
4854	1206
4854	1218
4854	1229
4858	1183
4858	1188
4858	1206
4858	1218
4858	1229
4859	1183
4859	1188
4859	1198
4859	1206
4859	1218
4860	1183
4860	1194
4860	1205
4860	1218
4860	1232
4862	1188
4862	1218
4862	1232
4862	1233
4862	45238
4863	1183
4863	1194
4863	1200
4863	1206
4863	1218
4865	1183
4865	1194
4865	1218
4865	1232
4865	1233
4866	1183
4866	1188
4866	1200
4866	1206
4866	1218
4869	1183
4869	1188
4869	1191
4869	1196
4869	1200
4869	1206
4869	1218
4869	1233
4870	1183
4870	1188
4870	1200
4870	1206
4870	44983
4871	1188
4871	1218
4871	1232
4871	1233
4871	45238
4873	1183
4873	1194
4873	1218
4873	1232
4873	1233
4876	1183
4876	1188
4876	1204
4876	1218
4876	1232
4877	1188
4877	1218
4877	1232
4877	1233
4877	45238
4878	1183
4878	1188
4878	1218
4878	1232
4878	1233
4883	1183
4883	1188
4883	1222
4883	1232
4883	1233
4884	1183
4884	1188
4884	1218
4884	1232
4884	1233
4888	1183
4888	1188
4888	1198
4888	1206
4888	1218
4889	1183
4889	1188
4889	1204
4889	1218
4889	1232
4890	1188
4890	1218
4890	1232
4890	1233
4890	45238
4891	1179
4891	1188
4891	1197
4891	1201
4891	1218
4893	1179
4893	1188
4893	1197
4893	1201
4893	1218
4894	1183
4894	1188
4894	1206
4894	1218
4894	1229
4899	1183
4899	1188
4899	1206
4899	1218
4899	1229
4900	1183
4900	1188
4900	1218
4900	1232
4900	1233
4901	1183
4901	1188
4901	1206
4901	1218
4901	1229
4902	1183
4902	1188
4902	1206
4902	1218
4902	1229
4904	1183
4904	1198
4904	1206
4904	1218
4904	1239
4905	1183
4905	1198
4905	1206
4905	1218
4905	1239
4908	1188
4908	1192
4908	1197
4908	1201
4908	1218
4909	1183
4909	1188
4909	1198
4909	1206
4909	45548
4910	1183
4910	1188
4910	1206
4910	1218
4910	1229
4911	1183
4911	1188
4911	1206
4911	1218
4911	1229
4912	1183
4912	1188
4912	1205
4912	1229
4912	1246
4913	1183
4913	1192
4913	1200
4913	1206
4913	1218
4914	1183
4914	1188
4914	1206
4914	1218
4914	1229
4915	1178
4915	1188
4915	1197
4915	1201
4915	1218
4916	1188
4916	1198
4916	1206
4916	45236
4916	45398
4917	1188
4917	1218
4917	1232
4917	1233
4917	45236
4918	1183
4918	1193
4918	1198
4918	1206
4918	1218
4919	1183
4919	1193
4919	1198
4919	1206
4919	1218
4920	1183
4920	1188
4920	1198
4920	1206
4920	1218
4922	1188
4922	1205
4922	1218
4922	1232
4922	45236
4924	1183
4924	1188
4924	1206
4924	1218
4924	1229
4925	1183
4925	1188
4925	1206
4925	1218
4925	1229
4926	1183
4926	1196
4926	1218
4926	1232
4926	1233
4927	1183
4927	1188
4927	1206
4927	1218
4927	1229
4928	1188
4928	1218
4928	1232
4928	1233
4928	45236
4930	1188
4930	1206
4930	1209
4930	1229
4930	45238
4931	1183
4931	1196
4931	1206
4931	1218
4931	1229
4932	1188
4932	1220
4932	1232
4932	1233
4932	45238
4933	1188
4933	1218
4933	1232
4933	1233
4933	45238
4934	1188
4934	1206
4934	1220
4934	1229
4934	45238
4935	1188
4935	1198
4935	1206
4935	45238
4935	45644
4936	1188
4936	1206
4936	1209
4936	1229
4936	45238
4937	1183
4937	1188
4937	1206
4937	1220
4937	1229
4938	1188
4938	1205
4938	1218
4938	1232
4938	45238
4939	1188
4939	1200
4939	1206
4939	1218
4939	45238
4940	1188
4940	1206
4940	1218
4940	1229
4940	45238
4941	1188
4941	1198
4941	1209
4941	1233
4941	45236
4942	1183
4942	1188
4942	1232
4942	1233
4942	45019
4943	1183
4943	1196
4943	1198
4943	1206
4943	1218
4944	1183
4944	1194
4944	1206
4944	1218
4944	1229
4945	1188
4945	1206
4945	1218
4945	1229
4945	45238
4946	1188
4946	1209
4946	1232
4946	1233
4946	45238
4947	1183
4947	1188
4947	1206
4947	1218
4947	1229
4948	1179
4948	1188
4948	1197
4948	1201
4948	1218
4949	1183
4949	1188
4949	1194
4949	1218
4949	1232
4949	1233
4950	1183
4950	1188
4950	1206
4950	1209
4950	1229
4951	1179
4951	1191
4951	1197
4951	1201
4951	1218
4955	1183
4955	1188
4955	1218
4955	1232
4955	1233
4957	1183
4957	1188
4957	1206
4957	1218
4957	1229
4958	1183
4958	1198
4958	1206
4958	1218
4958	1239
4959	1183
4959	1194
4959	1218
4959	1232
4959	1233
4961	1183
4961	1188
4961	1198
4961	1206
4961	1218
4962	1183
4962	1188
4962	1198
4962	1206
4962	1218
4966	1183
4966	1188
4966	1200
4966	1206
4966	1218
4968	1188
4968	1198
4968	1210
4968	1233
4968	45236
4970	1183
4970	1188
4970	1218
4970	1232
4970	1233
4971	1183
4971	1188
4971	1199
4971	1204
4971	1218
4972	1188
4972	1222
4972	1232
4972	1233
4972	45238
4973	1183
4973	1188
4973	1200
4973	1206
4973	1218
4974	1183
4974	1205
4974	1218
4974	1232
4974	1239
4978	1188
4978	1206
4978	1218
4978	1229
4978	45236
4979	1188
4979	1198
4979	1206
4979	1218
4979	45238
4980	1183
4980	1188
4980	1200
4980	1206
4980	1217
4981	1183
4981	1188
4981	1218
4981	1232
4981	1233
4982	1183
4982	1194
4982	1200
4982	1206
4982	1218
4983	1183
4983	1188
4983	1206
4983	1218
4983	1229
4985	1183
4985	1188
4985	1218
4985	1232
4985	1233
4986	1183
4986	1188
4986	1204
4986	1218
4986	1232
4987	1183
4987	1188
4987	1218
4987	1232
4987	1233
4990	1183
4990	1192
4990	1200
4990	1206
4990	1218
4995	1183
4995	1188
4995	1218
4995	1232
4995	1233
4997	1183
4997	1188
4997	1218
4997	1232
4997	1233
4999	1183
4999	1188
4999	1198
4999	1206
4999	1218
5000	1183
5000	1188
5000	1218
5000	1232
5000	1233
5001	1183
5001	1188
5001	1198
5001	1206
5001	1218
5002	1183
5002	1188
5002	1218
5002	1232
5002	1233
5004	1188
5004	1206
5004	1218
5004	1229
5004	45238
5005	1183
5005	1188
5005	1218
5005	1232
5005	1233
5006	1188
5006	1218
5006	1232
5006	1233
5006	45238
5007	1183
5007	1188
5007	1205
5007	1218
5007	1232
5009	1183
5009	1188
5009	1194
5009	1198
5009	1199
5009	1204
5009	1205
5009	1206
5009	1218
5009	1232
5009	1239
5010	1179
5010	1188
5010	1197
5010	1201
5010	1218
5013	1183
5013	1188
5013	1218
5013	1232
5013	1233
5014	1179
5014	1188
5014	1197
5014	1201
5014	1218
5015	1183
5015	1188
5015	1218
5015	1232
5015	1233
5016	1179
5016	1188
5016	1197
5016	1201
5016	1218
5017	1183
5017	1188
5017	1204
5017	1218
5017	1232
5018	1183
5018	1188
5018	1218
5018	1232
5018	1233
5021	1188
5021	1218
5021	1232
5021	1233
5021	45238
5026	1183
5026	1188
5026	1200
5026	1206
5026	1218
5028	1183
5028	1188
5028	1206
5028	1218
5028	1229
5029	1183
5029	1188
5029	1198
5029	1206
5029	1218
5030	1183
5030	1194
5030	1198
5030	1206
5030	1218
5031	1183
5031	1188
5031	1198
5031	1206
5031	1218
5034	1183
5034	1188
5034	1206
5034	1218
5034	1229
5036	1183
5036	1188
5036	1206
5036	1219
5036	1229
5037	1183
5037	1188
5037	1218
5037	1232
5037	1233
5038	1183
5038	1188
5038	1206
5038	1218
5038	1229
5039	1183
5039	1188
5039	1206
5039	1218
5039	1229
5040	1183
5040	1188
5040	1198
5040	1206
5040	1210
5041	1183
5041	1188
5041	1218
5041	1232
5041	1233
5042	1183
5042	1194
5042	1218
5042	1232
5042	1233
5043	1188
5043	1206
5043	1218
5043	1229
5043	45238
5045	1183
5045	1188
5045	1199
5045	1206
5045	45356
5046	1188
5046	1198
5046	1206
5046	1218
5046	45236
5047	1183
5047	1188
5047	1200
5047	1206
5047	1218
5048	1179
5048	1188
5048	1197
5048	1201
5048	1218
5049	1183
5049	1194
5049	1205
5049	1218
5049	1232
5050	1183
5050	1188
5050	1199
5050	1233
5050	45317
5052	1183
5052	1194
5052	1198
5052	1206
5052	1218
5054	1183
5054	1188
5054	1200
5054	1206
5054	1218
5055	1188
5055	1218
5055	1232
5055	1233
5055	45236
5056	1183
5056	1188
5056	1200
5056	1206
5056	1218
5057	1183
5057	1188
5057	1198
5057	1206
5057	1218
5058	1183
5058	1188
5058	1218
5058	1232
5058	1233
5063	1183
5063	1188
5063	1198
5063	1206
5063	1210
5064	1183
5064	1188
5064	1218
5064	1232
5064	1233
5066	1183
5066	1188
5066	1218
5066	1232
5066	1233
5067	1183
5067	1188
5067	1218
5067	1232
5067	1233
5068	1183
5068	1193
5068	1200
5068	1206
5068	1218
5069	1188
5069	1200
5069	1206
5069	1216
5069	45236
5070	1183
5070	1188
5070	1200
5070	1206
5070	1218
5072	1183
5072	1188
5072	1200
5072	1206
5072	1218
5073	1183
5073	1192
5073	1218
5073	1232
5073	1233
5074	1183
5074	1188
5074	1232
5074	1233
5074	44971
5075	1183
5075	1188
5075	1218
5075	1229
5075	1233
5076	1183
5076	1188
5076	1206
5076	1218
5076	1229
5077	1183
5077	1188
5077	1206
5077	1218
5077	1229
5078	1183
5078	1188
5078	1218
5078	1232
5078	1233
5079	1183
5079	1188
5079	1198
5079	1206
5079	1218
5080	1183
5080	1196
5080	1206
5080	1218
5080	1229
5081	1183
5081	1188
5081	1206
5081	1218
5081	1229
5082	1188
5082	1218
5082	1232
5082	1233
5082	45238
5083	1183
5083	1206
5083	1218
5083	1229
5083	1239
5084	1188
5084	1206
5084	1218
5084	1229
5084	45238
5085	1183
5085	1188
5085	1206
5085	1218
5085	1229
5086	1183
5086	1188
5086	1206
5086	1218
5086	1229
5087	1183
5087	1188
5087	1206
5087	1218
5087	1229
5088	1183
5088	1188
5088	1198
5088	1206
5088	1218
5090	1188
5090	1206
5090	1218
5090	1229
5090	45238
5092	1183
5092	1188
5092	1206
5092	1218
5092	1229
5093	1183
5093	1194
5093	1198
5093	1206
5093	45549
5094	1183
5094	1188
5094	1206
5094	1218
5094	1229
5096	1183
5096	1188
5096	1206
5096	1218
5096	1229
5097	1183
5097	1194
5097	1200
5097	1206
5097	1218
5099	1183
5099	1188
5099	1198
5099	1218
5099	1233
5100	1183
5100	1188
5100	1206
5100	1218
5100	1232
5101	1183
5101	1188
5101	1198
5101	1233
5101	1262
5102	1183
5102	1194
5102	1198
5102	1206
5102	1218
5105	1183
5105	1188
5105	1218
5105	1232
5105	1233
5106	1183
5106	1188
5106	1206
5106	1218
5106	1232
5108	1183
5108	1188
5108	1198
5108	1206
5108	1218
5110	1183
5110	1188
5110	1200
5110	1206
5110	1218
5116	1183
5116	1188
5116	1200
5116	1206
5116	1218
5117	1183
5117	1188
5117	1218
5117	1232
5117	1233
5120	1183
5120	1188
5120	1206
5120	1218
5120	1229
5121	1183
5121	1194
5121	1200
5121	1206
5121	1218
5122	1183
5122	1188
5122	1218
5122	1232
5122	1233
5123	1183
5123	1188
5123	1200
5123	1206
5123	1218
5124	1183
5124	1188
5124	1218
5124	1232
5124	1233
5125	1183
5125	1188
5125	1206
5125	1218
5125	1229
5126	1183
5126	1188
5126	1206
5126	1220
5126	1229
5127	1183
5127	1188
5127	1206
5127	1218
5127	1229
5128	1188
5128	1198
5128	1206
5128	1218
5128	45238
5129	1183
5129	1188
5129	1206
5129	1218
5129	1229
5130	1183
5130	1188
5130	1200
5130	1206
5130	1218
5131	1183
5131	1188
5131	1200
5131	1206
5131	1218
5133	1183
5133	1188
5133	1198
5133	1206
5133	1218
5134	1188
5134	1206
5134	1218
5134	1229
5134	45236
5135	1183
5135	1194
5135	1199
5135	1206
5135	1218
5136	1183
5136	1188
5136	1198
5136	1206
5136	1218
5138	1183
5138	1194
5138	1200
5138	1206
5138	1218
5140	1183
5140	1188
5140	1198
5140	1206
5140	1218
5141	1183
5141	1194
5141	1206
5141	1218
5141	1232
5142	1183
5142	1188
5142	1218
5142	1232
5142	1233
5143	1183
5143	1188
5143	1206
5143	1213
5143	1229
5144	1183
5144	1194
5144	1198
5144	1206
5144	1210
5145	1183
5145	1188
5145	1218
5145	1232
5145	1233
5146	1183
5146	1188
5146	1220
5146	1232
5146	1233
5150	1188
5150	1220
5150	1232
5150	1233
5150	45238
5151	1188
5151	1206
5151	1218
5151	1229
5151	45238
5152	1183
5152	1194
5152	1200
5152	1206
5152	1218
5153	1183
5153	1188
5153	1206
5153	1218
5153	1229
5159	1183
5159	1188
5159	1206
5159	1218
5159	1229
5160	1183
5160	1188
5160	1206
5160	1218
5160	1229
5161	1183
5161	1188
5161	1206
5161	1218
5161	1229
5162	1183
5162	1188
5162	1200
5162	1206
5162	1217
5164	1183
5164	1188
5164	1206
5164	1218
5164	1229
5165	1182
5165	1188
5165	1206
5165	1218
5165	1229
5168	1183
5168	1196
5168	1198
5168	1218
5168	1233
5169	1183
5169	1188
5169	1218
5169	1232
5169	1233
5171	1183
5171	1188
5171	1206
5171	1218
5171	1229
5173	1183
5173	1194
5173	1206
5173	1218
5173	1229
5175	1183
5175	1188
5175	1218
5175	1232
5175	1233
5177	1183
5177	1188
5177	1206
5177	1220
5177	1229
5180	1188
5180	1218
5180	1232
5180	1233
5180	45238
5181	1188
5181	1206
5181	1211
5181	1229
5181	45238
5182	1183
5182	1188
5182	1206
5182	1218
5182	1229
5183	1183
5183	1188
5183	1198
5183	1206
5183	1210
5184	1183
5184	1188
5184	1198
5184	1206
5184	1210
5186	1183
5186	1194
5186	1206
5186	1218
5186	1229
5187	1183
5187	1188
5187	1198
5187	1206
5187	1218
5188	1183
5188	1188
5188	1206
5188	1218
5188	1229
5191	1183
5191	1188
5191	1206
5191	1220
5191	1229
5192	1183
5192	1194
5192	1198
5192	1206
5192	1218
5193	1183
5193	1188
5193	1198
5193	1206
5193	1218
5195	1188
5195	1206
5195	1220
5195	1229
5195	45238
5196	1188
5196	1198
5196	1206
5196	1218
5196	45236
5198	1183
5198	1188
5198	1200
5198	1206
5198	1246
5199	1183
5199	1188
5199	1218
5199	1232
5199	1233
5200	1188
5200	1198
5200	1218
5200	1233
5200	45238
5202	1183
5202	1188
5202	1206
5202	1218
5202	1232
5203	1188
5203	1206
5203	1218
5203	1232
5203	45238
5239	1182
5239	1195
5239	1198
5239	1206
5239	1218
5240	1183
5240	1188
5240	1218
5240	1232
5240	1233
5241	1183
5241	1194
5241	1217
5241	1232
5241	1233
5242	1183
5242	1188
5242	1206
5242	1209
5242	1213
5242	1217
5242	1218
5242	1229
5243	1183
5243	1188
5243	1206
5243	1218
5243	1229
5245	1183
5245	1188
5245	1198
5245	1206
5245	1218
5246	1183
5246	1188
5246	1206
5246	1218
5246	1229
5248	1183
5248	1188
5248	1200
5248	1206
5248	1218
5249	1183
5249	1188
5249	1200
5249	1206
5249	1218
5250	1183
5250	1188
5250	1217
5250	1232
5250	1233
5251	1188
5251	1206
5251	1220
5251	1229
5251	45238
5253	1183
5253	1188
5253	1198
5253	1206
5253	1218
5255	1183
5255	1188
5255	1200
5255	1206
5255	1218
5256	1183
5256	1188
5256	1206
5256	1220
5256	1229
5257	1179
5257	1188
5257	1197
5257	1201
5257	1218
5258	1183
5258	1188
5258	1206
5258	1217
5258	1229
5259	1183
5259	1198
5259	1206
5259	1218
5259	1239
5260	1188
5260	1206
5260	1220
5260	1229
5260	45238
5261	1183
5261	1188
5261	1198
5261	1206
5261	1218
5262	1183
5262	1188
5262	1206
5262	1218
5262	1229
5263	1183
5263	1198
5263	1206
5263	1218
5263	1239
5264	1183
5264	1188
5264	1198
5264	1206
5264	1220
5267	1183
5267	1191
5267	1206
5267	1218
5267	1229
5268	1183
5268	1194
5268	1198
5268	1206
5268	1218
5269	1183
5269	1188
5269	1200
5269	1206
5269	1218
5271	1183
5271	1188
5271	1206
5271	1218
5271	1232
5274	1188
5274	1206
5274	1218
5274	1229
5274	45238
5275	1183
5275	1194
5275	1198
5275	1206
5275	1218
5276	1188
5276	1200
5276	1206
5276	1218
5276	45238
5277	1188
5277	1206
5277	1218
5277	1229
5277	45238
5278	1188
5278	1218
5278	1232
5278	1233
5278	45238
5279	1188
5279	1205
5279	1216
5279	1232
5279	45238
5280	1188
5280	1218
5280	1232
5280	1233
5280	45238
5281	1183
5281	1196
5281	1206
5281	1220
5281	1229
5282	1188
5282	1206
5282	1218
5282	1229
5282	45238
5283	1183
5283	1188
5283	1206
5283	1218
5283	1229
5284	1183
5284	1188
5284	1200
5284	1206
5284	1218
5285	1188
5285	1200
5285	1206
5285	1218
5285	45238
5291	1183
5291	1188
5291	1194
5291	1200
5291	1206
5291	1211
5291	1218
5291	1221
5292	1183
5292	1188
5292	1218
5292	1232
5292	1233
5293	1183
5293	1188
5293	1198
5293	1206
5293	1218
5297	1183
5297	1194
5297	1200
5297	1206
5297	1218
5298	1183
5298	1188
5298	1218
5298	1232
5298	1233
5301	1183
5301	1194
5301	1232
5301	1233
5301	1246
5303	1183
5303	1188
5303	1218
5303	1232
5303	1233
5305	1183
5305	1188
5305	1206
5305	1218
5305	1229
5312	1183
5312	1194
5312	1218
5312	1232
5312	1233
5313	1179
5313	1188
5313	1197
5313	1201
5313	1218
5314	1183
5314	1188
5314	1198
5314	1206
5314	1210
5316	1183
5316	1188
5316	1206
5316	1218
5316	1229
5317	1183
5317	1188
5317	1218
5317	1232
5317	1233
5319	1183
5319	1188
5319	1206
5319	1218
5319	1229
5322	1188
5322	1218
5322	1232
5322	1233
5322	45238
5324	1183
5324	1188
5324	1206
5324	1216
5324	1229
5325	1183
5325	1188
5325	1206
5325	1218
5325	1229
5330	1183
5330	1188
5330	1218
5330	1232
5330	1233
5333	1183
5333	1194
5333	1204
5333	1222
5333	1232
5335	1183
5335	1188
5335	1206
5335	1218
5335	1229
5338	1183
5338	1188
5338	1218
5338	1232
5338	1233
5340	1183
5340	1188
5340	1198
5340	1206
5340	1218
5342	1183
5342	1188
5342	1218
5342	1232
5342	1233
5344	1179
5344	1188
5344	1197
5344	1201
5344	1218
5346	1183
5346	1196
5346	1218
5346	1232
5346	1233
5356	1183
5356	1188
5356	1206
5356	1218
5356	1229
5357	1183
5357	1194
5357	1206
5357	1218
5357	1229
5358	1183
5358	1188
5358	1200
5358	1206
5358	1218
5359	1183
5359	1188
5359	1206
5359	1218
5359	1229
5360	1183
5360	1188
5360	1218
5360	1232
5360	1233
5364	1183
5364	1188
5364	1218
5364	1232
5364	1233
5365	1183
5365	1188
5365	1204
5365	1218
5365	1232
5367	1183
5367	1188
5367	1218
5367	1232
5367	1233
5370	1183
5370	1188
5370	1204
5370	1218
5370	1232
5372	1183
5372	1194
5372	1218
5372	1232
5372	1233
5373	1183
5373	1188
5373	1218
5373	1232
5373	1233
5380	1183
5380	1194
5380	1200
5380	1206
5380	1218
5383	1188
5383	1232
5383	1233
5383	1244
5383	45236
5384	1183
5384	1194
5384	1206
5384	1218
5384	1229
5387	1188
5387	1206
5387	1218
5387	1229
5387	1237
5389	1183
5389	1188
5389	1200
5389	1206
5389	1218
5390	1183
5390	1196
5390	1204
5390	1217
5390	1232
5391	1183
5391	1188
5391	1206
5391	1232
5391	45421
5394	1179
5394	1188
5394	1197
5394	1201
5394	1218
5396	1183
5396	1194
5396	1198
5396	1206
5396	1218
5400	1183
5400	1188
5400	1218
5400	1232
5400	1233
5401	1183
5401	1188
5401	1206
5401	1218
5401	1232
5402	1183
5402	1194
5402	1206
5402	1218
5402	1232
5403	1183
5403	1188
5403	1217
5403	1232
5403	1233
5404	1183
5404	1218
5404	1232
5404	1233
5404	1239
5405	1183
5405	1188
5405	1206
5405	1218
5405	1229
5406	1183
5406	1188
5406	1218
5406	1232
5406	1233
5407	1183
5407	1188
5407	1206
5407	1218
5407	1232
5409	1183
5409	1194
5409	1218
5409	1232
5409	1233
5410	1183
5410	1194
5410	1200
5410	1206
5410	1218
5411	1183
5411	1198
5411	1206
5411	1218
5411	1239
5412	1188
5412	1218
5412	1232
5412	1233
5412	45238
5415	1195
5415	1200
5415	1206
5415	1218
5415	45238
5419	1183
5419	1188
5419	1206
5419	1211
5419	1229
5421	1195
5421	1206
5421	1218
5421	1229
5421	45238
5425	1195
5425	1200
5425	1206
5425	1218
5425	45238
5427	1188
5427	1206
5427	1218
5427	1229
5427	45238
5428	1183
5428	1188
5428	1206
5428	1218
5428	1229
5429	1183
5429	1188
5429	1206
5429	1218
5429	1229
5432	1183
5432	1188
5432	1218
5432	1232
5432	1233
5436	1183
5436	1194
5436	1206
5436	1218
5436	1229
5437	1183
5437	1188
5437	1206
5437	1218
5437	1229
5438	1183
5438	1188
5438	1218
5438	1232
5438	1233
5439	1188
5439	1218
5439	1232
5439	1233
5439	45238
5440	1183
5440	1188
5440	1206
5440	1229
5440	45314
5441	1188
5441	1206
5441	1218
5441	1229
5441	45238
5442	1183
5442	1188
5442	1206
5442	1218
5442	1229
5443	1183
5443	1188
5443	1206
5443	1218
5443	1229
5449	1183
5449	1188
5449	1218
5449	1232
5449	1233
5451	1183
5451	1188
5451	1218
5451	1232
5451	1233
5452	1183
5452	1188
5452	1206
5452	1220
5452	1229
5458	1183
5458	1188
5458	1206
5458	1218
5458	1232
5460	1183
5460	1188
5460	1232
5460	1233
5460	1277
5461	1183
5461	1188
5461	1206
5461	1218
5461	1229
5463	1183
5463	1188
5463	1206
5463	1218
5463	1232
5470	1183
5470	1188
5470	1232
5470	1233
5470	44968
5471	1183
5471	1188
5471	1206
5471	1218
5471	1229
5480	1183
5480	1188
5480	1206
5480	1218
5480	1232
5481	1183
5481	1194
5481	1206
5481	1218
5481	1229
5485	1183
5485	1188
5485	1206
5485	1218
5485	1229
5487	1183
5487	1188
5487	1206
5487	1218
5487	1229
5493	1183
5493	1188
5493	1206
5493	1218
5493	1229
5494	1183
5494	1188
5494	1198
5494	1206
5494	1221
5496	1183
5496	1194
5496	1206
5496	1218
5496	1229
5499	1188
5499	1218
5499	1232
5499	1233
5499	45238
5500	1188
5500	1206
5500	1218
5500	1229
5500	45238
5502	1183
5502	1194
5502	1218
5502	1232
5502	1233
5503	1183
5503	1188
5503	1206
5503	1218
5503	1229
5504	1183
5504	1188
5504	1198
5504	1206
5504	1218
5506	1183
5506	1188
5506	1198
5506	1206
5506	1219
5507	1183
5507	1188
5507	1206
5507	1218
5507	1229
5509	1183
5509	1196
5509	1198
5509	1206
5509	1210
5511	1183
5511	1188
5511	1206
5511	1218
5511	1232
5512	1183
5512	1188
5512	1206
5512	1209
5512	1229
5513	1183
5513	1188
5513	1198
5513	1206
5513	1218
5520	1183
5520	1188
5520	1218
5520	1232
5520	1233
5521	1183
5521	1188
5521	1204
5521	1218
5521	1232
5522	1183
5522	1188
5522	1200
5522	1206
5522	1218
5523	1183
5523	1194
5523	1206
5523	1218
5523	1229
5525	1183
5525	1194
5525	1218
5525	1232
5525	1233
5526	1188
5526	1211
5526	1232
5526	1233
5526	45238
5527	1183
5527	1194
5527	1200
5527	1206
5527	1218
5528	1183
5528	1194
5528	1206
5528	1218
5528	1229
5529	1183
5529	1188
5529	1206
5529	1218
5529	1229
5530	1183
5530	1188
5530	1206
5530	1218
5530	1229
5532	1188
5532	1206
5532	1232
5532	45236
5532	45380
5534	1183
5534	1194
5534	1206
5534	1218
5534	1232
5535	1183
5535	1188
5535	1198
5535	1206
5535	1218
5536	1183
5536	1194
5536	1218
5536	1232
5536	1233
5537	1188
5537	1206
5537	1218
5537	1229
5537	45238
5538	1183
5538	1194
5538	1198
5538	1206
5538	1213
5539	1194
5539	1206
5539	1218
5539	1229
5539	45238
5541	1183
5541	1188
5541	1218
5541	1232
5541	1233
5542	1188
5542	1198
5542	1206
5542	1218
5542	45238
5545	1183
5545	1198
5545	1204
5545	1218
5545	1239
5546	1188
5546	1218
5546	1232
5546	1233
5546	45238
5547	1183
5547	1218
5547	1232
5547	1233
5547	1239
5551	1183
5551	1194
5551	1198
5551	1206
5551	1218
5552	1183
5552	1188
5552	1206
5552	1211
5552	1229
5554	1188
5554	1206
5554	1219
5554	1229
5554	45238
5555	1195
5555	1206
5555	1218
5555	1229
5555	45238
5556	1183
5556	1194
5556	1199
5556	1203
5556	1218
5559	1183
5559	1188
5559	1218
5559	1232
5559	1233
5570	1183
5570	1188
5570	1218
5570	1232
5570	1233
5572	1183
5572	1194
5572	1206
5572	1218
5572	1229
5574	1182
5574	1188
5574	1218
5574	1232
5574	1233
5576	1188
5576	1211
5576	1232
5576	1233
5576	45238
5577	1183
5577	1192
5577	1200
5577	1206
5577	1218
5578	1183
5578	1188
5578	1200
5578	1206
5578	1218
5579	1183
5579	1194
5579	1206
5579	1218
5579	1229
5580	1183
5580	1188
5580	1206
5580	1218
5580	1229
5582	1183
5582	1188
5582	1198
5582	1206
5582	45019
5583	1183
5583	1188
5583	1206
5583	1218
5583	1229
5584	1183
5584	1188
5584	1206
5584	1218
5584	1229
5585	1188
5585	1206
5585	1218
5585	1229
5585	45238
5587	1183
5587	1188
5587	1206
5587	1231
5587	1232
5592	1183
5592	1188
5592	1206
5592	1218
5592	1229
5593	1183
5593	1188
5593	1206
5593	1218
5593	1229
5595	1183
5595	1188
5595	1206
5595	1218
5595	1229
5596	1183
5596	1188
5596	1198
5596	1206
5596	1218
5597	1188
5597	1206
5597	1218
5597	1229
5597	45238
5598	1183
5598	1188
5598	1206
5598	1218
5598	1232
5599	1188
5599	1200
5599	1206
5599	1218
5599	45238
5601	1183
5601	1194
5601	1198
5601	1206
5601	1218
5604	1183
5604	1188
5604	1206
5604	1218
5604	1229
5605	1188
5605	1206
5605	1218
5605	1229
5605	45238
5606	1183
5606	1188
5606	1198
5606	1206
5606	1218
5610	1195
5610	1200
5610	1206
5610	45238
5610	45337
5611	1183
5611	1196
5611	1198
5611	1218
5611	1233
5614	1188
5614	1200
5614	1206
5614	1218
5614	45238
5615	1183
5615	1188
5615	1206
5615	1218
5615	1229
5616	1183
5616	1188
5616	1198
5616	1206
5616	1218
5617	1188
5617	1200
5617	1206
5617	1218
5617	45236
5618	1188
5618	1206
5618	1218
5618	1232
5618	45238
5619	1188
5619	1198
5619	1206
5619	1218
5619	45238
5623	1183
5623	1188
5623	1206
5623	1218
5623	1229
5624	1188
5624	1198
5624	1206
5624	1218
5624	45238
5630	1183
5630	1188
5630	1211
5630	1232
5630	1233
5634	1183
5634	1188
5634	1217
5634	1232
5634	1233
5635	1183
5635	1188
5635	1206
5635	1222
5635	1229
5636	1183
5636	1188
5636	1198
5636	1206
5636	1218
5638	1183
5638	1188
5638	1222
5638	1232
5638	1233
5643	1183
5643	1188
5643	1206
5643	1218
5643	1229
5644	1183
5644	1188
5644	1206
5644	1216
5644	1229
5646	1183
5646	1188
5646	1218
5646	1232
5646	1233
5648	1183
5648	1188
5648	1204
5648	1218
5648	1232
5655	1183
5655	1194
5655	1218
5655	1232
5655	1233
5656	1183
5656	1188
5656	1206
5656	1218
5656	1229
5658	1183
5658	1196
5658	1206
5658	1218
5658	1229
5663	1183
5663	1188
5663	1218
5663	1232
5663	1233
5664	1183
5664	1188
5664	1198
5664	1206
5664	1218
5665	1183
5665	1188
5665	1218
5665	1232
5665	1233
5666	1183
5666	1188
5666	1213
5666	1232
5666	1233
5667	1183
5667	1188
5667	1198
5667	1206
5667	1218
5670	1183
5670	1188
5670	1218
5670	1232
5670	1233
5671	1183
5671	1188
5671	1200
5671	1206
5671	1218
5672	1183
5672	1188
5672	1206
5672	1218
5672	1229
5674	1183
5674	1188
5674	1200
5674	1206
5674	1218
5675	1188
5675	1200
5675	1206
5675	1218
5675	45238
5677	1183
5677	1188
5677	1198
5677	1206
5677	1217
5678	1183
5678	1188
5678	1198
5678	1206
5678	1218
5679	1183
5679	1188
5679	1218
5679	1232
5679	1233
5680	1183
5680	1188
5680	1218
5680	1232
5680	1233
5682	1183
5682	1188
5682	1218
5682	1232
5682	1233
5684	1183
5684	1188
5684	1218
5684	1232
5684	1233
5687	1183
5687	1194
5687	1198
5687	1206
5687	1218
5689	1183
5689	1188
5689	1218
5689	1232
5689	1233
5690	1183
5690	1188
5690	1200
5690	1206
5690	1220
5691	1188
5691	1206
5691	1218
5691	1229
5691	45238
5694	1183
5694	1188
5694	1206
5694	1221
5694	1229
5697	1183
5697	1188
5697	1198
5697	1206
5697	1211
5698	1183
5698	1188
5698	1198
5698	1206
5698	1218
5699	1183
5699	1194
5699	1198
5699	1206
5699	1218
5700	1183
5700	1194
5700	1206
5700	1220
5700	1229
5701	1183
5701	1188
5701	1194
5701	1200
5701	1206
5701	1213
5701	1218
5701	1220
5701	1232
5701	1233
5701	45236
5701	45238
5704	1183
5704	1188
5704	1205
5704	1218
5704	1232
5705	1183
5705	1188
5705	1200
5705	1205
5705	1218
5706	1183
5706	1194
5706	1206
5706	1218
5706	1229
5707	1188
5707	1206
5707	1218
5707	1229
5707	45238
5709	1183
5709	1191
5709	1206
5709	1218
5709	1229
5710	1182
5710	1196
5710	1198
5710	1206
5710	1218
5711	1188
5711	1206
5711	1218
5711	1229
5711	45238
5713	1183
5713	1188
5713	1200
5713	1206
5713	1218
5714	1183
5714	1188
5714	1206
5714	1218
5714	1229
5715	1183
5715	1188
5715	1206
5715	1218
5715	1229
5716	1183
5716	1188
5716	1198
5716	1206
5716	1218
5719	1183
5719	1188
5719	1200
5719	1206
5719	1218
5720	1188
5720	1200
5720	1206
5720	1218
5720	45238
5722	1183
5722	1188
5722	1206
5722	1220
5722	1229
5724	1183
5724	1194
5724	1200
5724	1206
5724	1218
5726	1183
5726	1188
5726	1206
5726	1218
5726	1229
5727	1183
5727	1188
5727	1206
5727	1218
5727	1229
5728	1188
5728	1218
5728	1232
5728	1233
5728	45238
5729	1183
5729	1188
5729	1200
5729	1206
5729	1218
5734	1183
5734	1188
5734	1198
5734	1206
5734	1218
5737	1183
5737	1188
5737	1206
5737	1209
5737	1229
5738	1183
5738	1188
5738	1206
5738	1218
5738	1229
5739	1183
5739	1188
5739	1206
5739	1218
5739	1229
5740	1188
5740	1206
5740	1209
5740	1229
5740	45238
5742	1183
5742	1188
5742	1206
5742	1218
5742	1229
5743	1183
5743	1188
5743	1218
5743	1232
5743	1233
5745	1183
5745	1188
5745	1218
5745	1232
5745	1233
5746	1183
5746	1188
5746	1206
5746	1218
5746	1229
5747	1183
5747	1188
5747	1206
5747	1218
5747	1232
5752	1195
5752	1206
5752	1218
5752	1229
5752	45238
5753	1183
5753	1188
5753	1206
5753	1218
5753	1229
5754	1183
5754	1188
5754	1206
5754	1222
5754	1232
5757	1183
5757	1188
5757	1218
5757	1232
5757	1233
5760	1183
5760	1188
5760	1206
5760	1218
5760	1229
5761	1183
5761	1188
5761	1206
5761	1218
5761	1229
5762	1183
5762	1198
5762	1206
5762	1218
5762	1239
5763	1183
5763	1188
5763	1222
5763	1232
5763	1233
5764	1183
5764	1188
5764	1206
5764	1218
5764	1229
5765	1183
5765	1188
5765	1200
5765	1206
5765	1218
5766	1183
5766	1188
5766	1206
5766	1218
5766	1232
5768	1183
5768	1194
5768	1205
5768	1217
5768	1232
5771	1183
5771	1188
5771	1206
5771	1218
5771	1229
5773	1183
5773	1188
5773	1200
5773	1206
5773	1218
5777	1183
5777	1188
5777	1198
5777	1206
5777	1218
5782	1183
5782	1188
5782	1204
5782	1218
5782	1232
5785	1183
5785	1188
5785	1218
5785	1232
5785	1233
5787	1183
5787	1188
5787	1222
5787	1232
5787	1233
5788	1183
5788	1188
5788	1198
5788	1206
5788	1218
5791	1183
5791	1188
5791	1218
5791	1232
5791	1233
5793	1183
5793	1188
5793	1218
5793	1232
5793	1233
5794	1183
5794	1194
5794	1206
5794	1218
5794	1232
5796	1188
5796	1206
5796	1218
5796	1229
5796	45238
5797	1183
5797	1188
5797	1218
5797	1232
5797	1233
5798	1183
5798	1188
5798	1198
5798	1206
5798	1222
5801	1195
5801	1199
5801	1233
5801	45238
5801	45421
5802	1183
5802	1188
5802	1204
5802	1218
5802	1232
5803	1188
5803	1218
5803	1232
5803	1233
5803	45238
5806	1183
5806	1194
5806	1222
5806	1232
5806	1233
5808	1183
5808	1188
5808	1218
5808	1232
5808	1233
5809	1183
5809	1188
5809	1203
5809	1218
5809	1232
5814	1183
5814	1188
5814	1206
5814	1220
5814	1229
5815	1183
5815	1188
5815	1206
5815	1222
5815	1229
5816	1183
5816	1194
5816	1218
5816	1232
5816	1233
5817	1183
5817	1196
5817	1200
5817	1206
5817	1218
5818	1183
5818	1188
5818	1206
5818	1220
5818	1229
5821	1183
5821	1194
5821	1198
5821	1206
5821	1218
5823	1183
5823	1188
5823	1200
5823	1206
5823	1218
5824	1183
5824	1188
5824	1200
5824	1206
5824	1218
5826	1188
5826	1209
5826	1232
5826	1233
5826	45236
5828	1183
5828	1194
5828	1200
5828	1206
5828	1218
5833	1183
5833	1188
5833	1206
5833	1218
5833	1229
5834	1183
5834	1194
5834	1206
5834	1218
5834	1229
5835	1188
5835	1198
5835	1206
5835	1218
5835	45238
5836	1188
5836	1218
5836	1232
5836	1233
5836	45238
5840	1183
5840	1188
5840	1198
5840	1206
5840	1218
5842	1183
5842	1194
5842	1200
5842	1206
5842	1218
5844	1196
5844	1206
5844	1218
5844	1232
5844	45236
5847	1183
5847	1188
5847	1206
5847	1218
5847	1229
5848	1183
5848	1188
5848	1206
5848	1218
5848	1232
5850	1194
5850	1206
5850	1217
5850	1229
5850	45238
5851	1183
5851	1188
5851	1206
5851	1218
5851	1229
5857	1183
5857	1188
5857	1218
5857	1232
5857	1233
5859	1183
5859	1188
5859	1218
5859	1232
5859	1233
5867	1183
5867	1188
5867	1206
5867	1218
5867	1229
5868	1188
5868	1200
5868	1206
5868	1218
5868	45238
5870	1183
5870	1188
5870	1198
5870	1206
5870	1218
5872	1188
5872	1206
5872	1218
5872	1232
5872	45238
5874	1183
5874	1196
5874	1200
5874	1206
5874	1218
5875	1183
5875	1196
5875	1198
5875	1233
5875	45562
5876	1183
5876	1188
5876	1198
5876	1206
5876	1218
5878	1183
5878	1188
5878	1198
5878	1205
5878	1218
5879	1183
5879	1188
5879	1206
5879	1218
5879	1229
5880	1183
5880	1188
5880	1206
5880	1218
5880	1229
5881	1183
5881	1188
5881	1206
5881	1218
5881	1229
5885	1183
5885	1188
5885	1206
5885	1218
5885	1229
5887	1183
5887	1196
5887	1218
5887	1229
5887	1233
5888	1188
5888	1200
5888	1206
5888	1218
5888	45238
5890	1188
5890	1218
5890	1232
5890	1233
5890	45238
5907	1188
5907	1206
5907	1218
5907	1229
5907	45238
5908	1183
5908	1188
5908	1206
5908	1218
5908	1229
5909	1183
5909	1188
5909	1206
5909	1218
5909	1229
5910	1183
5910	1194
5910	1218
5910	1232
5910	1233
5912	1183
5912	1188
5912	1198
5912	1206
5912	1210
5912	1271
5912	1277
5912	45321
5916	1183
5916	1188
5916	1206
5916	1218
5916	1229
5919	1183
5919	1188
5919	1218
5919	1232
5919	1233
5922	1183
5922	1194
5922	1200
5922	1206
5922	1217
5924	1183
5924	1194
5924	1200
5924	1206
5924	1218
5926	1183
5926	1194
5926	1218
5926	1232
5926	1233
5927	1183
5927	1188
5927	1200
5927	1206
5927	1218
5928	1183
5928	1194
5928	1206
5928	1218
5928	1222
5928	1232
5932	1188
5932	1206
5932	1218
5932	1232
5932	45236
5935	1183
5935	1188
5935	1206
5935	1218
5935	1229
5937	1183
5937	1194
5937	1198
5937	1206
5937	1218
5938	1183
5938	1188
5938	1200
5938	1206
5938	1220
5940	1179
5940	1188
5940	1197
5940	1201
5940	1218
5941	1195
5941	1200
5941	1206
5941	1218
5941	45238
5942	1183
5942	1188
5942	1206
5942	1217
5942	1229
5943	1183
5943	1191
5943	1198
5943	1206
5943	1221
5943	45548
5946	1183
5946	1218
5946	1232
5946	1233
5946	1239
5947	1183
5947	1188
5947	1206
5947	1218
5947	1229
5950	1183
5950	1194
5950	1206
5950	1218
5950	1229
5951	1188
5951	1206
5951	1218
5951	1229
5951	45238
5955	1188
5955	1198
5955	1206
5955	1218
5955	1221
5955	1232
5955	1233
5955	45236
5956	1183
5956	1188
5956	1218
5956	1229
5956	1233
5957	1183
5957	1194
5957	1198
5957	1206
5957	1210
5958	1183
5958	1194
5958	1206
5958	1218
5958	1232
5960	1183
5960	1196
5960	1198
5960	1206
5960	1218
5961	1183
5961	1188
5961	1199
5961	1203
5961	1218
5964	1188
5964	1204
5964	1218
5964	1232
5964	45238
5965	1183
5965	1198
5965	1206
5965	1218
5965	1239
5966	1183
5966	1188
5966	1218
5966	1232
5966	1233
5967	1183
5967	1188
5967	1198
5967	1206
5967	1216
5968	1183
5968	1188
5968	1218
5968	1232
5968	1233
5970	1183
5970	1188
5970	1206
5970	1222
5970	1229
5971	1183
5971	1188
5971	1218
5971	1232
5971	1233
5972	1183
5972	1196
5972	1198
5972	1206
5972	1210
5976	1183
5976	1188
5976	1198
5976	1200
5976	1206
5976	1218
5976	1262
5978	1188
5978	1198
5978	1206
5978	1210
5978	45236
5988	1183
5988	1188
5988	1218
5988	1232
5988	1233
5989	1183
5989	1188
5989	1218
5989	1232
5989	1233
5991	1188
5991	1218
5991	1232
5991	1233
5991	45238
5992	1183
5992	1188
5992	1218
5992	1232
5992	1233
5995	1183
5995	1188
5995	1218
5995	1232
5995	1233
5998	1183
5998	1188
5998	1200
5998	1205
5998	1218
5999	1188
5999	1232
5999	1233
5999	45134
5999	45238
6000	1183
6000	1188
6000	1218
6000	1232
6000	1233
6001	1183
6001	1188
6001	1203
6001	1218
6001	1232
6002	1183
6002	1188
6002	1198
6002	1206
6002	1210
6003	1183
6003	1194
6003	1198
6003	1204
6003	1218
6004	1183
6004	1194
6004	1203
6004	1218
6004	1232
6005	1183
6005	1188
6005	1218
6005	1232
6005	1233
6007	1183
6007	1188
6007	1200
6007	1206
6007	1218
6007	1229
6007	1232
6007	45181
6008	1183
6008	1188
6008	1206
6008	1218
6008	1229
6010	1183
6010	1188
6010	1198
6010	1206
6010	1218
6011	1183
6011	1188
6011	1218
6011	1232
6011	1233
6012	1183
6012	1188
6012	1217
6012	1232
6012	1233
6013	1188
6013	1205
6013	1218
6013	1232
6013	45238
6014	1183
6014	1188
6014	1200
6014	1206
6014	1218
6015	1183
6015	1188
6015	1206
6015	1218
6015	1229
6016	1183
6016	1188
6016	1200
6016	1206
6016	1218
6019	1183
6019	1194
6019	1218
6019	1232
6019	1233
6020	1183
6020	1188
6020	1218
6020	1232
6020	1233
6021	1188
6021	1206
6021	1209
6021	1232
6021	45236
6025	1183
6025	1188
6025	1206
6025	1218
6025	1229
6027	1183
6027	1188
6027	1200
6027	1206
6027	1218
6028	1183
6028	1188
6028	1206
6028	1218
6028	1232
6030	1183
6030	1188
6030	1206
6030	1218
6030	1229
6031	1183
6031	1194
6031	1198
6031	1206
6031	1218
6034	1188
6034	1218
6034	1232
6034	1233
6034	45238
6035	1195
6035	1218
6035	1232
6035	1233
6035	45238
6037	1188
6037	1218
6037	1232
6037	1233
6037	45238
6042	1179
6042	1188
6042	1197
6042	1201
6042	1218
6048	1183
6048	1194
6048	1206
6048	1218
6048	1229
6050	1183
6050	1194
6050	1198
6050	1206
6050	1218
6052	1179
6052	1188
6052	1197
6052	1201
6052	1218
6053	1183
6053	1188
6053	1206
6053	1218
6053	1229
6056	1183
6056	1194
6056	1206
6056	1218
6056	1229
6057	1183
6057	1188
6057	1206
6057	1218
6057	1229
6058	1183
6058	1188
6058	1199
6058	1206
6058	1218
6060	1183
6060	1188
6060	1206
6060	1232
6060	45181
6061	1183
6061	1194
6061	1198
6061	1206
6061	1218
6062	1183
6062	1194
6062	1206
6062	1218
6062	1229
6064	1183
6064	1188
6064	1198
6064	1206
6064	1218
6065	1183
6065	1188
6065	1204
6065	1218
6065	1229
6067	1183
6067	1188
6067	1218
6067	1232
6067	1233
6069	1183
6069	1188
6069	1218
6069	1232
6069	1233
6074	1183
6074	1194
6074	1206
6074	1218
6074	1229
6075	1188
6075	1206
6075	1218
6075	1229
6075	45238
6079	1183
6079	1188
6079	1206
6079	1218
6079	1229
6080	1183
6080	1188
6080	1206
6080	1218
6080	1229
6081	1183
6081	1188
6081	1206
6081	1218
6081	1229
6082	1183
6082	1188
6082	1206
6082	1218
6082	1229
6085	1179
6085	1188
6085	1197
6085	1201
6085	1218
6087	1183
6087	1188
6087	1198
6087	1206
6087	1218
6089	1183
6089	1188
6089	1206
6089	1218
6089	1229
6091	1183
6091	1188
6091	1204
6091	1218
6091	1232
6093	1183
6093	1188
6093	1232
6093	1233
6093	44971
6094	1183
6094	1194
6094	1200
6094	1206
6094	1218
6097	1188
6097	1206
6097	1218
6097	1232
6097	45238
6099	1183
6099	1188
6099	1200
6099	1206
6099	1218
6100	1183
6100	1188
6100	1206
6100	1218
6100	1232
6104	1183
6104	1188
6104	1206
6104	1218
6104	1229
6107	1183
6107	1194
6107	1200
6107	1206
6107	1218
6108	1183
6108	1188
6108	1218
6108	1232
6108	1233
6109	1183
6109	1188
6109	1198
6109	1206
6109	1220
6110	1183
6110	1194
6110	1206
6110	1218
6110	1229
6112	1188
6112	1206
6112	1220
6112	1229
6112	45238
6117	1183
6117	1188
6117	1198
6117	1206
6117	1218
6118	1183
6118	1188
6118	1200
6118	1206
6118	1217
6118	1218
6119	1183
6119	1194
6119	1200
6119	1205
6119	1218
6122	1183
6122	1194
6122	1206
6122	1218
6122	1229
6124	1188
6124	1218
6124	1229
6124	1233
6124	45236
6127	1183
6127	1198
6127	1206
6127	1218
6127	1239
6128	1188
6128	1198
6128	1206
6128	1210
6128	45236
6129	1183
6129	1188
6129	1218
6129	1232
6129	1233
6133	1183
6133	1188
6133	1206
6133	1218
6133	1229
6134	1183
6134	1188
6134	1200
6134	1206
6134	1218
6136	1195
6136	1200
6136	1206
6136	1218
6136	45238
6137	1183
6137	1188
6137	1200
6137	1206
6137	1218
6138	1183
6138	1188
6138	1206
6138	1220
6138	1229
6141	1188
6141	1209
6141	1232
6141	1233
6141	45236
6142	1183
6142	1188
6142	1218
6142	1232
6142	1233
6146	1188
6146	1200
6146	1206
6146	1246
6146	45236
6151	1188
6151	1232
6151	1233
6151	45134
6151	45236
6152	1183
6152	1188
6152	1206
6152	1218
6152	1229
6154	1183
6154	1188
6154	1206
6154	1221
6154	1229
6155	1183
6155	1194
6155	1198
6155	1206
6155	1218
6158	1183
6158	1188
6158	1206
6158	1220
6158	1229
6160	1183
6160	1188
6160	1218
6160	1232
6160	1233
6162	1183
6162	1196
6162	1200
6162	1206
6162	1218
6164	1183
6164	1188
6164	1198
6164	1206
6164	1218
6165	1183
6165	1188
6165	1194
6165	1198
6165	1206
6165	1218
6165	1229
6165	1233
6166	1188
6166	1218
6166	1232
6166	1233
6166	45238
6168	1188
6168	1206
6168	1218
6168	1229
6168	45238
6172	1183
6172	1196
6172	1198
6172	1206
6172	1210
6173	1183
6173	1188
6173	1218
6173	1232
6173	1233
6174	1183
6174	1188
6174	1217
6174	1232
6174	1233
6175	1183
6175	1188
6175	1217
6175	1232
6175	1233
6176	1183
6176	1188
6176	1218
6176	1232
6176	1233
6183	1183
6183	1188
6183	1206
6183	1220
6183	1229
6184	1183
6184	1188
6184	1206
6184	1218
6184	1229
6185	1183
6185	1188
6185	1198
6185	1206
6185	1218
6188	1183
6188	1188
6188	1198
6188	1206
6188	1218
6189	1188
6189	1203
6189	1218
6189	1232
6189	45238
6190	1183
6190	1194
6190	1218
6190	1232
6190	1233
6191	1183
6191	1188
6191	1206
6191	1232
6191	44983
6193	1183
6193	1188
6193	1218
6193	1232
6193	1233
6194	1183
6194	1188
6194	1206
6194	1218
6194	1229
6195	1183
6195	1188
6195	1218
6195	1232
6195	1233
6198	1183
6198	1188
6198	1206
6198	1218
6198	1229
6200	1188
6200	1232
6200	1233
6200	45183
6200	45238
6201	1183
6201	1194
6201	1200
6201	1206
6201	1277
6203	1183
6203	1188
6203	1206
6203	1219
6203	1229
6206	1183
6206	1188
6206	1206
6206	1218
6206	1229
6208	1183
6208	1188
6208	1206
6208	1218
6208	1232
6209	1183
6209	1188
6209	1206
6209	1218
6209	1232
6217	1188
6217	1218
6217	1232
6217	1233
6217	45238
6219	1183
6219	1188
6219	1218
6219	1232
6219	1233
6220	1183
6220	1194
6220	1200
6220	1206
6220	1218
6221	1183
6221	1188
6221	1206
6221	1218
6221	1229
6222	1183
6222	1188
6222	1200
6222	1206
6222	1218
6223	1183
6223	1188
6223	1206
6223	1218
6223	1229
6224	1183
6224	1188
6224	1218
6224	1232
6224	1233
6225	1188
6225	1206
6225	1213
6225	1229
6225	45238
6226	1183
6226	1188
6226	1200
6226	1206
6226	1218
6229	1183
6229	1188
6229	1206
6229	1218
6229	1229
6230	1183
6230	1188
6230	1206
6230	1218
6230	1229
6232	1183
6232	1194
6232	1206
6232	1218
6232	1229
6233	1183
6233	1188
6233	1218
6233	1232
6233	1233
6234	1183
6234	1188
6234	1218
6234	1232
6234	1233
6236	1183
6236	1196
6236	1206
6236	1222
6236	1229
6242	1183
6242	1188
6242	1198
6242	1218
6242	1233
6245	1183
6245	1188
6245	1200
6245	1206
6245	1218
6246	1188
6246	1206
6246	1218
6246	1229
6246	45238
6254	1183
6254	1188
6254	1198
6254	1206
6254	1218
6255	1183
6255	1188
6255	1206
6255	1218
6255	1229
6256	1183
6256	1198
6256	1206
6256	1218
6256	1239
6259	1183
6259	1194
6259	1198
6259	1205
6259	1218
6260	1183
6260	1188
6260	1200
6260	1206
6260	1218
6261	1183
6261	1188
6261	1198
6261	1206
6261	1209
6261	45548
6263	1183
6263	1188
6263	1218
6263	1232
6263	1233
6264	1183
6264	1188
6264	1198
6264	1206
6264	1218
6266	1183
6266	1188
6266	1200
6266	1206
6266	1218
6267	1183
6267	1188
6267	1200
6267	1206
6267	1218
6268	1183
6268	1188
6268	1194
6268	1200
6268	1206
6268	1218
6269	1183
6269	1188
6269	1206
6269	1218
6269	1229
6270	1179
6270	1188
6270	1197
6270	1201
6270	45546
6273	1183
6273	1188
6273	1198
6273	1206
6273	1218
6274	1183
6274	1194
6274	1198
6274	1206
6274	1218
6279	1183
6279	1188
6279	1206
6279	1218
6279	1229
6283	1188
6283	1206
6283	1218
6283	1229
6283	45238
6285	1183
6285	1188
6285	1200
6285	1206
6285	1218
6293	1183
6293	1188
6293	1206
6293	1209
6293	1229
6296	1183
6296	1196
6296	1198
6296	1206
6296	1210
6297	1183
6297	1194
6297	1198
6297	1206
6297	1218
6299	1183
6299	1188
6299	1200
6299	1206
6299	1218
6300	1183
6300	1188
6300	1198
6300	1206
6300	1218
6301	1183
6301	1194
6301	1200
6301	1206
6301	1218
6302	1179
6302	1188
6302	1197
6302	1201
6302	1218
6303	1183
6303	1188
6303	1200
6303	1206
6303	1218
6304	1183
6304	1188
6304	1206
6304	1218
6304	1229
6306	1179
6306	1188
6306	1197
6306	1201
6306	1218
6307	1183
6307	1188
6307	1206
6307	1218
6307	1229
6308	1183
6308	1188
6308	1200
6308	1206
6308	1218
6310	1183
6310	1188
6310	1206
6310	1218
6310	1229
6311	1183
6311	1188
6311	1200
6311	1206
6311	1218
6312	1183
6312	1188
6312	1206
6312	1218
6312	1229
6313	1179
6313	1188
6313	1197
6313	1201
6313	1218
6314	1183
6314	1188
6314	1218
6314	1232
6314	1233
6315	1183
6315	1188
6315	1198
6315	1206
6315	1218
6316	1183
6316	1194
6316	1218
6316	1232
6316	1233
6317	1183
6317	1188
6317	1218
6317	1232
6317	1233
6318	1183
6318	1192
6318	1200
6318	1206
6318	1218
6319	1183
6319	1188
6319	1206
6319	1218
6319	1229
6320	1183
6320	1188
6320	1203
6320	1218
6320	1232
6321	1183
6321	1188
6321	1218
6321	1232
6321	1233
6322	1183
6322	1188
6322	1200
6322	1206
6322	1218
6326	1183
6326	1188
6326	1198
6326	1206
6326	1218
6327	1183
6327	1188
6327	1206
6327	1218
6327	1229
6332	1183
6332	1188
6332	1206
6332	1218
6332	1229
6333	1188
6333	1198
6333	1206
6333	1211
6333	45238
6334	1183
6334	1188
6334	1206
6334	1218
6334	1229
6335	1183
6335	1188
6335	1206
6335	1218
6335	1229
6336	1188
6336	1198
6336	1206
6336	1218
6336	45238
6337	1183
6337	1188
6337	1206
6337	1218
6337	1229
6340	1183
6340	1188
6340	1198
6340	1206
6340	1218
6341	1183
6341	1188
6341	1200
6341	1206
6341	1218
6344	1183
6344	1194
6344	1206
6344	1218
6344	1229
6347	1183
6347	1188
6347	1218
6347	1232
6347	1233
6349	1183
6349	1194
6349	1206
6349	1218
6349	1229
6350	1183
6350	1203
6350	1218
6350	1232
6350	1239
6351	1188
6351	1218
6351	1232
6351	1233
6351	45238
6352	1183
6352	1188
6352	1218
6352	1232
6352	1233
6353	1183
6353	1188
6353	1200
6353	1206
6353	1218
6354	1183
6354	1188
6354	1206
6354	1218
6354	1229
6355	1183
6355	1188
6355	1198
6355	1206
6355	1218
6356	1183
6356	1188
6356	1206
6356	1218
6356	1229
6357	1183
6357	1188
6357	1206
6357	1218
6357	1229
6358	1183
6358	1188
6358	1206
6358	1218
6358	1229
6360	1183
6360	1188
6360	1198
6360	1206
6360	1210
6362	1183
6362	1194
6362	1198
6362	1206
6362	1243
6364	1183
6364	1188
6364	1206
6364	1218
6364	1229
6366	1183
6366	1188
6366	1200
6366	1206
6366	1218
6367	1183
6367	1188
6367	1218
6367	1232
6367	1233
6368	1183
6368	1188
6368	1206
6368	1218
6368	1229
6369	1183
6369	1194
6369	1200
6369	1206
6369	1218
6370	1183
6370	1194
6370	1200
6370	1206
6370	1218
6371	1183
6371	1194
6371	1206
6371	1218
6371	1229
6374	1183
6374	1188
6374	1205
6374	1218
6374	1232
6375	1188
6375	1218
6375	1232
6375	1233
6375	45238
6379	1183
6379	1188
6379	1206
6379	1218
6379	1229
6381	1183
6381	1188
6381	1206
6381	1218
6381	1229
6382	1183
6382	1188
6382	1206
6382	1218
6382	1229
6384	1183
6384	1188
6384	1198
6384	1206
6384	1218
6386	1195
6386	1200
6386	1206
6386	1220
6386	45238
6387	1183
6387	1188
6387	1200
6387	1206
6387	1218
6388	1183
6388	1188
6388	1206
6388	1218
6388	1229
6389	1183
6389	1188
6389	1198
6389	1206
6389	1218
6391	1188
6391	1206
6391	1218
6391	1232
6391	45238
6392	1183
6392	1194
6392	1206
6392	1218
6392	1229
6394	1188
6394	1200
6394	1206
6394	1218
6394	45238
6395	1183
6395	1188
6395	1198
6395	1206
6395	1218
6396	1188
6396	1206
6396	1218
6396	1229
6396	45238
6397	1183
6397	1188
6397	1204
6397	1218
6397	1232
6397	1233
6397	1249
6402	1183
6402	1188
6402	1218
6402	1232
6402	1233
6404	1183
6404	1188
6404	1218
6404	1232
6404	1233
6407	1183
6407	1188
6407	1198
6407	1204
6407	45575
6408	1183
6408	1188
6408	1206
6408	1218
6408	1232
6411	1183
6411	1196
6411	1218
6411	1232
6411	1233
6412	1183
6412	1188
6412	1200
6412	1206
6412	1218
6415	1183
6415	1188
6415	1198
6415	1218
6415	1233
6416	1183
6416	1188
6416	1206
6416	1218
6416	1229
6417	1183
6417	1188
6417	1203
6417	1218
6417	1232
6419	1188
6419	1206
6419	1218
6419	1229
6419	45238
6420	1188
6420	1200
6420	1206
6420	1218
6420	45238
6421	1183
6421	1188
6421	1198
6421	1206
6421	1218
6422	1183
6422	1188
6422	1198
6422	1218
6422	1233
6424	1183
6424	1194
6424	1218
6424	1232
6424	1233
6426	1183
6426	1188
6426	1206
6426	1218
6426	1229
6431	1183
6431	1188
6431	1206
6431	1218
6431	1229
6432	1183
6432	1188
6432	1206
6432	1218
6432	1229
6433	1183
6433	1188
6433	1198
6433	1206
6433	1218
6434	1183
6434	1188
6434	1217
6434	1232
6434	1233
6437	1183
6437	1188
6437	1218
6437	1220
6437	1232
6437	1233
6438	1183
6438	1188
6438	1198
6438	1206
6438	1218
6441	1183
6441	1188
6441	1206
6441	1218
6441	1229
6442	1183
6442	1188
6442	1217
6442	1232
6442	1233
6445	1183
6445	1188
6445	1218
6445	1232
6445	1233
6446	1183
6446	1188
6446	1204
6446	1218
6446	1232
6448	1183
6448	1188
6448	1206
6448	1218
6448	1232
6449	1183
6449	1188
6449	1198
6449	1206
6449	1218
6454	1183
6454	1188
6454	1218
6454	1232
6454	1233
6458	1188
6458	1218
6458	1232
6458	1233
6458	45238
6463	1183
6463	1194
6463	1206
6463	1218
6463	1229
6464	1183
6464	1188
6464	1218
6464	1232
6464	1233
6465	1183
6465	1188
6465	1206
6465	1218
6465	1229
6471	1183
6471	1188
6471	1218
6471	1232
6471	1233
6474	1188
6474	1206
6474	1218
6474	1229
6474	45238
6475	1183
6475	1188
6475	1218
6475	1232
6475	1233
6478	1183
6478	1188
6478	1204
6478	1218
6478	1232
6479	1183
6479	1188
6479	1206
6479	1218
6479	1229
6484	1188
6484	1206
6484	1218
6484	1229
6484	45238
6485	1183
6485	1188
6485	1203
6485	1218
6485	1232
6486	1183
6486	1194
6486	1200
6486	1206
6486	1218
6488	1183
6488	1194
6488	1218
6488	1232
6488	1233
6491	1183
6491	1188
6491	1206
6491	1218
6491	1229
6492	1183
6492	1188
6492	1205
6492	1218
6492	1229
6494	1183
6494	1188
6494	1200
6494	1206
6494	1218
6497	1183
6497	1188
6497	1206
6497	1218
6497	1232
6498	1183
6498	1188
6498	1206
6498	1218
6498	1229
6499	1183
6499	1188
6499	1206
6499	1218
6499	1229
6501	1188
6501	1206
6501	1218
6501	1229
6501	45238
6502	1188
6502	1198
6502	1206
6502	1218
6502	45236
6504	1183
6504	1188
6504	1206
6504	1218
6504	1232
6505	1183
6505	1188
6505	1200
6505	1206
6505	1217
6506	1188
6506	1206
6506	1220
6506	1229
6506	45238
6507	1188
6507	1206
6507	1229
6507	45238
6507	45637
6509	1183
6509	1188
6509	1218
6509	1232
6509	1233
6510	1183
6510	1188
6510	1206
6510	1209
6510	1232
6513	1183
6513	1188
6513	1200
6513	1206
6513	1218
6514	1183
6514	1188
6514	1206
6514	1218
6514	1229
6516	1183
6516	1188
6516	1198
6516	1206
6516	1218
6518	1183
6518	1188
6518	1198
6518	1206
6518	1218
6519	1183
6519	1188
6519	1206
6519	1218
6519	1229
6520	1183
6520	1188
6520	1206
6520	1218
6520	1229
6521	1183
6521	1188
6521	1206
6521	1218
6521	1229
6522	1183
6522	1188
6522	1206
6522	1218
6522	1229
6523	1183
6523	1188
6523	1206
6523	1218
6523	1229
6524	1183
6524	1188
6524	1198
6524	1206
6524	1218
6525	1183
6525	1188
6525	1206
6525	1218
6525	1229
6526	1183
6526	1188
6526	1206
6526	1213
6526	1229
6527	1183
6527	1188
6527	1206
6527	1218
6527	1229
6528	1183
6528	1188
6528	1206
6528	1218
6528	1229
6529	1183
6529	1188
6529	1206
6529	1218
6529	1229
6530	1183
6530	1188
6530	1206
6530	1218
6530	1229
6531	1183
6531	1188
6531	1206
6531	1218
6531	1229
6532	1183
6532	1188
6532	1200
6532	1206
6532	1218
6533	1183
6533	1188
6533	1206
6533	1218
6533	1229
6534	1183
6534	1188
6534	1206
6534	1218
6534	1229
6535	1183
6535	1188
6535	1206
6535	1218
6535	1229
6536	1183
6536	1188
6536	1206
6536	1218
6536	1229
6537	1183
6537	1188
6537	1206
6537	1218
6537	1229
6538	1183
6538	1188
6538	1206
6538	1218
6538	1229
6539	1183
6539	1188
6539	1206
6539	1218
6539	1229
6540	1183
6540	1188
6540	1200
6540	1206
6540	1218
6541	1183
6541	1188
6541	1206
6541	1218
6541	1229
6543	1183
6543	1188
6543	1198
6543	1206
6543	1218
6544	1183
6544	1188
6544	1198
6544	1206
6544	1218
6545	1183
6545	1188
6545	1198
6545	1206
6545	1218
6546	1183
6546	1188
6546	1198
6546	1206
6546	1218
6547	1183
6547	1188
6547	1206
6547	1218
6547	1229
6548	1183
6548	1188
6548	1206
6548	1218
6548	1229
6549	1183
6549	1188
6549	1206
6549	1218
6549	1229
6550	1183
6550	1188
6550	1198
6550	1206
6550	1218
6551	1183
6551	1188
6551	1206
6551	1218
6551	1229
6552	1183
6552	1188
6552	1206
6552	1218
6552	1229
6553	1183
6553	1188
6553	1206
6553	1218
6553	1229
6554	1183
6554	1188
6554	1206
6554	1218
6554	1232
6555	1183
6555	1188
6555	1206
6555	1218
6555	1232
6556	1183
6556	1188
6556	1198
6556	1206
6556	1218
6558	1183
6558	1188
6558	1206
6558	1218
6558	1229
6559	1183
6559	1188
6559	1206
6559	1218
6559	1229
6560	1183
6560	1188
6560	1206
6560	1218
6560	1229
6561	1183
6561	1188
6561	1206
6561	1218
6561	1229
6562	1183
6562	1188
6562	1206
6562	1218
6562	1229
6563	1183
6563	1188
6563	1198
6563	1206
6563	1218
6565	1183
6565	1188
6565	1206
6565	1218
6565	1229
6566	1188
6566	1206
6566	1218
6566	1229
6566	45238
6567	1183
6567	1188
6567	1200
6567	1206
6567	1218
6568	1183
6568	1188
6568	1206
6568	1218
6568	1229
6569	1183
6569	1188
6569	1206
6569	1218
6569	1229
6572	1188
6572	1198
6572	1206
6572	1218
6572	45238
6573	1183
6573	1194
6573	1198
6573	1204
6573	1218
6574	1183
6574	1188
6574	1206
6574	1218
6574	1229
6575	1188
6575	1200
6575	1206
6575	1218
6575	45238
6578	1183
6578	1188
6578	1206
6578	1218
6578	1229
6579	1183
6579	1188
6579	1205
6579	1218
6579	1232
6580	1188
6580	1198
6580	1206
6580	1210
6580	45236
6581	1183
6581	1188
6581	1200
6581	1206
6581	1218
6584	1183
6584	1188
6584	1206
6584	1221
6584	1229
6585	1183
6585	1188
6585	1200
6585	1206
6585	1218
6586	1183
6586	1194
6586	1218
6586	1232
6586	1233
6587	1183
6587	1188
6587	1200
6587	1206
6587	1218
6588	1183
6588	1194
6588	1200
6588	1206
6588	1218
6592	1188
6592	1205
6592	1218
6592	1238
6592	45238
6593	1183
6593	1188
6593	1204
6593	1218
6593	1232
6596	1183
6596	1188
6596	1232
6596	1233
6596	45399
6599	1183
6599	1188
6599	1204
6599	1218
6599	1232
6600	1188
6600	1200
6600	1206
6600	1218
6600	45238
6601	1183
6601	1188
6601	1206
6601	1218
6601	1229
6602	1183
6602	1188
6602	1205
6602	1218
6602	1232
6603	1188
6603	1198
6603	1206
6603	1218
6603	45238
6604	1188
6604	1203
6604	1218
6604	1238
6604	45236
6606	1188
6606	1203
6606	1218
6606	1232
6606	45238
6607	1183
6607	1188
6607	1204
6607	1218
6607	1232
6608	1188
6608	1204
6608	1218
6608	1232
6608	45238
6609	1183
6609	1188
6609	1205
6609	1218
6609	1232
6611	1188
6611	1198
6611	1210
6611	1233
6611	45236
6613	1183
6613	1188
6613	1200
6613	1206
6613	1218
6614	1183
6614	1188
6614	1217
6614	1232
6614	1233
6615	1183
6615	1188
6615	1206
6615	1218
6615	1229
6616	1183
6616	1188
6616	1222
6616	1232
6616	1233
6618	1188
6618	1206
6618	1219
6618	1229
6618	45238
6620	1183
6620	1188
6620	1200
6620	1206
6620	1218
6622	1183
6622	1204
6622	1218
6622	1232
6622	1239
6623	1188
6623	1210
6623	1232
6623	1233
6623	45238
6626	1183
6626	1188
6626	1206
6626	1229
6626	1261
6628	1183
6628	1188
6628	1200
6628	1206
6628	1218
6629	1188
6629	1200
6629	1206
6629	1218
6629	45238
6630	1178
6630	1188
6630	1197
6630	1201
6630	1277
6632	1183
6632	1194
6632	1200
6632	1206
6632	1218
6635	1188
6635	1218
6635	1232
6635	1233
6635	45238
6636	1183
6636	1188
6636	1218
6636	1232
6636	1233
6637	1183
6637	1188
6637	1213
6637	1232
6637	1233
6638	1183
6638	1188
6638	1206
6638	1222
6638	1229
6640	1183
6640	1188
6640	1198
6640	1206
6640	1218
6642	1183
6642	1188
6642	1198
6642	1206
6642	1218
6643	1183
6643	1188
6643	1206
6643	1218
6643	1229
6644	1183
6644	1194
6644	1206
6644	1218
6644	1232
6648	1183
6648	1196
6648	1198
6648	1206
6648	1210
6649	1183
6649	1188
6649	1200
6649	1206
6649	1218
6650	1183
6650	1188
6650	1198
6650	1206
6650	1218
6655	1183
6655	1188
6655	1198
6655	1206
6655	1218
6656	1183
6656	1188
6656	1218
6656	1232
6656	1233
6658	1183
6658	1194
6658	1218
6658	1232
6658	1233
6660	1183
6660	1188
6660	1206
6660	1218
6660	1229
6661	1183
6661	1188
6661	1203
6661	1218
6661	1232
6662	1183
6662	1188
6662	1198
6662	1206
6662	1218
6663	1183
6663	1188
6663	1222
6663	1232
6663	1233
6664	1183
6664	1188
6664	1206
6664	1218
6664	1232
6665	1183
6665	1194
6665	1200
6665	1206
6665	1218
6666	1183
6666	1194
6666	1218
6666	1229
6666	1233
6667	1183
6667	1188
6667	1218
6667	1232
6667	1233
6673	1183
6673	1196
6673	1200
6673	1206
6673	1218
6675	1183
6675	1188
6675	1206
6675	1220
6675	1229
6676	1183
6676	1188
6676	1200
6676	1206
6676	1218
6677	1188
6677	1200
6677	1206
6677	1213
6677	45238
6678	1183
6678	1194
6678	1218
6678	1232
6678	1233
6684	1183
6684	1188
6684	1200
6684	1206
6684	1218
6685	1183
6685	1188
6685	1206
6685	1218
6685	1232
6687	1188
6687	1218
6687	1232
6687	1233
6687	45238
6689	1188
6689	1206
6689	1218
6689	1229
6689	45238
6691	1183
6691	1188
6691	1204
6691	1218
6691	1232
6692	1183
6692	1188
6692	1206
6692	1218
6692	1229
6693	1183
6693	1188
6693	1218
6693	1232
6693	1233
6694	1183
6694	1188
6694	1200
6694	1206
6694	1218
6695	1183
6695	1194
6695	1200
6695	1206
6695	1218
6698	1183
6698	1188
6698	1218
6698	1232
6698	1233
6700	1183
6700	1196
6700	1200
6700	1206
6700	1218
6704	1183
6704	1188
6704	1200
6704	1206
6704	1218
6705	1183
6705	1188
6705	1200
6705	1206
6705	1218
6708	1188
6708	1220
6708	1232
6708	1233
6708	45238
6710	1188
6710	1218
6710	1232
6710	1233
6710	45238
6714	1183
6714	1188
6714	1206
6714	1219
6714	1229
6715	1183
6715	1188
6715	1198
6715	1206
6715	1218
6717	1188
6717	1198
6717	1206
6717	1218
6717	45238
6719	1183
6719	1194
6719	1206
6719	1218
6719	1229
6720	1183
6720	1188
6720	1216
6720	1232
6720	1233
6721	1183
6721	1194
6721	1206
6721	1218
6721	1229
6723	1183
6723	1188
6723	1198
6723	1206
6723	1218
6724	1183
6724	1196
6724	1198
6724	1206
6724	1218
6726	1188
6726	1198
6726	1210
6726	1233
6726	45236
6728	1183
6728	1188
6728	1200
6728	1206
6728	1218
6729	1183
6729	1188
6729	1206
6729	1218
6729	1229
6730	1183
6730	1188
6730	1204
6730	1222
6730	1232
6731	1183
6731	1188
6731	1204
6731	1211
6731	1232
6733	1183
6733	1188
6733	1218
6733	1232
6733	1233
6736	1183
6736	1198
6736	1206
6736	1218
6736	1239
6737	1183
6737	1188
6737	1204
6737	1218
6737	1232
6739	1183
6739	1188
6739	1200
6739	1206
6739	1217
6740	1183
6740	1188
6740	1206
6740	1218
6740	1229
6743	1188
6743	1206
6743	1218
6743	1229
6743	45238
6748	1183
6748	1188
6748	1206
6748	1218
6748	1229
6751	1183
6751	1188
6751	1206
6751	1218
6751	1229
6752	1183
6752	1194
6752	1200
6752	1206
6752	1218
6753	1183
6753	1194
6753	1218
6753	1232
6753	1233
6754	1183
6754	1188
6754	1206
6754	1221
6754	1229
6755	1183
6755	1188
6755	1232
6755	1233
6755	45134
6756	1183
6756	1188
6756	1206
6756	1220
6756	1229
6757	1183
6757	1188
6757	1218
6757	1232
6757	1233
6758	1183
6758	1188
6758	1200
6758	1206
6758	1218
6759	1183
6759	1188
6759	1206
6759	1218
6759	1229
6763	1188
6763	1203
6763	1218
6763	1232
6763	45238
6764	1183
6764	1188
6764	1198
6764	1206
6764	1218
6765	1183
6765	1188
6765	1198
6765	1233
6765	45194
6768	1183
6768	1188
6768	1206
6768	1218
6768	1229
6769	1183
6769	1188
6769	1206
6769	1218
6769	1229
6770	1183
6770	1188
6770	1204
6770	1218
6770	1232
6772	1183
6772	1188
6772	1218
6772	1232
6772	1233
6773	1183
6773	1188
6773	1206
6773	1218
6773	1229
6774	1183
6774	1188
6774	1218
6774	1232
6774	1233
6775	1183
6775	1188
6775	1218
6775	1232
6775	1233
6779	1183
6779	1188
6779	1206
6779	1218
6779	1229
6780	1183
6780	1188
6780	1198
6780	1206
6780	1218
6781	1183
6781	1188
6781	1198
6781	1206
6781	1218
6782	1183
6782	1191
6782	1200
6782	1206
6782	1218
6783	1188
6783	1198
6783	1206
6783	1218
6783	45236
6784	1183
6784	1188
6784	1206
6784	1218
6784	1232
6784	1233
6785	1188
6785	1198
6785	1218
6785	1233
6785	45236
6787	1183
6787	1193
6787	1206
6787	1218
6787	1229
6788	1188
6788	1206
6788	1218
6788	1229
6788	45238
6790	1183
6790	1188
6790	1198
6790	1206
6790	1209
6790	45548
6791	1183
6791	1188
6791	1204
6791	1222
6791	1232
6792	1183
6792	1188
6792	1205
6792	1218
6792	1232
6795	1183
6795	1194
6795	1200
6795	1206
6795	1218
6798	1188
6798	1218
6798	1232
6798	1233
6798	45238
6799	1183
6799	1194
6799	1200
6799	1206
6799	1218
6800	1188
6800	1206
6800	1218
6800	1229
6800	45236
6803	1188
6803	1206
6803	1218
6803	1229
6803	45238
6805	1183
6805	1188
6805	1206
6805	1218
6805	1229
6806	1183
6806	1188
6806	1206
6806	1218
6806	1229
6807	1183
6807	1188
6807	1206
6807	1218
6807	1229
6809	1183
6809	1188
6809	1206
6809	1218
6809	1229
6809	1232
6809	1233
6809	45238
6813	1183
6813	1194
6813	1198
6813	1206
6813	1218
6814	1188
6814	1200
6814	1206
6814	1218
6814	45238
6815	1183
6815	1188
6815	1206
6815	1218
6815	1229
6816	1183
6816	1188
6816	1206
6816	1218
6816	1229
6819	1195
6819	1218
6819	1232
6819	1233
6819	45238
6820	1188
6820	1200
6820	1206
6820	1218
6820	45238
6821	1183
6821	1194
6821	1206
6821	1218
6821	1229
6823	1183
6823	1194
6823	1206
6823	1218
6823	1229
6824	1188
6824	1204
6824	1218
6824	1232
6824	45238
6825	1183
6825	1188
6825	1218
6825	1232
6825	1233
6827	1183
6827	1188
6827	1206
6827	1218
6827	1229
6833	1183
6833	1193
6833	1200
6833	1206
6833	1218
6834	1183
6834	1188
6834	1206
6834	1218
6834	1232
6835	1183
6835	1194
6835	1218
6835	1232
6835	1233
6836	1188
6836	1218
6836	1232
6836	1233
6836	45238
6837	1188
6837	1206
6837	1218
6837	1229
6837	45238
6838	1183
6838	1188
6838	1206
6838	1210
6838	1229
6839	1183
6839	1188
6839	1203
6839	1218
6839	1229
6840	1183
6840	1188
6840	1206
6840	1218
6840	1232
6842	1188
6842	1204
6842	1218
6842	1232
6842	45238
6843	1188
6843	1218
6843	1232
6843	1233
6843	45238
6844	1188
6844	1218
6844	1232
6844	1233
6844	45238
6845	1183
6845	1188
6845	1206
6845	1218
6845	1229
6846	1183
6846	1188
6846	1199
6846	1204
6846	1218
6847	1188
6847	1198
6847	1206
6847	1218
6847	45238
6848	1183
6848	1196
6848	1218
6848	1232
6848	1233
6849	1182
6849	1188
6849	1198
6849	1206
6849	1218
6850	1183
6850	1188
6850	1200
6850	1206
6850	1218
6851	1183
6851	1196
6851	1218
6851	1232
6851	1233
6852	1195
6852	1200
6852	1206
6852	1218
6852	45238
6853	1183
6853	1194
6853	1200
6853	1206
6853	1218
6854	1188
6854	1229
6854	1233
6854	1246
6854	45236
6855	1183
6855	1188
6855	1198
6855	1206
6855	1221
6856	1183
6856	1188
6856	1206
6856	1218
6856	1229
6858	1183
6858	1194
6858	1206
6858	1218
6858	1229
6859	1183
6859	1188
6859	1200
6859	1206
6859	45377
6863	1183
6863	1188
6863	1200
6863	1206
6863	1218
6866	1188
6866	1218
6866	1232
6866	1233
6866	45238
6867	1183
6867	1188
6867	1206
6867	1218
6867	1229
6868	1188
6868	1218
6868	1232
6868	1233
6868	45238
6869	1183
6869	1188
6869	1218
6869	1232
6869	1233
6870	1188
6870	1218
6870	1232
6870	1233
6870	45238
6871	1188
6871	1218
6871	1232
6871	1233
6871	45238
6872	1183
6872	1188
6872	1218
6872	1232
6872	1233
6873	1183
6873	1188
6873	1218
6873	1232
6873	1233
6875	1188
6875	1232
6875	1233
6875	45238
6875	45549
6876	1183
6876	1188
6876	1218
6876	1232
6876	1233
6877	1188
6877	1218
6877	1232
6877	1233
6877	45238
6878	1183
6878	1188
6878	1218
6878	1232
6878	1233
6879	1183
6879	1194
6879	1206
6879	1218
6879	1229
6882	1188
6882	1206
6882	1218
6882	1232
6882	45238
6883	1188
6883	1198
6883	1206
6883	1218
6883	45238
6884	1183
6884	1194
6884	1206
6884	1218
6884	1229
6885	1183
6885	1188
6885	1200
6885	1206
6885	1218
6889	1183
6889	1188
6889	1218
6889	1232
6889	1233
6891	1183
6891	1188
6891	1200
6891	1206
6891	1218
6892	1183
6892	1188
6892	1213
6892	1232
6892	1233
6893	1183
6893	1188
6893	1206
6893	1218
6893	1229
6894	1188
6894	1218
6894	1232
6894	1233
6894	45238
6898	1188
6898	1206
6898	1218
6898	1229
6898	45238
6899	1188
6899	1218
6899	1232
6899	1233
6899	45238
6900	1183
6900	1194
6900	1218
6900	1232
6900	1233
6901	1183
6901	1188
6901	1198
6901	1206
6901	1211
6902	1183
6902	1188
6902	1218
6902	1232
6902	1233
6903	1183
6903	1188
6903	1198
6903	1206
6903	1218
6904	1188
6904	1218
6904	1232
6904	1233
6904	45238
6906	1183
6906	1194
6906	1200
6906	1206
6906	1218
6907	1183
6907	1188
6907	1206
6907	1218
6907	1229
6908	1183
6908	1188
6908	1218
6908	1232
6908	1233
6909	1183
6909	1188
6909	1200
6909	1206
6909	1218
6910	1183
6910	1188
6910	1206
6910	1220
6910	1229
6912	1183
6912	1188
6912	1206
6912	1218
6912	1229
6915	1183
6915	1188
6915	1206
6915	1218
6915	1229
6917	1183
6917	1188
6917	1198
6917	1206
6917	1218
6918	1183
6918	1188
6918	1198
6918	1206
6918	1218
6919	1183
6919	1188
6919	1198
6919	1206
6919	1218
6921	1183
6921	1188
6921	1198
6921	1206
6921	1218
6923	1183
6923	1188
6923	1206
6923	1217
6923	1229
6924	1183
6924	1188
6924	1198
6924	1206
6924	1218
6925	1188
6925	1218
6925	1232
6925	1233
6925	45238
6928	1183
6928	1188
6928	1218
6928	1232
6928	1233
6929	1188
6929	1198
6929	1206
6929	1213
6929	45236
6930	1183
6930	1188
6930	1218
6930	1232
6930	1233
6931	1183
6931	1188
6931	1198
6931	1206
6931	1218
6932	1183
6932	1188
6932	1206
6932	1220
6932	1229
6933	1183
6933	1188
6933	1206
6933	1218
6933	1229
6936	1188
6936	1218
6936	1232
6936	1233
6936	45238
6937	1183
6937	1188
6937	1206
6937	1218
6937	1229
6938	1188
6938	1206
6938	1229
6938	1246
6938	45238
6940	1183
6940	1194
6940	1200
6940	1218
6940	1233
6941	1183
6941	1194
6941	1206
6941	1218
6941	1229
6942	1183
6942	1188
6942	1200
6942	1206
6942	1218
6943	1183
6943	1188
6943	1206
6943	1218
6943	1229
6944	1183
6944	1194
6944	1206
6944	1221
6944	1229
6945	1188
6945	1198
6945	1206
6945	1218
6945	45236
6946	1183
6946	1191
6946	1200
6946	1206
6946	45450
6947	1183
6947	1188
6947	1198
6947	1206
6947	1218
6948	1183
6948	1188
6948	1206
6948	1229
6948	1246
6949	1179
6949	1188
6949	1197
6949	1201
6949	1218
6950	1183
6950	1188
6950	1218
6950	1232
6950	1233
6951	1188
6951	1200
6951	1206
6951	1218
6951	45238
6953	1183
6953	1188
6953	1200
6953	1206
6953	1218
6954	1188
6954	1218
6954	1232
6954	1233
6954	45238
6955	1188
6955	1206
6955	1218
6955	1229
6955	45238
6956	1183
6956	1188
6956	1200
6956	1206
6956	1218
6959	1188
6959	1218
6959	1232
6959	1233
6959	45236
6961	1183
6961	1198
6961	1206
6961	1218
6961	1239
6965	1183
6965	1188
6965	1206
6965	1218
6965	1229
6968	1183
6968	1188
6968	1200
6968	1206
6968	1218
6971	1183
6971	1188
6971	1218
6971	1232
6971	1233
6973	1183
6973	1188
6973	1218
6973	1232
6973	1233
6980	1183
6980	1188
6980	1218
6980	1232
6980	1233
6981	1188
6981	1203
6981	1218
6981	1232
6981	45238
6985	1183
6985	1194
6985	1206
6985	1218
6985	1229
6986	1183
6986	1188
6986	1218
6986	1232
6986	1233
6988	1183
6988	1188
6988	1206
6988	1218
6988	1232
6989	1183
6989	1194
6989	1198
6989	1206
6989	1218
6990	1183
6990	1194
6990	1200
6990	1206
6990	1218
6993	1183
6993	1188
6993	1198
6993	1206
6993	1218
6995	1183
6995	1194
6995	1200
6995	1206
6995	1218
6996	1183
6996	1188
6996	1198
6996	1206
6996	1218
6996	1229
6996	1232
6996	1233
6997	1183
6997	1194
6997	1206
6997	1218
6997	1229
6998	1188
6998	1198
6998	1204
6998	1218
6998	45238
6999	1183
6999	1194
6999	1206
6999	1218
6999	1229
7000	1183
7000	1194
7000	1218
7000	1232
7000	1233
7001	1183
7001	1188
7001	1218
7001	1232
7001	1233
7002	1188
7002	1204
7002	1218
7002	1232
7002	45238
7004	1183
7004	1188
7004	1206
7004	1218
7004	1229
7005	1183
7005	1188
7005	1218
7005	1232
7005	1233
7007	1183
7007	1188
7007	1200
7007	1206
7007	1246
7008	1183
7008	1194
7008	1200
7008	1206
7008	1218
7009	1180
7009	1188
7009	1197
7009	1201
7009	1218
7010	1183
7010	1188
7010	1200
7010	1206
7010	1218
7012	1183
7012	1194
7012	1232
7012	1233
7012	45543
7015	1183
7015	1193
7015	1200
7015	1204
7015	1218
7019	1183
7019	1194
7019	1198
7019	1204
7019	1218
7021	1183
7021	1188
7021	1198
7021	1206
7021	1218
7022	1188
7022	1218
7022	1232
7022	1233
7022	45238
7024	1183
7024	1194
7024	1218
7024	1232
7024	1233
7025	1183
7025	1194
7025	1218
7025	1232
7025	1233
7026	1183
7026	1194
7026	1206
7026	1218
7026	1229
7027	1183
7027	1194
7027	1218
7027	1232
7027	1233
7028	1183
7028	1194
7028	1198
7028	1206
7028	1210
7030	1183
7030	1188
7030	1206
7030	1218
7030	1229
7032	1183
7032	1188
7032	1206
7032	1218
7032	1229
7033	1183
7033	1188
7033	1217
7033	1232
7033	1233
7034	1183
7034	1194
7034	1218
7034	1232
7034	1233
7036	1183
7036	1194
7036	1218
7036	1232
7036	1233
7037	1183
7037	1194
7037	1200
7037	1206
7037	1218
7038	1183
7038	1188
7038	1206
7038	1218
7038	1229
7040	1183
7040	1188
7040	1220
7040	1232
7040	1233
7043	1183
7043	1188
7043	1218
7043	1232
7043	1233
7044	1183
7044	1188
7044	1205
7044	1218
7044	1232
7046	1183
7046	1188
7046	1204
7046	1218
7046	1232
7047	1183
7047	1188
7047	1206
7047	1218
7047	1229
7049	1183
7049	1194
7049	1198
7049	1206
7049	1218
7050	1183
7050	1188
7050	1232
7050	1233
7050	45134
7052	1183
7052	1194
7052	1206
7052	1222
7052	1229
7052	1232
7052	1233
7053	1183
7053	1188
7053	1218
7053	1232
7053	1233
7054	1188
7054	1218
7054	1232
7054	1233
7054	45238
7055	1188
7055	1218
7055	1232
7055	1233
7055	45238
7056	1183
7056	1188
7056	1206
7056	1218
7056	1229
7059	1188
7059	1220
7059	1232
7059	1233
7059	45238
7068	1183
7068	1188
7068	1218
7068	1232
7068	1233
7069	1183
7069	1188
7069	1204
7069	1222
7069	1232
7070	1183
7070	1188
7070	1204
7070	1218
7070	1232
7071	1183
7071	1188
7071	1200
7071	1206
7071	1218
7072	1183
7072	1188
7072	1218
7072	1232
7072	1233
7075	1183
7075	1188
7075	1200
7075	1206
7075	1217
7075	1218
7076	1183
7076	1194
7076	1206
7076	1218
7076	1229
7077	1183
7077	1196
7077	1200
7077	1206
7077	1218
7078	1183
7078	1196
7078	1198
7078	1206
7078	1218
7079	1183
7079	1188
7079	1218
7079	1232
7079	1233
7081	1183
7081	1188
7081	1200
7081	1206
7081	1246
7082	1183
7082	1188
7082	1206
7082	1218
7082	1229
7083	1183
7083	1188
7083	1203
7083	1218
7083	1232
7086	1183
7086	1188
7086	1206
7086	1218
7086	1229
7088	1183
7088	1188
7088	1200
7088	1206
7088	1218
7089	1188
7089	1218
7089	1232
7089	1233
7089	45238
7090	1183
7090	1194
7090	1218
7090	1232
7090	1233
7091	1183
7091	1188
7091	1200
7091	1206
7091	45543
7092	1183
7092	1188
7092	1198
7092	1206
7092	1218
7093	1183
7093	1198
7093	1206
7093	1218
7093	1239
7095	1188
7095	1206
7095	1220
7095	1229
7095	45238
7097	1182
7097	1195
7097	1218
7097	1232
7097	1233
7098	1183
7098	1188
7098	1198
7098	1206
7098	1218
7099	1183
7099	1188
7099	1218
7099	1232
7099	1233
7101	1183
7101	1188
7101	1198
7101	1206
7101	1218
7101	1232
7102	1183
7102	1194
7102	1200
7102	1206
7102	1218
7103	1183
7103	1188
7103	1206
7103	1211
7103	1229
7104	1183
7104	1193
7104	1198
7104	1206
7104	1218
7106	1195
7106	1198
7106	1206
7106	1218
7106	45236
7107	1183
7107	1194
7107	1206
7107	1218
7107	1229
7108	1183
7108	1194
7108	1206
7108	1218
7108	1229
7109	1183
7109	1196
7109	1200
7109	1206
7109	1209
7109	1213
7109	1220
7110	1183
7110	1188
7110	1206
7110	1218
7110	1229
7112	1183
7112	1188
7112	1200
7112	1206
7112	1218
7113	1183
7113	1194
7113	1198
7113	1206
7113	1218
7115	1183
7115	1188
7115	1200
7115	1206
7115	1218
7116	1183
7116	1194
7116	1198
7116	1206
7116	1218
7117	1183
7117	1188
7117	1206
7117	1218
7117	1229
7118	1188
7118	1218
7118	1232
7118	1233
7118	45238
7119	1183
7119	1188
7119	1206
7119	1220
7119	1229
7120	1183
7120	1188
7120	1218
7120	1232
7120	1233
7122	1183
7122	1188
7122	1206
7122	1218
7122	1229
7123	1188
7123	1198
7123	1206
7123	1218
7123	45238
7124	1188
7124	1206
7124	1218
7124	1229
7124	45238
7125	1183
7125	1188
7125	1206
7125	1218
7125	1229
7126	1183
7126	1188
7126	1206
7126	1218
7126	1229
7128	1183
7128	1194
7128	1206
7128	1222
7128	1229
7128	44971
7131	1183
7131	1194
7131	1206
7131	1218
7131	1229
7133	1183
7133	1194
7133	1206
7133	1218
7133	1229
7134	1183
7134	1188
7134	1218
7134	1232
7134	1233
7135	1183
7135	1188
7135	1198
7135	1233
7135	45548
7136	1183
7136	1188
7136	1205
7136	1218
7136	1232
7137	1183
7137	1188
7137	1206
7137	1218
7137	1229
7139	1183
7139	1188
7139	1199
7139	1204
7139	1218
7140	1183
7140	1188
7140	1198
7140	1206
7140	1218
7142	1183
7142	1188
7142	1218
7142	1232
7142	1233
7144	1183
7144	1188
7144	1218
7144	1232
7144	1233
7145	1183
7145	1188
7145	1198
7145	1206
7145	1218
7147	1183
7147	1188
7147	1206
7147	1218
7147	1229
7148	1183
7148	1188
7148	1206
7148	1222
7148	1232
7149	1183
7149	1193
7149	1206
7149	1216
7149	1229
7150	1183
7150	1188
7150	1218
7150	1232
7150	1233
7152	1183
7152	1188
7152	1200
7152	1206
7152	1218
7153	1183
7153	1194
7153	1206
7153	1218
7153	1229
7154	1183
7154	1194
7154	1200
7154	1206
7154	1218
7156	1183
7156	1188
7156	1200
7156	1206
7156	1218
7157	1183
7157	1194
7157	1204
7157	1217
7157	1232
7158	1183
7158	1194
7158	1204
7158	1218
7158	1232
7159	1180
7159	1188
7159	1197
7159	1201
7159	1218
7160	1183
7160	1188
7160	1198
7160	1209
7160	1233
7160	45548
7161	1183
7161	1198
7161	1233
7161	1239
7161	45562
7165	1183
7165	1188
7165	1198
7165	1206
7165	1218
7166	1183
7166	1188
7166	1218
7166	1232
7166	1233
7167	1183
7167	1188
7167	1200
7167	1206
7167	1218
7168	1183
7168	1196
7168	1198
7168	1233
7168	45337
7169	1183
7169	1188
7169	1218
7169	1232
7169	1233
7170	1183
7170	1188
7170	1206
7170	1220
7170	1229
7171	1183
7171	1188
7171	1206
7171	1218
7171	1232
7173	1183
7173	1196
7173	1199
7173	1205
7173	1218
7177	1183
7177	1194
7177	1198
7177	1206
7177	1218
7179	1183
7179	1188
7179	1206
7179	1218
7179	1229
7181	1183
7181	1194
7181	1206
7181	1220
7181	1229
7182	1183
7182	1194
7182	1198
7182	1206
7182	1218
7183	1183
7183	1188
7183	1194
7183	1196
7183	1198
7183	1206
7183	1218
7183	1229
7183	1232
7184	1183
7184	1188
7184	1206
7184	1218
7184	1229
7187	1183
7187	1188
7187	1206
7187	1229
7187	45438
7188	1183
7188	1188
7188	1205
7188	1218
7188	1232
7189	1183
7189	1194
7189	1206
7189	1218
7189	1229
7190	1183
7190	1188
7190	1198
7190	1206
7190	1218
7191	1183
7191	1194
7191	1200
7191	1206
7191	1218
7192	1183
7192	1188
7192	1206
7192	1218
7192	1229
7194	1183
7194	1194
7194	1198
7194	1204
7194	1218
7195	1183
7195	1194
7195	1198
7195	1206
7195	45548
7196	1183
7196	1188
7196	1205
7196	1218
7196	1232
7198	1183
7198	1188
7198	1198
7198	1206
7198	1219
7199	1183
7199	1191
7199	1204
7199	1218
7199	1232
7200	1188
7200	1198
7200	1206
7200	1210
7200	45236
7201	1183
7201	1188
7201	1198
7201	1210
7201	1233
7203	1183
7203	1188
7203	1200
7203	1206
7203	1218
7204	1183
7204	1188
7204	1218
7204	1232
7204	1233
7205	1183
7205	1218
7205	1232
7205	1233
7205	1239
7207	1179
7207	1188
7207	1197
7207	1201
7207	1218
7208	1179
7208	1188
7208	1197
7208	1201
7208	1218
7209	1179
7209	1188
7209	1197
7209	1201
7209	1218
7210	1179
7210	1188
7210	1197
7210	1201
7210	1218
7211	1179
7211	1188
7211	1197
7211	1201
7211	1218
7212	1183
7212	1188
7212	1206
7212	1218
7212	1229
7213	1183
7213	1188
7213	1206
7213	1218
7213	1229
7214	1183
7214	1188
7214	1206
7214	1218
7214	1229
7215	1183
7215	1188
7215	1206
7215	1218
7215	1229
7216	1183
7216	1188
7216	1206
7216	1218
7216	1229
7217	1183
7217	1188
7217	1206
7217	1218
7217	1229
7218	1183
7218	1188
7218	1206
7218	1218
7218	1229
7219	1183
7219	1188
7219	1206
7219	1218
7219	1229
7220	1183
7220	1188
7220	1206
7220	1218
7220	1229
7221	1183
7221	1188
7221	1206
7221	1218
7221	1232
7222	1183
7222	1188
7222	1200
7222	1206
7222	1220
7224	1183
7224	1188
7224	1206
7224	1218
7224	1232
7228	1183
7228	1194
7228	1198
7228	1206
7228	1218
7229	1183
7229	1188
7229	1198
7229	1206
7229	1218
7230	1183
7230	1194
7230	1206
7230	1218
7230	1229
7234	1183
7234	1188
7234	1200
7234	1206
7234	1218
7235	1183
7235	1188
7235	1200
7235	1206
7235	1218
7236	1183
7236	1196
7236	1206
7236	1218
7236	1229
7237	1188
7237	1198
7237	1204
7237	1218
7237	45236
7238	1183
7238	1188
7238	1198
7238	1206
7238	1218
7239	1178
7239	1188
7239	1197
7239	1201
7239	1218
7240	1183
7240	1194
7240	1206
7240	1218
7240	1229
7241	1188
7241	1206
7241	1218
7241	1229
7241	45238
7242	1183
7242	1188
7242	1217
7242	1232
7242	1233
7243	1183
7243	1188
7243	1206
7243	1218
7243	1229
7244	1188
7244	1206
7244	1218
7244	1229
7244	45238
7245	1183
7245	1188
7245	1198
7245	1206
7245	1218
7246	1183
7246	1188
7246	1206
7246	1218
7246	1229
7247	1188
7247	1200
7247	1206
7247	1218
7247	45238
7248	1188
7248	1200
7248	1206
7248	1218
7248	45238
7250	1188
7250	1200
7250	1206
7250	1218
7250	45238
7257	1183
7257	1194
7257	1218
7257	1232
7257	1233
7258	1183
7258	1188
7258	1218
7258	1232
7258	1233
7261	1183
7261	1188
7261	1206
7261	1218
7261	1229
7262	1183
7262	1188
7262	1206
7262	1222
7262	1232
7263	1183
7263	1194
7263	1206
7263	1218
7263	1229
7264	1183
7264	1188
7264	1200
7264	1206
7264	1220
7265	1183
7265	1188
7265	1198
7265	1206
7265	1209
7266	1183
7266	1188
7266	1198
7266	1206
7266	1209
7267	1188
7267	1218
7267	1232
7267	1233
7267	45238
7268	1183
7268	1188
7268	1206
7268	1220
7268	1229
7269	1188
7269	1206
7269	1218
7269	1229
7269	45236
7270	1188
7270	1206
7270	1218
7270	1229
7270	45236
7271	1188
7271	1206
7271	1218
7271	1229
7271	45238
7272	1188
7272	1206
7272	1220
7272	1229
7272	45238
7273	1183
7273	1193
7273	1200
7273	1206
7273	1218
7275	1183
7275	1194
7275	1206
7275	1216
7275	1218
7275	1229
7276	1183
7276	1188
7276	1200
7276	1206
7276	45337
7277	1183
7277	1199
7277	1204
7277	1218
7277	1239
7278	1183
7278	1188
7278	1200
7278	1206
7278	1218
7279	1188
7279	1198
7279	1206
7279	1218
7279	45236
7280	1183
7280	1188
7280	1218
7280	1232
7280	1233
7282	1183
7282	1194
7282	1218
7282	1232
7282	1233
7283	1183
7283	1194
7283	1200
7283	1206
7283	1218
7285	1179
7285	1188
7285	1197
7285	1201
7285	1218
7287	1183
7287	1194
7287	1206
7287	1218
7287	1232
7289	1188
7289	1206
7289	1220
7289	1229
7289	45238
7290	1183
7290	1188
7290	1206
7290	1218
7290	1232
7291	1183
7291	1188
7291	1200
7291	1206
7291	44970
7292	1183
7292	1188
7292	1206
7292	1218
7292	1229
7293	1188
7293	1206
7293	1218
7293	1232
7293	45238
7294	1183
7294	1188
7294	1205
7294	1217
7294	1232
7295	1183
7295	1188
7295	1198
7295	1218
7295	1233
7296	1183
7296	1188
7296	1206
7296	1220
7296	1232
7297	1183
7297	1188
7297	1206
7297	1218
7297	1232
7298	1183
7298	1188
7298	1206
7298	1218
7298	1232
7299	1183
7299	1188
7299	1218
7299	1232
7299	1233
7300	1183
7300	1204
7300	1218
7300	1232
7300	1239
7301	1183
7301	1204
7301	1218
7301	1232
7301	1239
7303	1188
7303	1204
7303	1218
7303	1232
7303	45236
7304	1183
7304	1188
7304	1205
7304	1218
7304	1232
7306	1183
7306	1188
7306	1204
7306	1218
7306	1232
7307	1183
7307	1194
7307	1205
7307	1218
7307	1232
7309	1183
7309	1188
7309	1218
7309	1232
7309	1233
7310	1183
7310	1194
7310	1218
7310	1232
7310	1233
7311	1179
7311	1188
7311	1197
7311	1201
7311	1218
7312	1179
7312	1188
7312	1197
7312	1201
7312	1218
7313	1179
7313	1188
7313	1197
7313	1201
7313	1218
7314	1179
7314	1188
7314	1197
7314	1201
7314	1218
7315	1183
7315	1188
7315	1204
7315	1218
7315	1232
7316	1183
7316	1188
7316	1206
7316	1218
7316	1229
7317	1183
7317	1188
7317	1198
7317	1206
7317	1218
7319	1183
7319	1188
7319	1200
7319	1206
7319	1218
7320	1183
7320	1188
7320	1206
7320	1218
7320	1229
7322	1183
7322	1188
7322	1200
7322	1206
7322	1218
7325	1183
7325	1194
7325	1198
7325	1204
7325	1218
7327	1183
7327	1188
7327	1206
7327	1232
7327	1261
7328	1188
7328	1205
7328	1218
7328	1229
7328	45236
7329	1183
7329	1194
7329	1218
7329	1232
7329	1233
7330	1183
7330	1188
7330	1200
7330	1206
7330	45337
7331	1183
7331	1193
7331	1198
7331	1206
7331	1218
7332	1183
7332	1188
7332	1218
7332	1232
7332	1233
7333	1183
7333	1188
7333	1205
7333	1218
7333	1232
7335	1183
7335	1188
7335	1200
7335	1206
7335	1218
7336	1183
7336	1188
7336	1218
7336	1232
7336	1233
7337	1183
7337	1204
7337	1218
7337	1232
7337	1239
7339	1183
7339	1188
7339	1206
7339	1218
7339	1232
7340	1183
7340	1188
7340	1218
7340	1232
7340	1233
7341	1183
7341	1188
7341	1206
7341	1218
7341	1232
7342	1183
7342	1188
7342	1218
7342	1229
7342	1233
7343	1183
7343	1188
7343	1205
7343	1218
7343	1232
7344	1183
7344	1188
7344	1206
7344	1218
7344	1232
7345	1183
7345	1188
7345	1206
7345	1221
7345	1232
7346	1183
7346	1188
7346	1206
7346	1218
7346	1232
7347	1183
7347	1191
7347	1204
7347	1218
7347	1232
7348	1183
7348	1188
7348	1206
7348	1218
7348	1232
7349	1183
7349	1188
7349	1206
7349	1217
7349	1232
7350	1183
7350	1188
7350	1217
7350	1232
7350	1233
7351	1183
7351	1188
7351	1218
7351	1232
7351	1233
7352	1183
7352	1188
7352	1206
7352	1217
7352	1229
7353	1183
7353	1188
7353	1198
7353	1206
7353	1218
7355	1183
7355	1188
7355	1198
7355	1204
7355	44968
7356	1183
7356	1188
7356	1206
7356	1218
7356	1232
7357	1183
7357	1188
7357	1206
7357	1218
7357	1229
7358	1183
7358	1188
7358	1218
7358	1232
7358	1233
7359	1183
7359	1188
7359	1198
7359	1204
7359	1218
7360	1183
7360	1188
7360	1205
7360	1218
7360	1232
7361	1183
7361	1188
7361	1218
7361	1232
7361	1233
7362	1183
7362	1188
7362	1218
7362	1232
7362	1233
7363	1183
7363	1188
7363	1206
7363	1218
7363	1229
7364	1183
7364	1188
7364	1206
7364	1218
7364	1232
7365	1183
7365	1188
7365	1206
7365	1221
7365	1232
7366	1183
7366	1188
7366	1218
7366	1232
7366	1233
7367	1183
7367	1188
7367	1204
7367	1232
7367	44983
7368	1183
7368	1188
7368	1206
7368	1232
7368	44983
7369	1183
7369	1188
7369	1204
7369	1232
7369	44983
7371	1183
7371	1188
7371	1206
7371	1218
7371	1229
7372	1183
7372	1188
7372	1206
7372	1218
7372	1229
7373	1183
7373	1188
7373	1206
7373	1218
7373	1229
7374	1183
7374	1188
7374	1207
7374	1218
7374	1232
7376	1183
7376	1188
7376	1206
7376	1218
7376	1232
7377	1183
7377	1188
7377	1206
7377	1218
7377	1232
7379	1183
7379	1188
7379	1206
7379	1218
7379	1232
7380	1183
7380	1188
7380	1232
7380	1233
7380	44970
7381	1183
7381	1188
7381	1206
7381	1218
7381	1232
7382	1183
7382	1188
7382	1198
7382	1204
7382	1218
7383	1183
7383	1188
7383	1206
7383	1218
7383	1232
7384	1183
7384	1188
7384	1206
7384	1218
7384	1232
7385	1183
7385	1188
7385	1206
7385	1232
7385	44971
7386	1183
7386	1188
7386	1206
7386	1218
7386	1229
7387	1183
7387	1188
7387	1206
7387	1221
7387	1232
7388	1183
7388	1188
7388	1206
7388	1218
7388	1232
7389	1183
7389	1206
7389	1218
7389	1232
7389	1239
7390	1183
7390	1188
7390	1206
7390	1218
7390	1232
7391	1183
7391	1188
7391	1206
7391	1218
7391	1232
7392	1183
7392	1188
7392	1206
7392	1213
7392	1232
7393	1183
7393	1188
7393	1206
7393	1218
7393	1232
7396	1183
7396	1188
7396	1218
7396	1232
7396	1233
7397	1183
7397	1188
7397	1206
7397	1218
7397	1232
7399	1183
7399	1188
7399	1206
7399	1217
7399	1232
7400	1183
7400	1188
7400	1218
7400	1232
7400	1233
7401	1183
7401	1188
7401	1206
7401	1232
7401	45181
7402	1183
7402	1188
7402	1199
7402	1204
7402	1218
7403	1183
7403	1188
7403	1206
7403	1218
7403	1232
7404	1183
7404	1188
7404	1206
7404	1218
7404	1232
7405	1183
7405	1188
7405	1206
7405	1218
7405	1232
7406	1183
7406	1188
7406	1218
7406	1232
7406	1233
7407	1183
7407	1188
7407	1200
7407	1206
7407	1277
7408	1183
7408	1194
7408	1198
7408	1206
7408	1218
7409	1183
7409	1194
7409	1206
7409	1232
7409	45181
7410	1183
7410	1188
7410	1232
7410	1233
7410	45543
7411	1183
7411	1188
7411	1204
7411	1218
7411	1232
7412	1183
7412	1188
7412	1206
7412	1218
7412	1232
7413	1183
7413	1188
7413	1206
7413	1218
7413	1232
7414	1183
7414	1206
7414	1218
7414	1232
7414	1239
7415	1183
7415	1188
7415	1206
7415	1211
7415	1232
7416	1183
7416	1188
7416	1206
7416	1218
7416	1232
7417	1188
7417	1206
7417	1211
7417	1232
7417	45238
7420	1183
7420	1188
7420	1218
7420	1232
7420	1233
7422	1183
7422	1188
7422	1216
7422	1232
7422	1233
7424	1183
7424	1188
7424	1198
7424	1206
7424	1218
7426	1188
7426	1198
7426	1218
7426	1233
7426	45238
7428	1183
7428	1188
7428	1206
7428	1221
7428	1229
7429	1183
7429	1194
7429	1206
7429	1232
7429	44971
7430	1183
7430	1188
7430	1220
7430	1232
7430	1233
7431	1188
7431	1206
7431	1220
7431	1232
7431	45238
7433	1183
7433	1188
7433	1204
7433	1232
7433	44971
7434	1183
7434	1188
7434	1206
7434	1232
7434	1277
7435	1183
7435	1188
7435	1206
7435	1218
7435	1232
7436	1183
7436	1188
7436	1217
7436	1232
7436	1233
7437	1183
7437	1188
7437	1206
7437	1218
7437	1232
7438	1183
7438	1191
7438	1206
7438	1221
7438	1232
7438	1262
7439	1183
7439	1188
7439	1206
7439	1218
7439	1232
7440	1183
7440	1188
7440	1206
7440	1218
7440	1232
7441	1183
7441	1188
7441	1206
7441	1218
7441	1232
7442	1183
7442	1188
7442	1198
7442	1204
7442	1218
7443	1183
7443	1188
7443	1206
7443	1218
7443	1232
7444	1183
7444	1188
7444	1206
7444	1218
7444	1232
7445	1183
7445	1188
7445	1206
7445	1218
7445	1232
7446	1183
7446	1188
7446	1204
7446	1232
7446	1239
7446	44971
7447	1183
7447	1188
7447	1206
7447	1218
7447	1232
7448	1183
7448	1188
7448	1205
7448	1213
7448	1232
7449	1183
7449	1188
7449	1205
7449	1232
7449	44992
7450	1183
7450	1188
7450	1194
7450	1200
7450	1206
7450	1218
7450	1232
7450	1233
7451	1183
7451	1188
7451	1218
7451	1232
7451	1233
7452	1183
7452	1191
7452	1218
7452	1232
7452	1233
7453	1183
7453	1194
7453	1198
7453	1206
7453	1218
7454	1183
7454	1188
7454	1206
7454	1218
7454	1232
7455	1183
7455	1188
7455	1206
7455	1217
7455	1229
7457	1183
7457	1194
7457	1200
7457	1206
7457	1218
7458	1183
7458	1188
7458	1218
7458	1232
7458	1233
7459	1188
7459	1198
7459	1206
7459	45238
7459	45548
7460	1183
7460	1188
7460	1218
7460	1232
7460	1233
7461	1183
7461	1188
7461	1206
7461	1218
7461	1229
7464	1183
7464	1188
7464	1218
7464	1232
7464	1233
7465	1183
7465	1188
7465	1200
7465	1204
7465	1218
7466	1183
7466	1188
7466	1200
7466	1204
7466	1218
7467	1183
7467	1188
7467	1200
7467	1204
7467	1218
7469	1183
7469	1194
7469	1200
7469	1206
7469	1222
7469	1229
7469	1232
7469	1233
7470	1183
7470	1188
7470	1200
7470	1206
7470	1218
7473	1183
7473	1194
7473	1200
7473	1206
7473	1218
7474	1183
7474	1188
7474	1200
7474	1206
7474	1218
7477	1183
7477	1194
7477	1200
7477	1206
7477	1218
7478	1183
7478	1188
7478	1217
7478	1232
7478	1233
7479	1183
7479	1194
7479	1200
7479	1206
7479	1218
7480	1183
7480	1192
7480	1200
7480	1206
7480	1218
7481	1183
7481	1188
7481	1200
7481	1206
7481	1218
7483	1183
7483	1194
7483	1200
7483	1206
7483	1218
7485	1183
7485	1194
7485	1218
7485	1232
7485	1233
7486	1183
7486	1194
7486	1200
7486	1206
7486	1217
7488	1183
7488	1188
7488	1206
7488	1218
7488	1232
7490	1183
7490	1188
7490	1206
7490	1229
7490	44974
7491	1183
7491	1188
7491	1218
7491	1232
7491	1233
7492	1183
7492	1188
7492	1206
7492	1217
7492	1232
7493	1183
7493	1188
7493	1206
7493	1218
7493	1232
7494	1183
7494	1188
7494	1204
7494	1218
7494	1232
7495	1183
7495	1188
7495	1206
7495	1218
7495	1232
7496	1183
7496	1188
7496	1206
7496	1218
7496	1229
7497	1183
7497	1188
7497	1218
7497	1232
7497	1233
7498	1183
7498	1188
7498	1206
7498	1221
7498	1232
7500	1183
7500	1188
7500	1206
7500	1232
7500	44974
7501	1183
7501	1188
7501	1218
7501	1232
7501	1233
7502	1183
7502	1188
7502	1218
7502	1232
7502	1233
7503	1183
7503	1188
7503	1218
7503	1232
7503	1233
7504	1183
7504	1188
7504	1232
7504	1233
7504	1262
7505	1183
7505	1188
7505	1206
7505	1218
7505	1229
7506	1183
7506	1188
7506	1206
7506	1218
7506	1232
7507	1183
7507	1188
7507	1218
7507	1232
7507	1233
7508	1183
7508	1188
7508	1206
7508	1218
7508	1232
7509	1183
7509	1188
7509	1204
7509	1218
7509	1232
7510	1183
7510	1188
7510	1204
7510	1218
7510	1232
7511	1183
7511	1188
7511	1206
7511	1232
7511	44970
7512	1183
7512	1188
7512	1198
7512	1206
7512	1218
7513	1183
7513	1188
7513	1206
7513	1218
7513	1232
7514	1183
7514	1188
7514	1204
7514	1218
7514	1232
7515	1183
7515	1188
7515	1198
7515	1206
7515	1218
7516	1183
7516	1188
7516	1206
7516	1218
7516	1232
7517	1183
7517	1188
7517	1204
7517	1218
7517	1232
7518	1183
7518	1188
7518	1206
7518	1218
7518	1232
7519	1183
7519	1188
7519	1206
7519	1217
7519	1232
7520	1183
7520	1188
7520	1206
7520	1218
7520	1229
7521	1183
7521	1188
7521	1206
7521	1218
7521	1232
7522	1183
7522	1188
7522	1206
7522	1218
7522	1232
7523	1183
7523	1188
7523	1206
7523	1218
7523	1232
7524	1183
7524	1188
7524	1206
7524	1218
7524	1232
7526	1183
7526	1188
7526	1206
7526	1218
7526	1232
7527	1183
7527	1188
7527	1206
7527	1217
7527	1232
7530	1183
7530	1188
7530	1205
7530	1218
7530	1232
7531	1183
7531	1188
7531	1198
7531	1217
7531	1233
7532	1183
7532	1188
7532	1198
7532	1204
7532	1217
7535	1183
7535	1188
7535	1205
7535	1218
7535	1232
7536	1183
7536	1188
7536	1218
7536	1232
7536	1233
7537	1183
7537	1188
7537	1205
7537	1218
7537	1232
7538	1183
7538	1188
7538	1206
7538	1232
7538	1262
7539	1183
7539	1188
7539	1218
7539	1229
7539	1233
7540	1183
7540	1188
7540	1206
7540	1213
7540	1232
7541	1183
7541	1188
7541	1206
7541	1218
7541	1229
7542	1183
7542	1188
7542	1204
7542	1218
7542	1232
7543	1183
7543	1188
7543	1204
7543	1213
7543	1232
7544	1183
7544	1188
7544	1204
7544	1213
7544	1232
7545	1183
7545	1188
7545	1206
7545	1218
7545	1232
7546	1183
7546	1188
7546	1206
7546	1213
7546	1232
7547	1183
7547	1188
7547	1206
7547	1232
7547	44971
7548	1180
7548	1192
7548	1197
7548	1201
7548	45045
7549	1183
7549	1188
7549	1218
7549	1232
7549	1233
7550	1183
7550	1198
7550	1205
7550	1218
7550	1239
7551	1183
7551	1188
7551	1204
7551	1218
7551	1229
7552	1183
7552	1188
7552	1200
7552	1206
7552	1218
7552	1232
7553	1183
7553	1188
7553	1206
7553	1218
7553	1232
7554	1183
7554	1188
7554	1205
7554	1218
7554	1232
7555	1183
7555	1188
7555	1205
7555	1218
7555	1232
7556	1183
7556	1188
7556	1198
7556	1205
7556	1218
7557	1183
7557	1188
7557	1198
7557	1205
7557	1218
7558	1183
7558	1188
7558	1205
7558	1218
7558	1232
7559	1183
7559	1188
7559	1205
7559	1217
7559	1232
7560	1183
7560	1188
7560	1204
7560	1218
7560	1229
7562	1183
7562	1188
7562	1205
7562	1218
7562	1232
7565	1183
7565	1188
7565	1204
7565	1217
7565	1232
7566	1183
7566	1198
7566	1206
7566	1239
7566	44977
7567	1183
7567	1188
7567	1198
7567	1218
7567	1233
7568	1183
7568	1194
7568	1218
7568	1232
7568	1233
7569	1183
7569	1188
7569	1198
7569	1204
7569	1218
7570	1183
7570	1188
7570	1206
7570	1218
7570	1232
7571	1183
7571	1188
7571	1206
7571	1232
7571	1261
7572	1183
7572	1188
7572	1217
7572	1232
7572	1233
7573	1183
7573	1188
7573	1198
7573	1204
7573	44971
7576	1183
7576	1188
7576	1205
7576	1218
7576	1229
7577	1183
7577	1188
7577	1205
7577	1221
7577	1232
7579	1183
7579	1188
7579	1232
7579	1233
7579	44968
7580	1183
7580	1188
7580	1206
7580	1218
7580	1232
7581	1183
7581	1188
7581	1198
7581	1205
7581	1218
7582	1183
7582	1188
7582	1206
7582	1217
7582	1232
7583	1183
7583	1188
7583	1198
7583	1206
7583	1217
7584	1183
7584	1191
7584	1206
7584	1218
7584	1232
7585	1183
7585	1188
7585	1206
7585	1218
7585	1232
7586	1183
7586	1188
7586	1206
7586	1218
7586	1229
7587	1183
7587	1188
7587	1206
7587	1218
7587	1232
7588	1183
7588	1188
7588	1206
7588	1218
7588	1232
7589	1183
7589	1188
7589	1206
7589	1218
7589	1229
7590	1183
7590	1194
7590	1198
7590	1206
7590	1210
7594	1183
7594	1188
7594	1206
7594	1217
7594	1232
7595	1188
7595	1206
7595	1218
7595	1232
7595	45238
7598	1188
7598	1206
7598	1218
7598	1232
7598	45238
7600	1188
7600	1218
7600	1232
7600	1233
7600	45238
7601	1188
7601	1218
7601	1232
7601	1233
7601	45238
7602	1183
7602	1188
7602	1205
7602	1232
7602	44979
7604	1183
7604	1188
7604	1218
7604	1232
7604	1233
7606	1183
7606	1188
7606	1218
7606	1232
7606	1233
7607	1188
7607	1205
7607	1218
7607	1232
7607	45238
7609	1188
7609	1204
7609	1218
7609	1232
7609	45238
7610	1188
7610	1218
7610	1232
7610	1233
7610	45238
7612	1183
7612	1188
7612	1206
7612	1218
7612	1232
7613	1183
7613	1188
7613	1206
7613	1218
7613	1229
7614	1183
7614	1188
7614	1206
7614	1218
7614	1229
7618	1183
7618	1188
7618	1205
7618	1229
7618	1243
7619	1183
7619	1188
7619	1206
7619	1232
7619	44971
7621	1183
7621	1188
7621	1198
7621	1205
7621	1218
7623	1183
7623	1188
7623	1206
7623	1218
7623	1232
7626	1183
7626	1191
7626	1232
7626	1233
7626	44971
7628	1183
7628	1188
7628	1204
7628	1218
7628	1232
7632	1183
7632	1188
7632	1204
7632	1218
7632	1232
7633	1183
7633	1188
7633	1206
7633	1218
7633	1229
7633	1232
7633	1233
7634	1183
7634	1188
7634	1198
7634	1205
7634	1218
7635	1183
7635	1191
7635	1218
7635	1232
7635	1233
7640	1183
7640	1188
7640	1198
7640	1204
7640	1218
7644	1183
7644	1188
7644	1205
7644	1218
7644	1232
7645	1183
7645	1188
7645	1206
7645	1232
7645	1277
7646	1183
7646	1188
7646	1206
7646	1218
7646	1232
7650	1183
7650	1188
7650	1206
7650	1218
7650	1232
7654	1183
7654	1188
7654	1206
7654	1218
7654	1232
7656	1183
7656	1188
7656	1218
7656	1232
7656	1233
7658	1183
7658	1188
7658	1218
7658	1229
7658	1233
7661	1183
7661	1188
7661	1206
7661	1218
7661	1232
7662	1183
7662	1188
7662	1205
7662	1218
7662	1232
7663	1183
7663	1191
7663	1232
7663	1233
7663	45339
7665	1183
7665	1191
7665	1206
7665	1229
7665	1243
7667	1183
7667	1188
7667	1206
7667	1218
7667	1232
7668	1183
7668	1188
7668	1218
7668	1232
7668	1233
7672	1183
7672	1188
7672	1206
7672	1218
7672	1232
7675	1183
7675	1188
7675	1198
7675	1204
7675	1218
7676	1183
7676	1188
7676	1206
7676	1218
7676	1232
7677	1183
7677	1188
7677	1205
7677	1232
7677	1262
7678	1183
7678	1188
7678	1206
7678	1218
7678	1232
7679	1183
7679	1188
7679	1232
7679	1233
7679	1271
7680	1183
7680	1188
7680	1206
7680	1218
7680	1229
7681	1183
7681	1188
7681	1204
7681	1218
7681	1232
7682	1183
7682	1188
7682	1232
7682	1233
7682	1271
7683	1183
7683	1188
7683	1218
7683	1232
7683	1233
7684	1183
7684	1188
7684	1206
7684	1232
7684	1277
7685	1183
7685	1188
7685	1218
7685	1229
7685	1233
7686	1183
7686	1188
7686	1206
7686	1221
7686	1232
7687	1183
7687	1188
7687	1206
7687	1218
7687	1232
7688	1183
7688	1188
7688	1218
7688	1232
7688	1233
7689	1183
7689	1188
7689	1232
7689	1233
7689	1277
7690	1183
7690	1188
7690	1206
7690	1218
7690	1232
7691	1183
7691	1188
7691	1218
7691	1232
7691	1233
7692	1183
7692	1188
7692	1205
7692	1221
7692	1232
7693	1183
7693	1188
7693	1204
7693	1232
7693	44974
7694	1183
7694	1188
7694	1204
7694	1232
7694	1243
7695	1183
7695	1188
7695	1198
7695	1206
7695	1218
7696	1183
7696	1188
7696	1218
7696	1232
7696	1233
7698	1183
7698	1188
7698	1206
7698	1218
7698	1232
7699	1183
7699	1188
7699	1206
7699	1218
7699	1232
7699	1233
7700	1183
7700	1188
7700	1206
7700	1218
7700	1232
7701	1183
7701	1188
7701	1206
7701	1232
7701	45181
7702	1183
7702	1206
7702	1232
7702	1239
7702	44983
7703	1183
7703	1188
7703	1218
7703	1232
7703	1233
7705	1183
7705	1188
7705	1206
7705	1218
7705	1232
7706	1183
7706	1188
7706	1206
7706	1218
7706	1232
7707	1183
7707	1188
7707	1206
7707	1218
7707	1232
7710	1183
7710	1188
7710	1206
7710	1218
7710	1232
7711	1183
7711	1188
7711	1218
7711	1232
7711	1233
7712	1183
7712	1188
7712	1204
7712	1218
7712	1232
7713	1183
7713	1188
7713	1206
7713	1218
7713	1229
7714	1183
7714	1188
7714	1206
7714	1218
7714	1229
7715	1183
7715	1188
7715	1232
7715	1233
7715	44984
7717	1183
7717	1188
7717	1206
7717	1232
7717	44971
7719	1183
7719	1188
7719	1198
7719	1206
7719	1218
7720	1183
7720	1188
7720	1206
7720	1232
7720	44971
7721	1183
7721	1188
7721	1205
7721	1218
7721	1232
7722	1183
7722	1188
7722	1232
7722	1233
7722	44968
7723	1183
7723	1188
7723	1218
7723	1232
7723	1233
7724	1183
7724	1188
7724	1206
7724	1218
7724	1232
7725	1183
7725	1188
7725	1218
7725	1232
7725	1233
7727	1183
7727	1188
7727	1206
7727	1232
7727	44970
7730	1183
7730	1188
7730	1204
7730	1232
7730	44970
7732	1183
7732	1188
7732	1218
7732	1232
7732	1233
7733	1183
7733	1188
7733	1218
7733	1232
7733	1233
7734	1183
7734	1188
7734	1218
7734	1232
7734	1233
7735	1183
7735	1188
7735	1206
7735	1232
7735	44970
7736	1183
7736	1188
7736	1205
7736	1232
7736	44968
7737	1183
7737	1188
7737	1205
7737	1218
7737	1232
7738	1183
7738	1188
7738	1206
7738	1218
7738	1232
7739	1183
7739	1188
7739	1206
7739	1232
7739	44983
7740	1183
7740	1188
7740	1206
7740	1229
7740	44968
7741	1183
7741	1188
7741	1198
7741	1204
7741	44985
7742	1183
7742	1188
7742	1206
7742	1218
7742	1229
7743	1183
7743	1188
7743	1198
7743	1206
7743	1218
7744	1183
7744	1188
7744	1232
7744	1233
7744	44985
7745	1183
7745	1188
7745	1232
7745	1233
7745	44971
7746	1183
7746	1188
7746	1206
7746	1218
7746	1232
7747	1183
7747	1188
7747	1206
7747	1218
7747	1232
7748	1183
7748	1188
7748	1222
7748	1232
7748	1233
7749	1183
7749	1188
7749	1218
7749	1232
7749	1233
7750	1183
7750	1188
7750	1206
7750	1218
7750	1232
7751	1183
7751	1188
7751	1206
7751	1218
7751	1232
7752	1183
7752	1188
7752	1206
7752	1218
7752	1229
7753	1183
7753	1188
7753	1206
7753	1217
7753	1218
7753	1229
7753	1232
7755	1183
7755	1196
7755	1218
7755	1232
7755	1233
7756	1183
7756	1188
7756	1232
7756	1233
7756	44992
7758	1183
7758	1188
7758	1206
7758	1218
7758	1232
7759	1183
7759	1188
7759	1198
7759	1218
7759	1233
7760	1188
7760	1196
7760	1206
7760	1218
7760	1229
7760	1232
7760	45236
7760	45238
7764	1183
7764	1188
7764	1200
7764	1206
7764	1218
7771	1183
7771	1191
7771	1204
7771	1218
7771	1232
7772	1183
7772	1188
7772	1206
7772	1218
7772	1232
7774	1183
7774	1205
7774	1218
7774	1232
7774	1239
7775	1183
7775	1188
7775	1204
7775	1218
7775	1232
7780	1183
7780	1188
7780	1206
7780	1218
7780	1232
7783	1183
7783	1188
7783	1206
7783	1218
7783	1232
7784	1183
7784	1188
7784	1206
7784	1218
7784	1232
7785	1183
7785	1188
7785	1232
7785	1233
7785	44970
7787	1183
7787	1188
7787	1206
7787	1218
7787	1232
7788	1183
7788	1188
7788	1205
7788	1218
7788	1232
7789	1183
7789	1188
7789	1205
7789	1211
7789	1232
7790	1183
7790	1188
7790	1217
7790	1232
7790	1233
7791	1183
7791	1188
7791	1206
7791	1217
7791	1232
7792	1183
7792	1188
7792	1206
7792	1232
7792	44985
7793	1183
7793	1188
7793	1198
7793	1204
7793	1218
7794	1183
7794	1188
7794	1198
7794	1204
7794	1221
7795	1183
7795	1188
7795	1232
7795	1233
7795	1262
7796	1183
7796	1188
7796	1205
7796	1218
7796	1232
7797	1183
7797	1188
7797	1218
7797	1232
7797	1233
7798	1183
7798	1188
7798	1205
7798	1218
7798	1232
7799	1183
7799	1188
7799	1206
7799	1218
7799	1229
7800	1183
7800	1188
7800	1205
7800	1218
7800	1232
7801	1183
7801	1188
7801	1218
7801	1232
7801	1233
7802	1183
7802	1188
7802	1204
7802	1217
7802	1232
7803	1183
7803	1188
7803	1206
7803	1218
7803	1232
7805	1183
7805	1188
7805	1198
7805	1204
7805	44970
7806	1183
7806	1188
7806	1198
7806	1206
7806	1218
7807	1183
7807	1188
7807	1198
7807	1204
7807	44971
7808	1183
7808	1188
7808	1206
7808	1218
7808	1232
7809	1183
7809	1188
7809	1204
7809	1218
7809	1232
7810	1183
7810	1188
7810	1206
7810	1221
7810	1232
7811	1183
7811	1188
7811	1198
7811	1204
7811	1218
7812	1183
7812	1188
7812	1198
7812	1204
7812	1218
7813	1183
7813	1188
7813	1206
7813	1218
7813	1232
7815	1183
7815	1188
7815	1198
7815	1205
7815	1218
7816	1183
7816	1188
7816	1232
7816	1233
7816	44986
7818	1183
7818	1188
7818	1206
7818	1218
7818	1232
7820	1183
7820	1188
7820	1218
7820	1232
7820	1233
7821	1183
7821	1188
7821	1206
7821	1218
7821	1232
7822	1183
7822	1188
7822	1206
7822	1217
7822	1232
7823	1183
7823	1188
7823	1217
7823	1232
7823	1233
7824	1183
7824	1188
7824	1206
7824	1217
7824	1232
7825	1183
7825	1188
7825	1206
7825	1218
7825	1232
7826	1183
7826	1188
7826	1206
7826	1218
7826	1232
7827	1183
7827	1188
7827	1204
7827	1217
7827	1232
7828	1183
7828	1188
7828	1206
7828	1218
7828	1232
7829	1183
7829	1188
7829	1206
7829	1218
7829	1232
7830	1183
7830	1188
7830	1218
7830	1232
7830	1233
7831	1183
7831	1188
7831	1206
7831	1218
7831	1232
7832	1183
7832	1188
7832	1206
7832	1218
7832	1232
7833	1183
7833	1188
7833	1218
7833	1232
7833	1233
7836	1183
7836	1188
7836	1206
7836	1221
7836	1232
7838	1183
7838	1188
7838	1206
7838	1218
7838	1232
7840	1183
7840	1188
7840	1206
7840	1218
7840	1232
7841	1188
7841	1206
7841	1218
7841	1232
7841	45238
7843	1183
7843	1188
7843	1206
7843	1232
7843	44974
7844	1183
7844	1188
7844	1206
7844	1218
7844	1232
7845	1188
7845	1206
7845	1218
7845	1232
7845	45238
7849	1188
7849	1218
7849	1232
7849	1233
7849	45238
7850	1183
7850	1188
7850	1206
7850	1218
7850	1232
7852	1183
7852	1188
7852	1206
7852	1217
7852	1218
7852	1229
7852	1232
7853	1183
7853	1188
7853	1206
7853	1232
7853	45181
7854	1183
7854	1188
7854	1206
7854	1218
7854	1232
7855	1183
7855	1188
7855	1206
7855	1218
7855	1232
7856	1183
7856	1188
7856	1206
7856	1218
7856	1232
7857	1183
7857	1188
7857	1206
7857	1232
7857	44974
7858	1183
7858	1188
7858	1200
7858	1206
7858	1217
7859	1183
7859	1188
7859	1200
7859	1218
7859	1233
7862	1183
7862	1188
7862	1206
7862	1218
7862	1232
7863	1183
7863	1188
7863	1218
7863	1232
7863	1233
7864	1183
7864	1188
7864	1206
7864	1218
7864	1232
7865	1183
7865	1188
7865	1206
7865	1217
7865	1232
7866	1183
7866	1188
7866	1218
7866	1232
7866	1233
7868	1188
7868	1232
7868	1233
7868	45238
7868	45365
7869	1183
7869	1188
7869	1206
7869	1218
7869	1232
7870	1183
7870	1188
7870	1218
7870	1232
7870	1233
7871	1183
7871	1188
7871	1199
7871	1204
7871	1218
7872	1183
7872	1188
7872	1204
7872	1218
7872	1232
7873	1183
7873	1188
7873	1206
7873	1218
7873	1232
7874	1183
7874	1188
7874	1218
7874	1232
7874	1233
7875	1183
7875	1188
7875	1232
7875	1233
7875	44989
7876	1183
7876	1188
7876	1198
7876	1218
7876	1233
7877	1183
7877	1188
7877	1206
7877	1232
7877	45159
7878	1183
7878	1188
7878	1232
7878	1233
7878	44971
7880	1183
7880	1188
7880	1206
7880	1218
7880	1229
7881	1183
7881	1188
7881	1218
7881	1232
7881	1233
7882	1183
7882	1188
7882	1200
7882	1217
7882	1233
7883	1183
7883	1194
7883	1204
7883	1218
7883	1232
7884	1188
7884	1218
7884	1232
7884	1233
7884	45238
7885	1183
7885	1188
7885	1206
7885	1218
7885	1229
7886	1183
7886	1196
7886	1218
7886	1232
7886	1233
7887	1188
7887	1204
7887	1218
7887	1232
7887	45236
7888	1183
7888	1194
7888	1206
7888	1218
7888	1229
7889	1178
7889	1196
7889	1197
7889	1201
7889	1218
7890	1183
7890	1194
7890	1218
7890	1232
7890	1233
7892	1183
7892	1194
7892	1206
7892	1218
7892	1229
7893	1182
7893	1196
7893	1206
7893	1218
7893	1229
7894	1183
7894	1188
7894	1204
7894	1218
7894	1232
7897	1188
7897	1206
7897	1218
7897	1229
7897	45238
7898	1183
7898	1194
7898	1206
7898	1218
7898	1229
7899	1183
7899	1188
7899	1206
7899	1218
7899	1232
7900	1183
7900	1188
7900	1200
7900	1206
7900	1220
7902	1183
7902	1188
7902	1200
7902	1206
7902	1218
7903	1188
7903	1218
7903	1232
7903	1233
7903	45238
7904	1180
7904	1188
7904	1218
7904	1232
7904	1233
7905	1183
7905	1188
7905	1200
7905	1206
7905	1218
7906	1183
7906	1188
7906	1198
7906	1204
7906	1222
7907	1196
7907	1218
7907	1232
7907	1233
7907	45236
7908	1183
7908	1188
7908	1206
7908	1218
7908	1229
7909	1183
7909	1188
7909	1206
7909	1217
7909	1229
7910	1183
7910	1188
7910	1200
7910	1206
7910	1218
7912	1188
7912	1218
7912	1232
7912	1233
7912	45238
7913	1183
7913	1188
7913	1198
7913	1206
7913	1218
7914	1183
7914	1188
7914	1206
7914	1219
7914	1229
7915	1183
7915	1188
7915	1198
7915	1206
7915	1218
7916	1183
7916	1188
7916	1206
7916	1221
7916	1229
7917	1183
7917	1188
7917	1206
7917	1218
7917	1229
7918	1195
7918	1200
7918	1206
7918	1218
7918	45238
7919	1183
7919	1194
7919	1200
7919	1206
7919	45543
7922	1183
7922	1188
7922	1218
7922	1232
7922	1233
7924	1188
7924	1206
7924	1218
7924	1229
7924	45238
7925	1183
7925	1194
7925	1206
7925	1222
7925	1232
7926	1183
7926	1188
7926	1206
7926	1218
7926	1229
7928	1183
7928	1194
7928	1198
7928	1206
7928	1218
7929	1188
7929	1198
7929	1206
7929	1218
7929	45238
7930	1188
7930	1232
7930	1233
7930	45238
7930	45450
7931	1188
7931	1206
7931	1218
7931	1229
7931	45238
7932	1183
7932	1188
7932	1198
7932	1206
7932	1218
7933	1183
7933	1188
7933	1218
7933	1232
7933	1233
7934	1183
7934	1188
7934	1206
7934	1218
7934	1229
7935	1183
7935	1188
7935	1206
7935	1218
7935	1229
7936	1183
7936	1188
7936	1206
7936	1218
7936	1229
7937	1183
7937	1188
7937	1206
7937	1218
7937	1229
7938	1183
7938	1188
7938	1206
7938	1218
7938	1229
7939	1183
7939	1188
7939	1206
7939	1218
7939	1229
7940	1188
7940	1200
7940	1206
7940	1218
7940	45238
7941	1183
7941	1191
7941	1200
7941	1206
7941	1218
7942	1183
7942	1188
7942	1198
7942	1206
7942	1218
7943	1188
7943	1200
7943	1206
7943	1218
7943	45238
7944	1188
7944	1200
7944	1206
7944	1218
7944	45238
7945	1183
7945	1194
7945	1200
7945	1206
7945	1218
7946	1188
7946	1218
7946	1232
7946	1233
7946	45236
7950	1183
7950	1188
7950	1218
7950	1232
7950	1233
7951	1183
7951	1188
7951	1204
7951	1218
7951	1232
7952	1183
7952	1194
7952	1218
7952	1229
7952	1233
7953	1183
7953	1188
7953	1199
7953	1203
7953	1218
7954	1183
7954	1188
7954	1206
7954	1218
7954	1229
7955	1188
7955	1198
7955	1206
7955	1218
7955	45238
7957	1188
7957	1218
7957	1232
7957	1233
7957	45238
7958	1183
7958	1188
7958	1206
7958	1218
7958	1232
7959	1183
7959	1188
7959	1206
7959	1218
7959	1229
7960	1183
7960	1194
7960	1198
7960	1206
7960	1218
7961	1183
7961	1188
7961	1218
7961	1232
7961	1233
7964	1183
7964	1188
7964	1203
7964	1218
7964	1232
7965	1183
7965	1194
7965	1206
7965	1218
7965	1229
7966	1183
7966	1188
7966	1200
7966	1206
7966	1218
7968	1183
7968	1194
7968	1218
7968	1232
7968	1233
7969	1183
7969	1188
7969	1199
7969	1204
7969	1211
7970	1183
7970	1188
7970	1194
7970	1222
7970	1232
7970	1233
7970	45236
7971	1183
7971	1188
7971	1198
7971	1206
7971	1210
7973	1183
7973	1188
7973	1194
7973	1206
7973	1218
7973	1229
7974	1183
7974	1188
7974	1218
7974	1232
7974	1233
7975	1188
7975	1220
7975	1232
7975	1233
7975	45238
7978	1183
7978	1188
7978	1205
7978	1219
7978	1232
7979	1183
7979	1188
7979	1206
7979	1217
7979	1229
7980	1183
7980	1194
7980	1213
7980	1232
7980	1233
7981	1183
7981	1188
7981	1204
7981	1218
7981	1232
7982	1188
7982	1203
7982	1218
7982	1232
7982	45238
7983	1183
7983	1194
7983	1200
7983	1206
7983	1218
7985	1183
7985	1194
7985	1206
7985	1218
7985	1229
7987	1183
7987	1188
7987	1203
7987	1218
7987	1232
7988	1188
7988	1203
7988	1218
7988	1232
7988	45238
7989	1183
7989	1188
7989	1218
7989	1232
7989	1233
7991	1188
7991	1204
7991	1218
7991	1232
7991	45238
7992	1183
7992	1188
7992	1204
7992	1218
7992	1232
7993	1183
7993	1188
7993	1200
7993	1206
7993	1218
7994	1188
7994	1209
7994	1232
7994	1233
7994	45236
7996	1183
7996	1188
7996	1200
7996	1206
7996	1246
7997	1183
7997	1194
7997	1218
7997	1232
7997	1233
7998	1183
7998	1188
7998	1232
7998	1233
7998	45134
8000	1183
8000	1188
8000	1218
8000	1232
8000	1233
8002	1183
8002	1188
8002	1200
8002	1206
8002	1217
8003	1183
8003	1188
8003	1200
8003	1206
8003	1218
8004	1183
8004	1188
8004	1206
8004	1218
8004	1229
8005	1183
8005	1188
8005	1198
8005	1206
8005	1218
8007	1183
8007	1188
8007	1200
8007	1206
8007	1218
8009	1183
8009	1188
8009	1200
8009	1206
8009	1218
8012	1183
8012	1194
8012	1205
8012	1218
8012	1229
8015	1188
8015	1218
8015	1232
8015	1233
8015	45238
8016	1188
8016	1199
8016	1204
8016	1218
8016	45238
8018	1183
8018	1194
8018	1199
8018	1204
8018	1218
8021	1188
8021	1200
8021	1204
8021	1218
8021	45238
8023	1183
8023	1188
8023	1204
8023	1218
8023	1232
8024	1183
8024	1188
8024	1204
8024	1218
8024	1232
8025	1188
8025	1198
8025	1204
8025	1205
8025	1218
8025	1232
8025	45236
8025	45238
8026	1183
8026	1188
8026	1206
8026	1218
8026	1229
8028	1188
8028	1204
8028	1218
8028	1232
8028	45238
8030	1188
8030	1203
8030	1218
8030	1232
8030	45238
8031	1188
8031	1203
8031	1218
8031	1232
8031	45238
8032	1183
8032	1194
8032	1204
8032	1218
8032	1232
8036	1188
8036	1198
8036	1204
8036	1217
8036	45236
8037	1188
8037	1198
8037	1204
8037	1218
8037	45236
8038	1183
8038	1188
8038	1198
8038	1204
8038	1218
8039	1188
8039	1198
8039	1204
8039	1218
8039	45236
8042	1183
8042	1188
8042	1203
8042	1218
8042	1238
8046	1183
8046	1188
8046	1206
8046	1218
8046	1232
8047	1183
8047	1188
8047	1218
8047	1232
8047	1233
8048	1183
8048	1188
8048	1200
8048	1206
8048	1218
8049	1183
8049	1188
8049	1199
8049	1204
8049	1218
8050	1183
8050	1188
8050	1198
8050	1206
8050	1218
8051	1183
8051	1194
8051	1200
8051	1206
8051	1218
8052	1188
8052	1218
8052	1232
8052	1233
8052	45238
8053	1183
8053	1188
8053	1218
8053	1232
8053	1233
8054	1183
8054	1188
8054	1218
8054	1232
8054	1233
8056	1183
8056	1188
8056	1206
8056	1218
8056	1229
8057	1183
8057	1188
8057	1218
8057	1232
8057	1233
8061	1183
8061	1188
8061	1200
8061	1206
8061	1218
8063	1183
8063	1188
8063	1200
8063	1206
8063	1217
8064	1188
8064	1206
8064	1218
8064	1229
8064	45238
8065	1183
8065	1194
8065	1218
8065	1232
8065	1233
8067	1179
8067	1188
8067	1197
8067	1201
8067	1218
8069	1183
8069	1193
8069	1206
8069	1218
8069	1229
8071	1180
8071	1188
8071	1197
8071	1201
8071	1218
8072	1183
8072	1188
8072	1218
8072	1232
8072	1233
8074	1183
8074	1188
8074	1206
8074	1217
8074	1229
8075	1183
8075	1194
8075	1200
8075	1206
8075	1218
8076	1183
8076	1194
8076	1213
8076	1232
8076	1233
8078	1183
8078	1194
8078	1200
8078	1206
8078	1218
8079	1183
8079	1188
8079	1200
8079	1206
8079	44974
8080	1183
8080	1188
8080	1200
8080	1206
8080	1218
8081	1188
8081	1209
8081	1232
8081	1233
8081	45236
8082	1183
8082	1188
8082	1206
8082	1218
8082	1229
8083	1183
8083	1188
8083	1206
8083	1218
8083	1232
8084	1183
8084	1188
8084	1232
8084	1233
8084	44992
8085	1183
8085	1188
8085	1211
8085	1232
8085	1233
8086	1183
8086	1188
8086	1232
8086	1233
8086	44993
8087	1183
8087	1188
8087	1232
8087	1233
8087	44994
8088	1183
8088	1188
8088	1194
8088	1205
8088	1218
8088	1232
8088	1233
8089	1188
8089	1232
8089	1233
8089	44995
8089	45238
8090	1183
8090	1188
8090	1218
8090	1232
8090	1233
8091	1183
8091	1188
8091	1206
8091	1232
8091	1271
8093	1183
8093	1188
8093	1206
8093	1218
8093	1232
8094	1183
8094	1188
8094	1206
8094	1218
8094	1232
8095	1183
8095	1188
8095	1218
8095	1232
8095	1233
8097	1183
8097	1188
8097	1232
8097	1233
8097	45145
8098	1183
8098	1188
8098	1206
8098	1218
8098	1232
8099	1183
8099	1188
8099	1232
8099	1233
8099	44998
8100	1183
8100	1188
8100	1200
8100	1206
8100	1217
8102	1183
8102	1188
8102	1206
8102	1217
8102	1232
8103	1183
8103	1188
8103	1218
8103	1232
8103	1233
8104	1183
8104	1188
8104	1218
8104	1232
8104	1233
8105	1183
8105	1188
8105	1205
8105	1222
8105	1232
8106	1183
8106	1188
8106	1205
8106	1218
8106	1232
8107	1183
8107	1188
8107	1200
8107	1206
8107	1218
8108	1183
8108	1188
8108	1206
8108	1232
8108	45037
8109	1183
8109	1188
8109	1232
8109	1233
8109	45001
8110	1183
8110	1188
8110	1232
8110	1233
8110	45002
8111	1183
8111	1188
8111	1206
8111	1232
8111	45119
8112	1183
8112	1194
8112	1232
8112	1233
8112	44968
8113	1183
8113	1188
8113	1232
8113	1233
8113	45559
8114	1183
8114	1188
8114	1206
8114	1218
8114	1232
8115	1183
8115	1188
8115	1206
8115	1232
8115	44989
8116	1183
8116	1188
8116	1206
8116	1218
8116	1232
8117	1183
8117	1188
8117	1206
8117	1218
8117	1232
8118	1183
8118	1188
8118	1204
8118	1218
8118	1232
8119	1183
8119	1188
8119	1218
8119	1232
8119	1233
8120	1183
8120	1188
8120	1200
8120	1206
8120	1218
8121	1183
8121	1188
8121	1206
8121	1218
8121	1232
8122	1183
8122	1188
8122	1206
8122	1218
8122	1232
8123	1183
8123	1188
8123	1200
8123	1206
8123	1218
8124	1183
8124	1188
8124	1206
8124	1232
8124	45145
8125	1183
8125	1188
8125	1206
8125	1218
8125	1232
8126	1183
8126	1188
8126	1200
8126	1206
8126	1218
8127	1183
8127	1188
8127	1206
8127	1218
8127	1232
8128	1183
8128	1188
8128	1204
8128	1232
8128	44971
8129	1183
8129	1188
8129	1206
8129	1218
8129	1232
8130	1183
8130	1188
8130	1217
8130	1232
8130	1233
8131	1183
8131	1188
8131	1206
8131	1218
8131	1232
8137	1183
8137	1188
8137	1204
8137	1218
8137	1232
8138	1183
8138	1188
8138	1206
8138	1218
8138	1232
8139	1183
8139	1188
8139	1205
8139	1218
8139	1232
8140	1183
8140	1188
8140	1204
8140	1218
8140	1232
8141	1183
8141	1188
8141	1206
8141	1218
8141	1232
8143	1183
8143	1188
8143	1206
8143	1217
8143	1232
8144	1183
8144	1188
8144	1204
8144	1232
8144	44971
8145	1183
8145	1188
8145	1200
8145	1206
8145	1217
8146	1183
8146	1188
8146	1218
8146	1232
8146	1233
8147	1183
8147	1188
8147	1206
8147	1218
8147	1232
8148	1183
8148	1188
8148	1206
8148	1218
8148	1232
8149	1183
8149	1188
8149	1232
8149	1233
8149	45549
8150	1183
8150	1188
8150	1206
8150	1232
8150	45181
8151	1183
8151	1188
8151	1206
8151	1218
8151	1232
8153	1183
8153	1188
8153	1206
8153	1218
8153	1232
8154	1183
8154	1188
8154	1205
8154	1218
8154	1232
8155	1183
8155	1188
8155	1206
8155	1218
8155	1232
8157	1183
8157	1188
8157	1206
8157	1218
8157	1232
8158	1183
8158	1188
8158	1205
8158	1232
8158	1243
8159	1183
8159	1188
8159	1206
8159	1213
8159	1232
8160	1183
8160	1188
8160	1206
8160	1218
8160	1232
8161	1183
8161	1188
8161	1198
8161	1206
8161	1218
8162	1183
8162	1188
8162	1218
8162	1232
8162	1233
8163	1183
8163	1188
8163	1218
8163	1232
8163	1233
8164	1183
8164	1188
8164	1206
8164	1218
8164	1232
8166	1183
8166	1188
8166	1218
8166	1232
8166	1233
8167	1183
8167	1188
8167	1218
8167	1232
8167	1233
8168	1183
8168	1188
8168	1198
8168	1205
8168	1218
8169	1183
8169	1188
8169	1218
8169	1232
8169	1233
8170	1183
8170	1188
8170	1204
8170	1218
8170	1232
8171	1183
8171	1188
8171	1198
8171	1205
8171	1213
8172	1183
8172	1188
8172	1232
8172	1233
8172	44968
8173	1183
8173	1188
8173	1204
8173	1218
8173	1232
8174	1183
8174	1198
8174	1210
8174	1233
8174	1239
8175	1183
8175	1188
8175	1218
8175	1232
8175	1233
8176	1183
8176	1188
8176	1206
8176	1229
8176	45430
8177	1183
8177	1188
8177	1218
8177	1232
8177	1233
8178	1183
8178	1188
8178	1218
8178	1232
8178	1233
8179	1183
8179	1196
8179	1218
8179	1232
8179	1233
8180	1183
8180	1188
8180	1204
8180	1218
8180	1232
8181	1183
8181	1188
8181	1198
8181	1206
8181	1210
8182	1183
8182	1188
8182	1198
8182	1205
8182	1218
8183	1183
8183	1188
8183	1204
8183	1218
8183	1232
8184	1183
8184	1218
8184	1232
8184	1233
8184	1239
8185	1183
8185	1188
8185	1198
8185	1204
8185	1218
8186	1183
8186	1188
8186	1198
8186	1233
8186	44977
8188	1183
8188	1196
8188	1232
8188	1233
8188	44992
8189	1183
8189	1188
8189	1206
8189	1218
8189	1232
8190	1183
8190	1188
8190	1206
8190	1232
8190	44971
8191	1183
8191	1188
8191	1198
8191	1206
8191	1218
8192	1183
8192	1188
8192	1217
8192	1232
8192	1233
8193	1183
8193	1188
8193	1218
8193	1232
8193	1233
8194	1183
8194	1188
8194	1222
8194	1232
8194	1233
8195	1183
8195	1188
8195	1198
8195	1218
8195	1233
8196	1183
8196	1188
8196	1204
8196	1218
8196	1232
8197	1183
8197	1188
8197	1229
8197	1233
8197	45014
8199	1183
8199	1188
8199	1206
8199	1218
8199	1229
8200	1183
8200	1188
8200	1198
8200	1204
8200	44974
8201	1183
8201	1188
8201	1198
8201	1218
8201	1233
8202	1183
8202	1188
8202	1222
8202	1232
8202	1233
8203	1183
8203	1188
8203	1200
8203	1206
8203	1218
8204	1183
8204	1188
8204	1198
8204	1204
8204	1218
8205	1183
8205	1188
8205	1198
8205	1204
8205	44974
8206	1183
8206	1188
8206	1218
8206	1232
8206	1233
8207	1183
8207	1188
8207	1198
8207	1204
8207	1218
8208	1183
8208	1188
8208	1206
8208	1218
8208	1229
8209	1183
8209	1188
8209	1205
8209	1218
8209	1232
8210	1183
8210	1188
8210	1218
8210	1232
8210	1233
8211	1183
8211	1188
8211	1206
8211	1218
8211	1229
8212	1183
8212	1188
8212	1198
8212	1204
8212	1218
8213	1183
8213	1188
8213	1198
8213	1204
8213	1218
8214	1183
8214	1188
8214	1198
8214	1204
8214	1206
8214	1217
8214	1232
8214	44970
8216	1183
8216	1188
8216	1198
8216	1218
8216	1233
8217	1183
8217	1188
8217	1218
8217	1229
8217	1233
8218	1183
8218	1188
8218	1218
8218	1232
8218	1233
8219	1183
8219	1188
8219	1206
8219	1218
8219	1232
8220	1183
8220	1188
8220	1198
8220	1205
8220	1218
8221	1183
8221	1188
8221	1206
8221	1217
8221	1232
8222	1183
8222	1188
8222	1205
8222	1213
8222	1232
8223	1183
8223	1188
8223	1198
8223	1218
8223	1233
8225	1183
8225	1188
8225	1232
8225	1233
8225	45017
8226	1183
8226	1188
8226	1206
8226	1218
8226	1232
8227	1183
8227	1188
8227	1206
8227	1229
8227	44968
8228	1183
8228	1188
8228	1198
8228	1206
8228	1262
8230	1183
8230	1188
8230	1218
8230	1232
8230	1233
8231	1183
8231	1188
8231	1232
8231	1233
8231	44974
8232	1183
8232	1188
8232	1218
8232	1232
8232	1233
8233	1183
8233	1188
8233	1206
8233	1221
8233	1232
8234	1183
8234	1188
8234	1218
8234	1232
8234	1233
8235	1183
8235	1188
8235	1218
8235	1232
8235	1233
8236	1183
8236	1188
8236	1198
8236	1204
8236	1218
8237	1183
8237	1188
8237	1198
8237	1205
8237	1218
8239	1183
8239	1188
8239	1218
8239	1232
8239	1233
8240	1183
8240	1188
8240	1206
8240	1217
8240	1232
8241	1183
8241	1188
8241	1206
8241	1217
8241	1232
8242	1183
8242	1188
8242	1204
8242	1218
8242	1232
8243	1183
8243	1188
8243	1232
8243	1233
8243	44992
8244	1183
8244	1188
8244	1205
8244	1232
8244	44983
8245	1183
8245	1188
8245	1218
8245	1232
8245	1233
8246	1183
8246	1196
8246	1218
8246	1232
8246	1233
8247	1183
8247	1188
8247	1198
8247	1218
8247	1233
8248	1183
8248	1188
8248	1198
8248	1218
8248	1233
8250	1183
8250	1188
8250	1218
8250	1229
8250	1233
8251	1183
8251	1188
8251	1218
8251	1232
8251	1233
8252	1183
8252	1188
8252	1205
8252	1218
8252	1232
8254	1188
8254	1232
8254	1233
8254	44977
8254	45238
8255	1183
8255	1188
8255	1218
8255	1232
8255	1233
8256	1183
8256	1188
8256	1232
8256	1233
8256	45019
8257	1183
8257	1188
8257	1204
8257	1232
8257	45019
8258	1183
8258	1204
8258	1218
8258	1232
8258	1239
8259	1183
8259	1188
8259	1206
8259	1221
8259	1232
8260	1183
8260	1188
8260	1218
8260	1232
8260	1233
8261	1183
8261	1188
8261	1206
8261	1220
8261	1232
8262	1183
8262	1188
8262	1206
8262	1221
8262	1232
8263	1183
8263	1188
8263	1198
8263	1204
8263	1218
8265	1183
8265	1188
8265	1206
8265	1218
8265	1232
8266	1183
8266	1188
8266	1218
8266	1229
8266	1233
8268	1183
8268	1188
8268	1206
8268	1218
8268	1229
8269	1183
8269	1188
8269	1218
8269	1232
8269	1233
8270	1183
8270	1188
8270	1229
8270	1233
8270	1255
8271	1183
8271	1188
8271	1229
8271	1233
8271	1255
8272	1183
8272	1188
8272	1206
8272	1218
8272	1229
8273	1183
8273	1188
8273	1204
8273	1218
8273	1229
8274	1183
8274	1188
8274	1229
8274	1233
8274	1243
8275	1183
8275	1188
8275	1222
8275	1232
8275	1233
8276	1183
8276	1188
8276	1206
8276	1217
8276	1232
8277	1188
8277	1232
8277	1233
8277	44992
8277	45238
8278	1183
8278	1188
8278	1206
8278	1218
8278	1232
8279	1183
8279	1188
8279	1198
8279	1204
8279	1218
8280	1183
8280	1188
8280	1218
8280	1232
8280	1233
8281	1183
8281	1188
8281	1229
8281	1233
8281	44968
8282	1183
8282	1188
8282	1218
8282	1232
8282	1233
8283	1183
8283	1188
8283	1218
8283	1232
8283	1233
8284	1183
8284	1188
8284	1198
8284	1218
8284	1233
8285	1183
8285	1188
8285	1232
8285	1233
8285	45019
8286	1183
8286	1188
8286	1218
8286	1232
8286	1233
8287	1183
8287	1188
8287	1198
8287	1204
8287	1218
8288	1183
8288	1188
8288	1205
8288	1218
8288	1232
8289	1183
8289	1188
8289	1232
8289	1233
8289	45021
8290	1183
8290	1188
8290	1218
8290	1232
8290	1233
8291	1183
8291	1188
8291	1218
8291	1232
8291	1233
8292	1183
8292	1188
8292	1204
8292	1218
8292	1232
8293	1183
8293	1188
8293	1218
8293	1232
8293	1233
8294	1183
8294	1188
8294	1218
8294	1232
8294	1233
8295	1183
8295	1188
8295	1218
8295	1232
8295	1233
8296	1183
8296	1188
8296	1232
8296	1233
8296	44974
8297	1183
8297	1188
8297	1198
8297	1217
8297	1233
8298	1183
8298	1188
8298	1198
8298	1204
8298	1218
8300	1183
8300	1188
8300	1232
8300	1233
8300	45021
8301	1183
8301	1188
8301	1198
8301	1205
8301	1218
8303	1183
8303	1188
8303	1218
8303	1232
8303	1233
8304	1183
8304	1188
8304	1206
8304	1217
8304	1229
8305	1183
8305	1188
8305	1232
8305	1233
8305	44974
8306	1183
8306	1188
8306	1198
8306	1209
8306	1233
8307	1183
8307	1188
8307	1198
8307	1209
8307	1233
8308	1183
8308	1188
8308	1206
8308	1218
8308	1232
8309	1183
8309	1188
8309	1205
8309	1232
8309	44974
8310	1183
8310	1188
8310	1205
8310	1218
8310	1232
8311	1183
8311	1188
8311	1198
8311	1218
8311	1233
8312	1183
8312	1188
8312	1218
8312	1232
8312	1233
8313	1183
8313	1188
8313	1206
8313	1218
8313	1232
8314	1183
8314	1188
8314	1206
8314	1218
8314	1232
8315	1188
8315	1218
8315	1232
8315	1233
8315	45238
8316	1183
8316	1188
8316	1204
8316	1218
8316	1229
8317	1183
8317	1188
8317	1204
8317	1229
8317	44971
8318	1183
8318	1188
8318	1204
8318	1218
8318	1232
8319	1183
8319	1188
8319	1206
8319	1218
8319	1229
8320	1183
8320	1188
8320	1232
8320	1233
8320	44984
8321	1183
8321	1188
8321	1206
8321	1218
8321	1232
8322	1183
8322	1196
8322	1206
8322	1209
8322	1232
8323	1183
8323	1188
8323	1232
8323	1233
8323	1277
8324	1183
8324	1188
8324	1205
8324	1232
8324	45019
8325	1183
8325	1188
8325	1206
8325	1218
8325	1229
8326	1183
8326	1188
8326	1218
8326	1232
8326	1233
8327	1183
8327	1188
8327	1232
8327	1233
8327	44974
8328	1183
8328	1188
8328	1206
8328	1232
8328	45023
8329	1183
8329	1188
8329	1206
8329	1221
8329	1232
8330	1183
8330	1188
8330	1206
8330	1218
8330	1232
8331	1183
8331	1188
8331	1206
8331	1218
8331	1232
8332	1188
8332	1218
8332	1232
8332	1233
8332	45238
8333	1188
8333	1211
8333	1232
8333	1233
8333	45238
8334	1188
8334	1232
8334	1233
8334	45001
8334	45238
8335	1188
8335	1206
8335	1220
8335	1229
8335	45025
8335	45238
8337	1183
8337	1188
8337	1206
8337	1232
8337	44979
8338	1183
8338	1188
8338	1211
8338	1232
8338	1233
8339	1183
8339	1188
8339	1206
8339	1232
8339	1277
8340	1183
8340	1196
8340	1232
8340	1233
8340	1247
8341	1188
8341	1205
8341	1218
8341	1232
8341	44936
8342	1183
8342	1188
8342	1211
8342	1232
8342	1233
8343	1183
8343	1196
8343	1218
8343	1232
8343	1233
8344	1188
8344	1218
8344	1232
8344	1233
8344	45238
8345	1183
8345	1196
8345	1232
8345	1233
8345	44992
8346	1183
8346	1196
8346	1205
8346	1232
8346	1247
8347	1183
8347	1196
8347	1206
8347	1218
8347	1232
8348	1183
8348	1196
8348	1206
8348	1218
8348	1232
8349	1183
8349	1188
8349	1206
8349	1218
8349	1232
8350	1183
8350	1188
8350	1205
8350	1218
8350	1232
8351	1183
8351	1188
8351	1213
8351	1229
8351	1233
8352	1183
8352	1196
8352	1232
8352	1233
8352	1277
8353	1183
8353	1188
8353	1206
8353	1217
8353	1232
8354	1183
8354	1188
8354	1206
8354	1218
8354	1232
8356	1183
8356	1188
8356	1206
8356	1218
8356	1232
8357	1183
8357	1188
8357	1206
8357	1218
8357	1232
8358	1183
8358	1188
8358	1232
8358	1233
8358	45001
8359	1183
8359	1188
8359	1206
8359	1232
8359	44979
8360	1183
8360	1188
8360	1206
8360	1218
8360	1232
8361	1183
8361	1188
8361	1206
8361	1218
8361	1232
8362	1183
8362	1188
8362	1206
8362	1218
8362	1232
8363	1183
8363	1188
8363	1206
8363	1218
8363	1232
8364	1183
8364	1188
8364	1206
8364	1232
8364	1261
8365	1183
8365	1188
8365	1206
8365	1221
8365	1232
8366	1183
8366	1188
8366	1206
8366	1218
8366	1232
8367	1183
8367	1188
8367	1206
8367	1218
8367	1232
8368	1183
8368	1188
8368	1218
8368	1232
8368	1233
8369	1183
8369	1188
8369	1206
8369	1218
8369	1232
8370	1183
8370	1188
8370	1206
8370	1217
8370	1232
8371	1183
8371	1188
8371	1205
8371	1232
8371	45017
8372	1183
8372	1188
8372	1206
8372	1218
8372	1232
8373	1183
8373	1188
8373	1206
8373	1218
8373	1232
8374	1183
8374	1188
8374	1204
8374	1218
8374	1232
8375	1183
8375	1188
8375	1206
8375	1221
8375	1232
8376	1183
8376	1188
8376	1206
8376	1218
8376	1232
8377	1183
8377	1188
8377	1198
8377	1206
8377	1218
8378	1183
8378	1188
8378	1206
8378	1232
8378	44968
8379	1183
8379	1188
8379	1206
8379	1218
8379	1232
8380	1183
8380	1188
8380	1206
8380	1232
8380	45181
8381	1183
8381	1188
8381	1218
8381	1232
8381	1233
8382	1183
8382	1188
8382	1205
8382	1218
8382	1232
8383	1183
8383	1188
8383	1206
8383	1217
8383	1232
8384	1183
8384	1188
8384	1232
8384	1233
8384	45026
8385	1183
8385	1188
8385	1221
8385	1232
8385	1233
8386	1183
8386	1188
8386	1206
8386	1218
8386	1232
8387	1183
8387	1188
8387	1213
8387	1232
8387	1233
8388	1183
8388	1188
8388	1206
8388	1218
8388	1232
8389	1183
8389	1188
8389	1204
8389	1218
8389	1232
8390	1183
8390	1188
8390	1206
8390	1217
8390	1232
8391	1183
8391	1188
8391	1205
8391	1232
8391	44983
8392	1183
8392	1188
8392	1206
8392	1213
8392	1232
8393	1183
8393	1188
8393	1206
8393	1232
8393	44984
8394	1183
8394	1188
8394	1206
8394	1217
8394	1232
8395	1183
8395	1188
8395	1206
8395	1217
8395	1232
8396	1183
8396	1188
8396	1206
8396	1217
8396	1232
8398	1183
8398	1188
8398	1205
8398	1213
8398	1232
8399	1183
8399	1188
8399	1206
8399	1217
8399	1232
8400	1183
8400	1188
8400	1206
8400	1217
8400	1232
8401	1183
8401	1188
8401	1206
8401	1217
8401	1232
8402	1183
8402	1188
8402	1232
8402	1233
8402	45181
8403	1183
8403	1188
8403	1232
8403	1233
8403	45027
8404	1183
8404	1188
8404	1206
8404	1217
8404	1232
8405	1183
8405	1188
8405	1206
8405	1217
8405	1232
8406	1183
8406	1188
8406	1218
8406	1232
8406	1233
8407	1183
8407	1188
8407	1206
8407	1218
8407	1232
8408	1183
8408	1188
8408	1206
8408	1217
8408	1232
8409	1183
8409	1188
8409	1206
8409	1217
8409	1232
8410	1183
8410	1188
8410	1206
8410	1218
8410	1232
8411	1183
8411	1188
8411	1218
8411	1232
8411	1233
8412	1183
8412	1188
8412	1206
8412	1217
8412	1232
8413	1183
8413	1188
8413	1198
8413	1218
8413	1233
8414	1183
8414	1188
8414	1206
8414	1218
8414	1232
8415	1183
8415	1188
8415	1232
8415	1233
8415	1277
8416	1183
8416	1188
8416	1206
8416	1232
8416	1277
8417	1183
8417	1188
8417	1206
8417	1218
8417	1232
8418	1183
8418	1188
8418	1198
8418	1218
8418	1233
8419	1183
8419	1188
8419	1218
8419	1232
8419	1233
8420	1183
8420	1218
8420	1232
8420	1233
8420	1239
8421	1183
8421	1188
8421	1206
8421	1218
8421	1232
8422	1183
8422	1188
8422	1198
8422	1204
8422	45017
8423	1183
8423	1188
8423	1218
8423	1232
8423	1233
8424	1183
8424	1188
8424	1206
8424	1232
8424	45017
8425	1183
8425	1188
8425	1206
8425	1221
8425	1232
8426	1183
8426	1188
8426	1206
8426	1217
8426	1232
8427	1183
8427	1188
8427	1232
8427	1233
8427	1271
8428	1183
8428	1188
8428	1206
8428	1218
8428	1232
8429	1183
8429	1188
8429	1232
8429	1233
8429	1271
8430	1183
8430	1188
8430	1218
8430	1232
8430	1233
8431	1183
8431	1188
8431	1206
8431	1218
8431	1232
8432	1183
8432	1188
8432	1206
8432	1217
8432	1232
8433	1183
8433	1188
8433	1206
8433	1218
8433	1232
8434	1183
8434	1188
8434	1206
8434	1217
8434	1232
8435	1183
8435	1188
8435	1206
8435	1218
8435	1232
8436	1183
8436	1188
8436	1206
8436	1218
8436	1232
8437	1183
8437	1188
8437	1218
8437	1232
8437	1233
8438	1183
8438	1188
8438	1206
8438	1218
8438	1232
8439	1183
8439	1188
8439	1218
8439	1232
8439	1233
8440	1183
8440	1188
8440	1218
8440	1232
8440	1233
8441	1183
8441	1188
8441	1206
8441	1218
8441	1232
8442	1183
8442	1188
8442	1206
8442	1217
8442	1232
8444	1183
8444	1188
8444	1218
8444	1232
8444	1233
8445	1183
8445	1188
8445	1232
8445	1233
8445	45181
8446	1183
8446	1188
8446	1218
8446	1232
8446	1233
8447	1183
8447	1204
8447	1218
8447	1232
8447	1239
8448	1183
8448	1188
8448	1206
8448	1213
8448	1229
8449	1183
8449	1188
8449	1232
8449	1233
8449	44974
8450	1183
8450	1188
8450	1206
8450	1217
8450	1232
8451	1183
8451	1188
8451	1213
8451	1232
8451	1233
8452	1183
8452	1188
8452	1218
8452	1232
8452	1233
8453	1183
8453	1188
8453	1204
8453	1232
8453	45021
8454	1183
8454	1188
8454	1206
8454	1218
8454	1232
8455	1183
8455	1188
8455	1206
8455	1218
8455	1232
8456	1183
8456	1188
8456	1206
8456	1218
8456	1232
8457	1183
8457	1188
8457	1198
8457	1204
8457	1218
8458	1183
8458	1188
8458	1206
8458	1221
8458	1232
8459	1183
8459	1188
8459	1206
8459	1217
8459	1232
8460	1183
8460	1188
8460	1218
8460	1232
8460	1233
8461	1183
8461	1188
8461	1206
8461	1217
8461	1232
8462	1183
8462	1188
8462	1218
8462	1232
8462	1233
8463	1183
8463	1188
8463	1206
8463	1218
8463	1232
8464	1183
8464	1188
8464	1232
8464	1233
8464	1277
8465	1183
8465	1188
8465	1221
8465	1232
8465	1233
8466	1183
8466	1188
8466	1218
8466	1232
8466	1233
8467	1183
8467	1188
8467	1206
8467	1218
8467	1232
8468	1183
8468	1188
8468	1218
8468	1232
8468	1233
8469	1183
8469	1188
8469	1206
8469	1218
8469	1232
8470	1183
8470	1188
8470	1206
8470	1218
8470	1232
8471	1183
8471	1188
8471	1206
8471	1218
8471	1232
8472	1183
8472	1188
8472	1200
8472	1206
8472	1218
8473	1183
8473	1188
8473	1206
8473	1217
8473	1232
8474	1183
8474	1188
8474	1218
8474	1232
8474	1233
8475	1183
8475	1188
8475	1206
8475	1218
8475	1232
8476	1183
8476	1188
8476	1218
8476	1232
8476	1233
8477	1183
8477	1188
8477	1218
8477	1232
8477	1233
8478	1183
8478	1188
8478	1206
8478	1221
8478	1232
8479	1183
8479	1188
8479	1206
8479	1221
8479	1232
8480	1183
8480	1188
8480	1206
8480	1232
8480	1262
8481	1183
8481	1188
8481	1222
8481	1232
8481	1233
8482	1183
8482	1188
8482	1218
8482	1232
8482	1233
8483	1183
8483	1188
8483	1206
8483	1218
8483	1232
8484	1183
8484	1188
8484	1204
8484	1218
8484	1232
8485	1183
8485	1188
8485	1204
8485	1218
8485	1232
8486	1183
8486	1188
8486	1206
8486	1218
8486	1232
8487	1183
8487	1188
8487	1206
8487	1218
8487	1232
8488	1183
8488	1188
8488	1206
8488	1221
8488	1232
8489	1183
8489	1188
8489	1206
8489	1217
8489	1232
8490	1183
8490	1188
8490	1218
8490	1232
8490	1233
8491	1183
8491	1188
8491	1206
8491	1218
8491	1232
8492	1183
8492	1188
8492	1218
8492	1232
8492	1233
8493	1183
8493	1188
8493	1218
8493	1232
8493	1233
8494	1183
8494	1188
8494	1218
8494	1232
8494	1233
8495	1183
8495	1188
8495	1218
8495	1232
8495	1233
8496	1183
8496	1188
8496	1206
8496	1218
8496	1232
8497	1183
8497	1188
8497	1206
8497	1218
8497	1229
8498	1183
8498	1188
8498	1204
8498	1218
8498	1232
8499	1183
8499	1188
8499	1218
8499	1232
8499	1233
8500	1183
8500	1188
8500	1205
8500	1213
8500	1232
8501	1183
8501	1188
8501	1198
8501	1206
8501	1218
8502	1183
8502	1188
8502	1206
8502	1218
8502	1229
8503	1183
8503	1188
8503	1206
8503	1217
8503	1232
8504	1183
8504	1188
8504	1206
8504	1218
8504	1232
8505	1183
8505	1188
8505	1204
8505	1218
8505	1232
8506	1183
8506	1188
8506	1198
8506	1204
8506	1218
8507	1183
8507	1188
8507	1206
8507	1218
8507	1232
8508	1183
8508	1188
8508	1218
8508	1232
8508	1233
8509	1183
8509	1188
8509	1206
8509	1218
8509	1232
8510	1183
8510	1188
8510	1232
8510	1233
8510	44974
8511	1183
8511	1188
8511	1206
8511	1218
8511	1229
8512	1183
8512	1188
8512	1206
8512	1218
8512	1229
8513	1183
8513	1188
8513	1217
8513	1232
8513	1233
8514	1183
8514	1188
8514	1200
8514	1206
8514	1218
8515	1183
8515	1188
8515	1204
8515	1232
8515	45021
8516	1183
8516	1188
8516	1217
8516	1232
8516	1233
8517	1183
8517	1188
8517	1218
8517	1232
8517	1233
8518	1183
8518	1188
8518	1232
8518	1233
8518	44974
8519	1183
8519	1188
8519	1206
8519	1221
8519	1232
8520	1183
8520	1188
8520	1206
8520	1218
8520	1232
8521	1183
8521	1188
8521	1198
8521	1210
8521	1233
8522	1183
8522	1188
8522	1198
8522	1204
8522	45019
8523	1183
8523	1188
8523	1218
8523	1232
8523	1233
8524	1183
8524	1188
8524	1206
8524	1218
8524	1229
8525	1183
8525	1188
8525	1198
8525	1233
8525	44977
8526	1183
8526	1188
8526	1218
8526	1232
8526	1233
8527	1183
8527	1188
8527	1198
8527	1209
8527	1233
8528	1183
8528	1188
8528	1206
8528	1218
8528	1232
8529	1183
8529	1188
8529	1206
8529	1218
8529	1232
8530	1183
8530	1188
8530	1218
8530	1232
8530	1233
8531	1183
8531	1188
8531	1198
8531	1204
8531	1218
8532	1183
8532	1188
8532	1198
8532	1207
8532	1218
8533	1183
8533	1188
8533	1232
8533	1233
8533	44984
8534	1183
8534	1188
8534	1206
8534	1218
8534	1232
8535	1183
8535	1188
8535	1206
8535	1218
8535	1232
8536	1183
8536	1188
8536	1218
8536	1232
8536	1233
8537	1183
8537	1188
8537	1206
8537	1218
8537	1232
8538	1183
8538	1188
8538	1206
8538	1221
8538	1232
8539	1183
8539	1188
8539	1217
8539	1232
8539	1233
8540	1183
8540	1188
8540	1206
8540	1218
8540	1229
8541	1183
8541	1188
8541	1218
8541	1232
8541	1233
8542	1183
8542	1188
8542	1204
8542	1218
8542	1232
8543	1183
8543	1188
8543	1232
8543	1233
8543	45430
8544	1183
8544	1188
8544	1218
8544	1232
8544	1233
8545	1183
8545	1188
8545	1218
8545	1232
8545	1233
8546	1183
8546	1188
8546	1218
8546	1232
8546	1233
8547	1183
8547	1188
8547	1198
8547	1233
8547	44971
8548	1183
8548	1188
8548	1206
8548	1232
8548	44968
8549	1183
8549	1188
8549	1206
8549	1213
8549	1232
8550	1183
8550	1188
8550	1205
8550	1218
8550	1232
8551	1183
8551	1188
8551	1205
8551	1218
8551	1232
8552	1183
8552	1188
8552	1205
8552	1218
8552	1232
8553	1183
8553	1188
8553	1206
8553	1217
8553	1232
8554	1183
8554	1188
8554	1206
8554	1218
8554	1232
8555	1183
8555	1188
8555	1218
8555	1232
8555	1233
8556	1183
8556	1188
8556	1206
8556	1218
8556	1232
8557	1183
8557	1188
8557	1218
8557	1232
8557	1233
8558	1183
8558	1205
8558	1218
8558	1232
8558	1239
8559	1183
8559	1188
8559	1218
8559	1232
8559	1233
8560	1183
8560	1188
8560	1232
8560	1233
8560	1247
8561	1183
8561	1188
8561	1198
8561	1233
8561	44977
8562	1183
8562	1188
8562	1232
8562	1233
8562	1243
8563	1183
8563	1188
8563	1232
8563	1233
8563	45430
8564	1183
8564	1188
8564	1206
8564	1218
8564	1232
8565	1183
8565	1188
8565	1217
8565	1232
8565	1233
8566	1183
8566	1188
8566	1217
8566	1232
8566	1233
8567	1183
8567	1188
8567	1205
8567	1232
8567	44984
8569	1183
8569	1188
8569	1198
8569	1233
8569	44977
8570	1183
8570	1188
8570	1218
8570	1232
8570	1233
8571	1183
8571	1188
8571	1206
8571	1218
8571	1232
8572	1183
8572	1188
8572	1218
8572	1229
8572	1233
8573	1183
8573	1188
8573	1232
8573	1233
8573	44983
8574	1183
8574	1188
8574	1206
8574	1218
8574	1232
8575	1183
8575	1188
8575	1206
8575	1232
8575	44971
8576	1183
8576	1188
8576	1206
8576	1218
8576	1232
8577	1183
8577	1188
8577	1218
8577	1232
8577	1233
8578	1183
8578	1188
8578	1232
8578	1233
8578	45029
8582	1188
8582	1204
8582	1218
8582	1232
8582	45238
8583	1183
8583	1188
8583	1200
8583	1206
8583	44974
8584	1183
8584	1188
8584	1218
8584	1232
8584	1233
8586	1183
8586	1188
8586	1198
8586	1206
8586	1210
8588	1179
8588	1188
8588	1197
8588	1201
8588	1218
8589	1183
8589	1188
8589	1206
8589	1218
8589	1229
8590	1183
8590	1194
8590	1222
8590	1232
8590	1233
8591	1188
8591	1218
8591	1232
8591	1233
8591	45238
8592	1183
8592	1194
8592	1199
8592	1204
8592	1218
8593	1183
8593	1194
8593	1200
8593	1206
8593	1217
8595	1183
8595	1188
8595	1218
8595	1232
8595	1233
8596	1183
8596	1188
8596	1200
8596	1206
8596	1218
8598	1183
8598	1194
8598	1206
8598	1218
8598	1229
8599	1188
8599	1206
8599	1218
8599	1232
8599	45236
8600	1183
8600	1188
8600	1218
8600	1232
8600	1233
8601	1183
8601	1194
8601	1200
8601	1218
8601	1233
8602	1183
8602	1188
8602	1200
8602	1206
8602	1218
8604	1183
8604	1188
8604	1206
8604	1218
8604	1229
8605	1183
8605	1194
8605	1200
8605	1206
8605	1218
8606	1183
8606	1188
8606	1206
8606	1218
8606	1229
8607	1188
8607	1200
8607	1206
8607	1218
8607	45238
8608	1183
8608	1188
8608	1198
8608	1206
8608	1218
8609	1183
8609	1188
8609	1200
8609	1206
8609	1218
8610	1183
8610	1188
8610	1218
8610	1232
8610	1233
8611	1179
8611	1188
8611	1197
8611	1201
8611	1218
8612	1183
8612	1188
8612	1205
8612	1218
8612	1232
8613	1188
8613	1204
8613	1213
8613	1232
8613	44936
8614	1188
8614	1204
8614	1218
8614	1232
8614	45238
8615	1183
8615	1188
8615	1194
8615	1206
8615	1217
8615	1229
8615	1232
8615	1233
8616	1188
8616	1198
8616	1204
8616	1218
8616	45236
8617	1183
8617	1194
8617	1198
8617	1206
8617	45548
8618	1183
8618	1188
8618	1218
8618	1232
8618	1233
8620	1183
8620	1194
8620	1200
8620	1206
8620	1218
8621	1183
8621	1188
8621	1206
8621	1218
8621	1229
8622	1183
8622	1194
8622	1218
8622	1232
8622	1233
8623	1183
8623	1194
8623	1213
8623	1232
8623	1233
8624	1183
8624	1188
8624	1206
8624	1218
8624	1229
8628	1183
8628	1188
8628	1206
8628	1218
8628	1232
8629	1183
8629	1194
8629	1198
8629	1206
8629	1210
8630	1179
8630	1188
8630	1197
8630	1201
8630	1211
8631	1183
8631	1188
8631	1200
8631	1206
8631	1217
8632	1183
8632	1188
8632	1206
8632	1218
8632	1229
8633	1183
8633	1188
8633	1206
8633	1218
8633	1229
8634	1183
8634	1194
8634	1200
8634	1206
8634	1218
8636	1183
8636	1188
8636	1200
8636	1206
8636	1218
8637	1183
8637	1188
8637	1198
8637	1206
8637	1218
8640	1188
8640	1204
8640	1218
8640	1232
8640	45236
8641	1188
8641	1204
8641	1218
8641	1232
8641	45238
8642	1183
8642	1188
8642	1204
8642	1218
8642	1229
8643	1183
8643	1188
8643	1206
8643	1218
8643	1229
8644	1183
8644	1188
8644	1198
8644	1204
8644	1218
8645	1183
8645	1194
8645	1200
8645	1218
8645	1233
8647	1183
8647	1194
8647	1200
8647	1206
8647	1213
8648	1183
8648	1188
8648	1205
8648	1218
8648	1232
8649	1183
8649	1188
8649	1200
8649	1206
8649	1218
8650	1188
8650	1218
8650	1232
8650	1233
8650	45236
8651	1188
8651	1204
8651	1218
8651	1232
8651	45236
8653	1183
8653	1188
8653	1218
8653	1232
8653	1233
8656	1183
8656	1188
8656	1206
8656	1218
8656	1229
8657	1188
8657	1218
8657	1232
8657	1233
8657	45238
8658	1188
8658	1218
8658	1232
8658	1233
8658	45238
8660	1183
8660	1188
8660	1206
8660	1218
8660	1229
8661	1183
8661	1188
8661	1206
8661	1220
8661	1229
8662	1183
8662	1188
8662	1200
8662	1206
8662	1218
8663	1183
8663	1188
8663	1206
8663	1222
8663	1232
8665	1183
8665	1188
8665	1206
8665	1218
8665	1232
8666	1183
8666	1188
8666	1199
8666	1203
8666	1218
8667	1183
8667	1188
8667	1206
8667	1218
8667	1229
8675	1183
8675	1188
8675	1206
8675	1218
8675	1229
8676	1183
8676	1188
8676	1200
8676	1206
8676	1218
8678	1183
8678	1194
8678	1206
8678	1218
8678	1229
8679	1183
8679	1194
8679	1206
8679	1218
8679	1229
8680	1183
8680	1188
8680	1198
8680	1206
8680	1218
8681	1183
8681	1188
8681	1200
8681	1206
8681	1218
8683	1183
8683	1194
8683	1206
8683	1218
8683	1229
8684	1183
8684	1196
8684	1218
8684	1232
8684	1233
8685	1183
8685	1194
8685	1206
8685	1218
8685	1229
8686	1183
8686	1188
8686	1218
8686	1232
8686	1233
8688	1183
8688	1188
8688	1196
8688	1206
8688	1218
8688	1232
8688	1233
8688	44968
8689	1183
8689	1188
8689	1206
8689	1218
8689	1229
8690	1183
8690	1194
8690	1206
8690	1218
8690	1229
8692	1183
8692	1188
8692	1198
8692	1206
8692	1210
8694	1183
8694	1188
8694	1206
8694	1218
8694	1229
8696	1188
8696	1206
8696	1218
8696	1229
8696	45238
8697	1183
8697	1194
8697	1206
8697	1218
8697	1229
8700	1183
8700	1194
8700	1205
8700	1218
8700	1229
8702	1183
8702	1194
8702	1198
8702	1206
8702	1218
8703	1183
8703	1188
8703	1206
8703	1218
8703	1229
8705	1183
8705	1194
8705	1206
8705	1218
8705	1229
8706	1183
8706	1188
8706	1198
8706	1206
8706	1218
8707	1183
8707	1188
8707	1200
8707	1206
8707	1218
8710	1183
8710	1188
8710	1204
8710	1232
8710	44968
8712	1183
8712	1194
8712	1200
8712	1206
8712	1222
8714	1183
8714	1188
8714	1206
8714	1222
8714	1232
8715	1183
8715	1194
8715	1206
8715	1218
8715	1229
8716	1183
8716	1188
8716	1206
8716	1218
8716	1229
8719	1183
8719	1188
8719	1206
8719	1218
8719	1229
8720	1183
8720	1194
8720	1206
8720	1218
8720	1229
8722	1183
8722	1194
8722	1200
8722	1206
8722	1216
8723	1183
8723	1188
8723	1206
8723	1222
8723	1229
8724	1183
8724	1188
8724	1206
8724	1218
8724	1229
8726	1183
8726	1188
8726	1206
8726	1218
8726	1229
8727	1183
8727	1188
8727	1206
8727	1218
8727	1229
8729	1188
8729	1206
8729	1218
8729	1229
8729	45238
8730	1183
8730	1194
8730	1204
8730	1218
8730	1232
8733	1188
8733	1200
8733	1206
8733	1218
8733	45238
8735	1188
8735	1206
8735	1218
8735	1229
8735	45238
8736	1183
8736	1188
8736	1218
8736	1232
8736	1233
8737	1183
8737	1188
8737	1206
8737	1218
8737	1229
8738	1183
8738	1188
8738	1206
8738	1218
8738	1229
8739	1188
8739	1206
8739	1218
8739	1229
8739	45238
8741	1183
8741	1188
8741	1218
8741	1232
8741	1233
8742	1183
8742	1188
8742	1206
8742	1218
8742	1229
8746	1188
8746	1205
8746	1218
8746	1232
8746	45238
8748	1183
8748	1188
8748	1206
8748	1218
8748	1229
8749	1183
8749	1188
8749	1232
8749	1233
8749	1247
8750	1183
8750	1194
8750	1200
8750	1206
8750	1218
8752	1183
8752	1188
8752	1198
8752	1200
8752	1206
8752	1218
8753	1183
8753	1194
8753	1198
8753	1206
8753	1243
8754	1188
8754	1218
8754	1232
8754	1233
8754	45238
8755	1183
8755	1198
8755	1206
8755	1210
8755	1239
8756	1188
8756	1198
8756	1206
8756	1210
8756	45236
8757	1183
8757	1194
8757	1198
8757	1206
8757	1210
8758	1183
8758	1198
8758	1206
8758	1210
8758	1239
8759	1188
8759	1198
8759	1206
8759	1218
8759	45236
8760	1183
8760	1188
8760	1200
8760	1206
8760	1218
8761	1183
8761	1194
8761	1198
8761	1206
8761	1218
8762	1188
8762	1218
8762	1232
8762	1233
8762	45238
8763	1183
8763	1194
8763	1204
8763	1218
8763	1232
8764	1183
8764	1188
8764	1218
8764	1232
8764	1233
8765	1183
8765	1194
8765	1206
8765	1218
8765	1229
8766	1183
8766	1194
8766	1200
8766	1206
8766	1218
8767	1183
8767	1188
8767	1200
8767	1206
8767	1218
8770	1183
8770	1188
8770	1200
8770	1206
8770	1218
8774	1183
8774	1188
8774	1200
8774	1206
8774	45543
8777	1188
8777	1206
8777	1218
8777	1229
8777	45238
8778	1183
8778	1194
8778	1204
8778	1216
8778	1229
8780	1183
8780	1188
8780	1218
8780	1232
8780	1233
8781	1183
8781	1188
8781	1200
8781	1206
8781	1218
8782	1183
8782	1188
8782	1206
8782	1218
8782	1229
8783	1183
8783	1188
8783	1206
8783	1218
8783	1229
8784	1188
8784	1198
8784	1206
8784	1218
8784	45238
8787	1183
8787	1194
8787	1200
8787	1206
8787	45630
8790	1183
8790	1188
8790	1200
8790	1206
8790	1218
8791	1183
8791	1188
8791	1200
8791	1206
8791	1218
8792	1183
8792	1188
8792	1200
8792	1206
8792	1218
8793	1183
8793	1188
8793	1200
8793	1206
8793	1218
8794	1183
8794	1188
8794	1206
8794	1232
8794	45435
8797	1183
8797	1188
8797	1200
8797	1206
8797	1218
8798	1183
8798	1194
8798	1206
8798	1218
8798	1229
8799	1183
8799	1188
8799	1232
8799	1233
8799	45430
8800	1183
8800	1188
8800	1198
8800	1206
8800	1220
8801	1183
8801	1188
8801	1206
8801	1221
8801	1232
8801	45181
8802	1183
8802	1188
8802	1200
8802	1206
8802	1218
8803	1183
8803	1188
8803	1206
8803	1221
8803	1229
8804	1183
8804	1188
8804	1206
8804	1232
8804	45533
8805	1183
8805	1188
8805	1198
8805	1205
8805	1218
8806	1183
8806	1188
8806	1198
8806	1206
8806	1218
8807	1183
8807	1188
8807	1232
8807	1233
8807	1247
8808	1183
8808	1196
8808	1218
8808	1232
8808	1233
8813	1183
8813	1188
8813	1218
8813	1232
8813	1233
8814	1183
8814	1188
8814	1200
8814	1206
8814	45435
8815	1183
8815	1194
8815	1218
8815	1232
8815	1233
8816	1188
8816	1206
8816	1220
8816	1232
8816	45238
8818	1183
8818	1188
8818	1218
8818	1232
8818	1233
8819	1183
8819	1188
8819	1204
8819	1218
8819	1232
8820	1183
8820	1188
8820	1218
8820	1232
8820	1233
8821	1183
8821	1194
8821	1206
8821	1220
8821	1229
8822	1183
8822	1188
8822	1206
8822	1218
8822	1229
8823	1183
8823	1194
8823	1206
8823	1220
8823	1229
8824	1183
8824	1188
8824	1206
8824	1218
8824	1229
8825	1183
8825	1188
8825	1218
8825	1232
8825	1233
8826	1183
8826	1188
8826	1206
8826	1218
8826	1229
8828	1188
8828	1206
8828	1220
8828	1229
8828	45238
8829	1183
8829	1194
8829	1206
8829	1218
8829	1229
8830	1183
8830	1194
8830	1206
8830	1218
8830	1229
8831	1183
8831	1188
8831	1206
8831	1229
8831	45569
8832	1183
8832	1188
8832	1218
8832	1232
8832	1233
8834	1183
8834	1188
8834	1206
8834	1218
8834	1229
8838	1183
8838	1194
8838	1200
8838	1206
8838	1218
8839	1183
8839	1188
8839	1206
8839	1218
8839	1229
8840	1183
8840	1188
8840	1206
8840	1218
8840	1229
8841	1183
8841	1194
8841	1206
8841	1218
8841	1229
8842	1183
8842	1188
8842	1206
8842	1217
8842	1229
8844	1183
8844	1188
8844	1206
8844	1213
8844	1229
8847	1188
8847	1206
8847	1229
8847	45236
8847	45399
8848	1183
8848	1188
8848	1206
8848	1217
8848	1229
8849	1183
8849	1194
8849	1206
8849	1218
8849	1229
8850	1183
8850	1188
8850	1206
8850	1218
8850	1232
8852	1183
8852	1188
8852	1200
8852	1206
8852	1218
8853	1183
8853	1194
8853	1200
8853	1206
8853	1218
8858	1183
8858	1188
8858	1232
8858	1233
8858	44971
8859	1183
8859	1188
8859	1198
8859	1206
8859	1218
8861	1183
8861	1188
8861	1198
8861	1221
8861	1233
8862	1183
8862	1193
8862	1206
8862	1218
8862	1232
8863	1183
8863	1188
8863	1218
8863	1232
8863	1233
8864	1183
8864	1188
8864	1198
8864	1211
8864	1231
8864	1233
8865	1183
8865	1188
8865	1200
8865	1206
8865	1218
8867	1183
8867	1188
8867	1200
8867	1206
8867	1218
8869	1183
8869	1188
8869	1200
8869	1206
8869	1218
8870	1183
8870	1194
8870	1198
8870	1204
8870	1246
8872	1183
8872	1188
8872	1200
8872	1206
8872	1217
8873	1183
8873	1188
8873	1200
8873	1206
8873	1218
8874	1183
8874	1188
8874	1200
8874	1206
8874	1218
8875	1183
8875	1188
8875	1206
8875	1218
8875	1229
8876	1183
8876	1188
8876	1206
8876	1218
8876	1229
8877	1183
8877	1188
8877	1206
8877	1218
8877	1229
8878	1183
8878	1188
8878	1217
8878	1232
8878	1233
8889	1183
8889	1194
8889	1200
8889	1206
8889	1218
8890	1183
8890	1188
8890	1217
8890	1232
8890	1233
8892	1188
8892	1198
8892	1206
8892	1218
8892	45238
8893	1183
8893	1194
8893	1218
8893	1232
8893	1233
8894	1183
8894	1188
8894	1198
8894	1206
8894	1218
8895	1188
8895	1198
8895	1218
8895	1233
8895	45236
8896	1183
8896	1188
8896	1200
8896	1206
8896	1218
8897	1179
8897	1188
8897	1197
8897	1201
8897	1218
8898	1183
8898	1188
8898	1198
8898	1206
8898	1209
8899	1183
8899	1188
8899	1204
8899	1218
8899	1232
8900	1188
8900	1198
8900	1206
8900	1218
8900	45238
8901	1183
8901	1188
8901	1200
8901	1206
8901	1218
8903	1183
8903	1188
8903	1206
8903	1218
8903	1229
8906	1183
8906	1188
8906	1218
8906	1232
8906	1233
8907	1183
8907	1194
8907	1206
8907	1218
8907	1229
8908	1183
8908	1188
8908	1205
8908	1218
8908	1232
8909	1183
8909	1188
8909	1206
8909	1218
8909	1229
8910	1183
8910	1188
8910	1218
8910	1232
8910	1233
8911	1183
8911	1188
8911	1213
8911	1232
8911	1233
8912	1183
8912	1194
8912	1200
8912	1206
8912	1218
8913	1183
8913	1198
8913	1206
8913	1218
8913	1239
8914	1183
8914	1188
8914	1200
8914	1206
8914	1218
8915	1188
8915	1198
8915	1206
8915	1218
8915	45238
8916	1183
8916	1188
8916	1204
8916	1218
8916	1232
8917	1183
8917	1188
8917	1205
8917	1218
8917	1232
8918	1183
8918	1188
8918	1200
8918	1206
8918	1218
8919	1183
8919	1188
8919	1200
8919	1206
8919	1218
8923	1183
8923	1188
8923	1218
8923	1232
8923	1233
8924	1188
8924	1218
8924	1232
8924	1233
8924	45238
8925	1183
8925	1188
8925	1206
8925	1218
8925	1229
8927	1183
8927	1188
8927	1218
8927	1232
8927	1233
8928	1183
8928	1188
8928	1198
8928	1206
8928	1218
8929	1183
8929	1188
8929	1200
8929	1206
8929	1218
8930	1183
8930	1188
8930	1198
8930	1206
8930	1243
8932	1183
8932	1188
8932	1206
8932	1218
8932	1229
8933	1183
8933	1194
8933	1206
8933	1218
8933	1229
8934	1183
8934	1188
8934	1200
8934	1206
8934	1218
8935	1183
8935	1194
8935	1206
8935	1218
8935	1229
8936	1183
8936	1194
8936	1200
8936	1206
8936	1218
8937	1183
8937	1188
8937	1200
8937	1206
8937	1218
8938	1183
8938	1188
8938	1206
8938	1218
8938	1229
8939	1183
8939	1194
8939	1218
8939	1232
8939	1233
8940	1183
8940	1194
8940	1200
8940	1206
8940	1218
8941	1183
8941	1188
8941	1200
8941	1206
8941	1218
8942	1183
8942	1188
8942	1206
8942	1218
8942	1229
8944	1183
8944	1188
8944	1200
8944	1206
8944	1218
8945	1183
8945	1188
8945	1200
8945	1206
8945	1218
8946	1183
8946	1188
8946	1200
8946	1206
8946	1218
8947	1188
8947	1218
8947	1232
8947	1233
8947	45238
8948	1183
8948	1194
8948	1206
8948	1218
8948	1229
8949	1183
8949	1194
8949	1206
8949	1218
8949	1229
8950	1183
8950	1188
8950	1198
8950	1206
8950	1218
8951	1183
8951	1188
8951	1232
8951	1233
8951	45181
8952	1183
8952	1188
8952	1199
8952	1203
8952	1218
8953	1188
8953	1203
8953	1218
8953	1232
8953	45236
8954	1183
8954	1188
8954	1198
8954	1206
8954	1218
8955	1183
8955	1188
8955	1218
8955	1232
8955	1233
8956	1183
8956	1188
8956	1218
8956	1232
8956	1233
8957	1183
8957	1188
8957	1200
8957	1206
8957	1246
8959	1183
8959	1188
8959	1200
8959	1206
8959	1218
8960	1183
8960	1188
8960	1197
8960	1204
8960	1218
8961	1183
8961	1194
8961	1218
8961	1232
8961	1233
8962	1183
8962	1188
8962	1204
8962	1218
8962	1232
8963	1183
8963	1188
8963	1206
8963	1222
8963	1229
8966	1183
8966	1188
8966	1200
8966	1206
8966	1218
8967	1182
8967	1188
8967	1198
8967	1206
8967	1218
8970	1183
8970	1194
8970	1204
8970	1218
8970	1229
8971	1183
8971	1188
8971	1218
8971	1232
8971	1233
8972	1183
8972	1188
8972	1206
8972	1220
8972	1229
8973	1183
8973	1188
8973	1206
8973	1218
8973	1229
8976	1183
8976	1188
8976	1198
8976	1206
8976	1222
8977	1183
8977	1188
8977	1206
8977	1218
8977	1229
8978	1183
8978	1194
8978	1200
8978	1206
8978	1218
8979	1183
8979	1188
8979	1206
8979	1218
8979	1229
8980	1183
8980	1194
8980	1206
8980	1216
8980	1229
8983	1183
8983	1188
8983	1206
8983	1218
8983	1229
8984	1183
8984	1188
8984	1200
8984	1206
8984	1218
8985	1183
8985	1188
8985	1206
8985	1218
8985	1229
8986	1183
8986	1188
8986	1198
8986	1206
8986	1218
8987	1183
8987	1194
8987	1218
8987	1232
8987	1233
8988	1183
8988	1188
8988	1218
8988	1232
8988	1233
8989	1183
8989	1194
8989	1206
8989	1218
8989	1229
8990	1183
8990	1188
8990	1232
8990	1233
8990	1246
8990	45570
8992	1183
8992	1188
8992	1198
8992	1206
8992	1218
8993	1183
8993	1188
8993	1206
8993	1218
8993	1229
8994	1183
8994	1188
8994	1200
8994	1206
8994	1218
8995	1183
8995	1188
8995	1200
8995	1206
8995	1218
8996	1183
8996	1194
8996	1200
8996	1206
8996	1218
8997	1183
8997	1194
8997	1218
8997	1232
8997	1233
8998	1183
8998	1194
8998	1198
8998	1206
8998	1218
8999	1183
8999	1188
8999	1200
8999	1206
8999	1213
9001	1188
9001	1204
9001	1218
9001	1232
9001	44936
9002	1183
9002	1194
9002	1218
9002	1232
9002	1233
9003	1183
9003	1194
9003	1206
9003	1218
9003	1229
9004	1183
9004	1194
9004	1206
9004	1218
9004	1229
9005	1183
9005	1188
9005	1198
9005	1206
9005	45399
9007	1183
9007	1194
9007	1206
9007	1218
9007	1229
9008	1183
9008	1188
9008	1206
9008	1218
9008	1229
9008	1239
9010	1183
9010	1188
9010	1206
9010	1218
9010	1229
9011	1183
9011	1188
9011	1205
9011	1218
9011	1232
9013	1183
9013	1194
9013	1198
9013	1206
9013	1218
9018	1183
9018	1194
9018	1218
9018	1232
9018	1233
9019	1183
9019	1194
9019	1206
9019	1218
9019	1229
9020	1183
9020	1188
9020	1200
9020	1206
9020	1218
9021	1183
9021	1198
9021	1206
9021	1218
9021	1239
9022	1188
9022	1206
9022	1222
9022	1229
9022	45238
9024	1182
9024	1188
9024	1232
9024	1233
9024	45134
9026	1183
9026	1188
9026	1218
9026	1232
9026	1233
9027	1183
9027	1188
9027	1198
9027	1206
9027	1218
9028	1183
9028	1188
9028	1206
9028	1218
9028	1229
9029	1183
9029	1188
9029	1206
9029	1218
9029	1229
9030	1183
9030	1188
9030	1206
9030	1218
9030	1229
9031	1183
9031	1188
9031	1206
9031	1232
9031	44983
9032	1183
9032	1188
9032	1222
9032	1232
9032	1233
9033	1183
9033	1194
9033	1200
9033	1206
9033	1218
9034	1183
9034	1188
9034	1218
9034	1232
9034	1233
9035	1183
9035	1191
9035	1198
9035	1206
9035	44971
9036	1183
9036	1198
9036	1206
9036	1218
9036	1239
9037	1183
9037	1188
9037	1206
9037	1218
9037	1232
9038	1183
9038	1194
9038	1206
9038	1218
9038	1229
9039	1183
9039	1194
9039	1206
9039	1218
9039	1229
9040	1190
9040	1198
9040	1204
9040	1218
9040	45236
9041	1183
9041	1188
9041	1206
9041	1218
9041	1229
9042	1183
9042	1194
9042	1200
9042	1206
9042	1218
9043	1183
9043	1188
9043	1206
9043	1218
9043	1229
9045	1183
9045	1188
9045	1206
9045	1218
9045	1229
9046	1183
9046	1188
9046	1200
9046	1206
9046	1218
9047	1183
9047	1188
9047	1218
9047	1232
9047	1233
9048	1183
9048	1188
9048	1206
9048	1218
9048	1229
9049	1188
9049	1232
9049	1233
9049	45238
9049	45337
9050	1183
9050	1192
9050	1200
9050	1206
9050	1218
9052	1188
9052	1206
9052	1218
9052	1229
9052	45238
9053	1188
9053	1206
9053	1218
9053	1229
9053	45236
9054	1183
9054	1194
9054	1206
9054	1218
9054	1229
9055	1183
9055	1188
9055	1200
9055	1206
9055	1218
9056	1183
9056	1188
9056	1200
9056	1206
9056	1218
9057	1183
9057	1188
9057	1198
9057	1206
9057	1218
9059	1183
9059	1194
9059	1198
9059	1206
9059	1218
9063	1183
9063	1188
9063	1206
9063	1218
9063	1229
9064	1183
9064	1188
9064	1198
9064	1206
9064	45562
9065	1188
9065	1206
9065	1218
9065	1229
9065	45236
9066	1183
9066	1196
9066	1200
9066	1206
9066	1218
9067	1183
9067	1191
9067	1200
9067	1206
9067	1218
9069	1183
9069	1188
9069	1206
9069	1232
9069	1243
9070	1183
9070	1188
9070	1206
9070	1232
9070	45549
9071	1188
9071	1218
9071	1232
9071	1233
9071	45238
9072	1183
9072	1194
9072	1218
9072	1232
9072	1233
9073	1183
9073	1194
9073	1200
9073	1206
9073	1218
9074	1183
9074	1188
9074	1206
9074	1222
9074	1229
9075	1183
9075	1188
9075	1206
9075	1218
9075	1232
9076	1188
9076	1198
9076	1206
9076	1218
9076	45236
9078	1183
9078	1188
9078	1232
9078	1233
9078	45356
9079	1183
9079	1188
9079	1206
9079	1218
9079	1229
9080	1183
9080	1188
9080	1200
9080	1206
9080	1218
9082	1188
9082	1198
9082	1206
9082	1218
9082	45238
9084	1183
9084	1188
9084	1217
9084	1232
9084	1233
9086	1183
9086	1194
9086	1204
9086	1218
9086	1232
9087	1183
9087	1188
9087	1200
9087	1206
9087	1218
9088	1183
9088	1188
9088	1204
9088	1218
9088	1229
9091	1183
9091	1188
9091	1206
9091	1218
9091	1229
9092	1183
9092	1188
9092	1206
9092	1217
9092	1229
9093	1183
9093	1194
9093	1218
9093	1232
9093	1233
9094	1183
9094	1188
9094	1198
9094	1204
9094	1218
9095	1183
9095	1194
9095	1200
9095	1206
9095	45314
9096	1183
9096	1188
9096	1198
9096	1206
9096	1218
9097	1183
9097	1188
9097	1200
9097	1206
9097	1218
9098	1188
9098	1200
9098	1206
9098	1218
9098	45238
9099	1183
9099	1188
9099	1206
9099	1218
9099	1229
9100	1183
9100	1194
9100	1206
9100	1218
9100	1229
9101	1183
9101	1188
9101	1206
9101	1218
9101	1229
9104	1183
9104	1188
9104	1206
9104	1218
9104	1229
9106	1183
9106	1188
9106	1200
9106	1206
9106	1218
9106	1220
9106	1222
9106	1229
9106	1232
9106	1233
9106	45134
9109	1183
9109	1188
9109	1200
9109	1206
9109	1218
9112	1183
9112	1188
9112	1206
9112	1218
9112	1229
9113	1183
9113	1194
9113	1204
9113	1218
9113	1229
9116	1188
9116	1218
9116	1232
9116	1233
9116	45238
9118	1183
9118	1188
9118	1206
9118	1218
9118	1229
9119	1183
9119	1188
9119	1206
9119	1218
9119	1229
9120	1183
9120	1188
9120	1206
9120	1218
9120	1229
9121	1183
9121	1188
9121	1218
9121	1232
9121	1233
9122	1183
9122	1188
9122	1218
9122	1232
9122	1233
9125	1183
9125	1188
9125	1206
9125	1218
9125	1229
9126	1183
9126	1188
9126	1206
9126	1218
9126	1229
9127	1188
9127	1206
9127	1222
9127	1232
9127	45238
9128	1188
9128	1198
9128	1206
9128	1218
9128	45238
9131	1183
9131	1188
9131	1206
9131	1218
9131	1229
9132	1183
9132	1188
9132	1198
9132	1206
9132	1218
9133	1183
9133	1188
9133	1200
9133	1206
9133	1218
9135	1183
9135	1188
9135	1232
9135	1233
9135	45430
9141	1188
9141	1205
9141	1218
9141	1229
9141	45238
9143	1183
9143	1188
9143	1198
9143	1206
9143	45134
9147	1183
9147	1188
9147	1204
9147	1218
9147	1232
9149	1183
9149	1196
9149	1200
9149	1206
9149	1218
9150	1183
9150	1188
9150	1200
9150	1206
9150	1218
9151	1183
9151	1188
9151	1206
9151	1221
9151	1232
9152	1183
9152	1188
9152	1206
9152	1218
9152	1232
9153	1183
9153	1188
9153	1218
9153	1232
9153	1233
9154	1183
9154	1188
9154	1198
9154	1204
9154	44971
9155	1183
9155	1188
9155	1198
9155	1206
9155	1218
9156	1183
9156	1188
9156	1206
9156	1221
9156	1232
9157	1183
9157	1198
9157	1206
9157	1218
9157	1239
9158	1183
9158	1188
9158	1198
9158	1206
9158	1217
9159	1183
9159	1188
9159	1206
9159	1218
9159	1232
9160	1183
9160	1188
9160	1198
9160	1206
9160	1218
9161	1183
9161	1188
9161	1198
9161	1206
9161	1218
9162	1183
9162	1188
9162	1198
9162	1218
9162	1233
9163	1183
9163	1194
9163	1200
9163	1206
9163	1246
9164	1183
9164	1188
9164	1217
9164	1232
9164	1233
9165	1183
9165	1188
9165	1198
9165	1204
9165	1218
9166	1183
9166	1188
9166	1232
9166	1233
9166	1261
9167	1183
9167	1188
9167	1198
9167	1218
9167	1233
9168	1183
9168	1188
9168	1232
9168	1233
9168	44984
9169	1183
9169	1188
9169	1232
9169	1233
9169	44968
9170	1183
9170	1188
9170	1198
9170	1206
9170	1217
9171	1183
9171	1188
9171	1213
9171	1232
9171	1233
9172	1183
9172	1188
9172	1206
9172	1218
9172	1229
9173	1183
9173	1188
9173	1206
9173	1218
9173	1232
9174	1183
9174	1188
9174	1205
9174	1218
9174	1232
9175	1183
9175	1188
9175	1206
9175	1218
9175	1232
9176	1183
9176	1188
9176	1218
9176	1232
9176	1233
9177	1183
9177	1188
9177	1206
9177	1217
9177	1232
9178	1183
9178	1188
9178	1200
9178	1206
9178	44974
9179	1183
9179	1188
9179	1200
9179	1206
9179	44968
9180	1183
9180	1188
9180	1205
9180	1218
9180	1232
9181	1183
9181	1188
9181	1205
9181	1218
9181	1232
9182	1183
9182	1188
9182	1206
9182	1218
9182	1232
9183	1183
9183	1188
9183	1206
9183	1209
9183	1232
9184	1183
9184	1188
9184	1200
9184	1205
9184	44974
9185	1183
9185	1188
9185	1198
9185	1206
9185	1218
9186	1183
9186	1188
9186	1206
9186	1218
9186	1232
9187	1183
9187	1188
9187	1206
9187	1218
9187	1232
9188	1183
9188	1188
9188	1206
9188	1221
9188	1232
9189	1183
9189	1188
9189	1204
9189	1218
9189	1232
9190	1183
9190	1191
9190	1204
9190	1232
9190	44971
9191	1183
9191	1188
9191	1206
9191	1218
9191	1232
9192	1183
9192	1191
9192	1204
9192	1232
9192	44971
9193	1183
9193	1191
9193	1204
9193	1232
9193	44971
9194	1183
9194	1191
9194	1204
9194	1232
9194	44971
9195	1183
9195	1188
9195	1204
9195	1218
9195	1232
9196	1183
9196	1188
9196	1206
9196	1221
9196	1232
9197	1183
9197	1188
9197	1200
9197	1206
9197	1218
9198	1183
9198	1188
9198	1205
9198	1218
9198	1232
9199	1183
9199	1188
9199	1206
9199	1221
9199	1232
9200	1183
9200	1188
9200	1207
9200	1218
9200	1232
9201	1183
9201	1188
9201	1206
9201	1218
9201	1232
9202	1183
9202	1188
9202	1206
9202	1218
9202	1232
9203	1183
9203	1188
9203	1200
9203	1218
9203	1233
9204	1183
9204	1188
9204	1206
9204	1232
9204	45145
9205	1183
9205	1188
9205	1206
9205	1218
9205	1232
9206	1183
9206	1188
9206	1218
9206	1232
9206	1233
9207	1183
9207	1188
9207	1200
9207	1206
9207	1218
9207	1232
9208	1183
9208	1188
9208	1200
9208	1206
9208	1218
9209	1183
9209	1188
9209	1206
9209	1218
9209	1229
9210	1183
9210	1188
9210	1200
9210	1206
9210	1218
9211	1183
9211	1188
9211	1206
9211	1218
9211	1232
9212	1183
9212	1188
9212	1206
9212	1232
9212	45037
9213	1183
9213	1188
9213	1200
9213	1218
9213	1233
9214	1183
9214	1191
9214	1232
9214	1233
9214	45037
9215	1183
9215	1188
9215	1200
9215	1206
9215	1218
9216	1183
9216	1188
9216	1200
9216	1206
9216	1218
9217	1183
9217	1188
9217	1206
9217	1218
9217	1232
9218	1183
9218	1188
9218	1206
9218	1232
9218	44971
9219	1183
9219	1188
9219	1206
9219	1232
9219	44971
9220	1183
9220	1188
9220	1206
9220	1217
9220	1232
9221	1183
9221	1188
9221	1206
9221	1218
9221	1232
9222	1183
9222	1188
9222	1206
9222	1232
9222	44970
9223	1183
9223	1188
9223	1205
9223	1232
9223	45039
9224	1183
9224	1188
9224	1206
9224	1232
9224	45040
9225	1183
9225	1188
9225	1204
9225	1218
9225	1232
9227	1183
9227	1188
9227	1205
9227	1218
9227	1232
9228	1183
9228	1188
9228	1200
9228	1206
9228	1218
9229	1183
9229	1188
9229	1200
9229	1233
9229	44974
9230	1183
9230	1188
9230	1200
9230	1206
9230	1218
9231	1183
9231	1188
9231	1206
9231	1218
9231	1232
9232	1183
9232	1188
9232	1218
9232	1232
9232	1233
9234	1183
9234	1188
9234	1206
9234	1217
9234	1232
9235	1183
9235	1188
9235	1206
9235	1218
9235	1232
9236	1183
9236	1188
9236	1200
9236	1218
9236	1233
9237	1183
9237	1188
9237	1200
9237	1206
9237	1218
9238	1183
9238	1188
9238	1232
9238	1233
9238	44970
9239	1183
9239	1188
9239	1200
9239	1204
9239	1218
9240	1183
9240	1188
9240	1206
9240	1210
9240	1232
9241	1183
9241	1188
9241	1218
9241	1232
9241	1233
9242	1183
9242	1188
9242	1204
9242	1218
9242	1232
9243	1183
9243	1188
9243	1205
9243	1218
9243	1232
9244	1183
9244	1188
9244	1200
9244	1206
9244	1218
9245	1183
9245	1188
9245	1204
9245	1218
9245	1232
9246	1183
9246	1188
9246	1204
9246	1218
9246	1232
9247	1183
9247	1188
9247	1200
9247	1206
9247	1218
9248	1183
9248	1188
9248	1210
9248	1232
9248	1233
9249	1183
9249	1188
9249	1204
9249	1232
9249	44971
9250	1183
9250	1188
9250	1206
9250	1217
9250	1232
9251	1183
9251	1188
9251	1205
9251	1218
9251	1232
9252	1183
9252	1188
9252	1206
9252	1217
9252	1232
9253	1183
9253	1188
9253	1218
9253	1232
9253	1233
9254	1183
9254	1188
9254	1218
9254	1232
9254	1233
9255	1183
9255	1188
9255	1206
9255	1232
9255	44968
9256	1183
9256	1188
9256	1198
9256	1205
9256	1210
9257	1183
9257	1188
9257	1206
9257	1232
9257	44971
9258	1183
9258	1188
9258	1198
9258	1210
9258	1233
9259	1183
9259	1188
9259	1206
9259	1232
9259	44971
9261	1183
9261	1188
9261	1200
9261	1204
9261	1243
9262	1183
9262	1188
9262	1206
9262	1232
9262	45045
9263	1183
9263	1188
9263	1205
9263	1232
9263	45399
9264	1183
9264	1188
9264	1200
9264	1206
9264	1218
9265	1183
9265	1188
9265	1204
9265	1232
9265	44970
9266	1183
9266	1188
9266	1204
9266	1232
9266	45039
9267	1183
9267	1188
9267	1205
9267	1218
9267	1232
9268	1183
9268	1188
9268	1200
9268	1206
9268	44968
9269	1183
9269	1188
9269	1205
9269	1232
9269	45047
9270	1183
9270	1188
9270	1221
9270	1232
9270	1233
9271	1183
9271	1188
9271	1206
9271	1213
9271	1232
9272	1180
9272	1188
9272	1197
9272	1201
9272	1243
9273	1183
9273	1188
9273	1206
9273	1218
9273	1232
9274	1183
9274	1188
9274	1204
9274	1232
9274	45048
9275	1183
9275	1188
9275	1204
9275	1218
9275	1232
9276	1183
9276	1188
9276	1206
9276	1232
9276	45181
9277	1188
9277	1200
9277	1218
9277	1233
9277	45236
9279	1183
9279	1188
9279	1206
9279	1221
9279	1232
9280	1183
9280	1188
9280	1206
9280	1218
9280	1232
9282	1183
9282	1188
9282	1205
9282	1232
9282	44968
9284	1183
9284	1188
9284	1218
9284	1232
9284	1233
9285	1183
9285	1188
9285	1218
9285	1232
9285	1233
9286	1183
9286	1188
9286	1206
9286	1217
9286	1229
9287	1183
9287	1188
9287	1218
9287	1232
9287	1233
9288	1183
9288	1194
9288	1200
9288	1206
9288	1218
9289	1183
9289	1188
9289	1200
9289	1206
9289	1218
9290	1183
9290	1188
9290	1206
9290	1218
9290	1229
9291	1183
9291	1188
9291	1206
9291	1218
9291	1229
9293	1183
9293	1188
9293	1218
9293	1232
9293	1233
9294	1183
9294	1188
9294	1213
9294	1232
9294	1233
9295	1183
9295	1188
9295	1200
9295	1206
9295	1218
9296	1183
9296	1188
9296	1198
9296	1206
9296	1218
9297	1183
9297	1188
9297	1206
9297	1218
9297	1229
9298	1183
9298	1188
9298	1206
9298	1218
9298	1229
9299	1183
9299	1188
9299	1218
9299	1232
9299	1233
9300	1183
9300	1188
9300	1206
9300	1218
9300	1229
9301	1183
9301	1188
9301	1198
9301	1206
9301	1218
9302	1183
9302	1188
9302	1206
9302	1218
9302	1229
9303	1183
9303	1188
9303	1200
9303	1206
9303	1218
9304	1183
9304	1188
9304	1198
9304	1206
9304	1218
9305	1183
9305	1196
9305	1206
9305	1218
9305	1229
9306	1183
9306	1188
9306	1206
9306	1218
9306	1232
9307	1183
9307	1188
9307	1206
9307	1218
9307	1229
9308	1183
9308	1188
9308	1218
9308	1232
9308	1233
9309	1183
9309	1188
9309	1218
9309	1232
9309	1233
9310	1183
9310	1188
9310	1206
9310	1210
9310	1232
9314	1183
9314	1188
9314	1198
9314	1206
9314	1218
9315	1183
9315	1188
9315	1198
9315	1206
9315	1218
9316	1183
9316	1188
9316	1200
9316	1206
9316	1218
9316	45238
9317	1183
9317	1188
9317	1206
9317	1218
9317	1232
9318	1188
9318	1206
9318	1218
9318	1229
9318	45238
9319	1183
9319	1188
9319	1206
9319	1218
9319	1229
9320	1183
9320	1194
9320	1206
9320	1218
9320	1232
9321	1183
9321	1188
9321	1198
9321	1205
9321	1222
9322	1183
9322	1194
9322	1206
9322	1213
9322	1232
9323	1188
9323	1218
9323	1232
9323	1233
9323	45238
9326	1188
9326	1218
9326	1232
9326	1233
9326	45238
9327	1183
9327	1188
9327	1206
9327	1218
9327	1232
9328	1183
9328	1188
9328	1203
9328	1218
9328	1229
9329	1183
9329	1188
9329	1203
9329	1218
9329	1229
9330	1183
9330	1188
9330	1218
9330	1232
9330	1233
9331	1183
9331	1196
9331	1218
9331	1232
9331	1233
9332	1188
9332	1206
9332	1218
9332	1229
9332	45238
9333	1188
9333	1218
9333	1232
9333	1233
9333	45238
9334	1183
9334	1188
9334	1206
9334	1218
9334	1229
9335	1188
9335	1218
9335	1232
9335	1233
9335	45238
9336	1183
9336	1188
9336	1218
9336	1232
9336	1233
9337	1188
9337	1205
9337	1218
9337	1232
9337	45238
9338	1188
9338	1204
9338	1218
9338	1232
9338	45238
9340	1183
9340	1188
9340	1218
9340	1232
9340	1233
9341	1183
9341	1188
9341	1206
9341	1218
9341	1229
9342	1188
9342	1218
9342	1232
9342	1233
9342	45238
9343	1188
9343	1218
9343	1232
9343	1233
9343	45238
9344	1183
9344	1194
9344	1218
9344	1232
9344	1233
9345	1183
9345	1194
9345	1206
9345	1218
9345	1229
9346	1183
9346	1196
9346	1218
9346	1232
9346	1233
9347	1183
9347	1188
9347	1218
9347	1232
9347	1233
9348	1188
9348	1218
9348	1232
9348	1233
9348	45238
9351	1188
9351	1218
9351	1232
9351	1233
9351	45238
9352	1188
9352	1205
9352	1218
9352	1232
9352	45238
9353	1188
9353	1218
9353	1232
9353	1233
9353	45238
9355	1183
9355	1188
9355	1218
9355	1232
9355	1233
9358	1188
9358	1198
9358	1206
9358	1218
9358	45238
9359	1183
9359	1188
9359	1218
9359	1232
9359	1233
9360	1183
9360	1188
9360	1218
9360	1232
9360	1233
9361	1183
9361	1188
9361	1206
9361	1218
9361	1229
9362	1188
9362	1218
9362	1232
9362	1233
9362	45236
9365	1188
9365	1218
9365	1232
9365	1233
9365	45238
9366	1183
9366	1194
9366	1205
9366	1218
9366	1232
9367	1183
9367	1188
9367	1209
9367	1232
9367	1233
9368	1183
9368	1188
9368	1218
9368	1232
9368	1233
9369	1183
9369	1188
9369	1218
9369	1232
9369	1233
9370	1188
9370	1218
9370	1232
9370	1233
9370	45238
9371	1183
9371	1188
9371	1232
9371	1233
9371	44971
9372	1183
9372	1188
9372	1204
9372	1218
9372	1232
9373	1183
9373	1188
9373	1206
9373	1217
9373	1229
9374	1183
9374	1188
9374	1205
9374	1218
9374	1232
9375	1183
9375	1194
9375	1218
9375	1232
9375	1233
9376	1188
9376	1218
9376	1232
9376	1233
9376	45238
9377	1183
9377	1188
9377	1206
9377	1218
9377	1229
9378	1183
9378	1188
9378	1205
9378	1218
9378	1232
9379	1183
9379	1188
9379	1218
9379	1232
9379	1233
9381	1183
9381	1188
9381	1198
9381	1206
9381	1218
9382	1183
9382	1188
9382	1200
9382	1206
9382	1218
9383	1183
9383	1188
9383	1200
9383	1206
9383	1218
9384	1183
9384	1188
9384	1206
9384	1218
9384	1229
9385	1183
9385	1188
9385	1206
9385	1217
9385	1229
9386	1183
9386	1188
9386	1206
9386	1218
9386	1229
9387	1183
9387	1188
9387	1218
9387	1232
9387	1233
9388	1183
9388	1188
9388	1218
9388	1232
9388	1233
9389	1183
9389	1194
9389	1218
9389	1232
9389	1233
9390	1183
9390	1188
9390	1218
9390	1232
9390	1233
9391	1183
9391	1194
9391	1218
9391	1232
9391	1233
9392	1183
9392	1194
9392	1218
9392	1232
9392	1233
9394	1188
9394	1218
9394	1232
9394	1233
9394	45238
9398	1188
9398	1218
9398	1232
9398	1233
9398	45238
9401	1183
9401	1188
9401	1218
9401	1232
9401	1233
9402	1183
9402	1188
9402	1198
9402	1206
9402	1218
9403	1183
9403	1188
9403	1218
9403	1232
9403	1233
9404	1183
9404	1194
9404	1218
9404	1232
9404	1233
9405	1188
9405	1205
9405	1218
9405	1232
9405	45236
9406	1183
9406	1188
9406	1218
9406	1232
9406	1233
9407	1183
9407	1188
9407	1218
9407	1232
9407	1233
9408	1183
9408	1188
9408	1220
9408	1232
9408	1233
9409	1183
9409	1196
9409	1218
9409	1232
9409	1233
9410	1188
9410	1218
9410	1232
9410	1233
9410	45238
9411	1188
9411	1218
9411	1232
9411	1233
9411	45238
9412	1183
9412	1188
9412	1222
9412	1232
9412	1233
9413	1183
9413	1188
9413	1198
9413	1206
9413	1218
9414	1188
9414	1218
9414	1232
9414	1233
9414	45238
9415	1188
9415	1205
9415	1218
9415	1232
9415	45236
9416	1183
9416	1188
9416	1218
9416	1232
9416	1233
9418	1183
9418	1188
9418	1206
9418	1218
9418	1229
9419	1183
9419	1188
9419	1218
9419	1232
9419	1233
9420	1183
9420	1188
9420	1198
9420	1205
9420	1218
9421	1183
9421	1206
9421	1218
9421	1232
9421	1239
9422	1183
9422	1188
9422	1206
9422	1218
9422	1229
9423	1183
9423	1194
9423	1222
9423	1232
9423	1233
9425	1188
9425	1204
9425	1218
9425	1232
9425	45236
9426	1183
9426	1188
9426	1218
9426	1232
9426	1233
9427	1183
9427	1188
9427	1206
9427	1218
9427	1229
9428	1188
9428	1204
9428	1218
9428	1232
9428	45236
9429	1188
9429	1198
9429	1206
9429	1218
9429	45236
9430	1183
9430	1188
9430	1206
9430	1218
9430	1229
9431	1183
9431	1188
9431	1205
9431	1229
9431	1246
9432	1183
9432	1188
9432	1206
9432	1218
9432	1229
9433	1183
9433	1188
9433	1206
9433	1232
9433	1262
9434	1183
9434	1188
9434	1200
9434	1206
9434	1218
9435	1183
9435	1188
9435	1198
9435	1206
9435	1221
9436	1183
9436	1188
9436	1206
9436	1218
9436	1229
9437	1188
9437	1200
9437	1206
9437	1218
9437	45238
9438	1188
9438	1200
9438	1206
9438	1218
9438	45238
9439	1183
9439	1193
9439	1198
9439	1206
9439	1218
9440	1183
9440	1193
9440	1198
9440	1206
9440	1218
9441	1183
9441	1188
9441	1200
9441	1206
9441	1218
9442	1183
9442	1188
9442	1200
9442	1206
9442	1218
9443	1183
9443	1196
9443	1206
9443	1218
9443	1229
9444	1183
9444	1188
9444	1218
9444	1232
9444	1233
9445	1188
9445	1218
9445	1232
9445	1233
9445	45238
9446	1188
9446	1232
9446	1233
9446	44970
9446	45236
9447	1188
9447	1205
9447	1218
9447	1232
9447	45236
9448	1183
9448	1188
9448	1200
9448	1206
9448	1218
9449	1188
9449	1200
9449	1206
9449	45238
9449	45338
9450	1188
9450	1232
9450	1233
9450	45238
9450	45338
9451	1183
9451	1188
9451	1200
9451	1206
9451	1218
9452	1196
9452	1200
9452	1206
9452	1218
9452	45236
9453	1183
9453	1192
9453	1200
9453	1206
9453	1218
9454	1183
9454	1188
9454	1206
9454	1221
9454	1229
9455	1188
9455	1218
9455	1232
9455	1233
9455	45238
9457	1183
9457	1188
9457	1218
9457	1232
9457	1233
9458	1188
9458	1205
9458	1218
9458	1232
9458	45238
9459	1183
9459	1188
9459	1218
9459	1232
9459	1233
9460	1188
9460	1198
9460	1206
9460	1218
9460	45238
9462	1182
9462	1188
9462	1218
9462	1232
9462	1233
9463	1183
9463	1188
9463	1218
9463	1232
9463	1233
9464	1183
9464	1188
9464	1218
9464	1232
9464	1233
9466	1183
9466	1188
9466	1218
9466	1232
9466	1233
9467	1183
9467	1188
9467	1200
9467	1206
9467	1218
9468	1183
9468	1194
9468	1205
9468	1218
9468	1232
9469	1183
9469	1188
9469	1200
9469	1206
9469	1218
9471	1183
9471	1188
9471	1198
9471	1233
9471	44971
9472	1183
9472	1188
9472	1198
9472	1206
9472	1218
9473	1183
9473	1188
9473	1198
9473	1206
9473	1218
9477	1188
9477	1218
9477	1232
9477	1233
9477	45238
9479	1183
9479	1188
9479	1206
9479	1218
9479	1229
9480	1183
9480	1194
9480	1196
9480	1198
9480	1206
9480	1218
9480	45236
9481	1183
9481	1188
9481	1218
9481	1232
9481	1233
9482	1183
9482	1188
9482	1206
9482	1218
9482	1229
9483	1183
9483	1194
9483	1200
9483	1206
9483	45399
9484	1183
9484	1188
9484	1200
9484	1206
9484	1218
9485	1188
9485	1206
9485	1222
9485	1229
9485	45238
9486	1183
9486	1188
9486	1206
9486	1218
9486	1229
9489	1183
9489	1194
9489	1206
9489	1218
9489	1232
9490	1183
9490	1194
9490	1218
9490	1229
9490	1233
9492	1183
9492	1188
9492	1209
9492	1232
9492	1233
9493	1188
9493	1198
9493	1206
9493	1218
9493	45238
9494	1183
9494	1196
9494	1206
9494	1218
9494	1229
9496	1183
9496	1194
9496	1218
9496	1229
9496	1233
9497	1183
9497	1188
9497	1218
9497	1232
9497	1233
9498	1183
9498	1188
9498	1200
9498	1206
9498	45134
9500	1183
9500	1194
9500	1200
9500	1206
9500	1218
9503	1183
9503	1188
9503	1198
9503	1206
9503	45134
9516	1183
9516	1188
9516	1206
9516	1229
9516	1246
9517	1183
9517	1188
9517	1206
9517	1218
9517	1229
9518	1183
9518	1188
9518	1198
9518	1206
9518	1218
9519	1183
9519	1188
9519	1200
9519	1206
9519	1218
9520	1183
9520	1188
9520	1206
9520	1218
9520	1229
9522	1183
9522	1194
9522	1199
9522	1204
9522	1218
9523	1183
9523	1188
9523	1199
9523	1204
9523	1218
9524	1183
9524	1194
9524	1199
9524	1204
9524	1218
9525	1183
9525	1188
9525	1200
9525	1206
9525	45377
9526	1183
9526	1194
9526	1198
9526	1206
9526	1211
9527	1183
9527	1188
9527	1198
9527	1206
9527	1218
9528	1183
9528	1194
9528	1204
9528	1218
9528	1232
9529	1183
9529	1188
9529	1200
9529	1206
9529	1218
9530	1183
9530	1188
9530	1200
9530	1206
9530	1222
9531	1183
9531	1188
9531	1206
9531	1218
9531	1229
9533	1183
9533	1188
9533	1198
9533	1206
9533	1218
9534	1183
9534	1194
9534	1204
9534	1218
9534	1232
9535	1183
9535	1188
9535	1200
9535	1206
9535	1218
9536	1183
9536	1188
9536	1218
9536	1232
9536	1233
9537	1183
9537	1188
9537	1198
9537	1206
9537	1211
9539	1183
9539	1188
9539	1200
9539	1206
9539	1218
9540	1183
9540	1188
9540	1204
9540	1229
9540	45134
9542	1183
9542	1188
9542	1200
9542	1218
9542	1233
9543	1183
9543	1194
9543	1206
9543	1218
9543	1229
9544	1183
9544	1188
9544	1206
9544	1218
9544	1229
9545	1183
9545	1188
9545	1206
9545	1218
9545	1232
9545	44968
9546	1183
9546	1188
9546	1200
9546	1218
9546	1233
9547	1183
9547	1188
9547	1204
9547	1218
9547	1232
9548	1183
9548	1188
9548	1206
9548	1218
9548	1232
9549	1183
9549	1188
9549	1200
9549	1206
9549	44968
9550	1183
9550	1188
9550	1213
9550	1232
9550	1233
9551	1183
9551	1188
9551	1200
9551	1206
9551	1217
9551	1218
9551	1232
9551	1233
9553	1188
9553	1206
9553	1218
9553	1229
9553	45238
9554	1183
9554	1194
9554	1198
9554	1206
9554	1218
9555	1183
9555	1194
9555	1200
9555	1206
9555	1222
9556	1188
9556	1200
9556	1206
9556	1218
9556	45238
9558	1183
9558	1188
9558	1206
9558	1218
9558	1229
9559	1183
9559	1188
9559	1218
9559	1232
9559	1233
9560	1183
9560	1188
9560	1206
9560	1218
9560	1229
9561	1183
9561	1194
9561	1200
9561	1206
9561	1218
9563	1183
9563	1193
9563	1200
9563	1206
9563	1218
9564	1195
9564	1200
9564	1206
9564	1218
9564	45238
9565	1183
9565	1188
9565	1206
9565	1220
9565	1232
9566	1188
9566	1218
9566	1232
9566	1233
9566	45236
9568	1183
9568	1188
9568	1206
9568	1218
9568	1229
9569	1183
9569	1194
9569	1200
9569	1206
9569	1218
9570	1183
9570	1188
9570	1204
9570	1218
9570	1232
9571	1188
9571	1198
9571	1206
9571	1218
9571	45236
9572	1183
9572	1188
9572	1218
9572	1232
9572	1233
9573	1183
9573	1194
9573	1200
9573	1206
9573	1218
9574	1183
9574	1194
9574	1198
9574	1206
9574	1222
9575	1183
9575	1194
9575	1200
9575	1206
9575	1218
9576	1183
9576	1194
9576	1206
9576	1229
9576	45339
9577	1183
9577	1194
9577	1198
9577	1206
9577	1218
9579	1183
9579	1194
9579	1198
9579	1206
9579	1218
9581	1188
9581	1222
9581	1232
9581	1233
9581	45238
9582	1183
9582	1188
9582	1210
9582	1232
9582	1233
9584	1183
9584	1188
9584	1198
9584	1206
9584	1210
9585	1183
9585	1188
9585	1206
9585	1218
9585	1232
9586	1183
9586	1188
9586	1200
9586	1206
9586	1218
9588	1183
9588	1188
9588	1204
9588	1218
9588	1232
9592	1183
9592	1194
9592	1222
9592	1232
9592	1233
9597	1183
9597	1188
9597	1206
9597	1213
9597	1229
9598	1183
9598	1188
9598	1222
9598	1232
9598	1233
9599	1183
9599	1188
9599	1206
9599	1218
9599	1229
9600	1188
9600	1209
9600	1232
9600	1233
9600	45236
9602	1183
9602	1194
9602	1200
9602	1206
9602	1218
9603	1183
9603	1188
9603	1198
9603	1206
9603	1218
9604	1183
9604	1188
9604	1200
9604	1206
9604	1217
9605	1183
9605	1188
9605	1218
9605	1232
9605	1233
9607	1183
9607	1188
9607	1200
9607	1206
9607	1218
9608	1183
9608	1188
9608	1198
9608	1206
9608	1218
9609	1183
9609	1194
9609	1204
9609	1218
9609	1232
9610	1183
9610	1188
9610	1206
9610	1218
9610	1229
9613	1183
9613	1188
9613	1200
9613	1206
9613	1218
9614	1183
9614	1194
9614	1200
9614	1206
9614	1218
9615	1183
9615	1188
9615	1206
9615	1218
9615	1229
9615	1232
9615	1233
9618	1183
9618	1188
9618	1200
9618	1206
9618	45539
9620	1183
9620	1188
9620	1206
9620	1218
9620	1229
9622	1183
9622	1188
9622	1198
9622	1210
9622	1233
9622	45567
9623	1183
9623	1188
9623	1200
9623	1206
9623	1218
9624	1183
9624	1188
9624	1206
9624	1218
9624	1229
9625	1183
9625	1188
9625	1206
9625	1218
9625	1232
9626	1183
9626	1188
9626	1206
9626	1218
9626	1229
9627	1188
9627	1222
9627	1232
9627	1233
9627	45238
9628	1183
9628	1188
9628	1222
9628	1232
9628	1233
9631	1183
9631	1188
9631	1218
9631	1232
9631	1233
9632	1183
9632	1188
9632	1206
9632	1218
9632	1229
9634	1183
9634	1188
9634	1194
9634	1200
9634	1204
9634	1206
9634	1218
9634	1220
9634	1232
9635	1183
9635	1188
9635	1222
9635	1232
9635	1233
9636	1183
9636	1188
9636	1206
9636	1218
9636	1229
9637	1183
9637	1188
9637	1206
9637	1218
9637	1229
9638	1183
9638	1194
9638	1206
9638	1218
9638	1229
9640	1183
9640	1188
9640	1204
9640	1218
9640	1232
9641	1183
9641	1188
9641	1222
9641	1232
9641	1233
9642	1183
9642	1188
9642	1206
9642	1218
9642	1229
9643	1183
9643	1188
9643	1218
9643	1232
9643	1233
9645	1183
9645	1188
9645	1206
9645	1218
9645	1229
9646	1188
9646	1198
9646	1206
9646	1210
9646	45236
9647	1183
9647	1194
9647	1198
9647	1206
9647	1210
9648	1183
9648	1188
9648	1220
9648	1232
9648	1233
9650	1183
9650	1188
9650	1198
9650	1206
9650	1218
9651	1183
9651	1188
9651	1206
9651	1217
9651	1229
9652	1183
9652	1188
9652	1222
9652	1232
9652	1233
9653	1183
9653	1188
9653	1217
9653	1232
9653	1233
9654	1183
9654	1188
9654	1200
9654	1206
9654	1218
9655	1183
9655	1188
9655	1204
9655	1218
9655	1232
9656	1183
9656	1188
9656	1198
9656	1204
9656	1222
9658	1183
9658	1194
9658	1198
9658	1206
9658	45399
9659	1183
9659	1188
9659	1200
9659	1206
9659	1218
9660	1183
9660	1188
9660	1218
9660	1232
9660	1233
9661	1183
9661	1188
9661	1198
9661	1206
9661	1218
9663	1183
9663	1188
9663	1206
9663	1218
9663	1229
9665	1183
9665	1188
9665	1206
9665	1218
9665	1229
9666	1183
9666	1188
9666	1206
9666	1218
9666	1229
9667	1183
9667	1188
9667	1218
9667	1232
9667	1233
9669	1188
9669	1218
9669	1232
9669	1233
9669	45238
9670	1188
9670	1199
9670	1204
9670	1218
9670	45236
9671	1188
9671	1199
9671	1204
9671	1218
9671	45236
9673	1183
9673	1188
9673	1199
9673	1203
9673	1218
9674	1188
9674	1218
9674	1232
9674	1233
9674	45238
9675	1183
9675	1194
9675	1198
9675	1204
9675	1218
9676	1183
9676	1188
9676	1218
9676	1232
9676	1233
9677	1188
9677	1204
9677	1218
9677	1232
9677	44936
9678	1183
9678	1188
9678	1203
9678	1218
9678	1232
9679	1183
9679	1188
9679	1204
9679	1218
9679	1232
9681	1183
9681	1188
9681	1205
9681	1218
9681	1232
9682	1188
9682	1204
9682	1218
9682	1232
9682	45238
9684	1188
9684	1204
9684	1218
9684	1232
9684	45236
9685	1188
9685	1204
9685	1218
9685	1232
9685	45238
9686	1183
9686	1188
9686	1204
9686	1218
9686	1232
9687	1188
9687	1204
9687	1218
9687	1232
9687	45238
9689	1183
9689	1194
9689	1199
9689	1204
9689	1218
9690	1183
9690	1188
9690	1218
9690	1232
9690	1233
9691	1188
9691	1205
9691	1218
9691	1232
9691	45238
9692	1188
9692	1204
9692	1218
9692	1232
9692	45238
9693	1183
9693	1188
9693	1200
9693	1204
9693	1218
9694	1183
9694	1188
9694	1206
9694	1218
9694	1229
9695	1188
9695	1218
9695	1232
9695	1233
9695	45236
9697	1188
9697	1204
9697	1218
9697	1232
9697	45238
9698	1183
9698	1188
9698	1198
9698	1206
9698	1218
9699	1183
9699	1188
9699	1198
9699	1203
9699	1218
9700	1188
9700	1204
9700	1218
9700	1232
9700	45238
9701	1188
9701	1198
9701	1205
9701	1218
9701	45236
9702	1188
9702	1203
9702	1218
9702	1238
9702	45236
9703	1188
9703	1204
9703	1218
9703	1232
9703	45236
9704	1183
9704	1193
9704	1200
9704	1204
9704	1218
9705	1183
9705	1188
9705	1206
9705	1218
9705	1229
9706	1183
9706	1188
9706	1206
9706	1218
9706	1229
9707	1188
9707	1203
9707	1218
9707	1232
9707	45238
9708	1183
9708	1188
9708	1210
9708	1232
9708	1233
9709	1183
9709	1194
9709	1218
9709	1232
9709	1233
9710	1183
9710	1188
9710	1206
9710	1218
9710	1229
9711	1183
9711	1188
9711	1206
9711	1218
9711	1229
9712	1183
9712	1188
9712	1206
9712	1218
9712	1229
9713	1183
9713	1188
9713	1206
9713	1218
9713	1229
9714	1183
9714	1194
9714	1218
9714	1232
9714	1233
9715	1183
9715	1188
9715	1194
9715	1198
9715	1206
9715	1210
9715	1218
9716	1183
9716	1188
9716	1218
9716	1232
9716	1233
9718	1183
9718	1194
9718	1198
9718	1218
9718	1233
9719	1183
9719	1188
9719	1200
9719	1206
9719	1218
9721	1183
9721	1194
9721	1206
9721	1222
9721	1229
9722	1188
9722	1205
9722	1218
9722	1232
9722	45238
9723	1183
9723	1188
9723	1198
9723	1206
9723	1218
9724	1183
9724	1194
9724	1218
9724	1232
9724	1233
9725	1180
9725	1188
9725	1218
9725	1232
9725	1233
9727	1183
9727	1188
9727	1204
9727	1218
9727	1232
9728	1183
9728	1188
9728	1206
9728	1218
9728	1229
9729	1183
9729	1188
9729	1206
9729	1218
9729	1229
9730	1183
9730	1194
9730	1218
9730	1232
9730	1233
9731	1183
9731	1196
9731	1206
9731	1218
9731	1229
9732	1183
9732	1194
9732	1204
9732	1218
9732	1232
9735	1183
9735	1194
9735	1204
9735	1218
9735	1232
9736	1183
9736	1194
9736	1218
9736	1232
9736	1233
9738	1183
9738	1188
9738	1206
9738	1218
9738	1229
9739	1188
9739	1200
9739	1206
9739	1237
9739	1277
9741	1183
9741	1188
9741	1198
9741	1206
9741	1218
9741	1229
9742	1183
9742	1188
9742	1206
9742	1216
9742	1229
9743	1183
9743	1194
9743	1204
9743	1222
9743	1232
9745	1183
9745	1194
9745	1198
9745	1206
9745	1218
9746	1183
9746	1188
9746	1206
9746	1221
9746	1229
9747	1183
9747	1194
9747	1200
9747	1206
9747	45399
9748	1183
9748	1188
9748	1206
9748	1218
9748	1232
9749	1183
9749	1188
9749	1206
9749	1218
9749	1229
9750	1183
9750	1194
9750	1206
9750	1218
9750	1229
9751	1183
9751	1194
9751	1206
9751	1218
9751	1229
9752	1183
9752	1188
9752	1206
9752	1229
9752	45372
9753	1183
9753	1194
9753	1222
9753	1232
9753	1233
9754	1183
9754	1188
9754	1206
9754	1218
9754	1229
9755	1183
9755	1188
9755	1206
9755	1229
9755	45181
9756	1183
9756	1188
9756	1218
9756	1232
9756	1233
9757	1183
9757	1188
9757	1203
9757	1218
9757	1238
9758	1183
9758	1188
9758	1206
9758	1218
9758	1229
9759	1183
9759	1188
9759	1204
9759	1218
9759	1232
9760	1183
9760	1188
9760	1232
9760	1233
9760	44971
9761	1183
9761	1194
9761	1218
9761	1232
9761	1233
9762	1183
9762	1188
9762	1218
9762	1232
9762	1233
9763	1183
9763	1188
9763	1218
9763	1232
9763	1233
9764	1183
9764	1188
9764	1206
9764	1218
9764	1229
9765	1183
9765	1188
9765	1206
9765	1218
9765	1229
9766	1183
9766	1188
9766	1204
9766	1218
9766	1232
9767	1183
9767	1188
9767	1218
9767	1232
9767	1233
9768	1183
9768	1188
9768	1218
9768	1232
9768	1233
9769	1183
9769	1188
9769	1218
9769	1232
9769	1233
9770	1183
9770	1188
9770	1218
9770	1232
9770	1233
9771	1183
9771	1188
9771	1218
9771	1232
9771	1233
9772	1183
9772	1188
9772	1206
9772	1218
9772	1229
9773	1183
9773	1194
9773	1218
9773	1232
9773	1233
9774	1183
9774	1188
9774	1218
9774	1232
9774	1233
9775	1188
9775	1204
9775	1218
9775	1232
9775	45238
9776	1183
9776	1188
9776	1218
9776	1232
9776	1233
9777	1183
9777	1188
9777	1218
9777	1232
9777	1233
9778	1183
9778	1196
9778	1218
9778	1232
9778	1233
9779	1183
9779	1188
9779	1205
9779	1218
9779	1232
9780	1183
9780	1188
9780	1218
9780	1232
9780	1233
9781	1188
9781	1204
9781	1218
9781	1232
9781	45238
9782	1183
9782	1188
9782	1206
9782	1218
9782	1229
9783	1183
9783	1188
9783	1218
9783	1232
9783	1233
9784	1183
9784	1188
9784	1218
9784	1232
9784	1233
9785	1183
9785	1188
9785	1200
9785	1206
9785	1217
9786	1183
9786	1188
9786	1218
9786	1232
9786	1233
9787	1188
9787	1205
9787	1218
9787	1238
9787	45236
9788	1183
9788	1188
9788	1200
9788	1206
9788	45436
9789	1183
9789	1188
9789	1200
9789	1206
9789	1218
9790	1183
9790	1188
9790	1200
9790	1206
9790	1217
9790	45585
9791	1183
9791	1188
9791	1198
9791	1204
9791	1218
9792	1183
9792	1188
9792	1218
9792	1232
9792	1233
9793	1183
9793	1188
9793	1218
9793	1232
9793	1233
9794	1183
9794	1188
9794	1218
9794	1232
9794	1233
9795	1183
9795	1188
9795	1198
9795	1204
9795	1218
9796	1183
9796	1188
9796	1204
9796	1218
9796	1232
9798	1183
9798	1188
9798	1200
9798	1206
9798	1218
9799	1183
9799	1188
9799	1200
9799	1205
9799	1218
9800	1183
9800	1188
9800	1206
9800	1232
9800	44974
9801	1183
9801	1188
9801	1205
9801	1218
9801	1232
9803	1183
9803	1188
9803	1206
9803	1232
9803	1262
9804	1183
9804	1188
9804	1206
9804	1218
9804	1232
9805	1183
9805	1188
9805	1200
9805	1206
9805	1218
9805	1232
9805	1233
9805	45238
9807	1183
9807	1188
9807	1218
9807	1232
9807	1233
9808	1183
9808	1188
9808	1200
9808	1205
9808	1206
9808	1218
9808	1229
9810	1183
9810	1188
9810	1206
9810	1232
9810	44974
9811	1183
9811	1188
9811	1206
9811	1218
9811	1229
9811	1232
9812	1183
9812	1188
9812	1198
9812	1204
9812	1206
9812	1218
9812	1232
9813	1183
9813	1188
9813	1206
9813	1213
9813	1232
9814	1183
9814	1188
9814	1206
9814	1232
9814	1277
9815	1183
9815	1188
9815	1206
9815	1217
9815	1232
9816	1183
9816	1188
9816	1206
9816	1217
9816	1232
9817	1183
9817	1188
9817	1206
9817	1217
9817	1232
9818	1183
9818	1188
9818	1206
9818	1218
9818	1232
9819	1183
9819	1188
9819	1206
9819	1218
9819	1232
9820	1183
9820	1188
9820	1206
9820	1218
9820	1232
9821	1183
9821	1188
9821	1200
9821	1205
9821	44971
9822	1183
9822	1188
9822	1200
9822	1206
9822	1218
9823	1183
9823	1188
9823	1205
9823	1218
9823	1232
9824	1183
9824	1188
9824	1206
9824	1218
9824	1232
9825	1183
9825	1188
9825	1200
9825	1218
9825	1233
9826	1183
9826	1188
9826	1206
9826	1218
9826	1232
9827	1183
9827	1188
9827	1206
9827	1217
9827	1232
9828	1183
9828	1188
9828	1206
9828	1218
9828	1232
9829	1183
9829	1188
9829	1206
9829	1218
9829	1232
9830	1183
9830	1188
9830	1218
9830	1232
9830	1233
9831	1183
9831	1188
9831	1206
9831	1218
9831	1232
9832	1183
9832	1188
9832	1206
9832	1218
9832	1232
9833	1183
9833	1188
9833	1218
9833	1232
9833	1233
9834	1183
9834	1188
9834	1206
9834	1218
9834	1232
9835	1183
9835	1188
9835	1204
9835	1218
9835	1232
9836	1183
9836	1188
9836	1218
9836	1232
9836	1233
9837	1183
9837	1188
9837	1206
9837	1210
9837	1229
9838	1183
9838	1188
9838	1206
9838	1222
9838	1232
9839	1183
9839	1188
9839	1206
9839	1218
9839	1232
9840	1183
9840	1188
9840	1204
9840	1232
9840	44974
9841	1183
9841	1188
9841	1200
9841	1206
9841	1243
9842	1188
9842	1218
9842	1232
9842	1233
9842	45238
9843	1183
9843	1188
9843	1206
9843	1217
9843	1232
9844	1183
9844	1188
9844	1200
9844	1205
9844	1218
9845	1183
9845	1188
9845	1218
9845	1232
9845	1233
9846	1183
9846	1188
9846	1206
9846	1218
9846	1232
9847	1183
9847	1188
9847	1232
9847	1233
9847	44974
9848	1183
9848	1188
9848	1200
9848	1205
9848	1218
9848	1229
9849	1183
9849	1188
9849	1206
9849	1218
9849	1232
9850	1183
9850	1188
9850	1205
9850	1218
9850	1232
9851	1183
9851	1188
9851	1204
9851	1218
9851	1232
9852	1183
9852	1188
9852	1206
9852	1218
9852	1232
9853	1183
9853	1188
9853	1232
9853	1233
9853	1262
9854	1183
9854	1188
9854	1204
9854	1218
9854	1232
9855	1183
9855	1188
9855	1206
9855	1218
9855	1232
9856	1183
9856	1188
9856	1232
9856	1233
9856	44974
9857	1183
9857	1188
9857	1204
9857	1218
9857	1232
9858	1183
9858	1188
9858	1200
9858	1206
9858	1247
9860	1183
9860	1188
9860	1206
9860	1218
9860	1232
9861	1183
9861	1188
9861	1205
9861	1232
9861	44968
9862	1183
9862	1188
9862	1205
9862	1218
9862	1232
9863	1183
9863	1188
9863	1206
9863	1232
9863	44974
9864	1183
9864	1188
9864	1206
9864	1221
9864	1232
9865	1183
9865	1188
9865	1206
9865	1218
9865	1232
9866	1183
9866	1188
9866	1206
9866	1218
9866	1232
9867	1183
9867	1188
9867	1232
9867	1233
9867	44974
9868	1183
9868	1188
9868	1206
9868	1232
9868	1258
9869	1183
9869	1188
9869	1206
9869	1218
9869	1232
9870	1183
9870	1188
9870	1206
9870	1218
9870	1232
9871	1183
9871	1188
9871	1205
9871	1213
9871	1232
9872	1183
9872	1188
9872	1206
9872	1232
9872	45060
9873	1183
9873	1188
9873	1218
9873	1232
9873	1233
9874	1183
9874	1188
9874	1232
9874	1233
9874	44968
9875	1183
9875	1188
9875	1206
9875	1218
9875	1232
9876	1183
9876	1188
9876	1206
9876	1217
9876	1232
9877	1183
9877	1188
9877	1200
9877	1206
9877	1218
9878	1183
9878	1188
9878	1200
9878	1218
9878	1233
9879	1183
9879	1188
9879	1206
9879	1218
9879	1232
9880	1183
9880	1188
9880	1210
9880	1232
9880	1233
9881	1183
9881	1188
9881	1205
9881	1218
9881	1232
9882	1183
9882	1188
9882	1200
9882	1233
9882	44968
9883	1183
9883	1188
9883	1218
9883	1229
9883	1233
9884	1183
9884	1198
9884	1206
9884	1218
9884	1239
9886	1183
9886	1188
9886	1206
9886	1218
9886	1232
9887	1183
9887	1188
9887	1206
9887	1218
9887	1232
9888	1183
9888	1188
9888	1204
9888	1218
9888	1232
9889	1183
9889	1188
9889	1204
9889	1218
9889	1232
9890	1183
9890	1188
9890	1206
9890	1222
9890	1232
9891	1183
9891	1188
9891	1200
9891	1206
9891	44974
9892	1183
9892	1188
9892	1200
9892	1206
9892	1218
9893	1183
9893	1188
9893	1206
9893	1218
9893	1232
9894	1188
9894	1218
9894	1232
9894	1233
9894	45238
9895	1188
9895	1218
9895	1232
9895	1233
9895	45238
9897	1183
9897	1194
9897	1200
9897	1206
9897	1218
9899	1183
9899	1188
9899	1200
9899	1206
9899	1218
9900	1183
9900	1194
9900	1200
9900	1206
9900	1218
9902	1183
9902	1188
9902	1218
9902	1232
9902	1233
9903	1183
9903	1188
9903	1200
9903	1206
9903	1218
9904	1180
9904	1188
9904	1197
9904	1201
9904	1243
9905	1183
9905	1188
9905	1200
9905	1206
9905	1218
9906	1183
9906	1188
9906	1218
9906	1232
9906	1233
9907	1183
9907	1188
9907	1218
9907	1232
9907	1233
9908	1183
9908	1194
9908	1200
9908	1206
9908	1218
9909	1183
9909	1196
9909	1218
9909	1232
9909	1233
9912	1188
9912	1200
9912	1206
9912	1218
9912	45238
9913	1183
9913	1188
9913	1200
9913	1205
9913	1218
9914	1183
9914	1194
9914	1218
9914	1232
9914	1233
9915	1188
9915	1200
9915	1206
9915	1218
9915	45238
9919	1183
9919	1188
9919	1198
9919	1206
9919	1218
9923	1183
9923	1188
9923	1206
9923	1218
9923	1229
9924	1183
9924	1194
9924	1200
9924	1206
9924	1218
9925	1183
9925	1188
9925	1200
9925	1206
9925	1218
9926	1183
9926	1194
9926	1218
9926	1232
9926	1233
9927	1188
9927	1218
9927	1232
9927	1233
9927	45238
9928	1179
9928	1188
9928	1197
9928	1201
9928	1218
9929	1183
9929	1188
9929	1206
9929	1218
9929	1229
9930	1183
9930	1188
9930	1206
9930	1218
9930	1232
9931	1188
9931	1203
9931	1218
9931	1232
9931	45238
9933	1188
9933	1198
9933	1206
9933	1218
9933	45238
9934	1183
9934	1188
9934	1206
9934	1218
9934	1229
9935	1183
9935	1188
9935	1200
9935	1206
9935	1218
9936	1183
9936	1198
9936	1206
9936	1218
9936	1239
9937	1188
9937	1206
9937	1218
9937	1232
9937	45236
9938	1183
9938	1194
9938	1206
9938	1232
9938	1257
9938	45561
9938	45589
9939	1183
9939	1194
9939	1200
9939	1205
9939	1218
9940	1183
9940	1194
9940	1200
9940	1204
9940	1218
9943	1183
9943	1194
9943	1200
9943	1206
9943	1222
9943	45183
9944	1183
9944	1194
9944	1206
9944	1218
9944	1229
9945	1188
9945	1200
9945	1206
9945	1218
9945	45238
9946	1183
9946	1188
9946	1206
9946	1221
9946	1232
9947	1188
9947	1218
9947	1232
9947	1233
9947	45238
9948	1188
9948	1203
9948	1232
9948	45238
9948	45643
9949	1183
9949	1188
9949	1217
9949	1232
9949	1233
9951	1188
9951	1206
9951	1218
9951	1229
9951	45238
9952	1183
9952	1194
9952	1200
9952	1206
9952	1217
9953	1183
9953	1188
9953	1206
9953	1218
9953	1229
9954	1183
9954	1188
9954	1232
9954	1233
9954	45571
9955	1183
9955	1193
9955	1198
9955	1204
9955	1218
9956	1188
9956	1218
9956	1232
9956	1233
9956	45238
9957	1183
9957	1196
9957	1232
9957	1233
9957	45549
9958	1183
9958	1194
9958	1200
9958	1206
9958	1218
9959	1183
9959	1188
9959	1206
9959	1218
9959	1232
9960	1183
9960	1194
9960	1206
9960	1218
9960	1229
9961	1183
9961	1188
9961	1206
9961	1218
9961	1229
9962	1183
9962	1193
9962	1194
9962	1198
9962	1204
9962	1218
9962	1232
9963	1183
9963	1188
9963	1206
9963	1218
9963	1229
9964	1183
9964	1188
9964	1221
9964	1232
9964	1233
9965	1183
9965	1188
9965	1206
9965	1217
9965	1229
9966	1183
9966	1188
9966	1206
9966	1217
9966	1229
9967	1183
9967	1188
9967	1206
9967	1217
9967	1229
9968	1183
9968	1188
9968	1206
9968	1232
9968	45062
9969	1188
9969	1198
9969	1210
9969	1233
9969	45238
9970	1183
9970	1194
9970	1206
9970	1218
9970	1229
9971	1183
9971	1194
9971	1198
9971	1206
9971	1218
9974	1188
9974	1218
9974	1232
9974	1233
9974	45238
9975	1183
9975	1188
9975	1205
9975	1218
9975	1229
9976	1188
9976	1218
9976	1232
9976	1233
9976	45238
9977	1183
9977	1196
9977	1198
9977	1210
9977	1233
9979	1195
9979	1232
9979	1233
9979	45238
9979	45337
9981	1183
9981	1188
9981	1206
9981	1218
9981	1229
9983	1183
9983	1194
9983	1198
9983	1206
9983	1218
9985	1183
9985	1194
9985	1200
9985	1206
9985	1218
9989	1183
9989	1188
9989	1218
9989	1232
9989	1233
9990	1183
9990	1188
9990	1198
9990	1206
9990	1218
9991	1183
9991	1188
9991	1200
9991	1206
9991	45430
9992	1183
9992	1194
9992	1198
9992	1206
9992	1218
9993	1183
9993	1188
9993	1206
9993	1217
9993	1229
9994	1183
9994	1188
9994	1206
9994	1220
9994	1229
9995	1183
9995	1193
9995	1218
9995	1232
9995	1233
9996	1183
9996	1188
9996	1232
9996	1233
9996	44970
9997	1183
9997	1188
9997	1218
9997	1232
9997	1233
9998	1183
9998	1188
9998	1204
9998	1218
9998	1232
9999	1183
9999	1188
9999	1218
9999	1232
9999	1233
10000	1183
10000	1188
10000	1218
10000	1232
10000	1233
10002	1183
10002	1188
10002	1218
10002	1232
10002	1233
10004	1183
10004	1188
10004	1206
10004	1218
10004	1232
10005	1183
10005	1188
10005	1206
10005	1210
10005	1232
10007	1183
10007	1188
10007	1200
10007	1206
10007	1218
10008	1183
10008	1188
10008	1204
10008	1232
10008	45039
10009	1183
10009	1188
10009	1206
10009	1232
10009	45114
10010	1183
10010	1188
10010	1205
10010	1232
10010	44971
10011	1183
10011	1188
10011	1204
10011	1218
10011	1232
10013	1183
10013	1188
10013	1200
10013	1206
10013	1218
10014	1183
10014	1188
10014	1200
10014	1206
10014	1218
10015	1183
10015	1188
10015	1198
10015	1218
10015	1233
10016	1183
10016	1188
10016	1204
10016	1218
10016	1232
10017	1183
10017	1188
10017	1218
10017	1232
10017	1233
10018	1183
10018	1188
10018	1206
10018	1218
10018	1232
10019	1183
10019	1188
10019	1206
10019	1222
10019	1232
10020	1183
10020	1188
10020	1206
10020	1222
10020	1232
10021	1183
10021	1188
10021	1200
10021	1206
10021	1218
10022	1183
10022	1188
10022	1204
10022	1232
10022	44971
10023	1183
10023	1188
10023	1200
10023	1204
10023	1218
10024	1183
10024	1188
10024	1206
10024	1217
10024	1232
10025	1183
10025	1188
10025	1206
10025	1218
10025	1232
10026	1183
10026	1188
10026	1206
10026	1218
10026	1232
10027	1183
10027	1188
10027	1232
10027	1233
10027	45037
10029	1183
10029	1188
10029	1206
10029	1232
10029	45430
10030	1183
10030	1188
10030	1205
10030	1232
10030	44974
10031	1183
10031	1188
10031	1199
10031	1206
10031	1218
10032	1183
10032	1188
10032	1200
10032	1206
10032	1218
10033	1183
10033	1188
10033	1204
10033	1232
10033	44971
10034	1183
10034	1188
10034	1218
10034	1232
10034	1233
10036	1183
10036	1188
10036	1205
10036	1232
10036	45037
10037	1183
10037	1188
10037	1204
10037	1218
10037	1232
10038	1183
10038	1188
10038	1204
10038	1218
10038	1232
10039	1183
10039	1188
10039	1218
10039	1232
10039	1233
10040	1183
10040	1188
10040	1206
10040	1232
10040	44971
10041	1183
10041	1188
10041	1218
10041	1232
10041	1233
10042	1183
10042	1188
10042	1206
10042	1217
10042	1232
10043	1183
10043	1188
10043	1204
10043	1218
10043	1232
10044	1183
10044	1188
10044	1200
10044	1218
10044	1233
10045	1183
10045	1188
10045	1201
10045	1217
10045	1232
10046	1180
10046	1188
10046	1197
10046	1201
10046	1218
10047	1183
10047	1188
10047	1205
10047	1218
10047	1232
10048	1183
10048	1188
10048	1205
10048	1218
10048	1232
10049	1183
10049	1188
10049	1218
10049	1232
10049	1233
10050	1183
10050	1188
10050	1198
10050	1210
10050	1233
10052	1183
10052	1188
10052	1205
10052	1218
10052	1232
10053	1183
10053	1188
10053	1218
10053	1232
10053	1233
10054	1183
10054	1188
10054	1200
10054	1206
10054	45069
10055	1183
10055	1188
10055	1206
10055	1217
10055	1232
10058	1183
10058	1188
10058	1200
10058	1206
10058	1218
10060	1183
10060	1188
10060	1206
10060	1218
10060	1232
10061	1183
10061	1188
10061	1204
10061	1218
10061	1232
10062	1183
10062	1188
10062	1206
10062	1218
10062	1232
10064	1183
10064	1188
10064	1204
10064	1218
10064	1232
10065	1183
10065	1188
10065	1200
10065	1206
10065	1218
10067	1183
10067	1188
10067	1206
10067	1232
10067	44968
10069	1183
10069	1188
10069	1204
10069	1218
10069	1232
10070	1183
10070	1188
10070	1204
10070	1218
10070	1232
10071	1183
10071	1188
10071	1206
10071	1218
10071	1232
10072	1183
10072	1188
10072	1205
10072	1232
10072	44971
10074	1183
10074	1188
10074	1206
10074	1222
10074	1232
10075	1183
10075	1188
10075	1218
10075	1232
10075	1233
10076	1183
10076	1188
10076	1206
10076	1217
10076	1232
10077	1183
10077	1188
10077	1206
10077	1218
10077	1232
10078	1183
10078	1188
10078	1206
10078	1218
10078	1232
10079	1183
10079	1188
10079	1206
10079	1218
10079	1232
10081	1183
10081	1188
10081	1206
10081	1218
10081	1232
10082	1183
10082	1188
10082	1198
10082	1205
10082	1210
10084	1183
10084	1188
10084	1200
10084	1206
10084	1243
10086	1183
10086	1194
10086	1232
10086	1233
10086	44977
10087	1183
10087	1188
10087	1218
10087	1232
10087	1233
10088	1183
10088	1188
10088	1205
10088	1218
10088	1232
10089	1183
10089	1188
10089	1206
10089	1218
10089	1232
10090	1183
10090	1188
10090	1206
10090	1232
10090	44970
10091	1183
10091	1188
10091	1200
10091	1206
10091	1218
10095	1183
10095	1188
10095	1218
10095	1232
10095	1233
10096	1183
10096	1188
10096	1200
10096	1206
10096	1218
10097	1183
10097	1188
10097	1200
10097	1206
10097	1218
10098	1183
10098	1188
10098	1205
10098	1218
10098	1232
10099	1183
10099	1188
10099	1206
10099	1232
10099	44985
10100	1183
10100	1188
10100	1205
10100	1218
10100	1232
10101	1183
10101	1188
10101	1200
10101	1204
10101	1218
10102	1183
10102	1188
10102	1205
10102	1218
10102	1232
10103	1183
10103	1188
10103	1232
10103	1233
10103	44968
10104	1183
10104	1188
10104	1206
10104	1232
10104	44971
10106	1183
10106	1188
10106	1204
10106	1218
10106	1232
10107	1183
10107	1188
10107	1200
10107	1206
10107	44968
10108	1183
10108	1188
10108	1206
10108	1232
10108	44971
10109	1183
10109	1188
10109	1205
10109	1232
10109	44971
10110	1183
10110	1188
10110	1206
10110	1217
10110	1232
10111	1183
10111	1188
10111	1204
10111	1232
10111	44971
10114	1183
10114	1188
10114	1204
10114	1218
10114	1232
10115	1183
10115	1191
10115	1206
10115	1232
10115	44983
10116	1183
10116	1191
10116	1232
10116	1233
10116	45448
10117	1183
10117	1188
10117	1204
10117	1218
10117	1232
10118	1183
10118	1188
10118	1218
10118	1232
10118	1233
10119	1183
10119	1188
10119	1206
10119	1218
10119	1232
10120	1183
10120	1188
10120	1218
10120	1232
10120	1233
10121	1183
10121	1188
10121	1204
10121	1218
10121	1232
10122	1183
10122	1188
10122	1204
10122	1218
10122	1232
10123	1183
10123	1188
10123	1204
10123	1218
10123	1232
10124	1183
10124	1188
10124	1218
10124	1232
10124	1233
10125	1183
10125	1188
10125	1206
10125	1232
10125	45023
10126	1183
10126	1188
10126	1204
10126	1218
10126	1232
10127	1183
10127	1188
10127	1218
10127	1232
10127	1233
10129	1183
10129	1188
10129	1206
10129	1209
10129	1232
10130	1183
10130	1188
10130	1206
10130	1218
10130	1232
10131	1183
10131	1188
10131	1206
10131	1218
10131	1232
10132	1183
10132	1188
10132	1206
10132	1232
10132	44968
10133	1183
10133	1188
10133	1204
10133	1218
10133	1232
10134	1183
10134	1188
10134	1206
10134	1218
10134	1221
10134	1232
10135	1183
10135	1188
10135	1204
10135	1222
10135	1232
10136	1183
10136	1188
10136	1206
10136	1232
10136	45081
10137	1183
10137	1188
10137	1206
10137	1232
10137	45037
10138	1183
10138	1188
10138	1218
10138	1232
10138	1233
10139	1183
10139	1188
10139	1198
10139	1204
10139	1218
10140	1183
10140	1188
10140	1206
10140	1221
10140	1232
10141	1183
10141	1188
10141	1206
10141	1218
10141	1232
10142	1183
10142	1188
10142	1218
10142	1232
10142	1233
10143	1183
10143	1188
10143	1204
10143	1232
10143	44968
10144	1183
10144	1188
10144	1204
10144	1218
10144	1232
10145	1183
10145	1188
10145	1204
10145	1218
10145	1232
10146	1183
10146	1188
10146	1200
10146	1213
10146	1233
10147	1183
10147	1188
10147	1206
10147	1232
10147	44971
10148	1183
10148	1188
10148	1206
10148	1218
10148	1232
10149	1183
10149	1188
10149	1232
10149	1233
10149	44974
10152	1183
10152	1188
10152	1232
10152	1233
10152	1261
10153	1183
10153	1188
10153	1206
10153	1218
10153	1232
10155	1183
10155	1188
10155	1218
10155	1232
10155	1233
10156	1183
10156	1188
10156	1206
10156	1232
10156	44971
10157	1183
10157	1188
10157	1205
10157	1218
10157	1232
10158	1183
10158	1188
10158	1206
10158	1218
10158	1232
10159	1183
10159	1188
10159	1232
10159	1233
10159	45019
10160	1183
10160	1188
10160	1232
10160	1233
10160	45019
10161	1183
10161	1188
10161	1218
10161	1232
10161	1233
10162	1183
10162	1188
10162	1204
10162	1232
10162	44971
10163	1183
10163	1188
10163	1204
10163	1218
10163	1232
10165	1183
10165	1188
10165	1206
10165	1221
10165	1232
10166	1183
10166	1188
10166	1204
10166	1232
10166	1277
10167	1183
10167	1188
10167	1204
10167	1232
10167	44974
10168	1183
10168	1188
10168	1206
10168	1218
10168	1232
10169	1183
10169	1188
10169	1206
10169	1217
10169	1232
10170	1183
10170	1188
10170	1206
10170	1221
10170	1232
10171	1183
10171	1188
10171	1206
10171	1221
10171	1232
10172	1183
10172	1188
10172	1206
10172	1217
10172	1232
10173	1183
10173	1188
10173	1205
10173	1217
10173	1232
10174	1183
10174	1188
10174	1200
10174	1206
10174	1218
10175	1183
10175	1188
10175	1206
10175	1221
10175	1232
10176	1183
10176	1188
10176	1204
10176	1218
10176	1232
10177	1183
10177	1188
10177	1205
10177	1232
10177	1277
10179	1183
10179	1188
10179	1206
10179	1232
10179	1277
10181	1183
10181	1188
10181	1206
10181	1218
10181	1232
10182	1183
10182	1188
10182	1206
10182	1221
10182	1232
10183	1183
10183	1188
10183	1205
10183	1222
10183	1232
10184	1183
10184	1188
10184	1205
10184	1218
10184	1232
10185	1183
10185	1188
10185	1204
10185	1218
10185	1232
10186	1183
10186	1188
10186	1200
10186	1206
10186	44974
10187	1183
10187	1188
10187	1232
10187	1233
10187	44974
10188	1183
10188	1188
10188	1206
10188	1218
10188	1232
10189	1183
10189	1188
10189	1200
10189	1205
10189	1218
10190	1183
10190	1188
10190	1206
10190	1217
10190	1232
10191	1183
10191	1188
10191	1200
10191	1206
10191	44968
10192	1183
10192	1188
10192	1204
10192	1218
10192	1232
10193	1183
10193	1188
10193	1206
10193	1217
10193	1229
10194	1183
10194	1188
10194	1200
10194	1206
10194	44968
10195	1183
10195	1188
10195	1229
10195	1233
10195	1277
10196	1183
10196	1188
10196	1206
10196	1218
10196	1232
10197	1183
10197	1188
10197	1206
10197	1221
10197	1232
10198	1183
10198	1188
10198	1206
10198	1232
10198	1277
10199	1183
10199	1188
10199	1206
10199	1232
10199	1277
10200	1183
10200	1188
10200	1205
10200	1217
10200	1232
10201	1183
10201	1188
10201	1200
10201	1206
10201	44968
10202	1183
10202	1188
10202	1204
10202	1232
10202	1277
10203	1183
10203	1188
10203	1205
10203	1218
10203	1232
10204	1183
10204	1188
10204	1204
10204	1232
10204	44974
10205	1183
10205	1188
10205	1200
10205	1206
10205	1218
10205	1221
10205	1232
10206	1183
10206	1188
10206	1206
10206	1232
10206	44968
10208	1183
10208	1188
10208	1206
10208	1232
10208	1277
10210	1183
10210	1188
10210	1206
10210	1217
10210	1229
10211	1183
10211	1188
10211	1200
10211	1205
10211	1218
10212	1183
10212	1188
10212	1206
10212	1221
10212	1232
10213	1183
10213	1188
10213	1204
10213	1232
10213	1277
10214	1183
10214	1188
10214	1206
10214	1218
10214	1232
10215	1183
10215	1188
10215	1206
10215	1218
10215	1232
10216	1183
10216	1188
10216	1204
10216	1232
10216	45377
10217	1183
10217	1188
10217	1206
10217	1218
10217	1232
10220	1183
10220	1188
10220	1218
10220	1232
10220	1233
10221	1183
10221	1194
10221	1200
10221	1206
10221	1218
10222	1183
10222	1194
10222	1200
10222	1206
10222	1218
10224	1183
10224	1188
10224	1206
10224	1218
10224	1232
10226	1183
10226	1188
10226	1206
10226	1218
10226	1229
10227	1183
10227	1188
10227	1198
10227	1206
10227	45134
10228	1183
10228	1188
10228	1206
10228	1218
10228	1229
10229	1183
10229	1188
10229	1206
10229	1218
10229	1229
10230	1183
10230	1194
10230	1200
10230	1206
10230	1218
10231	1188
10231	1218
10231	1232
10231	1233
10231	45238
10232	1183
10232	1188
10232	1204
10232	1218
10232	1232
10233	1188
10233	1222
10233	1232
10233	1233
10233	45238
10234	1183
10234	1194
10234	1200
10234	1206
10234	1218
10235	1183
10235	1194
10235	1200
10235	1206
10235	1218
10236	1183
10236	1188
10236	1200
10236	1206
10236	1217
10237	1183
10237	1188
10237	1200
10237	1206
10237	1218
10238	1183
10238	1194
10238	1213
10238	1232
10238	1233
10239	1183
10239	1188
10239	1200
10239	1206
10239	1218
10240	1183
10240	1188
10240	1200
10240	1206
10240	1218
10241	1183
10241	1188
10241	1200
10241	1206
10241	1218
10242	1188
10242	1200
10242	1206
10242	1218
10242	45238
10243	1183
10243	1194
10243	1218
10243	1232
10243	1233
10245	1183
10245	1194
10245	1200
10245	1206
10245	1218
10246	1183
10246	1188
10246	1218
10246	1232
10246	1233
10247	1183
10247	1188
10247	1206
10247	1218
10247	1229
10249	1183
10249	1188
10249	1206
10249	1218
10249	1229
10250	1183
10250	1188
10250	1206
10250	1218
10250	1229
10251	1183
10251	1188
10251	1206
10251	1218
10251	1229
10252	1183
10252	1188
10252	1206
10252	1218
10252	1232
10253	1188
10253	1218
10253	1232
10253	1233
10253	45238
10254	1183
10254	1188
10254	1206
10254	1218
10254	1229
10256	1183
10256	1194
10256	1204
10256	1218
10256	1232
10257	1183
10257	1194
10257	1200
10257	1206
10257	1218
10258	1183
10258	1194
10258	1206
10258	1232
10258	1271
10259	1183
10259	1194
10259	1232
10259	1233
10259	45096
10260	1183
10260	1188
10260	1200
10260	1206
10260	44971
10261	1183
10261	1188
10261	1200
10261	1206
10261	1218
10262	1183
10262	1188
10262	1206
10262	1232
10262	1264
10263	1183
10263	1188
10263	1200
10263	1205
10263	1218
10265	1183
10265	1188
10265	1200
10265	1206
10265	1218
10266	1183
10266	1188
10266	1218
10266	1232
10266	1233
10267	1183
10267	1188
10267	1198
10267	1206
10267	1218
10268	1183
10268	1188
10268	1206
10268	1218
10268	1229
10269	1183
10269	1188
10269	1206
10269	1220
10269	1229
10270	1183
10270	1188
10270	1200
10270	1206
10270	1218
10272	1183
10272	1188
10272	1197
10272	1204
10272	1218
10273	1183
10273	1188
10273	1218
10273	1232
10273	1233
10274	1183
10274	1188
10274	1217
10274	1232
10274	1233
10277	1188
10277	1218
10277	1232
10277	1233
10277	45238
10278	1183
10278	1188
10278	1206
10278	1218
10278	1229
10279	1188
10279	1206
10279	1218
10279	1229
10279	45238
10280	1183
10280	1188
10280	1206
10280	1218
10280	1229
10281	1183
10281	1188
10281	1218
10281	1232
10281	1233
10281	45238
10282	1183
10282	1194
10282	1206
10282	1218
10282	1229
10283	1183
10283	1188
10283	1218
10283	1232
10283	1233
10284	1183
10284	1194
10284	1200
10284	1206
10284	1246
10285	1188
10285	1198
10285	1206
10285	1218
10285	45238
10286	1183
10286	1194
10286	1218
10286	1232
10286	1233
10287	1183
10287	1188
10287	1204
10287	1218
10287	1232
10288	1183
10288	1188
10288	1206
10288	1218
10288	1229
10289	1183
10289	1196
10289	1218
10289	1232
10289	1233
10290	1183
10290	1188
10290	1200
10290	1206
10290	1218
10291	1188
10291	1205
10291	1218
10291	1232
10291	45238
10292	1183
10292	1188
10292	1200
10292	1206
10292	1218
10293	1188
10293	1218
10293	1232
10293	1233
10293	45238
10294	1183
10294	1193
10294	1198
10294	1206
10294	1218
10295	1195
10295	1200
10295	1206
10295	1218
10295	45238
10296	1195
10296	1218
10296	1232
10296	1233
10296	45238
10297	1183
10297	1194
10297	1206
10297	1218
10297	1232
10298	1195
10298	1218
10298	1232
10298	1233
10298	45238
10300	1183
10300	1194
10300	1203
10300	1232
10300	1243
10301	1188
10301	1218
10301	1232
10301	1233
10301	45238
10302	1183
10302	1188
10302	1218
10302	1232
10302	1233
10303	1183
10303	1188
10303	1199
10303	1204
10303	1218
10304	1188
10304	1218
10304	1232
10304	1233
10304	45238
10305	1183
10305	1194
10305	1218
10305	1232
10305	1233
10306	1183
10306	1188
10306	1206
10306	1218
10306	1229
10307	1183
10307	1194
10307	1200
10307	1204
10307	1218
10308	1183
10308	1196
10308	1218
10308	1232
10308	1233
10309	1183
10309	1194
10309	1218
10309	1232
10309	1233
10310	1188
10310	1198
10310	1206
10310	1218
10310	45238
10312	1188
10312	1200
10312	1206
10312	1218
10312	45238
10313	1183
10313	1188
10313	1205
10313	1218
10313	1232
10314	1183
10314	1196
10314	1206
10314	1218
10314	1232
10315	1188
10315	1218
10315	1232
10315	1233
10315	45238
10316	1183
10316	1194
10316	1198
10316	1205
10316	1218
10318	1188
10318	1218
10318	1232
10318	1233
10318	45238
10319	1183
10319	1188
10319	1222
10319	1232
10319	1233
10321	1183
10321	1194
10321	1200
10321	1206
10321	1218
10322	1183
10322	1188
10322	1198
10322	1206
10322	1218
10323	1183
10323	1194
10323	1218
10323	1232
10323	1233
10325	1183
10325	1193
10325	1200
10325	1206
10325	1218
10326	1188
10326	1218
10326	1232
10326	1233
10326	45238
10327	1183
10327	1188
10327	1206
10327	1218
10327	1229
10328	1188
10328	1218
10328	1232
10328	1233
10328	45238
10329	1188
10329	1218
10329	1232
10329	1233
10329	45238
10330	1183
10330	1188
10330	1206
10330	1218
10330	1229
10331	1183
10331	1193
10331	1206
10331	1209
10331	1229
10332	1183
10332	1196
10332	1206
10332	1218
10332	1229
10333	1183
10333	1194
10333	1200
10333	1206
10333	1218
10335	1183
10335	1188
10335	1200
10335	1206
10335	1218
10336	1183
10336	1196
10336	1218
10336	1232
10336	1233
10337	1178
10337	1188
10337	1197
10337	1201
10337	1218
10339	1188
10339	1218
10339	1232
10339	1233
10339	45238
10340	1183
10340	1196
10340	1218
10340	1232
10340	1233
10341	1183
10341	1194
10341	1200
10341	1206
10341	1218
10342	1183
10342	1194
10342	1200
10342	1233
10342	1246
10343	1183
10343	1188
10343	1194
10343	1218
10343	1232
10343	1233
10344	1183
10344	1188
10344	1200
10344	1206
10344	1218
10345	1183
10345	1193
10345	1218
10345	1232
10345	1233
10346	1183
10346	1194
10346	1218
10346	1232
10346	1233
10347	1183
10347	1194
10347	1206
10347	1218
10347	1229
10348	1183
10348	1194
10348	1217
10348	1232
10348	1233
10349	1183
10349	1194
10349	1200
10349	1206
10349	1218
10350	1183
10350	1194
10350	1200
10350	1206
10350	1218
10351	1183
10351	1188
10351	1200
10351	1206
10351	1218
10352	1183
10352	1218
10352	1232
10352	1233
10352	1239
10353	1183
10353	1196
10353	1200
10353	1206
10353	1218
10354	1183
10354	1188
10354	1203
10354	1218
10354	1232
10355	1183
10355	1194
10355	1232
10355	1233
10355	1257
10356	1183
10356	1188
10356	1203
10356	1218
10356	1232
10358	1182
10358	1188
10358	1198
10358	1206
10358	1218
10359	1183
10359	1194
10359	1198
10359	1206
10359	1218
10360	1183
10360	1188
10360	1198
10360	1206
10360	1218
10361	1183
10361	1188
10361	1218
10361	1232
10361	1233
10362	1183
10362	1188
10362	1206
10362	1218
10362	1229
10363	1183
10363	1194
10363	1198
10363	1206
10363	1222
10364	1183
10364	1194
10364	1198
10364	1206
10364	1218
10365	1183
10365	1188
10365	1200
10365	1206
10365	1217
10366	1183
10366	1194
10366	1218
10366	1232
10366	1233
10367	1183
10367	1194
10367	1218
10367	1232
10367	1233
10368	1183
10368	1194
10368	1206
10368	1218
10368	1229
10369	1182
10369	1196
10369	1218
10369	1232
10369	1233
10370	1183
10370	1196
10370	1218
10370	1232
10370	1233
10371	1188
10371	1198
10371	1204
10371	1218
10371	45238
10372	1183
10372	1194
10372	1200
10372	1206
10372	1218
10373	1183
10373	1194
10373	1200
10373	1206
10373	1218
10374	1183
10374	1188
10374	1222
10374	1232
10374	1233
10375	1183
10375	1194
10375	1206
10375	1217
10375	1229
10376	1183
10376	1188
10376	1218
10376	1232
10376	1233
10377	1183
10377	1188
10377	1222
10377	1232
10377	1233
10378	1183
10378	1188
10378	1203
10378	1218
10378	1232
10379	1183
10379	1188
10379	1218
10379	1232
10379	1233
10380	1183
10380	1194
10380	1218
10380	1232
10380	1233
10381	1183
10381	1194
10381	1222
10381	1232
10381	1233
10382	1183
10382	1194
10382	1222
10382	1232
10382	1233
10383	1183
10383	1188
10383	1218
10383	1229
10383	1233
10384	1183
10384	1188
10384	1200
10384	1206
10384	1218
10385	1183
10385	1194
10385	1200
10385	1206
10385	1222
10386	1183
10386	1194
10386	1218
10386	1232
10386	1233
10387	1183
10387	1194
10387	1206
10387	1218
10387	1229
10388	1183
10388	1194
10388	1218
10388	1232
10388	1233
10389	1183
10389	1194
10389	1206
10389	1209
10389	1229
10390	1183
10390	1188
10390	1206
10390	1218
10390	1229
10391	1183
10391	1196
10391	1206
10391	1218
10391	1229
10392	1195
10392	1200
10392	1218
10392	1233
10392	45238
10393	1183
10393	1188
10393	1200
10393	1206
10393	1218
10394	1183
10394	1194
10394	1218
10394	1232
10394	1233
10395	1183
10395	1188
10395	1200
10395	1206
10395	1218
10396	1188
10396	1204
10396	1218
10396	1232
10396	45238
10397	1183
10397	1194
10397	1205
10397	1218
10397	1232
10398	1183
10398	1188
10398	1232
10398	1233
10398	45134
10399	1183
10399	1194
10399	1218
10399	1232
10399	1233
10400	1183
10400	1188
10400	1200
10400	1206
10400	1218
10401	1183
10401	1193
10401	1200
10401	1206
10401	45543
10402	1195
10402	1218
10402	1232
10402	1233
10402	45238
10406	1183
10406	1194
10406	1206
10406	1218
10406	1229
10407	1183
10407	1196
10407	1200
10407	1206
10407	1218
10408	1183
10408	1194
10408	1200
10408	1206
10408	1218
10409	1183
10409	1194
10409	1198
10409	1206
10409	1218
10410	1183
10410	1188
10410	1218
10410	1232
10410	1233
10411	1183
10411	1188
10411	1200
10411	1206
10411	1217
10412	1183
10412	1194
10412	1218
10412	1232
10412	1233
10413	1183
10413	1188
10413	1198
10413	1206
10413	1218
10414	1183
10414	1194
10414	1217
10414	1232
10414	1233
10415	1183
10415	1188
10415	1206
10415	1218
10415	1232
10416	1183
10416	1194
10416	1218
10416	1232
10416	1233
10417	1183
10417	1188
10417	1206
10417	1217
10417	1229
10418	1183
10418	1194
10418	1218
10418	1232
10418	1233
10419	1183
10419	1188
10419	1200
10419	1206
10419	1217
10420	1183
10420	1194
10420	1198
10420	1206
10420	1218
10421	1183
10421	1194
10421	1200
10421	1206
10421	1218
10423	1183
10423	1194
10423	1218
10423	1232
10423	1233
10424	1183
10424	1188
10424	1198
10424	1206
10424	1218
10425	1183
10425	1188
10425	1218
10425	1232
10425	1233
10426	1183
10426	1188
10426	1200
10426	1206
10426	1218
10427	1183
10427	1194
10427	1218
10427	1232
10427	1233
10428	1183
10428	1188
10428	1200
10428	1206
10428	1218
10429	1183
10429	1194
10429	1218
10429	1232
10429	1233
10430	1183
10430	1194
10430	1206
10430	1218
10430	1229
10431	1183
10431	1188
10431	1206
10431	1218
10431	1229
10432	1183
10432	1188
10432	1206
10432	1218
10432	1229
10433	1183
10433	1188
10433	1206
10433	1218
10433	1229
10434	1183
10434	1194
10434	1198
10434	1206
10434	1218
10435	1183
10435	1193
10435	1198
10435	1204
10435	1243
10436	1183
10436	1194
10436	1206
10436	1218
10436	1232
10437	1183
10437	1194
10437	1218
10437	1229
10437	1233
10438	1183
10438	1188
10438	1218
10438	1232
10438	1233
10439	1183
10439	1194
10439	1206
10439	1218
10439	1229
10440	1183
10440	1194
10440	1206
10440	1218
10440	1229
10441	1183
10441	1194
10441	1206
10441	1218
10441	1229
10442	1183
10442	1188
10442	1194
10442	1218
10442	1232
10442	1233
10443	1183
10443	1194
10443	1218
10443	1232
10443	1233
10444	1183
10444	1188
10444	1198
10444	1206
10444	1218
10444	1229
10444	1232
10444	1233
10445	1183
10445	1188
10445	1200
10445	1206
10445	1218
10446	1183
10446	1188
10446	1218
10446	1232
10446	1233
10447	1183
10447	1188
10447	1198
10447	1206
10447	1218
10448	1183
10448	1194
10448	1218
10448	1232
10448	1233
10449	1183
10449	1188
10449	1200
10449	1206
10449	1218
10450	1183
10450	1194
10450	1218
10450	1232
10450	1233
10451	1183
10451	1194
10451	1200
10451	1206
10451	1218
10452	1183
10452	1188
10452	1198
10452	1205
10452	1218
10453	1183
10453	1194
10453	1206
10453	1218
10453	1232
10454	1183
10454	1188
10454	1198
10454	1206
10454	1218
10455	1183
10455	1194
10455	1198
10455	1206
10455	1218
10456	1183
10456	1194
10456	1218
10456	1232
10456	1233
10457	1183
10457	1194
10457	1218
10457	1232
10457	1233
10458	1183
10458	1194
10458	1200
10458	1206
10458	1218
10459	1183
10459	1194
10459	1206
10459	1218
10459	1229
10460	1183
10460	1194
10460	1198
10460	1206
10460	1210
10461	1183
10461	1188
10461	1200
10461	1206
10461	1222
10462	1183
10462	1193
10462	1209
10462	1232
10462	1233
10463	1183
10463	1194
10463	1218
10463	1232
10463	1233
10464	1183
10464	1194
10464	1206
10464	1218
10464	1229
10464	1232
10464	44971
10465	1183
10465	1194
10465	1206
10465	1218
10465	1229
10465	45134
10466	1183
10466	1188
10466	1200
10466	1206
10466	1222
10467	1183
10467	1194
10467	1200
10467	1206
10467	1222
10468	1183
10468	1188
10468	1218
10468	1232
10468	1233
10469	1183
10469	1194
10469	1200
10469	1206
10469	1218
10470	1183
10470	1188
10470	1200
10470	1206
10470	1218
10471	1183
10471	1188
10471	1200
10471	1206
10471	1222
10472	1183
10472	1188
10472	1206
10472	1218
10472	1229
10473	1182
10473	1188
10473	1198
10473	1206
10473	1218
10474	1183
10474	1194
10474	1206
10474	1218
10474	1229
10475	1183
10475	1194
10475	1200
10475	1206
10475	1222
10475	1232
10475	1233
10476	1183
10476	1194
10476	1218
10476	1232
10476	1233
10477	1183
10477	1194
10477	1200
10477	1206
10477	1218
10478	1183
10478	1188
10478	1198
10478	1206
10478	1218
10479	1183
10479	1188
10479	1194
10479	1218
10479	1232
10479	1233
10480	1183
10480	1194
10480	1218
10480	1232
10480	1233
10481	1183
10481	1194
10481	1218
10481	1232
10481	1233
10482	1183
10482	1194
10482	1222
10482	1232
10482	1233
10483	1183
10483	1194
10483	1217
10483	1232
10483	1233
10486	1183
10486	1194
10486	1204
10486	1218
10486	1232
10487	1183
10487	1194
10487	1218
10487	1232
10487	1233
10488	1183
10488	1194
10488	1204
10488	1218
10488	1232
10489	1183
10489	1188
10489	1194
10489	1198
10489	1206
10489	1218
10489	1229
10489	1232
10489	1233
10489	45548
10490	1183
10490	1194
10490	1199
10490	1204
10490	1218
10491	1183
10491	1188
10491	1206
10491	1218
10491	1229
10492	1183
10492	1188
10492	1200
10492	1206
10492	1218
10493	1183
10493	1194
10493	1200
10493	1206
10493	1218
10494	1183
10494	1188
10494	1204
10494	1218
10494	1232
10495	1183
10495	1188
10495	1198
10495	1200
10495	1206
10495	1218
10495	1229
10495	1233
10495	1243
10496	1183
10496	1194
10496	1206
10496	1218
10496	1229
10497	1183
10497	1194
10497	1218
10497	1232
10497	1233
10498	1180
10498	1188
10498	1197
10498	1201
10498	44971
10499	1183
10499	1194
10499	1204
10499	1218
10499	1232
10500	1183
10500	1188
10500	1191
10500	1194
10500	1206
10500	1218
10500	1229
10500	1232
10500	1233
10501	1183
10501	1188
10501	1218
10501	1232
10501	1233
10502	1183
10502	1194
10502	1204
10502	1218
10502	1232
10503	1183
10503	1218
10503	1232
10503	1233
10503	1239
10504	1183
10504	1188
10504	1206
10504	1210
10504	1229
10505	1183
10505	1188
10505	1194
10505	1200
10505	1204
10505	1206
10505	1218
10505	1232
10505	1233
10505	1244
10506	1183
10506	1194
10506	1222
10506	1232
10506	1233
10507	1183
10507	1194
10507	1206
10507	1218
10507	1232
10508	1183
10508	1194
10508	1218
10508	1232
10508	1233
10509	1183
10509	1194
10509	1222
10509	1232
10509	1233
10510	1183
10510	1188
10510	1194
10510	1206
10510	1218
10510	1229
10510	1232
10510	1233
10511	1183
10511	1194
10511	1218
10511	1232
10511	1233
10512	1183
10512	1188
10512	1206
10512	1218
10512	1229
10513	1183
10513	1188
10513	1198
10513	1206
10513	1218
10514	1183
10514	1194
10514	1206
10514	1217
10514	1229
10515	1183
10515	1194
10515	1200
10515	1206
10515	1218
10516	1183
10516	1188
10516	1218
10516	1232
10516	1233
10517	1195
10517	1200
10517	1206
10517	1222
10517	45238
10518	1183
10518	1188
10518	1200
10518	1206
10518	1218
10519	1183
10519	1194
10519	1218
10519	1232
10519	1233
10520	1183
10520	1194
10520	1218
10520	1232
10520	1233
10521	1196
10521	1206
10521	1218
10521	1229
10521	45236
10522	1183
10522	1194
10522	1206
10522	1232
10522	45194
10523	1183
10523	1194
10523	1218
10523	1232
10523	1233
10524	1183
10524	1194
10524	1218
10524	1232
10524	1233
10525	1183
10525	1188
10525	1206
10525	1218
10525	1229
10525	1232
10525	1233
10526	1183
10526	1188
10526	1200
10526	1206
10526	1218
10527	1183
10527	1194
10527	1206
10527	1218
10527	1232
10528	1183
10528	1194
10528	1206
10528	1218
10528	1229
10530	1183
10530	1194
10530	1206
10530	1218
10530	1229
10531	1183
10531	1188
10531	1222
10531	1232
10531	1233
10532	1183
10532	1188
10532	1203
10532	1218
10532	1232
10533	1183
10533	1188
10533	1206
10533	1218
10533	1232
10534	1183
10534	1188
10534	1200
10534	1206
10534	44974
10535	1183
10535	1188
10535	1205
10535	1232
10535	44974
10536	1183
10536	1188
10536	1206
10536	1218
10536	1232
10537	1183
10537	1188
10537	1206
10537	1217
10537	1232
10538	1183
10538	1188
10538	1206
10538	1218
10538	1232
10539	1183
10539	1188
10539	1218
10539	1232
10539	1233
10540	1183
10540	1188
10540	1206
10540	1218
10540	1232
10542	1183
10542	1188
10542	1206
10542	1218
10542	1232
10543	1183
10543	1188
10543	1206
10543	1232
10543	1277
10544	1183
10544	1188
10544	1218
10544	1232
10544	1233
10545	1183
10545	1188
10545	1218
10545	1232
10545	1233
10547	1183
10547	1188
10547	1206
10547	1232
10547	44968
10548	1183
10548	1188
10548	1217
10548	1232
10548	1233
10549	1183
10549	1188
10549	1204
10549	1218
10549	1232
10552	1183
10552	1188
10552	1206
10552	1218
10552	1232
10553	1183
10553	1188
10553	1218
10553	1232
10553	1233
10554	1183
10554	1188
10554	1206
10554	1217
10554	1232
10555	1183
10555	1188
10555	1206
10555	1217
10555	1232
10556	1183
10556	1188
10556	1200
10556	1206
10556	44983
10557	1183
10557	1188
10557	1204
10557	1218
10557	1232
10558	1183
10558	1188
10558	1206
10558	1218
10558	1232
10559	1183
10559	1188
10559	1206
10559	1218
10559	1232
10560	1183
10560	1188
10560	1198
10560	1206
10560	1218
10561	1183
10561	1188
10561	1217
10561	1232
10561	1233
10562	1183
10562	1188
10562	1206
10562	1232
10562	1262
10563	1183
10563	1188
10563	1206
10563	1218
10563	1232
10564	1183
10564	1188
10564	1206
10564	1221
10564	1232
10565	1183
10565	1188
10565	1205
10565	1232
10565	1262
10566	1183
10566	1188
10566	1206
10566	1218
10566	1232
10567	1183
10567	1188
10567	1206
10567	1217
10567	1232
10568	1183
10568	1188
10568	1204
10568	1218
10568	1232
10569	1183
10569	1188
10569	1200
10569	1206
10569	1247
10570	1183
10570	1188
10570	1218
10570	1232
10570	1233
10571	1183
10571	1188
10571	1200
10571	1206
10571	44986
10572	1183
10572	1188
10572	1206
10572	1232
10572	1261
10573	1183
10573	1188
10573	1206
10573	1218
10573	1232
10574	1183
10574	1188
10574	1206
10574	1218
10574	1232
10575	1183
10575	1188
10575	1206
10575	1218
10575	1232
10576	1183
10576	1188
10576	1206
10576	1213
10576	1229
10577	1180
10577	1188
10577	1197
10577	1201
10577	1218
10578	1183
10578	1188
10578	1205
10578	1218
10578	1232
10579	1183
10579	1188
10579	1206
10579	1218
10579	1232
10580	1183
10580	1188
10580	1206
10580	1218
10580	1232
10581	1183
10581	1188
10581	1206
10581	1218
10581	1232
10582	1183
10582	1188
10582	1206
10582	1218
10582	1232
10583	1183
10583	1188
10583	1206
10583	1217
10583	1232
10584	1183
10584	1188
10584	1205
10584	1232
10584	44974
10585	1183
10585	1188
10585	1206
10585	1232
10585	1247
10586	1183
10586	1188
10586	1204
10586	1222
10586	1232
10587	1183
10587	1188
10587	1200
10587	1206
10587	1218
10588	1183
10588	1188
10588	1205
10588	1232
10588	1271
10589	1183
10589	1188
10589	1206
10589	1221
10589	1232
10590	1183
10590	1188
10590	1200
10590	1206
10590	1218
10591	1183
10591	1188
10591	1205
10591	1232
10591	44974
10592	1183
10592	1188
10592	1206
10592	1232
10592	44983
10593	1183
10593	1188
10593	1204
10593	1218
10593	1232
10594	1183
10594	1188
10594	1205
10594	1218
10594	1232
10595	1183
10595	1188
10595	1200
10595	1206
10595	45104
10596	1183
10596	1188
10596	1205
10596	1218
10596	1232
10597	1183
10597	1188
10597	1204
10597	1218
10597	1232
10598	1183
10598	1188
10598	1197
10598	1206
10598	44974
10599	1183
10599	1188
10599	1206
10599	1221
10599	1232
10600	1183
10600	1188
10600	1200
10600	1206
10600	1218
10601	1183
10601	1188
10601	1206
10601	1218
10601	1229
10602	1183
10602	1188
10602	1205
10602	1218
10602	1232
10603	1183
10603	1188
10603	1206
10603	1232
10603	45430
10604	1183
10604	1188
10604	1204
10604	1218
10604	1232
10605	1183
10605	1188
10605	1206
10605	1217
10605	1232
10606	1183
10606	1188
10606	1200
10606	1206
10606	1218
10607	1183
10607	1188
10607	1206
10607	1218
10607	1232
10608	1183
10608	1188
10608	1200
10608	1218
10608	1233
10609	1183
10609	1188
10609	1205
10609	1218
10609	1232
10610	1183
10610	1188
10610	1206
10610	1218
10610	1232
10611	1183
10611	1188
10611	1205
10611	1218
10611	1232
10612	1183
10612	1188
10612	1232
10612	1233
10612	44974
10613	1183
10613	1188
10613	1206
10613	1217
10613	1232
10614	1183
10614	1188
10614	1206
10614	1218
10614	1232
10615	1183
10615	1188
10615	1198
10615	1210
10615	1233
10616	1183
10616	1188
10616	1200
10616	1206
10616	1218
10617	1183
10617	1188
10617	1200
10617	1206
10617	1213
10618	1183
10618	1188
10618	1200
10618	1206
10618	1218
10619	1183
10619	1188
10619	1206
10619	1217
10619	1232
10620	1183
10620	1188
10620	1218
10620	1232
10620	1233
10621	1183
10621	1188
10621	1204
10621	1218
10621	1232
10622	1183
10622	1188
10622	1204
10622	1218
10622	1232
10623	1183
10623	1188
10623	1200
10623	1206
10623	44974
10624	1183
10624	1188
10624	1200
10624	1206
10624	1218
10625	1183
10625	1188
10625	1205
10625	1217
10625	1232
10626	1183
10626	1188
10626	1207
10626	1218
10626	1232
10627	1183
10627	1188
10627	1206
10627	1222
10627	1232
10628	1188
10628	1232
10628	1233
10628	44992
10628	45236
10629	1183
10629	1188
10629	1204
10629	1218
10629	1232
10630	1183
10630	1188
10630	1200
10630	1206
10630	1247
10631	1183
10631	1188
10631	1206
10631	1217
10631	1232
10632	1183
10632	1188
10632	1206
10632	1218
10632	1232
10633	1183
10633	1188
10633	1200
10633	1206
10633	1218
10634	1183
10634	1188
10634	1206
10634	1232
10634	44968
10635	1183
10635	1188
10635	1206
10635	1218
10635	1232
10636	1183
10636	1188
10636	1200
10636	1206
10636	1218
10637	1183
10637	1188
10637	1206
10637	1218
10637	1232
10638	1183
10638	1188
10638	1200
10638	1206
10638	1218
10639	1183
10639	1188
10639	1205
10639	1218
10639	1232
10640	1183
10640	1188
10640	1206
10640	1218
10640	1232
10641	1183
10641	1188
10641	1205
10641	1218
10641	1232
10642	1183
10642	1188
10642	1198
10642	1206
10642	1210
10643	1183
10643	1188
10643	1200
10643	1204
10643	1218
10644	1183
10644	1188
10644	1206
10644	1213
10644	1232
10645	1183
10645	1188
10645	1204
10645	1218
10645	1232
10646	1183
10646	1188
10646	1205
10646	1218
10646	1232
10647	1183
10647	1188
10647	1206
10647	1221
10647	1232
10648	1183
10648	1188
10648	1232
10648	1233
10648	44971
10649	1183
10649	1188
10649	1200
10649	1206
10649	1218
10650	1183
10650	1188
10650	1206
10650	1218
10650	1232
10651	1183
10651	1188
10651	1205
10651	1218
10651	1232
10652	1183
10652	1188
10652	1200
10652	1206
10652	44968
10653	1180
10653	1188
10653	1197
10653	1201
10653	1213
10654	1183
10654	1188
10654	1197
10654	1206
10654	1218
10655	1183
10655	1188
10655	1204
10655	1218
10655	1232
10656	1183
10656	1188
10656	1200
10656	1206
10656	1218
10657	1183
10657	1188
10657	1206
10657	1218
10657	1232
10658	1183
10658	1188
10658	1206
10658	1218
10658	1232
10659	1183
10659	1188
10659	1232
10659	1233
10659	45181
10660	1183
10660	1188
10660	1206
10660	1213
10660	1232
10661	1183
10661	1188
10661	1206
10661	1217
10661	1232
10662	1183
10662	1188
10662	1206
10662	1218
10662	1232
10663	1183
10663	1188
10663	1206
10663	1218
10663	1232
10664	1183
10664	1188
10664	1206
10664	1232
10664	44974
10665	1183
10665	1188
10665	1206
10665	1232
10665	45430
10666	1183
10666	1188
10666	1205
10666	1218
10666	1232
10667	1183
10667	1188
10667	1205
10667	1218
10667	1232
10668	1183
10668	1188
10668	1200
10668	1206
10668	44971
10669	1183
10669	1188
10669	1218
10669	1232
10669	1233
10670	1183
10670	1188
10670	1205
10670	1218
10670	1232
10671	1183
10671	1188
10671	1204
10671	1222
10671	1232
10672	1183
10672	1188
10672	1205
10672	1218
10672	1232
10674	1183
10674	1188
10674	1206
10674	1232
10674	1277
10675	1183
10675	1188
10675	1218
10675	1232
10675	1233
10676	1183
10676	1188
10676	1198
10676	1218
10676	1233
10677	1183
10677	1188
10677	1218
10677	1232
10677	1233
10678	1183
10678	1194
10678	1232
10678	1233
10678	44971
10679	1183
10679	1188
10679	1206
10679	1217
10679	1232
10680	1183
10680	1188
10680	1205
10680	1218
10680	1229
10681	1183
10681	1188
10681	1218
10681	1232
10681	1233
10682	1183
10682	1188
10682	1198
10682	1218
10682	1233
10683	1183
10683	1188
10683	1198
10683	1218
10683	1233
10684	1183
10684	1188
10684	1198
10684	1218
10684	1233
10686	1183
10686	1188
10686	1218
10686	1232
10686	1233
10687	1183
10687	1188
10687	1206
10687	1221
10687	1232
10688	1183
10688	1188
10688	1206
10688	1218
10688	1229
10689	1183
10689	1188
10689	1206
10689	1221
10689	1232
10690	1183
10690	1188
10690	1206
10690	1217
10690	1232
10691	1183
10691	1188
10691	1218
10691	1232
10691	1233
10692	1183
10692	1188
10692	1206
10692	1218
10692	1232
10693	1183
10693	1188
10693	1206
10693	1218
10693	1229
10694	1183
10694	1188
10694	1206
10694	1218
10694	1229
10695	1183
10695	1188
10695	1218
10695	1232
10695	1233
10696	1183
10696	1188
10696	1206
10696	1218
10696	1232
10697	1183
10697	1188
10697	1217
10697	1232
10697	1233
10698	1183
10698	1188
10698	1204
10698	1218
10698	1232
10699	1183
10699	1188
10699	1206
10699	1217
10699	1232
10700	1183
10700	1188
10700	1206
10700	1217
10700	1232
10701	1183
10701	1188
10701	1206
10701	1217
10701	1232
10703	1183
10703	1188
10703	1198
10703	1218
10703	1233
10704	1183
10704	1188
10704	1232
10704	1233
10704	1277
10705	1183
10705	1188
10705	1206
10705	1218
10705	1232
10706	1183
10706	1188
10706	1218
10706	1232
10706	1233
10707	1183
10707	1188
10707	1198
10707	1218
10707	1233
10708	1183
10708	1188
10708	1218
10708	1232
10708	1233
10709	1183
10709	1188
10709	1217
10709	1232
10709	1233
10710	1183
10710	1198
10710	1205
10710	1218
10710	1239
10711	1183
10711	1188
10711	1206
10711	1218
10711	1229
10712	1183
10712	1188
10712	1206
10712	1218
10712	1229
10713	1183
10713	1188
10713	1204
10713	1232
10713	44974
10714	1183
10714	1188
10714	1206
10714	1218
10714	1229
10715	1183
10715	1188
10715	1198
10715	1218
10715	1233
10716	1183
10716	1188
10716	1198
10716	1218
10716	1233
10717	1183
10717	1188
10717	1200
10717	1206
10717	1243
10718	1183
10718	1188
10718	1198
10718	1204
10718	1218
10719	1183
10719	1188
10719	1206
10719	1218
10719	1232
10720	1183
10720	1188
10720	1204
10720	1218
10720	1232
10721	1183
10721	1188
10721	1206
10721	1217
10721	1232
10722	1183
10722	1188
10722	1218
10722	1232
10722	1233
10723	1183
10723	1188
10723	1206
10723	1218
10723	1232
10724	1183
10724	1188
10724	1206
10724	1217
10724	1232
10725	1183
10725	1188
10725	1206
10725	1217
10725	1232
10726	1183
10726	1188
10726	1198
10726	1204
10726	1218
10727	1183
10727	1188
10727	1206
10727	1221
10727	1232
10728	1183
10728	1188
10728	1206
10728	1232
10728	1262
10729	1183
10729	1188
10729	1206
10729	1218
10729	1232
10730	1183
10730	1188
10730	1206
10730	1217
10730	1229
10732	1183
10732	1188
10732	1198
10732	1204
10732	1218
10733	1183
10733	1188
10733	1218
10733	1232
10733	1233
10734	1183
10734	1188
10734	1204
10734	1218
10734	1232
10735	1183
10735	1188
10735	1204
10735	1218
10735	1232
10736	1183
10736	1188
10736	1218
10736	1232
10736	1233
10737	1183
10737	1188
10737	1205
10737	1213
10737	1232
10738	1183
10738	1188
10738	1206
10738	1218
10738	1232
10739	1183
10739	1188
10739	1213
10739	1232
10739	1233
10740	1183
10740	1188
10740	1200
10740	1218
10740	1233
10741	1183
10741	1188
10741	1198
10741	1218
10741	1233
10742	1183
10742	1191
10742	1204
10742	1218
10742	1229
10743	1183
10743	1198
10743	1204
10743	1218
10743	1239
10745	1196
10745	1218
10745	1232
10745	1233
10745	45238
10746	1183
10746	1188
10746	1206
10746	1218
10746	1232
10747	1183
10747	1188
10747	1206
10747	1218
10747	1232
10748	1183
10748	1188
10748	1213
10748	1232
10748	1233
10749	1183
10749	1188
10749	1206
10749	1218
10749	1229
10750	1183
10750	1218
10750	1232
10750	1233
10750	1239
10751	1183
10751	1188
10751	1206
10751	1218
10751	1232
10752	1183
10752	1188
10752	1218
10752	1232
10752	1233
10753	1183
10753	1188
10753	1218
10753	1229
10753	1233
10754	1183
10754	1188
10754	1229
10754	1233
10754	44968
10755	1183
10755	1188
10755	1206
10755	1218
10755	1229
10756	1183
10756	1188
10756	1206
10756	1218
10756	1232
10757	1183
10757	1188
10757	1203
10757	1218
10757	1232
10758	1183
10758	1188
10758	1206
10758	1218
10758	1229
10759	1183
10759	1194
10759	1206
10759	1222
10759	1232
10760	1183
10760	1188
10760	1218
10760	1232
10760	1233
10761	1183
10761	1188
10761	1218
10761	1232
10761	1233
10762	1188
10762	1206
10762	1218
10762	1229
10762	45238
10763	1188
10763	1218
10763	1232
10763	1233
10763	45238
10765	1183
10765	1196
10765	1218
10765	1232
10765	1233
10766	1183
10766	1196
10766	1218
10766	1232
10766	1233
10767	1183
10767	1194
10767	1200
10767	1206
10767	1218
10769	1183
10769	1194
10769	1205
10769	1218
10769	1232
10770	1183
10770	1188
10770	1206
10770	1218
10770	1229
10771	1183
10771	1194
10771	1198
10771	1206
10771	1218
10772	1183
10772	1199
10772	1204
10772	1218
10772	1239
10773	1183
10773	1188
10773	1206
10773	1218
10773	1229
10775	1183
10775	1194
10775	1200
10775	1206
10775	1218
10777	1183
10777	1188
10777	1206
10777	1218
10777	1229
10778	1183
10778	1188
10778	1206
10778	1218
10778	1229
10779	1183
10779	1188
10779	1218
10779	1232
10779	1233
10780	1183
10780	1194
10780	1206
10780	1222
10780	1229
10782	1188
10782	1218
10782	1232
10782	1233
10782	45238
10784	1183
10784	1188
10784	1216
10784	1232
10784	1233
10785	1183
10785	1188
10785	1218
10785	1232
10785	1233
10786	1183
10786	1188
10786	1204
10786	1218
10786	1232
10787	1183
10787	1188
10787	1200
10787	1206
10787	1218
10790	1183
10790	1188
10790	1218
10790	1232
10790	1233
10791	1183
10791	1188
10791	1206
10791	1218
10791	1229
10793	1183
10793	1188
10793	1200
10793	1206
10793	1246
10794	1183
10794	1188
10794	1200
10794	1206
10794	1246
10796	1183
10796	1198
10796	1218
10796	1233
10796	1239
10797	1193
10797	1200
10797	1206
10797	1218
10797	45238
10798	1195
10798	1200
10798	1206
10798	1218
10798	45238
10800	1183
10800	1188
10800	1193
10800	1200
10800	1204
10800	1218
10800	1232
10801	1183
10801	1194
10801	1206
10801	1218
10801	1229
10802	1183
10802	1188
10802	1200
10802	1206
10802	1218
10803	1195
10803	1200
10803	1206
10803	1218
10803	45238
10804	1183
10804	1188
10804	1200
10804	1206
10804	1218
10805	1183
10805	1194
10805	1206
10805	1213
10805	1229
10806	1183
10806	1194
10806	1200
10806	1206
10806	1218
10807	1183
10807	1194
10807	1204
10807	1218
10807	1232
10808	1183
10808	1188
10808	1206
10808	1218
10808	1229
10810	1183
10810	1188
10810	1200
10810	1206
10810	1218
10813	1183
10813	1188
10813	1206
10813	1232
10813	44974
10814	1183
10814	1188
10814	1218
10814	1232
10814	1233
10815	1183
10815	1188
10815	1206
10815	1218
10815	1232
10816	1183
10816	1188
10816	1199
10816	1204
10816	1218
10817	1183
10817	1188
10817	1206
10817	1217
10817	1232
10818	1183
10818	1188
10818	1206
10818	1218
10818	1229
10818	1232
10818	1233
10819	1183
10819	1188
10819	1198
10819	1206
10819	1218
10823	1183
10823	1188
10823	1198
10823	1206
10823	1218
10824	1183
10824	1188
10824	1198
10824	1206
10824	1218
10825	1183
10825	1188
10825	1198
10825	1206
10825	1218
10826	1183
10826	1194
10826	1198
10826	1206
10826	1218
10827	1183
10827	1188
10827	1198
10827	1206
10827	1218
10828	1183
10828	1188
10828	1200
10828	1206
10828	1218
10829	1183
10829	1188
10829	1198
10829	1206
10829	1218
10830	1183
10830	1188
10830	1198
10830	1206
10830	1218
10831	1183
10831	1188
10831	1198
10831	1206
10831	1218
10832	1183
10832	1194
10832	1198
10832	1206
10832	1218
10833	1183
10833	1188
10833	1218
10833	1232
10833	1233
10834	1183
10834	1188
10834	1198
10834	1206
10834	1218
10836	1183
10836	1194
10836	1218
10836	1232
10836	1233
10837	1183
10837	1188
10837	1198
10837	1206
10837	1218
10838	1183
10838	1188
10838	1198
10838	1206
10838	1218
10839	1183
10839	1194
10839	1204
10839	1218
10839	1232
10840	1183
10840	1188
10840	1198
10840	1206
10840	1218
10841	1183
10841	1194
10841	1204
10841	1218
10841	1232
10843	1183
10843	1194
10843	1222
10843	1232
10843	1233
10844	1183
10844	1188
10844	1198
10844	1233
10844	45548
10847	1183
10847	1188
10847	1200
10847	1206
10847	1218
10848	1183
10848	1194
10848	1206
10848	1218
10848	1229
10849	1183
10849	1188
10849	1200
10849	1206
10849	45539
10850	1183
10850	1188
10850	1200
10850	1206
10850	1211
10852	1183
10852	1188
10852	1206
10852	1218
10852	1229
10853	1183
10853	1188
10853	1198
10853	1206
10853	1210
10854	1183
10854	1188
10854	1218
10854	1232
10854	1233
10855	1183
10855	1188
10855	1218
10855	1232
10855	1233
10856	1183
10856	1188
10856	1218
10856	1232
10856	1233
10857	1183
10857	1188
10857	1218
10857	1232
10857	1233
10858	1183
10858	1194
10858	1204
10858	1222
10858	1232
10859	1188
10859	1232
10859	1233
10859	45236
10859	45561
10860	1183
10860	1188
10860	1218
10860	1232
10860	1233
10862	1183
10862	1188
10862	1203
10862	1204
10862	1205
10862	1217
10862	1218
10862	1222
10862	1232
10862	1233
10862	1238
10862	45236
10862	45600
10862	45643
10863	1183
10863	1188
10863	1198
10863	1206
10863	1217
10864	1183
10864	1193
10864	1232
10864	1233
10864	45549
10865	1183
10865	1188
10865	1200
10865	1206
10865	1218
10866	1183
10866	1188
10866	1218
10866	1232
10866	1233
10867	1188
10867	1198
10867	1206
10867	1218
10867	45238
10868	1183
10868	1194
10868	1200
10868	1206
10868	1218
10869	1183
10869	1194
10869	1206
10869	1218
10869	1232
10870	1183
10870	1194
10870	1199
10870	1204
10870	1218
10872	1183
10872	1194
10872	1218
10872	1232
10872	1233
10873	1183
10873	1188
10873	1218
10873	1232
10873	1233
10874	1183
10874	1188
10874	1206
10874	1218
10874	1229
10875	1183
10875	1188
10875	1206
10875	1218
10875	1229
10876	1183
10876	1194
10876	1205
10876	1218
10876	1232
10878	1183
10878	1188
10878	1218
10878	1232
10878	1233
10879	1183
10879	1188
10879	1218
10879	1232
10879	1233
10880	1183
10880	1188
10880	1204
10880	1218
10880	1232
10881	1183
10881	1188
10881	1200
10881	1206
10881	1218
10882	1183
10882	1188
10882	1218
10882	1232
10882	1233
10883	1183
10883	1188
10883	1218
10883	1232
10883	1233
10884	1183
10884	1188
10884	1198
10884	1206
10884	1218
10885	1183
10885	1194
10885	1218
10885	1232
10885	1233
10886	1183
10886	1188
10886	1218
10886	1232
10886	1233
10888	1183
10888	1188
10888	1218
10888	1232
10888	1233
10889	1183
10889	1194
10889	1218
10889	1232
10889	1233
10890	1183
10890	1188
10890	1218
10890	1232
10890	1233
10891	1183
10891	1188
10891	1218
10891	1232
10891	1233
10892	1183
10892	1188
10892	1206
10892	1218
10892	1229
10893	1188
10893	1204
10893	1218
10893	1232
10893	45238
10894	1183
10894	1194
10894	1206
10894	1218
10894	1229
10895	1183
10895	1194
10895	1222
10895	1232
10895	1233
10896	1183
10896	1188
10896	1198
10896	1206
10896	1218
10897	1183
10897	1194
10897	1200
10897	1206
10897	1218
10898	1183
10898	1188
10898	1198
10898	1206
10898	1218
10899	1183
10899	1188
10899	1218
10899	1232
10899	1233
10900	1183
10900	1188
10900	1213
10900	1232
10900	1233
10901	1183
10901	1188
10901	1218
10901	1232
10901	1233
10902	1183
10902	1188
10902	1206
10902	1218
10902	1229
10903	1183
10903	1188
10903	1199
10903	1218
10903	1233
10904	1183
10904	1188
10904	1218
10904	1232
10904	1233
10905	1183
10905	1188
10905	1218
10905	1232
10905	1233
10906	1183
10906	1194
10906	1206
10906	1218
10906	1229
10907	1183
10907	1188
10907	1200
10907	1204
10907	1218
10910	1183
10910	1198
10910	1206
10910	1218
10910	1239
10911	1183
10911	1188
10911	1218
10911	1232
10911	1233
10912	1183
10912	1188
10912	1218
10912	1232
10912	1233
10913	1183
10913	1194
10913	1200
10913	1206
10913	1218
10914	1188
10914	1204
10914	1218
10914	1232
10914	45238
10915	1183
10915	1188
10915	1200
10915	1206
10915	1218
10916	1183
10916	1188
10916	1204
10916	1218
10916	1232
10917	1183
10917	1194
10917	1200
10917	1206
10917	1218
10918	1183
10918	1188
10918	1218
10918	1232
10918	1233
10919	1188
10919	1203
10919	1218
10919	1232
10919	45238
10921	1183
10921	1188
10921	1200
10921	1206
10921	1218
10922	1195
10922	1200
10922	1206
10922	1218
10922	45238
10923	1183
10923	1194
10923	1204
10923	1218
10923	1232
10924	1183
10924	1188
10924	1200
10924	1206
10924	1218
10926	1183
10926	1188
10926	1218
10926	1232
10926	1233
10927	1183
10927	1188
10927	1200
10927	1204
10927	1218
10928	1188
10928	1203
10928	1218
10928	1232
10928	45236
10929	1183
10929	1188
10929	1218
10929	1232
10929	1233
10930	1183
10930	1188
10930	1218
10930	1232
10930	1233
10931	1188
10931	1204
10931	1218
10931	1232
10931	45238
10932	1183
10932	1188
10932	1198
10932	1206
10932	1218
10933	1183
10933	1194
10933	1198
10933	1206
10933	1210
10934	1183
10934	1188
10934	1204
10934	1218
10934	1232
10936	1188
10936	1218
10936	1232
10936	1233
10936	45238
10937	1183
10937	1194
10937	1204
10937	1218
10937	1232
10938	1188
10938	1218
10938	1232
10938	1233
10938	45238
10939	1183
10939	1188
10939	1217
10939	1232
10939	1233
10940	1183
10940	1188
10940	1206
10940	1218
10940	1229
10941	1183
10941	1188
10941	1200
10941	1206
10941	1218
10942	1183
10942	1194
10942	1204
10942	1218
10942	1232
10943	1195
10943	1199
10943	1204
10943	1218
10943	45236
10944	1183
10944	1188
10944	1218
10944	1232
10944	1233
10945	1183
10945	1188
10945	1200
10945	1206
10945	1218
10946	1183
10946	1188
10946	1206
10946	1218
10946	1232
10947	1183
10947	1188
10947	1204
10947	1218
10947	1232
10948	1183
10948	1194
10948	1200
10948	1206
10948	1217
10949	1183
10949	1194
10949	1218
10949	1232
10949	1233
10950	1183
10950	1188
10950	1198
10950	1199
10950	1200
10950	1206
10950	1218
10950	1220
10950	1229
10950	1232
10950	1233
10950	45134
10951	1183
10951	1188
10951	1218
10951	1232
10951	1233
10953	1183
10953	1188
10953	1200
10953	1206
10953	1218
10954	1183
10954	1188
10954	1200
10954	1206
10954	45436
10955	1183
10955	1188
10955	1200
10955	1206
10955	1218
10956	1183
10956	1188
10956	1218
10956	1232
10956	1233
10957	1183
10957	1188
10957	1200
10957	1204
10957	1218
10958	1188
10958	1198
10958	1210
10958	1233
10958	45236
10958	45567
10960	1183
10960	1188
10960	1199
10960	1231
10960	1233
10961	1183
10961	1193
10961	1200
10961	1204
10961	1218
10962	1183
10962	1188
10962	1200
10962	1206
10962	1218
10963	1188
10963	1198
10963	1204
10963	1277
10963	45238
10964	1183
10964	1188
10964	1218
10964	1232
10964	1233
10968	1183
10968	1188
10968	1204
10968	1218
10968	1232
10969	1183
10969	1195
10969	1204
10969	1218
10969	1232
10970	1183
10970	1188
10970	1218
10970	1229
10970	1233
10971	1183
10971	1188
10971	1198
10971	1218
10971	1233
10972	1183
10972	1188
10972	1206
10972	1229
10972	44968
10973	1183
10973	1188
10973	1206
10973	1218
10973	1232
10974	1188
10974	1218
10974	1232
10974	1233
10974	45236
10976	1183
10976	1188
10976	1206
10976	1221
10976	1229
10978	1183
10978	1194
10978	1200
10978	1206
10978	1218
10979	1183
10979	1188
10979	1200
10979	1206
10979	1218
10982	1183
10982	1188
10982	1218
10982	1232
10982	1233
10983	1183
10983	1194
10983	1206
10983	1222
10983	1232
10984	1183
10984	1188
10984	1218
10984	1232
10984	1233
10985	1183
10985	1188
10985	1198
10985	1206
10985	1218
10986	1183
10986	1188
10986	1198
10986	1206
10986	1218
10987	1183
10987	1188
10987	1218
10987	1232
10987	1233
10988	1183
10988	1188
10988	1198
10988	1206
10988	1218
10989	1183
10989	1188
10989	1218
10989	1232
10989	1233
10990	1183
10990	1194
10990	1218
10990	1232
10990	1233
10991	1183
10991	1188
10991	1218
10991	1232
10991	1233
10992	1183
10992	1194
10992	1218
10992	1232
10992	1233
10993	1183
10993	1188
10993	1218
10993	1232
10993	1233
10994	1183
10994	1188
10994	1220
10994	1232
10994	1233
10994	45238
10995	1183
10995	1188
10995	1218
10995	1232
10995	1233
10996	1183
10996	1188
10996	1204
10996	1218
10996	1232
10997	1183
10997	1188
10997	1204
10997	1218
10997	1229
10998	1183
10998	1188
10998	1204
10998	1218
10998	1232
10999	1183
10999	1194
10999	1206
10999	1218
10999	1232
11001	1188
11001	1206
11001	1209
11001	1232
11001	45238
11002	1183
11002	1188
11002	1206
11002	1218
11002	1229
11003	1183
11003	1188
11003	1206
11003	1222
11003	1229
11004	1183
11004	1188
11004	1199
11004	1203
11004	1218
11006	1183
11006	1188
11006	1198
11006	1206
11006	1218
11007	1183
11007	1194
11007	1200
11007	1206
11007	1217
11008	1183
11008	1188
11008	1206
11008	1218
11008	1229
11009	1183
11009	1188
11009	1206
11009	1220
11009	1229
11010	1183
11010	1194
11010	1217
11010	1232
11010	1233
11012	1183
11012	1188
11012	1218
11012	1232
11012	1233
11013	1183
11013	1194
11013	1218
11013	1232
11013	1233
11014	1183
11014	1188
11014	1204
11014	1218
11014	1232
11015	1183
11015	1188
11015	1198
11015	1206
11015	1218
11016	1183
11016	1188
11016	1218
11016	1232
11016	1233
11017	1183
11017	1188
11017	1198
11017	1206
11017	1217
11018	1183
11018	1194
11018	1200
11018	1206
11018	1218
11020	1183
11020	1194
11020	1200
11020	1206
11020	1218
11021	1183
11021	1188
11021	1198
11021	1206
11021	1219
11022	1183
11022	1194
11022	1200
11022	1206
11022	1222
11023	1183
11023	1188
11023	1218
11023	1232
11023	1233
11025	1183
11025	1188
11025	1194
11025	1198
11025	1206
11025	1218
11025	1220
11025	1232
11025	1233
11026	1183
11026	1194
11026	1218
11026	1232
11026	1233
11029	1183
11029	1194
11029	1218
11029	1232
11029	1233
11030	1183
11030	1194
11030	1232
11030	1233
11030	44971
11031	1188
11031	1204
11031	1218
11031	1232
11031	45238
11032	1183
11032	1194
11032	1218
11032	1232
11032	1233
11033	1183
11033	1194
11033	1206
11033	1218
11033	1229
11034	1183
11034	1194
11034	1198
11034	1206
11034	1218
11035	1188
11035	1218
11035	1232
11035	1233
11035	45236
11036	1183
11036	1194
11036	1205
11036	1218
11036	1232
11037	1195
11037	1218
11037	1232
11037	1233
11037	45238
11038	1183
11038	1194
11038	1218
11038	1232
11038	1233
11039	1183
11039	1194
11039	1198
11039	1206
11039	1210
11040	1183
11040	1188
11040	1210
11040	1232
11040	1233
11041	1183
11041	1194
11041	1222
11041	1232
11041	1233
11042	1183
11042	1188
11042	1206
11042	1210
11042	1229
11043	1183
11043	1188
11043	1222
11043	1232
11043	1233
11044	1183
11044	1188
11044	1218
11044	1232
11044	1233
11045	1183
11045	1188
11045	1200
11045	1206
11045	1218
11046	1183
11046	1188
11046	1194
11046	1198
11046	1206
11046	1217
11046	1218
11046	1232
11046	1233
11047	1183
11047	1194
11047	1218
11047	1232
11047	1233
11048	1183
11048	1194
11048	1200
11048	1204
11048	1218
11049	1183
11049	1188
11049	1200
11049	1206
11049	1218
11050	1183
11050	1188
11050	1200
11050	1206
11050	1218
11051	1183
11051	1194
11051	1218
11051	1232
11051	1233
11052	1183
11052	1193
11052	1218
11052	1232
11052	1233
11053	1183
11053	1188
11053	1194
11053	1200
11053	1206
11053	1218
11053	1232
11053	1233
11054	1183
11054	1194
11054	1213
11054	1232
11054	1233
11056	1183
11056	1188
11056	1218
11056	1232
11056	1233
11057	1183
11057	1188
11057	1218
11057	1232
11057	1233
11058	1183
11058	1188
11058	1218
11058	1232
11058	1233
11059	1183
11059	1188
11059	1198
11059	1206
11059	1218
11060	1183
11060	1194
11060	1218
11060	1232
11060	1233
11061	1183
11061	1188
11061	1218
11061	1232
11061	1233
11062	1183
11062	1188
11062	1218
11062	1232
11062	1233
11063	1183
11063	1194
11063	1200
11063	1206
11063	1218
11064	1183
11064	1194
11064	1218
11064	1232
11064	1233
11065	1183
11065	1188
11065	1204
11065	1218
11065	1232
11066	1183
11066	1188
11066	1200
11066	1206
11066	1217
11068	1195
11068	1200
11068	1206
11068	1232
11068	1233
11068	45238
11068	45578
11069	1183
11069	1188
11069	1218
11069	1232
11069	1233
11070	1183
11070	1194
11070	1200
11070	1206
11070	1218
11071	1183
11071	1194
11071	1218
11071	1232
11071	1233
11072	1183
11072	1188
11072	1206
11072	1218
11072	1229
11073	1183
11073	1188
11073	1198
11073	1206
11073	1218
11074	1183
11074	1194
11074	1200
11074	1206
11074	1218
11075	1183
11075	1196
11075	1205
11075	1218
11075	1232
11076	1183
11076	1188
11076	1218
11076	1232
11076	1233
11077	1183
11077	1188
11077	1218
11077	1232
11077	1233
11079	1183
11079	1188
11079	1218
11079	1232
11079	1233
11080	1183
11080	1196
11080	1198
11080	1206
11080	1218
11081	1183
11081	1194
11081	1204
11081	1218
11081	1232
11082	1183
11082	1188
11082	1198
11082	1204
11082	1218
11083	1183
11083	1188
11083	1204
11083	1218
11083	1232
11084	1183
11084	1194
11084	1205
11084	1218
11084	1232
11085	1183
11085	1194
11085	1218
11085	1232
11085	1233
11087	1183
11087	1188
11087	1206
11087	1218
11087	1229
11088	1183
11088	1188
11088	1206
11088	1218
11088	1229
11089	1183
11089	1188
11089	1204
11089	1218
11089	1232
11090	1183
11090	1194
11090	1218
11090	1232
11090	1233
11091	1183
11091	1194
11091	1206
11091	1222
11091	1229
11092	1183
11092	1194
11092	1206
11092	1218
11092	1229
11093	1183
11093	1188
11093	1218
11093	1232
11093	1233
11094	1183
11094	1188
11094	1204
11094	1218
11094	1232
11095	1188
11095	1206
11095	1220
11095	1229
11095	45238
11097	1183
11097	1194
11097	1218
11097	1232
11097	1233
11098	1183
11098	1188
11098	1198
11098	1206
11098	1218
11099	1188
11099	1209
11099	1232
11099	1233
11099	45236
11100	1183
11100	1194
11100	1203
11100	1218
11100	1229
11101	1183
11101	1188
11101	1206
11101	1218
11101	1229
11102	1183
11102	1188
11102	1204
11102	1218
11102	1232
11103	1183
11103	1188
11103	1218
11103	1232
11103	1233
11104	1183
11104	1194
11104	1200
11104	1206
11104	1218
11105	1183
11105	1188
11105	1206
11105	1218
11105	1229
11106	1183
11106	1194
11106	1218
11106	1232
11106	1233
11107	1183
11107	1188
11107	1200
11107	1206
11107	1218
11107	1232
11107	1233
11108	1183
11108	1194
11108	1218
11108	1232
11108	1233
11109	1183
11109	1194
11109	1218
11109	1232
11109	1233
11111	1183
11111	1188
11111	1218
11111	1232
11111	1233
11112	1183
11112	1188
11112	1198
11112	1206
11112	1218
11114	1183
11114	1188
11114	1198
11114	1206
11114	1218
11115	1183
11115	1194
11115	1206
11115	1218
11115	1229
11116	1183
11116	1188
11116	1218
11116	1232
11116	1233
11117	1183
11117	1188
11117	1218
11117	1232
11117	1233
11118	1183
11118	1188
11118	1206
11118	1218
11118	1229
11119	1183
11119	1194
11119	1198
11119	1206
11119	1218
11120	1183
11120	1188
11120	1206
11120	1218
11120	1229
11121	1183
11121	1188
11121	1218
11121	1232
11121	1233
11122	1183
11122	1188
11122	1213
11122	1232
11122	1233
11124	1183
11124	1188
11124	1206
11124	1218
11124	1229
11125	1183
11125	1188
11125	1206
11125	1218
11125	1229
11126	1183
11126	1188
11126	1206
11126	1218
11126	1229
11127	1183
11127	1194
11127	1218
11127	1232
11127	1233
11128	1183
11128	1188
11128	1204
11128	1218
11128	1232
11129	1183
11129	1194
11129	1200
11129	1206
11129	45134
11130	1183
11130	1194
11130	1218
11130	1232
11130	1233
11131	1183
11131	1188
11131	1232
11131	1233
11131	45134
11132	1183
11132	1188
11132	1218
11132	1232
11132	1233
11133	1183
11133	1188
11133	1200
11133	1206
11133	1218
11134	1183
11134	1188
11134	1218
11134	1232
11134	1233
11135	1183
11135	1194
11135	1206
11135	1218
11135	1232
11136	1195
11136	1232
11136	1233
11136	45238
11136	45578
11137	1183
11137	1188
11137	1218
11137	1232
11137	1233
11138	1183
11138	1188
11138	1200
11138	1206
11138	1218
11139	1183
11139	1188
11139	1204
11139	1218
11139	1232
11140	1183
11140	1194
11140	1222
11140	1232
11140	1233
11141	1183
11141	1194
11141	1229
11141	1233
11141	45194
11141	45338
11142	1183
11142	1188
11142	1200
11142	1206
11142	1218
11143	1183
11143	1194
11143	1222
11143	1232
11143	1233
11144	1182
11144	1196
11144	1206
11144	1218
11144	1229
11145	1183
11145	1188
11145	1206
11145	1218
11145	1229
11146	1183
11146	1218
11146	1232
11146	1233
11146	1239
11147	1183
11147	1188
11147	1206
11147	1217
11147	1229
11148	1183
11148	1194
11148	1218
11148	1232
11148	1233
11149	1183
11149	1188
11149	1206
11149	1218
11149	1229
11150	1183
11150	1194
11150	1218
11150	1232
11150	1233
11151	1183
11151	1194
11151	1218
11151	1232
11151	1233
11152	1183
11152	1188
11152	1218
11152	1232
11152	1233
11154	1183
11154	1188
11154	1205
11154	1218
11154	1232
11154	1233
11154	45236
11154	45561
11155	1188
11155	1206
11155	1218
11155	1232
11155	45238
11156	1183
11156	1194
11156	1204
11156	1218
11156	1232
11157	1183
11157	1188
11157	1218
11157	1232
11157	1233
11158	1183
11158	1188
11158	1198
11158	1206
11158	1218
11159	1183
11159	1188
11159	1218
11159	1232
11159	1233
11160	1183
11160	1188
11160	1198
11160	1206
11160	1218
11161	1183
11161	1194
11161	1218
11161	1229
11161	1233
11162	1183
11162	1194
11162	1200
11162	1206
11162	1218
11163	1183
11163	1194
11163	1218
11163	1232
11163	1233
11164	1183
11164	1188
11164	1218
11164	1232
11164	1233
11165	1183
11165	1188
11165	1198
11165	1200
11165	1206
11165	1218
11166	1195
11166	1200
11166	1206
11166	1231
11166	45238
11167	1183
11167	1194
11167	1205
11167	1218
11167	1232
11169	1183
11169	1194
11169	1218
11169	1232
11169	1233
11170	1183
11170	1194
11170	1213
11170	1232
11170	1233
11171	1183
11171	1188
11171	1200
11171	1206
11171	1218
11172	1183
11172	1194
11172	1206
11172	1218
11172	1229
11173	1183
11173	1194
11173	1218
11173	1232
11173	1233
11174	1183
11174	1194
11174	1200
11174	1206
11174	1218
11175	1183
11175	1194
11175	1205
11175	1218
11175	1232
11176	1183
11176	1194
11176	1206
11176	1218
11176	1229
11177	1183
11177	1194
11177	1200
11177	1206
11177	1277
11178	1183
11178	1188
11178	1198
11178	1206
11178	1218
11179	1183
11179	1188
11179	1198
11179	1206
11179	1218
11180	1183
11180	1188
11180	1198
11180	1206
11180	1218
11181	1183
11181	1194
11181	1218
11181	1232
11181	1233
11182	1183
11182	1194
11182	1218
11182	1229
11182	1233
11183	1183
11183	1188
11183	1200
11183	1206
11183	45543
11185	1183
11185	1194
11185	1218
11185	1232
11185	1233
11186	1183
11186	1194
11186	1218
11186	1232
11186	1233
11187	1183
11187	1188
11187	1200
11187	1206
11187	1218
11188	1183
11188	1188
11188	1206
11188	1232
11188	44971
11189	1183
11189	1194
11189	1218
11189	1232
11189	1233
11190	1183
11190	1204
11190	1218
11190	1232
11190	1239
11191	1183
11191	1194
11191	1200
11191	1206
11191	1218
11192	1183
11192	1194
11192	1200
11192	1206
11192	45543
11193	1183
11193	1194
11193	1218
11193	1232
11193	1233
11194	1183
11194	1188
11194	1218
11194	1232
11194	1233
11195	1183
11195	1193
11195	1198
11195	1218
11195	1233
11196	1183
11196	1188
11196	1232
11196	1233
11196	44971
11197	1183
11197	1196
11197	1198
11197	1206
11197	1218
11198	1183
11198	1194
11198	1229
11198	1233
11198	44971
11199	1183
11199	1194
11199	1218
11199	1232
11199	1233
11200	1183
11200	1194
11200	1218
11200	1232
11200	1233
11204	1183
11204	1194
11204	1200
11204	1206
11204	1218
11205	1188
11205	1204
11205	1218
11205	1232
11205	45238
11206	1183
11206	1194
11206	1218
11206	1232
11206	1233
11207	1183
11207	1206
11207	1218
11207	1229
11207	1239
11208	1183
11208	1188
11208	1198
11208	1206
11208	1210
11208	1218
11208	1233
11209	1183
11209	1188
11209	1200
11209	1206
11209	45539
11210	1188
11210	1220
11210	1232
11210	1233
11210	45238
11211	1188
11211	1200
11211	1206
11211	1220
11211	45238
11212	1183
11212	1188
11212	1198
11212	1206
11212	1218
11214	1183
11214	1188
11214	1222
11214	1232
11214	1233
11215	1183
11215	1188
11215	1198
11215	1206
11215	1218
11216	1183
11216	1188
11216	1206
11216	1218
11216	1229
11217	1183
11217	1196
11217	1218
11217	1232
11217	1233
11218	1183
11218	1194
11218	1206
11218	1218
11218	1229
11219	1183
11219	1194
11219	1200
11219	1206
11219	1218
11220	1183
11220	1194
11220	1200
11220	1206
11220	1217
11221	1183
11221	1194
11221	1218
11221	1232
11221	1233
11222	1183
11222	1194
11222	1200
11222	1206
11222	1218
11224	1188
11224	1218
11224	1232
11224	1233
11224	45238
11225	1183
11225	1188
11225	1206
11225	1218
11225	1232
11226	1183
11226	1188
11226	1204
11226	1218
11226	1232
11228	1183
11228	1188
11228	1198
11228	1206
11228	1218
11229	1183
11229	1188
11229	1206
11229	1218
11229	1229
11230	1183
11230	1188
11230	1206
11230	1218
11230	1229
11231	1183
11231	1196
11231	1213
11231	1232
11231	1233
11233	1183
11233	1188
11233	1206
11233	1217
11233	1229
11234	1183
11234	1188
11234	1198
11234	1206
11234	1218
11235	1183
11235	1188
11235	1200
11235	1206
11235	1222
11236	1183
11236	1188
11236	1200
11236	1206
11236	1218
11237	1183
11237	1191
11237	1232
11237	1233
11237	45543
11238	1183
11238	1194
11238	1206
11238	1218
11238	1229
11239	1183
11239	1188
11239	1206
11239	1222
11239	1229
11240	1183
11240	1194
11240	1198
11240	1206
11240	1218
11241	1183
11241	1194
11241	1206
11241	1218
11241	1229
11242	1183
11242	1188
11242	1200
11242	1218
11242	1233
11243	1183
11243	1194
11243	1200
11243	1206
11243	1218
11244	1183
11244	1194
11244	1200
11244	1206
11244	1218
11245	1183
11245	1194
11245	1198
11245	1206
11245	1218
11246	1183
11246	1188
11246	1206
11246	1218
11246	1229
11247	1183
11247	1188
11247	1200
11247	1206
11247	1218
11248	1183
11248	1188
11248	1218
11248	1232
11248	1233
11249	1183
11249	1188
11249	1204
11249	1222
11249	1232
11250	1183
11250	1188
11250	1206
11250	1217
11250	1229
11251	1183
11251	1194
11251	1200
11251	1206
11251	1218
11252	1183
11252	1194
11252	1200
11252	1206
11252	1218
11253	1183
11253	1188
11253	1198
11253	1206
11253	1218
11254	1183
11254	1194
11254	1200
11254	1206
11254	1218
11255	1183
11255	1188
11255	1206
11255	1218
11255	1229
11256	1183
11256	1188
11256	1206
11256	1218
11256	1232
11257	1183
11257	1194
11257	1198
11257	1218
11257	1233
11258	1183
11258	1188
11258	1206
11258	1218
11258	1232
11259	1183
11259	1188
11259	1232
11259	1233
11259	44970
11260	1183
11260	1188
11260	1204
11260	1232
11260	44968
11261	1183
11261	1188
11261	1217
11261	1232
11261	1233
11262	1183
11262	1188
11262	1218
11262	1232
11262	1233
11264	1183
11264	1188
11264	1206
11264	1213
11264	1232
11265	1183
11265	1188
11265	1232
11265	1233
11265	44985
11266	1183
11266	1196
11266	1232
11266	1233
11266	1277
11267	1183
11267	1188
11267	1232
11267	1233
11267	44984
11268	1183
11268	1188
11268	1232
11268	1233
11268	44984
11269	1183
11269	1188
11269	1232
11269	1233
11269	44971
11270	1183
11270	1188
11270	1205
11270	1218
11270	1232
11271	1183
11271	1188
11271	1206
11271	1218
11271	1232
11272	1183
11272	1188
11272	1206
11272	1218
11272	1232
11273	1183
11273	1188
11273	1218
11273	1232
11273	1233
11274	1183
11274	1196
11274	1232
11274	1233
11274	45039
11275	1183
11275	1188
11275	1232
11275	1233
11275	1277
11276	1183
11276	1188
11276	1204
11276	1232
11276	1277
11277	1183
11277	1188
11277	1218
11277	1232
11277	1233
11278	1183
11278	1188
11278	1232
11278	1233
11278	1277
11279	1183
11279	1198
11279	1218
11279	1233
11279	1239
11280	1183
11280	1188
11280	1200
11280	1206
11280	1218
11281	1183
11281	1188
11281	1218
11281	1232
11281	1233
11282	1183
11282	1188
11282	1204
11282	1218
11282	1232
11283	1183
11283	1194
11283	1218
11283	1232
11283	1233
11284	1183
11284	1188
11284	1206
11284	1218
11284	1229
11285	1183
11285	1194
11285	1206
11285	1218
11285	1229
11286	1183
11286	1194
11286	1200
11286	1206
11286	1222
11287	1183
11287	1188
11287	1217
11287	1229
11287	1233
11288	1183
11288	1188
11288	1206
11288	1217
11288	1229
11289	1183
11289	1188
11289	1218
11289	1232
11289	1233
11290	1183
11290	1194
11290	1206
11290	1218
11290	1229
11292	1183
11292	1188
11292	1206
11292	1218
11292	1229
11293	1183
11293	1188
11293	1200
11293	1206
11293	1218
11294	1183
11294	1194
11294	1198
11294	1205
11294	1218
11295	1188
11295	1206
11295	1218
11295	1229
11295	45238
11296	1183
11296	1188
11296	1200
11296	1206
11296	1218
11297	1188
11297	1200
11297	1206
11297	1218
11297	45238
11298	1183
11298	1188
11298	1206
11298	1218
11298	1229
11299	1183
11299	1188
11299	1206
11299	1218
11299	1229
11300	1183
11300	1194
11300	1200
11300	1206
11300	1218
11302	1183
11302	1188
11302	1218
11302	1232
11302	1233
11303	1183
11303	1196
11303	1206
11303	1218
11303	1229
11305	1183
11305	1188
11305	1200
11305	1206
11305	1218
11306	1188
11306	1200
11306	1206
11306	1218
11306	45238
11307	1183
11307	1194
11307	1218
11307	1232
11307	1233
11309	1183
11309	1188
11309	1218
11309	1232
11309	1233
11310	1188
11310	1200
11310	1206
11310	1246
11310	45238
11311	1183
11311	1188
11311	1206
11311	1217
11311	1229
11312	1183
11312	1188
11312	1206
11312	1218
11312	1229
11313	1183
11313	1188
11313	1206
11313	1218
11313	1229
11314	1183
11314	1188
11314	1218
11314	1232
11314	1233
11315	1183
11315	1188
11315	1206
11315	1218
11315	1229
11316	1183
11316	1188
11316	1200
11316	1206
11316	1218
11317	1183
11317	1194
11317	1200
11317	1206
11317	1218
11318	1183
11318	1188
11318	1198
11318	1206
11318	1218
11319	1183
11319	1188
11319	1206
11319	1218
11319	1229
11320	1179
11320	1188
11320	1197
11320	1201
11320	1218
11321	1183
11321	1188
11321	1200
11321	1206
11321	1218
11322	1188
11322	1204
11322	1218
11322	1232
11322	45238
11323	1183
11323	1193
11323	1200
11323	1204
11323	1218
11324	1183
11324	1188
11324	1204
11324	1232
11324	45017
11325	1183
11325	1188
11325	1206
11325	1218
11325	1232
11326	1183
11326	1188
11326	1206
11326	1218
11326	1229
11327	1188
11327	1200
11327	1206
11327	1218
11327	45238
11328	1183
11328	1194
11328	1206
11328	1217
11328	1218
11328	1229
11328	1233
11329	1183
11329	1188
11329	1198
11329	1206
11329	1218
11330	1183
11330	1188
11330	1218
11330	1232
11330	1233
11331	1183
11331	1188
11331	1206
11331	1218
11331	1229
11332	1183
11332	1188
11332	1200
11332	1206
11332	45134
11333	1183
11333	1194
11333	1204
11333	1218
11333	1232
11334	1183
11334	1188
11334	1198
11334	1206
11334	1218
11336	1183
11336	1188
11336	1218
11336	1232
11336	1233
11337	1183
11337	1188
11337	1200
11337	1206
11337	1218
11338	1183
11338	1188
11338	1200
11338	1206
11338	1218
11339	1183
11339	1188
11339	1198
11339	1206
11339	1218
11340	1183
11340	1188
11340	1206
11340	1218
11340	1229
11341	1183
11341	1188
11341	1218
11341	1232
11341	1233
11342	1183
11342	1188
11342	1218
11342	1232
11342	1233
11344	1183
11344	1188
11344	1200
11344	1206
11344	45543
11345	1183
11345	1204
11345	1218
11345	1232
11345	1239
11346	1183
11346	1188
11346	1213
11346	1229
11346	1233
11347	1180
11347	1195
11347	1200
11347	1206
11347	1218
11348	1183
11348	1188
11348	1218
11348	1232
11348	1233
11349	1183
11349	1188
11349	1206
11349	1218
11349	1229
11351	1183
11351	1188
11351	1206
11351	1218
11351	1232
11352	1183
11352	1194
11352	1206
11352	1218
11352	1229
11353	1183
11353	1194
11353	1198
11353	1206
11353	1218
11354	1183
11354	1188
11354	1206
11354	1218
11354	1229
11355	1183
11355	1188
11355	1198
11355	1206
11355	1218
11356	1188
11356	1218
11356	1232
11356	1233
11356	45238
11358	1183
11358	1194
11358	1218
11358	1232
11358	1233
11359	1188
11359	1218
11359	1232
11359	1233
11359	45238
11360	1183
11360	1196
11360	1206
11360	1222
11360	1229
11361	1188
11361	1218
11361	1232
11361	1233
11361	45238
11362	1188
11362	1204
11362	1218
11362	1232
11362	1233
11362	45238
11363	1183
11363	1188
11363	1206
11363	1217
11363	1229
11364	1188
11364	1206
11364	1218
11364	1229
11364	45238
11365	1183
11365	1188
11365	1218
11365	1232
11365	1233
11366	1183
11366	1194
11366	1206
11366	1222
11366	1229
11367	1183
11367	1188
11367	1210
11367	1232
11367	1233
11368	1183
11368	1188
11368	1218
11368	1232
11368	1233
11369	1183
11369	1188
11369	1210
11369	1232
11369	1233
11370	1183
11370	1188
11370	1198
11370	1206
11370	1218
11372	1188
11372	1200
11372	1206
11372	1218
11372	45238
11373	1183
11373	1188
11373	1206
11373	1213
11373	1229
11374	1183
11374	1188
11374	1218
11374	1232
11374	1233
11375	1183
11375	1194
11375	1198
11375	1204
11375	1218
11376	1195
11376	1200
11376	1206
11376	1218
11376	45238
11377	1183
11377	1188
11377	1206
11377	1217
11377	1229
11378	1188
11378	1198
11378	1206
11378	1218
11378	45238
11379	1183
11379	1188
11379	1206
11379	1218
11379	1229
11380	1183
11380	1188
11380	1200
11380	1206
11380	1218
11381	1183
11381	1188
11381	1206
11381	1218
11381	1229
11382	1183
11382	1188
11382	1206
11382	1217
11382	1229
11383	1183
11383	1188
11383	1198
11383	1204
11383	1246
11385	1188
11385	1218
11385	1232
11385	1233
11385	45238
11386	1188
11386	1206
11386	1218
11386	1229
11386	45238
11387	1188
11387	1206
11387	1218
11387	1229
11387	45238
11388	1183
11388	1188
11388	1203
11388	1218
11388	1229
11389	1183
11389	1188
11389	1232
11389	1233
11389	1262
11390	1183
11390	1206
11390	1218
11390	1232
11390	1239
11391	1183
11391	1188
11391	1198
11391	1206
11391	1218
11392	1183
11392	1188
11392	1198
11392	1204
11392	45112
11393	1183
11393	1188
11393	1198
11393	1206
11393	1218
11394	1183
11394	1188
11394	1218
11394	1232
11394	1233
11395	1183
11395	1188
11395	1218
11395	1232
11395	1233
11396	1183
11396	1188
11396	1204
11396	1232
11396	44984
11397	1183
11397	1188
11397	1210
11397	1232
11397	1233
11398	1183
11398	1188
11398	1204
11398	1218
11398	1232
11399	1183
11399	1188
11399	1217
11399	1232
11399	1233
11400	1183
11400	1188
11400	1204
11400	1218
11400	1232
11401	1183
11401	1188
11401	1218
11401	1232
11401	1233
11402	1183
11402	1188
11402	1204
11402	1229
11402	1247
11403	1183
11403	1188
11403	1218
11403	1232
11403	1233
11404	1183
11404	1188
11404	1232
11404	1233
11404	44970
11405	1183
11405	1188
11405	1206
11405	1218
11405	1238
11406	1183
11406	1188
11406	1198
11406	1204
11406	1218
11407	1183
11407	1188
11407	1218
11407	1229
11407	1233
11408	1183
11408	1188
11408	1198
11408	1204
11408	1218
11409	1183
11409	1188
11409	1213
11409	1229
11409	1233
11410	1183
11410	1188
11410	1229
11410	1233
11410	1243
11411	1183
11411	1188
11411	1204
11411	1232
11411	1243
11412	1183
11412	1188
11412	1213
11412	1229
11412	1233
11413	1183
11413	1188
11413	1200
11413	1218
11413	1233
11414	1183
11414	1188
11414	1206
11414	1229
11414	44968
11415	1183
11415	1188
11415	1232
11415	1233
11415	44974
11416	1183
11416	1188
11416	1204
11416	1218
11416	1232
11417	1183
11417	1188
11417	1204
11417	1218
11417	1232
11418	1183
11418	1188
11418	1204
11418	1218
11418	1232
11419	1183
11419	1188
11419	1206
11419	1218
11419	1232
11420	1183
11420	1188
11420	1206
11420	1218
11420	1232
11421	1183
11421	1188
11421	1206
11421	1218
11421	1229
11422	1183
11422	1188
11422	1218
11422	1232
11422	1233
11423	1183
11423	1188
11423	1206
11423	1221
11423	1232
11424	1183
11424	1221
11424	1232
11424	1233
11424	1239
11425	1183
11425	1188
11425	1218
11425	1229
11425	1233
11426	1183
11426	1188
11426	1206
11426	1229
11426	44974
11427	1183
11427	1188
11427	1206
11427	1218
11427	1232
11428	1183
11428	1188
11428	1206
11428	1218
11428	1232
11429	1183
11429	1188
11429	1218
11429	1232
11429	1233
11430	1183
11430	1188
11430	1198
11430	1204
11430	1218
11431	1183
11431	1188
11431	1198
11431	1204
11431	1209
11432	1183
11432	1188
11432	1206
11432	1218
11432	1229
11433	1183
11433	1188
11433	1205
11433	1218
11433	1232
11434	1183
11434	1188
11434	1205
11434	1218
11434	1232
11435	1183
11435	1188
11435	1206
11435	1218
11435	1229
11436	1183
11436	1188
11436	1206
11436	1221
11436	1232
11437	1183
11437	1188
11437	1218
11437	1229
11437	1233
11438	1183
11438	1188
11438	1204
11438	1218
11438	1232
11439	1183
11439	1188
11439	1218
11439	1232
11439	1233
11440	1183
11440	1188
11440	1198
11440	1210
11440	1233
11441	1183
11441	1188
11441	1218
11441	1232
11441	1233
11442	1183
11442	1204
11442	1232
11442	1239
11442	44971
11443	1183
11443	1188
11443	1217
11443	1232
11443	1233
11444	1183
11444	1198
11444	1218
11444	1233
11444	1239
11445	1183
11445	1188
11445	1205
11445	1218
11445	1232
11446	1183
11446	1188
11446	1204
11446	1218
11446	1232
11447	1183
11447	1188
11447	1205
11447	1218
11447	1232
11448	1183
11448	1188
11448	1198
11448	1206
11448	1218
11449	1183
11449	1188
11449	1198
11449	1218
11449	1233
11450	1183
11450	1188
11450	1198
11450	1206
11450	1218
11451	1183
11451	1188
11451	1232
11451	1233
11451	44974
11452	1183
11452	1188
11452	1218
11452	1232
11452	1233
11453	1183
11453	1188
11453	1198
11453	1218
11453	1233
11454	1183
11454	1188
11454	1204
11454	1218
11454	1232
11455	1183
11455	1188
11455	1206
11455	1217
11455	1232
11456	1183
11456	1188
11456	1218
11456	1232
11456	1233
11457	1183
11457	1188
11457	1206
11457	1218
11457	1229
11459	1183
11459	1188
11459	1206
11459	1232
11459	44974
11460	1183
11460	1188
11460	1232
11460	1233
11460	45017
11461	1183
11461	1188
11461	1218
11461	1232
11461	1233
11462	1183
11462	1188
11462	1217
11462	1232
11462	1233
11463	1183
11463	1188
11463	1205
11463	1218
11463	1232
11464	1183
11464	1188
11464	1218
11464	1232
11464	1233
11465	1183
11465	1188
11465	1206
11465	1229
11465	45114
11466	1183
11466	1188
11466	1198
11466	1205
11466	1218
11467	1183
11467	1188
11467	1198
11467	1205
11467	1262
11468	1183
11468	1188
11468	1229
11468	1233
11468	1243
11469	1183
11469	1188
11469	1198
11469	1218
11469	1233
11470	1183
11470	1188
11470	1206
11470	1217
11470	1229
11471	1183
11471	1188
11471	1206
11471	1217
11471	1229
11473	1183
11473	1188
11473	1218
11473	1232
11473	1233
11474	1183
11474	1188
11474	1218
11474	1232
11474	1233
11475	1183
11475	1188
11475	1205
11475	1218
11475	1232
11476	1183
11476	1188
11476	1198
11476	1233
11476	44977
11477	1183
11477	1188
11477	1206
11477	1218
11477	1229
11478	1183
11478	1188
11478	1205
11478	1218
11478	1232
11479	1183
11479	1188
11479	1204
11479	1232
11479	44974
11480	1183
11480	1188
11480	1204
11480	1232
11480	44971
11481	1183
11481	1188
11481	1204
11481	1222
11481	1232
11482	1183
11482	1188
11482	1218
11482	1232
11482	1233
11483	1183
11483	1188
11483	1206
11483	1221
11483	1232
11484	1183
11484	1188
11484	1205
11484	1218
11484	1232
11485	1183
11485	1188
11485	1213
11485	1232
11485	1233
11486	1183
11486	1188
11486	1198
11486	1204
11486	1218
11487	1183
11487	1188
11487	1218
11487	1232
11487	1233
11488	1183
11488	1195
11488	1198
11488	1218
11488	1233
11489	1183
11489	1188
11489	1198
11489	1218
11489	1233
11490	1183
11490	1188
11490	1206
11490	1218
11490	1229
11491	1183
11491	1188
11491	1198
11491	1205
11491	1218
11492	1183
11492	1188
11492	1198
11492	1218
11492	1233
11493	1183
11493	1188
11493	1218
11493	1229
11493	1233
11494	1183
11494	1188
11494	1232
11494	1233
11494	44974
11495	1183
11495	1188
11495	1198
11495	1218
11495	1233
11496	1183
11496	1188
11496	1198
11496	1205
11496	1218
11497	1183
11497	1188
11497	1206
11497	1229
11497	44971
11498	1183
11498	1188
11498	1218
11498	1232
11498	1233
11499	1183
11499	1188
11499	1218
11499	1229
11499	1233
11500	1183
11500	1188
11500	1198
11500	1209
11500	1233
11501	1183
11501	1188
11501	1198
11501	1204
11501	44971
11502	1183
11502	1188
11502	1218
11502	1229
11502	1233
11503	1183
11503	1188
11503	1218
11503	1229
11503	1233
11504	1183
11504	1188
11504	1232
11504	1233
11504	1277
11505	1183
11505	1198
11505	1210
11505	1233
11505	1239
11506	1183
11506	1188
11506	1232
11506	1233
11506	44985
11507	1183
11507	1191
11507	1204
11507	1232
11507	44971
11508	1183
11508	1198
11508	1218
11508	1233
11508	1239
11509	1183
11509	1188
11509	1229
11509	1233
11509	1243
11510	1183
11510	1188
11510	1198
11510	1218
11510	1233
11511	1183
11511	1188
11511	1198
11511	1204
11511	1218
11512	1183
11512	1188
11512	1198
11512	1218
11512	1233
11513	1183
11513	1188
11513	1200
11513	1206
11513	1218
11514	1183
11514	1188
11514	1198
11514	1206
11514	1218
11515	1183
11515	1188
11515	1206
11515	1218
11515	1232
11516	1188
11516	1205
11516	1218
11516	1232
11516	45238
11517	1183
11517	1188
11517	1204
11517	1232
11517	44985
11518	1183
11518	1188
11518	1206
11518	1218
11518	1229
11519	1188
11519	1229
11519	1233
11519	1277
11519	45238
11520	1183
11520	1188
11520	1198
11520	1218
11520	1233
11521	1183
11521	1188
11521	1218
11521	1232
11521	1233
11522	1183
11522	1188
11522	1218
11522	1232
11522	1233
11523	1183
11523	1188
11523	1218
11523	1232
11523	1233
11524	1183
11524	1188
11524	1218
11524	1232
11524	1233
11525	1183
11525	1188
11525	1204
11525	1218
11525	1232
11526	1183
11526	1188
11526	1218
11526	1229
11526	1233
11527	1188
11527	1206
11527	1218
11527	1229
11527	45238
11528	1183
11528	1188
11528	1218
11528	1232
11528	1233
11529	1183
11529	1188
11529	1204
11529	1218
11529	1229
11530	1188
11530	1205
11530	1218
11530	1232
11530	44936
11531	1183
11531	1188
11531	1206
11531	1218
11531	1232
11532	1188
11532	1209
11532	1232
11532	1233
11532	45238
11533	1183
11533	1188
11533	1198
11533	1233
11533	44971
11534	1183
11534	1188
11534	1206
11534	1218
11534	1232
11536	1188
11536	1232
11536	1233
11536	1277
11536	45238
11537	1183
11537	1188
11537	1200
11537	1218
11537	1233
11538	1183
11538	1188
11538	1204
11538	1218
11538	1232
11539	1183
11539	1198
11539	1204
11539	1218
11539	1239
11540	1183
11540	1188
11540	1218
11540	1232
11540	1233
11541	1183
11541	1188
11541	1204
11541	1218
11541	1232
11542	1183
11542	1188
11542	1204
11542	1218
11542	1232
11543	1183
11543	1188
11543	1232
11543	1233
11543	44974
11544	1183
11544	1188
11544	1218
11544	1232
11544	1233
11545	1183
11545	1188
11545	1217
11545	1232
11545	1233
11546	1183
11546	1188
11546	1198
11546	1218
11546	1233
11547	1183
11547	1188
11547	1229
11547	1233
11547	44974
11548	1183
11548	1188
11548	1206
11548	1217
11548	1232
11549	1183
11549	1188
11549	1205
11549	1218
11549	1232
11550	1183
11550	1188
11550	1198
11550	1204
11550	44971
11551	1183
11551	1188
11551	1213
11551	1232
11551	1233
11552	1183
11552	1188
11552	1209
11552	1232
11552	1233
11553	1183
11553	1188
11553	1218
11553	1232
11553	1233
11554	1183
11554	1188
11554	1204
11554	1218
11554	1232
11555	1183
11555	1188
11555	1198
11555	1204
11555	1218
11556	1183
11556	1188
11556	1218
11556	1232
11556	1233
11557	1183
11557	1204
11557	1232
11557	1239
11557	44970
11558	1183
11558	1188
11558	1204
11558	1218
11558	1229
11559	1183
11559	1188
11559	1206
11559	1218
11559	1232
11560	1183
11560	1188
11560	1204
11560	1218
11560	1232
11561	1183
11561	1188
11561	1218
11561	1232
11561	1233
11562	1183
11562	1188
11562	1232
11562	1233
11562	44985
11563	1183
11563	1188
11563	1232
11563	1233
11563	44985
11564	1183
11564	1188
11564	1218
11564	1229
11564	1233
11565	1183
11565	1188
11565	1204
11565	1218
11565	1232
11566	1183
11566	1188
11566	1206
11566	1218
11566	1232
11567	1183
11567	1188
11567	1198
11567	1218
11567	1233
11568	1183
11568	1188
11568	1205
11568	1218
11568	1232
11569	1183
11569	1188
11569	1218
11569	1232
11569	1233
11570	1183
11570	1188
11570	1217
11570	1232
11570	1233
11571	1183
11571	1188
11571	1198
11571	1205
11571	1218
11572	1183
11572	1188
11572	1204
11572	1222
11572	1232
11573	1183
11573	1188
11573	1204
11573	1218
11573	1232
11574	1183
11574	1188
11574	1218
11574	1232
11574	1233
11575	1183
11575	1188
11575	1218
11575	1232
11575	1233
11576	1183
11576	1188
11576	1206
11576	1232
11576	44974
11577	1183
11577	1188
11577	1206
11577	1218
11577	1229
11578	1183
11578	1188
11578	1206
11578	1232
11578	44971
11579	1183
11579	1188
11579	1218
11579	1232
11579	1233
11580	1183
11580	1188
11580	1198
11580	1218
11580	1233
11581	1183
11581	1188
11581	1198
11581	1233
11581	44977
11582	1183
11582	1188
11582	1200
11582	1204
11582	1218
11583	1183
11583	1188
11583	1232
11583	1233
11583	45181
11584	1183
11584	1188
11584	1206
11584	1232
11584	45062
11585	1183
11585	1188
11585	1204
11585	1232
11585	45062
11586	1183
11586	1188
11586	1218
11586	1232
11586	1233
11587	1183
11587	1188
11587	1206
11587	1232
11587	44968
11588	1183
11588	1188
11588	1205
11588	1232
11588	44974
11589	1183
11589	1213
11589	1232
11589	1233
11589	1239
11590	1183
11590	1188
11590	1218
11590	1232
11590	1233
11591	1183
11591	1188
11591	1218
11591	1232
11591	1233
11592	1183
11592	1188
11592	1198
11592	1218
11592	1233
11593	1183
11593	1188
11593	1204
11593	1232
11593	44974
11595	1183
11595	1188
11595	1206
11595	1217
11595	1232
11596	1183
11596	1188
11596	1206
11596	1218
11596	1232
11597	1183
11597	1188
11597	1205
11597	1218
11597	1232
11598	1183
11598	1188
11598	1204
11598	1218
11598	1232
11599	1183
11599	1188
11599	1218
11599	1232
11599	1233
11600	1183
11600	1188
11600	1204
11600	1218
11600	1232
11602	1183
11602	1188
11602	1218
11602	1232
11602	1233
11603	1183
11603	1188
11603	1198
11603	1204
11603	1218
11604	1183
11604	1188
11604	1218
11604	1232
11604	1233
11605	1183
11605	1188
11605	1232
11605	1233
11605	44970
11606	1183
11606	1188
11606	1218
11606	1232
11606	1233
11607	1183
11607	1188
11607	1206
11607	1218
11607	1232
11608	1183
11608	1188
11608	1198
11608	1205
11608	1218
11609	1183
11609	1188
11609	1206
11609	1232
11609	1243
11610	1183
11610	1188
11610	1232
11610	1233
11610	1243
11611	1183
11611	1188
11611	1232
11611	1233
11611	44985
11612	1183
11612	1188
11612	1218
11612	1232
11612	1233
11613	1188
11613	1232
11613	1233
11613	44974
11613	45238
11614	1183
11614	1188
11614	1198
11614	1204
11614	1218
11615	1183
11615	1188
11615	1200
11615	1204
11615	1218
11616	1183
11616	1188
11616	1218
11616	1232
11616	1233
11617	1183
11617	1188
11617	1213
11617	1232
11617	1233
11618	1183
11618	1188
11618	1206
11618	1217
11618	1232
11619	1183
11619	1188
11619	1218
11619	1232
11619	1233
11620	1188
11620	1218
11620	1232
11620	1233
11620	45238
11621	1183
11621	1188
11621	1217
11621	1232
11621	1233
11622	1183
11622	1188
11622	1204
11622	1218
11622	1232
11623	1183
11623	1188
11623	1198
11623	1205
11623	1218
11624	1183
11624	1188
11624	1198
11624	1204
11624	44983
11625	1183
11625	1188
11625	1206
11625	1218
11625	1232
11626	1183
11626	1188
11626	1232
11626	1233
11626	44968
11627	1183
11627	1188
11627	1213
11627	1232
11627	1233
11628	1188
11628	1198
11628	1218
11628	1233
11628	45238
11629	1183
11629	1188
11629	1198
11629	1233
11629	44977
11630	1183
11630	1188
11630	1204
11630	1218
11630	1232
11631	1183
11631	1188
11631	1218
11631	1229
11631	1233
11632	1183
11632	1188
11632	1198
11632	1218
11632	1233
11633	1183
11633	1188
11633	1232
11633	1233
11633	44974
11634	1183
11634	1188
11634	1218
11634	1232
11634	1233
11635	1183
11635	1204
11635	1218
11635	1232
11635	1239
11636	1183
11636	1188
11636	1206
11636	1218
11636	1232
11637	1183
11637	1188
11637	1205
11637	1218
11637	1229
11638	1183
11638	1188
11638	1204
11638	1218
11638	1232
11639	1183
11639	1188
11639	1206
11639	1213
11639	1229
11640	1183
11640	1188
11640	1206
11640	1218
11640	1232
11641	1183
11641	1188
11641	1218
11641	1232
11641	1233
11642	1183
11642	1188
11642	1217
11642	1232
11642	1233
11643	1183
11643	1188
11643	1218
11643	1232
11643	1233
11644	1183
11644	1188
11644	1198
11644	1218
11644	1233
11645	1183
11645	1188
11645	1198
11645	1218
11645	1233
11646	1183
11646	1188
11646	1206
11646	1218
11646	1229
11647	1183
11647	1188
11647	1198
11647	1218
11647	1233
11648	1183
11648	1188
11648	1198
11648	1218
11648	1233
11649	1183
11649	1188
11649	1198
11649	1204
11649	1218
11650	1183
11650	1188
11650	1206
11650	1218
11650	1232
11651	1183
11651	1188
11651	1218
11651	1232
11651	1233
11652	1183
11652	1188
11652	1206
11652	1218
11652	1232
11653	1183
11653	1188
11653	1206
11653	1221
11653	1232
11654	1183
11654	1188
11654	1218
11654	1232
11654	1233
11655	1183
11655	1188
11655	1198
11655	1233
11655	44971
11656	1183
11656	1188
11656	1204
11656	1218
11656	1232
11657	1183
11657	1188
11657	1206
11657	1218
11657	1232
11658	1183
11658	1188
11658	1232
11658	1233
11658	44985
11659	1183
11659	1188
11659	1213
11659	1232
11659	1233
11660	1183
11660	1188
11660	1204
11660	1213
11660	1232
11661	1183
11661	1188
11661	1218
11661	1232
11661	1233
11662	1183
11662	1188
11662	1218
11662	1232
11662	1233
11663	1183
11663	1188
11663	1218
11663	1232
11663	1233
11664	1183
11664	1188
11664	1198
11664	1204
11664	1218
11665	1183
11665	1188
11665	1204
11665	1218
11665	1229
11666	1188
11666	1218
11666	1232
11666	1233
11666	45238
11667	1183
11667	1188
11667	1198
11667	1204
11667	1218
11668	1183
11668	1188
11668	1218
11668	1232
11668	1233
11669	1183
11669	1188
11669	1206
11669	1217
11669	1232
11670	1183
11670	1188
11670	1206
11670	1218
11670	1232
11671	1183
11671	1188
11671	1206
11671	1218
11671	1232
11672	1183
11672	1188
11672	1206
11672	1218
11672	1229
11673	1183
11673	1188
11673	1198
11673	1205
11673	1218
11674	1183
11674	1188
11674	1218
11674	1232
11674	1233
11675	1183
11675	1188
11675	1198
11675	1204
11675	1218
11676	1183
11676	1188
11676	1198
11676	1205
11676	1218
11677	1183
11677	1188
11677	1206
11677	1218
11677	1232
11678	1183
11678	1188
11678	1218
11678	1232
11678	1233
11679	1183
11679	1188
11679	1218
11679	1232
11679	1233
11680	1183
11680	1188
11680	1198
11680	1233
11680	44977
11681	1188
11681	1198
11681	1205
11681	1218
11681	45238
11682	1183
11682	1188
11682	1198
11682	1206
11682	1218
11683	1183
11683	1188
11683	1218
11683	1232
11683	1233
11684	1183
11684	1188
11684	1205
11684	1218
11684	1232
11685	1183
11685	1188
11685	1218
11685	1232
11685	1233
11686	1183
11686	1188
11686	1218
11686	1232
11686	1233
11687	1183
11687	1188
11687	1206
11687	1218
11687	1232
11688	1183
11688	1188
11688	1198
11688	1206
11688	44977
11689	1183
11689	1188
11689	1206
11689	1229
11689	44971
11690	1183
11690	1188
11690	1206
11690	1218
11690	1229
11691	1183
11691	1188
11691	1198
11691	1205
11691	1218
11692	1183
11692	1188
11692	1206
11692	1217
11692	1232
11693	1183
11693	1188
11693	1218
11693	1232
11693	1233
11694	1183
11694	1188
11694	1232
11694	1233
11694	44974
11695	1183
11695	1188
11695	1218
11695	1232
11695	1233
11696	1183
11696	1188
11696	1210
11696	1232
11696	1233
11697	1183
11697	1188
11697	1204
11697	1218
11697	1232
11698	1183
11698	1188
11698	1218
11698	1232
11698	1233
11699	1183
11699	1188
11699	1232
11699	1233
11699	45118
11700	1183
11700	1188
11700	1206
11700	1232
11700	45118
11701	1183
11701	1188
11701	1218
11701	1232
11701	1233
11702	1183
11702	1188
11702	1204
11702	1218
11702	1232
11703	1183
11703	1188
11703	1198
11703	1204
11703	1218
11704	1183
11704	1188
11704	1198
11704	1205
11704	1218
11705	1183
11705	1188
11705	1206
11705	1229
11705	44968
11706	1183
11706	1188
11706	1204
11706	1218
11706	1229
11707	1183
11707	1188
11707	1204
11707	1218
11707	1229
11708	1183
11708	1188
11708	1206
11708	1218
11708	1232
11709	1183
11709	1188
11709	1218
11709	1232
11709	1233
11710	1183
11710	1188
11710	1198
11710	1204
11710	1218
11712	1183
11712	1188
11712	1218
11712	1232
11712	1233
11713	1183
11713	1188
11713	1218
11713	1232
11713	1233
11714	1183
11714	1188
11714	1198
11714	1218
11714	1233
11715	1183
11715	1188
11715	1206
11715	1218
11715	1232
11716	1183
11716	1188
11716	1198
11716	1204
11716	1218
11717	1183
11717	1188
11717	1200
11717	1204
11717	1218
11718	1183
11718	1188
11718	1204
11718	1218
11718	1232
11719	1183
11719	1188
11719	1218
11719	1232
11719	1233
11720	1183
11720	1232
11720	1233
11720	1239
11720	45119
11721	1183
11721	1191
11721	1218
11721	1232
11721	1233
11722	1183
11722	1188
11722	1206
11722	1217
11722	1232
11723	1183
11723	1188
11723	1206
11723	1218
11723	1232
11724	1183
11724	1188
11724	1204
11724	1218
11724	1232
11725	1183
11725	1188
11725	1218
11725	1229
11725	1233
11726	1183
11726	1188
11726	1200
11726	1233
11726	1243
11727	1183
11727	1188
11727	1218
11727	1232
11727	1233
11728	1183
11728	1188
11728	1198
11728	1204
11728	1218
11729	1183
11729	1188
11729	1213
11729	1229
11729	1233
11730	1183
11730	1196
11730	1198
11730	1205
11730	1210
11731	1183
11731	1198
11731	1205
11731	1218
11731	1239
11732	1183
11732	1188
11732	1205
11732	1218
11732	1232
11733	1183
11733	1194
11733	1222
11733	1232
11733	1233
11735	1180
11735	1188
11735	1197
11735	1201
11735	1218
11736	1183
11736	1188
11736	1206
11736	1218
11736	1229
11737	1188
11737	1206
11737	1218
11737	1229
11737	45238
11738	1188
11738	1218
11738	1232
11738	1233
11738	45238
11739	1183
11739	1193
11739	1198
11739	1206
11739	1218
11740	1188
11740	1204
11740	1218
11740	1232
11740	45236
11741	1188
11741	1200
11741	1206
11741	1218
11741	45238
11742	1183
11742	1194
11742	1206
11742	1217
11742	1229
11743	1183
11743	1194
11743	1218
11743	1232
11743	1233
11744	1183
11744	1188
11744	1218
11744	1232
11744	1233
11745	1183
11745	1194
11745	1206
11745	1209
11745	1229
11746	1183
11746	1188
11746	1206
11746	1218
11746	1229
11747	1183
11747	1188
11747	1200
11747	1206
11747	1218
11748	1183
11748	1188
11748	1206
11748	1218
11748	1229
11750	1183
11750	1194
11750	1222
11750	1232
11750	1233
11751	1183
11751	1196
11751	1206
11751	1218
11751	1229
11752	1183
11752	1188
11752	1198
11752	1206
11752	1218
11753	1183
11753	1188
11753	1198
11753	1206
11753	1218
11754	1183
11754	1188
11754	1206
11754	1218
11754	1229
11755	1183
11755	1194
11755	1206
11755	1218
11755	1229
11756	1183
11756	1188
11756	1218
11756	1232
11756	1233
11757	1183
11757	1198
11757	1206
11757	1218
11757	1239
11758	1179
11758	1188
11758	1197
11758	1201
11758	1218
11761	1183
11761	1188
11761	1206
11761	1218
11761	1229
11762	1183
11762	1188
11762	1198
11762	1206
11762	1218
11763	1183
11763	1188
11763	1198
11763	1206
11763	1218
11764	1183
11764	1188
11764	1200
11764	1206
11764	1218
11765	1183
11765	1188
11765	1200
11765	1206
11765	1218
11768	1183
11768	1196
11768	1200
11768	1206
11768	1218
11770	1183
11770	1188
11770	1204
11770	1218
11770	1232
11771	1188
11771	1218
11771	1232
11771	1233
11771	45238
11772	1183
11772	1194
11772	1206
11772	1220
11772	1229
11774	1183
11774	1188
11774	1198
11774	1206
11774	1218
11775	1183
11775	1188
11775	1206
11775	1218
11775	1229
11776	1183
11776	1188
11776	1204
11776	1232
11776	45134
11777	1188
11777	1200
11777	1206
11777	1218
11777	45238
11778	1183
11778	1188
11778	1200
11778	1206
11778	1218
11779	1188
11779	1218
11779	1232
11779	1233
11779	45238
11780	1183
11780	1188
11780	1206
11780	1218
11780	1232
11781	1183
11781	1194
11781	1204
11781	1218
11781	1232
11783	1183
11783	1194
11783	1204
11783	1218
11783	1232
11784	1188
11784	1200
11784	1233
11784	1246
11784	45238
11786	1183
11786	1188
11786	1198
11786	1206
11786	45548
11787	1183
11787	1188
11787	1218
11787	1232
11787	1233
11788	1195
11788	1200
11788	1206
11788	1218
11788	45238
11789	1183
11789	1188
11789	1200
11789	1206
11789	1218
11790	1183
11790	1193
11790	1204
11790	1229
11790	1243
11791	1183
11791	1196
11791	1218
11791	1232
11791	1233
11792	1183
11792	1188
11792	1206
11792	1218
11792	1229
11793	1183
11793	1188
11793	1206
11793	1218
11793	1229
11794	1182
11794	1188
11794	1206
11794	1218
11794	1229
11795	1183
11795	1188
11795	1218
11795	1232
11795	1233
11797	1183
11797	1188
11797	1200
11797	1204
11797	1218
11798	1183
11798	1194
11798	1218
11798	1232
11798	1233
11799	1183
11799	1188
11799	1198
11799	1206
11799	1209
11799	45548
11800	1183
11800	1188
11800	1198
11800	1206
11800	1218
11802	1183
11802	1194
11802	1198
11802	1206
11802	1218
11803	1183
11803	1194
11803	1198
11803	1206
11803	1218
11804	1183
11804	1188
11804	1205
11804	1217
11804	1232
11805	1183
11805	1188
11805	1198
11805	1206
11805	1218
11806	1183
11806	1188
11806	1218
11806	1232
11806	1233
11807	1183
11807	1188
11807	1200
11807	1206
11807	1218
11808	1183
11808	1188
11808	1218
11808	1232
11808	1233
11809	1183
11809	1188
11809	1200
11809	1206
11809	45404
11811	1183
11811	1188
11811	1200
11811	1206
11811	1218
11812	1183
11812	1188
11812	1200
11812	1206
11812	1218
11813	1183
11813	1188
11813	1204
11813	1218
11813	1232
11815	1188
11815	1203
11815	1218
11815	1232
11815	45238
11816	1183
11816	1188
11816	1218
11816	1232
11816	1233
11817	1183
11817	1188
11817	1218
11817	1232
11817	1233
11818	1188
11818	1218
11818	1232
11818	1233
11818	45236
11819	1183
11819	1188
11819	1204
11819	1218
11819	1232
11820	1188
11820	1218
11820	1232
11820	1233
11820	45236
11821	1183
11821	1188
11821	1200
11821	1206
11821	1218
11822	1183
11822	1188
11822	1218
11822	1232
11822	1233
11823	1183
11823	1188
11823	1198
11823	1206
11823	1218
11824	1183
11824	1194
11824	1198
11824	1206
11824	1218
11825	1183
11825	1188
11825	1218
11825	1232
11825	1233
11826	1183
11826	1188
11826	1222
11826	1232
11826	1233
11827	1183
11827	1194
11827	1218
11827	1232
11827	1233
11828	1183
11828	1188
11828	1206
11828	1229
11828	45380
11828	45436
11829	1183
11829	1188
11829	1198
11829	1206
11829	1218
11830	1183
11830	1194
11830	1217
11830	1232
11830	1233
11831	1183
11831	1194
11831	1206
11831	1218
11831	1229
11832	1183
11832	1188
11832	1218
11832	1232
11832	1233
11839	1183
11839	1188
11839	1198
11839	1206
11839	1218
11840	1183
11840	1188
11840	1198
11840	1206
11840	1218
11841	1183
11841	1194
11841	1218
11841	1232
11841	1233
11842	1183
11842	1188
11842	1200
11842	1206
11842	1218
11843	1183
11843	1188
11843	1200
11843	1206
11843	1218
11844	1183
11844	1188
11844	1200
11844	1206
11844	1218
11846	1183
11846	1188
11846	1200
11846	1206
11846	1217
11846	1218
11846	1232
11846	1233
11847	1183
11847	1194
11847	1218
11847	1232
11847	1233
11848	1183
11848	1188
11848	1200
11848	1206
11848	1218
11849	1188
11849	1206
11849	1218
11849	1229
11849	45238
11851	1183
11851	1188
11851	1204
11851	1222
11851	1229
11852	1183
11852	1188
11852	1198
11852	1206
11852	1218
11853	1183
11853	1188
11853	1206
11853	1222
11853	1229
11854	1183
11854	1194
11854	1206
11854	1229
11854	45339
11855	1183
11855	1188
11855	1206
11855	1218
11855	1229
11857	1183
11857	1194
11857	1218
11857	1232
11857	1233
11858	1183
11858	1188
11858	1200
11858	1206
11858	1218
11860	1183
11860	1188
11860	1204
11860	1222
11860	1229
11861	1183
11861	1188
11861	1204
11861	1232
11861	45134
11862	1183
11862	1194
11862	1205
11862	1218
11862	1229
11863	1183
11863	1194
11863	1204
11863	1218
11863	1232
11864	1183
11864	1194
11864	1206
11864	1218
11864	1229
11866	1183
11866	1194
11866	1218
11866	1232
11866	1233
11867	1183
11867	1194
11867	1200
11867	1206
11867	1222
11868	1183
11868	1188
11868	1206
11868	1218
11868	1229
11869	1188
11869	1218
11869	1232
11869	1233
11869	45238
11870	1183
11870	1188
11870	1216
11870	1232
11870	1233
11871	1183
11871	1188
11871	1198
11871	1206
11871	1218
11872	1183
11872	1188
11872	1200
11872	1206
11872	1218
11873	1183
11873	1194
11873	1198
11873	1206
11873	1218
11874	1183
11874	1188
11874	1206
11874	1218
11874	1229
11875	1183
11875	1188
11875	1206
11875	1218
11875	1229
11876	1188
11876	1206
11876	1218
11876	1229
11876	45238
11877	1183
11877	1188
11877	1206
11877	1218
11877	1229
11878	1183
11878	1194
11878	1222
11878	1232
11878	1233
11878	1239
11878	45430
11879	1183
11879	1188
11879	1198
11879	1206
11879	1218
11880	1182
11880	1196
11880	1232
11880	1233
11880	45543
11882	1183
11882	1194
11882	1218
11882	1232
11882	1233
11883	1183
11883	1188
11883	1198
11883	1204
11883	1218
11884	1183
11884	1194
11884	1206
11884	1218
11884	1229
11885	1183
11885	1188
11885	1200
11885	1206
11885	1218
11886	1183
11886	1188
11886	1206
11886	1218
11886	1229
11887	1183
11887	1194
11887	1198
11887	1206
11887	1218
11888	1183
11888	1194
11888	1218
11888	1232
11888	1233
11889	1183
11889	1188
11889	1198
11889	1206
11889	1218
11890	1183
11890	1188
11890	1206
11890	1217
11890	1232
11891	1183
11891	1188
11891	1198
11891	1218
11891	1233
11892	1183
11892	1188
11892	1200
11892	1206
11892	1218
11893	1183
11893	1194
11893	1206
11893	1218
11893	1229
11895	1183
11895	1188
11895	1198
11895	1218
11895	1233
11896	1183
11896	1194
11896	1198
11896	1206
11896	45424
11897	1183
11897	1188
11897	1198
11897	1206
11897	1218
11899	1183
11899	1188
11899	1200
11899	1206
11899	1218
11901	1183
11901	1188
11901	1205
11901	1218
11901	1232
11902	1183
11902	1188
11902	1218
11902	1232
11902	1233
11903	1183
11903	1188
11903	1198
11903	1206
11903	1210
11904	1183
11904	1188
11904	1206
11904	1218
11904	1229
11905	1183
11905	1188
11905	1218
11905	1232
11905	1233
11906	1183
11906	1188
11906	1206
11906	1218
11906	1229
11907	1183
11907	1188
11907	1217
11907	1232
11907	1233
11907	45566
11908	1183
11908	1188
11908	1218
11908	1232
11908	1233
11909	1183
11909	1194
11909	1218
11909	1232
11909	1233
11910	1183
11910	1188
11910	1206
11910	1218
11910	1229
11911	1195
11911	1200
11911	1206
11911	1222
11911	45238
11912	1188
11912	1206
11912	1218
11912	1232
11912	45238
11913	1188
11913	1206
11913	1218
11913	1229
11913	45238
11914	1183
11914	1194
11914	1200
11914	1205
11914	1218
11915	1183
11915	1194
11915	1198
11915	1206
11915	1218
11916	1183
11916	1194
11916	1206
11916	1218
11916	1229
11917	1188
11917	1218
11917	1232
11917	1233
11917	45238
11918	1188
11918	1218
11918	1232
11918	1233
11918	45238
11919	1188
11919	1218
11919	1232
11919	1233
11919	45238
11920	1183
11920	1194
11920	1218
11920	1232
11920	1233
11921	1183
11921	1194
11921	1232
11921	1233
11921	45134
11922	1183
11922	1194
11922	1206
11922	1217
11922	1229
11923	1183
11923	1188
11923	1218
11923	1232
11923	1233
11924	1188
11924	1200
11924	1206
11924	1218
11924	45238
11925	1183
11925	1188
11925	1200
11925	1206
11925	1218
11926	1183
11926	1188
11926	1198
11926	1206
11926	1218
11927	1183
11927	1188
11927	1194
11927	1206
11927	1218
11927	1229
11927	1232
11927	1233
11927	45238
11928	1183
11928	1188
11928	1200
11928	1206
11928	1218
11929	1183
11929	1188
11929	1200
11929	1206
11929	44971
11930	1192
11930	1203
11930	1218
11930	1238
11930	45236
11931	1183
11931	1188
11931	1206
11931	1218
11931	1229
11932	1183
11932	1188
11932	1218
11932	1232
11932	1233
11933	1183
11933	1188
11933	1198
11933	1206
11933	1218
11934	1183
11934	1188
11934	1206
11934	1218
11934	1229
11935	1183
11935	1194
11935	1232
11935	1233
11935	45134
11936	1183
11936	1188
11936	1206
11936	1218
11936	1229
11937	1183
11937	1188
11937	1218
11937	1232
11937	1233
11938	1183
11938	1194
11938	1218
11938	1232
11938	1233
11939	1183
11939	1188
11939	1200
11939	1206
11939	1218
11940	1183
11940	1194
11940	1200
11940	1206
11940	1218
11941	1183
11941	1188
11941	1232
11941	1233
11941	45134
11942	1183
11942	1188
11942	1198
11942	1206
11942	1218
11943	1179
11943	1188
11943	1197
11943	1201
11943	1218
11944	1183
11944	1194
11944	1200
11944	1206
11944	1218
11944	1222
11944	1229
11944	1233
11944	1244
11945	1183
11945	1188
11945	1194
11945	1218
11945	1219
11945	1232
11945	1233
11946	1183
11946	1194
11946	1206
11946	1218
11946	1229
11947	1183
11947	1188
11947	1218
11947	1232
11947	1233
11948	1183
11948	1194
11948	1218
11948	1232
11948	1233
11949	1183
11949	1194
11949	1200
11949	1206
11949	45134
11950	1183
11950	1194
11950	1200
11950	1206
11950	1218
11951	1183
11951	1194
11951	1206
11951	1218
11951	1229
11952	1183
11952	1188
11952	1206
11952	1218
11952	1229
11953	1183
11953	1188
11953	1232
11953	1233
11953	45134
11954	1183
11954	1194
11954	1204
11954	1218
11954	1232
11955	1183
11955	1188
11955	1194
11955	1200
11955	1206
11955	1218
11955	1229
11955	1233
11956	1183
11956	1188
11956	1218
11956	1232
11956	1233
11957	1183
11957	1188
11957	1200
11957	1206
11957	1218
11958	1183
11958	1194
11958	1218
11958	1232
11958	1233
11959	1183
11959	1188
11959	1198
11959	1206
11959	1218
11960	1183
11960	1218
11960	1232
11960	1233
11960	1239
11961	1183
11961	1194
11961	1218
11961	1232
11961	1233
11962	1183
11962	1188
11962	1218
11962	1232
11962	1233
11963	1183
11963	1188
11963	1206
11963	1218
11963	1229
11964	1183
11964	1188
11964	1206
11964	1218
11964	1229
11965	1183
11965	1194
11965	1206
11965	1218
11965	1229
11966	1183
11966	1194
11966	1200
11966	1206
11966	1218
11967	1183
11967	1194
11967	1204
11967	1218
11967	1232
11968	1183
11968	1194
11968	1218
11968	1232
11968	1233
11979	1183
11979	1188
11979	1206
11979	1218
11979	1229
11980	1183
11980	1194
11980	1206
11980	1218
11980	1229
11981	1183
11981	1188
11981	1218
11981	1232
11981	1233
11982	1183
11982	1188
11982	1200
11982	1206
11982	1218
11983	1183
11983	1188
11983	1206
11983	1220
11983	1232
11984	1183
11984	1198
11984	1206
11984	1218
11984	1239
11985	1183
11985	1194
11985	1218
11985	1232
11985	1233
11987	1183
11987	1188
11987	1198
11987	1206
11987	1218
11988	1183
11988	1188
11988	1206
11988	1218
11988	1229
11989	1183
11989	1188
11989	1206
11989	1210
11989	1229
11990	1183
11990	1194
11990	1200
11990	1206
11990	1218
11991	1183
11991	1194
11991	1200
11991	1206
11991	1218
11992	1183
11992	1194
11992	1200
11992	1206
11992	1218
11994	1183
11994	1194
11994	1200
11994	1206
11994	1217
11995	1183
11995	1194
11995	1218
11995	1232
11995	1233
11996	1183
11996	1188
11996	1218
11996	1232
11996	1233
11997	1183
11997	1188
11997	1200
11997	1206
11997	1222
11998	1183
11998	1194
11998	1200
11998	1206
11998	1218
11999	1183
11999	1188
11999	1198
11999	1218
11999	1233
12000	1183
12000	1188
12000	1218
12000	1232
12000	1233
12001	1183
12001	1188
12001	1200
12001	1206
12001	1218
12002	1183
12002	1188
12002	1203
12002	1218
12002	1238
12003	1183
12003	1188
12003	1217
12003	1232
12003	1233
12004	1183
12004	1188
12004	1198
12004	1206
12004	1218
12004	1229
12004	1232
12004	1233
12004	1243
12004	45548
12006	1183
12006	1188
12006	1200
12006	1206
12006	1218
12007	1183
12007	1194
12007	1206
12007	1216
12007	1229
12008	1183
12008	1194
12008	1218
12008	1232
12008	1233
12009	1183
12009	1194
12009	1198
12009	1206
12009	1218
12010	1179
12010	1191
12010	1197
12010	1201
12010	1218
12011	1183
12011	1194
12011	1198
12011	1206
12011	1218
12012	1183
12012	1188
12012	1200
12012	1206
12012	1217
12013	1183
12013	1188
12013	1206
12013	1218
12013	1229
12014	1183
12014	1188
12014	1204
12014	1218
12014	1232
12015	1183
12015	1188
12015	1200
12015	1206
12015	1218
12017	1183
12017	1188
12017	1206
12017	1217
12017	1229
12018	1183
12018	1188
12018	1218
12018	1232
12018	1233
12019	1183
12019	1193
12019	1198
12019	1206
12019	1218
12020	1183
12020	1193
12020	1198
12020	1206
12020	1218
12021	1183
12021	1193
12021	1198
12021	1206
12021	1218
12022	1183
12022	1194
12022	1206
12022	1218
12022	1232
12023	1183
12023	1188
12023	1218
12023	1232
12023	1233
12024	1183
12024	1188
12024	1206
12024	1218
12024	1229
12025	1183
12025	1188
12025	1194
12025	1213
12025	1218
12025	1232
12025	1233
12026	1183
12026	1194
12026	1200
12026	1206
12026	1218
12027	1183
12027	1188
12027	1218
12027	1232
12027	1233
12028	1183
12028	1191
12028	1205
12028	1218
12028	1238
12029	1183
12029	1194
12029	1206
12029	1218
12029	1229
12030	1183
12030	1188
12030	1198
12030	1206
12030	1218
12031	1183
12031	1196
12031	1218
12031	1232
12031	1233
12032	1183
12032	1188
12032	1217
12032	1232
12032	1233
12033	1183
12033	1194
12033	1205
12033	1218
12033	1232
12034	1183
12034	1194
12034	1203
12034	1218
12034	1229
12035	1183
12035	1188
12035	1218
12035	1232
12035	1233
12036	1188
12036	1200
12036	1206
12036	1218
12036	45236
12039	1183
12039	1194
12039	1206
12039	1218
12039	1229
12040	1183
12040	1188
12040	1198
12040	1206
12040	1218
12040	45308
12041	1183
12041	1188
12041	1206
12041	1218
12041	1220
12041	1229
12041	1232
12041	1233
12044	1183
12044	1196
12044	1218
12044	1232
12044	1233
12045	1179
12045	1188
12045	1197
12045	1201
12045	1218
12046	1183
12046	1188
12046	1217
12046	1232
12046	1233
12046	45181
12047	1183
12047	1188
12047	1206
12047	1218
12047	1229
12049	1183
12049	1188
12049	1222
12049	1232
12049	1233
12050	1183
12050	1188
12050	1200
12050	1206
12050	1218
12051	1188
12051	1199
12051	1205
12051	1218
12051	45238
12052	1183
12052	1188
12052	1218
12052	1232
12052	1233
12053	1183
12053	1188
12053	1218
12053	1232
12053	1233
12054	1183
12054	1188
12054	1198
12054	1206
12054	1218
12056	1183
12056	1188
12056	1206
12056	1218
12056	1229
12057	1183
12057	1188
12057	1200
12057	1206
12057	1218
12059	1183
12059	1188
12059	1206
12059	1218
12059	1229
12060	1183
12060	1195
12060	1206
12060	1218
12060	1229
12061	1183
12061	1188
12061	1204
12061	1218
12061	1232
12062	1183
12062	1188
12062	1198
12062	1205
12062	1218
12063	1188
12063	1218
12063	1232
12063	1233
12063	45238
12064	1183
12064	1194
12064	1218
12064	1232
12064	1233
12065	1183
12065	1188
12065	1232
12065	1233
12065	45543
12066	1188
12066	1218
12066	1232
12066	1233
12066	45238
12067	1183
12067	1194
12067	1206
12067	1218
12067	1229
12068	1188
12068	1200
12068	1206
12068	1218
12068	45238
12069	1183
12069	1188
12069	1218
12069	1232
12069	1233
12070	1183
12070	1188
12070	1200
12070	1206
12070	1218
12071	1188
12071	1218
12071	1232
12071	1233
12071	45238
12075	1183
12075	1188
12075	1218
12075	1232
12075	1233
12083	1183
12083	1188
12083	1218
12083	1232
12083	1233
12086	1183
12086	1194
12086	1206
12086	1221
12086	1229
12105	1183
12105	1188
12105	1198
12105	1206
12105	1218
12106	1183
12106	1188
12106	1218
12106	1232
12106	1233
12109	1188
12109	1200
12109	1206
12109	1218
12109	45238
12110	1183
12110	1188
12110	1218
12110	1232
12110	1233
12114	1183
12114	1188
12114	1198
12114	1206
12114	1218
12115	1188
12115	1206
12115	1218
12115	1229
12115	45238
12118	1183
12118	1194
12118	1218
12118	1232
12118	1233
12122	1183
12122	1188
12122	1206
12122	1218
12122	1229
12124	1188
12124	1218
12124	1232
12124	1233
12124	45238
12149	1183
12149	1188
12149	1209
12149	1232
12149	1233
12151	1188
12151	1198
12151	1204
12151	1218
12151	45236
12157	1183
12157	1194
12157	1204
12157	1218
12157	1232
12162	1183
12162	1188
12162	1206
12162	1218
12162	1229
12167	1188
12167	1198
12167	1206
12167	1209
12167	45238
12173	1183
12173	1194
12173	1200
12173	1206
12173	1218
12174	1179
12174	1188
12174	1197
12174	1201
12174	1218
12175	1183
12175	1188
12175	1206
12175	1218
12175	1232
12176	1195
12176	1200
12176	1206
12176	1218
12176	45238
12178	1183
12178	1188
12178	1206
12178	1218
12178	1232
12179	1183
12179	1188
12179	1206
12179	1218
12179	1229
12180	1195
12180	1218
12180	1232
12180	1233
12180	45238
12181	1183
12181	1196
12181	1200
12181	1206
12181	1218
12183	1188
12183	1198
12183	1206
12183	1218
12183	45236
12184	1183
12184	1191
12184	1218
12184	1232
12184	1233
12185	1183
12185	1194
12185	1200
12185	1206
12185	1218
12187	1183
12187	1188
12187	1218
12187	1232
12187	1233
12188	1183
12188	1194
12188	1218
12188	1232
12188	1233
12191	1183
12191	1188
12191	1200
12191	1206
12191	1218
12194	1188
12194	1200
12194	1206
12194	45238
12194	45337
12195	1194
12195	1198
12195	1206
12195	1222
12195	45236
12196	1183
12196	1194
12196	1204
12196	1218
12196	1232
12197	1183
12197	1188
12197	1206
12197	1218
12197	1229
12198	1183
12198	1194
12198	1200
12198	1206
12198	1218
12199	1188
12199	1200
12199	1206
12199	1218
12199	45238
12202	1183
12202	1194
12202	1200
12202	1206
12202	1218
12205	1183
12205	1188
12205	1204
12205	1218
12205	1232
12206	1188
12206	1200
12206	1206
12206	1218
12206	45238
12209	1188
12209	1200
12209	1206
12209	1218
12209	45238
12210	1183
12210	1194
12210	1200
12210	1206
12210	1218
12211	1183
12211	1188
12211	1218
12211	1232
12211	1233
12212	1183
12212	1194
12212	1198
12212	1206
12212	1218
12214	1178
12214	1188
12214	1197
12214	1201
12214	1218
12215	1183
12215	1191
12215	1200
12215	1206
12215	1218
12216	1183
12216	1194
12216	1218
12216	1232
12216	1233
12219	1183
12219	1196
12219	1206
12219	1218
12219	1229
12220	1183
12220	1188
12220	1206
12220	1217
12220	1229
12222	1183
12222	1188
12222	1198
12222	1206
12222	1218
12225	1183
12225	1188
12225	1218
12225	1232
12225	1233
12226	1183
12226	1188
12226	1218
12226	1232
12226	1233
12227	1183
12227	1188
12227	1206
12227	1218
12227	1229
12229	1183
12229	1188
12229	1205
12229	1218
12229	1229
12231	1183
12231	1194
12231	1200
12231	1206
12231	1218
12232	1183
12232	1188
12232	1218
12232	1232
12232	1233
12234	1183
12234	1194
12234	1198
12234	1206
12234	1210
12235	1183
12235	1188
12235	1206
12235	1218
12235	1229
12237	1183
12237	1194
12237	1198
12237	1206
12237	45548
12238	1183
12238	1188
12238	1218
12238	1232
12238	1233
12239	1188
12239	1218
12239	1232
12239	1233
12239	45238
12240	1195
12240	1198
12240	1206
12240	1218
12240	45238
12242	1180
12242	1188
12242	1218
12242	1232
12242	1233
12243	1183
12243	1188
12243	1200
12243	1206
12243	1218
12243	1229
12243	1246
12244	1183
12244	1188
12244	1206
12244	1218
12244	1229
12246	1188
12246	1218
12246	1232
12246	1233
12246	45238
12255	1183
12255	1188
12255	1206
12255	1222
12255	1229
12257	1183
12257	1196
12257	1232
12257	1233
12257	44971
12259	1183
12259	1188
12259	1218
12259	1232
12259	1233
12261	1183
12261	1194
12261	1218
12261	1232
12261	1233
12263	1183
12263	1188
12263	1218
12263	1232
12263	1233
12268	1183
12268	1188
12268	1199
12268	1206
12268	1218
12270	1183
12270	1188
12270	1218
12270	1232
12270	1233
12279	1188
12279	1199
12279	1205
12279	1218
12279	45238
12283	1183
12283	1188
12283	1218
12283	1232
12283	1233
12284	1188
12284	1218
12284	1229
12284	1233
12284	45238
12285	1183
12285	1196
12285	1218
12285	1232
12285	1233
12288	1183
12288	1188
12288	1206
12288	1218
12288	1232
12297	1183
12297	1188
12297	1200
12297	1206
12297	1218
12299	1183
12299	1194
12299	1218
12299	1232
12299	1233
12307	1183
12307	1188
12307	1218
12307	1232
12307	1233
12310	1183
12310	1188
12310	1213
12310	1232
12310	45604
12316	1183
12316	1188
12316	1218
12316	1232
12316	1233
12324	1188
12324	1198
12324	1206
12324	1209
12324	45238
12327	1183
12327	1188
12327	1218
12327	1232
12327	1233
12328	1188
12328	1206
12328	1218
12328	1229
12328	45238
12329	1188
12329	1198
12329	1218
12329	1233
12329	45236
12330	1188
12330	1200
12330	1206
12330	1218
12330	45238
12333	1183
12333	1188
12333	1218
12333	1233
12333	1238
12334	1183
12334	1188
12334	1204
12334	1218
12334	1232
12335	1183
12335	1188
12335	1198
12335	1206
12335	1218
12336	1188
12336	1200
12336	1206
12336	1218
12336	45238
12337	1188
12337	1232
12337	1233
12337	45236
12337	45572
12339	1183
12339	1188
12339	1206
12339	1218
12339	1229
12340	1183
12340	1188
12340	1206
12340	1218
12340	1229
12341	1188
12341	1198
12341	1206
12341	1218
12341	45238
12343	1188
12343	1194
12343	1218
12343	1232
12343	1233
12343	45238
12345	1188
12345	1206
12345	1218
12345	1229
12345	45238
12346	1195
12346	1206
12346	1218
12346	1229
12346	45238
12347	1188
12347	1198
12347	1206
12347	1218
12347	45238
12348	1195
12348	1218
12348	1232
12348	1233
12348	45238
12349	1188
12349	1206
12349	1218
12349	1229
12349	45238
12350	1188
12350	1206
12350	1218
12350	1229
12350	45238
12351	1183
12351	1194
12351	1200
12351	1206
12351	1246
12352	1188
12352	1218
12352	1232
12352	1233
12352	45238
12353	1188
12353	1206
12353	1229
12353	1246
12353	45238
12355	1183
12355	1188
12355	1206
12355	1218
12355	1229
12360	1183
12360	1188
12360	1206
12360	1232
12360	1262
12361	1183
12361	1188
12361	1206
12361	1232
12361	45062
12363	1183
12363	1188
12363	1206
12363	1232
12363	1271
12364	1188
12364	1206
12364	1232
12364	45062
12364	45238
12370	1188
12370	1206
12370	1232
12370	45062
12370	45238
12376	1183
12376	1188
12376	1218
12376	1232
12376	45604
12380	1183
12380	1188
12380	1206
12380	1232
12380	44968
12384	1183
12384	1194
12384	1198
12384	1233
12384	45644
12386	1183
12386	1194
12386	1198
12386	1218
12386	1233
12387	1183
12387	1188
12387	1198
12387	1218
12387	1233
12388	1183
12388	1194
12388	1218
12388	1232
12388	1233
12393	1183
12393	1188
12393	1232
12393	1233
12393	45593
12394	1183
12394	1188
12394	1218
12394	1232
12394	1233
12397	1183
12397	1188
12397	1218
12397	1232
12397	1233
12401	1183
12401	1188
12401	1205
12401	1218
12401	1232
12406	1183
12406	1193
12406	1206
12406	1218
12406	1232
12411	1183
12411	1188
12411	1218
12411	1232
12411	1233
12417	1195
12417	1206
12417	1218
12417	1229
12417	45238
12418	1188
12418	1218
12418	1232
12418	1233
12418	45238
12438	1183
12438	1188
12438	1218
12438	1232
12438	1233
12444	1188
12444	1218
12444	1232
12444	1233
12444	45238
12450	1183
12450	1188
12450	1229
12450	1233
12450	1247
12451	1183
12451	1188
12451	1206
12451	1229
12451	44971
12457	1183
12457	1188
12457	1229
12457	1233
12457	44968
12458	1188
12458	1232
12458	1233
12458	45238
12458	45635
12459	1188
12459	1206
12459	1218
12459	1232
12459	45236
12460	1188
12460	1232
12460	1233
12460	45238
12460	45635
12462	1183
12462	1188
12462	1206
12462	1221
12462	1232
12464	1188
12464	1232
12464	1233
12464	45236
12464	45543
12467	1183
12467	1188
12467	1198
12467	1218
12467	1233
12471	1183
12471	1196
12471	1232
12471	1233
12471	45121
12485	1188
12485	1206
12485	1222
12485	1232
12485	45236
12490	1183
12490	1188
12490	1200
12490	1206
12490	1218
12516	1183
12516	1188
12516	1217
12516	1232
12516	1233
12521	1183
12521	1188
12521	1218
12521	1232
12521	1233
12538	1183
12538	1188
12538	1200
12538	1206
12538	1218
12540	1183
12540	1196
12540	1218
12540	1232
12540	1233
12543	1183
12543	1194
12543	1218
12543	1229
12543	1233
12544	1183
12544	1194
12544	1206
12544	1217
12544	1229
12546	1195
12546	1205
12546	1218
12546	1229
12546	45236
12547	1183
12547	1188
12547	1198
12547	1206
12547	1218
12548	1183
12548	1194
12548	1200
12548	1206
12548	1218
12549	1183
12549	1188
12549	1206
12549	1218
12549	1229
12550	1183
12550	1194
12550	1198
12550	1206
12550	1218
12550	1229
12550	1233
12550	45539
12551	1183
12551	1188
12551	1198
12551	1210
12551	1233
12552	1183
12552	1188
12552	1218
12552	1232
12552	1233
12553	1183
12553	1188
12553	1206
12553	1218
12553	1229
12554	1183
12554	1188
12554	1206
12554	1218
12554	1229
12555	1183
12555	1194
12555	1218
12555	1232
12555	1233
12556	1183
12556	1188
12556	1200
12556	1206
12556	1218
12557	1183
12557	1188
12557	1198
12557	1206
12557	1218
12558	1183
12558	1194
12558	1200
12558	1206
12558	1218
12559	1183
12559	1194
12559	1213
12559	1232
12559	1233
12561	1183
12561	1188
12561	1205
12561	1217
12561	1232
12562	1183
12562	1194
12562	1218
12562	1232
12562	1233
12563	1183
12563	1188
12563	1198
12563	1206
12563	1218
12564	1183
12564	1188
12564	1200
12564	1206
12564	1217
12565	1183
12565	1188
12565	1206
12565	1220
12565	1229
12568	1183
12568	1194
12568	1200
12568	1206
12568	1218
12570	1183
12570	1188
12570	1206
12570	1218
12570	1229
12571	1183
12571	1188
12571	1203
12571	1218
12571	1232
12572	1183
12572	1194
12572	1206
12572	1218
12572	1229
12573	1183
12573	1194
12573	1200
12573	1206
12573	1218
12574	1182
12574	1188
12574	1206
12574	1218
12574	1229
12576	1183
12576	1188
12576	1200
12576	1206
12576	1218
12577	1183
12577	1188
12577	1218
12577	1232
12577	1233
12578	1183
12578	1188
12578	1218
12578	1232
12578	1233
12579	1183
12579	1188
12579	1200
12579	1206
12579	1218
12581	1183
12581	1188
12581	1199
12581	1218
12581	1233
12595	1183
12595	1188
12595	1218
12595	1232
12595	1233
12596	1183
12596	1194
12596	1199
12596	1205
12596	1218
12603	1183
12603	1188
12603	1198
12603	1206
12603	1218
12606	1183
12606	1188
12606	1206
12606	1217
12606	1229
12613	1183
12613	1188
12613	1198
12613	1206
12613	45548
12615	1183
12615	1188
12615	1198
12615	1206
12615	1210
12616	1183
12616	1188
12616	1198
12616	1206
12616	1218
12617	1183
12617	1188
12617	1206
12617	1218
12617	1229
12618	1183
12618	1188
12618	1217
12618	1232
12618	1233
12620	1183
12620	1188
12620	1218
12620	1232
12620	1233
12621	1183
12621	1188
12621	1204
12621	1218
12621	1232
12622	1183
12622	1188
12622	1200
12622	1206
12622	1218
12623	1183
12623	1188
12623	1200
12623	1206
12623	1218
12624	1183
12624	1188
12624	1218
12624	1232
12624	1233
12625	1183
12625	1204
12625	1218
12625	1232
12625	1239
12627	1188
12627	1206
12627	1219
12627	1229
12627	45238
12629	1183
12629	1188
12629	1206
12629	1218
12629	1229
12632	1180
12632	1188
12632	1197
12632	1201
12632	1218
12633	1183
12633	1194
12633	1206
12633	1232
12633	44968
12634	1195
12634	1206
12634	1218
12634	1232
12634	45236
12635	1183
12635	1194
12635	1206
12635	1218
12635	1232
12636	1183
12636	1188
12636	1206
12636	1218
12636	1232
12637	1183
12637	1195
12637	1232
12637	1233
12637	45119
12639	1183
12639	1188
12639	1210
12639	1229
12639	1233
12640	1188
12640	1200
12640	1206
12640	1218
12640	45238
12641	1183
12641	1209
12641	1218
12641	1229
12641	1233
12641	1239
12642	1183
12642	1194
12642	1222
12642	1232
12642	1233
12644	1183
12644	1188
12644	1218
12644	1232
12644	1233
12648	1183
12648	1188
12648	1200
12648	1206
12648	1218
12655	1183
12655	1188
12655	1222
12655	1232
12655	1233
12656	1183
12656	1191
12656	1199
12656	1204
12656	1218
12657	1183
12657	1188
12657	1206
12657	1218
12657	1232
12667	1183
12667	1188
12667	1218
12667	1232
12667	1233
12668	1183
12668	1188
12668	1206
12668	1217
12668	1229
12671	1183
12671	1188
12671	1206
12671	1217
12671	1229
12672	1183
12672	1194
12672	1200
12672	1206
12672	1218
12674	1183
12674	1188
12674	1218
12674	1232
12674	1233
12676	1183
12676	1188
12676	1206
12676	1218
12676	1229
12677	1183
12677	1188
12677	1198
12677	1206
12677	1218
12679	1183
12679	1188
12679	1206
12679	1218
12679	1229
12680	1183
12680	1188
12680	1200
12680	1206
12680	1218
12682	1188
12682	1222
12682	1232
12682	1233
12682	45238
12683	1183
12683	1188
12683	1218
12683	1232
12683	1233
12684	1183
12684	1188
12684	1218
12684	1232
12684	1233
12685	1183
12685	1188
12685	1206
12685	1216
12685	1229
12687	1183
12687	1188
12687	1206
12687	1218
12687	1229
12689	1183
12689	1194
12689	1200
12689	1206
12689	1218
12690	1183
12690	1194
12690	1199
12690	1231
12690	1233
12692	1183
12692	1188
12692	1218
12692	1232
12692	1233
12695	1183
12695	1188
12695	1200
12695	1206
12695	1218
12698	1188
12698	1206
12698	1218
12698	1229
12698	45238
12699	1183
12699	1194
12699	1218
12699	1232
12699	1233
12700	1183
12700	1194
12700	1198
12700	1204
12700	1218
12701	1183
12701	1188
12701	1232
12701	1233
12701	1271
12704	1183
12704	1188
12704	1218
12704	1232
12704	1233
12707	1183
12707	1194
12707	1200
12707	1204
12707	1218
12708	1183
12708	1188
12708	1218
12708	1232
12708	1233
12710	1183
12710	1206
12710	1217
12710	1232
12710	1249
12712	1183
12712	1194
12712	1200
12712	1206
12712	1218
12715	1183
12715	1188
12715	1198
12715	1203
12715	1218
12717	1183
12717	1194
12717	1206
12717	1220
12717	1229
12718	1183
12718	1194
12718	1204
12718	1218
12718	1232
12719	1183
12719	1188
12719	1218
12719	1232
12719	1233
12720	1183
12720	1196
12720	1218
12720	1232
12720	1233
12721	1183
12721	1196
12721	1218
12721	1232
12721	1233
12722	1183
12722	1188
12722	1198
12722	1206
12722	1211
12723	1183
12723	1194
12723	1222
12723	1232
12723	1233
12724	1183
12724	1188
12724	1218
12724	1232
12724	1233
12726	1183
12726	1188
12726	1204
12726	1218
12726	1232
12728	1183
12728	1188
12728	1218
12728	1232
12728	1233
12729	1183
12729	1188
12729	1218
12729	1232
12729	1233
12730	1183
12730	1194
12730	1218
12730	1232
12730	1233
12731	1183
12731	1188
12731	1218
12731	1232
12731	1233
12732	1183
12732	1194
12732	1218
12732	1232
12732	1233
12733	1183
12733	1188
12733	1200
12733	1206
12733	1218
12734	1183
12734	1194
12734	1218
12734	1232
12734	1233
12735	1183
12735	1188
12735	1198
12735	1206
12735	1218
12736	1188
12736	1206
12736	1218
12736	1229
12736	45238
12737	1183
12737	1188
12737	1198
12737	1206
12737	1218
12743	1183
12743	1194
12743	1199
12743	1206
12743	1218
12745	1188
12745	1200
12745	1206
12745	1218
12745	45238
12746	1183
12746	1192
12746	1205
12746	1218
12746	1232
12747	1183
12747	1194
12747	1232
12747	1233
12747	45567
12748	1183
12748	1196
12748	1200
12748	1206
12748	1218
12749	1183
12749	1188
12749	1218
12749	1232
12749	1233
12751	1183
12751	1188
12751	1198
12751	1233
12751	45399
12754	1183
12754	1188
12754	1198
12754	1206
12754	1218
12755	1183
12755	1188
12755	1218
12755	1232
12755	1233
12757	1183
12757	1194
12757	1217
12757	1232
12757	1233
12758	1183
12758	1188
12758	1218
12758	1232
12758	1233
12759	1183
12759	1188
12759	1218
12759	1232
12759	1233
12760	1183
12760	1188
12760	1199
12760	1204
12760	1222
12761	1183
12761	1194
12761	1200
12761	1206
12761	1246
12765	1183
12765	1188
12765	1218
12765	1232
12765	1233
12767	1183
12767	1188
12767	1206
12767	1218
12767	1232
12768	1183
12768	1188
12768	1200
12768	1206
12768	1218
12769	1183
12769	1188
12769	1198
12769	1206
12769	1219
12771	1183
12771	1188
12771	1217
12771	1232
12771	1233
12773	1183
12773	1188
12773	1218
12773	1232
12773	1233
12774	1183
12774	1194
12774	1218
12774	1232
12774	1233
12776	1183
12776	1188
12776	1200
12776	1206
12776	1218
12777	1183
12777	1194
12777	1206
12777	1218
12777	1229
12778	1193
12778	1232
12778	1233
12778	45238
12778	45568
12779	1179
12779	1188
12779	1197
12779	1201
12779	45546
12781	1188
12781	1204
12781	1218
12781	1229
12781	45236
12782	1183
12782	1194
12782	1218
12782	1232
12782	1233
12786	1183
12786	1194
12786	1232
12786	1233
12786	1261
12790	1183
12790	1188
12790	1206
12790	1218
12790	1229
12793	1183
12793	1188
12793	1198
12793	1204
12793	1218
12794	1188
12794	1218
12794	1232
12794	1233
12794	45238
12795	1183
12795	1193
12795	1206
12795	1218
12795	1229
12796	1183
12796	1188
12796	1200
12796	1206
12796	1218
12797	1183
12797	1194
12797	1222
12797	1232
12797	1233
12798	1183
12798	1194
12798	1206
12798	1218
12798	1229
12800	1183
12800	1188
12800	1200
12800	1206
12800	1220
12801	1183
12801	1188
12801	1206
12801	1218
12801	1229
12802	1188
12802	1218
12802	1232
12802	1233
12802	45238
12803	1183
12803	1194
12803	1200
12803	1205
12803	1218
12816	1183
12816	1188
12816	1206
12816	1209
12816	1229
12817	1188
12817	1218
12817	1232
12817	45238
12817	45604
12819	1183
12819	1188
12819	1199
12819	1203
12819	1218
12822	1183
12822	1194
12822	1200
12822	1206
12822	1218
12826	1183
12826	1188
12826	1218
12826	1229
12826	1233
12828	1183
12828	1194
12828	1206
12828	1218
12828	1229
12831	1183
12831	1194
12831	1200
12831	1206
12831	1218
12832	1183
12832	1188
12832	1206
12832	1217
12832	1229
12833	1183
12833	1188
12833	1206
12833	1218
12833	1229
12834	1188
12834	1218
12834	1232
12834	1233
12834	45238
12841	1183
12841	1188
12841	1198
12841	1206
12841	1218
12848	1183
12848	1188
12848	1206
12848	1217
12848	1229
12850	1183
12850	1188
12850	1232
12850	1233
12850	45543
12852	1183
12852	1194
12852	1200
12852	1206
12852	1277
12853	1188
12853	1216
12853	1232
12853	1233
12853	45238
12854	1183
12854	1194
12854	1218
12854	1232
12854	1233
12855	1183
12855	1188
12855	1198
12855	1206
12855	1210
12856	1188
12856	1198
12856	1206
12856	1210
12856	45238
12857	1183
12857	1188
12857	1200
12857	1206
12857	1217
12857	1218
12857	1232
12857	1233
12858	1183
12858	1188
12858	1218
12858	1232
12858	1233
12859	1183
12859	1188
12859	1206
12859	1218
12859	1229
12860	1183
12860	1188
12860	1206
12860	1218
12860	1229
12861	1183
12861	1188
12861	1206
12861	1217
12861	1229
12862	1188
12862	1200
12862	1206
12862	1222
12862	45238
12863	1183
12863	1194
12863	1198
12863	1206
12863	1210
12864	1188
12864	1218
12864	1229
12864	1232
12864	1233
12864	45238
12864	45337
12865	1183
12865	1188
12865	1200
12865	1206
12865	45134
12866	1183
12866	1188
12866	1206
12866	1218
12866	1229
12867	1183
12867	1188
12867	1200
12867	1206
12867	1218
12868	1183
12868	1188
12868	1200
12868	1205
12868	1218
12870	1183
12870	1188
12870	1206
12870	1218
12870	1229
12872	1183
12872	1188
12872	1218
12872	1232
12872	1233
12873	1188
12873	1218
12873	1232
12873	1233
12873	45238
12874	1183
12874	1188
12874	1198
12874	1206
12874	1218
12874	1232
12874	1233
12874	44971
12874	45430
12874	45548
12875	1183
12875	1188
12875	1194
12875	1198
12875	1200
12875	1206
12875	1211
12875	1218
12875	1232
12875	1233
12876	1183
12876	1194
12876	1200
12876	1206
12876	1222
12877	1188
12877	1206
12877	1218
12877	1229
12877	45238
12878	1183
12878	1188
12878	1218
12878	1232
12878	1233
12879	1183
12879	1194
12879	1198
12879	1206
12879	1211
12883	1183
12883	1193
12883	1200
12883	1206
12883	1218
12887	1183
12887	1188
12887	1198
12887	1218
12887	1233
12910	1183
12910	1188
12910	1206
12910	1218
12910	1232
12917	1188
12917	1206
12917	1218
12917	1229
12917	45238
12936	1183
12936	1188
12936	1206
12936	1218
12936	1229
12939	1183
12939	1194
12939	1198
12939	1206
12939	45548
12940	1183
12940	1188
12940	1218
12940	1232
12940	1233
12941	1183
12941	1194
12941	1200
12941	1206
12941	1218
12942	1183
12942	1194
12942	1200
12942	1206
12942	1218
12944	1183
12944	1188
12944	1206
12944	1218
12944	1229
12945	1183
12945	1188
12945	1206
12945	1218
12945	1229
12946	1183
12946	1188
12946	1200
12946	1206
12946	1218
12947	1183
12947	1194
12947	1206
12947	1218
12947	1229
12948	1183
12948	1188
12948	1198
12948	1206
12948	1218
12950	1183
12950	1194
12950	1206
12950	1218
12950	1229
12952	1183
12952	1188
12952	1218
12952	1232
12952	1233
12953	1183
12953	1188
12953	1198
12953	1206
12953	1218
12954	1183
12954	1188
12954	1206
12954	1218
12954	1229
12955	1182
12955	1188
12955	1198
12955	1206
12955	1218
12957	1188
12957	1198
12957	1206
12957	1210
12957	45236
12958	1183
12958	1188
12958	1200
12958	1206
12958	1213
12959	1183
12959	1188
12959	1206
12959	1229
12959	45399
12961	1183
12961	1188
12961	1206
12961	1218
12961	1229
12963	1183
12963	1188
12963	1206
12963	1218
12963	1229
12964	1183
12964	1188
12964	1198
12964	1218
12964	1233
12966	1183
12966	1188
12966	1206
12966	1219
12966	1229
12975	1183
12975	1188
12975	1200
12975	1206
12975	1218
12982	1178
12982	1188
12982	1218
12982	1232
12982	1233
12982	45238
12990	1183
12990	1188
12990	1232
12990	1233
12990	45134
12991	1188
12991	1218
12991	1232
12991	1233
12991	45238
12993	1183
12993	1188
12993	1218
12993	1232
12993	1233
12994	1183
12994	1218
12994	1232
12994	1233
12994	1239
12995	1183
12995	1188
12995	1200
12995	1206
12995	1217
12996	1183
12996	1188
12996	1206
12996	1218
12996	1232
12997	1183
12997	1196
12997	1218
12997	1232
12997	1233
12999	1183
12999	1188
12999	1200
12999	1206
12999	1217
12999	1218
12999	1232
12999	1233
13006	1183
13006	1194
13006	1206
13006	1222
13006	1229
13007	1183
13007	1188
13007	1232
13007	1233
13007	45019
13008	1183
13008	1188
13008	1200
13008	1206
13008	1218
13009	1183
13009	1188
13009	1232
13009	1233
13009	45128
13010	1183
13010	1188
13010	1206
13010	1218
13010	1229
13017	1188
13017	1206
13017	1220
13017	1229
13017	45238
13019	1183
13019	1194
13019	1205
13019	1218
13019	1232
13023	1188
13023	1198
13023	1206
13023	1218
13023	45238
13039	1188
13039	1198
13039	1210
13039	1233
13039	45236
13048	1183
13048	1188
13048	1198
13048	1206
13048	1218
13050	1188
13050	1218
13050	1232
13050	1233
13050	45238
13051	1188
13051	1198
13051	1206
13051	1218
13051	45238
13053	1183
13053	1188
13053	1200
13053	1206
13053	1218
13055	1188
13055	1213
13055	1232
13055	1233
13055	45238
13059	1183
13059	1188
13059	1206
13059	1218
13059	1232
13060	1183
13060	1188
13060	1199
13060	1206
13060	1221
13067	1183
13067	1194
13067	1222
13067	1232
13067	1233
13068	1183
13068	1188
13068	1232
13068	1233
13068	1263
13070	1188
13070	1204
13070	1218
13070	1232
13070	45238
13072	1183
13072	1194
13072	1206
13072	1218
13072	1229
13073	1183
13073	1188
13073	1206
13073	1218
13073	1232
13075	1183
13075	1188
13075	1198
13075	1206
13075	1217
13076	1183
13076	1188
13076	1200
13076	1206
13076	1218
13079	1183
13079	1194
13079	1218
13079	1232
13079	1233
13080	1188
13080	1210
13080	1232
13080	1233
13080	45238
13082	1183
13082	1188
13082	1218
13082	1232
13082	1233
13091	1188
13091	1206
13091	1218
13091	1229
13091	45238
13103	1188
13103	1200
13103	1206
13103	1222
13103	45238
13104	1183
13104	1194
13104	1209
13104	1229
13104	1233
13105	1188
13105	1218
13105	1232
13105	1233
13105	45238
13106	1183
13106	1194
13106	1222
13106	1229
13106	1233
13108	1183
13108	1188
13108	1206
13108	1218
13108	1229
13109	1183
13109	1188
13109	1221
13109	1232
13109	1233
13111	1183
13111	1188
13111	1200
13111	1206
13111	1213
13112	1188
13112	1210
13112	1232
13112	1233
13112	45238
13115	1183
13115	1188
13115	1218
13115	1232
13115	1233
13116	1183
13116	1188
13116	1218
13116	1232
13116	1233
13118	1183
13118	1188
13118	1218
13118	1232
13118	1233
13119	1183
13119	1188
13119	1218
13119	1232
13119	1233
13120	1183
13120	1188
13120	1200
13120	1206
13120	1217
13121	1183
13121	1188
13121	1218
13121	1232
13121	1233
13122	1183
13122	1188
13122	1218
13122	1232
13122	1233
13123	1183
13123	1188
13123	1218
13123	1232
13123	1233
13124	1183
13124	1188
13124	1218
13124	1232
13124	1233
13125	1183
13125	1188
13125	1218
13125	1232
13125	1233
13126	1183
13126	1188
13126	1218
13126	1232
13126	1233
13127	1183
13127	1188
13127	1206
13127	1218
13127	1229
13128	1183
13128	1188
13128	1200
13128	1206
13128	1218
13129	1183
13129	1188
13129	1206
13129	1222
13129	1229
13130	1183
13130	1188
13130	1218
13130	1232
13130	1233
13131	1183
13131	1188
13131	1206
13131	1218
13131	1232
13133	1183
13133	1188
13133	1218
13133	1232
13133	1233
13135	1183
13135	1194
13135	1206
13135	1218
13135	1229
13137	1183
13137	1188
13137	1218
13137	1232
13137	1233
13138	1183
13138	1188
13138	1218
13138	1232
13138	1233
13139	1183
13139	1188
13139	1200
13139	1206
13139	1218
13140	1183
13140	1188
13140	1218
13140	1232
13140	1233
13141	1183
13141	1188
13141	1218
13141	1232
13141	1233
13142	1183
13142	1188
13142	1218
13142	1232
13142	1233
13144	1183
13144	1188
13144	1229
13144	1233
13144	1262
13145	1183
13145	1188
13145	1218
13145	1232
13145	1233
13146	1183
13146	1188
13146	1218
13146	1232
13146	1233
13147	1183
13147	1188
13147	1218
13147	1232
13147	1233
13148	1188
13148	1218
13148	1232
13148	1233
13148	45238
13149	1183
13149	1188
13149	1206
13149	1218
13149	1232
13150	1183
13150	1188
13150	1194
13150	1200
13150	1206
13150	1218
13150	1229
13150	1232
13150	1233
13151	1183
13151	1188
13151	1218
13151	1232
13151	1233
13152	1183
13152	1188
13152	1218
13152	1232
13152	1233
13153	1183
13153	1188
13153	1218
13153	1232
13153	1233
13154	1183
13154	1188
13154	1200
13154	1206
13154	1218
13156	1183
13156	1188
13156	1218
13156	1232
13156	1233
13157	1183
13157	1188
13157	1218
13157	1232
13157	1233
13158	1183
13158	1196
13158	1211
13158	1232
13158	1233
13159	1183
13159	1188
13159	1206
13159	1218
13159	1229
13161	1183
13161	1188
13161	1206
13161	1218
13161	1232
13162	1183
13162	1188
13162	1218
13162	1232
13162	1233
13163	1183
13163	1188
13163	1200
13163	1206
13163	1217
13164	1183
13164	1188
13164	1218
13164	1232
13164	1233
13165	1183
13165	1188
13165	1218
13165	1232
13165	1233
13166	1183
13166	1188
13166	1218
13166	1232
13166	1233
13167	1183
13167	1188
13167	1222
13167	1232
13167	1233
13168	1183
13168	1188
13168	1218
13168	1232
13168	1233
13169	1183
13169	1188
13169	1218
13169	1232
13169	1233
13170	1183
13170	1188
13170	1218
13170	1232
13170	1233
13171	1183
13171	1188
13171	1220
13171	1232
13171	1233
13172	1183
13172	1188
13172	1218
13172	1232
13172	1233
13173	1183
13173	1188
13173	1218
13173	1232
13173	1233
13174	1188
13174	1218
13174	1232
13174	1233
13174	45238
13175	1183
13175	1188
13175	1200
13175	1206
13175	1218
13176	1183
13176	1188
13176	1206
13176	1218
13176	1229
13177	1183
13177	1188
13177	1200
13177	1206
13177	1218
13178	1183
13178	1188
13178	1218
13178	1232
13178	1233
13179	1183
13179	1194
13179	1206
13179	1218
13179	1229
13180	1183
13180	1188
13180	1218
13180	1232
13180	1233
13181	1183
13181	1188
13181	1206
13181	1221
13181	1229
13182	1183
13182	1188
13182	1221
13182	1232
13182	1233
13183	1183
13183	1196
13183	1204
13183	1218
13183	1232
13184	1183
13184	1188
13184	1218
13184	1232
13184	1233
13185	1183
13185	1188
13185	1206
13185	1220
13185	1229
13187	1188
13187	1198
13187	1206
13187	1209
13187	45238
13190	1182
13190	1196
13190	1198
13190	1206
13190	1218
13191	1188
13191	1218
13191	1220
13191	1232
13191	1233
13193	1183
13193	1188
13193	1218
13193	1232
13193	1233
13202	1183
13202	1188
13202	1218
13202	1232
13202	1233
13207	1183
13207	1188
13207	1206
13207	1209
13207	1229
13208	1183
13208	1188
13208	1204
13208	1218
13208	1232
13217	1183
13217	1188
13217	1222
13217	1232
13217	1233
13222	1183
13222	1188
13222	1218
13222	1232
13222	1233
13224	1183
13224	1188
13224	1206
13224	1210
13224	1229
13225	1183
13225	1188
13225	1218
13225	1232
13225	1233
13226	1183
13226	1188
13226	1206
13226	1210
13226	1229
13227	1183
13227	1188
13227	1206
13227	1218
13227	1229
13229	1183
13229	1188
13229	1218
13229	1232
13229	1233
13230	1183
13230	1188
13230	1206
13230	1218
13230	1229
13232	1183
13232	1188
13232	1206
13232	1218
13232	1229
13234	1183
13234	1188
13234	1218
13234	1232
13234	1233
13237	1183
13237	1188
13237	1200
13237	1206
13237	1218
13239	1183
13239	1188
13239	1204
13239	1218
13239	1232
13240	1188
13240	1218
13240	1232
13240	1233
13240	45238
13241	1183
13241	1188
13241	1200
13241	1206
13241	1218
13242	1183
13242	1194
13242	1206
13242	1218
13242	1229
13243	1183
13243	1188
13243	1218
13243	1232
13243	1233
13251	1183
13251	1188
13251	1218
13251	1232
13251	1233
13252	1183
13252	1188
13252	1200
13252	1206
13252	1218
13257	1183
13257	1194
13257	1218
13257	1232
13257	1233
13258	1183
13258	1188
13258	1218
13258	1232
13258	1233
13259	1183
13259	1194
13259	1218
13259	1232
13259	1233
13261	1183
13261	1194
13261	1218
13261	1232
13261	1233
13262	1183
13262	1194
13262	1218
13262	1232
13262	1233
13267	1183
13267	1188
13267	1218
13267	1232
13267	1233
13268	1183
13268	1188
13268	1198
13268	1206
13268	1218
13269	1183
13269	1194
13269	1218
13269	1232
13269	1233
13270	1183
13270	1194
13270	1206
13270	1218
13270	1229
13271	1183
13271	1188
13271	1200
13271	1206
13271	1218
13272	1188
13272	1206
13272	1222
13272	1229
13272	45238
13273	1183
13273	1194
13273	1200
13273	1206
13273	1218
13274	1183
13274	1194
13274	1200
13274	1206
13274	1218
13275	1183
13275	1196
13275	1206
13275	1218
13275	1232
13276	1183
13276	1194
13276	1218
13276	1232
13276	1233
13277	1183
13277	1196
13277	1218
13277	1232
13277	1233
13278	1183
13278	1194
13278	1200
13278	1206
13278	1218
13279	1183
13279	1188
13279	1203
13279	1218
13279	1232
13280	1183
13280	1194
13280	1206
13280	1218
13280	1229
13281	1183
13281	1188
13281	1200
13281	1206
13281	1218
13282	1183
13282	1194
13282	1200
13282	1206
13282	1218
13283	1183
13283	1188
13283	1206
13283	1218
13283	1229
13284	1183
13284	1188
13284	1206
13284	1218
13284	1229
13285	1183
13285	1188
13285	1218
13285	1232
13285	1233
13286	1183
13286	1194
13286	1218
13286	1232
13286	1233
13287	1183
13287	1196
13287	1218
13287	1232
13287	1233
13288	1183
13288	1188
13288	1200
13288	1206
13288	1217
13289	1183
13289	1188
13289	1200
13289	1206
13289	1218
13290	1183
13290	1188
13290	1200
13290	1206
13290	1218
13291	1183
13291	1188
13291	1198
13291	1206
13291	1209
13292	1188
13292	1222
13292	1232
13292	1233
13292	45236
13293	1183
13293	1188
13293	1218
13293	1232
13293	1233
13294	1183
13294	1188
13294	1218
13294	1232
13294	1233
13295	1183
13295	1194
13295	1222
13295	1232
13295	1233
13296	1183
13296	1188
13296	1206
13296	1218
13296	1229
13297	1183
13297	1194
13297	1200
13297	1206
13297	1217
13298	1183
13298	1194
13298	1218
13298	1232
13298	1233
13305	1183
13305	1188
13305	1206
13305	1218
13305	1229
13310	1183
13310	1188
13310	1218
13310	1232
13310	1233
13311	1183
13311	1188
13311	1218
13311	1232
13311	1233
13316	1183
13316	1188
13316	1206
13316	1218
13316	1229
13318	1183
13318	1188
13318	1206
13318	1218
13318	1232
13320	1183
13320	1188
13320	1198
13320	1218
13320	1233
13321	1188
13321	1218
13321	1232
13321	1233
13321	45238
13324	1188
13324	1198
13324	1206
13324	1218
13324	45238
13326	1183
13326	1188
13326	1200
13326	1206
13326	1218
13327	1183
13327	1188
13327	1200
13327	1206
13327	45543
13330	1183
13330	1194
13330	1200
13330	1206
13330	1218
13331	1183
13331	1188
13331	1200
13331	1206
13331	1218
13332	1183
13332	1188
13332	1218
13332	1232
13332	1233
13334	1183
13334	1194
13334	1200
13334	1206
13334	1218
13335	1183
13335	1188
13335	1204
13335	1218
13335	1232
13337	1183
13337	1188
13337	1206
13337	1218
13337	1232
13338	1183
13338	1188
13338	1200
13338	1206
13338	1218
13340	1183
13340	1188
13340	1200
13340	1206
13340	1218
13342	1188
13342	1232
13342	1233
13342	1246
13342	45238
13343	1183
13343	1188
13343	1218
13343	1232
13343	1233
13344	1188
13344	1218
13344	1232
13344	1233
13344	45238
13345	1183
13345	1188
13345	1218
13345	1232
13345	1233
13346	1183
13346	1194
13346	1222
13346	1232
13346	1233
13347	1188
13347	1200
13347	1206
13347	1218
13347	45238
13348	1188
13348	1203
13348	1218
13348	1238
13348	45236
13349	1183
13349	1194
13349	1206
13349	1218
13349	1229
13350	1183
13350	1188
13350	1206
13350	1218
13350	1229
13351	1183
13351	1188
13351	1206
13351	1218
13351	1229
13352	1183
13352	1188
13352	1206
13352	1217
13352	1232
13353	1183
13353	1188
13353	1200
13353	1206
13353	1213
13355	1183
13355	1194
13355	1206
13355	1220
13355	1229
13359	1188
13359	1198
13359	1206
13359	1218
13359	45238
13362	1183
13362	1188
13362	1198
13362	1206
13362	1218
13367	1188
13367	1200
13367	1206
13367	1246
13367	45238
13368	1188
13368	1206
13368	1211
13368	1229
13368	45238
13370	1183
13370	1194
13370	1232
13370	1233
13370	44983
13378	1183
13378	1194
13378	1206
13378	1218
13378	1229
13381	1183
13381	1188
13381	1218
13381	1232
13381	1233
13383	1183
13383	1188
13383	1218
13383	1232
13383	1233
13388	1183
13388	1188
13388	1206
13388	1218
13388	1229
13390	1183
13390	1194
13390	1229
13390	1233
13390	1257
13390	45586
13391	1183
13391	1188
13391	1218
13391	1232
13391	1233
13392	1188
13392	1206
13392	1218
13392	1229
13392	45238
13394	1183
13394	1188
13394	1218
13394	1232
13394	1233
13396	1183
13396	1188
13396	1200
13396	1206
13396	1218
13397	1183
13397	1188
13397	1220
13397	1232
13397	1233
13398	1183
13398	1188
13398	1200
13398	1206
13398	1218
13401	1183
13401	1194
13401	1206
13401	1229
13401	1246
13402	1179
13402	1188
13402	1197
13402	1201
13402	1218
13405	1183
13405	1188
13405	1232
13405	1233
13405	45543
13406	1183
13406	1188
13406	1206
13406	1218
13406	1229
13407	1182
13407	1188
13407	1198
13407	1206
13407	1218
13409	1183
13409	1188
13409	1204
13409	1218
13409	1229
13412	1183
13412	1188
13412	1198
13412	1220
13412	1233
13415	1183
13415	1188
13415	1198
13415	1206
13415	1218
13419	1183
13419	1188
13419	1198
13419	1206
13419	1229
13419	45548
13420	1188
13420	1198
13420	1210
13420	1233
13420	45236
13421	1183
13421	1188
13421	1206
13421	1218
13421	1229
13423	1183
13423	1188
13423	1205
13423	1218
13423	1229
13425	1188
13425	1200
13425	1206
13425	1218
13425	45238
13426	1183
13426	1188
13426	1198
13426	1218
13426	1233
13429	1183
13429	1194
13429	1206
13429	1220
13429	1229
13431	1188
13431	1206
13431	1218
13431	1229
13431	45238
13433	1183
13433	1188
13433	1206
13433	1217
13433	1229
13434	1183
13434	1188
13434	1206
13434	1218
13434	1229
13435	1183
13435	1188
13435	1218
13435	1232
13435	1233
13438	1188
13438	1218
13438	1232
13438	1233
13438	45238
13442	1183
13442	1188
13442	1200
13442	1206
13442	1218
13443	1183
13443	1188
13443	1200
13443	1206
13443	1222
13446	1183
13446	1188
13446	1218
13446	1229
13446	1233
13447	1195
13447	1218
13447	1232
13447	1233
13447	45238
13448	1188
13448	1200
13448	1206
13448	1218
13448	45238
13450	1183
13450	1194
13450	1200
13450	1206
13450	1218
13451	1183
13451	1194
13451	1200
13451	1206
13451	1218
13455	1183
13455	1194
13455	1198
13455	1206
13455	1218
13456	1183
13456	1188
13456	1198
13456	1206
13456	45548
13457	1193
13457	1198
13457	1218
13457	1233
13457	45238
13459	1183
13459	1194
13459	1206
13459	1218
13459	1232
13461	1183
13461	1194
13461	1206
13461	1209
13461	1229
13462	1183
13462	1188
13462	1200
13462	1206
13462	1218
13465	1183
13465	1188
13465	1232
13465	1233
13465	45543
13466	1183
13466	1194
13466	1218
13466	1232
13466	1233
13467	1183
13467	1188
13467	1200
13467	1206
13467	1218
13469	1183
13469	1188
13469	1198
13469	1233
13469	1246
13469	1257
13469	45548
13473	1183
13473	1188
13473	1232
13473	1233
13473	44971
13477	1188
13477	1198
13477	1206
13477	1218
13477	45238
13480	1183
13480	1188
13480	1200
13480	1206
13480	1218
13481	1183
13481	1188
13481	1206
13481	1218
13481	1229
13482	1183
13482	1188
13482	1206
13482	1218
13482	1229
13488	1183
13488	1188
13488	1218
13488	1232
13488	1233
13489	1183
13489	1188
13489	1200
13489	1206
13489	1218
13490	1183
13490	1194
13490	1217
13490	1232
13490	1233
13493	1183
13493	1188
13493	1218
13493	1232
13493	1233
13494	1183
13494	1188
13494	1218
13494	1232
13494	1233
13497	1183
13497	1188
13497	1198
13497	1206
13497	1218
13501	1183
13501	1194
13501	1206
13501	1218
13501	1229
13505	1183
13505	1194
13505	1200
13505	1206
13505	1218
13507	1183
13507	1188
13507	1206
13507	1222
13507	1229
13512	1195
13512	1200
13512	1206
13512	45238
13512	45421
13515	1183
13515	1188
13515	1218
13515	1232
13515	45604
13521	1183
13521	1188
13521	1198
13521	1218
13521	1233
13523	1183
13523	1194
13523	1218
13523	1232
13523	1233
13526	1183
13526	1188
13526	1218
13526	1232
13526	1233
13533	1188
13533	1198
13533	1206
13533	1218
13533	45238
13534	1183
13534	1194
13534	1206
13534	1229
13534	45356
13536	1183
13536	1196
13536	1206
13536	1218
13536	1229
13537	1183
13537	1188
13537	1198
13537	1206
13537	45548
13538	1188
13538	1206
13538	1220
13538	1229
13538	45238
13542	1183
13542	1204
13542	1218
13542	1232
13542	1239
13543	1183
13543	1188
13543	1200
13543	1206
13543	1218
13544	1183
13544	1194
13544	1218
13544	1232
13544	1233
13545	1183
13545	1188
13545	1206
13545	1222
13545	1229
13546	1183
13546	1194
13546	1200
13546	1206
13546	1218
13549	1195
13549	1218
13549	1232
13549	1233
13549	45238
13550	1183
13550	1188
13550	1206
13550	1218
13550	1229
13551	1183
13551	1188
13551	1218
13551	1232
13551	1233
13553	1183
13553	1206
13553	1218
13553	1229
13553	1239
13554	1188
13554	1218
13554	1232
13554	1233
13554	45238
13555	1183
13555	1188
13555	1206
13555	1218
13555	1229
13556	1183
13556	1194
13556	1200
13556	1206
13556	1218
13557	1183
13557	1188
13557	1198
13557	1206
13557	1218
13558	1183
13558	1188
13558	1206
13558	1218
13558	1229
13560	1179
13560	1188
13560	1197
13560	1201
13560	1218
13561	1183
13561	1194
13561	1198
13561	1206
13561	1218
13562	1183
13562	1188
13562	1218
13562	1232
13562	1233
13565	1195
13565	1204
13565	1218
13565	1229
13565	45236
13568	1188
13568	1218
13568	1232
13568	1233
13568	45238
13569	1183
13569	1188
13569	1218
13569	1232
13569	1233
13572	1183
13572	1188
13572	1206
13572	1221
13572	1232
13573	1183
13573	1188
13573	1218
13573	1232
13573	1233
13575	1183
13575	1193
13575	1200
13575	1206
13575	1218
13576	1188
13576	1205
13576	1218
13576	1232
13576	45238
13577	1183
13577	1188
13577	1206
13577	1218
13577	1229
13578	1183
13578	1194
13578	1199
13578	1204
13578	1220
13579	1183
13579	1188
13579	1218
13579	1232
13579	1233
13601	1183
13601	1194
13601	1218
13601	1232
13601	1233
13602	1188
13602	1204
13602	1218
13602	1232
13602	45238
13603	1183
13603	1188
13603	1218
13603	1232
13603	1233
13604	1183
13604	1188
13604	1232
13604	1233
13604	1261
13605	1183
13605	1194
13605	1198
13605	1206
13605	1218
13606	1183
13606	1188
13606	1218
13606	1229
13606	1232
13606	1233
13607	1183
13607	1188
13607	1200
13607	1206
13607	1218
13610	1183
13610	1188
13610	1206
13610	1218
13610	1229
13611	1183
13611	1188
13611	1204
13611	1218
13611	1232
13612	1183
13612	1188
13612	1218
13612	1232
13612	1233
13613	1183
13613	1188
13613	1222
13613	1232
13613	1233
13614	1195
13614	1200
13614	1206
13614	1222
13614	45238
13617	1183
13617	1188
13617	1218
13617	1232
13617	1233
13618	1183
13618	1194
13618	1200
13618	1206
13618	1218
13619	1188
13619	1200
13619	1206
13619	1218
13619	45238
13621	1183
13621	1188
13621	1206
13621	1218
13621	1232
13623	1188
13623	1203
13623	1218
13623	1232
13623	45238
13635	1183
13635	1194
13635	1206
13635	1218
13635	1229
13637	1183
13637	1196
13637	1206
13637	1218
13637	1229
13639	1183
13639	1191
13639	1206
13639	1218
13639	1232
13640	1188
13640	1232
13640	1233
13640	1246
13640	45238
13640	45545
13641	1188
13641	1200
13641	1206
13641	1218
13641	45238
13642	1183
13642	1188
13642	1206
13642	1218
13642	1229
13644	1188
13644	1200
13644	1206
13644	1218
13644	45238
13645	1183
13645	1194
13645	1218
13645	1232
13645	1233
13646	1183
13646	1188
13646	1206
13646	1218
13646	1229
13650	1183
13650	1194
13650	1206
13650	1218
13650	1232
13651	1195
13651	1199
13651	1204
13651	1218
13651	45236
13653	1183
13653	1196
13653	1206
13653	1218
13653	1229
13654	1183
13654	1188
13654	1200
13654	1206
13654	1218
13656	1183
13656	1188
13656	1200
13656	1206
13656	1218
13657	1183
13657	1188
13657	1206
13657	1218
13657	1229
13660	1183
13660	1188
13660	1204
13660	1218
13660	1232
13666	1183
13666	1188
13666	1218
13666	1232
13666	1233
13667	1183
13667	1188
13667	1200
13667	1206
13667	1218
13668	1183
13668	1194
13668	1218
13668	1232
13668	1233
13669	1183
13669	1188
13669	1200
13669	1206
13669	1218
13670	1183
13670	1194
13670	1198
13670	1206
13670	1210
13671	1183
13671	1188
13671	1232
13671	1233
13671	45134
13672	1183
13672	1194
13672	1206
13672	1218
13672	1229
13673	1183
13673	1188
13673	1206
13673	1218
13673	1229
13674	1183
13674	1188
13674	1218
13674	1232
13674	1233
13675	1183
13675	1194
13675	1218
13675	1232
13675	1233
13676	1183
13676	1206
13676	1210
13676	1229
13676	1239
13677	1183
13677	1188
13677	1218
13677	1232
13677	1233
13678	1183
13678	1188
13678	1217
13678	1232
13678	1233
13679	1183
13679	1188
13679	1218
13679	1232
13679	1233
13680	1183
13680	1188
13680	1194
13680	1199
13680	1204
13680	1218
13680	1232
13680	1233
13681	1183
13681	1188
13681	1206
13681	1218
13681	1232
13682	1183
13682	1188
13682	1206
13682	1218
13682	1229
13683	1183
13683	1188
13683	1204
13683	1218
13683	1232
13684	1183
13684	1188
13684	1204
13684	1218
13684	1232
13685	1188
13685	1206
13685	1218
13685	1229
13685	45238
13687	1188
13687	1218
13687	1232
13687	1233
13687	45238
13689	1188
13689	1218
13689	1232
13689	1233
13689	45238
13690	1188
13690	1206
13690	1218
13690	1229
13690	45238
13691	1183
13691	1194
13691	1218
13691	1232
13691	1233
13708	1183
13708	1188
13708	1218
13708	1232
13708	1233
13710	1183
13710	1188
13710	1232
13710	1233
13710	45399
13711	1183
13711	1188
13711	1218
13711	1232
13711	1233
13717	1183
13717	1188
13717	1206
13717	1218
13717	1229
13718	1188
13718	1204
13718	1218
13718	1232
13718	45238
13719	1183
13719	1194
13719	1222
13719	1232
13719	1233
13720	1188
13720	1206
13720	1218
13720	1229
13720	45238
13721	1183
13721	1194
13721	1218
13721	1232
13721	1233
13725	1195
13725	1218
13725	1232
13725	1233
13725	45238
13726	1183
13726	1188
13726	1218
13726	1232
13726	1233
13727	1183
13727	1188
13727	1218
13727	1232
13727	1233
13728	1183
13728	1188
13728	1200
13728	1206
13728	1218
13732	1183
13732	1194
13732	1200
13732	1206
13732	1222
13734	1188
13734	1198
13734	1206
13734	1211
13734	45236
13735	1183
13735	1188
13735	1206
13735	1210
13735	1220
13735	1232
13736	1183
13736	1188
13736	1198
13736	1218
13736	1233
13739	1183
13739	1188
13739	1218
13739	1232
13739	1233
13740	1183
13740	1188
13740	1229
13740	1233
13740	44968
13741	1183
13741	1188
13741	1206
13741	1218
13741	1229
13742	1183
13742	1188
13742	1218
13742	1229
13742	1233
13743	1183
13743	1188
13743	1218
13743	1232
13743	1233
13744	1183
13744	1188
13744	1218
13744	1232
13744	1233
13752	1183
13752	1188
13752	1200
13752	1206
13752	1218
13757	1183
13757	1188
13757	1218
13757	1232
13757	1233
13759	1183
13759	1188
13759	1218
13759	1232
13759	1233
13760	1183
13760	1188
13760	1206
13760	1218
13760	1232
13761	1183
13761	1188
13761	1218
13761	1232
13761	1233
13762	1188
13762	1203
13762	1220
13762	1232
13762	45236
13762	45600
13763	1183
13763	1194
13763	1200
13763	1206
13763	1218
13764	1183
13764	1188
13764	1218
13764	1232
13764	1233
13765	1183
13765	1196
13765	1200
13765	1206
13765	1218
13766	1183
13766	1188
13766	1218
13766	1232
13766	1233
13767	1188
13767	1198
13767	1204
13767	1218
13767	45236
13768	1188
13768	1203
13768	1218
13768	1238
13768	45236
13769	1183
13769	1188
13769	1218
13769	1232
13769	1233
13771	1183
13771	1196
13771	1218
13771	1232
13771	1233
13772	1183
13772	1188
13772	1198
13772	1206
13772	1218
13773	1183
13773	1194
13773	1200
13773	1206
13773	1277
13774	1180
13774	1188
13774	1197
13774	1201
13774	1218
13775	1183
13775	1194
13775	1206
13775	1218
13775	1229
13777	1183
13777	1194
13777	1218
13777	1232
13777	1233
13778	1183
13778	1188
13778	1203
13778	1218
13778	1232
13779	1183
13779	1188
13779	1200
13779	1206
13779	1218
13780	1183
13780	1194
13780	1204
13780	1218
13780	1232
13783	1183
13783	1194
13783	1206
13783	1220
13783	1229
13784	1183
13784	1196
13784	1218
13784	1232
13784	1233
13785	1183
13785	1188
13785	1218
13785	1232
13785	1233
13786	1183
13786	1194
13786	1200
13786	1206
13786	1218
13786	1232
13786	1233
13787	1183
13787	1196
13787	1222
13787	1232
13787	1233
13789	1183
13789	1188
13789	1218
13789	1232
13789	1233
13790	1183
13790	1194
13790	1206
13790	1218
13790	1232
13791	1183
13791	1188
13791	1218
13791	1232
13791	1233
13792	1183
13792	1188
13792	1206
13792	1220
13792	1229
13793	1183
13793	1188
13793	1205
13793	1218
13793	1232
13793	1233
13793	45236
13794	1183
13794	1188
13794	1200
13794	1206
13794	1218
13795	1183
13795	1188
13795	1217
13795	1229
13795	1233
13796	1183
13796	1188
13796	1218
13796	1232
13796	1233
13797	1183
13797	1188
13797	1198
13797	1206
13797	1218
13798	1183
13798	1188
13798	1200
13798	1206
13798	1218
13799	1183
13799	1194
13799	1198
13799	1199
13799	1204
13799	1218
13799	1239
13800	1183
13800	1194
13800	1206
13800	1218
13800	1232
13801	1188
13801	1204
13801	1218
13801	1232
13801	45238
13802	1188
13802	1205
13802	1222
13802	1232
13802	45238
13803	1188
13803	1218
13803	1232
13803	1233
13803	45238
13804	1183
13804	1188
13804	1204
13804	1218
13804	1232
13805	1183
13805	1188
13805	1206
13805	1218
13805	1229
13806	1183
13806	1188
13806	1218
13806	1232
13806	1233
13807	1183
13807	1194
13807	1218
13807	1232
13807	1233
13808	1183
13808	1188
13808	1218
13808	1232
13808	1233
13809	1183
13809	1188
13809	1200
13809	1206
13809	1218
13809	1232
13809	1233
13810	1183
13810	1194
13810	1218
13810	1232
13810	1233
13812	1183
13812	1188
13812	1217
13812	1232
13812	1233
13813	1188
13813	1199
13813	1204
13813	1218
13813	45236
13814	1183
13814	1188
13814	1200
13814	1206
13814	1218
13815	1180
13815	1188
13815	1197
13815	1201
13815	1204
13815	1218
13815	1232
13815	45236
13816	1183
13816	1188
13816	1232
13816	1233
13816	1244
13817	1188
13817	1218
13817	1232
13817	1233
13817	45238
13818	1183
13818	1188
13818	1204
13818	1218
13818	1232
13819	1183
13819	1188
13819	1206
13819	1218
13819	1232
13820	1183
13820	1194
13820	1206
13820	1218
13820	1229
13821	1183
13821	1188
13821	1206
13821	1218
13821	1229
13822	1188
13822	1218
13822	1232
13822	1233
13822	45238
13823	1183
13823	1188
13823	1200
13823	1206
13823	45436
13824	1183
13824	1188
13824	1206
13824	1220
13824	1229
13825	1183
13825	1196
13825	1218
13825	1232
13825	1233
13826	1183
13826	1188
13826	1198
13826	1206
13826	1218
13827	1183
13827	1188
13827	1222
13827	1232
13827	1233
13828	1183
13828	1188
13828	1218
13828	1232
13828	1233
13829	1183
13829	1188
13829	1218
13829	1232
13829	1233
13832	1183
13832	1194
13832	1218
13832	1232
13832	1233
13833	1183
13833	1188
13833	1218
13833	1232
13833	1233
13834	1183
13834	1188
13834	1206
13834	1217
13834	1232
13835	1183
13835	1188
13835	1218
13835	1232
13835	1233
13836	1183
13836	1188
13836	1204
13836	1218
13836	1232
13837	1183
13837	1188
13837	1218
13837	1232
13837	1233
13838	1183
13838	1188
13838	1198
13838	1206
13838	1218
13839	1183
13839	1188
13839	1200
13839	1206
13839	1218
13840	1183
13840	1188
13840	1217
13840	1232
13840	1233
13841	1183
13841	1188
13841	1206
13841	1218
13841	1229
13843	1188
13843	1232
13843	1233
13843	45546
13843	45602
13844	1183
13844	1196
13844	1198
13844	1206
13844	1218
13845	1188
13845	1206
13845	1218
13845	1229
13845	45238
13846	1183
13846	1188
13846	1200
13846	1204
13846	1218
13847	1179
13847	1188
13847	1197
13847	1201
13847	1218
13851	1179
13851	1188
13851	1197
13851	1201
13851	45546
13853	1183
13853	1188
13853	1218
13853	1232
13853	1233
13855	1183
13855	1188
13855	1200
13855	1206
13855	1218
13856	1188
13856	1206
13856	1211
13856	1229
13856	45238
13859	1183
13859	1194
13859	1199
13859	1204
13859	1218
13860	1183
13860	1188
13860	1216
13860	1232
13860	1233
13864	1183
13864	1188
13864	1200
13864	1206
13864	45448
13868	1183
13868	1188
13868	1218
13868	1232
13868	1233
13869	1183
13869	1194
13869	1206
13869	1218
13869	1229
13870	1183
13870	1194
13870	1206
13870	1218
13870	1229
13872	1188
13872	1218
13872	1232
13872	1233
13872	45238
13879	1183
13879	1194
13879	1232
13879	1233
13879	45435
13881	1183
13881	1188
13881	1200
13881	1206
13881	1218
13885	1188
13885	1218
13885	1232
13885	1233
13885	45236
13886	1183
13886	1188
13886	1218
13886	1232
13886	1233
13887	1183
13887	1194
13887	1206
13887	1232
13887	45543
13888	1183
13888	1188
13888	1199
13888	1206
13888	1218
13893	1183
13893	1194
13893	1200
13893	1206
13893	1213
13898	1180
13898	1188
13898	1197
13898	1201
13898	1218
13899	1183
13899	1196
13899	1218
13899	1229
13899	1233
13901	1188
13901	1218
13901	1232
13901	1233
13901	45238
13907	1183
13907	1206
13907	1218
13907	1229
13907	1239
13911	1179
13911	1188
13911	1197
13911	1201
13911	1218
13912	1182
13912	1188
13912	1198
13912	1218
13912	1233
13914	1179
13914	1188
13914	1197
13914	1201
13914	1218
13915	1183
13915	1188
13915	1218
13915	1232
13915	1233
13918	1188
13918	1218
13918	1232
13918	1233
13918	45238
13923	1179
13923	1188
13923	1197
13923	1201
13923	1218
13924	1183
13924	1188
13924	1218
13924	1232
13924	1233
13927	1183
13927	1188
13927	1206
13927	1221
13927	1229
13929	1183
13929	1188
13929	1206
13929	1218
13929	1229
13935	1183
13935	1188
13935	1218
13935	1232
13935	1233
13936	1183
13936	1191
13936	1192
13936	1205
13936	1218
13936	1229
13937	1183
13937	1194
13937	1199
13937	1204
13937	1218
13938	1183
13938	1188
13938	1199
13938	1203
13938	1218
13939	1188
13939	1232
13939	1233
13939	45238
13939	45613
13942	1183
13942	1194
13942	1206
13942	1217
13942	1229
13944	1183
13944	1194
13944	1206
13944	1209
13944	1229
13946	1183
13946	1188
13946	1218
13946	1232
13946	1233
13947	1183
13947	1188
13947	1200
13947	1206
13947	1218
13952	1183
13952	1194
13952	1200
13952	1206
13952	1222
13953	1183
13953	1188
13953	1198
13953	1206
13953	1213
13954	1183
13954	1194
13954	1200
13954	1206
13954	1218
13956	1183
13956	1188
13956	1206
13956	1218
13956	1229
13957	1183
13957	1188
13957	1200
13957	1206
13957	1217
13960	1183
13960	1194
13960	1218
13960	1232
13960	1233
13964	1188
13964	1218
13964	1232
13964	1233
13964	45236
13965	1183
13965	1194
13965	1222
13965	1232
13965	1233
13969	1183
13969	1194
13969	1204
13969	1218
13969	1232
13970	1183
13970	1188
13970	1196
13970	1206
13970	1218
13970	1229
13970	1231
13970	1232
13970	1233
13970	45236
13971	1183
13971	1196
13971	1218
13971	1232
13971	1233
13974	1182
13974	1188
13974	1198
13974	1206
13974	1218
13975	1182
13975	1188
13975	1198
13975	1206
13975	1218
13976	1183
13976	1188
13976	1200
13976	1206
13976	1218
13976	1229
13976	1232
13976	1233
13977	1183
13977	1194
13977	1200
13977	1206
13977	1218
13980	1183
13980	1188
13980	1200
13980	1206
13980	1218
13983	1183
13983	1188
13983	1232
13983	1233
13983	45181
13984	1183
13984	1188
13984	1206
13984	1218
13984	1229
13987	1183
13987	1194
13987	1218
13987	1232
13987	1233
13988	1183
13988	1188
13988	1206
13988	1217
13988	1232
13990	1183
13990	1188
13990	1206
13990	1218
13990	1229
13993	1183
13993	1194
13993	1200
13993	1206
13993	1218
13995	1183
13995	1188
13995	1232
13995	1233
13995	45181
13997	1183
13997	1188
13997	1198
13997	1206
13997	1218
13998	1183
13998	1194
13998	1218
13998	1232
13998	1233
13999	1183
13999	1188
13999	1218
13999	1232
13999	1233
14000	1183
14000	1194
14000	1229
14000	1233
14000	45134
14001	1183
14001	1188
14001	1200
14001	1206
14001	1218
14002	1183
14002	1194
14002	1218
14002	1232
14002	1233
14003	1183
14003	1194
14003	1204
14003	1218
14003	1232
14006	1183
14006	1194
14006	1206
14006	1218
14006	1229
14007	1183
14007	1188
14007	1206
14007	1218
14007	1229
14008	1183
14008	1194
14008	1196
14008	1220
14008	1232
14008	1233
14009	1183
14009	1188
14009	1200
14009	1206
14009	1218
14010	1183
14010	1194
14010	1200
14010	1206
14010	1222
14012	1183
14012	1194
14012	1200
14012	1206
14012	1218
14013	1183
14013	1194
14013	1218
14013	1232
14013	1233
14015	1183
14015	1188
14015	1198
14015	1206
14015	1218
14016	1183
14016	1188
14016	1218
14016	1232
14016	1233
14017	1188
14017	1205
14017	1218
14017	1238
14017	45238
14020	1183
14020	1196
14020	1205
14020	1218
14020	1232
14021	1183
14021	1196
14021	1206
14021	1218
14021	1229
14023	1188
14023	1218
14023	1232
14023	1233
14023	45238
14024	1183
14024	1194
14024	1200
14024	1206
14024	1218
14025	1183
14025	1188
14025	1198
14025	1218
14025	1233
14026	1183
14026	1206
14026	1218
14026	1229
14026	1239
14030	1183
14030	1188
14030	1218
14030	1232
14030	1233
14032	1183
14032	1194
14032	1200
14032	1206
14032	1218
14034	1183
14034	1188
14034	1206
14034	1218
14034	1232
14037	1183
14037	1194
14037	1198
14037	1206
14037	1218
14038	1183
14038	1194
14038	1198
14038	1206
14038	1218
14039	1183
14039	1188
14039	1198
14039	1204
14039	1218
14040	1183
14040	1194
14040	1198
14040	1206
14040	1218
14041	1183
14041	1188
14041	1206
14041	1218
14041	1229
14042	1182
14042	1188
14042	1218
14042	1232
14042	1233
14044	1183
14044	1188
14044	1218
14044	1232
14044	1233
14045	1183
14045	1188
14045	1200
14045	1206
14045	1217
14046	1183
14046	1194
14046	1200
14046	1206
14046	1222
14047	1183
14047	1188
14047	1200
14047	1206
14047	1217
14048	1183
14048	1194
14048	1218
14048	1232
14048	1233
14049	1183
14049	1194
14049	1200
14049	1206
14049	1218
14050	1183
14050	1188
14050	1198
14050	1206
14050	1210
14050	1232
14050	1233
14052	1183
14052	1188
14052	1204
14052	1218
14052	1232
14053	1183
14053	1188
14053	1204
14053	1218
14053	1232
14054	1183
14054	1188
14054	1205
14054	1218
14054	1232
14055	1183
14055	1194
14055	1200
14055	1206
14055	1218
14056	1183
14056	1188
14056	1206
14056	1218
14056	1229
14060	1183
14060	1188
14060	1206
14060	1218
14060	1232
14061	1183
14061	1188
14061	1206
14061	1217
14061	1232
14062	1183
14062	1188
14062	1206
14062	1218
14062	1232
14064	1183
14064	1188
14064	1206
14064	1221
14064	1232
14066	1183
14066	1188
14066	1232
14066	1233
14066	44974
14067	1183
14067	1188
14067	1218
14067	1232
14067	1233
14068	1183
14068	1188
14068	1198
14068	1204
14068	1218
14069	1183
14069	1188
14069	1218
14069	1232
14069	1233
14070	1183
14070	1188
14070	1205
14070	1218
14070	1232
14071	1183
14071	1188
14071	1206
14071	1218
14071	1232
14072	1183
14072	1188
14072	1205
14072	1218
14072	1232
14073	1183
14073	1188
14073	1218
14073	1232
14073	1233
14074	1183
14074	1188
14074	1218
14074	1232
14074	1233
14075	1183
14075	1188
14075	1206
14075	1218
14075	1232
14076	1183
14076	1188
14076	1218
14076	1232
14076	1233
14077	1183
14077	1188
14077	1206
14077	1232
14077	1243
14078	1183
14078	1188
14078	1198
14078	1204
14078	1218
14079	1183
14079	1188
14079	1218
14079	1232
14079	1233
14080	1183
14080	1188
14080	1221
14080	1232
14080	1233
14081	1183
14081	1188
14081	1206
14081	1218
14081	1232
14082	1183
14082	1188
14082	1218
14082	1232
14082	1233
14083	1183
14083	1188
14083	1206
14083	1221
14083	1232
14084	1183
14084	1188
14084	1206
14084	1232
14084	44968
14085	1183
14085	1188
14085	1204
14085	1218
14085	1232
14086	1183
14086	1188
14086	1206
14086	1221
14086	1232
14087	1183
14087	1188
14087	1218
14087	1232
14087	1233
14088	1183
14088	1188
14088	1218
14088	1232
14088	1233
14089	1183
14089	1188
14089	1218
14089	1232
14089	1233
14090	1183
14090	1188
14090	1206
14090	1218
14090	1232
14091	1183
14091	1188
14091	1205
14091	1217
14091	1232
14092	1183
14092	1188
14092	1206
14092	1232
14092	44968
14093	1183
14093	1188
14093	1206
14093	1229
14093	44971
14095	1183
14095	1188
14095	1206
14095	1218
14095	1232
14096	1183
14096	1188
14096	1206
14096	1217
14096	1232
14097	1183
14097	1188
14097	1204
14097	1218
14097	1232
14098	1183
14098	1188
14098	1218
14098	1232
14098	1233
14099	1183
14099	1188
14099	1218
14099	1232
14099	1233
14101	1183
14101	1188
14101	1218
14101	1232
14101	1233
14102	1183
14102	1188
14102	1198
14102	1206
14102	1218
14103	1183
14103	1188
14103	1204
14103	1232
14103	45148
14105	1183
14105	1188
14105	1204
14105	1218
14105	1232
14107	1183
14107	1188
14107	1204
14107	1218
14107	1232
14108	1183
14108	1188
14108	1218
14108	1232
14108	1233
14109	1183
14109	1194
14109	1206
14109	1232
14109	44977
14110	1183
14110	1188
14110	1198
14110	1218
14110	1233
14111	1183
14111	1188
14111	1204
14111	1218
14111	1232
14112	1183
14112	1188
14112	1206
14112	1217
14112	1232
14113	1183
14113	1188
14113	1213
14113	1232
14113	1233
14114	1183
14114	1188
14114	1206
14114	1218
14114	1229
14115	1183
14115	1188
14115	1205
14115	1218
14115	1232
14116	1183
14116	1188
14116	1205
14116	1218
14116	1232
14117	1183
14117	1188
14117	1206
14117	1221
14117	1232
14118	1183
14118	1188
14118	1206
14118	1218
14118	1232
14119	1183
14119	1188
14119	1206
14119	1217
14119	1232
14120	1183
14120	1188
14120	1206
14120	1221
14120	1232
14121	1183
14121	1188
14121	1218
14121	1232
14121	1233
14122	1183
14122	1188
14122	1218
14122	1232
14122	1233
14123	1183
14123	1188
14123	1206
14123	1232
14123	44983
14124	1183
14124	1188
14124	1206
14124	1217
14124	1232
14125	1183
14125	1188
14125	1206
14125	1218
14125	1232
14126	1183
14126	1188
14126	1204
14126	1218
14126	1232
14127	1183
14127	1188
14127	1204
14127	1232
14127	44974
14128	1183
14128	1188
14128	1206
14128	1218
14128	1232
14129	1183
14129	1188
14129	1200
14129	1218
14129	1233
14130	1183
14130	1188
14130	1205
14130	1218
14130	1232
14131	1183
14131	1188
14131	1232
14131	1233
14131	44968
14132	1183
14132	1188
14132	1206
14132	1218
14132	1232
14133	1183
14133	1188
14133	1200
14133	1206
14133	1262
14134	1183
14134	1188
14134	1218
14134	1232
14134	1233
14135	1183
14135	1188
14135	1205
14135	1232
14135	45140
14136	1183
14136	1188
14136	1206
14136	1232
14136	45014
14137	1183
14137	1188
14137	1204
14137	1218
14137	1232
14138	1183
14138	1188
14138	1218
14138	1232
14138	1233
14139	1188
14139	1205
14139	1218
14139	1232
14139	45238
14140	1183
14140	1188
14140	1200
14140	1206
14140	1218
14141	1183
14141	1188
14141	1206
14141	1217
14141	1232
14142	1183
14142	1188
14142	1204
14142	1218
14142	1232
14143	1183
14143	1188
14143	1205
14143	1218
14143	1232
14144	1183
14144	1188
14144	1206
14144	1232
14144	44974
14145	1183
14145	1188
14145	1217
14145	1232
14145	1233
14146	1183
14146	1188
14146	1204
14146	1218
14146	1232
14147	1183
14147	1188
14147	1206
14147	1232
14147	45145
14150	1183
14150	1188
14150	1206
14150	1232
14150	44971
14151	1183
14151	1188
14151	1200
14151	1206
14151	1243
14152	1183
14152	1188
14152	1204
14152	1232
14152	45339
14153	1183
14153	1188
14153	1206
14153	1232
14153	1277
14155	1183
14155	1188
14155	1232
14155	1233
14155	44974
14156	1183
14156	1188
14156	1198
14156	1205
14156	1218
14157	1183
14157	1188
14157	1198
14157	1218
14157	1233
14158	1183
14158	1188
14158	1211
14158	1232
14158	1233
14159	1183
14159	1188
14159	1218
14159	1232
14159	1233
14160	1183
14160	1188
14160	1197
14160	1201
14160	1218
14161	1183
14161	1188
14161	1198
14161	1204
14161	1213
14163	1183
14163	1188
14163	1200
14163	1218
14163	1233
14164	1183
14164	1188
14164	1206
14164	1232
14164	44971
14165	1183
14165	1188
14165	1204
14165	1232
14165	44968
14166	1183
14166	1188
14166	1206
14166	1218
14166	1232
14167	1183
14167	1188
14167	1218
14167	1232
14167	1233
14168	1183
14168	1188
14168	1218
14168	1229
14168	1233
14169	1183
14169	1188
14169	1218
14169	1229
14169	1233
14170	1183
14170	1188
14170	1218
14170	1232
14170	1233
14171	1183
14171	1188
14171	1218
14171	1232
14171	1233
14172	1183
14172	1188
14172	1218
14172	1232
14172	1233
14173	1183
14173	1188
14173	1218
14173	1232
14173	1233
14174	1183
14174	1188
14174	1218
14174	1232
14174	1233
14175	1183
14175	1188
14175	1205
14175	1218
14175	1232
14176	1183
14176	1188
14176	1206
14176	1210
14176	1232
14178	1183
14178	1188
14178	1206
14178	1217
14178	1232
14179	1183
14179	1188
14179	1206
14179	1218
14179	1232
14180	1183
14180	1188
14180	1206
14180	1217
14180	1232
14181	1183
14181	1188
14181	1204
14181	1218
14181	1232
14182	1183
14182	1188
14182	1205
14182	1218
14182	1232
14183	1183
14183	1188
14183	1206
14183	1218
14183	1232
14184	1183
14184	1188
14184	1206
14184	1218
14184	1232
14185	1183
14185	1188
14185	1206
14185	1218
14185	1232
14186	1183
14186	1188
14186	1206
14186	1218
14186	1232
14187	1183
14187	1188
14187	1204
14187	1218
14187	1232
14188	1183
14188	1188
14188	1206
14188	1217
14188	1232
14189	1183
14189	1188
14189	1198
14189	1204
14189	1218
14190	1183
14190	1188
14190	1218
14190	1229
14190	1233
14191	1183
14191	1188
14191	1198
14191	1233
14191	44970
14192	1183
14192	1188
14192	1204
14192	1218
14192	1232
14193	1183
14193	1188
14193	1206
14193	1218
14193	1232
14194	1183
14194	1188
14194	1206
14194	1218
14194	1232
14195	1183
14195	1188
14195	1198
14195	1205
14195	1218
14196	1183
14196	1188
14196	1206
14196	1221
14196	1232
14197	1183
14197	1188
14197	1198
14197	1218
14197	1233
14198	1183
14198	1188
14198	1200
14198	1218
14198	1233
14199	1183
14199	1188
14199	1198
14199	1204
14199	1218
14200	1183
14200	1188
14200	1206
14200	1218
14200	1232
14201	1183
14201	1188
14201	1204
14201	1218
14201	1232
14202	1183
14202	1188
14202	1218
14202	1232
14202	1233
14203	1183
14203	1188
14203	1206
14203	1232
14203	45145
14204	1183
14204	1188
14204	1205
14204	1218
14204	1232
14205	1183
14205	1188
14205	1206
14205	1217
14205	1232
14206	1183
14206	1188
14206	1204
14206	1218
14206	1232
14207	1183
14207	1188
14207	1198
14207	1204
14207	1218
14208	1183
14208	1188
14208	1206
14208	1218
14208	1232
14209	1183
14209	1188
14209	1200
14209	1206
14209	1218
14210	1183
14210	1188
14210	1200
14210	1206
14210	44983
14211	1183
14211	1188
14211	1206
14211	1218
14211	1232
14212	1183
14212	1188
14212	1200
14212	1206
14212	45168
14213	1183
14213	1188
14213	1206
14213	1232
14213	44971
14214	1183
14214	1188
14214	1206
14214	1218
14214	1232
14215	1183
14215	1188
14215	1206
14215	1218
14215	1232
14216	1183
14216	1188
14216	1205
14216	1218
14216	1232
14217	1183
14217	1188
14217	1204
14217	1232
14217	1277
14218	1183
14218	1188
14218	1198
14218	1218
14218	1233
14219	1183
14219	1188
14219	1206
14219	1217
14219	1232
14220	1183
14220	1188
14220	1198
14220	1204
14220	1218
14221	1183
14221	1188
14221	1206
14221	1218
14221	1232
14222	1183
14222	1188
14222	1206
14222	1232
14222	45155
14223	1183
14223	1188
14223	1218
14223	1232
14223	1233
14224	1183
14224	1188
14224	1204
14224	1232
14224	1277
14225	1183
14225	1188
14225	1204
14225	1232
14225	1277
14226	1183
14226	1188
14226	1218
14226	1232
14226	1233
14227	1183
14227	1188
14227	1218
14227	1232
14227	1233
14228	1183
14228	1188
14228	1197
14228	1201
14228	1218
14229	1183
14229	1188
14229	1206
14229	1218
14229	1229
14230	1183
14230	1188
14230	1218
14230	1232
14230	1233
14231	1183
14231	1188
14231	1218
14231	1232
14231	1233
14232	1183
14232	1188
14232	1232
14232	1233
14232	45134
14233	1183
14233	1188
14233	1204
14233	1218
14233	1232
14235	1183
14235	1188
14235	1204
14235	1218
14235	1232
14236	1183
14236	1188
14236	1198
14236	1218
14236	1233
14237	1183
14237	1198
14237	1218
14237	1233
14237	1239
14238	1183
14238	1188
14238	1218
14238	1232
14238	1233
14239	1183
14239	1188
14239	1218
14239	1232
14239	1233
14240	1183
14240	1188
14240	1206
14240	1218
14240	1232
14241	1183
14241	1188
14241	1218
14241	1232
14241	1233
14242	1183
14242	1188
14242	1198
14242	1206
14242	1218
14243	1183
14243	1188
14243	1205
14243	1218
14243	1229
14244	1183
14244	1188
14244	1198
14244	1204
14244	1218
14246	1183
14246	1188
14246	1218
14246	1232
14246	1233
14246	44974
14248	1183
14248	1188
14248	1198
14248	1218
14248	1233
14249	1183
14249	1188
14249	1218
14249	1232
14249	1233
14250	1183
14250	1188
14250	1198
14250	1205
14250	1210
14251	1183
14251	1188
14251	1200
14251	1204
14251	1218
14252	1183
14252	1188
14252	1232
14252	1233
14252	44979
14253	1183
14253	1188
14253	1198
14253	1218
14253	1233
14254	1183
14254	1188
14254	1206
14254	1218
14254	1229
14255	1183
14255	1188
14255	1206
14255	1218
14255	1229
14256	1183
14256	1188
14256	1218
14256	1232
14256	1233
14257	1183
14257	1188
14257	1198
14257	1218
14257	1233
14258	1183
14258	1188
14258	1198
14258	1206
14258	1218
14259	1183
14259	1188
14259	1198
14259	1206
14259	1221
14260	1183
14260	1188
14260	1206
14260	1217
14260	1232
14261	1183
14261	1188
14261	1198
14261	1218
14261	1233
14262	1183
14262	1188
14262	1232
14262	1233
14262	44984
14263	1183
14263	1188
14263	1198
14263	1206
14263	1210
14264	1183
14264	1188
14264	1218
14264	1232
14264	1233
14265	1183
14265	1188
14265	1198
14265	1218
14265	1233
14266	1183
14266	1218
14266	1232
14266	1233
14266	1239
14267	1183
14267	1188
14267	1206
14267	1232
14267	44971
14268	1183
14268	1188
14268	1204
14268	1218
14268	1232
14269	1183
14269	1188
14269	1200
14269	1218
14269	1233
14270	1183
14270	1188
14270	1198
14270	1218
14270	1233
14271	1183
14271	1188
14271	1217
14271	1229
14271	1233
14272	1183
14272	1188
14272	1198
14272	1233
14272	44977
14273	1183
14273	1191
14273	1206
14273	1232
14273	44971
14274	1183
14274	1188
14274	1205
14274	1218
14274	1232
14275	1183
14275	1188
14275	1206
14275	1218
14275	1232
14276	1183
14276	1188
14276	1218
14276	1232
14276	1233
14277	1183
14277	1188
14277	1218
14277	1229
14277	1233
14278	1183
14278	1188
14278	1198
14278	1218
14278	1233
14279	1183
14279	1188
14279	1206
14279	1229
14279	1243
14280	1183
14280	1188
14280	1211
14280	1232
14280	1233
14281	1183
14281	1188
14281	1206
14281	1218
14281	1232
14282	1183
14282	1188
14282	1197
14282	1201
14282	45151
14283	1183
14283	1188
14283	1204
14283	1218
14283	1232
14284	1183
14284	1188
14284	1218
14284	1232
14284	1233
14285	1183
14285	1188
14285	1206
14285	1218
14285	1232
14286	1183
14286	1192
14286	1200
14286	1205
14286	1243
14287	1183
14287	1188
14287	1206
14287	1217
14287	1232
14288	1183
14288	1188
14288	1206
14288	1218
14288	1232
14289	1183
14289	1192
14289	1200
14289	1206
14289	1218
14290	1183
14290	1188
14290	1206
14290	1218
14290	1232
14291	1183
14291	1188
14291	1206
14291	1218
14291	1232
14292	1183
14292	1188
14292	1206
14292	1218
14292	1232
14294	1183
14294	1188
14294	1218
14294	1232
14294	1233
14295	1183
14295	1188
14295	1218
14295	1232
14295	1233
14296	1183
14296	1188
14296	1218
14296	1232
14296	1233
14297	1183
14297	1188
14297	1198
14297	1204
14297	1218
14298	1183
14298	1188
14298	1206
14298	1217
14298	1232
14299	1183
14299	1188
14299	1198
14299	1218
14299	1233
14300	1183
14300	1188
14300	1218
14300	1232
14300	1233
14301	1183
14301	1188
14301	1198
14301	1204
14301	1218
14302	1183
14302	1188
14302	1218
14302	1232
14302	1233
14303	1183
14303	1218
14303	1232
14303	1233
14303	1239
14304	1183
14304	1188
14304	1232
14304	1233
14304	44968
14305	1183
14305	1188
14305	1218
14305	1232
14305	1233
14306	1183
14306	1188
14306	1204
14306	1218
14306	1232
14307	1183
14307	1188
14307	1206
14307	1218
14307	1232
14308	1183
14308	1188
14308	1218
14308	1232
14308	1233
14310	1183
14310	1188
14310	1206
14310	1232
14310	44983
14311	1183
14311	1188
14311	1206
14311	1232
14311	44974
14312	1188
14312	1205
14312	1218
14312	1232
14312	45238
14314	1183
14314	1188
14314	1198
14314	1205
14314	1213
14315	1183
14315	1188
14315	1200
14315	1206
14315	1218
14316	1183
14316	1188
14316	1218
14316	1232
14316	1233
14317	1183
14317	1188
14317	1204
14317	1232
14317	45339
14318	1183
14318	1188
14318	1200
14318	1218
14318	1233
14319	1183
14319	1188
14319	1206
14319	1218
14319	1232
14320	1183
14320	1188
14320	1198
14320	1204
14320	1218
14321	1183
14321	1188
14321	1206
14321	1218
14321	1232
14322	1183
14322	1188
14322	1232
14322	1233
14322	44974
14323	1183
14323	1188
14323	1218
14323	1232
14323	1233
14324	1183
14324	1188
14324	1200
14324	1206
14324	45023
14325	1183
14325	1188
14325	1205
14325	1218
14325	1232
14326	1183
14326	1188
14326	1206
14326	1232
14326	45183
14327	1183
14327	1188
14327	1206
14327	1218
14327	1232
14328	1183
14328	1188
14328	1205
14328	1217
14328	1232
14329	1183
14329	1188
14329	1206
14329	1218
14329	1232
14330	1183
14330	1188
14330	1206
14330	1218
14330	1232
14331	1183
14331	1188
14331	1206
14331	1218
14331	1232
14332	1183
14332	1188
14332	1206
14332	1218
14332	1232
14333	1183
14333	1188
14333	1206
14333	1232
14333	44971
14334	1183
14334	1188
14334	1204
14334	1218
14334	1232
14335	1183
14335	1188
14335	1206
14335	1232
14335	44968
14336	1183
14336	1188
14336	1206
14336	1217
14336	1232
14337	1183
14337	1188
14337	1206
14337	1218
14337	1232
14338	1183
14338	1188
14338	1206
14338	1218
14338	1232
14339	1183
14339	1188
14339	1206
14339	1218
14339	1232
14340	1183
14340	1188
14340	1204
14340	1218
14340	1232
14341	1183
14341	1188
14341	1206
14341	1218
14341	1232
14342	1188
14342	1205
14342	1218
14342	1232
14342	45238
14343	1183
14343	1188
14343	1206
14343	1218
14343	1232
14344	1183
14344	1188
14344	1232
14344	1233
14344	44968
14345	1183
14345	1188
14345	1205
14345	1218
14345	1232
14346	1183
14346	1188
14346	1217
14346	1232
14346	1233
14347	1183
14347	1188
14347	1200
14347	1206
14347	45399
14348	1183
14348	1188
14348	1200
14348	1206
14348	1218
14349	1183
14349	1188
14349	1206
14349	1218
14349	1232
14350	1183
14350	1188
14350	1206
14350	1218
14350	1232
14351	1183
14351	1188
14351	1207
14351	1218
14351	1232
14352	1183
14352	1188
14352	1198
14352	1218
14352	1233
14353	1183
14353	1188
14353	1206
14353	1218
14353	1229
14354	1183
14354	1188
14354	1206
14354	1218
14354	1229
14355	1183
14355	1188
14355	1218
14355	1229
14355	1233
14356	1183
14356	1188
14356	1198
14356	1204
14356	1218
14357	1183
14357	1188
14357	1204
14357	1218
14357	1232
14358	1183
14358	1188
14358	1218
14358	1232
14358	1233
14359	1183
14359	1188
14359	1205
14359	1218
14359	1232
14360	1183
14360	1188
14360	1217
14360	1232
14360	1233
14361	1183
14361	1188
14361	1217
14361	1232
14361	1233
14362	1183
14362	1188
14362	1198
14362	1204
14362	1218
14363	1183
14363	1188
14363	1200
14363	1206
14363	1218
14364	1183
14364	1188
14364	1232
14364	1233
14364	44974
14365	1183
14365	1188
14365	1218
14365	1229
14365	1233
14366	1183
14366	1188
14366	1218
14366	1232
14366	1233
14367	1183
14367	1188
14367	1218
14367	1232
14367	1233
14368	1183
14368	1188
14368	1206
14368	1218
14368	1232
14369	1183
14369	1188
14369	1204
14369	1218
14369	1232
14370	1183
14370	1188
14370	1204
14370	1232
14370	44974
14371	1183
14371	1188
14371	1204
14371	1218
14371	1232
14372	1183
14372	1188
14372	1205
14372	1232
14372	44968
14373	1183
14373	1188
14373	1218
14373	1232
14373	1233
14374	1183
14374	1188
14374	1204
14374	1232
14374	44974
14375	1183
14375	1188
14375	1206
14375	1232
14375	44968
14376	1183
14376	1188
14376	1204
14376	1232
14376	45134
14377	1183
14377	1188
14377	1200
14377	1218
14377	1233
14378	1183
14378	1188
14378	1204
14378	1218
14378	1232
14379	1183
14379	1188
14379	1218
14379	1232
14379	1233
14380	1183
14380	1188
14380	1204
14380	1217
14380	1232
14381	1183
14381	1188
14381	1232
14381	1233
14381	44974
14382	1183
14382	1188
14382	1206
14382	1232
14382	45128
14383	1183
14383	1188
14383	1200
14383	1206
14383	1218
14384	1183
14384	1188
14384	1200
14384	1233
14384	1247
14385	1183
14385	1188
14385	1218
14385	1232
14385	1233
14386	1183
14386	1188
14386	1218
14386	1232
14386	1233
14387	1183
14387	1188
14387	1198
14387	1205
14387	1218
14388	1183
14388	1188
14388	1198
14388	1205
14388	1218
14389	1183
14389	1188
14389	1200
14389	1233
14389	44974
14390	1183
14390	1188
14390	1204
14390	1218
14390	1232
14391	1183
14391	1188
14391	1218
14391	1232
14391	1233
14392	1183
14392	1188
14392	1206
14392	1232
14392	44971
14393	1183
14393	1188
14393	1206
14393	1232
14393	45162
14394	1183
14394	1188
14394	1218
14394	1232
14394	1233
14395	1183
14395	1188
14395	1206
14395	1217
14395	1232
14396	1183
14396	1188
14396	1206
14396	1217
14396	1232
14397	1183
14397	1188
14397	1217
14397	1232
14397	1233
14398	1183
14398	1188
14398	1206
14398	1218
14398	1232
14399	1183
14399	1188
14399	1200
14399	1204
14399	1218
14400	1183
14400	1188
14400	1232
14400	1233
14400	44974
14401	1183
14401	1188
14401	1204
14401	1218
14401	1232
14403	1183
14403	1188
14403	1206
14403	1217
14403	1232
14405	1183
14405	1188
14405	1210
14405	1232
14405	1233
14406	1183
14406	1188
14406	1206
14406	1218
14406	1232
14407	1183
14407	1188
14407	1218
14407	1232
14407	1233
14408	1183
14408	1188
14408	1200
14408	1206
14408	1218
14410	1183
14410	1188
14410	1218
14410	1232
14410	1233
14411	1183
14411	1188
14411	1200
14411	1233
14411	1243
14412	1183
14412	1188
14412	1218
14412	1232
14412	1233
14413	1183
14413	1188
14413	1218
14413	1232
14413	1233
14414	1183
14414	1188
14414	1200
14414	1218
14414	1233
14415	1183
14415	1188
14415	1218
14415	1232
14415	1233
14416	1183
14416	1188
14416	1218
14416	1232
14416	1233
14417	1183
14417	1188
14417	1232
14417	1233
14417	1262
14418	1183
14418	1188
14418	1218
14418	1232
14418	1233
14419	1183
14419	1188
14419	1204
14419	1217
14419	1232
14420	1183
14420	1188
14420	1204
14420	1218
14420	1232
14421	1183
14421	1188
14421	1204
14421	1218
14421	1232
14422	1183
14422	1188
14422	1204
14422	1218
14422	1232
14423	1183
14423	1188
14423	1232
14423	1233
14423	44968
14424	1183
14424	1188
14424	1218
14424	1232
14424	1233
14425	1183
14425	1188
14425	1217
14425	1232
14425	1233
14426	1183
14426	1188
14426	1200
14426	1218
14426	1233
14427	1183
14427	1188
14427	1206
14427	1221
14427	1232
14428	1183
14428	1188
14428	1200
14428	1218
14428	1233
14429	1183
14429	1188
14429	1232
14429	1233
14429	45161
14430	1183
14430	1188
14430	1200
14430	1218
14430	1233
14431	1183
14431	1188
14431	1204
14431	1222
14431	1232
14432	1183
14432	1188
14432	1206
14432	1232
14432	45153
14433	1183
14433	1188
14433	1198
14433	1204
14433	44968
14434	1183
14434	1188
14434	1206
14434	1218
14434	1232
14436	1183
14436	1198
14436	1206
14436	1218
14436	1239
14437	1183
14437	1188
14437	1222
14437	1232
14437	1233
14438	1183
14438	1188
14438	1218
14438	1232
14438	1233
14439	1183
14439	1188
14439	1206
14439	1218
14439	1232
14440	1183
14440	1188
14440	1200
14440	1218
14440	1233
14441	1183
14441	1188
14441	1204
14441	1218
14441	1232
14442	1183
14442	1188
14442	1218
14442	1232
14442	1233
14443	1183
14443	1188
14443	1204
14443	1218
14443	1232
14444	1183
14444	1188
14444	1206
14444	1218
14444	1232
14445	1183
14445	1188
14445	1218
14445	1232
14445	1233
14446	1183
14446	1188
14446	1206
14446	1218
14446	1232
14447	1183
14447	1188
14447	1206
14447	1232
14447	44971
14449	1183
14449	1188
14449	1232
14449	1233
14449	44970
14450	1183
14450	1188
14450	1206
14450	1218
14450	1232
14451	1183
14451	1188
14451	1206
14451	1218
14451	1232
14452	1183
14452	1188
14452	1206
14452	1218
14452	1232
14453	1183
14453	1188
14453	1198
14453	1204
14453	44974
14454	1183
14454	1188
14454	1218
14454	1232
14454	1233
14455	1183
14455	1188
14455	1206
14455	1221
14455	1232
14456	1183
14456	1188
14456	1198
14456	1204
14456	44974
14457	1183
14457	1188
14457	1198
14457	1205
14457	1221
14458	1183
14458	1188
14458	1206
14458	1218
14458	1232
14459	1183
14459	1188
14459	1198
14459	1218
14459	1233
14460	1183
14460	1188
14460	1206
14460	1217
14460	1232
14461	1183
14461	1188
14461	1218
14461	1232
14461	1233
14462	1183
14462	1188
14462	1206
14462	1229
14462	44968
14463	1183
14463	1188
14463	1198
14463	1204
14463	1218
14464	1183
14464	1188
14464	1206
14464	1221
14464	1232
14465	1183
14465	1188
14465	1218
14465	1232
14465	1233
14466	1183
14466	1188
14466	1206
14466	1218
14466	1232
14467	1183
14467	1188
14467	1218
14467	1232
14467	1233
14468	1183
14468	1188
14468	1206
14468	1221
14468	1232
14469	1183
14469	1188
14469	1206
14469	1218
14469	1232
14470	1183
14470	1188
14470	1232
14470	1233
14470	45138
14471	1183
14471	1188
14471	1207
14471	1220
14471	1232
14472	1183
14472	1188
14472	1218
14472	1232
14472	1233
14473	1183
14473	1188
14473	1205
14473	1218
14473	1232
14474	1183
14474	1188
14474	1198
14474	1206
14474	1218
14474	1232
14474	1233
14475	1183
14475	1188
14475	1198
14475	1204
14475	1218
14476	1183
14476	1188
14476	1206
14476	1218
14476	1229
14477	1183
14477	1188
14477	1206
14477	1218
14477	1232
14478	1183
14478	1188
14478	1198
14478	1204
14478	44971
14479	1183
14479	1188
14479	1204
14479	1218
14479	1232
14480	1183
14480	1188
14480	1218
14480	1232
14480	1233
14481	1183
14481	1188
14481	1218
14481	1232
14481	1233
14482	1183
14482	1188
14482	1218
14482	1232
14482	1233
14483	1183
14483	1188
14483	1204
14483	1218
14483	1229
14484	1183
14484	1188
14484	1206
14484	1218
14484	1229
14485	1183
14485	1188
14485	1206
14485	1222
14485	1232
14486	1183
14486	1188
14486	1206
14486	1218
14486	1232
14487	1183
14487	1188
14487	1232
14487	1233
14487	44971
14488	1183
14488	1188
14488	1232
14488	1233
14488	44971
14489	1183
14489	1188
14489	1200
14489	1206
14489	1218
14490	1183
14490	1188
14490	1205
14490	1213
14490	1232
14491	1183
14491	1188
14491	1206
14491	1218
14491	1232
14492	1183
14492	1188
14492	1198
14492	1218
14492	1232
14492	1233
14492	44968
14494	1183
14494	1188
14494	1200
14494	1206
14494	1218
14495	1183
14495	1188
14495	1198
14495	1218
14495	1233
14496	1183
14496	1188
14496	1204
14496	1232
14496	45435
14497	1183
14497	1188
14497	1218
14497	1232
14497	1233
14498	1183
14498	1188
14498	1198
14498	1204
14498	1218
14499	1183
14499	1188
14499	1218
14499	1232
14499	1233
14500	1183
14500	1188
14500	1218
14500	1229
14500	1233
14501	1183
14501	1188
14501	1206
14501	1218
14501	1232
14502	1183
14502	1188
14502	1206
14502	1218
14502	1232
14503	1183
14503	1188
14503	1218
14503	1232
14503	1233
14504	1183
14504	1188
14504	1206
14504	1218
14504	1232
14505	1183
14505	1188
14505	1206
14505	1232
14505	1277
14506	1183
14506	1188
14506	1218
14506	1232
14506	1233
14507	1183
14507	1188
14507	1218
14507	1232
14507	1233
14508	1183
14508	1188
14508	1218
14508	1232
14508	1233
14509	1183
14509	1188
14509	1218
14509	1232
14509	1233
14510	1183
14510	1188
14510	1206
14510	1218
14510	1229
14512	1183
14512	1188
14512	1210
14512	1232
14512	1233
14513	1183
14513	1188
14513	1218
14513	1232
14513	1233
14514	1183
14514	1188
14514	1218
14514	1232
14514	1233
14515	1183
14515	1188
14515	1218
14515	1232
14515	1233
14516	1183
14516	1188
14516	1198
14516	1204
14516	1218
14518	1183
14518	1188
14518	1204
14518	1218
14518	1232
14519	1183
14519	1188
14519	1204
14519	1218
14519	1232
14520	1183
14520	1188
14520	1204
14520	1218
14520	1232
14521	1183
14521	1188
14521	1206
14521	1218
14521	1232
14523	1183
14523	1188
14523	1200
14523	1206
14523	44986
14524	1183
14524	1188
14524	1218
14524	1232
14524	1233
14525	1183
14525	1194
14525	1222
14525	1232
14525	1233
14526	1183
14526	1194
14526	1204
14526	1218
14526	1232
14527	1183
14527	1194
14527	1222
14527	1232
14527	1233
14528	1183
14528	1188
14528	1198
14528	1206
14528	1218
14529	1183
14529	1188
14529	1200
14529	1206
14529	1218
14530	1183
14530	1194
14530	1218
14530	1232
14530	1233
14531	1183
14531	1188
14531	1218
14531	1232
14531	1233
14532	1183
14532	1196
14532	1222
14532	1232
14532	1233
14533	1188
14533	1218
14533	1232
14533	1233
14533	45238
14534	1183
14534	1194
14534	1206
14534	1218
14534	1229
14535	1183
14535	1194
14535	1217
14535	1232
14535	1233
14536	1183
14536	1194
14536	1200
14536	1206
14536	45134
14538	1183
14538	1188
14538	1206
14538	1218
14538	1232
14539	1195
14539	1206
14539	1232
14539	45236
14539	45546
14540	1183
14540	1188
14540	1200
14540	1206
14540	1218
14541	1183
14541	1188
14541	1218
14541	1232
14541	1233
14542	1183
14542	1188
14542	1198
14542	1218
14542	1233
14543	1183
14543	1188
14543	1206
14543	1218
14543	1229
14547	1183
14547	1194
14547	1218
14547	1232
14547	1233
14549	1183
14549	1194
14549	1218
14549	1229
14549	1233
14550	1183
14550	1188
14550	1200
14550	1218
14550	1233
14552	1188
14552	1206
14552	1218
14552	1232
14552	45238
14553	1183
14553	1194
14553	1200
14553	1206
14553	1218
14555	1183
14555	1188
14555	1206
14555	1218
14555	1229
14557	1183
14557	1188
14557	1206
14557	1232
14557	45181
14559	1183
14559	1188
14559	1206
14559	1218
14559	1229
14560	1183
14560	1188
14560	1206
14560	1218
14560	1232
14561	1183
14561	1188
14561	1200
14561	1206
14561	1218
14567	1183
14567	1194
14567	1206
14567	1218
14567	1229
14568	1183
14568	1188
14568	1198
14568	1233
14568	1247
14569	1183
14569	1188
14569	1218
14569	1232
14569	1233
14573	1183
14573	1194
14573	1232
14573	1233
14573	1271
14574	1183
14574	1190
14574	1200
14574	1206
14575	1183
14575	1188
14575	1200
14575	1206
14575	1218
14577	1188
14577	1200
14577	1206
14577	1218
14577	45238
14581	1183
14581	1188
14581	1205
14581	1218
14581	1232
14582	1183
14582	1188
14582	1200
14582	1206
14582	45543
14584	1183
14584	1188
14584	1218
14584	1232
14584	1233
14586	1183
14586	1188
14586	1218
14586	1232
14586	1233
14594	1188
14594	1199
14594	1204
14594	1218
14594	45236
14595	1183
14595	1188
14595	1198
14595	1206
14595	1218
14596	1183
14596	1188
14596	1198
14596	1206
14596	45548
14597	1183
14597	1194
14597	1198
14597	1206
14597	1222
14598	1183
14598	1188
14598	1198
14598	1206
14598	1222
14599	1183
14599	1188
14599	1198
14599	1206
14599	1218
14602	1183
14602	1188
14602	1198
14602	1206
14602	1218
14604	1183
14604	1188
14604	1198
14604	1206
14604	1218
14605	1183
14605	1188
14605	1198
14605	1206
14605	1218
14606	1183
14606	1188
14606	1200
14606	1206
14606	1218
14607	1183
14607	1194
14607	1218
14607	1232
14607	1233
14608	1183
14608	1194
14608	1198
14608	1206
14608	1218
14609	1183
14609	1188
14609	1200
14609	1206
14609	1218
14610	1183
14610	1194
14610	1198
14610	1206
14610	1218
14611	1183
14611	1194
14611	1222
14611	1232
14611	1233
14614	1179
14614	1188
14614	1197
14614	1201
14614	1218
14615	1183
14615	1194
14615	1200
14615	1206
14615	1218
14616	1183
14616	1194
14616	1218
14616	1232
14616	1233
14617	1183
14617	1194
14617	1218
14617	1232
14617	1233
14618	1183
14618	1188
14618	1198
14618	1206
14618	1218
14619	1183
14619	1194
14619	1200
14619	1206
14619	1218
14620	1183
14620	1194
14620	1218
14620	1232
14620	1233
14621	1183
14621	1188
14621	1198
14621	1206
14621	1218
14622	1183
14622	1194
14622	1206
14622	1217
14622	1229
14623	1183
14623	1194
14623	1206
14623	1218
14623	1229
14624	1183
14624	1188
14624	1200
14624	1206
14624	1218
14625	1183
14625	1194
14625	1198
14625	1206
14625	1218
14626	1183
14626	1188
14626	1198
14626	1206
14626	1218
14627	1183
14627	1194
14627	1200
14627	1206
14627	1218
14628	1183
14628	1188
14628	1200
14628	1206
14628	1222
14629	1183
14629	1188
14629	1218
14629	1232
14629	1233
14631	1183
14631	1194
14631	1218
14631	1232
14631	1233
14632	1183
14632	1188
14632	1203
14632	1218
14632	1232
14642	1183
14642	1188
14642	1218
14642	1232
14642	1233
14643	1183
14643	1194
14643	1206
14643	1218
14643	1229
14644	1183
14644	1188
14644	1218
14644	1232
14644	1233
14645	1183
14645	1194
14645	1198
14645	1206
14645	1218
14648	1183
14648	1188
14648	1232
14648	1233
14648	44971
14658	1183
14658	1188
14658	1218
14658	1232
14658	1233
14660	1183
14660	1188
14660	1232
14660	1233
14660	45595
14661	1183
14661	1188
14661	1194
14661	1200
14661	1206
14661	1218
14661	1221
14661	1232
14664	1183
14664	1188
14664	1218
14664	1232
14664	1233
14665	1183
14665	1188
14665	1206
14665	1218
14665	1232
14666	1183
14666	1188
14666	1206
14666	1218
14666	1232
14667	1183
14667	1188
14667	1204
14667	1218
14667	1232
14672	1183
14672	1188
14672	1206
14672	1218
14672	1232
14676	1183
14676	1188
14676	1206
14676	1218
14676	1232
14677	1183
14677	1188
14677	1206
14677	1218
14677	1232
14678	1183
14678	1188
14678	1206
14678	1218
14678	1232
14681	1183
14681	1188
14681	1206
14681	1229
14681	1247
14682	1183
14682	1188
14682	1206
14682	1218
14682	1232
14683	1180
14683	1188
14683	1197
14683	1201
14683	1218
14687	1183
14687	1188
14687	1218
14687	1232
14687	1233
14689	1183
14689	1188
14689	1218
14689	1232
14689	1233
14690	1183
14690	1188
14690	1218
14690	1232
14690	1233
14691	1183
14691	1188
14691	1205
14691	1232
14691	45048
14692	1183
14692	1188
14692	1206
14692	1218
14692	1232
14693	1183
14693	1188
14693	1206
14693	1218
14693	1232
14694	1183
14694	1188
14694	1206
14694	1217
14694	1232
14696	1183
14696	1188
14696	1204
14696	1218
14696	1232
14698	1183
14698	1188
14698	1232
14698	1233
14698	45096
14699	1183
14699	1188
14699	1206
14699	1218
14699	1232
14705	1183
14705	1188
14705	1232
14705	1233
14705	44974
14706	1183
14706	1188
14706	1204
14706	1222
14706	1232
14709	1183
14709	1188
14709	1206
14709	1217
14709	1232
14713	1183
14713	1188
14713	1206
14713	1218
14713	1232
14714	1183
14714	1188
14714	1206
14714	1218
14714	1232
14716	1183
14716	1188
14716	1218
14716	1232
14716	1233
14717	1183
14717	1188
14717	1200
14717	1206
14717	1213
14718	1183
14718	1188
14718	1204
14718	1218
14718	1232
14719	1183
14719	1188
14719	1206
14719	1218
14719	1232
14720	1183
14720	1188
14720	1206
14720	1218
14720	1232
14724	1183
14724	1188
14724	1200
14724	1206
14724	1218
14727	1183
14727	1188
14727	1232
14727	1233
14727	44974
14728	1183
14728	1188
14728	1206
14728	1217
14728	1232
14729	1183
14729	1188
14729	1206
14729	1232
14729	1262
14730	1183
14730	1188
14730	1205
14730	1218
14730	1232
14731	1183
14731	1188
14731	1205
14731	1218
14731	1232
14732	1183
14732	1188
14732	1206
14732	1232
14732	45575
14735	1183
14735	1188
14735	1218
14735	1232
14735	1233
14737	1183
14737	1188
14737	1206
14737	1217
14737	1232
14738	1183
14738	1188
14738	1198
14738	1204
14738	44974
14739	1183
14739	1188
14739	1200
14739	1205
14739	1218
14740	1183
14740	1188
14740	1206
14740	1218
14740	1232
14743	1183
14743	1188
14743	1206
14743	1218
14743	1232
14745	1183
14745	1188
14745	1205
14745	1209
14745	1232
14746	1183
14746	1188
14746	1218
14746	1232
14746	1233
14747	1183
14747	1188
14747	1218
14747	1232
14747	1233
14748	1183
14748	1188
14748	1218
14748	1232
14748	1233
14750	1183
14750	1188
14750	1217
14750	1232
14750	1233
14753	1183
14753	1188
14753	1218
14753	1232
14753	1233
14758	1183
14758	1188
14758	1206
14758	1232
14758	44974
14759	1183
14759	1188
14759	1206
14759	1218
14759	1232
14763	1183
14763	1188
14763	1206
14763	1232
14763	45575
14765	1183
14765	1188
14765	1206
14765	1232
14765	45575
14767	1183
14767	1188
14767	1206
14767	1232
14767	45181
14772	1183
14772	1188
14772	1206
14772	1232
14772	44983
14775	1183
14775	1188
14775	1206
14775	1218
14775	1232
14778	1183
14778	1188
14778	1206
14778	1218
14778	1232
14779	1183
14779	1190
14779	1198
14779	1205
14779	45204
14781	1183
14781	1188
14781	1204
14781	1218
14781	1232
14782	1183
14782	1188
14782	1206
14782	1218
14782	1232
14785	1183
14785	1190
14785	1206
14785	1218
14785	1232
14787	1183
14787	1188
14787	1232
14787	1233
14787	45128
14791	1188
14791	1206
14791	1218
14791	1232
14791	45238
14792	1183
14792	1188
14792	1221
14792	1232
14792	1233
14799	1183
14799	1188
14799	1206
14799	1232
14799	44974
14801	1183
14801	1188
14801	1204
14801	1218
14801	1232
14805	1183
14805	1205
14805	1218
14805	1232
14805	1239
14806	1183
14806	1188
14806	1205
14806	1218
14806	1232
14815	1183
14815	1188
14815	1221
14815	1232
14815	1233
14816	1183
14816	1188
14816	1206
14816	1217
14816	1232
14818	1183
14818	1188
14818	1206
14818	1213
14818	1232
14820	1183
14820	1188
14820	1206
14820	1218
14820	1229
14821	1183
14821	1188
14821	1218
14821	1232
14821	1233
14824	1183
14824	1188
14824	1232
14824	1233
14824	44974
14826	1183
14826	1188
14826	1218
14826	1232
14826	1233
14827	1183
14827	1188
14827	1232
14827	1233
14827	45019
14829	1183
14829	1188
14829	1198
14829	1206
14829	1218
14833	1183
14833	1188
14833	1204
14833	1218
14833	1232
14838	1183
14838	1194
14838	1206
14838	1218
14838	1229
14845	1183
14845	1194
14845	1218
14845	1232
14845	1233
14848	1183
14848	1194
14848	1200
14848	1206
14848	1218
14849	1183
14849	1188
14849	1206
14849	1218
14849	1229
14850	1183
14850	1194
14850	1218
14850	1232
14850	1233
14852	1188
14852	1218
14852	1232
14852	1233
14852	45238
14853	1183
14853	1188
14853	1200
14853	1206
14853	1218
14855	1183
14855	1188
14855	1218
14855	1232
14855	1233
14856	1183
14856	1188
14856	1204
14856	1218
14856	1232
14857	1183
14857	1188
14857	1198
14857	1206
14857	1218
14863	1183
14863	1188
14863	1218
14863	1232
14863	1233
14867	1183
14867	1194
14867	1200
14867	1206
14867	1218
14877	1183
14877	1194
14877	1200
14877	1206
14877	1218
14878	1183
14878	1196
14878	1206
14878	1218
14878	1229
14879	1183
14879	1188
14879	1206
14879	1218
14879	1232
14880	1183
14880	1188
14880	1206
14880	1218
14880	1232
14882	1183
14882	1188
14882	1194
14882	1218
14882	1232
14882	1233
14882	45236
14883	1183
14883	1188
14883	1200
14883	1206
14883	1218
14884	1183
14884	1188
14884	1218
14884	1232
14884	1233
14885	1183
14885	1188
14885	1200
14885	1206
14885	1218
14886	1183
14886	1188
14886	1218
14886	1232
14886	1233
14887	1183
14887	1194
14887	1206
14887	1217
14887	1229
14888	1183
14888	1188
14888	1200
14888	1206
14888	45436
14889	1183
14889	1194
14889	1222
14889	1232
14889	1233
14890	1183
14890	1188
14890	1200
14890	1206
14890	1222
14893	1183
14893	1188
14893	1206
14893	1218
14893	1229
14895	1183
14895	1194
14895	1206
14895	1218
14895	1229
14897	1183
14897	1188
14897	1218
14897	1232
14897	1233
14898	1183
14898	1188
14898	1198
14898	1206
14898	1218
14906	1183
14906	1188
14906	1218
14906	1232
14906	1233
14907	1179
14907	1188
14907	1197
14907	1201
14907	1218
14908	1183
14908	1188
14908	1198
14908	1204
14908	1218
14909	1183
14909	1196
14909	1200
14909	1206
14909	1218
14910	1183
14910	1194
14910	1200
14910	1206
14910	45543
14911	1183
14911	1194
14911	1198
14911	1206
14911	1218
14913	1183
14913	1188
14913	1198
14913	1206
14913	1218
14914	1183
14914	1188
14914	1206
14914	1218
14914	1229
14917	1183
14917	1188
14917	1218
14917	1232
14917	1233
14918	1183
14918	1188
14918	1200
14918	1206
14918	1218
14920	1183
14920	1188
14920	1222
14920	1232
14920	1233
14921	1183
14921	1188
14921	1200
14921	1206
14921	1218
14922	1183
14922	1194
14922	1222
14922	1232
14922	1233
14923	1183
14923	1188
14923	1199
14923	1231
14923	1233
14925	1183
14925	1188
14925	1204
14925	1218
14925	1232
14927	1183
14927	1188
14927	1198
14927	1206
14927	1218
14929	1183
14929	1188
14929	1198
14929	1206
14929	1218
14930	1183
14930	1188
14930	1205
14930	1218
14930	1232
14931	1183
14931	1188
14931	1232
14931	1233
14931	45019
14932	1183
14932	1188
14932	1218
14932	1232
14932	1233
14933	1183
14933	1188
14933	1206
14933	1232
14933	44983
14934	1183
14934	1188
14934	1204
14934	1218
14934	1232
14936	1183
14936	1188
14936	1198
14936	1206
14936	1218
14937	1183
14937	1188
14937	1198
14937	1206
14937	1218
14938	1183
14938	1188
14938	1218
14938	1232
14938	1233
14940	1183
14940	1188
14940	1218
14940	1232
14940	1233
14941	1183
14941	1188
14941	1200
14941	1206
14941	1218
14942	1183
14942	1188
14942	1198
14942	1200
14942	1206
14942	1218
14943	1183
14943	1188
14943	1198
14943	1206
14943	1218
14944	1183
14944	1188
14944	1206
14944	1209
14944	1229
14945	1183
14945	1188
14945	1206
14945	1218
14945	1229
14946	1183
14946	1188
14946	1204
14946	1232
14946	45134
14947	1183
14947	1188
14947	1218
14947	1232
14947	1233
14949	1183
14949	1193
14949	1200
14949	1204
14949	1218
14951	1183
14951	1188
14951	1206
14951	1218
14951	1229
14953	1183
14953	1188
14953	1204
14953	1218
14953	1232
14955	1183
14955	1188
14955	1206
14955	1218
14955	1229
14957	1183
14957	1188
14957	1218
14957	1232
14957	1233
14960	1183
14960	1188
14960	1200
14960	1206
14960	1218
14965	1183
14965	1188
14965	1218
14965	1232
14965	1233
14966	1183
14966	1188
14966	1198
14966	1218
14966	1233
14967	1183
14967	1188
14967	1206
14967	1218
14967	1232
14970	1183
14970	1188
14970	1205
14970	1222
14970	1232
14972	1183
14972	1194
14972	1218
14972	1232
14972	1233
14974	1183
14974	1188
14974	1198
14974	1218
14974	1233
14977	1183
14977	1194
14977	1206
14977	1218
14977	1229
14980	1183
14980	1188
14980	1206
14980	1217
14980	1229
14982	1183
14982	1188
14982	1200
14982	1206
14982	1218
14984	1183
14984	1188
14984	1218
14984	1232
14984	1233
14986	1183
14986	1188
14986	1206
14986	1217
14986	1232
14987	1183
14987	1194
14987	1204
14987	1218
14987	1229
14989	1188
14989	1218
14989	1232
14989	1233
14989	45238
14990	1183
14990	1194
14990	1204
14990	1218
14990	1232
14991	1183
14991	1194
14991	1200
14991	1206
14991	1218
14992	1183
14992	1188
14992	1218
14992	1232
14992	1233
14993	1183
14993	1188
14993	1218
14993	1232
14993	1233
14994	1183
14994	1194
14994	1218
14994	1232
14994	1233
14995	1188
14995	1206
14995	1218
14995	1232
14995	45236
14996	1183
14996	1194
14996	1218
14996	1232
14996	1233
14997	1183
14997	1194
14997	1200
14997	1206
14997	1218
14998	1183
14998	1194
14998	1232
14998	1233
14998	45567
14999	1183
14999	1188
14999	1218
14999	1232
14999	1233
15000	1183
15000	1194
15000	1218
15000	1232
15000	1233
15001	1183
15001	1188
15001	1200
15001	1206
15001	1218
15003	1183
15003	1188
15003	1206
15003	1218
15003	1229
15004	1183
15004	1188
15004	1206
15004	1218
15004	1229
15007	1188
15007	1198
15007	1204
15007	1218
15007	45236
15008	1183
15008	1194
15008	1218
15008	1232
15008	1233
15009	1183
15009	1188
15009	1206
15009	1221
15009	1229
15010	1183
15010	1188
15010	1206
15010	1218
15010	1229
15012	1183
15012	1188
15012	1198
15012	1206
15012	1218
15014	1182
15014	1188
15014	1198
15014	1206
15014	1218
15015	1182
15015	1188
15015	1198
15015	1206
15015	1218
15016	1183
15016	1188
15016	1206
15016	1218
15016	1229
15017	1183
15017	1188
15017	1218
15017	1232
15017	1233
15018	1183
15018	1188
15018	1198
15018	1206
15018	1218
15019	1183
15019	1188
15019	1206
15019	1222
15019	1229
15020	1188
15020	1218
15020	1232
15020	1233
15020	45238
15021	1183
15021	1188
15021	1218
15021	1232
15021	1233
15024	1183
15024	1188
15024	1218
15024	1232
15024	1233
15025	1183
15025	1194
15025	1218
15025	1232
15025	1233
15026	1183
15026	1188
15026	1198
15026	1206
15026	1210
15027	1183
15027	1188
15027	1218
15027	1232
15027	1233
15029	1183
15029	1188
15029	1198
15029	1206
15029	1218
15030	1183
15030	1188
15030	1210
15030	1229
15030	1233
15032	1188
15032	1204
15032	1218
15032	1232
15032	45236
15033	1183
15033	1188
15033	1218
15033	1232
15033	1233
15034	1183
15034	1188
15034	1218
15034	1232
15034	1233
15035	1183
15035	1194
15035	1222
15035	1232
15035	1233
15037	1183
15037	1188
15037	1198
15037	1206
15037	1218
15038	1188
15038	1206
15038	1218
15038	1229
15038	45238
15039	1183
15039	1188
15039	1218
15039	1232
15039	1233
15040	1183
15040	1188
15040	1198
15040	1210
15040	1233
15040	45548
15043	1188
15043	1200
15043	1206
15043	1218
15043	45238
15045	1183
15045	1196
15045	1204
15045	1218
15045	1232
15046	1188
15046	1205
15046	1218
15046	1238
15046	45236
15047	1188
15047	1199
15047	1204
15047	1218
15047	45236
15048	1183
15048	1188
15048	1204
15048	1205
15048	1218
15048	1232
15048	45236
15050	1183
15050	1193
15050	1204
15050	1232
15050	1243
15052	1183
15052	1188
15052	1200
15052	1204
15052	1218
15053	1183
15053	1198
15053	1206
15053	1218
15053	1239
15054	1188
15054	1204
15054	1218
15054	1232
15054	45238
15055	1183
15055	1188
15055	1199
15055	1203
15055	1218
15056	1183
15056	1188
15056	1194
15056	1205
15056	1218
15056	1232
15057	1183
15057	1188
15057	1204
15057	1218
15057	1232
15058	1188
15058	1204
15058	1218
15058	1232
15058	44936
15059	1188
15059	1204
15059	1221
15059	1232
15059	45236
15061	1188
15061	1204
15061	1218
15061	1232
15061	45238
15062	1183
15062	1188
15062	1218
15062	1232
15062	1233
15067	1183
15067	1194
15067	1203
15067	1218
15067	1232
15068	1183
15068	1188
15068	1199
15068	1203
15068	1218
15070	1183
15070	1188
15070	1204
15070	1218
15070	1232
15072	1183
15072	1194
15072	1199
15072	1204
15072	1218
15073	1183
15073	1188
15073	1232
15073	1233
15073	1244
15074	1188
15074	1204
15074	1218
15074	1232
15074	45238
15075	1188
15075	1204
15075	1218
15075	1232
15075	45238
15077	1183
15077	1194
15077	1200
15077	1206
15077	1218
15079	1183
15079	1188
15079	1200
15079	1233
15079	1243
15082	1183
15082	1188
15082	1206
15082	1221
15082	1232
15089	1183
15089	1188
15089	1205
15089	1232
15089	44974
15093	1183
15093	1188
15093	1204
15093	1218
15093	1232
15094	1183
15094	1188
15094	1232
15094	1233
15094	1247
15096	1183
15096	1188
15096	1204
15096	1218
15096	1232
15097	1183
15097	1188
15097	1198
15097	1204
15097	1218
15099	1183
15099	1188
15099	1206
15099	1218
15099	1232
15100	1183
15100	1188
15100	1206
15100	1218
15100	1232
15103	1183
15103	1188
15103	1218
15103	1232
15103	1233
15117	1183
15117	1188
15117	1206
15117	1218
15117	1232
15122	1183
15122	1188
15122	1206
15122	1232
15122	45062
15123	1183
15123	1188
15123	1205
15123	1217
15123	1232
15127	1183
15127	1188
15127	1206
15127	1218
15127	1232
15128	1183
15128	1198
15128	1204
15128	1218
15128	1239
15130	1183
15130	1188
15130	1206
15130	1217
15130	1232
15135	1183
15135	1188
15135	1206
15135	1218
15135	1232
15139	1183
15139	1188
15139	1204
15139	1218
15139	1232
15141	1183
15141	1188
15141	1206
15141	1218
15141	1232
15142	1183
15142	1188
15142	1206
15142	1232
15142	44968
15145	1183
15145	1188
15145	1198
15145	1206
15145	1218
15146	1183
15146	1188
15146	1200
15146	1206
15146	44968
15147	1183
15147	1188
15147	1200
15147	1206
15147	1218
15155	1183
15155	1188
15155	1206
15155	1229
15155	44974
15156	1183
15156	1188
15156	1200
15156	1204
15156	1218
15159	1183
15159	1188
15159	1198
15159	1204
15159	1218
15160	1183
15160	1188
15160	1200
15160	1205
15160	1218
15161	1183
15161	1188
15161	1232
15161	1233
15161	44974
15164	1183
15164	1188
15164	1204
15164	1218
15164	1232
15169	1183
15169	1188
15169	1206
15169	1232
15169	45549
15170	1183
15170	1188
15170	1200
15170	1233
15170	44968
15172	1183
15172	1188
15172	1204
15172	1218
15172	1232
15173	1183
15173	1188
15173	1206
15173	1218
15173	1232
15174	1183
15174	1188
15174	1206
15174	1218
15174	1229
15175	1183
15175	1188
15175	1205
15175	1232
15175	45134
15184	1183
15184	1188
15184	1200
15184	1206
15184	1218
15189	1183
15189	1205
15189	1232
15189	1239
15189	44970
15190	1183
15190	1188
15190	1198
15190	1206
15190	1217
15191	1183
15191	1188
15191	1206
15191	1221
15191	1232
15193	1183
15193	1188
15193	1198
15193	1204
15193	1206
15193	45134
15194	1183
15194	1188
15194	1198
15194	1205
15194	1206
15194	1218
15196	1183
15196	1188
15196	1206
15196	1218
15196	1229
15200	1183
15200	1188
15200	1206
15200	1232
15200	45436
15201	1183
15201	1188
15201	1198
15201	1205
15201	1218
15202	1183
15202	1188
15202	1204
15202	1232
15202	45214
15204	1180
15204	1183
15204	1188
15204	1204
15204	1218
15204	1232
15205	1183
15205	1188
15205	1206
15205	1218
15205	1232
15208	1183
15208	1188
15208	1204
15208	1232
15208	44971
15209	1183
15209	1188
15209	1206
15209	1217
15209	1232
15210	1183
15210	1188
15210	1206
15210	1217
15210	1232
15217	1183
15217	1188
15217	1206
15217	1218
15217	1232
15220	1183
15220	1188
15220	1206
15220	1218
15220	1232
15221	1183
15221	1188
15221	1198
15221	1204
15221	44970
15221	45339
15222	1183
15222	1188
15222	1206
15222	1232
15222	44968
15223	1183
15223	1188
15223	1200
15223	1218
15223	1233
15225	1183
15225	1188
15225	1200
15225	1233
15225	44974
15227	1183
15227	1188
15227	1206
15227	1218
15227	1232
15230	1183
15230	1188
15230	1206
15230	1218
15230	1229
15231	1183
15231	1188
15231	1206
15231	1218
15231	1232
15235	1183
15235	1188
15235	1198
15235	1206
15235	1218
15238	1183
15238	1188
15238	1206
15238	1218
15238	1232
15240	1183
15240	1188
15240	1206
15240	1218
15240	1232
15241	1183
15241	1188
15241	1206
15241	1218
15241	1232
15243	1179
15243	1188
15243	1218
15243	1232
15243	1233
15244	1183
15244	1188
15244	1205
15244	1218
15244	1232
15246	1183
15246	1188
15246	1206
15246	1218
15246	1232
15250	1183
15250	1188
15250	1204
15250	1218
15250	1232
15251	1183
15251	1188
15251	1200
15251	1206
15251	44974
15253	1183
15253	1188
15253	1218
15253	1232
15253	1233
15254	1183
15254	1188
15254	1218
15254	1229
15254	1233
15255	1183
15255	1188
15255	1205
15255	1218
15255	1232
15259	1183
15259	1188
15259	1198
15259	1204
15259	1218
15260	1183
15260	1188
15260	1205
15260	1232
15260	1262
15262	1183
15262	1188
15262	1205
15262	1218
15262	1232
15263	1183
15263	1188
15263	1206
15263	1218
15263	1232
15265	1183
15265	1188
15265	1200
15265	1206
15265	44968
15267	1183
15267	1188
15267	1210
15267	1232
15267	1233
15267	1239
15269	1183
15269	1188
15269	1206
15269	1232
15269	45045
15272	1183
15272	1188
15272	1205
15272	1206
15272	1218
15272	1232
15276	1183
15276	1188
15276	1198
15276	1206
15276	1218
15278	1183
15278	1188
15278	1206
15278	1232
15278	45145
15280	1183
15280	1188
15280	1206
15280	1218
15280	1232
15281	1183
15281	1188
15281	1198
15281	1205
15281	1210
15281	44977
15282	1183
15282	1188
15282	1198
15282	1204
15282	1218
15285	1183
15285	1188
15285	1200
15285	1204
15285	1218
15290	1183
15290	1188
15290	1204
15290	1218
15290	1232
15291	1183
15291	1188
15291	1206
15291	1221
15291	1232
15293	1182
15293	1188
15293	1198
15293	1218
15293	1233
15294	1188
15294	1232
15294	1233
15294	1243
15294	45236
15296	1183
15296	1194
15296	1206
15296	1232
15296	45543
15297	1188
15297	1204
15297	1218
15297	1229
15297	45236
15299	1188
15299	1200
15299	1206
15299	1218
15299	45238
15300	1183
15300	1188
15300	1232
15300	1233
15300	44971
15301	1183
15301	1188
15301	1198
15301	1206
15301	1218
15302	1183
15302	1188
15302	1218
15302	1232
15302	1233
15303	1183
15303	1188
15303	1200
15303	1206
15303	1218
15304	1183
15304	1188
15304	1198
15304	1206
15304	1218
15309	1183
15309	1194
15309	1198
15309	1206
15309	1218
15310	1183
15310	1188
15310	1206
15310	1218
15310	1229
15311	1183
15311	1194
15311	1198
15311	1206
15311	1271
15312	1183
15312	1188
15312	1206
15312	1218
15312	1232
15313	1183
15313	1188
15313	1218
15313	1232
15313	1233
15314	1183
15314	1194
15314	1205
15314	1218
15314	1229
15315	1183
15315	1194
15315	1218
15315	1232
15315	1233
15316	1183
15316	1204
15316	1218
15316	1232
15316	1239
15317	1183
15317	1194
15317	1200
15317	1206
15317	1218
15318	1183
15318	1188
15318	1206
15318	1218
15318	1232
15320	1183
15320	1188
15320	1218
15320	1232
15320	1233
15321	1183
15321	1194
15321	1198
15321	1206
15321	1218
15322	1183
15322	1188
15322	1198
15322	1216
15322	1233
15324	1183
15324	1188
15324	1200
15324	1206
15324	1218
15325	1183
15325	1194
15325	1232
15325	1233
15325	1271
15326	1188
15326	1200
15326	1206
15326	1218
15326	45238
15327	1183
15327	1188
15327	1206
15327	1218
15327	1232
15328	1183
15328	1188
15328	1218
15328	1232
15328	1233
15329	1195
15329	1222
15329	1232
15329	1233
15329	45238
15330	1194
15330	1204
15330	1218
15330	1232
15330	45238
15331	1183
15331	1188
15331	1204
15331	1213
15331	1232
15332	1183
15332	1194
15332	1200
15332	1206
15332	1218
15333	1183
15333	1188
15333	1217
15333	1232
15333	1233
15334	1183
15334	1188
15334	1218
15334	1232
15334	1233
15335	1188
15335	1218
15335	1232
15335	1233
15335	45238
15336	1183
15336	1200
15336	1206
15336	1218
15336	1249
15337	1183
15337	1194
15337	1218
15337	1232
15337	1233
15339	1188
15339	1218
15339	1232
15339	45236
15339	45604
15342	1183
15342	1188
15342	1232
15342	1233
15342	44974
15345	1183
15345	1188
15345	1213
15345	1232
15345	1233
15347	1188
15347	1206
15347	1218
15347	1229
15347	45238
15350	1188
15350	1198
15350	1206
15350	1218
15350	45236
15358	1183
15358	1188
15358	1218
15358	1232
15358	1233
15359	1183
15359	1188
15359	1218
15359	1232
15359	1233
15367	1183
15367	1188
15367	1218
15367	1232
15367	1233
15369	1188
15369	1218
15369	1232
15369	1233
15369	45600
15370	1183
15370	1188
15370	1232
15370	1233
15370	1276
15372	1183
15372	1188
15372	1218
15372	1232
15372	1233
15385	1183
15385	1188
15385	1206
15385	1218
15385	1229
15386	1183
15386	1188
15386	1198
15386	1218
15386	1233
15390	1183
15390	1188
15390	1206
15390	1232
15390	44971
15393	1188
15393	1218
15393	1232
15393	1233
15393	45238
15397	1188
15397	1206
15397	1218
15397	1229
15397	45238
15406	1183
15406	1194
15406	1200
15406	1206
15406	1218
15412	1183
15412	1188
15412	1205
15412	1217
15412	1232
15413	1183
15413	1188
15413	1198
15413	1206
15413	1218
15414	1183
15414	1188
15414	1204
15414	1218
15414	1232
15416	1183
15416	1188
15416	1206
15416	1218
15416	1229
15417	1183
15417	1194
15417	1218
15417	1232
15417	1233
15419	1183
15419	1188
15419	1200
15419	1206
15419	1218
15421	1183
15421	1188
15421	1198
15421	1206
15421	1218
15422	1183
15422	1188
15422	1200
15422	1206
15422	1213
15423	1183
15423	1188
15423	1218
15423	1229
15423	1232
15423	1233
15423	45543
15424	1183
15424	1188
15424	1218
15424	1232
15424	1233
15425	1183
15425	1188
15425	1198
15425	1206
15425	1218
15427	1183
15427	1188
15427	1206
15427	1218
15427	1229
15431	1183
15431	1188
15431	1198
15431	1204
15431	1218
15432	1183
15432	1188
15432	1198
15432	1206
15432	1218
15433	1183
15433	1188
15433	1206
15433	1218
15433	1229
15435	1183
15435	1188
15435	1198
15435	1206
15435	1218
15437	1183
15437	1188
15437	1218
15437	1232
15437	1233
15438	1183
15438	1188
15438	1206
15438	1218
15438	1229
15439	1183
15439	1188
15439	1206
15439	1232
15439	45145
15440	1183
15440	1194
15440	1206
15440	1218
15440	1229
15442	1183
15442	1188
15442	1194
15442	1198
15442	1206
15442	1218
15442	1232
15442	1233
15443	1183
15443	1188
15443	1198
15443	1206
15443	1218
15444	1183
15444	1188
15444	1206
15444	1218
15444	1229
15445	1183
15445	1188
15445	1231
15445	1232
15445	1233
15450	1183
15450	1188
15450	1198
15450	1206
15450	1218
15453	1183
15453	1188
15453	1200
15453	1206
15453	1217
15454	1183
15454	1188
15454	1206
15454	1217
15454	1229
15455	1183
15455	1188
15455	1206
15455	1210
15455	1229
15460	1183
15460	1188
15460	1218
15460	1232
15460	1233
15461	1183
15461	1188
15461	1206
15461	1218
15461	1229
15464	1183
15464	1188
15464	1205
15464	1218
15464	1232
15465	1183
15465	1188
15465	1198
15465	1206
15465	1218
15467	1183
15467	1188
15467	1200
15467	1204
15467	1218
15468	1183
15468	1194
15468	1198
15468	1206
15468	1218
15470	1183
15470	1188
15470	1218
15470	1232
15470	1233
15471	1183
15471	1188
15471	1200
15471	1206
15471	1218
15473	1183
15473	1188
15473	1206
15473	1217
15473	1229
15475	1183
15475	1194
15475	1198
15475	1206
15475	45548
15480	1183
15480	1194
15480	1218
15480	1232
15480	1233
15483	1183
15483	1188
15483	1198
15483	1218
15483	1233
15484	1183
15484	1194
15484	1206
15484	1218
15484	1229
15489	1183
15489	1188
15489	1206
15489	1218
15489	1229
15495	1188
15495	1218
15495	1232
15495	1233
15495	1237
15496	1183
15496	1188
15496	1218
15496	1232
15496	1233
15500	1183
15500	1188
15500	1198
15500	1206
15500	1218
15501	1183
15501	1188
15501	1198
15501	1206
15501	1218
15502	1183
15502	1188
15502	1200
15502	1206
15502	1218
15503	1183
15503	1196
15503	1200
15503	1206
15503	1217
15504	1183
15504	1188
15504	1198
15504	1206
15504	1218
15505	1183
15505	1188
15505	1206
15505	1217
15505	1229
15506	1183
15506	1188
15506	1206
15506	1217
15506	1229
15507	1183
15507	1188
15507	1206
15507	1218
15507	1229
15508	1188
15508	1218
15508	1232
15508	1233
15508	45238
15509	1183
15509	1206
15509	1218
15509	1229
15509	1239
15511	1188
15511	1206
15511	1218
15511	1229
15511	45238
15513	1183
15513	1218
15513	1229
15513	1233
15513	1239
15517	1183
15517	1188
15517	1218
15517	1232
15517	1233
15518	1183
15518	1188
15518	1198
15518	1206
15518	1219
15519	1183
15519	1194
15519	1200
15519	1206
15519	1218
15524	1183
15524	1194
15524	1200
15524	1206
15524	1218
15525	1188
15525	1206
15525	1229
15525	45238
15525	45380
15527	1183
15527	1188
15527	1218
15527	1232
15527	1233
15529	1183
15529	1188
15529	1206
15529	1229
15529	45399
15531	1183
15531	1188
15531	1218
15531	1232
15531	1233
15535	1183
15535	1188
15535	1204
15535	1218
15535	1232
15538	1180
15538	1188
15538	1197
15538	1201
15538	45549
15539	1188
15539	1232
15539	1233
15539	45238
15539	45337
15540	1183
15540	1194
15540	1200
15540	1206
15540	1218
15541	1183
15541	1194
15541	1218
15541	1232
15541	1233
15542	1183
15542	1194
15542	1218
15542	1232
15542	1233
15543	1188
15543	1232
15543	1233
15543	45236
15543	45561
15544	1188
15544	1218
15544	1232
15544	1233
15544	45238
15545	1183
15545	1193
15545	1200
15545	1206
15545	1218
15546	1188
15546	1196
15546	1200
15546	1206
15546	1218
15546	1232
15546	1233
15546	45236
15547	1183
15547	1188
15547	1218
15547	1232
15547	1233
15548	1188
15548	1218
15548	1232
15548	1233
15548	45238
15549	1183
15549	1191
15549	1204
15549	1218
15549	1232
15551	1183
15551	1194
15551	1206
15551	1218
15551	1229
15552	1183
15552	1188
15552	1206
15552	1218
15552	1232
15553	1183
15553	1188
15553	1203
15553	1218
15553	1232
15554	1188
15554	1206
15554	1229
15554	1264
15554	45238
15557	1183
15557	1194
15557	1229
15557	1233
15557	45339
15558	1182
15558	1188
15558	1198
15558	1206
15558	1218
15561	1183
15561	1194
15561	1218
15561	1229
15561	1233
15562	1183
15562	1188
15562	1198
15562	1206
15562	1218
15563	1183
15563	1194
15563	1206
15563	1218
15563	1232
15564	1188
15564	1200
15564	1206
15564	1218
15564	45238
15568	1188
15568	1218
15568	1232
15568	1233
15568	45238
15569	1183
15569	1193
15569	1204
15569	1229
15569	1243
15570	1188
15570	1200
15570	1204
15570	1218
15570	45238
15579	1188
15579	1206
15579	1218
15579	1229
15579	45238
15581	1188
15581	1198
15581	1206
15581	1220
15581	45238
15582	1188
15582	1199
15582	1205
15582	1218
15582	45236
15584	1179
15584	1188
15584	1197
15584	1201
15584	1218
15588	1188
15588	1204
15588	1218
15588	1232
15588	45236
15589	1183
15589	1188
15589	1204
15589	1218
15589	1232
15591	1188
15591	1198
15591	1206
15591	1218
15591	45236
15593	1182
15593	1188
15593	1198
15593	1218
15593	1233
15595	1183
15595	1188
15595	1200
15595	1206
15595	1220
15597	1183
15597	1188
15597	1204
15597	1218
15597	1232
15599	1183
15599	1194
15599	1218
15599	1232
15599	1233
15600	1183
15600	1188
15600	1206
15600	1218
15600	1229
15601	1183
15601	1188
15601	1198
15601	1206
15601	1213
15602	1183
15602	1188
15602	1198
15602	1206
15602	1213
15603	1188
15603	1222
15603	1232
15603	1233
15603	45238
15604	1188
15604	1206
15604	1218
15604	1229
15604	45238
15605	1188
15605	1218
15605	1232
15605	1233
15605	45238
15606	1183
15606	1188
15606	1198
15606	1206
15606	45134
15607	1183
15607	1188
15607	1206
15607	1218
15607	1229
15607	1232
15607	1233
15609	1183
15609	1194
15609	1218
15609	1232
15609	1233
15610	1183
15610	1194
15610	1198
15610	1206
15610	1218
15611	1183
15611	1194
15611	1206
15611	1209
15611	1229
15614	1183
15614	1188
15614	1218
15614	1232
15614	1233
15615	1183
15615	1194
15615	1206
15615	1218
15615	1229
15617	1188
15617	1206
15617	1218
15617	1229
15617	45236
15618	1183
15618	1188
15618	1218
15618	1232
15618	1233
15619	1183
15619	1194
15619	1206
15619	1218
15619	1229
15620	1183
15620	1194
15620	1205
15620	1218
15620	1229
15621	1183
15621	1188
15621	1218
15621	1232
15621	1233
15622	1183
15622	1194
15622	1200
15622	1206
15622	1218
15624	1183
15624	1188
15624	1200
15624	1205
15624	1218
15625	1183
15625	1194
15625	1204
15625	1218
15625	1232
15626	1183
15626	1188
15626	1218
15626	1232
15626	1233
15627	1183
15627	1188
15627	1198
15627	1210
15627	1233
15628	1183
15628	1188
15628	1205
15628	1218
15628	1232
15629	1183
15629	1188
15629	1200
15629	1206
15629	1218
15630	1183
15630	1188
15630	1206
15630	1218
15630	1229
15631	1183
15631	1188
15631	1200
15631	1206
15631	1218
15632	1188
15632	1206
15632	1218
15632	1229
15632	45236
15633	1183
15633	1188
15633	1218
15633	1232
15633	1233
15634	1183
15634	1188
15634	1206
15634	1232
15634	45060
15640	1188
15640	1200
15640	1206
15640	1218
15640	45238
15641	1183
15641	1188
15641	1229
15641	1233
15641	44971
15643	1183
15643	1188
15643	1200
15643	1206
15643	1220
15644	1183
15644	1188
15644	1211
15644	1232
15644	1233
15645	1183
15645	1188
15645	1206
15645	1218
15645	1229
15647	1188
15647	1218
15647	1232
15647	1233
15647	45238
15648	1183
15648	1188
15648	1198
15648	1206
15648	1218
15649	1183
15649	1188
15649	1206
15649	1218
15649	1229
15650	1183
15650	1188
15650	1206
15650	1218
15650	1229
15651	1183
15651	1188
15651	1218
15651	1232
15651	1233
15652	1183
15652	1188
15652	1204
15652	1218
15652	1232
15653	1183
15653	1188
15653	1231
15653	1232
15653	1233
15654	1188
15654	1203
15654	1218
15654	1232
15654	45238
15655	1183
15655	1188
15655	1218
15655	1232
15655	1233
15656	1183
15656	1188
15656	1218
15656	1232
15656	1233
15657	1183
15657	1188
15657	1218
15657	1232
15657	1233
15658	1183
15658	1188
15658	1218
15658	1232
15658	1233
15659	1188
15659	1206
15659	1218
15659	1229
15659	45238
15661	1183
15661	1188
15661	1198
15661	1218
15661	1233
15662	1183
15662	1188
15662	1218
15662	1232
15662	1233
15663	1180
15663	1188
15663	1218
15663	1232
15663	1233
15664	1183
15664	1194
15664	1200
15664	1206
15664	1218
15665	1183
15665	1191
15665	1206
15665	1218
15665	1232
15666	1183
15666	1188
15666	1200
15666	1206
15666	1218
15667	1183
15667	1188
15667	1206
15667	1218
15667	1229
15668	1183
15668	1188
15668	1200
15668	1206
15668	1276
15670	1183
15670	1194
15670	1222
15670	1232
15670	1233
15671	1183
15671	1188
15671	1200
15671	1206
15671	1218
15671	1232
15671	1233
15674	1183
15674	1188
15674	1218
15674	1232
15674	1233
15675	1183
15675	1188
15675	1218
15675	1229
15675	1233
15676	1183
15676	1188
15676	1217
15676	1232
15676	1233
15677	1183
15677	1188
15677	1206
15677	1218
15677	1229
15678	1183
15678	1188
15678	1218
15678	1232
15678	1233
15680	1183
15680	1194
15680	1200
15680	1206
15680	1222
15681	1183
15681	1188
15681	1200
15681	1206
15681	1218
15682	1183
15682	1188
15682	1198
15682	1206
15682	1218
15683	1183
15683	1188
15683	1218
15683	1232
15683	1233
15684	1183
15684	1194
15684	1218
15684	1232
15684	1233
15685	1183
15685	1188
15685	1229
15685	1233
15685	44971
15686	1183
15686	1188
15686	1198
15686	1206
15686	1218
15687	1183
15687	1194
15687	1218
15687	1232
15687	1233
15689	1183
15689	1188
15689	1198
15689	1206
15689	1218
15689	1232
15689	1233
15690	1183
15690	1188
15690	1198
15690	1218
15690	1233
15691	1183
15691	1194
15691	1206
15691	1218
15691	1229
15692	1183
15692	1194
15692	1206
15692	1218
15692	1229
15693	1183
15693	1188
15693	1200
15693	1206
15693	1218
15694	1183
15694	1188
15694	1206
15694	1218
15694	1229
15695	1183
15695	1194
15695	1206
15695	1218
15695	1229
15696	1188
15696	1205
15696	1218
15696	1232
15696	45238
15697	1183
15697	1188
15697	1206
15697	1218
15697	1229
15698	1183
15698	1194
15698	1218
15698	1232
15698	1233
15699	1188
15699	1204
15699	1218
15699	1232
15699	45236
15700	1183
15700	1188
15700	1218
15700	1232
15700	1233
15704	1188
15704	1218
15704	1232
15704	1233
15704	45238
15721	1183
15721	1188
15721	1218
15721	1232
15721	1233
15729	1183
15729	1217
15729	1229
15729	1233
15729	1239
15732	1183
15732	1193
15732	1206
15732	1218
15732	1232
15734	1183
15734	1194
15734	1198
15734	1206
15734	1218
15736	1188
15736	1203
15736	1218
15736	1232
15736	45236
15744	1183
15744	1188
15744	1200
15744	1233
15744	45181
15745	1183
15745	1188
15745	1200
15745	1218
15745	1233
15747	1188
15747	1218
15747	1232
15747	1233
15747	45238
15757	1183
15757	1188
15757	1218
15757	1232
15757	1233
15763	1188
15763	1218
15763	1232
15763	1233
15763	45238
15764	1183
15764	1194
15764	1217
15764	1232
15764	1233
15772	1182
15772	1188
15772	1198
15772	1218
15772	1233
15775	1182
15775	1188
15775	1198
15775	1218
15775	1233
15783	1183
15783	1188
15783	1206
15783	1218
15783	1229
15785	1188
15785	1218
15785	1232
15785	1233
15785	45238
15789	1183
15789	1188
15789	1206
15789	1218
15789	1229
15806	1183
15806	1188
15806	1204
15806	1218
15806	1232
15810	1188
15810	1218
15810	1232
15810	1233
15810	45238
15822	1183
15822	1188
15822	1218
15822	1232
15822	1233
15825	1195
15825	1206
15825	1218
15825	1229
15825	45238
15827	1183
15827	1188
15827	1200
15827	1206
15827	1218
15836	1183
15836	1188
15836	1218
15836	1232
15836	1233
15838	1183
15838	1194
15838	1232
15838	1233
15838	45543
15842	1183
15842	1188
15842	1222
15842	1232
15842	1233
15844	1188
15844	1200
15844	1206
15844	1218
15844	45238
15846	1183
15846	1194
15846	1218
15846	1232
15846	1233
15850	1188
15850	1198
15850	1206
15850	1210
15850	45238
15857	1183
15857	1194
15857	1206
15857	1218
15857	1229
15868	1188
15868	1218
15868	1232
15868	1233
15868	45238
15869	1183
15869	1188
15869	1198
15869	1218
15869	1233
15877	1183
15877	1188
15877	1198
15877	1206
15877	1218
15883	1188
15883	1218
15883	1232
15883	1233
15883	45236
15884	1183
15884	1188
15884	1206
15884	1218
15884	1229
15888	1183
15888	1196
15888	1231
15888	1232
15888	1233
15897	1183
15897	1192
15897	1204
15897	1218
15897	1232
15911	1183
15911	1188
15911	1218
15911	1229
15911	1233
15914	1188
15914	1198
15914	1210
15914	1233
15914	45238
15932	1183
15932	1194
15932	1198
15932	1206
15932	1220
15933	1183
15933	1188
15933	1198
15933	1206
15933	1218
15934	1183
15934	1188
15934	1198
15934	1206
15934	1218
15935	1183
15935	1188
15935	1198
15935	1218
15935	1233
15937	1183
15937	1188
15937	1221
15937	1232
15937	1233
15939	1183
15939	1188
15939	1218
15939	1229
15939	1233
15943	1188
15943	1204
15943	1218
15943	1232
15943	45236
15952	1183
15952	1188
15952	1200
15952	1206
15952	1218
15955	1178
15955	1183
15955	1188
15955	1218
15955	1232
15955	1233
15956	1183
15956	1188
15956	1222
15956	1232
15956	1233
15972	1183
15972	1188
15972	1218
15972	1232
15972	1233
15973	1183
15973	1188
15973	1218
15973	1232
15973	1233
15975	1183
15975	1188
15975	1218
15975	1232
15975	1233
15976	1183
15976	1193
15976	1232
15976	1233
15976	1246
15977	1183
15977	1194
15977	1206
15977	1218
15977	1232
15987	1183
15987	1188
15987	1206
15987	1218
15987	1229
15999	1183
15999	1188
15999	1198
15999	1205
15999	1218
16009	1183
16009	1188
16009	1200
16009	1218
16009	1233
16017	1180
16017	1188
16017	1218
16017	1232
16017	1233
16019	1183
16019	1188
16019	1218
16019	1232
16019	1233
16020	1183
16020	1188
16020	1218
16020	1232
16020	1233
16023	1183
16023	1218
16023	1232
16023	1233
16023	1239
16025	1183
16025	1188
16025	1218
16025	1232
16025	1233
16026	1183
16026	1194
16026	1232
16026	1233
16026	1264
16034	1183
16034	1204
16034	1218
16034	1232
16034	1239
16037	1183
16037	1188
16037	1217
16037	1232
16037	1233
16038	1183
16038	1194
16038	1198
16038	1210
16038	1233
16040	1183
16040	1188
16040	1198
16040	1206
16040	1210
16045	1183
16045	1188
16045	1198
16045	1218
16045	1233
16048	1183
16048	1194
16048	1218
16048	1232
16048	1233
16050	1183
16050	1188
16050	1206
16050	1218
16050	1232
16059	1183
16059	1188
16059	1200
16059	1206
16059	1218
16066	1183
16066	1188
16066	1218
16066	1232
16066	1233
16070	1183
16070	1188
16070	1218
16070	1232
16070	1233
16071	1188
16071	1204
16071	1218
16071	1232
16071	45236
16073	1188
16073	1204
16073	1218
16073	1232
16073	45236
16074	1183
16074	1188
16074	1218
16074	1232
16074	1233
16080	1183
16080	1194
16080	1198
16080	1206
16080	1210
16083	1183
16083	1188
16083	1198
16083	1218
16083	1233
16086	1182
16086	1188
16086	1218
16086	1232
16086	1233
16087	1183
16087	1188
16087	1218
16087	1232
16087	1233
16088	1183
16088	1188
16088	1198
16088	1218
16088	1233
16089	1183
16089	1188
16089	1218
16089	1232
16089	1233
16090	1183
16090	1188
16090	1232
16090	1233
16090	44971
16091	1183
16091	1188
16091	1206
16091	1217
16091	1232
16092	1188
16092	1204
16092	1218
16092	1232
16092	45236
16101	1183
16101	1188
16101	1200
16101	1206
16101	1218
16106	1188
16106	1218
16106	1232
16106	1233
16106	45238
16114	1183
16114	1188
16114	1204
16114	1218
16114	1232
16116	1183
16116	1188
16116	1217
16116	1232
16116	1233
16121	1183
16121	1194
16121	1206
16121	1218
16121	1229
16123	1183
16123	1194
16123	1206
16123	1218
16123	1229
16134	1183
16134	1188
16134	1206
16134	1218
16134	1229
16136	1188
16136	1204
16136	1218
16136	1232
16136	45236
16138	1188
16138	1218
16138	1232
16138	1233
16138	45238
16142	1183
16142	1194
16142	1198
16142	1218
16142	1233
16153	1183
16153	1188
16153	1198
16153	1206
16153	1218
16161	1183
16161	1194
16161	1206
16161	1218
16161	1232
16162	1183
16162	1188
16162	1218
16162	1232
16162	1233
16168	1183
16168	1204
16168	1232
16168	1239
16168	45561
16180	1183
16180	1194
16180	1199
16180	1218
16180	1233
16193	1188
16193	1205
16193	1218
16193	1232
16193	45236
16195	1183
16195	1194
16195	1218
16195	1232
16195	1233
16198	1183
16198	1188
16198	1206
16198	1218
16198	1229
16204	1183
16204	1188
16204	1200
16204	1206
16204	1218
16207	1188
16207	1218
16207	1232
16207	1233
16207	45238
16211	1183
16211	1188
16211	1218
16211	1232
16211	1233
16223	1183
16223	1188
16223	1200
16223	1206
16223	1218
16224	1188
16224	1200
16224	1206
16224	1218
16224	45238
16234	1183
16234	1188
16234	1206
16234	1232
16234	1262
16236	1183
16236	1188
16236	1232
16236	1233
16236	1261
16237	1183
16237	1188
16237	1218
16237	1232
16237	1233
16245	1183
16245	1188
16245	1198
16245	1218
16245	1233
16248	1183
16248	1194
16248	1232
16248	1233
16248	45181
16258	1188
16258	1218
16258	1232
16258	1233
16258	45238
16263	1183
16263	1188
16263	1218
16263	1232
16263	1233
16265	1183
16265	1188
16265	1232
16265	1233
16265	1246
16267	1183
16267	1188
16267	1198
16267	1221
16267	1233
16269	1183
16269	1188
16269	1218
16269	1232
16269	1233
16270	1183
16270	1188
16270	1200
16270	1206
16270	1218
16271	1188
16271	1204
16271	1218
16271	1232
16271	45236
16273	1183
16273	1188
16273	1232
16273	1233
16273	44971
16281	1183
16281	1188
16281	1204
16281	1218
16281	1232
16282	1183
16282	1188
16282	1204
16282	1218
16282	1232
16286	1183
16286	1188
16286	1198
16286	1218
16286	1233
16287	1182
16287	1195
16287	1198
16287	1218
16287	1233
16289	1183
16289	1188
16289	1206
16289	1218
16289	1229
16290	1183
16290	1194
16290	1198
16290	1206
16290	1218
16293	1183
16293	1188
16293	1194
16293	1198
16293	1200
16293	1206
16293	1218
16293	1232
16293	1233
16295	1183
16295	1188
16295	1206
16295	1218
16295	1229
16296	1183
16296	1188
16296	1206
16296	1218
16296	1229
16306	1183
16306	1194
16306	1218
16306	1229
16306	1233
16312	1183
16312	1188
16312	1200
16312	1206
16312	1218
16313	1188
16313	1218
16313	1229
16313	1233
16313	45236
16316	1183
16316	1188
16316	1198
16316	1206
16316	1218
16323	1183
16323	1188
16323	1200
16323	1213
16323	1233
16325	1183
16325	1194
16325	1200
16325	1233
16325	45134
16326	1183
16326	1188
16326	1206
16326	1218
16326	1232
16330	1183
16330	1198
16330	1218
16330	1233
16330	1239
16334	1188
16334	1200
16334	1206
16334	1218
16334	45238
16335	1183
16335	1194
16335	1198
16335	1206
16335	1210
16337	1183
16337	1194
16337	1198
16337	1206
16337	1218
16338	1183
16338	1188
16338	1198
16338	1206
16338	1218
16341	1183
16341	1198
16341	1206
16341	1218
16341	1239
16342	1183
16342	1188
16342	1198
16342	1206
16342	1264
16343	1183
16343	1194
16343	1218
16343	1232
16343	1233
16344	1183
16344	1196
16344	1200
16344	1204
16344	1218
16345	1188
16345	1218
16345	1232
16345	1233
16345	45238
16346	1183
16346	1194
16346	1198
16346	1206
16346	1218
16348	1183
16348	1188
16348	1206
16348	1222
16348	1229
16349	1183
16349	1188
16349	1198
16349	1206
16349	1218
16353	1183
16353	1188
16353	1206
16353	1218
16353	1229
16355	1183
16355	1188
16355	1206
16355	1218
16355	1232
16356	1183
16356	1188
16356	1205
16356	1206
16356	1218
16356	1229
16357	1183
16357	1194
16357	1200
16357	1206
16357	1218
16359	1188
16359	1205
16359	1218
16359	1229
16359	45238
16360	1188
16360	1206
16360	1218
16360	1229
16360	45238
16361	1183
16361	1188
16361	1206
16361	1218
16361	1229
16362	1180
16362	1183
16362	1192
16362	1195
16362	1206
16362	1218
16362	1232
16363	1183
16363	1188
16363	1218
16363	1232
16363	1233
16364	1183
16364	1188
16364	1200
16364	1206
16364	1218
16365	1183
16365	1188
16365	1218
16365	1232
16365	1233
16366	1183
16366	1194
16366	1206
16366	1218
16366	1229
16370	1188
16370	1232
16370	1233
16370	45019
16370	45238
16371	1183
16371	1194
16371	1206
16371	1217
16371	1232
16372	1183
16372	1188
16372	1218
16372	1232
16372	1233
16380	1183
16380	1188
16380	1218
16380	1232
16380	1233
16398	1182
16398	1195
16398	1218
16398	1232
16398	1233
16400	1183
16400	1188
16400	1218
16400	1232
16400	1233
16402	1183
16402	1196
16402	1218
16402	1232
16402	1233
16405	1183
16405	1188
16405	1206
16405	1218
16405	1229
16413	1183
16413	1194
16413	1198
16413	1206
16413	1210
16414	1183
16414	1194
16414	1205
16414	1218
16414	1229
16416	1183
16416	1188
16416	1194
16416	1218
16416	1229
16416	1233
16416	45586
16418	1183
16418	1188
16418	1200
16418	1206
16418	1218
16422	1183
16422	1188
16422	1206
16422	1218
16422	1232
16427	1183
16427	1194
16427	1229
16427	1233
16427	44971
16428	1218
16428	1220
16428	1232
16428	45602
16428	45604
16430	1188
16430	1204
16430	1218
16430	1232
16430	45238
16432	1183
16432	1188
16432	1218
16432	1232
16432	45604
16436	1183
16436	1188
16436	1206
16436	1218
16436	1229
16437	1188
16437	1198
16437	1206
16437	45019
16437	45238
16441	1188
16441	1204
16441	1229
16441	45236
16441	45461
16442	1188
16442	1206
16442	1218
16442	1229
16442	45236
16443	1195
16443	1199
16443	1204
16443	1218
16443	45236
16445	1183
16445	1198
16445	1205
16445	1218
16445	1239
16447	1183
16447	1188
16447	1198
16447	1206
16447	1218
16448	1188
16448	1198
16448	1209
16448	1233
16448	45236
16449	1183
16449	1194
16449	1218
16449	1232
16449	1233
16450	1183
16450	1194
16450	1206
16450	1218
16450	1232
16451	1183
16451	1188
16451	1218
16451	1232
16451	1233
16453	1183
16453	1188
16453	1221
16453	1232
16453	1233
16457	1183
16457	1188
16457	1206
16457	1218
16457	1229
16462	1183
16462	1194
16462	1218
16462	1232
16462	1233
16469	1183
16469	1194
16469	1206
16469	1218
16469	1232
16472	1183
16472	1188
16472	1232
16472	1233
16472	45134
16473	1188
16473	1218
16473	1232
16473	1233
16473	45236
16485	1183
16485	1188
16485	1198
16485	1218
16485	1233
16487	1183
16487	1205
16487	1218
16487	1232
16487	1239
16489	1183
16489	1188
16489	1232
16489	1233
16489	45549
16490	1183
16490	1188
16490	1200
16490	1206
16490	1218
16491	1180
16491	1194
16491	1206
16491	1213
16491	1232
16494	1188
16494	1232
16494	1233
16494	45181
16494	45238
16494	45603
16495	1183
16495	1198
16495	1218
16495	1233
16495	1239
16496	1183
16496	1188
16496	1198
16496	1206
16496	1218
16496	1232
16496	1233
16497	1183
16497	1194
16497	1198
16497	1221
16497	1233
16499	1183
16499	1194
16499	1204
16499	1218
16499	1232
16503	1188
16503	1204
16503	1218
16503	1232
16503	45236
16504	1183
16504	1194
16504	1231
16504	1232
16504	1233
16505	1183
16505	1188
16505	1198
16505	1213
16505	1233
16506	1183
16506	1188
16506	1218
16506	1232
16506	1233
16507	1183
16507	1188
16507	1218
16507	1232
16507	1233
16509	1188
16509	1218
16509	1232
16509	1233
16509	45236
16511	1183
16511	1188
16511	1206
16511	1217
16511	1232
16513	1188
16513	1218
16513	1232
16513	1233
16513	45236
16514	1183
16514	1188
16514	1218
16514	1232
16514	1233
16518	1188
16518	1198
16518	1218
16518	1233
16518	45238
16519	1183
16519	1194
16519	1198
16519	1218
16519	1233
16522	1183
16522	1188
16522	1206
16522	1218
16522	1229
16524	1183
16524	1194
16524	1206
16524	1232
16524	45181
16526	1183
16526	1194
16526	1198
16526	1206
16526	1217
16530	1183
16530	1188
16530	1218
16530	1232
16530	1233
16533	1183
16533	1188
16533	1218
16533	1232
16533	1233
16534	1183
16534	1194
16534	1213
16534	1232
16534	1233
16535	1183
16535	1188
16535	1198
16535	1206
16535	1218
16536	1183
16536	1194
16536	1218
16536	1232
16536	1233
16548	1183
16548	1188
16548	1198
16548	1206
16548	1218
16555	1183
16555	1188
16555	1232
16555	1233
16555	45194
16563	1183
16563	1188
16563	1218
16563	1229
16563	1233
16566	1183
16566	1194
16566	1218
16566	1232
16566	1233
16569	1183
16569	1188
16569	1218
16569	1232
16569	1233
16573	1183
16573	1194
16573	1218
16573	1232
16573	1233
16575	1183
16575	1188
16575	1218
16575	1232
16575	1233
16576	1183
16576	1188
16576	1198
16576	1218
16576	1233
16587	1183
16587	1188
16587	1194
16587	1206
16587	1218
16587	1232
16587	1233
16588	1183
16588	1188
16588	1205
16588	1218
16588	1229
16595	1183
16595	1188
16595	1217
16595	1229
16595	1233
16597	1183
16597	1188
16597	1232
16597	1233
16597	44971
16601	1182
16601	1188
16601	1198
16601	1218
16601	1233
16602	1183
16602	1188
16602	1206
16602	1218
16602	1229
16606	1183
16606	1194
16606	1198
16606	1206
16606	1218
16608	1183
16608	1194
16608	1218
16608	1229
16608	1233
16612	1183
16612	1188
16612	1198
16612	1218
16612	1233
16621	1183
16621	1188
16621	1218
16621	1232
16621	1233
16622	1183
16622	1188
16622	1204
16622	1218
16622	1232
16626	1183
16626	1196
16626	1218
16626	1232
16626	1233
16627	1183
16627	1194
16627	1218
16627	1232
16627	1233
16628	1182
16628	1195
16628	1218
16628	1232
16628	1233
16632	1183
16632	1188
16632	1200
16632	1206
16632	1218
16635	1183
16635	1188
16635	1218
16635	1229
16635	1233
16644	1183
16644	1188
16644	1206
16644	1229
16644	44971
16667	1183
16667	1194
16667	1206
16667	1222
16667	1232
16669	1183
16669	1192
16669	1206
16669	1232
16669	45561
16670	1183
16670	1188
16670	1218
16670	1232
16670	1233
16681	1192
16681	1198
16681	1218
16681	1233
16681	45236
16695	1183
16695	1188
16695	1218
16695	1232
16695	1233
16700	1183
16700	1194
16700	1218
16700	1232
16700	1233
16701	1183
16701	1188
16701	1218
16701	1232
16701	1233
16702	1183
16702	1188
16702	1218
16702	1232
16702	1233
16703	1183
16703	1188
16703	1218
16703	1232
16703	1233
16704	1183
16704	1194
16704	1218
16704	1229
16704	1233
16705	1188
16705	1205
16705	1218
16705	1232
16705	45236
16710	1183
16710	1218
16710	1232
16710	1233
16710	1239
16715	1188
16715	1218
16715	1232
16715	1233
16715	45238
16722	1183
16722	1194
16722	1217
16722	1232
16722	1233
16722	44971
16729	1183
16729	1188
16729	1218
16729	1232
16729	1233
16737	1183
16737	1188
16737	1200
16737	1206
16737	1218
16744	1183
16744	1188
16744	1218
16744	1229
16744	1233
16747	1183
16747	1194
16747	1218
16747	1229
16747	1233
16748	1183
16748	1188
16748	1218
16748	1232
16748	1233
16755	1183
16755	1188
16755	1218
16755	1232
16755	1233
16759	1183
16759	1196
16759	1229
16759	1233
16759	45543
16760	1179
16760	1188
16760	1218
16760	1232
16760	1233
16761	1183
16761	1188
16761	1218
16761	1232
16761	1233
16762	1183
16762	1188
16762	1206
16762	1218
16762	1229
16765	1183
16765	1188
16765	1218
16765	1232
16765	1233
16770	1196
16770	1205
16770	1218
16770	1232
16770	45236
16772	1183
16772	1188
16772	1218
16772	1232
16772	1233
16775	1183
16775	1188
16775	1198
16775	1218
16775	1232
16775	1233
16775	45236
16780	1183
16780	1188
16780	1194
16780	1205
16780	1218
16780	1232
16780	1233
16782	1188
16782	1218
16782	1232
16782	1233
16782	45238
16784	1183
16784	1188
16784	1206
16784	1220
16784	1232
16786	1183
16786	1188
16786	1198
16786	1206
16786	1218
16796	1183
16796	1188
16796	1198
16796	1206
16796	1217
16797	1183
16797	1188
16797	1218
16797	1232
16797	1233
16799	1183
16799	1188
16799	1206
16799	1218
16799	1229
16800	1183
16800	1188
16800	1218
16800	1229
16800	1233
16804	1183
16804	1188
16804	1218
16804	1229
16804	1233
16805	1183
16805	1193
16805	1222
16805	1229
16805	1233
16808	1183
16808	1188
16808	1218
16808	1232
16808	1233
16824	1188
16824	1218
16824	1232
16824	1233
16824	45236
16828	1183
16828	1194
16828	1206
16828	1218
16828	1232
16834	1183
16834	1206
16834	1232
16834	1239
16834	1262
16845	1183
16845	1188
16845	1206
16845	1222
16845	1229
16847	1183
16847	1194
16847	1206
16847	1218
16847	1229
16853	1183
16853	1188
16853	1204
16853	1218
16853	1232
16854	1188
16854	1218
16854	1232
16854	1233
16854	45238
16857	1183
16857	1188
16857	1217
16857	1232
16857	1233
16873	1183
16873	1188
16873	1218
16873	1229
16873	1233
16882	1183
16882	1194
16882	1198
16882	1211
16882	1233
16892	1183
16892	1188
16892	1218
16892	1232
16892	1233
16903	1183
16903	1194
16903	1218
16903	1232
16903	1233
16906	1188
16906	1218
16906	1232
16906	1233
16906	45238
16913	1188
16913	1218
16913	1229
16913	1233
16913	45236
16915	1188
16915	1218
16915	1232
16915	1233
16915	45238
16919	1183
16919	1188
16919	1218
16919	1232
16919	1233
16926	1183
16926	1194
16926	1198
16926	1206
16926	1218
16937	1182
16937	1188
16937	1198
16937	1218
16937	1233
16939	1183
16939	1188
16939	1198
16939	1218
16939	1233
16945	1183
16945	1194
16945	1217
16945	1229
16945	1233
16948	1183
16948	1188
16948	1218
16948	1229
16948	1233
16957	1188
16957	1210
16957	1232
16957	1233
16957	45238
16958	1183
16958	1188
16958	1218
16958	1232
16958	1233
16959	1183
16959	1188
16959	1218
16959	1232
16959	1233
16960	1183
16960	1188
16960	1222
16960	1232
16960	1233
16961	1183
16961	1188
16961	1218
16961	1232
16961	1233
16962	1183
16962	1188
16962	1198
16962	1218
16962	1233
16963	1183
16963	1188
16963	1218
16963	1232
16963	1233
16964	1183
16964	1188
16964	1206
16964	1217
16964	1229
16965	1183
16965	1194
16965	1218
16965	1232
16965	1233
16969	1183
16969	1188
16969	1218
16969	1232
16969	1233
16970	1183
16970	1188
16970	1218
16970	1232
16970	1233
16972	1188
16972	1218
16972	1232
16972	1233
16972	45236
16973	1183
16973	1188
16973	1218
16973	1232
16973	1233
16975	1183
16975	1188
16975	1218
16975	1232
16975	1233
16976	1183
16976	1188
16976	1198
16976	1218
16976	1233
16977	1183
16977	1188
16977	1218
16977	1232
16977	1233
16978	1183
16978	1188
16978	1198
16978	1205
16978	1218
16980	1183
16980	1220
16980	1232
16980	1233
16980	1239
16984	1183
16984	1188
16984	1206
16984	1218
16984	1229
16988	1183
16988	1188
16988	1198
16988	1218
16988	1233
16989	1183
16989	1188
16989	1198
16989	1218
16989	1233
16993	1183
16993	1188
16993	1218
16993	1232
16993	1233
16994	1183
16994	1188
16994	1198
16994	1218
16994	1233
17003	1183
17003	1188
17003	1206
17003	1218
17003	1232
17007	1183
17007	1188
17007	1217
17007	1232
17007	1233
17015	1183
17015	1188
17015	1206
17015	1222
17015	1229
17032	1183
17032	1188
17032	1218
17032	1229
17032	1233
17038	1188
17038	1218
17038	1232
17038	1233
17038	45236
17048	1188
17048	1198
17048	1204
17048	1218
17048	45236
17049	1183
17049	1188
17049	1198
17049	1206
17049	1218
17052	1183
17052	1193
17052	1218
17052	1232
17052	1233
17053	1183
17053	1194
17053	1232
17053	1233
17053	1246
17054	1182
17054	1188
17054	1218
17054	1232
17054	1233
17055	1183
17055	1188
17055	1218
17055	1232
17055	1233
17056	1183
17056	1188
17056	1198
17056	1218
17056	1233
17060	1183
17060	1196
17060	1232
17060	1233
17060	45570
17061	1183
17061	1188
17061	1232
17061	1233
17061	44971
17062	1183
17062	1196
17062	1218
17062	1232
17062	1233
17063	1183
17063	1193
17063	1206
17063	1218
17063	1232
17064	1183
17064	1188
17064	1198
17064	1233
17064	45430
17069	1183
17069	1194
17069	1218
17069	1232
17069	1233
17072	1183
17072	1194
17072	1206
17072	1218
17072	1232
17078	1183
17078	1188
17078	1218
17078	1232
17078	1233
17079	1183
17079	1188
17079	1218
17079	1232
17079	1233
17080	1183
17080	1188
17080	1199
17080	1221
17080	1233
17081	1183
17081	1188
17081	1218
17081	1232
17081	1233
17082	1188
17082	1232
17082	1233
17082	45014
17082	45238
17083	1183
17083	1194
17083	1218
17083	1232
17083	1233
17085	1183
17085	1194
17085	1218
17085	1232
17085	1233
17086	1183
17086	1188
17086	1218
17086	1232
17086	1233
17087	1183
17087	1194
17087	1204
17087	1220
17087	1232
17088	1183
17088	1194
17088	1198
17088	1218
17088	1233
17090	1183
17090	1188
17090	1206
17090	1218
17090	1232
17091	1183
17091	1188
17091	1206
17091	1218
17091	1232
17092	1183
17092	1194
17092	1218
17092	1232
17092	1233
17094	1183
17094	1194
17094	1218
17094	1229
17094	1233
17096	1188
17096	1204
17096	1218
17096	1232
17096	45236
17097	1183
17097	1194
17097	1206
17097	1229
17097	45181
17098	1183
17098	1188
17098	1194
17098	1218
17098	1232
17098	1233
17101	1188
17101	1199
17101	1233
17101	44983
17101	45236
17104	1188
17104	1218
17104	1232
17104	1233
17104	45238
17106	1183
17106	1188
17106	1218
17106	1232
17106	1233
17108	1183
17108	1188
17108	1218
17108	1232
17108	1233
17109	1183
17109	1188
17109	1218
17109	1232
17109	1233
17110	1183
17110	1188
17110	1206
17110	1232
17110	44983
17111	1188
17111	1204
17111	1218
17111	1232
17111	45236
17112	1183
17112	1188
17112	1204
17112	1218
17112	1232
17113	1183
17113	1188
17113	1218
17113	1232
17113	1233
17114	1183
17114	1188
17114	1221
17114	1232
17114	1233
17116	1183
17116	1188
17116	1218
17116	1232
17116	1233
17118	1183
17118	1188
17118	1206
17118	1218
17118	1232
17119	1183
17119	1194
17119	1206
17119	1218
17119	1232
17120	1183
17120	1194
17120	1206
17120	1218
17120	1232
17122	1183
17122	1188
17122	1218
17122	1229
17122	1233
17124	1183
17124	1188
17124	1218
17124	1232
17124	1233
17125	1183
17125	1194
17125	1218
17125	1229
17125	1233
17127	1188
17127	1198
17127	1218
17127	1233
17127	45236
17130	1183
17130	1194
17130	1206
17130	1229
17130	45435
17133	1183
17133	1188
17133	1198
17133	1206
17133	1218
17134	1183
17134	1188
17134	1206
17134	1232
17134	45181
17141	1183
17141	1194
17141	1206
17141	1218
17141	1232
17143	1183
17143	1188
17143	1206
17143	1218
17143	1232
17149	1183
17149	1194
17149	1218
17149	1232
17149	1233
17152	1183
17152	1194
17152	1206
17152	1218
17152	1232
17153	1183
17153	1194
17153	1206
17153	1222
17153	1232
17162	1183
17162	1193
17162	1204
17162	1218
17162	1229
17178	1183
17178	1194
17178	1218
17178	1232
17178	1233
17179	1183
17179	1194
17179	1198
17179	1233
17179	45548
17180	1183
17180	1188
17180	1205
17180	1232
17180	1243
17183	1183
17183	1188
17183	1218
17183	1232
17183	1233
17184	1183
17184	1194
17184	1198
17184	1233
17184	45548
17185	1183
17185	1188
17185	1198
17185	1210
17185	1233
17186	1183
17186	1194
17186	1198
17186	1218
17186	1233
17187	1183
17187	1188
17187	1210
17187	1232
17187	1233
17188	1183
17188	1194
17188	1198
17188	1204
17188	1222
17190	1183
17190	1194
17190	1198
17190	1233
17190	45548
17191	1188
17191	1204
17191	1222
17191	1232
17191	45236
17196	1183
17196	1204
17196	1218
17196	1232
17196	1239
17197	1183
17197	1188
17197	1218
17197	1232
17197	1233
17198	1183
17198	1232
17198	1233
17198	1239
17198	45380
17199	1183
17199	1194
17199	1218
17199	1232
17199	1233
17200	1183
17200	1194
17200	1199
17200	1205
17200	1218
17201	1183
17201	1194
17201	1229
17201	1233
17201	44971
17203	1183
17203	1188
17203	1198
17203	1218
17203	1233
17204	1183
17204	1188
17204	1218
17204	1232
17204	1233
17205	1188
17205	1204
17205	1232
17205	1244
17205	45236
17208	1183
17208	1188
17208	1218
17208	1232
17208	1233
17209	1188
17209	1218
17209	1232
17209	1233
17209	45238
17210	1183
17210	1194
17210	1218
17210	1229
17210	1233
17211	1183
17211	1188
17211	1232
17211	1233
17211	44971
17213	1183
17213	1188
17213	1229
17213	1233
17213	1244
17214	1183
17214	1194
17214	1218
17214	1232
17214	1233
17218	1183
17218	1193
17218	1218
17218	1232
17218	1233
17223	1183
17223	1188
17223	1205
17223	1218
17223	1232
17227	1183
17227	1188
17227	1198
17227	1203
17227	1218
17229	1188
17229	1218
17229	1232
17229	1233
17229	45238
17230	1183
17230	1188
17230	1218
17230	1232
17230	1233
17231	1183
17231	1188
17231	1198
17231	1206
17231	1218
17232	1183
17232	1188
17232	1206
17232	1218
17232	1229
17233	1183
17233	1188
17233	1198
17233	1218
17233	1233
17234	1183
17234	1188
17234	1210
17234	1232
17234	1233
17236	1188
17236	1198
17236	1218
17236	1233
17236	45236
17237	1183
17237	1194
17237	1218
17237	1232
17237	1233
17238	1183
17238	1188
17238	1218
17238	1232
17238	1233
17239	1188
17239	1198
17239	1210
17239	1233
17239	45236
17240	1183
17240	1188
17240	1229
17240	1233
17240	45181
17241	1183
17241	1188
17241	1206
17241	1218
17241	1229
17243	1183
17243	1188
17243	1218
17243	1232
17243	1233
17244	1188
17244	1198
17244	1204
17244	1218
17244	45236
17246	1183
17246	1188
17246	1218
17246	1232
17246	1233
17247	1183
17247	1188
17247	1198
17247	1218
17247	1233
17248	1183
17248	1194
17248	1218
17248	1232
17248	1233
17250	1183
17250	1188
17250	1218
17250	1232
17250	1233
17251	1183
17251	1188
17251	1198
17251	1218
17251	1233
17252	1183
17252	1188
17252	1218
17252	1232
17252	1233
17254	1183
17254	1194
17254	1206
17254	1218
17254	1232
17256	1183
17256	1188
17256	1206
17256	1221
17256	1232
17257	1183
17257	1188
17257	1199
17257	1206
17257	1218
17258	1183
17258	1188
17258	1205
17258	1218
17258	1232
17259	1183
17259	1188
17259	1200
17259	1218
17259	1233
17260	1183
17260	1188
17260	1200
17260	1206
17260	44974
17262	1183
17262	1188
17262	1218
17262	1232
17262	1233
17263	1180
17263	1188
17263	1197
17263	1201
17263	1218
17264	1183
17264	1188
17264	1206
17264	1232
17264	45181
17265	1183
17265	1188
17265	1218
17265	1229
17265	1233
17266	1183
17266	1188
17266	1206
17266	1218
17266	1232
17267	1183
17267	1188
17267	1205
17267	1218
17267	1232
17268	1183
17268	1188
17268	1222
17268	1232
17268	1233
17269	1183
17269	1188
17269	1213
17269	1229
17269	1233
17269	1247
17270	1183
17270	1188
17270	1218
17270	1232
17270	1233
17271	1183
17271	1188
17271	1206
17271	1218
17271	1232
17272	1183
17272	1188
17272	1198
17272	1206
17272	1221
17273	1183
17273	1188
17273	1229
17273	1233
17273	45183
17274	1183
17274	1188
17274	1218
17274	1232
17274	1233
17275	1183
17275	1188
17275	1206
17275	1218
17275	1232
17276	1183
17276	1188
17276	1218
17276	1232
17276	1233
17277	1183
17277	1188
17277	1206
17277	1218
17277	1232
17278	1183
17278	1188
17278	1218
17278	1232
17278	1233
17279	1183
17279	1188
17279	1198
17279	1204
17279	1218
17280	1183
17280	1188
17280	1218
17280	1232
17280	1233
17281	1183
17281	1188
17281	1205
17281	1229
17281	44974
17282	1183
17282	1188
17282	1198
17282	1204
17282	1218
17283	1183
17283	1188
17283	1206
17283	1218
17283	1229
17284	1183
17284	1188
17284	1218
17284	1232
17284	1233
17285	1183
17285	1188
17285	1206
17285	1218
17285	1232
17286	1183
17286	1188
17286	1218
17286	1232
17286	1233
17287	1183
17287	1188
17287	1206
17287	1218
17287	1229
17288	1183
17288	1188
17288	1213
17288	1232
17288	1233
17289	1183
17289	1188
17289	1218
17289	1232
17289	1233
17290	1183
17290	1188
17290	1232
17290	1233
17290	44968
17292	1183
17292	1188
17292	1232
17292	1233
17292	1277
17293	1183
17293	1188
17293	1218
17293	1232
17293	1233
17294	1183
17294	1188
17294	1221
17294	1232
17294	1233
17295	1183
17295	1188
17295	1206
17295	1218
17295	1229
17296	1183
17296	1188
17296	1200
17296	1206
17296	1218
17297	1183
17297	1188
17297	1218
17297	1232
17297	1233
17298	1183
17298	1188
17298	1206
17298	1221
17298	1232
17299	1183
17299	1188
17299	1206
17299	1218
17299	1232
17300	1183
17300	1188
17300	1199
17300	1213
17300	1233
17301	1183
17301	1188
17301	1213
17301	1232
17301	1233
17302	1183
17302	1188
17302	1218
17302	1232
17302	1233
17304	1183
17304	1205
17304	1232
17304	1239
17304	44984
17305	1183
17305	1198
17305	1233
17305	1239
17305	44984
17306	1183
17306	1188
17306	1232
17306	1233
17306	45181
17307	1183
17307	1188
17307	1218
17307	1232
17307	1233
17308	1183
17308	1188
17308	1206
17308	1218
17308	1232
17309	1183
17309	1188
17309	1206
17309	1217
17309	1229
17310	1183
17310	1188
17310	1204
17310	1218
17310	1232
17311	1183
17311	1188
17311	1198
17311	1204
17311	44970
17312	1183
17312	1188
17312	1218
17312	1232
17312	1233
17313	1183
17313	1191
17313	1206
17313	1229
17313	44971
17314	1183
17314	1188
17314	1218
17314	1232
17314	1233
17315	1183
17315	1188
17315	1218
17315	1232
17315	1233
17316	1183
17316	1188
17316	1232
17316	1233
17316	44974
17317	1183
17317	1188
17317	1204
17317	1218
17317	1232
17318	1183
17318	1188
17318	1198
17318	1204
17318	44970
17319	1183
17319	1188
17319	1198
17319	1218
17319	1233
17320	1183
17320	1218
17320	1229
17320	1233
17320	1239
17321	1183
17321	1188
17321	1218
17321	1229
17321	1233
17322	1183
17322	1218
17322	1232
17322	1233
17322	1239
17323	1183
17323	1188
17323	1218
17323	1232
17323	1233
17324	1183
17324	1188
17324	1209
17324	1232
17324	1233
17325	1183
17325	1188
17325	1218
17325	1232
17325	1233
17326	1183
17326	1188
17326	1206
17326	1217
17326	1229
17327	1183
17327	1218
17327	1232
17327	1233
17327	1239
17328	1183
17328	1188
17328	1218
17328	1232
17328	1233
17329	1183
17329	1188
17329	1218
17329	1232
17329	1233
17330	1183
17330	1188
17330	1204
17330	1218
17330	1232
17331	1183
17331	1188
17331	1232
17331	1233
17331	45187
17332	1183
17332	1188
17332	1218
17332	1232
17332	1233
17333	1183
17333	1188
17333	1218
17333	1229
17333	1233
17334	1183
17334	1188
17334	1218
17334	1232
17334	1233
17335	1183
17335	1188
17335	1218
17335	1232
17335	1233
17336	1183
17336	1188
17336	1206
17336	1218
17336	1232
17337	1183
17337	1188
17337	1206
17337	1232
17337	44968
17338	1183
17338	1188
17338	1198
17338	1210
17338	1233
17339	1183
17339	1188
17339	1198
17339	1204
17339	1218
17340	1183
17340	1198
17340	1210
17340	1233
17340	1239
17341	1183
17341	1188
17341	1232
17341	1233
17341	44983
17342	1183
17342	1188
17342	1206
17342	1218
17342	1229
17343	1183
17343	1188
17343	1218
17343	1232
17343	1233
17344	1183
17344	1188
17344	1218
17344	1232
17344	1233
17345	1183
17345	1188
17345	1206
17345	1218
17345	1232
17346	1183
17346	1188
17346	1206
17346	1218
17346	1229
17347	1183
17347	1188
17347	1198
17347	1204
17347	1218
17349	1183
17349	1188
17349	1218
17349	1232
17349	1233
17350	1183
17350	1188
17350	1218
17350	1229
17350	1233
17351	1183
17351	1188
17351	1204
17351	1218
17351	1232
17352	1183
17352	1188
17352	1198
17352	1204
17352	1218
17353	1183
17353	1188
17353	1218
17353	1232
17353	1233
17354	1183
17354	1188
17354	1232
17354	1233
17354	45339
17355	1183
17355	1188
17355	1198
17355	1205
17355	1218
17356	1183
17356	1188
17356	1218
17356	1232
17356	1233
17357	1183
17357	1188
17357	1218
17357	1232
17357	1233
17358	1183
17358	1188
17358	1206
17358	1218
17358	1232
17359	1183
17359	1188
17359	1218
17359	1229
17359	1233
17360	1183
17360	1188
17360	1205
17360	1218
17360	1232
17361	1183
17361	1188
17361	1204
17361	1232
17361	44985
17362	1183
17362	1188
17362	1213
17362	1232
17362	1233
17362	1247
17363	1183
17363	1188
17363	1232
17363	1233
17363	45181
17365	1183
17365	1188
17365	1205
17365	1232
17365	45017
17366	1183
17366	1188
17366	1198
17366	1218
17366	1233
17368	1183
17368	1198
17368	1204
17368	1239
17368	44971
17369	1183
17369	1188
17369	1232
17369	1233
17369	44974
17370	1183
17370	1188
17370	1198
17370	1206
17370	1221
17371	1183
17371	1188
17371	1198
17371	1210
17371	1233
17372	1183
17372	1188
17372	1218
17372	1232
17372	1233
17373	1183
17373	1188
17373	1198
17373	1204
17373	1218
17374	1183
17374	1188
17374	1198
17374	1204
17374	1218
17375	1183
17375	1188
17375	1198
17375	1218
17375	1233
17376	1183
17376	1188
17376	1218
17376	1229
17376	1233
17377	1183
17377	1188
17377	1198
17377	1218
17377	1233
17378	1183
17378	1188
17378	1198
17378	1218
17378	1233
17379	1183
17379	1188
17379	1218
17379	1232
17379	1233
17380	1183
17380	1188
17380	1204
17380	1218
17380	1232
17381	1183
17381	1188
17381	1198
17381	1218
17381	1233
17382	1183
17382	1188
17382	1198
17382	1218
17382	1233
17383	1183
17383	1188
17383	1232
17383	1233
17383	45430
17384	1183
17384	1188
17384	1206
17384	1218
17384	1232
17385	1183
17385	1188
17385	1218
17385	1232
17385	1233
17386	1183
17386	1188
17386	1218
17386	1232
17386	1233
17387	1183
17387	1188
17387	1218
17387	1232
17387	1233
17388	1183
17388	1188
17388	1218
17388	1232
17388	1233
17389	1183
17389	1188
17389	1218
17389	1232
17389	1233
17390	1183
17390	1188
17390	1198
17390	1204
17390	44971
17391	1183
17391	1188
17391	1218
17391	1232
17391	1233
17392	1183
17392	1188
17392	1218
17392	1232
17392	1233
17393	1183
17393	1188
17393	1218
17393	1232
17393	1233
17394	1183
17394	1188
17394	1218
17394	1232
17394	1233
17395	1183
17395	1188
17395	1218
17395	1232
17395	1233
17396	1183
17396	1188
17396	1198
17396	1204
17396	1218
17397	1183
17397	1188
17397	1206
17397	1218
17397	1229
17398	1183
17398	1188
17398	1204
17398	1218
17398	1232
17399	1183
17399	1188
17399	1218
17399	1232
17399	1233
17400	1183
17400	1188
17400	1232
17400	1233
17400	44970
17401	1183
17401	1188
17401	1204
17401	1218
17401	1232
17402	1183
17402	1188
17402	1232
17402	1233
17402	45045
17403	1183
17403	1188
17403	1217
17403	1232
17403	1233
17404	1183
17404	1188
17404	1198
17404	1218
17404	1233
17405	1183
17405	1188
17405	1206
17405	1218
17405	1232
17406	1183
17406	1188
17406	1198
17406	1204
17406	1218
17407	1183
17407	1188
17407	1232
17407	1233
17407	45017
17408	1183
17408	1188
17408	1206
17408	1218
17408	1232
17409	1183
17409	1188
17409	1218
17409	1232
17409	1233
17410	1183
17410	1188
17410	1198
17410	1204
17410	1218
17411	1183
17411	1188
17411	1218
17411	1232
17411	1233
17412	1183
17412	1188
17412	1218
17412	1232
17412	1233
17413	1183
17413	1188
17413	1206
17413	1218
17413	1232
17414	1183
17414	1188
17414	1232
17414	1233
17414	44968
17415	1183
17415	1188
17415	1232
17415	1233
17415	44968
17416	1183
17416	1188
17416	1205
17416	1217
17416	1232
17417	1183
17417	1188
17417	1206
17417	1221
17417	1232
17418	1183
17418	1188
17418	1205
17418	1218
17418	1232
17419	1183
17419	1188
17419	1218
17419	1229
17419	1233
17420	1183
17420	1188
17420	1198
17420	1218
17420	1233
17421	1183
17421	1188
17421	1198
17421	1204
17421	1218
17422	1183
17422	1188
17422	1222
17422	1232
17422	1233
17423	1183
17423	1188
17423	1213
17423	1232
17423	1233
17424	1183
17424	1188
17424	1218
17424	1232
17424	1233
17425	1183
17425	1188
17425	1232
17425	1233
17425	44974
17426	1183
17426	1191
17426	1232
17426	1233
17426	45112
17427	1183
17427	1188
17427	1213
17427	1232
17427	1233
17428	1183
17428	1188
17428	1198
17428	1218
17428	1233
17429	1183
17429	1188
17429	1198
17429	1205
17429	1218
17430	1183
17430	1188
17430	1206
17430	1217
17430	1232
17431	1183
17431	1188
17431	1204
17431	1218
17431	1232
17432	1183
17432	1188
17432	1206
17432	1232
17432	44971
17433	1183
17433	1188
17433	1206
17433	1229
17433	44971
17435	1183
17435	1188
17435	1218
17435	1229
17435	1233
17436	1183
17436	1188
17436	1218
17436	1232
17436	1233
17437	1183
17437	1188
17437	1206
17437	1218
17437	1232
17438	1183
17438	1188
17438	1198
17438	1205
17438	1218
17439	1183
17439	1188
17439	1232
17439	1233
17439	1277
17440	1183
17440	1188
17440	1218
17440	1232
17440	1233
17441	1183
17441	1188
17441	1218
17441	1232
17441	1233
17442	1183
17442	1188
17442	1198
17442	1204
17442	1218
17443	1183
17443	1188
17443	1198
17443	1204
17443	1213
17444	1183
17444	1188
17444	1218
17444	1229
17444	1233
17444	44974
17448	1183
17448	1188
17448	1198
17448	1218
17448	1233
17449	1183
17449	1188
17449	1204
17449	1218
17449	1232
17451	1183
17451	1188
17451	1205
17451	1218
17451	1232
17452	1183
17452	1188
17452	1205
17452	1218
17452	1229
17453	1183
17453	1188
17453	1209
17453	1232
17453	1233
17454	1183
17454	1188
17454	1221
17454	1232
17454	1233
17455	1183
17455	1188
17455	1206
17455	1218
17455	1232
17456	1183
17456	1188
17456	1218
17456	1232
17456	1233
17457	1183
17457	1188
17457	1206
17457	1221
17457	1232
17458	1183
17458	1188
17458	1206
17458	1218
17458	1232
17459	1183
17459	1188
17459	1221
17459	1232
17459	1233
17460	1183
17460	1188
17460	1198
17460	1204
17460	1218
17461	1183
17461	1188
17461	1218
17461	1232
17461	1233
17462	1183
17462	1188
17462	1218
17462	1232
17462	1233
17463	1183
17463	1188
17463	1218
17463	1232
17463	1233
17464	1183
17464	1188
17464	1206
17464	1218
17464	1232
17465	1183
17465	1188
17465	1218
17465	1232
17465	1233
17468	1183
17468	1188
17468	1206
17468	1218
17468	1229
17469	1183
17469	1188
17469	1206
17469	1218
17469	1229
17470	1183
17470	1188
17470	1218
17470	1232
17470	1233
17471	1183
17471	1188
17471	1198
17471	1205
17471	1218
17472	1183
17472	1188
17472	1218
17472	1232
17472	1233
17473	1183
17473	1188
17473	1206
17473	1232
17473	44971
17475	1183
17475	1188
17475	1218
17475	1232
17475	1233
17476	1183
17476	1188
17476	1205
17476	1218
17476	1232
17477	1183
17477	1188
17477	1218
17477	1229
17477	1233
17478	1183
17478	1188
17478	1206
17478	1218
17478	1232
17479	1183
17479	1198
17479	1218
17479	1233
17479	1239
17480	1183
17480	1188
17480	1206
17480	1217
17480	1232
17481	1183
17481	1188
17481	1206
17481	1218
17481	1232
17482	1183
17482	1188
17482	1218
17482	1232
17482	1233
17483	1183
17483	1188
17483	1200
17483	1218
17483	1233
17484	1183
17484	1204
17484	1218
17484	1232
17484	1239
17485	1183
17485	1188
17485	1206
17485	1218
17485	1232
17486	1183
17486	1188
17486	1218
17486	1229
17486	1233
17487	1183
17487	1188
17487	1218
17487	1232
17487	1233
17488	1183
17488	1188
17488	1206
17488	1217
17488	1232
17489	1183
17489	1188
17489	1206
17489	1232
17489	44968
17490	1183
17490	1188
17490	1198
17490	1206
17490	1218
17491	1183
17491	1188
17491	1206
17491	1229
17491	44974
17492	1183
17492	1188
17492	1204
17492	1218
17492	1232
17493	1183
17493	1188
17493	1204
17493	1218
17493	1232
17494	1183
17494	1188
17494	1204
17494	1218
17494	1232
17495	1183
17495	1188
17495	1204
17495	1218
17495	1232
17496	1183
17496	1188
17496	1198
17496	1204
17496	1218
17498	1183
17498	1188
17498	1204
17498	1218
17498	1232
17499	1183
17499	1188
17499	1206
17499	1217
17499	1232
17500	1183
17500	1188
17500	1206
17500	1232
17500	44971
17502	1183
17502	1188
17502	1221
17502	1232
17502	1233
17503	1183
17503	1188
17503	1206
17503	1232
17503	44971
17504	1183
17504	1188
17504	1204
17504	1218
17504	1232
17505	1183
17505	1188
17505	1232
17505	1233
17505	44974
17506	1183
17506	1188
17506	1218
17506	1232
17506	1233
17507	1183
17507	1188
17507	1204
17507	1232
17507	44984
17508	1183
17508	1188
17508	1206
17508	1217
17508	1232
17509	1183
17509	1188
17509	1206
17509	1218
17509	1229
17510	1183
17510	1188
17510	1229
17510	1233
17510	44971
17511	1183
17511	1188
17511	1206
17511	1218
17511	1232
17513	1183
17513	1188
17513	1217
17513	1232
17513	1233
17514	1183
17514	1188
17514	1206
17514	1218
17514	1232
17515	1183
17515	1188
17515	1206
17515	1218
17515	1232
17516	1183
17516	1188
17516	1206
17516	1218
17516	1229
17518	1183
17518	1188
17518	1218
17518	1229
17518	1233
17519	1183
17519	1188
17519	1218
17519	1232
17519	1233
17520	1183
17520	1188
17520	1204
17520	1232
17520	45017
17521	1183
17521	1188
17521	1218
17521	1232
17521	1233
17522	1183
17522	1188
17522	1232
17522	1233
17522	44971
17523	1183
17523	1188
17523	1205
17523	1218
17523	1232
17524	1183
17524	1188
17524	1205
17524	1218
17524	1232
17525	1183
17525	1188
17525	1205
17525	1218
17525	1232
17526	1183
17526	1188
17526	1218
17526	1232
17526	1233
17527	1183
17527	1188
17527	1206
17527	1221
17527	1232
17528	1183
17528	1188
17528	1221
17528	1232
17528	1233
17529	1183
17529	1188
17529	1218
17529	1232
17529	1233
17530	1183
17530	1188
17530	1218
17530	1232
17530	1233
17531	1183
17531	1188
17531	1198
17531	1206
17531	1218
17532	1183
17532	1188
17532	1209
17532	1232
17532	1233
17533	1183
17533	1188
17533	1198
17533	1218
17533	1233
17534	1183
17534	1232
17534	1233
17534	1239
17534	44985
17535	1183
17535	1188
17535	1206
17535	1217
17535	1232
17536	1183
17536	1188
17536	1218
17536	1232
17536	1233
17537	1183
17537	1188
17537	1206
17537	1218
17537	1232
17538	1183
17538	1188
17538	1204
17538	1218
17538	1232
17539	1183
17539	1188
17539	1218
17539	1229
17539	1233
17540	1183
17540	1188
17540	1213
17540	1232
17540	1233
17541	1183
17541	1188
17541	1204
17541	1218
17541	1232
17542	1183
17542	1188
17542	1232
17542	1233
17542	44974
17543	1183
17543	1188
17543	1205
17543	1232
17543	44971
17544	1183
17544	1188
17544	1218
17544	1232
17544	1233
17545	1183
17545	1188
17545	1198
17545	1218
17545	1233
17546	1183
17546	1188
17546	1198
17546	1205
17546	45017
17547	1183
17547	1188
17547	1198
17547	1218
17547	1233
17548	1183
17548	1188
17548	1232
17548	1233
17548	1261
17549	1183
17549	1188
17549	1218
17549	1232
17549	1233
17550	1183
17550	1188
17550	1205
17550	1218
17550	1232
17551	1183
17551	1188
17551	1217
17551	1232
17551	1233
17552	1183
17552	1188
17552	1218
17552	1229
17552	1233
17553	1183
17553	1188
17553	1206
17553	1218
17553	1232
17554	1183
17554	1188
17554	1218
17554	1232
17554	1233
17555	1183
17555	1188
17555	1206
17555	1218
17555	1232
17556	1183
17556	1191
17556	1218
17556	1232
17556	1233
17557	1183
17557	1188
17557	1204
17557	1218
17557	1232
17558	1183
17558	1188
17558	1205
17558	1222
17558	1232
17559	1183
17559	1188
17559	1206
17559	1217
17559	1232
17560	1183
17560	1188
17560	1218
17560	1229
17560	1233
17561	1183
17561	1218
17561	1232
17561	1233
17561	1239
17562	1183
17562	1188
17562	1198
17562	1204
17562	1206
17562	1218
17563	1183
17563	1188
17563	1206
17563	1218
17563	1232
17564	1183
17564	1188
17564	1198
17564	1218
17564	1233
17565	1183
17565	1188
17565	1218
17565	1232
17565	1233
17566	1183
17566	1188
17566	1204
17566	1218
17566	1232
17570	1183
17570	1188
17570	1198
17570	1204
17570	1218
17572	1183
17572	1188
17572	1232
17572	1233
17572	44970
17573	1183
17573	1188
17573	1232
17573	1233
17573	44992
17574	1183
17574	1188
17574	1232
17574	1233
17574	1243
17575	1183
17575	1206
17575	1213
17575	1232
17575	1239
17577	1183
17577	1188
17577	1229
17577	1233
17577	1243
17578	1183
17578	1188
17578	1213
17578	1232
17578	1233
17578	1247
17579	1183
17579	1188
17579	1204
17579	1218
17579	1232
17580	1183
17580	1188
17580	1204
17580	1218
17580	1229
17581	1183
17581	1188
17581	1218
17581	1232
17581	1233
17582	1183
17582	1188
17582	1204
17582	1218
17582	1232
17583	1183
17583	1188
17583	1198
17583	1204
17583	1218
17584	1183
17584	1188
17584	1198
17584	1218
17584	1233
17585	1183
17585	1188
17585	1206
17585	1217
17585	1232
17586	1183
17586	1188
17586	1206
17586	1221
17586	1232
17587	1183
17587	1188
17587	1204
17587	1232
17587	44968
17588	1183
17588	1188
17588	1206
17588	1221
17588	1232
17589	1183
17589	1188
17589	1204
17589	1221
17589	1232
17590	1183
17590	1188
17590	1206
17590	1232
17590	44968
17593	1183
17593	1188
17593	1206
17593	1218
17593	1229
17594	1183
17594	1188
17594	1206
17594	1218
17594	1229
17595	1183
17595	1188
17595	1205
17595	1218
17595	1229
17596	1183
17596	1188
17596	1205
17596	1229
17596	44970
17597	1183
17597	1188
17597	1206
17597	1218
17597	1229
17598	1183
17598	1188
17598	1198
17598	1218
17598	1233
17599	1183
17599	1188
17599	1218
17599	1232
17599	1233
17600	1183
17600	1188
17600	1229
17600	1233
17600	44986
17601	1183
17601	1188
17601	1218
17601	1232
17601	1233
17602	1183
17602	1188
17602	1205
17602	1218
17602	1232
17603	1183
17603	1188
17603	1218
17603	1232
17603	1233
17604	1183
17604	1188
17604	1206
17604	1218
17604	1232
17605	1183
17605	1188
17605	1232
17605	1233
17605	44974
17606	1183
17606	1188
17606	1206
17606	1232
17606	44974
17607	1183
17607	1188
17607	1206
17607	1221
17607	1232
17610	1183
17610	1188
17610	1206
17610	1217
17610	1232
17611	1183
17611	1188
17611	1218
17611	1229
17611	1233
17612	1183
17612	1188
17612	1205
17612	1218
17612	1232
17613	1183
17613	1188
17613	1198
17613	1204
17613	1218
17614	1183
17614	1188
17614	1209
17614	1232
17614	1233
17615	1183
17615	1188
17615	1198
17615	1204
17615	1218
17616	1183
17616	1188
17616	1205
17616	1217
17616	1232
17618	1183
17618	1188
17618	1206
17618	1221
17618	1232
17619	1183
17619	1188
17619	1206
17619	1218
17619	1232
17620	1183
17620	1188
17620	1218
17620	1232
17620	1233
17621	1183
17621	1188
17621	1206
17621	1218
17621	1232
17622	1183
17622	1188
17622	1198
17622	1204
17622	1218
17623	1183
17623	1188
17623	1206
17623	1218
17623	1232
17624	1183
17624	1188
17624	1218
17624	1229
17624	1233
17625	1183
17625	1188
17625	1218
17625	1229
17625	1233
17626	1183
17626	1204
17626	1218
17626	1229
17626	1239
17627	1183
17627	1188
17627	1218
17627	1232
17627	1233
17628	1183
17628	1188
17628	1206
17628	1221
17628	1232
17629	1183
17629	1188
17629	1198
17629	1206
17629	1218
17630	1183
17630	1218
17630	1232
17630	1233
17630	1239
17631	1183
17631	1188
17631	1232
17631	1233
17631	44970
17632	1183
17632	1188
17632	1218
17632	1232
17632	1233
17633	1183
17633	1188
17633	1221
17633	1232
17633	1233
17634	1183
17634	1188
17634	1206
17634	1217
17634	1232
17636	1183
17636	1188
17636	1205
17636	1221
17636	1232
17637	1183
17637	1188
17637	1217
17637	1232
17637	1233
17638	1183
17638	1188
17638	1213
17638	1232
17638	1233
17639	1183
17639	1188
17639	1217
17639	1232
17639	1233
17640	1183
17640	1188
17640	1232
17640	1233
17640	44974
17641	1183
17641	1188
17641	1218
17641	1232
17641	1233
17642	1183
17642	1188
17642	1204
17642	1218
17642	1232
17643	1183
17643	1188
17643	1217
17643	1232
17643	1233
17644	1183
17644	1188
17644	1204
17644	1218
17644	1232
17645	1183
17645	1188
17645	1204
17645	1232
17645	44983
17646	1183
17646	1188
17646	1206
17646	1218
17646	1232
17647	1183
17647	1188
17647	1198
17647	1204
17647	1218
17648	1183
17648	1188
17648	1206
17648	1218
17648	1232
17649	1183
17649	1188
17649	1218
17649	1232
17649	1233
17650	1183
17650	1188
17650	1206
17650	1217
17650	1232
17653	1183
17653	1188
17653	1199
17653	1204
17653	1218
17654	1183
17654	1188
17654	1206
17654	1229
17654	44968
17655	1183
17655	1188
17655	1206
17655	1218
17655	1232
17656	1183
17656	1188
17656	1198
17656	1218
17656	1233
17657	1183
17657	1188
17657	1217
17657	1232
17657	1233
17658	1183
17658	1188
17658	1232
17658	1233
17658	45161
17659	1183
17659	1188
17659	1218
17659	1232
17659	1233
17660	1183
17660	1188
17660	1206
17660	1217
17660	1232
17661	1183
17661	1188
17661	1206
17661	1232
17661	44971
17662	1183
17662	1188
17662	1206
17662	1218
17662	1232
17664	1183
17664	1188
17664	1218
17664	1232
17664	1233
17665	1183
17665	1188
17665	1206
17665	1217
17665	1232
17667	1183
17667	1188
17667	1206
17667	1213
17667	1232
17668	1183
17668	1188
17668	1205
17668	1218
17668	1232
17669	1183
17669	1188
17669	1205
17669	1232
17669	44974
17670	1183
17670	1188
17670	1205
17670	1232
17670	44968
17672	1183
17672	1188
17672	1218
17672	1229
17672	1233
17673	1183
17673	1188
17673	1218
17673	1232
17673	1233
17674	1183
17674	1188
17674	1206
17674	1218
17674	1232
17675	1183
17675	1188
17675	1204
17675	1218
17675	1232
17676	1183
17676	1188
17676	1218
17676	1232
17676	1233
17677	1183
17677	1188
17677	1232
17677	1233
17677	44974
17678	1183
17678	1188
17678	1206
17678	1218
17678	1232
17679	1183
17679	1188
17679	1232
17679	1233
17679	44968
17680	1183
17680	1188
17680	1206
17680	1222
17680	1232
17681	1183
17681	1188
17681	1232
17681	1233
17681	44974
17682	1183
17682	1188
17682	1218
17682	1232
17682	1233
17683	1183
17683	1188
17683	1218
17683	1232
17683	1233
17684	1183
17684	1188
17684	1218
17684	1232
17684	1233
17685	1183
17685	1188
17685	1206
17685	1218
17685	1232
17687	1183
17687	1188
17687	1200
17687	1218
17687	1233
17688	1183
17688	1188
17688	1218
17688	1232
17688	1233
17689	1183
17689	1188
17689	1222
17689	1232
17689	1233
17690	1183
17690	1188
17690	1218
17690	1232
17690	1233
17692	1183
17692	1188
17692	1198
17692	1218
17692	1233
17693	1183
17693	1188
17693	1232
17693	1233
17693	45533
17694	1183
17694	1188
17694	1200
17694	1218
17694	1233
17695	1183
17695	1188
17695	1232
17695	1233
17695	44974
17696	1183
17696	1188
17696	1200
17696	1218
17696	1233
17697	1183
17697	1188
17697	1200
17697	1206
17697	1218
17698	1183
17698	1188
17698	1200
17698	1218
17698	1233
17699	1183
17699	1188
17699	1218
17699	1232
17699	1233
17700	1183
17700	1188
17700	1218
17700	1229
17700	1233
17701	1183
17701	1188
17701	1205
17701	1218
17701	1229
17702	1183
17702	1188
17702	1198
17702	1218
17702	1233
17703	1183
17703	1188
17703	1198
17703	1206
17703	1221
17704	1183
17704	1188
17704	1206
17704	1232
17704	44968
17706	1183
17706	1188
17706	1198
17706	1205
17706	1218
17707	1183
17707	1188
17707	1205
17707	1218
17707	1232
17708	1183
17708	1188
17708	1218
17708	1232
17708	1233
17709	1183
17709	1188
17709	1206
17709	1218
17709	1232
17710	1183
17710	1188
17710	1204
17710	1218
17710	1232
17711	1183
17711	1188
17711	1206
17711	1218
17711	1232
17712	1183
17712	1188
17712	1198
17712	1210
17712	1233
17713	1183
17713	1188
17713	1206
17713	1221
17713	1232
17714	1183
17714	1188
17714	1206
17714	1218
17714	1232
17715	1183
17715	1188
17715	1206
17715	1218
17715	1229
17716	1183
17716	1188
17716	1204
17716	1232
17716	44971
17717	1183
17717	1188
17717	1198
17717	1205
17717	1218
17718	1183
17718	1188
17718	1206
17718	1229
17718	44971
17719	1183
17719	1188
17719	1218
17719	1232
17719	1233
17720	1183
17720	1188
17720	1232
17720	1233
17720	44974
17721	1183
17721	1188
17721	1198
17721	1205
17721	1218
17722	1183
17722	1188
17722	1204
17722	1218
17722	1232
17723	1183
17723	1188
17723	1204
17723	1218
17723	1229
17724	1183
17724	1188
17724	1218
17724	1229
17724	1233
17725	1183
17725	1188
17725	1200
17725	1233
17725	44974
17726	1183
17726	1198
17726	1205
17726	1210
17726	1239
17727	1183
17727	1188
17727	1206
17727	1232
17727	1263
17728	1183
17728	1188
17728	1198
17728	1205
17728	1218
17729	1183
17729	1188
17729	1206
17729	1218
17729	1229
17730	1183
17730	1188
17730	1204
17730	1218
17730	1232
17731	1183
17731	1188
17731	1206
17731	1218
17731	1232
17732	1183
17732	1188
17732	1198
17732	1206
17732	1218
17733	1183
17733	1188
17733	1218
17733	1232
17733	1233
17734	1183
17734	1188
17734	1218
17734	1232
17734	1233
17735	1183
17735	1198
17735	1205
17735	1218
17735	1239
17736	1183
17736	1188
17736	1218
17736	1232
17736	1233
17737	1183
17737	1205
17737	1218
17737	1232
17737	1239
17738	1183
17738	1188
17738	1218
17738	1232
17738	1233
17739	1183
17739	1188
17739	1206
17739	1213
17739	1232
17741	1183
17741	1188
17741	1206
17741	1217
17741	1229
17742	1183
17742	1188
17742	1218
17742	1229
17742	1233
17743	1183
17743	1188
17743	1218
17743	1229
17743	1233
17744	1183
17744	1188
17744	1205
17744	1221
17744	1232
17745	1183
17745	1188
17745	1218
17745	1232
17745	1233
17746	1183
17746	1205
17746	1232
17746	1239
17746	44971
17747	1183
17747	1188
17747	1206
17747	1218
17747	1229
17748	1183
17748	1188
17748	1204
17748	1232
17748	44971
17750	1183
17750	1188
17750	1205
17750	1218
17750	1232
17751	1183
17751	1188
17751	1206
17751	1218
17751	1232
17752	1183
17752	1199
17752	1205
17752	1218
17752	1239
17754	1183
17754	1188
17754	1218
17754	1232
17754	1233
17755	1183
17755	1188
17755	1198
17755	1204
17755	1218
17756	1183
17756	1188
17756	1232
17756	1233
17756	44970
17757	1183
17757	1188
17757	1218
17757	1232
17757	1233
17758	1183
17758	1188
17758	1218
17758	1232
17758	1233
17759	1183
17759	1188
17759	1206
17759	1232
17759	44970
17760	1183
17760	1188
17760	1206
17760	1217
17760	1232
17761	1183
17761	1188
17761	1206
17761	1218
17761	1229
17762	1183
17762	1188
17762	1204
17762	1218
17762	1232
17763	1183
17763	1188
17763	1200
17763	1218
17763	1233
17764	1183
17764	1188
17764	1204
17764	1218
17764	1232
17766	1183
17766	1188
17766	1218
17766	1232
17766	1233
17767	1183
17767	1188
17767	1206
17767	1218
17767	1229
17768	1183
17768	1188
17768	1218
17768	1232
17768	1233
17769	1183
17769	1188
17769	1206
17769	1217
17769	1232
17770	1183
17770	1188
17770	1204
17770	1218
17770	1232
17771	1183
17771	1188
17771	1200
17771	1204
17771	1218
17772	1183
17772	1188
17772	1206
17772	1217
17772	1232
17773	1183
17773	1188
17773	1206
17773	1218
17773	1232
17774	1183
17774	1188
17774	1205
17774	1218
17774	1232
17775	1183
17775	1188
17775	1198
17775	1217
17775	1233
17776	1183
17776	1188
17776	1206
17776	1218
17776	1232
17777	1183
17777	1204
17777	1218
17777	1232
17777	1239
17778	1183
17778	1188
17778	1205
17778	1218
17778	1232
17779	1183
17779	1188
17779	1206
17779	1218
17779	1232
17780	1183
17780	1188
17780	1218
17780	1232
17780	1233
17781	1183
17781	1188
17781	1218
17781	1232
17781	1233
17782	1183
17782	1188
17782	1206
17782	1217
17782	1232
17783	1183
17783	1188
17783	1206
17783	1218
17783	1229
17786	1183
17786	1188
17786	1200
17786	1206
17786	1218
17787	1183
17787	1188
17787	1218
17787	1232
17787	1233
17788	1183
17788	1188
17788	1204
17788	1218
17788	1232
17789	1183
17789	1188
17789	1206
17789	1221
17789	1232
17790	1183
17790	1188
17790	1198
17790	1206
17790	1218
17791	1183
17791	1188
17791	1206
17791	1217
17791	1232
17792	1183
17792	1210
17792	1232
17792	1233
17792	1239
17793	1183
17793	1188
17793	1206
17793	1218
17793	1229
17794	1183
17794	1188
17794	1206
17794	1218
17794	1229
17795	1183
17795	1188
17795	1218
17795	1232
17795	1233
17797	1183
17797	1188
17797	1198
17797	1204
17797	1218
17798	1183
17798	1188
17798	1198
17798	1204
17798	1218
17799	1183
17799	1188
17799	1229
17799	1233
17799	44974
17800	1183
17800	1188
17800	1229
17800	1233
17800	44970
17801	1183
17801	1188
17801	1218
17801	1232
17801	1233
17802	1183
17802	1188
17802	1206
17802	1218
17802	1232
17803	1183
17803	1188
17803	1206
17803	1229
17803	44968
17804	1183
17804	1188
17804	1204
17804	1218
17804	1232
17805	1183
17805	1188
17805	1198
17805	1204
17805	1218
17806	1183
17806	1188
17806	1205
17806	1218
17806	1232
17808	1183
17808	1188
17808	1206
17808	1232
17808	44974
17809	1183
17809	1232
17809	1233
17809	1239
17809	45017
17810	1183
17810	1188
17810	1217
17810	1229
17810	1233
17811	1183
17811	1188
17811	1206
17811	1232
17811	45339
17812	1183
17812	1188
17812	1206
17812	1232
17812	45045
17813	1183
17813	1188
17813	1204
17813	1232
17813	45045
17814	1183
17814	1188
17814	1206
17814	1218
17814	1232
17815	1183
17815	1188
17815	1205
17815	1213
17815	1232
17816	1183
17816	1188
17816	1218
17816	1232
17816	1233
17817	1183
17817	1188
17817	1198
17817	1204
17817	1218
17818	1183
17818	1188
17818	1206
17818	1229
17818	44968
17819	1183
17819	1188
17819	1206
17819	1218
17819	1229
17820	1183
17820	1188
17820	1213
17820	1232
17820	1233
17821	1183
17821	1188
17821	1232
17821	1233
17821	45118
17822	1183
17822	1188
17822	1218
17822	1232
17822	1233
17823	1183
17823	1188
17823	1213
17823	1232
17823	1233
17824	1183
17824	1188
17824	1218
17824	1232
17824	1233
17825	1183
17825	1188
17825	1204
17825	1232
17825	44970
17826	1183
17826	1188
17826	1200
17826	1218
17826	1233
17827	1183
17827	1188
17827	1200
17827	1233
17827	44974
17828	1183
17828	1188
17828	1232
17828	1233
17828	44974
17829	1183
17829	1188
17829	1218
17829	1232
17829	1233
17830	1183
17830	1188
17830	1206
17830	1217
17830	1229
17831	1183
17831	1188
17831	1203
17831	1217
17831	1232
17832	1183
17832	1188
17832	1204
17832	1217
17832	1232
17833	1183
17833	1188
17833	1218
17833	1232
17833	1233
17834	1183
17834	1188
17834	1232
17834	1233
17834	1247
17835	1183
17835	1188
17835	1206
17835	1221
17835	1232
17836	1183
17836	1188
17836	1206
17836	1221
17836	1232
17837	1183
17837	1188
17837	1217
17837	1232
17837	1233
17838	1183
17838	1188
17838	1206
17838	1232
17838	45183
17839	1183
17839	1188
17839	1204
17839	1218
17839	1232
17840	1183
17840	1188
17840	1232
17840	1233
17840	45181
17841	1183
17841	1188
17841	1206
17841	1232
17841	45181
17842	1183
17842	1188
17842	1206
17842	1232
17842	45181
17843	1183
17843	1188
17843	1206
17843	1218
17843	1232
17844	1183
17844	1188
17844	1217
17844	1232
17844	1233
17845	1183
17845	1188
17845	1205
17845	1218
17845	1232
17846	1183
17846	1188
17846	1206
17846	1218
17846	1232
17847	1183
17847	1188
17847	1206
17847	1229
17847	45045
17849	1183
17849	1188
17849	1206
17849	1218
17849	1232
17850	1183
17850	1188
17850	1217
17850	1232
17850	1233
17851	1183
17851	1188
17851	1206
17851	1232
17851	45183
17852	1183
17852	1188
17852	1206
17852	1218
17852	1232
17853	1183
17853	1188
17853	1206
17853	1218
17853	1232
17854	1183
17854	1188
17854	1206
17854	1218
17854	1232
17855	1183
17855	1198
17855	1218
17855	1233
17855	1239
17856	1183
17856	1188
17856	1205
17856	1218
17856	1232
17857	1183
17857	1188
17857	1218
17857	1232
17857	1233
17858	1183
17858	1188
17858	1206
17858	1221
17858	1232
17859	1183
17859	1191
17859	1232
17859	1233
17859	45204
17860	1183
17860	1188
17860	1218
17860	1229
17860	1233
17861	1183
17861	1188
17861	1200
17861	1218
17861	1233
17862	1183
17862	1188
17862	1206
17862	1217
17862	1232
17863	1183
17863	1188
17863	1206
17863	1218
17863	1232
17864	1183
17864	1188
17864	1206
17864	1218
17864	1232
17865	1183
17865	1188
17865	1206
17865	1218
17865	1232
17866	1183
17866	1188
17866	1206
17866	1218
17866	1232
17867	1183
17867	1188
17867	1199
17867	1206
17867	1218
17868	1183
17868	1194
17868	1198
17868	1206
17868	1218
17869	1183
17869	1188
17869	1206
17869	1218
17869	1229
17872	1183
17872	1198
17872	1205
17872	1218
17872	1239
17876	1183
17876	1188
17876	1206
17876	1218
17876	1229
17878	1183
17878	1194
17878	1206
17878	1218
17878	1229
17881	1183
17881	1194
17881	1218
17881	1232
17881	1233
17883	1183
17883	1188
17883	1218
17883	1232
17883	1233
17884	1183
17884	1194
17884	1198
17884	1218
17884	1233
17885	1183
17885	1188
17885	1221
17885	1232
17885	1233
17886	1183
17886	1194
17886	1206
17886	1218
17886	1232
17887	1188
17887	1218
17887	1229
17887	1233
17887	45238
17888	1188
17888	1218
17888	1232
17888	1233
17888	45238
17894	1183
17894	1188
17894	1203
17894	1218
17894	1232
17895	1183
17895	1188
17895	1198
17895	1218
17895	1233
17896	1183
17896	1188
17896	1206
17896	1218
17896	1229
17897	1183
17897	1188
17897	1206
17897	1218
17897	1232
17900	1188
17900	1198
17900	1233
17900	1244
17900	45238
17901	1183
17901	1188
17901	1198
17901	1206
17901	1218
17902	1188
17902	1200
17902	1206
17902	1218
17902	1232
17902	1233
17902	45236
17902	45238
17904	1178
17904	1188
17904	1218
17904	1232
17904	1233
17905	1183
17905	1188
17905	1198
17905	1218
17905	1233
17906	1183
17906	1188
17906	1218
17906	1232
17906	1233
17910	1183
17910	1188
17910	1206
17910	1218
17910	1229
17916	1188
17916	1218
17916	1232
17916	1233
17916	45236
17917	1183
17917	1188
17917	1198
17917	1206
17917	1218
17918	1183
17918	1188
17918	1218
17918	1232
17918	1233
17919	1183
17919	1188
17919	1198
17919	1206
17919	1218
17920	1183
17920	1188
17920	1198
17920	1206
17920	1218
17921	1183
17921	1188
17921	1206
17921	1218
17921	1229
17925	1183
17925	1188
17925	1206
17925	1217
17925	1232
17926	1183
17926	1188
17926	1206
17926	1218
17926	1232
17927	1183
17927	1188
17927	1222
17927	1232
17927	1233
17928	1183
17928	1188
17928	1218
17928	1229
17928	1233
17929	1183
17929	1188
17929	1198
17929	1217
17929	1233
17930	1183
17930	1188
17930	1206
17930	1218
17930	1232
17931	1183
17931	1188
17931	1218
17931	1232
17931	1233
17932	1183
17932	1188
17932	1218
17932	1232
17932	1233
17933	1183
17933	1188
17933	1218
17933	1232
17933	1233
17934	1183
17934	1188
17934	1218
17934	1232
17934	1233
17936	1183
17936	1188
17936	1198
17936	1205
17936	1218
17936	1232
17936	1233
17939	1188
17939	1232
17939	1233
17939	1247
17939	45236
17941	1183
17941	1188
17941	1198
17941	1218
17941	1233
17942	1182
17942	1188
17942	1198
17942	1218
17942	1233
17943	1183
17943	1188
17943	1218
17943	1232
17943	1233
17944	1183
17944	1188
17944	1218
17944	1229
17944	1233
17945	1183
17945	1188
17945	1218
17945	1232
17945	1233
17946	1183
17946	1188
17946	1198
17946	1218
17946	1233
17947	1183
17947	1188
17947	1198
17947	1218
17947	1233
17949	1183
17949	1188
17949	1218
17949	1232
17949	1233
17950	1183
17950	1194
17950	1218
17950	1232
17950	1233
17951	1183
17951	1188
17951	1206
17951	1218
17951	1229
17953	1183
17953	1194
17953	1198
17953	1233
17953	1244
17954	1183
17954	1188
17954	1198
17954	1218
17954	1233
17955	1183
17955	1188
17955	1198
17955	1221
17955	1233
17956	1183
17956	1188
17956	1198
17956	1218
17956	1233
17957	1183
17957	1194
17957	1198
17957	1218
17957	1233
17958	1183
17958	1194
17958	1198
17958	1218
17958	1233
17959	1182
17959	1188
17959	1198
17959	1233
17959	45548
17961	1183
17961	1194
17961	1218
17961	1232
17961	1233
17962	1183
17962	1188
17962	1217
17962	1229
17962	1233
17964	1183
17964	1188
17964	1198
17964	1218
17964	1233
17965	1183
17965	1188
17965	1198
17965	1218
17965	1233
17966	1183
17966	1188
17966	1194
17966	1218
17966	1232
17966	1233
17967	1183
17967	1194
17967	1218
17967	1229
17967	1233
17968	1183
17968	1188
17968	1198
17968	1218
17968	1233
17969	1183
17969	1188
17969	1218
17969	1232
17969	1233
17970	1183
17970	1188
17970	1218
17970	1229
17970	1233
17971	1183
17971	1188
17971	1217
17971	1229
17971	1233
17972	1183
17972	1188
17972	1218
17972	1229
17972	1233
17973	1183
17973	1188
17973	1217
17973	1229
17973	1233
17974	1183
17974	1194
17974	1204
17974	1218
17974	1232
17975	1183
17975	1188
17975	1218
17975	1232
17975	1233
17976	1183
17976	1194
17976	1206
17976	1218
17976	1232
17978	1183
17978	1188
17978	1198
17978	1210
17978	1233
17984	1183
17984	1204
17984	1218
17984	1232
17984	1239
17986	1183
17986	1194
17986	1198
17986	1218
17986	1233
17988	1183
17988	1188
17988	1206
17988	1218
17988	1229
17990	1183
17990	1188
17990	1204
17990	1218
17990	1232
17991	1183
17991	1188
17991	1205
17991	1218
17991	1232
17991	1233
17991	45236
17992	1183
17992	1188
17992	1218
17992	1232
17992	1233
17993	1183
17993	1194
17993	1218
17993	1232
17993	1233
17994	1183
17994	1188
17994	1218
17994	1232
17994	1233
17995	1183
17995	1188
17995	1198
17995	1218
17995	1233
17996	1178
17996	1188
17996	1218
17996	1232
17996	1233
17998	1183
17998	1194
17998	1221
17998	1232
17998	1233
17999	1178
17999	1188
17999	1197
17999	1201
17999	1218
18002	1188
18002	1213
18002	1232
18002	1233
18002	45238
18004	1183
18004	1194
18004	1218
18004	1232
18004	1233
18013	1183
18013	1188
18013	1198
18013	1206
18013	1218
18015	1183
18015	1188
18015	1218
18015	1229
18015	1233
18017	1183
18017	1188
18017	1199
18017	1233
18017	44971
18018	1183
18018	1194
18018	1198
18018	1218
18018	1233
18019	1183
18019	1188
18019	1204
18019	1206
18019	1218
18019	1232
18019	44971
18019	45236
18020	1183
18020	1194
18020	1206
18020	1221
18020	1232
18020	45181
18021	1183
18021	1194
18021	1205
18021	1218
18021	1229
18022	1188
18022	1206
18022	1218
18022	1232
18022	45236
18031	1183
18031	1194
18031	1218
18031	1232
18031	1233
18032	1183
18032	1196
18032	1198
18032	1218
18032	1233
18033	1178
18033	1188
18033	1197
18033	1201
18033	1218
18034	1183
18034	1188
18034	1218
18034	1229
18034	1233
18035	1183
18035	1188
18035	1232
18035	1233
18035	44968
18036	1183
18036	1196
18036	1218
18036	1232
18036	1233
18037	1183
18037	1194
18037	1218
18037	1232
18037	1233
18038	1183
18038	1188
18038	1218
18038	1229
18038	1233
18039	1183
18039	1188
18039	1218
18039	1229
18039	1233
18040	1183
18040	1188
18040	1218
18040	1229
18040	1233
18041	1183
18041	1188
18041	1218
18041	1229
18041	1233
18042	1183
18042	1204
18042	1218
18042	1232
18042	1239
18043	1183
18043	1194
18043	1222
18043	1232
18043	1233
18044	1183
18044	1194
18044	1218
18044	1232
18044	1233
18045	1183
18045	1188
18045	1206
18045	1221
18045	1232
18047	1188
18047	1218
18047	1232
18047	1233
18047	45236
18051	1188
18051	1218
18051	1232
18051	1233
18051	45238
18053	1183
18053	1188
18053	1218
18053	1229
18053	1233
18056	1183
18056	1188
18056	1221
18056	1232
18056	1233
18057	1183
18057	1194
18057	1218
18057	1232
18057	1233
18058	1183
18058	1194
18058	1218
18058	1232
18058	1233
18060	1183
18060	1188
18060	1206
18060	1218
18060	1229
18061	1183
18061	1194
18061	1198
18061	1206
18061	1218
18063	1183
18063	1193
18063	1218
18063	1232
18063	1233
18064	1183
18064	1194
18064	1232
18064	1233
18064	1276
18065	1180
18065	1188
18065	1197
18065	1201
18065	1218
18066	1183
18066	1199
18066	1204
18066	1218
18066	1249
18067	1183
18067	1188
18067	1218
18067	1232
18067	1233
18068	1183
18068	1188
18068	1218
18068	1232
18068	1233
18069	1183
18069	1188
18069	1218
18069	1229
18069	1233
18071	1183
18071	1188
18071	1206
18071	1218
18071	1232
18072	1183
18072	1188
18072	1218
18072	1232
18072	1233
18073	1183
18073	1188
18073	1218
18073	1232
18073	1233
18074	1183
18074	1194
18074	1218
18074	1232
18074	1233
18075	1183
18075	1188
18075	1218
18075	1232
18075	1233
18076	1183
18076	1188
18076	1217
18076	1229
18076	1233
18079	1183
18079	1188
18079	1206
18079	1218
18079	1232
18080	1183
18080	1188
18080	1198
18080	1218
18080	1233
18081	1183
18081	1194
18081	1218
18081	1229
18081	1233
18082	1183
18082	1194
18082	1218
18082	1229
18082	1233
18083	1183
18083	1188
18083	1198
18083	1218
18083	1233
18084	1183
18084	1188
18084	1218
18084	1232
18084	1233
18085	1183
18085	1188
18085	1209
18085	1232
18085	1233
18086	1183
18086	1194
18086	1218
18086	1232
18086	1233
18087	1183
18087	1188
18087	1198
18087	1218
18087	1233
18088	1183
18088	1194
18088	1232
18088	1233
18088	1276
18088	45583
18089	1188
18089	1218
18089	1232
18089	1233
18089	45236
18091	1183
18091	1188
18091	1218
18091	1232
18091	1233
18092	1183
18092	1188
18092	1198
18092	1218
18092	1233
18093	1183
18093	1188
18093	1218
18093	1232
18093	1233
18094	1188
18094	1218
18094	1232
18094	1233
18094	45236
18095	1183
18095	1188
18095	1204
18095	1218
18095	1232
18098	1183
18098	1188
18098	1218
18098	1232
18098	1233
18100	1188
18100	1218
18100	1232
18100	1233
18100	45238
18101	1183
18101	1188
18101	1204
18101	1218
18101	1232
18102	1188
18102	1218
18102	1232
18102	1233
18102	45236
18103	1183
18103	1188
18103	1206
18103	1218
18103	1229
18104	1183
18104	1188
18104	1218
18104	1232
18104	1233
18105	1183
18105	1194
18105	1218
18105	1232
18105	1233
18107	1183
18107	1188
18107	1204
18107	1218
18107	1232
18108	1183
18108	1188
18108	1218
18108	1229
18108	1233
18110	1183
18110	1188
18110	1205
18110	1218
18110	1232
18111	1183
18111	1188
18111	1204
18111	1218
18111	1229
18113	1188
18113	1218
18113	1232
18113	1233
18113	45236
18114	1188
18114	1204
18114	1218
18114	1232
18114	45236
18115	1183
18115	1188
18115	1205
18115	1218
18115	1232
18117	1183
18117	1188
18117	1218
18117	1232
18117	1233
18118	1183
18118	1194
18118	1218
18118	1232
18118	1233
18119	1183
18119	1188
18119	1217
18119	1229
18119	1233
18120	1183
18120	1194
18120	1218
18120	1229
18120	1233
18121	1183
18121	1194
18121	1218
18121	1229
18121	1233
18122	1188
18122	1218
18122	1232
18122	1233
18122	45236
18123	1183
18123	1188
18123	1218
18123	1232
18123	1233
18124	1183
18124	1188
18124	1218
18124	1232
18124	1233
18125	1188
18125	1232
18125	1233
18125	1246
18125	45236
18126	1183
18126	1188
18126	1218
18126	1232
18126	1233
18127	1183
18127	1194
18127	1218
18127	1232
18127	1233
18129	1183
18129	1188
18129	1218
18129	1232
18129	1233
18130	1188
18130	1218
18130	1232
18130	1233
18130	45236
18131	1188
18131	1232
18131	1233
18131	1246
18131	45238
18132	1182
18132	1188
18132	1218
18132	1232
18132	1233
18133	1183
18133	1194
18133	1218
18133	1232
18133	1233
18134	1183
18134	1194
18134	1203
18134	1218
18134	1229
18134	1232
18134	1233
18134	44971
18135	1183
18135	1188
18135	1218
18135	1229
18135	1233
18136	1183
18136	1188
18136	1205
18136	1218
18136	1229
18141	1183
18141	1188
18141	1198
18141	1218
18141	1233
18142	1183
18142	1194
18142	1232
18142	1233
18142	1246
18143	1183
18143	1188
18143	1206
18143	1218
18143	1229
18144	1183
18144	1188
18144	1206
18144	1218
18144	1232
18146	1183
18146	1194
18146	1206
18146	1218
18146	1232
18147	1183
18147	1188
18147	1218
18147	1229
18147	1233
18148	1183
18148	1194
18148	1198
18148	1206
18148	1218
18149	1183
18149	1194
18149	1198
18149	1218
18149	1233
18156	1188
18156	1198
18156	1233
18156	1246
18156	45236
18157	1183
18157	1218
18157	1232
18157	1233
18157	1239
18158	1183
18158	1194
18158	1218
18158	1229
18158	1233
18159	1188
18159	1198
18159	1218
18159	1233
18159	45238
18160	1177
18160	1183
18160	1188
18160	1218
18160	1232
18160	1233
18161	1183
18161	1188
18161	1232
18161	1233
18161	45543
18162	1183
18162	1194
18162	1222
18162	1229
18162	1233
18166	1188
18166	1232
18166	1233
18166	45236
18166	45615
18172	1183
18172	1194
18172	1206
18172	1218
18172	1232
18173	1183
18173	1194
18173	1206
18173	1218
18173	1232
18176	1180
18176	1188
18176	1197
18176	1201
18176	1218
18177	1183
18177	1188
18177	1198
18177	1204
18177	1218
18178	1195
18178	1199
18178	1218
18178	1233
18178	45238
18180	1183
18180	1204
18180	1218
18180	1232
18180	1239
18199	1183
18199	1188
18199	1210
18199	1232
18199	1233
18200	1188
18200	1198
18200	1210
18200	1233
18200	45236
18202	1183
18202	1194
18202	1218
18202	1232
18202	1233
18204	1183
18204	1188
18204	1198
18204	1218
18204	1233
18206	1183
18206	1188
18206	1221
18206	1232
18206	1233
18208	1183
18208	1188
18208	1206
18208	1218
18208	1229
18210	1183
18210	1218
18210	1229
18210	1233
18210	1239
18211	1183
18211	1188
18211	1218
18211	1232
18211	1233
18212	1183
18212	1188
18212	1198
18212	1218
18212	1233
18213	1183
18213	1204
18213	1218
18213	1232
18213	1239
18214	1183
18214	1194
18214	1218
18214	1232
18214	1233
18215	1183
18215	1196
18215	1218
18215	1232
18215	1233
18220	1183
18220	1188
18220	1198
18220	1218
18220	1233
18222	1183
18222	1188
18222	1218
18222	1232
18222	1233
18224	1183
18224	1188
18224	1198
18224	1218
18224	1233
18227	1183
18227	1188
18227	1222
18227	1232
18227	1233
18229	1183
18229	1204
18229	1218
18229	1232
18229	1239
18230	1183
18230	1188
18230	1198
18230	1205
18230	1218
18232	1188
18232	1204
18232	1218
18232	1238
18232	45238
18233	1183
18233	1188
18233	1218
18233	1232
18233	1233
18235	1183
18235	1188
18235	1218
18235	1232
18235	1233
18238	1183
18238	1188
18238	1218
18238	1232
18238	1233
18240	1183
18240	1188
18240	1198
18240	1218
18240	1233
18243	1183
18243	1188
18243	1200
18243	1204
18243	1218
18244	1183
18244	1194
18244	1198
18244	1218
18244	1233
18245	1182
18245	1195
18245	1198
18245	1218
18245	1233
18246	1183
18246	1188
18246	1218
18246	1232
18246	1233
18247	1183
18247	1188
18247	1206
18247	1218
18247	1232
18249	1188
18249	1218
18249	1232
18249	1233
18249	45238
18250	1183
18250	1188
18250	1218
18250	1232
18250	1233
18254	1183
18254	1188
18254	1218
18254	1232
18254	1233
18255	1183
18255	1188
18255	1218
18255	1232
18255	1233
18256	1188
18256	1218
18256	1232
18256	1233
18256	45238
18257	1183
18257	1188
18257	1218
18257	1232
18257	1233
18258	1183
18258	1188
18258	1198
18258	1217
18258	1233
18259	1183
18259	1188
18259	1198
18259	1217
18259	1233
18260	1183
18260	1194
18260	1218
18260	1232
18260	1233
18261	1183
18261	1188
18261	1218
18261	1229
18261	1233
18265	1183
18265	1188
18265	1222
18265	1232
18265	1233
18268	1183
18268	1188
18268	1198
18268	1218
18268	1233
18271	1183
18271	1188
18271	1198
18271	1218
18271	1233
18279	1183
18279	1194
18279	1232
18279	1233
18279	45181
18281	1183
18281	1188
18281	1217
18281	1229
18281	1233
18282	1183
18282	1188
18282	1218
18282	1229
18282	1233
18283	1183
18283	1194
18283	1198
18283	1233
18283	1247
18284	1183
18284	1194
18284	1205
18284	1218
18284	1232
18285	1183
18285	1188
18285	1204
18285	1218
18285	1238
18287	1183
18287	1188
18287	1218
18287	1232
18287	1233
18289	1183
18289	1188
18289	1198
18289	1206
18289	1217
18290	1178
18290	1188
18290	1197
18290	1201
18290	1218
18291	1183
18291	1188
18291	1198
18291	1206
18291	1218
18293	1183
18293	1188
18293	1198
18293	1218
18293	1233
18294	1183
18294	1194
18294	1198
18294	1233
18294	1247
18295	1183
18295	1194
18295	1218
18295	1232
18295	1233
18298	1183
18298	1194
18298	1232
18298	1233
18298	1257
18299	1183
18299	1188
18299	1206
18299	1217
18299	1232
18300	1183
18300	1188
18300	1218
18300	1232
18300	1233
18301	1183
18301	1195
18301	1206
18301	1229
18301	45536
18302	1183
18302	1188
18302	1198
18302	1206
18302	1218
18304	1183
18304	1188
18304	1222
18304	1232
18304	1233
18306	1183
18306	1188
18306	1206
18306	1232
18306	44983
18307	1183
18307	1194
18307	1218
18307	1232
18307	1233
18313	1183
18313	1204
18313	1218
18313	1232
18313	1239
18328	1183
18328	1194
18328	1206
18328	1218
18328	1229
18329	1183
18329	1194
18329	1206
18329	1218
18329	1229
18332	1183
18332	1188
18332	1232
18332	1233
18332	1243
18337	1183
18337	1188
18337	1205
18337	1218
18337	1229
18337	1232
18337	1233
18337	45236
18339	1183
18339	1194
18339	1204
18339	1232
18339	1246
18340	1188
18340	1196
18340	1199
18340	1218
18340	1232
18340	1233
18340	45236
18342	1183
18342	1196
18342	1206
18342	1218
18342	1232
18343	1188
18343	1205
18343	1232
18343	44968
18343	45236
18349	1183
18349	1188
18349	1218
18349	1232
18349	1233
18350	1183
18350	1188
18350	1222
18350	1232
18350	1233
18351	1183
18351	1188
18351	1218
18351	1232
18351	1233
18352	1183
18352	1194
18352	1220
18352	1229
18352	1233
18353	1183
18353	1188
18353	1220
18353	1229
18353	1233
18354	1183
18354	1194
18354	1232
18354	1233
18354	44968
18354	44971
18355	1183
18355	1194
18355	1232
18355	1233
18355	45543
18356	1183
18356	1188
18356	1221
18356	1232
18356	1233
18358	1183
18358	1188
18358	1198
18358	1204
18358	1218
18360	1183
18360	1188
18360	1198
18360	1218
18360	1233
18361	1183
18361	1188
18361	1198
18361	1218
18361	1233
18362	1183
18362	1194
18362	1218
18362	1232
18362	1233
18367	1183
18367	1196
18367	1218
18367	1229
18367	1233
18368	1183
18368	1188
18368	1218
18368	1229
18368	1233
18369	1183
18369	1188
18369	1198
18369	1206
18369	1218
18370	1183
18370	1194
18370	1218
18370	1229
18370	1233
18371	1183
18371	1194
18371	1199
18371	1218
18371	1233
18373	1183
18373	1194
18373	1232
18373	1233
18373	44971
18374	1183
18374	1194
18374	1206
18374	1213
18374	1232
18378	1183
18378	1194
18378	1206
18378	1217
18378	1232
18379	1183
18379	1194
18379	1206
18379	1218
18379	1232
18382	1183
18382	1194
18382	1206
18382	1218
18382	1229
18383	1183
18383	1188
18383	1218
18383	1232
18383	1233
18387	1183
18387	1194
18387	1205
18387	1218
18387	1232
18390	1183
18390	1188
18390	1199
18390	1222
18390	1233
18392	1183
18392	1188
18392	1218
18392	1232
18392	1233
18393	1188
18393	1218
18393	1232
18393	1233
18393	45238
18394	1183
18394	1188
18394	1199
18394	1206
18394	1218
18399	1183
18399	1194
18399	1218
18399	1232
18399	1233
18401	1183
18401	1188
18401	1218
18401	1229
18401	1233
18402	1183
18402	1188
18402	1218
18402	1232
18402	1233
18403	1183
18403	1188
18403	1222
18403	1232
18403	1233
18408	1183
18408	1206
18408	1229
18408	1239
18408	45561
18410	1188
18410	1218
18410	1232
18410	1233
18410	1237
18413	1183
18413	1194
18413	1198
18413	1218
18413	1233
18414	1188
18414	1218
18414	1232
18414	1233
18414	45236
18415	1183
18415	1188
18415	1218
18415	1232
18415	1233
18417	1183
18417	1188
18417	1217
18417	1229
18417	1233
18418	1183
18418	1188
18418	1218
18418	1232
18418	1233
18419	1196
18419	1199
18419	1218
18419	1233
18419	45236
18420	1183
18420	1194
18420	1218
18420	1232
18420	1233
18421	1183
18421	1188
18421	1232
18421	1233
18421	1243
18422	1188
18422	1232
18422	1233
18422	45238
18422	45543
18423	1183
18423	1194
18423	1222
18423	1232
18423	1233
18424	1183
18424	1188
18424	1218
18424	1229
18424	1233
18425	1183
18425	1194
18425	1218
18425	1232
18425	1233
18427	1183
18427	1194
18427	1218
18427	1232
18427	1233
18428	1183
18428	1194
18428	1218
18428	1232
18428	1233
18429	1183
18429	1188
18429	1206
18429	1218
18429	1232
18430	1183
18430	1188
18430	1218
18430	1232
18430	1233
18431	1183
18431	1188
18431	1218
18431	1232
18431	1233
18432	1183
18432	1188
18432	1206
18432	1220
18432	1232
18443	1183
18443	1188
18443	1232
18443	1233
18443	1246
18449	1183
18449	1194
18449	1218
18449	1232
18449	1233
18453	1195
18453	1199
18453	1204
18453	1218
18453	45236
18458	1188
18458	1198
18458	1233
18458	45238
18458	45548
18458	45549
18460	1183
18460	1196
18460	1218
18460	1229
18460	1233
18462	1183
18462	1188
18462	1206
18462	1218
18462	1232
18463	1183
18463	1194
18463	1200
18463	1204
18463	1244
18475	1183
18475	1194
18475	1206
18475	1218
18475	1232
18482	1196
18482	1204
18482	1218
18482	1229
18482	45236
18487	1188
18487	1206
18487	1218
18487	1232
18487	45238
18502	1183
18502	1188
18502	1206
18502	1217
18502	1232
18511	1183
18511	1188
18511	1205
18511	1218
18511	1232
18525	1183
18525	1194
18525	1218
18525	1232
18525	1233
18527	1183
18527	1188
18527	1198
18527	1233
18527	45548
18530	1183
18530	1194
18530	1218
18530	1232
18530	1233
18533	1183
18533	1194
18533	1222
18533	1229
18533	1233
18536	1183
18536	1188
18536	1218
18536	1232
18536	1233
18538	1183
18538	1188
18538	1222
18538	1232
18538	1233
18540	1183
18540	1194
18540	1232
18540	1233
18540	45543
18543	1183
18543	1188
18543	1198
18543	1205
18543	1218
18551	1183
18551	1188
18551	1206
18551	1218
18551	1232
18553	1183
18553	1188
18553	1218
18553	1232
18553	1233
18556	1188
18556	1198
18556	1206
18556	1218
18556	45238
18558	1183
18558	1188
18558	1231
18558	1232
18558	1233
18560	1183
18560	1194
18560	1232
18560	1233
18560	45339
18562	1183
18562	1188
18562	1218
18562	1229
18562	1233
18565	1183
18565	1194
18565	1232
18565	1233
18565	45545
18566	1183
18566	1194
18566	1205
18566	1229
18566	45168
18568	1183
18568	1194
18568	1232
18568	1233
18568	45194
18569	1188
18569	1218
18569	1232
18569	1233
18569	45238
18570	1183
18570	1194
18570	1218
18570	1232
18570	1233
18572	1188
18572	1205
18572	1218
18572	1238
18572	45238
18574	1183
18574	1193
18574	1218
18574	1232
18574	1233
18575	1183
18575	1188
18575	1206
18575	1221
18575	1232
18576	1183
18576	1188
18576	1198
18576	1233
18576	45538
18579	1188
18579	1232
18579	1233
18579	1246
18579	45238
18580	1180
18580	1188
18580	1197
18580	1201
18580	1218
18581	1183
18581	1194
18581	1198
18581	1206
18581	1218
18582	1183
18582	1194
18582	1198
18582	1218
18582	1233
18586	1183
18586	1194
18586	1198
18586	1233
18586	45181
18593	1183
18593	1188
18593	1229
18593	1233
18593	45546
18594	1183
18594	1194
18594	1204
18594	1218
18594	1232
18598	1183
18598	1194
18598	1198
18598	1218
18598	1233
18599	1183
18599	1188
18599	1206
18599	1218
18599	1232
18605	1183
18605	1188
18605	1206
18605	1218
18605	1229
18608	1183
18608	1194
18608	1198
18608	1233
18608	45194
18609	1183
18609	1188
18609	1199
18609	1206
18609	1218
18611	1183
18611	1191
18611	1204
18611	1232
18611	45183
18611	45539
18611	45554
18612	1183
18612	1188
18612	1205
18612	1206
18612	1232
18612	45194
18613	1183
18613	1188
18613	1232
18613	1233
18613	44971
18616	1183
18616	1188
18616	1218
18616	1232
18616	1233
18618	1183
18618	1188
18618	1218
18618	1232
18618	1233
18619	1183
18619	1194
18619	1204
18619	1218
18619	1232
18620	1183
18620	1188
18620	1198
18620	1218
18620	1233
18621	1183
18621	1194
18621	1199
18621	1205
18621	1218
18623	1183
18623	1194
18623	1204
18623	1218
18623	1232
18624	1183
18624	1188
18624	1218
18624	1232
18624	1233
18625	1183
18625	1194
18625	1198
18625	1206
18625	1218
18626	1188
18626	1222
18626	1232
18626	1233
18626	45238
18629	1183
18629	1194
18629	1198
18629	1204
18629	45561
18630	1188
18630	1232
18630	1233
18630	1246
18630	45238
18631	1188
18631	1205
18631	1232
18631	45238
18631	45538
18632	1183
18632	1194
18632	1229
18632	1233
18632	44983
18633	1183
18633	1188
18633	1229
18633	1233
18633	45181
18635	1188
18635	1218
18635	1232
18635	1233
18635	45236
18638	1183
18638	1194
18638	1218
18638	1232
18638	1233
18639	1183
18639	1188
18639	1198
18639	1218
18639	1233
18640	1183
18640	1194
18640	1218
18640	1232
18640	1233
18641	1183
18641	1194
18641	1218
18641	1232
18641	1233
18642	1183
18642	1194
18642	1218
18642	1232
18642	1233
18689	1183
18689	1194
18689	1218
18689	1229
18689	1233
18690	1183
18690	1194
18690	1206
18690	1229
18690	45584
18696	1183
18696	1188
18696	1204
18696	1218
18696	1232
18698	1183
18698	1194
18698	1232
18698	1233
18698	45181
18703	1183
18703	1194
18703	1200
18703	1206
18703	1218
18703	1229
18703	1233
18718	1183
18718	1194
18718	1232
18718	1233
18718	45543
18720	1183
18720	1194
18720	1218
18720	1232
18720	1233
18723	1183
18723	1188
18723	1218
18723	1229
18723	1233
18727	1183
18727	1194
18727	1232
18727	1233
18727	44968
18727	44971
18728	1183
18728	1188
18728	1218
18728	1229
18728	1233
18730	1183
18730	1194
18730	1232
18730	1233
18730	45545
18731	1183
18731	1193
18731	1222
18731	1232
18731	1233
18732	1183
18732	1188
18732	1206
18732	1218
18732	1229
18733	1183
18733	1188
18733	1198
18733	1218
18733	1233
18734	1183
18734	1194
18734	1218
18734	1232
18734	1233
18735	1183
18735	1188
18735	1232
18735	1233
18735	1247
18736	1183
18736	1196
18736	1218
18736	1232
18736	1233
18738	1195
18738	1218
18738	1232
18738	1233
18738	45238
18739	1183
18739	1188
18739	1217
18739	1232
18739	1233
18739	44971
18740	1183
18740	1188
18740	1213
18740	1232
18740	1233
18741	1183
18741	1196
18741	1218
18741	1232
18741	1233
18743	1183
18743	1194
18743	1218
18743	1232
18743	1233
18744	1183
18744	1188
18744	1218
18744	1232
18744	1233
18745	1183
18745	1194
18745	1232
18745	1233
18745	44983
18746	1183
18746	1188
18746	1218
18746	1232
18746	1233
18750	1188
18750	1198
18750	1209
18750	1233
18750	45236
18751	1188
18751	1198
18751	1218
18751	1233
18751	45238
18753	1188
18753	1232
18753	1233
18753	45238
18753	45377
18758	1183
18758	1188
18758	1218
18758	1229
18758	1233
18759	1183
18759	1188
18759	1206
18759	1217
18759	1229
18763	1188
18763	1232
18763	1233
18763	45181
18763	45236
18764	1188
18764	1232
18764	1233
18764	45236
18764	45561
18765	1188
18765	1204
18765	1218
18765	1232
18765	45236
18766	1188
18766	1204
18766	1232
18766	1243
18766	45236
18768	1183
18768	1193
18768	1204
18768	1229
18768	1243
18769	1188
18769	1204
18769	1218
18769	1232
18769	45236
18770	1183
18770	1194
18770	1205
18770	1218
18770	1232
18773	1183
18773	1188
18773	1204
18773	1218
18773	1229
18775	1188
18775	1204
18775	1218
18775	1232
18775	45236
18777	1188
18777	1204
18777	1218
18777	1232
18777	45236
18779	1188
18779	1204
18779	1232
18779	1246
18779	45236
18784	1188
18784	1204
18784	1218
18784	1232
18784	45236
18785	1188
18785	1204
18785	1222
18785	1232
18785	45236
18788	1188
18788	1198
18788	1204
18788	1218
18788	45236
18789	1178
18789	1188
18789	1197
18789	1201
18789	1218
18790	1180
18790	1188
18790	1197
18790	1201
18790	45561
18791	1188
18791	1233
18791	1238
18791	45236
18791	45643
18792	1183
18792	1188
18792	1198
18792	1205
18792	45194
18794	1188
18794	1218
18794	1232
18794	1233
18794	45236
18795	1183
18795	1188
18795	1204
18795	1218
18795	1232
18796	1183
18796	1188
18796	1206
18796	1217
18796	1232
18805	1188
18805	1222
18805	1232
18805	1233
18805	45238
18829	1188
18829	1206
18829	1218
18829	1229
18829	45238
18830	1183
18830	1199
18830	1204
18830	1239
18830	1243
18837	1188
18837	1218
18837	1232
18837	1233
18837	45238
18839	1188
18839	1232
18839	1233
18839	45238
18839	45596
18842	1195
18842	1206
18842	1218
18842	1229
18842	45238
18843	1183
18843	1194
18843	1218
18843	1229
18843	1233
18846	1188
18846	1201
18846	1233
18846	1238
18846	45236
18846	45643
18847	1183
18847	1194
18847	1232
18847	1233
18847	45181
18850	1188
18850	1198
18850	1218
18850	1233
18850	45236
18852	1183
18852	1188
18852	1206
18852	1218
18852	1229
18853	1183
18853	1188
18853	1206
18853	1222
18853	1232
18855	1183
18855	1188
18855	1206
18855	1218
18855	1229
18857	1183
18857	1188
18857	1229
18857	1233
18857	44971
18859	1183
18859	1188
18859	1217
18859	1232
18859	1233
18860	1183
18860	1188
18860	1198
18860	1218
18860	1233
18861	1183
18861	1194
18861	1204
18861	1232
18861	45194
18862	1183
18862	1188
18862	1218
18862	1232
18862	1233
18866	1183
18866	1188
18866	1218
18866	1232
18866	1233
18867	1183
18867	1194
18867	1232
18867	1233
18867	45181
18868	1183
18868	1194
18868	1218
18868	1232
18868	1233
18869	1183
18869	1188
18869	1218
18869	1232
18869	1233
18870	1183
18870	1188
18870	1218
18870	1232
18870	1233
18871	1183
18871	1188
18871	1218
18871	1232
18871	1233
18872	1183
18872	1188
18872	1218
18872	1229
18872	1233
18873	1183
18873	1232
18873	1233
18873	1239
18873	44971
18874	1183
18874	1194
18874	1232
18874	1233
18874	44971
18876	1183
18876	1194
18876	1200
18876	1233
18876	44971
18876	45543
18877	1183
18877	1194
18877	1218
18877	1232
18877	1233
18878	1183
18878	1194
18878	1232
18878	1233
18878	45577
18879	1183
18879	1188
18879	1232
18879	1233
18879	45168
18883	1183
18883	1188
18883	1218
18883	1232
18883	1233
18891	1183
18891	1188
18891	1206
18891	1218
18891	1232
18895	1183
18895	1194
18895	1232
18895	1233
18895	45545
18899	1188
18899	1218
18899	1232
18899	1233
18899	45238
18900	1183
18900	1194
18900	1218
18900	1232
18900	1233
18905	1195
18905	1218
18905	1229
18905	1233
18905	45238
18910	1183
18910	1191
18910	1198
18910	1206
18910	1218
18911	1188
18911	1218
18911	1232
18911	1233
18911	45238
18912	1188
18912	1232
18912	1233
18912	45238
18912	45573
18914	1183
18914	1194
18914	1218
18914	1232
18914	1233
18921	1188
18921	1206
18921	1218
18921	1229
18921	45238
18923	1183
18923	1194
18923	1221
18923	1229
18923	1233
18929	1183
18929	1188
18929	1216
18929	1232
18929	1233
18930	1183
18930	1188
18930	1206
18930	1232
18930	44968
18931	1183
18931	1194
18931	1217
18931	1232
18931	1233
18932	1183
18932	1188
18932	1218
18932	1232
18932	1233
18935	1183
18935	1188
18935	1232
18935	1233
18935	45543
18936	1183
18936	1188
18936	1232
18936	1233
18936	44971
18937	1183
18937	1188
18937	1206
18937	1217
18937	1229
18940	1183
18940	1194
18940	1218
18940	1232
18940	1233
18941	1183
18941	1191
18941	1206
18941	1218
18941	1229
18942	1183
18942	1188
18942	1232
18942	1233
18942	44968
18943	1183
18943	1188
18943	1194
18943	1218
18943	1232
18943	1233
18944	1183
18944	1188
18944	1206
18944	1232
18944	44971
18944	45574
18945	1183
18945	1194
18945	1204
18945	1218
18945	1232
18946	1183
18946	1188
18946	1218
18946	1232
18946	1233
18948	1183
18948	1188
18948	1198
18948	1218
18948	1233
18950	1183
18950	1188
18950	1217
18950	1232
18950	1233
18952	1183
18952	1188
18952	1218
18952	1232
18952	1233
18953	1183
18953	1188
18953	1206
18953	1218
18953	1232
18955	1183
18955	1188
18955	1232
18955	1233
18955	44968
18956	1183
18956	1188
18956	1218
18956	1232
18956	1233
18957	1183
18957	1188
18957	1218
18957	1232
18957	1233
18958	1183
18958	1188
18958	1218
18958	1232
18958	1233
18959	1183
18959	1188
18959	1218
18959	1232
18959	1233
18960	1183
18960	1188
18960	1218
18960	1232
18960	1233
18961	1183
18961	1188
18961	1218
18961	1232
18961	1233
18962	1183
18962	1188
18962	1198
18962	1218
18962	1233
18963	1183
18963	1188
18963	1218
18963	1232
18963	1233
18964	1183
18964	1188
18964	1218
18964	1232
18964	1233
18965	1183
18965	1188
18965	1218
18965	1232
18965	1233
18967	1183
18967	1188
18967	1218
18967	1229
18967	1232
18967	1233
18969	1183
18969	1188
18969	1218
18969	1232
18969	1233
18970	1183
18970	1188
18970	1232
18970	1233
18970	45621
18972	1183
18972	1188
18972	1218
18972	1232
18972	45604
18974	1183
18974	1188
18974	1218
18974	1232
18974	1233
18975	1183
18975	1188
18975	1218
18975	1232
18975	1233
18976	1183
18976	1188
18976	1218
18976	1232
18976	1233
18977	1183
18977	1188
18977	1232
18977	1233
18977	45543
18981	1183
18981	1196
18981	1198
18981	1209
18981	1233
18982	1183
18982	1188
18982	1218
18982	1232
18982	1233
18983	1183
18983	1188
18983	1199
18983	1231
18983	1233
18984	1183
18984	1194
18984	1232
18984	1233
18984	44983
18985	1183
18985	1194
18985	1205
18985	1218
18985	1232
18986	1183
18986	1194
18986	1232
18986	1233
18986	45181
18987	1188
18987	1218
18987	1232
18987	1233
18987	45236
18990	1183
18990	1194
18990	1205
18990	1217
18990	1232
18992	1183
18992	1188
18992	1232
18992	45543
18992	45604
18993	1183
18993	1196
18993	1199
18993	1206
18993	1218
18994	1183
18994	1188
18994	1218
18994	1232
18994	1233
18999	1183
18999	1188
18999	1206
18999	1217
18999	1232
19001	1188
19001	1204
19001	1218
19001	1232
19001	45236
19004	1183
19004	1198
19004	1210
19004	1233
19004	1239
19006	1183
19006	1188
19006	1198
19006	1218
19006	1233
19008	1183
19008	1188
19008	1206
19008	1218
19008	1232
19009	1188
19009	1198
19009	1206
19009	1218
19009	45238
19011	1188
19011	1205
19011	1218
19011	1232
19011	45236
19014	1183
19014	1188
19014	1218
19014	1232
19014	1233
19018	1183
19018	1188
19018	1217
19018	1232
19018	1233
19019	1183
19019	1194
19019	1198
19019	1206
19019	1209
19020	1183
19020	1188
19020	1218
19020	1232
19020	1233
19022	1183
19022	1191
19022	1206
19022	1232
19022	44971
19023	1183
19023	1188
19023	1232
19023	1233
19023	44971
19025	1195
19025	1204
19025	1218
19025	1232
19025	45236
19027	1183
19027	1188
19027	1232
19027	1233
19027	45543
19028	1183
19028	1188
19028	1218
19028	1232
19028	1233
19029	1183
19029	1191
19029	1218
19029	1232
19029	1233
19031	1183
19031	1192
19031	1218
19031	1232
19031	1233
19033	1188
19033	1204
19033	1238
19033	45236
19033	45643
19037	1183
19037	1188
19037	1218
19037	1232
19037	1233
19042	1183
19042	1218
19042	1232
19042	1233
19042	1239
19047	1188
19047	1232
19047	1233
19047	45238
19047	45337
19058	1183
19058	1188
19058	1218
19058	1232
19058	1233
19059	1183
19059	1188
19059	1232
19059	1233
19059	45194
19060	1183
19060	1194
19060	1232
19060	1233
19060	44971
19061	1183
19061	1194
19061	1205
19061	1218
19061	1232
19062	1183
19062	1196
19062	1232
19062	1233
19062	1257
19063	1188
19063	1232
19063	1233
19063	45238
19063	45549
19064	1183
19064	1194
19064	1218
19064	1232
19064	1233
19066	1183
19066	1194
19066	1206
19066	1221
19066	1232
19068	1183
19068	1194
19068	1205
19068	1218
19068	1232
19070	1183
19070	1194
19070	1218
19070	1232
19070	1233
19072	1183
19072	1196
19072	1218
19072	1232
19072	1233
19073	1183
19073	1194
19073	1218
19073	1232
19073	1233
19074	1183
19074	1194
19074	1232
19074	1233
19074	45579
19075	1183
19075	1194
19075	1218
19075	1232
19075	1233
19076	1183
19076	1188
19076	1218
19076	1232
19076	1233
19078	1183
19078	1194
19078	1218
19078	1232
19078	1233
19079	1183
19079	1188
19079	1198
19079	1217
19079	1233
19081	1183
19081	1188
19081	1206
19081	1218
19081	1232
19082	1180
19082	1188
19082	1197
19082	1201
19082	1218
19083	1188
19083	1206
19083	1232
19083	45236
19083	45578
19084	1188
19084	1205
19084	1232
19084	45236
19084	45567
19085	1183
19085	1194
19085	1204
19085	1218
19085	1232
19086	1183
19086	1188
19086	1232
19086	1233
19086	44971
19087	1183
19087	1188
19087	1218
19087	1232
19087	1233
19089	1183
19089	1188
19089	1198
19089	1206
19089	1218
19090	1183
19090	1188
19090	1206
19090	1218
19090	1232
19097	1183
19097	1188
19097	1199
19097	1206
19097	1243
19098	1183
19098	1188
19098	1218
19098	1232
19098	1233
19105	1183
19105	1188
19105	1204
19105	1222
19105	1232
19107	1183
19107	1194
19107	1209
19107	1229
19107	1232
19107	1233
19107	45584
19108	1183
19108	1194
19108	1198
19108	1218
19108	1233
19110	1183
19110	1188
19110	1206
19110	1218
19110	1232
19115	1183
19115	1188
19115	1218
19115	1232
19115	1233
19120	1188
19120	1198
19120	1233
19120	1246
19120	45236
19120	45591
19122	1188
19122	1229
19122	1233
19122	45236
19122	45579
19122	45590
19125	1188
19125	1204
19125	1218
19125	1232
19125	45236
19126	1178
19126	1196
19126	1218
19126	1232
19126	1233
19127	1188
19127	1218
19127	1232
19127	1233
19127	45238
19128	1188
19128	1232
19128	1233
19128	45238
19128	45337
19130	1188
19130	1229
19130	1233
19130	45238
19130	45549
19131	1188
19131	1198
19131	1233
19131	45238
19131	45549
19133	1188
19133	1218
19133	1232
19133	1233
19133	45238
19135	1188
19135	1232
19135	1233
19135	1237
19135	45435
19136	1188
19136	1232
19136	1233
19136	45238
19136	45546
19137	1183
19137	1188
19137	1204
19137	1218
19137	1232
19141	1195
19141	1222
19141	1232
19141	1233
19141	45238
19142	1188
19142	1232
19142	1233
19142	45238
19142	45546
19143	1188
19143	1222
19143	1232
19143	1233
19143	45238
19145	1183
19145	1188
19145	1222
19145	1232
19145	1233
19146	1183
19146	1194
19146	1206
19146	1218
19146	1229
19147	1183
19147	1188
19147	1218
19147	1232
19147	1233
19148	1183
19148	1194
19148	1206
19148	1229
19148	44971
19152	1183
19152	1194
19152	1199
19152	1231
19152	1233
19153	1183
19153	1188
19153	1206
19153	1218
19153	1232
19156	1183
19156	1188
19156	1198
19156	1205
19156	1218
19157	1188
19157	1222
19157	1232
19157	1233
19157	45238
19158	1180
19158	1188
19158	1197
19158	1201
19158	1217
19159	1188
19159	1218
19159	1232
19159	1233
19159	45238
19166	1183
19166	1188
19166	1198
19166	1206
19166	1218
19171	1183
19171	1188
19171	1217
19171	1229
19171	1233
19172	1188
19172	1218
19172	1232
19172	1233
19172	45238
19173	1183
19173	1188
19173	1217
19173	1232
19173	1233
19173	45585
19178	1183
19178	1194
19178	1206
19178	1218
19178	1232
19181	1183
19181	1188
19181	1206
19181	1218
19181	1229
19182	1183
19182	1188
19182	1206
19182	1229
19182	45575
19184	1183
19184	1188
19184	1206
19184	1218
19184	1232
19185	1183
19185	1188
19185	1206
19185	1218
19185	1232
19186	1183
19186	1188
19186	1218
19186	1232
19186	1233
19187	1183
19187	1218
19187	1232
19187	1233
19187	1239
19188	1183
19188	1188
19188	1206
19188	1232
19188	44979
19189	1183
19189	1188
19189	1206
19189	1217
19189	1232
19190	1183
19190	1188
19190	1206
19190	1209
19190	1232
19191	1183
19191	1188
19191	1206
19191	1232
19191	44974
19192	1182
19192	1188
19192	1206
19192	1232
19192	1263
19193	1183
19193	1188
19193	1206
19193	1218
19193	1232
19194	1183
19194	1188
19194	1206
19194	1218
19194	1232
19195	1183
19195	1188
19195	1218
19195	1232
19195	1233
19196	1183
19196	1188
19196	1232
19196	1233
19196	45183
19197	1183
19197	1188
19197	1218
19197	1232
19197	1233
19198	1183
19198	1188
19198	1218
19198	1232
19198	1233
19199	1183
19199	1188
19199	1206
19199	1218
19199	1232
19200	1183
19200	1191
19200	1218
19200	1232
19200	1233
19201	1183
19201	1188
19201	1232
19201	1233
19201	45181
19202	1183
19202	1188
19202	1206
19202	1218
19202	1232
19203	1183
19203	1188
19203	1206
19203	1218
19203	1232
19204	1183
19204	1188
19204	1206
19204	1218
19204	1232
19205	1180
19205	1188
19205	1197
19205	1201
19205	1218
19206	1183
19206	1204
19206	1218
19206	1232
19206	1239
19207	1183
19207	1188
19207	1206
19207	1232
19207	45575
19208	1183
19208	1188
19208	1206
19208	1229
19208	45575
19209	1183
19209	1188
19209	1205
19209	1232
19209	44971
19210	1183
19210	1188
19210	1206
19210	1218
19210	1232
19211	1183
19211	1188
19211	1206
19211	1232
19211	45575
19212	1183
19212	1188
19212	1204
19212	1232
19212	44971
19213	1183
19213	1188
19213	1198
19213	1233
19213	44977
19214	1183
19214	1188
19214	1206
19214	1218
19214	1232
19215	1183
19215	1188
19215	1206
19215	1218
19215	1232
19216	1183
19216	1188
19216	1206
19216	1232
19216	44977
19217	1183
19217	1188
19217	1205
19217	1232
19217	44971
19218	1183
19218	1188
19218	1217
19218	1232
19218	1233
19219	1183
19219	1188
19219	1206
19219	1218
19219	1232
19220	1183
19220	1188
19220	1232
19220	1233
19220	45194
19221	1183
19221	1188
19221	1206
19221	1218
19221	1232
19222	1183
19222	1188
19222	1209
19222	1232
19222	1233
19223	1183
19223	1188
19223	1206
19223	1218
19223	1232
19224	1183
19224	1188
19224	1204
19224	1218
19224	1232
19225	1183
19225	1188
19225	1206
19225	1218
19225	1232
19226	1183
19226	1188
19226	1206
19226	1217
19226	1229
19227	1183
19227	1188
19227	1204
19227	1218
19227	1232
19228	1183
19228	1188
19228	1206
19228	1218
19228	1232
19229	1183
19229	1188
19229	1218
19229	1232
19229	1233
19230	1183
19230	1188
19230	1205
19230	1218
19230	1232
19231	1183
19231	1188
19231	1198
19231	1204
19231	1218
19232	1183
19232	1188
19232	1205
19232	1218
19232	1232
19233	1183
19233	1188
19233	1206
19233	1218
19233	1232
19234	1183
19234	1188
19234	1206
19234	1229
19234	44971
19235	1183
19235	1188
19235	1198
19235	1204
19235	1213
19236	1183
19236	1188
19236	1198
19236	1206
19236	1218
19237	1183
19237	1232
19237	1233
19237	1239
19237	45134
19238	1183
19238	1188
19238	1229
19238	1233
19238	44986
19239	1183
19239	1188
19239	1205
19239	1232
19239	45194
19240	1183
19240	1188
19240	1205
19240	1218
19240	1232
19241	1183
19241	1188
19241	1206
19241	1218
19241	1232
19242	1183
19242	1188
19242	1206
19242	1218
19242	1232
19243	1183
19243	1188
19243	1204
19243	1232
19243	1243
19244	1183
19244	1188
19244	1206
19244	1218
19244	1232
19245	1183
19245	1188
19245	1206
19245	1218
19245	1232
19246	1183
19246	1188
19246	1206
19246	1217
19246	1232
19247	1183
19247	1188
19247	1204
19247	1218
19247	1232
19248	1183
19248	1188
19248	1198
19248	1204
19248	44971
19249	1183
19249	1188
19249	1205
19249	1217
19249	1232
19250	1183
19250	1188
19250	1218
19250	1232
19250	1233
19251	1183
19251	1188
19251	1206
19251	1218
19251	1232
19252	1183
19252	1188
19252	1206
19252	1218
19252	1232
19253	1183
19253	1188
19253	1204
19253	1218
19253	1232
19254	1183
19254	1188
19254	1232
19254	1233
19254	45575
19255	1183
19255	1188
19255	1232
19255	1233
19255	45575
19256	1183
19256	1188
19256	1218
19256	1232
19256	1233
19257	1183
19257	1188
19257	1200
19257	1206
19257	45575
19258	1183
19258	1188
19258	1206
19258	1232
19258	45575
19259	1183
19259	1188
19259	1229
19259	1233
19259	44974
19260	1183
19260	1188
19260	1200
19260	1206
19260	44968
19261	1183
19261	1188
19261	1200
19261	1218
19261	1233
19262	1183
19262	1188
19262	1206
19262	1229
19262	45575
19263	1183
19263	1188
19263	1204
19263	1218
19263	1232
19264	1183
19264	1188
19264	1206
19264	1218
19264	1232
19265	1182
19265	1188
19265	1206
19265	1218
19265	1232
19266	1183
19266	1188
19266	1206
19266	1229
19266	45575
19267	1183
19267	1188
19267	1200
19267	1218
19267	1233
19268	1183
19268	1188
19268	1206
19268	1213
19268	1232
19269	1183
19269	1188
19269	1206
19269	1218
19269	1229
19270	1183
19270	1188
19270	1206
19270	1232
19270	44968
19271	1183
19271	1188
19271	1200
19271	1206
19271	1218
19272	1183
19272	1188
19272	1206
19272	1218
19272	1232
19273	1183
19273	1206
19273	1218
19273	1232
19273	1239
19274	1183
19274	1188
19274	1206
19274	1218
19274	1232
19275	1183
19275	1188
19275	1205
19275	1218
19275	1232
19276	1183
19276	1188
19276	1205
19276	1218
19276	1232
19277	1183
19277	1188
19277	1198
19277	1218
19277	1233
19278	1183
19278	1188
19278	1198
19278	1204
19278	1218
19279	1188
19279	1213
19279	1232
19279	1233
19279	45238
19280	1183
19280	1188
19280	1198
19280	1233
19280	45380
19281	1183
19281	1188
19281	1204
19281	1232
19281	44968
19282	1183
19282	1188
19282	1206
19282	1218
19282	1232
19283	1183
19283	1188
19283	1205
19283	1218
19283	1232
19284	1183
19284	1188
19284	1232
19284	1233
19284	44971
19285	1183
19285	1188
19285	1206
19285	1218
19285	1232
19286	1183
19286	1188
19286	1200
19286	1206
19286	45575
19287	1183
19287	1188
19287	1198
19287	1206
19287	1218
19288	1183
19288	1188
19288	1206
19288	1232
19288	44968
19289	1183
19289	1188
19289	1206
19289	1232
19289	45575
19290	1183
19290	1188
19290	1206
19290	1217
19290	1232
19291	1183
19291	1188
19291	1206
19291	1229
19291	44968
19292	1183
19292	1188
19292	1206
19292	1232
19292	1261
19293	1183
19293	1188
19293	1206
19293	1218
19293	1232
19294	1183
19294	1188
19294	1206
19294	1232
19294	44968
19295	1183
19295	1188
19295	1206
19295	1218
19295	1232
19296	1183
19296	1188
19296	1206
19296	1218
19296	1232
19297	1183
19297	1188
19297	1206
19297	1218
19297	1232
19298	1183
19298	1188
19298	1206
19298	1222
19298	1232
19299	1183
19299	1188
19299	1206
19299	1232
19299	45575
19300	1183
19300	1188
19300	1206
19300	1218
19300	1232
19301	1183
19301	1188
19301	1200
19301	1206
19301	45134
19302	1183
19302	1188
19302	1198
19302	1205
19302	45575
19303	1183
19303	1188
19303	1232
19303	1233
19303	45183
19304	1183
19304	1188
19304	1206
19304	1229
19304	44974
19305	1183
19305	1188
19305	1206
19305	1232
19305	1261
19306	1183
19306	1188
19306	1232
19306	1233
19306	44974
19307	1183
19307	1188
19307	1232
19307	1233
19307	44974
19308	1183
19308	1188
19308	1206
19308	1218
19308	1232
19309	1183
19309	1188
19309	1206
19309	1218
19309	1232
19310	1183
19310	1188
19310	1206
19310	1218
19310	1232
19311	1183
19311	1188
19311	1206
19311	1232
19311	45350
19312	1183
19312	1188
19312	1206
19312	1232
19312	45019
19313	1183
19313	1188
19313	1206
19313	1232
19313	45337
19314	1183
19314	1188
19314	1206
19314	1218
19314	1232
19315	1183
19315	1188
19315	1205
19315	1218
19315	1232
19316	1183
19316	1188
19316	1198
19316	1218
19316	1233
19317	1183
19317	1188
19317	1204
19317	1218
19317	1232
19318	1183
19318	1188
19318	1206
19318	1218
19318	1232
19319	1183
19319	1188
19319	1206
19319	1218
19319	1232
19320	1183
19320	1188
19320	1206
19320	1218
19320	1232
19321	1183
19321	1188
19321	1198
19321	1233
19321	44977
19322	1183
19322	1188
19322	1200
19322	1218
19322	1233
19323	1183
19323	1188
19323	1206
19323	1232
19323	44971
19324	1183
19324	1188
19324	1205
19324	1218
19324	1232
19325	1183
19325	1188
19325	1206
19325	1218
19325	1232
19326	1183
19326	1188
19326	1206
19326	1218
19326	1232
19327	1183
19327	1188
19327	1206
19327	1218
19327	1229
19328	1183
19328	1188
19328	1206
19328	1218
19328	1229
19329	1183
19329	1188
19329	1206
19329	1218
19329	1232
19330	1183
19330	1188
19330	1198
19330	1206
19330	1218
19331	1183
19331	1188
19331	1206
19331	1218
19331	1232
19332	1183
19332	1188
19332	1206
19332	1218
19332	1232
19333	1183
19333	1188
19333	1206
19333	1218
19333	1232
19334	1183
19334	1188
19334	1205
19334	1232
19334	44968
19335	1183
19335	1188
19335	1206
19335	1229
19335	45575
19336	1183
19336	1204
19336	1232
19336	1239
19336	45575
19337	1183
19337	1188
19337	1206
19337	1218
19337	1232
19338	1183
19338	1188
19338	1206
19338	1229
19338	44968
19339	1183
19339	1188
19339	1206
19339	1232
19339	45575
19340	1183
19340	1188
19340	1206
19340	1229
19340	1255
19341	1183
19341	1188
19341	1213
19341	1232
19341	1233
19342	1180
19342	1188
19342	1197
19342	1201
19342	1218
19343	1183
19343	1188
19343	1206
19343	1218
19343	1232
19344	1183
19344	1188
19344	1206
19344	1232
19344	45183
19345	1183
19345	1188
19345	1206
19345	1229
19345	44968
19346	1183
19346	1188
19346	1206
19346	1218
19346	1232
19347	1183
19347	1188
19347	1206
19347	1218
19347	1232
19348	1183
19348	1188
19348	1218
19348	1232
19348	1233
19349	1183
19349	1188
19349	1218
19349	1232
19349	1233
19350	1183
19350	1188
19350	1206
19350	1218
19350	1232
19351	1183
19351	1188
19351	1204
19351	1218
19351	1232
19352	1183
19352	1188
19352	1204
19352	1232
19352	45575
19353	1183
19353	1188
19353	1218
19353	1229
19353	1233
19354	1183
19354	1188
19354	1206
19354	1232
19354	44968
19355	1183
19355	1188
19355	1200
19355	1205
19355	45575
19356	1183
19356	1188
19356	1206
19356	1218
19356	1232
19357	1183
19357	1188
19357	1206
19357	1232
19357	45575
19358	1183
19358	1188
19358	1218
19358	1232
19358	1233
19359	1183
19359	1188
19359	1206
19359	1218
19359	1232
19360	1183
19360	1188
19360	1206
19360	1218
19360	1229
19361	1183
19361	1188
19361	1205
19361	1232
19361	45045
19362	1183
19362	1188
19362	1205
19362	1218
19362	1232
19363	1183
19363	1188
19363	1218
19363	1232
19363	1233
19364	1183
19364	1188
19364	1206
19364	1232
19364	45582
19365	1183
19365	1188
19365	1206
19365	1218
19365	1232
19366	1183
19366	1188
19366	1198
19366	1206
19366	1218
19367	1183
19367	1188
19367	1205
19367	1232
19367	44968
19368	1183
19368	1188
19368	1206
19368	1232
19368	45575
19369	1183
19369	1188
19369	1206
19369	1218
19369	1232
19370	1183
19370	1188
19370	1217
19370	1232
19370	1233
19371	1183
19371	1188
19371	1206
19371	1213
19371	1232
19372	1183
19372	1188
19372	1205
19372	1213
19372	1232
19373	1183
19373	1188
19373	1205
19373	1232
19373	44974
19374	1183
19374	1188
19374	1198
19374	1204
19374	1218
19375	1183
19375	1188
19375	1206
19375	1232
19375	1261
19376	1183
19376	1188
19376	1200
19376	1233
19376	44968
19377	1183
19377	1188
19377	1213
19377	1232
19377	1233
19378	1183
19378	1188
19378	1206
19378	1218
19378	1232
19379	1183
19379	1188
19379	1198
19379	1204
19379	1218
19380	1183
19380	1188
19380	1206
19380	1217
19380	1232
19381	1183
19381	1188
19381	1204
19381	1218
19381	1232
19382	1183
19382	1188
19382	1229
19382	1233
19382	45575
19383	1183
19383	1188
19383	1206
19383	1218
19383	1232
19384	1183
19384	1188
19384	1206
19384	1218
19384	1232
19385	1183
19385	1188
19385	1218
19385	1232
19385	1233
19386	1183
19386	1188
19386	1206
19386	1218
19386	1232
19387	1183
19387	1188
19387	1198
19387	1218
19387	1233
19388	1183
19388	1188
19388	1206
19388	1218
19388	1232
19389	1183
19389	1188
19389	1204
19389	1218
19389	1232
19390	1183
19390	1188
19390	1206
19390	1218
19390	1232
19391	1183
19391	1188
19391	1204
19391	1218
19391	1232
19392	1183
19392	1188
19392	1204
19392	1218
19392	1232
19393	1183
19393	1188
19393	1205
19393	1218
19393	1232
19394	1183
19394	1188
19394	1206
19394	1218
19394	1232
19395	1183
19395	1188
19395	1206
19395	1232
19395	45194
19396	1183
19396	1188
19396	1205
19396	1232
19396	45194
19397	1183
19397	1188
19397	1218
19397	1232
19397	1233
19398	1183
19398	1188
19398	1206
19398	1232
19398	44968
19399	1183
19399	1188
19399	1204
19399	1218
19399	1232
19400	1183
19400	1188
19400	1206
19400	1218
19400	1232
19401	1183
19401	1188
19401	1198
19401	1206
19401	1218
19402	1183
19402	1188
19402	1198
19402	1204
19402	44971
19403	1183
19403	1198
19403	1204
19403	1218
19403	1239
19404	1183
19404	1188
19404	1205
19404	1218
19404	1232
19405	1183
19405	1188
19405	1206
19405	1218
19405	1232
19406	1183
19406	1188
19406	1232
19406	1233
19406	45134
19407	1183
19407	1188
19407	1200
19407	1206
19407	1218
19408	1183
19408	1188
19408	1206
19408	1218
19408	1232
19409	1183
19409	1188
19409	1205
19409	1218
19409	1232
19410	1183
19410	1188
19410	1232
19410	1233
19410	1263
19411	1183
19411	1188
19411	1205
19411	1218
19411	1232
19412	1183
19412	1188
19412	1206
19412	1217
19412	1232
19413	1183
19413	1188
19413	1218
19413	1229
19413	1233
19414	1183
19414	1188
19414	1205
19414	1218
19414	1232
19415	1183
19415	1188
19415	1204
19415	1218
19415	1232
19416	1183
19416	1188
19416	1218
19416	1232
19416	1233
19417	1183
19417	1188
19417	1229
19417	1233
19417	44974
19418	1183
19418	1188
19418	1206
19418	1232
19418	44968
19419	1183
19419	1188
19419	1218
19419	1232
19419	1233
19420	1183
19420	1188
19420	1206
19420	1218
19420	1232
19421	1183
19421	1188
19421	1206
19421	1218
19421	1232
19422	1183
19422	1188
19422	1205
19422	1222
19422	1232
19423	1183
19423	1188
19423	1206
19423	1218
19423	1232
19424	1183
19424	1188
19424	1206
19424	1218
19424	1232
19425	1183
19425	1188
19425	1204
19425	1232
19425	44971
19426	1183
19426	1188
19426	1206
19426	1217
19426	1232
19427	1183
19427	1188
19427	1206
19427	1217
19427	1232
19428	1183
19428	1196
19428	1204
19428	1222
19428	1232
19429	1183
19429	1188
19429	1198
19429	1204
19429	1218
19430	1183
19430	1198
19430	1218
19430	1233
19430	1239
19431	1183
19431	1188
19431	1198
19431	1205
19431	1218
19432	1183
19432	1188
19432	1205
19432	1218
19432	1232
19433	1183
19433	1188
19433	1218
19433	1232
19433	1233
19434	1183
19434	1188
19434	1206
19434	1218
19434	1232
19435	1183
19435	1188
19435	1206
19435	1218
19435	1229
19436	1183
19436	1188
19436	1206
19436	1218
19436	1232
19437	1183
19437	1188
19437	1206
19437	1218
19437	1232
19438	1183
19438	1188
19438	1206
19438	1218
19438	1232
19439	1183
19439	1188
19439	1204
19439	1218
19439	1232
19440	1183
19440	1188
19440	1204
19440	1218
19440	1232
19441	1183
19441	1188
19441	1206
19441	1218
19441	1232
19442	1183
19442	1188
19442	1205
19442	1218
19442	1232
19443	1183
19443	1206
19443	1218
19443	1232
19443	1239
19444	1183
19444	1188
19444	1206
19444	1218
19444	1232
19445	1183
19445	1188
19445	1206
19445	1232
19445	44971
19446	1183
19446	1188
19446	1218
19446	1232
19446	1233
19447	1183
19447	1188
19447	1198
19447	1204
19447	1218
19448	1183
19448	1188
19448	1204
19448	1218
19448	1232
19449	1183
19449	1188
19449	1206
19449	1218
19449	1232
19450	1183
19450	1188
19450	1204
19450	1218
19450	1232
19451	1183
19451	1188
19451	1206
19451	1218
19451	1232
19452	1183
19452	1188
19452	1218
19452	1232
19452	1233
19453	1183
19453	1188
19453	1232
19453	1233
19453	44971
19454	1183
19454	1188
19454	1205
19454	1218
19454	1232
19455	1183
19455	1188
19455	1204
19455	1218
19455	1232
19456	1183
19456	1188
19456	1198
19456	1218
19456	1233
19457	1183
19457	1188
19457	1206
19457	1218
19457	1232
19458	1183
19458	1188
19458	1217
19458	1232
19458	1233
19459	1183
19459	1188
19459	1206
19459	1218
19459	1232
19460	1183
19460	1188
19460	1232
19460	1233
19460	45581
19461	1183
19461	1188
19461	1218
19461	1232
19461	1233
19463	1183
19463	1188
19463	1206
19463	1217
19463	1232
19464	1183
19464	1188
19464	1206
19464	1218
19464	1232
19465	1183
19465	1188
19465	1206
19465	1218
19465	1232
19466	1183
19466	1188
19466	1232
19466	1233
19466	45621
19477	1188
19477	1201
19477	1238
19477	45236
19477	45643
19479	1188
19479	1232
19479	1233
19479	45236
19479	45622
19480	1183
19480	1188
19480	1206
19480	1218
19480	1232
19481	1183
19481	1194
19481	1206
19481	1218
19481	1232
19488	1182
19488	1196
19488	1218
19488	1232
19488	1233
19493	1188
19493	1204
19493	1218
19493	1232
19493	45236
19496	1183
19496	1188
19496	1198
19496	1205
19496	1218
19497	1183
19497	1188
19497	1206
19497	1232
19497	45339
19498	1188
19498	1232
19498	1233
19498	45238
19498	45635
19500	1183
19500	1188
19500	1198
19500	1218
19500	1233
19501	1183
19501	1192
19501	1204
19501	1218
19501	1232
19502	1183
19502	1188
19502	1218
19502	1229
19502	1233
19503	1188
19503	1203
19503	1233
19503	1238
19503	45236
19503	45643
19505	1183
19505	1188
19505	1198
19505	1204
19505	1218
19507	1183
19507	1188
19507	1232
19507	1233
19507	1244
19508	1182
19508	1196
19508	1218
19508	1232
19508	1233
19509	1183
19509	1188
19509	1217
19509	1232
19509	1233
19510	1183
19510	1188
19510	1206
19510	1232
19510	45181
19511	1183
19511	1188
19511	1218
19511	1232
19511	1233
19512	1183
19512	1188
19512	1218
19512	1232
19512	1233
19517	1183
19517	1194
19517	1206
19517	1218
19517	1232
19518	1183
19518	1194
19518	1206
19518	1232
19518	44971
19522	1183
19522	1194
19522	1205
19522	1217
19522	1229
19524	1183
19524	1188
19524	1218
19524	1229
19524	1233
19531	1183
19531	1194
19531	1198
19531	1206
19531	1218
19533	1183
19533	1188
19533	1213
19533	1232
19533	1233
19535	1183
19535	1200
19535	1204
19535	1239
19535	1244
19537	1183
19537	1194
19537	1218
19537	1229
19537	1233
19539	1183
19539	1188
19539	1206
19539	1218
19539	1232
19552	1183
19552	1188
19552	1218
19552	1232
19552	1233
19554	1183
19554	1194
19554	1201
19554	1229
19554	45546
19555	1183
19555	1188
19555	1218
19555	1232
19555	1233
19571	1183
19571	1204
19571	1205
19571	1232
19571	1239
19571	44983
19573	1183
19573	1194
19573	1218
19573	1232
19573	1233
19574	1183
19574	1194
19574	1232
19574	1233
19574	45561
19575	1183
19575	1188
19575	1206
19575	1232
19575	45585
19577	1183
19577	1188
19577	1218
19577	1232
19577	1233
19578	1188
19578	1218
19578	1232
19578	1233
19578	45238
19579	1183
19579	1194
19579	1198
19579	1218
19579	1233
19581	1183
19581	1232
19581	1233
19581	1239
19581	45194
19582	1188
19582	1203
19582	1238
19582	45236
19582	45643
19583	1183
19583	1194
19583	1217
19583	1232
19583	1233
19584	1183
19584	1194
19584	1198
19584	1218
19584	1233
19585	1183
19585	1188
19585	1218
19585	1232
19585	1233
19586	1183
19586	1188
19586	1218
19586	1229
19586	1233
19587	1183
19587	1188
19587	1232
19587	1233
19587	45585
19588	1188
19588	1218
19588	1229
19588	1233
19588	45238
19589	1183
19589	1194
19589	1232
19589	1233
19589	45181
19593	1183
19593	1188
19593	1198
19593	1206
19593	1218
19606	1183
19606	1188
19606	1218
19606	1232
19606	1233
19610	1183
19610	1188
19610	1206
19610	1232
19610	45586
19613	1188
19613	1218
19613	1232
19613	1233
19613	45602
19615	1183
19615	1188
19615	1206
19615	1218
19615	1229
19616	1183
19616	1188
19616	1199
19616	1204
19616	1218
19626	1183
19626	1194
19626	1206
19626	1229
19626	45586
19629	1183
19629	1188
19629	1206
19629	1218
19629	1229
19638	1183
19638	1193
19638	1198
19638	1218
19638	1233
19640	1188
19640	1201
19640	1238
19640	45236
19640	45643
19641	1183
19641	1188
19641	1232
19641	1233
19641	45543
19642	1183
19642	1188
19642	1218
19642	1232
19642	1233
19643	1183
19643	1188
19643	1218
19643	1232
19643	1233
19644	1183
19644	1188
19644	1218
19644	1232
19644	1233
19645	1183
19645	1188
19645	1218
19645	1232
19645	1233
19646	1183
19646	1188
19646	1218
19646	1232
19646	45604
19647	1183
19647	1188
19647	1218
19647	1232
19647	1233
19648	1183
19648	1188
19648	1218
19648	1232
19648	1233
19649	1183
19649	1188
19649	1218
19649	1232
19649	1233
19650	1183
19650	1188
19650	1198
19650	1218
19650	1233
19651	1183
19651	1188
19651	1218
19651	1232
19651	1233
19652	1183
19652	1188
19652	1218
19652	1232
19652	1233
19653	1188
19653	1218
19653	1232
19653	1233
19653	45600
19656	1183
19656	1188
19656	1218
19656	1232
19656	1233
19657	1183
19657	1188
19657	1218
19657	1232
19657	1233
19659	1188
19659	1218
19659	1232
19659	1233
19659	45238
19660	1183
19660	1188
19660	1218
19660	1232
19660	1233
19661	1183
19661	1188
19661	1218
19661	1232
19661	1233
19662	1183
19662	1188
19662	1218
19662	1232
19662	1233
19663	1183
19663	1188
19663	1218
19663	1232
19663	1233
19668	1183
19668	1188
19668	1200
19668	1206
19668	44971
19669	1183
19669	1193
19669	1206
19669	1232
19669	44974
19671	1183
19671	1188
19671	1232
19671	1233
19671	45585
19672	1183
19672	1188
19672	1232
19672	1233
19672	45561
19673	1177
19673	1188
19673	1218
19673	1232
19673	1233
19688	1183
19688	1188
19688	1206
19688	1213
19688	1232
19692	1183
19692	1188
19692	1231
19692	1232
19692	1233
19693	1183
19693	1191
19693	1218
19693	1232
19693	1233
19694	1183
19694	1192
19694	1206
19694	1218
19694	1232
19701	1183
19701	1188
19701	1218
19701	1232
19701	1233
19702	1183
19702	1188
19702	1218
19702	1232
19702	1233
19704	1183
19704	1188
19704	1232
19704	1233
19704	45128
19705	1198
19705	45548
19706	1183
19706	1188
19706	1218
19706	1232
19706	1233
19707	1183
19707	1188
19707	1232
19707	1233
19707	45421
19709	1183
19709	1204
19709	1220
19709	1232
19709	1239
19712	1183
19712	1188
19712	1198
19712	1204
19712	1218
19713	1183
19713	1188
19713	1206
19713	1218
19713	1229
19714	1183
19714	1194
19714	1206
19714	1222
19714	1232
19717	1183
19717	1188
19717	1198
19717	1206
19717	1218
19717	1232
19717	1233
19717	45543
19718	1183
19718	1188
19718	1206
19718	1232
19718	45587
19719	1183
19719	1188
19719	1206
19719	1232
19719	45592
19720	1188
19720	1232
19720	1233
19720	1237
19720	45588
19722	1183
19722	1188
19722	1198
19722	1206
19722	1218
19724	1183
19724	1188
19724	1218
19724	1232
19724	1233
19725	1183
19725	1188
19725	1206
19725	1217
19725	1232
19727	1183
19727	1194
19727	1218
19727	1229
19727	1233
19728	1183
19728	1191
19728	1218
19728	1232
19728	1233
19729	1183
19729	1194
19729	1232
19729	1233
19729	45543
19740	1183
19740	1194
19740	1199
19740	1218
19740	1233
19748	1183
19748	1188
19748	1206
19748	1218
19748	1232
19748	1233
19748	44971
19750	1180
19750	1195
19750	1197
19750	1201
19750	45561
19752	1183
19752	1194
19752	1229
19752	1233
19752	1257
19752	45543
19756	1183
19756	1194
19756	1206
19756	1217
19756	1232
19757	1188
19757	1198
19757	1204
19757	1218
19757	45236
19760	1183
19760	1188
19760	1206
19760	1218
19760	1229
19760	1232
19760	1233
19761	1183
19761	1188
19761	1206
19761	1217
19761	1232
19763	1183
19763	1188
19763	1199
19763	1233
19763	45128
19764	1188
19764	1198
19764	1211
19764	1233
19764	45238
19765	1183
19765	1188
19765	1206
19765	1232
19765	44971
19766	1183
19766	1188
19766	1204
19766	1222
19766	1229
19776	1183
19776	1188
19776	1206
19776	1229
19776	1231
19781	1193
19781	1229
19781	1233
19781	1246
19781	45238
19781	45421
19782	1183
19782	1206
19782	1218
19782	1232
19782	1239
19787	1188
19787	1218
19787	1232
19787	1233
19787	45238
19788	1183
19788	1188
19788	1232
19788	1233
19788	45181
19789	1188
19789	1218
19789	1232
19789	1233
19789	45600
19793	1183
19793	1188
19793	1222
19793	1232
19793	1233
19794	1183
19794	1188
19794	1218
19794	1229
19794	1233
19795	1183
19795	1188
19795	1198
19795	1218
19795	1233
19796	1183
19796	1194
19796	1218
19796	1232
19796	1233
19816	1183
19816	1188
19816	1206
19816	1218
19816	1229
19819	1183
19819	1188
19819	1232
19819	1233
19819	45594
19826	1188
19826	1218
19826	1229
19826	1233
19826	45238
19843	1183
19843	1191
19843	1218
19843	1232
19843	1233
19849	1183
19849	1194
19849	1232
19849	1233
19849	45543
19855	1183
19855	1188
19855	1206
19855	1218
19855	1232
19856	1183
19856	1194
19856	1205
19856	1218
19856	1232
19863	1188
19863	1218
19863	1232
19863	1233
19863	45238
19866	1188
19866	1218
19866	1232
19866	1233
19866	45238
19867	1188
19867	1218
19867	1232
19867	1233
19867	45238
19869	1183
19869	1188
19869	1232
19869	1233
19869	45635
19873	1183
19873	1194
19873	1232
19873	1233
19873	45583
19876	1183
19876	1188
19876	1206
19876	1229
19876	45586
19902	1183
19902	1188
19902	1232
19902	1233
19902	45380
19904	1183
19904	1188
19904	1218
19904	1229
19904	1233
19908	1183
19908	1194
19908	1206
19908	1218
19908	1232
19910	1183
19910	1194
19910	1206
19910	1229
19910	45569
19926	1188
19926	1218
19926	1232
19926	1233
19926	45238
19929	1193
19929	1218
19929	1232
19929	1233
19929	45238
19941	1183
19941	1188
19941	1218
19941	1229
19941	1233
19942	1183
19942	1188
19942	1217
19942	1229
19942	1233
19951	1183
19951	1188
19951	1197
19951	1201
19951	1218
19958	1183
19958	1188
19958	1198
19958	1233
19958	1243
19958	45548
19960	1188
19960	1218
19960	1232
19960	1233
19960	1237
19962	1183
19962	1188
19962	1206
19962	1218
19962	1232
19970	1183
19970	1204
19970	1218
19970	1232
19970	1239
19974	1183
19974	1188
19974	1206
19974	1218
19974	1229
19975	1183
19975	1194
19975	1206
19975	1218
19975	1232
19977	1183
19977	1188
19977	1200
19977	1206
19977	1217
19977	1218
19977	1229
19977	1232
19977	1233
19978	1183
19978	1188
19978	1206
19978	1218
19978	1232
19981	1183
19981	1196
19981	1218
19981	1232
19981	1233
19984	1183
19984	1194
19984	1198
19984	1210
19984	1233
19985	1183
19985	1188
19985	1218
19985	1232
19985	1233
19988	1183
19988	1194
19988	1205
19988	1218
19988	1232
19989	1183
19989	1194
19989	1218
19989	1232
19989	1233
19990	1183
19990	1198
19990	1210
19990	1233
19990	1239
19991	1183
19991	1194
19991	1218
19991	1232
19991	1233
19993	1183
19993	1188
19993	1206
19993	1218
19993	1232
19995	1183
19995	1188
19995	1198
19995	1218
19995	1233
19996	1183
19996	1188
19996	1198
19996	1218
19996	1233
19998	1188
19998	1204
19998	1218
19998	1232
19998	45236
20001	1183
20001	1188
20001	1198
20001	1218
20001	1233
20002	1183
20002	1188
20002	1218
20002	1229
20002	1233
20003	1183
20003	1194
20003	1198
20003	1218
20003	1233
20005	1183
20005	1188
20005	1206
20005	1218
20005	1229
20014	1195
20014	1218
20014	1232
20014	1233
20014	45238
20020	1183
20020	1188
20020	1206
20020	1218
20020	1232
20025	1183
20025	1188
20025	1206
20025	1218
20025	1229
20028	1188
20028	1218
20028	1232
20028	1233
20028	45238
20030	1183
20030	1196
20030	1204
20030	1205
20030	1232
20030	45561
20056	1183
20056	1188
20056	1206
20056	1218
20056	1232
20074	1183
20074	1191
20074	1229
20074	1233
20074	45543
20080	1188
20080	1218
20080	1232
20080	1233
20080	45600
20089	1188
20089	1204
20089	1232
20089	45236
20089	45543
20090	1183
20090	1188
20090	1204
20090	1218
20090	1232
20111	1188
20111	1218
20111	1232
20111	1233
20111	45236
20118	1188
20118	1218
20118	1232
20118	1233
20118	45238
20119	1188
20119	1218
20119	1232
20119	1233
20119	45238
20123	1188
20123	1218
20123	1232
20123	1233
20123	45238
20124	1183
20124	1188
20124	1218
20124	1232
20124	1233
20126	1188
20126	1218
20126	1232
20126	1233
20126	45238
20128	1183
20128	1188
20128	1198
20128	1206
20128	1217
20131	1183
20131	1188
20131	1222
20131	1232
20131	1233
20133	1183
20133	1188
20133	1218
20133	1232
20133	1233
20137	1183
20137	1188
20137	1218
20137	1232
20137	1233
20138	1188
20138	1218
20138	1232
20138	1233
20138	45236
20139	1183
20139	1188
20139	1218
20139	1232
20139	1233
20140	1188
20140	1232
20140	1233
20140	45238
20140	45543
20141	1188
20141	1218
20141	1232
20141	1233
20141	45236
20146	1188
20146	1222
20146	1232
20146	1233
20146	45238
20149	1183
20149	1188
20149	1218
20149	1232
20149	1233
20153	1183
20153	1188
20153	1218
20153	1232
20153	1233
20154	1183
20154	1188
20154	1218
20154	1232
20154	1233
20155	1183
20155	1188
20155	1218
20155	1232
20155	1233
20156	1183
20156	1188
20156	1204
20156	1218
20156	1232
20158	1183
20158	1188
20158	1218
20158	1232
20158	1233
20159	1183
20159	1188
20159	1218
20159	1232
20159	1233
20160	1183
20160	1188
20160	1232
20160	1233
20160	45543
20161	1183
20161	1188
20161	1198
20161	1218
20161	1233
20164	1183
20164	1188
20164	1221
20164	1232
20164	1233
20165	1183
20165	1188
20165	1218
20165	1232
20165	1233
20166	1183
20166	1188
20166	1218
20166	1232
20166	1233
20169	1183
20169	1188
20169	1218
20169	1232
20169	45604
20170	1183
20170	1188
20170	1218
20170	1232
20170	1233
20171	1183
20171	1188
20171	1218
20171	1232
20171	1233
20172	1183
20172	1188
20172	1218
20172	1232
20172	1233
20173	1183
20173	1188
20173	1218
20173	1232
20173	1233
20174	1183
20174	1188
20174	1198
20174	1218
20174	1233
20176	1188
20176	1218
20176	1232
20176	1233
20176	45238
20177	1183
20177	1188
20177	1218
20177	1232
20177	1233
20178	1188
20178	1232
20178	1233
20178	45337
20178	45602
20182	1183
20182	1188
20182	1218
20182	1232
20182	1233
20183	1183
20183	1188
20183	1218
20183	1232
20183	1233
20186	1188
20186	1204
20186	1218
20186	1232
20186	45236
20187	1183
20187	1188
20187	1204
20187	1222
20187	1232
20189	1183
20189	1188
20189	1218
20189	1232
20189	1233
20191	1183
20191	1188
20191	1198
20191	1218
20191	1233
20192	1183
20192	1188
20192	1218
20192	1232
20192	1233
20196	1183
20196	1188
20196	1232
20196	45604
20196	45631
20200	1183
20200	1193
20200	1218
20200	1232
20200	1233
20201	1183
20201	1188
20201	1218
20201	1232
20201	1233
20202	1188
20202	1209
20202	1232
20202	1233
20202	45236
20206	1188
20206	1198
20206	1206
20206	1218
20206	44936
21222	1188
21222	1218
21222	1232
21222	1233
21222	45238
21223	1183
21223	1188
21223	1218
21223	1232
21223	1233
21224	1183
21224	1188
21224	1218
21224	1232
21224	1233
21225	1188
21225	1218
21225	1232
21225	1233
21225	45238
21226	1188
21226	1232
21226	1233
21226	45238
21226	45611
21227	1183
21227	1188
21227	1218
21227	1232
21227	1233
21230	1183
21230	1188
21230	1204
21230	1218
21230	1232
21231	1188
21231	1218
21231	1232
21231	1233
21231	45238
21232	1188
21232	1232
21232	1233
21232	45238
21232	45543
21233	1188
21233	1232
21233	1233
21233	45603
21233	45611
21234	1183
21234	1188
21234	1218
21234	1232
21234	1233
21235	1183
21235	1188
21235	1218
21235	1232
21235	1233
21236	1183
21236	1188
21236	1218
21236	1232
21236	1233
21239	1183
21239	1188
21239	1218
21239	1232
21239	1233
21242	1183
21242	1188
21242	1232
21242	1233
21242	45543
21245	1183
21245	1188
21245	1218
21245	1232
21245	1233
21247	1183
21247	1188
21247	1232
21247	1233
21247	45181
21250	1188
21250	1204
21250	1218
21250	1232
21250	45236
21251	1188
21251	1218
21251	1232
21251	1233
21251	45238
21254	1183
21254	1188
21254	1232
21254	1233
21254	45543
21256	1188
21256	1218
21256	1232
21256	45238
21256	45604
21257	1178
21257	1193
21257	1218
21257	1232
21257	1233
21259	1183
21259	1188
21259	1218
21259	1232
21259	45604
21262	1183
21262	1188
21262	1218
21262	1232
21262	1233
21263	1183
21263	1188
21263	1218
21263	1232
21263	1233
21264	1183
21264	1188
21264	1232
21264	1233
21264	45181
21265	1188
21265	1218
21265	1232
21265	1233
21265	45238
21267	1188
21267	1218
21267	1232
21267	1233
21267	45236
21270	1183
21270	1188
21270	1218
21270	1232
21270	1233
21271	1188
21271	1218
21271	1220
21271	1232
21271	1233
21272	1183
21272	1188
21272	1218
21272	1232
21272	1233
21273	1188
21273	1232
21273	1233
21273	45602
21273	45629
21274	1188
21274	1198
21274	1218
21274	1233
21274	45602
21278	1188
21278	1232
21278	1233
21278	1237
21278	45561
21279	1188
21279	1218
21279	1232
21279	1233
21279	45602
21280	1183
21280	1188
21280	1218
21280	1232
21280	1233
21281	1183
21281	1188
21281	1218
21281	1232
21281	1233
21282	1188
21282	1218
21282	1232
21282	1233
21282	45600
21283	1183
21283	1188
21283	1218
21283	1232
21283	1233
21284	1183
21284	1188
21284	1232
21284	1233
21284	45593
21286	1178
21286	1188
21286	1218
21286	1232
21286	1233
21287	1183
21287	1188
21287	1218
21287	1232
21287	1233
21290	1183
21290	1188
21290	1218
21290	1232
21290	1233
21292	1183
21292	1188
21292	1218
21292	1232
21292	45604
21293	1183
21293	1188
21293	1218
21293	1232
21293	1233
21295	1183
21295	1188
21295	1218
21295	1232
21295	1233
21296	1183
21296	1188
21296	1218
21296	1232
21296	1233
21296	45602
21298	1183
21298	1188
21298	1232
21298	1233
21298	45181
21299	1183
21299	1188
21299	1218
21299	1232
21299	1233
21303	1188
21303	1218
21303	1232
21303	1233
21303	45602
21304	1183
21304	1188
21304	1218
21304	1232
21304	1233
21305	1183
21305	1188
21305	1218
21305	1232
21305	1233
21306	1183
21306	1188
21306	1218
21306	1232
21306	45604
21307	1188
21307	1232
21307	1233
21307	45238
21307	45635
21308	1183
21308	1188
21308	1218
21308	1232
21308	1233
21310	1183
21310	1188
21310	1218
21310	1232
21310	1233
21311	1188
21311	1218
21311	1232
21311	1233
21311	45236
21312	1183
21312	1188
21312	1218
21312	1232
21312	1233
21313	1188
21313	1218
21313	1232
21313	1233
21313	45602
21314	1188
21314	1218
21314	1232
21314	1233
21314	45238
21316	1183
21316	1188
21316	1218
21316	1232
21316	1233
21317	1183
21317	1188
21317	1198
21317	1218
21317	1233
21323	1183
21323	1188
21323	1218
21323	1232
21323	1233
21324	1183
21324	1188
21324	1198
21324	1218
21324	1232
21324	1233
21324	45548
21326	1188
21326	1232
21326	1233
21326	45236
21326	45635
21329	1183
21329	1188
21329	1222
21329	1232
21329	1233
21330	1183
21330	1188
21330	1218
21330	1232
21330	1233
21331	1183
21331	1188
21331	1218
21331	1232
21331	45604
21332	1183
21332	1188
21332	1218
21332	1232
21332	1233
21336	1183
21336	1188
21336	1218
21336	1232
21336	1233
21337	1183
21337	1188
21337	1218
21337	1232
21337	1233
21338	1188
21338	1218
21338	1220
21338	1232
21338	1233
21339	1183
21339	1188
21339	1218
21339	1232
21339	1233
21340	1188
21340	1204
21340	1218
21340	1232
21340	45236
21341	1183
21341	1188
21341	1218
21341	1232
21341	1233
21342	1188
21342	1218
21342	1232
21342	1233
21342	45602
21343	1183
21343	1188
21343	1218
21343	1232
21343	1233
21344	1183
21344	1188
21344	1218
21344	1232
21344	1233
21345	1188
21345	1218
21345	1220
21345	1232
21345	1233
21346	1188
21346	1218
21346	1232
21346	1233
21346	45600
21347	1188
21347	1218
21347	1232
21347	45602
21347	45604
21348	1183
21348	1188
21348	1218
21348	1232
21348	1233
21349	1183
21349	1188
21349	1218
21349	1232
21349	1233
21350	1183
21350	1188
21350	1218
21350	1232
21350	1233
21351	1188
21351	1218
21351	1232
21351	1233
21351	45238
21352	1183
21352	1188
21352	1218
21352	1232
21352	1233
21353	1188
21353	1218
21353	1232
21353	1233
21353	45238
21354	1188
21354	1218
21354	1232
21354	1233
21354	45602
21355	1188
21355	1218
21355	1232
21355	1233
21355	45600
21356	1183
21356	1188
21356	1218
21356	1232
21356	1233
21357	1188
21357	1218
21357	1232
21357	1233
21357	45236
21358	1183
21358	1188
21358	1218
21358	1232
21358	1233
21360	1183
21360	1188
21360	1218
21360	1232
21360	1233
21361	1183
21361	1188
21361	1218
21361	1232
21361	1233
21362	1183
21362	1188
21362	1218
21362	1232
21362	1233
21363	1183
21363	1188
21363	1218
21363	1232
21363	1233
21364	1183
21364	1188
21364	1218
21364	1232
21364	1233
21366	1183
21366	1188
21366	1218
21366	1232
21366	1233
21367	1183
21367	1188
21367	1218
21367	1232
21367	1233
21369	1183
21369	1188
21369	1218
21369	1232
21369	1233
21370	1183
21370	1188
21370	1232
21370	1233
21370	45624
21375	1183
21375	1188
21375	1218
21375	1232
21375	1233
21377	1183
21377	1188
21377	1218
21377	1232
21377	1233
21380	1183
21380	1188
21380	1206
21380	1217
21380	1219
21380	1220
21380	1229
21380	1232
21380	45604
21383	1183
21383	1188
21383	1204
21383	1218
21383	1232
21385	1183
21385	1188
21385	1198
21385	1218
21385	1233
21386	1183
21386	1188
21386	1218
21386	1232
21386	1233
21387	1188
21387	1218
21387	1232
21387	1233
21387	45238
21388	1183
21388	1188
21388	1211
21388	1232
21388	1233
21389	1183
21389	1188
21389	1218
21389	1232
21389	1233
21390	1183
21390	1188
21390	1218
21390	1232
21390	1233
21392	1183
21392	1188
21392	1218
21392	1232
21392	1233
21393	1183
21393	1188
21393	1218
21393	1232
21393	1233
21394	1188
21394	1218
21394	1232
21394	1233
21394	45602
21395	1183
21395	1188
21395	1218
21395	1232
21395	1233
21396	1188
21396	1218
21396	1232
21396	1233
21396	45236
21397	1183
21397	1188
21397	1218
21397	1232
21397	1233
21398	1183
21398	1188
21398	1218
21398	1232
21398	1233
21400	1183
21400	1188
21400	1218
21400	1232
21400	1233
21401	1183
21401	1188
21401	1218
21401	1232
21401	1233
21402	1183
21402	1188
21402	1198
21402	1206
21402	1210
21402	1218
21402	1232
21402	1233
21403	1188
21403	1218
21403	1232
21403	1233
21403	45602
21404	1183
21404	1188
21404	1218
21404	1232
21404	1233
21405	1183
21405	1188
21405	1218
21405	1232
21405	1233
21407	1183
21407	1188
21407	1218
21407	1232
21407	1233
21408	1183
21408	1188
21408	1218
21408	1232
21408	1233
21409	1183
21409	1188
21409	1218
21409	1232
21409	1233
21410	1188
21410	1218
21410	1232
21410	1233
21410	45238
21418	1183
21418	1188
21418	1205
21418	1218
21418	1232
21420	1183
21420	1188
21420	1218
21420	1232
21420	1233
21421	1183
21421	1188
21421	1218
21421	1232
21421	1233
21422	1183
21422	1188
21422	1218
21422	1232
21422	1233
21422	45365
21422	45623
21427	1183
21427	1188
21427	1232
21427	1233
21427	45181
21431	1183
21431	1188
21431	1218
21431	1232
21431	1233
21432	1183
21432	1188
21432	1218
21432	1232
21432	1233
21433	1183
21433	1188
21433	1232
21433	1233
21433	45181
21434	1188
21434	1232
21434	1233
21434	45546
21434	45602
21435	1183
21435	1188
21435	1198
21435	1218
21435	1233
21437	1183
21437	1188
21437	1218
21437	1232
21437	1233
21438	1183
21438	1188
21438	1218
21438	1232
21438	1233
21439	1183
21439	1188
21439	1218
21439	1232
21439	1233
21440	1183
21440	1188
21440	1218
21440	1232
21440	1233
21441	1183
21441	1188
21441	1218
21441	1232
21441	1233
21443	1183
21443	1188
21443	1198
21443	1218
21443	1233
21444	1183
21444	1188
21444	1218
21444	1232
21444	1233
21446	1183
21446	1188
21446	1218
21446	1232
21446	1233
21447	1183
21447	1188
21447	1232
21447	1233
21447	45399
21448	1183
21448	1188
21448	1218
21448	1232
21448	1233
21449	1188
21449	1218
21449	1232
21449	1233
21449	45600
21451	1183
21451	1188
21451	1218
21451	1232
21451	1233
21452	1183
21452	1188
21452	1218
21452	1232
21452	1233
21455	1183
21455	1188
21455	1218
21455	1232
21455	1233
21456	1188
21456	1204
21456	1218
21456	1232
21456	45236
21457	1183
21457	1188
21457	1210
21457	1232
21457	1233
21459	1183
21459	1188
21459	1218
21459	1232
21459	1233
21460	1183
21460	1188
21460	1232
21460	1233
21460	1276
21461	1188
21461	1218
21461	1232
21461	1233
21461	45600
21463	1183
21463	1188
21463	1218
21463	1232
21463	1233
21464	1188
21464	1193
21464	1210
21464	1232
21464	1233
21464	45238
21464	45637
21465	1188
21465	1218
21465	1232
21465	1233
21465	45238
21467	1183
21467	1188
21467	1218
21467	1232
21467	1233
21468	1183
21468	1188
21468	1218
21468	1232
21468	45604
21469	1183
21469	1188
21469	1232
21469	1233
21469	45181
21470	1183
21470	1188
21470	1232
21470	1233
21470	45181
21471	1183
21471	1188
21471	1232
21471	45399
21471	45604
21474	1183
21474	1188
21474	1218
21474	1232
21474	1233
21476	1183
21476	1188
21476	1218
21476	1232
21476	1233
21479	1183
21479	1188
21479	1218
21479	1232
21479	1233
21480	1183
21480	1188
21480	1218
21480	1232
21480	1233
21483	1188
21483	1218
21483	1232
21483	1233
21483	45602
21484	1188
21484	1218
21484	1232
21484	1233
21484	45238
21485	1183
21485	1188
21485	1221
21485	1232
21485	1233
21486	1188
21486	1204
21486	1218
21486	1232
21486	45236
21487	1183
21487	1188
21487	1218
21487	1232
21487	1233
21488	1188
21488	1218
21488	1232
21488	1233
21488	45602
21489	1183
21489	1188
21489	1213
21489	1232
21489	1233
21492	1178
21492	1188
21492	1218
21492	1232
21492	1233
21493	1188
21493	1232
21493	1233
21493	45337
21493	45602
21493	45606
21494	1183
21494	1188
21494	1218
21494	1232
21494	1233
21495	1183
21495	1188
21495	1222
21495	1232
21495	1233
21496	1183
21496	1188
21496	1218
21496	1232
21496	1233
21498	1188
21498	1204
21498	1218
21498	1232
21498	45236
21499	1183
21499	1188
21499	1221
21499	1232
21499	1233
21500	1188
21500	1232
21500	1233
21500	45380
21500	45602
21501	1183
21501	1188
21501	1232
21501	1233
21501	45543
21502	1183
21502	1188
21502	1232
21502	1233
21502	44977
21504	1183
21504	1188
21504	1218
21504	1232
21504	1233
21505	1183
21505	1188
21505	1218
21505	1232
21505	1233
21506	1183
21506	1188
21506	1218
21506	1232
21506	1233
21507	1183
21507	1188
21507	1232
21507	1233
21507	45543
21508	1183
21508	1188
21508	1218
21508	1232
21508	1233
21509	1183
21509	1188
21509	1218
21509	1232
21509	1233
21510	1188
21510	1218
21510	1232
21510	1233
21510	45236
21511	1183
21511	1188
21511	1218
21511	1232
21511	1233
21512	1183
21512	1188
21512	1204
21512	1218
21512	1232
21514	1183
21514	1188
21514	1218
21514	1232
21514	1233
21515	1183
21515	1188
21515	1218
21515	1232
21515	1233
21516	1183
21516	1188
21516	1218
21516	1232
21516	1233
21517	1183
21517	1188
21517	1218
21517	1232
21517	1233
21519	1183
21519	1188
21519	1218
21519	1232
21519	1233
21520	1183
21520	1188
21520	1218
21520	1232
21520	1233
21521	1183
21521	1188
21521	1218
21521	1232
21521	1233
21522	1183
21522	1188
21522	1218
21522	1232
21522	1233
21524	1183
21524	1188
21524	1218
21524	1232
21524	1233
21525	1183
21525	1188
21525	1218
21525	1232
21525	1233
21528	1183
21528	1188
21528	1218
21528	1232
21528	1233
21529	1183
21529	1188
21529	1218
21529	1232
21529	1233
21530	1183
21530	1188
21530	1218
21530	1232
21530	1233
21531	1188
21531	1232
21531	1233
21531	45236
21531	45593
21533	1188
21533	1218
21533	1232
21533	1233
21533	45236
21534	1183
21534	1188
21534	1232
21534	1233
21534	45635
21535	1183
21535	1188
21535	1218
21535	1232
21535	1233
21536	1183
21536	1188
21536	1218
21536	1232
21536	1233
21537	1183
21537	1188
21537	1218
21537	1232
21537	45604
21547	1188
21547	1218
21547	1232
21547	1233
21547	45236
21558	1188
21558	1221
21558	1232
21558	1233
21558	45236
21559	1188
21559	1218
21559	1232
21559	1233
21559	45238
21560	1188
21560	1218
21560	1232
21560	1233
21560	45236
21561	1183
21561	1188
21561	1218
21561	1232
21561	1233
21562	1188
21562	1218
21562	1232
21562	1233
21562	45602
21563	1183
21563	1188
21563	1222
21563	1232
21563	1233
21564	1188
21564	1218
21564	1232
21564	1233
21564	45236
21565	1183
21565	1188
21565	1232
21565	1233
21565	45181
21566	1183
21566	1188
21566	1218
21566	1232
21566	1233
21567	1183
21567	1188
21567	1232
21567	1233
21567	45621
21568	1183
21568	1188
21568	1218
21568	1232
21568	1233
21569	1183
21569	1188
21569	1218
21569	1232
21569	1233
21570	1188
21570	1218
21570	1220
21570	1232
21570	1233
21571	1183
21571	1188
21571	1218
21571	1232
21571	1233
21572	1183
21572	1188
21572	1218
21572	1232
21572	1233
21573	1183
21573	1188
21573	1218
21573	1232
21573	1233
21574	1183
21574	1188
21574	1232
21574	1233
21574	45543
21575	1183
21575	1188
21575	1218
21575	1232
21575	1233
21576	1183
21576	1188
21576	1218
21576	1232
21576	1233
21578	1183
21578	1193
21578	1198
21578	1218
21578	1233
21581	1188
21581	1218
21581	1232
21581	1233
21581	45602
21583	1183
21583	1188
21583	1218
21583	1232
21583	1233
21584	1183
21584	1188
21584	1232
21584	1233
21584	45181
21585	1188
21585	1218
21585	1232
21585	1233
21585	45238
21586	1183
21586	1188
21586	1218
21586	1232
21586	45604
21587	1183
21587	1188
21587	1218
21587	1232
21587	1233
21588	1183
21588	1188
21588	1218
21588	1232
21588	1233
21589	1188
21589	1218
21589	1232
21589	1233
21589	45236
21590	1183
21590	1193
21590	1218
21590	1232
21590	1233
21592	1183
21592	1188
21592	1218
21592	1232
21592	1233
21593	1183
21593	1188
21593	1198
21593	1218
21593	1233
21596	1183
21596	1188
21596	1232
21596	1233
21596	45181
21598	1188
21598	1204
21598	1218
21598	1232
21598	45236
21599	1183
21599	1188
21599	1218
21599	1232
21599	1233
21603	1183
21603	1188
21603	1204
21603	1218
21603	1232
21604	1193
21604	1218
21604	1232
21604	1233
21604	45238
21605	1188
21605	1218
21605	1232
21605	1233
21605	45600
21606	1183
21606	1188
21606	1218
21606	1232
21606	1233
21607	1183
21607	1188
21607	1218
21607	1232
21607	1233
21608	1188
21608	1204
21608	1218
21608	1232
21608	45236
21609	1183
21609	1188
21609	1218
21609	1232
21609	1233
21610	1183
21610	1188
21610	1204
21610	1218
21610	1232
21611	1183
21611	1188
21611	1218
21611	1232
21611	1233
21613	1188
21613	1218
21613	1232
21613	1233
21613	1237
21614	1188
21614	1218
21614	1232
21614	1233
21614	1237
21615	1183
21615	1188
21615	1218
21615	1232
21615	1233
21616	1183
21616	1188
21616	1204
21616	1218
21616	1232
21617	1183
21617	1188
21617	1218
21617	1232
21617	1233
21619	1183
21619	1188
21619	1218
21619	1232
21619	1233
21621	1183
21621	1188
21621	1218
21621	1232
21621	1233
21622	1183
21622	1188
21622	1232
21622	1233
21622	45377
21623	1183
21623	1188
21623	1204
21623	1218
21623	1232
21624	1183
21624	1188
21624	1204
21624	1218
21624	1232
21625	1183
21625	1188
21625	1218
21625	1232
21625	1233
21626	1183
21626	1188
21626	1218
21626	1232
21626	1233
21627	1183
21627	1188
21627	1204
21627	1218
21627	1232
21628	1183
21628	1188
21628	1218
21628	1232
21628	1233
21630	1183
21630	1188
21630	1218
21630	1232
21630	1233
21631	1183
21631	1188
21631	1218
21631	1232
21631	1233
21632	1183
21632	1188
21632	1218
21632	1232
21632	1233
21633	1183
21633	1188
21633	1218
21633	1232
21633	1233
21634	1183
21634	1188
21634	1218
21634	1232
21634	1233
21635	1188
21635	1218
21635	1232
21635	1233
21635	45600
21637	1183
21637	1188
21637	1218
21637	1232
21637	1233
21638	1183
21638	1188
21638	1218
21638	1232
21638	1233
21639	1183
21639	1188
21639	1218
21639	1232
21639	1233
21640	1183
21640	1188
21640	1194
21640	1198
21640	1218
21640	1232
21640	1233
21640	1239
21640	1262
21641	1188
21641	1204
21641	1218
21641	1232
21641	45236
21642	1183
21642	1188
21642	1218
21642	1232
21642	1233
21643	1183
21643	1188
21643	1232
21643	1233
21643	45380
21644	1183
21644	1188
21644	1218
21644	1232
21644	1233
21645	1188
21645	1218
21645	1232
21645	1233
21645	45238
21646	1188
21646	1204
21646	1218
21646	1232
21646	45236
21647	1188
21647	1218
21647	1232
21647	1233
21647	45238
21650	1183
21650	1188
21650	1218
21650	1232
21650	1233
21652	1183
21652	1188
21652	1218
21652	1232
21652	1233
21653	1183
21653	1188
21653	1218
21653	1232
21653	1233
21654	1183
21654	1188
21654	1205
21654	1218
21654	1232
21655	1183
21655	1188
21655	1218
21655	1232
21655	1233
21656	1183
21656	1188
21656	1218
21656	1232
21656	1233
21657	1188
21657	1218
21657	1232
21657	1233
21657	45602
21658	1183
21658	1188
21658	1218
21658	1232
21658	1233
21659	1183
21659	1188
21659	1218
21659	1232
21659	1233
21660	1183
21660	1188
21660	1218
21660	1232
21660	1233
21661	1188
21661	1198
21661	1210
21661	1233
21661	45602
21662	1183
21662	1188
21662	1218
21662	1232
21662	1233
21665	1183
21665	1188
21665	1218
21665	1232
21665	1233
21669	1183
21669	1188
21669	1218
21669	1232
21669	1233
21670	1183
21670	1188
21670	1218
21670	1232
21670	1233
21671	1183
21671	1188
21671	1218
21671	1232
21671	1233
21673	1183
21673	1188
21673	1218
21673	1232
21673	1233
21674	1183
21674	1188
21674	1218
21674	1232
21674	1233
21676	1183
21676	1188
21676	1232
21676	1233
21676	45181
21677	1188
21677	1218
21677	1232
21677	1233
21677	45602
21683	1183
21683	1188
21683	1218
21683	1232
21683	1233
21687	1183
21687	1188
21687	1204
21687	1218
21687	1232
21688	1193
21688	1218
21688	1232
21688	1233
21688	45238
21689	1188
21689	1213
21689	1232
21689	1233
21689	45236
21694	1183
21694	1188
21694	1218
21694	1232
21694	1233
21695	1183
21695	1188
21695	1222
21695	1232
21695	1233
21696	1183
21696	1188
21696	1218
21696	1232
21696	1233
21698	1183
21698	1188
21698	1218
21698	1232
21698	1233
21699	1183
21699	1188
21699	1232
21699	1233
21699	45543
21701	1188
21701	1218
21701	1232
21701	1233
21701	45236
21702	1183
21702	1188
21702	1218
21702	1232
21702	1233
21703	1183
21703	1188
21703	1218
21703	1232
21703	1233
21704	1183
21704	1188
21704	1218
21704	1232
21704	1233
21705	1183
21705	1188
21705	1222
21705	1232
21705	1233
21708	1188
21708	1218
21708	1232
21708	1233
21708	45238
21711	1188
21711	1218
21711	1232
21711	1233
21711	45236
21712	1183
21712	1188
21712	1218
21712	1232
21712	1233
21713	1183
21713	1188
21713	1218
21713	1232
21713	1233
21716	1188
21716	1232
21716	1233
21716	45380
21716	45602
21719	1183
21719	1188
21719	1218
21719	1232
21719	1233
21720	1183
21720	1188
21720	1218
21720	1232
21720	1233
21722	1183
21722	1188
21722	1232
21722	1233
21722	45630
21726	1183
21726	1188
21726	1218
21726	1232
21726	45604
21728	1178
21728	1188
21728	1218
21728	1232
21728	1233
21728	45238
21729	1183
21729	1188
21729	1200
21729	1218
21729	1233
21731	1183
21731	1188
21731	1204
21731	1218
21731	1232
21733	1183
21733	1188
21733	1218
21733	1232
21733	1233
21735	1183
21735	1188
21735	1218
21735	1232
21735	1233
21738	1183
21738	1193
21738	1232
21738	1233
21738	45181
21739	1188
21739	1232
21739	1233
21739	45181
21739	45238
21740	1183
21740	1188
21740	1218
21740	1232
21740	1233
21741	1183
21741	1188
21741	1218
21741	1232
21741	1233
21742	1183
21742	1188
21742	1218
21742	1232
21742	1233
21743	1183
21743	1188
21743	1218
21743	1232
21743	1233
21744	1188
21744	1222
21744	1232
21744	1233
21744	45238
21745	1188
21745	1218
21745	1232
21745	1233
21745	45602
21746	1183
21746	1188
21746	1218
21746	1232
21746	1233
21749	1183
21749	1188
21749	1218
21749	1232
21749	1233
21751	1183
21751	1188
21751	1218
21751	1232
21751	1233
21752	1188
21752	1232
21752	1233
21752	45238
21752	45630
21753	1188
21753	1232
21753	1233
21753	45602
21753	45620
21756	1183
21756	1188
21756	1218
21756	1232
21756	1233
21757	1188
21757	1218
21757	1232
21757	1233
21757	45236
21759	1188
21759	1232
21759	1233
21759	45238
21759	45609
21760	1183
21760	1188
21760	1218
21760	1232
21760	1233
21762	1183
21762	1188
21762	1218
21762	1232
21762	1233
21763	1183
21763	1188
21763	1218
21763	1232
21763	45604
21764	1188
21764	1218
21764	1232
21764	1233
21764	45602
21765	1188
21765	1218
21765	1232
21765	1233
21765	45602
21766	1183
21766	1188
21766	1232
21766	1233
21766	45593
21767	1183
21767	1188
21767	1218
21767	1232
21767	1233
21768	1183
21768	1188
21768	1218
21768	1232
21768	1233
21769	1188
21769	1204
21769	1218
21769	1232
21769	45236
21770	1183
21770	1188
21770	1218
21770	1232
21770	1233
21771	1183
21771	1188
21771	1218
21771	1232
21771	1233
21772	1183
21772	1188
21772	1218
21772	1232
21772	1233
21773	1183
21773	1188
21773	1218
21773	1232
21773	1233
21774	1188
21774	1218
21774	1232
21774	1233
21774	45602
21775	1183
21775	1188
21775	1218
21775	1232
21775	1233
21776	1183
21776	1188
21776	1218
21776	1232
21776	1233
21778	1183
21778	1188
21778	1218
21778	1232
21778	1233
21780	1183
21780	1188
21780	1204
21780	1218
21780	1232
21780	1233
21780	45236
21781	1183
21781	1188
21781	1218
21781	1232
21781	1233
21782	1183
21782	1188
21782	1221
21782	1232
21782	1233
21783	1183
21783	1188
21783	1218
21783	1232
21783	1233
21784	1188
21784	1204
21784	1218
21784	1232
21784	45236
21785	1183
21785	1188
21785	1218
21785	1232
21785	1233
21786	1183
21786	1188
21786	1218
21786	1232
21786	1233
21787	1183
21787	1188
21787	1232
21787	1233
21787	45614
21788	1183
21788	1188
21788	1218
21788	1232
21788	1233
21789	1183
21789	1188
21789	1218
21789	1232
21789	1233
21790	1183
21790	1188
21790	1218
21790	1232
21790	1233
21791	1183
21791	1188
21791	1218
21791	1232
21791	1233
21792	1183
21792	1188
21792	1218
21792	1232
21792	1233
21793	1183
21793	1188
21793	1218
21793	1232
21793	1233
21794	1183
21794	1188
21794	1232
21794	1233
21794	45619
21795	1183
21795	1188
21795	1218
21795	1232
21795	1233
21796	1183
21796	1188
21796	1218
21796	1232
21796	1233
21797	1183
21797	1188
21797	1218
21797	1232
21797	1233
21798	1183
21798	1188
21798	1221
21798	1232
21798	1233
21799	1183
21799	1188
21799	1218
21799	1232
21799	1233
21800	1183
21800	1188
21800	1218
21800	1232
21800	1233
21801	1183
21801	1188
21801	1218
21801	1232
21801	1233
21802	1183
21802	1188
21802	1218
21802	1232
21802	1233
21803	1183
21803	1188
21803	1204
21803	1218
21803	1232
21804	1183
21804	1188
21804	1218
21804	1232
21804	1233
21805	1183
21805	1188
21805	1218
21805	1232
21805	1233
21806	1188
21806	1218
21806	1232
21806	1233
21806	45602
21807	1183
21807	1188
21807	1218
21807	1232
21807	1233
21808	1188
21808	1232
21808	1233
21808	45238
21808	45618
21809	1183
21809	1188
21809	1218
21809	1232
21809	1233
21814	1183
21814	1188
21814	1218
21814	1232
21814	1233
21817	1183
21817	1188
21817	1205
21817	1218
21817	1232
21818	1183
21818	1188
21818	1218
21818	1232
21818	1233
21822	1188
21822	1232
21822	1233
21822	45602
21822	45629
21824	1183
21824	1188
21824	1232
21824	1233
21824	45181
21825	1183
21825	1188
21825	1218
21825	1232
21825	1233
21828	1183
21828	1188
21828	1218
21828	1232
21828	1233
21829	1183
21829	1188
21829	1218
21829	1232
21829	1233
21834	1183
21834	1188
21834	1218
21834	1232
21834	1233
21835	1183
21835	1188
21835	1221
21835	1232
21835	1233
21836	1183
21836	1188
21836	1218
21836	1232
21836	1233
21837	1183
21837	1188
21837	1205
21837	1218
21837	1232
21838	1183
21838	1188
21838	1232
21838	1233
21838	45543
21840	1183
21840	1188
21840	1218
21840	1232
21840	1233
21842	1183
21842	1188
21842	1218
21842	1232
21842	1233
21845	1183
21845	1188
21845	1218
21845	1232
21845	1233
21849	1183
21849	1188
21849	1218
21849	1232
21849	1233
21851	1183
21851	1188
21851	1218
21851	1232
21851	1233
21854	1183
21854	1188
21854	1218
21854	1232
21854	1233
21857	1183
21857	1188
21857	1210
21857	1232
21857	1233
21861	1183
21861	1188
21861	1232
21861	1233
21861	45625
21865	1183
21865	1188
21865	1232
21865	1233
21865	45561
21868	1183
21868	1188
21868	1221
21868	1232
21868	1233
21869	1183
21869	1188
21869	1218
21869	1232
21869	1233
21870	1183
21870	1188
21870	1218
21870	1232
21870	1233
21871	1183
21871	1188
21871	1218
21871	1232
21871	1233
21872	1188
21872	1218
21872	1232
21872	1233
21872	45238
21874	1183
21874	1188
21874	1218
21874	1232
21874	1233
21877	1183
21877	1188
21877	1218
21877	1232
21877	1233
21880	1183
21880	1188
21880	1218
21880	1232
21880	1233
21882	1183
21882	1188
21882	1218
21882	1232
21882	1233
21884	1188
21884	1218
21884	1232
21884	1233
21884	45238
21891	1183
21891	1188
21891	1210
21891	1232
21891	1233
21892	1183
21892	1188
21892	1204
21892	1218
21892	1232
21893	1183
21893	1188
21893	1218
21893	1232
21893	1233
21894	1183
21894	1188
21894	1218
21894	1232
21894	1233
21898	1183
21898	1188
21898	1218
21898	1232
21898	1233
21900	1183
21900	1188
21900	1218
21900	1232
21900	1233
21902	1183
21902	1188
21902	1218
21902	1232
21902	1233
21903	1188
21903	1218
21903	1232
21903	1233
21903	45602
21905	1183
21905	1188
21905	1204
21905	1218
21905	1232
21907	1183
21907	1188
21907	1218
21907	1232
21907	1233
21908	1183
21908	1188
21908	1218
21908	1232
21908	1233
21909	1183
21909	1188
21909	1218
21909	1232
21909	1233
21910	1183
21910	1188
21910	1218
21910	1232
21910	1233
21912	1183
21912	1188
21912	1218
21912	1232
21912	45604
21913	1183
21913	1188
21913	1204
21913	1218
21913	1232
21914	1183
21914	1188
21914	1205
21914	1218
21914	1232
21915	1183
21915	1188
21915	1218
21915	1232
21915	1233
21919	1183
21919	1188
21919	1206
21919	1218
21919	1232
21919	1233
21919	45548
21920	1183
21920	1188
21920	1218
21920	1232
21920	1233
21923	1183
21923	1188
21923	1218
21923	1232
21923	1233
21924	1183
21924	1188
21924	1218
21924	1232
21924	1233
21925	1183
21925	1188
21925	1218
21925	1232
21925	1233
21927	1183
21927	1188
21927	1218
21927	1232
21927	1233
21929	1183
21929	1188
21929	1218
21929	1232
21929	1233
21930	1183
21930	1188
21930	1232
21930	1233
21930	45181
21932	1183
21932	1188
21932	1218
21932	1232
21932	1233
21935	1183
21935	1188
21935	1218
21935	1232
21935	1233
21937	1183
21937	1188
21937	1204
21937	1218
21937	1232
21938	1183
21938	1188
21938	1218
21938	1232
21938	1233
21939	1183
21939	1188
21939	1218
21939	1232
21939	45604
21940	1183
21940	1188
21940	1218
21940	1232
21940	1233
21941	1183
21941	1188
21941	1232
21941	1233
21941	45543
21942	1183
21942	1188
21942	1218
21942	1232
21942	1233
21943	1183
21943	1188
21943	1218
21943	1232
21943	1233
21944	1183
21944	1188
21944	1218
21944	1232
21944	1233
21945	1183
21945	1188
21945	1218
21945	1232
21945	1233
21948	1183
21948	1188
21948	1218
21948	1232
21948	1233
21951	1183
21951	1188
21951	1218
21951	1232
21951	1233
21952	1183
21952	1188
21952	1218
21952	1232
21952	1233
21953	1183
21953	1188
21953	1204
21953	1218
21953	1232
21955	1183
21955	1188
21955	1218
21955	1232
21955	1233
21959	1183
21959	1188
21959	1218
21959	1232
21959	1233
21960	1183
21960	1188
21960	1218
21960	1232
21960	1233
21961	1188
21961	1218
21961	1232
21961	1233
21961	45602
21962	1178
21962	1188
21962	1218
21962	1232
21962	1233
21964	1183
21964	1188
21964	1218
21964	1232
21964	1233
21965	1188
21965	1218
21965	1232
21965	1233
21965	45236
21967	1188
21967	1218
21967	1232
21967	1233
21967	45600
21970	1188
21970	1218
21970	1232
21970	1233
21970	45238
21977	1183
21977	1188
21977	1218
21977	1232
21977	1233
21978	1183
21978	1188
21978	1218
21978	1232
21978	1233
21978	45604
21979	1183
21979	1188
21979	1218
21979	1232
21979	1233
21980	1183
21980	1188
21980	1218
21980	1232
21980	1233
21982	1188
21982	1218
21982	1232
21982	1233
21982	45602
21983	1188
21983	1218
21983	1232
21983	1233
21983	45238
21984	1183
21984	1188
21984	1218
21984	1232
21984	1233
21985	1183
21985	1188
21985	1218
21985	1232
21985	1233
21986	1188
21986	1198
21986	1218
21986	1233
21986	45236
21988	1188
21988	1204
21988	1218
21988	1232
21988	45236
21989	1183
21989	1188
21989	1218
21989	1232
21989	1233
21990	1183
21990	1188
21990	1218
21990	1232
21990	1233
21991	1188
21991	1218
21991	1232
21991	1233
21991	45236
21992	1188
21992	1218
21992	1232
21992	1233
21992	1237
21993	1183
21993	1188
21993	1218
21993	1232
21993	1233
21994	1183
21994	1188
21994	1218
21994	1232
21994	1233
21996	1183
21996	1188
21996	1232
21996	1233
21996	45546
21999	1183
21999	1188
21999	1218
21999	1232
21999	1233
22000	1183
22000	1188
22000	1218
22000	1232
22000	1233
22001	1183
22001	1188
22001	1218
22001	1232
22001	1233
22002	1183
22002	1188
22002	1218
22002	1232
22002	1233
22006	1188
22006	1218
22006	1232
22006	1233
22006	45602
22008	1183
22008	1188
22008	1204
22008	1218
22008	1232
22009	1183
22009	1188
22009	1218
22009	1232
22009	1233
22010	1183
22010	1188
22010	1218
22010	1232
22010	1233
22014	1183
22014	1188
22014	1232
22014	1233
22014	1276
22015	1188
22015	1218
22015	1232
22015	1233
22015	45236
22017	1183
22017	1188
22017	1204
22017	1218
22017	1232
22019	1188
22019	1232
22019	1233
22019	1257
22019	45602
22020	1183
22020	1188
22020	1218
22020	1232
22020	1233
22021	1183
22021	1188
22021	1218
22021	1232
22021	1233
22022	1188
22022	1232
22022	1233
22022	45236
22022	45578
22023	1183
22023	1188
22023	1232
22023	1233
22023	45630
22024	1183
22024	1188
22024	1218
22024	1232
22024	1233
22025	1183
22025	1188
22025	1218
22025	1232
22025	1233
22026	1183
22026	1188
22026	1218
22026	1232
22026	1233
22027	1178
22027	1188
22027	1218
22027	1232
22027	1233
22028	1183
22028	1188
22028	1218
22028	1232
22028	1233
22029	1183
22029	1188
22029	1218
22029	1232
22029	1233
22033	1183
22033	1188
22033	1218
22033	1232
22033	1233
22036	1183
22036	1188
22036	1218
22036	1232
22036	1233
22038	1188
22038	1218
22038	1232
22038	1233
22038	45238
22039	1183
22039	1188
22039	1218
22039	1232
22039	1233
22040	1183
22040	1188
22040	1204
22040	1218
22040	1232
22042	1183
22042	1188
22042	1218
22042	1232
22042	1233
22043	1183
22043	1188
22043	1218
22043	1232
22043	1233
22044	1183
22044	1188
22044	1232
22044	1233
22044	45628
22046	1183
22046	1188
22046	1218
22046	1232
22046	1233
22047	1183
22047	1188
22047	1218
22047	1232
22047	1233
22049	1188
22049	1218
22049	1232
22049	1233
22049	45600
22053	1183
22053	1188
22053	1218
22053	1232
22053	1233
22054	1188
22054	1232
22054	1233
22054	45602
22054	45635
22057	1183
22057	1188
22057	1218
22057	1232
22057	45604
22058	1188
22058	1232
22058	1233
22058	45238
22058	45635
22060	1183
22060	1188
22060	1218
22060	1232
22060	1233
22061	1183
22061	1188
22061	1218
22061	1232
22061	1233
22063	1178
22063	1188
22063	1232
22063	1233
22063	45134
22065	1188
22065	1218
22065	1232
22065	1233
22065	45236
22066	1183
22066	1188
22066	1218
22066	1232
22066	1233
22067	1183
22067	1188
22067	1221
22067	1232
22067	1233
22068	1183
22068	1188
22068	1218
22068	1232
22068	1233
22069	1183
22069	1188
22069	1218
22069	1232
22069	1233
22071	1188
22071	1198
22071	1233
22071	45181
22071	45236
22075	1188
22075	1218
22075	1232
22075	1233
22075	45238
22076	1183
22076	1188
22076	1218
22076	1232
22076	1233
22077	1183
22077	1188
22077	1218
22077	1232
22077	1233
22078	1183
22078	1188
22078	1218
22078	1232
22078	1233
22080	1183
22080	1193
22080	1218
22080	1232
22080	1233
22081	1183
22081	1188
22081	1218
22081	1232
22081	1233
22082	1183
22082	1188
22082	1218
22082	1232
22082	1233
22082	45238
22083	1183
22083	1188
22083	1218
22083	1232
22083	1233
22087	1183
22087	1188
22087	1204
22087	1222
22087	1232
22089	1183
22089	1188
22089	1218
22089	1232
22089	1233
22090	1183
22090	1188
22090	1232
22090	1233
22090	45399
22090	45633
22091	1183
22091	1188
22091	1218
22091	1232
22091	1233
22092	1188
22092	1218
22092	1232
22092	1233
22092	45238
22093	1183
22093	1188
22093	1218
22093	1232
22093	1233
22094	1183
22094	1188
22094	1218
22094	1232
22094	1233
22095	1188
22095	1222
22095	1232
22095	1233
22095	45238
22097	1183
22097	1188
22097	1218
22097	1232
22097	1233
22098	1183
22098	1188
22098	1218
22098	1232
22098	1233
22099	1183
22099	1188
22099	1218
22099	1232
22099	1233
22100	1183
22100	1188
22100	1198
22100	1218
22100	1233
22102	1183
22102	1188
22102	1218
22102	1232
22102	1233
22104	1183
22104	1188
22104	1204
22104	1218
22104	1232
22105	1183
22105	1188
22105	1218
22105	1232
22105	1233
22108	1183
22108	1188
22108	1204
22108	1221
22108	1232
22109	1178
22109	1188
22109	1218
22109	1232
22109	1233
22109	45600
22110	1183
22110	1193
22110	1218
22110	1232
22110	1233
22112	1183
22112	1188
22112	1218
22112	1232
22112	1233
22113	1188
22113	1204
22113	1218
22113	1232
22113	45236
22115	1183
22115	1188
22115	1232
22115	1233
22115	45630
22116	1183
22116	1193
22116	1232
22116	1233
22116	45593
22118	1183
22118	1188
22118	1218
22118	1232
22118	1233
22120	1183
22120	1188
22120	1218
22120	1232
22120	1233
22121	1183
22121	1188
22121	1213
22121	1232
22121	1233
22124	1183
22124	1188
22124	1218
22124	1232
22124	1233
22126	1183
22126	1188
22126	1218
22126	1232
22126	1233
22127	1188
22127	1222
22127	1232
22127	1233
22127	45238
22129	1183
22129	1188
22129	1218
22129	1232
22129	1233
22132	1183
22132	1188
22132	1218
22132	1232
22132	1233
22135	1183
22135	1188
22135	1218
22135	1232
22135	1233
22136	1183
22136	1188
22136	1221
22136	1232
22136	1233
22137	1178
22137	1183
22137	1188
22137	1221
22137	1232
22137	1233
22138	1183
22138	1188
22138	1218
22138	1232
22138	1233
22139	1183
22139	1188
22139	1221
22139	1232
22139	1233
22141	1183
22141	1188
22141	1222
22141	1232
22141	1233
22142	1183
22142	1188
22142	1218
22142	1232
22142	1233
22143	1183
22143	1188
22143	1218
22143	1232
22143	1233
22144	1178
22144	1183
22144	1188
22144	1218
22144	1232
22144	1233
22146	1188
22146	1232
22146	1233
22146	45602
22146	45635
22149	1195
22149	1232
22149	1233
22149	45238
22149	45543
22151	1183
22151	1188
22151	1198
22151	1218
22151	1233
22154	1183
22154	1188
22154	1204
22154	1218
22154	1232
22155	1188
22155	1204
22155	1218
22155	1232
22155	45236
22158	1188
22158	1218
22158	1232
22158	1233
22158	45236
22159	1183
22159	1188
22159	1204
22159	1218
22159	1232
22160	1188
22160	1210
22160	1232
22160	1233
22160	45238
22162	1183
22162	1188
22162	1218
22162	1232
22162	1233
22164	1183
22164	1188
22164	1218
22164	1232
22164	1233
22167	1178
22167	1188
22167	1218
22167	1232
22167	45604
22168	1183
22168	1188
22168	1218
22168	1232
22168	1233
22172	1183
22172	1188
22172	1218
22172	1232
22172	1233
22176	1183
22176	1188
22176	1218
22176	1232
22176	1233
22177	1182
22177	1188
22177	1232
22177	1233
22177	45617
22178	1188
22178	1232
22178	1233
22178	45602
22178	45635
22180	1183
22180	1188
22180	1218
22180	1232
22180	45604
22181	1179
22181	1188
22181	1218
22181	1232
22181	1233
22181	45238
22182	1183
22182	1188
22182	1232
22182	1233
22182	45181
22186	1188
22186	1204
22186	1218
22186	1232
22186	45236
22189	1183
22189	1188
22189	1218
22189	1232
22189	1233
22190	1183
22190	1188
22190	1221
22190	1232
22190	1233
22190	45181
22191	1183
22191	1188
22191	1218
22191	1232
22191	1233
22192	1183
22192	1188
22192	1232
22192	1233
22192	1257
22192	45608
22193	1183
22193	1188
22193	1218
22193	1232
22193	1233
22194	1183
22194	1188
22194	1218
22194	1232
22194	1233
22196	1183
22196	1188
22196	1204
22196	1218
22196	1232
22197	1183
22197	1188
22197	1195
22197	1198
22197	1218
22197	1233
22197	45236
22198	1183
22198	1188
22198	1218
22198	1232
22198	1233
22199	1183
22199	1188
22199	1218
22199	1232
22199	1233
22201	1188
22201	1232
22201	1233
22201	45602
22201	45635
22202	1183
22202	1188
22202	1232
22202	1233
22202	45630
22203	1183
22203	1188
22203	1218
22203	1232
22203	45604
22204	1183
22204	1188
22204	1218
22204	1232
22204	1233
22205	1183
22205	1188
22205	1218
22205	1232
22205	1233
22206	1183
22206	1188
22206	1218
22206	1232
22206	1233
22207	1183
22207	1188
22207	1218
22207	1232
22207	1233
22209	1183
22209	1188
22209	1232
22209	1233
22209	45377
22210	1183
22210	1188
22210	1218
22210	1232
22210	1233
22214	1183
22214	1188
22214	1218
22214	1232
22214	1233
22215	1183
22215	1188
22215	1232
22215	1233
22215	45630
22216	1183
22216	1188
22216	1218
22216	1232
22216	1233
22217	1188
22217	1204
22217	1218
22217	1232
22217	45236
22218	1183
22218	1188
22218	1218
22218	1232
22218	1233
22219	1183
22219	1188
22219	1218
22219	1232
22219	1233
22220	1183
22220	1188
22220	1218
22220	1232
22220	1233
22221	1188
22221	1218
22221	1232
22221	1233
22221	45600
22223	1183
22223	1188
22223	1232
22223	1233
22223	44992
22224	1183
22224	1188
22224	1218
22224	1232
22224	45604
22226	1183
22226	1188
22226	1218
22226	1232
22226	1233
22228	1183
22228	1188
22228	1204
22228	1218
22228	1232
22229	1183
22229	1188
22229	1218
22229	1232
22229	1233
22230	1188
22230	1218
22230	1232
22230	1233
22230	45236
22232	1183
22232	1188
22232	1218
22232	1232
22232	1233
22233	1183
22233	1188
22233	1218
22233	1232
22233	1233
22234	1188
22234	1218
22234	1232
22234	1233
22234	45600
22237	1183
22237	1188
22237	1218
22237	1232
22237	1233
22240	1183
22240	1188
22240	1218
22240	1232
22240	1233
22241	1183
22241	1188
22241	1218
22241	1232
22241	1233
22242	1188
22242	1193
22242	1209
22242	1210
22242	1232
22242	1233
22242	45238
22243	1183
22243	1188
22243	1218
22243	1232
22243	1233
22244	1183
22244	1188
22244	1204
22244	1218
22244	1232
22247	1183
22247	1188
22247	1218
22247	1232
22247	1233
22248	1183
22248	1188
22248	1218
22248	1232
22248	1233
22252	1183
22252	1188
22252	1218
22252	1232
22252	1233
22254	1183
22254	1188
22254	1218
22254	1232
22254	1233
22258	1183
22258	1188
22258	1218
22258	1232
22258	1233
22259	1183
22259	1188
22259	1232
22259	1233
22259	45561
22260	1183
22260	1188
22260	1218
22260	1232
22260	1233
22261	1188
22261	1218
22261	1232
22261	1233
22261	45236
22262	1183
22262	1188
22262	1218
22262	1232
22262	1233
22263	1183
22263	1188
22263	1218
22263	1232
22263	1233
22264	1183
22264	1188
22264	1218
22264	1232
22264	1233
22265	1183
22265	1188
22265	1218
22265	1232
22265	1233
22267	1183
22267	1188
22267	1218
22267	1232
22267	1233
22268	1183
22268	1188
22268	1232
22268	1233
22268	45543
22271	1183
22271	1188
22271	1218
22271	1232
22271	1233
22274	1183
22274	1188
22274	1218
22274	1232
22274	1233
22276	1183
22276	1188
22276	1232
22276	1233
22276	1276
22277	1183
22277	1188
22277	1232
22277	1233
22277	1257
22280	1183
22280	1188
22280	1204
22280	1218
22280	1232
22282	1183
22282	1188
22282	1218
22282	1232
22282	1233
22283	1183
22283	1188
22283	1218
22283	1232
22283	1233
22284	1183
22284	1188
22284	1218
22284	1232
22284	1233
22286	1183
22286	1188
22286	1218
22286	1232
22286	1233
22287	1188
22287	1209
22287	1232
22287	1233
22287	45236
22288	1178
22288	1188
22288	1218
22288	1232
22288	1233
22289	1183
22289	1188
22289	1218
22289	1232
22289	1233
22291	1183
22291	1188
22291	1218
22291	1232
22291	1233
22292	1183
22292	1188
22292	1218
22292	1232
22292	1233
22293	1183
22293	1188
22293	1218
22293	1232
22293	1233
22294	1183
22294	1188
22294	1198
22294	1218
22294	1233
22297	1188
22297	1205
22297	1218
22297	1232
22297	45236
22298	1183
22298	1188
22298	1218
22298	1232
22298	1233
22300	1183
22300	1188
22300	1204
22300	1221
22300	1232
22301	1183
22301	1188
22301	1218
22301	1232
22301	1233
22302	1183
22302	1188
22302	1218
22302	1232
22302	1233
22303	1183
22303	1188
22303	1218
22303	1232
22303	1233
22304	1183
22304	1188
22304	1218
22304	1232
22304	1233
22305	1183
22305	1188
22305	1218
22305	1232
22305	1233
22307	1183
22307	1188
22307	1204
22307	1218
22307	1232
22310	1183
22310	1188
22310	1218
22310	1232
22310	1233
22313	1183
22313	1188
22313	1217
22313	1218
22313	1229
22313	1232
22313	1233
22313	45604
22314	1183
22314	1188
22314	1204
22314	1218
22314	1232
22315	1183
22315	1188
22315	1218
22315	1232
22315	1233
22317	1183
22317	1188
22317	1218
22317	1232
22317	1233
22319	1183
22319	1188
22319	1218
22319	1232
22319	1233
22320	1183
22320	1188
22320	1221
22320	1232
22320	1233
22321	1183
22321	1188
22321	1198
22321	1218
22321	1233
22325	1183
22325	1188
22325	1218
22325	1232
22325	1233
22327	1183
22327	1188
22327	1218
22327	1232
22327	1233
22328	1183
22328	1188
22328	1204
22328	1218
22328	1232
22329	1183
22329	1188
22329	1218
22329	1232
22329	1233
22330	1183
22330	1188
22330	1218
22330	1232
22330	1233
22332	1183
22332	1188
22332	1205
22332	1218
22332	1232
22333	1183
22333	1188
22333	1210
22333	1232
22333	1233
22334	1183
22334	1188
22334	1205
22334	1218
22334	1232
22335	1183
22335	1188
22335	1218
22335	1232
22335	1233
22336	1183
22336	1188
22336	1218
22336	1232
22336	1233
22337	1183
22337	1188
22337	1218
22337	1232
22337	1233
22339	1188
22339	1218
22339	1232
22339	1233
22339	45600
22341	1183
22341	1188
22341	1218
22341	1232
22341	1233
22342	1188
22342	1218
22342	1232
22342	1233
22342	45238
22343	1183
22343	1188
22343	1204
22343	1218
22343	1232
22344	1183
22344	1188
22344	1218
22344	1232
22344	1233
22345	1188
22345	1218
22345	1232
22345	1233
22345	45236
22346	1188
22346	1218
22346	1232
22346	1233
22346	45236
22347	1183
22347	1188
22347	1218
22347	1232
22347	1233
22348	1183
22348	1188
22348	1218
22348	1232
22348	1233
22349	1183
22349	1188
22349	1218
22349	1232
22349	1233
22350	1183
22350	1188
22350	1218
22350	1232
22350	1233
22351	1183
22351	1188
22351	1218
22351	1232
22351	1233
22352	1183
22352	1188
22352	1218
22352	1232
22352	1233
22353	1183
22353	1188
22353	1198
22353	1218
22353	1233
22354	1183
22354	1188
22354	1218
22354	1232
22354	1233
22355	1188
22355	1218
22355	1232
22355	1233
22355	45600
22356	1183
22356	1188
22356	1218
22356	1232
22356	1233
22357	1183
22357	1188
22357	1205
22357	1218
22357	1232
22358	1183
22358	1188
22358	1218
22358	1232
22358	1233
22359	1183
22359	1188
22359	1218
22359	1232
22359	1233
22361	1183
22361	1188
22361	1232
22361	1233
22361	45134
22362	1183
22362	1188
22362	1218
22362	1232
22362	1233
22363	1183
22363	1188
22363	1218
22363	1232
22363	1233
22364	1183
22364	1188
22364	1232
22364	1233
22364	45399
22365	1188
22365	1218
22365	1232
22365	1233
22365	45236
22366	1188
22366	1218
22366	1232
22366	1233
22366	45236
22367	1183
22367	1188
22367	1218
22367	1232
22367	1233
22368	1183
22368	1188
22368	1218
22368	1232
22368	1233
22369	1183
22369	1188
22369	1218
22369	1232
22369	1233
22370	1183
22370	1188
22370	1218
22370	1232
22370	1233
22371	1183
22371	1188
22371	1218
22371	1232
22371	1233
22372	1183
22372	1188
22372	1218
22372	1232
22372	1233
22373	1188
22373	1218
22373	1232
22373	1233
22373	45238
22374	1178
22374	1188
22374	1232
22374	1233
22374	45611
22375	1183
22375	1188
22375	1218
22375	1232
22375	1233
22376	1183
22376	1188
22376	1218
22376	1232
22376	1233
22377	1178
22377	1188
22377	1218
22377	1232
22377	1233
22378	1188
22378	1218
22378	1232
22378	1233
22378	45236
22379	1183
22379	1188
22379	1218
22379	1232
22379	1233
22380	1183
22380	1188
22380	1218
22380	1232
22380	1233
22381	1183
22381	1188
22381	1198
22381	1218
22381	1233
22382	1183
22382	1188
22382	1218
22382	1232
22382	1233
22383	1183
22383	1188
22383	1221
22383	1232
22383	1233
22384	1183
22384	1188
22384	1218
22384	1232
22384	1233
22385	1183
22385	1188
22385	1218
22385	1232
22385	1233
22387	1183
22387	1188
22387	1218
22387	1232
22387	1233
22388	1183
22388	1188
22388	1218
22388	1232
22388	1233
22389	1183
22389	1188
22389	1218
22389	1232
22389	1233
22390	1183
22390	1188
22390	1218
22390	1232
22390	1233
22391	1183
22391	1188
22391	1218
22391	1232
22391	1233
22392	1183
22392	1188
22392	1232
22392	1233
22392	45134
22393	1188
22393	1218
22393	1232
22393	1233
22393	45602
22395	1183
22395	1188
22395	1218
22395	1232
22395	1233
22396	1188
22396	1218
22396	1232
22396	1233
22396	45236
22397	1188
22397	1205
22397	1218
22397	1232
22397	45236
22398	1188
22398	1218
22398	1232
22398	1233
22398	45236
22399	1188
22399	1232
22399	1233
22399	45561
22399	45601
22400	1183
22400	1188
22400	1218
22400	1232
22400	1233
22401	1183
22401	1188
22401	1218
22401	1232
22401	1233
22402	1188
22402	1218
22402	1232
22402	1233
22402	45602
22403	1183
22403	1188
22403	1218
22403	1232
22403	1233
22404	1183
22404	1188
22404	1218
22404	1232
22404	1233
22405	1183
22405	1188
22405	1218
22405	1232
22405	1233
22407	1188
22407	1218
22407	1232
22407	1233
22407	45236
22408	1183
22408	1188
22408	1204
22408	1218
22408	1232
22409	1183
22409	1188
22409	1204
22409	1218
22409	1232
22410	1183
22410	1188
22410	1218
22410	1232
22410	1233
22411	1183
22411	1188
22411	1218
22411	1232
22411	1233
22412	1183
22412	1188
22412	1218
22412	1232
22412	1233
22413	1188
22413	1218
22413	1232
22413	1233
22413	45600
22414	1183
22414	1188
22414	1218
22414	1232
22414	1233
22415	1183
22415	1188
22415	1221
22415	1232
22415	1233
22416	1183
22416	1188
22416	1232
22416	1233
22416	1257
22417	1183
22417	1188
22417	1218
22417	1232
22417	1233
22418	1183
22418	1188
22418	1232
22418	1233
22418	45612
22419	1188
22419	1218
22419	1232
22419	1233
22419	45236
22420	1183
22420	1188
22420	1218
22420	1232
22420	1233
22421	1183
22421	1188
22421	1218
22421	1232
22421	1233
22422	1183
22422	1188
22422	1218
22422	1232
22422	1233
22423	1183
22423	1188
22423	1221
22423	1232
22423	1233
22424	1183
22424	1188
22424	1218
22424	1232
22424	1233
22425	1188
22425	1218
22425	1232
22425	1233
22425	45236
22426	1183
22426	1188
22426	1218
22426	1232
22426	1233
22427	1183
22427	1188
22427	1218
22427	1232
22427	1233
22428	1188
22428	1218
22428	1232
22428	1233
22428	45238
22429	1183
22429	1188
22429	1218
22429	1232
22429	1233
22430	1183
22430	1188
22430	1204
22430	1218
22430	1232
22431	1183
22431	1188
22431	1218
22431	1232
22431	1233
22432	1183
22432	1188
22432	1218
22432	1232
22432	1233
22433	1188
22433	1218
22433	1232
22433	1233
22433	45236
22434	1188
22434	1232
22434	1233
22434	45238
22434	45380
22436	1183
22436	1188
22436	1218
22436	1232
22436	1233
22437	1183
22437	1188
22437	1217
22437	1218
22437	1229
22437	1232
22437	1233
22440	1183
22440	1188
22440	1220
22440	1232
22440	1233
22441	1183
22441	1188
22441	1218
22441	1232
22441	45604
22442	1183
22442	1188
22442	1218
22442	1232
22442	1233
22443	1183
22443	1188
22443	1218
22443	1232
22443	1233
22444	1183
22444	1188
22444	1218
22444	1232
22444	1233
22445	1183
22445	1188
22445	1221
22445	1232
22445	1233
22447	1183
22447	1188
22447	1218
22447	1232
22447	1233
22449	1183
22449	1188
22449	1218
22449	1232
22449	1233
22450	1188
22450	1232
22450	1233
22450	45238
22450	45630
22452	1188
22452	1218
22452	1232
22452	1233
22452	45602
22453	1183
22453	1188
22453	1218
22453	1232
22453	1233
22454	1183
22454	1188
22454	1218
22454	1232
22454	1233
22455	1188
22455	1218
22455	1232
22455	1233
22455	1237
22456	1183
22456	1188
22456	1218
22456	1232
22456	1233
22457	1183
22457	1188
22457	1218
22457	1232
22457	1233
22458	1182
22458	1188
22458	1218
22458	1232
22458	1233
22459	1188
22459	1205
22459	1222
22459	1232
22459	45236
22460	1183
22460	1188
22460	1232
22460	1233
22460	1261
22461	1188
22461	1218
22461	1232
22461	1233
22461	45238
22462	1183
22462	1188
22462	1218
22462	1232
22462	1233
22463	1183
22463	1188
22463	1218
22463	1232
22463	1233
22464	1183
22464	1188
22464	1218
22464	1232
22464	45604
22466	1183
22466	1188
22466	1232
22466	1233
22466	45399
22467	1183
22467	1188
22467	1232
22467	1233
22467	45399
22468	1183
22468	1188
22468	1218
22468	1232
22468	1233
22469	1183
22469	1188
22469	1218
22469	1232
22469	1233
22470	1188
22470	1218
22470	1232
22470	1233
22470	45236
22471	1188
22471	1218
22471	1232
22471	1233
22471	45602
22474	1183
22474	1188
22474	1218
22474	1232
22474	1233
22475	1183
22475	1188
22475	1218
22475	1232
22475	1233
22476	1183
22476	1188
22476	1205
22476	1218
22476	1232
22477	1183
22477	1188
22477	1209
22477	1232
22477	1233
22478	1178
22478	1188
22478	1218
22478	1232
22478	1233
22480	1183
22480	1188
22480	1218
22480	1232
22480	1233
22481	1183
22481	1188
22481	1218
22481	1232
22481	1233
22482	1183
22482	1188
22482	1210
22482	1232
22482	1233
22484	1183
22484	1188
22484	1198
22484	1218
22484	1233
22487	1183
22487	1188
22487	1218
22487	1232
22487	1233
22488	1183
22488	1188
22488	1218
22488	1232
22488	1233
22489	1188
22489	1218
22489	1232
22489	1233
22489	45238
22491	1183
22491	1188
22491	1218
22491	1231
22491	1232
22491	45604
22492	1183
22492	1188
22492	1218
22492	1232
22492	1233
22493	1183
22493	1188
22493	1218
22493	1232
22493	1233
22494	1183
22494	1188
22494	1218
22494	1232
22494	1233
22495	1188
22495	1232
22495	1233
22495	45236
22495	45637
22496	1183
22496	1188
22496	1218
22496	1232
22496	1233
22498	1183
22498	1188
22498	1218
22498	1232
22498	1233
22499	1188
22499	1232
22499	1233
22499	45238
22499	45377
22500	1188
22500	1218
22500	1232
22500	1233
22500	45236
22502	1188
22502	1218
22502	1232
22502	1233
22502	45600
22503	1188
22503	1218
22503	1232
22503	1233
22503	45600
22504	1188
22504	1218
22504	1232
22504	1233
22504	45238
22505	1183
22505	1188
22505	1218
22505	1232
22505	1233
22508	1183
22508	1188
22508	1218
22508	1232
22508	1233
22509	1183
22509	1188
22509	1218
22509	1232
22509	1233
22510	1188
22510	1218
22510	1220
22510	1232
22510	1233
22512	1188
22512	1205
22512	1218
22512	1232
22512	45236
22514	1183
22514	1188
22514	1218
22514	1232
22514	1233
22515	1183
22515	1188
22515	1218
22515	1232
22515	1233
22516	1183
22516	1188
22516	1204
22516	1218
22516	1232
22517	1183
22517	1188
22517	1218
22517	1232
22517	1233
22518	1183
22518	1188
22518	1221
22518	1232
22518	1233
22518	45181
22519	1188
22519	1218
22519	1220
22519	1232
22519	1233
22522	1183
22522	1188
22522	1218
22522	1232
22522	1233
22523	1188
22523	1218
22523	1232
22523	1233
22523	45238
22524	1183
22524	1188
22524	1218
22524	1232
22524	1233
22525	1188
22525	1218
22525	1232
22525	1233
22525	45600
22529	1183
22529	1188
22529	1218
22529	1232
22529	1233
22530	1183
22530	1188
22530	1218
22530	1232
22530	1233
22531	1183
22531	1188
22531	1218
22531	1232
22531	1233
22532	1183
22532	1188
22532	1204
22532	1232
22532	45561
22533	1183
22533	1188
22533	1204
22533	1218
22533	1232
22534	1188
22534	1232
22534	1233
22534	45238
22534	45616
22537	1183
22537	1188
22537	1232
22537	1233
22537	45632
22538	1183
22538	1188
22538	1204
22538	1218
22538	1232
22539	1183
22539	1188
22539	1218
22539	1232
22539	1233
22540	1183
22540	1188
22540	1218
22540	1232
22540	1233
22541	1183
22541	1188
22541	1232
22541	1233
22541	45610
22542	1183
22542	1188
22542	1218
22542	1232
22542	1233
22543	1183
22543	1188
22543	1232
22543	1233
22543	45543
22544	1183
22544	1188
22544	1218
22544	1232
22544	1233
22546	1183
22546	1188
22546	1218
22546	1232
22546	1233
22547	1183
22547	1188
22547	1232
22547	1233
22547	45134
22549	1183
22549	1188
22549	1210
22549	1232
22549	1233
22550	1188
22550	1218
22550	1232
22550	1233
22550	45238
22550	45605
22552	1183
22552	1188
22552	1218
22552	1232
22552	1233
22554	1183
22554	1188
22554	1218
22554	1232
22554	1233
22555	1183
22555	1188
22555	1218
22555	1232
22555	1233
22557	1183
22557	1188
22557	1218
22557	1232
22557	1233
22558	1183
22558	1188
22558	1232
22558	1233
22558	45636
22560	1188
22560	1218
22560	1232
22560	1233
22560	1237
22561	1183
22561	1188
22561	1218
22561	1232
22561	1233
22562	1183
22562	1188
22562	1232
22562	1233
22562	45627
22563	1188
22563	1220
22563	1232
22563	1233
22563	45602
22564	1183
22564	1188
22564	1232
22564	1233
22564	45626
22565	1183
22565	1188
22565	1218
22565	1232
22565	1233
22566	1188
22566	1232
22566	1233
22566	45238
22566	45543
22567	1183
22567	1188
22567	1218
22567	1232
22567	1233
22568	1183
22568	1188
22568	1232
22568	1233
22568	45635
22569	1188
22569	1218
22569	1232
22569	1233
22569	45602
22570	1188
22570	1232
22570	1233
22570	45380
22570	45602
22571	1183
22571	1188
22571	1232
22571	1233
22571	45543
22573	1183
22573	1188
22573	1218
22573	1232
22573	1233
22574	1183
22574	1188
22574	1218
22574	1232
22574	1233
22575	1183
22575	1188
22575	1218
22575	1232
22575	1233
22576	1183
22576	1188
22576	1221
22576	1232
22576	1233
22577	1188
22577	1218
22577	1232
22577	1233
22577	45238
22578	1178
22578	1188
22578	1218
22578	1232
22578	1233
22579	1183
22579	1188
22579	1222
22579	1232
22579	1233
22580	1183
22580	1188
22580	1218
22580	1232
22580	1233
22582	1183
22582	1188
22582	1218
22582	1232
22582	1233
22583	1188
22583	1218
22583	1232
22583	1233
22583	45602
22584	1188
22584	1218
22584	1232
22584	1233
22584	45236
22585	1178
22585	1188
22585	1218
22585	1232
22585	1233
22587	1183
22587	1188
22587	1218
22587	1232
22587	1233
22588	1183
22588	1188
22588	1218
22588	1232
22588	1233
22589	1183
22589	1188
22589	1232
22589	1233
22589	1276
22590	1183
22590	1188
22590	1221
22590	1232
22590	1233
22591	1183
22591	1188
22591	1218
22591	1232
22591	1233
22592	1183
22592	1189
22592	1218
22592	1232
22592	1233
22593	1183
22593	1188
22593	1218
22593	1232
22593	1233
22595	1183
22595	1188
22595	1204
22595	1218
22595	1232
22596	1183
22596	1188
22596	1218
22596	1232
22596	1233
22597	1188
22597	1218
22597	1232
22597	1233
22597	45238
22598	1188
22598	1232
22598	1233
22598	45236
22598	45611
22599	1183
22599	1188
22599	1218
22599	1232
22599	1233
22600	1183
22600	1188
22600	1218
22600	1232
22600	1233
22601	1183
22601	1188
22601	1221
22601	1232
22601	1233
22603	1183
22603	1188
22603	1218
22603	1232
22603	1233
22604	1183
22604	1188
22604	1218
22604	1232
22604	1233
22605	1183
22605	1188
22605	1218
22605	1232
22605	1233
22606	1183
22606	1188
22606	1221
22606	1232
22606	1233
22608	1183
22608	1188
22608	1218
22608	1232
22608	1233
22612	1183
22612	1188
22612	1218
22612	1232
22612	1233
22613	1183
22613	1188
22613	1218
22613	1232
22613	1233
22614	1183
22614	1188
22614	1218
22614	1232
22614	1233
22615	1183
22615	1188
22615	1218
22615	1232
22615	1233
22617	1183
22617	1188
22617	1218
22617	1232
22617	1233
22619	1183
22619	1188
22619	1204
22619	1221
22619	1232
22620	1183
22620	1188
22620	1218
22620	1232
22620	1233
22621	1183
22621	1188
22621	1221
22621	1232
22621	1233
22622	1183
22622	1188
22622	1232
22622	1233
22622	45561
22623	1183
22623	1188
22623	1232
22623	1233
22623	45637
22624	1183
22624	1188
22624	1198
22624	1218
22624	1233
22625	1183
22625	1188
22625	1204
22625	1232
22625	45134
22626	1183
22626	1188
22626	1218
22626	1232
22626	1233
22628	1183
22628	1188
22628	1218
22628	1232
22628	1233
22629	1183
22629	1188
22629	1218
22629	1232
22629	1233
22630	1188
22630	1218
22630	1232
22630	1233
22630	45238
22633	1183
22633	1193
22633	1204
22633	1218
22633	1232
22634	1183
22634	1188
22634	1205
22634	1218
22634	1232
22635	1183
22635	1188
22635	1218
22635	1232
22635	1233
22636	1188
22636	1218
22636	1232
22636	1233
22636	45238
22637	1183
22637	1188
22637	1218
22637	1232
22637	1233
22638	1183
22638	1188
22638	1218
22638	1232
22638	1233
22640	1183
22640	1188
22640	1218
22640	1232
22640	1233
22641	1183
22641	1188
22641	1232
22641	1233
22641	45625
22642	1188
22642	1218
22642	1232
22642	1233
22642	45238
22643	1183
22643	1188
22643	1218
22643	1232
22643	1233
22644	1188
22644	1218
22644	1232
22644	1233
22644	45238
22645	1183
22645	1188
22645	1218
22645	1232
22645	1233
22646	1183
22646	1188
22646	1218
22646	1232
22646	1233
22647	1183
22647	1188
22647	1218
22647	1232
22647	1233
22649	1188
22649	1232
22649	1233
22649	1257
22649	45238
22649	45607
22649	45613
22651	1188
22651	1232
22651	1233
22651	45238
22651	45611
22652	1183
22652	1188
22652	1218
22652	1232
22652	1233
22654	1183
22654	1188
22654	1218
22654	1232
22654	1233
22655	1183
22655	1188
22655	1218
22655	1232
22655	1233
22656	1183
22656	1188
22656	1218
22656	1232
22656	1233
22657	1183
22657	1188
22657	1218
22657	1232
22657	1233
22658	1183
22658	1188
22658	1222
22658	1232
22658	1233
22659	1183
22659	1188
22659	1232
22659	1233
22659	45543
22660	1183
22660	1188
22660	1218
22660	1232
22660	1233
22662	1188
22662	1218
22662	1232
22662	1233
22662	45238
22664	1183
22664	1188
22664	1218
22664	1232
22664	1233
22667	1183
22667	1188
22667	1232
22667	1233
22667	45634
22668	1183
22668	1188
22668	1204
22668	1218
22668	1232
22669	1183
22669	1188
22669	1222
22669	1232
22669	1233
22670	1188
22670	1218
22670	1232
22670	1233
22670	45238
22671	1188
22671	1232
22671	1233
22671	45236
22671	45543
22672	1183
22672	1188
22672	1218
22672	1232
22672	1233
22675	1183
22675	1188
22675	1218
22675	1232
22675	1233
22676	1183
22676	1188
22676	1205
22676	1218
22676	1232
22677	1183
22677	1188
22677	1218
22677	1232
22677	1233
22680	1183
22680	1188
22680	1218
22680	1232
22680	1233
22684	1183
22684	1188
22684	1232
22684	1233
22684	45543
22685	1183
22685	1188
22685	1218
22685	1232
22685	1233
22685	45604
22686	1183
22686	1188
22686	1218
22686	1232
22686	1233
22687	1183
22687	1188
22687	1204
22687	1218
22687	1232
22688	1188
22688	1218
22688	1232
22688	1233
22688	45238
22689	1183
22689	1188
22689	1218
22689	1232
22689	1233
22690	1188
22690	1218
22690	1232
22690	1233
22690	45238
22691	1183
22691	1188
22691	1218
22691	1232
22691	1233
22692	1188
22692	1218
22692	1232
22692	1233
22692	1237
22694	1188
22694	1204
22694	1218
22694	1232
22694	45236
22697	1178
22697	1188
22697	1218
22697	1232
22697	1233
22698	1183
22698	1188
22698	1222
22698	1232
22698	1233
22699	1183
22699	1188
22699	1218
22699	1232
22699	1233
22700	1188
22700	1232
22700	1233
22700	45602
22700	45635
22701	1188
22701	1218
22701	1232
22701	1233
22701	45600
22710	1183
22710	1188
22710	1218
22710	1232
22710	1233
22712	1183
22712	1188
22712	1218
22712	1232
22712	1233
22713	1183
22713	1188
22713	1218
22713	1232
22713	1233
22714	1183
22714	1188
22714	1218
22714	1232
22714	1233
22715	1183
22715	1188
22715	1204
22715	1218
22715	1232
22717	1183
22717	1188
22717	1218
22717	1232
22717	1233
22718	1188
22718	1218
22718	1232
22718	1233
22718	45602
22719	1188
22719	1218
22719	1232
22719	1233
22719	45602
22720	1183
22720	1188
22720	1198
22720	1218
22720	1233
22721	1188
22721	1218
22721	1232
22721	1233
22721	45238
22723	1188
22723	1218
22723	1232
22723	1233
22723	45600
22724	1183
22724	1188
22724	1218
22724	1232
22724	1233
22725	1183
22725	1188
22725	1218
22725	1232
22725	1233
22726	1183
22726	1188
22726	1218
22726	1232
22726	1233
22727	1183
22727	1188
22727	1218
22727	1232
22727	1233
22728	1183
22728	1188
22728	1218
22728	1232
22728	1233
22729	1188
22729	1218
22729	1232
22729	1233
22729	45236
22730	1183
22730	1188
22730	1218
22730	1232
22730	1233
22731	1183
22731	1188
22731	1218
22731	1232
22731	1233
22732	1188
22732	1218
22732	1232
22732	1233
22732	45238
22733	1183
22733	1188
22733	1218
22733	1232
22733	1233
22734	1188
22734	1218
22734	1232
22734	1233
22734	45602
22735	1183
22735	1188
22735	1218
22735	1232
22735	1233
22736	1188
22736	1198
22736	1218
22736	1233
22736	45602
22737	1183
22737	1188
22737	1218
22737	1232
22737	1233
22738	1188
22738	1204
22738	1232
22738	45236
22738	45561
22739	1188
22739	1232
22739	1233
22739	45602
22739	45642
22740	1188
22740	1218
22740	1232
22740	1233
22740	45238
22741	1183
22741	1193
22741	1218
22741	1232
22741	1233
22742	1183
22742	1188
22742	1218
22742	1232
22742	1233
22743	1183
22743	1193
22743	1218
22743	1232
22743	1233
22745	1183
22745	1188
22745	1218
22745	1232
22745	1233
22746	1183
22746	1188
22746	1198
22746	1218
22746	1233
22747	1183
22747	1188
22747	1218
22747	1232
22747	1233
22748	1183
22748	1188
22748	1218
22748	1232
22748	1233
22750	1183
22750	1188
22750	1218
22750	1232
22750	1233
22751	1183
22751	1188
22751	1221
22751	1232
22751	1233
22752	1183
22752	1188
22752	1218
22752	1232
22752	1233
22753	1183
22753	1188
22753	1218
22753	1232
22753	1233
22754	1183
22754	1188
22754	1218
22754	1232
22754	1233
22755	1183
22755	1188
22755	1218
22755	1232
22755	1233
22756	1188
22756	1218
22756	1232
22756	1233
22756	45236
22757	1188
22757	1218
22757	1232
22757	1233
22757	45236
22758	1183
22758	1188
22758	1218
22758	1232
22758	1233
22759	1188
22759	1218
22759	1232
22759	1233
22759	45236
22760	1188
22760	1218
22760	1232
22760	1233
22760	45236
22761	1188
22761	1218
22761	1232
22761	1233
22761	45602
22762	1183
22762	1188
22762	1218
22762	1232
22762	1233
22763	1183
22763	1188
22763	1218
22763	1232
22763	1233
22764	1183
22764	1188
22764	1218
22764	1232
22764	1233
22765	1188
22765	1218
22765	1232
22765	1233
22765	45238
22766	1183
22766	1188
22766	1218
22766	1232
22766	1233
22768	1183
22768	1188
22768	1198
22768	1218
22768	1233
22769	1183
22769	1188
22769	1218
22769	1232
22769	1233
22770	1183
22770	1188
22770	1218
22770	1232
22770	1233
22771	1188
22771	1218
22771	1232
22771	1233
22771	45638
22773	1183
22773	1188
22773	1218
22773	1232
22773	1233
22774	1183
22774	1188
22774	1218
22774	1232
22774	1233
22775	1183
22775	1188
22775	1232
22775	1233
22775	45181
22776	1183
22776	1188
22776	1218
22776	1232
22776	1233
22777	1183
22777	1188
22777	1218
22777	1232
22777	1233
22778	1183
22778	1188
22778	1198
22778	1218
22778	1233
22780	1183
22780	1188
22780	1218
22780	1232
22780	1233
22783	1183
22783	1188
22783	1218
22783	1232
22783	1233
22784	1183
22784	1188
22784	1218
22784	1232
22784	1233
22786	1178
22786	1188
22786	1218
22786	1232
22786	1233
22789	1183
22789	1188
22789	1218
22789	1232
22789	1233
22790	1188
22790	1232
22790	1233
22790	1246
22790	45546
22790	45602
22793	1183
22793	1194
22793	1232
22793	1233
22793	1246
22793	1257
22797	1183
22797	1188
22797	1232
22797	1233
22797	1246
22800	1183
22800	1188
22800	1218
22800	1232
22800	1233
22802	1183
22802	1188
22802	1218
22802	1232
22802	1233
22803	1188
22803	1232
22803	1233
22803	1276
22803	45603
22805	1183
22805	1188
22805	1218
22805	1232
22805	1233
22806	1183
22806	1188
22806	1221
22806	1232
22806	1233
22806	45181
22807	1188
22807	1218
22807	1232
22807	1233
22807	45602
22807	45637
22808	1188
22808	1206
22808	1218
22808	1229
22808	45238
22810	1183
22810	1188
22810	1218
22810	1232
22810	1233
22813	1188
22813	1229
22813	1233
22813	45238
22813	45543
22814	1183
22814	1188
22814	1217
22814	1232
22814	1233
22815	1183
22815	1188
22815	1218
22815	1232
22815	1233
22817	1188
22817	1232
22817	1233
22817	1237
22817	45610
22818	1188
22818	1218
22818	1232
22818	1233
22818	45602
22820	1188
22820	1218
22820	1232
22820	1233
22820	45238
22821	1178
22821	1188
22821	1232
22821	1233
22821	1246
22822	1188
22822	1218
22822	1232
22822	1233
22822	45238
22823	1188
22823	1218
22823	1232
22823	1233
22823	1237
22824	1183
22824	1188
22824	1218
22824	1232
22824	1233
22827	1183
22827	1193
22827	1198
22827	1218
22827	1233
22828	1183
22828	1188
22828	1210
22828	1232
22828	1233
22828	45639
22828	45640
22829	1183
22829	1188
22829	1204
22829	1218
22829	1232
22830	1188
22830	1204
22830	1218
22830	1232
22830	45236
22831	1178
22831	1188
22831	1218
22831	1232
22831	1233
22831	45238
22833	1178
22833	1188
22833	1232
22833	1233
22833	45613
22834	1188
22834	1218
22834	1232
22834	1233
22834	45602
22836	1188
22836	1232
22836	1233
22836	45238
22836	45641
22837	1183
22837	1194
22837	1204
22837	1218
22837	1232
22838	1183
22838	1188
22838	1204
22838	1218
22838	1232
22840	1188
22840	1218
22840	1232
22840	1233
22840	45602
22842	1183
22842	1188
22842	1232
22842	1233
22842	45181
22843	1188
22843	1218
22843	1232
22843	1233
22843	45603
22844	1188
22844	1232
22844	1233
22844	1246
22844	45238
22847	1188
22847	1218
22847	1232
22847	1233
22847	45238
22849	1188
22849	1218
22849	1232
22849	1233
22849	45602
22852	1183
22852	1188
22852	1218
22852	1232
22852	1233
22854	1183
22854	1188
22854	1218
22854	1232
22854	1233
22855	1183
22855	1188
22855	1221
22855	1232
22855	1233
22857	1188
22857	1232
22857	1233
22857	45238
22857	45543
22864	1183
22865	1209
22865	45602
22868	1183
22869	1183
22870	1204
22870	45236
22872	1204
22872	45236
22875	1183
22876	1183
22878	45238
22878	45543
22882	1183
22882	1204
22883	1204
22883	45600
22884	1183
22885	45236
22886	1183
22887	45238
22888	45238
22889	1183
22889	45543
22892	1183
22894	1178
22894	1183
22894	45546
22895	1183
22896	1183
22897	1183
22897	1221
22899	1183
22901	1183
22902	45600
22903	1198
22903	1209
22903	45602
22904	1183
22906	1204
22906	45236
22907	1205
22907	45236
22908	1205
22908	45236
22909	45546
22909	45602
22910	45600
22911	45600
22912	45238
22913	1183
22916	1204
22916	45236
22921	1183
22922	1183
22923	1183
22924	1183
22924	1198
22924	45548
22926	1183
22927	1183
22928	1183
22929	1183
22929	1246
22931	1183
22931	1198
22932	1183
22933	1183
22934	1183
22935	1183
22938	1183
22938	45181
22940	1183
22941	1183
22944	1204
22944	45236
22945	45600
22947	1183
22947	1198
22947	1204
22948	1183
22949	1183
22950	45238
22951	1222
22951	45236
22953	45238
22954	1183
22954	1204
22955	1183
22955	1193
22955	45561
22956	1246
22956	45602
22956	45647
22956	45649
22957	1183
22958	1183
22959	1183
22961	1183
22961	1213
22962	1183
22963	1183
22964	1177
22964	1193
22965	1204
22965	45236
22966	45602
22967	1183
22968	1183
22969	1198
22969	45236
22970	1183
22971	1183
22972	1183
22972	1204
22973	1183
22973	1198
22977	1183
22977	1198
22977	45548
22979	1183
22981	1183
22982	1183
22982	1194
22983	1183
22983	1194
22984	1183
22985	1183
22986	1246
22986	45602
22987	1204
22987	45236
22990	1183
22990	1222
22991	45543
22991	45602
22992	45602
22993	1183
22994	1204
22994	45236
22995	1183
22995	1217
22996	1183
22997	1183
22998	45546
22998	45602
22999	1183
23001	1183
23002	1183
23003	1183
23004	1183
23005	1183
23005	1222
23006	1193
23006	1247
23006	45238
23007	1183
23007	1217
23008	1198
23008	45236
23010	1183
23012	1183
23013	1183
23013	1198
23014	1183
23017	45236
23018	1183
23019	1183
23020	1205
23020	45236
23021	1183
23022	1183
23026	1183
23028	1183
23029	1204
23029	45236
23029	45561
23030	45236
23031	1204
23031	1205
23031	45236
23032	1183
23033	1183
23034	1183
23035	1183
23036	1183
23037	1183
23038	1183
23038	1204
23040	45600
23041	45238
23042	1183
23043	1183
23043	45610
23047	45546
23047	45600
23049	1183
23049	1231
23050	1183
23053	1183
23054	1183
23054	1188
23054	1218
23054	1232
23054	1233
23055	1183
23057	1183
23058	1183
23058	1217
23059	1183
23059	45181
23060	1183
23060	1205
23061	1183
23061	1193
23061	1205
23062	1183
23063	1178
23064	1183
23065	1183
23066	1183
23067	1183
23068	45602
23069	1183
23070	1183
23071	45602
23072	1183
23073	45600
23074	45236
23075	1183
23076	1183
23077	1183
23078	1183
23079	1183
23079	45543
23080	1183
23081	1183
23081	45546
23082	1183
23083	45238
23083	45543
23084	1183
23085	45236
23086	45236
23087	1183
23088	1183
23089	45236
23090	1183
23091	1183
23091	1205
23092	1183
23094	45600
23095	1183
23100	1183
23100	1205
23101	1183
23101	1204
23102	45543
23102	45602
23103	1177
23105	1183
23106	45236
23108	1183
23109	1183
23109	1217
23112	1222
23112	45238
23113	1183
23113	1222
23114	1183
23116	1183
23118	1183
23118	1221
23119	1183
23120	45602
23123	1183
23123	1198
23123	45548
23124	1183
23124	1198
23124	1217
23124	45548
23125	45600
23127	1183
23129	1183
23131	1183
23132	1183
23133	1178
23134	1183
23135	1183
23136	1183
23136	45604
23137	45600
23138	45238
23138	45546
23140	1183
23141	1183
23141	1204
23142	45238
23144	1183
23144	1217
23145	1183
23148	1204
23148	45236
23152	1183
23152	1204
23153	1183
23154	1183
23156	1237
23157	1237
23159	1183
23160	1183
23163	1183
23164	1183
23164	45181
23166	45600
23168	45238
23168	45543
23169	1183
23169	1204
23171	1183
23172	1183
23173	1183
23175	1183
23176	1183
23177	45238
23177	45543
23178	1183
23179	45604
23179	45646
23181	45238
23182	45238
23183	1183
23183	1217
23187	45238
23189	1183
23189	45181
23191	45238
23192	1204
23192	45236
23193	1183
23193	1217
23194	1183
23194	1217
23196	45236
23197	1183
23198	1183
23199	1183
23200	1183
23201	1183
23201	1204
23203	1183
23204	1183
23204	45543
23205	1183
23206	1183
23209	1183
23210	45600
23211	1183
23211	1205
23212	1183
23213	1183
23214	1183
23214	1204
23214	1222
23214	1263
23216	45546
23216	45602
23217	1183
23217	45546
23218	1205
23218	45236
23219	1183
23219	45399
23220	1183
23221	1183
23222	1183
23223	1183
23224	1183
23225	1183
23225	45604
23226	1183
23226	1204
23228	45238
23230	45602
23232	1198
23232	45645
23233	45602
23235	1183
23236	1183
23237	1213
23237	45236
23238	1183
23239	1183
23239	1198
23239	45548
23240	1183
23241	1204
23241	45236
23243	1183
23244	45236
23248	1183
23248	1193
23251	1237
23251	45561
23254	1183
23254	1204
23258	1183
23260	1183
23261	1183
23262	1183
23262	1193
23263	1183
23264	1183
23267	1183
23267	1193
23270	1183
23271	45238
23273	45236
23274	1183
23274	1198
23275	1183
23276	1183
23276	1263
23276	45648
23278	1183
23278	45546
23279	1183
23283	1183
23284	1183
23285	1183
23285	1205
23285	45181
23286	1178
23286	45236
23287	1178
23287	1183
23288	1183
23291	1183
23294	1183
23294	45650
23296	1183
23297	1183
23299	1183
23300	1183
23302	1183
23302	1193
23302	1204
23307	1183
23308	45238
23309	45602
23311	1183
23311	1188
23311	1197
23311	1201
23311	1218
\.


--
-- Data for Name: trial2drug; Type: TABLE DATA; Schema: clean; Owner: postgres
--

COPY trial2drug (trial_id, drug_id) FROM stdin;
\.


--
-- Data for Name: trial2method; Type: TABLE DATA; Schema: clean; Owner: postgres
--

COPY trial2method (trial_id, method_id) FROM stdin;
138	10
139	10
140	9
142	9
145	10
146	10
149	10
150	10
151	9
152	10
153	10
154	10
155	10
156	9
157	10
158	9
160	10
162	10
163	10
164	9
165	10
166	10
168	10
169	10
170	10
171	10
172	9
173	10
174	10
176	10
177	10
178	10
179	10
180	10
181	10
182	10
185	11
186	10
188	10
189	10
190	10
191	10
192	10
196	10
197	10
198	10
199	10
200	10
201	10
202	10
203	10
204	10
205	10
207	9
208	10
209	10
210	10
211	10
212	10
215	11
216	10
218	9
219	9
220	10
224	10
225	9
227	10
228	9
229	7
231	10
232	10
234	9
235	9
236	9
237	10
238	9
240	10
241	10
242	15
243	9
244	15
245	10
247	10
249	10
252	10
253	9
254	9
255	9
256	9
257	10
258	10
259	10
261	10
262	10
263	7
264	9
265	6
265	10
268	10
269	10
270	10
271	10
273	7
274	10
275	10
276	10
278	10
279	10
280	10
281	10
282	10
283	9
284	10
285	10
286	10
288	6
288	10
289	10
290	10
291	9
293	7
294	10
297	9
299	10
300	11
301	10
302	10
303	10
304	10
306	10
307	10
308	10
310	10
311	10
312	9
313	10
314	10
316	10
318	10
319	10
320	10
322	9
324	10
325	10
326	10
329	10
330	10
331	10
332	10
334	7
336	7
337	7
338	10
339	10
340	10
342	10
343	10
344	10
345	11
348	10
352	10
353	10
355	10
356	10
357	7
358	10
359	10
362	10
363	10
364	10
365	10
366	10
367	9
369	10
370	10
372	10
373	10
374	10
375	10
377	10
382	10
383	10
384	10
385	9
387	10
388	10
390	10
391	10
392	10
393	10
394	10
395	10
396	9
399	9
401	10
404	10
406	10
408	10
409	10
412	10
414	10
416	10
417	10
418	10
419	10
421	11
422	6
422	10
423	10
425	10
426	10
427	10
428	10
430	10
431	10
433	10
434	10
435	10
436	10
438	9
439	9
440	10
441	10
442	10
443	9
444	10
445	10
446	10
447	9
452	10
455	10
457	9
458	9
459	11
460	9
462	7
463	10
464	9
466	10
467	9
478	9
479	10
480	10
481	10
482	7
483	10
486	10
487	10
488	10
489	11
490	10
491	10
493	10
494	10
495	10
496	10
497	10
498	10
499	11
500	10
503	9
504	10
505	10
507	10
508	10
509	10
510	10
511	10
512	10
513	10
514	10
515	10
517	10
518	10
519	10
520	10
521	10
522	10
523	9
525	10
526	10
527	9
528	10
529	10
530	11
531	11
535	10
536	10
538	10
540	10
543	10
544	10
548	10
549	9
552	9
553	10
554	10
557	9
559	9
560	10
561	10
563	10
564	10
565	9
565	10
566	10
567	7
567	11
568	11
569	10
571	10
572	10
574	7
575	7
576	10
577	10
578	10
579	10
582	10
585	11
586	10
586	11
587	10
589	10
590	10
591	10
593	10
594	9
595	10
596	10
597	10
598	10
599	10
601	10
604	10
607	10
608	10
609	10
611	10
612	10
614	10
615	10
618	10
619	10
621	10
623	10
624	10
625	10
626	10
628	10
629	10
630	10
632	10
633	10
634	10
636	10
637	10
638	10
639	10
640	10
641	10
643	10
644	10
646	9
649	9
653	10
656	10
657	9
658	10
661	10
662	6
662	10
663	10
664	10
665	10
666	10
667	10
668	10
669	10
670	10
671	10
672	9
673	10
674	10
676	10
677	10
678	10
680	10
681	10
682	10
683	10
685	7
686	10
687	10
688	10
689	10
691	10
694	10
697	10
699	10
700	9
700	11
705	9
706	10
707	10
709	10
710	6
710	10
712	10
713	10
714	7
715	7
716	10
717	10
718	10
719	9
722	10
725	9
726	10
727	10
728	10
729	10
730	7
730	9
731	7
732	10
733	9
734	10
735	9
736	10
737	10
738	10
739	10
740	10
741	9
742	9
744	10
746	7
748	10
749	10
750	9
751	10
752	11
753	10
755	9
758	9
759	10
762	10
763	10
765	10
766	10
767	10
768	10
769	10
770	10
772	9
773	10
774	10
775	10
776	10
777	10
778	10
779	10
780	10
782	10
783	9
784	10
785	10
786	10
788	10
789	10
790	10
791	10
792	10
793	10
796	10
797	10
798	10
799	10
801	10
802	10
804	10
805	10
807	10
808	10
809	9
810	7
811	10
812	10
813	10
814	10
815	10
816	10
818	11
819	10
820	10
822	10
824	10
825	10
827	10
829	11
830	9
831	10
833	10
834	10
836	9
837	9
838	11
839	10
840	10
841	10
842	10
843	10
844	9
845	9
846	10
847	9
848	10
849	9
852	10
854	10
855	10
856	10
857	7
858	10
859	10
860	10
861	9
862	10
863	10
864	10
865	9
866	10
867	10
869	9
870	10
871	9
873	10
874	10
875	10
876	10
877	10
878	10
879	10
881	10
882	10
883	10
884	10
886	10
887	10
888	10
890	7
891	6
891	10
892	10
893	9
894	10
895	7
896	10
898	9
899	10
900	10
901	10
902	10
903	10
904	10
905	9
906	9
907	9
908	10
909	10
911	10
912	10
914	9
915	10
916	10
917	10
919	10
920	7
921	9
923	10
924	10
925	10
926	10
927	10
928	10
929	10
932	10
933	10
934	9
936	10
937	10
938	10
939	10
940	10
941	10
943	10
944	10
946	10
947	10
948	10
949	10
950	10
951	10
952	10
953	7
953	10
954	10
955	10
956	10
958	10
959	9
960	10
964	10
966	10
967	10
968	10
970	1
971	10
972	9
973	10
974	10
977	10
979	7
981	10
987	10
988	10
989	7
991	10
992	10
993	10
994	10
995	9
996	10
997	9
998	9
999	9
1000	10
1001	10
1004	10
1006	10
1007	10
1008	10
1011	10
1012	9
1013	10
1014	9
1015	10
1016	10
1017	9
1019	10
1021	10
1022	10
1023	10
1024	10
1025	10
1026	10
1027	10
1029	9
1031	10
1032	10
1033	10
1034	10
1035	10
1038	10
1039	10
1041	9
1043	10
1044	9
1045	10
1046	9
1048	10
1049	10
1050	10
1051	10
1052	7
1053	10
1054	10
1056	10
1057	10
1060	10
1061	10
1066	10
1067	10
1070	10
1073	10
1075	10
1076	10
1078	10
1080	9
1081	9
1083	10
1084	9
1085	9
1087	10
1089	10
1090	10
1091	10
1092	10
1094	10
1095	10
1096	10
1098	10
1099	10
1101	10
1103	10
1104	10
1105	7
1106	10
1108	10
1109	10
1110	10
1111	10
1112	10
1113	9
1114	9
1115	10
1116	10
1117	11
1118	10
1119	10
1120	10
1121	10
1122	10
1124	10
1125	10
1126	9
1127	9
1129	10
1130	10
1131	10
1132	10
1135	10
1136	10
1138	10
1139	10
1140	10
1141	10
1142	10
1143	9
1144	10
1145	10
1147	10
1148	10
1149	10
1150	10
1151	10
1152	9
1153	10
1154	10
1155	10
1157	10
1158	10
1159	10
1161	7
1164	9
1165	9
1170	10
1171	9
1172	11
1177	10
1178	7
1180	7
1184	10
1185	9
1187	6
1187	10
1188	9
1190	10
1191	7
1194	10
1196	10
1197	10
1199	10
1200	7
1202	10
1203	11
1204	10
1206	7
1208	10
1211	7
1212	10
1216	9
1221	10
1223	9
1224	10
1226	6
1226	10
1227	10
1228	7
1231	9
1232	10
1233	10
1235	10
1236	10
1237	10
1238	10
1240	10
1241	10
1242	9
1243	9
1244	9
1246	10
1247	10
1248	10
1249	10
1250	10
1251	10
1252	9
1254	10
1255	11
1256	9
1259	10
1260	10
1262	9
1264	10
1265	10
1266	9
1267	10
1269	10
1270	9
1271	7
1272	11
1273	9
1274	10
1275	10
1277	10
1278	10
1279	10
1280	10
1281	10
1282	10
1283	11
1284	10
1285	9
1286	10
1288	10
1289	10
1290	10
1292	10
1293	10
1297	10
1299	10
1301	10
1303	10
1304	10
1305	9
1306	11
1307	10
1309	10
1310	11
1311	10
1312	10
1313	9
1314	10
1318	9
1319	10
1320	10
1322	10
1323	10
1325	10
1326	10
1327	10
1328	10
1329	10
1330	10
1333	7
1334	10
1335	10
1336	7
1336	9
1338	9
1339	9
1340	10
1341	10
1342	10
1343	11
1345	10
1350	10
1354	10
1355	10
1357	10
1358	7
1359	10
1360	9
1361	9
1362	7
1363	10
1364	7
1365	10
1366	10
1368	9
1369	9
1371	10
1372	9
1373	10
1375	10
1378	9
1379	9
1381	11
1383	10
1384	10
1387	10
1388	10
1394	9
1396	10
1399	2
1399	10
1404	7
1404	11
1407	9
1408	10
1409	9
1410	7
1411	11
1414	7
1414	10
1415	10
1416	7
1416	9
1417	10
1418	10
1419	10
1423	10
1425	10
1426	9
1430	9
1431	10
1441	9
1442	10
1444	10
1446	10
1454	10
1455	10
1456	10
1458	9
1459	7
1461	9
1463	10
1464	9
1466	9
1468	10
1469	10
1472	10
1475	7
1475	9
1478	9
1479	9
1480	9
1481	7
1482	10
1483	11
1484	7
1486	9
1489	7
1491	10
1494	10
1495	10
1497	9
1499	10
1500	10
1501	10
1502	10
1503	10
1504	10
1505	7
1505	9
1506	7
1507	9
1508	7
1509	10
1513	10
1514	10
1515	10
1517	10
1518	10
1520	10
1521	9
1523	9
1525	10
1528	9
1529	7
1533	10
1534	9
1535	10
1539	10
1541	10
1542	9
1543	10
1544	10
1545	10
1546	9
1550	10
1551	10
1552	10
1553	10
1555	11
1557	9
1558	10
1559	10
1560	11
1561	10
1562	10
1563	9
1563	11
1564	9
1565	10
1566	11
1567	10
1568	10
1569	10
1571	10
1574	9
1575	9
1576	9
1577	10
1579	10
1580	10
1581	7
1582	10
1584	10
1585	10
1586	10
1587	10
1590	10
1591	9
1592	10
1593	10
1594	10
1595	10
1596	9
1597	10
1598	10
1599	10
1600	10
1601	10
1602	10
1604	10
1605	10
1606	10
1609	10
1610	10
1612	10
1614	10
1616	9
1617	10
1618	10
1619	10
1620	10
1623	9
1626	9
1627	10
1628	9
1630	10
1631	10
1634	10
1635	7
1636	9
1637	10
1638	9
1639	10
1640	10
1641	6
1641	10
1642	10
1643	10
1644	9
1649	10
1650	10
1651	10
1652	10
1654	9
1655	9
1657	10
1658	9
1659	9
1661	10
1663	10
1664	10
1665	10
1666	9
1667	6
1667	10
1669	10
1671	10
1672	10
1674	10
1676	10
1677	11
1678	10
1679	10
1680	10
1681	10
1682	10
1683	10
1685	10
1687	10
1688	10
1690	9
1691	10
1692	10
1693	10
1694	10
1695	10
1696	10
1697	10
1698	10
1700	10
1702	11
1703	10
1704	10
1705	7
1706	10
1708	10
1709	11
1710	10
1711	10
1712	7
1713	11
1714	10
1716	10
1717	9
1718	11
1719	9
1720	10
1721	10
1722	10
1723	10
1724	10
1725	9
1726	10
1727	10
1729	10
1730	10
1731	10
1733	10
1734	10
1735	7
1736	10
1737	10
1738	10
1741	10
1742	10
1743	10
1744	9
1745	10
1746	9
1749	9
1752	10
1753	10
1756	10
1758	10
1760	10
1763	9
1765	10
1766	10
1767	10
1768	9
1769	10
1771	10
1772	9
1773	10
1774	10
1778	9
1780	10
1783	7
1783	10
1785	10
1786	10
1791	10
1792	9
1794	10
1797	10
1799	10
1800	10
1801	10
1802	10
1803	10
1804	11
1805	3
1806	22
1807	10
1808	10
1812	9
1813	10
1815	10
1818	10
1821	7
1821	11
1823	10
1824	10
1825	10
1828	10
1829	10
1830	9
1831	11
1833	10
1834	10
1835	7
1837	10
1838	10
1839	7
1839	9
1840	9
1841	10
1842	9
1843	9
1844	6
1845	14
1849	10
1849	21
1851	9
1853	10
1859	10
1860	22
1865	10
1867	10
1868	9
1869	9
1870	10
1872	9
1874	10
1876	9
1880	10
1882	9
1883	10
1884	10
1886	22
1887	9
1888	10
1889	9
1891	10
1892	10
1893	10
1895	10
1897	10
1899	10
1900	10
1901	9
1902	9
1903	9
1904	9
1907	9
1909	10
1911	10
1912	9
1913	10
1914	10
1915	10
1916	10
1917	10
1919	10
1920	10
1921	10
1922	10
1923	10
1924	10
1925	10
1928	10
1929	11
1930	11
1931	9
1933	9
1934	9
1936	10
1939	10
1940	10
1941	10
1943	10
1945	10
1947	10
1949	9
1950	7
1952	10
1953	10
1955	7
1956	10
1961	10
1964	10
1965	10
1966	10
1967	10
1968	10
1969	9
1970	11
1972	10
1973	10
1975	10
1976	7
1977	10
1978	10
1979	10
1982	10
1983	10
1984	11
1985	10
1986	11
1987	10
1990	10
1991	10
1995	10
1996	10
1997	10
1998	10
1999	10
2000	10
2001	10
2002	7
2003	10
2005	9
2006	10
2007	10
2009	10
2010	10
2011	10
2013	9
2014	10
2015	10
2016	9
2018	7
2018	9
2019	10
2020	10
2021	10
2022	10
2023	9
2026	9
2027	10
2030	10
2031	9
2035	10
2036	7
2037	10
2038	10
2039	10
2041	10
2042	6
2042	10
2044	10
2045	6
2045	10
2046	10
2047	10
2048	10
2050	10
2051	10
2052	9
2053	10
2054	10
2055	10
2056	10
2058	10
2059	10
2060	10
2061	10
2063	9
2065	6
2065	10
2066	10
2067	10
2068	10
2069	11
2070	10
2073	10
2074	10
2075	10
2076	10
2077	9
2079	9
2080	10
2081	10
2082	10
2083	10
2084	10
2089	10
2090	10
2091	10
2094	10
2096	9
2097	10
2098	10
2099	9
2101	10
2102	10
2103	10
2105	10
2106	10
2107	10
2110	10
2111	10
2112	10
2113	11
2114	10
2116	9
2117	9
2118	10
2119	7
2120	9
2122	9
2128	10
2129	10
2130	10
2131	10
2132	9
2134	9
2135	10
2136	10
2139	10
2141	10
2142	10
2143	10
2144	10
2145	10
2146	9
2147	10
2148	10
2149	10
2150	10
2153	10
2155	9
2156	10
2158	7
2159	9
2160	10
2161	9
2162	10
2164	10
2165	10
2166	9
2167	10
2168	10
2171	21
2173	11
2174	10
2176	10
2180	10
2181	10
2181	11
2184	10
2187	10
2189	10
2190	10
2191	10
2192	10
2193	10
2194	11
2196	10
2197	10
2198	10
2199	10
2200	10
2201	10
2202	10
2203	10
2204	10
2205	7
2205	21
2206	10
2207	10
2209	10
2211	10
2212	9
2213	10
2214	10
2215	10
2216	10
2217	9
2220	9
2222	11
2225	10
2226	10
2227	10
2229	9
2231	10
2233	10
2234	10
2235	10
2237	10
2238	10
2239	10
2240	10
2241	9
2242	10
2243	10
2244	9
2246	10
2248	10
2249	10
2252	10
2254	10
2255	10
2257	10
2258	10
2261	10
2262	10
2263	10
2265	9
2266	10
2268	10
2269	10
2271	9
2272	10
2274	9
2276	10
2279	10
2281	22
2283	10
2284	10
2285	10
2286	10
2287	9
2289	10
2290	10
2292	10
2293	10
2297	10
2298	10
2299	7
2301	10
2304	10
2305	10
2306	10
2307	10
2310	10
2311	9
2316	10
2317	10
2318	10
2322	10
2324	10
2325	10
2327	10
2328	10
2329	10
2330	10
2334	10
2335	10
2336	10
2337	10
2339	10
2340	10
2341	10
2343	10
2344	9
2345	10
2346	9
2347	10
2348	10
2349	10
2350	10
2351	9
2353	6
2353	9
2354	10
2356	11
2361	10
2363	10
2365	10
2368	9
2369	10
2370	10
2371	10
2373	10
2375	10
2376	10
2377	10
2379	10
2380	10
2381	10
2382	9
2383	9
2384	10
2385	10
2386	10
2387	10
2388	10
2389	10
2390	10
2391	10
2393	9
2394	10
2395	10
2396	9
2398	10
2399	10
2401	10
2403	10
2404	10
2405	10
2406	10
2407	10
2408	10
2409	10
2414	10
2415	10
2416	10
2417	10
2418	10
2420	9
2421	10
2422	10
2424	10
2425	10
2427	10
2428	10
2429	10
2431	10
2432	10
2434	10
2437	10
2438	10
2439	10
2440	10
2441	10
2442	10
2445	10
2450	10
2451	10
2453	10
2454	11
2457	10
2458	11
2462	10
2465	10
2466	10
2467	10
2469	10
2471	10
2472	10
2473	10
2474	10
2476	9
2477	9
2478	9
2479	10
2480	10
2481	9
2482	10
2483	10
2487	10
2491	10
2493	10
2494	10
2496	10
2497	10
2499	10
2500	10
2501	10
2502	10
2503	9
2504	10
2505	10
2506	10
2509	10
2510	11
2511	10
2512	10
2513	9
2514	10
2515	10
2516	10
2517	10
2521	10
2522	10
2523	10
2524	10
2525	10
2528	10
2529	10
2530	10
2533	10
2534	10
2535	10
2536	9
2537	10
2538	10
2539	10
2540	10
2541	9
2542	10
2544	10
2545	10
2546	10
2547	10
2548	10
2549	10
2551	10
2557	10
2560	10
2565	10
2569	10
2570	6
2570	10
2574	10
2575	10
2577	9
2579	10
2581	10
2582	10
2583	10
2585	10
2587	9
2589	10
2593	10
2594	10
2595	10
2598	10
2600	9
2601	9
2602	7
2603	9
2606	10
2608	10
2609	10
2610	10
2611	10
2612	10
2613	9
2614	10
2615	10
2617	9
2620	10
2621	9
2622	10
2623	10
2624	10
2625	9
2626	10
2627	10
2628	10
2630	11
2631	10
2632	10
2633	10
2636	10
2638	10
2639	10
2640	9
2641	9
2643	10
2644	10
2645	9
2646	10
2647	10
2648	9
2649	10
2650	10
2651	7
2654	10
2655	10
2661	10
2665	10
2666	10
2667	11
2673	6
2673	10
2674	10
2675	10
2676	10
2679	7
2680	9
2681	9
2683	9
2684	9
2685	10
2686	11
2689	9
2690	10
2691	10
2692	10
2693	10
2694	10
2697	10
2698	10
2700	9
2703	10
2705	10
2707	10
2708	10
2709	10
2710	10
2711	10
2712	10
2713	10
2714	10
2715	10
2716	10
2717	10
2719	10
2720	10
2724	10
2729	10
2733	10
2735	10
2736	9
2737	10
2738	10
2739	10
2741	9
2744	10
2749	10
2751	10
2754	10
2757	9
2758	10
2759	10
2760	10
2764	10
2765	10
2767	7
2768	10
2769	10
2770	10
2771	10
2772	10
2773	10
2774	10
2775	9
2776	9
2777	7
2778	10
2779	10
2782	11
2783	9
2784	10
2785	9
2789	9
2792	10
2795	6
2795	10
2796	9
2797	10
2798	10
2800	10
2801	10
2802	11
2804	10
2806	10
2807	10
2809	10
2810	10
2811	9
2812	10
2815	7
2816	10
2817	10
2820	10
2821	10
2822	10
2825	10
2829	10
2830	10
2833	10
2834	10
2835	10
2837	10
2838	10
2839	10
2841	10
2842	10
2843	10
2844	10
2845	10
2846	10
2847	9
2850	10
2852	10
2853	10
2856	10
2857	10
2861	10
2862	10
2863	10
2864	10
2866	10
2867	6
2867	10
2868	9
2869	10
2873	10
2874	10
2875	9
2876	10
2877	10
2878	10
2881	10
2883	10
2889	10
2890	10
2892	10
2893	9
2895	10
2896	9
2899	10
2900	9
2902	10
2903	10
2905	10
2906	10
2907	10
2909	10
2911	10
2914	10
2915	10
2917	9
2918	10
2919	10
2920	9
2921	10
2922	10
2923	9
2924	9
2925	9
2926	9
2929	9
2930	9
2931	10
2935	10
2936	9
2938	10
2939	10
2941	9
2942	9
2943	10
2945	10
2946	9
2947	10
2948	10
2954	11
2955	10
2956	10
2957	10
2958	10
2965	10
2966	10
2967	10
2969	10
2970	10
2971	10
2972	10
2973	10
2975	7
2976	10
2977	10
2978	10
2981	10
2983	10
2985	10
2987	10
2989	10
2991	10
2992	10
2993	10
2994	10
2995	10
2996	10
3000	10
3001	10
3002	10
3004	10
3007	11
3008	10
3011	11
3015	10
3016	9
3017	10
3018	6
3019	9
3020	9
3021	7
3026	9
3028	10
3031	10
3032	9
3035	10
3038	11
3039	9
3041	9
3043	10
3044	10
3045	7
3049	9
3050	7
3051	10
3054	10
3055	9
3058	9
3060	10
3062	4
3062	9
3063	10
3064	9
3065	10
3067	10
3068	10
3069	10
3072	9
3073	9
3074	10
3075	10
3076	10
3077	10
3082	9
3083	9
3088	9
3091	10
3093	10
3095	10
3096	9
3100	10
3102	10
3103	7
3104	10
3106	11
3107	9
3108	10
3109	10
3110	6
3110	10
3113	10
3114	10
3115	7
3116	11
3120	10
3121	10
3122	10
3124	10
3125	10
3126	11
3129	9
3131	9
3134	10
3136	10
3137	10
3139	10
3142	9
3143	11
3145	9
3146	10
3147	9
3148	9
3150	11
3151	10
3152	10
3153	10
3154	10
3155	9
3156	9
3158	9
3161	21
3162	10
3164	9
3168	10
3169	10
3170	10
3173	10
3174	9
3176	10
3178	10
3180	10
3182	10
3183	10
3184	10
3186	7
3188	10
3190	10
3192	7
3193	11
3196	10
3197	9
3198	10
3200	10
3201	10
3202	9
3204	10
3205	10
3206	10
3207	10
3208	9
3209	10
3210	11
3211	10
3212	9
3213	9
3215	10
3221	9
3222	9
3225	10
3227	9
3228	9
3233	9
3235	10
3239	10
3240	10
3241	10
3242	10
3243	10
3246	11
3247	7
3249	9
3250	9
3251	9
3252	9
3253	9
3255	9
3257	9
3258	10
3262	9
3264	10
3265	7
3267	9
3268	9
3269	7
3270	9
3271	10
3272	9
3276	10
3279	7
3280	6
3280	10
3281	10
3282	9
3284	10
3285	9
3286	10
3294	10
3297	9
3298	10
3299	10
3302	10
3303	10
3304	10
3305	10
3306	10
3307	10
3310	9
3311	10
3314	10
3315	10
3316	9
3321	11
3322	9
3323	10
3325	10
3328	7
3330	10
3333	9
3334	9
3335	10
3336	10
3338	10
3339	10
3342	10
3344	10
3347	10
3350	9
3353	11
3354	9
3355	9
3356	10
3357	9
3359	10
3360	9
3361	10
3362	9
3363	10
3363	11
3364	10
3365	10
3367	9
3369	9
3371	9
3372	10
3376	10
3377	10
3378	9
3379	9
3380	10
3381	9
3382	7
3384	10
3385	10
3389	9
3391	10
3392	10
3393	10
3397	10
3402	9
3403	9
3406	10
3409	9
3412	10
3413	9
3417	7
3417	10
3418	9
3419	7
3421	10
3422	10
3423	9
3427	10
3428	10
3429	10
3432	7
3436	10
3437	10
3438	10
3439	9
3442	9
3444	10
3445	9
3448	49
3449	9
3450	10
3451	10
3452	10
3453	10
3456	9
3457	10
3458	10
3459	10
3460	9
3462	10
3463	9
3464	7
3466	10
3467	10
3469	11
3473	11
3474	10
3475	10
3476	9
3477	10
3478	11
3479	10
3482	10
3484	10
3485	10
3486	10
3487	9
3488	10
3489	7
3490	7
3493	10
3494	11
3495	10
3500	10
3503	10
3506	10
3508	9
3509	9
3510	7
3511	10
3512	10
3513	9
3514	10
3515	10
3516	9
3517	9
3517	17
3518	9
3519	9
3521	10
3522	10
3523	10
3525	6
3525	10
3526	10
3532	10
3534	10
3535	9
3537	10
3538	10
3540	10
3543	10
3544	7
3545	10
3547	10
3548	10
3549	11
3550	9
3557	9
3558	10
3559	10
3561	10
3566	10
3568	11
3569	10
3570	10
3571	10
3573	10
3575	10
3578	10
3580	9
3583	10
3584	10
3589	9
3590	10
3591	9
3592	10
3596	10
3600	9
3601	22
3603	9
3605	10
3607	11
3610	10
3611	11
3614	10
3615	10
3618	10
3619	10
3624	10
3625	10
3628	9
3630	10
3633	9
3634	9
3635	9
3638	10
3639	7
3642	10
3644	10
3645	10
3652	9
3654	9
3655	9
3658	9
3659	9
3661	9
3667	10
3670	10
3671	10
3672	10
3675	10
3676	10
3678	9
3680	9
3683	7
3684	7
3685	10
3686	10
3691	10
3695	10
3697	10
3701	10
3702	7
3707	10
3708	10
3709	10
3710	10
3713	10
3715	9
3716	10
3717	10
3718	10
3721	10
3722	10
3723	10
3724	7
3724	9
3726	10
3727	9
3728	10
3728	18
3730	10
3733	10
3734	9
3735	10
3736	9
3737	10
3740	11
3742	9
3744	6
3744	10
3746	10
3748	10
3751	10
3757	10
3758	9
3759	10
3762	6
3762	10
3764	10
3765	9
3766	10
3768	10
3769	11
3772	10
3774	10
3775	10
3779	10
3780	10
3790	10
3791	7
3792	10
3795	9
3799	10
3821	9
3822	9
3823	9
3825	10
3826	10
3827	10
3830	7
3833	9
3834	10
3836	10
3838	10
3842	9
3843	10
3844	9
3852	10
3854	10
3861	10
3862	9
3864	10
3866	9
3868	10
3872	10
3873	10
3874	10
3875	10
3876	10
3880	9
3936	7
3938	9
3943	10
3944	10
3945	10
3946	9
3947	9
3949	10
3951	10
3954	9
3955	7
3957	10
3961	10
3962	6
3962	10
3968	10
3974	10
3978	9
3979	10
3980	10
3981	7
3983	10
3985	10
3991	10
3993	10
3995	9
3996	9
3997	9
3999	9
4001	10
4006	7
4007	7
4008	10
4047	10
4048	10
4055	7
4057	9
4059	10
4060	9
4063	9
4068	9
4074	7
4075	10
4076	10
4078	10
4079	10
4081	7
4081	10
4082	7
4082	10
4083	6
4083	9
4084	11
4085	10
4088	7
4090	10
4091	10
4092	10
4093	10
4094	7
4095	9
4096	10
4097	9
4097	21
4099	7
4100	9
4100	21
4101	10
4106	10
4112	10
4114	10
4117	10
4122	9
4123	9
4124	9
4125	10
4126	7
4127	7
4128	9
4129	10
4135	7
4136	10
4137	7
4138	10
4139	9
4141	7
4143	9
4145	9
4146	10
4147	10
4148	10
4150	10
4151	9
4152	9
4153	9
4155	10
4156	10
4159	7
4160	10
4161	10
4162	9
4163	9
4164	10
4168	10
4171	7
4172	10
4173	7
4174	7
4178	9
4179	10
4180	9
4183	9
4185	9
4186	9
4187	9
4188	9
4189	7
4190	9
4194	7
4196	9
4197	9
4198	9
4207	10
4208	10
4212	7
4213	9
4214	9
4216	9
4218	9
4219	7
4221	10
4222	10
4224	7
4228	10
4229	9
4231	9
4233	10
4234	9
4235	11
4236	11
4237	7
4245	10
4248	10
4252	10
4255	7
4256	9
4263	10
4264	9
4265	10
4268	10
4270	10
4272	9
4273	11
4275	9
4278	10
4283	9
4284	9
4285	9
4286	9
4287	9
4288	10
4289	7
4290	10
4291	11
4292	9
4293	7
4296	9
4297	9
4298	10
4301	7
4302	9
4303	9
4304	9
4305	10
4306	9
4307	9
4308	10
4309	9
4310	10
4312	10
4313	7
4314	9
4315	6
4315	10
4316	9
4318	9
4319	10
4320	10
4323	9
4326	9
4329	10
4330	10
4331	7
4332	10
4333	9
4335	10
4336	10
4338	9
4338	21
4339	9
4340	9
4342	11
4347	11
4348	6
4348	7
4348	10
4349	10
4351	11
4352	9
4355	9
4358	10
4359	9
4369	7
4370	7
4372	10
4374	9
4375	10
4376	10
4387	9
4388	9
4389	7
4390	10
4391	9
4392	10
4395	7
4397	10
4399	7
4400	9
4401	10
4402	9
4405	10
4408	10
4409	9
4411	10
4412	9
4414	9
4416	9
4418	9
4419	10
4420	10
4422	9
4423	9
4424	10
4425	7
4426	10
4428	6
4428	10
4430	10
4431	9
4433	10
4435	10
4439	9
4440	10
4442	9
4443	9
4450	21
4453	10
4456	9
4457	9
4460	10
4461	10
4462	10
4463	10
4464	9
4472	9
4474	10
4475	9
4476	7
4478	7
4481	10
4482	9
4484	9
4487	10
4488	7
4489	9
4490	11
4491	10
4492	10
4494	10
4496	10
4497	10
4498	10
4499	10
4500	9
4501	9
4502	10
4503	9
4504	11
4506	9
4507	9
4511	9
4512	10
4513	10
4515	7
4516	10
4517	10
4520	10
4521	10
4522	9
4523	7
4524	9
4528	9
4531	10
4535	11
4536	10
4538	7
4539	9
4540	9
4543	10
4544	7
4545	9
4549	7
4550	11
4551	10
4554	9
4558	10
4560	10
4561	10
4562	10
4565	10
4570	10
4571	9
4572	9
4573	11
4574	10
4575	10
4576	9
4577	9
4578	10
4579	9
4580	7
4581	7
4582	10
4583	10
4586	7
4588	7
4589	11
4590	9
4592	9
4594	9
4595	9
4599	9
4602	10
4603	9
4605	9
4609	9
4610	9
4612	9
4614	10
4616	6
4616	10
4617	10
4620	9
4621	10
4622	10
4623	10
4628	9
4631	10
4632	10
4633	9
4634	10
4635	10
4637	9
4639	10
4640	10
4642	9
4645	11
4646	10
4648	9
4649	10
4650	10
4651	11
4655	10
4656	11
4657	9
4660	10
4661	9
4664	9
4665	9
4671	10
4695	10
4700	10
4704	7
4708	11
4709	11
4720	9
4720	16
4721	11
4722	9
4724	11
4725	10
4727	9
4736	9
4738	9
4752	9
4753	9
4754	7
4755	9
4756	9
4757	9
4758	9
4760	11
4762	9
4764	9
4765	9
4766	10
4768	11
4769	10
4770	9
4771	9
4772	9
4773	10
4774	9
4775	9
4777	9
4778	10
4779	10
4780	9
4781	10
4784	9
4785	9
4787	9
4788	21
4789	11
4790	9
4791	3
4791	9
4792	9
4794	9
4795	10
4796	10
4797	9
4798	9
4800	9
4802	7
4803	9
4804	9
4806	10
4809	9
4810	9
4811	9
4812	9
4813	9
4814	9
4817	9
4818	9
4822	10
4823	9
4824	9
4825	10
4826	9
4827	9
4830	9
4831	9
4832	9
4833	10
4834	9
4835	9
4836	9
4837	9
4840	10
4842	10
4844	9
4845	10
4846	10
4847	9
4848	9
4849	16
4851	10
4853	7
4854	9
4858	10
4859	10
4860	10
4862	9
4863	9
4865	9
4865	13
4866	9
4869	9
4869	21
4870	9
4871	9
4873	9
4876	11
4877	9
4878	10
4883	10
4884	10
4888	9
4889	9
4890	10
4891	9
4893	3
4893	9
4893	11
4894	9
4899	10
4900	10
4901	10
4902	7
4904	9
4905	9
4908	9
4909	10
4910	9
4911	9
4912	9
4913	9
4914	9
4915	9
4916	7
4917	9
4918	9
4919	9
4922	10
4924	9
4925	7
4926	7
4927	10
4928	9
4931	10
4933	7
4936	11
4938	9
4939	7
4940	9
4941	7
4942	10
4943	7
4944	9
4945	7
4946	10
4947	9
4948	10
4949	10
4951	10
4955	11
4961	10
4962	7
4966	9
4968	10
4970	9
4974	9
4978	9
4980	10
4981	10
4982	9
4983	10
4985	10
4986	9
4987	9
4990	9
4997	9
4999	10
5000	9
5004	21
5005	9
5009	9
5013	9
5014	9
5015	9
5017	9
5018	9
5021	9
5026	9
5028	10
5029	10
5030	7
5031	9
5034	9
5036	11
5037	9
5038	10
5039	10
5041	10
5045	10
5047	9
5048	11
5049	7
5050	9
5052	10
5054	7
5055	10
5057	10
5068	11
5070	21
5072	11
5073	11
5074	10
5077	9
5079	9
5080	9
5082	10
5083	7
5084	9
5086	10
5090	9
5093	9
5094	9
5096	10
5097	9
5099	10
5101	10
5102	10
5105	9
5106	10
5108	10
5110	9
5116	9
5117	10
5120	9
5121	10
5122	10
5123	11
5124	11
5125	11
5126	10
5127	10
5128	9
5129	10
5130	10
5130	11
5131	7
5133	7
5134	9
5134	11
5135	11
5136	10
5138	9
5140	10
5141	7
5142	9
5143	11
5144	10
5145	9
5151	7
5151	16
5152	7
5153	10
5159	10
5160	7
5160	16
5161	11
5162	10
5164	6
5164	10
5165	9
5166	11
5168	10
5169	9
5171	9
5173	10
5175	9
5177	10
5180	10
5181	10
5182	10
5183	10
5184	10
5186	10
5188	10
5191	10
5192	10
5195	9
5196	7
5198	9
5199	10
5200	6
5200	7
5202	10
5203	10
5239	7
5240	9
5241	9
5242	10
5243	10
5245	9
5246	9
5248	9
5249	9
5250	10
5251	6
5251	10
5253	10
5255	10
5256	10
5257	10
5258	10
5259	10
5260	6
5260	10
5261	7
5262	9
5263	10
5264	7
5267	10
5268	9
5269	10
5271	9
5274	11
5275	7
5276	9
5277	9
5278	7
5279	7
5280	9
5281	10
5282	11
5283	9
5284	7
5285	7
5287	10
5288	9
5289	10
5290	10
5291	10
5292	6
5292	10
5293	9
5297	9
5298	7
5301	10
5303	9
5305	9
5312	10
5313	9
5314	10
5316	10
5317	10
5319	10
5322	6
5322	9
5324	9
5325	9
5330	10
5333	10
5335	9
5338	9
5340	7
5342	10
5344	9
5346	9
5356	10
5357	9
5358	10
5359	9
5360	9
5364	10
5364	15
5365	9
5367	9
5370	9
5372	10
5373	10
5380	9
5383	10
5384	9
5387	9
5390	9
5391	9
5394	6
5396	10
5400	9
5401	10
5402	9
5403	10
5404	9
5405	11
5406	9
5407	9
5409	9
5410	9
5411	7
5412	22
5415	9
5416	9
5419	7
5420	10
5421	21
5422	10
5424	9
5425	9
5426	22
5427	9
5428	6
5429	9
5430	22
5431	10
5432	10
5433	22
5434	22
5436	9
5437	9
5437	10
5438	9
5439	9
5440	11
5441	18
5442	22
5443	22
5444	22
5445	9
5446	10
5447	10
5448	10
5449	10
5451	10
5452	10
5454	10
5456	10
5457	10
5458	22
5460	22
5461	21
5463	3
5464	10
5465	10
5466	10
5467	10
5468	10
5470	22
5471	22
5472	10
5473	10
5474	10
5475	10
5477	9
5477	10
5478	10
5479	6
5479	10
5480	22
5481	9
5484	9
5485	9
5487	7
5491	10
5492	10
5493	10
5494	10
5496	9
5499	9
5500	9
5502	9
5503	21
5504	9
5506	6
5506	10
5507	6
5507	10
5509	10
5511	10
5512	6
5512	10
5513	9
5520	9
5521	9
5522	9
5523	9
5525	9
5526	10
5527	9
5528	9
5529	24
5530	9
5532	9
5534	9
5535	10
5536	10
5537	9
5538	10
5539	9
5541	10
5542	9
5545	9
5546	21
5547	10
5551	10
5554	9
5555	9
5556	9
5558	10
5559	10
5560	10
5561	10
5562	10
5563	10
5564	6
5564	10
5565	10
5568	10
5569	10
5570	10
5571	10
5572	9
5574	22
5577	9
5578	9
5579	10
5580	9
5582	10
5583	10
5584	10
5585	9
5587	10
5592	6
5592	10
5593	6
5595	11
5596	9
5597	9
5598	10
5599	9
5601	9
5604	9
5605	9
5606	10
5610	9
5611	9
5614	9
5615	6
5615	10
5616	10
5617	9
5619	21
5623	9
5624	10
5630	10
5634	10
5635	7
5636	10
5638	7
5638	10
5643	10
5644	10
5646	10
5648	9
5655	7
5656	10
5658	9
5663	9
5663	10
5664	9
5665	10
5666	10
5667	10
5670	10
5671	7
5672	10
5674	10
5675	7
5677	10
5678	10
5679	21
5680	10
5682	6
5684	10
5687	9
5689	10
5690	10
5691	9
5694	10
5697	10
5698	10
5699	10
5700	10
5701	10
5704	9
5705	9
5705	21
5706	21
5707	11
5709	21
5710	21
5711	9
5713	10
5714	10
5715	10
5716	10
5719	6
5720	9
5722	10
5724	21
5726	10
5727	9
5728	10
5729	9
5729	21
5734	9
5737	10
5738	10
5739	21
5740	9
5741	9
5742	9
5743	6
5743	10
5745	6
5745	10
5746	21
5747	21
5749	22
5752	21
5753	7
5754	9
5757	10
5760	9
5761	6
5761	10
5762	9
5763	10
5764	10
5765	9
5766	9
5768	9
5771	9
5773	9
5777	10
5782	9
5785	10
5787	10
5788	10
5791	9
5793	9
5794	9
5796	9
5797	9
5798	10
5801	9
5802	9
5803	9
5806	9
5806	21
5808	10
5809	10
5814	10
5815	10
5817	6
5817	10
5818	6
5818	10
5821	10
5823	9
5824	9
5826	9
5828	9
5834	9
5835	9
5836	9
5840	10
5842	9
5844	9
5847	9
5848	9
5850	9
5851	9
5852	22
5853	22
5854	22
5857	9
5859	22
5860	22
5862	22
5867	10
5868	9
5870	9
5872	21
5874	21
5875	9
5876	9
5878	10
5879	9
5880	9
5881	9
5885	9
5887	9
5888	21
5890	21
5891	10
5892	7
5894	7
5895	22
5896	10
5897	22
5898	22
5899	22
5905	10
5907	21
5908	10
5909	10
5910	10
5912	10
5919	10
5922	11
5926	9
5927	9
5928	9
5928	11
5932	10
5935	9
5937	10
5938	10
5940	10
5941	21
5942	10
5943	10
5944	22
5945	6
5945	10
5946	10
5947	21
5948	22
5949	22
5950	9
5951	9
5955	11
5956	9
5957	7
5957	10
5958	10
5960	10
5961	9
5964	10
5965	9
5966	9
5967	10
5968	10
5970	10
5971	10
5972	10
5976	10
5978	9
5988	10
5989	9
5991	9
5992	9
5995	6
5995	10
5998	9
5999	10
6000	6
6000	10
6001	10
6002	10
6003	10
6004	9
6005	10
6007	9
6007	21
6008	10
6010	11
6011	9
6012	10
6013	9
6014	11
6015	9
6016	9
6019	9
6020	9
6021	9
6025	9
6027	10
6028	10
6030	9
6031	10
6034	9
6035	21
6037	9
6042	10
6048	21
6050	21
6052	21
6053	10
6056	9
6057	10
6058	10
6060	21
6061	21
6062	21
6064	10
6065	10
6067	10
6069	22
6070	9
6074	10
6075	9
6079	10
6080	10
6081	9
6082	11
6083	10
6085	10
6087	10
6089	6
6089	10
6090	22
6091	10
6093	9
6094	9
6095	22
6097	9
6099	10
6100	10
6104	22
6106	10
6107	9
6108	10
6109	9
6110	9
6112	10
6117	10
6119	10
6122	10
6124	21
6127	10
6128	10
6129	9
6133	9
6134	9
6136	9
6137	9
6138	10
6141	9
6142	9
6146	9
6151	9
6152	10
6155	10
6158	10
6160	10
6162	21
6164	10
6165	7
6166	21
6168	21
6172	10
6173	6
6173	10
6174	10
6175	10
6176	10
6183	10
6184	10
6185	10
6188	11
6189	21
6190	11
6191	21
6193	10
6194	10
6195	10
6198	21
6200	21
6201	10
6203	6
6203	10
6204	10
6205	10
6206	6
6206	10
6207	10
6208	10
6209	10
6210	10
6211	10
6212	6
6212	10
6213	6
6213	10
6214	6
6214	11
6215	10
6216	6
6216	10
6217	10
6218	6
6218	10
6219	21
6220	21
6221	10
6222	21
6223	21
6224	21
6225	10
6226	9
6229	21
6230	10
6232	9
6233	21
6234	6
6236	10
6242	10
6245	9
6246	9
6248	10
6254	22
6255	21
6256	9
6258	22
6259	21
6260	9
6261	7
6263	10
6264	10
6266	9
6267	6
6267	10
6268	9
6268	11
6268	21
6269	10
6270	21
6271	22
6273	21
6274	6
6274	9
6279	7
6283	9
6285	10
6293	6
6293	10
6296	10
6297	9
6299	9
6300	11
6301	10
6302	9
6303	9
6304	10
6306	9
6307	10
6308	10
6310	9
6311	10
6312	10
6313	9
6314	10
6315	10
6316	10
6317	10
6318	9
6319	10
6320	10
6321	10
6322	10
6326	9
6327	10
6332	6
6332	10
6333	10
6334	6
6334	10
6335	6
6335	10
6336	21
6337	10
6340	10
6341	10
6342	10
6344	6
6344	10
6347	6
6347	9
6349	21
6350	10
6351	21
6352	9
6353	21
6354	9
6355	10
6356	21
6357	10
6358	21
6360	10
6362	21
6364	21
6366	10
6367	9
6367	10
6368	6
6368	10
6369	7
6370	7
6371	10
6374	21
6375	21
6379	21
6381	10
6382	10
6383	21
6384	10
6386	21
6387	21
6388	9
6389	7
6391	21
6392	22
6394	21
6395	21
6396	9
6397	9
6398	10
6399	10
6401	6
6401	10
6402	10
6404	10
6408	22
6409	21
6410	10
6411	21
6412	21
6413	22
6415	10
6416	21
6417	7
6419	21
6420	21
6421	10
6422	9
6424	10
6426	10
6431	10
6432	10
6433	10
6434	21
6437	9
6438	10
6439	10
6441	10
6441	11
6442	21
6445	6
6445	10
6446	21
6448	10
6449	10
6454	6
6454	24
6458	21
6463	10
6464	10
6465	21
6471	10
6474	6
6475	10
6478	21
6479	21
6484	21
6485	11
6486	21
6488	21
6491	21
6492	6
6492	10
6494	6
6497	21
6498	21
6499	21
6501	21
6502	10
6504	21
6505	10
6506	6
6506	10
6507	18
6509	21
6510	6
6510	10
6513	21
6514	21
6516	10
6518	21
6519	10
6520	10
6521	10
6522	10
6523	6
6523	10
6524	10
6525	10
6526	10
6527	10
6528	21
6529	21
6530	10
6531	10
6532	10
6533	10
6534	10
6535	10
6536	10
6537	10
6538	10
6539	10
6540	10
6541	10
6543	10
6544	10
6545	10
6546	10
6547	10
6548	10
6549	10
6550	10
6551	10
6552	10
6553	10
6554	10
6555	10
6556	10
6558	10
6559	10
6560	10
6561	10
6562	10
6563	10
6565	10
6566	10
6567	10
6568	10
6569	10
6572	21
6573	10
6574	10
6575	21
6578	10
6579	21
6580	21
6581	21
6584	7
6584	10
6585	10
6586	10
6587	10
6588	21
6589	10
6590	22
6592	21
6593	21
6596	7
6599	21
6600	21
6601	7
6602	21
6603	21
6604	10
6606	21
6607	21
6608	21
6609	21
6611	21
6613	21
6614	10
6615	21
6616	21
6618	21
6620	21
6622	21
6623	21
6626	21
6628	21
6629	21
6630	21
6632	21
6635	21
6636	21
6637	21
6638	21
6640	21
6642	21
6643	9
6644	9
6648	21
6649	7
6650	21
6655	10
6656	21
6658	21
6660	21
6661	21
6662	21
6663	10
6664	21
6665	21
6666	7
6667	10
6673	21
6675	6
6675	10
6676	7
6677	7
6678	10
6684	6
6684	10
6685	9
6687	15
6689	21
6691	21
6692	21
6693	21
6694	21
6695	10
6698	10
6700	9
6704	10
6705	10
6708	10
6710	21
6714	10
6715	10
6717	21
6719	21
6720	10
6721	10
6723	10
6724	10
6726	10
6728	10
6729	10
6730	10
6731	10
6733	10
6736	10
6737	21
6739	10
6740	10
6743	9
6748	21
6751	10
6752	10
6753	10
6754	7
6754	10
6755	6
6755	10
6756	6
6756	9
6757	9
6758	10
6759	9
6763	21
6764	21
6765	21
6768	10
6769	21
6770	10
6772	21
6773	10
6774	9
6775	21
6779	10
6780	10
6781	10
6782	21
6783	21
6784	22
6785	10
6787	21
6788	21
6790	10
6791	10
6792	10
6795	7
6795	10
6798	16
6799	21
6800	21
6803	11
6805	10
6806	10
6807	21
6809	9
6809	11
6813	10
6814	7
6815	7
6816	6
6816	10
6819	21
6820	21
6821	10
6823	9
6824	10
6825	21
6827	21
6828	10
6829	22
6830	22
6833	21
6834	21
6835	10
6836	21
6837	11
6838	7
6839	10
6840	21
6842	21
6843	21
6844	21
6845	10
6846	9
6847	9
6848	10
6849	9
6850	10
6851	6
6851	10
6852	21
6853	10
6854	9
6855	9
6856	21
6858	10
6859	10
6863	21
6866	21
6867	10
6868	9
6869	9
6870	9
6871	21
6872	21
6873	21
6875	21
6876	9
6877	21
6878	21
6879	10
6882	21
6883	21
6884	21
6885	10
6886	22
6888	10
6889	22
6891	10
6892	21
6893	9
6894	21
6897	22
6898	21
6899	21
6900	21
6901	10
6902	21
6903	7
6904	9
6906	6
6906	10
6907	10
6908	21
6909	9
6910	9
6912	10
6913	22
6914	22
6915	9
6917	9
6918	9
6919	9
6921	10
6923	9
6924	6
6924	10
6925	10
6928	10
6929	10
6930	9
6931	10
6932	9
6933	9
6936	9
6937	7
6938	9
6940	9
6941	9
6942	11
6943	9
6944	10
6945	10
6946	6
6946	9
6947	10
6948	10
6949	6
6950	10
6951	7
6953	6
6953	10
6954	9
6955	9
6956	9
6959	9
6961	10
6965	7
6968	10
6971	9
6973	21
6980	9
6981	9
6985	10
6986	9
6988	9
6989	10
6990	9
6993	10
6993	15
6995	9
6996	10
6997	6
6997	10
6998	9
6999	9
7000	10
7001	9
7002	10
7002	15
7004	9
7005	9
7007	10
7008	9
7009	9
7010	10
7012	7
7012	10
7015	9
7019	10
7021	7
7022	11
7024	9
7025	9
7026	9
7027	7
7028	9
7030	10
7032	9
7033	10
7034	11
7036	10
7037	9
7038	10
7040	10
7043	9
7044	9
7046	9
7047	10
7049	10
7050	10
7052	10
7053	10
7055	7
7055	10
7056	10
7059	9
7068	9
7069	10
7070	10
7070	15
7071	9
7072	10
7075	10
7076	10
7077	7
7078	10
7079	9
7081	10
7082	10
7082	15
7083	7
7083	10
7086	10
7088	10
7089	9
7090	10
7091	10
7092	10
7093	9
7095	9
7095	10
7097	6
7097	10
7098	9
7099	6
7099	10
7101	9
7101	10
7102	7
7103	10
7104	9
7106	7
7107	6
7107	10
7108	9
7109	9
7109	10
7110	10
7112	6
7112	10
7113	10
7115	6
7115	7
7117	6
7117	9
7118	9
7119	11
7120	9
7122	9
7123	9
7124	9
7125	10
7126	9
7128	7
7131	7
7133	7
7133	11
7133	15
7134	10
7135	7
7136	9
7137	11
7139	9
7140	10
7142	9
7144	10
7145	10
7147	9
7148	10
7149	10
7150	9
7152	10
7153	9
7154	9
7156	9
7157	10
7158	7
7159	10
7160	10
7161	10
7165	10
7166	10
7167	10
7168	9
7169	10
7170	7
7170	10
7171	11
7173	9
7173	11
7177	10
7179	11
7181	10
7182	10
7183	7
7183	10
7184	10
7187	10
7188	9
7189	9
7190	10
7191	10
7192	6
7192	10
7194	10
7195	10
7196	9
7198	11
7199	9
7200	10
7201	11
7203	9
7203	10
7204	6
7204	11
7205	10
7207	10
7208	10
7209	9
7210	9
7211	10
7212	9
7213	10
7214	9
7215	9
7216	9
7217	9
7218	10
7219	10
7220	10
7221	6
7221	9
7222	9
7224	10
7228	10
7229	10
7230	9
7234	9
7235	6
7235	10
7236	9
7237	7
7238	10
7239	9
7240	9
7241	9
7242	10
7243	9
7244	9
7245	10
7246	7
7247	9
7248	9
7250	9
7257	11
7258	9
7261	6
7261	10
7262	10
7263	10
7264	11
7265	10
7266	10
7267	9
7268	9
7269	9
7270	10
7271	9
7272	9
7273	9
7275	10
7276	9
7277	7
7278	6
7278	10
7279	7
7280	6
7280	10
7282	7
7282	10
7283	9
7285	9
7287	10
7289	9
7290	10
7291	9
7292	6
7292	10
7293	10
7294	22
7295	22
7296	10
7297	10
7298	10
7299	9
7300	9
7301	10
7303	9
7304	3
7306	9
7307	9
7309	7
7310	9
7311	9
7312	9
7313	10
7314	9
7315	10
7316	11
7317	10
7319	10
7320	10
7322	10
7325	9
7327	11
7328	9
7329	10
7330	9
7331	11
7332	22
7333	22
7335	22
7336	22
7337	22
7339	22
7340	22
7341	22
7342	22
7343	10
7344	22
7345	22
7346	22
7347	22
7348	22
7349	22
7350	22
7351	22
7352	22
7353	22
7355	22
7356	22
7357	22
7358	9
7359	22
7360	22
7361	22
7362	22
7363	22
7364	22
7365	22
7366	22
7367	22
7368	9
7369	22
7371	22
7372	22
7373	22
7374	22
7376	22
7377	10
7379	22
7380	22
7381	22
7382	22
7383	22
7384	22
7385	22
7386	22
7387	22
7388	22
7389	22
7390	22
7391	25
7392	22
7393	22
7396	10
7396	21
7397	22
7399	10
7400	22
7401	22
7402	22
7403	22
7404	22
7405	22
7406	22
7407	9
7408	9
7409	9
7410	9
7411	22
7412	22
7413	22
7414	10
7415	10
7416	10
7417	22
7420	10
7422	6
7422	10
7424	10
7426	22
7428	9
7429	10
7430	10
7431	22
7433	22
7434	22
7435	22
7436	9
7437	10
7439	10
7440	22
7441	22
7442	22
7443	22
7444	22
7445	17
7446	10
7447	9
7448	9
7449	9
7450	9
7451	10
7452	9
7453	9
7454	10
7455	7
7457	10
7458	11
7459	10
7460	10
7461	10
7464	9
7465	10
7466	10
7467	10
7469	10
7470	10
7473	9
7474	9
7477	10
7478	10
7479	10
7480	9
7481	9
7483	10
7485	9
7486	10
7488	10
7490	9
7491	9
7492	9
7493	9
7494	9
7495	9
7496	9
7497	9
7498	9
7500	9
7501	9
7502	9
7503	9
7504	9
7505	9
7506	9
7507	9
7508	9
7509	9
7510	21
7511	9
7512	9
7513	9
7514	9
7515	10
7516	9
7517	9
7518	9
7519	9
7520	9
7521	10
7522	10
7523	9
7524	9
7526	9
7527	9
7530	9
7531	22
7532	21
7535	21
7536	21
7536	22
7537	22
7538	21
7539	21
7540	21
7541	21
7542	21
7543	22
7544	21
7545	21
7546	22
7547	21
7548	9
7549	9
7550	9
7551	9
7552	21
7553	9
7554	21
7555	22
7556	21
7557	21
7558	21
7559	22
7560	21
7562	21
7565	21
7566	21
7567	21
7568	21
7569	21
7570	21
7571	21
7572	21
7573	9
7576	21
7577	21
7579	9
7580	9
7581	9
7582	22
7583	9
7584	9
7585	9
7586	21
7587	9
7588	9
7589	9
7590	11
7594	21
7595	21
7598	21
7600	21
7601	21
7602	21
7604	9
7606	21
7607	21
7609	9
7610	9
7612	9
7613	9
7614	9
7618	9
7619	9
7621	9
7623	9
7626	9
7628	9
7632	21
7633	9
7634	21
7635	21
7640	21
7644	21
7645	21
7646	21
7650	9
7654	21
7656	10
7658	9
7661	9
7662	9
7663	9
7665	9
7667	9
7668	9
7672	9
7675	22
7676	9
7677	10
7678	9
7679	10
7680	9
7681	9
7682	9
7683	9
7684	21
7685	21
7686	21
7687	21
7688	10
7689	10
7690	22
7691	21
7692	21
7693	22
7694	21
7695	21
7696	21
7698	21
7699	3
7699	9
7700	25
7701	21
7702	21
7703	21
7705	21
7706	21
7707	9
7710	3
7711	9
7712	9
7713	17
7714	9
7715	9
7717	9
7719	9
7720	10
7721	9
7722	22
7723	21
7724	10
7725	21
7727	10
7730	21
7732	9
7733	9
7734	9
7735	10
7736	9
7737	9
7738	9
7739	9
7740	9
7741	9
7742	9
7743	9
7744	9
7745	9
7746	9
7747	9
7748	9
7749	10
7750	10
7751	9
7752	9
7753	9
7753	21
7755	21
7756	22
7758	21
7759	10
7760	21
7764	21
7771	21
7772	21
7774	21
7775	21
7780	21
7783	21
7784	21
7785	21
7787	21
7788	21
7789	21
7790	11
7791	10
7792	10
7793	21
7794	21
7795	21
7796	21
7797	21
7798	21
7799	21
7800	6
7800	21
7801	21
7802	11
7803	21
7805	21
7806	21
7807	21
7808	21
7809	21
7810	21
7811	17
7812	21
7813	21
7815	10
7816	21
7818	10
7820	10
7821	9
7822	11
7823	9
7824	10
7825	10
7826	10
7827	11
7828	9
7829	9
7830	9
7831	10
7832	9
7833	9
7836	22
7838	22
7840	3
7841	10
7843	22
7844	10
7845	22
7849	22
7850	22
7852	22
7853	22
7854	22
7855	10
7856	22
7857	22
7858	22
7859	22
7862	22
7863	22
7864	22
7865	22
7866	22
7868	22
7869	22
7870	22
7871	22
7872	7
7873	22
7874	22
7875	22
7876	22
7877	22
7878	22
7880	10
7881	22
7882	22
7883	10
7884	9
7885	9
7886	9
7887	9
7888	11
7888	13
7889	11
7889	13
7890	10
7892	9
7893	7
7894	9
7897	7
7898	9
7899	10
7900	6
7900	10
7902	9
7903	9
7904	9
7905	6
7905	10
7906	10
7907	11
7908	10
7909	10
7910	6
7910	10
7912	9
7913	10
7914	10
7915	10
7916	9
7917	10
7918	24
7919	9
7922	9
7924	10
7925	10
7926	9
7928	10
7929	9
7930	9
7931	9
7932	9
7933	9
7934	10
7935	6
7935	10
7936	9
7937	9
7938	9
7939	9
7940	9
7941	9
7942	11
7943	9
7944	9
7945	10
7946	24
7950	11
7951	9
7952	7
7953	9
7954	24
7955	9
7957	24
7958	10
7959	10
7960	10
7961	11
7964	10
7965	10
7966	10
7968	10
7969	9
7970	10
7971	10
7973	9
7974	9
7975	9
7978	9
7979	7
7980	10
7981	10
7982	9
7983	10
7985	7
7987	10
7988	10
7989	10
7992	11
7993	24
7994	9
7996	10
7997	7
7998	7
8000	10
8002	10
8003	9
8004	11
8005	10
8007	10
8009	6
8009	10
8012	10
8015	9
8016	9
8018	11
8021	9
8023	9
8024	9
8025	9
8026	9
8028	9
8030	10
8031	9
8032	9
8036	9
8037	9
8038	7
8039	24
8042	9
8046	10
8047	10
8048	11
8049	10
8050	9
8051	10
8052	17
8053	9
8054	10
8056	10
8057	9
8061	9
8063	9
8064	9
8065	10
8067	10
8069	11
8071	9
8072	9
8072	17
8074	9
8075	10
8076	10
8078	10
8079	9
8080	10
8081	9
8082	7
8083	9
8084	9
8085	10
8087	9
8088	9
8089	9
8090	21
8091	21
8093	21
8094	21
8095	21
8097	21
8098	9
8099	9
8100	10
8102	21
8103	21
8104	21
8105	21
8106	21
8107	21
8108	21
8109	10
8110	10
8111	21
8112	21
8113	21
8114	21
8115	21
8116	21
8117	21
8118	21
8119	21
8120	21
8121	21
8122	21
8123	21
8124	21
8125	21
8126	21
8127	21
8128	21
8129	21
8130	21
8131	21
8137	21
8138	21
8139	21
8140	21
8141	21
8143	21
8144	21
8145	21
8146	21
8147	21
8148	21
8149	21
8150	21
8151	21
8153	10
8154	21
8155	21
8157	10
8158	21
8159	21
8160	21
8161	10
8162	21
8163	21
8164	21
8166	21
8167	21
8168	21
8169	21
8170	21
8171	21
8172	21
8173	21
8174	21
8175	24
8176	21
8177	21
8178	21
8179	21
8180	21
8181	21
8182	21
8183	21
8184	21
8185	21
8186	21
8188	24
8189	24
8190	21
8191	21
8192	21
8193	21
8194	21
8195	21
8196	22
8197	21
8199	21
8200	21
8201	21
8202	21
8203	21
8204	21
8205	21
8206	21
8207	22
8208	21
8209	21
8210	21
8211	21
8212	21
8213	21
8214	21
8216	21
8217	24
8218	21
8219	24
8220	21
8221	21
8222	21
8223	21
8225	21
8226	24
8227	21
8228	21
8230	21
8231	21
8232	21
8233	21
8234	21
8235	24
8236	21
8237	9
8239	21
8240	21
8241	21
8242	21
8243	21
8244	21
8245	21
8246	21
8247	21
8248	21
8250	21
8251	21
8252	21
8254	21
8255	21
8256	21
8257	21
8258	22
8259	21
8260	21
8261	21
8262	21
8263	21
8265	24
8266	21
8268	21
8269	7
8270	21
8271	21
8272	21
8273	21
8274	21
8275	9
8276	9
8277	9
8278	9
8279	9
8280	9
8281	9
8282	10
8283	9
8284	9
8285	10
8286	9
8287	9
8288	9
8289	9
8290	9
8291	24
8292	9
8293	9
8294	9
8295	9
8296	24
8297	24
8298	21
8300	21
8301	21
8303	21
8304	21
8305	21
8306	21
8307	21
8308	21
8309	21
8310	21
8311	21
8312	21
8313	24
8314	21
8315	24
8316	21
8317	21
8318	24
8319	21
8320	21
8321	21
8322	10
8323	21
8324	21
8325	21
8326	10
8327	21
8328	10
8329	21
8330	21
8331	11
8332	21
8333	6
8333	10
8334	10
8335	10
8337	21
8338	24
8339	21
8340	24
8341	24
8342	10
8343	24
8344	21
8345	24
8346	22
8347	24
8348	24
8349	21
8350	21
8351	21
8352	21
8353	21
8354	21
8356	21
8357	21
8358	24
8359	21
8360	21
8361	21
8362	21
8363	21
8364	21
8365	21
8366	21
8367	21
8368	24
8369	11
8370	24
8371	21
8372	24
8373	24
8374	24
8375	24
8376	24
8377	24
8378	9
8379	24
8380	9
8381	9
8382	24
8383	9
8384	18
8385	24
8386	24
8387	24
8388	24
8389	24
8390	24
8391	24
8392	24
8393	9
8394	24
8395	10
8396	10
8398	10
8399	10
8400	10
8401	10
8402	10
8403	10
8404	10
8405	10
8406	10
8407	10
8408	10
8409	10
8410	10
8411	24
8412	21
8413	24
8414	10
8415	21
8416	21
8417	10
8418	10
8419	10
8420	10
8421	24
8422	24
8423	21
8424	11
8425	10
8426	24
8427	24
8428	24
8429	24
8430	24
8431	24
8432	21
8433	24
8434	24
8435	21
8436	24
8437	24
8438	24
8439	21
8440	24
8441	21
8442	24
8444	24
8445	21
8446	24
8447	24
8448	24
8449	24
8450	24
8451	24
8452	24
8453	24
8454	24
8455	24
8456	10
8457	24
8458	24
8459	24
8460	10
8461	24
8462	24
8463	24
8464	24
8465	24
8466	24
8467	24
8468	21
8469	24
8470	24
8471	24
8472	24
8473	24
8474	24
8475	24
8476	24
8477	24
8478	24
8479	24
8480	24
8481	24
8482	24
8483	24
8484	24
8485	21
8486	24
8487	24
8488	24
8489	24
8490	24
8491	9
8492	24
8493	24
8494	24
8495	24
8496	24
8497	24
8498	24
8499	24
8500	24
8501	24
8502	24
8503	10
8504	10
8505	10
8506	24
8507	24
8508	24
8509	24
8510	24
8511	24
8512	24
8513	24
8514	21
8515	24
8516	11
8517	24
8518	24
8519	24
8520	24
8521	24
8522	24
8523	24
8524	24
8525	24
8526	24
8527	24
8528	24
8529	21
8530	24
8531	21
8532	24
8533	24
8534	24
8535	24
8536	25
8537	24
8538	24
8539	24
8540	24
8541	24
8542	24
8543	24
8544	24
8545	24
8546	21
8547	21
8548	24
8549	24
8550	24
8551	24
8552	24
8553	24
8554	10
8555	21
8556	10
8557	24
8558	24
8559	21
8560	24
8561	24
8562	24
8563	24
8564	24
8565	24
8566	24
8567	24
8569	24
8570	24
8571	24
8572	24
8573	24
8574	24
8575	24
8576	24
8577	24
8578	24
8582	9
8583	9
8583	17
8584	9
8586	10
8588	10
8588	11
8589	9
8590	9
8591	9
8592	11
8593	10
8595	9
8596	10
8598	9
8599	11
8600	9
8601	9
8602	9
8604	6
8604	10
8605	10
8606	9
8607	9
8608	10
8609	6
8609	10
8610	10
8611	10
8612	9
8613	9
8614	7
8615	10
8616	9
8617	10
8618	10
8620	10
8621	10
8622	10
8623	10
8624	10
8628	11
8629	10
8630	9
8631	10
8632	7
8633	10
8634	10
8636	10
8637	7
8637	10
8640	9
8642	10
8643	10
8644	10
8645	9
8647	9
8648	9
8649	11
8650	9
8651	9
8653	10
8654	24
8656	10
8657	22
8658	22
8660	9
8661	9
8662	10
8663	11
8665	9
8666	10
8667	9
8675	9
8676	10
8678	6
8678	10
8679	10
8680	9
8681	10
8683	9
8684	24
8685	6
8685	10
8686	10
8688	22
8689	10
8690	7
8692	7
8694	6
8694	10
8696	9
8697	10
8700	9
8702	10
8703	10
8705	10
8706	10
8707	6
8707	10
8710	22
8712	7
8714	7
8715	10
8716	9
8716	16
8719	10
8720	9
8722	7
8723	10
8724	10
8726	10
8727	9
8729	9
8730	10
8733	7
8733	10
8735	9
8736	9
8737	10
8738	9
8739	9
8741	22
8742	9
8746	11
8748	7
8749	9
8750	9
8752	10
8753	7
8754	9
8755	11
8756	10
8757	10
8758	11
8759	7
8760	10
8761	7
8762	9
8763	10
8764	6
8764	10
8765	10
8766	9
8767	10
8770	22
8774	9
8777	9
8778	10
8780	10
8781	10
8782	7
8782	10
8783	10
8784	9
8787	7
8787	11
8790	6
8790	10
8791	10
8792	7
8793	6
8793	10
8794	9
8797	9
8798	10
8799	9
8800	9
8801	22
8802	10
8803	11
8804	10
8805	9
8806	10
8807	22
8808	9
8813	9
8814	9
8815	22
8816	22
8817	22
8818	9
8819	22
8820	22
8821	11
8822	10
8823	9
8824	9
8825	9
8826	10
8828	6
8828	10
8829	10
8830	10
8831	9
8832	9
8834	10
8835	10
8837	10
8838	10
8839	9
8840	9
8841	10
8842	10
8844	22
8847	9
8848	10
8849	11
8850	11
8851	22
8852	22
8853	7
8854	22
8857	22
8858	22
8859	10
8861	11
8862	10
8863	9
8864	9
8865	10
8867	10
8869	10
8870	10
8872	10
8873	10
8874	6
8874	10
8875	9
8876	9
8877	10
8878	10
8889	9
8890	10
8892	9
8893	9
8894	10
8895	10
8896	9
8897	9
8898	10
8899	11
8900	9
8901	10
8903	7
8903	10
8906	11
8907	9
8908	9
8909	6
8909	10
8910	9
8911	10
8912	11
8913	7
8913	11
8914	6
8914	10
8915	9
8916	9
8917	2
8917	24
8918	6
8918	10
8919	4
8919	11
8923	9
8924	10
8925	7
8927	10
8928	6
8928	10
8929	10
8930	9
8931	9
8932	6
8932	10
8933	11
8934	11
8935	10
8936	10
8937	10
8938	9
8939	7
8940	6
8940	10
8941	6
8941	10
8942	7
8944	9
8945	10
8946	10
8947	9
8948	11
8949	9
8950	9
8951	10
8952	9
8953	7
8954	10
8955	10
8956	9
8957	7
8959	9
8960	9
8961	9
8962	9
8963	9
8966	10
8967	7
8970	10
8971	10
8972	11
8973	9
8976	10
8977	11
8978	9
8979	9
8979	25
8980	10
8983	9
8984	9
8985	10
8986	10
8987	11
8988	22
8989	10
8990	6
8990	11
8992	10
8993	10
8994	9
8994	13
8995	9
8995	13
8996	9
8997	7
8998	10
8999	9
8999	10
9001	11
9002	10
9003	10
9004	10
9005	9
9007	9
9008	2
9008	9
9010	7
9011	9
9013	9
9018	10
9019	11
9020	10
9021	11
9022	9
9024	10
9026	7
9027	10
9028	11
9029	11
9030	9
9031	9
9032	6
9032	9
9033	6
9033	10
9034	10
9035	10
9036	9
9037	10
9038	10
9039	9
9040	10
9040	16
9041	9
9042	10
9043	6
9043	10
9045	10
9046	9
9047	9
9048	10
9049	9
9050	9
9052	9
9053	9
9054	10
9055	10
9056	6
9056	9
9057	14
9059	10
9063	11
9064	10
9065	9
9066	17
9066	24
9067	9
9069	27
9070	22
9071	14
9072	9
9073	9
9074	9
9075	11
9076	7
9078	10
9079	10
9080	10
9082	7
9084	10
9086	10
9087	10
9088	9
9091	7
9092	11
9093	9
9094	10
9095	10
9096	9
9097	6
9097	10
9098	2
9098	9
9099	10
9100	9
9101	6
9101	10
9104	6
9104	9
9106	7
9106	9
9109	7
9112	6
9112	10
9113	10
9116	6
9116	9
9117	22
9118	9
9119	10
9120	10
9121	9
9122	9
9125	9
9126	10
9127	10
9128	22
9130	22
9131	22
9132	9
9133	10
9134	22
9135	9
9141	9
9142	22
9143	10
9144	22
9147	9
9149	9
9150	9
9151	22
9152	22
9153	22
9154	22
9155	22
9156	22
9157	22
9158	22
9159	22
9160	22
9161	22
9162	22
9163	22
9164	22
9165	22
9166	22
9167	22
9168	22
9169	22
9170	22
9171	22
9172	22
9173	10
9174	22
9175	22
9176	7
9177	22
9178	22
9179	22
9180	22
9181	22
9182	22
9183	22
9184	22
9185	22
9186	22
9187	22
9188	22
9189	22
9190	22
9191	22
9192	22
9193	22
9194	22
9195	22
9196	22
9197	22
9198	22
9199	7
9200	22
9201	22
9202	22
9203	22
9204	22
9205	22
9206	22
9207	22
9208	22
9209	22
9210	22
9211	22
9212	22
9213	22
9214	22
9215	22
9216	22
9217	22
9218	22
9219	22
9220	22
9221	22
9222	22
9223	22
9224	10
9225	22
9227	10
9228	22
9229	22
9230	22
9231	22
9232	22
9234	9
9234	22
9235	22
9236	22
9238	22
9239	22
9240	22
9241	10
9242	22
9243	22
9244	22
9245	22
9246	22
9247	22
9248	7
9249	22
9250	22
9251	22
9252	22
9253	22
9254	22
9255	22
9256	22
9257	22
9258	11
9259	22
9261	25
9262	22
9263	6
9263	9
9264	22
9265	22
9266	22
9267	7
9268	22
9269	22
9270	22
9271	22
9272	22
9273	22
9274	22
9275	22
9276	22
9277	22
9278	22
9279	9
9280	9
9282	9
9284	22
9285	22
9286	10
9287	9
9288	9
9289	10
9290	10
9291	10
9293	9
9294	10
9295	10
9296	7
9297	10
9298	9
9299	10
9300	10
9301	10
9302	10
9303	9
9304	10
9305	10
9306	6
9306	10
9307	9
9308	10
9309	10
9310	22
9314	10
9315	7
9316	9
9317	9
9318	11
9319	9
9320	9
9321	9
9322	9
9323	9
9326	9
9327	9
9328	9
9329	9
9330	9
9331	9
9332	9
9333	9
9334	11
9335	9
9336	9
9337	9
9338	9
9340	9
9341	9
9342	9
9343	9
9344	9
9345	9
9346	10
9347	9
9348	9
9351	9
9352	9
9353	9
9355	9
9358	9
9359	9
9360	9
9361	9
9362	9
9365	9
9366	9
9367	9
9368	9
9369	9
9370	9
9371	9
9372	9
9373	9
9374	9
9375	9
9376	9
9377	9
9378	9
9379	9
9381	10
9382	9
9383	9
9384	10
9385	9
9386	9
9387	9
9388	9
9389	10
9390	10
9391	9
9392	9
9394	9
9398	9
9401	10
9402	10
9403	10
9404	10
9405	10
9406	10
9407	10
9408	9
9409	10
9410	9
9411	9
9412	9
9413	9
9414	9
9415	10
9416	10
9418	9
9419	6
9419	10
9420	9
9421	9
9422	11
9423	10
9425	10
9426	10
9427	10
9428	9
9429	9
9430	9
9431	9
9432	9
9433	9
9434	9
9435	9
9437	9
9438	9
9439	9
9440	9
9441	9
9442	9
9443	9
9444	9
9445	9
9446	9
9447	9
9448	9
9449	9
9450	9
9451	9
9452	9
9453	9
9454	9
9455	9
9457	9
9458	9
9458	17
9459	9
9460	9
9462	9
9463	6
9463	9
9464	9
9466	10
9467	10
9468	7
9469	10
9471	10
9472	10
9473	10
9477	9
9479	9
9480	9
9480	21
9481	9
9482	9
9483	7
9483	9
9484	10
9485	9
9486	7
9486	9
9489	9
9490	9
9492	10
9493	9
9494	9
9495	22
9496	7
9497	10
9498	9
9500	7
9503	10
9516	9
9517	6
9517	24
9518	9
9519	9
9520	9
9522	24
9523	10
9524	9
9525	6
9525	10
9526	10
9527	11
9528	9
9529	9
9530	7
9531	6
9531	9
9533	10
9534	9
9535	6
9535	9
9536	9
9537	10
9539	10
9540	9
9542	10
9543	9
9544	9
9545	9
9545	22
9546	22
9547	22
9548	22
9549	22
9550	22
9551	9
9553	9
9554	7
9555	9
9556	9
9558	7
9558	10
9559	6
9559	10
9560	9
9561	10
9563	9
9563	13
9564	9
9565	3
9565	9
9566	7
9567	22
9568	7
9569	10
9570	9
9571	9
9572	7
9573	10
9574	7
9575	10
9576	10
9577	9
9579	7
9581	10
9582	9
9584	9
9585	7
9586	7
9588	7
9588	10
9592	6
9592	9
9597	10
9598	7
9599	10
9600	9
9602	10
9603	10
9604	9
9605	9
9607	10
9608	10
9609	10
9610	7
9610	10
9613	9
9614	10
9615	7
9618	7
9622	10
9623	7
9624	11
9625	9
9626	9
9627	9
9628	9
9631	9
9632	10
9634	9
9634	10
9635	9
9636	9
9637	9
9638	7
9640	7
9641	9
9642	10
9643	9
9645	9
9646	9
9647	9
9648	9
9650	9
9651	10
9652	9
9653	9
9654	10
9655	7
9656	9
9658	10
9659	10
9660	6
9660	9
9661	9
9663	7
9665	7
9666	7
9667	9
9669	9
9670	9
9673	9
9674	9
9675	9
9676	10
9677	9
9678	9
9679	11
9681	9
9682	9
9684	9
9685	9
9686	9
9687	9
9687	16
9689	9
9690	9
9691	9
9692	3
9692	9
9693	9
9694	9
9695	9
9697	9
9697	16
9698	7
9699	7
9700	9
9701	9
9702	9
9703	9
9704	7
9705	9
9706	9
9707	9
9708	10
9709	10
9710	10
9711	7
9712	10
9713	10
9714	10
9715	10
9716	10
9719	6
9719	7
9721	10
9722	9
9723	10
9724	9
9725	3
9725	9
9725	21
9727	10
9728	10
9729	6
9729	10
9730	9
9731	24
9732	10
9735	10
9736	10
9738	10
9739	6
9739	10
9741	7
9742	6
9742	10
9743	10
9745	7
9746	7
9747	10
9748	10
9749	10
9750	9
9751	6
9751	10
9752	7
9753	9
9754	10
9755	9
9756	10
9757	9
9758	10
9759	10
9760	10
9761	6
9761	10
9762	9
9763	10
9764	9
9765	10
9766	10
9767	10
9768	10
9769	10
9770	10
9771	10
9772	6
9772	9
9773	10
9774	9
9775	9
9776	10
9777	6
9777	10
9778	10
9779	9
9781	10
9782	9
9783	9
9784	10
9785	10
9786	10
9787	9
9788	10
9789	10
9790	10
9791	10
9792	10
9793	10
9794	10
9795	10
9796	10
9797	22
9798	6
9798	9
9799	9
9800	9
9801	9
9803	9
9804	9
9805	9
9807	9
9808	9
9810	9
9811	9
9812	9
9813	9
9814	9
9815	9
9816	9
9817	9
9818	9
9819	9
9820	9
9821	9
9822	9
9823	9
9824	9
9825	9
9826	9
9827	9
9828	9
9829	9
9830	9
9831	9
9832	9
9833	9
9834	9
9835	9
9836	9
9837	9
9838	9
9839	9
9840	9
9841	9
9842	9
9843	9
9844	9
9845	9
9846	9
9847	9
9848	9
9849	9
9850	9
9851	9
9852	9
9853	9
9854	9
9855	9
9856	9
9857	9
9858	9
9860	9
9861	9
9862	9
9863	9
9864	9
9865	9
9866	9
9867	9
9868	9
9869	9
9870	9
9871	9
9872	9
9873	9
9874	9
9875	9
9876	9
9877	9
9878	9
9879	9
9880	9
9881	9
9882	9
9883	7
9884	10
9886	9
9887	9
9888	9
9889	9
9890	9
9891	9
9892	9
9893	9
9894	9
9895	11
9897	7
9899	9
9902	6
9902	9
9903	9
9904	9
9905	6
9905	9
9906	9
9907	9
9908	9
9909	7
9912	9
9913	9
9914	9
9915	7
9915	10
9917	22
9918	22
9919	22
9920	22
9923	10
9924	10
9925	10
9926	11
9927	9
9927	16
9928	24
9929	10
9930	9
9931	9
9933	9
9934	10
9935	10
9936	10
9937	9
9938	9
9939	10
9940	10
9943	9
9944	9
9946	10
9947	9
9948	9
9948	11
9949	6
9949	10
9951	10
9952	10
9953	7
9954	9
9955	9
9956	9
9957	9
9958	7
9958	10
9959	10
9960	9
9961	10
9962	24
9963	9
9964	10
9965	10
9966	10
9967	10
9968	10
9969	10
9970	9
9971	10
9973	10
9974	22
9975	7
9976	9
9977	10
9978	22
9979	9
9981	7
9983	10
9985	7
9986	9
9989	6
9989	10
9990	10
9991	10
9992	9
9993	10
9994	6
9994	10
9995	9
9996	7
9997	22
9998	22
9999	22
10000	22
10002	22
10004	22
10005	22
10007	22
10008	10
10009	22
10010	22
10011	22
10013	22
10014	22
10015	22
10016	22
10017	22
10018	22
10019	22
10020	22
10021	22
10022	9
10023	22
10024	22
10025	22
10026	22
10027	22
10029	22
10030	22
10031	22
10032	22
10033	22
10034	22
10036	22
10037	22
10038	22
10039	22
10040	22
10041	22
10042	22
10043	22
10044	22
10045	10
10046	22
10047	22
10048	22
10049	10
10050	11
10052	22
10053	10
10054	22
10055	22
10058	22
10060	22
10061	7
10062	22
10064	22
10065	22
10067	22
10069	22
10070	22
10071	22
10072	22
10074	22
10075	22
10076	22
10077	22
10078	22
10079	22
10081	10
10082	22
10084	10
10086	22
10087	22
10088	22
10089	22
10090	22
10091	22
10095	22
10096	22
10097	22
10098	22
10099	9
10100	22
10101	22
10102	22
10103	22
10104	22
10106	22
10107	22
10108	22
10109	22
10110	22
10111	22
10114	22
10115	22
10116	22
10117	22
10118	22
10119	22
10120	22
10121	9
10122	22
10123	22
10124	22
10125	25
10126	9
10126	27
10127	22
10129	25
10130	25
10131	25
10132	27
10133	27
10134	27
10135	25
10136	25
10137	25
10138	25
10139	21
10139	25
10140	25
10141	25
10142	25
10143	22
10144	10
10145	10
10146	25
10147	25
10148	28
10149	11
10149	25
10152	27
10153	25
10155	27
10156	27
10157	26
10158	25
10159	25
10160	25
10161	25
10162	22
10163	22
10165	22
10166	22
10167	22
10168	22
10169	22
10170	22
10171	22
10172	22
10173	22
10174	22
10175	22
10176	22
10177	22
10179	22
10181	22
10182	22
10183	22
10184	22
10185	22
10186	22
10187	22
10188	22
10189	22
10190	10
10191	22
10192	22
10193	22
10194	22
10195	22
10196	22
10197	22
10198	22
10199	22
10200	22
10201	22
10202	22
10203	22
10204	22
10205	22
10206	22
10208	22
10210	22
10211	22
10212	22
10213	22
10214	22
10215	22
10216	22
10217	25
10220	24
10221	9
10222	9
10224	10
10226	9
10227	10
10228	9
10229	9
10230	9
10231	9
10232	10
10233	9
10234	9
10235	10
10236	9
10237	10
10238	10
10239	9
10240	9
10241	9
10243	10
10245	9
10246	9
10247	9
10249	24
10250	9
10251	11
10252	9
10253	9
10254	10
10256	10
10257	10
10258	27
10259	27
10260	25
10261	25
10262	25
10263	25
10265	10
10266	6
10266	10
10267	9
10268	10
10269	7
10270	10
10271	22
10272	9
10273	7
10274	9
10277	9
10278	9
10279	9
10280	9
10281	9
10281	21
10282	9
10283	9
10284	10
10285	9
10286	9
10287	9
10288	9
10289	9
10291	9
10291	13
10292	10
10293	9
10294	9
10295	9
10295	16
10296	9
10297	9
10298	9
10300	9
10301	9
10302	9
10302	13
10303	9
10304	9
10305	9
10306	7
10306	10
10307	9
10308	9
10309	9
10310	9
10312	9
10313	9
10314	9
10315	9
10316	9
10318	9
10319	9
10321	10
10322	10
10323	9
10325	9
10326	9
10327	10
10327	18
10328	9
10329	9
10330	9
10331	10
10332	9
10333	9
10335	9
10336	9
10336	16
10337	9
10337	13
10339	7
10339	10
10340	7
10341	10
10342	10
10343	7
10344	7
10345	7
10346	10
10347	10
10348	10
10349	11
10349	18
10350	7
10351	11
10352	11
10353	7
10354	7
10354	10
10355	7
10356	10
10358	10
10359	10
10360	10
10361	10
10362	7
10363	7
10364	7
10365	10
10366	7
10367	7
10368	10
10369	10
10370	7
10371	11
10372	10
10373	10
10374	7
10374	11
10375	6
10375	10
10376	10
10377	7
10378	10
10379	10
10380	10
10381	7
10382	10
10383	10
10384	10
10385	7
10386	10
10387	10
10388	10
10389	10
10390	10
10391	10
10392	7
10393	10
10393	18
10394	6
10394	7
10395	10
10396	10
10397	7
10398	6
10398	10
10399	7
10400	7
10401	10
10401	18
10402	11
10406	7
10406	18
10407	9
10408	7
10408	10
10409	7
10410	10
10411	10
10412	6
10412	10
10413	10
10414	10
10415	6
10415	10
10416	11
10416	13
10417	10
10418	7
10419	10
10420	10
10421	10
10422	6
10422	10
10423	7
10424	10
10425	10
10426	10
10427	10
10428	10
10429	10
10430	10
10431	10
10432	10
10433	10
10434	7
10435	7
10436	6
10436	10
10437	7
10438	6
10438	10
10439	11
10440	10
10441	10
10442	6
10442	10
10443	10
10444	10
10444	25
10445	10
10446	10
10447	6
10447	10
10448	10
10449	10
10450	10
10451	7
10452	10
10453	10
10454	10
10455	10
10456	10
10457	10
10458	6
10458	10
10459	10
10460	10
10461	10
10462	10
10463	10
10464	10
10465	10
10466	10
10467	10
10468	11
10470	7
10471	10
10472	7
10472	10
10473	10
10474	7
10475	7
10476	10
10477	7
10477	10
10478	10
10479	11
10480	10
10481	10
10482	10
10483	10
10486	10
10487	7
10488	7
10489	7
10490	7
10491	10
10492	6
10492	7
10493	10
10494	10
10495	7
10496	10
10497	10
10498	10
10499	11
10500	10
10500	18
10501	7
10502	7
10503	6
10503	10
10504	10
10505	6
10505	10
10506	7
10507	10
10508	7
10509	10
10510	7
10511	11
10512	7
10512	10
10513	10
10514	11
10515	6
10515	10
10516	7
10517	6
10517	7
10518	7
10519	7
10520	11
10521	6
10521	10
10522	7
10523	7
10524	10
10525	10
10526	11
10527	7
10528	10
10530	6
10530	11
10531	10
10532	10
10533	9
10534	9
10535	9
10536	9
10537	9
10538	9
10539	9
10540	9
10542	9
10543	9
10544	9
10545	9
10547	9
10548	9
10549	9
10552	9
10553	9
10554	9
10555	9
10556	9
10557	9
10558	9
10559	9
10560	10
10561	9
10562	7
10563	9
10564	9
10565	9
10566	9
10567	9
10568	9
10569	9
10570	9
10571	9
10572	9
10573	9
10574	9
10575	11
10576	9
10577	9
10578	9
10579	10
10580	9
10581	9
10582	9
10583	9
10584	9
10585	10
10586	9
10587	9
10588	10
10589	9
10590	9
10591	9
10592	9
10593	9
10594	9
10595	9
10596	9
10597	2
10597	9
10598	9
10599	9
10600	9
10601	9
10602	9
10603	9
10604	9
10605	9
10606	9
10607	9
10608	9
10609	9
10610	9
10611	9
10612	9
10613	9
10614	9
10615	9
10616	9
10617	9
10618	9
10619	9
10620	9
10621	9
10622	9
10623	9
10624	9
10625	9
10626	9
10627	9
10628	9
10629	9
10630	9
10631	9
10632	9
10633	9
10634	9
10635	9
10636	9
10637	9
10638	9
10639	9
10640	9
10641	9
10642	9
10643	9
10644	9
10645	9
10646	9
10647	9
10648	9
10649	9
10650	9
10651	9
10652	9
10653	9
10654	9
10655	9
10656	9
10657	9
10658	9
10659	9
10660	9
10661	9
10662	9
10663	9
10664	9
10665	9
10666	9
10667	9
10668	10
10669	9
10670	9
10671	9
10672	9
10674	9
10675	9
10676	9
10677	9
10678	9
10679	9
10680	9
10681	9
10682	9
10683	9
10684	9
10686	9
10687	9
10688	9
10689	9
10690	9
10691	9
10692	9
10693	9
10694	9
10695	9
10696	9
10697	9
10698	9
10699	9
10700	9
10701	9
10703	9
10704	9
10705	9
10706	9
10707	9
10708	9
10709	9
10710	9
10711	9
10712	9
10713	9
10714	9
10715	9
10716	9
10717	9
10718	9
10719	9
10720	9
10721	9
10722	9
10723	9
10724	9
10725	9
10726	9
10727	9
10728	9
10729	9
10730	9
10732	9
10733	9
10734	9
10735	9
10736	9
10737	9
10738	9
10739	22
10740	9
10741	9
10742	22
10743	10
10745	22
10746	22
10747	22
10748	22
10749	22
10750	7
10751	22
10752	22
10753	22
10754	22
10755	22
10756	22
10757	10
10758	10
10759	10
10760	10
10761	10
10762	24
10763	10
10765	9
10766	9
10767	9
10768	22
10769	9
10770	10
10771	10
10772	9
10773	10
10775	9
10777	11
10778	10
10779	9
10780	10
10782	9
10784	6
10784	10
10785	7
10785	10
10786	9
10787	6
10787	11
10788	22
10789	22
10790	22
10791	9
10791	21
10792	10
10793	10
10794	7
10796	9
10797	9
10798	9
10800	7
10801	9
10802	10
10803	9
10804	10
10805	10
10806	7
10807	7
10808	7
10808	10
10810	10
10813	9
10814	9
10815	22
10816	7
10817	10
10818	9
10818	24
10819	10
10823	10
10824	10
10825	10
10826	10
10827	10
10828	10
10829	6
10829	7
10829	10
10830	10
10831	10
10832	10
10833	7
10834	10
10836	10
10837	10
10838	10
10839	10
10840	10
10841	10
10843	10
10844	10
10847	10
10848	10
10849	7
10850	10
10852	9
10853	9
10854	9
10855	9
10856	10
10857	9
10858	7
10859	10
10860	10
10862	10
10863	9
10864	7
10865	10
10866	10
10867	10
10868	9
10869	9
10870	9
10872	7
10873	9
10874	9
10875	10
10876	9
10878	7
10878	10
10879	9
10880	10
10881	9
10882	9
10883	10
10884	10
10885	9
10886	7
10888	11
10889	10
10890	10
10891	10
10892	9
10893	9
10894	7
10895	10
10896	10
10897	10
10898	10
10899	10
10900	10
10901	9
10902	9
10903	9
10904	10
10905	9
10906	9
10907	9
10910	10
10911	9
10912	10
10913	10
10914	9
10915	9
10916	9
10917	10
10918	9
10919	10
10921	10
10922	9
10923	9
10924	6
10924	10
10926	10
10927	9
10928	10
10929	9
10930	7
10931	10
10932	10
10933	10
10934	9
10936	9
10937	9
10938	9
10939	10
10940	7
10940	10
10941	9
10942	9
10943	7
10944	9
10945	9
10946	9
10947	9
10948	10
10949	10
10950	10
10951	10
10953	9
10954	9
10955	10
10958	10
10960	9
10961	9
10962	11
10963	9
10964	9
10968	9
10969	9
10970	9
10971	9
10972	9
10973	9
10974	9
10975	7
10976	10
10978	9
10979	7
10982	10
10983	10
10984	7
10984	10
10985	10
10986	10
10987	7
10987	10
10988	10
10989	10
10990	10
10991	10
10992	10
10993	10
10995	10
10996	10
10997	7
10998	10
10999	11
11001	10
11002	10
11003	7
11004	7
11006	7
11007	10
11008	10
11009	6
11009	10
11010	10
11012	7
11013	7
11014	11
11015	10
11016	7
11017	10
11018	10
11020	10
11021	11
11022	7
11023	6
11023	10
11025	10
11025	18
11026	7
11029	7
11030	7
11032	7
11033	6
11033	10
11034	7
11035	7
11036	11
11037	11
11038	10
11039	10
11040	7
11041	7
11042	10
11043	10
11044	10
11045	10
11046	10
11047	10
11048	11
11049	10
11050	6
11050	10
11051	10
11052	10
11053	10
11054	10
11056	7
11056	10
11057	7
11057	10
11058	10
11059	10
11060	10
11061	7
11062	10
11063	11
11064	7
11065	10
11066	10
11068	7
11068	9
11069	10
11070	7
11071	7
11072	7
11073	10
11074	11
11075	6
11075	10
11076	10
11077	10
11079	6
11079	10
11080	6
11080	7
11081	7
11082	10
11083	7
11084	7
11085	10
11087	10
11088	7
11089	10
11090	10
11091	7
11092	10
11093	10
11094	7
11095	6
11095	10
11097	10
11098	10
11099	10
11100	7
11101	10
11102	7
11102	18
11103	6
11103	10
11104	7
11105	7
11106	7
11107	9
11107	10
11108	10
11109	7
11111	7
11112	10
11114	10
11115	10
11116	10
11117	7
11118	10
11119	10
11120	10
11121	7
11122	10
11124	7
11125	10
11126	10
11127	10
11128	9
11129	10
11130	7
11131	7
11132	6
11132	10
11133	10
11134	10
11135	10
11136	7
11137	10
11138	10
11139	11
11140	7
11141	11
11142	10
11143	10
11144	6
11144	10
11145	7
11146	10
11147	10
11148	10
11149	7
11150	7
11151	11
11152	6
11152	10
11155	7
11156	9
11157	9
11158	11
11159	7
11159	11
11160	10
11161	10
11163	7
11164	10
11165	10
11166	7
11167	10
11168	11
11169	7
11170	10
11171	10
11172	7
11172	18
11173	10
11174	10
11175	10
11176	7
11177	7
11177	13
11177	18
11178	10
11179	10
11180	10
11181	7
11182	11
11183	6
11183	10
11185	10
11186	7
11187	10
11188	9
11188	10
11189	10
11189	18
11190	6
11190	10
11191	11
11192	11
11193	7
11194	7
11195	10
11196	7
11197	7
11198	7
11199	10
11200	10
11204	10
11205	10
11206	10
11207	10
11208	7
11209	7
11210	10
11211	10
11212	10
11214	10
11215	11
11216	10
11217	11
11218	7
11219	6
11219	10
11220	10
11221	6
11221	10
11222	6
11222	9
11224	9
11225	6
11225	11
11226	10
11228	10
11229	7
11230	10
11231	6
11231	10
11233	10
11234	9
11235	9
11236	9
11237	6
11237	10
11238	10
11239	10
11240	7
11241	10
11243	6
11243	10
11244	10
11245	7
11246	10
11247	10
11248	11
11249	10
11250	10
11251	6
11251	10
11252	10
11253	10
11254	10
11255	9
11256	11
11257	9
11258	9
11259	9
11260	9
11261	9
11262	9
11264	9
11265	9
11266	9
11267	9
11268	9
11269	9
11270	9
11271	9
11272	9
11273	9
11274	9
11275	9
11276	9
11277	9
11278	10
11279	9
11280	10
11280	18
11281	9
11282	9
11283	9
11284	11
11285	9
11286	10
11287	6
11287	10
11288	10
11289	9
11290	9
11290	17
11292	9
11293	9
11294	3
11294	9
11295	7
11296	22
11297	22
11298	11
11299	9
11300	9
11302	6
11302	10
11303	9
11303	17
11305	3
11305	9
11306	9
11307	17
11309	11
11310	9
11311	7
11312	9
11313	9
11314	11
11315	10
11316	10
11317	10
11318	9
11319	6
11319	10
11320	9
11321	10
11322	9
11323	9
11324	9
11325	10
11326	9
11327	9
11328	10
11329	9
11330	6
11330	10
11331	9
11332	9
11333	9
11334	9
11336	10
11337	10
11338	10
11339	10
11340	10
11341	7
11342	7
11344	6
11344	10
11345	9
11346	22
11347	22
11348	9
11349	10
11351	7
11352	9
11353	10
11354	9
11355	9
11356	9
11358	11
11359	9
11360	10
11361	9
11363	6
11363	10
11364	9
11365	10
11366	7
11367	10
11368	10
11369	7
11370	7
11370	10
11372	9
11373	7
11374	10
11375	9
11376	9
11377	10
11378	9
11379	10
11380	9
11381	9
11382	10
11383	9
11385	9
11386	9
11387	9
11388	10
11389	9
11390	9
11391	9
11392	9
11393	10
11394	9
11395	9
11396	9
11397	27
11398	9
11399	10
11400	9
11401	9
11402	9
11403	9
11404	9
11405	9
11406	9
11407	9
11408	9
11409	9
11410	9
11411	9
11412	11
11413	9
11414	9
11415	9
11416	9
11417	9
11418	9
11419	9
11420	9
11421	9
11422	9
11423	9
11424	9
11425	9
11426	27
11427	9
11428	15
11429	9
11430	11
11431	9
11432	9
11433	9
11434	9
11435	9
11436	9
11437	9
11438	9
11439	9
11440	9
11441	9
11442	9
11443	9
11444	10
11445	9
11446	9
11447	9
11448	9
11449	9
11450	9
11451	9
11452	9
11453	9
11454	9
11455	10
11456	9
11457	9
11459	9
11460	9
11461	9
11462	9
11463	9
11464	9
11465	9
11466	9
11467	9
11468	9
11469	9
11470	9
11471	9
11473	9
11474	9
11475	9
11476	9
11477	9
11478	9
11479	10
11480	10
11481	9
11482	9
11483	9
11484	9
11485	9
11486	9
11487	9
11488	9
11489	9
11490	9
11491	9
11492	9
11493	9
11494	9
11495	9
11496	9
11497	9
11498	9
11499	9
11500	9
11501	9
11502	9
11503	9
11504	10
11505	9
11506	9
11507	9
11508	9
11509	9
11510	9
11511	9
11512	9
11513	9
11514	9
11515	9
11516	9
11517	9
11518	9
11519	9
11520	9
11521	9
11522	9
11523	9
11524	9
11525	9
11526	9
11527	9
11528	9
11529	9
11530	9
11531	9
11532	9
11533	9
11534	9
11536	9
11537	9
11537	22
11538	9
11539	9
11540	9
11541	11
11542	11
11543	9
11544	9
11545	9
11546	9
11547	9
11548	9
11549	9
11550	7
11551	9
11552	9
11553	9
11554	9
11555	9
11556	10
11557	9
11558	9
11559	9
11560	9
11561	9
11562	9
11563	9
11564	9
11565	9
11566	9
11567	9
11568	9
11569	9
11570	9
11571	9
11572	9
11573	9
11574	9
11575	9
11576	9
11577	9
11578	9
11579	9
11580	9
11581	9
11582	9
11583	9
11584	9
11585	9
11586	9
11587	9
11588	9
11589	9
11590	9
11591	9
11592	9
11593	9
11595	9
11596	9
11597	9
11598	9
11599	9
11600	9
11602	9
11603	9
11604	9
11605	9
11606	9
11607	9
11608	9
11609	9
11610	9
11611	9
11612	9
11613	9
11614	9
11615	9
11616	9
11617	9
11618	9
11619	9
11620	9
11621	9
11622	9
11623	9
11624	9
11624	22
11625	9
11626	9
11627	9
11628	9
11629	9
11630	9
11631	9
11632	9
11633	9
11634	9
11635	9
11636	9
11637	11
11638	9
11639	9
11640	9
11641	9
11642	9
11643	9
11644	9
11645	9
11646	9
11647	9
11648	11
11649	9
11650	9
11651	9
11652	9
11653	9
11654	9
11655	9
11656	9
11657	9
11658	9
11659	9
11660	9
11661	9
11662	9
11663	9
11664	9
11665	9
11666	9
11667	9
11668	9
11669	9
11670	9
11671	9
11672	9
11673	9
11674	9
11675	9
11676	9
11677	9
11678	9
11679	9
11680	9
11681	9
11682	9
11683	9
11684	9
11685	9
11686	9
11687	9
11688	9
11689	9
11690	9
11691	9
11692	9
11693	9
11694	9
11695	9
11696	9
11697	9
11698	9
11699	9
11700	9
11701	9
11702	9
11703	9
11704	9
11705	9
11706	9
11707	9
11708	9
11709	9
11710	9
11712	10
11713	9
11714	9
11715	9
11716	9
11717	9
11718	9
11719	9
11720	9
11721	9
11722	9
11723	9
11724	9
11725	9
11726	9
11727	9
11728	9
11729	9
11730	9
11731	11
11732	9
11733	7
11733	10
11735	3
11735	9
11736	9
11737	9
11738	9
11739	10
11740	9
11741	9
11742	10
11743	10
11744	11
11746	11
11747	9
11748	10
11750	9
11751	9
11752	10
11753	10
11754	11
11755	11
11756	10
11757	10
11758	9
11758	13
11761	9
11762	7
11763	24
11764	9
11765	9
11768	9
11770	10
11771	9
11772	6
11772	10
11774	10
11775	10
11776	10
11777	9
11778	9
11779	9
11780	9
11781	9
11783	9
11784	9
11786	10
11787	10
11788	9
11789	9
11790	10
11791	10
11792	9
11793	9
11794	10
11795	9
11797	10
11798	6
11798	7
11799	10
11800	10
11802	10
11803	10
11804	10
11805	10
11806	9
11807	10
11808	10
11809	9
11811	10
11812	10
11813	9
11815	9
11816	10
11817	9
11818	9
11819	9
11820	9
11821	9
11822	9
11823	10
11824	7
11824	10
11825	10
11826	9
11827	10
11829	7
11830	10
11831	10
11832	10
11839	7
11840	10
11841	9
11842	10
11843	10
11844	10
11846	7
11847	7
11848	9
11849	9
11851	10
11851	18
11852	10
11853	10
11854	10
11855	10
11857	9
11858	10
11860	10
11861	10
11862	10
11863	9
11864	9
11866	10
11867	7
11868	10
11869	9
11870	7
11871	10
11872	10
11873	10
11874	10
11875	10
11876	9
11877	10
11879	10
11880	9
11882	10
11883	9
11884	9
11885	6
11885	9
11887	11
11888	10
11889	10
11890	10
11891	10
11892	7
11893	10
11895	9
11896	7
11897	10
11899	6
11899	10
11901	10
11902	10
11903	10
11904	10
11905	10
11906	10
11907	6
11907	9
11908	9
11909	10
11909	25
11910	10
11911	7
11912	7
11913	7
11914	10
11915	7
11916	6
11916	7
11917	7
11918	11
11919	7
11920	7
11921	7
11922	6
11922	10
11923	10
11924	7
11925	10
11926	10
11927	7
11928	6
11928	10
11929	10
11930	11
11931	10
11932	10
11933	10
11934	6
11934	10
11935	10
11936	10
11937	11
11938	10
11939	11
11940	10
11941	7
11942	10
11943	6
11943	10
11944	10
11945	10
11946	11
11947	7
11948	7
11949	7
11950	10
11951	10
11952	10
11953	10
11954	11
11955	10
11956	10
11957	10
11958	6
11958	10
11959	10
11960	10
11961	6
11961	7
11962	10
11963	10
11964	10
11965	10
11966	10
11967	7
11968	11
11980	7
11981	10
11982	10
11983	10
11984	10
11985	11
11987	10
11988	10
11989	10
11990	10
11991	6
11991	10
11992	11
11992	18
11994	10
11995	10
11996	6
11996	10
11997	10
11998	10
11999	7
12000	10
12000	18
12001	10
12002	10
12003	10
12006	10
12008	10
12008	18
12009	21
12010	11
12011	9
12012	9
12013	9
12014	9
12015	10
12017	10
12018	6
12018	10
12019	9
12020	9
12021	7
12022	9
12022	13
12023	9
12024	10
12025	7
12026	10
12027	10
12028	10
12029	7
12030	7
12030	18
12031	7
12032	10
12033	10
12034	10
12035	9
12036	11
12039	7
12040	10
12041	10
12044	9
12045	10
12047	9
12049	7
12050	9
12051	9
12052	9
12053	9
12054	10
12056	9
12057	9
12059	7
12060	7
12061	9
12062	10
12063	9
12064	11
12065	9
12066	3
12066	9
12067	9
12068	9
12069	9
12070	10
12071	3
12071	9
12072	22
12075	22
12106	10
12167	7
12167	11
12173	9
12219	10
12243	7
12341	21
12467	10
12550	10
12613	10
12613	25
12615	9
12615	25
12616	10
12616	25
12617	10
12617	25
12618	10
12620	10
12621	9
12621	25
12622	10
12622	25
12623	10
12624	9
12625	9
12625	25
12644	9
12644	25
12655	9
12655	25
12656	10
12656	25
12657	10
12668	10
12671	10
12671	25
12672	9
12672	25
12674	6
12674	10
12676	10
12676	25
12677	9
12677	25
12679	10
12680	7
12680	25
12682	10
12683	10
12684	9
12687	10
12736	9
12736	25
12875	10
13150	10
13316	10
13534	10
13536	10
13537	10
13576	9
13680	7
13680	9
13682	10
13689	9
13799	10
13826	10
13927	10
14052	9
14052	25
14053	9
14053	25
14054	9
14054	25
14060	9
14060	25
14061	9
14061	25
14062	9
14062	25
14064	9
14064	25
14066	9
14066	25
14067	9
14067	25
14068	9
14068	27
14069	9
14069	25
14070	9
14070	25
14071	9
14071	25
14072	9
14072	29
14073	9
14073	27
14074	9
14074	25
14075	9
14075	25
14076	9
14076	25
14077	9
14077	25
14078	9
14078	25
14079	9
14079	25
14080	9
14080	25
14081	9
14081	27
14082	9
14082	25
14083	9
14083	25
14084	9
14084	25
14085	9
14085	25
14086	9
14086	25
14087	9
14087	25
14088	9
14088	30
14089	9
14089	31
14090	9
14090	27
14091	9
14091	25
14092	9
14092	25
14093	9
14093	32
14095	9
14095	25
14096	10
14096	32
14097	9
14097	33
14098	9
14098	25
14103	9
14103	34
14105	9
14105	25
14107	9
14107	25
14108	9
14108	25
14109	9
14109	31
14110	11
14110	32
14111	9
14111	25
14112	9
14112	25
14113	9
14113	25
14114	2
14114	9
14115	9
14115	25
14116	9
14116	25
14117	9
14117	25
14118	9
14118	25
14119	9
14119	35
14120	9
14120	25
14121	11
14121	25
14122	9
14122	25
14123	9
14123	25
14124	9
14124	25
14125	9
14125	25
14126	9
14126	29
14127	9
14127	27
14128	9
14128	27
14129	9
14129	36
14130	9
14130	25
14131	9
14131	25
14132	9
14132	25
14133	9
14133	25
14134	9
14134	25
14135	9
14135	25
14136	9
14136	25
14137	9
14137	25
14138	9
14138	25
14139	9
14139	25
14140	9
14140	25
14141	9
14141	25
14142	9
14142	25
14143	9
14143	25
14144	9
14144	27
14144	32
14145	11
14145	25
14146	9
14146	25
14147	9
14147	25
14150	9
14150	25
14151	9
14151	28
14152	9
14152	25
14153	9
14153	29
14155	9
14155	25
14156	9
14156	25
14157	9
14157	25
14158	9
14158	25
14159	9
14159	27
14160	9
14160	25
14161	9
14161	27
14163	9
14163	25
14164	10
14164	25
14165	9
14165	27
14166	9
14166	25
14167	9
14167	25
14168	9
14168	25
14169	9
14169	25
14170	9
14170	25
14171	9
14171	25
14172	9
14172	25
14173	9
14173	25
14174	9
14174	25
14175	9
14175	25
14176	9
14176	27
14178	9
14178	27
14179	9
14179	25
14180	10
14180	25
14181	9
14181	27
14182	9
14182	25
14183	9
14183	25
14184	9
14184	25
14185	9
14185	31
14186	9
14186	25
14187	9
14187	25
14188	9
14188	25
14189	9
14189	25
14190	9
14190	25
14191	9
14191	27
14192	9
14192	25
14193	9
14193	25
14194	9
14194	25
14195	9
14195	25
14196	9
14196	25
14197	9
14197	25
14198	9
14198	25
14199	9
14199	25
14200	9
14200	25
14201	9
14201	37
14202	9
14202	38
14203	9
14203	25
14204	9
14204	25
14205	9
14205	25
14206	9
14206	25
14207	9
14207	25
14208	9
14208	32
14209	9
14209	25
14210	9
14210	25
14211	9
14211	25
14212	9
14212	25
14213	9
14213	25
14214	9
14214	25
14215	9
14215	37
14216	9
14216	25
14217	9
14217	25
14218	9
14218	25
14219	9
14219	25
14220	9
14220	25
14221	9
14221	25
14222	9
14222	25
14223	10
14223	25
14224	9
14224	39
14225	9
14225	39
14226	10
14226	32
14227	9
14227	25
14228	9
14228	25
14229	11
14229	29
14230	9
14230	25
14231	9
14231	25
14232	9
14232	25
14233	9
14233	25
14235	9
14235	25
14236	9
14236	32
14237	9
14237	25
14238	9
14238	40
14239	9
14239	27
14240	9
14240	25
14241	9
14241	25
14242	9
14242	25
14243	9
14243	25
14244	9
14244	25
14246	9
14246	25
14248	9
14248	25
14249	9
14249	25
14250	9
14250	25
14251	9
14251	25
14252	9
14252	25
14253	11
14253	25
14254	9
14254	31
14255	9
14255	25
14256	9
14256	25
14257	9
14257	25
14258	9
14258	25
14259	9
14259	31
14260	9
14260	25
14261	9
14261	25
14262	9
14262	25
14263	9
14263	25
14264	9
14264	25
14265	9
14265	25
14266	9
14266	31
14267	9
14267	25
14268	9
14268	27
14269	9
14269	36
14270	9
14270	31
14271	9
14271	25
14272	7
14272	41
14273	9
14273	25
14274	9
14274	25
14275	9
14275	25
14276	9
14276	25
14277	9
14277	25
14278	9
14278	25
14279	9
14279	25
14280	9
14280	42
14281	9
14281	42
14282	9
14282	27
14283	9
14283	25
14284	9
14284	25
14285	9
14285	27
14286	9
14286	42
14287	9
14287	25
14288	9
14288	25
14289	9
14289	25
14290	25
14291	9
14291	25
14292	9
14292	25
14294	9
14294	39
14295	9
14295	25
14296	2
14296	9
14297	9
14297	25
14298	9
14298	25
14299	9
14299	25
14300	9
14300	25
14301	9
14301	25
14302	9
14302	25
14303	9
14303	25
14304	9
14304	32
14305	9
14305	25
14306	9
14306	29
14307	9
14307	29
14308	9
14308	25
14310	9
14310	25
14311	9
14311	25
14312	9
14312	25
14314	9
14314	32
14315	9
14315	27
14316	9
14316	25
14317	9
14317	25
14318	9
14318	27
14319	9
14319	25
14320	9
14320	25
14321	9
14321	25
14322	9
14322	25
14323	9
14323	25
14324	9
14324	25
14325	9
14325	25
14326	9
14326	25
14327	9
14327	25
14328	43
14329	9
14329	25
14330	9
14330	25
14331	9
14331	25
14332	9
14332	44
14333	10
14333	25
14334	9
14334	25
14335	9
14335	25
14336	9
14336	25
14337	7
14337	25
14338	9
14338	25
14339	9
14339	25
14340	9
14340	25
14341	9
14341	25
14342	9
14342	25
14343	9
14343	25
14344	9
14344	25
14345	9
14345	25
14346	9
14346	42
14347	9
14347	42
14348	9
14348	25
14349	9
14349	25
14350	9
14350	25
14351	9
14351	25
14352	9
14352	25
14353	9
14353	25
14354	11
14354	25
14355	9
14355	25
14356	9
14356	25
14357	9
14357	25
14358	9
14358	25
14359	9
14359	25
14360	9
14360	45
14361	9
14361	45
14362	9
14362	27
14363	9
14363	25
14364	9
14364	25
14365	9
14365	42
14366	9
14366	25
14367	9
14367	25
14368	9
14368	25
14369	9
14369	32
14370	9
14370	32
14371	9
14371	32
14372	9
14372	42
14373	9
14373	25
14374	9
14374	25
14375	9
14375	42
14376	9
14376	42
14377	9
14377	36
14378	9
14378	25
14379	9
14379	25
14380	9
14380	25
14381	9
14381	25
14382	9
14382	25
14383	9
14383	25
14384	9
14384	25
14385	9
14385	25
14386	9
14386	25
14387	9
14387	25
14388	9
14388	42
14389	9
14389	42
14390	9
14390	42
14391	9
14391	25
14392	9
14392	42
14393	9
14393	25
14394	9
14394	25
14395	10
14395	25
14396	10
14396	25
14397	9
14397	46
14398	9
14398	25
14399	9
14399	25
14400	24
14400	28
14401	9
14401	25
14403	9
14403	25
14403	27
14405	9
14405	25
14406	9
14406	25
14407	9
14407	25
14408	9
14408	25
14410	30
14411	9
14411	36
14412	9
14412	25
14413	9
14413	25
14414	9
14414	25
14415	9
14415	25
14416	9
14416	25
14417	9
14417	25
14418	9
14418	25
14419	9
14419	25
14420	9
14420	25
14421	9
14421	27
14422	9
14422	25
14423	9
14423	25
14424	9
14424	27
14425	9
14425	25
14426	9
14426	36
14427	9
14427	25
14428	9
14428	25
14429	9
14429	47
14430	9
14430	27
14431	9
14431	25
14432	9
14432	27
14433	9
14433	27
14434	9
14434	25
14436	9
14436	25
14437	9
14437	25
14438	9
14438	44
14439	9
14439	25
14440	9
14440	25
14441	9
14441	39
14442	9
14442	25
14443	9
14443	25
14444	9
14444	25
14445	9
14445	25
14446	9
14446	25
14447	9
14447	25
14449	11
14449	25
14450	9
14450	25
14451	9
14451	25
14452	9
14452	25
14453	9
14453	25
14454	9
14454	27
14455	9
14455	27
14456	9
14456	25
14457	46
14458	9
14458	25
14459	9
14459	25
14460	9
14460	25
14461	9
14461	25
14462	9
14462	25
14463	9
14463	25
14464	9
14464	25
14465	9
14465	28
14466	9
14466	25
14467	9
14467	25
14468	9
14468	25
14469	9
14469	25
14470	9
14470	48
14471	10
14471	42
14472	9
14472	42
14473	9
14473	27
14474	9
14474	25
14475	9
14475	27
14476	9
14476	25
14477	9
14477	25
14478	9
14478	25
14479	9
14479	25
14480	9
14480	25
14481	9
14481	25
14482	9
14482	25
14483	11
14483	25
14484	9
14484	25
14485	9
14485	25
14486	9
14486	25
14487	9
14487	25
14488	9
14488	25
14489	9
14489	42
14490	9
14490	25
14491	9
14491	25
14492	9
14492	25
14492	40
14494	9
14494	25
14495	9
14495	25
14496	9
14496	25
14497	9
14497	25
14498	9
14498	25
14499	9
14499	40
14500	9
14500	27
14501	9
14501	25
14502	9
14502	27
14503	9
14503	25
14504	10
14504	25
14505	9
14505	25
14506	9
14506	25
14507	9
14507	27
14508	11
14508	25
14509	9
14509	25
14510	9
14510	25
14512	9
14512	25
14513	9
14513	25
14514	24
14514	25
14515	9
14515	25
14516	9
14516	25
14518	11
14518	25
14519	11
14519	25
14520	9
14520	25
14521	9
14521	25
14523	9
14523	25
14524	9
14524	25
14582	6
14661	9
14714	9
14934	37
15397	21
15397	22
15442	10
16293	10
16362	3
16362	9
16496	7
16496	10
16784	10
17902	9
19977	10
21380	11
21402	7
21402	10
21402	11
21640	11
22808	9
138	101
139	101
140	102
142	102
143	102
144	101
145	101
146	102
147	102
149	102
150	101
151	102
152	102
153	102
154	102
155	102
156	101
157	102
158	101
160	102
162	102
163	102
164	102
165	102
166	101
168	101
169	102
170	102
171	102
172	102
173	101
174	102
176	101
177	102
178	102
179	101
180	102
181	102
182	101
185	101
186	101
187	101
188	102
189	101
190	102
191	101
192	102
196	102
197	101
198	101
199	101
200	102
201	101
202	101
203	102
204	101
205	102
207	101
208	101
209	101
210	101
211	102
212	102
215	101
216	101
218	102
219	101
220	101
224	102
225	101
226	102
227	101
228	102
229	101
231	102
232	102
234	102
235	101
236	101
237	102
238	102
239	101
240	102
241	102
242	102
243	102
244	102
245	102
246	102
247	102
249	102
252	102
253	102
254	101
255	101
256	101
257	101
258	101
259	102
261	102
262	102
263	101
264	102
265	102
268	101
269	102
270	101
271	101
273	101
274	101
275	102
276	101
278	102
279	102
280	102
281	102
282	102
283	101
284	101
285	101
286	101
287	102
288	101
289	102
290	102
291	102
293	102
294	102
297	102
298	102
299	101
300	102
301	102
302	102
303	102
304	102
306	101
307	102
308	101
309	102
310	102
311	101
312	102
313	102
314	101
316	102
317	102
318	101
319	101
320	101
322	102
323	101
324	101
325	102
326	102
327	102
329	102
330	102
331	102
332	101
333	102
334	101
336	101
337	101
338	102
339	102
340	102
342	102
343	102
344	102
345	102
346	102
348	101
352	102
353	102
355	101
356	101
357	101
358	102
359	102
360	102
361	102
362	102
363	101
364	102
365	102
366	102
367	102
369	101
370	102
371	102
372	102
373	101
374	101
375	102
377	102
378	102
379	102
380	102
382	102
383	102
384	102
385	102
386	102
387	102
388	101
390	102
391	102
392	102
393	101
394	102
395	102
396	101
399	102
401	101
404	102
405	102
406	102
407	102
408	102
409	101
410	102
411	102
412	102
414	102
415	102
416	102
417	102
418	102
419	101
420	102
421	101
422	101
423	102
424	102
425	101
426	102
427	102
428	101
429	101
430	101
431	101
433	101
434	101
435	102
436	101
438	102
439	101
440	102
441	102
442	101
443	102
444	102
445	102
446	102
447	101
449	101
450	102
452	102
453	102
454	102
455	102
457	102
458	101
459	101
460	101
462	101
463	101
464	101
465	101
466	101
467	102
471	102
473	101
475	101
478	101
479	102
480	101
480	102
481	101
482	101
483	101
486	102
487	102
488	102
489	101
490	102
491	102
492	101
493	102
494	102
495	102
496	102
497	102
498	102
499	101
500	102
501	102
503	102
504	101
505	101
507	101
508	101
509	102
510	102
511	102
512	101
513	101
514	102
515	102
517	101
518	102
519	102
520	102
521	102
522	102
523	102
525	102
526	101
527	101
528	102
529	101
530	101
531	101
535	102
536	101
537	102
538	102
539	101
540	102
543	102
544	101
545	102
547	101
548	101
549	102
551	102
552	101
553	101
554	102
557	101
559	102
560	102
561	101
563	101
564	101
565	102
566	101
567	101
568	102
569	101
571	102
572	101
574	101
575	102
576	102
577	102
578	101
579	102
582	102
585	101
586	101
587	101
589	101
590	101
591	101
593	101
594	101
595	101
596	102
597	102
598	101
599	101
601	102
602	102
604	102
605	102
607	101
608	101
609	101
611	102
612	102
613	102
614	102
615	101
617	101
618	102
619	102
620	102
621	102
623	102
624	101
625	102
626	102
628	101
629	102
630	102
632	102
633	101
634	101
635	102
636	102
637	101
638	102
639	102
640	102
641	102
642	101
643	102
644	102
646	101
648	101
649	102
650	101
652	102
653	102
656	102
657	101
658	102
660	101
661	101
662	101
663	101
664	101
665	102
666	102
667	101
668	101
669	102
670	101
671	101
672	101
673	102
674	101
676	101
677	102
678	102
679	101
680	102
681	101
682	101
683	101
685	102
686	101
687	102
688	102
689	101
690	101
691	102
694	102
696	101
697	101
698	102
699	101
700	101
702	101
703	102
704	101
705	102
706	102
707	102
708	102
709	102
710	102
712	102
713	102
714	101
715	101
716	101
717	101
718	102
719	102
720	102
721	101
722	101
723	102
725	102
726	102
727	102
728	102
729	102
730	101
731	101
732	102
733	102
734	102
735	101
736	101
737	101
738	101
739	101
740	101
741	101
742	102
744	102
746	102
747	101
748	101
749	101
750	101
751	102
752	102
753	101
755	101
758	102
759	102
762	102
763	102
765	102
766	102
767	102
768	102
769	101
770	101
771	102
772	102
773	102
774	102
775	102
776	102
777	102
778	101
779	102
780	102
782	102
783	102
784	101
785	102
786	102
788	102
789	102
790	102
791	102
792	101
793	102
796	102
797	102
798	102
799	102
800	102
801	102
802	101
804	102
805	102
807	101
808	101
809	101
810	101
811	102
812	101
813	102
814	102
815	101
816	102
818	102
819	101
820	102
822	102
824	102
825	102
827	102
829	102
830	102
831	102
833	102
834	102
836	101
837	101
838	101
839	101
840	102
841	101
842	101
843	101
844	102
845	102
846	102
847	102
848	101
849	101
850	102
851	101
852	102
854	101
855	102
856	102
857	101
858	102
859	102
860	101
861	102
862	102
863	102
864	102
865	102
866	102
867	102
869	101
870	102
871	102
873	102
874	102
875	102
876	102
877	102
878	102
879	102
881	102
882	102
883	102
884	102
885	102
886	102
887	101
888	101
890	101
891	102
892	102
893	102
894	102
895	101
896	102
898	101
899	102
900	102
901	102
902	101
903	102
904	101
905	101
906	101
907	102
908	101
909	101
911	101
912	102
913	101
914	102
915	102
916	102
917	101
918	102
919	101
920	102
921	102
922	102
923	102
924	102
925	102
926	102
927	102
928	102
929	102
930	101
931	102
932	102
933	102
934	102
935	102
936	101
937	101
938	102
939	102
940	102
941	101
943	101
944	102
946	102
947	102
948	102
949	101
950	102
951	102
952	101
953	101
954	102
955	101
956	101
957	102
958	101
959	101
960	101
964	101
966	102
967	101
968	102
969	102
970	101
971	101
972	101
973	102
974	101
975	102
977	101
978	102
979	101
981	101
982	101
983	101
984	101
985	102
987	102
988	101
989	102
991	102
992	102
993	102
994	102
995	101
996	102
997	102
998	102
999	102
1000	102
1001	102
1004	101
1006	102
1007	101
1008	102
1010	102
1011	102
1012	102
1013	102
1014	102
1015	102
1016	102
1017	102
1019	102
1021	102
1022	102
1023	102
1024	102
1025	102
1026	102
1027	101
1028	102
1029	102
1031	101
1032	102
1033	102
1034	101
1035	102
1038	101
1039	101
1041	101
1043	102
1044	102
1045	102
1046	102
1048	101
1049	101
1050	102
1051	102
1052	101
1053	101
1054	102
1056	101
1057	101
1059	102
1060	101
1061	101
1066	101
1067	101
1070	102
1073	102
1075	101
1076	102
1078	101
1080	102
1081	102
1082	102
1083	101
1084	102
1085	101
1086	102
1087	102
1089	102
1090	101
1091	102
1092	102
1094	101
1095	101
1096	102
1097	102
1098	101
1099	101
1101	102
1103	101
1104	101
1105	101
1106	101
1108	101
1109	102
1110	101
1111	102
1112	102
1113	102
1114	101
1115	102
1116	102
1117	101
1118	102
1119	102
1120	102
1121	101
1122	101
1124	102
1125	102
1126	102
1127	101
1128	101
1129	102
1130	101
1131	102
1132	102
1133	101
1135	102
1136	101
1137	102
1138	102
1139	102
1140	102
1141	101
1142	102
1143	101
1144	102
1145	102
1146	102
1147	102
1148	101
1149	101
1150	102
1151	101
1152	101
1153	102
1154	102
1155	101
1156	101
1157	101
1158	101
1159	101
1160	101
1161	101
1162	101
1164	101
1165	102
1170	102
1171	102
1172	102
1173	101
1175	101
1176	101
1177	101
1178	101
1179	101
1180	101
1181	101
1182	101
1184	101
1185	101
1187	101
1188	101
1190	101
1191	102
1194	102
1196	102
1197	102
1198	101
1199	101
1200	101
1201	102
1202	102
1203	101
1204	101
1206	101
1208	101
1211	101
1212	101
1213	102
1216	101
1218	101
1219	101
1221	102
1222	101
1223	101
1224	101
1226	101
1227	102
1228	101
1231	101
1232	102
1233	101
1235	102
1236	101
1237	101
1238	102
1240	102
1241	102
1242	101
1243	101
1244	102
1245	102
1246	101
1247	102
1248	102
1249	102
1250	102
1251	101
1252	101
1253	101
1254	102
1255	101
1256	102
1257	101
1259	102
1260	102
1261	102
1262	102
1264	101
1265	101
1266	102
1267	102
1269	102
1270	102
1271	101
1272	101
1273	102
1274	101
1275	102
1277	102
1278	102
1279	102
1280	102
1281	101
1282	101
1283	101
1284	102
1285	102
1286	102
1287	102
1288	101
1289	102
1290	102
1292	101
1293	101
1297	102
1298	101
1299	102
1301	102
1303	102
1304	102
1305	102
1306	101
1307	102
1309	102
1310	102
1311	102
1312	102
1313	102
1314	102
1315	101
1316	102
1317	102
1318	102
1319	101
1320	101
1322	102
1323	101
1325	101
1326	101
1327	102
1328	101
1329	102
1330	101
1332	101
1333	102
1334	102
1335	102
1336	101
1338	101
1339	101
1340	102
1341	101
1342	101
1343	101
1344	102
1345	101
1347	102
1350	101
1354	101
1355	101
1356	101
1357	101
1358	101
1359	102
1360	102
1361	101
1362	102
1363	101
1364	101
1365	102
1366	101
1368	101
1369	101
1371	102
1372	102
1373	101
1374	102
1375	102
1377	101
1378	102
1379	102
1381	102
1382	101
1383	101
1384	101
1387	101
1388	102
1390	101
1392	102
1393	102
1394	101
1395	101
1396	101
1397	101
1398	101
1399	101
1400	102
1401	102
1404	101
1407	102
1408	101
1409	101
1410	101
1411	101
1412	101
1414	101
1415	102
1416	101
1417	101
1418	101
1419	101
1422	101
1423	102
1424	102
1425	102
1426	102
1427	101
1429	102
1430	102
1431	101
1433	102
1435	102
1437	101
1441	102
1442	102
1444	101
1446	102
1447	101
1448	102
1454	102
1455	102
1456	101
1457	101
1458	101
1459	101
1460	101
1461	101
1462	102
1463	101
1464	101
1465	102
1466	101
1467	101
1468	102
1469	101
1470	101
1472	101
1473	101
1475	101
1477	102
1478	101
1479	101
1480	102
1481	101
1482	102
1483	101
1484	101
1486	102
1489	101
1490	101
1491	102
1492	102
1494	102
1495	102
1496	101
1497	102
1499	102
1500	101
1501	101
1502	102
1503	102
1504	101
1505	101
1506	101
1507	101
1508	102
1509	101
1513	101
1514	102
1515	101
1517	102
1518	101
1519	101
1520	101
1521	101
1521	102
1523	102
1524	101
1525	102
1527	102
1528	101
1529	101
1530	102
1531	101
1533	101
1534	101
1535	102
1537	102
1538	102
1539	101
1540	102
1541	101
1542	102
1543	102
1544	101
1545	101
1546	102
1547	102
1548	101
1549	102
1550	102
1551	102
1552	102
1553	102
1555	102
1556	101
1557	102
1558	101
1559	102
1560	101
1561	101
1562	102
1563	101
1564	101
1565	102
1566	101
1567	101
1568	101
1569	101
1570	102
1571	102
1572	101
1574	101
1575	101
1576	101
1577	101
1579	101
1580	102
1581	101
1582	101
1583	101
1584	102
1585	102
1586	102
1587	101
1590	101
1591	101
1592	101
1593	102
1594	101
1595	101
1596	102
1597	102
1598	102
1599	102
1600	101
1601	102
1602	101
1604	102
1605	101
1606	102
1607	101
1608	102
1609	101
1610	102
1612	102
1614	101
1616	102
1617	102
1618	102
1619	102
1620	102
1621	102
1622	101
1623	101
1626	101
1626	102
1627	101
1628	101
1630	102
1631	101
1634	102
1635	102
1636	102
1637	102
1638	102
1639	102
1640	102
1641	101
1642	102
1643	102
1644	101
1649	102
1650	102
1651	101
1652	102
1653	101
1654	101
1655	101
1656	101
1657	101
1658	102
1659	102
1661	102
1663	101
1664	101
1665	102
1666	101
1667	101
1669	101
1670	102
1671	102
1672	102
1674	101
1675	101
1676	102
1677	101
1678	102
1679	102
1680	102
1681	101
1682	102
1683	101
1685	102
1687	102
1688	101
1690	101
1691	102
1692	102
1693	101
1694	101
1695	102
1696	101
1697	101
1698	102
1699	102
1700	102
1701	102
1702	102
1703	102
1704	102
1705	101
1706	102
1707	102
1708	101
1709	102
1710	102
1711	101
1712	101
1713	101
1714	102
1715	102
1716	102
1717	101
1718	101
1719	101
1720	102
1721	102
1722	101
1723	102
1724	102
1725	101
1726	101
1727	101
1728	101
1729	102
1730	102
1731	101
1733	102
1734	102
1735	101
1736	102
1737	102
1738	101
1739	102
1740	102
1741	101
1742	102
1743	102
1744	102
1745	102
1746	102
1747	101
1748	101
1749	101
1750	101
1751	101
1752	102
1753	102
1754	102
1755	102
1756	101
1757	102
1758	102
1759	101
1760	101
1762	102
1763	101
1764	102
1765	102
1766	102
1767	102
1768	102
1769	101
1771	102
1772	102
1773	102
1774	101
1777	102
1778	101
1779	102
1780	101
1781	101
1782	102
1783	101
1784	101
1785	101
1786	101
1787	101
1788	101
1790	101
1791	101
1792	102
1793	102
1794	101
1795	101
1797	101
1799	101
1800	101
1801	101
1802	101
1803	102
1804	101
1805	102
1806	102
1807	101
1808	101
1810	102
1811	102
1812	101
1813	101
1814	102
1815	101
1816	102
1818	101
1819	102
1821	101
1822	102
1823	102
1824	102
1825	101
1826	102
1827	101
1828	101
1829	101
1830	101
1831	101
1833	102
1834	102
1835	102
1837	102
1838	101
1839	101
1840	102
1841	102
1842	101
1843	101
1844	102
1845	101
1848	101
1849	101
1849	102
1850	101
1851	102
1853	102
1854	102
1855	102
1857	101
1859	101
1860	102
1861	102
1862	102
1863	102
1865	101
1867	102
1868	101
1869	101
1870	102
1871	102
1872	102
1873	102
1874	102
1875	102
1876	102
1877	102
1879	101
1880	101
1881	101
1882	102
1883	101
1884	101
1885	102
1886	102
1887	102
1888	102
1889	101
1890	102
1891	101
1892	102
1893	101
1895	102
1897	101
1898	102
1899	102
1900	101
1901	101
1902	102
1903	102
1904	101
1907	101
1909	102
1911	102
1912	102
1913	102
1914	102
1915	101
1916	102
1917	102
1918	102
1919	101
1920	102
1921	101
1922	102
1923	101
1924	101
1925	101
1928	102
1929	101
1930	101
1931	101
1933	102
1934	102
1935	102
1936	102
1938	102
1939	102
1940	101
1941	101
1943	102
1945	102
1947	101
1949	102
1950	101
1951	101
1952	101
1953	102
1954	101
1955	101
1956	102
1957	101
1958	101
1959	101
1960	101
1961	102
1962	102
1963	101
1964	101
1965	102
1966	102
1967	101
1968	101
1969	102
1970	102
1971	102
1972	102
1973	101
1975	101
1976	102
1977	102
1978	101
1979	102
1982	101
1983	102
1984	102
1985	102
1986	101
1987	101
1989	101
1990	101
1991	102
1992	102
1995	102
1996	102
1997	101
1998	102
1999	102
2000	102
2001	101
2002	102
2003	102
2004	101
2005	102
2006	102
2007	102
2008	102
2009	102
2010	102
2011	102
2013	101
2014	101
2015	102
2016	101
2018	101
2019	102
2020	102
2021	101
2022	101
2023	102
2024	101
2026	102
2027	101
2028	102
2030	101
2031	102
2034	102
2035	102
2036	101
2037	101
2038	102
2039	101
2040	102
2041	102
2042	102
2044	102
2045	102
2046	102
2047	102
2048	102
2049	102
2050	102
2051	101
2052	101
2053	102
2054	101
2055	102
2056	102
2057	101
2058	102
2059	102
2060	102
2061	102
2062	102
2063	101
2065	101
2066	102
2067	102
2068	102
2069	101
2070	102
2071	101
2072	102
2073	102
2074	101
2075	101
2076	102
2077	101
2079	102
2080	101
2081	101
2082	101
2083	101
2084	101
2087	101
2089	101
2090	101
2091	101
2093	102
2094	102
2095	101
2096	101
2097	101
2098	102
2099	101
2100	101
2101	101
2102	101
2103	102
2104	102
2105	102
2106	102
2107	102
2110	101
2111	102
2112	101
2113	102
2114	101
2115	102
2116	102
2117	102
2118	101
2119	102
2120	102
2122	102
2128	102
2129	102
2130	102
2131	102
2132	101
2134	102
2135	101
2136	101
2139	102
2140	101
2141	101
2142	101
2143	102
2144	102
2145	101
2146	102
2147	101
2148	102
2149	101
2150	101
2151	102
2153	102
2154	102
2155	102
2156	102
2157	101
2158	101
2159	101
2160	102
2161	101
2162	102
2163	102
2164	102
2165	101
2166	101
2167	101
2168	101
2171	101
2173	102
2174	101
2175	102
2176	102
2180	102
2181	101
2184	102
2187	102
2188	102
2189	102
2190	101
2191	101
2192	101
2193	101
2194	101
2195	102
2196	102
2197	102
2198	102
2199	101
2200	102
2201	102
2202	102
2203	102
2204	102
2205	101
2206	101
2207	101
2208	101
2209	101
2211	102
2212	101
2213	101
2214	102
2215	102
2216	101
2217	101
2219	102
2220	102
2222	102
2224	101
2225	102
2226	101
2227	101
2229	101
2231	101
2232	102
2233	101
2234	101
2235	102
2236	101
2237	101
2238	102
2239	101
2240	101
2241	102
2242	101
2243	101
2244	101
2246	101
2248	102
2249	102
2251	102
2252	102
2254	102
2255	102
2257	102
2258	102
2260	102
2261	102
2262	101
2263	101
2265	102
2266	101
2267	102
2268	102
2269	102
2271	102
2272	102
2274	101
2276	101
2279	101
2280	101
2281	102
2282	102
2283	102
2284	102
2285	102
2286	101
2287	102
2289	102
2290	102
2292	102
2293	102
2294	102
2295	102
2296	101
2297	101
2298	102
2299	102
2300	102
2301	101
2302	102
2304	101
2305	101
2306	102
2307	101
2309	102
2310	102
2311	101
2314	102
2316	101
2317	102
2318	102
2321	101
2322	102
2324	102
2325	102
2327	101
2328	101
2329	102
2330	102
2332	102
2333	101
2334	102
2335	101
2336	101
2337	102
2339	102
2340	102
2341	102
2343	102
2344	102
2345	102
2346	101
2347	102
2348	102
2349	101
2350	102
2351	102
2352	102
2353	102
2354	102
2355	101
2356	101
2358	101
2359	101
2360	101
2361	102
2363	102
2364	102
2365	101
2368	101
2369	101
2370	101
2371	102
2372	101
2373	101
2375	101
2376	102
2377	102
2379	102
2380	102
2381	101
2382	101
2383	101
2384	102
2385	101
2386	102
2387	101
2388	102
2389	102
2390	101
2391	101
2393	102
2394	102
2395	102
2396	102
2398	101
2399	101
2400	102
2401	101
2402	101
2403	101
2404	102
2405	102
2406	101
2407	102
2408	102
2409	101
2414	101
2415	102
2416	101
2417	102
2418	101
2420	102
2421	102
2422	101
2423	102
2424	102
2425	101
2426	101
2427	101
2428	102
2429	101
2431	102
2432	102
2434	101
2437	102
2438	102
2439	101
2440	102
2441	102
2442	101
2443	101
2444	102
2445	101
2450	101
2451	102
2453	101
2454	101
2457	102
2458	101
2459	101
2460	102
2462	101
2465	101
2466	101
2467	102
2469	101
2470	101
2471	101
2472	101
2473	102
2474	102
2476	102
2477	101
2478	102
2479	101
2480	102
2481	101
2482	101
2483	101
2486	102
2487	101
2488	101
2489	102
2490	102
2491	101
2493	102
2494	102
2496	102
2497	101
2498	102
2499	102
2500	102
2501	101
2502	101
2503	102
2504	101
2505	102
2506	102
2509	101
2510	102
2511	101
2512	102
2513	102
2514	102
2515	102
2516	102
2517	102
2519	101
2520	101
2521	102
2522	102
2523	102
2524	101
2525	102
2526	101
2527	102
2528	102
2529	102
2530	102
2531	102
2533	101
2534	102
2535	102
2536	102
2537	102
2538	102
2539	101
2540	101
2541	101
2542	102
2544	102
2545	101
2546	101
2547	102
2548	102
2549	102
2550	102
2551	102
2552	102
2557	101
2560	101
2565	102
2567	101
2569	101
2570	102
2574	102
2575	102
2577	101
2579	102
2581	101
2582	102
2583	102
2584	102
2585	102
2586	102
2587	102
2588	102
2589	102
2590	102
2591	101
2593	102
2594	102
2595	101
2596	101
2597	101
2598	102
2600	101
2601	101
2602	101
2603	101
2604	101
2606	102
2607	101
2608	102
2609	102
2610	101
2611	101
2612	102
2613	102
2614	102
2615	102
2617	102
2620	101
2621	102
2622	102
2623	102
2624	101
2625	102
2626	102
2627	102
2628	102
2630	102
2631	102
2632	102
2633	102
2635	102
2636	101
2637	101
2638	102
2639	101
2640	102
2641	101
2642	102
2643	102
2644	101
2645	101
2646	101
2647	101
2648	102
2649	102
2650	101
2651	101
2652	102
2654	102
2655	101
2656	101
2657	101
2661	101
2662	102
2663	101
2665	102
2666	101
2667	102
2672	102
2673	101
2674	101
2675	102
2676	102
2677	102
2678	101
2679	101
2680	102
2681	101
2683	101
2684	102
2685	101
2686	102
2687	101
2688	102
2689	102
2690	102
2691	102
2692	102
2693	102
2694	102
2696	102
2697	101
2698	102
2700	101
2703	101
2705	101
2707	101
2708	102
2709	102
2710	102
2711	102
2712	102
2713	102
2714	102
2715	101
2716	101
2717	102
2719	102
2720	101
2723	101
2724	102
2729	101
2733	101
2734	101
2735	102
2736	101
2737	101
2738	102
2739	101
2741	101
2744	101
2749	101
2751	101
2753	101
2754	102
2756	101
2757	101
2758	102
2759	102
2760	102
2761	102
2764	101
2765	101
2767	102
2768	102
2769	102
2770	102
2771	102
2772	102
2773	102
2774	102
2775	101
2776	101
2777	101
2778	101
2779	101
2780	101
2781	101
2782	101
2783	101
2784	102
2785	102
2786	102
2787	102
2788	101
2789	101
2792	101
2793	102
2795	101
2796	101
2797	102
2798	101
2799	102
2800	102
2801	102
2802	101
2804	102
2806	102
2807	102
2809	101
2810	102
2811	102
2812	102
2813	102
2814	101
2815	102
2816	102
2817	101
2820	102
2821	102
2822	102
2824	101
2825	102
2826	102
2827	102
2828	101
2829	102
2830	102
2834	101
2835	101
2836	101
2837	101
2841	101
2842	101
2843	101
2844	101
2846	101
2848	101
2850	102
2853	101
2859	101
2861	101
2863	101
2864	101
2866	101
2867	101
2868	101
2869	101
2871	101
2872	102
2874	102
2875	101
2876	102
2877	102
2878	102
2880	101
2881	102
2882	101
2883	102
2889	101
2890	102
2891	102
2892	102
2893	101
2895	102
2896	101
2899	101
2900	102
2902	102
2903	102
2904	101
2905	102
2906	101
2907	101
2909	101
2911	101
2914	102
2915	102
2916	101
2917	101
2918	101
2919	101
2920	101
2921	102
2922	102
2923	102
2924	102
2925	101
2926	101
2927	102
2929	102
2930	102
2931	101
2935	102
2936	102
2937	101
2938	101
2939	101
2941	101
2942	101
2943	102
2945	102
2946	102
2947	102
2948	101
2952	101
2954	102
2955	101
2956	101
2957	101
2958	102
2959	101
2962	101
2964	102
2965	102
2966	102
2967	101
2969	102
2970	101
2971	101
2972	101
2973	102
2975	102
2976	101
2977	101
2978	102
2981	101
2983	101
2985	102
2986	102
2987	102
2989	102
2991	101
2992	102
2993	102
2994	102
2995	102
2996	102
2999	101
3000	102
3001	101
3002	101
3004	102
3005	101
3006	102
3007	101
3008	101
3009	101
3010	102
3011	101
3015	101
3016	101
3017	101
3018	102
3019	101
3020	102
3021	101
3023	101
3024	101
3025	102
3026	102
3028	101
3031	102
3032	101
3035	101
3038	101
3039	101
3041	102
3042	102
3043	102
3044	101
3045	101
3049	101
3050	102
3051	101
3054	102
3055	101
3058	101
3059	101
3060	101
3062	101
3063	101
3064	101
3065	101
3067	101
3068	101
3069	101
3070	102
3072	101
3073	101
3074	101
3075	101
3076	101
3077	102
3078	101
3079	101
3080	102
3082	101
3083	101
3088	101
3090	101
3091	102
3092	102
3093	102
3094	101
3095	101
3096	101
3097	101
3100	102
3101	102
3102	101
3103	101
3104	101
3106	101
3107	101
3108	101
3109	102
3110	101
3111	102
3113	101
3114	101
3115	101
3116	101
3119	102
3120	102
3121	101
3122	101
3124	101
3125	101
3126	101
3128	101
3129	101
3130	102
3131	101
3134	101
3135	102
3136	102
3137	102
3139	102
3140	102
3141	102
3142	102
3143	101
3145	101
3146	102
3147	102
3148	101
3149	101
3150	102
3151	101
3152	101
3153	102
3154	101
3155	102
3156	101
3158	101
3160	101
3161	102
3162	101
3164	101
3167	102
3168	102
3169	102
3170	102
3172	102
3173	101
3174	102
3176	101
3177	101
3178	101
3180	101
3181	102
3182	101
3183	101
3184	102
3186	101
3188	102
3189	101
3190	101
3191	102
3192	101
3193	101
3195	101
3196	101
3197	101
3198	102
3200	101
3201	101
3202	102
3203	101
3204	101
3205	101
3206	101
3207	102
3208	101
3209	101
3210	102
3211	101
3212	102
3213	102
3214	102
3215	102
3219	101
3220	101
3221	102
3222	102
3225	102
3227	102
3228	102
3229	101
3233	101
3234	101
3235	101
3236	102
3237	101
3239	102
3240	101
3241	102
3242	101
3243	102
3244	101
3246	101
3247	101
3248	101
3249	101
3250	102
3251	101
3252	101
3253	101
3255	101
3256	102
3257	101
3258	102
3260	101
3261	102
3262	101
3263	101
3264	101
3265	101
3266	101
3267	101
3268	101
3269	101
3270	102
3271	102
3272	102
3275	102
3276	101
3279	101
3280	102
3281	101
3282	101
3283	101
3284	101
3285	101
3286	102
3287	101
3292	101
3294	101
3295	101
3296	102
3297	101
3298	101
3299	101
3301	102
3302	101
3303	102
3304	101
3305	101
3306	102
3307	101
3308	102
3309	101
3310	101
3311	101
3314	101
3315	101
3316	102
3318	101
3320	101
3321	101
3322	101
3323	101
3325	101
3326	101
3328	101
3330	101
3333	101
3334	101
3335	101
3336	101
3338	102
3339	101
3342	102
3344	101
3346	101
3347	101
3350	101
3353	101
3354	102
3355	101
3356	102
3357	102
3359	101
3360	101
3361	101
3362	102
3363	101
3364	101
3365	101
3367	101
3369	102
3371	101
3372	101
3376	101
3377	101
3378	101
3379	101
3380	101
3381	102
3382	101
3384	101
3385	101
3386	102
3387	101
3388	102
3389	102
3390	101
3391	101
3392	101
3393	102
3394	101
3395	101
3397	101
3398	101
3402	101
3403	101
3406	101
3409	102
3410	101
3412	102
3413	102
3415	101
3417	101
3418	102
3419	101
3421	101
3422	101
3423	101
3424	101
3425	102
3426	102
3427	101
3428	102
3429	101
3430	101
3431	102
3432	101
3435	101
3436	101
3437	102
3438	101
3439	101
3440	101
3442	101
3443	101
3444	102
3445	101
3446	101
3448	101
3449	101
3450	101
3451	102
3452	102
3453	101
3454	101
3455	101
3456	101
3457	101
3458	102
3459	101
3460	101
3461	101
3462	101
3463	101
3464	101
3465	102
3466	101
3467	101
3468	101
3469	101
3470	102
3471	102
3473	101
3474	101
3475	102
3476	102
3477	101
3478	101
3479	102
3480	102
3482	102
3483	102
3484	102
3485	101
3486	102
3487	101
3488	102
3489	101
3490	101
3491	101
3493	102
3494	101
3495	101
3500	102
3503	101
3504	102
3505	102
3506	101
3507	101
3508	102
3509	102
3510	101
3511	101
3512	102
3513	101
3514	101
3515	101
3516	101
3517	101
3518	101
3519	101
3521	101
3522	101
3523	101
3525	101
3526	101
3527	101
3528	101
3530	101
3531	101
3532	101
3534	101
3535	102
3537	101
3538	102
3540	101
3543	101
3544	101
3545	102
3547	101
3548	102
3549	102
3550	101
3551	102
3552	102
3553	101
3557	101
3558	101
3559	102
3560	102
3561	102
3566	101
3568	101
3569	102
3570	102
3571	101
3573	101
3575	102
3578	101
3580	101
3583	102
3584	102
3585	102
3589	101
3590	101
3591	101
3592	101
3596	101
3598	102
3599	101
3600	102
3601	102
3603	101
3605	101
3607	101
3610	101
3611	101
3614	101
3615	101
3618	101
3619	101
3624	102
3625	102
3628	101
3630	102
3631	102
3633	101
3634	101
3635	101
3638	101
3639	102
3641	102
3642	101
3644	101
3645	101
3652	101
3654	101
3655	101
3657	101
3658	102
3659	102
3661	101
3667	101
3670	101
3671	102
3672	101
3673	101
3674	102
3675	102
3676	102
3677	102
3678	101
3680	101
3681	101
3682	101
3683	101
3684	101
3685	101
3686	101
3690	101
3691	102
3695	102
3697	101
3701	102
3702	101
3707	101
3708	101
3709	102
3710	102
3711	101
3713	101
3715	101
3716	102
3717	102
3718	102
3721	102
3722	102
3723	101
3724	101
3726	102
3727	101
3728	101
3730	101
3733	101
3734	101
3735	102
3736	101
3737	102
3740	101
3742	101
3744	101
3746	101
3748	101
3751	102
3757	101
3758	101
3759	102
3762	102
3764	101
3765	101
3766	101
3768	101
3769	102
3772	101
3774	102
3775	102
3779	102
3780	101
3790	101
3791	102
3792	102
3793	101
3795	101
3799	101
3801	101
3821	101
3822	101
3823	101
3824	102
3825	101
3826	102
3827	101
3830	101
3833	101
3834	101
3835	102
3836	101
3838	101
3842	101
3843	102
3844	102
3845	102
3846	102
3847	101
3848	101
3849	101
3850	101
3852	101
3854	102
3860	101
3861	101
3862	101
3864	102
3866	102
3868	101
3872	102
3873	102
3874	101
3875	101
3876	101
3878	101
3880	101
3881	101
3936	101
3938	101
3939	101
3940	101
3941	101
3943	101
3944	101
3945	102
3946	101
3947	101
3949	102
3951	102
3954	101
3955	102
3956	101
3957	102
3958	101
3961	101
3962	101
3968	101
3972	101
3974	102
3978	102
3979	101
3980	101
3981	101
3983	101
3985	101
3986	101
3991	102
3993	101
3995	101
3996	101
3997	101
3999	101
4001	102
4002	101
4006	101
4007	101
4008	102
4047	102
4048	102
4055	101
4057	101
4058	102
4059	102
4060	101
4061	102
4062	101
4063	101
4068	102
4074	101
4074	102
4075	101
4076	102
4078	101
4079	102
4081	101
4081	102
4082	102
4083	101
4084	101
4085	101
4088	101
4090	101
4091	101
4092	101
4093	101
4094	101
4095	101
4096	101
4097	101
4099	101
4100	101
4101	102
4102	102
4103	102
4104	101
4106	101
4110	102
4112	101
4113	101
4114	101
4115	101
4116	101
4117	101
4119	102
4121	101
4122	101
4123	102
4124	102
4125	101
4126	101
4127	101
4128	102
4129	101
4135	101
4136	101
4137	102
4138	102
4139	101
4140	102
4141	101
4143	102
4145	101
4146	102
4147	102
4148	102
4149	101
4150	101
4151	101
4152	101
4153	101
4155	102
4156	101
4157	101
4159	101
4160	101
4161	102
4162	101
4163	101
4164	102
4166	102
4167	101
4168	102
4169	102
4171	101
4172	102
4173	101
4174	101
4178	102
4179	101
4180	101
4183	101
4185	101
4186	102
4187	102
4188	102
4189	101
4190	101
4192	101
4194	102
4196	101
4197	101
4198	102
4201	102
4202	102
4203	101
4207	101
4208	102
4210	101
4211	102
4212	101
4213	101
4214	101
4216	101
4218	102
4219	101
4221	102
4222	101
4224	101
4227	102
4228	101
4229	101
4231	101
4232	101
4233	101
4234	102
4235	102
4236	101
4237	101
4239	102
4241	101
4244	102
4245	102
4248	101
4251	101
4252	101
4253	101
4255	101
4256	101
4258	102
4261	101
4263	101
4264	101
4265	101
4268	102
4270	101
4272	101
4273	101
4275	101
4276	101
4278	101
4280	102
4283	102
4284	101
4285	102
4286	102
4287	101
4288	101
4289	102
4290	101
4291	101
4292	102
4293	101
4296	101
4297	101
4298	102
4299	102
4300	102
4301	101
4302	101
4303	102
4304	101
4305	101
4306	101
4307	101
4308	102
4309	102
4310	101
4312	102
4313	101
4314	101
4315	101
4316	101
4318	101
4319	101
4320	101
4322	101
4323	101
4324	101
4326	101
4327	101
4329	101
4330	102
4331	102
4332	102
4333	101
4334	101
4335	101
4336	102
4337	101
4338	101
4339	101
4340	101
4342	101
4343	101
4345	101
4347	101
4348	101
4349	101
4351	101
4352	101
4355	101
4356	101
4358	102
4359	101
4365	102
4369	102
4370	101
4372	101
4374	101
4375	101
4376	102
4387	102
4388	101
4389	101
4390	101
4391	101
4392	102
4393	101
4394	102
4395	101
4397	101
4399	101
4400	101
4401	101
4402	101
4403	101
4404	102
4405	102
4406	101
4408	101
4409	102
4411	101
4412	102
4413	102
4414	101
4415	102
4416	102
4418	101
4419	101
4420	102
4422	101
4423	101
4424	101
4425	101
4426	101
4427	102
4428	102
4430	101
4431	101
4433	101
4435	101
4439	101
4440	102
4442	101
4443	101
4444	101
4445	102
4447	102
4449	101
4450	102
4451	101
4452	102
4453	102
4456	101
4457	101
4460	101
4461	101
4462	101
4463	101
4464	102
4466	101
4467	101
4469	102
4470	101
4472	101
4474	101
4475	102
4476	101
4477	102
4478	101
4479	101
4480	101
4481	102
4482	101
4483	101
4484	101
4486	101
4487	101
4488	101
4489	101
4490	101
4491	101
4492	102
4494	102
4496	101
4497	101
4498	101
4499	102
4500	101
4501	102
4502	101
4503	101
4504	101
4505	101
4506	101
4507	102
4510	102
4511	101
4512	101
4513	101
4515	102
4516	101
4517	101
4520	102
4521	102
4522	101
4523	102
4524	101
4527	102
4528	101
4531	101
4532	101
4533	101
4535	101
4536	101
4538	101
4539	101
4540	101
4542	102
4543	101
4544	102
4545	101
4546	102
4547	102
4549	102
4550	101
4551	102
4554	101
4558	101
4560	101
4561	102
4562	101
4563	102
4564	102
4565	102
4566	102
4567	102
4568	101
4569	101
4570	101
4571	101
4572	101
4573	101
4574	101
4575	101
4576	101
4577	101
4578	101
4579	101
4580	101
4581	101
4582	101
4583	101
4586	101
4588	102
4589	101
4590	101
4592	102
4594	101
4595	101
4599	101
4602	101
4603	101
4605	101
4606	101
4609	101
4610	102
4612	102
4614	101
4616	101
4617	101
4620	101
4621	101
4622	101
4623	101
4624	101
4627	101
4628	101
4629	101
4631	101
4632	101
4633	102
4634	101
4635	101
4637	101
4639	101
4640	101
4641	102
4642	101
4644	102
4645	101
4646	101
4647	102
4648	101
4649	102
4650	101
4651	101
4655	101
4656	101
4657	101
4660	102
4661	101
4664	101
4665	102
4669	101
4671	102
4672	101
4673	102
4674	101
4675	101
4676	101
4677	102
4678	101
4679	101
4680	101
4681	101
4682	101
4683	101
4684	101
4685	101
4686	101
4687	102
4688	101
4689	101
4690	101
4691	101
4692	101
4693	101
4694	101
4695	101
4696	101
4697	101
4700	101
4704	102
4705	102
4706	102
4708	101
4709	101
4710	101
4711	102
4712	102
4720	101
4721	101
4722	101
4724	101
4725	101
4727	101
4728	102
4730	102
4732	102
4733	102
4734	101
4735	101
4736	102
4737	102
4738	102
4739	102
4752	101
4753	101
4754	101
4755	101
4756	101
4757	101
4758	101
4760	101
4762	101
4764	101
4765	101
4766	101
4768	101
4769	101
4770	101
4771	101
4772	101
4773	101
4774	102
4775	101
4777	101
4778	102
4779	102
4780	101
4781	101
4784	101
4785	101
4787	101
4788	101
4789	101
4790	101
4791	101
4792	101
4794	101
4795	101
4796	101
4797	101
4798	102
4800	101
4802	101
4803	102
4804	101
4806	102
4809	102
4810	101
4811	101
4812	101
4813	102
4814	101
4817	101
4818	102
4822	102
4823	101
4824	101
4825	101
4826	101
4827	102
4830	101
4831	101
4832	101
4833	101
4834	101
4835	102
4836	102
4837	101
4840	101
4842	102
4844	101
4845	101
4846	101
4847	101
4848	101
4849	101
4851	101
4853	101
4854	101
4858	101
4859	101
4860	102
4862	102
4863	101
4865	101
4866	101
4869	101
4870	101
4871	101
4873	101
4876	101
4877	101
4878	101
4883	101
4884	101
4888	101
4889	101
4890	101
4891	101
4893	101
4894	101
4899	102
4900	101
4901	101
4902	101
4904	101
4905	102
4908	101
4909	101
4910	101
4911	101
4912	101
4913	101
4914	101
4915	101
4916	102
4917	101
4918	101
4919	101
4920	101
4922	101
4924	101
4925	101
4926	101
4927	101
4928	101
4930	101
4931	102
4932	102
4933	101
4934	102
4935	101
4936	101
4937	102
4938	101
4939	101
4940	101
4941	101
4942	101
4943	101
4944	101
4945	102
4946	101
4947	102
4948	101
4949	102
4950	101
4951	101
4955	101
4957	102
4958	101
4959	101
4961	102
4962	102
4966	102
4968	101
4970	102
4971	102
4972	101
4973	101
4974	102
4978	101
4979	101
4980	102
4981	101
4982	101
4983	101
4985	101
4986	101
4987	101
4990	101
4995	102
4997	101
4999	101
5000	102
5001	102
5002	101
5004	102
5005	101
5006	101
5007	101
5009	101
5010	102
5013	102
5014	102
5015	102
5016	101
5017	101
5018	102
5021	101
5026	101
5028	101
5029	102
5030	102
5031	102
5034	102
5036	101
5037	102
5038	101
5039	101
5040	101
5041	102
5042	101
5043	101
5045	101
5046	101
5047	101
5048	102
5049	101
5050	102
5052	101
5054	102
5055	101
5056	101
5057	101
5058	101
5063	101
5064	102
5066	102
5067	101
5068	101
5069	101
5070	102
5072	101
5073	101
5074	101
5075	102
5076	102
5077	101
5078	102
5079	101
5080	101
5081	101
5082	102
5083	102
5084	101
5085	101
5086	101
5087	101
5088	101
5090	101
5092	101
5093	101
5094	101
5096	101
5097	101
5099	102
5100	101
5101	101
5102	101
5105	102
5106	102
5108	101
5110	101
5116	101
5117	102
5120	101
5121	101
5122	101
5123	101
5124	101
5125	102
5126	101
5127	101
5128	101
5129	101
5130	101
5131	101
5133	101
5134	101
5135	101
5136	101
5138	101
5140	102
5141	101
5142	101
5143	101
5144	101
5145	101
5146	101
5147	102
5150	101
5151	101
5152	101
5153	102
5159	102
5160	101
5161	102
5162	102
5164	101
5165	101
5166	102
5168	102
5169	101
5171	101
5172	102
5173	101
5175	102
5177	101
5180	101
5181	101
5182	101
5183	101
5184	101
5186	101
5187	102
5188	101
5191	102
5192	102
5193	102
5195	102
5196	101
5197	102
5198	102
5199	102
5200	102
5202	101
5203	101
5239	101
5240	101
5241	102
5242	101
5243	101
5245	101
5246	101
5248	101
5249	101
5250	102
5251	101
5253	102
5255	101
5256	102
5257	101
5258	101
5259	101
5260	101
5261	101
5262	101
5263	101
5264	101
5267	101
5268	102
5269	101
5271	101
5274	101
5275	101
5276	101
5277	101
5278	101
5279	101
5280	101
5281	101
5282	101
5283	102
5284	101
5285	101
5287	101
5288	101
5289	101
5290	101
5291	101
5292	101
5293	102
5297	101
5298	101
5301	101
5303	102
5305	101
5312	101
5313	102
5314	101
5316	102
5317	102
5319	101
5322	101
5324	101
5325	102
5330	102
5333	102
5335	102
5338	101
5340	101
5342	101
5344	101
5346	101
5356	101
5357	101
5358	101
5359	102
5360	102
5364	101
5365	101
5367	102
5370	101
5372	102
5373	102
5380	101
5383	101
5384	101
5387	102
5389	101
5390	101
5391	101
5394	102
5396	101
5400	101
5401	102
5402	101
5403	101
5404	102
5405	101
5406	101
5407	101
5409	101
5410	101
5411	101
5412	102
5415	101
5416	102
5419	102
5420	102
5421	102
5422	102
5424	102
5425	101
5426	102
5427	101
5428	102
5429	102
5430	102
5431	102
5432	102
5433	102
5434	102
5436	102
5437	101
5438	102
5439	101
5440	102
5441	101
5442	102
5443	102
5444	102
5445	102
5446	101
5447	101
5448	101
5449	101
5451	101
5452	101
5454	101
5456	101
5457	101
5458	102
5460	102
5461	102
5463	101
5464	101
5465	101
5466	101
5467	101
5468	101
5470	102
5471	102
5472	101
5473	101
5474	101
5475	101
5477	101
5478	101
5479	101
5480	102
5481	101
5484	102
5485	101
5487	102
5491	102
5492	102
5493	101
5494	102
5496	101
5499	101
5500	101
5502	101
5503	102
5504	101
5506	101
5507	102
5509	101
5511	101
5512	101
5513	102
5520	101
5521	102
5522	101
5523	101
5525	101
5526	101
5527	101
5528	101
5529	102
5530	102
5532	101
5534	101
5535	102
5536	101
5537	101
5538	101
5539	101
5541	102
5542	101
5545	102
5546	102
5547	101
5551	101
5552	101
5554	101
5555	101
5556	101
5558	101
5559	101
5560	101
5561	101
5562	101
5563	101
5564	101
5565	101
5568	101
5569	101
5570	101
5571	101
5572	101
5574	102
5576	101
5577	101
5578	101
5579	102
5580	101
5582	101
5583	101
5584	101
5585	101
5587	101
5592	101
5593	101
5595	101
5596	102
5597	101
5598	101
5599	101
5601	102
5604	101
5604	102
5605	101
5606	101
5610	101
5611	101
5614	101
5615	101
5616	101
5617	101
5618	101
5619	101
5623	101
5624	101
5630	101
5634	101
5635	101
5636	101
5638	101
5643	101
5644	101
5646	101
5648	101
5655	101
5656	102
5658	101
5663	101
5664	102
5665	101
5666	101
5667	102
5670	101
5671	101
5672	101
5674	101
5675	101
5677	101
5678	101
5679	101
5680	102
5682	101
5684	102
5687	101
5689	102
5690	101
5691	101
5694	101
5697	101
5698	101
5699	101
5700	101
5701	101
5704	101
5705	101
5706	102
5707	101
5709	102
5710	102
5711	102
5713	101
5714	101
5715	101
5716	102
5719	101
5720	101
5722	101
5724	101
5726	102
5727	101
5728	101
5729	101
5729	102
5734	102
5737	101
5738	101
5739	102
5740	101
5741	102
5742	101
5743	102
5745	102
5746	102
5747	101
5749	102
5752	101
5753	102
5754	102
5757	101
5760	101
5761	101
5761	102
5762	101
5763	101
5764	101
5765	101
5766	101
5768	102
5771	101
5773	101
5777	101
5782	101
5785	101
5787	101
5788	101
5791	101
5793	101
5794	101
5796	101
5797	102
5798	101
5801	101
5802	101
5803	101
5806	101
5808	102
5809	101
5814	101
5815	101
5816	102
5817	102
5818	102
5821	101
5823	101
5824	101
5826	101
5828	101
5833	101
5834	101
5835	101
5836	101
5840	101
5842	101
5844	101
5847	102
5848	101
5850	101
5851	102
5852	102
5853	102
5854	102
5857	102
5859	102
5860	102
5862	102
5867	101
5868	101
5870	101
5872	102
5874	101
5875	101
5876	102
5878	101
5879	101
5880	101
5881	101
5885	101
5887	102
5888	101
5890	101
5891	101
5892	102
5894	102
5895	102
5896	101
5897	102
5898	101
5899	101
5905	101
5907	101
5908	102
5909	102
5910	101
5912	101
5916	101
5919	102
5922	101
5924	101
5926	101
5927	101
5928	101
5932	102
5935	101
5937	102
5938	102
5940	101
5941	101
5942	101
5943	101
5944	101
5945	102
5946	102
5947	102
5948	102
5949	102
5950	101
5951	101
5955	101
5956	101
5957	101
5958	101
5960	102
5961	101
5964	102
5965	101
5966	101
5967	101
5968	101
5970	101
5971	101
5972	102
5976	101
5978	101
5988	101
5989	101
5991	101
5992	101
5995	102
5998	101
5999	101
6000	102
6001	101
6002	101
6003	101
6004	101
6005	101
6007	101
6008	102
6010	101
6011	101
6012	101
6013	101
6014	101
6015	101
6016	101
6019	102
6020	101
6021	101
6025	101
6027	102
6028	102
6030	101
6031	101
6034	101
6035	102
6037	101
6042	101
6048	101
6050	102
6052	101
6053	101
6056	101
6057	101
6058	102
6060	101
6061	101
6062	101
6064	101
6065	101
6067	101
6069	102
6070	102
6074	101
6075	101
6079	102
6080	102
6081	101
6082	102
6083	102
6085	101
6087	102
6089	101
6090	102
6091	101
6093	102
6094	102
6095	102
6097	102
6099	101
6100	102
6104	102
6106	102
6107	101
6108	101
6109	102
6110	102
6112	102
6117	101
6118	101
6119	101
6122	101
6124	101
6127	101
6128	101
6129	102
6133	101
6134	101
6136	101
6137	101
6138	101
6141	101
6142	101
6146	101
6151	101
6152	101
6154	101
6155	101
6158	102
6160	101
6162	101
6164	101
6165	101
6166	101
6168	102
6172	102
6173	101
6174	101
6175	101
6176	102
6183	102
6184	101
6185	101
6188	101
6189	101
6190	101
6191	101
6193	101
6194	101
6195	102
6198	101
6200	101
6201	101
6203	101
6204	101
6205	101
6206	101
6207	101
6208	101
6209	101
6210	101
6211	102
6212	101
6213	101
6214	101
6215	101
6216	101
6217	101
6218	101
6219	101
6220	102
6221	102
6222	101
6223	101
6224	101
6225	102
6226	101
6229	101
6230	102
6232	101
6233	101
6234	102
6236	101
6242	101
6245	101
6246	101
6248	101
6254	101
6255	102
6256	101
6258	102
6259	102
6260	101
6261	102
6263	101
6264	101
6266	101
6267	101
6268	101
6269	102
6270	101
6271	102
6273	102
6274	102
6279	101
6283	101
6285	101
6293	102
6296	102
6297	101
6299	101
6300	101
6301	102
6302	101
6303	101
6304	101
6306	101
6307	101
6308	101
6310	101
6311	101
6312	101
6313	101
6314	101
6315	101
6316	101
6317	101
6318	101
6319	101
6320	101
6321	101
6322	101
6326	101
6327	101
6332	102
6333	102
6334	102
6335	102
6336	101
6337	101
6340	102
6341	101
6342	102
6344	101
6347	102
6349	102
6350	101
6351	101
6352	102
6353	101
6354	101
6355	101
6356	101
6357	101
6358	101
6360	101
6362	101
6364	102
6366	101
6367	101
6368	102
6369	101
6370	101
6371	101
6374	101
6375	101
6379	102
6381	102
6382	101
6383	102
6384	101
6386	101
6387	101
6388	101
6389	101
6391	101
6392	102
6394	101
6395	101
6396	101
6397	101
6398	101
6399	101
6401	101
6402	101
6404	101
6407	101
6408	102
6409	102
6410	101
6411	101
6412	102
6413	102
6415	101
6416	101
6417	102
6419	101
6420	101
6421	102
6422	101
6424	101
6426	102
6431	101
6432	102
6433	102
6434	102
6437	101
6438	101
6439	101
6441	102
6442	102
6445	101
6446	101
6448	102
6449	101
6454	101
6458	102
6463	101
6464	101
6465	101
6471	101
6474	101
6475	102
6478	101
6479	101
6484	101
6485	101
6486	101
6488	102
6491	101
6492	101
6494	101
6497	102
6498	102
6499	102
6501	101
6502	101
6504	102
6505	102
6506	101
6507	101
6509	102
6510	101
6513	101
6514	101
6516	101
6518	102
6519	101
6520	102
6521	102
6522	102
6523	102
6524	102
6525	101
6526	102
6527	102
6528	102
6529	102
6530	102
6531	102
6532	102
6533	102
6534	102
6535	102
6536	102
6537	102
6538	101
6539	102
6540	102
6541	102
6543	101
6544	102
6545	102
6546	102
6547	101
6548	101
6549	101
6550	102
6551	101
6552	102
6553	101
6554	102
6555	101
6556	102
6558	102
6559	102
6560	101
6561	102
6562	102
6563	102
6565	102
6566	102
6567	102
6568	102
6569	102
6572	101
6573	101
6574	101
6575	101
6578	101
6579	101
6580	102
6581	101
6584	101
6585	101
6586	101
6587	101
6588	101
6589	101
6590	102
6592	101
6593	102
6596	101
6599	101
6600	101
6601	101
6602	101
6603	101
6604	101
6606	101
6607	102
6608	101
6609	101
6611	101
6613	101
6614	101
6615	102
6616	101
6618	101
6620	101
6622	101
6623	101
6626	101
6628	101
6629	101
6630	102
6632	101
6635	101
6636	101
6637	101
6638	101
6640	102
6642	101
6643	102
6644	101
6648	101
6649	101
6650	101
6655	101
6656	101
6658	101
6660	101
6661	101
6662	101
6663	101
6664	101
6665	101
6666	101
6667	101
6673	101
6675	101
6676	101
6677	101
6678	101
6684	101
6685	101
6687	101
6689	102
6691	102
6692	101
6693	101
6694	101
6695	101
6698	101
6700	101
6704	102
6705	102
6708	101
6710	101
6714	101
6715	101
6717	101
6719	102
6720	101
6721	101
6723	101
6724	101
6726	101
6728	101
6729	101
6730	101
6731	101
6733	101
6736	101
6737	101
6739	101
6740	101
6743	101
6748	102
6751	101
6752	101
6753	102
6754	102
6755	101
6756	102
6757	101
6758	102
6759	101
6763	101
6764	102
6765	101
6768	101
6769	101
6770	101
6772	101
6773	101
6774	101
6775	101
6779	101
6780	101
6781	101
6782	101
6783	101
6784	101
6785	101
6787	102
6788	101
6790	101
6791	101
6792	101
6795	101
6798	101
6799	101
6800	101
6803	101
6805	101
6806	101
6807	102
6809	101
6813	102
6814	101
6815	101
6816	102
6819	101
6820	101
6821	101
6823	101
6824	101
6825	102
6827	101
6828	102
6829	101
6830	101
6833	101
6834	102
6835	102
6836	101
6837	102
6838	102
6839	101
6840	101
6842	102
6843	101
6844	102
6845	102
6846	101
6847	102
6848	101
6849	101
6850	101
6851	102
6852	101
6853	101
6854	101
6855	101
6856	102
6858	101
6859	101
6863	102
6866	102
6867	101
6868	101
6869	101
6870	102
6871	101
6872	101
6873	102
6875	101
6876	101
6877	102
6878	101
6879	101
6882	101
6883	101
6884	101
6885	102
6886	101
6888	102
6889	101
6891	102
6892	101
6893	101
6894	102
6897	102
6898	101
6899	101
6900	101
6901	101
6902	101
6903	101
6904	101
6906	102
6907	101
6908	102
6909	101
6910	102
6912	101
6913	102
6914	102
6915	101
6917	102
6918	102
6919	102
6921	101
6923	102
6924	102
6925	102
6928	101
6929	102
6930	101
6931	102
6932	102
6933	101
6936	101
6937	101
6938	101
6940	101
6941	101
6942	101
6943	102
6944	102
6945	101
6946	102
6947	101
6948	102
6949	101
6950	101
6951	101
6953	101
6954	102
6955	101
6956	102
6959	102
6961	101
6965	102
6968	101
6971	101
6973	102
6980	101
6981	101
6985	101
6986	101
6988	101
6989	101
6990	102
6993	101
6995	101
6996	101
6997	101
6998	101
6999	101
7000	101
7001	101
7002	101
7004	101
7005	101
7007	101
7008	101
7009	101
7010	101
7012	101
7015	101
7019	101
7021	101
7022	101
7024	101
7025	101
7026	101
7027	101
7028	101
7030	101
7032	101
7033	101
7034	101
7036	101
7037	101
7038	101
7040	101
7043	101
7044	101
7046	101
7047	101
7049	101
7050	101
7052	101
7052	102
7053	101
7054	101
7055	101
7056	101
7059	101
7068	101
7069	101
7070	101
7071	101
7072	101
7075	101
7076	101
7077	101
7078	101
7079	102
7081	102
7082	102
7083	101
7086	101
7088	102
7089	101
7090	101
7091	102
7092	101
7093	101
7095	101
7097	101
7098	101
7099	101
7101	101
7102	102
7103	101
7104	101
7106	102
7107	101
7108	101
7109	101
7109	102
7110	101
7112	101
7113	101
7115	101
7116	101
7117	101
7118	101
7119	102
7120	102
7122	102
7123	101
7124	102
7125	102
7126	102
7128	101
7131	101
7133	101
7134	101
7135	101
7136	101
7137	101
7139	101
7140	101
7142	101
7144	101
7145	101
7147	102
7148	101
7149	101
7150	101
7152	101
7153	101
7154	101
7156	101
7157	101
7158	102
7159	101
7160	101
7161	101
7165	102
7166	101
7167	101
7168	101
7169	101
7170	101
7171	101
7173	101
7177	102
7179	101
7181	101
7182	101
7183	101
7184	101
7187	102
7188	101
7189	101
7190	101
7191	101
7192	102
7194	101
7195	101
7196	101
7198	101
7199	101
7200	102
7201	102
7203	101
7204	101
7205	101
7207	102
7208	102
7209	102
7210	102
7211	102
7212	102
7213	101
7214	102
7215	102
7216	102
7217	102
7218	101
7219	101
7220	102
7221	101
7222	102
7224	101
7228	101
7229	101
7230	102
7234	101
7235	102
7236	101
7237	101
7238	101
7239	101
7240	101
7241	101
7242	101
7243	101
7244	101
7245	102
7246	102
7247	101
7248	102
7250	101
7257	101
7258	101
7261	101
7262	101
7263	101
7264	101
7265	101
7266	101
7267	101
7268	101
7269	101
7270	101
7271	102
7272	102
7273	101
7275	101
7276	101
7277	102
7278	101
7279	101
7280	102
7282	101
7283	101
7285	101
7287	101
7289	102
7290	101
7291	102
7292	101
7293	102
7294	101
7295	101
7296	102
7297	101
7298	101
7299	101
7300	101
7301	101
7303	102
7304	102
7306	102
7307	102
7309	101
7310	102
7311	102
7312	101
7313	102
7314	102
7315	101
7316	102
7317	101
7319	102
7320	101
7322	101
7325	102
7327	102
7328	101
7329	102
7330	101
7331	101
7332	102
7333	101
7335	101
7336	101
7337	102
7339	101
7340	102
7341	102
7342	101
7343	102
7344	101
7345	101
7346	101
7347	102
7348	102
7349	101
7350	101
7351	102
7352	102
7353	101
7355	102
7356	101
7357	102
7358	101
7359	101
7360	102
7361	101
7362	102
7363	101
7364	102
7365	101
7366	101
7367	101
7368	101
7369	101
7371	102
7372	102
7373	101
7374	101
7376	101
7377	101
7379	101
7380	102
7381	101
7382	102
7383	101
7384	102
7385	101
7386	101
7387	101
7388	102
7389	102
7390	102
7391	101
7392	101
7393	101
7396	101
7397	102
7399	102
7400	102
7401	102
7402	102
7403	102
7404	102
7405	102
7406	101
7407	102
7408	101
7409	101
7410	101
7411	102
7412	102
7413	102
7414	101
7415	102
7416	101
7417	102
7420	102
7422	102
7424	102
7426	101
7428	102
7429	101
7430	102
7431	102
7433	101
7434	102
7435	101
7436	102
7437	102
7438	101
7439	101
7440	101
7441	102
7442	101
7443	101
7444	101
7445	101
7446	101
7447	101
7448	101
7449	101
7450	101
7451	101
7452	101
7453	102
7454	102
7455	101
7457	102
7458	101
7459	101
7460	101
7461	101
7464	102
7465	101
7466	101
7467	101
7469	101
7470	102
7473	101
7474	101
7477	101
7478	102
7479	101
7480	101
7481	101
7483	101
7485	101
7486	101
7488	102
7490	102
7491	101
7492	101
7493	101
7494	101
7495	101
7496	102
7497	101
7498	102
7500	101
7501	101
7502	101
7503	101
7504	102
7505	102
7506	102
7507	102
7508	102
7509	102
7510	101
7511	101
7512	101
7513	101
7514	102
7515	102
7516	101
7517	101
7518	102
7519	101
7520	102
7521	101
7522	101
7523	101
7524	101
7526	102
7527	102
7530	101
7531	101
7532	101
7535	101
7536	101
7537	101
7538	101
7539	102
7540	102
7541	102
7542	102
7543	102
7544	101
7545	101
7546	101
7547	101
7548	102
7549	102
7550	102
7551	101
7552	101
7553	102
7554	101
7555	101
7556	102
7557	102
7558	101
7559	101
7560	101
7562	101
7565	102
7566	101
7567	102
7568	102
7569	101
7570	102
7571	101
7572	101
7573	101
7576	102
7577	101
7579	101
7580	101
7581	102
7582	102
7583	101
7584	101
7585	101
7586	102
7587	101
7588	102
7589	102
7590	101
7594	101
7595	102
7598	102
7600	102
7601	102
7602	102
7604	102
7606	101
7607	102
7609	101
7610	102
7612	101
7613	101
7614	101
7618	101
7619	102
7621	102
7623	101
7626	102
7628	101
7632	101
7633	101
7634	102
7635	102
7640	101
7644	101
7645	101
7646	102
7650	101
7654	101
7656	101
7658	102
7661	101
7662	102
7663	102
7665	101
7667	101
7668	101
7672	101
7675	102
7676	101
7677	101
7678	102
7679	101
7680	101
7681	102
7682	102
7683	102
7684	101
7685	102
7686	101
7687	101
7688	101
7689	101
7690	101
7691	102
7692	101
7693	101
7694	102
7695	101
7696	102
7698	102
7699	101
7700	101
7701	102
7702	101
7703	101
7705	101
7706	102
7707	102
7710	101
7711	101
7712	102
7713	101
7714	101
7715	102
7717	101
7719	101
7720	101
7721	101
7722	101
7723	102
7724	102
7725	102
7727	101
7730	101
7732	101
7733	101
7734	102
7735	101
7736	101
7737	102
7738	101
7739	102
7740	101
7741	101
7742	102
7743	102
7744	102
7745	102
7746	102
7747	102
7748	102
7749	101
7750	101
7751	102
7752	102
7753	102
7755	101
7756	102
7758	101
7759	101
7760	101
7764	102
7771	101
7772	102
7774	101
7775	101
7780	101
7783	101
7784	102
7785	102
7787	102
7788	102
7789	102
7790	102
7791	102
7792	102
7793	102
7794	101
7795	101
7796	101
7797	101
7798	101
7799	101
7800	102
7801	102
7802	102
7803	101
7805	101
7806	102
7807	101
7808	102
7809	102
7810	101
7811	101
7812	101
7813	101
7815	102
7816	101
7818	102
7820	101
7821	101
7822	102
7823	102
7824	102
7825	101
7826	102
7827	102
7828	102
7829	101
7830	102
7831	101
7832	101
7833	102
7836	101
7838	102
7840	102
7841	102
7843	102
7844	101
7845	102
7849	102
7850	101
7852	102
7853	101
7854	102
7855	102
7856	102
7857	102
7858	101
7859	101
7862	101
7863	101
7864	102
7865	102
7866	102
7868	102
7869	101
7870	102
7871	102
7872	102
7873	102
7874	102
7875	101
7876	102
7877	102
7878	102
7880	101
7881	101
7882	101
7883	101
7884	101
7885	101
7886	101
7887	101
7888	101
7889	101
7890	101
7892	101
7893	102
7894	101
7897	101
7898	102
7899	101
7900	101
7902	101
7903	101
7904	101
7905	101
7906	101
7907	101
7908	101
7909	101
7910	101
7912	102
7913	102
7914	102
7915	102
7916	101
7917	102
7918	101
7919	101
7922	102
7924	101
7925	101
7926	102
7928	101
7929	102
7930	102
7931	101
7932	102
7933	102
7934	102
7935	101
7936	102
7937	102
7938	102
7939	102
7940	101
7941	101
7942	101
7943	101
7944	101
7945	101
7946	102
7950	101
7951	101
7952	101
7953	101
7954	101
7955	102
7957	102
7958	101
7959	102
7960	101
7961	101
7964	101
7965	101
7966	101
7968	101
7969	101
7970	101
7970	102
7971	101
7973	101
7974	101
7975	101
7978	101
7979	101
7980	101
7981	101
7982	101
7983	101
7985	101
7987	101
7988	101
7989	101
7991	101
7992	101
7993	101
7994	101
7996	102
7997	101
7998	102
8000	102
8002	102
8003	101
8004	101
8005	101
8007	101
8009	102
8012	101
8015	102
8016	101
8018	101
8021	101
8023	101
8024	101
8024	102
8025	101
8026	101
8028	101
8030	101
8031	101
8032	101
8036	102
8037	101
8038	101
8039	101
8042	101
8046	101
8047	101
8048	101
8049	101
8050	101
8051	101
8052	101
8053	101
8054	101
8056	101
8057	101
8061	101
8063	101
8064	101
8065	102
8067	101
8069	101
8071	101
8072	101
8074	101
8075	101
8076	101
8078	101
8079	101
8080	102
8081	101
8082	102
8083	101
8084	101
8085	102
8086	101
8087	101
8088	101
8089	102
8090	101
8091	101
8093	102
8094	102
8095	102
8097	101
8098	101
8099	102
8100	102
8102	102
8103	101
8104	101
8105	101
8106	101
8107	101
8108	101
8109	102
8110	102
8111	101
8112	101
8113	101
8114	101
8115	101
8116	101
8117	101
8118	101
8119	101
8120	101
8121	101
8122	101
8123	102
8124	101
8125	101
8126	101
8127	101
8128	101
8129	101
8130	101
8131	101
8137	101
8138	101
8139	101
8140	101
8141	102
8143	101
8144	101
8145	101
8146	101
8147	101
8148	101
8149	101
8150	101
8151	101
8153	101
8154	102
8155	101
8157	101
8158	101
8159	101
8160	101
8161	101
8162	101
8163	101
8164	101
8166	101
8167	101
8168	101
8169	101
8170	101
8171	101
8172	101
8173	101
8174	101
8175	101
8176	101
8177	101
8178	101
8179	101
8180	101
8181	101
8182	101
8183	101
8184	101
8185	101
8186	101
8188	101
8189	101
8190	101
8191	101
8192	101
8193	101
8194	101
8195	101
8196	101
8197	101
8199	101
8200	101
8201	101
8202	101
8203	101
8204	101
8205	101
8206	101
8207	101
8208	101
8209	101
8210	101
8211	101
8212	101
8213	101
8214	101
8216	101
8217	101
8218	102
8219	102
8220	101
8221	101
8222	101
8223	102
8225	102
8226	101
8227	101
8228	101
8230	101
8231	101
8232	102
8233	101
8234	102
8235	101
8236	102
8237	101
8239	101
8240	101
8241	101
8242	102
8243	101
8244	101
8245	101
8246	101
8247	101
8248	101
8250	101
8251	101
8252	101
8254	101
8255	101
8256	101
8257	101
8258	101
8259	101
8260	101
8261	101
8262	101
8263	101
8265	101
8266	101
8268	102
8269	101
8270	101
8271	101
8272	101
8273	101
8274	101
8275	101
8276	101
8277	101
8278	101
8279	101
8280	102
8281	101
8282	101
8283	101
8284	101
8285	101
8286	101
8287	101
8288	101
8289	102
8290	101
8291	102
8292	101
8293	101
8294	101
8295	101
8296	102
8297	102
8298	101
8300	101
8301	101
8303	101
8304	101
8305	101
8306	101
8307	101
8308	101
8309	101
8310	101
8311	101
8312	101
8313	102
8314	101
8315	101
8316	101
8317	101
8318	102
8319	101
8320	101
8321	101
8322	101
8323	101
8324	101
8325	101
8326	102
8327	102
8328	101
8329	101
8330	101
8331	102
8332	101
8333	101
8334	101
8335	101
8337	101
8338	101
8339	101
8340	101
8341	101
8342	101
8343	102
8344	101
8345	101
8346	101
8347	101
8348	101
8349	101
8350	101
8351	101
8352	101
8353	101
8354	101
8356	101
8357	102
8358	101
8359	102
8360	101
8361	101
8362	101
8363	101
8364	101
8365	101
8366	101
8367	101
8368	101
8369	101
8370	101
8371	101
8372	101
8373	101
8374	101
8375	101
8376	101
8377	101
8378	101
8379	101
8380	102
8381	102
8382	102
8383	101
8384	101
8385	101
8386	102
8387	102
8388	101
8389	102
8390	101
8391	102
8392	102
8393	102
8394	101
8395	101
8396	101
8398	101
8399	101
8400	101
8401	101
8402	101
8403	101
8404	101
8405	101
8406	101
8407	101
8408	101
8409	101
8410	101
8411	101
8412	101
8413	101
8414	101
8415	102
8416	101
8417	101
8418	101
8419	101
8420	101
8421	101
8422	101
8423	101
8424	101
8425	101
8426	101
8427	101
8428	101
8429	101
8430	101
8431	101
8432	101
8433	101
8434	101
8435	101
8436	101
8437	101
8438	101
8439	101
8440	101
8441	101
8442	101
8444	101
8445	101
8446	101
8447	101
8448	101
8449	101
8450	101
8451	101
8452	101
8453	101
8454	101
8455	101
8456	101
8457	101
8458	101
8459	101
8460	101
8461	101
8462	101
8463	101
8464	101
8465	101
8466	101
8467	101
8468	101
8469	101
8470	101
8471	101
8472	101
8473	101
8474	101
8475	101
8476	101
8477	101
8478	101
8479	101
8480	101
8481	101
8482	101
8483	101
8484	101
8485	101
8486	101
8487	101
8488	101
8489	101
8490	101
8491	101
8492	101
8493	101
8494	101
8495	101
8496	101
8497	101
8498	101
8499	101
8500	101
8501	101
8502	101
8503	101
8504	101
8505	101
8506	101
8507	101
8508	101
8509	101
8510	101
8511	101
8512	101
8513	101
8514	101
8515	101
8516	101
8517	101
8518	101
8519	101
8520	101
8521	101
8522	101
8523	101
8524	101
8525	101
8526	101
8527	102
8528	101
8529	101
8530	101
8531	101
8532	101
8533	101
8534	101
8535	101
8536	101
8537	101
8538	101
8539	101
8540	101
8541	101
8542	101
8543	101
8544	101
8545	101
8546	101
8547	101
8548	101
8549	101
8550	101
8551	101
8552	101
8553	101
8554	101
8555	101
8556	101
8557	101
8558	101
8559	101
8560	101
8561	101
8562	101
8563	101
8564	101
8565	101
8566	101
8567	101
8569	101
8570	101
8571	101
8572	101
8573	101
8574	101
8575	101
8576	101
8577	101
8578	101
8582	102
8583	101
8584	101
8586	101
8588	102
8589	101
8590	101
8591	101
8592	101
8593	101
8595	101
8596	101
8598	101
8599	101
8600	102
8601	101
8602	101
8604	102
8605	101
8606	101
8607	101
8608	102
8609	101
8610	101
8611	101
8612	101
8613	101
8614	101
8615	101
8616	101
8617	101
8618	101
8618	102
8620	101
8621	101
8622	101
8623	101
8624	101
8628	101
8629	101
8630	101
8631	101
8632	102
8633	101
8634	101
8636	101
8637	101
8640	101
8641	101
8642	101
8643	101
8644	101
8645	101
8647	101
8648	101
8649	101
8650	101
8651	101
8653	101
8654	101
8656	101
8657	101
8658	101
8660	102
8661	101
8662	102
8663	101
8665	101
8666	101
8667	101
8675	101
8676	101
8678	101
8679	101
8680	101
8681	102
8683	101
8684	101
8685	101
8686	101
8688	102
8689	101
8690	101
8692	101
8694	101
8696	101
8697	101
8700	101
8702	101
8703	101
8705	101
8706	101
8707	101
8710	101
8712	101
8714	101
8715	101
8716	101
8719	101
8720	101
8722	101
8723	101
8724	101
8726	101
8727	102
8729	101
8730	101
8733	101
8735	101
8736	102
8737	101
8738	101
8739	101
8741	101
8742	102
8746	101
8748	101
8749	101
8750	101
8752	101
8753	101
8754	101
8755	101
8756	101
8757	101
8758	101
8759	101
8760	101
8761	101
8762	101
8763	101
8764	102
8765	101
8766	101
8767	101
8770	101
8774	102
8777	101
8778	101
8780	101
8781	101
8782	101
8783	101
8784	101
8787	101
8790	101
8791	101
8792	102
8793	101
8794	102
8797	101
8798	101
8799	101
8800	101
8801	101
8802	101
8803	101
8804	101
8805	101
8806	101
8807	101
8808	101
8813	101
8814	101
8815	101
8816	102
8817	102
8818	102
8819	102
8820	101
8821	101
8822	101
8823	102
8824	101
8825	102
8826	101
8828	102
8829	101
8830	102
8831	101
8832	102
8834	101
8835	101
8837	102
8838	101
8839	102
8840	101
8841	101
8842	101
8844	101
8847	102
8848	101
8849	102
8850	102
8851	101
8852	102
8853	101
8854	102
8857	102
8858	101
8859	101
8861	101
8862	101
8863	101
8864	101
8865	101
8867	101
8869	101
8870	101
8872	101
8873	101
8874	101
8875	101
8876	102
8877	101
8878	101
8889	101
8890	102
8892	101
8893	101
8894	101
8895	101
8896	101
8897	101
8898	101
8899	101
8900	101
8901	101
8903	102
8906	101
8907	101
8908	101
8909	102
8910	101
8911	101
8912	101
8913	101
8914	102
8915	102
8916	101
8917	101
8918	101
8919	101
8923	101
8924	102
8925	102
8927	101
8928	101
8929	102
8930	101
8931	101
8932	101
8933	101
8934	101
8935	101
8936	102
8937	101
8938	101
8939	102
8940	101
8941	101
8942	102
8944	101
8945	101
8946	101
8947	101
8948	102
8949	102
8950	101
8951	102
8952	101
8953	101
8954	102
8955	102
8956	101
8957	101
8959	101
8960	101
8961	101
8962	101
8963	101
8966	102
8967	101
8970	101
8971	102
8972	101
8973	101
8976	101
8977	101
8978	101
8979	101
8980	101
8983	102
8984	101
8985	101
8986	101
8987	101
8988	102
8989	101
8990	101
8992	101
8993	102
8994	101
8995	101
8996	101
8997	101
8998	101
8999	101
9001	101
9002	101
9003	101
9004	101
9005	101
9007	102
9008	101
9010	101
9011	101
9013	101
9018	101
9019	101
9020	101
9021	101
9022	101
9024	102
9026	102
9027	101
9028	101
9029	101
9030	102
9031	101
9032	102
9033	101
9033	102
9034	101
9035	101
9036	101
9037	101
9038	101
9039	101
9040	101
9041	102
9042	101
9043	101
9045	101
9046	101
9047	102
9048	101
9049	101
9050	102
9052	101
9053	101
9054	101
9055	101
9056	102
9057	102
9059	101
9063	102
9064	102
9065	102
9066	102
9067	101
9069	101
9070	101
9071	101
9072	101
9073	101
9074	101
9075	101
9076	101
9078	101
9079	101
9080	101
9082	101
9082	102
9084	101
9086	101
9087	101
9088	102
9091	101
9092	101
9093	101
9094	101
9095	101
9096	102
9097	101
9098	101
9099	101
9100	101
9101	101
9104	101
9106	101
9109	101
9112	101
9113	101
9116	101
9117	102
9118	101
9119	101
9120	101
9121	101
9122	101
9125	101
9126	101
9127	102
9128	101
9130	102
9131	101
9132	102
9133	101
9134	102
9135	101
9141	101
9142	102
9143	101
9144	101
9147	101
9149	101
9150	101
9151	101
9152	101
9153	101
9154	101
9155	101
9156	101
9157	101
9158	101
9159	102
9160	102
9161	101
9162	101
9163	101
9164	101
9165	102
9166	101
9167	101
9168	101
9169	101
9170	101
9171	101
9172	101
9173	101
9174	101
9175	101
9176	101
9178	101
9179	101
9180	101
9181	101
9182	101
9183	101
9184	101
9186	101
9187	101
9188	101
9190	101
9191	101
9192	101
9193	101
9194	101
9195	101
9196	101
9197	101
9198	101
9199	101
9200	101
9201	102
9202	102
9203	101
9204	101
9205	101
9206	102
9207	101
9208	101
9209	101
9210	101
9211	101
9212	101
9213	101
9214	101
9215	101
9216	101
9217	101
9218	101
9219	101
9220	102
9221	101
9222	101
9223	101
9224	101
9225	101
9227	102
9228	101
9229	101
9230	101
9231	101
9232	102
9234	101
9235	102
9236	101
9237	101
9238	101
9239	101
9240	101
9241	101
9242	102
9243	101
9244	101
9245	101
9246	101
9247	101
9248	101
9249	101
9250	101
9251	101
9252	102
9253	101
9254	101
9255	101
9256	101
9257	102
9258	101
9259	101
9261	101
9262	101
9263	101
9264	101
9265	101
9266	101
9267	101
9268	101
9269	101
9270	101
9271	101
9272	101
9273	101
9274	101
9275	101
9276	101
9277	102
9278	102
9279	101
9280	101
9282	101
9284	102
9285	102
9286	102
9287	102
9288	102
9289	101
9290	102
9291	101
9293	102
9294	101
9295	102
9296	101
9297	101
9298	102
9299	102
9300	102
9301	102
9302	101
9303	101
9304	102
9305	101
9306	102
9307	102
9308	102
9309	102
9310	101
9314	102
9315	102
9316	101
9317	101
9318	102
9319	101
9320	101
9321	101
9322	102
9323	101
9326	101
9327	101
9328	101
9329	101
9330	102
9331	101
9332	101
9333	101
9334	101
9335	101
9336	101
9337	101
9338	101
9340	101
9341	101
9342	101
9343	101
9344	101
9345	101
9346	101
9347	102
9348	101
9351	102
9352	101
9353	101
9355	101
9358	101
9359	101
9360	101
9361	101
9362	101
9365	101
9366	101
9367	101
9368	101
9369	101
9370	101
9371	102
9372	101
9373	101
9374	101
9375	101
9376	101
9377	101
9378	101
9379	101
9381	101
9382	101
9383	101
9384	101
9385	101
9386	101
9387	101
9388	101
9389	101
9390	101
9391	101
9392	101
9394	101
9398	101
9401	101
9402	101
9403	101
9404	101
9405	101
9406	101
9407	101
9408	101
9409	101
9410	101
9411	101
9412	101
9413	101
9414	101
9415	102
9416	101
9418	101
9419	101
9420	101
9421	101
9422	101
9423	101
9425	101
9426	102
9427	101
9428	101
9429	101
9430	101
9431	101
9432	101
9433	101
9434	101
9435	101
9436	101
9437	101
9438	101
9439	101
9440	101
9441	101
9442	101
9443	101
9444	102
9445	101
9446	101
9447	101
9448	101
9449	101
9450	102
9451	101
9452	101
9453	101
9454	102
9455	102
9457	102
9458	101
9459	101
9460	101
9462	101
9463	102
9464	101
9466	101
9467	101
9468	101
9469	101
9471	101
9472	101
9473	101
9477	101
9479	102
9480	101
9481	101
9482	101
9483	101
9484	101
9485	101
9486	101
9489	101
9490	101
9492	101
9493	101
9494	101
9495	102
9496	101
9497	101
9498	101
9500	101
9503	101
9516	102
9517	102
9518	102
9519	101
9520	101
9522	101
9523	101
9524	101
9525	101
9526	101
9527	101
9528	101
9529	102
9530	101
9531	101
9533	101
9534	101
9535	102
9536	101
9537	101
9539	101
9540	101
9542	101
9543	101
9544	101
9545	101
9546	101
9547	101
9548	101
9549	101
9550	101
9551	101
9553	101
9554	101
9555	101
9556	101
9558	101
9559	101
9560	102
9561	101
9563	101
9564	101
9565	101
9566	102
9567	102
9568	101
9569	102
9570	102
9571	101
9572	101
9573	101
9574	101
9575	102
9576	101
9577	102
9579	101
9581	101
9582	102
9584	101
9585	101
9586	101
9588	101
9592	101
9597	102
9598	101
9599	101
9600	101
9602	101
9603	101
9604	101
9605	101
9607	101
9608	101
9609	101
9610	101
9613	101
9614	101
9615	101
9618	101
9620	101
9622	101
9623	102
9624	101
9625	102
9626	101
9627	101
9628	101
9631	102
9632	101
9634	101
9634	102
9635	101
9636	101
9637	102
9638	101
9640	101
9641	102
9642	101
9643	102
9645	102
9646	102
9647	102
9648	102
9650	102
9651	101
9652	101
9653	101
9654	102
9655	101
9656	102
9658	101
9659	101
9660	102
9661	102
9663	101
9665	101
9666	101
9667	102
9669	101
9670	101
9671	101
9673	101
9674	101
9675	101
9676	101
9677	101
9678	101
9679	101
9681	101
9682	101
9684	101
9685	101
9686	101
9687	101
9689	101
9690	102
9691	101
9692	101
9693	101
9694	101
9695	101
9697	101
9698	101
9699	101
9700	101
9701	101
9702	101
9703	101
9704	101
9705	102
9706	102
9707	101
9708	101
9709	101
9710	101
9711	101
9712	101
9713	101
9714	101
9715	101
9716	101
9718	101
9719	101
9721	101
9722	101
9723	101
9724	101
9725	101
9727	101
9728	101
9729	101
9730	101
9731	101
9732	101
9735	101
9736	101
9738	101
9739	101
9741	101
9742	101
9743	101
9745	101
9746	101
9747	101
9748	101
9749	101
9750	101
9751	101
9752	101
9753	101
9754	101
9755	101
9756	101
9757	102
9758	102
9759	101
9760	101
9761	101
9762	101
9763	102
9764	101
9765	101
9766	101
9767	101
9768	101
9769	101
9770	101
9771	101
9772	101
9773	101
9774	101
9775	102
9776	101
9777	101
9778	101
9779	101
9780	101
9781	101
9782	102
9783	101
9784	101
9785	102
9786	101
9787	101
9788	101
9789	101
9790	101
9791	101
9792	101
9793	101
9794	101
9795	102
9796	101
9797	101
9798	101
9799	101
9800	101
9801	101
9803	101
9804	101
9805	101
9807	101
9808	101
9810	101
9811	101
9812	101
9813	101
9814	101
9815	101
9816	101
9817	101
9818	101
9819	101
9820	101
9821	101
9822	101
9823	101
9824	101
9825	101
9826	101
9827	101
9828	101
9829	101
9830	101
9831	101
9832	101
9833	101
9834	101
9835	101
9836	101
9837	101
9838	101
9839	101
9840	101
9841	101
9842	101
9843	101
9844	101
9845	101
9846	101
9847	101
9848	101
9848	102
9849	101
9850	101
9851	101
9852	101
9853	101
9854	101
9855	101
9856	101
9857	101
9858	101
9860	101
9861	101
9862	101
9863	101
9864	101
9865	101
9866	101
9867	101
9868	101
9869	101
9870	101
9871	101
9872	101
9873	101
9874	101
9875	101
9876	101
9877	101
9878	101
9879	101
9880	101
9881	101
9882	101
9883	101
9884	101
9886	101
9887	101
9888	101
9889	101
9890	101
9891	101
9892	101
9893	101
9894	101
9895	101
9897	102
9899	102
9900	101
9902	101
9903	102
9904	101
9905	101
9906	101
9907	101
9908	102
9909	101
9912	101
9913	101
9914	101
9915	101
9917	102
9918	102
9919	102
9920	102
9923	101
9924	101
9925	101
9926	101
9927	101
9928	101
9929	101
9930	101
9931	101
9933	101
9934	101
9935	101
9936	101
9937	101
9938	101
9939	101
9940	101
9943	101
9944	101
9945	101
9946	101
9947	101
9948	101
9949	101
9951	101
9952	101
9953	101
9954	101
9955	101
9956	101
9957	101
9958	101
9959	101
9960	101
9961	101
9962	101
9963	101
9964	102
9965	102
9966	102
9967	102
9968	102
9969	101
9970	101
9971	101
9973	102
9974	101
9975	101
9976	101
9977	101
9978	101
9979	101
9981	101
9983	101
9985	102
9986	101
9989	102
9990	101
9991	101
9992	101
9993	101
9994	101
9995	101
9996	101
9997	102
9998	102
9999	101
10000	101
10002	101
10004	101
10005	101
10007	101
10008	101
10009	101
10010	101
10011	102
10013	101
10014	101
10015	102
10016	101
10017	101
10018	101
10019	101
10020	101
10021	101
10022	102
10023	101
10024	101
10025	101
10026	101
10027	101
10029	102
10030	101
10031	101
10032	101
10033	101
10034	101
10036	101
10037	101
10038	101
10039	101
10040	101
10041	101
10042	101
10043	101
10044	101
10045	101
10046	101
10047	101
10048	101
10049	101
10050	101
10052	102
10053	101
10054	101
10055	101
10058	101
10060	101
10061	102
10062	101
10064	101
10065	101
10067	101
10069	101
10070	101
10071	101
10072	102
10074	101
10075	101
10076	101
10077	101
10078	101
10079	101
10081	101
10082	101
10084	101
10086	101
10087	101
10088	101
10089	101
10090	101
10091	101
10095	101
10096	101
10097	101
10098	101
10099	101
10100	101
10101	101
10102	101
10103	101
10104	101
10106	101
10107	102
10108	101
10109	102
10110	101
10111	101
10114	101
10115	102
10116	101
10117	101
10118	101
10119	101
10120	101
10121	101
10122	101
10123	101
10124	101
10125	101
10126	101
10127	102
10129	101
10130	101
10131	102
10132	101
10133	101
10134	101
10135	101
10136	101
10137	101
10138	101
10139	101
10140	101
10141	101
10142	101
10143	101
10144	101
10145	101
10146	101
10147	102
10148	102
10149	101
10152	101
10153	101
10155	101
10156	101
10157	101
10158	101
10159	101
10160	101
10161	101
10162	101
10163	102
10165	101
10166	101
10167	101
10168	101
10169	101
10170	101
10171	101
10172	101
10173	101
10174	102
10175	101
10176	102
10177	101
10179	101
10181	102
10182	101
10183	101
10184	101
10185	101
10186	101
10187	101
10188	101
10189	101
10190	101
10191	101
10192	102
10193	101
10194	101
10195	102
10196	101
10197	101
10198	102
10199	101
10200	101
10201	101
10202	101
10203	101
10204	101
10205	101
10206	101
10208	102
10210	101
10211	102
10212	102
10213	101
10214	101
10215	101
10216	101
10217	101
10220	101
10221	101
10222	101
10224	102
10226	101
10227	101
10228	101
10229	101
10230	101
10231	101
10232	101
10233	101
10234	101
10235	101
10236	101
10237	101
10238	101
10239	101
10240	101
10241	101
10242	101
10243	101
10245	101
10246	101
10247	101
10249	101
10250	101
10251	101
10252	101
10253	101
10254	101
10256	101
10257	101
10258	101
10259	101
10260	102
10261	101
10262	101
10263	101
10265	102
10266	102
10267	102
10268	101
10269	101
10270	101
10271	101
10272	101
10273	101
10274	101
10277	101
10278	101
10279	101
10280	101
10281	101
10282	101
10283	101
10284	101
10285	101
10286	101
10287	101
10288	101
10289	101
10290	101
10291	101
10292	101
10293	101
10294	101
10295	101
10296	101
10297	101
10298	101
10300	101
10301	101
10302	101
10303	101
10304	101
10305	101
10306	101
10307	101
10308	101
10309	101
10310	101
10312	101
10313	101
10314	101
10315	101
10316	101
10318	101
10319	101
10321	101
10322	101
10323	101
10325	101
10326	101
10327	101
10328	101
10329	101
10330	101
10331	101
10332	101
10333	101
10335	101
10336	101
10337	101
10339	101
10340	101
10341	101
10342	101
10343	101
10344	101
10345	101
10346	101
10347	101
10348	101
10349	101
10350	101
10351	101
10352	101
10353	101
10354	101
10355	101
10356	101
10358	101
10359	101
10360	101
10361	101
10362	101
10363	101
10364	101
10365	101
10366	101
10367	101
10368	101
10369	101
10370	101
10371	101
10372	101
10373	101
10374	101
10375	101
10376	101
10377	101
10378	101
10379	101
10380	101
10381	101
10382	101
10383	101
10384	101
10385	101
10386	101
10387	101
10388	101
10389	101
10390	101
10391	101
10392	101
10393	101
10394	101
10395	101
10396	101
10397	101
10398	101
10399	101
10400	101
10401	101
10402	101
10406	101
10407	101
10408	101
10409	101
10410	101
10411	101
10412	101
10413	101
10414	101
10415	101
10416	101
10417	101
10418	101
10419	101
10420	101
10421	101
10422	101
10423	101
10424	101
10425	101
10426	101
10427	101
10428	101
10429	101
10430	101
10431	101
10432	101
10433	101
10434	101
10435	101
10436	101
10437	101
10438	101
10439	101
10440	101
10441	101
10442	101
10443	101
10444	101
10445	101
10446	101
10447	101
10448	101
10449	101
10450	101
10451	101
10452	101
10453	101
10454	101
10455	101
10456	101
10457	101
10458	101
10459	101
10460	101
10461	101
10462	101
10463	101
10464	101
10465	101
10466	101
10467	101
10468	101
10469	101
10470	101
10471	101
10472	101
10473	101
10474	101
10475	101
10476	101
10477	101
10478	101
10479	101
10480	101
10481	101
10482	101
10483	101
10486	101
10487	101
10488	101
10489	101
10490	101
10491	101
10492	101
10493	101
10494	101
10495	101
10496	101
10497	101
10498	101
10499	101
10500	101
10501	101
10502	101
10503	101
10504	101
10505	101
10506	101
10507	101
10508	101
10509	101
10510	101
10511	101
10512	101
10513	101
10514	101
10515	101
10516	101
10517	101
10518	101
10519	101
10520	101
10521	101
10522	101
10523	101
10524	101
10525	101
10526	101
10527	101
10528	101
10530	101
10531	101
10532	101
10533	101
10534	101
10535	101
10536	101
10537	101
10538	101
10539	102
10540	101
10542	101
10543	101
10544	101
10545	101
10547	101
10548	101
10549	101
10552	101
10553	101
10554	101
10555	101
10556	101
10557	102
10558	101
10559	101
10560	101
10561	101
10562	101
10563	101
10564	101
10565	101
10566	101
10567	101
10568	101
10569	101
10570	101
10571	101
10572	101
10573	101
10574	101
10575	101
10576	101
10577	101
10578	101
10579	101
10580	101
10581	101
10582	101
10583	101
10584	101
10585	101
10586	101
10587	101
10588	101
10589	101
10590	101
10591	101
10592	101
10593	101
10594	101
10595	101
10596	101
10597	101
10598	101
10599	101
10600	101
10601	101
10602	101
10603	101
10604	101
10605	101
10606	101
10607	101
10608	101
10609	102
10610	101
10611	101
10612	101
10613	101
10614	101
10615	101
10616	101
10617	101
10618	101
10619	101
10620	102
10621	101
10622	101
10623	101
10624	101
10625	101
10626	101
10627	101
10628	101
10629	101
10630	101
10631	101
10632	101
10633	101
10634	102
10635	101
10636	101
10637	101
10638	101
10639	101
10640	101
10641	101
10642	101
10643	101
10644	101
10645	101
10646	101
10647	101
10648	101
10649	101
10650	101
10651	101
10652	101
10653	102
10654	101
10655	101
10656	101
10657	101
10658	101
10659	101
10660	101
10661	101
10662	101
10663	101
10664	101
10665	101
10666	101
10667	101
10668	101
10669	101
10670	101
10671	101
10672	101
10674	101
10675	101
10676	101
10677	101
10678	101
10679	101
10680	101
10681	101
10682	101
10683	101
10684	101
10686	101
10687	101
10688	101
10689	101
10690	101
10691	101
10692	101
10693	101
10694	101
10695	101
10696	102
10697	101
10698	101
10699	101
10700	101
10701	101
10703	101
10704	102
10705	101
10706	101
10707	101
10708	101
10709	101
10710	101
10711	101
10712	101
10713	101
10714	101
10715	101
10716	101
10717	101
10718	101
10719	101
10720	101
10721	101
10722	101
10723	101
10724	101
10725	101
10726	101
10727	101
10728	101
10729	101
10730	101
10732	101
10733	101
10734	101
10735	101
10736	101
10737	101
10738	101
10739	101
10740	101
10741	101
10742	102
10743	101
10745	102
10746	102
10747	101
10748	101
10749	101
10750	101
10751	101
10752	101
10753	101
10754	101
10755	101
10756	101
10757	101
10758	101
10759	101
10760	101
10761	101
10762	101
10763	101
10765	101
10766	101
10767	101
10768	101
10769	101
10770	101
10771	101
10772	102
10773	101
10775	101
10777	101
10778	101
10779	101
10780	101
10782	101
10784	102
10785	101
10786	102
10787	101
10788	102
10789	102
10790	101
10791	101
10792	101
10793	101
10794	101
10796	101
10797	101
10798	101
10800	101
10801	101
10802	101
10803	101
10804	101
10805	101
10806	101
10807	101
10808	101
10810	101
10813	101
10814	101
10815	102
10816	101
10817	101
10818	101
10819	101
10823	101
10824	101
10825	102
10826	101
10827	102
10828	101
10829	101
10830	101
10831	101
10832	101
10833	102
10834	101
10836	101
10837	101
10838	101
10839	101
10840	101
10841	101
10843	101
10844	101
10847	101
10848	101
10849	101
10850	101
10852	101
10853	101
10854	101
10855	101
10856	101
10857	101
10858	101
10859	101
10860	102
10862	101
10863	101
10864	101
10865	101
10866	102
10867	101
10868	101
10869	101
10870	101
10872	101
10873	101
10874	101
10875	101
10876	101
10878	102
10879	101
10880	101
10881	101
10882	101
10883	101
10884	101
10885	101
10886	101
10888	101
10889	101
10890	101
10891	102
10892	101
10893	101
10894	101
10895	101
10896	101
10897	101
10898	102
10899	101
10900	101
10901	101
10902	101
10903	101
10904	102
10905	101
10906	102
10907	101
10910	102
10911	101
10912	101
10913	101
10914	101
10915	101
10916	101
10917	101
10918	101
10919	101
10921	102
10922	101
10923	101
10924	102
10926	101
10927	101
10928	101
10929	101
10930	101
10931	101
10932	101
10933	101
10934	101
10936	101
10937	101
10938	101
10939	101
10940	101
10941	101
10942	101
10943	101
10944	101
10945	101
10946	101
10947	101
10948	101
10949	102
10950	101
10951	101
10953	101
10954	101
10955	101
10956	101
10957	101
10958	101
10960	101
10961	101
10962	101
10963	101
10964	102
10968	101
10969	101
10970	102
10971	101
10972	101
10973	101
10974	101
10975	101
10976	102
10978	101
10979	101
10982	101
10983	101
10984	101
10985	101
10986	101
10987	101
10988	101
10989	101
10990	101
10991	101
10992	101
10993	101
10994	101
10995	101
10996	101
10997	101
10998	101
10999	101
11001	101
11002	101
11003	101
11004	101
11006	101
11007	101
11008	101
11009	101
11010	101
11012	101
11013	101
11014	101
11015	101
11016	101
11017	101
11018	101
11020	101
11021	101
11022	101
11023	101
11025	101
11026	101
11029	101
11030	101
11031	101
11032	101
11033	101
11034	101
11035	101
11036	101
11037	101
11038	101
11039	101
11040	101
11041	101
11042	101
11043	101
11044	101
11045	101
11046	101
11047	101
11048	101
11049	101
11050	101
11051	101
11052	101
11053	101
11054	101
11056	101
11057	101
11058	101
11059	101
11060	101
11061	101
11062	101
11063	101
11064	101
11065	101
11066	101
11068	101
11069	101
11070	101
11071	101
11072	101
11073	101
11074	101
11075	102
11076	101
11077	101
11079	101
11080	101
11081	101
11082	101
11083	101
11084	101
11085	101
11087	101
11088	101
11089	101
11090	101
11091	101
11092	101
11093	101
11094	101
11095	101
11097	101
11098	101
11099	101
11100	101
11101	101
11102	101
11103	101
11104	101
11105	101
11106	101
11107	101
11108	101
11109	101
11111	101
11112	101
11114	101
11115	101
11116	101
11117	101
11118	101
11119	101
11120	101
11121	101
11122	101
11124	101
11125	101
11126	101
11127	101
11128	102
11129	101
11130	101
11131	101
11132	101
11133	101
11134	101
11135	101
11136	101
11137	101
11138	101
11139	101
11140	101
11141	101
11142	101
11143	101
11144	101
11145	101
11146	101
11147	101
11148	101
11149	101
11150	101
11151	101
11152	101
11154	101
11155	101
11156	101
11157	101
11158	101
11159	101
11160	101
11161	101
11162	101
11163	101
11164	101
11165	101
11166	101
11167	101
11168	101
11169	101
11170	101
11171	101
11172	101
11173	101
11174	101
11175	101
11176	101
11177	101
11178	101
11179	101
11180	101
11181	101
11182	101
11183	101
11185	101
11186	101
11187	101
11188	101
11189	101
11190	101
11191	101
11192	101
11193	101
11194	101
11195	101
11196	101
11197	101
11198	101
11199	101
11200	101
11204	101
11205	101
11206	101
11207	101
11208	101
11209	101
11210	101
11211	101
11212	101
11214	101
11215	101
11216	101
11217	101
11218	101
11219	101
11220	101
11221	101
11222	101
11224	101
11225	101
11226	101
11228	101
11229	101
11230	101
11231	102
11233	101
11234	102
11235	101
11236	101
11237	101
11238	101
11239	101
11240	101
11241	101
11242	101
11243	101
11244	101
11245	101
11246	101
11247	101
11248	101
11249	101
11250	101
11251	101
11252	101
11253	101
11254	101
11255	101
11256	101
11257	101
11258	101
11259	101
11260	101
11261	101
11262	102
11264	101
11265	101
11266	101
11267	101
11268	101
11269	101
11270	101
11271	101
11272	101
11273	101
11274	101
11275	101
11276	101
11277	101
11278	101
11279	101
11280	101
11281	101
11282	102
11283	101
11284	101
11285	101
11286	101
11287	102
11288	101
11289	101
11290	101
11292	101
11293	101
11294	101
11295	101
11296	101
11297	102
11298	101
11299	101
11300	101
11302	101
11303	101
11305	101
11306	101
11307	102
11309	101
11310	101
11311	101
11312	101
11313	101
11314	101
11315	101
11316	101
11317	101
11318	102
11319	101
11320	101
11321	101
11322	102
11323	101
11324	101
11325	101
11326	101
11327	101
11328	101
11329	101
11330	101
11331	101
11332	101
11333	101
11334	101
11336	101
11337	101
11338	101
11339	101
11340	101
11341	101
11342	101
11344	101
11345	101
11346	101
11347	101
11348	101
11349	101
11351	101
11352	102
11353	101
11354	102
11355	101
11356	101
11358	101
11359	101
11360	101
11361	101
11362	101
11363	101
11364	101
11365	101
11366	101
11367	101
11368	101
11369	101
11370	101
11372	101
11373	101
11374	101
11375	101
11376	101
11377	101
11378	101
11379	101
11380	101
11381	101
11382	101
11383	101
11385	101
11386	101
11387	101
11388	101
11389	101
11390	101
11391	101
11392	102
11393	101
11394	101
11395	101
11396	101
11397	101
11398	101
11399	101
11400	101
11401	101
11402	101
11403	101
11404	101
11405	101
11406	101
11407	101
11408	101
11409	101
11410	101
11411	101
11412	101
11413	101
11414	101
11415	101
11416	101
11417	101
11418	101
11419	101
11420	101
11421	101
11422	101
11423	101
11424	101
11425	101
11426	101
11427	101
11428	101
11429	101
11430	101
11431	101
11432	101
11433	101
11434	101
11435	101
11436	101
11437	101
11438	101
11439	101
11440	101
11441	101
11442	101
11443	101
11444	101
11445	101
11446	101
11447	101
11448	101
11449	101
11450	101
11451	101
11452	101
11453	101
11454	101
11455	101
11456	101
11457	101
11459	101
11460	101
11461	101
11462	101
11463	101
11464	101
11465	101
11466	101
11467	101
11468	101
11469	101
11470	101
11471	101
11473	101
11474	101
11475	101
11476	101
11477	101
11478	101
11479	101
11480	101
11481	101
11482	101
11483	101
11484	101
11485	101
11486	101
11487	101
11488	101
11489	101
11490	101
11491	101
11492	101
11493	101
11494	101
11495	101
11496	101
11497	101
11498	101
11499	101
11500	101
11501	101
11502	101
11503	101
11504	101
11505	101
11506	101
11507	102
11508	101
11509	101
11510	101
11511	101
11512	101
11513	101
11514	101
11515	101
11516	101
11517	101
11518	101
11519	101
11520	101
11521	101
11522	101
11523	101
11524	101
11525	101
11526	101
11527	101
11528	101
11529	101
11530	101
11531	101
11532	101
11533	101
11534	101
11536	101
11537	101
11538	101
11539	101
11540	101
11541	101
11542	101
11543	101
11544	101
11545	101
11546	101
11547	101
11548	101
11549	101
11550	101
11551	101
11552	101
11553	101
11554	101
11555	101
11556	101
11557	101
11558	101
11559	101
11560	101
11561	101
11562	101
11563	101
11564	101
11565	101
11566	101
11567	101
11568	101
11569	101
11570	101
11571	101
11572	101
11573	101
11574	101
11575	101
11576	101
11577	101
11578	101
11579	101
11580	101
11581	101
11582	101
11583	101
11584	101
11585	101
11586	101
11587	101
11588	101
11589	101
11590	101
11591	101
11592	101
11593	101
11595	101
11596	101
11597	101
11598	101
11599	101
11600	101
11602	101
11603	101
11604	101
11605	101
11606	101
11607	101
11608	101
11609	101
11610	102
11611	101
11612	101
11613	101
11614	101
11615	101
11616	101
11617	101
11618	101
11619	101
11620	101
11621	101
11622	101
11623	101
11624	101
11625	101
11626	101
11627	101
11628	101
11629	101
11630	101
11631	101
11632	101
11633	101
11634	101
11635	101
11636	101
11637	101
11638	101
11639	101
11640	101
11641	101
11642	101
11643	101
11644	101
11645	101
11646	101
11647	101
11648	101
11649	101
11650	101
11651	101
11652	101
11653	101
11654	101
11655	101
11656	101
11657	101
11658	101
11659	101
11660	101
11661	101
11662	101
11663	101
11664	101
11665	101
11666	101
11667	101
11668	101
11669	101
11670	101
11671	101
11672	101
11673	101
11674	101
11675	101
11676	101
11677	101
11678	101
11679	101
11680	101
11681	101
11682	101
11683	101
11684	101
11685	101
11686	101
11687	101
11688	101
11689	101
11690	101
11691	101
11692	101
11693	101
11694	101
11695	101
11696	101
11697	101
11698	101
11699	101
11700	101
11701	101
11702	101
11703	101
11704	101
11705	101
11706	101
11707	101
11708	101
11709	101
11710	101
11712	101
11713	101
11714	101
11715	101
11716	101
11717	101
11718	101
11719	101
11720	101
11721	102
11722	101
11723	101
11724	101
11725	101
11726	101
11727	101
11728	101
11729	101
11730	101
11731	101
11732	101
11733	101
11735	101
11736	101
11737	101
11738	101
11739	101
11740	101
11741	101
11742	101
11743	101
11744	101
11745	101
11746	101
11747	101
11748	101
11750	101
11751	101
11752	101
11753	101
11754	101
11755	101
11756	101
11757	101
11758	101
11761	101
11762	101
11763	101
11764	101
11765	101
11768	101
11770	101
11771	101
11772	101
11774	101
11775	101
11776	101
11777	101
11778	101
11779	101
11780	101
11781	101
11783	101
11784	101
11786	101
11787	101
11788	101
11789	101
11790	101
11791	101
11792	102
11793	101
11794	101
11795	101
11797	101
11798	101
11799	101
11800	101
11802	101
11803	102
11804	101
11805	101
11806	101
11807	101
11808	101
11809	101
11811	101
11812	101
11813	101
11815	101
11816	101
11817	101
11818	101
11819	101
11820	101
11821	101
11822	101
11823	101
11824	101
11825	101
11826	101
11827	101
11828	101
11829	101
11830	101
11831	101
11832	101
11839	101
11840	101
11841	101
11842	101
11843	101
11844	101
11846	101
11847	101
11848	102
11849	101
11851	101
11852	101
11853	102
11854	101
11855	101
11857	101
11858	101
11860	101
11861	101
11862	101
11863	101
11864	101
11866	101
11867	102
11868	101
11869	101
11870	101
11871	101
11872	101
11873	101
11874	101
11875	101
11876	101
11877	102
11878	101
11879	101
11880	101
11882	101
11883	101
11884	101
11885	101
11886	101
11887	101
11888	101
11889	101
11890	101
11891	101
11892	101
11893	101
11895	101
11896	101
11897	101
11899	101
11901	101
11902	101
11903	101
11904	101
11905	102
11906	102
11907	101
11908	101
11909	101
11910	101
11911	101
11912	101
11913	101
11914	101
11915	101
11916	101
11917	101
11918	101
11919	101
11920	101
11921	101
11922	101
11923	101
11924	101
11925	101
11926	101
11927	101
11928	101
11929	101
11930	101
11931	101
11932	101
11933	101
11934	101
11935	101
11936	101
11937	101
11938	101
11939	101
11940	101
11941	101
11942	101
11943	101
11944	101
11945	101
11946	101
11947	101
11948	101
11949	101
11950	101
11951	101
11952	101
11953	101
11954	101
11955	101
11956	101
11957	101
11958	101
11959	101
11960	101
11961	101
11962	101
11963	101
11964	101
11965	101
11966	101
11967	101
11968	101
11979	101
11980	101
11981	101
11982	101
11983	101
11984	101
11985	101
11987	101
11988	101
11989	101
11990	101
11991	101
11992	101
11994	101
11995	101
11996	101
11997	101
11998	101
11999	101
12000	101
12001	101
12002	101
12003	101
12004	101
12006	101
12007	101
12008	102
12009	102
12010	101
12011	101
12012	101
12013	101
12014	101
12015	101
12017	101
12018	101
12019	102
12020	101
12021	101
12022	101
12023	101
12024	101
12025	101
12026	101
12027	101
12028	101
12029	101
12030	101
12031	101
12032	101
12033	101
12034	101
12035	101
12036	101
12039	101
12040	101
12041	101
12041	102
12044	102
12045	101
12046	101
12047	101
12049	101
12050	101
12051	101
12052	101
12053	101
12054	101
12056	101
12057	101
12059	101
12060	101
12061	101
12062	101
12063	101
12064	101
12065	102
12066	101
12067	101
12068	101
12069	101
12070	101
12071	101
12072	102
12075	102
12083	102
12086	102
12105	102
12106	102
12109	101
12114	102
12115	101
12118	102
12122	102
12124	101
12135	102
12149	101
12151	102
12157	102
12162	102
12167	101
12173	101
12174	101
12175	101
12176	101
12178	101
12179	101
12180	101
12181	101
12183	102
12184	101
12185	101
12187	101
12188	101
12191	101
12194	101
12195	101
12196	101
12197	101
12198	101
12199	101
12202	101
12205	101
12206	101
12209	101
12210	101
12211	101
12212	101
12214	101
12215	101
12216	101
12219	101
12220	101
12222	101
12227	101
12229	101
12231	101
12232	101
12234	101
12235	101
12237	101
12238	101
12240	102
12242	101
12243	101
12244	101
12246	101
12251	101
12254	101
12255	101
12256	101
12257	101
12261	101
12268	101
12279	101
12284	101
12285	102
12288	102
12296	101
12297	101
12299	101
12324	101
12328	101
12329	101
12330	101
12333	101
12334	101
12335	101
12336	101
12337	101
12339	101
12340	102
12341	101
12343	101
12345	101
12346	101
12347	101
12348	101
12349	101
12350	101
12351	101
12352	101
12353	101
12355	102
12361	101
12363	101
12364	101
12370	101
12380	101
12381	102
12384	101
12386	102
12387	101
12388	101
12392	101
12393	101
12394	101
12395	101
12396	101
12401	101
12406	101
12411	101
12414	101
12417	101
12418	101
12422	102
12444	101
12450	101
12451	101
12457	101
12459	102
12462	101
12467	101
12471	101
12485	101
12490	101
12516	101
12521	101
12538	101
12540	101
12543	101
12544	101
12546	101
12547	101
12548	101
12549	101
12550	101
12551	101
12552	101
12553	101
12554	101
12555	101
12556	101
12557	101
12558	101
12559	101
12561	101
12562	101
12563	101
12564	101
12565	101
12568	101
12570	101
12571	101
12572	101
12573	101
12574	101
12576	101
12577	101
12578	101
12579	101
12581	101
12595	101
12596	101
12603	101
12606	101
12608	102
12613	101
12615	101
12616	101
12617	101
12618	101
12620	101
12621	101
12622	101
12623	101
12624	101
12625	101
12627	101
12629	102
12632	101
12633	101
12634	101
12635	101
12636	101
12637	101
12639	101
12640	101
12641	101
12642	101
12644	101
12648	101
12655	101
12656	101
12657	101
12666	102
12667	102
12668	101
12671	101
12672	101
12674	102
12676	101
12677	101
12679	102
12680	101
12682	102
12683	102
12684	101
12685	102
12687	102
12689	101
12690	101
12692	101
12693	101
12695	101
12698	101
12699	101
12700	101
12701	101
12704	101
12707	101
12708	101
12710	101
12712	101
12715	101
12717	101
12718	101
12719	101
12720	101
12721	101
12722	101
12723	101
12724	101
12726	101
12728	101
12729	101
12730	101
12731	102
12732	101
12733	101
12734	101
12735	101
12736	101
12743	101
12745	101
12746	101
12747	101
12748	101
12749	101
12751	101
12753	101
12754	101
12755	101
12757	101
12758	101
12760	101
12761	101
12765	101
12768	101
12769	102
12771	101
12773	101
12774	101
12776	101
12777	101
12778	101
12779	101
12781	101
12782	101
12786	101
12790	101
12793	101
12794	101
12795	101
12796	102
12797	101
12798	101
12800	101
12801	101
12802	102
12803	101
12816	102
12819	101
12822	101
12826	101
12828	101
12831	101
12832	101
12833	101
12834	101
12841	101
12848	102
12852	101
12853	101
12854	101
12855	101
12856	101
12857	101
12858	101
12859	101
12860	101
12861	101
12862	101
12863	101
12864	101
12865	101
12866	101
12868	101
12870	101
12872	101
12873	101
12874	101
12875	101
12876	101
12877	101
12878	101
12879	101
12883	101
12910	101
12936	101
12939	101
12940	101
12941	101
12942	101
12944	101
12945	101
12946	101
12947	101
12948	101
12950	101
12952	101
12953	101
12954	101
12955	101
12957	101
12958	101
12959	101
12961	101
12963	101
12964	101
12966	101
12975	101
12980	102
12990	101
12991	101
12993	101
12994	101
12995	101
12996	101
12997	101
12999	101
13006	101
13007	102
13008	101
13010	101
13017	101
13019	101
13023	101
13039	101
13048	102
13051	101
13053	101
13055	102
13059	102
13060	101
13067	101
13068	101
13070	101
13071	102
13072	101
13073	101
13075	101
13076	101
13079	102
13080	101
13082	101
13091	101
13103	101
13104	101
13105	101
13106	101
13108	101
13111	102
13112	101
13114	102
13115	102
13116	101
13118	101
13119	101
13120	101
13121	101
13122	101
13123	101
13124	101
13125	101
13126	101
13127	101
13128	101
13129	102
13130	101
13131	101
13133	101
13135	101
13137	101
13138	101
13139	101
13140	101
13141	101
13142	101
13144	101
13145	102
13146	101
13147	101
13148	101
13149	101
13150	101
13150	102
13151	101
13152	101
13153	101
13154	101
13156	101
13157	101
13158	101
13159	102
13161	101
13162	101
13163	101
13164	101
13165	101
13166	101
13167	101
13168	101
13169	101
13170	101
13171	101
13172	101
13173	102
13174	101
13175	101
13176	101
13177	101
13178	102
13179	101
13180	101
13181	101
13182	101
13183	101
13184	101
13185	101
13186	101
13187	101
13190	102
13193	101
13202	101
13208	101
13217	101
13222	102
13224	101
13225	101
13226	101
13227	101
13229	101
13230	101
13232	101
13234	101
13237	101
13239	101
13240	101
13241	101
13242	102
13243	101
13243	102
13251	102
13252	101
13257	101
13258	101
13259	101
13261	101
13262	101
13267	101
13268	101
13269	101
13270	101
13271	101
13272	101
13273	101
13274	101
13275	101
13276	101
13277	101
13278	101
13279	101
13280	101
13281	101
13282	101
13283	101
13284	101
13285	101
13286	102
13287	101
13288	101
13289	101
13290	101
13291	101
13292	101
13293	101
13294	101
13295	101
13296	101
13297	101
13298	101
13305	101
13310	101
13311	101
13316	101
13318	101
13319	101
13320	101
13321	101
13324	101
13325	101
13326	101
13327	101
13330	101
13331	101
13332	101
13334	101
13335	101
13337	101
13338	101
13340	101
13342	101
13343	102
13344	101
13345	101
13346	101
13347	101
13348	101
13349	101
13350	102
13351	101
13352	101
13353	101
13355	102
13359	101
13362	101
13367	102
13368	102
13370	102
13378	101
13379	102
13381	102
13388	101
13390	101
13391	101
13392	101
13396	101
13397	101
13398	102
13401	101
13402	101
13406	101
13407	101
13409	101
13412	101
13415	101
13419	102
13420	101
13421	102
13422	101
13423	102
13425	101
13426	101
13429	101
13431	101
13433	101
13434	101
13438	102
13442	101
13443	101
13446	101
13447	102
13448	101
13450	101
13451	101
13455	101
13456	101
13457	101
13459	101
13461	101
13462	101
13463	101
13466	101
13467	102
13468	102
13469	101
13473	101
13475	101
13477	101
13478	101
13480	101
13481	101
13482	101
13489	101
13490	101
13493	101
13494	102
13497	101
13498	101
13501	101
13505	101
13507	101
13512	102
13521	101
13522	101
13523	101
13524	101
13525	101
13526	101
13533	101
13534	101
13536	101
13537	102
13538	101
13542	101
13543	101
13544	101
13545	101
13546	101
13549	101
13550	101
13551	101
13553	101
13554	101
13555	101
13556	101
13557	101
13558	101
13560	101
13561	101
13562	101
13565	101
13568	101
13569	101
13572	102
13573	101
13575	101
13576	101
13577	102
13578	101
13579	101
13601	101
13602	101
13603	101
13604	101
13605	101
13606	101
13607	101
13610	101
13611	101
13612	102
13613	101
13614	101
13617	101
13618	101
13619	101
13621	102
13623	101
13635	101
13637	101
13639	101
13640	101
13641	101
13642	101
13644	101
13645	101
13646	101
13650	101
13651	101
13653	101
13654	101
13656	101
13657	101
13660	101
13666	101
13667	101
13668	101
13669	101
13670	101
13671	101
13672	101
13673	101
13674	101
13675	101
13676	101
13677	101
13678	101
13679	101
13680	101
13681	101
13682	101
13683	101
13684	101
13685	101
13687	101
13689	101
13690	101
13691	101
13708	101
13710	101
13711	101
13717	101
13718	101
13719	101
13720	101
13721	101
13725	101
13726	101
13727	101
13728	101
13732	101
13734	101
13735	101
13736	101
13739	101
13740	102
13741	102
13742	102
13743	102
13744	101
13752	101
13757	101
13759	102
13760	102
13761	101
13762	101
13763	101
13764	101
13765	101
13766	101
13767	101
13768	101
13769	101
13771	101
13772	101
13773	101
13774	101
13775	101
13777	101
13778	101
13779	101
13780	101
13783	101
13784	101
13785	101
13786	101
13787	101
13789	101
13790	101
13791	101
13792	101
13793	101
13794	101
13795	101
13796	101
13797	101
13798	101
13799	101
13800	101
13801	101
13802	101
13803	101
13804	101
13805	101
13806	101
13807	101
13808	101
13809	101
13810	101
13812	101
13813	101
13814	101
13815	101
13816	101
13817	101
13818	101
13819	101
13820	101
13821	101
13822	101
13823	101
13824	101
13825	101
13826	101
13827	101
13828	101
13829	101
13832	101
13833	101
13834	101
13835	101
13836	101
13837	101
13838	101
13839	101
13840	101
13841	101
13844	102
13845	102
13846	101
13847	101
13851	101
13855	101
13856	101
13859	101
13864	101
13868	102
13869	101
13870	101
13872	101
13879	102
13881	101
13885	101
13887	101
13888	101
13893	101
13898	102
13899	101
13907	101
13911	101
13912	101
13914	102
13915	101
13916	102
13918	101
13923	101
13924	101
13927	101
13929	101
13935	101
13936	101
13937	101
13938	101
13942	102
13944	101
13946	102
13947	101
13952	101
13953	101
13954	102
13956	101
13957	102
13960	102
13964	101
13965	101
13969	101
13970	101
13971	101
13974	101
13975	101
13976	101
13977	101
13980	102
13983	101
13984	101
13987	101
13988	101
13990	101
13993	101
13995	101
13997	101
13998	101
13999	101
14000	101
14001	101
14002	101
14003	101
14006	101
14007	101
14008	101
14009	101
14010	101
14012	101
14013	101
14015	101
14016	101
14017	101
14020	101
14021	101
14023	101
14024	101
14025	101
14026	101
14030	101
14032	101
14034	102
14037	101
14038	101
14039	101
14040	101
14041	102
14042	102
14044	101
14045	101
14046	101
14047	101
14048	101
14049	101
14050	101
14052	101
14053	101
14054	101
14055	101
14056	101
14060	101
14061	101
14062	101
14064	101
14066	101
14067	101
14068	101
14069	101
14070	101
14071	101
14072	101
14073	101
14074	101
14075	101
14076	101
14077	101
14078	101
14079	101
14080	101
14081	101
14082	101
14083	101
14084	101
14085	101
14086	101
14087	101
14088	101
14089	101
14090	101
14091	101
14092	101
14093	101
14095	101
14096	101
14097	101
14098	101
14099	101
14101	101
14102	102
14103	101
14105	101
14107	101
14108	101
14109	101
14110	101
14111	101
14112	101
14113	101
14114	101
14115	101
14116	101
14117	101
14118	101
14119	101
14120	101
14121	101
14122	101
14123	101
14124	101
14125	101
14126	101
14127	101
14128	101
14129	101
14130	101
14131	101
14132	101
14133	101
14134	101
14135	101
14136	101
14137	101
14138	101
14139	101
14140	101
14141	101
14142	101
14143	101
14144	101
14145	101
14146	101
14147	101
14150	101
14151	101
14152	101
14153	101
14155	101
14156	101
14157	101
14158	101
14159	101
14160	101
14161	101
14163	101
14164	101
14165	101
14166	101
14167	101
14168	101
14169	101
14170	101
14171	101
14172	101
14173	101
14174	101
14175	101
14176	101
14178	101
14179	101
14180	101
14181	101
14182	101
14183	101
14184	101
14185	101
14186	101
14187	101
14188	101
14189	101
14190	101
14191	101
14192	101
14193	101
14194	101
14195	101
14196	101
14197	101
14198	101
14199	101
14200	101
14201	101
14202	101
14203	101
14204	101
14205	101
14206	101
14207	101
14208	101
14209	101
14210	101
14211	101
14212	101
14213	101
14214	101
14215	101
14216	101
14217	101
14218	101
14219	101
14220	101
14221	101
14222	101
14223	101
14224	101
14225	101
14226	101
14227	101
14228	101
14229	101
14230	101
14231	101
14232	101
14233	101
14235	101
14236	101
14237	101
14238	101
14239	101
14240	101
14241	101
14242	101
14243	101
14244	101
14246	101
14248	101
14249	101
14250	101
14251	101
14252	101
14253	101
14254	101
14255	101
14256	101
14257	101
14258	101
14259	101
14260	101
14261	101
14262	101
14263	101
14264	101
14265	101
14266	101
14267	101
14268	101
14269	101
14270	101
14271	101
14272	101
14273	101
14274	101
14275	101
14276	101
14277	101
14278	101
14279	101
14280	101
14281	101
14282	101
14283	101
14284	101
14285	101
14286	101
14287	101
14288	101
14289	101
14290	101
14291	101
14292	101
14294	101
14295	101
14296	101
14297	101
14298	101
14299	101
14300	101
14301	101
14302	101
14303	101
14304	101
14305	101
14306	101
14307	101
14308	101
14310	101
14311	101
14312	101
14314	101
14315	101
14316	101
14317	101
14318	101
14319	101
14320	101
14321	101
14322	101
14323	101
14324	101
14325	101
14326	101
14327	101
14328	101
14329	101
14330	101
14331	101
14332	101
14333	101
14334	101
14335	101
14336	101
14337	101
14338	101
14339	101
14340	101
14341	101
14342	101
14343	101
14344	101
14345	101
14346	101
14347	101
14348	101
14349	101
14350	101
14351	101
14352	101
14353	101
14354	101
14355	101
14356	101
14357	101
14358	101
14359	101
14360	101
14361	101
14362	101
14363	101
14364	101
14365	101
14366	101
14367	101
14368	101
14369	101
14370	101
14371	101
14372	101
14373	101
14374	101
14375	101
14376	101
14377	101
14378	101
14379	101
14380	101
14381	101
14382	101
14383	101
14384	101
14385	101
14386	101
14387	101
14388	101
14389	101
14390	101
14391	101
14392	101
14393	101
14394	101
14395	101
14396	101
14397	101
14398	101
14399	101
14400	101
14401	101
14403	101
14405	101
14406	101
14407	101
14408	101
14410	101
14411	101
14412	101
14413	101
14414	101
14415	101
14416	101
14417	101
14418	101
14419	101
14420	101
14421	101
14422	101
14423	101
14424	101
14425	101
14426	101
14427	101
14428	101
14429	101
14430	101
14431	101
14432	101
14433	101
14434	101
14436	101
14437	101
14438	101
14439	101
14440	101
14441	101
14442	101
14443	101
14444	101
14445	101
14446	101
14447	101
14449	101
14450	101
14451	101
14452	101
14453	101
14454	101
14455	101
14456	101
14457	101
14458	101
14459	101
14460	101
14461	101
14462	101
14463	101
14464	101
14465	101
14466	101
14467	101
14468	101
14469	101
14470	101
14471	101
14472	101
14473	101
14474	101
14475	101
14476	101
14477	101
14478	101
14479	101
14480	101
14481	101
14482	101
14483	101
14484	101
14485	101
14486	101
14487	101
14488	101
14489	101
14490	101
14491	101
14492	101
14494	101
14495	101
14496	101
14497	101
14498	101
14499	101
14500	101
14501	101
14502	101
14503	101
14504	101
14505	101
14506	101
14507	101
14508	101
14509	101
14510	101
14512	101
14513	101
14514	101
14515	101
14516	101
14518	101
14519	101
14520	101
14521	101
14523	101
14524	101
14525	101
14526	101
14527	101
14528	101
14529	101
14530	101
14531	101
14532	101
14533	101
14534	101
14535	101
14536	101
14538	101
14539	101
14540	101
14541	101
14542	101
14543	101
14547	101
14549	101
14550	101
14552	101
14553	101
14555	101
14557	101
14559	101
14560	101
14561	101
14567	101
14568	101
14569	102
14573	101
14574	101
14575	102
14577	101
14581	101
14582	101
14584	102
14586	101
14591	101
14594	101
14595	101
14596	101
14597	101
14598	101
14599	101
14602	101
14604	101
14605	101
14606	101
14607	101
14608	101
14609	101
14610	101
14611	101
14614	101
14615	101
14616	101
14617	101
14618	101
14619	101
14620	101
14621	101
14622	101
14623	101
14624	101
14625	101
14626	101
14627	101
14628	101
14629	102
14631	101
14632	101
14640	101
14642	101
14643	101
14644	101
14645	101
14648	101
14660	101
14661	101
14664	101
14665	101
14676	101
14677	101
14693	101
14694	101
14698	101
14706	101
14709	101
14714	101
14716	101
14717	101
14718	101
14728	101
14732	101
14735	101
14739	101
14747	101
14750	101
14759	102
14763	101
14765	101
14767	101
14772	101
14781	101
14782	101
14787	101
14791	101
14792	101
14799	101
14805	101
14806	101
14815	101
14820	101
14824	101
14826	101
14827	101
14829	101
14833	101
14838	101
14845	101
14848	101
14849	101
14850	101
14852	101
14853	101
14855	101
14856	101
14857	102
14863	102
14867	101
14877	102
14878	101
14879	101
14880	101
14882	101
14883	101
14884	101
14885	101
14886	101
14887	101
14888	102
14889	101
14890	101
14893	101
14895	101
14897	101
14898	101
14906	101
14907	101
14908	101
14909	101
14910	101
14911	101
14913	101
14914	101
14917	101
14918	101
14920	101
14921	101
14922	101
14923	101
14925	101
14927	102
14929	102
14930	101
14931	101
14932	101
14933	101
14934	101
14935	101
14936	101
14937	101
14938	101
14940	102
14941	102
14942	102
14943	102
14944	101
14945	101
14946	101
14947	102
14949	101
14951	101
14953	101
14955	101
14957	101
14960	101
14966	101
14967	101
14970	101
14972	101
14974	102
14977	101
14980	101
14982	101
14984	101
14986	101
14987	101
14989	101
14990	101
14991	101
14992	102
14993	101
14994	101
14995	101
14996	101
14997	101
14998	101
14999	101
15000	101
15001	101
15003	101
15004	101
15007	101
15008	101
15009	101
15010	101
15012	101
15014	101
15015	101
15016	101
15017	101
15018	101
15019	101
15020	101
15021	101
15024	101
15025	101
15026	101
15027	101
15029	101
15030	101
15032	101
15033	101
15034	101
15035	101
15037	101
15038	101
15039	101
15040	101
15043	101
15045	101
15046	101
15047	101
15048	101
15050	101
15052	101
15053	102
15054	101
15055	101
15056	101
15057	101
15058	101
15059	101
15061	101
15062	101
15067	101
15068	101
15070	101
15072	101
15073	101
15074	101
15075	101
15077	101
15230	101
15253	101
15267	101
15293	101
15294	101
15296	101
15297	101
15299	101
15300	101
15301	101
15302	101
15303	101
15304	101
15309	101
15310	101
15311	101
15312	101
15313	101
15314	101
15315	101
15316	101
15317	102
15318	102
15321	101
15322	101
15324	101
15325	101
15326	101
15327	101
15328	101
15329	101
15330	101
15331	101
15332	101
15333	101
15334	101
15335	101
15336	101
15337	101
15347	101
15350	101
15358	101
15385	101
15386	101
15393	101
15394	101
15397	101
15406	101
15412	101
15413	101
15414	101
15416	101
15417	101
15419	101
15421	101
15422	101
15423	101
15425	101
15427	101
15431	101
15432	101
15433	101
15435	101
15437	101
15438	101
15440	101
15442	101
15443	101
15444	101
15445	101
15450	101
15453	101
15454	101
15455	101
15460	101
15461	101
15464	101
15465	101
15467	101
15468	101
15471	101
15473	101
15475	101
15480	101
15483	101
15484	101
15489	101
15495	101
15496	101
15499	101
15500	101
15501	101
15502	102
15503	101
15504	101
15505	102
15506	102
15507	101
15508	101
15509	101
15511	101
15513	101
15517	101
15518	102
15519	101
15524	101
15525	101
15527	101
15529	101
15531	101
15535	101
15538	101
15539	101
15540	101
15541	101
15542	101
15543	101
15544	101
15545	101
15546	101
15547	101
15548	101
15549	101
15551	101
15552	101
15553	101
15554	101
15557	101
15558	101
15561	101
15562	101
15563	101
15564	101
15568	102
15569	101
15570	101
15579	101
15581	102
15582	101
15584	101
15588	101
15589	101
15591	101
15593	101
15595	102
15597	101
15599	101
15600	102
15601	101
15602	101
15603	101
15604	101
15605	101
15606	101
15607	101
15609	101
15610	101
15611	101
15614	101
15615	101
15617	102
15618	101
15619	101
15620	101
15621	102
15622	101
15624	101
15625	101
15626	101
15627	101
15628	101
15629	101
15630	101
15631	101
15632	101
15633	101
15634	101
15635	101
15640	101
15641	101
15643	102
15644	102
15645	101
15647	101
15648	101
15649	101
15650	101
15651	101
15652	101
15653	102
15654	101
15655	101
15656	101
15657	101
15658	101
15659	101
15661	101
15662	102
15663	101
15664	101
15665	101
15666	101
15667	101
15668	101
15670	101
15671	101
15674	101
15675	101
15676	101
15677	101
15678	101
15680	101
15681	101
15682	101
15683	101
15684	101
15685	101
15686	101
15687	101
15689	101
15690	101
15691	101
15692	101
15693	101
15694	101
15695	101
15696	101
15697	101
15698	101
15699	101
15700	101
15721	101
15729	101
15732	101
15734	101
15736	101
15744	101
15745	101
15747	101
15757	101
15763	101
15764	101
15772	101
15775	101
15783	101
15785	101
15789	101
15806	101
15810	101
15822	101
15825	101
15827	101
15836	101
15838	101
15842	101
15844	101
15846	101
15850	101
15857	101
15868	101
15869	101
15877	101
15883	101
15884	101
15888	101
15894	101
15897	101
15911	101
15914	101
15932	102
15933	101
15934	101
15935	101
15937	101
15939	101
15943	101
15952	101
15955	101
15956	101
15972	101
15973	101
15975	101
15976	101
15977	101
15981	101
15984	101
15987	101
15999	101
16009	101
16017	101
16019	101
16020	101
16023	101
16025	101
16026	101
16034	101
16037	101
16038	101
16040	101
16045	101
16048	101
16050	101
16059	101
16066	101
16070	101
16071	101
16073	101
16074	101
16080	101
16083	101
16086	101
16087	101
16088	101
16089	101
16090	101
16091	101
16092	101
16101	101
16106	101
16114	101
16116	101
16121	101
16123	102
16134	101
16136	101
16138	101
16142	101
16153	101
16161	101
16163	101
16168	101
16180	101
16193	101
16195	101
16198	101
16204	101
16207	101
16211	101
16223	101
16224	101
16234	101
16236	101
16237	101
16245	101
16248	101
16258	101
16263	101
16265	101
16267	101
16269	101
16270	101
16271	101
16273	101
16286	101
16287	101
16289	101
16290	101
16293	101
16295	101
16296	101
16306	101
16312	101
16313	101
16316	101
16323	101
16325	101
16326	101
16328	101
16330	101
16334	101
16335	101
16337	101
16338	101
16341	101
16342	101
16343	101
16344	101
16345	101
16346	101
16348	101
16349	101
16353	101
16355	101
16356	101
16357	101
16359	101
16360	101
16362	101
16363	101
16364	101
16365	101
16366	101
16370	101
16371	101
16398	101
16400	101
16402	101
16405	101
16413	101
16414	101
16416	101
16418	102
16422	101
16427	101
16430	101
16436	101
16437	101
16441	101
16442	101
16443	101
16445	101
16447	101
16448	101
16449	101
16450	101
16451	101
16453	101
16457	101
16462	101
16469	101
16472	101
16473	101
16485	101
16487	101
16489	101
16490	101
16491	101
16494	101
16495	101
16496	101
16497	101
16499	101
16503	101
16504	101
16505	101
16506	101
16507	101
16509	101
16511	101
16513	101
16514	101
16518	101
16519	101
16522	101
16524	101
16526	101
16530	101
16533	101
16534	101
16535	101
16536	101
16548	101
16555	101
16563	101
16566	101
16569	101
16573	101
16575	101
16576	101
16587	101
16588	101
16595	101
16597	101
16601	101
16602	101
16606	101
16608	101
16612	101
16621	101
16622	101
16626	101
16627	101
16628	101
16632	101
16635	101
16644	101
16667	101
16669	101
16670	101
16681	101
16695	101
16700	101
16701	101
16702	101
16703	101
16704	101
16705	101
16710	101
16715	101
16722	101
16729	101
16737	101
16744	101
16747	101
16748	101
16755	101
16759	101
16760	101
16761	101
16762	101
16765	101
16770	101
16772	101
16775	101
16780	101
16782	101
16784	102
16786	101
16796	101
16797	101
16799	101
16800	101
16804	101
16805	101
16808	101
16824	101
16828	101
16834	101
16845	101
16847	101
16853	101
16854	101
16857	101
16873	101
16882	102
16892	101
16903	101
16913	102
16915	101
16919	101
16926	101
16937	101
16939	102
16945	101
16948	101
16957	101
16958	101
16959	101
16960	101
16961	101
16962	101
16963	101
16964	101
16965	101
16969	101
16970	101
16972	101
16973	101
16975	101
16976	101
16977	101
16978	101
16980	101
16984	101
16988	101
16989	101
16993	101
16994	101
17003	101
17007	101
17015	101
17032	101
17048	101
17049	101
17052	101
17053	101
17054	101
17055	101
17056	101
17060	101
17061	101
17062	101
17063	101
17064	101
17069	101
17072	101
17078	101
17080	101
17081	101
17082	101
17083	101
17085	101
17086	101
17087	101
17088	101
17090	101
17091	101
17092	101
17094	101
17096	101
17097	101
17098	101
17101	101
17104	101
17106	101
17108	101
17109	101
17110	101
17111	101
17112	101
17113	101
17114	101
17116	101
17118	101
17119	101
17120	101
17122	101
17124	101
17125	101
17127	101
17130	101
17133	101
17134	101
17141	101
17143	101
17149	101
17152	101
17153	101
17162	101
17178	101
17179	101
17180	101
17183	101
17184	101
17185	102
17187	102
17188	101
17191	101
17196	101
17197	101
17198	101
17199	101
17200	101
17201	101
17203	101
17204	101
17205	101
17210	101
17211	101
17213	101
17214	102
17218	101
17223	101
17227	101
17229	101
17230	101
17231	101
17232	101
17233	101
17234	101
17236	101
17237	101
17238	101
17239	101
17240	102
17241	101
17243	101
17244	101
17246	101
17247	101
17248	101
17250	101
17251	101
17252	101
17254	101
17263	101
17338	101
17408	101
17786	101
17867	101
17868	101
17869	102
17872	101
17876	101
17878	101
17881	101
17883	102
17884	101
17885	101
17886	101
17887	101
17888	101
17894	101
17895	101
17896	101
17897	101
17900	101
17901	101
17902	101
17904	101
17905	101
17906	101
17910	101
17916	102
17917	101
17918	101
17919	101
17920	101
17921	101
17925	101
17926	101
17927	101
17928	101
17929	101
17930	101
17931	101
17932	101
17933	101
17934	101
17936	101
17939	101
17941	101
17942	101
17943	101
17944	101
17945	101
17946	101
17947	101
17949	102
17950	101
17951	101
17953	101
17954	101
17955	101
17956	101
17957	101
17958	101
17959	101
17961	101
17962	101
17964	101
17965	101
17966	101
17967	101
17968	102
17969	101
17970	101
17971	101
17972	101
17973	101
17974	101
17975	101
17976	101
17978	101
17984	101
17986	101
17988	101
17990	101
17991	101
17992	101
17993	101
17994	101
17995	101
17996	101
17998	101
17999	101
18002	101
18004	101
18013	101
18015	101
18017	102
18018	101
18019	101
18020	101
18021	101
18022	101
18031	101
18032	101
18033	101
18034	101
18035	101
18036	101
18037	101
18038	101
18039	101
18040	101
18041	101
18042	101
18043	101
18044	101
18045	101
18047	101
18051	101
18053	101
18056	101
18057	101
18058	101
18060	101
18061	101
18063	101
18064	101
18065	101
18066	101
18067	102
18068	101
18069	101
18071	101
18072	101
18073	101
18074	101
18075	101
18076	101
18079	101
18080	101
18081	101
18082	101
18083	101
18084	101
18085	101
18086	101
18087	101
18088	101
18089	101
18091	101
18092	101
18093	101
18094	101
18095	101
18098	101
18100	101
18101	101
18102	101
18103	101
18104	101
18105	101
18107	101
18108	101
18110	101
18111	101
18113	101
18114	101
18115	101
18117	101
18118	101
18119	101
18120	101
18121	101
18122	101
18123	101
18124	101
18125	101
18126	101
18127	101
18129	101
18130	101
18131	101
18132	101
18133	101
18134	101
18135	101
18136	101
18141	101
18142	101
18143	101
18144	101
18146	101
18147	101
18148	101
18149	101
18156	101
18157	101
18158	101
18159	101
18160	101
18161	101
18162	101
18172	101
18173	101
18176	101
18177	101
18178	101
18180	101
18199	101
18200	101
18202	101
18204	101
18206	101
18208	101
18210	101
18211	101
18212	101
18213	101
18214	101
18215	101
18222	101
18224	101
18227	101
18229	101
18230	101
18232	101
18233	101
18235	101
18238	101
18240	101
18244	101
18245	101
18247	101
18250	101
18254	101
18255	102
18257	101
18258	101
18259	101
18260	101
18261	101
18265	101
18268	101
18271	101
18279	101
18281	101
18282	101
18283	101
18284	101
18285	101
18287	101
18289	101
18290	101
18291	101
18293	101
18294	101
18295	101
18298	101
18299	101
18300	101
18301	101
18302	101
18304	101
18306	101
18307	101
18313	101
18328	101
18329	101
18332	101
18337	101
18339	101
18340	101
18342	101
18343	101
18349	101
18350	101
18351	101
18352	101
18353	101
18354	101
18355	101
18356	101
18358	101
18360	101
18361	101
18362	101
18367	101
18368	101
18369	101
18371	101
18373	101
18374	101
18378	101
18379	101
18382	101
18383	101
18387	101
18390	101
18393	101
18394	101
18399	101
18401	101
18402	101
18403	101
18408	101
18413	101
18414	101
18415	101
18417	101
18418	101
18419	101
18420	101
18421	101
18422	101
18423	101
18424	101
18425	101
18427	101
18428	101
18429	101
18430	101
18431	101
18432	101
18443	101
18449	101
18453	101
18458	101
18460	101
18462	101
18463	101
18475	101
18482	101
18502	101
18511	101
18525	101
18527	101
18530	101
18533	101
18538	101
18540	101
18543	102
18551	101
18556	101
18558	101
18560	101
18562	101
18565	101
18566	101
18568	101
18569	101
18570	101
18572	101
18574	101
18575	101
18576	101
18579	101
18580	101
18581	101
18582	101
18586	101
18593	101
18594	101
18598	101
18599	101
18605	101
18608	101
18609	101
18611	101
18612	101
18613	101
18618	101
18619	101
18620	101
18621	101
18623	101
18624	101
18625	101
18626	101
18629	101
18630	101
18631	101
18632	101
18633	101
18635	101
18638	101
18639	101
18640	101
18641	101
18642	101
18689	101
18690	101
18696	101
18698	101
18703	101
18718	101
18720	101
18723	101
18727	101
18728	101
18730	101
18731	101
18732	101
18733	101
18734	101
18735	101
18736	101
18738	101
18739	101
18740	101
18741	101
18743	101
18744	101
18745	101
18746	101
18750	101
18751	101
18753	101
18758	101
18759	101
18763	101
18764	101
18765	101
18766	101
18768	101
18769	101
18770	101
18773	101
18775	101
18777	101
18779	101
18784	101
18785	101
18788	101
18789	101
18790	101
18791	101
18792	101
18794	101
18795	101
18796	101
18805	101
18829	101
18830	101
18839	102
18842	101
18843	101
18846	101
18847	101
18850	101
18852	101
18853	101
18855	101
18857	101
18859	101
18860	101
18861	101
18862	101
18866	101
18867	101
18868	101
18869	101
18870	101
18871	101
18872	101
18873	101
18874	101
18876	101
18877	101
18878	101
18879	101
18883	101
18891	101
18895	101
18900	101
18905	101
18910	101
18911	101
18912	101
18914	101
18921	101
18923	101
18929	101
18930	101
18931	101
18932	101
18935	101
18936	101
18937	101
18940	101
18941	101
18942	101
18943	101
18944	101
18945	101
18946	101
18948	101
18950	101
18952	101
18953	101
18955	101
18962	101
18967	101
18981	101
18982	101
18983	101
18984	101
18985	101
18986	101
18987	101
18990	101
18993	101
18999	101
19004	101
19006	101
19008	101
19009	101
19011	101
19014	101
19018	101
19019	101
19020	101
19022	101
19023	101
19025	101
19027	101
19028	101
19029	101
19031	101
19033	101
19042	101
19058	101
19059	101
19060	101
19061	101
19062	101
19063	101
19064	101
19066	101
19068	101
19070	101
19072	101
19073	101
19074	101
19075	101
19076	101
19078	101
19079	101
19081	101
19082	101
19083	101
19084	101
19085	101
19086	101
19087	101
19089	101
19090	101
19097	101
19098	101
19105	101
19107	101
19108	101
19110	101
19115	101
19120	101
19122	101
19126	101
19127	101
19128	101
19130	101
19131	101
19133	101
19136	101
19137	101
19141	101
19143	101
19145	101
19146	101
19147	101
19148	101
19152	101
19153	101
19156	101
19157	101
19158	101
19159	101
19166	101
19171	101
19172	101
19173	101
19178	101
19181	101
19182	101
19184	101
19185	101
19186	101
19187	101
19188	101
19189	101
19190	101
19191	101
19192	101
19193	101
19194	101
19195	101
19196	101
19197	101
19198	101
19199	101
19200	101
19201	101
19202	101
19203	101
19204	101
19205	101
19206	101
19207	101
19208	101
19209	101
19210	101
19211	101
19212	101
19213	101
19214	101
19215	101
19216	101
19217	101
19218	101
19219	101
19220	101
19221	101
19222	101
19223	101
19224	101
19225	101
19226	101
19227	101
19228	101
19229	101
19230	101
19231	101
19232	101
19233	101
19234	101
19235	101
19236	101
19237	101
19238	101
19239	101
19240	101
19241	101
19242	101
19243	101
19244	101
19245	101
19246	101
19247	101
19248	101
19249	101
19250	101
19251	101
19252	101
19253	101
19254	101
19255	101
19256	101
19257	101
19258	101
19259	101
19260	101
19261	101
19262	101
19263	101
19264	101
19265	101
19266	101
19267	101
19268	101
19269	101
19270	101
19271	101
19272	101
19273	101
19274	101
19275	101
19276	101
19277	101
19278	101
19279	101
19280	101
19281	101
19282	101
19283	101
19284	101
19285	101
19286	101
19287	101
19288	101
19289	101
19290	101
19291	101
19292	101
19293	101
19294	101
19295	101
19296	101
19297	101
19298	101
19299	101
19300	101
19301	101
19302	101
19303	101
19304	101
19305	101
19306	101
19307	101
19308	101
19309	101
19310	101
19311	101
19312	101
19313	101
19314	101
19315	101
19316	101
19317	101
19318	101
19319	101
19320	101
19321	101
19322	101
19323	101
19324	101
19325	101
19326	101
19327	101
19328	101
19329	101
19330	101
19331	101
19332	101
19333	101
19334	101
19335	101
19336	101
19337	101
19338	101
19339	101
19340	101
19341	101
19342	101
19343	101
19344	101
19345	101
19346	101
19347	101
19348	101
19349	101
19350	101
19351	101
19352	101
19353	101
19354	101
19355	101
19356	101
19357	101
19358	101
19359	101
19360	101
19361	101
19362	101
19363	101
19364	101
19365	101
19366	101
19367	101
19368	101
19369	101
19370	101
19371	101
19372	101
19373	101
19374	101
19375	101
19376	101
19377	101
19378	101
19379	101
19380	101
19381	101
19382	101
19383	101
19384	101
19385	101
19386	101
19387	101
19388	101
19389	101
19390	101
19391	101
19392	101
19393	101
19394	101
19395	101
19396	101
19397	101
19398	101
19399	101
19400	101
19401	101
19402	101
19403	101
19404	101
19405	101
19406	101
19407	101
19408	101
19409	101
19410	101
19411	101
19412	101
19413	101
19414	101
19415	101
19416	101
19417	101
19418	101
19419	101
19420	101
19421	101
19422	101
19423	101
19424	101
19425	101
19426	101
19427	101
19428	101
19429	101
19430	101
19431	101
19432	101
19433	101
19434	101
19435	101
19436	101
19437	101
19438	101
19439	101
19440	101
19441	101
19442	101
19443	101
19444	101
19445	101
19446	101
19447	101
19448	101
19449	101
19450	101
19451	101
19452	101
19453	101
19454	101
19455	101
19456	101
19457	101
19458	101
19459	101
19460	101
19461	101
19463	101
19464	101
19465	101
19477	101
19480	101
19481	101
19488	101
19496	101
19497	101
19500	101
19501	101
19502	101
19503	101
19505	101
19507	101
19508	101
19509	101
19510	101
19511	101
19512	101
19517	101
19518	101
19522	101
19524	101
19531	101
19533	101
19535	101
19537	101
19539	101
19552	101
19554	101
19555	101
19571	101
19573	101
19574	101
19575	101
19577	101
19578	101
19579	101
19581	101
19582	101
19583	101
19584	101
19585	101
19586	101
19587	101
19588	101
19589	101
19593	101
19606	101
19610	101
19615	101
19616	101
19626	101
19629	102
19640	101
19652	101
19657	101
19668	101
19669	101
19671	101
19673	101
19688	101
19692	101
19694	101
19701	101
19702	101
19704	101
19706	101
19707	101
19709	101
19712	101
19713	101
19714	101
19717	101
19718	101
19719	101
19720	101
19722	101
19724	101
19725	101
19727	101
19728	101
19729	101
19740	101
19748	102
19752	101
19756	101
19757	101
19760	101
19761	101
19763	101
19764	101
19765	101
19766	101
19776	101
19781	101
19782	101
19793	101
19794	101
19795	101
19796	101
19816	101
19819	101
19826	101
19843	101
19849	101
19855	101
19856	101
19866	101
19867	101
19873	101
19876	101
19904	101
19908	101
19910	101
19929	101
19941	101
19942	101
19958	101
19960	101
19962	102
19970	101
19974	101
19975	101
19977	101
19978	101
19981	101
19984	101
19985	101
19988	101
19989	101
19990	101
19991	101
19993	101
19996	101
19998	101
20001	101
20003	101
20005	101
20014	101
20020	101
20025	101
20030	101
20056	101
20074	101
20118	101
20119	101
20123	101
20124	101
20126	101
20128	101
20206	101
21380	101
21402	101
21558	101
21640	101
21919	101
22068	101
22197	101
22313	101
22437	101
22612	101
22793	101
22808	101
22813	101
22837	101
22838	101
\.


--
-- Name: trial_id_seq; Type: SEQUENCE SET; Schema: clean; Owner: postgres
--

SELECT pg_catalog.setval('trial_id_seq', 1, false);


--
-- Name: condition_pkey; Type: CONSTRAINT; Schema: clean; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY condition
    ADD CONSTRAINT condition_pkey PRIMARY KEY (id);


--
-- Name: document_pkey; Type: CONSTRAINT; Schema: clean; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY document
    ADD CONSTRAINT document_pkey PRIMARY KEY (id);


--
-- Name: drug_pkey; Type: CONSTRAINT; Schema: clean; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY drug
    ADD CONSTRAINT drug_pkey PRIMARY KEY (id);


--
-- Name: method_pkey; Type: CONSTRAINT; Schema: clean; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY method
    ADD CONSTRAINT method_pkey PRIMARY KEY (id);


--
-- Name: provenance_pkey; Type: CONSTRAINT; Schema: clean; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY provenance
    ADD CONSTRAINT provenance_pkey PRIMARY KEY (id);


--
-- Name: register_entry_pkey; Type: CONSTRAINT; Schema: clean; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY register_entry
    ADD CONSTRAINT register_entry_pkey PRIMARY KEY (id);


--
-- Name: results_doc_pkey; Type: CONSTRAINT; Schema: clean; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY results_doc
    ADD CONSTRAINT results_doc_pkey PRIMARY KEY (id);


--
-- Name: source_pkey; Type: CONSTRAINT; Schema: clean; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY source
    ADD CONSTRAINT source_pkey PRIMARY KEY (id);


--
-- Name: trial2condition_pkey; Type: CONSTRAINT; Schema: clean; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY trial2condition
    ADD CONSTRAINT trial2condition_pkey PRIMARY KEY (trial_id, condition_id);


--
-- Name: trial2drug_pkey; Type: CONSTRAINT; Schema: clean; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY trial2drug
    ADD CONSTRAINT trial2drug_pkey PRIMARY KEY (trial_id, drug_id);


--
-- Name: trial2method_pkey; Type: CONSTRAINT; Schema: clean; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY trial2method
    ADD CONSTRAINT trial2method_pkey PRIMARY KEY (trial_id, method_id);


--
-- Name: trial_pkey; Type: CONSTRAINT; Schema: clean; Owner: postgres; Tablespace: 
--

ALTER TABLE ONLY trial
    ADD CONSTRAINT trial_pkey PRIMARY KEY (id);


--
-- PostgreSQL database dump complete
--

